Scp160p	O
,	O
a	O
multiple	O
KH	O
-	O
domain	O
protein	O
,	O
is	O
a	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	S-Species

Abstract	O

Scp160p	O
is	O
a	O
160	O
kDa	O
protein	O
in	O
the	O
yeast	S-Species
Saccharomyces	B-Species
cerevisiae	E-Species
that	O
contains	O
14	O
repeats	O
of	O
the	O
hnRNP	O
K	O
-	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
and	O
demonstrates	O
significant	O
sequence	O
homology	O
to	O
a	O
family	O
of	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

As	O
a	O
first	O
step	O
towards	O
defining	O
the	O
function	O
of	O
Scp160p	O
,	O
we	O
have	O
characterized	O
the	O
subcellular	O
distribution	O
and	O
in	O
vivo	O
interactions	O
of	O
this	O
protein	O
.	O

Using	O
sucrose	O
gradient	O
fractionation	O
studies	O
we	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
predominantly	O
associated	O
with	O
polyribosomes	O
.	O

Furthermore	O
,	O
we	O
have	O
found	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
by	O
EDTA	O
in	O
the	O
form	O
of	O
a	O
large	O
complex	O
of	O
>=	O
1300	O
kDa	O
that	O
is	O
sensitive	O
both	O
to	O
RNase	O
and	O
NaCl	O
.	O

Using	O
affinity	O
-	O
chromatography	O
to	O
isolate	O
these	O
complexes	O
,	O
we	O
have	O
identified	O
two	O
protein	O
components	O
other	O
than	O
Scp160p	O
:	O
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
confirms	O
these	O
complexes	O
to	O
be	O
mRNPs	O
.	O

The	O
presence	O
of	O
Bfr1p	O
is	O
intriguing	O
because	O
the	O
null	O
phenotype	O
for	O
this	O
gene	O
is	O
essentially	O
the	O
same	O
as	O
that	O
reported	O
for	O
scp160	O
-	O
null	O
cells	O
:	O
increased	O
cell	O
size	O
and	O
aberrant	O
DNA	O
content	O
.	O

These	O
results	O
demonstrate	O
that	O
Scp160p	O
associates	O
with	O
polyribosome	O
-	O
bound	O
mRNP	O
complexes	O
in	O
vivo	O
,	O
implicating	O
a	O
role	O
for	O
this	O
protein	O
in	O
one	O
or	O
more	O
levels	O
of	O
mRNA	O
metabolism	O
in	O
yeast	S-Species
.	O

INTRODUCTION	O

Scp160p	O
is	O
a	O
1222	O
amino	O
acid	O
Saccharomyces	B-Species
cerevisiae	E-Species
protein	O
that	O
contains	O
14	O
copies	O
of	O
the	O
hnRNP	O
K	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
a	O
highly	O
conserved	O
motif	O
found	O
in	O
many	O
proteins	O
involved	O
in	O
RNA	O
metabolism	O
(	O
1	O
)	O
.	O

KH	O
domain	O
-	O
containing	O
proteins	O
appear	O
to	O
have	O
diverse	O
functions	O
and	O
have	O
been	O
identified	O
in	O
all	O
kingdoms	O
of	O
life	O
,	O
including	O
the	O
ribosomal	O
protein	O
S3	O
from	O
Escherichia	B-Species
coli	E-Species
(	O
1	O
)	O
,	O
Mer1p	O
from	O
S	B-Species
.	I-Species
cerevisiae	E-Species
,	O
a	O
meiosis	O
-	O
specific	O
splicing	O
factor	O
(	O
1	O
)	O
,	O
MEX	O
-	O
3	O
from	O
Caenorhabditis	B-Species
elegans	E-Species
,	O
presumably	O
involved	O
in	O
mRNA	O
localization	O
during	O
development	O
(	O
2	O
)	O
,	O
and	O
FMRP	O
,	O
the	O
fragile	O
-	O
X	O
mental	O
retardation	O
protein	O
in	O
humans	S-Species
(	O
3	O
)	O
.	O

A	O
partial	O
clone	O
of	O
Scp160p	O
,	O
known	O
as	O
HX	O
,	O
was	O
one	O
of	O
the	O
first	O
multiple	O
-	O
KH	O
proteins	O
identified	O
(	O
1	O
)	O
.	O

Whole	O
cell	O
immunofluorescence	O
studies	O
have	O
demonstrated	O
that	O
Scp160p	O
localizes	O
to	O
the	O
cytoplasm	O
,	O
with	O
enrichment	O
around	O
the	O
nuclear	O
envelope	O
,	O
and	O
what	O
appears	O
to	O
be	O
the	O
endoplasmic	O
reticulum	O
(	O
3	O
)	O
.	O

Deletion	O
of	O
the	O
SCP160	O
locus	O
in	O
yeast	S-Species
is	O
not	O
lethal	O
,	O
but	O
results	O
in	O
a	O
complex	O
phenotype	O
,	O
including	O
increased	O
DNA	O
content	O
per	O
cell	O
,	O
missegregation	O
of	O
genetic	O
markers	O
during	O
sporulation	O
,	O
and	O
abnormal	O
cell	O
morphology	O
,	O
including	O
increased	O
size	O
and	O
irregular	O
shape	O
(	O
4	O
)	O
.	O

Observation	O
of	O
this	O
phenotype	O
led	O
to	O
the	O
hypothesis	O
that	O
Scp160p	O
may	O
function	O
in	O
regulating	O
ploidy	O
during	O
cell	O
division	O
.	O

More	O
recently	O
,	O
Weber	O
and	O
colleagues	O
demonstrated	O
in	O
vitro	O
RNA	O
binding	O
activity	O
of	O
Scp160p	O
using	O
northwestern	O
blot	O
analyses	O
;	O
the	O
protein	O
was	O
found	O
to	O
bind	O
efficiently	O
to	O
ribohomopolymers	O
and	O
rRNA	O
,	O
but	O
not	O
to	O
tRNA	O
(	O
5	O
)	O
.	O

Cell	O
fractionation	O
studies	O
revealed	O
that	O
a	O
large	O
percentage	O
of	O
Scp160p	O
associates	O
with	O
membrane	O
-	O
pellets	O
,	O
and	O
is	O
released	O
by	O
treatment	O
with	O
either	O
10	O
mM	O
EDTA	O
or	O
500	O
mM	O
NaCl	O
(	O
5	O
)	O
.	O

While	O
these	O
authors	O
interpreted	O
these	O
results	O
to	O
suggest	O
that	O
the	O
nuclear	O
envelope	O
/	O
ER	O
localization	O
of	O
Scp160p	O
was	O
due	O
primarily	O
to	O
interactions	O
of	O
the	O
protein	O
with	O
membrane	O
-	O
bound	O
polyribosomes	O
,	O
clear	O
evidence	O
of	O
this	O
association	O
has	O
not	O
been	O
reported	O
(	O
5	O
)	O
.	O

Currently	O
,	O
the	O
relationship	O
between	O
the	O
phenotype	O
of	O
scp160	O
null	O
mutants	O
and	O
the	O
RNA	O
-	O
binding	O
activity	O
of	O
Scp160p	O
remains	O
unclear	O
.	O

Scp160p	O
demonstrates	O
significant	O
sequence	O
homology	O
(	O
~	O
23	O
%	O
identity	O
and	O
~	O
40	O
%	O
similarity	O
at	O
the	O
amino	O
acid	O
level	O
)	O
to	O
a	O
class	O
of	O
vertebrate	O
KH	O
-	O
domain	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

First	O
identified	O
in	O
chicken	S-Species
,	O
vigilin	O
homologues	O
have	O
now	O
been	O
found	O
in	O
human	S-Species
(	O
6	O
)	O
,	O
Xenopus	B-Species
laevis	E-Species
(	O
7	O
)	O
,	O
Drosophila	B-Species
melanogaster	E-Species
(	O
8	O
)	O
,	O
C	B-Species
.	I-Species
elegans	E-Species
(	O
5	O
)	O
and	O
Schizosaccharomyces	B-Species
pombe	E-Species
.	O

While	O
all	O
of	O
the	O
vigilin	O
proteins	O
studied	O
to	O
date	O
are	O
reported	O
to	O
bind	O
nucleic	O
acid	O
,	O
both	O
the	O
type	O
of	O
nucleic	O
acid	O
bound	O
and	O
the	O
functional	O
significance	O
of	O
these	O
interactions	O
remain	O
unclear	O
.	O

For	O
example	O
,	O
Kruse	O
and	O
colleagues	O
reported	O
from	O
their	O
work	O
with	O
human	S-Species
cells	O
in	O
culture	O
that	O
vigilin	O
may	O
be	O
involved	O
in	O
the	O
binding	O
and	O
transport	O
of	O
tRNA	O
(	O
9	O
-	O
11	O
)	O
.	O

In	O
contrast	O
,	O
Dodson	O
and	O
Shapiro	O
concluded	O
from	O
their	O
work	O
with	O
Xenopus	O
vigilin	O
that	O
,	O
in	O
response	O
to	O
estrogen	O
,	O
the	O
protein	O
bound	O
specifically	O
to	O
the	O
3	O
'	O
UTR	O
of	O
vitellogenin	O
mRNA	O
(	O
7	O
,	O
12	O
)	O
,	O
potentially	O
stabilizing	O
the	O
message	O
(	O
13	O
)	O
.	O

Lastly	O
,	O
DDP1	O
,	O
the	O
Drosophila	O
homolog	O
of	O
vigilin	O
,	O
was	O
reported	O
recently	O
to	O
interact	O
with	O
the	O
dodeca	O
-	O
satellite	O
repeat	O
regions	O
of	O
centromeric	O
heterochromatin	O
in	O
embryonic	O
and	O
larval	O
cell	O
nuclei	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
this	O
protein	O
in	O
heterochromatin	O
structure	O
(	O
8	O
)	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
begin	O
elucidating	O
the	O
function	O
of	O
Scp160p	O
in	O
yeast	S-Species
by	O
characterizing	O
the	O
subcellular	O
distribution	O
and	O
macromolecular	O
interactions	O
of	O
this	O
protein	O
.	O

We	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
associated	O
predominantly	O
with	O
polyribosomes	O
,	O
and	O
that	O
following	O
treatment	O
with	O
EDTA	O
,	O
Scp160p	O
remains	O
in	O
an	O
RNase	O
/	O
NaCl	O
-	O
sensitive	O
complex	O
of	O
apparent	O
molecular	O
weight	O
approximately	O
>=	O
1300	O
kDa	O
.	O

Affinity	O
purification	O
of	O
this	O
complex	O
revealed	O
the	O
presence	O
of	O
poly	O
(	O
A	O
)	O
-	O
binding	O
protein	O
(	O
Pab1p	O
)	O
,	O
a	O
well	O
-	O
characterized	O
component	O
of	O
eukaryotic	O
mRNPs	O
(	O
14	O
,	O
15	O
)	O
.	O

Finally	O
,	O
a	O
third	O
abundant	O
protein	O
component	O
of	O
this	O
complex	O
was	O
identified	O
as	O
Bfr1p	O
,	O
a	O
protein	O
not	O
previously	O
reported	O
to	O
associate	O
with	O
mRNPs	O
.	O

While	O
the	O
function	O
of	O
Bfr1p	O
remains	O
unknown	O
,	O
gene	O
deletion	O
reportedly	O
leads	O
to	O
a	O
phenotype	O
remarkably	O
similar	O
to	O
that	O
of	O
scp160	O
deletion	O
(	O
16	O
)	O
.	O

These	O
results	O
indicate	O
a	O
role	O
for	O
Scp160p	O
in	O
mRNA	O
metabolism	O
in	O
yeast	S-Species
,	O
and	O
by	O
extension	O
,	O
support	O
results	O
seen	O
with	O
Xenopus	O
vigilin	O
in	O
its	O
interactions	O
with	O
mRNA	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
data	O
reported	O
here	O
demonstrate	O
Scp160p	O
to	O
be	O
the	O
first	O
example	O
of	O
a	O
KH	O
-	O
domain	O
protein	O
that	O
functions	O
as	O
a	O
component	O
of	O
polyribosome	O
-	O
associated	O
mRNP	O
complexes	O
in	O
the	O
yeast	S-Species
,	O
S	B-Species
.	I-Species
cerevisiae	E-Species
.	O

MATERIALS	O
AND	O
METHODS	O

Plasmids	O
,	O
yeast	S-Species
strains	O
and	O
culture	O
conditions	O

All	O
recombinant	O
DNA	O
manipulations	O
were	O
performed	O
according	O
to	O
standard	O
techniques	O
and	O
utilized	O
E	B-Species
.	I-Species
coli	E-Species
strain	O
XL1	O
-	O
Blue	O
(	O
Stratagene	O
)	O
.	O

The	O
yeast	S-Species
strain	O
JFy1511	O
,	O
expressing	O
FLAG	O
-	O
Scp160p	O
,	O
was	O
derived	O
by	O
two	O
-	O
step	O
gene	O
replacement	O
from	O
strain	O
yJJ52	O
(	O
MAT	O
alpha	O
gal7	O
Delta	O
102	O
ura3	O
-	O
52	O
trp1	O
-	O
289	O
ade1	O
lys1	O
leu2	O
-	O
3	O
,	O
112	O
;	O
generously	O
donated	O
by	O
Drs	O
Mark	O
Parthun	O
and	O
Judith	O
Jaehning	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
)	O
,	O
and	O
confirmed	O
by	O
PCR	O
.	O

The	O
wild	O
-	O
type	O
SCP160	O
coding	O
sequence	O
was	O
obtained	O
by	O
PCR	O
amplification	O
from	O
a	O
genomic	O
DNA	O
preparation	O
from	O
yJFK1	O
(	O
MAT	O
alpha	O
gal7	O
Delta	O
102	O
ura3	O
-	O
52	O
trp1	O
-	O
289	O
ade1	O
lys1	O
leu2	O
-	O
3	O
,	O
112	O
Delta	O
GAL80	O
:	O
:	O
URA3	O
)	O
,	O
using	O
a	O
16	O
:	O
1	O
mixture	O
of	O
Taq	O
(	O
Fisher	O
Biotech	O
)	O
and	O
Pfu	O
(	O
Stratagene	O
)	O
DNA	O
polymerases	O
and	O
the	O
following	O
primers	O
:	O
Scp160F1	O
(	O
5	O
'	O
-	O
GCCGGTCGA	O
-	O
CTAACTGCAATGTCTGAAGAACAAACCGCTATTG	O
-	O
3	O
'	O
)	O
and	O
Scp160R1	O
(	O
5	O
'	O
-	O
GCGCGTCGACGAGCTTGTCTATCTT	O
-	O
CTTAAGG	O
-	O
3	O
'	O
)	O
.	O

A	O
wild	O
-	O
type	O
SCP160	O
genomic	O
clone	O
,	O
containing	O
1	O
kb	O
upstream	O
and	O
300	O
bp	O
downstream	O
sequence	O
was	O
PCR	O
amplified	O
from	O
yJFK1	O
genomic	O
DNA	O
using	O
the	O
primers	O
Scp160F0	O
(	O
5	O
'	O
-	O
GCCGAGCTCACACCAGCTTTGTCCTGG	O
-	O
3	O
'	O
)	O
and	O
Scp160R2	O
(	O
5	O
'	O
-	O
GCGCAAGCTTGTGCGGTA	O
-	O
TCCCAGTCTATG	O
-	O
3	O
'	O
)	O
.	O

The	O
resultant	O
clone	O
was	O
confirmed	O
by	O
dideoxy	O
sequencing	O
.	O

The	O
N	O
-	O
terminal	O
FLAG	O
and	O
HA	O
tags	O
were	O
added	O
using	O
PCR	O
with	O
the	O
primers	O
ScpFLAGF1	O
(	O
5	O
'	O
-	O
CCAT	O
-	O
TATAACTGCAATGGACTACAAGGACGACGACGACGAC	O
-	O
AAGATGTCTGAAGAACAAACCGCTATTG	O
-	O
3	O
'	O
)	O
and	O
ScpHAF1	O
(	O
5	O
'	O
-	O
CCCCCTCCTGTCGACATTATAACTGCAATGCACCA	O
-	O
TCACCATCACCATTCTGAAGAACAAACCGCTATTG	O
-	O
3	O
'	O
)	O
respectively	O
.	O

For	O
integration	O
,	O
constructs	O
containing	O
the	O
1	O
kb	O
upstream	O
and	O
300	O
bp	O
downstream	O
sequence	O
were	O
subcloned	O
into	O
the	O
plasmid	O
YIplac211	O
(	O
17	O
)	O
using	O
SacI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
HA	O
-	O
tagged	O
construct	O
was	O
subcloned	O
into	O
the	O
low	O
copy	O
number	O
plasmid	O
,	O
YCplac22	O
using	O
SacI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
SCP160	O
deletion	O
construct	O
was	O
made	O
by	O
removal	O
of	O
a	O
3	O
.	O
4	O
kb	O
ApaI	O
-	O
KpnI	O
fragment	O
from	O
the	O
coding	O
region	O
of	O
this	O
construct	O
,	O
followed	O
by	O
treatment	O
with	O
Klenow	O
fragment	O
and	O
re	O
-	O
ligation	O
following	O
attachment	O
of	O
BamHI	O
linker	O
oligonucleotides	O
.	O

Genomic	O
integration	O
of	O
the	O
plasmid	O
sequences	O
and	O
subsequent	O
removal	O
of	O
the	O
endogenous	O
SCP160	O
allele	O
were	O
achieved	O
by	O
standard	O
two	O
-	O
step	O
gene	O
replacement	O
techniques	O
(	O
18	O
)	O
and	O
confirmed	O
by	O
PCR	O
.	O

The	O
N	O
-	O
terminally	O
HA	O
-	O
tagged	O
allele	O
of	O
BFR1	O
was	O
generated	O
by	O
PCR	O
-	O
amplifiction	O
of	O
the	O
BFR1	O
locus	O
from	O
wild	O
-	O
type	O
(	O
W303	O
)	O
yeast	S-Species
genomic	O
DNA	O
using	O
the	O
primers	O
BFR1HAF1	O
(	O
5	O
'	O
-	O
CCGCGGATCCATGTACC	O
-	O
CATACGACGTCCCAGACTACGCTATGTCCTCCCAAC	O
-	O
AACACAA	O
-	O
3	O
'	O
)	O
and	O
BFR1HINDR1	O
(	O
5	O
'	O
-	O
CCGCAAGCTTGTCG	O
-	O
ACTATTTCATATGCCACAGGAAACAG	O
-	O
3	O
'	O
)	O
,	O
and	O
subcloned	O
into	O
YIPlac211	O
.	O

The	O
BFR1	O
promoter	O
region	O
was	O
PCR	O
-	O
amplified	O
in	O
a	O
similar	O
manner	O
using	O
the	O
primers	O
BFR1SACF1	O
(	O
5	O
'	O
-	O
CCGCGAG	O
-	O
CTCAGCATTAAGCATTCACGAGC	O
-	O
3	O
'	O
)	O
and	O
BFR1BAMR1	O
(	O
5	O
'	O
-	O
CCGCGGATCCGGCAATGGCTGTGTTGTTAGA	O
-	O
3	O
'	O
)	O
and	O
subcloned	O
into	O
the	O
appropriate	O
position	O
upstream	O
of	O
the	O
HA	O
-	O
Bfr1p	O
open	O
reading	O
frame	O
in	O
the	O
plasmid	O
backbone	O
.	O

The	O
entire	O
open	O
reading	O
frame	O
was	O
confirmed	O
by	O
dideoxy	O
sequencing	O
.	O

Finally	O
,	O
the	O
HA	O
-	O
BFR1	O
allele	O
was	O
substituted	O
into	O
the	O
yeast	S-Species
genome	O
in	O
place	O
of	O
the	O
native	O
allele	O
using	O
linearization	O
with	O
SphI	O
and	O
standard	O
two	O
-	O
step	O
gene	O
replacement	O
techniques	O
.	O

All	O
yeast	S-Species
transformations	O
and	O
culture	O
manipulations	O
were	O
performed	O
according	O
to	O
standard	O
protocols	O
as	O
described	O
elsewhere	O
(	O
19	O
)	O
.	O

Confirmation	O
of	O
genomic	O
integrations	O

All	O
genomic	O
integrations	O
were	O
confirmed	O
by	O
PCR	O
amplifications	O
from	O
purified	O
yeast	S-Species
genomic	O
DNA	O
.	O

For	O
scp160	O
deletion	O
mutants	O
,	O
the	O
primers	O
Scp160PF	O
(	O
5	O
'	O
-	O
GATTTCCTAACTTTCC	O
-	O
GTCTA	O
-	O
3	O
'	O
)	O
and	O
Scp160R5	O
(	O
5	O
'	O
-	O
GCGCAAGCTTCACCGCCTTATAACGAAGAC	O
-	O
3	O
'	O
)	O
that	O
flanked	O
the	O
deleted	O
region	O
were	O
used	O
.	O

Similarly	O
,	O
epitope	O
tags	O
on	O
Scp160p	O
were	O
confirmed	O
by	O
PCR	O
using	O
primers	O
that	O
flanked	O
the	O
tag	O
sequence	O
.	O

Positive	O
clones	O
were	O
further	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
crude	O
cell	O
lysates	O
using	O
the	O
appropriate	O
anti	O
-	O
tag	O
antibodies	O
.	O

The	O
presence	O
of	O
HA	O
-	O
Bfr1p	O
in	O
cells	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
soluble	O
cell	O
lysates	O
using	O
12CA5	O
mAb	O
(	O
Boehringer	O
Mannheim	O
)	O
.	O

Polyribosome	O
isolation	O

Polyribosomes	O
were	O
isolated	O
using	O
a	O
combination	O
of	O
protocols	O
described	O
by	O
Stansfield	O
and	O
colleagues	O
(	O
20	O
)	O
and	O
by	O
Dr	O
Maurice	O
Swanson	O
(	O
personal	O
communication	O
)	O
.	O

In	O
brief	O
,	O
a	O
100	O
ml	O
culture	O
of	O
yeast	S-Species
was	O
grown	O
in	O
either	O
YEPD	O
or	O
Hartwell	O
synthetic	O
medium	O
,	O
to	O
early	O
-	O
log	O
phase	O
(	O
OD600	O
=	O
1	O
.	O
0	O
)	O
,	O
at	O
which	O
time	O
cyclohexamide	O
(	O
Sigma	O
)	O
was	O
added	O
directly	O
to	O
the	O
culture	O
to	O
a	O
final	O
concentration	O
of	O
100	O
micro	O
g	O
/	O
ml	O
.	O

The	O
culture	O
was	O
incubated	O
on	O
ice	O
for	O
15	O
min	O
,	O
and	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
4000	O
r	O
.	O
p	O
.	O
m	O
.	O
/	O
10	O
min	O
)	O
.	O

Following	O
two	O
washes	O
in	O
10	O
ml	O
of	O
water	O
containing	O
100	O
micro	O
g	O
/	O
ml	O
cyclohexamide	O
,	O
cells	O
were	O
lysed	O
by	O
vortex	O
agitation	O
with	O
an	O
equal	O
volume	O
of	O
glass	O
beads	O
in	O
1	O
ml	O
lysis	O
buffer	O
(	O
25	O
mM	O
Tris	O
pH	O
7	O
.	O
2	O
,	O
50	O
mM	O
KCl	O
,	O
30	O
mM	O
MgCl2	O
,	O
5	O
mM	O
beta	O
-	O
mercaptoethanol	O
,	O
200	O
micro	O
g	O
/	O
ml	O
cyclohexamide	O
,	O
2	O
micro	O
g	O
/	O
ml	O
aprotonin	O
,	O
1	O
mM	O
PMSF	O
,	O
0	O
.	O
5	O
micro	O
g	O
/	O
ml	O
leupeptin	O
,	O
2	O
.	O
9	O
micro	O
g	O
/	O
ml	O
E64	O
,	O
1	O
micro	O
g	O
/	O
ml	O
antipain	O
,	O
0	O
.	O
2	O
micro	O
g	O
/	O
ml	O
chymostatin	O
)	O
.	O

Lysate	O
was	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
,	O
and	O
centrifuged	O
10	O
min	O
at	O
3000	O
g	O
at	O
4	O
degrees	O
C	O
.	O

The	O
supernatant	O
was	O
again	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
and	O
centrifuged	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
degrees	O
C	O
,	O
and	O
then	O
assayed	O
for	O
absorbance	O
at	O
260	O
nm	O
.	O

Approximately	O
12	O
OD260	O
units	O
were	O
loaded	O
onto	O
a	O
11	O
ml	O
15	O
-	O
45	O
%	O
sucrose	O
gradient	O
made	O
in	O
10	O
mM	O
Tris	O
,	O
pH	O
7	O
.	O
4	O
,	O
70	O
mM	O
NH4Cl	O
,	O
4	O
mM	O
MgOAc	O
,	O
using	O
a	O
Gradient	O
Master	O
automatic	O
system	O
,	O
and	O
the	O
gradient	O
was	O
centrifuged	O
in	O
a	O
SW41ti	O
rotor	O
(	O
Beckman	O
)	O
at	O
39	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
2	O
.	O
5	O
h	O
.	O

0	O
.	O
5	O
ml	O
fractions	O
were	O
collected	O
using	O
an	O
Isco	O
gradient	O
fractionator	O
,	O
and	O
gradient	O
profiles	O
were	O
determined	O
by	O
monitoring	O
absorbance	O
at	O
254	O
nm	O
.	O

For	O
EDTA	O
controls	O
,	O
lysis	O
buffer	O
containing	O
5	O
mM	O
MgCl2	O
was	O
used	O
,	O
and	O
30	O
mM	O
EDTA	O
was	O
added	O
to	O
the	O
sample	O
before	O
loading	O
onto	O
the	O
gradient	O
.	O

Where	O
indicated	O
,	O
addition	O
of	O
50	O
U	O
/	O
ml	O
of	O
RNase	O
One	O
(	O
Promega	O
)	O
was	O
performed	O
prior	O
to	O
loading	O
the	O
sample	O
onto	O
the	O
gradient	O
.	O

Gel	O
filtration	O
chromatography	O

Gel	O
filtration	O
chromatography	O
was	O
performed	O
using	O
a	O
120	O
ml	O
Hi	O
-	O
Prep	O
S	O
-	O
300	O
Sephacryl	O
column	O
(	O
Pharmacia	O
)	O
with	O
a	O
cut	O
-	O
off	O
of	O
1300	O
kDa	O
,	O
attached	O
to	O
an	O
FPLC	O
system	O
(	O
Pharmacia	O
)	O
.	O

The	O
column	O
had	O
been	O
calibrated	O
previously	O
using	O
the	O
following	O
molecular	O
weight	O
standards	O
(	O
Sigma	O
)	O
:	O
blue	O
dextran	O
(	O
2000	O
kDa	O
)	O
,	O
thyroglobulin	O
(	O
669	O
kDa	O
)	O
,	O
apoferritin	O
(	O
443	O
kDa	O
)	O
,	O
alcohol	O
dehydrogenase	O
(	O
150	O
kDa	O
)	O
,	O
and	O
bovine	S-Species
serum	O
albumin	O
(	O
66	O
kDa	O
)	O
.	O

Yeast	S-Species
were	O
lysed	O
as	O
described	O
for	O
polyribosome	O
analysis	O
,	O
with	O
an	O
additional	O
clarification	O
by	O
passage	O
through	O
a	O
0	O
.	O
2	O
micro	O
m	O
syringe	O
-	O
tip	O
filter	O
(	O
Acrodisc	O
)	O
and	O
run	O
over	O
the	O
column	O
at	O
a	O
rate	O
of	O
0	O
.	O
5	O
ml	O
/	O
min	O
in	O
polyribosome	O
lysis	O
buffer	O
following	O
treatment	O
with	O
the	O
indicated	O
reagents	O
.	O

Fractions	O
(	O
2	O
.	O
0	O
ml	O
)	O
were	O
collected	O
,	O
from	O
which	O
12	O
micro	O
l	O
were	O
combined	O
with	O
sample	O
buffer	O
(	O
2	O
%	O
SDS	O
,	O
10	O
%	O
glycerol	O
,	O
100	O
mM	O
dithiothreitol	O
,	O
60	O
mM	O
Tris	O
pH	O
6	O
.	O
8	O
,	O
0	O
.	O
001	O
%	O
bromophenol	O
blue	O
)	O
and	O
analyzed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

alpha	O
-	O
FLAG	O
affinity	O
chromatography	O

For	O
most	O
experiments	O
,	O
one	O
liter	O
yeast	S-Species
cultures	O
were	O
grown	O
to	O
early	O
log	O
-	O
phase	O
and	O
harvested	O
by	O
centrifugation	O
.	O

Cells	O
were	O
washed	O
twice	O
in	O
T75	O
buffer	O
(	O
25	O
mM	O
Tris	O
pH	O
7	O
.	O
5	O
,	O
75	O
mM	O
NaCl	O
)	O
and	O
then	O
were	O
lysed	O
by	O
vortex	O
agitation	O
with	O
an	O
equal	O
volume	O
of	O
glass	O
beads	O
in	O
4	O
ml	O
T75	O
buffer	O
containing	O
30	O
mM	O
EDTA	O
.	O

Lysate	O
was	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
,	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
3000	O
g	O
at	O
4	O
degrees	O
C	O
.	O

The	O
supernatant	O
was	O
again	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
and	O
centrifuged	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
degrees	O
C	O
,	O
and	O
finally	O
passed	O
through	O
a	O
0	O
.	O
2	O
micro	O
m	O
syringe	O
filter	O
.	O

Lysate	O
was	O
then	O
pre	O
-	O
purified	O
by	O
running	O
over	O
the	O
S	O
-	O
300	O
gel	O
-	O
filtration	O
column	O
in	O
T75	O
buffer	O
,	O
with	O
pooling	O
of	O
the	O
void	O
volume	O
fractions	O
(	O
~	O
10	O
ml	O
total	O
)	O
.	O

For	O
several	O
experiments	O
(	O
Fig	O
.	O
5A	O
,	O
B	O
,	O
E	O
and	O
F	O
)	O
,	O
a	O
low	O
concentration	O
(	O
<	O
10	O
micro	O
g	O
/	O
ml	O
)	O
of	O
FLAG	O
peptide	O
(	O
N	O
-	O
DYKDDDDK	O
-	O
C	O
)	O
was	O
added	O
to	O
this	O
sample	O
.	O

This	O
void	O
material	O
was	O
then	O
loaded	O
onto	O
a	O
1	O
ml	O
M2	O
alpha	O
-	O
FLAG	O
column	O
(	O
Sigma	O
)	O
;	O
column	O
flow	O
-	O
through	O
was	O
passed	O
over	O
the	O
column	O
a	O
second	O
time	O
.	O

The	O
column	O
was	O
then	O
washed	O
extensively	O
with	O
75	O
ml	O
T75	O
buffer	O
;	O
material	O
bound	O
to	O
the	O
column	O
was	O
eluted	O
with	O
5	O
ml	O
T75	O
containing	O
184	O
mg	O
/	O
ml	O
FLAG	O
peptide	O
.	O

The	O
peptide	O
solution	O
was	O
allowed	O
to	O
incubate	O
on	O
the	O
column	O
for	O
20	O
min	O
prior	O
to	O
collection	O
of	O
the	O
first	O
1	O
ml	O
fraction	O
;	O
subsequent	O
fractions	O
were	O
collected	O
every	O
10	O
min	O
.	O

Samples	O
of	O
crude	O
material	O
,	O
S	O
-	O
300	O
void	O
,	O
alpha	O
-	O
FLAG	O
flow	O
-	O
through	O
,	O
first	O
and	O
last	O
wash	O
,	O
and	O
eluate	O
fractions	O
were	O
analyzed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

For	O
Figure	O
5A	O
and	O
E	O
,	O
samples	O
of	O
first	O
and	O
last	O
wash	O
and	O
eluate	O
fractions	O
were	O
concentrated	O
,	O
run	O
on	O
SDS	O
-	O
PAGE	O
and	O
stained	O
with	O
colloidal	O
G250	O
Coomassie	O
.	O

Concentration	O
of	O
samples	O

Where	O
indicated	O
,	O
samples	O
were	O
concentrated	O
using	O
the	O
method	O
of	O
Traub	O
et	O
al	O
.	O

(	O
21	O
)	O
.	O

400	O
micro	O
l	O
of	O
sample	O
were	O
transferred	O
to	O
a	O
microfuge	O
tube	O
,	O
and	O
combined	O
with	O
400	O
micro	O
l	O
of	O
methanol	O
,	O
and	O
100	O
micro	O
l	O
of	O
chloroform	O
.	O

Samples	O
were	O
then	O
vortexed	O
vigorously	O
,	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
12	O
000	O
g	O
.	O

The	O
supernatant	O
was	O
discarded	O
,	O
leaving	O
the	O
interface	O
intact	O
,	O
and	O
an	O
additional	O
400	O
micro	O
l	O
of	O
methanol	O
was	O
added	O
to	O
each	O
tube	O
.	O

Samples	O
were	O
then	O
inverted	O
several	O
times	O
,	O
and	O
centrifuged	O
again	O
for	O
5	O
min	O
.	O

The	O
supernatant	O
was	O
discarded	O
,	O
and	O
the	O
protein	O
pellet	O
was	O
air	O
-	O
dried	O
and	O
resuspended	O
in	O
1	O
x	O
sample	O
buffer	O
.	O

Western	O
blot	O
analysis	O

Western	O
blot	O
analysis	O
was	O
performed	O
essentially	O
as	O
described	O
previously	O
(	O
19	O
)	O
.	O

Briefly	O
,	O
samples	O
to	O
be	O
analyzed	O
were	O
mixed	O
with	O
sample	O
buffer	O
,	O
boiled	O
,	O
electrophoresed	O
through	O
a	O
10	O
%	O
SDS	O
-	O
polyacrylamide	O
gel	O
,	O
and	O
electro	O
-	O
blotted	O
onto	O
nitrocellulose	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

FLAG	O
-	O
Scp160p	O
fusion	O
protein	O
was	O
detected	O
by	O
incubation	O
of	O
the	O
filter	O
with	O
mouse	S-Species
M2	O
anti	O
-	O
FLAG	O
monoclonal	O
antibody	O
(	O
10	O
micro	O
g	O
/	O
ml	O
final	O
concentration	O
)	O
,	O
followed	O
by	O
HRP	O
-	O
conjugated	O
sheep	S-Species
anti	O
-	O
mouse	S-Species
secondary	O
antibody	O
(	O
Amersham	O
)	O
,	O
diluted	O
1	O
:	O
5000	O
as	O
per	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
and	O
ECL	O
reagent	O
(	O
Amersham	O
)	O
,	O
followed	O
by	O
exposure	O
to	O
X	O
-	O
ray	O
film	O
.	O

HA	O
-	O
tagged	O
Scp160p	O
and	O
HA	O
-	O
tagged	O
Bfr1p	O
were	O
detected	O
using	O
the	O
12CA5	O
mAb	O
(	O
Boehringer	O
Mannheim	O
)	O
at	O
a	O
final	O
concentration	O
of	O
0	O
.	O
8	O
micro	O
g	O
/	O
ml	O
;	O
Pab1p	O
and	O
Pub1p	O
were	O
detected	O
using	O
1G1	O
mAb	O
at	O
1	O
:	O
5000	O
,	O
and	O
4C3	O
mAb	O
at	O
1	O
:	O
1000	O
,	O
respectively	O
,	O
both	O
generous	O
gifts	O
from	O
Dr	O
Maurice	O
Swanson	O
(	O
22	O
,	O
23	O
)	O
.	O

Where	O
appropriate	O
,	O
films	O
were	O
analyzed	O
by	O
scanning	O
densitometry	O
(	O
Molecular	O
Dynamics	O
)	O
,	O
and	O
quantitated	O
using	O
ImageQuant	O
software	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Colloidal	O
G250	O
coomassie	O
staining	O

Procedure	O
used	O
was	O
that	O
of	O
Neuhoff	O
(	O
24	O
)	O
.	O

Briefly	O
,	O
a	O
one	O
liter	O
stock	O
of	O
staining	O
solution	O
was	O
prepared	O
containing	O
1	O
g	O
Coomassie	O
brilliant	O
blue	O
G	O
-	O
250	O
(	O
Sigma	O
)	O
,	O
100	O
g	O
ammonium	O
sulfate	O
(	O
Sigma	O
)	O
,	O
and	O
11	O
.	O
76	O
ml	O
85	O
%	O
phosphoric	O
acid	O
(	O
Fisher	O
)	O
.	O

Following	O
SDS	O
-	O
PAGE	O
,	O
gels	O
were	O
fixed	O
in	O
40	O
%	O
methanol	O
,	O
10	O
%	O
acetic	O
acid	O
for	O
10	O
min	O
.	O

Gels	O
were	O
then	O
rinsed	O
several	O
times	O
in	O
water	O
,	O
then	O
stained	O
using	O
40	O
ml	O
of	O
the	O
stock	O
staining	O
solution	O
mixed	O
with	O
10	O
ml	O
methanol	O
,	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

Stain	O
was	O
then	O
poured	O
off	O
,	O
and	O
residual	O
stain	O
was	O
removed	O
by	O
rinsing	O
in	O
water	O
.	O

By	O
performing	O
a	O
standard	O
analysis	O
using	O
bovine	S-Species
serum	O
albumin	O
,	O
the	O
stain	O
was	O
able	O
to	O
detect	O
~	O
15	O
ng	O
total	O
protein	O
per	O
lane	O
.	O

Pichia	O
expression	O
system	O

An	O
N	O
-	O
terminally	O
HIS6	O
/	O
FLAG	O
-	O
tagged	O
allele	O
of	O
the	O
SCP160	O
coding	O
sequence	O
was	O
blunt	O
-	O
end	O
sub	O
-	O
cloned	O
into	O
the	O
BamHI	O
/	O
SnaBI	O
sites	O
of	O
the	O
Pichia	O
expression	O
vector	O
pPIC3	O
.	O
5K	O
(	O
Invitrogen	O
)	O
.	O

The	O
construct	O
was	O
then	O
linearized	O
using	O
SalI	O
and	O
integrated	O
into	O
the	O
genome	O
of	O
the	O
Pichia	O
strain	O
GS115	O
(	O
Invitrogen	O
)	O
.	O

High	O
expression	O
transformants	O
were	O
selected	O
initially	O
on	O
histidine	O
-	O
deficient	O
medium	O
followed	O
by	O
selection	O
on	O
increasing	O
concentrations	O
of	O
G418	O
(	O
US	O
Biological	O
)	O
.	O

Crude	O
lysates	O
of	O
the	O
resultant	O
transformants	O
were	O
then	O
confirmed	O
by	O
western	O
blot	O
analysis	O
with	O
the	O
anti	O
-	O
FLAG	O
antibody	O
M2	O
,	O
and	O
the	O
best	O
expressing	O
strain	O
was	O
cultured	O
in	O
a	O
fermenter	O
,	O
harvested	O
,	O
and	O
lysed	O
by	O
agitation	O
with	O
glass	O
beads	O
.	O

To	O
purify	O
Scp160p	O
,	O
2	O
ml	O
of	O
crude	O
lysate	O
was	O
first	O
diluted	O
to	O
10	O
ml	O
with	O
25	O
mM	O
Tris	O
,	O
pH	O
7	O
.	O
5	O
,	O
1	O
M	O
NaCl	O
,	O
then	O
twice	O
passed	O
over	O
a	O
1	O
ml	O
alpha	O
-	O
FLAG	O
affinity	O
column	O
.	O

The	O
column	O
was	O
then	O
washed	O
with	O
75	O
ml	O
of	O
25	O
mM	O
Tris	O
,	O
pH	O
7	O
.	O
5	O
,	O
1	O
M	O
NaCl	O
,	O
and	O
then	O
eluted	O
with	O
184	O
micro	O
g	O
/	O
ml	O
FLAG	O
peptide	O
prepared	O
in	O
the	O
same	O
buffer	O
.	O

RESULTS	O

Expression	O
of	O
tagged	O
Scp160p	O
in	O
yeast	S-Species

An	O
N	O
-	O
terminal	O
FLAG	O
-	O
tagged	O
form	O
of	O
Scp160p	O
was	O
created	O
to	O
facilitate	O
detection	O
of	O
the	O
protein	O
in	O
cells	O
and	O
extracts	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

To	O
probe	O
functionality	O
of	O
this	O
fusion	O
protein	O
,	O
we	O
used	O
two	O
-	O
step	O
gene	O
replacement	O
(	O
18	O
)	O
to	O
substitute	O
the	O
modified	O
allele	O
into	O
the	O
SCP160	O
locus	O
of	O
haploid	O
yeast	S-Species
,	O
and	O
then	O
tested	O
the	O
morphological	O
phenotype	O
of	O
the	O
resultant	O
cells	O
.	O

All	O
strains	O
were	O
confirmed	O
by	O
PCR	O
analysis	O
of	O
the	O
SCP160	O
locus	O
with	O
appropriate	O
primers	O
(	O
Materials	O
and	O
Methods	O
)	O
,	O
and	O
expression	O
of	O
the	O
tagged	O
protein	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
with	O
the	O
appropriate	O
antibody	O
(	O
M2	O
alpha	O
FLAG	O
)	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

In	O
all	O
cases	O
,	O
yeast	S-Species
expressing	O
tagged	O
Scp160p	O
in	O
place	O
of	O
the	O
native	O
protein	O
appeared	O
indistinguishable	O
from	O
the	O
corresponding	O
wild	O
-	O
type	O
strains	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
also	O
deleted	O
almost	O
the	O
entire	O
SCP160	O
coding	O
region	O
from	O
the	O
genomes	O
of	O
these	O
yeast	S-Species
strains	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
and	O
confirmed	O
the	O
expected	O
mutant	O
phenotype	O
(	O
data	O
not	O
shown	O
)	O
.	O

Scp160p	O
associates	O
with	O
polyribosomes	O

To	O
test	O
the	O
hypothesis	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
we	O
used	O
sucrose	O
gradient	O
ultracentrifugation	O
to	O
size	O
-	O
fractionate	O
subcellular	O
components	O
of	O
lysates	O
prepared	O
from	O
yeast	S-Species
expressing	O
the	O
N	O
-	O
terminal	O
FLAG	O
-	O
tagged	O
Scp160p	O
protein	O
.	O

Western	O
blot	O
analyses	O
of	O
gradient	O
fractions	O
with	O
an	O
alpha	O
-	O
FLAG	O
antibody	O
(	O
M2	O
,	O
Boehringer	O
Mannheim	O
)	O
,	O
revealed	O
a	O
160	O
kDa	O
band	O
that	O
was	O
most	O
abundant	O
in	O
the	O
denser	O
fractions	O
,	O
consistent	O
with	O
the	O
location	O
of	O
polyribosomes	O
(	O
>	O
80S	O
)	O
(	O
Fig	O
.	O
2A	O
,	O
solid	O
arrow	O
)	O
.	O

A	O
convenient	O
internal	O
control	O
for	O
these	O
gradients	O
was	O
provided	O
by	O
an	O
unknown	O
endogenous	O
yeast	S-Species
cross	O
-	O
reacting	O
protein	O
at	O
~	O
100	O
kDa	O
,	O
that	O
exemplified	O
the	O
migration	O
pattern	O
of	O
a	O
free	O
protein	O
,	O
appearing	O
only	O
in	O
the	O
upper	O
fractions	O
of	O
the	O
gradient	O
(	O
Fig	O
.	O
2A	O
,	O
open	O
arrow	O
)	O
.	O

To	O
determine	O
whether	O
the	O
migration	O
pattern	O
of	O
Scp160p	O
in	O
these	O
sucrose	O
gradients	O
truly	O
reflected	O
association	O
with	O
yeast	S-Species
polyribosomes	O
,	O
lysates	O
were	O
pre	O
-	O
treated	O
with	O
either	O
30	O
mM	O
EDTA	O
or	O
50	O
U	O
/	O
ml	O
RNase	O
One	O
(	O
Promega	O
)	O
immediately	O
prior	O
to	O
sucrose	O
gradient	O
fractionation	O
.	O

EDTA	O
chelates	O
Mg2	O
+	O
cations	O
,	O
resulting	O
in	O
the	O
dissociation	O
of	O
the	O
small	O
and	O
large	O
ribosomal	O
subunits	O
,	O
reflected	O
in	O
gradient	O
profiles	O
(	O
OD254	O
)	O
by	O
the	O
disappearance	O
of	O
80S	O
monosomes	O
and	O
polyribosomes	O
along	O
with	O
a	O
marked	O
increase	O
in	O
the	O
abundance	O
of	O
free	O
ribosomal	O
subunits	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
greatest	O
intensity	O
of	O
FLAG	O
-	O
Scp160p	O
signal	O
was	O
seen	O
only	O
in	O
the	O
upper	O
-	O
most	O
fractions	O
of	O
the	O
gradient	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Alternatively	O
,	O
pre	O
-	O
treatment	O
of	O
lysates	O
with	O
RNase	O
,	O
which	O
results	O
in	O
inter	O
-	O
ribosomal	O
severing	O
of	O
translating	O
messages	O
,	O
gave	O
rise	O
to	O
a	O
large	O
pool	O
of	O
single	O
80S	O
ribosomes	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

Again	O
,	O
FLAG	O
-	O
Scp160p	O
was	O
shifted	O
to	O
the	O
uppermost	O
fractions	O
of	O
these	O
gradients	O
.	O

Although	O
some	O
of	O
the	O
Scp160p	O
signal	O
was	O
detected	O
in	O
fractions	O
larger	O
than	O
40S	O
,	O
the	O
migration	O
pattern	O
of	O
the	O
100	O
kDa	O
cross	O
-	O
reacting	O
protein	O
in	O
these	O
experiments	O
indicated	O
that	O
RNase	O
treatment	O
caused	O
an	O
apparent	O
diffusion	O
of	O
material	O
in	O
the	O
upper	O
portion	O
of	O
the	O
gradient	O
.	O

Characterization	O
of	O
Scp160p	O
-	O
containing	O
complexes	O
following	O
EDTA	O
and	O
RNase	O
treatment	O

Gel	O
-	O
filtration	O
chromatography	O
was	O
used	O
to	O
determine	O
the	O
apparent	O
molecular	O
weight	O
of	O
Scp160p	O
following	O
its	O
release	O
from	O
polyribosomes	O
by	O
both	O
EDTA	O
and	O
RNase	O
treatment	O
.	O

Lysates	O
were	O
prepared	O
as	O
described	O
above	O
for	O
sucrose	O
gradient	O
analysis	O
,	O
but	O
were	O
instead	O
size	O
fractionated	O
over	O
a	O
Sephacryl	O
S	O
-	O
300	O
Hi	O
-	O
Prep	O
column	O
,	O
with	O
an	O
inclusion	O
cut	O
-	O
off	O
of	O
1300	O
kDa	O
.	O

As	O
expected	O
,	O
Scp160p	O
from	O
untreated	O
lysates	O
eluted	O
in	O
the	O
void	O
volume	O
,	O
confirming	O
its	O
association	O
with	O
large	O
complexes	O
,	O
ostensibly	O
polyribosomes	O
(	O
Fig	O
.	O
3A	O
,	O
solid	O
arrow	O
)	O
.	O

In	O
EDTA	O
treated	O
lysates	O
,	O
all	O
Scp160p	O
signal	O
was	O
still	O
detected	O
in	O
the	O
void	O
volume	O
,	O
indicating	O
it	O
remained	O
in	O
a	O
complex	O
of	O
>	O
1300	O
kDa	O
(	O
Fig	O
.	O
3B	O
,	O
solid	O
arrow	O
)	O
.	O

In	O
contrast	O
,	O
limited	O
RNase	O
treatment	O
(	O
10	O
min	O
)	O
resulted	O
in	O
the	O
appearance	O
of	O
an	O
Scp160p	O
-	O
containing	O
species	O
of	O
~	O
450	O
kDa	O
,	O
in	O
addition	O
to	O
a	O
fraction	O
still	O
visible	O
in	O
the	O
void	O
(	O
Fig	O
.	O
3C	O
,	O
solid	O
arrow	O
)	O
.	O

More	O
extensive	O
RNase	O
treatment	O
(	O
30	O
min	O
)	O
led	O
to	O
complete	O
conversion	O
to	O
the	O
450	O
kDa	O
species	O
(	O
Fig	O
.	O
3D	O
,	O
solid	O
arrow	O
)	O
.	O

Sequential	O
treatment	O
,	O
first	O
with	O
RNase	O
,	O
then	O
with	O
EDTA	O
,	O
also	O
resulted	O
in	O
a	O
450	O
kDa	O
species	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
all	O
components	O
of	O
this	O
apparent	O
450	O
kDa	O
complex	O
were	O
also	O
present	O
following	O
EDTA	O
treatment	O
alone	O
.	O

As	O
before	O
,	O
the	O
100	O
kDa	O
,	O
endogenous	O
alpha	O
-	O
FLAG	O
cross	O
-	O
reacting	O
protein	O
(	O
Fig	O
.	O
3	O
,	O
open	O
arrows	O
)	O
served	O
as	O
a	O
convenient	O
internal	O
control	O
,	O
eluting	O
from	O
the	O
column	O
at	O
a	O
volume	O
consistent	O
with	O
its	O
expected	O
monomeric	O
size	O
.	O

To	O
characterize	O
further	O
the	O
stability	O
of	O
the	O
large	O
(	O
apparent	O
molecular	O
weight	O
>	O
1300	O
kDa	O
)	O
,	O
EDTA	O
-	O
resistant	O
complex	O
,	O
lysates	O
were	O
treated	O
with	O
increasing	O
concentrations	O
of	O
NaCl	O
prior	O
to	O
size	O
fractionation	O
(	O
Fig	O
.	O
3	O
,	O
panels	O
E	O
,	O
F	O
and	O
G	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3E	O
,	O
at	O
75	O
mM	O
NaCl	O
,	O
the	O
large	O
complex	O
remained	O
intact	O
.	O

However	O
,	O
at	O
a	O
NaCl	O
concentration	O
of	O
150	O
mM	O
,	O
the	O
Scp160p	O
complex	O
was	O
partially	O
reduced	O
to	O
450	O
kDa	O
,	O
with	O
some	O
signal	O
still	O
remaining	O
in	O
the	O
void	O
(	O
Fig	O
.	O
3F	O
,	O
solid	O
arrow	O
)	O
.	O

Following	O
treatment	O
with	O
1	O
M	O
NaCl	O
,	O
Scp160p	O
was	O
only	O
visible	O
as	O
the	O
450	O
kDa	O
species	O
(	O
Fig	O
.	O
3G	O
,	O
solid	O
arrow	O
)	O
.	O

The	O
fact	O
that	O
RNase	O
treatment	O
and	O
high	O
salt	O
both	O
generated	O
Scp160p	O
species	O
of	O
similar	O
apparent	O
molecular	O
weight	O
suggests	O
that	O
these	O
high	O
salt	O
concentrations	O
resulted	O
in	O
the	O
disassociation	O
of	O
RNA	O
,	O
and	O
perhaps	O
other	O
components	O
,	O
from	O
Scp160p	O
.	O

Pab1p	O
and	O
Bfr1p	O
are	O
present	O
in	O
EDTA	O
-	O
resistant	O
Scp160p	O
-	O
containing	O
complexes	O

To	O
determine	O
if	O
the	O
>	O
1300	O
kDa	O
Scp160p	O
-	O
containing	O
complexes	O
remaining	O
after	O
EDTA	O
treatment	O
were	O
mRNPs	O
,	O
we	O
assayed	O
for	O
the	O
presence	O
of	O
the	O
yeast	S-Species
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
following	O
alpha	O
-	O
FLAG	O
affinity	O
purification	O
as	O
illustrated	O
in	O
Figure	O
4	O
.	O

Pab1p	O
is	O
an	O
abundant	O
and	O
well	O
-	O
characterized	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	S-Species
,	O
as	O
well	O
as	O
higher	O
eukaryotes	O
(	O
14	O
,	O
15	O
,	O
25	O
)	O
.	O

As	O
seen	O
in	O
Figure	O
5A	O
and	O
B	O
,	O
Pab1p	O
did	O
co	O
-	O
purify	O
with	O
FLAG	O
-	O
Scp160p	O
;	O
moreover	O
,	O
treatment	O
with	O
RNase	O
immediately	O
prior	O
to	O
FLAG	O
-	O
purification	O
completely	O
abolished	O
this	O
interaction	O
(	O
Fig	O
.	O
5C	O
)	O
,	O
indicating	O
an	O
RNA	O
-	O
dependant	O
association	O
between	O
these	O
two	O
proteins	O
.	O

We	O
also	O
probed	O
the	O
isolated	O
complexes	O
for	O
the	O
presence	O
of	O
another	O
abundant	O
mRNP	O
-	O
component	O
protein	O
,	O
Pub1p	O
(	O
23	O
,	O
26	O
)	O
.	O

Pub1p	O
,	O
as	O
opposed	O
to	O
Pab1p	O
,	O
is	O
not	O
reported	O
to	O
associate	O
with	O
polyribosomes	O
,	O
and	O
is	O
hypothesized	O
to	O
bind	O
a	O
pool	O
of	O
non	O
-	O
translatable	O
mRNAs	O
(	O
23	O
)	O
.	O

As	O
predicted	O
,	O
Pub1p	O
did	O
not	O
co	O
-	O
purify	O
with	O
Scp160p	O
(	O
Fig	O
.	O
5D	O
)	O
.	O

The	O
absence	O
of	O
Pub1p	O
in	O
Scp160p	O
-	O
containing	O
complexes	O
served	O
as	O
a	O
negative	O
control	O
,	O
demonstrating	O
that	O
abundant	O
RNA	O
-	O
binding	O
proteins	O
did	O
not	O
co	O
-	O
purify	O
non	O
-	O
specifically	O
by	O
this	O
protocol	O
.	O

In	O
addition	O
,	O
we	O
performed	O
mock	O
purifications	O
using	O
lysates	O
from	O
yeast	S-Species
expressing	O
the	O
wild	O
-	O
type	O
allele	O
of	O
SCP160	O
without	O
the	O
FLAG	O
epitope	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
or	O
with	O
an	O
unrelated	O
FLAG	O
-	O
tagged	O
protein	O
,	O
human	S-Species
galactose	O
1	O
-	O
phosphate	O
uridylyltransferase	O
(	O
GALT	O
)	O
(	O
Fig	O
.	O
5G	O
,	O
lower	O
panel	O
)	O
.	O

In	O
neither	O
case	O
did	O
Pab1p	O
bind	O
and	O
elute	O
from	O
the	O
FLAG	O
affinity	O
column	O
.	O

Finally	O
,	O
no	O
bands	O
were	O
visible	O
by	O
colloidal	O
G250	O
Coomassie	O
staining	O
of	O
samples	O
from	O
the	O
mock	O
(	O
wild	O
-	O
type	O
)	O
preparations	O
(	O
Fig	O
.	O
5E	O
)	O
,	O
further	O
demonstrating	O
the	O
specificity	O
of	O
this	O
procedure	O
.	O

By	O
colloidal	O
G250	O
Coomassie	O
staining	O
(	O
Materials	O
and	O
Methods	O
)	O
of	O
the	O
FLAG	O
-	O
purified	O
complex	O
,	O
we	O
observed	O
in	O
addition	O
to	O
Scp160p	O
,	O
two	O
major	O
bands	O
,	O
at	O
~	O
70	O
kDa	O
and	O
~	O
55	O
kDa	O
,	O
which	O
ostensibly	O
represent	O
co	O
-	O
purifying	O
proteins	O
(	O
Fig	O
.	O
5A	O
,	O
bottom	O
panel	O
)	O
.	O

Western	O
blot	O
analysis	O
suggested	O
that	O
the	O
~	O
70	O
kDa	O
species	O
is	O
Pab1p	O
.	O

To	O
identify	O
the	O
55	O
kDa	O
protein	O
,	O
that	O
band	O
was	O
excised	O
from	O
the	O
gel	O
,	O
and	O
sent	O
to	O
the	O
Keck	O
microchemical	O
facility	O
at	O
Yale	O
University	O
for	O
analysis	O
by	O
in	O
gel	O
tryptic	O
digestion	O
,	O
followed	O
by	O
MALDI	O
-	O
mass	O
spectrometry	O
.	O

The	O
results	O
of	O
these	O
analyses	O
clearly	O
identified	O
the	O
unknown	O
protein	O
as	O
Bfr1p	O
.	O

To	O
confirm	O
this	O
result	O
,	O
an	O
N	O
-	O
terminal	O
HA	O
tag	O
was	O
engineered	O
onto	O
the	O
genomic	O
BFR1	O
locus	O
in	O
strains	O
expressing	O
FLAG	O
-	O
tagged	O
or	O
wild	O
-	O
type	O
Scp160p	O
.	O

Scp160p	O
complexes	O
were	O
then	O
isolated	O
from	O
both	O
of	O
these	O
strains	O
using	O
the	O
protocol	O
described	O
above	O
.	O

As	O
seen	O
in	O
Figure	O
6	O
,	O
an	O
HA	O
-	O
tagged	O
protein	O
of	O
~	O
55	O
kDa	O
(	O
center	O
panel	O
)	O
appears	O
in	O
alpha	O
-	O
FLAG	O
column	O
elutions	O
only	O
when	O
FLAG	O
-	O
Scp160p	O
is	O
also	O
present	O
(	O
top	O
panel	O
)	O
.	O

No	O
signal	O
is	O
visible	O
in	O
mock	O
purifications	O
of	O
extracts	O
where	O
Scp160p	O
is	O
not	O
FLAG	O
-	O
tagged	O
(	O
bottom	O
panel	O
)	O
.	O

Monomeric	O
Scp160p	O
migrates	O
as	O
a	O
~	O
450	O
kDa	O
protein	O
under	O
native	O
conditions	O

As	O
a	O
first	O
step	O
to	O
characterize	O
the	O
post	O
RNase	O
/	O
NaCl	O
450	O
kDa	O
Scp160p	O
species	O
we	O
compared	O
it	O
with	O
Scp160p	O
over	O
-	O
expressed	O
and	O
purified	O
from	O
an	O
exogenous	O
host	O
,	O
the	O
yeast	S-Species
Pichia	B-Species
pastoris	E-Species
.	O

The	O
purified	O
N	O
-	O
terminal	O
FLAG	O
/	O
hexahistidine	O
-	O
tagged	O
Scp160p	O
was	O
run	O
over	O
an	O
S300	O
gel	O
filtration	O
column	O
;	O
2	O
ml	O
fractions	O
were	O
collected	O
and	O
analyzed	O
by	O
alpha	O
-	O
FLAG	O
western	O
blot	O
.	O

As	O
seen	O
in	O
Figure	O
7A	O
,	O
purified	O
Scp160p	O
eluted	O
at	O
a	O
volume	O
consistent	O
with	O
a	O
>	O
443	O
kDa	O
protein	O
.	O

To	O
confirm	O
that	O
no	O
other	O
proteins	O
were	O
associated	O
with	O
the	O
purified	O
Scp160p	O
,	O
12	O
micro	O
l	O
of	O
the	O
protein	O
was	O
run	O
on	O
SDS	O
-	O
PAGE	O
and	O
subjected	O
to	O
colloidal	O
G250	O
Coomassie	O
staining	O
before	O
loading	O
on	O
the	O
S	O
-	O
300	O
column	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

As	O
shown	O
,	O
no	O
bands	O
other	O
than	O
Scp160p	O
were	O
visible	O
.	O

Several	O
KH	O
-	O
domain	O
proteins	O
,	O
including	O
Sam68	O
and	O
FMRP	O
,	O
have	O
been	O
reported	O
to	O
form	O
homodimers	O
in	O
vivo	O
(	O
27	O
)	O
.	O

Therefore	O
,	O
we	O
explored	O
the	O
possibility	O
that	O
the	O
~	O
450	O
kDa	O
Scp160p	O
species	O
might	O
contain	O
two	O
or	O
more	O
copies	O
of	O
Scp160p	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
yeast	S-Species
expressing	O
FLAG	O
-	O
Scp160p	O
were	O
transfected	O
with	O
a	O
centromeric	O
plasmid	O
,	O
YCplac22	O
-	O
HA	O
-	O
Scp160p	O
,	O
encoding	O
a	O
distinct	O
,	O
HA	O
-	O
tagged	O
allele	O
of	O
the	O
protein	O
.	O

The	O
functionality	O
of	O
this	O
tagged	O
protein	O
had	O
previously	O
been	O
demonstrated	O
by	O
polyribosome	O
association	O
as	O
well	O
as	O
complementation	O
of	O
the	O
null	O
morphological	O
phenotype	O
in	O
cells	O
expressing	O
only	O
HA	O
-	O
Scp160p	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
seen	O
in	O
Figure	O
7C	O
,	O
when	O
yeast	S-Species
co	O
-	O
expressing	O
the	O
two	O
alleles	O
were	O
lysed	O
and	O
the	O
FLAG	O
-	O
tagged	O
protein	O
was	O
isolated	O
as	O
described	O
above	O
,	O
no	O
HA	O
-	O
Scp160p	O
co	O
-	O
purified	O
with	O
the	O
FLAG	O
-	O
Scp160p	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
Scp160p	O
does	O
not	O
form	O
homo	O
-	O
dimers	O
or	O
higher	O
-	O
order	O
multimers	O
in	O
vivo	O
,	O
and	O
that	O
the	O
~	O
450	O
kDa	O
species	O
of	O
Scp160p	O
observed	O
is	O
simply	O
the	O
monomeric	O
protein	O
.	O

DISCUSSION	O

The	O
data	O
presented	O
here	O
demonstrate	O
two	O
main	O
points	O
regarding	O
the	O
biochemical	O
associations	O
and	O
function	O
of	O
Scp160p	O
in	O
yeast	S-Species
.	O

First	O
,	O
the	O
sucrose	O
gradient	O
fractionation	O
data	O
clearly	O
demonstrate	O
that	O
Scp160p	O
exists	O
primarily	O
associated	O
with	O
large	O
complexes	O
,	O
likely	O
to	O
be	O
polyribosomes	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
a	O
vigilin	O
family	O
member	O
has	O
been	O
shown	O
to	O
associate	O
with	O
polyribosomes	O
in	O
this	O
manner	O
.	O

Interestingly	O
,	O
Weber	O
and	O
colleagues	O
did	O
not	O
observe	O
sucrose	O
gradient	O
fractionation	O
data	O
consistent	O
with	O
polyribosome	O
association	O
of	O
Scp160p	O
(	O
5	O
)	O
.	O

These	O
authors	O
hypothesized	O
that	O
Scp160p	O
associates	O
only	O
with	O
membrane	O
-	O
bound	O
polyribosomes	O
,	O
and	O
that	O
Scp160p	O
is	O
not	O
found	O
complexed	O
with	O
cytosolic	O
polyribosomes	O
(	O
5	O
)	O
.	O

Our	O
data	O
do	O
not	O
support	O
this	O
hypothesis	O
,	O
since	O
unlike	O
Weber	O
and	O
colleagues	O
,	O
we	O
were	O
able	O
to	O
detect	O
significant	O
amounts	O
of	O
Scp160p	O
associated	O
with	O
polyribosomes	O
without	O
using	O
detergents	O
during	O
preparation	O
.	O

There	O
are	O
several	O
possible	O
explanations	O
for	O
this	O
discrepancy	O
.	O

First	O
,	O
the	O
lysate	O
buffer	O
utilized	O
by	O
that	O
group	O
contained	O
100	O
mM	O
NaCl	O
,	O
whereas	O
our	O
buffer	O
contained	O
50	O
mM	O
KCl	O
.	O

Our	O
data	O
shown	O
in	O
Figure	O
3	O
suggest	O
that	O
100	O
mM	O
NaCl	O
may	O
have	O
caused	O
an	O
instability	O
in	O
the	O
Scp160p	O
-	O
RNA	O
interaction	O
,	O
leading	O
to	O
release	O
from	O
polyribosomes	O
during	O
their	O
procedure	O
.	O

Secondly	O
,	O
Weber	O
'	O
s	O
lysate	O
buffer	O
reportedly	O
contained	O
heparin	O
to	O
inhibit	O
ribonucleases	O
;	O
a	O
number	O
of	O
reports	O
(	O
28	O
,	O
29	O
)	O
suggest	O
that	O
heparin	O
can	O
disrupt	O
RNA	O
-	O
protein	O
interactions	O
.	O

Although	O
we	O
have	O
not	O
in	O
the	O
past	O
included	O
heparin	O
in	O
any	O
of	O
our	O
experiments	O
,	O
we	O
have	O
observed	O
disruption	O
of	O
the	O
polyribosome	O
association	O
in	O
buffer	O
containing	O
residual	O
diethylpyrocarbonate	O
,	O
another	O
inhibitor	O
of	O
ribonucleases	O
(	O
data	O
not	O
shown	O
)	O
.	O

Second	O
,	O
our	O
data	O
provide	O
compelling	O
evidence	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
as	O
a	O
component	O
of	O
an	O
mRNP	O
complex	O
.	O

Since	O
Scp160p	O
does	O
not	O
remain	O
associated	O
with	O
either	O
single	O
ribosomes	O
or	O
ribosomal	O
subunits	O
following	O
treatment	O
with	O
EDTA	O
or	O
RNase	O
,	O
it	O
seems	O
unlikely	O
that	O
Scp160p	O
is	O
a	O
constitutive	O
component	O
of	O
the	O
translational	O
machinery	O
.	O

Partial	O
purification	O
of	O
the	O
EDTA	O
-	O
resistant	O
Scp160p	O
complexes	O
allowed	O
us	O
to	O
demonstrate	O
the	O
presence	O
of	O
Pab1p	O
but	O
not	O
Pub1p	O
in	O
these	O
preparations	O
,	O
which	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
as	O
a	O
component	O
of	O
mRNP	O
complexes	O
.	O

Previously	O
,	O
Scp160p	O
had	O
been	O
shown	O
to	O
bind	O
ribohomopolymers	O
and	O
rRNA	O
in	O
vitro	O
,	O
although	O
the	O
in	O
vivo	O
nucleic	O
acid	O
targets	O
of	O
Scp160p	O
were	O
unknown	O
(	O
5	O
)	O
.	O

The	O
presence	O
of	O
Pab1p	O
in	O
RNase	O
-	O
sensitive	O
Scp160p	O
complexes	O
indicates	O
that	O
Scp160p	O
is	O
primarily	O
bound	O
to	O
polyadenylated	O
RNAs	O
.	O

Whether	O
or	O
not	O
Scp160p	O
binds	O
only	O
specific	O
sets	O
of	O
mRNAs	O
will	O
be	O
the	O
subject	O
of	O
future	O
studies	O
.	O

In	O
addition	O
to	O
Scp160p	O
and	O
Pab1p	O
,	O
we	O
have	O
identified	O
a	O
third	O
component	O
of	O
the	O
complex	O
,	O
the	O
protein	O
Bfr1p	O
.	O

The	O
gene	O
,	O
BFR1	O
,	O
was	O
originally	O
identified	O
in	O
a	O
screen	O
for	O
high	O
-	O
copy	O
suppressors	O
of	O
Brefeldin	O
-	O
A	O
induced	O
lethality	O
,	O
suggesting	O
a	O
role	O
in	O
the	O
secretory	O
pathway	O
(	O
16	O
)	O
.	O

Interestingly	O
,	O
however	O
,	O
bfr1	O
null	O
mutants	O
do	O
not	O
demonstrate	O
any	O
defects	O
in	O
the	O
secretory	O
pathway	O
,	O
but	O
rather	O
display	O
similar	O
phenotypes	O
to	O
scp160	O
null	O
mutants	O
,	O
most	O
notably	O
increased	O
ploidy	O
and	O
increased	O
cell	O
size	O
(	O
16	O
)	O
.	O

It	O
is	O
therefore	O
unclear	O
whether	O
Bfr1p	O
is	O
capable	O
of	O
functioning	O
in	O
both	O
RNA	O
metabolism	O
and	O
secretion	O
directly	O
,	O
or	O
if	O
the	O
Scp160p	O
-	O
Bfr1p	O
complex	O
regulates	O
the	O
expression	O
of	O
one	O
or	O
more	O
secretory	O
genes	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

Additionally	O
,	O
two	O
-	O
hybrid	O
analysis	O
indicated	O
an	O
interaction	O
of	O
Bfr1p	O
with	O
the	O
protein	O
Bbp1p	O
,	O
a	O
component	O
of	O
the	O
mitotic	O
spindle	O
apparatus	O
(	O
30	O
)	O
.	O

While	O
Bbp1p	O
is	O
an	O
essential	O
gene	O
,	O
overexpression	O
leads	O
to	O
a	O
phenotype	O
similar	O
to	O
both	O
bfr1	O
and	O
scp160	O
null	O
strains	O
(	O
30	O
)	O
.	O

Future	O
work	O
will	O
address	O
the	O
functional	O
relationship	O
between	O
Scp160p	O
and	O
Bfr1p	O
including	O
the	O
possibility	O
that	O
these	O
proteins	O
represent	O
a	O
regulatory	O
mechanism	O
connecting	O
the	O
translational	O
machinery	O
with	O
cell	O
division	O
and	O
/	O
or	O
the	O
secretory	O
pathway	O
.	O

Following	O
treatment	O
with	O
either	O
RNase	O
or	O
>	O
150	O
mM	O
NaCl	O
,	O
Scp160p	O
remained	O
as	O
an	O
apparent	O
~	O
450	O
kDa	O
species	O
.	O

Considering	O
that	O
purified	O
Scp160p	O
alone	O
also	O
migrates	O
at	O
this	O
size	O
,	O
we	O
conclude	O
that	O
this	O
apparent	O
complex	O
may	O
consist	O
only	O
of	O
Scp160p	O
,	O
although	O
the	O
presence	O
of	O
other	O
small	O
components	O
cannot	O
be	O
ruled	O
out	O
at	O
this	O
time	O
.	O

Furthermore	O
,	O
by	O
utilizing	O
yeast	S-Species
co	O
-	O
expressing	O
two	O
distinct	O
epitope	O
-	O
tagged	O
versions	O
of	O
Scp160p	O
,	O
we	O
have	O
ruled	O
out	O
the	O
possibility	O
of	O
self	O
-	O
association	O
of	O
Scp160p	O
.	O

Although	O
both	O
tagged	O
proteins	O
appear	O
functional	O
,	O
it	O
remains	O
a	O
formal	O
possibility	O
that	O
the	O
tags	O
somehow	O
prevented	O
formation	O
of	O
FLAG	O
-	O
HA	O
hetero	O
-	O
complexes	O
.	O

Nonetheless	O
,	O
it	O
seems	O
most	O
likely	O
that	O
native	O
Scp160p	O
monomers	O
may	O
simply	O
migrate	O
aberrantly	O
under	O
native	O
conditions	O
due	O
to	O
an	O
unusual	O
shape	O
or	O
some	O
other	O
physical	O
property	O
.	O

In	O
conclusion	O
we	O
have	O
shown	O
convincing	O
evidence	O
that	O
Scp160p	O
exists	O
in	O
yeast	S-Species
cytoplasmic	O
extracts	O
primarily	O
associated	O
with	O
polyribosomes	O
.	O

We	O
have	O
purified	O
Scp160p	O
following	O
disruption	O
of	O
polyribosomes	O
with	O
EDTA	O
,	O
and	O
identified	O
two	O
associated	O
proteins	O
:	O
Pab1p	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
suggests	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
as	O
a	O
component	O
of	O
an	O
mRNP	O
,	O
demonstrating	O
Scp160p	O
to	O
be	O
the	O
first	O
S	B-Species
.	I-Species
cerevisiae	E-Species
multiple	O
-	O
KH	O
domain	O
protein	O
characterized	O
to	O
function	O
in	O
this	O
way	O
.	O

HP1	O
modulates	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
in	O
Drosophila	B-Species
melanogaster	E-Species

Abstract	O

Heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
was	O
originally	O
described	O
as	O
a	O
non	O
-	O
histone	O
chromosomal	O
protein	O
and	O
is	O
required	O
for	O
transcriptional	O
gene	O
silencing	O
and	O
the	O
formation	O
of	O
heterochromatin	O
.	O

Although	O
it	O
is	O
localized	O
primarily	O
at	O
pericentric	O
heterochromatin	O
,	O
a	O
scattered	O
distribution	O
over	O
a	O
large	O
number	O
of	O
euchromatic	O
loci	O
is	O
also	O
evident	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
Drosophila	S-Species
HP1	O
is	O
essential	O
for	O
the	O
maintenance	O
of	O
active	O
transcription	O
of	O
euchromatic	O
genes	O
functionally	O
involved	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
including	O
those	O
required	O
for	O
DNA	O
replication	O
and	O
mitosis	O
.	O

Depletion	O
of	O
HP1	O
in	O
proliferating	O
embryonic	O
cells	O
caused	O
aberrant	O
progression	O
of	O
the	O
cell	O
cycle	O
at	O
S	O
phase	O
and	O
G2	O
/	O
M	O
phase	O
,	O
linked	O
to	O
aberrant	O
chromosome	O
segregation	O
,	O
cytokinesis	O
,	O
and	O
an	O
increase	O
in	O
apoptosis	O
.	O

The	O
chromosomal	O
distribution	O
of	O
Aurora	O
B	O
,	O
and	O
the	O
level	O
of	O
phosphorylation	O
of	O
histone	O
H3	O
serine	O
10	O
were	O
also	O
altered	O
in	O
the	O
absence	O
of	O
HP1	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
analysis	O
,	O
we	O
further	O
demonstrate	O
that	O
the	O
promoters	O
of	O
a	O
number	O
of	O
cell	O
-	O
cycle	O
regulator	O
genes	O
are	O
bound	O
to	O
HP1	O
,	O
supporting	O
a	O
direct	O
role	O
for	O
HP1	O
in	O
their	O
active	O
transcription	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
HP1	O
is	O
essential	O
for	O
the	O
maintenance	O
of	O
cell	O
-	O
cycle	O
progression	O
and	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulatory	O
genes	O
.	O

The	O
results	O
also	O
support	O
the	O
view	O
that	O
HP1	O
is	O
a	O
positive	O
regulator	O
of	O
transcription	O
in	O
euchromatin	O
.	O

INTRODUCTION	O

Chromatin	O
in	O
higher	O
eukaryotes	O
is	O
subdivided	O
into	O
different	O
functional	O
compartments	O
termed	O
heterochromatin	O
and	O
euchromatin	O
(	O
1	O
)	O
.	O

Heterochromatin	O
differs	O
from	O
euchromatin	O
in	O
its	O
DNA	O
composition	O
,	O
replication	O
timing	O
,	O
condensation	O
throughout	O
the	O
cell	O
cycle	O
,	O
and	O
its	O
ability	O
to	O
silence	O
euchromatic	O
genes	O
placed	O
adjacent	O
to	O
or	O
within	O
its	O
territory	O
,	O
often	O
described	O
as	O
position	O
-	O
effect	O
-	O
variegation	O
(	O
PEV	O
)	O
(	O
2	O
)	O
.	O

Heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
was	O
the	O
first	O
protein	O
identified	O
in	O
Drosophila	B-Species
melanogaster	E-Species
as	O
a	O
heterochromatin	O
-	O
associated	O
protein	O
(	O
3	O
)	O
;	O
the	O
corresponding	O
gene	O
has	O
been	O
cloned	O
from	O
a	O
number	O
of	O
organisms	O
and	O
is	O
highly	O
conserved	O
from	O
yeast	S-Species
to	O
human	S-Species
(	O
4	O
)	O
.	O

Polytene	O
chromosome	O
staining	O
showed	O
that	O
,	O
in	O
Drosophila	S-Species
,	O
HP1	O
is	O
distributed	O
mainly	O
in	O
pericentric	O
heterochromatin	O
,	O
telomeric	O
heterochromatin	O
,	O
the	O
banded	O
small	O
fourth	O
chromosome	O
(	O
5	O
-	O
8	O
)	O
,	O
as	O
well	O
as	O
~	O
200	O
individual	O
loci	O
scattered	O
throughout	O
the	O
euchromatic	O
chromosomal	O
arms	O
(	O
5	O
)	O
.	O

The	O
gene	O
encoding	O
HP1	O
in	O
D	B-Species
.	I-Species
melanogaster	E-Species
,	O
Su	O
(	O
var	O
)	O
2	O
-	O
5	O
,	O
was	O
isolated	O
as	O
a	O
suppressor	O
of	O
PEV	O
(	O
9	O
-	O
11	O
)	O
.	O

The	O
protein	O
contains	O
a	O
highly	O
conserved	O
motif	O
,	O
the	O
chromo	O
(	O
chromatin	O
organization	O
modifier	O
)	O
domain	O
,	O
similar	O
to	O
Polycomb	O
(	O
Pc	O
)	O
,	O
a	O
repressor	O
of	O
homeotic	O
genes	O
(	O
12	O
)	O
.	O

The	O
association	O
between	O
HP1	O
and	O
pericentric	O
heterochromatin	O
is	O
believed	O
to	O
occur	O
via	O
the	O
chromo	O
domain	O
of	O
HP1	O
and	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
histone	O
H3	O
methylated	O
at	O
lysine	O
9	O
(	O
13	O
,	O
14	O
)	O
,	O
generated	O
by	O
histone	O
methyltransferase	O
-	O
Su	O
(	O
var	O
)	O
3	O
-	O
9	O
,	O
a	O
partner	O
of	O
HP1	O
in	O
pericentric	O
heterochromatin	O
(	O
15	O
)	O
.	O

The	O
C	O
-	O
terminal	O
chromo	O
'	O
shadow	O
'	O
domain	O
of	O
HP1	O
interacts	O
with	O
other	O
silencing	O
complexes	O
to	O
suppress	O
local	O
transcriptional	O
activity	O
(	O
15	O
-	O
18	O
)	O
.	O

However	O
,	O
studies	O
of	O
HP1	O
chromosomal	O
distribution	O
also	O
showed	O
that	O
HP1	O
does	O
not	O
always	O
co	O
-	O
localize	O
with	O
lysine	O
9	O
methylated	O
histone	O
H3	O
or	O
Su	O
(	O
var	O
)	O
3	O
-	O
9	O
,	O
especially	O
in	O
euchromatic	O
regions	O
(	O
19	O
-	O
21	O
)	O
;	O
in	O
some	O
cases	O
,	O
HP1	O
is	O
found	O
directly	O
bound	O
to	O
DNA	O
(	O
22	O
,	O
23	O
)	O
.	O

All	O
these	O
features	O
argue	O
for	O
distinct	O
roles	O
for	O
HP1	O
in	O
chromatin	O
and	O
in	O
epigenetic	O
gene	O
regulation	O
.	O

HP1	O
is	O
believed	O
to	O
be	O
an	O
essential	O
structural	O
protein	O
protecting	O
the	O
integrity	O
of	O
chromosomes	O
during	O
cell	O
division	O
(	O
8	O
,	O
24	O
)	O
.	O

Swi6	O
,	O
the	O
homolog	O
of	O
HP1	O
in	O
fission	B-Species
yeast	E-Species
,	O
is	O
dispensable	O
for	O
survival	O
,	O
but	O
its	O
deletion	O
results	O
in	O
lagging	O
chromosomes	O
during	O
anaphase	O
,	O
and	O
a	O
high	O
rate	O
of	O
chromosome	O
loss	O
(	O
25	O
,	O
26	O
)	O
.	O

Mutations	O
of	O
HP1	O
in	O
D	B-Species
.	I-Species
melanogaster	E-Species
result	O
in	O
late	O
larval	O
lethality	O
,	O
chromosome	O
breakages	O
/	O
loss	O
,	O
telomere	O
fusion	O
and	O
a	O
high	O
frequency	O
of	O
cells	O
with	O
abnormal	O
anaphase	O
(	O
8	O
,	O
27	O
)	O
.	O

Null	O
alleles	O
of	O
the	O
HP1	O
functional	O
partner	O
in	O
mice	S-Species
(	O
SUVAR39	O
)	O
also	O
showed	O
various	O
chromosomal	O
defects	O
(	O
28	O
)	O
,	O
supporting	O
a	O
conserved	O
role	O
for	O
heterochromatin	O
proteins	O
in	O
the	O
regulation	O
of	O
chromosome	O
dynamics	O
during	O
cell	O
-	O
cycle	O
progression	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
remains	O
to	O
be	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
Drosophila	S-Species
embryonic	O
Kc	O
cells	O
and	O
an	O
RNA	O
interference	O
(	O
RNAi	O
)	O
-	O
based	O
approach	O
to	O
demonstrate	O
that	O
HP1	O
plays	O
an	O
important	O
role	O
at	O
S	O
phase	O
and	O
G2	O
/	O
M	O
phases	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
further	O
show	O
that	O
nearly	O
one	O
-	O
third	O
of	O
known	O
/	O
predicted	O
cell	O
-	O
cycle	O
regulators	O
require	O
HP1	O
to	O
maintain	O
their	O
active	O
transcription	O
.	O

These	O
genes	O
include	O
MCMs	O
,	O
Orc4	O
,	O
CDC45L	O
,	O
INCENP	O
,	O
Aurora	O
B	O
,	O
CAF1	O
,	O
Bub1	O
,	O
Bub3	O
and	O
a	O
few	O
other	O
cell	O
-	O
cycle	O
regulators	O
.	O

ChIP	O
analysis	O
suggests	O
that	O
HP1	O
plays	O
a	O
direct	O
role	O
in	O
their	O
transcription	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
this	O
study	O
provide	O
an	O
alternative	O
explanation	O
for	O
the	O
specific	O
role	O
of	O
HP1	O
in	O
the	O
regulation	O
of	O
chromatin	O
dynamics	O
and	O
in	O
cell	O
-	O
cycle	O
progression	O
.	O

MATERIALS	O
AND	O
METHODS	O

RNAi	O
in	O
Kc	O
cells	O

Drosophila	S-Species
Kc	O
cells	O
were	O
routinely	O
cultured	O
at	O
25	O
degrees	O
C	O
in	O
Schneider	O
Drosophila	S-Species
medium	O
(	O
GIBCO	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
160	O
mu	O
g	O
/	O
ml	O
penicillin	O
,	O
250	O
mu	O
g	O
/	O
ml	O
streptomycin	O
,	O
and	O
4	O
mM	O
l	O
-	O
glutamine	O
.	O

Double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
of	O
HP1	O
was	O
generated	O
by	O
incubation	O
of	O
single	O
-	O
stranded	O
RNA	O
in	O
annealing	O
buffer	O
(	O
100	O
mM	O
potassium	O
acetate	O
,	O
30	O
mM	O
HEPES	O
-	O
KOH	O
,	O
pH	O
7	O
.	O
4	O
,	O
2	O
mM	O
magnesium	O
acetate	O
)	O
for	O
3	O
min	O
at	O
95	O
degrees	O
C	O
and	O
then	O
placed	O
in	O
a	O
beaker	O
with	O
water	O
at	O
75	O
degrees	O
C	O
and	O
allowed	O
to	O
cool	O
slowly	O
to	O
room	O
temperature	O
.	O

The	O
detailed	O
procedure	O
of	O
RNAi	O
was	O
carried	O
out	O
according	O
to	O
the	O
established	O
protocols	O
(	O
)	O
.	O

Briefly	O
,	O
Kc	O
cells	O
were	O
seeded	O
in	O
a	O
six	O
-	O
well	O
dish	O
using	O
serum	O
-	O
free	O
medium	O
at	O
1	O
x	O
106	O
cells	O
/	O
ml	O
.	O

HP1	O
dsRNA	O
(	O
5	O
mu	O
g	O
/	O
ml	O
)	O
was	O
added	O
to	O
the	O
cultured	O
Kc	O
cells	O
.	O

After	O
60	O
min	O
at	O
room	O
temperature	O
,	O
2	O
ml	O
of	O
medium	O
containing	O
10	O
%	O
serum	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plates	O
transferred	O
to	O
25	O
degrees	O
C	O
for	O
up	O
to	O
8	O
days	O
.	O

Western	O
blotting	O
and	O
RT	O
-	O
PCR	O
were	O
carried	O
out	O
using	O
the	O
extract	O
/	O
total	O
RNA	O
isolated	O
from	O
control	O
and	O
dsRNA	O
-	O
treated	O
cells	O
on	O
days	O
2	O
,	O
6	O
and	O
8	O
.	O

Cell	O
-	O
cycle	O
and	O
apoptosis	O
analysis	O

The	O
procedure	O
for	O
flow	O
cytometric	O
analysis	O
of	O
Kc	O
cells	O
followed	O
that	O
in	O
the	O
manual	O
provided	O
with	O
the	O
BrdU	O
flow	O
kit	O
(	O
BD	O
PharMingen	O
)	O
.	O

The	O
cells	O
were	O
fed	O
with	O
BrdU	O
for	O
4	O
h	O
,	O
then	O
scraped	O
and	O
collected	O
.	O

Fluorescence	O
was	O
measured	O
using	O
a	O
FACSCalibur	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Data	O
collection	O
and	O
analysis	O
were	O
performed	O
using	O
CellQuest	O
software	O
.	O

Electrophoresis	O
and	O
immunoblotting	O

Cell	O
extracts	O
(	O
15	O
mu	O
g	O
)	O
were	O
fractionated	O
by	O
10	O
%	O
SDS	O
-	O
PAGE	O
,	O
then	O
transferred	O
to	O
Hybond	O
-	O
P	O
PVDF	O
membranes	O
(	O
Amersham	O
)	O
and	O
probed	O
with	O
primary	O
antibodies	O
(	O
CIA9	O
)	O
,	O
and	O
secondary	O
antibodies	O
(	O
anti	O
-	O
rabbit	S-Species
or	O
anti	O
-	O
mouse	S-Species
horseradish	S-Species
peroxidase	O
-	O
conjugated	O
IgG	O
)	O
,	O
obtained	O
from	O
Jackson	O
Immunoresearch	O
Laboratories	O
.	O

Enhanced	O
chemiluminescence	O
reagents	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
were	O
used	O
for	O
signal	O
detection	O
.	O

For	O
the	O
analysis	O
of	O
H3	O
ser10	O
phosphorylation	O
,	O
we	O
used	O
whole	O
-	O
cell	O
extracts	O
from	O
700	O
000	O
Kc	O
cells	O
(	O
control	O
and	O
RNAi	O
at	O
day	O
8	O
)	O
.	O

Western	O
blotting	O
was	O
performed	O
using	O
polyclonal	O
antibodies	O
against	O
ser10	O
-	O
phosphorylated	O
histone	O
H3	O
at	O
a	O
dilution	O
of	O
1	O
:	O
1000	O
(	O
Upstate	O
)	O
.	O

Kc	O
control	O
cells	O
arrested	O
in	O
mitosis	O
by	O
incubation	O
in	O
25	O
micro	O
M	O
colchicine	O
(	O
Sigma	O
)	O
for	O
24	O
h	O
were	O
also	O
analyzed	O
for	O
comparison	O
.	O

Immunofluorescence	O

Kc	O
cells	O
were	O
seeded	O
onto	O
polylysine	O
slides	O
,	O
fixed	O
with	O
4	O
%	O
formaldehyde	O
for	O
15	O
min	O
and	O
permeabilized	O
with	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
for	O
5	O
min	O
.	O

The	O
incubation	O
with	O
primary	O
antibodies	O
was	O
carried	O
out	O
in	O
blocking	O
solution	O
for	O
1	O
h	O
.	O

For	O
staining	O
of	O
mitotic	O
cells	O
,	O
the	O
cells	O
were	O
permeabilized	O
using	O
PBST	O
(	O
PBS	O
containing	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
)	O
and	O
stained	O
with	O
polyclonal	O
antibody	O
against	O
Drosophila	S-Species
Aurora	O
B	O
at	O
1	O
:	O
200	O
dilution	O
and	O
monoclonal	O
mouse	S-Species
at	O
anti	O
-	O
beta	O
-	O
tubulin	O
1	O
:	O
300	O
dilution	O
(	O
Chemicon	O
International	O
)	O
as	O
primary	O
antibodies	O
.	O

Secondary	O
antibodies	O
were	O
anti	O
-	O
rabbit	S-Species
coupled	O
with	O
Alexa	O
488	O
(	O
1	O
:	O
500	O
)	O
and	O
anti	O
-	O
mouse	S-Species
coupled	O
to	O
Alexa	O
546	O
(	O
1	O
:	O
500	O
)	O
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
Oregon	O
)	O
.	O

Images	O
were	O
acquired	O
using	O
a	O
confocal	O
LSM510	O
META	O
microscope	O
(	O
Zeiss	O
)	O
.	O

Stacks	O
of	O
images	O
were	O
analyzed	O
using	O
the	O
IMARIS	O
4	O
.	O
0	O
program	O
(	O
Media	O
cybernetics	O
,	O
Carlsbad	O
,	O
CA	O
)	O
.	O

Antibodies	O

Affinity	O
-	O
purified	O
polyclonal	O
antibodies	O
of	O
HP1	O
(	O
rabbit	S-Species
#	O
192	O
and	O
#	O
187	O
,	O
5	O
mu	O
g	O
)	O
and	O
5	O
mu	O
g	O
of	O
polyclonal	O
anti	O
-	O
HA	O
antibodies	O
(	O
Sigma	O
)	O
were	O
used	O
in	O
each	O
ChIP	O
reaction	O
.	O

The	O
specificity	O
of	O
the	O
HP1	O
polyclonal	O
antibodies	O
was	O
determined	O
using	O
various	O
approaches	O
,	O
including	O
western	O
blotting	O
assay	O
,	O
immunofluorescence	O
staining	O
and	O
immunoprecipitation	O
to	O
pull	O
down	O
HP1	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
monoclonal	O
antibody	O
HP1	O
-	O
CIA9	O
(	O
5	O
)	O
was	O
used	O
at	O
a	O
dilution	O
of	O
1	O
:	O
20	O
in	O
immunoblotting	O
assays	O
.	O

Microarray	O
analysis	O
and	O
RT	O
-	O
PCR	O

Total	O
RNA	O
was	O
isolated	O
from	O
control	O
and	O
HP1	O
-	O
depleted	O
Kc	O
cells	O
at	O
day	O
8	O
using	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
.	O

RNA	O
labeling	O
and	O
microarray	O
data	O
analysis	O
followed	O
the	O
standard	O
protocol	O
from	O
Affymetrix	O
.	O

We	O
used	O
ANOVA	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
to	O
assess	O
the	O
expression	O
confidence	O
for	O
each	O
gene	O
.	O

For	O
RT	O
-	O
PCR	O
analysis	O
,	O
poly	O
(	O
A	O
)	O
+	O
mRNA	O
was	O
purified	O
with	O
the	O
Oligotex	O
Direct	O
mRNA	O
kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
purified	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
the	O
Thermoscript	O
kit	O
(	O
Invitrogen	O
)	O
.	O

The	O
cDNA	O
was	O
then	O
used	O
for	O
PCR	O
amplification	O
for	O
35	O
cycles	O
with	O
gene	O
-	O
specific	O
primers	O
.	O

PCR	O
products	O
were	O
scanned	O
after	O
electrophoretic	O
separation	O
with	O
a	O
Typhoon	O
Scanner	O
,	O
quantified	O
using	O
ImageQuant	O
software	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
normalized	O
for	O
amplification	O
of	O
the	O
Actin5c	O
transcript	O
.	O

The	O
sequence	O
of	O
primers	O
used	O
for	O
RT	O
-	O
PCR	O
and	O
ChIP	O
analysis	O
are	O
provided	O
in	O
the	O
Supplementary	O
Material	O
.	O

ChIP	O

ChIP	O
was	O
performed	O
according	O
to	O
Orlando	O
et	O
al	O
.	O

(	O
29	O
)	O
and	O
the	O
protocol	O
provided	O
by	O
Upstate	O
(	O
)	O
with	O
some	O
modifications	O
.	O

In	O
brief	O
,	O
1	O
-	O
2	O
x	O
108	O
Kc	O
cells	O
were	O
prepared	O
and	O
fixed	O
in	O
1	O
%	O
formaldehyde	O
.	O

Nuclei	O
were	O
isolated	O
according	O
to	O
a	O
standard	O
procedure	O
in	O
Current	O
Protocols	O
(	O
)	O
,	O
then	O
resuspended	O
in	O
1	O
.	O
7	O
ml	O
of	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
,	O
pH	O
8	O
.	O
0	O
,	O
10	O
mM	O
EDTA	O
,	O
1	O
%	O
SDS	O
and	O
protease	O
inhibitors	O
)	O
and	O
sonicated	O
using	O
a	O
Branson	O
sonifier	O
250	O
.	O

Chromatin	O
fractions	O
in	O
the	O
size	O
range	O
0	O
.	O
2	O
-	O
0	O
.	O
8	O
kb	O
were	O
used	O
to	O
perform	O
immunoprecipitation	O
experiments	O
.	O

We	O
used	O
5	O
mu	O
g	O
affinity	O
-	O
purified	O
polyclonal	O
antibodies	O
(	O
#	O
192	O
and	O
#	O
182	O
for	O
HP1	O
;	O
HA	O
antibody	O
for	O
control	O
)	O
and	O
1	O
ml	O
of	O
salmon	O
sperm	O
DNA	O
/	O
protein	O
-	O
A	O
-	O
agarose	O
(	O
Upstate	O
)	O
pre	O
-	O
cleared	O
chromatin	O
lysate	O
in	O
each	O
reaction	O
.	O

The	O
mixture	O
was	O
then	O
rotated	O
at	O
4	O
degrees	O
C	O
overnight	O
and	O
the	O
recovered	O
beads	O
were	O
washed	O
twice	O
with	O
1	O
ml	O
of	O
Low	O
salt	O
buffer	O
(	O
Upstate	O
)	O
,	O
once	O
with	O
High	O
salt	O
buffer	O
(	O
Upstate	O
)	O
,	O
once	O
with	O
LiCl	O
buffer	O
(	O
Upstate	O
)	O
and	O
twice	O
with	O
TE	O
at	O
4	O
degrees	O
C	O
for	O
8	O
min	O
.	O

ChIP	O
DNA	O
was	O
extracted	O
according	O
to	O
the	O
standard	O
procedures	O
(	O
29	O
)	O
.	O

RESULTS	O

Depletion	O
of	O
HP1	O
in	O
Drosophila	S-Species
Kc	O
cells	O

Various	O
chromosomal	O
defects	O
in	O
the	O
cell	O
cycle	O
have	O
been	O
observed	O
in	O
embryos	O
or	O
larval	O
tissues	O
of	O
Drosophila	S-Species
HP1	O
mutants	O
(	O
8	O
,	O
27	O
)	O
.	O

However	O
,	O
the	O
presence	O
of	O
maternally	O
loaded	O
HP1	O
in	O
embryos	O
and	O
the	O
lethality	O
of	O
HP1	O
mutants	O
at	O
late	O
larval	O
stages	O
have	O
so	O
far	O
precluded	O
a	O
systematic	O
study	O
of	O
the	O
role	O
of	O
HP1	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

Therefore	O
,	O
we	O
used	O
Drosophila	S-Species
Kc	O
cells	O
,	O
a	O
cell	O
line	O
derived	O
from	O
Drosophila	S-Species
embryos	O
,	O
as	O
a	O
model	O
system	O
to	O
address	O
this	O
problem	O
.	O

HP1	O
transcripts	O
were	O
depleted	O
using	O
an	O
RNAi	O
-	O
based	O
approach	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
reduction	O
in	O
HP1	O
expression	O
was	O
measured	O
both	O
by	O
RT	O
-	O
PCR	O
and	O
by	O
western	O
blotting	O
analysis	O
(	O
Figure	O
1A	O
)	O
.	O

A	O
significant	O
reduction	O
in	O
the	O
HP1	O
expression	O
was	O
already	O
evident	O
after	O
2	O
days	O
treatment	O
with	O
HP1	O
dsRNA	O
.	O

Cells	O
at	O
day	O
8	O
showed	O
a	O
reduction	O
in	O
HP1	O
of	O
~	O
90	O
%	O
(	O
Figure	O
1A	O
)	O
and	O
were	O
therefore	O
used	O
in	O
all	O
subsequent	O
experiments	O
.	O

Cell	O
-	O
cycle	O
progression	O
at	O
S	O
and	O
G2	O
/	O
M	O
phase	O
is	O
altered	O
in	O
the	O
absence	O
of	O
HP1	O

The	O
impact	O
of	O
HP1	O
loss	O
on	O
the	O
cell	O
cycle	O
of	O
Kc	O
cells	O
was	O
determined	O
using	O
cell	O
-	O
cycle	O
profile	O
analysis	O
of	O
HP1	O
-	O
depleted	O
and	O
control	O
cells	O
.	O

The	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
was	O
determined	O
by	O
BrdU	O
incorporation	O
,	O
and	O
total	O
DNA	O
content	O
by	O
7	O
-	O
amino	O
-	O
actinomycin	O
(	O
7	O
-	O
AAD	O
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
depletion	O
of	O
HP1	O
(	O
day	O
8	O
)	O
caused	O
a	O
decrease	O
in	O
S	O
-	O
phase	O
cells	O
of	O
at	O
least	O
4	O
-	O
fold	O
,	O
and	O
a	O
2	O
-	O
fold	O
decrease	O
in	O
G2	O
/	O
M	O
-	O
phase	O
cells	O
(	O
Figure	O
1B	O
)	O
,	O
although	O
no	O
significant	O
effect	O
was	O
found	O
at	O
the	O
G1	O
phase	O
.	O

In	O
addition	O
,	O
depletion	O
of	O
HP1	O
caused	O
a	O
greater	O
than	O
7	O
-	O
fold	O
increase	O
in	O
the	O
number	O
of	O
apoptotic	O
cells	O
.	O

These	O
results	O
,	O
therefore	O
,	O
confirm	O
that	O
HP1	O
is	O
an	O
important	O
regulator	O
during	O
the	O
cell	O
cycle	O
,	O
especially	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
.	O

Cell	O
-	O
cycle	O
regulators	O
require	O
HP1	O
to	O
maintain	O
their	O
active	O
transcription	O

To	O
ask	O
whether	O
the	O
cell	O
-	O
cycle	O
defects	O
were	O
due	O
to	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
functionally	O
involved	O
in	O
S	O
phase	O
and	O
the	O
G2	O
/	O
M	O
phase	O
,	O
we	O
next	O
assessed	O
global	O
changes	O
in	O
gene	O
transcription	O
following	O
depletion	O
of	O
HP1	O
.	O

Expression	O
profile	O
analysis	O
was	O
performed	O
using	O
total	O
RNA	O
isolated	O
from	O
both	O
HP1	O
-	O
depleted	O
Kc	O
cells	O
and	O
control	O
Kc	O
cells	O
,	O
and	O
an	O
Affymetrix	O
Drosophila	S-Species
chip	O
.	O

For	O
each	O
experiment	O
,	O
we	O
used	O
total	O
RNA	O
isolated	O
from	O
two	O
independent	O
HP1	O
-	O
depleted	O
and	O
control	O
samples	O
,	O
and	O
at	O
least	O
two	O
independent	O
experiments	O
were	O
performed	O
.	O

The	O
microarray	O
analysis	O
showed	O
that	O
loss	O
of	O
HP1	O
function	O
in	O
Kc	O
cells	O
resulted	O
in	O
alterations	O
in	O
transcription	O
of	O
>	O
500	O
genes	O
:	O
~	O
400	O
genes	O
were	O
down	O
-	O
regulated	O
and	O
~	O
120	O
genes	O
were	O
up	O
-	O
regulated	O
(	O
>	O
1	O
.	O
5	O
-	O
fold	O
,	O
ANOVA	O
)	O
.	O

The	O
function	O
of	O
these	O
genes	O
ranged	O
from	O
cellular	O
enzymes	O
,	O
signal	O
transduction	O
molecules	O
,	O
and	O
membrane	O
and	O
cell	O
structural	O
proteins	O
,	O
to	O
nucleic	O
acid	O
-	O
binding	O
proteins	O
and	O
cell	O
-	O
cycle	O
regulators	O
(	O
Figure	O
2A	O
)	O
.	O

At	O
the	O
chromosomal	O
level	O
,	O
the	O
genes	O
targeted	O
by	O
HP1	O
appeared	O
to	O
be	O
distributed	O
along	O
all	O
euchromatic	O
chromosomal	O
arms	O
(	O
data	O
not	O
shown	O
)	O
,	O
supporting	O
a	O
global	O
role	O
of	O
HP1	O
in	O
euchromatic	O
gene	O
regulation	O
(	O
20	O
)	O
.	O

Among	O
60	O
known	O
/	O
predicted	O
genes	O
associated	O
with	O
DNA	O
replication	O
function	O
,	O
15	O
were	O
down	O
-	O
regulated	O
in	O
the	O
absence	O
of	O
HP1	O
(	O
Figure	O
2B	O
)	O
.	O

These	O
included	O
McM2	O
,	O
McM5	O
,	O
McM6	O
and	O
CDC45L	O
,	O
which	O
are	O
required	O
for	O
processive	O
DNA	O
replication	O
and	O
correct	O
chromosome	O
condensation	O
(	O
30	O
-	O
32	O
)	O
.	O

Other	O
genes	O
involved	O
in	O
DNA	O
replication	O
,	O
such	O
as	O
components	O
of	O
the	O
origin	O
recognition	O
complex	O
(	O
Orc	O
)	O
--	O
Orc4	O
,	O
Caf1	O
,	O
Gnf1	O
,	O
Dref1	O
,	O
DNA	O
polymerase	O
-	O
gamma	O
and	O
Tam	O
--	O
were	O
also	O
down	O
-	O
regulated	O
(	O
Figure	O
2B	O
)	O
.	O

Aurora	O
B	O
and	O
inner	O
centromere	O
protein	O
(	O
INCENP	O
)	O
,	O
known	O
to	O
be	O
required	O
for	O
kinetochore	O
assembly	O
,	O
chromosome	O
condensation	O
and	O
bipolar	O
chromosome	O
attachment	O
during	O
mitosis	O
(	O
33	O
)	O
,	O
also	O
showed	O
a	O
reduction	O
in	O
transcription	O
.	O

A	O
similar	O
loss	O
of	O
transcription	O
was	O
observed	O
in	O
Bub1	O
and	O
Bub3	O
(	O
Figure	O
2B	O
)	O
,	O
encoding	O
mitotic	O
checkpoint	O
control	O
proteins	O
(	O
34	O
,	O
35	O
)	O
.	O

Loss	O
function	O
of	O
Bub1	O
has	O
been	O
shown	O
to	O
cause	O
chromatin	O
bridges	O
to	O
extend	O
between	O
the	O
two	O
separating	O
groups	O
of	O
chromosomes	O
,	O
and	O
extensive	O
chromosome	O
fragmentation	O
in	O
anaphase	O
cells	O
(	O
35	O
)	O
.	O

We	O
confirmed	O
the	O
changes	O
in	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
using	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
,	O
which	O
gave	O
results	O
consistent	O
with	O
the	O
microarray	O
analysis	O
.	O

In	O
addition	O
,	O
cell	O
-	O
cycle	O
regulator	O
genes	O
,	O
such	O
as	O
McM3	O
,	O
McM7	O
and	O
Asp	O
(	O
abnormal	O
spindle	O
)	O
,	O
were	O
also	O
confirmed	O
to	O
be	O
down	O
-	O
regulated	O
(	O
Figure	O
2C	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
HP1	O
is	O
indeed	O
involved	O
in	O
the	O
regulation	O
of	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
.	O

HP1	O
is	O
required	O
for	O
Aurora	O
B	O
distribution	O
and	O
histone	O
H3	O
phosphorylation	O

INCENP	O
is	O
localized	O
to	O
the	O
centromeric	O
region	O
of	O
chromosomes	O
at	O
metaphase	O
and	O
the	O
spindle	O
midzone	O
at	O
anaphase	O
,	O
which	O
then	O
targets	O
Aurora	O
B	O
,	O
a	O
kinase	O
essential	O
for	O
histone	O
H3	O
ser10	O
phosphorylation	O
,	O
to	O
these	O
sites	O
(	O
36	O
)	O
.	O

Loss	O
of	O
function	O
of	O
both	O
these	O
'	O
chromosomal	O
passenger	O
'	O
proteins	O
causes	O
abnormal	O
chromosomal	O
segregation	O
at	O
metaphase	O
,	O
as	O
well	O
as	O
certain	O
cytokinesis	O
defects	O
(	O
36	O
,	O
37	O
)	O
.	O

The	O
loss	O
of	O
transcription	O
of	O
both	O
INCENP	O
and	O
Aurora	O
B	O
after	O
depletion	O
of	O
HP1	O
,	O
therefore	O
,	O
raised	O
the	O
possibility	O
that	O
localization	O
of	O
Aurora	O
B	O
(	O
Figure	O
3	O
and	O
data	O
not	O
shown	O
)	O
may	O
be	O
altered	O
.	O

Staining	O
of	O
HP1	O
-	O
depleted	O
Kc	O
cells	O
with	O
anti	O
-	O
Aurora	O
B	O
antibodies	O
indeed	O
revealed	O
an	O
altered	O
localization	O
of	O
Aurora	O
B	O
and	O
,	O
in	O
a	O
number	O
of	O
cases	O
,	O
a	O
complete	O
loss	O
of	O
Aurora	O
B	O
(	O
Figure	O
3A	O
)	O
.	O

Consistent	O
with	O
the	O
loss	O
function	O
of	O
Aurora	O
B	O
,	O
the	O
spindles	O
in	O
the	O
metaphase	O
cells	O
were	O
also	O
disorganized	O
,	O
with	O
a	O
large	O
number	O
of	O
cells	O
showing	O
an	O
altered	O
prometaphase	O
chromosome	O
alignment	O
(	O
Figure	O
3A	O
)	O
.	O

Some	O
showed	O
extensive	O
chromosome	O
fragmentation	O
(	O
Figure	O
3B	O
)	O
,	O
or	O
the	O
presence	O
of	O
a	O
third	O
spindle	O
pole	O
-	O
like	O
structure	O
as	O
indicated	O
by	O
beta	O
-	O
tubulin	O
(	O
Figure	O
3A	O
)	O
.	O

At	O
telophase	O
,	O
we	O
observed	O
defective	O
separating	O
cells	O
with	O
an	O
extra	O
cell	O
envelope	O
-	O
like	O
structure	O
without	O
nuclei	O
(	O
Figure	O
3A	O
)	O
.	O

Chromatin	O
bridges	O
or	O
lagging	O
chromatids	O
at	O
telophase	O
were	O
also	O
evident	O
in	O
some	O
cells	O
(	O
Figure	O
3C	O
)	O
;	O
however	O
,	O
in	O
some	O
cases	O
,	O
localization	O
of	O
Aurora	O
B	O
appeared	O
not	O
to	O
be	O
affected	O
,	O
arguing	O
that	O
other	O
pathways	O
are	O
possibly	O
involved	O
.	O

We	O
next	O
analyzed	O
changes	O
in	O
histone	O
H3	O
serine	O
10	O
phosphorylation	O
,	O
since	O
the	O
loss	O
of	O
transcription	O
of	O
INCENP	O
is	O
known	O
to	O
affect	O
localization	O
of	O
Aurora	O
B	O
(	O
33	O
)	O
,	O
which	O
is	O
essential	O
in	O
the	O
regulation	O
of	O
histone	O
H3	O
phosphorylation	O
(	O
36	O
)	O
.	O

Total	O
cell	O
extracts	O
from	O
HP1	O
-	O
depleted	O
Kc	O
cells	O
were	O
analyzed	O
by	O
western	O
blotting	O
(	O
Figure	O
3D	O
)	O
.	O

The	O
results	O
indeed	O
showed	O
a	O
severalfold	O
reduction	O
in	O
H3	O
ser10	O
phosphorylation	O
after	O
depletion	O
of	O
HP1	O
,	O
consistent	O
with	O
the	O
functional	O
disruption	O
of	O
INCENP	O
and	O
Aurora	O
B	O
in	O
the	O
absence	O
of	O
HP1	O
.	O

HP1	O
directly	O
targets	O
genes	O
encoding	O
cell	O
-	O
cycle	O
regulators	O
in	O
euchromatin	O

To	O
test	O
whether	O
the	O
loss	O
of	O
transcription	O
of	O
genes	O
involved	O
in	O
DNA	O
replication	O
and	O
mitosis	O
was	O
a	O
direct	O
effect	O
of	O
the	O
loss	O
of	O
HP1	O
,	O
we	O
performed	O
a	O
ChIP	O
analysis	O
to	O
determine	O
whether	O
HP1	O
is	O
physically	O
associated	O
with	O
these	O
genes	O
.	O

Chromatin	O
lysates	O
from	O
formaldehyde	O
-	O
fixed	O
Kc	O
cells	O
were	O
sonicated	O
into	O
small	O
chromatin	O
fragments	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
8	O
kb	O
)	O
and	O
immunoprecipitated	O
with	O
polyclonal	O
antibodies	O
against	O
Drosophila	S-Species
HP1	O
.	O

As	O
a	O
control	O
,	O
we	O
used	O
a	O
mock	O
precipitation	O
(	O
beads	O
only	O
)	O
and	O
polyclonal	O
antibodies	O
against	O
HA	O
.	O

Our	O
ChIP	O
results	O
showed	O
that	O
known	O
transposable	O
elements	O
distributed	O
in	O
heterochromatin	O
,	O
such	O
as	O
F	O
-	O
element	O
,	O
TART	O
and	O
1360	O
(	O
7	O
,	O
38	O
)	O
,	O
were	O
all	O
enriched	O
in	O
HP1	O
binding	O
(	O
Figure	O
4	O
)	O
,	O
which	O
is	O
also	O
consistent	O
with	O
a	O
previous	O
study	O
(	O
20	O
)	O
.	O

Using	O
the	O
same	O
ChIP	O
DNA	O
material	O
,	O
we	O
then	O
attempted	O
to	O
determine	O
whether	O
HP1	O
was	O
enriched	O
in	O
genes	O
involved	O
in	O
DNA	O
replication	O
.	O

Primers	O
were	O
designed	O
to	O
cover	O
the	O
promoter	O
regions	O
of	O
selected	O
genes	O
.	O

The	O
results	O
showed	O
that	O
McM3	O
,	O
McM5	O
and	O
Tam	O
were	O
all	O
enriched	O
in	O
HP1	O
binding	O
(	O
Figure	O
4	O
)	O
.	O

However	O
,	O
McM7	O
appeared	O
to	O
be	O
HP1	O
-	O
negative	O
,	O
although	O
its	O
transcription	O
was	O
also	O
affected	O
by	O
the	O
loss	O
of	O
HP1	O
function	O
.	O

Genes	O
essential	O
for	O
mitosis	O
,	O
such	O
as	O
Aurora	O
B	O
,	O
were	O
also	O
HP1	O
-	O
positive	O
(	O
Figure	O
4	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
these	O
cell	O
-	O
cycle	O
regulator	O
genes	O
are	O
directly	O
targeted	O
by	O
HP1	O
in	O
their	O
promoter	O
regions	O
.	O

DISCUSSION	O

In	O
this	O
study	O
,	O
we	O
used	O
microarray	O
and	O
RT	O
-	O
PCR	O
techniques	O
to	O
demonstrate	O
that	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
is	O
misregulated	O
in	O
the	O
absence	O
of	O
HP1	O
.	O

Certain	O
defects	O
in	O
S	O
phase	O
may	O
be	O
a	O
direct	O
consequence	O
of	O
the	O
loss	O
of	O
transcription	O
of	O
DNA	O
replication	O
genes	O
such	O
as	O
McM2	O
,	O
McM5	O
,	O
McM6	O
,	O
CDC45L	O
,	O
Orc4	O
and	O
others	O
,	O
since	O
these	O
genes	O
have	O
been	O
functionally	O
implicated	O
in	O
the	O
initiation	O
of	O
DNA	O
replication	O
and	O
/	O
or	O
the	O
progression	O
of	O
replication	O
forks	O
(	O
39	O
)	O
.	O

Depletion	O
or	O
mutation	O
of	O
these	O
genes	O
has	O
been	O
shown	O
to	O
result	O
in	O
DNA	O
damage	O
(	O
32	O
)	O
,	O
the	O
blockage	O
of	O
replication	O
forks	O
(	O
39	O
)	O
,	O
increased	O
chromosome	O
loss	O
/	O
genome	O
instability	O
,	O
and	O
defective	O
condensation	O
(	O
30	O
)	O
.	O

The	O
reduction	O
in	O
the	O
number	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phase	O
may	O
be	O
a	O
consequence	O
of	O
the	O
reduction	O
in	O
transcription	O
or	O
functional	O
disruption	O
of	O
INCENP	O
,	O
Aurora	O
B	O
,	O
Bub1	O
,	O
and	O
Bub3	O
(	O
34	O
,	O
36	O
)	O
.	O

Chromosome	O
segregation	O
defects	O
,	O
such	O
as	O
chromosome	O
fragmentation	O
and	O
chromatin	O
bridges	O
in	O
anaphase	O
/	O
telophase	O
cells	O
,	O
and	O
certain	O
cytokinesis	O
defects	O
in	O
HP1	O
-	O
depleted	O
cells	O
,	O
mimic	O
the	O
phenotype	O
of	O
cells	O
with	O
loss	O
function	O
of	O
INCENP	O
,	O
Aurora	O
B	O
or	O
Bub1	O
(	O
35	O
-	O
37	O
)	O
.	O

The	O
mislocalization	O
of	O
Aurora	O
B	O
in	O
the	O
absence	O
of	O
HP1	O
is	O
also	O
consistent	O
with	O
the	O
loss	O
of	O
transcription	O
and	O
functional	O
disruption	O
of	O
INCENP	O
(	O
37	O
)	O
,	O
and	O
the	O
reduction	O
in	O
Aurora	O
B	O
transcription	O
may	O
be	O
partially	O
responsible	O
for	O
the	O
observed	O
chromosomal	O
defects	O
,	O
including	O
loss	O
of	O
histone	O
H3	O
phosphorylation	O
at	O
serine	O
10	O
.	O

HP1	O
is	O
also	O
known	O
to	O
physically	O
interact	O
with	O
certain	O
components	O
of	O
replication	O
complexes	O
such	O
as	O
ORCs	O
and	O
MCMs	O
(	O
30	O
,	O
40	O
,	O
41	O
)	O
,	O
with	O
the	O
inner	O
centromere	O
protein	O
INCENP	O
(	O
42	O
)	O
and	O
the	O
chromatin	O
assembly	O
factor	O
CAF1	O
(	O
43	O
)	O
promoting	O
delivery	O
of	O
HP1	O
to	O
heterochromatin	O
sites	O
(	O
44	O
)	O
.	O

Loss	O
of	O
HP1	O
is	O
,	O
therefore	O
,	O
expected	O
to	O
cause	O
disruption	O
to	O
such	O
HP1	O
-	O
associated	O
complexes	O
,	O
and	O
will	O
partially	O
contribute	O
to	O
the	O
chromatin	O
/	O
chromosomal	O
defects	O
in	O
HP1	O
mutants	O
(	O
8	O
,	O
27	O
)	O
and	O
HP1	O
-	O
depleted	O
Kc	O
cells	O
.	O

It	O
is	O
therefore	O
well	O
possible	O
that	O
the	O
loss	O
of	O
transcription	O
of	O
these	O
cell	O
-	O
cycle	O
regulator	O
genes	O
,	O
and	O
consequent	O
disruption	O
of	O
HP1	O
functional	O
complexes	O
or	O
heterochromatin	O
structure	O
,	O
all	O
contributed	O
to	O
the	O
cell	O
-	O
cycle	O
defects	O
observed	O
.	O

The	O
ChIP	O
assay	O
supports	O
the	O
hypothesis	O
that	O
the	O
loss	O
of	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulator	O
genes	O
is	O
a	O
direct	O
effect	O
of	O
the	O
lack	O
of	O
HP1	O
.	O

Aurora	O
B	O
,	O
McM3	O
,	O
and	O
McM5	O
were	O
all	O
bound	O
by	O
HP1	O
at	O
their	O
promoter	O
regions	O
,	O
although	O
other	O
cell	O
-	O
cycle	O
regulators	O
,	O
such	O
as	O
McM7	O
,	O
were	O
HP1	O
-	O
negative	O
,	O
implying	O
that	O
the	O
altered	O
transcription	O
in	O
these	O
genes	O
might	O
be	O
a	O
secondary	O
effect	O
of	O
the	O
loss	O
of	O
HP1	O
.	O

A	O
previous	O
study	O
in	O
Drosophila	S-Species
Kc	O
cells	O
(	O
20	O
)	O
employed	O
an	O
approach	O
based	O
on	O
the	O
ectopic	O
expression	O
of	O
a	O
fusion	O
protein	O
of	O
HP1	O
with	O
a	O
prokaryotic	O
DNA	O
adenine	O
methyltransferase	O
and	O
identified	O
a	O
number	O
of	O
methylated	O
targets	O
in	O
the	O
genome	O
.	O

In	O
this	O
study	O
,	O
MCM3	O
and	O
MCM5	O
were	O
not	O
found	O
to	O
be	O
methylated	O
,	O
indicating	O
lack	O
of	O
association	O
with	O
HP1	O
.	O

On	O
the	O
other	O
hand	O
,	O
heterochromatin	O
repeats	O
,	O
such	O
F	O
-	O
element	O
and	O
1360	O
,	O
were	O
consistently	O
found	O
to	O
be	O
HP1	O
-	O
enriched	O
both	O
here	O
and	O
in	O
the	O
previous	O
study	O
.	O

It	O
remains	O
to	O
be	O
determined	O
whether	O
these	O
discrepancies	O
are	O
due	O
to	O
the	O
different	O
experimental	O
systems	O
used	O
.	O

However	O
,	O
we	O
note	O
that	O
the	O
previous	O
study	O
was	O
performed	O
using	O
a	O
cDNA	O
array	O
,	O
while	O
we	O
observe	O
binding	O
of	O
endogenous	O
HP1	O
at	O
the	O
promoter	O
of	O
these	O
genes	O
.	O

Similarly	O
,	O
another	O
study	O
using	O
chromatin	O
immunoprecipitation	O
in	O
larvae	O
also	O
showed	O
few	O
HP1	O
-	O
positive	O
genes	O
that	O
were	O
not	O
detected	O
in	O
Kc	O
cells	O
by	O
the	O
Dam	O
ID	O
approach	O
(	O
21	O
)	O
.	O

A	O
large	O
number	O
of	O
genes	O
affected	O
by	O
the	O
loss	O
of	O
D	B-Species
.	I-Species
melanogaster	E-Species
HP1	O
in	O
larval	O
tissues	O
(	O
21	O
)	O
seem	O
to	O
be	O
different	O
from	O
that	O
in	O
embryonic	O
Kc	O
cells	O
.	O

The	O
change	O
in	O
the	O
transcription	O
of	O
Aurora	O
B	O
and	O
few	O
cell	O
-	O
cycle	O
regulators	O
reported	O
in	O
this	O
study	O
is	O
also	O
not	O
found	O
among	O
the	O
HP1	O
-	O
affected	O
genes	O
at	O
larval	O
stage	O
(	O
21	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
specific	O
role	O
(	O
s	O
)	O
of	O
HP1	O
in	O
different	O
stages	O
of	O
development	O
.	O

Alternatively	O
,	O
it	O
is	O
also	O
possible	O
that	O
the	O
impact	O
of	O
HP1	O
in	O
the	O
transcription	O
of	O
cell	O
-	O
cycle	O
regulators	O
in	O
proliferating	O
cells	O
is	O
underestimated	O
when	O
performing	O
the	O
analyses	O
on	O
larval	O
tissues	O
,	O
and	O
thus	O
on	O
mixed	O
populations	O
of	O
both	O
proliferating	O
and	O
differentiating	O
/	O
differentiated	O
cells	O
.	O

HP1	O
is	O
generally	O
known	O
as	O
a	O
transcriptional	O
repressor	O
,	O
as	O
supported	O
by	O
several	O
lines	O
of	O
evidence	O
:	O
silencing	O
of	O
a	O
euchromatic	O
reporter	O
gene	O
in	O
heterochromatin	O
requires	O
HP1	O
(	O
10	O
,	O
11	O
)	O
,	O
tethering	O
of	O
HP1	O
next	O
to	O
a	O
euchromatic	O
reporter	O
gene	O
causes	O
silencing	O
(	O
45	O
)	O
,	O
and	O
the	O
repression	O
of	O
genes	O
within	O
euchromatic	O
region	O
31	O
bound	O
by	O
HP1	O
is	O
relieved	O
in	O
the	O
absence	O
of	O
HP1	O
(	O
46	O
)	O
.	O

In	O
contrast	O
,	O
genes	O
in	O
heterochromatin	O
,	O
known	O
as	O
heterochromatic	O
genes	O
,	O
such	O
as	O
light	O
and	O
rolled	O
,	O
seem	O
to	O
require	O
HP1	O
to	O
maintain	O
their	O
active	O
transcription	O
(	O
47	O
,	O
48	O
)	O
.	O

The	O
level	O
of	O
transcription	O
of	O
heterochromatic	O
genes	O
was	O
dramatically	O
reduced	O
in	O
a	O
mutated	O
HP1	O
background	O
(	O
47	O
-	O
49	O
)	O
.	O

It	O
was	O
therefore	O
proposed	O
that	O
HP1	O
may	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
transcription	O
of	O
these	O
genes	O
(	O
50	O
,	O
51	O
)	O
,	O
although	O
the	O
exact	O
regulation	O
mechanism	O
remains	O
unclear	O
.	O

A	O
study	O
of	O
heat	O
-	O
shock	O
genes	O
found	O
that	O
HP1	O
is	O
associated	O
with	O
RNA	O
transcripts	O
in	O
the	O
coding	O
region	O
,	O
and	O
is	O
also	O
a	O
positive	O
regulator	O
of	O
their	O
transcription	O
(	O
52	O
,	O
53	O
)	O
.	O

The	O
chromatin	O
association	O
of	O
HP1	O
at	O
the	O
promoter	O
region	O
of	O
active	O
euchromatic	O
genes	O
demonstrated	O
from	O
this	O
work	O
and	O
others	O
,	O
and	O
its	O
independence	O
from	O
histone	O
H3K9	O
methylation	O
(	O
21	O
)	O
,	O
all	O
suggest	O
that	O
mechanism	O
whereby	O
HP1	O
modulates	O
transcription	O
of	O
euchromatic	O
genes	O
is	O
potentially	O
distinct	O
from	O
its	O
role	O
in	O
heterochromatin	O
formation	O
.	O

Collectively	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
HP1	O
plays	O
an	O
essential	O
role	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
and	O
support	O
the	O
view	O
that	O
HP1	O
,	O
in	O
addition	O
to	O
its	O
role	O
in	O
heterochromatin	O
,	O
can	O
act	O
as	O
a	O
positive	O
transcriptional	O
regulator	O
of	O
euchromatic	O
genes	O
.	O

SUPPLEMENTARY	O
MATERIAL	O

Supplementary	O
Material	O
is	O
available	O
at	O
NAR	O
Online	O
.	O

Supplementary	O
Material	O

Structural	O
organization	O
and	O
interactions	O
of	O
transmembrane	O
domains	O
in	O
tetraspanin	O
proteins	O

Abstract	O

Background	O

Proteins	O
of	O
the	O
tetraspanin	O
family	O
contain	O
four	O
transmembrane	O
domains	O
(	O
TM1	O
-	O
4	O
)	O
linked	O
by	O
two	O
extracellular	O
loops	O
and	O
a	O
short	O
intracellular	O
loop	O
,	O
and	O
have	O
short	O
intracellular	O
N	O
-	O
and	O
C	O
-	O
termini	O
.	O

While	O
structure	O
and	O
function	O
analysis	O
of	O
the	O
larger	O
extracellular	O
loop	O
has	O
been	O
performed	O
,	O
the	O
organization	O
and	O
role	O
of	O
transmembrane	O
domains	O
have	O
not	O
been	O
systematically	O
assessed	O
.	O

Results	O

Among	O
28	O
human	S-Species
tetraspanin	O
proteins	O
,	O
the	O
TM1	O
-	O
3	O
sequences	O
display	O
a	O
distinct	O
heptad	O
repeat	O
motif	O
(	O
abcdefg	O
)	O
n	O
.	O

In	O
TM1	O
,	O
position	O
a	O
is	O
occupied	O
by	O
structurally	O
conserved	O
bulky	O
residues	O
and	O
position	O
d	O
contains	O
highly	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
.	O

In	O
TM2	O
,	O
position	O
a	O
is	O
occupied	O
by	O
conserved	O
small	O
residues	O
(	O
Gly	O
/	O
Ala	O
/	O
Thr	O
)	O
,	O
and	O
position	O
d	O
has	O
a	O
conserved	O
Gly	O
and	O
two	O
bulky	O
aliphatic	O
residues	O
.	O

In	O
TM3	O
,	O
three	O
a	O
positions	O
of	O
the	O
heptad	O
repeat	O
are	O
filled	O
by	O
two	O
leucines	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
,	O
and	O
two	O
d	O
positions	O
are	O
occupied	O
by	O
either	O
Phe	O
/	O
Tyr	O
or	O
Val	O
/	O
Ile	O
/	O
Leu	O
residues	O
.	O

No	O
heptad	O
motif	O
is	O
apparent	O
in	O
TM4	O
sequences	O
.	O

Mutations	O
of	O
conserved	O
glycines	O
in	O
human	S-Species
CD9	O
(	O
Gly25	O
and	O
Gly32	O
in	O
TM1	O
;	O
Gly67	O
and	O
Gly74	O
in	O
TM2	O
)	O
caused	O
aggregation	O
of	O
mutant	O
proteins	O
inside	O
the	O
cell	O
.	O

Modeling	O
of	O
the	O
TM1	O
-	O
TM2	O
interface	O
in	O
CD9	O
,	O
using	O
a	O
novel	O
algorithm	O
,	O
predicts	O
tight	O
packing	O
of	O
conserved	O
bulky	O
residues	O
against	O
conserved	O
Gly	O
residues	O
along	O
the	O
two	O
helices	O
.	O

The	O
homodimeric	O
interface	O
of	O
CD9	O
was	O
mapped	O
,	O
by	O
disulfide	O
cross	O
-	O
linking	O
of	O
single	O
-	O
cysteine	O
mutants	O
,	O
to	O
the	O
vicinity	O
of	O
residues	O
Leu14	O
and	O
Phe17	O
in	O
TM1	O
(	O
positions	O
g	O
and	O
c	O
)	O
and	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
(	O
positions	O
d	O
,	O
g	O
and	O
a	O
,	O
respectively	O
)	O
.	O

Mutations	O
of	O
a	O
and	O
d	O
residues	O
in	O
both	O
TM1	O
and	O
TM2	O
(	O
Gly25	O
,	O
Gly32	O
,	O
Gly67	O
and	O
Gly74	O
)	O
,	O
involved	O
in	O
intramolecular	O
TM1	O
-	O
TM2	O
interaction	O
,	O
also	O
strongly	O
diminished	O
intermolecular	O
interaction	O
,	O
as	O
assessed	O
by	O
cross	O
-	O
linking	O
of	O
Cys80	O
.	O

Conclusion	O

Our	O
results	O
suggest	O
that	O
tetraspanin	O
intra	O
-	O
and	O
intermolecular	O
interactions	O
are	O
mediated	O
by	O
conserved	O
residues	O
in	O
adjacent	O
,	O
but	O
distinct	O
regions	O
of	O
TM1	O
and	O
TM2	O
.	O

A	O
key	O
structural	O
element	O
that	O
defines	O
TM1	O
-	O
TM2	O
interaction	O
in	O
tetraspanins	O
is	O
the	O
specific	O
packing	O
of	O
bulky	O
residues	O
against	O
small	O
residues	O
.	O

Background	O

Tetraspanins	O
constitute	O
a	O
large	O
family	O
of	O
integral	O
membrane	O
proteins	O
,	O
characteristically	O
containing	O
4	O
,	O
6	O
or	O
8	O
conserved	O
cysteine	O
residues	O
in	O
the	O
large	O
extracellular	O
loop	O
(	O
including	O
the	O
CCG	O
and	O
PxxCC	O
motifs	O
)	O
,	O
which	O
form	O
disulfide	O
bonds	O
,	O
and	O
several	O
conserved	O
polar	O
residues	O
in	O
the	O
intracellular	O
loop	O
and	O
transmembrane	O
regions	O
[	O
1	O
,	O
2	O
]	O
.	O

There	O
are	O
32	O
putative	O
tetraspanin	O
family	O
members	O
in	O
mammals	O
,	O
37	O
in	O
Drosophila	B-Species
melanogaster	E-Species
and	O
20	O
in	O
Caenorhabditis	B-Species
elegans	E-Species
.	O

Tetraspanins	O
play	O
diverse	O
roles	O
in	O
cell	O
adhesion	O
,	O
migration	O
and	O
fusion	O
processes	O
,	O
cellular	O
activation	O
and	O
signaling	O
(	O
reviewed	O
in	O
refs	O
.	O
[	O
2	O
-	O
4	O
]	O
)	O
.	O

Mammalian	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
CD63	O
,	O
CD81	O
,	O
CD82	O
,	O
CD151	O
,	O
rds	O
/	O
peripherin	O
,	O
and	O
uroplakins	O
Ia	O
and	O
Ib	O
have	O
been	O
most	O
extensively	O
studied	O
,	O
with	O
mouse	S-Species
knock	O
-	O
out	O
models	O
available	O
for	O
CD9	O
[	O
5	O
-	O
7	O
]	O
,	O
CD81	O
[	O
8	O
,	O
9	O
]	O
,	O
CD151	O
[	O
10	O
]	O
and	O
a	O
few	O
others	O
.	O

However	O
,	O
the	O
majority	O
of	O
tetraspanins	O
are	O
characterized	O
very	O
little	O
,	O
if	O
at	O
all	O
,	O
at	O
genetic	O
,	O
biochemical	O
or	O
structural	O
levels	O
.	O

The	O
large	O
extracellular	O
loop	O
(	O
LEL	O
)	O
of	O
tetraspanins	O
has	O
received	O
most	O
attention	O
,	O
since	O
it	O
contains	O
functionally	O
important	O
sites	O
.	O

Sequence	O
QRD	O
(	O
194	O
-	O
196	O
)	O
in	O
CD151	O
is	O
important	O
for	O
association	O
with	O
integrins	O
,	O
which	O
has	O
functional	O
consequences	O
for	O
integrin	O
-	O
dependent	O
cell	O
spreading	O
and	O
multicellular	O
cable	O
formation	O
[	O
11	O
]	O
.	O

A	O
site	O
in	O
the	O
LEL	O
of	O
CD9	O
,	O
SFQ	O
(	O
residues	O
173	O
-	O
175	O
)	O
,	O
is	O
essential	O
for	O
CD9	O
function	O
in	O
sperm	O
-	O
egg	O
fusion	O
[	O
12	O
]	O
.	O

The	O
crystal	O
structure	O
of	O
tetraspanin	O
CD81	O
LEL	O
revealed	O
five	O
alpha	O
-	O
helixes	O
,	O
A	O
-	O
E	O
[	O
13	O
]	O
.	O

Helices	O
A	O
,	O
B	O
and	O
E	O
form	O
a	O
relatively	O
conserved	O
region	O
in	O
tetraspanins	O
,	O
whereas	O
the	O
region	O
between	O
helices	O
B	O
and	O
E	O
is	O
the	O
most	O
variable	O
[	O
14	O
]	O
.	O

Interestingly	O
,	O
the	O
variable	O
region	O
contains	O
most	O
of	O
the	O
functionally	O
important	O
sites	O
involved	O
in	O
tetraspanin	O
protein	O
-	O
protein	O
interactions	O
.	O

A	O
remarkable	O
biochemical	O
property	O
of	O
tetraspanin	O
molecules	O
is	O
their	O
ability	O
to	O
associate	O
with	O
a	O
large	O
number	O
of	O
other	O
transmembrane	O
proteins	O
,	O
including	O
integrins	O
,	O
membrane	O
-	O
associated	O
growth	O
factors	O
and	O
receptors	O
,	O
MHC	O
class	O
II	O
molecules	O
,	O
Ig	O
superfamily	O
proteins	O
,	O
and	O
each	O
other	O
[	O
2	O
,	O
3	O
,	O
15	O
]	O
.	O

Several	O
of	O
these	O
lateral	O
associations	O
of	O
tetraspanins	O
are	O
detected	O
in	O
"	O
mild	O
"	O
detergents	O
(	O
Brij	O
series	O
,	O
CHAPS	O
)	O
,	O
but	O
are	O
disrupted	O
by	O
"	O
strong	O
"	O
detergents	O
such	O
as	O
Triton	O
X	O
-	O
100	O
or	O
SDS	O
.	O

Multiprotein	O
complexes	O
of	O
tetraspanins	O
and	O
associated	O
molecules	O
,	O
also	O
called	O
the	O
"	O
tetraspanin	O
web	O
"	O
[	O
16	O
]	O
,	O
may	O
represent	O
a	O
distinct	O
tetraspanin	O
-	O
enriched	O
membrane	O
microdomain	O
[	O
17	O
,	O
18	O
]	O
.	O

The	O
formation	O
of	O
this	O
microdomain	O
is	O
influenced	O
by	O
palmitoylation	O
of	O
several	O
conserved	O
juxtamembrane	O
cysteine	O
residues	O
in	O
tetraspanins	O
[	O
19	O
-	O
21	O
]	O
.	O

The	O
transmembrane	O
domains	O
,	O
encompassing	O
nearly	O
half	O
of	O
a	O
tetraspanin	O
protein	O
,	O
are	O
the	O
most	O
conserved	O
part	O
of	O
the	O
molecule	O
(	O
Stipp	O
et	O
al	O
.	O
[	O
1	O
]	O
and	O
this	O
study	O
)	O
.	O

However	O
,	O
very	O
little	O
functional	O
information	O
is	O
available	O
on	O
these	O
domains	O
.	O

The	O
differential	O
detergent	O
sensitivity	O
of	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
suggests	O
that	O
hydrophobic	O
interactions	O
between	O
TM	O
helices	O
may	O
play	O
a	O
role	O
.	O

Indeed	O
,	O
when	O
the	O
large	O
extracellular	O
loop	O
(	O
LEL	O
)	O
of	O
CD151	O
is	O
deleted	O
,	O
the	O
molecule	O
is	O
still	O
able	O
to	O
associate	O
with	O
other	O
tetraspanins	O
[	O
22	O
]	O
.	O

Thus	O
,	O
TM	O
domains	O
are	O
strong	O
candidates	O
for	O
mediating	O
tetraspanin	O
-	O
tetraspanin	O
interactions	O
.	O

The	O
importance	O
of	O
TM	O
domain	O
interactions	O
in	O
intramolecular	O
organization	O
was	O
demonstrated	O
in	O
a	O
study	O
showing	O
that	O
CD82	O
fragment	O
TM2	O
-	O
4	O
,	O
lacking	O
TM1	O
,	O
was	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
but	O
was	O
transported	O
to	O
the	O
cell	O
surface	O
upon	O
co	O
-	O
expression	O
of	O
TM1	O
[	O
23	O
]	O
.	O

This	O
in	O
vivo	O
reconstitution	O
experiment	O
demonstrated	O
a	O
strong	O
interaction	O
between	O
TM1	O
and	O
the	O
rest	O
of	O
the	O
molecule	O
.	O

Expression	O
of	O
a	O
truncated	O
CD9	O
molecule	O
(	O
TM3	O
-	O
LEL	O
-	O
TM4	O
)	O
results	O
in	O
intracellular	O
accumulation	O
of	O
the	O
protein	O
and	O
significant	O
misfolding	O
of	O
the	O
LEL	O
,	O
as	O
judged	O
by	O
inappropriate	O
disulfide	O
formation	O
and	O
diminished	O
antibody	O
reactivity	O
(	O
our	O
unpublished	O
data	O
)	O
.	O

Similarly	O
,	O
a	O
CD9	O
epitope	O
in	O
the	O
LEL	O
is	O
lost	O
in	O
molecules	O
lacking	O
either	O
TM2	O
+	O
TM3	O
or	O
just	O
TM4	O
[	O
24	O
]	O
.	O

Thus	O
,	O
TM	O
domain	O
interactions	O
and	O
packing	O
are	O
crucial	O
for	O
proper	O
folding	O
,	O
stability	O
and	O
transport	O
of	O
tetraspanin	O
molecules	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
showed	O
that	O
covalent	O
cross	O
-	O
linking	O
of	O
membrane	O
-	O
proximal	O
cysteine	O
residues	O
can	O
be	O
used	O
as	O
a	O
tool	O
for	O
detection	O
of	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
[	O
25	O
]	O
.	O

Inhibition	O
of	O
cysteine	O
palmitoylation	O
by	O
2	O
-	O
bromopalmitate	O
(	O
2	O
-	O
BP	O
)	O
made	O
cysteines	O
available	O
for	O
cross	O
-	O
linking	O
and	O
enabled	O
demonstration	O
of	O
specific	O
tetraspanin	O
homodimerization	O
and	O
low	O
levels	O
of	O
heterodimerization	O
.	O

We	O
concluded	O
that	O
tetraspanin	O
homodimers	O
,	O
formed	O
in	O
the	O
Golgi	O
,	O
may	O
be	O
a	O
fundamental	O
structural	O
unit	O
within	O
tetraspanin	O
microdomains	O
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
detailed	O
sequence	O
analysis	O
of	O
human	S-Species
tetraspanin	O
TM	O
domains	O
.	O

We	O
show	O
that	O
a	O
heptad	O
repeat	O
containing	O
conserved	O
glycine	O
,	O
asparagine	O
and	O
large	O
hydrophobic	O
residues	O
occurs	O
in	O
TM1	O
and	O
TM2	O
domains	O
,	O
and	O
predict	O
tight	O
intramolecular	O
association	O
of	O
these	O
two	O
domains	O
by	O
packing	O
of	O
the	O
large	O
residues	O
against	O
the	O
small	O
residues	O
.	O

Moreover	O
,	O
by	O
using	O
cysteine	O
cross	O
-	O
linking	O
we	O
map	O
a	O
dimerization	O
interface	O
in	O
the	O
human	S-Species
CD9	O
protein	O
,	O
and	O
show	O
that	O
conserved	O
heptad	O
motif	O
glycine	O
residues	O
are	O
also	O
important	O
for	O
intermolecular	O
CD9	O
associations	O
.	O

Results	O

Sequence	O
analysis	O
of	O
tetraspanin	O
transmembrane	O
domains	O
:	O
presence	O
of	O
the	O
heptad	O
repeat	O
motif	O

We	O
focused	O
our	O
attention	O
on	O
28	O
human	S-Species
tetraspanins	O
identified	O
from	O
the	O
SWISS	O
-	O
PROT	O
and	O
GenBank	O
databases	O
.	O

All	O
tetraspanins	O
have	O
in	O
common	O
four	O
hydrophobic	O
stretches	O
(	O
TM	O
domains	O
)	O
of	O
20	O
-	O
25	O
residues	O
,	O
and	O
contain	O
highly	O
conserved	O
residues	O
in	O
the	O
second	O
extracellular	O
loop	O
,	O
in	O
particular	O
the	O
Cys	O
-	O
Cys	O
-	O
Gly	O
(	O
CCG	O
)	O
motif	O
.	O

Detailed	O
analysis	O
of	O
the	O
large	O
extracellular	O
loop	O
sequences	O
[	O
14	O
]	O
,	O
and	O
dendrograms	O
based	O
on	O
full	O
-	O
length	O
alignment	O
can	O
be	O
found	O
in	O
earlier	O
studies	O
[	O
26	O
,	O
27	O
]	O
.	O

The	O
length	O
of	O
each	O
transmembrane	O
domain	O
was	O
established	O
based	O
on	O
previous	O
sequence	O
analysis	O
of	O
tetraspanin	O
sequences	O
[	O
27	O
,	O
28	O
]	O
,	O
and	O
on	O
annotations	O
to	O
the	O
database	O
entries	O
.	O

Manual	O
adjustments	O
based	O
on	O
sequence	O
homology	O
and	O
hydrophobicity	O
profiles	O
were	O
done	O
to	O
fully	O
delineate	O
the	O
TM	O
domains	O
.	O

The	O
resulting	O
lengths	O
of	O
TM	O
domains	O
were	O
:	O
TM1	O
-	O
23	O
residues	O
;	O
TM2	O
-	O
21	O
residues	O
;	O
TM3	O
-	O
25	O
residues	O
;	O
TM4	O
-	O
25	O
residues	O
.	O

Two	O
more	O
residues	O
could	O
be	O
added	O
onto	O
the	O
N	O
-	O
terminal	O
part	O
of	O
TM2	O
;	O
however	O
,	O
relatively	O
small	O
sequence	O
conservation	O
of	O
these	O
residues	O
among	O
tetraspanins	O
and	O
occurrence	O
of	O
polar	O
/	O
charged	O
side	O
chains	O
in	O
some	O
tetraspanins	O
precluded	O
us	O
from	O
doing	O
so	O
for	O
the	O
global	O
alignment	O
.	O

Figures	O
1	O
and	O
2	O
show	O
a	O
multiple	O
sequence	O
alignment	O
of	O
four	O
TM	O
domains	O
of	O
28	O
human	S-Species
tetraspanins	O
.	O

For	O
each	O
position	O
within	O
the	O
domains	O
,	O
consensus	O
residues	O
were	O
determined	O
and	O
classified	O
(	O
with	O
individual	O
color	O
code	O
)	O
in	O
4	O
categories	O
:	O
1	O
)	O
large	O
hydrophobic	O
residues	O
(	O
including	O
Val	O
,	O
Met	O
,	O
Leu	O
,	O
Ile	O
,	O
Phe	O
,	O
Tyr	O
,	O
Trp	O
)	O
,	O
2	O
)	O
small	O
residues	O
(	O
Gly	O
,	O
Ala	O
,	O
Ser	O
and	O
Thr	O
)	O
,	O
3	O
)	O
Cys	O
,	O
and	O
4	O
)	O
Asn	O
.	O

When	O
more	O
than	O
two	O
types	O
of	O
residues	O
occupied	O
a	O
given	O
position	O
in	O
a	O
TM	O
,	O
a	O
dual	O
-	O
color	O
pattern	O
that	O
reflected	O
the	O
prevalence	O
of	O
the	O
particular	O
residue	O
type	O
was	O
used	O
(	O
Figure	O
1	O
)	O
.	O

Cysteine	O
residues	O
were	O
shown	O
separately	O
due	O
to	O
their	O
importance	O
as	O
palmitoylation	O
target	O
sites	O
.	O

The	O
highly	O
conserved	O
asparagine	O
residue	O
in	O
TM1	O
was	O
considered	O
separately	O
.	O

No	O
proline	O
residues	O
are	O
found	O
in	O
TM	O
domains	O
1	O
-	O
3	O
of	O
human	S-Species
tetraspanins	O
.	O

An	O
inspection	O
of	O
the	O
multiple	O
sequence	O
alignment	O
reveals	O
a	O
repeating	O
heptad	O
amino	O
acid	O
pattern	O
,	O
(	O
abcdefg	O
)	O
n	O
,	O
in	O
TM1	O
,	O
2	O
and	O
3	O
(	O
Figure	O
1	O
,	O
2	O
)	O
.	O

Heptad	O
repeats	O
promote	O
helical	O
coiled	O
coil	O
interactions	O
in	O
multiple	O
soluble	O
and	O
membrane	O
-	O
spanning	O
proteins	O
[	O
29	O
-	O
31	O
]	O
.	O

In	O
the	O
heptad	O
repeat	O
,	O
hydrophobic	O
residues	O
in	O
positions	O
a	O
and	O
d	O
are	O
of	O
special	O
importance	O
,	O
as	O
they	O
directly	O
mediate	O
interhelical	O
contacts	O
by	O
creating	O
a	O
tight	O
knobs	O
-	O
into	O
-	O
holes	O
packing	O
in	O
the	O
coiled	O
coil	O
structure	O
[	O
32	O
]	O
.	O

For	O
instance	O
,	O
in	O
the	O
leucine	O
zipper	O
of	O
the	O
yeast	S-Species
transcription	O
factor	O
GCN4	O
,	O
positions	O
a	O
and	O
d	O
contain	O
Val	O
and	O
Leu	O
residues	O
,	O
respectively	O
,	O
with	O
an	O
Asn	O
residue	O
in	O
a	O
single	O
a	O
position	O
forming	O
a	O
hydrogen	O
bond	O
across	O
the	O
GCN4	O
dimer	O
interface	O
[	O
33	O
]	O
.	O

In	O
TM1	O
of	O
tetraspanins	O
,	O
highly	O
conserved	O
Asn	O
,	O
Gly	O
and	O
Gly	O
residues	O
(	O
numbers	O
18	O
,	O
25	O
and	O
32	O
in	O
the	O
CD9	O
sequence	O
)	O
appear	O
at	O
d	O
positions	O
of	O
the	O
heptad	O
repeats	O
,	O
and	O
residues	O
14	O
,	O
21	O
and	O
28	O
are	O
at	O
a	O
positions	O
(	O
Figure	O
1	O
)	O
.	O

In	O
TM2	O
,	O
residues	O
67	O
,	O
74	O
and	O
81	O
(	O
consensus	O
Gly	O
,	O
Gly	O
and	O
Ala	O
,	O
respectively	O
)	O
occupy	O
a	O
positions	O
,	O
whereas	O
residues	O
63	O
,	O
70	O
and	O
77	O
are	O
at	O
d	O
positions	O
.	O

Another	O
highly	O
conserved	O
glycine	O
,	O
Gly80	O
,	O
occupies	O
the	O
3rd	O
g	O
position	O
in	O
TM2	O
.	O

In	O
TM3	O
,	O
the	O
conserved	O
pattern	O
consists	O
of	O
two	O
leucine	O
residues	O
(	O
Leu89	O
and	O
Leu96	O
)	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
(	O
Glu	O
/	O
Gln103	O
)	O
in	O
a	O
positions	O
(	O
Figure	O
2	O
)	O
.	O

Two	O
d	O
positions	O
are	O
also	O
conserved	O
-	O
Phe	O
/	O
Tyr92	O
and	O
Ile	O
/	O
Val	O
/	O
Leu99	O
.	O

TM4	O
lacks	O
a	O
conserved	O
heptad	O
pattern	O
and	O
has	O
only	O
a	O
single	O
conserved	O
position	O
,	O
Glu	O
/	O
Gln209	O
(	O
with	O
four	O
exceptions	O
)	O
.	O

These	O
features	O
of	O
TM1	O
-	O
4	O
of	O
tetraspanins	O
are	O
displayed	O
on	O
helical	O
wheel	O
diagrams	O
(	O
Figure	O
3	O
)	O
.	O

Analysis	O
of	O
TM1	O
sequences	O

The	O
conserved	O
Asn	O
-	O
Gly	O
-	O
Gly	O
motif	O
,	O
occupying	O
designated	O
d	O
positions	O
of	O
the	O
heptad	O
repeat	O
,	O
is	O
the	O
most	O
prominent	O
structural	O
feature	O
of	O
TM1	O
.	O

We	O
also	O
compared	O
sequences	O
of	O
CD9	O
orthologs	O
from	O
10	O
different	O
organisms	O
(	O
the	O
most	O
available	O
for	O
any	O
tetraspanin	O
)	O
to	O
gain	O
further	O
insight	O
into	O
conservation	O
and	O
variability	O
of	O
the	O
TM1	O
sequence	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
,	O
positions	O
a	O
,	O
d	O
and	O
g	O
in	O
TM1	O
are	O
among	O
the	O
most	O
conserved	O
(	O
0	O
,	O
1	O
and	O
1	O
substitution	O
,	O
respectively	O
)	O
,	O
while	O
interspecies	O
variability	O
tends	O
to	O
occur	O
in	O
other	O
positions	O
:	O
b	O
(	O
5	O
substitutions	O
)	O
,	O
c	O
(	O
4	O
substitutions	O
)	O
,	O
e	O
(	O
4	O
substitutions	O
)	O
and	O
f	O
(	O
4	O
substitutions	O
)	O
.	O

Thus	O
,	O
the	O
positions	O
typically	O
involved	O
in	O
coiled	O
coil	O
interactions	O
(	O
a	O
and	O
d	O
)	O
are	O
the	O
most	O
conserved	O
.	O

When	O
residues	O
of	O
TM1	O
are	O
plotted	O
as	O
a	O
helical	O
wheel	O
,	O
additional	O
structural	O
features	O
are	O
revealed	O
(	O
Figure	O
3	O
)	O
.	O

There	O
are	O
highly	O
conserved	O
aliphatic	O
and	O
aromatic	O
residues	O
in	O
the	O
first	O
three	O
a	O
positions	O
of	O
the	O
heptad	O
motif	O
(	O
Phe15	O
,	O
Trp22	O
and	O
Leu29	O
in	O
CD9	O
)	O
,	O
as	O
well	O
as	O
in	O
g	O
positions	O
(	O
Leu14	O
,	O
Phe21	O
,	O
Val28	O
in	O
CD9	O
)	O
.	O

The	O
"	O
ridges	O
"	O
formed	O
by	O
these	O
bulky	O
residues	O
are	O
flanking	O
the	O
"	O
groove	O
"	O
-	O
forming	O
Gly	O
residues	O
of	O
the	O
Asn	O
-	O
Gly	O
-	O
Gly	O
position	O
d	O
motif	O
.	O

In	O
contrast	O
,	O
b	O
,	O
c	O
,	O
e	O
and	O
f	O
positions	O
show	O
an	O
overall	O
higher	O
variability	O
among	O
tetraspanins	O
,	O
as	O
also	O
seen	O
in	O
the	O
comparison	O
of	O
CD9	O
orthologs	O
described	O
above	O
.	O

Analysis	O
of	O
TM2	O
sequences	O

A	O
landmark	O
feature	O
of	O
TM2	O
in	O
tetraspanins	O
is	O
the	O
presence	O
of	O
highly	O
conserved	O
glycine	O
residues	O
(	O
Gly67	O
,	O
74	O
,	O
77	O
and	O
80	O
in	O
CD9	O
,	O
Figure	O
1	O
)	O
.	O

Other	O
substitutions	O
at	O
these	O
positions	O
are	O
almost	O
exclusively	O
small	O
residues	O
,	O
such	O
as	O
Ala	O
or	O
Ser	O
.	O

In	O
addition	O
,	O
Ala	O
,	O
Ser	O
or	O
Thr	O
occupy	O
position	O
81	O
.	O

This	O
residue	O
,	O
together	O
with	O
Gly67	O
and	O
Gly74	O
,	O
forms	O
face	O
a	O
of	O
the	O
helix	O
.	O

Residue	O
Gly77	O
(	O
position	O
d	O
)	O
is	O
preceded	O
by	O
conserved	O
,	O
chiefly	O
large	O
hydrophobic	O
residues	O
on	O
the	O
same	O
helical	O
face	O
(	O
Leu63	O
and	O
Met70	O
in	O
CD9	O
)	O
.	O

Extremely	O
conserved	O
Gly80	O
falls	O
into	O
heptad	O
position	O
g	O
(	O
Figure	O
3	O
)	O
.	O

Among	O
CD9	O
orthologs	O
,	O
heptad	O
positions	O
a	O
and	O
d	O
are	O
absolutely	O
conserved	O
,	O
whereas	O
other	O
positions	O
have	O
the	O
following	O
number	O
of	O
substitutions	O
:	O
b	O
-	O
3	O
;	O
c	O
-	O
2	O
;	O
e	O
-	O
1	O
;	O
f	O
-	O
3	O
;	O
g	O
-	O
1	O
(	O
Figure	O
4	O
)	O
.	O

Two	O
of	O
the	O
f	O
position	O
residues	O
in	O
TM2	O
(	O
65	O
and	O
79	O
)	O
also	O
show	O
higher	O
variability	O
among	O
different	O
tetraspanins	O
(	O
Figures	O
1	O
,	O
3	O
)	O
.	O

Cysteine	O
residues	O
are	O
frequently	O
found	O
near	O
the	O
cytoplasmic	O
end	O
of	O
TM2	O
helix	O
at	O
positions	O
78	O
and	O
79	O
;	O
these	O
cysteines	O
are	O
likely	O
to	O
be	O
palmitoylated	O
.	O

Analysis	O
of	O
TM3	O
and	O
TM4	O
sequences	O

The	O
TM3	O
domain	O
provides	O
another	O
example	O
of	O
the	O
heptad	O
repeat	O
pattern	O
.	O

Position	O
a	O
is	O
occupied	O
by	O
two	O
highly	O
conserved	O
leucine	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
(	O
Leu89	O
,	O
Leu96	O
and	O
Glu	O
/	O
Gln103	O
in	O
CD9	O
)	O
.	O

Furthermore	O
,	O
two	O
d	O
positions	O
are	O
conserved	O
-	O
Phe	O
/	O
Tyr92	O
(	O
aromatic	O
residue	O
)	O
and	O
Ile	O
/	O
Val99	O
(	O
beta	O
-	O
branched	O
aliphatic	O
residue	O
;	O
Figures	O
2	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
residue	O
100	O
in	O
position	O
e	O
is	O
generally	O
Phe	O
or	O
Leu	O
.	O

Among	O
CD9	O
orthologs	O
,	O
position	O
a	O
has	O
1	O
substitution	O
,	O
positions	O
b	O
,	O
c	O
and	O
f	O
each	O
have	O
6	O
,	O
positions	O
d	O
and	O
e	O
each	O
have	O
2	O
,	O
and	O
g	O
has	O
4	O
.	O

Thus	O
,	O
as	O
for	O
TM1	O
and	O
TM2	O
,	O
positions	O
a	O
and	O
d	O
are	O
among	O
the	O
most	O
conserved	O
,	O
but	O
overall	O
TM3	O
has	O
more	O
variable	O
positions	O
than	O
TM1	O
or	O
TM2	O
(	O
Figure	O
3	O
)	O
.	O

Less	O
than	O
half	O
of	O
TM3	O
sequences	O
contain	O
cysteine	O
residues	O
,	O
and	O
those	O
tend	O
to	O
occur	O
at	O
the	O
internal	O
positions	O
of	O
the	O
helix	O
(	O
Figure	O
2	O
)	O
.	O

TM4	O
shows	O
less	O
conservation	O
among	O
various	O
tetraspanin	O
family	O
members	O
than	O
the	O
other	O
TM	O
domains	O
(	O
Figures	O
2	O
,	O
3	O
)	O
.	O

The	O
only	O
highly	O
conserved	O
feature	O
is	O
the	O
glutamate	O
/	O
glutamine	O
residue	O
in	O
position	O
209	O
.	O

In	O
addition	O
,	O
one	O
or	O
two	O
cysteine	O
residues	O
can	O
be	O
found	O
at	O
the	O
C	O
-	O
terminal	O
end	O
of	O
TM4	O
in	O
some	O
tetraspanins	O
(	O
e	O
.	O
g	O
.	O
CD9	O
,	O
CD81	O
,	O
CD151	O
)	O
,	O
and	O
many	O
sequences	O
contain	O
additional	O
polar	O
residues	O
(	O
Arg	O
,	O
Lys	O
,	O
His	O
,	O
Asn	O
,	O
Gln	O
)	O
.	O

No	O
conserved	O
heptad	O
motif	O
was	O
identified	O
in	O
TM4	O
,	O
as	O
also	O
confirmed	O
by	O
analysis	O
of	O
substitutions	O
in	O
CD9	O
orthologs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutational	O
analysis	O
of	O
conserved	O
glycine	O
residues	O
in	O
TM1	O
and	O
TM2	O

The	O
conserved	O
nature	O
of	O
the	O
Asn	O
and	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
prompted	O
an	O
analysis	O
of	O
their	O
functional	O
role	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
probed	O
whether	O
mutations	O
of	O
these	O
residues	O
destabilize	O
the	O
protein	O
molecule	O
.	O

We	O
expressed	O
a	O
construct	O
of	O
the	O
first	O
and	O
second	O
TMs	O
of	O
CD9	O
,	O
connected	O
by	O
the	O
small	O
extracellular	O
loop	O
,	O
and	O
tagged	O
with	O
a	O
C	O
-	O
terminal	O
green	O
fluorescent	O
protein	O
(	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
molecule	O
)	O
.	O

In	O
human	S-Species
rhabdomyosarcoma	O
RD	O
cells	O
,	O
the	O
wild	O
-	O
type	O
fusion	O
protein	O
localized	O
mostly	O
in	O
a	O
reticular	O
,	O
intracellular	O
pattern	O
,	O
without	O
forming	O
any	O
large	O
aggregates	O
(	O
Figure	O
5	O
,	O
panel	O
A	O
)	O
.	O

Remarkably	O
,	O
when	O
double	O
mutants	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
Gly67Leu	O
+	O
Gly74Leu	O
were	O
expressed	O
,	O
the	O
protein	O
formed	O
distinct	O
large	O
aggregates	O
in	O
a	O
high	O
proportion	O
of	O
cells	O
(	O
Figure	O
5	O
,	O
panels	O
C	O
and	O
E	O
)	O
.	O

In	O
contrast	O
,	O
double	O
mutant	O
Gly77Leu	O
+	O
Gly80Leu	O
did	O
not	O
form	O
such	O
aggregates	O
(	O
Figure	O
5	O
,	O
panel	O
G	O
)	O
.	O

Results	O
with	O
respective	O
single	O
mutants	O
were	O
similar	O
to	O
that	O
with	O
double	O
mutants	O
,	O
with	O
the	O
aggregation	O
being	O
somewhat	O
more	O
pronounced	O
for	O
Leu	O
substitutions	O
of	O
Gly67	O
and	O
Gly74	O
compared	O
to	O
Gly25	O
and	O
Gly32	O
mutations	O
.	O

No	O
aggregation	O
was	O
observed	O
for	O
Asn18Ser	O
and	O
Asn18Tyr	O
mutants	O
(	O
data	O
not	O
shown	O
)	O
.	O

Also	O
,	O
nearly	O
identical	O
results	O
were	O
obtained	O
with	O
human	S-Species
HT1080	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
interpret	O
these	O
results	O
as	O
an	O
indication	O
that	O
aggregating	O
mutants	O
are	O
destabilized	O
or	O
misfolded	O
while	O
non	O
-	O
aggregating	O
mutants	O
retain	O
the	O
wild	O
-	O
type	O
conformation	O
.	O

Intriguingly	O
,	O
mutations	O
to	O
the	O
conserved	O
GG7	O
motifs	O
caused	O
protein	O
aggregation	O
while	O
the	O
mutation	O
of	O
other	O
glycines	O
had	O
no	O
detectable	O
effect	O
.	O

These	O
results	O
also	O
suggest	O
that	O
wild	O
-	O
type	O
GFP	O
,	O
which	O
has	O
weak	O
tendency	O
to	O
self	O
-	O
associate	O
,	O
could	O
enhance	O
non	O
-	O
specific	O
interactions	O
of	O
destabilized	O
mutant	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
moieties	O
,	O
leading	O
to	O
their	O
aggregation	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
aggregation	O
of	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
Gly67Leu	O
+	O
Gly74Leu	O
double	O
mutants	O
was	O
suppressed	O
when	O
monomeric	O
GFP	O
molecule	O
,	O
Leu221Lys	O
[	O
34	O
]	O
was	O
used	O
(	O
Figure	O
5	O
,	O
panels	O
D	O
and	O
F	O
)	O
.	O

The	O
use	O
of	O
monomeric	O
GFP	O
did	O
not	O
affect	O
intercellular	O
localization	O
of	O
wild	O
-	O
type	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
(	O
Figure	O
5	O
,	O
panel	O
B	O
)	O
,	O
or	O
a	O
Gly77Leu	O
+	O
Gly80Leu	O
double	O
mutant	O
(	O
Figure	O
5	O
,	O
panel	O
H	O
)	O
.	O

In	O
summary	O
,	O
Leu	O
substitutions	O
of	O
Gly	O
residues	O
that	O
are	O
part	O
of	O
the	O
Asn	O
-	O
Gly	O
-	O
Gly	O
(	O
NGG7	O
)	O
motif	O
in	O
TM1	O
,	O
or	O
Gly	O
-	O
Gly	O
-	O
Ala	O
(	O
GGA7	O
)	O
motif	O
in	O
TM2	O
,	O
resulted	O
in	O
destabilization	O
and	O
aggregation	O
of	O
GFP	O
-	O
fused	O
TM	O
(	O
1	O
+	O
2	O
)	O
proteins	O
,	O
whereas	O
substitutions	O
of	O
Gly77	O
or	O
Gly80	O
,	O
which	O
are	O
not	O
part	O
of	O
these	O
motifs	O
(	O
Figure	O
3	O
)	O
,	O
failed	O
to	O
show	O
such	O
aggregation	O
.	O

Prediction	O
and	O
modelling	O
of	O
interaction	O
between	O
TM1	O
and	O
TM2	O

Consecutive	O
helices	O
in	O
polytopic	O
membrane	O
proteins	O
frequently	O
interact	O
[	O
35	O
]	O
.	O

Sequence	O
analysis	O
of	O
TM1	O
and	O
TM2	O
helices	O
of	O
tetraspanins	O
reveals	O
a	O
remarkable	O
complementarity	O
in	O
the	O
distribution	O
of	O
large	O
and	O
small	O
residues	O
at	O
heptad	O
positions	O
a	O
and	O
d	O
along	O
the	O
helical	O
axis	O
(	O
Figure	O
3	O
)	O
,	O
suggesting	O
that	O
these	O
residues	O
may	O
interact	O
.	O

To	O
further	O
elucidate	O
the	O
potential	O
for	O
TM1	O
-	O
TM2	O
interaction	O
,	O
the	O
putative	O
interface	O
was	O
modeled	O
using	O
a	O
novel	O
algorithm	O
that	O
considers	O
mutational	O
data	O
during	O
each	O
step	O
of	O
a	O
Monte	O
Carlo	O
simulated	O
annealing	O
cycle	O
(	O
see	O
Methods	O
for	O
details	O
)	O
.	O

Specifically	O
,	O
Gly25Leu	O
,	O
Gly32Leu	O
,	O
Gly67Leu	O
and	O
Gly74Leu	O
were	O
scored	O
as	O
disruptive	O
mutations	O
,	O
while	O
Asn18Ser	O
,	O
Gly77Leu	O
and	O
Gly80Leu	O
were	O
scored	O
as	O
silent	O
mutations	O
,	O
based	O
on	O
their	O
effects	O
on	O
protein	O
stability	O
(	O
Figure	O
5	O
and	O
data	O
not	O
shown	O
)	O
.	O

The	O
resulting	O
model	O
predicts	O
left	O
-	O
handed	O
crossing	O
of	O
TM1	O
and	O
TM2	O
helices	O
at	O
an	O
angle	O
of	O
+	O
28	O
degrees	O
.	O

The	O
key	O
element	O
of	O
the	O
structure	O
is	O
the	O
apposition	O
of	O
bulky	O
and	O
small	O
heptad	O
position	O
a	O
and	O
d	O
residues	O
,	O
as	O
follows	O
:	O
Gly32	O
-	O
Leu63	O
;	O
Gly67	O
-	O
Leu29	O
;	O
Gly25	O
-	O
Met70	O
;	O
Gly74	O
-	O
Trp22	O
;	O
Asn18	O
-	O
Gly77	O
;	O
Ala81	O
-	O
Phe15	O
(	O
Figure	O
6	O
)	O
.	O

Our	O
model	O
predicts	O
that	O
each	O
of	O
these	O
residue	O
pairs	O
are	O
in	O
van	O
der	O
Waals	O
contact	O
.	O

Additionally	O
,	O
two	O
potential	O
H	O
-	O
bonds	O
are	O
predicted	O
in	O
this	O
model	O
,	O
indicating	O
close	O
packing	O
:	O
Gly67	O
C	O
alpha	O
to	O
Gly25	O
carbonyl	O
oxygen	O
,	O
and	O
Trp22	O
C	O
alpha	O
to	O
Met70	O
carbonyl	O
oxygen	O
.	O

The	O
packing	O
is	O
tighter	O
in	O
the	O
ectodomain	O
-	O
proximal	O
portion	O
of	O
the	O
helices	O
(	O
Figure	O
6	O
,	O
panel	O
B	O
)	O
,	O
as	O
determined	O
by	O
C	O
alpha	O
-	O
C	O
alpha	O
distances	O
between	O
interacting	O
residue	O
pairs	O
.	O

The	O
key	O
elements	O
of	O
the	O
model	O
are	O
corroborated	O
by	O
the	O
presence	O
of	O
apparently	O
complementary	O
substitutions	O
in	O
TM1	O
and	O
TM2	O
sequences	O
of	O
different	O
tetraspanins	O
(	O
Figure	O
1	O
,	O
boxed	O
residues	O
)	O
.	O

For	O
example	O
,	O
Gly74	O
is	O
predicted	O
to	O
interact	O
with	O
Trp22	O
.	O

In	O
8	O
of	O
the	O
10	O
tetraspanins	O
that	O
contain	O
a	O
substitution	O
for	O
Gly74	O
,	O
a	O
compensatory	O
substitution	O
occurs	O
at	O
the	O
Trp22	O
position	O
(	O
Figure	O
1	O
)	O
.	O

Thus	O
,	O
a	O
larger	O
non	O
-	O
glycine	O
side	O
chain	O
at	O
position	O
74	O
may	O
necessitate	O
a	O
less	O
bulky	O
non	O
-	O
Trp	O
side	O
chain	O
in	O
position	O
22	O
.	O

Likewise	O
,	O
the	O
presence	O
of	O
a	O
C	O
beta	O
at	O
position	O
25	O
,	O
typically	O
occupied	O
by	O
glycine	O
,	O
necessitates	O
a	O
non	O
-	O
beta	O
-	O
branched	O
amino	O
acid	O
at	O
position	O
70	O
,	O
which	O
is	O
occupied	O
by	O
a	O
beta	O
-	O
branched	O
residue	O
in	O
nearly	O
half	O
of	O
all	O
cases	O
.	O

Indeed	O
,	O
we	O
find	O
that	O
in	O
each	O
of	O
5	O
cases	O
in	O
which	O
position	O
25	O
contains	O
a	O
C	O
beta	O
,	O
a	O
leucine	O
residue	O
occurs	O
in	O
position	O
70	O
.	O

This	O
analysis	O
is	O
consistent	O
with	O
our	O
molecular	O
model	O
that	O
suggests	O
Leu70	O
will	O
pack	O
most	O
favorably	O
against	O
a	O
C	O
beta	O
at	O
position	O
25	O
than	O
a	O
beta	O
-	O
branched	O
residue	O
or	O
a	O
methionine	O
.	O

Role	O
of	O
TM1	O
and	O
TM2	O
heptad	O
motif	O
residues	O
in	O
CD9	O
dimerization	O

To	O
probe	O
CD9	O
dimerization	O
,	O
we	O
used	O
a	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
approach	O
.	O

We	O
established	O
previously	O
a	O
simple	O
and	O
efficient	O
method	O
for	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
[	O
25	O
]	O
.	O

After	O
cells	O
are	O
pre	O
-	O
treated	O
with	O
2	O
-	O
BP	O
for	O
16	O
-	O
24	O
hours	O
to	O
expose	O
normally	O
palmitoylated	O
cysteines	O
,	O
the	O
cysteines	O
can	O
be	O
cross	O
-	O
linked	O
using	O
any	O
of	O
the	O
following	O
methods	O
:	O
a	O
)	O
Spontaneous	O
oxidation	O
in	O
Brij97	O
lysates	O
(	O
a	O
condition	O
that	O
preserves	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
)	O
,	O
b	O
)	O
In	O
situ	O
cross	O
-	O
linking	O
,	O
by	O
pre	O
-	O
lysis	O
oxidation	O
of	O
cells	O
with	O
Cu2	O
+	O
-	O
phenanthroline	O
(	O
CuP	O
)	O
to	O
promote	O
disulfide	O
bond	O
formation	O
.	O

c	O
)	O
In	O
situ	O
cross	O
-	O
linking	O
with	O
thiol	O
-	O
reactive	O
cross	O
-	O
linking	O
agents	O
of	O
defined	O
length	O
(	O
e	O
.	O
g	O
.	O
DTME	O
,	O
BMB	O
)	O
.	O

The	O
first	O
two	O
approaches	O
produce	O
in	O
essence	O
"	O
zero	O
-	O
length	O
"	O
disulfides	O
,	O
indicative	O
of	O
close	O
proximity	O
of	O
target	O
cysteines	O
and	O
presumably	O
high	O
specificity	O
of	O
interaction	O
.	O

In	O
contrast	O
,	O
chemical	O
cross	O
-	O
linkers	O
with	O
6	O
-	O
20	O
A	O
spacer	O
arm	O
may	O
cross	O
-	O
link	O
with	O
higher	O
efficiency	O
,	O
but	O
not	O
necessarily	O
higher	O
specificity	O
.	O

However	O
,	O
they	O
provide	O
advantages	O
such	O
as	O
variable	O
membrane	O
permeability	O
,	O
and	O
potential	O
linkage	O
cleavability	O
.	O

For	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
membrane	O
-	O
permeable	O
cross	O
-	O
linker	O
DTME	O
(	O
13	O
.	O
3	O
A	O
-	O
long	O
,	O
reducible	O
)	O
provides	O
highly	O
specific	O
and	O
efficient	O
cross	O
-	O
linking	O
[	O
25	O
]	O
.	O

Here	O
we	O
have	O
used	O
a	O
cysteine	O
cross	O
-	O
linking	O
strategy	O
,	O
in	O
combination	O
with	O
cysteine	O
-	O
scanning	O
mutagenesis	O
,	O
to	O
map	O
the	O
residues	O
from	O
TM1	O
and	O
TM2	O
contributing	O
to	O
the	O
CD9	O
dimerization	O
interface	O
.	O

For	O
subsequent	O
cross	O
-	O
linking	O
experiments	O
using	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
protein	O
,	O
the	O
non	O
-	O
dimerizing	O
form	O
of	O
GFP	O
was	O
used	O
.	O

This	O
avoids	O
potential	O
GFP	O
-	O
dependent	O
dimerization	O
and	O
aggregation	O
that	O
can	O
be	O
observed	O
with	O
wild	O
-	O
type	O
GFP	O
,	O
especially	O
when	O
fusions	O
with	O
transmembrane	O
proteins	O
are	O
studied	O
[	O
36	O
]	O
.	O

Importantly	O
,	O
the	O
Leu221Lys	O
mutation	O
in	O
GFP	O
prevented	O
aggregation	O
of	O
mutant	O
forms	O
of	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
,	O
which	O
was	O
observed	O
with	O
wild	O
-	O
type	O
GFP	O
fusion	O
(	O
Figure	O
5	O
)	O
.	O

The	O
TM	O
(	O
1	O
+	O
2	O
)	O
fragment	O
of	O
CD9	O
contains	O
three	O
native	O
cysteines	O
-	O
Cys9	O
,	O
Cys78	O
and	O
Cys79	O
.	O

Single	O
-	O
cysteine	O
mutants	O
of	O
TM	O
(	O
1	O
+	O
2	O
)	O
were	O
constructed	O
,	O
in	O
which	O
a	O
cysteine	O
was	O
placed	O
at	O
various	O
faces	O
of	O
TM1	O
or	O
TM2	O
while	O
all	O
of	O
the	O
wild	O
-	O
type	O
cysteines	O
were	O
simultaneously	O
replaced	O
by	O
serines	O
.	O

The	O
mutant	O
proteins	O
were	O
transiently	O
expressed	O
in	O
RD	O
cells	O
(	O
having	O
little	O
endogenous	O
CD9	O
)	O
,	O
which	O
were	O
then	O
treated	O
for	O
16	O
-	O
18	O
hours	O
with	O
2	O
-	O
BP	O
.	O

To	O
achieve	O
maximal	O
specificity	O
in	O
cross	O
-	O
linking	O
we	O
used	O
a	O
"	O
zero	O
-	O
length	O
"	O
agent	O
,	O
CuP	O
.	O

First	O
,	O
single	O
-	O
cysteine	O
replacements	O
were	O
constructed	O
for	O
residues	O
Leu14	O
,	O
Phe15	O
,	O
Gly16	O
,	O
Phe17	O
and	O
Asn18	O
,	O
covering	O
just	O
over	O
one	O
complete	O
helical	O
turn	O
at	O
the	O
beginning	O
of	O
TM1	O
.	O

While	O
residue	O
Asn18	O
is	O
highly	O
conserved	O
,	O
positions	O
14	O
,	O
15	O
and	O
17	O
are	O
occupied	O
by	O
bulky	O
hydrophobic	O
residues	O
in	O
most	O
tetraspanins	O
,	O
whereas	O
position	O
16	O
shows	O
less	O
conservation	O
(	O
Figures	O
1	O
,	O
4	O
)	O
.	O

All	O
of	O
the	O
single	O
-	O
cysteine	O
mutants	O
showed	O
diffused	O
pattern	O
of	O
protein	O
localization	O
,	O
without	O
any	O
signs	O
of	O
aggregation	O
.	O

As	O
shown	O
in	O
Figure	O
7A	O
,	O
the	O
highest	O
level	O
of	O
intermolecular	O
cross	O
-	O
linking	O
was	O
observed	O
for	O
Leu14Cys	O
and	O
Phe17Cys	O
mutants	O
,	O
a	O
lower	O
level	O
for	O
Phe15Cys	O
and	O
Gly16Cys	O
mutants	O
,	O
and	O
very	O
little	O
cross	O
-	O
linking	O
for	O
Asn18Cys	O
substitution	O
.	O

These	O
results	O
indicate	O
that	O
:	O
a	O
)	O
the	O
first	O
two	O
transmembrane	O
domains	O
of	O
CD9	O
alone	O
can	O
mediate	O
its	O
dimerization	O
,	O
and	O
b	O
)	O
the	O
g	O
and	O
c	O
residues	O
of	O
TM1	O
(	O
e	O
.	O
g	O
.	O
Leu14	O
and	O
Phe17	O
,	O
Figure	O
3	O
)	O
are	O
likely	O
to	O
be	O
part	O
of	O
the	O
intermolecular	O
interface	O
.	O

Similarly	O
,	O
single	O
-	O
cysteine	O
substitutions	O
were	O
made	O
for	O
residues	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
;	O
in	O
addition	O
,	O
proteins	O
carrying	O
a	O
single	O
wild	O
-	O
type	O
cysteine	O
,	O
Cys9	O
,	O
Cys78	O
or	O
Cys79	O
,	O
were	O
tested	O
.	O

No	O
protein	O
aggregation	O
was	O
observed	O
for	O
any	O
of	O
these	O
single	O
-	O
cysteine	O
mutants	O
.	O

As	O
shown	O
in	O
Figure	O
7B	O
,	O
the	O
relatively	O
low	O
level	O
of	O
intermolecular	O
cross	O
-	O
linking	O
of	O
wild	O
-	O
type	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
protein	O
was	O
enhanced	O
dramatically	O
in	O
single	O
-	O
cysteine	O
TM2	O
mutants	O
Gly80Cys	O
and	O
Ala81Cys	O
.	O

The	O
Gly77Cys	O
mutant	O
also	O
had	O
an	O
elevated	O
level	O
of	O
cross	O
-	O
linking	O
.	O

In	O
contrast	O
,	O
any	O
of	O
the	O
three	O
native	O
cysteines	O
(	O
9	O
,	O
78	O
and	O
79	O
)	O
produced	O
level	O
of	O
cross	O
-	O
linking	O
not	O
much	O
greater	O
than	O
the	O
wild	O
-	O
type	O
TM	O
(	O
1	O
+	O
2	O
)	O
protein	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
cysteine	O
-	O
reactive	O
cross	O
-	O
linker	O
BMB	O
(	O
data	O
not	O
shown	O
)	O
.	O

Likewise	O
,	O
comparable	O
results	O
were	O
obtained	O
with	O
single	O
-	O
cysteine	O
mutants	O
of	O
untagged	O
,	O
full	O
-	O
length	O
CD9	O
,	O
using	O
CuP	O
(	O
Figure	O
7C	O
)	O
as	O
well	O
as	O
DTME	O
cross	O
-	O
linker	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
cross	O
-	O
linking	O
results	O
for	O
TM1	O
and	O
TM2	O
are	O
consistent	O
with	O
our	O
model	O
that	O
places	O
residues	O
Leu14	O
,	O
Phe17	O
and	O
Gly80	O
on	O
the	O
same	O
side	O
of	O
the	O
TM1	O
-	O
TM2	O
pair	O
(	O
Figure	O
6	O
,	O
panel	O
C	O
)	O
.	O

The	O
strong	O
cross	O
-	O
linking	O
with	O
Leu14Cys	O
,	O
Phe17Cys	O
and	O
Gly80Cys	O
places	O
the	O
intermolecular	O
interface	O
toward	O
the	O
c	O
and	O
g	O
phases	O
of	O
the	O
TM1	O
helix	O
,	O
and	O
the	O
g	O
phase	O
of	O
the	O
TM2	O
helix	O
,	O
away	O
from	O
its	O
e	O
and	O
f	O
faces	O
containing	O
wild	O
-	O
type	O
cysteines	O
78	O
and	O
79	O
.	O

Critical	O
residues	O
at	O
the	O
TM1	O
-	O
TM2	O
interface	O
also	O
affect	O
dimerization	O
indirectly	O
.	O

To	O
assess	O
specific	O
CD9	O
dimerization	O
,	O
we	O
used	O
a	O
Gly80Cys	O
substitution	O
at	O
the	O
intermolecular	O
interface	O
for	O
cross	O
-	O
linking	O
.	O

As	O
shown	O
in	O
Figure	O
8A	O
,	O
single	O
replacements	O
of	O
conserved	O
heptad	O
residues	O
in	O
positions	O
18	O
,	O
25	O
,	O
32	O
,	O
67	O
and	O
74	O
(	O
Asn18Ser	O
,	O
Gly25	O
/	O
32	O
/	O
67	O
/	O
74	O
-->	O
Leu	O
)	O
strongly	O
decreased	O
the	O
cross	O
-	O
linking	O
mediated	O
by	O
Cys80	O
.	O

The	O
effect	O
was	O
most	O
pronounced	O
for	O
mutations	O
of	O
residues	O
,	O
Gly32	O
and	O
Gly67	O
,	O
located	O
in	O
the	O
tightly	O
packed	O
extracellular	O
end	O
of	O
TM	O
helices	O
(	O
Figure	O
6	O
)	O
.	O

In	O
contrast	O
,	O
mutations	O
of	O
residues	O
closer	O
to	O
the	O
cytoplasmic	O
end	O
of	O
TM2	O
(	O
Gly74	O
and	O
especially	O
Ala81	O
)	O
had	O
only	O
modest	O
to	O
very	O
little	O
effect	O
on	O
cross	O
-	O
linking	O
.	O

Relatively	O
low	O
efficiency	O
of	O
intermolecular	O
cross	O
-	O
linking	O
via	O
native	O
residues	O
Cys9	O
,	O
78	O
,	O
and	O
79	O
(	O
Figures	O
7B	O
,	O
C	O
)	O
correlates	O
well	O
with	O
the	O
predicted	O
location	O
of	O
Cys78	O
and	O
79	O
away	O
from	O
the	O
dimeric	O
interface	O
(	O
Figure	O
3	O
)	O
,	O
and	O
suggests	O
that	O
the	O
extramembrane	O
N	O
-	O
terminal	O
part	O
of	O
CD9	O
(	O
residues	O
1	O
-	O
13	O
)	O
does	O
not	O
self	O
-	O
associate	O
.	O

We	O
next	O
examined	O
whether	O
mutations	O
of	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
decreased	O
low	O
-	O
level	O
background	O
cross	O
-	O
linking	O
via	O
native	O
cysteines	O
.	O

As	O
expected	O
,	O
these	O
mutations	O
had	O
virtually	O
no	O
effect	O
on	O
dimer	O
formation	O
of	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
(	O
Figure	O
8B	O
)	O
.	O

The	O
level	O
of	O
covalent	O
dimer	O
formed	O
was	O
not	O
diminished	O
for	O
triple	O
Asn18Ser	O
+	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
double	O
Gly67Leu	O
+	O
Gly74Leu	O
mutants	O
,	O
compared	O
to	O
wild	O
-	O
type	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
molecule	O
.	O

Similarly	O
,	O
the	O
same	O
triple	O
and	O
double	O
mutations	O
in	O
the	O
context	O
of	O
full	O
-	O
length	O
CD9	O
-	O
GFP	O
protein	O
(	O
with	O
six	O
cysteines	O
)	O
produced	O
wild	O
-	O
type	O
levels	O
of	O
cross	O
-	O
linking	O
(	O
Figure	O
8C	O
)	O
.	O

We	O
interpret	O
these	O
findings	O
as	O
evidence	O
for	O
at	O
least	O
two	O
types	O
of	O
associations	O
between	O
CD9	O
molecules	O
:	O
primary	O
,	O
involving	O
residues	O
14	O
,	O
17	O
and	O
80	O
,	O
and	O
dependent	O
on	O
integrity	O
of	O
conserved	O
heptad	O
residues	O
in	O
TM1	O
and	O
TM2	O
,	O
and	O
less	O
efficient	O
secondary	O
interactions	O
,	O
probably	O
representing	O
random	O
collision	O
events	O
,	O
and	O
independent	O
of	O
the	O
heptad	O
residues	O
(	O
see	O
Discussion	O
for	O
more	O
details	O
)	O
.	O

TM3	O
and	O
TM4	O
cysteine	O
residues	O
in	O
CD9	O
dimerization	O

After	O
identifying	O
the	O
roles	O
of	O
conserved	O
TM1	O
and	O
TM2	O
residues	O
in	O
CD9	O
dimerization	O
,	O
we	O
next	O
probed	O
whether	O
residues	O
proximal	O
to	O
TM	O
domains	O
3	O
and	O
4	O
are	O
also	O
involved	O
.	O

To	O
this	O
end	O
,	O
disulfide	O
cross	O
-	O
linking	O
of	O
full	O
-	O
length	O
CD9	O
molecules	O
containing	O
3	O
C	O
-	O
terminal	O
cysteines	O
(	O
87	O
,	O
just	O
before	O
TM3	O
;	O
218	O
and	O
219	O
in	O
TM4	O
)	O
or	O
3	O
N	O
-	O
terminal	O
cysteines	O
(	O
9	O
,	O
78	O
and	O
79	O
)	O
was	O
compared	O
(	O
Figure	O
9	O
)	O
.	O

We	O
found	O
that	O
the	O
C	O
-	O
terminal	O
cysteines	O
were	O
only	O
slightly	O
better	O
than	O
N	O
-	O
terminal	O
cysteines	O
with	O
respect	O
to	O
detection	O
of	O
CD9	O
dimers	O
.	O

However	O
,	O
markedly	O
more	O
trimers	O
and	O
tetramers	O
were	O
detected	O
using	O
C	O
-	O
terminal	O
cysteines	O
.	O

Thus	O
,	O
residues	O
87	O
,	O
218	O
and	O
219	O
at	O
TM3	O
and	O
TM4	O
in	O
CD9	O
can	O
together	O
form	O
contacts	O
across	O
the	O
dimeric	O
interface	O
and	O
also	O
additional	O
contacts	O
with	O
other	O
neighboring	O
CD9	O
molecules	O
.	O

Discussion	O

Here	O
we	O
provide	O
the	O
first	O
detailed	O
analysis	O
of	O
tetraspanin	O
protein	O
transmembrane	O
domains	O
.	O

First	O
,	O
we	O
show	O
1	O
)	O
the	O
presence	O
of	O
a	O
heptad	O
repeat	O
motif	O
in	O
TM1	O
and	O
TM2	O
,	O
containing	O
highly	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
,	O
2	O
)	O
a	O
leucine	O
and	O
glutamate	O
/	O
glutamine	O
-	O
containing	O
heptad	O
motif	O
in	O
TM3	O
,	O
and	O
3	O
)	O
high	O
variability	O
and	O
absence	O
of	O
heptad	O
repeats	O
in	O
TM4	O
sequences	O
.	O

Second	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
specific	O
,	O
intramolecular	O
interaction	O
between	O
TM1	O
and	O
TM2	O
domains	O
,	O
in	O
which	O
bulky	O
hydrophobic	O
residues	O
pack	O
against	O
GG7	O
motif	O
,	O
and	O
present	O
a	O
molecular	O
model	O
for	O
this	O
interaction	O
.	O

Third	O
,	O
experimental	O
mapping	O
of	O
the	O
CD9	O
dimerization	O
interface	O
firmly	O
establishes	O
an	O
additional	O
role	O
for	O
conserved	O
TM1	O
and	O
TM2	O
residues	O
in	O
dimeric	O
intermolecular	O
interactions	O
.	O

Fourth	O
,	O
preliminary	O
evidence	O
is	O
provided	O
to	O
suggest	O
that	O
TM3	O
and	O
TM4	O
domains	O
contribute	O
to	O
expansion	O
of	O
CD9	O
dimers	O
into	O
higher	O
order	O
multimers	O
.	O

Conserved	O
residues	O
in	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
:	O
role	O
in	O
intramolecular	O
packing	O

We	O
hypothesized	O
that	O
the	O
first	O
two	O
transmembrane	O
domains	O
of	O
tetraspanins	O
might	O
interact	O
with	O
each	O
other	O
because	O
:	O
a	O
)	O
consecutive	O
TM	O
domains	O
frequently	O
associate	O
in	O
known	O
protein	O
3D	O
structures	O
[	O
35	O
]	O
,	O
and	O
b	O
)	O
they	O
both	O
contain	O
a	O
series	O
of	O
highly	O
conserved	O
amino	O
acids	O
-	O
several	O
Gly	O
residues	O
and	O
an	O
Asn	O
residue	O
(	O
Figure	O
1	O
)	O
.	O

Conserved	O
Gly	O
residues	O
are	O
a	O
frequent	O
theme	O
in	O
the	O
organization	O
of	O
interacting	O
transmembrane	O
domains	O
.	O

Analysis	O
of	O
3D	O
helix	O
packing	O
in	O
polytopic	O
membrane	O
proteins	O
reveals	O
that	O
Gly	O
residues	O
tend	O
to	O
localize	O
in	O
buried	O
positions	O
,	O
especially	O
at	O
the	O
helix	O
-	O
helix	O
interfaces	O
and	O
helix	O
crossing	O
points	O
[	O
37	O
,	O
38	O
]	O
.	O

Due	O
to	O
the	O
absence	O
of	O
a	O
side	O
chain	O
,	O
Gly	O
provides	O
a	O
flat	O
surface	O
for	O
packing	O
of	O
a	O
side	O
chain	O
from	O
another	O
residue	O
,	O
without	O
loss	O
of	O
side	O
-	O
chain	O
entropy	O
upon	O
interaction	O
.	O

The	O
most	O
common	O
Gly	O
-	O
containing	O
motif	O
is	O
GxxxG	O
[	O
39	O
,	O
40	O
]	O
.	O

In	O
glycophorin	O
A	O
(	O
GpA	O
)	O
,	O
the	O
major	O
glycoprotein	O
in	O
erythrocyte	O
cell	O
membranes	O
,	O
Gly79	O
and	O
Gly83	O
are	O
part	O
of	O
the	O
LIxxGVxxGVxxT	O
sequence	O
that	O
promotes	O
homodimerization	O
of	O
parallel	O
transmembrane	O
alpha	O
-	O
helixes	O
[	O
41	O
,	O
42	O
]	O
.	O

In	O
the	O
GpA	O
dimerization	O
motif	O
,	O
Gly	O
residues	O
allow	O
for	O
tight	O
packing	O
in	O
the	O
right	O
-	O
handed	O
helical	O
crossing	O
[	O
43	O
]	O
.	O

There	O
are	O
also	O
examples	O
of	O
left	O
-	O
handed	O
helical	O
crossing	O
in	O
the	O
context	O
of	O
a	O
GxxxG	O
motif	O
[	O
44	O
]	O
.	O

Other	O
membrane	O
proteins	O
that	O
use	O
the	O
GxxxG	O
motif	O
for	O
homo	O
-	O
or	O
heterodimerization	O
include	O
bacteriophage	B-Species
M13	E-Species
coat	O
proteins	O
[	O
45	O
]	O
,	O
yeast	S-Species
alpha	O
factor	O
receptor	O
[	O
46	O
]	O
,	O
integrin	O
alpha	O
IIb	O
subunit	O
[	O
47	O
]	O
,	O
and	O
ErbB1	O
receptor	O
tyrosine	O
kinase	O
[	O
48	O
]	O
.	O

Other	O
small	O
residues	O
,	O
such	O
as	O
Ala	O
and	O
Ser	O
,	O
can	O
substitute	O
for	O
Gly	O
in	O
this	O
motif	O
[	O
49	O
]	O
.	O

A	O
protein	O
motif	O
in	O
which	O
Gly	O
residues	O
are	O
separated	O
by	O
6	O
other	O
residues	O
(	O
GG7	O
)	O
is	O
also	O
common	O
in	O
transmembrane	O
helices	O
,	O
especially	O
in	O
transporter	O
/	O
channel	O
-	O
like	O
membrane	O
proteins	O
[	O
50	O
]	O
.	O

However	O
,	O
the	O
structural	O
features	O
associated	O
with	O
this	O
motif	O
are	O
not	O
well	O
known	O
.	O

In	O
particular	O
,	O
it	O
is	O
unclear	O
whether	O
left	O
-	O
handed	O
GG7	O
heptad	O
repeat	O
motif	O
(	O
as	O
opposed	O
to	O
the	O
"	O
classic	O
"	O
right	O
-	O
handed	O
GxxxG	O
motif	O
)	O
can	O
drive	O
membrane	O
helix	O
association	O
.	O

In	O
a	O
recent	O
work	O
addressing	O
this	O
issue	O
,	O
Lear	O
et	O
al	O
.	O

[	O
51	O
]	O
showed	O
that	O
a	O
synthetic	O
peptide	O
containing	O
Gly	O
at	O
heptad	O
positions	O
a	O
and	O
d	O
could	O
self	O
-	O
associate	O
in	O
vitro	O
,	O
likely	O
in	O
an	O
antiparallel	O
orientation	O
.	O

Heptad	O
repeats	O
containing	O
conserved	O
Gly	O
residues	O
occur	O
in	O
TM	O
domains	O
of	O
alpha	O
and	O
beta	O
chains	O
of	O
MHC	O
class	O
II	O
proteins	O
,	O
and	O
mutations	O
of	O
the	O
Gly	O
residues	O
disrupt	O
the	O
alpha	O
beta	O
heterodimer	O
[	O
52	O
]	O
.	O

These	O
examples	O
demonstrate	O
that	O
Gly	O
-	O
based	O
heptad	O
motifs	O
may	O
be	O
used	O
for	O
both	O
intra	O
-	O
and	O
intermolecular	O
associations	O
.	O

In	O
this	O
work	O
,	O
we	O
identified	O
a	O
highly	O
conserved	O
GG7	O
motif	O
in	O
the	O
first	O
two	O
tetraspanin	O
TM	O
domains	O
.	O

The	O
GG7	O
sequence	O
in	O
tetraspanins	O
is	O
a	O
part	O
of	O
a	O
larger	O
motif	O
that	O
also	O
includes	O
a	O
conserved	O
Asn	O
residue	O
in	O
TM1	O
(	O
NGG7	O
)	O
and	O
an	O
Ala	O
/	O
Ser	O
/	O
Thr	O
residue	O
in	O
TM2	O
(	O
GGA7	O
)	O
.	O

The	O
seven	O
-	O
residue	O
periodicity	O
of	O
these	O
motifs	O
strongly	O
suggests	O
their	O
involvement	O
in	O
left	O
-	O
handed	O
coiled	O
coil	O
packing	O
reminiscent	O
of	O
the	O
leucine	O
zipper	O
,	O
rather	O
than	O
right	O
-	O
handed	O
packing	O
of	O
the	O
GpA	O
-	O
like	O
GxxxG	O
motif	O
.	O

For	O
antiparallel	O
helices	O
,	O
the	O
left	O
-	O
handed	O
crossing	O
is	O
in	O
fact	O
predominant	O
over	O
the	O
right	O
-	O
handed	O
in	O
known	O
TM	O
domain	O
structures	O
[	O
44	O
]	O
.	O

In	O
our	O
model	O
,	O
heptad	O
Gly	O
residues	O
in	O
NGG7	O
and	O
GGA7	O
sequences	O
provide	O
specific	O
packing	O
between	O
antiparallel	O
tetraspanin	O
TM1	O
and	O
TM2	O
helices	O
by	O
allowing	O
tight	O
van	O
der	O
Waals	O
interactions	O
with	O
large	O
hydrophobic	O
residues	O
(	O
Figure	O
6	O
)	O
.	O

Highly	O
efficient	O
packing	O
of	O
bulky	O
side	O
chains	O
against	O
glycine	O
residues	O
is	O
observed	O
in	O
known	O
transmembrane	O
protein	O
3D	O
structures	O
[	O
38	O
,	O
53	O
,	O
54	O
]	O
.	O

An	O
example	O
includes	O
packing	O
of	O
helices	O
M1	O
and	O
M2	O
in	O
potassium	O
channel	O
KcsA	O
,	O
where	O
Val91	O
in	O
M2	O
is	O
paired	O
with	O
Gly43	O
in	O
M1	O
,	O
and	O
Leu36	O
in	O
M1	O
contacts	O
Ala98	O
and	O
Gly99	O
in	O
helix	O
M2	O
[	O
54	O
,	O
55	O
]	O
.	O

In	O
addition	O
to	O
facilitating	O
helix	O
-	O
helix	O
packing	O
,	O
Gly	O
residues	O
frequently	O
provide	O
additional	O
C	O
alpha	O
H	O
.	O
.	O
.	O
O	O
hydrogen	O
bonds	O
between	O
two	O
helices	O
[	O
44	O
]	O
.	O

In	O
our	O
model	O
,	O
two	O
C	O
alpha	O
-	O
backbone	O
carbonyl	O
H	O
-	O
bonds	O
are	O
predicted	O
-	O
between	O
residues	O
Gly27	O
-	O
Gly67	O
,	O
and	O
Trp22	O
-	O
Met70	O
.	O

Although	O
polar	O
and	O
charged	O
amino	O
acid	O
residues	O
(	O
such	O
as	O
Asn	O
in	O
the	O
TM1	O
heptad	O
motif	O
)	O
are	O
infrequent	O
in	O
transmembrane	O
domains	O
,	O
they	O
are	O
functionally	O
important	O
.	O

Polar	O
residues	O
such	O
as	O
glutamine	O
,	O
glutamic	O
acid	O
,	O
aspartic	O
acid	O
and	O
asparagine	O
can	O
promote	O
strong	O
oligomerization	O
of	O
model	O
membrane	O
-	O
associated	O
helices	O
[	O
56	O
-	O
58	O
]	O
.	O

Ruan	O
et	O
al	O
.	O

[	O
59	O
]	O
used	O
asparagine	O
scanning	O
mutagenesis	O
to	O
probe	O
the	O
interface	O
of	O
self	O
-	O
associating	O
polyleucine	O
helices	O
by	O
detecting	O
their	O
enhanced	O
self	O
-	O
interaction	O
in	O
vitro	O
and	O
in	O
the	O
E	B-Species
.	I-Species
coli	E-Species
-	O
based	O
ToxR	O
assay	O
.	O

Thus	O
,	O
a	O
hydrogen	O
bond	O
in	O
an	O
apolar	O
environment	O
can	O
result	O
in	O
strong	O
,	O
though	O
not	O
necessarily	O
specific	O
,	O
association	O
of	O
transmembrane	O
helices	O
.	O

In	O
fact	O
,	O
mutations	O
to	O
polar	O
residues	O
in	O
transmembrane	O
proteins	O
are	O
commonly	O
associated	O
with	O
disease	O
[	O
60	O
]	O
.	O

Because	O
of	O
this	O
potential	O
for	O
non	O
-	O
specific	O
interactions	O
,	O
polar	O
residues	O
tend	O
to	O
localize	O
at	O
buried	O
positions	O
in	O
TM	O
domains	O
.	O

In	O
our	O
case	O
,	O
the	O
conserved	O
Asn18	O
residue	O
in	O
CD9	O
is	O
predicted	O
to	O
be	O
a	O
part	O
of	O
the	O
TM1	O
-	O
TM2	O
interface	O
,	O
though	O
our	O
model	O
does	O
not	O
predict	O
any	O
electrostatic	O
interaction	O
between	O
Asn18	O
and	O
TM2	O
(	O
Figure	O
6	O
)	O
.	O

Consistently	O
,	O
substitution	O
such	O
as	O
Asn18Tyr	O
(	O
and	O
Gly77Leu	O
)	O
in	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
protein	O
was	O
not	O
destabilizing	O
as	O
analyzed	O
by	O
protein	O
aggregation	O
.	O

Curiously	O
,	O
the	O
full	O
-	O
length	O
Asn18Ser	O
CD9	O
migrated	O
slightly	O
slower	O
on	O
SDS	O
-	O
PAGE	O
gel	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
Asn18	O
does	O
play	O
a	O
role	O
in	O
maintaining	O
conformation	O
of	O
the	O
molecule	O
.	O

The	O
Asn18Cys	O
single	O
-	O
cysteine	O
mutant	O
shows	O
very	O
little	O
intermolecular	O
cross	O
-	O
linking	O
(	O
Figure	O
7A	O
)	O
,	O
supporting	O
the	O
proposed	O
location	O
of	O
this	O
residue	O
at	O
the	O
intramolecular	O
interface	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
the	O
"	O
pocket	O
"	O
between	O
TM1	O
and	O
TM2	O
lined	O
by	O
Asn18	O
and	O
Gly77	O
might	O
be	O
important	O
for	O
accommodating	O
palmitate	O
moieties	O
that	O
target	O
Cys78	O
and	O
Cys79	O
residues	O
,	O
and	O
/	O
or	O
important	O
for	O
access	O
by	O
the	O
putative	O
palmitoyl	O
transferase	O
to	O
those	O
residues	O
.	O

Understanding	O
the	O
exact	O
role	O
of	O
these	O
highly	O
conserved	O
Asn18	O
and	O
Gly77	O
residues	O
in	O
tetraspanins	O
awaits	O
further	O
investigation	O
.	O

In	O
summary	O
,	O
we	O
identified	O
conserved	O
glycine	O
residues	O
of	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
as	O
key	O
elements	O
required	O
for	O
intramolecular	O
packing	O
.	O

Mutations	O
of	O
these	O
key	O
residues	O
(	O
Gly25	O
,	O
Gly32	O
,	O
Gly67	O
and	O
Gly74	O
in	O
CD9	O
)	O
resulted	O
in	O
protein	O
destabilization	O
and	O
aggregation	O
.	O

There	O
is	O
ample	O
evidence	O
in	O
the	O
literature	O
for	O
mutations	O
in	O
transmembrane	O
proteins	O
that	O
lead	O
to	O
protein	O
destabilization	O
,	O
misassembly	O
and	O
pathologic	O
conditions	O
[	O
61	O
]	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
conserved	O
heptad	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
as	O
plausible	O
targets	O
of	O
destabilizing	O
mutations	O
with	O
potential	O
functional	O
consequences	O
.	O

Intermolecular	O
interactions	O
in	O
tetraspanins	O

Tetraspanin	O
CD9	O
forms	O
mostly	O
homodimers	O
,	O
but	O
also	O
a	O
low	O
level	O
of	O
heterodimers	O
with	O
CD81	O
and	O
CD151	O
[	O
25	O
]	O
.	O

Thus	O
,	O
mapping	O
the	O
dimerization	O
interface	O
is	O
an	O
important	O
next	O
step	O
in	O
structure	O
-	O
function	O
analysis	O
of	O
tetraspanins	O
.	O

Disulfide	O
-	O
mediated	O
cross	O
-	O
linking	O
,	O
often	O
in	O
combination	O
with	O
cysteine	O
-	O
scanning	O
mutagenesis	O
,	O
is	O
a	O
common	O
strategy	O
to	O
probe	O
oligomerization	O
or	O
intersubunit	O
interactions	O
of	O
transmembrane	O
proteins	O
such	O
as	O
histidine	O
kinase	O
EnvZ	O
[	O
62	O
]	O
,	O
M	O
(	O
3	O
)	O
muscarinic	O
acetylcholine	O
receptor	O
[	O
63	O
]	O
,	O
E	B-Species
.	I-Species
coli	E-Species
lactose	O
permease	O
[	O
64	O
]	O
,	O
synaptobrevin	O
[	O
65	O
]	O
,	O
integrins	O
[	O
66	O
]	O
and	O
many	O
others	O
.	O

In	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
membrane	O
-	O
proximal	O
cysteine	O
residues	O
are	O
especially	O
useful	O
targets	O
for	O
disulfide	O
trapping	O
,	O
as	O
their	O
linkage	O
can	O
be	O
enhanced	O
by	O
pre	O
-	O
treating	O
cells	O
with	O
2	O
-	O
BP	O
.	O

While	O
the	O
ability	O
of	O
wild	O
-	O
type	O
cysteines	O
in	O
CD9	O
to	O
be	O
cross	O
-	O
linked	O
may	O
indicate	O
that	O
they	O
are	O
close	O
to	O
the	O
dimerization	O
interface	O
,	O
more	O
precise	O
mapping	O
was	O
achieved	O
here	O
using	O
cysteine	O
-	O
scanning	O
mutagenesis	O
.	O

Our	O
data	O
clearly	O
identify	O
regions	O
,	O
near	O
the	O
cytoplasmic	O
face	O
of	O
TM1	O
and	O
TM2	O
,	O
important	O
for	O
dimerization	O
.	O

Intermolecular	O
zero	O
-	O
length	O
cross	O
-	O
linking	O
was	O
highest	O
when	O
single	O
cysteines	O
were	O
placed	O
in	O
positions	O
14	O
,	O
17	O
,	O
77	O
,	O
80	O
and	O
81	O
in	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
molecule	O
,	O
or	O
at	O
positions	O
77	O
,	O
80	O
or	O
81	O
in	O
the	O
full	O
-	O
length	O
CD9	O
protein	O
.	O

Positions	O
14	O
,	O
17	O
and	O
80	O
are	O
distinct	O
from	O
the	O
intramolecular	O
interface	O
and	O
are	O
on	O
the	O
same	O
side	O
of	O
the	O
TM1	O
-	O
TM2	O
pair	O
(	O
Figure	O
6	O
)	O
.	O

Thus	O
,	O
they	O
are	O
well	O
-	O
positioned	O
to	O
participate	O
in	O
an	O
interaction	O
with	O
another	O
molecule	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
model	O
predicts	O
that	O
wild	O
-	O
type	O
cysteines	O
(	O
Cys78	O
,	O
79	O
)	O
,	O
which	O
do	O
not	O
yield	O
very	O
efficient	O
zero	O
-	O
length	O
cross	O
-	O
linking	O
,	O
are	O
on	O
the	O
other	O
side	O
of	O
TM1	O
-	O
TM2	O
pair	O
.	O

While	O
using	O
the	O
cysteine	O
at	O
position	O
80	O
as	O
the	O
dimeric	O
interface	O
probe	O
,	O
mutations	O
of	O
conserved	O
residues	O
in	O
TM1	O
and	O
TM2	O
(	O
especially	O
Gly32	O
and	O
Gly67	O
to	O
Leu	O
)	O
clearly	O
reduced	O
intermolecular	O
cross	O
-	O
linking	O
.	O

We	O
do	O
not	O
suggest	O
that	O
those	O
residues	O
are	O
directly	O
involved	O
in	O
intermolecular	O
interaction	O
.	O

Rather	O
,	O
we	O
propose	O
that	O
destabilization	O
of	O
the	O
intramolecular	O
TM1	O
-	O
TM2	O
interaction	O
by	O
Gly	O
to	O
Leu	O
substitutions	O
(	O
discussed	O
above	O
)	O
causes	O
an	O
overall	O
conformational	O
change	O
that	O
reduces	O
dimer	O
formation	O
.	O

An	O
Ala81Leu	O
mutation	O
did	O
not	O
reduce	O
cross	O
-	O
linking	O
via	O
Cys80	O
,	O
even	O
though	O
single	O
-	O
cysteine	O
Ala81Cys	O
molecules	O
themselves	O
produced	O
a	O
high	O
level	O
of	O
cross	O
-	O
linking	O
.	O

These	O
results	O
,	O
together	O
with	O
data	O
on	O
Gly32Leu	O
and	O
Gly67Leu	O
mutations	O
,	O
are	O
consistent	O
with	O
our	O
model	O
predicting	O
that	O
helices	O
1	O
and	O
2	O
interact	O
more	O
tightly	O
near	O
the	O
extracellular	O
end	O
and	O
less	O
at	O
the	O
cytoplasmic	O
end	O
.	O

This	O
would	O
give	O
more	O
flexibility	O
to	O
a	O
cysteine	O
at	O
position	O
81	O
and	O
also	O
limit	O
the	O
effect	O
of	O
an	O
Ala81Leu	O
mutation	O
.	O

Location	O
of	O
this	O
residue	O
at	O
the	O
membrane	O
/	O
cytoplasmic	O
border	O
could	O
also	O
make	O
it	O
more	O
accessible	O
to	O
CuP	O
reagent	O
as	O
compared	O
to	O
residues	O
buried	O
in	O
TM	O
domain	O
,	O
thus	O
elevating	O
the	O
efficiency	O
of	O
disulfide	O
formation	O
of	O
the	O
Ala81Cys	O
mutant	O
.	O

Multiple	O
interfaces	O
in	O
tetraspanin	O
molecules	O

In	O
the	O
full	O
-	O
length	O
CD9	O
molecules	O
,	O
the	O
3	O
C	O
-	O
terminal	O
cysteines	O
(	O
Cys87	O
,	O
218	O
and	O
219	O
)	O
located	O
at	O
or	O
in	O
TM3	O
and	O
TM4	O
promoted	O
efficient	O
dimer	O
and	O
even	O
more	O
efficient	O
oligomer	O
formation	O
compared	O
to	O
the	O
3	O
N	O
-	O
terminal	O
cysteines	O
(	O
Figure	O
9	O
)	O
.	O

Cys87	O
alone	O
can	O
be	O
used	O
to	O
capture	O
CD9	O
dimers	O
[	O
25	O
]	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
of	O
two	O
dimeric	O
interfaces	O
in	O
CD9	O
molecule	O
-	O
the	O
TM	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
and	O
the	O
TM	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
interface	O
(	O
Figure	O
10	O
)	O
.	O

In	O
a	O
TM	O
(	O
1	O
+	O
2	O
)	O
molecule	O
,	O
the	O
destabilization	O
of	O
1	O
-	O
2	O
interaction	O
,	O
e	O
.	O
g	O
.	O
by	O
Gly	O
-->	O
Leu	O
mutations	O
,	O
would	O
affect	O
the	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
,	O
as	O
discussed	O
above	O
.	O

However	O
,	O
these	O
mutations	O
would	O
not	O
interfere	O
with	O
the	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
interface	O
in	O
a	O
full	O
-	O
length	O
molecule	O
,	O
which	O
includes	O
Cys87	O
,	O
218	O
and	O
219	O
.	O

Thus	O
,	O
cross	O
-	O
linking	O
of	O
full	O
-	O
length	O
molecules	O
,	O
containing	O
all	O
6	O
cysteine	O
residues	O
,	O
would	O
be	O
unaffected	O
,	O
as	O
seen	O
in	O
Figure	O
8C	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
Cys9	O
,	O
Cys78	O
and	O
Cys79	O
are	O
apparently	O
not	O
at	O
the	O
primary	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
.	O

Their	O
relative	O
inefficiency	O
in	O
cross	O
-	O
linking	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
protein	O
likely	O
reflects	O
weak	O
secondary	O
contacts	O
between	O
the	O
molecules	O
,	O
or	O
possibly	O
random	O
collision	O
events	O
.	O

Such	O
events	O
should	O
be	O
independent	O
of	O
mutations	O
in	O
the	O
conserved	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
,	O
as	O
was	O
demonstrated	O
in	O
Figure	O
8B	O
.	O

The	O
potential	O
existence	O
of	O
two	O
interfaces	O
in	O
tetraspanin	O
molecules	O
,	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
and	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
,	O
should	O
provide	O
enhanced	O
flexibility	O
for	O
forming	O
additional	O
intermolecular	O
contacts	O
.	O

Current	O
understanding	O
of	O
tetraspanin	O
microdomains	O
assumes	O
a	O
few	O
strong	O
,	O
primary	O
homotypic	O
and	O
heterotypic	O
tetraspanin	O
complexes	O
(	O
e	O
.	O
g	O
.	O
CD9	O
-	O
CD9	O
,	O
CD9	O
-	O
CD81	O
,	O
CD151	O
-	O
alpha	O
3	O
integrin	O
,	O
CD81	O
-	O
EWI2	O
)	O
that	O
help	O
bring	O
together	O
various	O
other	O
proteins	O
,	O
forming	O
secondary	O
-	O
type	O
associations	O
.	O

Such	O
properties	O
of	O
tetraspanins	O
may	O
bring	O
signaling	O
molecules	O
such	O
as	O
protein	O
kinase	O
C	O
or	O
phosphatidylinositol	O
4	O
-	O
kinase	O
to	O
the	O
vicinity	O
of	O
integrins	O
[	O
67	O
,	O
68	O
]	O
.	O

The	O
organization	O
of	O
the	O
TM3	O
domain	O
points	O
to	O
a	O
potential	O
role	O
in	O
protein	O
-	O
protein	O
interactions	O
.	O

A	O
motif	O
of	O
Leu	O
-	O
Leu	O
-	O
Glu	O
(	O
Gln	O
)	O
spaced	O
7	O
residues	O
apart	O
(	O
heptad	O
positions	O
a	O
)	O
,	O
with	O
highly	O
conserved	O
residues	O
in	O
two	O
consecutive	O
positions	O
d	O
,	O
poses	O
as	O
a	O
likely	O
interaction	O
module	O
.	O

If	O
responsible	O
for	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
,	O
it	O
would	O
form	O
another	O
distinct	O
interface	O
of	O
tetraspanin	O
molecule	O
.	O

Our	O
preliminary	O
data	O
indicate	O
that	O
replacing	O
the	O
Leu	O
and	O
Glu	O
residues	O
in	O
TM3	O
of	O
CD9	O
with	O
Ala	O
has	O
no	O
effect	O
on	O
cell	O
surface	O
expression	O
of	O
the	O
protein	O
and	O
its	O
dimerization	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
remains	O
to	O
be	O
tested	O
if	O
interactions	O
with	O
other	O
proteins	O
will	O
be	O
affected	O
.	O

Similarly	O
,	O
the	O
TM4	O
domain	O
may	O
provide	O
additional	O
contributions	O
to	O
lateral	O
tetraspanin	O
associations	O
.	O

Much	O
higher	O
sequence	O
variability	O
,	O
and	O
the	O
lack	O
of	O
a	O
distinct	O
heptad	O
pattern	O
suggests	O
that	O
TM4	O
is	O
a	O
major	O
contributor	O
to	O
diversity	O
among	O
tetraspanin	O
complexes	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
TM3	O
and	O
TM4	O
domains	O
in	O
tetraspanins	O
is	O
the	O
subject	O
of	O
ongoing	O
investigation	O
.	O

Conclusion	O

We	O
have	O
defined	O
the	O
TM1	O
-	O
TM2	O
intramolecular	O
interface	O
in	O
tetraspanin	O
CD9	O
,	O
providing	O
evidence	O
for	O
glycines	O
(	O
Gly25	O
and	O
Gly32	O
in	O
TM1	O
,	O
Gly67	O
and	O
Gly74	O
in	O
TM2	O
)	O
packing	O
against	O
apposing	O
bulky	O
aliphatic	O
residues	O
.	O

Second	O
,	O
we	O
mapped	O
an	O
intermolecular	O
CD9	O
interface	O
(	O
involved	O
in	O
CD9	O
homodimer	O
formation	O
)	O
to	O
the	O
vicinity	O
of	O
residues	O
Leu14	O
and	O
Phe17	O
in	O
TM1	O
and	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
.	O

Finally	O
,	O
we	O
provide	O
preliminary	O
evidence	O
that	O
TM3	O
and	O
TM4	O
in	O
CD9	O
may	O
contribute	O
to	O
a	O
second	O
intermolecular	O
interface	O
.	O

Key	O
CD9	O
residues	O
involved	O
in	O
intra	O
-	O
and	O
intermolecular	O
interactions	O
are	O
highly	O
conserved	O
throughout	O
the	O
tetraspanin	O
family	O
,	O
thus	O
suggesting	O
that	O
our	O
findings	O
will	O
apply	O
to	O
most	O
tetraspanins	O
.	O

Methods	O

Materials	O

Cell	O
culture	O
reagents	O
were	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

2	O
-	O
bromopalmitate	O
was	O
from	O
Fluka	O
(	O
Milwaukee	O
,	O
WI	O
)	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
NEM	O
)	O
and	O
1	O
,	O
10	O
-	O
phenanthroline	O
were	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
,	O
and	O
chemical	O
cross	O
-	O
linkers	O
dithio	O
-	O
bis	O
-	O
maleimidoethane	O
(	O
DTME	O
)	O
and	O
1	O
,	O
4	O
-	O
Bis	O
-	O
maleimidobutane	O
(	O
BMB	O
)	O
were	O
purchased	O
from	O
Pierce	O
Endogen	O
(	O
Rockford	O
,	O
IL	O
)	O
.	O

Triton	O
X	O
-	O
100	O
,	O
protease	O
inhibitor	O
cocktail	O
and	O
FuGENE	O
6	O
transfection	O
reagent	O
were	O
obtained	O
from	O
Roche	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

Restriction	O
endonucleases	O
and	O
Pfu	O
DNA	O
polymerase	O
were	O
obtained	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
and	O
Stratagene	O
(	O
Carlsbad	O
,	O
CA	O
)	O
,	O
respectively	O
.	O

All	O
other	O
chemicals	O
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
or	O
Fisher	O
Scientific	O
(	O
Pittsburg	O
,	O
PA	O
)	O
.	O

Sequence	O
analysis	O

Tetraspanin	O
sequences	O
were	O
obtained	O
from	O
SWISS	O
-	O
PROT	O
and	O
GenBank	O
databases	O
.	O

Locus	O
designations	O
,	O
accession	O
numbers	O
and	O
the	O
most	O
commonly	O
used	O
protein	O
names	O
are	O
summarized	O
in	O
Tables	O
1	O
and	O
2	O
.	O

TM	O
segments	O
were	O
delineated	O
by	O
inspection	O
of	O
hydrophobicity	O
profiles	O
,	O
using	O
database	O
annotations	O
and	O
previous	O
analyses	O
of	O
TM	O
sequences	O
as	O
a	O
guide	O
(	O
[	O
28	O
]	O
,	O
M	O
.	O
Hemler	O
,	O
unpublished	O
)	O
,	O
and	O
aligned	O
manually	O
.	O

Residue	O
numbers	O
in	O
human	S-Species
CD9	O
sequence	O
are	O
used	O
a	O
reference	O
point	O
throughout	O
the	O
study	O
.	O

DNA	O
cloning	O
and	O
mutagenesis	O

Sequence	O
encoding	O
CD9	O
protein	O
was	O
cloned	O
into	O
vector	O
pcDNA3	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
and	O
pEGFP	O
-	O
N1	O
(	O
Clontech	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
,	O
for	O
expression	O
of	O
untagged	O
and	O
C	O
-	O
terminally	O
GFP	O
-	O
tagged	O
CD9	O
,	O
respectively	O
.	O

pEGFP	O
-	O
N1	O
encoding	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
fusion	O
protein	O
was	O
constructed	O
by	O
subcloning	O
DNA	O
for	O
residues	O
1	O
-	O
83	O
of	O
CD9	O
into	O
HindIII	O
and	O
PstI	O
sites	O
of	O
the	O
vector	O
;	O
to	O
introduce	O
the	O
PstI	O
site	O
,	O
codon	O
GTG	O
for	O
Val82	O
was	O
changed	O
to	O
CTG	O
(	O
coding	O
for	O
Ala	O
)	O
.	O

In	O
the	O
resulting	O
fusion	O
protein	O
,	O
there	O
is	O
a	O
13	O
-	O
amino	O
acid	O
linker	O
(	O
with	O
no	O
cysteines	O
)	O
between	O
CD9	O
and	O
GFP	O
.	O

To	O
minimize	O
the	O
low	O
inherent	O
ability	O
of	O
GFP	O
to	O
homodimerize	O
,	O
which	O
could	O
potentially	O
influence	O
the	O
results	O
of	O
CD9	O
cross	O
-	O
linking	O
,	O
we	O
used	O
a	O
monomeric	O
GFP	O
mutant	O
,	O
Leu221	O
-->	O
Lys	O
[	O
34	O
]	O
,	O
for	O
cross	O
-	O
linking	O
experiments	O
.	O

Mutations	O
were	O
introduced	O
in	O
full	O
-	O
length	O
and	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
proteins	O
by	O
a	O
PCR	O
-	O
based	O
strategy	O
using	O
mutagenic	O
primers	O
and	O
Pfu	O
DNA	O
polymerase	O
.	O

All	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Protein	O
expression	O
,	O
microscopy	O
,	O
cysteine	O
disulfide	O
cross	O
-	O
linking	O
and	O
Western	O
blotting	O

DNA	O
constructs	O
encoding	O
TM	O
(	O
1	O
+	O
2	O
)	O
-	O
GFP	O
or	O
full	O
-	O
length	O
CD9	O
proteins	O
were	O
transfected	O
into	O
human	S-Species
rhabdomyosarcoma	O
RD	O
cells	O
using	O
the	O
FuGENE	O
6	O
reagent	O
.	O

Cells	O
expressing	O
GFP	O
fusion	O
proteins	O
were	O
analysed	O
by	O
fluorescence	O
microscopy	O
18	O
-	O
28	O
hours	O
post	O
-	O
transfection	O
.	O

Images	O
were	O
captured	O
using	O
Spot	O
1	O
.	O
4	O
.	O
0	O
camera	O
(	O
Diagnostic	O
Instruments	O
,	O
Sterling	O
Heights	O
,	O
MI	O
)	O
attached	O
to	O
Nikon	O
Eclipse	O
TE300	O
microscope	O
.	O

For	O
experiments	O
involving	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
,	O
cells	O
were	O
treated	O
with	O
50	O
mu	O
M	O
2	O
-	O
BP	O
starting	O
24	O
-	O
26	O
hours	O
post	O
-	O
transfection	O
and	O
continuing	O
for	O
16	O
-	O
18	O
hours	O
.	O

Cross	O
-	O
linking	O
was	O
carried	O
out	O
by	O
incubating	O
cells	O
in	O
HBSM	O
buffer	O
(	O
25	O
mM	O
Hepes	O
-	O
NaOH	O
,	O
pH	O
7	O
.	O
2	O
,	O
150	O
mM	O
NaCl	O
,	O
2	O
mM	O
MgCl2	O
)	O
containing	O
either	O
a	O
)	O
0	O
.	O
6	O
mM	O
CuSO4	O
and	O
1	O
.	O
8	O
mM	O
1	O
,	O
10	O
-	O
phenanthroline	O
(	O
CuP	O
complex	O
)	O
or	O
b	O
)	O
0	O
.	O
2	O
mg	O
/	O
ml	O
homobifunctional	O
cysteine	O
-	O
reactive	O
cross	O
-	O
linker	O
(	O
e	O
.	O
g	O
.	O
DTME	O
)	O
,	O
diluted	O
from	O
fresh	O
10	O
mg	O
/	O
ml	O
solution	O
in	O
DMSO	O
.	O

After	O
incubation	O
for	O
10	O
-	O
15	O
minutes	O
(	O
with	O
CuP	O
)	O
or	O
30	O
-	O
45	O
minutes	O
(	O
with	O
cross	O
-	O
linker	O
)	O
,	O
cells	O
were	O
washed	O
twice	O
for	O
10	O
minutes	O
with	O
HBSM	O
containing	O
10	O
mM	O
NEM	O
to	O
block	O
residual	O
free	O
cysteines	O
.	O

Cells	O
were	O
lysed	O
in	O
HBSM	O
containing	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0	O
.	O
1	O
%	O
SDS	O
and	O
a	O
cocktail	O
of	O
protease	O
inhibitors	O
with	O
1	O
mM	O
EDTA	O
at	O
4	O
degrees	O
C	O
for	O
45	O
-	O
60	O
minutes	O
.	O

Cell	O
lysate	O
was	O
clarified	O
by	O
centrifugation	O
at	O
14	O
,	O
000	O
x	O
g	O
for	O
15	O
minutes	O
,	O
an	O
aliquot	O
was	O
removed	O
,	O
and	O
proteins	O
from	O
it	O
were	O
precipitated	O
by	O
addition	O
of	O
trichloroacetic	O
acid	O
to	O
10	O
%	O
on	O
ice	O
followed	O
by	O
centrifugation	O
at	O
14	O
,	O
000	O
x	O
g	O
for	O
10	O
minutes	O
.	O

After	O
two	O
washes	O
with	O
ice	O
-	O
cold	O
acetone	O
,	O
protein	O
pellet	O
was	O
solubilized	O
in	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
without	O
a	O
reducing	O
agent	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
6	O
.	O
8	O
,	O
1	O
%	O
SDS	O
,	O
8	O
%	O
glycerol	O
)	O
.	O

In	O
some	O
experiments	O
,	O
CD9	O
protein	O
was	O
immunoprecipitated	O
using	O
monoclonal	O
antibody	O
Alb6	O
(	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
.	O

Proteins	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	O
JL	O
-	O
8	O
(	O
Clontech	O
)	O
for	O
GFP	O
or	O
Alb6	O
for	O
CD9	O
.	O

Bands	O
from	O
X	O
-	O
ray	O
films	O
were	O
quantitated	O
using	O
GeneTools	O
(TM)	O
software	O
from	O
Syngene	O
(	O
Frederick	O
,	O
MD	O
)	O
.	O

Modeling	O
of	O
TM1	O
-	O
TM2	O
interaction	O

An	O
atomic	O
model	O
of	O
the	O
CD9	O
TM1	O
-	O
TM2	O
dimer	O
was	O
constructed	O
with	O
a	O
Monte	O
Carlo	O
-	O
simulated	O
annealing	O
(	O
MCSA	O
)	O
algorithm	O
[	O
69	O
]	O
.	O

Two	O
idealized	O
alpha	O
-	O
helices	O
corresponding	O
to	O
TM1	O
residues	O
Tyr12	O
through	O
Leu35	O
and	O
TM2	O
residues	O
Gly59	O
through	O
Val82	O
were	O
docked	O
with	O
six	O
orthogonal	O
parameters	O
:	O
three	O
rigid	O
body	O
translations	O
and	O
three	O
rotations	O
.	O

During	O
each	O
step	O
of	O
a	O
MCSA	O
cycle	O
,	O
there	O
was	O
an	O
equal	O
probability	O
of	O
changing	O
either	O
one	O
parameter	O
or	O
all	O
six	O
parameters	O
to	O
random	O
values	O
.	O

A	O
conformation	O
'	O
s	O
energy	O
was	O
calculated	O
in	O
vacuo	O
with	O
the	O
AMBER	O
united	O
-	O
atom	O
force	O
field	O
for	O
van	O
der	O
Waals	O
interactions	O
[	O
70	O
]	O
.	O

The	O
van	O
der	O
Waals	O
term	O
was	O
modified	O
as	O
described	O
by	O
Kuhlman	O
and	O
Baker	O
[	O
71	O
]	O
.	O

If	O
a	O
structure	O
had	O
favorable	O
dimerization	O
energy	O
,	O
the	O
energies	O
of	O
select	O
mutants	O
were	O
calculated	O
.	O

Structures	O
were	O
selected	O
with	O
a	O
novel	O
scoring	O
function	O
that	O
maximizes	O
the	O
Boltzmann	O
probability	O
of	O
dimerization	O
for	O
silent	O
mutations	O
while	O
minimizing	O
the	O
probability	O
for	O
disruptive	O
mutations	O
.	O

Asn18Ser	O
,	O
Gly77Leu	O
,	O
and	O
Gly80Leu	O
were	O
scored	O
as	O
silent	O
mutations	O
while	O
Gly25Leu	O
,	O
Gly32Leu	O
,	O
Gly67Leu	O
,	O
and	O
Gly74Leu	O
were	O
considered	O
to	O
be	O
disruptive	O
.	O

Each	O
MCSA	O
cycle	O
consisted	O
of	O
50	O
,	O
000	O
steps	O
with	O
an	O
exponential	O
temperature	O
decay	O
from	O
10	O
,	O
000	O
to	O
10	O
K	O
.	O

Ten	O
MCSA	O
cycles	O
through	O
global	O
sample	O
space	O
were	O
used	O
to	O
restrict	O
the	O
search	O
area	O
.	O

Parameters	O
were	O
restricted	O
to	O
+/-	O
2	O
standard	O
deviations	O
from	O
their	O
mean	O
value	O
for	O
structures	O
within	O
10	O
kcal	O
of	O
the	O
best	O
structure	O
.	O

MCSA	O
cycles	O
were	O
repeated	O
as	O
described	O
above	O
with	O
additional	O
optimization	O
of	O
chi	O
values	O
:	O
rotamers	O
at	O
the	O
protein	O
-	O
protein	O
interface	O
were	O
optimized	O
with	O
Dead	O
End	O
Elimination	O
[	O
72	O
]	O
,	O
and	O
chi	O
values	O
were	O
further	O
optimized	O
with	O
Monte	O
Carlo	O
.	O

All	O
MCSA	O
cycles	O
converged	O
upon	O
structures	O
that	O
were	O
within	O
a	O
root	O
mean	O
squared	O
deviation	O
(	O
RMSD	O
)	O
of	O
1	O
.	O
5	O
A	O
with	O
the	O
best	O
structure	O
,	O
and	O
structures	O
that	O
scored	O
within	O
5	O
kcal	O
of	O
the	O
best	O
score	O
had	O
an	O
RMSD	O
of	O
less	O
than	O
0	O
.	O
5	O
A	O
with	O
the	O
best	O
structure	O
.	O

List	O
of	O
abbreviations	O

2	O
-	O
BP	O
,	O
2	O
-	O
bromopalmitate	O
;	O
CuP	O
,	O
Cu2	O
+	O
-	O
phenanthroline	O
;	O
DTME	O
,	O
dithio	O
-	O
bis	O
-	O
maleimidoethane	O
;	O
LEL	O
,	O
large	O
extracellular	O
loop	O
;	O
NEM	O
,	O
N	O
-	O
ethylmaleimide	O
;	O
TM	O
,	O
transmembrane	O
(	O
domain	O
)	O
.	O

Authors	O
'	O
contributions	O

OVK	O
carried	O
out	O
sequence	O
comparisons	O
,	O
mutational	O
analysis	O
and	O
cross	O
-	O
linking	O
experiments	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

DGM	O
built	O
the	O
TM1	O
-	O
TM2	O
interaction	O
model	O
and	O
contributed	O
to	O
the	O
manuscript	O
.	O

WFD	O
supervised	O
DGM	O
'	O
s	O
work	O
.	O

MEH	O
coordinated	O
the	O
whole	O
study	O
and	O
prepared	O
the	O
final	O
manuscript	O
.	O

Epigenetic	O
inactivation	O
and	O
aberrant	O
transcription	O
of	O
CSMD1	O
in	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O

Abstract	O

Background	O

The	O
p23	O
.	O
2	O
region	O
of	O
human	S-Species
chromosome	O
8	O
is	O
frequently	O
deleted	O
in	O
several	O
types	O
of	O
epithelial	O
cancer	O
and	O
those	O
deletions	O
appear	O
to	O
be	O
associated	O
with	O
poor	O
prognosis	O
.	O

Cub	O
and	O
Sushi	O
Multiple	O
Domains	O
1	O
(	O
CSMD1	O
)	O
was	O
positionally	O
cloned	O
as	O
a	O
candidate	O
for	O
the	O
8p23	O
suppressor	O
but	O
point	O
mutations	O
in	O
this	O
gene	O
are	O
rare	O
relative	O
to	O
the	O
frequency	O
of	O
allelic	O
loss	O
.	O

In	O
an	O
effort	O
to	O
identify	O
alternative	O
mechanisms	O
of	O
inactivation	O
,	O
we	O
have	O
characterized	O
CSMD1	O
expression	O
and	O
epigenetic	O
modifications	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
.	O

Results	O

Only	O
one	O
of	O
the	O
20	O
cell	O
lines	O
examined	O
appears	O
to	O
express	O
a	O
structurally	O
normal	O
CSMD1	O
transcript	O
.	O

The	O
rest	O
express	O
transcripts	O
which	O
either	O
lack	O
internal	O
exons	O
,	O
terminate	O
abnormally	O
or	O
initiate	O
at	O
cryptic	O
promoters	O
.	O

None	O
of	O
these	O
truncated	O
transcripts	O
is	O
predicted	O
to	O
encode	O
a	O
functional	O
CSMD1	O
protein	O
.	O

Cell	O
lines	O
that	O
express	O
little	O
or	O
no	O
CSMD1	O
RNA	O
exhibit	O
DNA	O
methylation	O
of	O
a	O
specific	O
region	O
of	O
the	O
CpG	O
island	O
surrounding	O
CSMD1	O
'	O
s	O
first	O
exon	O
.	O

Conclusion	O

Correlating	O
methylation	O
patterns	O
and	O
expression	O
suggests	O
that	O
it	O
is	O
modification	O
of	O
the	O
genomic	O
DNA	O
preceding	O
the	O
first	O
exon	O
that	O
is	O
associated	O
with	O
gene	O
silencing	O
and	O
that	O
methylation	O
of	O
CpG	O
dinucleotides	O
further	O
3	O
'	O
does	O
not	O
contribute	O
to	O
inactivation	O
of	O
the	O
gene	O
.	O

Taken	O
together	O
,	O
the	O
cell	O
line	O
data	O
suggest	O
that	O
epigenetic	O
silencing	O
and	O
aberrant	O
splicing	O
rather	O
than	O
point	O
mutations	O
may	O
be	O
contributing	O
to	O
the	O
reduction	O
in	O
CSMD1	O
expression	O
in	O
squamous	O
cancers	O
.	O

These	O
mechanisms	O
can	O
now	O
serve	O
as	O
a	O
focus	O
for	O
further	O
analysis	O
of	O
primary	O
squamous	O
cancers	O
.	O

Background	O

CUB	O
and	O
Sushi	O
Multiple	O
Domains	O
1	O
(	O
CSMD1	O
)	O
was	O
cloned	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
or	O
progression	O
gene	O
from	O
a	O
region	O
of	O
human	S-Species
chromosome	O
8	O
deleted	O
in	O
tumors	O
of	O
the	O
upper	O
aerodigestive	O
tract	O
,	O
prostate	O
,	O
ovary	O
and	O
bladder	O
[	O
1	O
-	O
7	O
]	O
.	O

Deletion	O
of	O
8p23	O
.	O
2	O
or	O
reduced	O
expression	O
of	O
CSMD1	O
has	O
been	O
associated	O
with	O
poor	O
prognosis	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
and	O
in	O
prostate	O
cancers	O
[	O
2	O
,	O
5	O
,	O
8	O
]	O
.	O

CSMD1	O
,	O
consisting	O
of	O
70	O
exons	O
spread	O
over	O
two	O
megabases	O
of	O
8p23	O
.	O
2	O
,	O
encodes	O
a	O
rare	O
11	O
.	O
5	O
kb	O
transcript	O
most	O
abundantly	O
expressed	O
in	O
the	O
brain	O
[	O
1	O
]	O
.	O

It	O
is	O
the	O
founding	O
member	O
of	O
a	O
novel	O
,	O
evolutionarily	O
highly	O
conserved	O
gene	O
family	O
whose	O
proteins	O
contain	O
multiple	O
domains	O
thought	O
to	O
be	O
sites	O
of	O
protein	O
-	O
protein	O
or	O
protein	O
-	O
ligand	O
interactions	O
and	O
whose	O
structure	O
suggests	O
that	O
they	O
may	O
be	O
transmembrane	O
receptors	O
or	O
adhesion	O
proteins	O
[	O
9	O
,	O
10	O
]	O
.	O

Tumor	O
suppressor	O
genes	O
are	O
expected	O
to	O
be	O
inactivated	O
in	O
cancers	O
either	O
genetically	O
by	O
mutations	O
or	O
epigenetically	O
by	O
modification	O
of	O
their	O
promoters	O
.	O

While	O
CSMD1	O
transcripts	O
are	O
detectable	O
in	O
upper	O
aerodigestive	O
tract	O
epithelium	O
,	O
preliminary	O
analysis	O
of	O
several	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
suggested	O
that	O
CSMD1	O
expression	O
was	O
lost	O
in	O
these	O
lines	O
[	O
1	O
]	O
.	O

Although	O
the	O
region	O
containing	O
CSMD1	O
is	O
frequently	O
deleted	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
and	O
prostatic	O
adenocarcinomas	O
[	O
3	O
,	O
11	O
-	O
15	O
]	O
,	O
point	O
mutations	O
in	O
the	O
gene	O
are	O
relatively	O
rare	O
in	O
primary	O
squamous	O
cancers	O
[	O
16	O
]	O
and	O
in	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
(	O
Schmidt	O
,	O
Richter	O
and	O
Scholnick	O
,	O
unpublished	O
)	O
.	O

Nonsense	O
or	O
splice	O
junction	O
mutations	O
in	O
CSMD1	O
have	O
not	O
been	O
reported	O
and	O
not	O
enough	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
protein	O
to	O
accurately	O
assess	O
the	O
effect	O
of	O
the	O
few	O
missense	O
mutations	O
that	O
have	O
been	O
detected	O
.	O

Thus	O
,	O
if	O
CSMD1	O
is	O
inactivated	O
in	O
tumors	O
,	O
alternative	O
mechanisms	O
for	O
gene	O
silencing	O
must	O
be	O
operating	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
while	O
most	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
do	O
not	O
express	O
full	O
length	O
CSMD1	O
transcripts	O
,	O
nearly	O
all	O
produce	O
abnormal	O
transcripts	O
unlikely	O
to	O
encode	O
functional	O
CSMD1	O
proteins	O
.	O

Methylation	O
of	O
the	O
DNA	O
preceding	O
CSMD1	O
'	O
s	O
first	O
exon	O
is	O
correlated	O
with	O
reduction	O
in	O
the	O
level	O
of	O
expression	O
and	O
cell	O
lines	O
expressing	O
at	O
low	O
levels	O
do	O
not	O
appear	O
to	O
elongate	O
the	O
full	O
11	O
.	O
5	O
kb	O
transcript	O
.	O

Other	O
anomalies	O
of	O
expression	O
include	O
incorrect	O
splicing	O
and	O
the	O
use	O
of	O
cryptic	O
promoters	O
.	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
these	O
promoters	O
may	O
result	O
from	O
the	O
global	O
demethylation	O
of	O
the	O
genome	O
associated	O
with	O
tumorigenesis	O
(	O
reviewed	O
by	O
Ehrlich	O
[	O
17	O
]	O
)	O
.	O

Taken	O
together	O
these	O
data	O
demonstrate	O
that	O
mechanisms	O
other	O
than	O
point	O
mutation	O
are	O
responsible	O
for	O
the	O
aberrant	O
CSMD1	O
expression	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
,	O
and	O
these	O
data	O
suggest	O
potential	O
targets	O
for	O
further	O
investigation	O
in	O
primary	O
tumors	O
.	O

Results	O

CSMD1	O
promoter	O
methylation	O
in	O
HNSCC	O
cell	O
lines	O
is	O
correlated	O
with	O
expression	O
levels	O

Preliminary	O
evidence	O
suggested	O
that	O
CSMD1	O
expression	O
is	O
lost	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
[	O
1	O
]	O
but	O
that	O
point	O
mutations	O
were	O
rare	O
[	O
[	O
16	O
]	O
,	O
and	O
Schmidt	O
,	O
Richter	O
and	O
Scholnick	O
,	O
unpublished	O
]	O
.	O

To	O
date	O
,	O
only	O
two	O
of	O
the	O
20	O
cell	O
lines	O
we	O
have	O
tested	O
for	O
CSMD1	O
expression	O
,	O
UPCI	O
:	O
SCC066	O
and	O
PCI	O
-	O
13	O
,	O
express	O
large	O
transcripts	O
initiated	O
at	O
the	O
normal	O
CSMD1	O
promoter	O
.	O

These	O
data	O
suggest	O
that	O
a	O
mechanism	O
(	O
s	O
)	O
other	O
than	O
point	O
mutation	O
must	O
be	O
responsible	O
for	O
the	O
loss	O
of	O
expression	O
.	O

CSMD1	O
'	O
s	O
first	O
exon	O
is	O
embedded	O
in	O
a	O
3	O
.	O
7	O
kb	O
CpG	O
island	O
(	O
data	O
from	O
the	O
UCSC	O
genome	O
browser	O
[	O
18	O
]	O
)	O
suggesting	O
that	O
promoter	O
methylation	O
might	O
epigenetically	O
silence	O
the	O
gene	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
surveyed	O
32	O
head	O
and	O
neck	O
cancer	O
cell	O
lines	O
for	O
CSMD1	O
promoter	O
methylation	O
using	O
the	O
Combined	O
Bisulfite	O
Restriction	O
Analysis	O
(	O
COBRA	O
)	O
technique	O
described	O
by	O
Xiong	O
and	O
Laird	O
(	O
Methods	O
)	O
[	O
19	O
]	O
.	O

COBRA	O
analysis	O
of	O
the	O
three	O
amplicons	O
diagrammed	O
in	O
Figure	O
1	O
suggested	O
that	O
28	O
of	O
the	O
cell	O
lines	O
(	O
87	O
%	O
)	O
had	O
more	O
promoter	O
methylation	O
than	O
did	O
normal	O
upper	O
aerodigestive	O
epithelium	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
selected	O
nine	O
of	O
these	O
cell	O
lines	O
for	O
high	O
resolution	O
analysis	O
of	O
promoter	O
methylation	O
by	O
sequencing	O
of	O
clones	O
from	O
bisulfite	O
converted	O
genomic	O
DNA	O
.	O

This	O
approach	O
has	O
the	O
distinct	O
advantage	O
of	O
allowing	O
determination	O
of	O
the	O
state	O
of	O
all	O
the	O
CpG	O
dinucleotides	O
within	O
an	O
amplicon	O
on	O
an	O
allele	O
by	O
allele	O
basis	O
.	O

Amplicons	O
1	O
and	O
2	O
have	O
19	O
and	O
20	O
CpG	O
dinucleotides	O
,	O
respectively	O
.	O

Amplicon	O
3	O
could	O
not	O
be	O
examined	O
by	O
this	O
technique	O
because	O
it	O
is	O
unclonable	O
after	O
bisulfite	O
conversion	O
.	O

The	O
methylation	O
data	O
were	O
correlated	O
to	O
CSMD1	O
expression	O
levels	O
as	O
measured	O
by	O
quantitative	O
RT	O
-	O
PCR	O
using	O
an	O
amplicon	O
spanning	O
exons	O
1	O
and	O
2	O
(	O
Methods	O
)	O
.	O

A	O
pool	O
of	O
cDNA	O
from	O
five	O
normal	O
oropharyngeal	O
epithelium	O
specimens	O
served	O
as	O
a	O
basis	O
for	O
comparison	O
to	O
the	O
cell	O
lines	O
.	O

Our	O
data	O
from	O
amplicon	O
1	O
demonstrate	O
a	O
clear	O
relationship	O
between	O
methylation	O
and	O
the	O
level	O
of	O
expression	O
(	O
Figure	O
2	O
)	O
.	O

The	O
bisulfite	O
sequencing	O
data	O
confirm	O
that	O
there	O
is	O
relatively	O
little	O
promoter	O
methylation	O
in	O
normal	O
tissue	O
(	O
clones	O
1	O
-	O
20	O
,	O
Figure	O
2A	O
)	O
.	O

This	O
is	O
also	O
the	O
case	O
in	O
cell	O
line	O
UPCI	O
:	O
SCC066	O
which	O
expresses	O
a	O
large	O
CSMD1	O
transcript	O
from	O
the	O
normal	O
promoter	O
at	O
a	O
level	O
approximately	O
33	O
%	O
of	O
that	O
of	O
normal	O
tissue	O
(	O
clones	O
32	O
-	O
39	O
,	O
Figure	O
2B	O
)	O
.	O

PCI	O
-	O
13	O
,	O
our	O
highest	O
expressing	O
line	O
at	O
125	O
%	O
of	O
normal	O
epithelium	O
,	O
displays	O
two	O
distinct	O
patterns	O
of	O
promoter	O
methylation	O
with	O
some	O
clones	O
heavily	O
methylated	O
(	O
clones	O
21	O
-	O
24	O
,	O
and	O
30	O
)	O
and	O
others	O
with	O
no	O
methylation	O
(	O
clones	O
25	O
-	O
39	O
and	O
31	O
;	O
Figure	O
2B	O
)	O
.	O

This	O
pattern	O
is	O
consistent	O
with	O
either	O
heterozygosity	O
for	O
methylation	O
or	O
the	O
co	O
-	O
existence	O
of	O
2	O
distinct	O
populations	O
within	O
the	O
cell	O
line	O
,	O
one	O
heavily	O
methylated	O
and	O
one	O
unmethylated	O
.	O

We	O
cannot	O
distinguish	O
between	O
these	O
two	O
possibilities	O
using	O
the	O
currently	O
available	O
data	O
.	O

The	O
remaining	O
cell	O
lines	O
express	O
CSMD1	O
at	O
a	O
level	O
half	O
that	O
of	O
UPCI	O
:	O
SCC066	O
or	O
less	O
(	O
ranging	O
from	O
17	O
%	O
to	O
1	O
%	O
of	O
normal	O
epithelium	O
)	O
and	O
they	O
exhibit	O
considerably	O
greater	O
methylation	O
of	O
amplicon	O
1	O
(	O
clones	O
40	O
-	O
76	O
,	O
Figure	O
2C	O
)	O
.	O

Cell	O
lines	O
with	O
more	O
amplicon	O
1	O
methylation	O
tend	O
to	O
express	O
the	O
gene	O
at	O
lower	O
levels	O
but	O
the	O
relationship	O
is	O
not	O
strictly	O
quantitative	O
(	O
Figure	O
2C	O
)	O
.	O

In	O
contrast	O
,	O
our	O
data	O
revealed	O
no	O
relationship	O
between	O
expression	O
level	O
and	O
methylation	O
of	O
amplicon	O
2	O
(	O
located	O
towards	O
the	O
3	O
'	O
end	O
of	O
exon	O
1	O
,	O
Figure	O
1	O
)	O
.	O

For	O
example	O
,	O
all	O
of	O
the	O
10	O
clones	O
of	O
amplicon	O
2	O
sequenced	O
from	O
PCI	O
-	O
13	O
were	O
methylated	O
at	O
19	O
or	O
20	O
of	O
their	O
20	O
CpG	O
dinucleotides	O
.	O

UPCI	O
:	O
SCC066	O
,	O
on	O
the	O
other	O
hand	O
,	O
has	O
nearly	O
no	O
methylation	O
in	O
amplicon	O
2	O
with	O
only	O
a	O
single	O
methylated	O
CpG	O
dinucleotide	O
detected	O
in	O
one	O
clone	O
out	O
of	O
the	O
nine	O
sequenced	O
.	O

Amplicon	O
2	O
ranges	O
from	O
completely	O
unmethylated	O
to	O
heavily	O
methylated	O
in	O
the	O
seven	O
remaining	O
cell	O
lines	O
(	O
data	O
not	O
shown	O
)	O
.	O

Low	O
transcript	O
levels	O
are	O
accompanied	O
by	O
a	O
failure	O
to	O
elongate	O
the	O
full	O
CSMD1	O
transcript	O

On	O
the	O
surface	O
,	O
the	O
quantitative	O
RT	O
-	O
PCR	O
data	O
presented	O
in	O
Figure	O
2	O
suggest	O
that	O
the	O
cell	O
lines	O
we	O
consider	O
low	O
expressing	O
might	O
still	O
have	O
up	O
to	O
17	O
%	O
of	O
the	O
normal	O
level	O
of	O
CSMD1	O
transcript	O
.	O

A	O
survey	O
of	O
20	O
cell	O
lines	O
using	O
a	O
battery	O
of	O
RT	O
-	O
PCR	O
primer	O
pairs	O
located	O
throughout	O
the	O
11	O
.	O
5	O
kb	O
transcript	O
reveals	O
that	O
this	O
is	O
not	O
the	O
case	O
.	O

These	O
lines	O
included	O
OKF6	O
-	O
TERT1	O
,	O
a	O
TERT	O
immortalized	O
,	O
p16	O
deficient	O
but	O
untransformed	O
oral	O
keratinocyte	O
cell	O
line	O
[	O
20	O
]	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
low	O
expressing	O
cell	O
lines	O
shown	O
in	O
Figure	O
2C	O
express	O
considerably	O
more	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
11	O
.	O
5	O
kb	O
transcript	O
than	O
they	O
do	O
exons	O
further	O
3	O
'	O
,	O
a	O
phenomenon	O
well	O
illustrated	O
by	O
cell	O
line	O
PCI	O
-	O
100	O
.	O

This	O
line	O
expresses	O
the	O
exon	O
1	O
/	O
exon	O
2	O
amplicon	O
at	O
approximately	O
15	O
%	O
of	O
the	O
level	O
of	O
normal	O
epithelium	O
.	O

In	O
contrast	O
,	O
we	O
had	O
previously	O
reported	O
that	O
CSMD1	O
transcripts	O
were	O
not	O
detectable	O
in	O
this	O
line	O
by	O
combined	O
RT	O
-	O
PCR	O
and	O
Southern	O
blotting	O
using	O
three	O
sets	O
of	O
intron	O
spanning	O
primers	O
[	O
1	O
]	O
.	O

The	O
most	O
5	O
'	O
of	O
those	O
amplicons	O
spans	O
exons	O
9	O
through	O
26	O
.	O

Analysis	O
with	O
additional	O
primer	O
pairs	O
resolves	O
this	O
apparent	O
paradox	O
by	O
demonstrating	O
that	O
the	O
amount	O
of	O
transcript	O
declines	O
sharply	O
and	O
reproducibly	O
as	O
one	O
examines	O
progressively	O
more	O
3	O
'	O
exons	O
(	O
Figure	O
3	O
)	O
.	O

The	O
same	O
effect	O
is	O
seen	O
using	O
either	O
oligo	O
-	O
dT	O
or	O
random	O
hexamer	O
primed	O
cDNA	O
.	O

No	O
transcript	O
of	O
this	O
structure	O
has	O
been	O
detected	O
in	O
normal	O
epithelium	O
nor	O
have	O
we	O
detected	O
any	O
sequence	O
alterations	O
in	O
PCI	O
-	O
100	O
that	O
would	O
explain	O
why	O
the	O
full	O
transcript	O
is	O
not	O
expressed	O
.	O

It	O
is	O
not	O
clear	O
whether	O
PCI	O
-	O
100	O
produces	O
a	O
small	O
number	O
of	O
discrete	O
size	O
classes	O
of	O
transcript	O
,	O
if	O
individual	O
transcripts	O
terminate	O
at	O
random	O
points	O
within	O
the	O
very	O
large	O
introns	O
in	O
this	O
part	O
of	O
the	O
gene	O
(	O
the	O
first	O
10	O
introns	O
average	O
~	O
150	O
kb	O
in	O
length	O
)	O
,	O
or	O
if	O
the	O
short	O
transcripts	O
result	O
from	O
the	O
elevated	O
activity	O
of	O
a	O
previously	O
undetected	O
posttranscriptional	O
control	O
mechanism	O
.	O

Inactivation	O
of	O
CSMD1	O
by	O
aberrant	O
splicing	O

Two	O
cell	O
lines	O
,	O
UPCI	O
:	O
SCC066	O
and	O
PCI	O
-	O
13	O
,	O
express	O
large	O
CSMD1	O
transcripts	O
initiated	O
at	O
the	O
normal	O
promoter	O
.	O

Subsequent	O
finer	O
scale	O
analysis	O
demonstrates	O
that	O
PCI	O
-	O
13	O
'	O
s	O
transcript	O
lacks	O
exons	O
4	O
and	O
5	O
,	O
resulting	O
in	O
a	O
frameshift	O
-	O
induced	O
nonsense	O
codon	O
in	O
exon	O
6	O
(	O
Figure	O
4	O
)	O
.	O

Sequencing	O
of	O
the	O
PCI	O
-	O
13	O
RT	O
-	O
PCR	O
product	O
demonstrates	O
the	O
direct	O
juxtaposition	O
of	O
wildtype	O
exons	O
3	O
and	O
6	O
and	O
that	O
the	O
transcript	O
contains	O
no	O
novel	O
sequences	O
or	O
splices	O
that	O
would	O
prevent	O
the	O
frameshift	O
.	O

UPCI	O
:	O
SCC066	O
produces	O
two	O
transcripts	O
,	O
a	O
normal	O
one	O
that	O
includes	O
exons	O
4	O
and	O
5	O
and	O
another	O
that	O
lacks	O
them	O
(	O
Figure	O
4	O
)	O
.	O

RT	O
-	O
PCR	O
of	O
human	S-Species
fetal	O
brain	O
cDNA	O
reveals	O
very	O
low	O
levels	O
of	O
an	O
RT	O
-	O
PCR	O
product	O
corresponding	O
in	O
size	O
to	O
that	O
expected	O
from	O
the	O
internally	O
deleted	O
transcript	O
.	O

This	O
band	O
is	O
not	O
readily	O
visible	O
at	O
the	O
exposure	O
used	O
for	O
Figure	O
4A	O
.	O

We	O
have	O
not	O
detected	O
a	O
similar	O
sized	O
PCR	O
product	O
in	O
RNA	O
from	O
oropharyngeal	O
epithelium	O
but	O
this	O
may	O
reflect	O
the	O
fact	O
that	O
CSMD1	O
transcripts	O
are	O
~	O
10x	O
less	O
abundant	O
in	O
oropharyngeal	O
epithelium	O
than	O
they	O
are	O
in	O
fetal	O
brain	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
transcripts	O
lacking	O
exons	O
4	O
and	O
5	O
appear	O
to	O
result	O
from	O
aberrant	O
splicing	O
rather	O
than	O
somatic	O
deletion	O
of	O
these	O
two	O
exons	O
or	O
mutations	O
of	O
their	O
splicing	O
consensus	O
sequences	O
.	O

Exons	O
4	O
and	O
5	O
can	O
be	O
amplified	O
from	O
PCI	O
-	O
13	O
genomic	O
DNA	O
and	O
sequencing	O
of	O
those	O
PCR	O
products	O
demonstrates	O
that	O
both	O
their	O
coding	O
sequences	O
and	O
consensus	O
splice	O
sites	O
are	O
wildtype	O
.	O

Activation	O
of	O
cryptic	O
promoters	O
in	O
cancer	O
cell	O
lines	O

The	O
RT	O
-	O
PCR	O
survey	O
revealed	O
a	O
second	O
transcriptional	O
anomaly	O
exhibited	O
by	O
4	O
cell	O
lines	O
:	O
SCC9	O
,	O
041	O
,	O
PCI	O
-	O
1	O
and	O
PCI	O
-	O
2	O
.	O

Like	O
PCI	O
-	O
100	O
,	O
these	O
lines	O
express	O
low	O
levels	O
of	O
the	O
very	O
5	O
'	O
end	O
of	O
the	O
transcript	O
and	O
even	O
lower	O
levels	O
of	O
more	O
3	O
'	O
exons	O
within	O
the	O
first	O
half	O
of	O
the	O
transcript	O
.	O

However	O
,	O
these	O
lines	O
are	O
distinct	O
in	O
expressing	O
higher	O
levels	O
of	O
the	O
3	O
'	O
half	O
of	O
the	O
transcript	O
,	O
suggesting	O
that	O
alternative	O
promoters	O
in	O
the	O
middle	O
of	O
the	O
gene	O
may	O
be	O
used	O
.	O

SCC9	O
was	O
chosen	O
for	O
further	O
study	O
because	O
it	O
expresses	O
the	O
3	O
'	O
half	O
of	O
the	O
transcript	O
at	O
a	O
level	O
dramatically	O
higher	O
than	O
normal	O
for	O
oropharyngeal	O
epithelium	O
.	O

Northern	O
blotting	O
detects	O
a	O
comparatively	O
abundant	O
6	O
.	O
4	O
kb	O
truncated	O
transcript	O
as	O
well	O
as	O
smaller	O
amounts	O
of	O
an	O
8	O
.	O
7	O
kb	O
transcript	O
in	O
SCC9	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
other	O
three	O
cell	O
lines	O
express	O
their	O
truncated	O
CSMD1	O
transcripts	O
at	O
lower	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

Sequence	O
analysis	O
of	O
CSMD1	O
cDNA	O
clones	O
from	O
SCC9	O
demonstrates	O
that	O
many	O
transcripts	O
are	O
improperly	O
spliced	O
,	O
resulting	O
in	O
retention	O
of	O
intronic	O
sequences	O
and	O
/	O
or	O
deletion	O
of	O
exonic	O
sequences	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
particular	O
,	O
retention	O
of	O
sequences	O
from	O
intron	O
40	O
is	O
common	O
.	O

The	O
high	O
frequency	O
of	O
faulty	O
splicing	O
may	O
explain	O
the	O
broadness	O
of	O
the	O
6	O
.	O
4	O
kb	O
CSMD1	O
band	O
in	O
Figure	O
5A	O
and	O
suggests	O
that	O
the	O
8	O
.	O
7	O
kb	O
transcript	O
may	O
also	O
be	O
incompletely	O
or	O
improperly	O
spliced	O
.	O

5	O
'	O
RACE	O
[	O
21	O
]	O
reveals	O
that	O
the	O
SCC9	O
message	O
is	O
initiated	O
just	O
upstream	O
of	O
an	O
Alu	O
element	O
in	O
intron	O
36	O
(	O
Figure	O
5B	O
)	O
.	O

Only	O
the	O
5	O
'	O
-	O
most	O
120	O
base	O
pairs	O
of	O
the	O
Alu	O
element	O
are	O
present	O
in	O
the	O
genome	O
.	O

RT	O
-	O
PCR	O
using	O
a	O
forward	O
primer	O
specific	O
for	O
the	O
novel	O
sequences	O
of	O
the	O
SCC9	O
transcript	O
(	O
prm1904	O
,	O
cgtttagttcgacacacttcatgt	O
)	O
demonstrates	O
that	O
cell	O
lines	O
041	O
,	O
PCI	O
-	O
1	O
and	O
PCI	O
-	O
2	O
do	O
not	O
initiate	O
their	O
CSMD1	O
transcripts	O
at	O
the	O
same	O
point	O
,	O
suggesting	O
that	O
other	O
cryptic	O
promoters	O
are	O
active	O
in	O
these	O
lines	O
.	O

The	O
sequence	O
of	O
this	O
novel	O
exon	O
has	O
been	O
entered	O
in	O
Genbank	O
as	O
accession	O
number	O
DQ093422	O
.	O

DNA	O
methyltransferase	O
inhibitors	O
activate	O
the	O
same	O
cryptic	O
promoter	O
used	O
in	O
cell	O
line	O
SCC9	O

Expression	O
from	O
epigenetically	O
silenced	O
promoters	O
can	O
sometimes	O
be	O
restored	O
by	O
treatment	O
with	O
inhibitors	O
of	O
DNA	O
methyltransferase	O
or	O
histone	O
deacetylase	O
activity	O
(	O
[	O
22	O
]	O
)	O
.	O

We	O
selected	O
two	O
low	O
expressing	O
cell	O
lines	O
with	O
promoter	O
methylation	O
,	O
UPCI	O
:	O
SCC104	O
and	O
094	O
,	O
for	O
treatment	O
with	O
various	O
concentrations	O
of	O
5	O
-	O
azacytidine	O
or	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
aza	O
-	O
dC	O
)	O
as	O
well	O
as	O
combinations	O
of	O
either	O
of	O
those	O
drugs	O
with	O
the	O
histone	O
deacetylase	O
inhibitor	O
trichostatin	O
A	O
.	O

These	O
treatments	O
did	O
not	O
reactivate	O
the	O
silenced	O
CSMD1	O
promoter	O
.	O

COBRA	O
analysis	O
of	O
genomic	O
DNA	O
from	O
the	O
treated	O
cells	O
suggested	O
that	O
the	O
drugs	O
did	O
not	O
robustly	O
affect	O
methylation	O
of	O
the	O
CSMD1	O
promoter	O
even	O
at	O
levels	O
high	O
enough	O
to	O
be	O
toxic	O
to	O
the	O
cells	O
.	O

These	O
experiments	O
did	O
however	O
shed	O
light	O
on	O
the	O
cryptic	O
promoter	O
used	O
in	O
SCC9	O
cells	O
and	O
on	O
the	O
interpretation	O
of	O
experiments	O
using	O
methyltransferase	O
inhibitors	O
.	O

Treatment	O
of	O
cell	O
line	O
094	O
with	O
relatively	O
high	O
doses	O
of	O
5aza	O
-	O
dC	O
results	O
in	O
the	O
expression	O
of	O
the	O
3	O
'	O
end	O
of	O
the	O
CSMD1	O
transcript	O
.	O

This	O
transcript	O
was	O
not	O
detected	O
in	O
control	O
094	O
cells	O
undergoing	O
mock	O
drug	O
treatment	O
(	O
Figure	O
6	O
)	O
nor	O
was	O
it	O
detected	O
in	O
094	O
cells	O
growing	O
under	O
normal	O
culture	O
conditions	O
(	O
data	O
not	O
shown	O
)	O
.	O

RT	O
-	O
PCR	O
of	O
cDNA	O
from	O
drug	O
-	O
treated	O
094	O
cells	O
using	O
the	O
primer	O
developed	O
from	O
the	O
novel	O
5	O
'	O
exon	O
of	O
SCC9	O
'	O
s	O
truncated	O
transcript	O
(	O
prm1904	O
,	O
see	O
above	O
)	O
yielded	O
a	O
product	O
identical	O
in	O
size	O
to	O
that	O
amplified	O
from	O
SCC9	O
cDNA	O
(	O
Figure	O
6	O
)	O
.	O

The	O
identity	O
of	O
the	O
product	O
was	O
confirmed	O
by	O
DNA	O
sequencing	O
which	O
also	O
revealed	O
that	O
the	O
drug	O
-	O
induced	O
094	O
transcript	O
was	O
more	O
faithfully	O
spliced	O
than	O
the	O
transcript	O
expressed	O
in	O
SCC9	O
(	O
data	O
not	O
shown	O
)	O
.	O

Discussion	O

Our	O
data	O
clearly	O
demonstrate	O
that	O
expression	O
of	O
normal	O
CSMD1	O
transcripts	O
is	O
rare	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
.	O

Of	O
the	O
HNSCC	O
cell	O
lines	O
examined	O
,	O
only	O
UPCI	O
:	O
SCC066	O
appears	O
to	O
express	O
a	O
normal	O
transcript	O
from	O
the	O
expected	O
promoter	O
.	O

Even	O
that	O
cell	O
line	O
produces	O
a	O
second	O
species	O
of	O
aberrantly	O
spliced	O
transcript	O
lacking	O
internal	O
exons	O
.	O

Our	O
data	O
suggest	O
that	O
epigenetic	O
modification	O
of	O
the	O
DNA	O
5	O
'	O
of	O
the	O
transcription	O
start	O
site	O
may	O
contribute	O
to	O
the	O
down	O
-	O
regulation	O
of	O
CSMD1	O
.	O

In	O
addition	O
,	O
a	O
low	O
level	O
of	O
expression	O
appears	O
to	O
be	O
associated	O
with	O
production	O
of	O
prematurely	O
terminated	O
transcripts	O
.	O

This	O
degree	O
of	O
complexity	O
might	O
be	O
expected	O
from	O
a	O
2	O
megabase	O
,	O
70	O
exon	O
gene	O
.	O

Methylation	O
of	O
a	O
specific	O
region	O
of	O
the	O
CpG	O
island	O
,	O
-	O
395	O
to	O
-	O
112	O
bp	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
(	O
amplicon	O
1	O
)	O
,	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
activity	O
of	O
the	O
normal	O
CSMD1	O
promoter	O
.	O

In	O
contrast	O
,	O
methylation	O
of	O
amplicon	O
2	O
,	O
located	O
within	O
the	O
first	O
exon	O
,	O
shows	O
no	O
such	O
relationship	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
relationship	O
between	O
the	O
amount	O
of	O
methylation	O
in	O
amplicon	O
1	O
and	O
the	O
level	O
of	O
expression	O
may	O
not	O
be	O
strictly	O
quantitative	O
.	O

Differences	O
between	O
cell	O
lines	O
with	O
amplicon	O
1	O
methylation	O
could	O
arise	O
through	O
a	O
number	O
of	O
mechanisms	O
,	O
for	O
example	O
,	O
variations	O
in	O
the	O
levels	O
of	O
transcription	O
factors	O
between	O
cell	O
lines	O
.	O

In	O
cases	O
where	O
there	O
is	O
considerable	O
heterogeneity	O
in	O
the	O
methylation	O
pattern	O
within	O
a	O
cell	O
line	O
like	O
PCI	O
-	O
100	O
,	O
alleles	O
with	O
less	O
methylation	O
may	O
be	O
expressed	O
at	O
higher	O
levels	O
than	O
those	O
more	O
heavily	O
methylated	O
(	O
compare	O
clones	O
51	O
and	O
52	O
to	O
clone	O
58	O
in	O
Figure	O
2C	O
)	O
.	O

Alternatively	O
,	O
the	O
presence	O
of	O
methylation	O
in	O
amplicon	O
1	O
could	O
be	O
a	O
qualitative	O
but	O
not	O
strictly	O
quantitative	O
indicator	O
of	O
methylation	O
of	O
a	O
critical	O
segment	O
of	O
the	O
promoter	O
not	O
discovered	O
in	O
this	O
study	O
.	O

The	O
normal	O
CSMD1	O
promoter	O
was	O
not	O
reactivated	O
by	O
drugs	O
that	O
inhibit	O
DNA	O
methyltransferases	O
and	O
histone	O
deacetylases	O
,	O
nor	O
did	O
the	O
drugs	O
abolish	O
CSMD1	O
promoter	O
methylation	O
,	O
even	O
at	O
toxic	O
doses	O
.	O

Not	O
all	O
genes	O
with	O
promoter	O
methylation	O
respond	O
to	O
such	O
treatments	O
[	O
23	O
]	O
.	O

These	O
drug	O
treatments	O
did	O
,	O
however	O
,	O
provide	O
a	O
potential	O
explanation	O
for	O
the	O
use	O
of	O
a	O
normally	O
cryptic	O
promoter	O
by	O
cell	O
line	O
SCC9	O
.	O

The	O
CSMD1	O
transcript	O
in	O
this	O
line	O
is	O
initiated	O
near	O
a	O
partial	O
Alu	O
element	O
.	O

5	O
-	O
aza	O
-	O
dC	O
treatment	O
of	O
cell	O
line	O
094	O
activates	O
the	O
same	O
cryptic	O
promoter	O
.	O

This	O
suggests	O
that	O
cryptic	O
promoters	O
may	O
be	O
naturally	O
activated	O
by	O
general	O
hypomethylation	O
of	O
the	O
genome	O
in	O
cancer	O
cells	O
and	O
the	O
subsequent	O
release	O
of	O
repetitive	O
elements	O
from	O
epigenetic	O
repression	O
(	O
reviewed	O
by	O
Ehrlich	O
[	O
17	O
]	O
)	O
.	O

The	O
SCC9	O
transcript	O
does	O
not	O
appear	O
to	O
encode	O
a	O
functional	O
protein	O
but	O
,	O
with	O
a	O
very	O
large	O
gene	O
like	O
CSMD1	O
,	O
there	O
is	O
a	O
potential	O
for	O
some	O
abnormally	O
initiated	O
transcripts	O
to	O
encode	O
truncated	O
proteins	O
with	O
dominant	O
negative	O
properties	O
.	O

The	O
second	O
ramification	O
of	O
this	O
finding	O
is	O
for	O
the	O
interpretation	O
of	O
data	O
obtained	O
by	O
treating	O
cells	O
with	O
methyltransferase	O
inhibitors	O
.	O

Detection	O
of	O
CSMD1	O
transcripts	O
solely	O
with	O
primers	O
mapping	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
could	O
have	O
been	O
erroneously	O
interpreted	O
as	O
representing	O
reactivation	O
of	O
the	O
normal	O
promoter	O
.	O

It	O
seems	O
imperative	O
that	O
such	O
experiments	O
demonstrate	O
that	O
transcripts	O
detected	O
after	O
drug	O
treatment	O
are	O
actually	O
initiated	O
at	O
the	O
normal	O
promoter	O
.	O

Aberrant	O
splicing	O
also	O
appears	O
to	O
play	O
a	O
role	O
in	O
the	O
production	O
of	O
defective	O
CSMD1	O
transcripts	O
.	O

Loss	O
of	O
splicing	O
fidelity	O
has	O
been	O
proposed	O
as	O
a	O
characteristic	O
of	O
cancer	O
cells	O
[	O
24	O
,	O
25	O
]	O
and	O
this	O
would	O
be	O
consistent	O
with	O
the	O
variety	O
of	O
misspliced	O
transcripts	O
we	O
detected	O
from	O
SCC9	O
.	O

However	O
,	O
the	O
removal	O
of	O
exons	O
4	O
and	O
5	O
from	O
the	O
CSMD1	O
transcript	O
in	O
PCI	O
-	O
13	O
may	O
reflect	O
a	O
more	O
specific	O
phenomenon	O
than	O
a	O
general	O
inability	O
to	O
splice	O
large	O
introns	O
;	O
this	O
line	O
is	O
still	O
capable	O
of	O
splicing	O
large	O
introns	O
as	O
evidenced	O
by	O
its	O
successful	O
splicing	O
of	O
exon	O
3	O
to	O
exon	O
6	O
,	O
eliminating	O
an	O
intron	O
of	O
over	O
666	O
kb	O
.	O

The	O
failure	O
to	O
include	O
exons	O
4	O
and	O
5	O
may	O
be	O
due	O
to	O
inactivation	O
of	O
a	O
splicing	O
enhancer	O
in	O
intron	O
3	O
,	O
or	O
to	O
less	O
efficient	O
splicing	O
due	O
to	O
the	O
fact	O
that	O
exons	O
4	O
and	O
5	O
do	O
not	O
begin	O
with	O
the	O
consensus	O
G	O
residue	O
(	O
Figure	O
4B	O
)	O
[	O
26	O
]	O
.	O

Conclusion	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
CSMD1	O
function	O
is	O
lost	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
through	O
a	O
variety	O
of	O
mechanisms	O
other	O
than	O
point	O
mutagenesis	O
.	O

Epigenetic	O
modifications	O
of	O
amplicon	O
1	O
and	O
defective	O
splicing	O
appear	O
to	O
be	O
fruitful	O
areas	O
to	O
explore	O
in	O
primary	O
head	O
and	O
neck	O
squamous	O
cancers	O
.	O

Methods	O

Cell	O
lines	O
and	O
tissue	O
samples	O

DNA	O
from	O
HNSCC	O
cell	O
lines	O
UMSCC9	O
,	O
UMSCC35	O
,	O
UMSCC37	O
,	O
UMSCC38	O
,	O
UMSCC45	O
,	O
UMSCC49	O
,	O
UMSCC65	O
,	O
UMSCC68	O
,	O
and	O
UMSCC76	O
was	O
provided	O
by	O
Dr	O
.	O
Thomas	O
Carey	O
,	O
University	O
of	O
Michigan	O
[	O
27	O
]	O
.	O

Dr	O
.	O
Ruud	O
Brakenhoff	O
,	O
Vrije	O
Universitat	O
,	O
provided	O
cell	O
lines	O
040	O
,	O
041	O
,	O
and	O
094	O
[	O
28	O
]	O
;	O
Dr	O
.	O
Theresa	O
Whiteside	O
,	O
University	O
of	O
Pittsburgh	O
,	O
provided	O
cell	O
lines	O
PCI	O
-	O
1	O
,	O
PCI	O
-	O
2	O
,	O
PCI	O
-	O
4B	O
,	O
PCI	O
-	O
13	O
,	O
PCI	O
-	O
30	O
,	O
PCI	O
-	O
50	O
,	O
PCI	O
-	O
51	O
,	O
PCI	O
-	O
52	O
,	O
PCI	O
-	O
100	O
[	O
29	O
]	O
,	O
SCC4	O
,	O
SCC9	O
[	O
30	O
,	O
31	O
]	O
,	O
and	O
UPCI	O
:	O
SCC068	O
,	O
UPCI	O
:	O
SCC74	O
,	O
UPCI	O
:	O
SCC104	O
,	O
UPCI	O
:	O
SCC182	O
,	O
UPCI	O
:	O
SCC203	O
,	O
and	O
UPCI	O
:	O
SCC220	O
[	O
developed	O
by	O
Dr	O
.	O
Susanne	O
Gollin	O
,	O
University	O
of	O
Pittsburgh	O
,	O
32	O
]	O
.	O

Dr	O
.	O
Gollin	O
provided	O
cell	O
lines	O
UPCI	O
:	O
SCC056	O
,	O
UPCI	O
:	O
SCC066	O
,	O
and	O
UPCI	O
:	O
SCC114	O
[	O
14	O
,	O
16	O
,	O
32	O
]	O
.	O

The	O
immortal	O
but	O
untransformed	O
keratinocyte	O
line	O
OKF6	O
-	O
TERT1	O
was	O
obtained	O
from	O
Dr	O
.	O
James	O
Rheinwald	O
,	O
Harvard	O
University	O
[	O
20	O
]	O
.	O

Normal	O
oropharyngeal	O
epithelium	O
was	O
isolated	O
from	O
discarded	O
tissue	O
from	O
uvulopalatopharyngoplasties	O
(	O
UPPP	O
)	O
collected	O
anonymously	O
with	O
the	O
approval	O
of	O
the	O
Washington	O
University	O
Human	S-Species
Studies	O
Committee	O
.	O

Cell	O
Culture	O
and	O
Tissue	O
Preparation	O

Squamous	O
cell	O
carcinoma	O
cell	O
lines	O
were	O
grown	O
in	O
DMEM	O
or	O
DMEM	O
:	O
F	O
-	O
12	O
,	O
1	O
:	O
1	O
Mixture	O
(	O
BioWhittaker	O
)	O
containing	O
10	O
%	O
fetal	O
bovine	S-Species
serum	O
(	O
Sigma	O
)	O
.	O

DMEM	O
medium	O
was	O
supplemented	O
with	O
1X	O
MEM	O
Nonessential	O
Amino	O
Acids	O
(	O
BioWhittaker	O
)	O
.	O

Upper	O
aerodigestive	O
tract	O
epithelium	O
was	O
separated	O
from	O
the	O
rest	O
of	O
the	O
UPPP	O
specimen	O
by	O
digestion	O
with	O
Dispase	O
II	O
(	O
Roche	O
)	O
using	O
a	O
protocol	O
adapted	O
from	O
Oda	O
and	O
Watson	O
[	O
33	O
]	O
.	O

Nucleic	O
acid	O
preparation	O
and	O
bisulfite	O
conversion	O

Genomic	O
DNA	O
was	O
isolated	O
by	O
using	O
either	O
Nucleospin	O
Tissue	O
kits	O
(	O
Clontech	O
)	O
,	O
QIAamp	O
DNA	O
Blood	O
Mini	O
kits	O
(	O
Qiagen	O
)	O
or	O
Trizol	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
instructions	O
.	O

Total	O
RNA	O
isolation	O
,	O
synthesis	O
of	O
first	O
strand	O
cDNA	O
,	O
RT	O
-	O
PCR	O
and	O
5	O
'	O
RACE	O
PCR	O
were	O
performed	O
essentially	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

Poly	O
-	O
A	O
+	O
RNA	O
for	O
Northern	O
blotting	O
was	O
selected	O
from	O
total	O
RNA	O
using	O
Oligotex	O
beads	O
(	O
Qiagen	O
)	O
.	O

Northern	O
blotting	O
and	O
hybridization	O
were	O
performed	O
as	O
previously	O
described	O
[	O
1	O
]	O
.	O

cDNA	O
synthesis	O
was	O
primed	O
using	O
oligo	O
dT	O
or	O
random	O
primers	O
and	O
extended	O
by	O
either	O
Thermoscript	O
or	O
Superscript	O
III	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
was	O
run	O
in	O
Perkin	O
-	O
Elmer	O
480	O
or	O
Applied	O
Biosystems	O
9700	O
thermal	O
cyclers	O
for	O
35	O
cycles	O
unless	O
otherwise	O
noted	O
.	O

Images	O
of	O
ethidium	O
bromide	O
stained	O
gels	O
were	O
captured	O
with	O
a	O
Gel	O
-	O
Doc	O
imaging	O
station	O
(	O
Biorad	O
)	O
.	O

Quantitative	O
PCR	O
was	O
run	O
in	O
an	O
Applied	O
Biosystems	O
5700	O
thermal	O
cycler	O
using	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Primers	O
prm2426	O
(	O
gtgtggagtatctgcagacatga	O
)	O
and	O
prm2427	O
(	O
ctggactaagcctccacagttct	O
)	O
were	O
used	O
to	O
amplify	O
a	O
132	O
base	O
segment	O
spanning	O
CSMD1	O
'	O
s	O
first	O
and	O
second	O
exons	O
.	O

An	O
amplicon	O
from	O
human	S-Species
18S	O
RNA	O
was	O
used	O
as	O
a	O
basis	O
for	O
comparisons	O
across	O
cell	O
lines	O
(	O
primers	O
prm2396	O
,	O
ttcggaactgaggccatgat	O
and	O
prm2397	O
,	O
tttcgctctggtccgtcttg	O
)	O
.	O

Calculations	O
were	O
performed	O
using	O
the	O
Delta	O
Delta	O
Ct	O
method	O
in	O
GeneAmp	O
5700	O
SDS	O
software	O
(	O
version	O
1	O
.	O
3	O
)	O
and	O
Microsoft	O
Excel	O
.	O

Quantitation	O
was	O
based	O
on	O
the	O
average	O
values	O
obtained	O
from	O
duplicate	O
reactions	O
.	O

The	O
level	O
of	O
CSMD1	O
expression	O
in	O
normal	O
oropharyngeal	O
epithelium	O
was	O
determined	O
from	O
pooled	O
cDNA	O
from	O
five	O
UPPP	O
specimens	O
.	O

We	O
used	O
the	O
CpGenome	O
DNA	O
Modification	O
kit	O
(	O
Intergen	O
)	O
for	O
bisulfite	O
conversion	O
of	O
the	O
genomic	O
DNA	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
,	O
with	O
the	O
following	O
exception	O
.	O

Incubation	O
of	O
the	O
conversion	O
reaction	O
was	O
carried	O
out	O
in	O
a	O
thermal	O
cycler	O
for	O
six	O
cycles	O
each	O
consisting	O
of	O
three	O
minutes	O
at	O
94	O
degrees	O
C	O
followed	O
by	O
three	O
hours	O
at	O
50	O
degrees	O
C	O
(	O
Christina	O
Menke	O
and	O
Paul	O
Goodfellow	O
,	O
personal	O
communication	O
)	O
.	O

Analysis	O
of	O
CSMD1	O
Promoter	O
Methylation	O

Methylation	O
of	O
three	O
segments	O
of	O
the	O
CSMD1	O
CpG	O
island	O
was	O
examined	O
using	O
the	O
Combined	O
Bisulfite	O
Restriction	O
Analysis	O
technique	O
(	O
COBRA	O
)	O
[	O
19	O
]	O
.	O

All	O
three	O
segments	O
were	O
amplified	O
by	O
using	O
the	O
nested	O
primers	O
and	O
PCR	O
conditions	O
listed	O
in	O
Table	O
1	O
.	O

Amplicon	O
1	O
extends	O
from	O
-	O
395	O
to	O
-	O
112	O
bp	O
,	O
amplicon	O
2	O
from	O
+	O
175	O
to	O
+	O
396	O
bp	O
,	O
and	O
amplicon	O
3	O
from	O
+	O
398	O
to	O
+	O
718	O
bp	O
relative	O
to	O
the	O
first	O
base	O
of	O
the	O
transcript	O
.	O

A	O
small	O
region	O
surrounding	O
the	O
transcription	O
start	O
site	O
(	O
-	O
111	O
to	O
+	O
174	O
bp	O
)	O
could	O
not	O
be	O
examined	O
because	O
no	O
PCR	O
primers	O
could	O
be	O
designed	O
from	O
its	O
extremely	O
GC	O
-	O
rich	O
sequence	O
.	O

The	O
first	O
round	O
PCR	O
used	O
2	O
mu	O
l	O
of	O
bisulfite	O
converted	O
genomic	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
10	O
mu	O
l	O
.	O

Subsequent	O
amplifications	O
with	O
nested	O
primers	O
used	O
4	O
mu	O
l	O
of	O
first	O
round	O
product	O
as	O
template	O
in	O
reactions	O
with	O
a	O
final	O
volume	O
of	O
20	O
mu	O
l	O
.	O

All	O
PCR	O
was	O
carried	O
out	O
for	O
35	O
cycles	O
.	O

A	O
portion	O
of	O
the	O
second	O
round	O
PCR	O
product	O
was	O
run	O
on	O
a	O
1	O
.	O
5	O
%	O
agarose	O
gel	O
,	O
stained	O
with	O
ethidium	O
bromide	O
,	O
and	O
quantified	O
using	O
the	O
ImageQuant	O
software	O
package	O
(	O
v1	O
.	O
2	O
for	O
Macintosh	O
,	O
Molecular	O
Dynamics	O
)	O
so	O
that	O
equal	O
amounts	O
of	O
each	O
could	O
be	O
used	O
in	O
restriction	O
digests	O
.	O

Restriction	O
digests	O
for	O
COBRA	O
were	O
performed	O
with	O
either	O
BstU	O
I	O
or	O
Taq	O
alpha	O
I	O
(	O
5	O
or	O
10	O
units	O
per	O
reaction	O
,	O
respectively	O
;	O
New	O
England	O
Biolabs	O
)	O
for	O
4	O
hours	O
in	O
a	O
final	O
volume	O
of	O
10	O
mu	O
l	O
.	O

Taq	O
alpha	O
I	O
digests	O
were	O
performed	O
only	O
when	O
no	O
methylation	O
was	O
detected	O
with	O
BstU	O
I	O
.	O

BstU	O
I	O
digests	O
also	O
included	O
an	O
internal	O
control	O
DNA	O
fragment	O
to	O
confirm	O
complete	O
digestion	O
.	O

This	O
DNA	O
fragment	O
contains	O
a	O
single	O
BstU	O
I	O
site	O
and	O
was	O
amplified	O
from	O
a	O
cloned	O
CSMD1	O
cDNA	O
using	O
primers	O
prm2020	O
(	O
agatcccccagtgtctccctgtgt	O
)	O
and	O
prm2021	O
(	O
actgctggtgccgtggtaatgact	O
)	O
.	O

The	O
control	O
PCR	O
product	O
is	O
1019	O
bp	O
long	O
and	O
is	O
digested	O
to	O
two	O
fragments	O
of	O
605	O
and	O
414	O
bp	O
by	O
BstU	O
I	O
.	O

Digestion	O
products	O
were	O
fractionated	O
on	O
a	O
10	O
%	O
polyacrylamide	O
gel	O
,	O
stained	O
with	O
ethidium	O
bromide	O
,	O
and	O
visualized	O
with	O
a	O
Gel	O
-	O
Doc	O
video	O
imaging	O
workstation	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

High	O
resolution	O
analysis	O
of	O
methylation	O
was	O
performed	O
by	O
sequence	O
analysis	O
of	O
individual	O
clones	O
from	O
amplicons	O
1	O
and	O
2	O
.	O

DNA	O
from	O
amplicon	O
3	O
proved	O
unclonable	O
and	O
gel	O
electrophoresis	O
suggests	O
that	O
its	O
very	O
AT	O
rich	O
sequence	O
results	O
in	O
a	O
bent	O
DNA	O
configuration	O
.	O

PCR	O
products	O
were	O
purified	O
using	O
the	O
Nucleospin	O
Extraction	O
columns	O
(	O
Clontech	O
)	O
and	O
inserted	O
into	O
the	O
pCR2	O
.	O
1	O
-	O
TOPO	O
vector	O
using	O
the	O
TOPO	O
TA	O
Cloning	O
kit	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Plasmid	O
DNA	O
from	O
individual	O
colonies	O
was	O
isolated	O
using	O
the	O
Nucleospin	O
Plus	O
Plasmid	O
Miniprep	O
kit	O
(	O
Clontech	O
)	O
and	O
sequenced	O
with	O
a	O
reverse	O
vector	O
primer	O
(	O
agcggataacaatttcacacagga	O
)	O
using	O
fluorescence	O
based	O
sequencing	O
with	O
Big	O
Dye	O
Terminator	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Treatment	O
of	O
cultured	O
cells	O
with	O
DNA	O
methyltransferase	O
inhibitors	O

Cell	O
line	O
094	O
was	O
treated	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5aza	O
-	O
dC	O
)	O
(	O
Sigma	O
)	O
dissolved	O
in	O
DMSO	O
.	O

Two	O
100	O
mm	O
cell	O
culture	O
dishes	O
containing	O
5	O
x	O
105	O
cells	O
were	O
established	O
for	O
each	O
of	O
the	O
drug	O
concentrations	O
tested	O
.	O

Cells	O
were	O
grown	O
for	O
72	O
hours	O
in	O
media	O
containing	O
DMEM	O
:	O
F	O
-	O
12	O
,	O
1	O
:	O
1	O
Mixture	O
(	O
BioWhittaker	O
)	O
with	O
1X	O
MEM	O
Nonessential	O
Amino	O
Acids	O
(	O
BioWhittaker	O
)	O
and	O
10	O
%	O
fetal	O
bovine	S-Species
serum	O
and	O
then	O
switched	O
to	O
media	O
containing	O
5aza	O
-	O
dC	O
at	O
concentrations	O
of	O
0	O
mu	O
m	O
,	O
5	O
mu	O
M	O
,	O
25	O
mu	O
M	O
,	O
or	O
100	O
mu	O
M	O
.	O

Cells	O
were	O
fed	O
daily	O
for	O
4	O
-	O
5	O
days	O
and	O
then	O
both	O
plates	O
were	O
harvested	O
in	O
3	O
ml	O
of	O
Trizol	O
(	O
Invitrogen	O
)	O
for	O
isolation	O
of	O
RNA	O
and	O
DNA	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

RT	O
-	O
PCR	O
used	O
for	O
detection	O
of	O
CSMD1	O
transcripts	O
in	O
these	O
treated	O
cells	O
was	O
run	O
for	O
40	O
cycles	O
.	O

Abbreviations	O

5aza	O
-	O
dC	O
=	O
5	O
-	O
aza	O
-	O
2	O
'	O
deoxycytidine	O
,	O
COBRA	O
=	O
Combined	O
Bisulfite	O
Restriction	O
Analysis	O
,	O
CSMD1	O
=	O
Cub	O
and	O
sushi	O
multiple	O
domains	O
1	O
,	O
HNSCC	O
=	O
head	O
&	O
neck	O
squamous	O
cell	O
carcinoma	O
,	O
RT	O
-	O
PCR	O
=	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
SCC	O
=	O
squamous	O
cell	O
carcinoma	O
,	O
UPPP	O
=	O
uvulopalatopharyngoplasty	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O

Authors	O
'	O
contributions	O

TMR	O
performed	O
the	O
DNA	O
methylation	O
analysis	O
,	O
and	O
parts	O
of	O
the	O
transcript	O
survey	O
.	O

BDT	O
cloned	O
and	O
characterized	O
the	O
novel	O
first	O
exon	O
expressed	O
in	O
cell	O
line	O
SCC9	O
.	O

SBS	O
performed	O
parts	O
of	O
the	O
transcript	O
survey	O
and	O
characterized	O
the	O
deletion	O
of	O
exons	O
4	O
and	O
5	O
in	O
PCI	O
-	O
13	O
.	O

All	O
three	O
authors	O
participated	O
in	O
the	O
analysis	O
of	O
the	O
data	O
and	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
.	O

Plasma	O
D	O
-	O
dimer	O
concentration	O
in	O
patients	S-Species
with	O
systemic	O
sclerosis	O

Abstract	O

Background	O

Systemic	O
sclerosis	O
(	O
SSc	O
)	O
is	O
an	O
autoimmune	O
disorder	O
of	O
the	O
connective	O
tissue	O
characterized	O
by	O
widespread	O
vascular	O
lesions	O
and	O
fibrosis	O
.	O

Little	O
is	O
known	O
so	O
far	O
on	O
the	O
activation	O
of	O
the	O
hemostatic	O
and	O
fibrinolytic	O
systems	O
in	O
SSc	O
,	O
and	O
most	O
preliminary	O
evidences	O
are	O
discordant	O
.	O

Methods	O

To	O
verify	O
whether	O
SSc	O
patients	S-Species
might	O
display	O
a	O
prothrombotic	O
condition	O
,	O
plasma	O
D	O
-	O
dimer	O
was	O
assessed	O
in	O
28	O
consecutive	O
SSc	O
patients	S-Species
and	O
in	O
33	O
control	O
subjects	O
,	O
matched	O
for	O
age	O
,	O
sex	O
and	O
environmental	O
habit	O
.	O

Results	O
and	O
discussion	O

When	O
compared	O
to	O
healthy	O
controls	O
,	O
geometric	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
IC95	O
%	O
)	O
of	O
plasma	O
D	O
-	O
dimer	O
were	O
significantly	O
increased	O
in	O
SSc	O
patients	S-Species
(	O
362	O
ng	O
/	O
mL	O
,	O
IC	O
95	O
%	O
:	O
361	O
-	O
363	O
ng	O
/	O
mL	O
vs	O
229	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
228	O
-	O
231	O
ng	O
/	O
mL	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

After	O
stratifying	O
SSc	O
patients	S-Species
according	O
to	O
disease	O
subset	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
those	O
with	O
limited	O
cutaneous	O
pattern	O
and	O
controls	O
,	O
whereas	O
patients	S-Species
with	O
diffuse	O
cutaneous	O
pattern	O
displayed	O
substantially	O
increased	O
values	O
.	O

No	O
correlation	O
was	O
found	O
between	O
plasma	O
D	O
-	O
dimer	O
concentration	O
and	O
age	O
,	O
sex	O
,	O
autoantibody	O
pattern	O
,	O
serum	O
creatinine	O
,	O
erythrosedimentation	O
rate	O
,	O
nailfold	O
videocapillaroscopic	O
pattern	O
and	O
pulmonary	O
involvement	O
.	O

Conclusion	O

We	O
demonstrated	O
that	O
SSc	O
patients	S-Species
with	O
diffuse	O
subset	O
are	O
characterized	O
by	O
increased	O
plasma	O
D	O
-	O
dimer	O
values	O
,	O
reflecting	O
a	O
potential	O
activation	O
of	O
both	O
the	O
hemostatic	O
and	O
fibrinolytic	O
cascades	O
,	O
which	O
might	O
finally	O
predispose	O
these	O
patients	S-Species
to	O
thrombotic	O
complications	O
.	O

Background	O

Systemic	O
sclerosis	O
(	O
SSc	O
)	O
is	O
an	O
autoimmune	O
disorder	O
of	O
the	O
connective	O
tissue	O
characterized	O
by	O
widespread	O
vascular	O
lesions	O
and	O
fibrosis	O
.	O

In	O
SSc	O
,	O
vasospasm	O
causes	O
frequent	O
episodes	O
of	O
reperfusion	O
injury	O
and	O
free	O
radical	O
-	O
mediated	O
endothelial	O
dysfunction	O
,	O
which	O
might	O
finally	O
influence	O
the	O
onset	O
of	O
local	O
thrombotic	O
complications	O
.	O

The	O
characteristic	O
vascular	O
involvement	O
affects	O
primarily	O
small	O
arteries	O
and	O
capillaries	O
,	O
causing	O
reduced	O
blood	O
flow	O
and	O
tissue	O
ischemia	O
and	O
supporting	O
the	O
typical	O
clinical	O
manifestations	O
of	O
this	O
unique	O
autoimmune	O
disorder	O
[	O
1	O
]	O
.	O

However	O
,	O
mechanisms	O
involved	O
in	O
the	O
endothelial	O
injury	O
are	O
as	O
yet	O
elusive	O
and	O
most	O
biochemical	O
evidences	O
are	O
often	O
inconclusive	O
or	O
controversial	O
.	O

Some	O
earlier	O
investigations	O
suggested	O
that	O
SSc	O
patients	S-Species
might	O
be	O
characterized	O
by	O
a	O
procoagulant	O
state	O
,	O
reporting	O
depressed	O
basal	O
and	O
stimulated	O
fibrinolytic	O
activity	O
,	O
while	O
others	O
studies	O
have	O
reported	O
normal	O
plasma	O
fibrinolytic	O
activity	O
and	O
normal	O
skin	O
and	O
plasma	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
levels	O
[	O
2	O
-	O
4	O
]	O
.	O

It	O
has	O
been	O
also	O
reported	O
that	O
the	O
lack	O
of	O
a	O
consistent	O
and	O
homogenous	O
increase	O
of	O
some	O
fibrinolytic	O
markers	O
,	O
in	O
the	O
presence	O
of	O
normal	O
levels	O
of	O
antithrombin	O
,	O
might	O
indirectly	O
highlight	O
an	O
impairment	O
of	O
the	O
heparan	O
sulphate	O
-	O
antithrombin	O
system	O
,	O
which	O
would	O
finally	O
promote	O
thrombin	O
generation	O
[	O
3	O
]	O
.	O

Conversely	O
,	O
Cerinic	O
and	O
colleagues	O
provided	O
evidence	O
that	O
fibrinolysis	O
might	O
be	O
impaired	O
in	O
SSc	O
,	O
as	O
shown	O
by	O
reduced	O
D	O
-	O
dimer	O
and	O
decreased	O
levels	O
of	O
plasminogen	O
activator	O
inhibitor	O
[	O
4	O
]	O
.	O

In	O
synthesis	O
,	O
there	O
are	O
no	O
conclusive	O
evidences	O
on	O
the	O
activity	O
of	O
the	O
hemostatic	O
and	O
fibrinolytic	O
pathways	O
in	O
SSc	O
so	O
far	O
.	O

D	O
-	O
dimer	O
,	O
a	O
breakdown	O
product	O
of	O
cross	O
-	O
linked	O
fibrin	O
,	O
was	O
proven	O
useful	O
for	O
the	O
diagnostic	O
evaluation	O
of	O
several	O
thrombotic	O
disorders	O
.	O

Moreover	O
,	O
an	O
increased	O
D	O
-	O
dimer	O
value	O
in	O
plasma	O
is	O
a	O
reliable	O
marker	O
of	O
a	O
systemic	O
prothrombotic	O
state	O
,	O
likely	O
superior	O
to	O
alternative	O
fibrinolytic	O
markers	O
,	O
and	O
its	O
measurement	O
might	O
be	O
helpful	O
in	O
predicting	O
or	O
preventing	O
thrombotic	O
events	O
in	O
the	O
single	O
patient	S-Species
[	O
5	O
]	O
.	O

Therefore	O
,	O
to	O
investigate	O
whether	O
SSc	O
patients	S-Species
might	O
be	O
characterized	O
by	O
a	O
potential	O
prothrombotic	O
condition	O
,	O
plasma	O
D	O
-	O
dimer	O
vales	O
were	O
measured	O
in	O
a	O
subset	O
of	O
SSc	O
patients	S-Species
,	O
compared	O
with	O
those	O
of	O
a	O
healthy	O
matched	O
control	O
population	O
and	O
further	O
associated	O
with	O
SSc	O
disease	O
subset	O
.	O

Methods	O

Plasma	O
D	O
-	O
dimer	O
was	O
measured	O
in	O
28	O
consecutive	O
SSc	O
patients	S-Species
(	O
2	O
males	O
and	O
26	O
females	O
;	O
mean	O
age	O
50	O
+/-	O
15	O
years	O
,	O
17	O
with	O
limited	O
and	O
11	O
with	O
diffuse	O
disease	O
patterns	O
)	O
,	O
who	O
fulfilled	O
the	O
American	O
Rheumatism	O
Association	O
'	O
s	O
criteria	O
for	O
the	O
diagnosis	O
of	O
SSc	O
[	O
6	O
]	O
and	O
in	O
33	O
control	O
subjects	O
,	O
matched	O
for	O
age	O
(	O
48	O
+/-	O
13	O
years	O
)	O
,	O
sex	O
(	O
3	O
males	O
,	O
30	O
females	O
)	O
and	O
environmental	O
habit	O
,	O
recruited	O
among	O
healthy	O
hospital	O
personnel	O
.	O

Samples	O
were	O
collected	O
in	O
the	O
morning	O
;	O
all	O
subjects	O
were	O
in	O
a	O
fasted	O
state	O
.	O

The	O
research	O
was	O
carried	O
out	O
according	O
to	O
the	O
principles	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
an	O
informed	O
consent	O
for	O
testing	O
was	O
received	O
from	O
all	O
individuals	O
recruited	O
to	O
the	O
study	O
.	O

Blood	O
was	O
collected	O
after	O
an	O
overnight	O
fast	O
into	O
siliconized	O
vacuum	O
tubes	O
,	O
containing	O
0	O
.	O
105	O
mol	O
/	O
l	O
sodium	O
citrate	O
(	O
Becton	O
-	O
Dickinson	O
,	O
Oxford	O
,	O
UK	O
)	O
.	O

Samples	O
were	O
gently	O
mixed	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
15	O
degrees	O
C	O
at	O
1500	O
x	O
g	O
;	O
plasma	O
was	O
separated	O
and	O
stored	O
in	O
aliquots	O
at	O
-	O
70	O
degrees	O
C	O
until	O
measurement	O
.	O

Plasma	O
D	O
-	O
dimer	O
was	O
measured	O
employing	O
Vidas	O
DD	O
,	O
a	O
rapid	O
and	O
quantitative	O
automated	O
enzyme	O
linked	O
immunosorbent	O
assay	O
with	O
fluorescent	O
detection	O
,	O
on	O
the	O
Mini	O
Vidas	O
immunoanalyzer	O
(	O
bioMerieux	O
,	O
Marcy	O
l	O
'	O
Etoile	O
,	O
France	O
)	O
.	O

Analytical	O
imprecision	O
,	O
expressed	O
in	O
terms	O
of	O
mean	O
inter	O
-	O
assay	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
,	O
was	O
quoted	O
by	O
the	O
manufacturer	O
as	O
being	O
lower	O
than	O
5	O
%	O
.	O

Significance	O
of	O
differences	O
between	O
samples	O
was	O
assessed	O
,	O
following	O
logarithmic	O
conversion	O
of	O
data	O
,	O
by	O
parametric	O
tests	O
(	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
ANOVA	O
test	O
,	O
Pearson	O
'	O
s	O
correlation	O
)	O
;	O
the	O
level	O
of	O
statistical	O
significance	O
was	O
set	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Results	O
and	O
discussion	O

When	O
compared	O
to	O
healthy	O
controls	O
,	O
geometric	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
IC95	O
%	O
)	O
of	O
plasma	O
D	O
-	O
dimer	O
concentration	O
appeared	O
significantly	O
increased	O
in	O
SSc	O
patients	S-Species
(	O
362	O
ng	O
/	O
mL	O
,	O
IC	O
95	O
%	O
:	O
361	O
-	O
363	O
ng	O
/	O
mL	O
vs	O
229	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
228	O
-	O
231	O
ng	O
/	O
mL	O
,	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

After	O
stratifying	O
SSc	O
patients	S-Species
according	O
to	O
disease	O
subset	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
those	O
with	O
limited	O
cutaneous	O
pattern	O
(	O
lcSSc	O
)	O
and	O
controls	O
(	O
geometric	O
mean	O
plasma	O
D	O
-	O
dimer	O
:	O
283	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
282	O
-	O
285	O
ng	O
/	O
mL	O
;	O
p	O
=	O
0	O
.	O
61	O
)	O
,	O
whereas	O
patients	S-Species
with	O
diffuse	O
cutaneous	O
pattern	O
(	O
dcSSc	O
)	O
displayed	O
substantially	O
increased	O
values	O
(	O
geometric	O
mean	O
plasma	O
D	O
-	O
dimer	O
:	O
538	O
ng	O
/	O
mL	O
,	O
IC95	O
%	O
:	O
536	O
-	O
539	O
ng	O
/	O
mL	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Additionally	O
,	O
patients	S-Species
with	O
active	O
disease	O
,	O
as	O
evaluated	O
according	O
to	O
the	O
European	O
Scleroderma	O
Study	O
Group	O
criteria	O
[	O
7	O
]	O
,	O
displayed	O
higher	O
D	O
-	O
dimer	O
levels	O
as	O
compared	O
to	O
patients	S-Species
with	O
inactive	O
disease	O
(	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O

As	O
further	O
shown	O
in	O
table	O
1	O
,	O
D	O
-	O
dimer	O
concentration	O
correlated	O
significantly	O
with	O
the	O
modified	O
Rodnan	O
total	O
skin	O
score	O
(	O
TSS	O
)	O
and	O
the	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
plasma	O
D	O
-	O
dimer	O
concentration	O
and	O
age	O
,	O
sex	O
,	O
autoantibody	O
pattern	O
,	O
serum	O
creatinine	O
,	O
erythrosedimentation	O
rate	O
,	O
nailfold	O
videocapillaroscopic	O
pattern	O
and	O
pulmonary	O
involvement	O
,	O
ascertained	O
according	O
to	O
the	O
score	O
proposed	O
by	O
Medsger	O
et	O
al	O
[	O
8	O
]	O
.	O

The	O
pathogenesis	O
of	O
the	O
endothelial	O
injury	O
in	O
SSc	O
is	O
as	O
yet	O
elusive	O
and	O
most	O
biochemical	O
evidences	O
are	O
often	O
inconclusive	O
or	O
controversial	O
.	O

Although	O
endothelial	O
cell	O
apoptosis	O
and	O
impaired	O
angiogenesis	O
have	O
received	O
major	O
attention	O
among	O
the	O
mechanisms	O
involved	O
in	O
the	O
characteristic	O
vascular	O
dysfunction	O
,	O
recent	O
studies	O
provided	O
clear	O
evidence	O
of	O
a	O
significant	O
activation	O
of	O
the	O
coagulation	O
cascade	O
,	O
resulting	O
in	O
a	O
procoagulant	O
state	O
that	O
might	O
finally	O
raise	O
the	O
relative	O
risk	O
of	O
thrombotic	O
events	O
in	O
these	O
patients	S-Species
.	O

In	O
SSc	O
,	O
the	O
peculiar	O
vascular	O
lesions	O
and	O
fibrosis	O
were	O
claimed	O
to	O
impair	O
endothelial	O
function	O
,	O
as	O
suggested	O
by	O
impairment	O
of	O
fibrinolysis	O
and	O
activation	O
of	O
the	O
coagulation	O
pathway	O
.	O

The	O
following	O
loss	O
of	O
the	O
balance	O
between	O
fibrinolysis	O
and	O
coagulation	O
might	O
finally	O
contribute	O
to	O
vessel	O
engulfment	O
with	O
fibrin	O
and	O
breakdown	O
of	O
vessel	O
patency	O
,	O
symptomatic	O
of	O
a	O
tendency	O
to	O
the	O
development	O
of	O
thrombotic	O
complications	O
in	O
this	O
particular	O
autoimmune	O
disorder	O
[	O
4	O
]	O
.	O

D	O
-	O
dimer	O
is	O
a	O
heterogeneous	O
class	O
of	O
end	O
-	O
stage	O
degradation	O
products	O
that	O
directly	O
reflect	O
the	O
level	O
of	O
lysed	O
cross	O
-	O
linked	O
fibrin	O
,	O
occurring	O
in	O
vivo	O
with	O
a	O
wide	O
range	O
of	O
molecular	O
weights	O
.	O

Therefore	O
,	O
D	O
-	O
dimer	O
is	O
a	O
well	O
-	O
recognized	O
marker	O
of	O
a	O
systemic	O
prothrombotic	O
state	O
[	O
5	O
,	O
9	O
]	O
and	O
appears	O
a	O
strong	O
,	O
consistent	O
predictor	O
of	O
cardiovascular	O
events	O
in	O
the	O
general	O
population	O
,	O
in	O
patients	S-Species
with	O
cardiovascular	O
disease	O
and	O
in	O
other	O
pathologies	O
characterized	O
by	O
an	O
increased	O
risk	O
of	O
thrombosis	O
[	O
10	O
-	O
12	O
]	O
.	O

Accordingly	O
,	O
D	O
-	O
dimer	O
measurement	O
could	O
be	O
reliably	O
used	O
as	O
an	O
initial	O
screening	O
test	O
in	O
patients	S-Species
with	O
clinically	O
suspected	O
thrombosis	O
,	O
as	O
its	O
high	O
negative	O
predictive	O
value	O
enables	O
to	O
validly	O
rule	O
out	O
ongoing	O
thrombotic	O
complications	O
[	O
12	O
]	O
.	O

Little	O
is	O
known	O
on	O
the	O
thrombotic	O
tendency	O
of	O
SSc	O
patients	S-Species
so	O
far	O
[	O
13	O
]	O
.	O

At	O
variance	O
with	O
previous	O
investigations	O
[	O
2	O
-	O
4	O
]	O
,	O
we	O
demonstrated	O
that	O
SSc	O
patients	S-Species
with	O
diffuse	O
subset	O
are	O
characterized	O
by	O
increased	O
plasma	O
D	O
-	O
dimer	O
values	O
,	O
reflecting	O
a	O
potential	O
activation	O
of	O
both	O
the	O
coagulation	O
and	O
fibrinolytic	O
pathways	O
.	O

Conclusion	O

Although	O
increased	O
D	O
-	O
dimer	O
values	O
in	O
SSc	O
patients	S-Species
were	O
occasionally	O
observed	O
in	O
earlier	O
studies	O
,	O
the	O
association	O
between	O
plasma	O
D	O
-	O
dimer	O
and	O
disease	O
subset	O
is	O
likely	O
an	O
original	O
and	O
innovative	O
issue	O
.	O

The	O
significant	O
correlation	O
observed	O
with	O
disease	O
activity	O
,	O
cutaneous	O
involvement	O
and	O
forced	O
vital	O
capacity	O
,	O
further	O
suggests	O
that	O
SSc	O
patients	S-Species
,	O
especially	O
those	O
with	O
diffuse	O
subset	O
,	O
display	O
a	O
hypercoagulable	O
state	O
,	O
which	O
might	O
finally	O
predispose	O
this	O
peculiar	O
subset	O
of	O
patients	S-Species
to	O
the	O
development	O
of	O
thrombotic	O
complications	O
.	O

Authors	O
'	O
contributions	O

GL	O
:	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
drafted	O
the	O
manuscript	O
;	O
AV	O
:	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
the	O
statistical	O
analysis	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
;	O
PC	O
:	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
;	O
GLS	O
:	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
;	O
MM	O
:	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
and	O
performed	O
the	O
measurement	O
;	O
GCG	O
:	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Enp1	O
,	O
a	O
yeast	S-Species
protein	O
associated	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
,	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
and	O
40S	O
subunit	O
synthesis	O

Abstract	O

ENP1	O
is	O
an	O
essential	O
Saccharomyces	B-Species
cerevisiae	E-Species
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

Enp1	O
protein	O
is	O
localized	O
in	O
the	O
nucleus	O
and	O
concentrated	O
in	O
the	O
nucleolus	O
.	O

An	O
enp1	O
-	O
1	O
temperature	O
-	O
sensitive	O
mutant	O
inhibited	O
35S	O
pre	O
-	O
rRNA	O
early	O
processing	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
as	O
shown	O
by	O
northern	O
analysis	O
of	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
.	O

Pulse	O
-	O
chase	O
analysis	O
further	O
revealed	O
that	O
the	O
enp1	O
-	O
1	O
strain	O
was	O
defective	O
in	O
the	O
synthesis	O
of	O
20S	O
pre	O
-	O
rRNA	O
and	O
hence	O
18S	O
rRNA	O
,	O
which	O
led	O
to	O
reduced	O
formation	O
of	O
40S	O
ribosomal	O
subunits	O
.	O

Co	O
-	O
precipitation	O
analysis	O
revealed	O
that	O
Enp1	O
was	O
associated	O
with	O
Nop1	O
protein	O
,	O
as	O
well	O
as	O
with	O
U3	O
and	O
U14	O
RNAs	O
,	O
two	O
snoRNAs	O
implicated	O
in	O
early	O
pre	O
-	O
rRNA	O
processing	O
steps	O
.	O

These	O
results	O
suggest	O
a	O
direct	O
role	O
for	O
Enp1	O
in	O
the	O
early	O
steps	O
of	O
rRNA	O
processing	O
.	O

INTRODUCTION	O

Ribosome	O
biogenesis	O
is	O
one	O
of	O
the	O
major	O
cellular	O
activities	O
in	O
eukaryotic	O
cells	O
.	O

It	O
takes	O
place	O
primarily	O
in	O
a	O
specialized	O
subnuclear	O
compartment	O
,	O
the	O
nucleolus	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
the	O
yeast	S-Species
Saccharomyces	B-Species
cerevisiae	E-Species
,	O
each	O
rRNA	O
gene	O
is	O
transcribed	O
by	O
RNA	O
polymerase	O
I	O
into	O
a	O
35S	O
rRNA	O
precursor	O
,	O
consisting	O
of	O
18S	O
,	O
5	O
.	O
8S	O
and	O
25S	O
rRNA	O
sequences	O
flanked	O
by	O
two	O
external	O
transcribed	O
spacers	O
(	O
ETS	O
)	O
and	O
separated	O
by	O
two	O
internal	O
transcribed	O
spacers	O
(	O
ITS	O
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O

This	O
35S	O
precursor	O
goes	O
through	O
a	O
series	O
of	O
modifications	O
and	O
processing	O
steps	O
to	O
generate	O
the	O
mature	O
18S	O
,	O
5	O
.	O
8S	O
and	O
25S	O
rRNAs	O
.	O

The	O
processing	O
occurs	O
first	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
,	O
resulting	O
in	O
the	O
20S	O
pre	O
-	O
rRNA	O
and	O
27SA2	O
pre	O
-	O
rRNA	O
.	O

The	O
20S	O
pre	O
-	O
rRNA	O
is	O
then	O
cleaved	O
,	O
leading	O
to	O
the	O
mature	O
18S	O
rRNA	O
found	O
in	O
the	O
40S	O
ribosomal	O
subunit	O
.	O

The	O
27SA2	O
pre	O
-	O
rRNA	O
is	O
processed	O
through	O
two	O
alternative	O
pathways	O
.	O

The	O
majority	O
of	O
27SA2	O
pre	O
-	O
rRNA	O
is	O
cleaved	O
at	O
sites	O
A3	O
and	O
B2	O
to	O
form	O
the	O
27SA3	O
pre	O
-	O
rRNA	O
,	O
which	O
is	O
subsequently	O
processed	O
to	O
produce	O
27SBS	O
.	O

Alternatively	O
,	O
27SA2	O
pre	O
-	O
rRNA	O
can	O
be	O
processed	O
at	O
sites	O
B1L	O
and	O
B2	O
to	O
generate	O
27SBL	O
pre	O
-	O
rRNA	O
.	O

Both	O
27SBS	O
and	O
27SBL	O
pre	O
-	O
rRNAs	O
are	O
then	O
cleaved	O
at	O
sites	O
C1	O
and	O
C2	O
to	O
generate	O
the	O
mature	O
25S	O
rRNA	O
,	O
and	O
7SS	O
or	O
7SL	O
intermediates	O
,	O
which	O
are	O
then	O
processed	O
to	O
mature	O
5	O
.	O
8SS	O
or	O
5	O
.	O
8SL	O
rRNAs	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
25S	O
rRNA	O
and	O
5	O
.	O
8S	O
rRNA	O
are	O
the	O
RNA	O
components	O
of	O
the	O
60S	O
ribosomal	O
subunit	O
(	O
3	O
)	O
.	O

During	O
the	O
course	O
of	O
rRNA	O
modification	O
and	O
processing	O
,	O
many	O
of	O
the	O
ribosomal	O
proteins	O
are	O
assembled	O
onto	O
the	O
rRNA	O
molecules	O
to	O
form	O
the	O
ribosome	O
complex	O
.	O

Ribosome	O
biogenesis	O
needs	O
a	O
large	O
number	O
of	O
trans	O
-	O
acting	O
factors	O
,	O
including	O
small	O
nucleolar	O
RNAs	O
(	O
snoRNAs	O
)	O
,	O
protein	O
components	O
of	O
the	O
snoRNP	O
complexes	O
,	O
rRNA	O
modifying	O
enzymes	O
,	O
endo	O
-	O
and	O
exonucleases	O
,	O
putative	O
RNA	O
helicases	O
and	O
other	O
protein	O
factors	O
(	O
3	O
,	O
4	O
)	O
.	O

In	O
yeast	S-Species
cells	O
there	O
are	O
more	O
than	O
100	O
different	O
snoRNAs	O
playing	O
important	O
roles	O
in	O
rRNA	O
modification	O
and	O
processing	O
.	O

On	O
the	O
basis	O
of	O
their	O
structure	O
,	O
the	O
snoRNAs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
the	O
box	O
C	O
/	O
D	O
family	O
and	O
box	O
H	O
/	O
ACA	O
family	O
.	O

Only	O
one	O
snoRNA	O
,	O
MRP	O
RNA	O
,	O
belongs	O
to	O
neither	O
family	O
(	O
5	O
-	O
7	O
)	O
.	O

While	O
the	O
majority	O
of	O
the	O
snoRNAs	O
participate	O
in	O
RNA	O
pseudouridylation	O
and	O
2	O
'	O
-	O
O	O
-	O
ribose	O
methylation	O
,	O
a	O
few	O
of	O
them	O
,	O
including	O
MRP	O
snoRNA	O
,	O
box	O
C	O
/	O
D	O
snoRNAs	O
U3	O
and	O
U14	O
,	O
and	O
box	O
H	O
/	O
ACA	O
snoRNAs	O
snR10	O
and	O
snR30	O
,	O
are	O
required	O
for	O
processing	O
of	O
the	O
pre	O
-	O
rRNA	O
(	O
8	O
-	O
12	O
)	O
.	O

Not	O
only	O
are	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
essential	O
for	O
early	O
cleavages	O
of	O
35S	O
pre	O
-	O
rRNA	O
to	O
18S	O
rRNA	O
,	O
the	O
proteins	O
associated	O
with	O
them	O
,	O
including	O
Nop1	O
,	O
Nop5	O
,	O
Gar1	O
and	O
Nop10	O
,	O
have	O
also	O
been	O
shown	O
to	O
be	O
required	O
for	O
18S	O
rRNA	O
synthesis	O
(	O
13	O
-	O
16	O
)	O
.	O

The	O
ENP1	O
(	O
Essential	O
Nuclear	O
Protein	O
1	O
)	O
gene	O
was	O
identified	O
in	O
a	O
genetic	O
screen	O
for	O
suppressors	O
of	O
an	O
ost4	O
mutation	O
(	O
oligosaccharide	O
transferase	O
4	O
)	O
(	O
17	O
)	O
.	O

However	O
,	O
in	O
subsequent	O
studies	O
it	O
was	O
found	O
not	O
to	O
be	O
involved	O
in	O
OST4	O
function	O
(	O
18	O
)	O
.	O

ENP1	O
is	O
an	O
essential	O
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

The	O
Enp1	O
protein	O
is	O
highly	O
conserved	O
and	O
homologs	O
are	O
found	O
in	O
all	O
eukaryotes	O
.	O

The	O
yeast	S-Species
protein	O
was	O
localized	O
to	O
the	O
nucleus	O
in	O
a	O
previous	O
study	O
(	O
18	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
Enp1	O
human	S-Species
homolog	O
,	O
called	O
bystin	O
,	O
was	O
reported	O
to	O
localize	O
to	O
the	O
cytoplasm	O
and	O
was	O
proposed	O
to	O
be	O
involved	O
in	O
cell	O
adhesion	O
(	O
19	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
the	O
Enp1	O
protein	O
not	O
only	O
is	O
nuclear	O
but	O
is	O
enriched	O
in	O
the	O
nucleolus	O
.	O

We	O
also	O
found	O
that	O
Enp1	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
40S	O
ribosomal	O
subunits	O
,	O
and	O
its	O
presence	O
is	O
necessary	O
for	O
the	O
pre	O
-	O
rRNA	O
processing	O
to	O
form	O
20S	O
pre	O
-	O
rRNA	O
and	O
18S	O
rRNA	O
.	O

An	O
association	O
between	O
Enp1	O
and	O
U3	O
and	O
U14	O
snoRNAs	O
,	O
and	O
with	O
the	O
nucleolar	O
protein	O
Nop1	O
,	O
was	O
established	O
.	O

We	O
also	O
found	O
that	O
human	S-Species
Enp1	O
,	O
expressed	O
in	O
yeast	S-Species
,	O
was	O
located	O
in	O
the	O
nucleus	O
and	O
the	O
nucleolus	O
,	O
suggesting	O
that	O
the	O
function	O
of	O
this	O
protein	O
is	O
conserved	O
.	O

MATERIALS	O
AND	O
METHODS	O

Yeast	S-Species
strains	O
and	O
media	O

The	O
S	B-Species
.	I-Species
cerevisiae	E-Species
strains	O
used	O
in	O
this	O
study	O
are	O
all	O
derivatives	O
of	O
a	O
wild	O
-	O
type	O
diploid	O
strain	O
W303	O
(	O
MATa	O
/	O
MAT	O
alpha	O
ura3	O
-	O
1	O
/	O
ura3	O
-	O
1	O
leu2	O
-	O
3	O
,	O
112	O
/	O
leu2	O
-	O
3	O
,	O
112	O
trp1	O
-	O
1	O
/	O
trp1	O
-	O
1	O
his3	O
-	O
11	O
,	O
15	O
/	O
his3	O
-	O
11	O
,	O
15	O
ade2	O
-	O
1	O
/	O
ade2	O
-	O
1	O
can1	O
-	O
100	O
/	O
can1	O
-	O
100	O
)	O
except	O
for	O
strain	O
RS1938	O
.	O

Strain	O
JBY45	O
(	O
MATa	O
/	O
MAT	O
alpha	O
ENP1	O
/	O
Delta	O
enp1	O
:	O
:	O
his5	O
+	O
)	O
was	O
constructed	O
by	O
replacing	O
one	O
copy	O
of	O
the	O
ENP1	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
with	O
the	O
Schizosaccharomyces	B-Species
pombe	E-Species
his5	O
+	O
gene	O
(	O
18	O
)	O
.	O

Strain	O
JBY46	O
[	O
MATa	O
Delta	O
enp1	O
:	O
:	O
his5	O
+	O
/	O
pJB23	O
(	O
ENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
is	O
a	O
haploid	O
strain	O
derived	O
from	O
JBY45	O
with	O
wild	O
-	O
type	O
ENP1	O
on	O
a	O
low	O
copy	O
number	O
plasmid	O
.	O

Strain	O
JBY48	O
[	O
MATa	O
Delta	O
enp1	O
:	O
:	O
his5	O
+	O
/	O
pJB19	O
(	O
enp1	O
-	O
1	O
,	O
TRP1	O
,	O
CEN6	O
)	O
]	O
and	O
strain	O
JBY49	O
[	O
MATa	O
Delta	O
enp1	O
:	O
:	O
his5	O
+	O
/	O
pJB39	O
(	O
enp1	O
-	O
2	O
,	O
TRP1	O
,	O
CEN6	O
)	O
]	O
have	O
plasmids	O
with	O
enp1	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutations	O
.	O

Strain	O
JBY51	O
(	O
MATa	O
Delta	O
enp1	O
:	O
:	O
his5	O
+	O
TRP1	O
:	O
:	O
enp1	O
-	O
1	O
)	O
is	O
an	O
enp1	O
ts	O
strain	O
generated	O
by	O
integrating	O
the	O
enp1	O
-	O
1	O
gene	O
at	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
.	O

Strain	O
CWY13	O
[	O
MATa	O
Delta	O
enp1	O
:	O
:	O
his5	O
+	O
/	O
pJB24	O
(	O
pMET25	O
-	O
GFP	O
-	O
ENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
has	O
GFP	O
-	O
ENP1	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
.	O

Strain	O
CWY14	O
(	O
MATa	O
ENP1	O
-	O
TAP	O
)	O
was	O
created	O
by	O
fusing	O
sequences	O
encoding	O
a	O
Tandem	O
Affinity	O
Purification	O
(	O
TAP	O
)	O
tag	O
(	O
20	O
,	O
21	O
)	O
to	O
the	O
3	O
'	O
end	O
of	O
ENP1	O
.	O

Strain	O
YRH39	O
(	O
MAT	O
alpha	O
HST2	O
-	O
TAP	O
)	O
was	O
created	O
by	O
fusing	O
sequences	O
encoding	O
a	O
TAP	O
tag	O
to	O
the	O
3	O
'	O
end	O
of	O
HST2	O
.	O

Strain	O
RS1938	O
(	O
Delta	O
nop1	O
:	O
:	O
URA3	O
pUN100	O
-	O
ProtA	O
-	O
NOP1	O
)	O
was	O
created	O
by	O
transforming	O
RS1935	O
(	O
MATa	O
/	O
alpha	O
leu2	O
/	O
leu2	O
ura3	O
/	O
ura3	O
lys2	O
/	O
lys2	O
ade2	O
/	O
ade2	O
Delta	O
nop1	O
:	O
:	O
URA3	O
/	O
NOP1	O
)	O
with	O
pUN100	O
-	O
ProtA	O
-	O
NOP1	O
(	O
strain	O
and	O
plasmid	O
supplied	O
by	O
T	O
.	O
Schafer	O
)	O
,	O
followed	O
by	O
tetrad	O
dissection	O
.	O

Strain	O
CWY15	O
[	O
MATa	O
/	O
pCW109	O
(	O
pMET25	O
-	O
GFP	O
-	O
hENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
has	O
a	O
human	S-Species
homolog	O
of	O
Enp1	O
expressed	O
in	O
W303	O
-	O
1a	O
.	O

The	O
media	O
used	O
were	O
prepared	O
as	O
described	O
(	O
22	O
)	O
.	O

Cloning	O
of	O
ENP1	O

pRS426	O
-	O
MEG1	O
(	O
The	O
original	O
name	O
of	O
ENP1	O
)	O
was	O
a	O
gift	O
from	O
Dr	O
William	O
J	O
.	O
Lennarz	O
.	O

It	O
contains	O
the	O
ENP1	O
gene	O
within	O
a	O
2	O
.	O
6	O
kb	O
EcoRI	O
genomic	O
fragment	O
cloned	O
into	O
pRS426	O
(	O
18	O
)	O
.	O

The	O
EcoRI	O
fragment	O
was	O
subsequently	O
cloned	O
into	O
pRS314	O
(	O
TRP1	O
,	O
CEN6	O
)	O
,	O
pRS316	O
(	O
URA3	O
,	O
CEN6	O
)	O
and	O
pRS424	O
(	O
TRP1	O
,	O
2	O
micro	O
)	O
to	O
create	O
pJB20	O
,	O
pJB23	O
and	O
pJB21	O
,	O
respectively	O
.	O

pGFP	O
-	O
N	O
-	O
FUS	O
is	O
a	O
centromeric	O
plasmid	O
for	O
fusing	O
green	O
fluorescence	O
protein	O
(	O
GFP	O
)	O
to	O
a	O
polypeptide	O
'	O
s	O
N	O
-	O
terminus	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
(	O
23	O
)	O
.	O

Cloning	O
the	O
ENP1	O
ORF	O
into	O
pGFP	O
-	O
N	O
-	O
FUS	O
via	O
XbaI	O
and	O
SalI	O
sites	O
generated	O
plasmid	O
pJB24	O
.	O

pJB19	O
(	O
enp1	O
-	O
1	O
,	O
TRP1	O
,	O
CEN6	O
)	O
contains	O
the	O
enp1	O
-	O
1	O
mutant	O
gene	O
.	O

The	O
human	S-Species
homolog	O
of	O
yeast	S-Species
Enp1	O
was	O
PCR	O
amplified	O
from	O
a	O
human	S-Species
cDNA	O
clone	O
BC007340	O
(	O
Research	O
Genetics	O
)	O
,	O
then	O
cloned	O
into	O
pGFP	O
-	O
N	O
-	O
FUS	O
,	O
p415	O
-	O
ADH	O
,	O
p415	O
-	O
GPD	O
and	O
p415	O
-	O
TEF	O
(	O
24	O
)	O
via	O
XbaI	O
and	O
SalI	O
sites	O
to	O
generate	O
pCW109	O
,	O
pCW113	O
,	O
pCW115	O
and	O
pCW117	O
,	O
respectively	O
.	O

The	O
fragment	O
of	O
the	O
human	S-Species
Enp1	O
homolog	O
(	O
amino	O
acids	O
152	O
-	O
437	O
)	O
was	O
also	O
cloned	O
into	O
these	O
vectors	O
to	O
generate	O
pCW110	O
,	O
pCW114	O
,	O
pCW116	O
and	O
pCW118	O
.	O

Random	O
mutagenesis	O
of	O
ENP1	O
to	O
generate	O
enp1	O
ts	O
mutants	O

The	O
enp1	O
ts	O
mutants	O
were	O
generated	O
with	O
a	O
protocol	O
introducing	O
random	O
mutations	O
by	O
PCR	O
(	O
25	O
)	O
.	O

The	O
PCR	O
was	O
performed	O
with	O
oligonucleotides	O
ENP1	O
-	O
MUT5	O
'	O
(	O
5	O
'	O
-	O
GGTGGTGTCAGT	O
AGGGGA	O
-	O
3	O
'	O
)	O
,	O
ENP1	O
-	O
MUT3	O
'	O
(	O
5	O
'	O
-	O
CAGTCTGCAATATA	O
TGGAC	O
-	O
3	O
'	O
)	O
and	O
plasmid	O
template	O
pJB20	O
(	O
see	O
above	O
)	O
.	O

The	O
nucleotide	O
concentrations	O
in	O
the	O
reaction	O
were	O
1	O
mM	O
each	O
for	O
dATP	O
,	O
dGTP	O
,	O
dCTP	O
and	O
dTTP	O
.	O

After	O
strain	O
JBY46	O
was	O
transformed	O
with	O
the	O
PCR	O
product	O
and	O
with	O
pJB20	O
gapped	O
by	O
NheI	O
and	O
NsiI	O
,	O
the	O
transformants	O
were	O
replica	O
-	O
plated	O
onto	O
two	O
plates	O
containing	O
5	O
-	O
FOA	O
synthetic	O
medium	O
without	O
tryptophan	O
;	O
one	O
replica	O
was	O
incubated	O
at	O
23	O
degrees	O
C	O
and	O
the	O
other	O
at	O
37	O
degrees	O
C	O
.	O

Colonies	O
growing	O
at	O
23	O
degrees	O
C	O
but	O
not	O
at	O
37	O
degrees	O
C	O
were	O
picked	O
as	O
candidates	O
.	O

Since	O
approximately	O
10	O
%	O
of	O
the	O
colonies	O
were	O
inviable	O
at	O
both	O
temperatures	O
,	O
we	O
knew	O
that	O
10	O
%	O
of	O
the	O
ENP1	O
PCR	O
products	O
lost	O
their	O
function	O
after	O
the	O
PCR	O
mutagenesis	O
.	O

This	O
confirmed	O
the	O
effectiveness	O
of	O
the	O
mutagenesis	O
procedure	O
.	O

Two	O
candidates	O
showed	O
good	O
growth	O
at	O
23	O
degrees	O
C	O
but	O
no	O
growth	O
at	O
37	O
degrees	O
C	O
.	O

They	O
were	O
named	O
strains	O
JBY48	O
and	O
JBY49	O
and	O
contained	O
plasmids	O
with	O
the	O
enp1	O
-	O
1	O
and	O
enp1	O
-	O
2	O
mutations	O
,	O
respectively	O
.	O

The	O
mutated	O
enp1	O
-	O
1	O
gene	O
on	O
pJB19	O
was	O
cloned	O
into	O
an	O
integration	O
vector	O
,	O
pRS304	O
,	O
as	O
an	O
EcoRI	O
fragment	O
.	O

The	O
plasmid	O
was	O
subsequently	O
linearized	O
with	O
SnaBI	O
within	O
the	O
TRP1	O
marker	O
and	O
was	O
integrated	O
at	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
of	O
strain	O
JBY46	O
.	O

Selection	O
on	O
5	O
-	O
FOA	O
was	O
used	O
to	O
remove	O
plasmid	O
pJB23	O
,	O
creating	O
strain	O
JBY51	O
.	O

Sucrose	O
gradient	O
analysis	O

Polyribosome	O
preparation	O
and	O
analysis	O
were	O
carried	O
out	O
essentially	O
as	O
described	O
(	O
26	O
)	O
.	O

Cells	O
grown	O
in	O
YPD	O
were	O
collected	O
at	O
mid	O
-	O
log	O
phase	O
(	O
OD600	O
0	O
.	O
8	O
-	O
1	O
.	O
0	O
)	O
and	O
were	O
broken	O
with	O
glass	O
beads	O
.	O

The	O
lysate	O
was	O
frozen	O
immediately	O
in	O
liquid	O
N2	O
and	O
was	O
stored	O
at	O
-	O
80	O
degrees	O
C	O
.	O

Lysate	O
(	O
30	O
U	O
of	O
absorbance	O
at	O
OD260	O
)	O
was	O
layered	O
over	O
a	O
7	O
-	O
47	O
%	O
(	O
w	O
/	O
v	O
)	O
sucrose	O
gradient	O
,	O
which	O
was	O
centrifuged	O
at	O
28	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
5	O
h	O
at	O
4	O
degrees	O
C	O
in	O
a	O
SW28	O
rotor	O
and	O
was	O
analyzed	O
with	O
an	O
ISCO	O
UA	O
-	O
5	O
gradient	O
UV	O
detection	O
system	O
on	O
absorbency	O
at	O
254	O
nm	O
.	O

Immunofluorescence	O

Immunofluorescence	O
analysis	O
was	O
carried	O
out	O
essentially	O
as	O
described	O
(	O
27	O
)	O
.	O

Cells	O
were	O
fixed	O
with	O
3	O
.	O
7	O
%	O
formaldehyde	O
at	O
room	O
temperature	O
for	O
1	O
.	O
5	O
h	O
.	O

Antibodies	O
included	O
a	O
mouse	S-Species
monoclonal	O
anti	O
-	O
Nop1	O
(	O
a	O
gift	O
from	O
John	O
P	O
.	O
Aris	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
,	O
Florida	O
)	O
and	O
a	O
Texas	O
-	O
red	O
-	O
conjugated	O
donkey	S-Species
-	O
anti	O
-	O
mouse	S-Species
antibody	O
(	O
Jackson	O
Lab	O
)	O
,	O
both	O
used	O
at	O
1	O
:	O
500	O
dilution	O
.	O

Images	O
were	O
taken	O
on	O
a	O
Zeiss	O
Axioplan2	O
microscope	O
equipped	O
with	O
a	O
Zeiss	O
AxioCam	O
camera	O
.	O

Pulse	O
-	O
chase	O
labeling	O
analysis	O
of	O
rRNA	O

For	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
pulse	O
-	O
chase	O
analysis	O
,	O
cells	O
were	O
grown	O
in	O
synthetic	O
medium	O
without	O
methionine	O
at	O
room	O
temperature	O
or	O
37	O
degrees	O
C	O
for	O
2	O
h	O
.	O

When	O
the	O
OD600	O
reached	O
1	O
.	O
0	O
,	O
6	O
ml	O
of	O
the	O
culture	O
were	O
pulse	O
-	O
labeled	O
with	O
250	O
micro	O
Ci	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
(	O
Amersham	O
Pharmacia	O
)	O
for	O
3	O
min	O
and	O
chased	O
with	O
cold	O
methionine	O
(	O
500	O
micro	O
g	O
/	O
ml	O
)	O
for	O
2	O
,	O
4	O
or	O
12	O
min	O
.	O

For	O
each	O
time	O
point	O
of	O
the	O
chase	O
1	O
.	O
25	O
ml	O
of	O
culture	O
was	O
mixed	O
with	O
ice	O
and	O
collected	O
.	O

The	O
pellets	O
were	O
frozen	O
immediately	O
in	O
liquid	O
N2	O
and	O
stored	O
at	O
-	O
80	O
degrees	O
C	O
before	O
total	O
RNA	O
was	O
purified	O
using	O
a	O
hot	O
phenol	O
method	O
(	O
28	O
)	O
.	O

The	O
RNAs	O
were	O
separated	O
on	O
a	O
1	O
.	O
2	O
%	O
agarose	O
formaldehyde	O
gel	O
and	O
transferred	O
onto	O
Hybond	O
-	O
N	O
+	O
nylon	O
membranes	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

After	O
being	O
sprayed	O
with	O
EN3HANCE	O
(	O
Du	O
Pont	O
)	O
,	O
the	O
membranes	O
were	O
exposed	O
to	O
film	O
at	O
-	O
80	O
degrees	O
C	O
(	O
29	O
)	O
.	O

Northern	O
analysis	O

Cells	O
were	O
grown	O
inYPD	O
at	O
room	O
temperature	O
or	O
37	O
degrees	O
C	O
for	O
2	O
-	O
4	O
h	O
.	O

When	O
the	O
OD600	O
reached	O
1	O
.	O
0	O
,	O
10	O
ml	O
of	O
cells	O
were	O
collected	O
and	O
frozen	O
immediately	O
.	O

Total	O
RNA	O
was	O
extracted	O
as	O
described	O
(	O
28	O
)	O
.	O

Five	O
micrograms	O
of	O
RNA	O
were	O
separated	O
on	O
1	O
.	O
2	O
%	O
agarose	O
formaldehyde	O
gels	O
(	O
for	O
high	O
molecular	O
weight	O
RNA	O
)	O
or	O
on	O
6	O
%	O
polyacrylamide	O
7	O
M	O
urea	O
denaturing	O
gels	O
(	O
for	O
low	O
molecular	O
weight	O
RNA	O
)	O
for	O
each	O
sample	O
.	O

The	O
RNA	O
was	O
then	O
transferred	O
to	O
Zeta	O
-	O
Probe	O
GT	O
nylon	O
membranes	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Probes	O
for	O
hybridyzation	O
were	O
specific	O
oligonucleotides	O
end	O
-	O
labeled	O
using	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
.	O

After	O
hybridization	O
and	O
washes	O
,	O
membranes	O
were	O
exposed	O
to	O
phosphorimager	O
screens	O
or	O
X	O
-	O
ray	O
films	O
(	O
29	O
)	O
.	O

Oligonucleotides	O
specific	O
for	O
various	O
regions	O
of	O
35S	O
pre	O
-	O
rRNA	O
are	O
:	O
1	O
,	O
GGTCTCTCTGCTGCCG	O
GAAATG	O
;	O
3	O
,	O
AATGAGCCATTCGCAGTTTCACTG	O
;	O
4	O
,	O
GCTCTCATGCTCTTGCCAAAAC	O
;	O
5	O
,	O
TGTTTGTTACCT	O
CTGGGCCCCG	O
;	O
6	O
,	O
TCCAGTTACGAAAATTCTTG	O
;	O
7	O
,	O
CGTATCGCATTTCGCTGCGTTC	O
;	O
8	O
,	O
GTTCGCCTAGAC	O
GCTCTCTCTTC	O
;	O
9	O
,	O
GCGAGATTCCCCTACCCAC	O
.	O

The	O
regions	O
complementary	O
to	O
these	O
oligonucleotides	O
are	O
shown	O
in	O
Figure	O
6A	O
.	O

The	O
oligonucleotides	O
probing	O
box	O
C	O
/	O
D	O
snoRNAs	O
are	O
:	O
U3	O
,	O
TTCGGTTTCTCACTCACTCTGGGGTAC	O
;	O
U14	O
,	O
GGAACCAGTCTTTCATCACCGTG	O
.	O

The	O
oligonucleotides	O
probing	O
box	O
H	O
/	O
ACA	O
snoRNAs	O
are	O
:	O
snoRNA10	O
,	O
CCTTG	O
CAACGGTCCTCATCCGGG	O
;	O
snoRNA30	O
,	O
GTCCGAAGC	O
GCCATCTAGATGA	O
.	O

RNA	O
and	O
protein	O
precipitation	O
analysis	O

Cells	O
were	O
grown	O
in	O
YPD	O
(	O
1	O
l	O
)	O
to	O
OD600	O
1	O
.	O
0	O
,	O
then	O
collected	O
,	O
washed	O
once	O
in	O
ice	O
-	O
cold	O
PBS	O
and	O
broken	O
using	O
glass	O
beads	O
in	O
10	O
ml	O
IPP150	O
buffer	O
(	O
10	O
mM	O
Tris	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
and	O
0	O
.	O
1	O
%	O
NP	O
-	O
40	O
)	O
with	O
protease	O
inhibitors	O
.	O

The	O
lysates	O
were	O
mixed	O
with	O
200	O
micro	O
l	O
IgG	O
agarose	O
beads	O
for	O
2	O
h	O
at	O
4	O
degrees	O
C	O
.	O

After	O
several	O
washes	O
with	O
50	O
ml	O
IPP150	O
buffer	O
,	O
the	O
IgG	O
beads	O
were	O
collected	O
and	O
the	O
RNA	O
associated	O
with	O
the	O
beads	O
extracted	O
by	O
the	O
hot	O
phenol	O
method	O
(	O
28	O
)	O
.	O

One	O
-	O
tenth	O
of	O
the	O
precipitated	O
RNA	O
was	O
then	O
separated	O
on	O
6	O
%	O
polyacrylamide	O
7	O
M	O
urea	O
denaturing	O
gels	O
and	O
electro	O
-	O
transferred	O
to	O
Zeta	O
-	O
Probe	O
GT	O
nylon	O
membranes	O
.	O

They	O
were	O
probed	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
labeled	O
oligonucleotides	O
.	O

For	O
the	O
lanes	O
showing	O
total	O
RNA	O
,	O
2	O
micro	O
g	O
RNA	O
prepared	O
from	O
exponentially	O
growing	O
cultures	O
were	O
loaded	O
.	O

For	O
co	O
-	O
precipitation	O
analysis	O
of	O
proteins	O
,	O
the	O
IgG	O
beads	O
were	O
resuspended	O
in	O
2	O
x	O
Laemmli	O
sample	O
buffer	O
,	O
boiled	O
for	O
5	O
min	O
and	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Approximately	O
1	O
%	O
of	O
the	O
precipitate	O
was	O
loaded	O
onto	O
each	O
lane	O
.	O

For	O
the	O
total	O
protein	O
,	O
0	O
.	O
1	O
%	O
of	O
the	O
extract	O
prior	O
to	O
precipitation	O
was	O
loaded	O
onto	O
each	O
lane	O
.	O

Following	O
electrophoresis	O
,	O
the	O
proteins	O
were	O
transferred	O
to	O
nitrocellulose	O
membranes	O
and	O
detected	O
using	O
anti	O
-	O
Nop1	O
antibody	O
at	O
1	O
:	O
3000	O
dilution	O
(	O
provided	O
by	O
J	O
.	O
Aris	O
)	O
and	O
anti	O
-	O
L3	O
antibody	O
(	O
provided	O
by	O
J	O
.	O
Warner	O
)	O
at	O
1	O
:	O
3000	O
dilution	O
followed	O
by	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
mouse	S-Species
secondary	O
antibody	O
at	O
1	O
:	O
5000	O
dilution	O
.	O

The	O
antibody	O
complexes	O
were	O
detected	O
using	O
ECL	O
-	O
Plus	O
reagents	O
(	O
Amersham	O
Pharmacia	O
)	O
as	O
specified	O
by	O
the	O
manufacturer	O
.	O

RESULTS	O

Construction	O
and	O
analysis	O
of	O
ENP1	O
temperature	O
-	O
sensitive	O
alleles	O

ENP1	O
is	O
an	O
essential	O
yeast	S-Species
gene	O
conserved	O
among	O
eukaryotes	O
(	O
18	O
)	O
.	O

To	O
study	O
its	O
functions	O
,	O
we	O
first	O
created	O
a	O
diploid	O
strain	O
,	O
JBY45	O
,	O
heterozygous	O
for	O
the	O
Delta	O
enp1	O
mutation	O
.	O

Then	O
two	O
enp1	O
ts	O
mutant	O
alleles	O
(	O
enp1	O
-	O
1	O
and	O
enp1	O
-	O
2	O
)	O
were	O
generated	O
by	O
random	O
PCR	O
mutagenesis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Both	O
mutant	O
alleles	O
were	O
recessive	O
to	O
the	O
wild	O
-	O
type	O
ENP1	O
gene	O
.	O

The	O
enp1	O
-	O
1	O
gene	O
was	O
integrated	O
into	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
to	O
create	O
strain	O
JBY51	O
and	O
all	O
subsequent	O
experiments	O
were	O
done	O
with	O
this	O
enp1	O
allele	O
.	O

At	O
23	O
degrees	O
C	O
the	O
growth	O
of	O
JBY51	O
was	O
comparable	O
to	O
that	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
,	O
but	O
at	O
37	O
degrees	O
C	O
it	O
did	O
not	O
grow	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
enp1	O
-	O
1	O
contains	O
two	O
point	O
mutations	O
,	O
resulting	O
in	O
substitutions	O
of	O
two	O
amino	O
acids	O
:	O
W242	O
-->	O
G	O
and	O
V415	O
-->	O
A	O
.	O

No	O
attempt	O
was	O
made	O
to	O
determine	O
whether	O
both	O
mutations	O
were	O
required	O
for	O
the	O
ts	O
phenotype	O
.	O

Flow	O
cytometry	O
of	O
strain	O
JBY51	O
showed	O
DNA	O
content	O
profiles	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
strain	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
ENP1	O
is	O
not	O
involved	O
in	O
cell	O
cycle	O
regulation	O
.	O

Enp1	O
is	O
enriched	O
in	O
the	O
nucleolus	O

Enp1	O
tagged	O
at	O
the	O
C	O
-	O
terminus	O
with	O
the	O
myc	O
epitope	O
was	O
previously	O
found	O
to	O
localize	O
to	O
the	O
nucleus	O
(	O
18	O
)	O
.	O

To	O
expand	O
this	O
analysis	O
,	O
we	O
fused	O
GFP	O
to	O
the	O
N	O
-	O
terminus	O
of	O
Enp1	O
,	O
and	O
expressed	O
the	O
tagged	O
Enp1	O
protein	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
as	O
the	O
sole	O
source	O
of	O
Enp1	O
protein	O
in	O
the	O
cells	O
.	O

Cells	O
of	O
strain	O
CWY13	O
(	O
pMET25	O
-	O
GFP	O
-	O
ENP1	O
)	O
were	O
grown	O
in	O
media	O
with	O
methionine	O
(	O
transcription	O
partially	O
repressed	O
)	O
or	O
without	O
methionine	O
(	O
transcription	O
not	O
repressed	O
)	O
.	O

Growth	O
of	O
CWY13	O
was	O
comparable	O
to	O
that	O
of	O
wild	O
-	O
type	O
cells	O
in	O
both	O
media	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
the	O
GFP	O
tagged	O
Enp1	O
protein	O
was	O
functional	O
.	O

In	O
cells	O
cultured	O
in	O
medium	O
without	O
methionine	O
,	O
in	O
which	O
the	O
ENP	O
transcription	O
was	O
not	O
repressed	O
,	O
the	O
GFP	O
-	O
Enp1	O
protein	O
was	O
expressed	O
at	O
a	O
high	O
level	O
and	O
showed	O
strong	O
green	O
fluorescence	O
distributed	O
throughout	O
the	O
nucleus	O
(	O
data	O
not	O
shown	O
)	O
,	O
consistent	O
with	O
the	O
original	O
observation	O
(	O
18	O
)	O
.	O

With	O
methionine	O
added	O
to	O
the	O
medium	O
,	O
however	O
,	O
the	O
fluorescent	O
signal	O
of	O
GFP	O
-	O
Enp1	O
was	O
weaker	O
and	O
surprisingly	O
showed	O
crescent	O
or	O
cap	O
-	O
like	O
patterns	O
typical	O
of	O
nucleolar	O
proteins	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

This	O
nucleolar	O
enrichment	O
was	O
confirmed	O
by	O
its	O
co	O
-	O
localization	O
with	O
the	O
nucleolar	O
protein	O
Nop1	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

ENP1	O
mutation	O
leads	O
to	O
reduced	O
levels	O
of	O
40S	O
ribosomal	O
subunits	O

The	O
nucleolar	O
enrichment	O
suggested	O
that	O
Enp1	O
might	O
play	O
some	O
role	O
in	O
ribosome	O
synthesis	O
.	O

To	O
test	O
this	O
possibility	O
,	O
cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
,	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
and	O
a	O
top2	O
ts	O
strain	O
RS191	O
(	O
30	O
)	O
were	O
grown	O
in	O
YPD	O
at	O
23	O
or	O
37	O
degrees	O
C	O
and	O
their	O
ribosome	O
profiles	O
analyzed	O
after	O
separation	O
on	O
sucrose	O
gradients	O
.	O

At	O
23	O
degrees	O
C	O
,	O
enp1	O
-	O
1	O
cells	O
showed	O
polysome	O
profiles	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
and	O
top2	O
-	O
1	O
strains	O
(	O
Fig	O
.	O
4A	O
-	O
C	O
)	O
.	O

In	O
contrast	O
,	O
after	O
incubation	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
(	O
37	O
degrees	O
C	O
)	O
for	O
40	O
min	O
(	O
data	O
not	O
shown	O
)	O
and	O
2	O
h	O
,	O
enp1	O
-	O
1	O
cells	O
had	O
reduced	O
levels	O
of	O
40S	O
ribosomal	O
subunits	O
,	O
80S	O
monosomes	O
and	O
polysomes	O
,	O
along	O
with	O
a	O
dramatic	O
increase	O
in	O
the	O
free	O
60S	O
subunit	O
peak	O
(	O
Fig	O
.	O
4F	O
)	O
,	O
while	O
the	O
wild	O
-	O
type	O
and	O
top2	O
-	O
1	O
cells	O
showed	O
little	O
change	O
in	O
polysome	O
profile	O
at	O
37	O
degrees	O
C	O
(	O
Fig	O
.	O
4D	O
and	O
E	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
changes	O
of	O
the	O
enp1	O
-	O
1	O
polysome	O
profile	O
were	O
due	O
to	O
specific	O
defects	O
caused	O
by	O
the	O
enp1	O
-	O
1	O
mutation	O
,	O
and	O
not	O
due	O
simply	O
to	O
the	O
shift	O
to	O
37	O
degrees	O
C	O
for	O
a	O
wild	O
-	O
type	O
or	O
ts	O
strain	O
.	O

The	O
processing	O
of	O
pre	O
-	O
rRNA	O
for	O
18S	O
rRNA	O
is	O
impaired	O
in	O
enp1	O
mutants	O

In	O
most	O
cases	O
reductions	O
in	O
ribosomal	O
subunit	O
levels	O
are	O
the	O
results	O
of	O
defects	O
in	O
pre	O
-	O
rRNA	O
processing	O
or	O
ribosome	O
assembly	O
or	O
both	O
(	O
3	O
)	O
.	O

To	O
study	O
the	O
mechanism	O
by	O
which	O
Enp1	O
affects	O
the	O
40S	O
subunit	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
enp1	O
mutations	O
on	O
processing	O
of	O
the	O
pre	O
-	O
rRNA	O
using	O
pulse	O
-	O
chase	O
labeling	O
.	O

[	O
methyl	O
-	O
3H	O
]	O
methionine	O
is	O
preferred	O
for	O
labeling	O
rRNAs	O
in	O
pulse	O
-	O
chase	O
analysis	O
because	O
rRNAs	O
are	O
specifically	O
methylated	O
during	O
the	O
early	O
steps	O
of	O
the	O
processing	O
.	O

Cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
and	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
were	O
grown	O
at	O
23	O
or	O
37	O
degrees	O
C	O
for	O
2	O
h	O
before	O
they	O
were	O
labeled	O
with	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
for	O
3	O
min	O
and	O
chased	O
with	O
cold	O
methionine	O
for	O
2	O
,	O
4	O
and	O
12	O
min	O
.	O

In	O
wild	O
-	O
type	O
cells	O
,	O
the	O
labeled	O
35S	O
rRNA	O
precursor	O
,	O
27S	O
and	O
20S	O
rRNA	O
intermediates	O
were	O
rapidly	O
chased	O
into	O
mature	O
25S	O
and	O
18S	O
rRNAs	O
(	O
Fig	O
.	O
5	O
)	O
,	O
at	O
23	O
or	O
37	O
degrees	O
C	O
.	O

In	O
contrast	O
,	O
enp1	O
-	O
1	O
cells	O
showed	O
dramatic	O
changes	O
after	O
incubation	O
at	O
37	O
degrees	O
C	O
.	O

Although	O
at	O
23	O
degrees	O
C	O
the	O
synthesis	O
and	O
processing	O
were	O
comparable	O
to	O
those	O
of	O
wild	O
-	O
type	O
cells	O
,	O
cells	O
cultured	O
at	O
37	O
degrees	O
C	O
for	O
2	O
h	O
had	O
neither	O
20S	O
pre	O
-	O
rRNA	O
nor	O
18S	O
rRNA	O
,	O
while	O
25S	O
rRNA	O
was	O
generated	O
at	O
normal	O
levels	O
.	O

The	O
37	O
degrees	O
C	O
grown	O
enp1	O
-	O
1	O
cells	O
also	O
had	O
low	O
levels	O
of	O
aberrant	O
23S	O
and	O
possibly	O
21S	O
intermediates	O
(	O
Fig	O
.	O
5	O
)	O
.	O

The	O
defect	O
in	O
18S	O
rRNA	O
synthesis	O
was	O
further	O
supported	O
by	O
pulse	O
-	O
chase	O
experiments	O
carried	O
out	O
using	O
[	O
5	O
,	O
6	O
-	O
3H	O
]	O
uracil	O
.	O

The	O
results	O
obtained	O
were	O
essentially	O
the	O
same	O
;	O
no	O
20S	O
pre	O
-	O
rRNA	O
or	O
18S	O
rRNA	O
was	O
produced	O
,	O
while	O
processing	O
to	O
25S	O
rRNA	O
was	O
not	O
affected	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
the	O
enp1	O
mutation	O
leads	O
to	O
specific	O
defects	O
in	O
the	O
processing	O
pathway	O
for	O
20S	O
pre	O
-	O
rRNA	O
and	O
18S	O
rRNA	O
,	O
resulting	O
in	O
reduced	O
40S	O
subunit	O
synthesis	O
and	O
a	O
lowered	O
level	O
of	O
the	O
40S	O
subunit	O
.	O

Enp1	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
sites	O

To	O
define	O
the	O
processing	O
steps	O
affected	O
by	O
the	O
enp1	O
mutation	O
,	O
the	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
and	O
mature	O
RNAs	O
were	O
analyzed	O
by	O
northern	O
blotting	O
.	O

Total	O
RNAs	O
were	O
isolated	O
from	O
cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
and	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
grown	O
at	O
37	O
degrees	O
C	O
for	O
2	O
or	O
4	O
h	O
.	O

After	O
separation	O
on	O
formaldehyde	O
agarose	O
,	O
RNAs	O
were	O
transferred	O
onto	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
specific	O
to	O
various	O
regions	O
of	O
the	O
35S	O
pre	O
-	O
rRNA	O
(	O
Fig	O
.	O
6A	O
)	O
.	O

After	O
incubation	O
at	O
37	O
degrees	O
C	O
,	O
enp1	O
-	O
1	O
cells	O
had	O
wild	O
-	O
type	O
levels	O
of	O
25S	O
rRNA	O
,	O
but	O
reduced	O
levels	O
of	O
18S	O
rRNA	O
(	O
Fig	O
.	O
6B	O
)	O
.	O

A	O
probe	O
specific	O
to	O
ITS1	O
(	O
P5	O
)	O
further	O
revealed	O
that	O
enp1	O
-	O
1	O
cells	O
incubated	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
accumulated	O
two	O
aberrant	O
rRNAs	O
,	O
23S	O
and	O
21S	O
(	O
Fig	O
.	O
6C	O
)	O
.	O

Aberrant	O
rRNA	O
processing	O
products	O
of	O
similar	O
sizes	O
have	O
been	O
described	O
in	O
numerous	O
studies	O
(	O
14	O
,	O
31	O
-	O
34	O
)	O
and	O
result	O
from	O
defects	O
in	O
processing	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
.	O

Additional	O
probes	O
were	O
used	O
to	O
verify	O
the	O
origins	O
of	O
the	O
23S	O
and	O
21S	O
RNAs	O
in	O
the	O
enp1	O
-	O
1	O
strain	O
.	O

The	O
23S	O
product	O
was	O
detected	O
by	O
oligos	O
1	O
,	O
2	O
,	O
4	O
and	O
5	O
,	O
but	O
not	O
by	O
oligos	O
6	O
,	O
7	O
or	O
8	O
(	O
Fig	O
.	O
6D	O
,	O
E	O
,	O
C	O
,	O
F	O
,	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
this	O
RNA	O
extends	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
35S	O
rRNA	O
to	O
the	O
A3	O
site	O
.	O

The	O
21S	O
product	O
was	O
detected	O
by	O
oligos	O
4	O
and	O
5	O
,	O
but	O
not	O
by	O
oligos	O
1	O
,	O
2	O
,	O
6	O
,	O
7	O
and	O
8	O
(	O
Fig	O
.	O
6E	O
,	O
C	O
,	O
D	O
,	O
F	O
,	O
G	O
and	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
it	O
extends	O
from	O
the	O
A1	O
to	O
the	O
A3	O
site	O
.	O

At	O
37	O
degrees	O
C	O
the	O
enp1	O
-	O
1	O
cells	O
also	O
had	O
less	O
32S	O
and	O
20S	O
rRNA	O
intermediates	O
(	O
Fig	O
.	O
6B	O
and	O
E	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
enp1	O
mutation	O
led	O
to	O
complete	O
or	O
nearly	O
complete	O
inhibition	O
of	O
processing	O
at	O
site	O
A0	O
and	O
A2	O
,	O
and	O
partial	O
inhibition	O
of	O
processing	O
at	O
site	O
A1	O
.	O

As	O
a	O
consequence	O
,	O
the	O
35S	O
pre	O
-	O
rRNA	O
was	O
cleaved	O
at	O
site	O
A3	O
instead	O
,	O
producing	O
23S	O
and	O
21S	O
rRNA	O
products	O
.	O

Consistent	O
with	O
this	O
theory	O
,	O
the	O
27SA2	O
rRNA	O
intermediate	O
level	O
was	O
greatly	O
reduced	O
in	O
enp1	O
cells	O
at	O
37	O
degrees	O
C	O
(	O
Fig	O
.	O
6C	O
)	O
due	O
to	O
the	O
inhibition	O
of	O
processing	O
at	O
A2	O
,	O
while	O
the	O
27SB	O
pre	O
-	O
rRNA	O
level	O
was	O
similar	O
to	O
wild	O
-	O
type	O
cells	O
(	O
Fig	O
.	O
6G	O
)	O
.	O

Moreover	O
,	O
no	O
difference	O
in	O
the	O
5	O
.	O
8	O
rRNA	O
level	O
was	O
observed	O
between	O
the	O
wild	O
-	O
type	O
cells	O
and	O
enp1	O
cells	O
(	O
Fig	O
.	O
6H	O
)	O
.	O

Enp1	O
is	O
associated	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
and	O
with	O
Nop1	O

It	O
has	O
previously	O
been	O
shown	O
that	O
mutations	O
in	O
the	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
and	O
in	O
their	O
associated	O
proteins	O
affect	O
processing	O
of	O
35S	O
pre	O
-	O
rRNA	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
.	O

Because	O
of	O
the	O
similarity	O
with	O
the	O
processing	O
defects	O
of	O
enp1	O
-	O
1	O
strains	O
,	O
we	O
tested	O
the	O
association	O
between	O
Enp1	O
and	O
snoRNAs	O
.	O

To	O
do	O
this	O
,	O
we	O
created	O
a	O
strain	O
in	O
which	O
a	O
TAP	O
tag	O
was	O
fused	O
to	O
the	O
C	O
-	O
terminus	O
of	O
Enp1	O
.	O

The	O
TAP	O
tag	O
contains	O
Staphylococcus	B-Species
aureus	E-Species
Protein	O
A	O
as	O
well	O
as	O
calmodulin	O
-	O
binding	O
peptide	O
sequences	O
,	O
so	O
the	O
tagged	O
Enp1	O
binds	O
IgG	O
beads	O
with	O
high	O
specificity	O
.	O

Cells	O
grew	O
well	O
with	O
the	O
TAP	O
-	O
tagged	O
Enp1	O
as	O
the	O
only	O
source	O
of	O
Enp1	O
protein	O
,	O
showing	O
that	O
it	O
was	O
functional	O
.	O

As	O
a	O
control	O
,	O
we	O
used	O
a	O
TAP	O
tag	O
on	O
an	O
unrelated	O
cytoplasmic	O
protein	O
,	O
Hst2	O
.	O

Strain	O
CWY14	O
(	O
ENP1	O
-	O
TAP	O
)	O
and	O
the	O
Hst2	O
-	O
TAP	O
tagged	O
strain	O
were	O
grown	O
in	O
YPD	O
to	O
mid	O
-	O
exponential	O
phase	O
before	O
being	O
harvested	O
.	O

Extracts	O
were	O
prepared	O
and	O
mixed	O
with	O
IgG	O
agarose	O
beads	O
to	O
precipitate	O
Enp1	O
-	O
TAP	O
and	O
associated	O
RNAs	O
.	O

Total	O
RNAs	O
were	O
extracted	O
from	O
washed	O
IgG	O
beads	O
,	O
separated	O
on	O
6	O
%	O
polyacrylamide	O
denaturing	O
gels	O
,	O
transferred	O
to	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
.	O

Northern	O
analysis	O
revealed	O
that	O
Enp1	O
-	O
TAP	O
precipitates	O
were	O
enriched	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
relative	O
to	O
precipitates	O
from	O
the	O
Hst2	O
-	O
tagged	O
strain	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

The	O
Enp1	O
-	O
TAP	O
samples	O
were	O
not	O
enriched	O
with	O
snR30	O
snoRNA	O
(	O
Fig	O
.	O
7A	O
)	O
,	O
nor	O
with	O
U24	O
or	O
U18	O
snoRNAs	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
found	O
no	O
change	O
in	O
the	O
levels	O
of	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
in	O
the	O
enp1	O
mutant	O
,	O
indicating	O
that	O
the	O
mutation	O
did	O
not	O
affect	O
snoRNAs	O
levels	O
(	O
Fig	O
.	O
6I	O
)	O
.	O

The	O
results	O
indicate	O
that	O
Enp1	O
associates	O
in	O
vivo	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
.	O

Much	O
less	O
U3	O
RNA	O
co	O
-	O
immunoprecipitated	O
with	O
Enp1	O
-	O
TAP	O
than	O
with	O
Protein	O
A	O
-	O
tagged	O
Nop1	O
,	O
which	O
is	O
known	O
to	O
associate	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

However	O
,	O
Protein	O
A	O
-	O
Nop1	O
was	O
much	O
more	O
efficiently	O
precipitated	O
than	O
was	O
the	O
Enp1	O
-	O
TAP	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
similar	O
amounts	O
of	O
RNAs	O
are	O
associated	O
with	O
the	O
two	O
proteins	O
and	O
that	O
the	O
proteins	O
are	O
part	O
of	O
the	O
same	O
complex	O
.	O

To	O
address	O
this	O
further	O
,	O
we	O
checked	O
for	O
the	O
presence	O
of	O
Nop1	O
in	O
the	O
Enp1	O
-	O
TAP	O
immunoprecipitates	O
.	O

Figure	O
7B	O
shows	O
that	O
Nop1	O
indeed	O
is	O
in	O
the	O
Enp1	O
precipitate	O
but	O
not	O
in	O
the	O
Hst2	O
control	O
,	O
whereas	O
an	O
abundant	O
ribosomal	O
protein	O
,	O
L3	O
,	O
is	O
in	O
neither	O
precipitate	O
.	O

U3	O
and	O
U14	O
snoRNAs	O
have	O
been	O
shown	O
to	O
interact	O
with	O
rRNA	O
precursors	O
and	O
these	O
interactions	O
are	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
(	O
35	O
-	O
37	O
)	O
.	O

Using	O
an	O
in	O
vitro	O
system	O
,	O
U3	O
was	O
also	O
shown	O
to	O
be	O
associated	O
with	O
its	O
rRNA	O
substrate	O
and	O
processing	O
product	O
(	O
38	O
)	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
Enp1	O
might	O
also	O
be	O
associated	O
with	O
rRNAs	O
since	O
its	O
function	O
in	O
rRNA	O
processing	O
appeared	O
linked	O
to	O
those	O
of	O
U3	O
and	O
U14	O
snoRNAs	O
.	O

To	O
test	O
this	O
possibility	O
,	O
we	O
further	O
analyzed	O
the	O
RNAs	O
that	O
co	O
-	O
precipiate	O
with	O
TAP	O
-	O
tagged	O
Enp1	O
.	O

The	O
RNAs	O
were	O
separated	O
on	O
1	O
.	O
2	O
%	O
agarose	O
formaldehyde	O
gels	O
or	O
on	O
polyacrylamide	O
denaturing	O
gels	O
,	O
transferred	O
to	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
for	O
pre	O
-	O
rRNAs	O
.	O

A	O
probe	O
(	O
P4	O
;	O
see	O
Fig	O
.	O
6	O
)	O
specific	O
to	O
20s	O
and	O
its	O
precursors	O
revealed	O
that	O
pre	O
-	O
rRNAs	O
35S	O
,	O
33S	O
,	O
32S	O
and	O
20S	O
specifically	O
co	O
-	O
precipitated	O
with	O
Enp1	O
-	O
TAP	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

No	O
such	O
enrichment	O
was	O
found	O
using	O
a	O
probe	O
(	O
P8	O
;	O
see	O
Fig	O
.	O
6	O
)	O
specific	O
for	O
27S	O
RNAs	O
or	O
a	O
probe	O
for	O
5	O
.	O
8S	O
RNA	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

These	O
results	O
clearly	O
demonstrated	O
that	O
Enp1	O
is	O
associated	O
with	O
substrates	O
and	O
products	O
of	O
the	O
early	O
steps	O
of	O
18S	O
rRNA	O
processing	O
.	O

Comparison	O
of	O
Enp1	O
with	O
homologs	O
in	O
other	O
organisms	O

Homologs	O
of	O
Enp1	O
protein	O
in	O
human	S-Species
,	O
Drosophila	S-Species
and	O
Caenorhabditis	B-Species
elegans	E-Species
have	O
been	O
reported	O
(	O
18	O
)	O
.	O

A	O
previously	O
described	O
human	S-Species
homolog	O
,	O
bystin	O
,	O
was	O
only	O
306	O
amino	O
acids	O
in	O
length	O
,	O
and	O
lacked	O
sequences	O
corresponding	O
to	O
the	O
N	O
-	O
terminal	O
163	O
amino	O
acids	O
of	O
yeast	S-Species
Enp1	O
(	O
19	O
)	O
.	O

In	O
contrast	O
,	O
we	O
identified	O
a	O
human	S-Species
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
,	O
BC007340	O
in	O
a	O
Blast	O
search	O
that	O
revealed	O
an	O
ORF	O
of	O
1311	O
nucleotides	O
encoding	O
a	O
437	O
amino	O
acid	O
polypeptide	O
(	O
39	O
)	O
.	O

Comparison	O
of	O
this	O
437	O
amino	O
acid	O
polypeptide	O
with	O
human	S-Species
bystin	O
(	O
19	O
)	O
showed	O
that	O
they	O
were	O
encoded	O
by	O
the	O
same	O
gene	O
on	O
human	S-Species
chromosome	O
6	O
.	O

The	O
reported	O
sequence	O
for	O
human	S-Species
bystin	O
is	O
a	O
fragment	O
of	O
the	O
437	O
amino	O
acid	O
human	S-Species
Enp1	O
protein	O
,	O
due	O
to	O
a	O
truncated	O
cDNA	O
sequence	O
.	O

Also	O
,	O
a	O
sequence	O
discrepancy	O
at	O
the	O
C	O
-	O
terminus	O
is	O
due	O
to	O
inaccurate	O
DNA	O
sequence	O
of	O
the	O
human	S-Species
bystin	O
,	O
as	O
confirmed	O
by	O
available	O
human	S-Species
genome	O
and	O
EST	O
sequences	O
.	O

Searches	O
of	O
the	O
database	O
of	O
other	O
organisms	O
identified	O
Enp1	O
homologs	O
in	O
S	B-Species
.	I-Species
pombe	E-Species
,	O
Arabidopsis	B-Species
thaliana	E-Species
,	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
Drosophila	B-Species
melanogaster	E-Species
and	O
mouse	S-Species
.	O

The	O
alignment	O
of	O
the	O
homologs	O
showed	O
that	O
they	O
shared	O
homology	O
from	O
the	O
N	O
-	O
terminus	O
to	O
the	O
C	O
-	O
terminus	O
,	O
with	O
the	O
C	O
-	O
terminal	O
half	O
extremely	O
well	O
conserved	O
,	O
with	O
close	O
to	O
90	O
%	O
similarity	O
(	O
Fig	O
.	O
8	O
)	O
.	O

One	O
interesting	O
observation	O
is	O
that	O
the	O
two	O
amino	O
acids	O
changed	O
in	O
the	O
enp1	O
-	O
1	O
mutant	O
,	O
W242	O
and	O
V415	O
,	O
are	O
conserved	O
among	O
all	O
homologs	O
.	O

The	O
human	S-Species
Enp1	O
homolog	O
was	O
cloned	O
and	O
expressed	O
in	O
yeast	S-Species
and	O
tested	O
for	O
function	O
.	O

Expressed	O
under	O
the	O
control	O
of	O
ADH	O
,	O
TEF	O
or	O
GPD	O
promoter	O
,	O
the	O
human	S-Species
Enp1	O
homolog	O
did	O
not	O
complement	O
a	O
yeast	S-Species
enp1	O
null	O
mutant	O
.	O

However	O
,	O
a	O
GFP	O
fusion	O
to	O
the	O
N	O
-	O
terminus	O
of	O
human	S-Species
Enp1	O
homolog	O
localized	O
to	O
the	O
nucleus	O
and	O
was	O
enriched	O
in	O
the	O
nucleolus	O
(	O
data	O
not	O
shown	O
)	O
.	O

DISCUSSION	O

ENP1	O
is	O
a	O
yeast	S-Species
gene	O
first	O
identified	O
in	O
a	O
genetic	O
screen	O
for	O
complementation	O
of	O
mutations	O
in	O
ost4	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
oligosaccharide	O
transferase	O
(	O
17	O
)	O
,	O
although	O
subsequent	O
work	O
showed	O
that	O
it	O
is	O
unlikely	O
that	O
Enp1	O
has	O
any	O
connection	O
to	O
oligosaccharide	O
transferase	O
(	O
18	O
)	O
.	O

ENP1	O
was	O
shown	O
to	O
be	O
essential	O
for	O
viability	O
and	O
the	O
Enp1	O
protein	O
localized	O
to	O
the	O
nucleus	O
(	O
18	O
)	O
.	O

When	O
we	O
re	O
-	O
examined	O
the	O
localization	O
of	O
Enp1	O
,	O
we	O
observed	O
that	O
the	O
protein	O
was	O
enriched	O
in	O
the	O
nucleolus	O
.	O

This	O
finding	O
led	O
us	O
to	O
test	O
for	O
a	O
role	O
of	O
Enp1	O
in	O
ribosome	O
synthesis	O
.	O

Using	O
an	O
enp1	O
ts	O
mutant	O
,	O
we	O
found	O
that	O
depletion	O
of	O
Enp1	O
caused	O
a	O
40S	O
ribosomal	O
subunit	O
deficiency	O
.	O

Further	O
analysis	O
revealed	O
that	O
this	O
deficiency	O
was	O
not	O
due	O
to	O
a	O
change	O
of	O
the	O
subunit	O
'	O
s	O
stability	O
,	O
but	O
to	O
a	O
defect	O
in	O
the	O
synthesis	O
of	O
the	O
subunit	O
'	O
s	O
18S	O
rRNA	O
component	O
.	O

Pulse	O
-	O
chase	O
analysis	O
of	O
RNA	O
synthesis	O
in	O
an	O
enp1	O
-	O
1	O
strain	O
revealed	O
that	O
no	O
20S	O
pre	O
-	O
rRNA	O
or	O
18S	O
rRNA	O
was	O
made	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
,	O
while	O
levels	O
of	O
25S	O
rRNA	O
appeared	O
normal	O
.	O

Low	O
levels	O
of	O
precursors	O
to	O
18S	O
rRNA	O
were	O
detected	O
in	O
the	O
mutants	O
,	O
and	O
they	O
were	O
extremely	O
unstable	O
.	O

Northern	O
analysis	O
of	O
steady	O
state	O
RNA	O
levels	O
demonstrated	O
that	O
the	O
enp1	O
mutation	O
specifically	O
inhibited	O
the	O
pre	O
-	O
rRNA	O
early	O
cleavages	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
,	O
which	O
are	O
required	O
for	O
the	O
production	O
of	O
the	O
20S	O
pre	O
-	O
rRNA	O
and	O
the	O
18S	O
rRNA	O
.	O

These	O
defects	O
of	O
the	O
enp1	O
mutation	O
on	O
rRNA	O
processing	O
are	O
very	O
similar	O
to	O
those	O
caused	O
by	O
mutation	O
of	O
KRR1	O
,	O
another	O
essential	O
nucleolar	O
gene	O
required	O
for	O
synthesis	O
of	O
the	O
40S	O
,	O
but	O
not	O
the	O
60S	O
subunit	O
(	O
40	O
)	O
.	O

Co	O
-	O
precipitation	O
analyses	O
provided	O
strong	O
evidence	O
that	O
Enp1	O
is	O
directly	O
involved	O
in	O
pre	O
-	O
rRNA	O
processing	O
.	O

In	O
these	O
experiments	O
,	O
TAP	O
-	O
tagged	O
Enp1	O
bound	O
to	O
IgG	O
beads	O
specifically	O
co	O
-	O
precipitated	O
with	O
two	O
snoRNAs	O
,	O
U3	O
and	O
U14	O
,	O
and	O
with	O
the	O
35S	O
,	O
33S	O
,	O
32S	O
and	O
20S	O
pre	O
-	O
rRNAs	O
.	O

Among	O
the	O
more	O
than	O
100	O
snoRNAs	O
in	O
yeast	S-Species
cells	O
,	O
U3	O
,	O
U14	O
,	O
snR10	O
,	O
snR30	O
and	O
MRP	O
RNA	O
are	O
the	O
only	O
ones	O
required	O
for	O
rRNA	O
processing	O
.	O

It	O
has	O
been	O
shown	O
that	O
mutations	O
in	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
and	O
protein	O
components	O
of	O
the	O
snoRNPs	O
affect	O
processing	O
at	O
sites	O
A0	O
,	O
A1	O
or	O
A2	O
(	O
15	O
,	O
16	O
,	O
41	O
,	O
42	O
)	O
.	O

Enp1	O
'	O
s	O
interaction	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
suggests	O
that	O
Enp1	O
'	O
s	O
function	O
in	O
rRNA	O
processing	O
involves	O
these	O
two	O
snoRNAs	O
.	O

The	O
fact	O
that	O
the	O
nucleolar	O
protein	O
,	O
Nop1	O
,	O
known	O
to	O
bind	O
to	O
U3	O
and	O
U14	O
RNAs	O
,	O
also	O
was	O
found	O
in	O
the	O
Enp1	O
precipitate	O
,	O
provides	O
additional	O
evidence	O
that	O
Enp1	O
is	O
part	O
of	O
a	O
complex	O
involved	O
in	O
processing	O
of	O
rRNA	O
.	O

Recently	O
,	O
a	O
genome	O
-	O
wide	O
study	O
of	O
yeast	S-Species
protein	O
complexes	O
,	O
using	O
a	O
TAP	O
tag	O
method	O
similar	O
to	O
ours	O
,	O
reported	O
a	O
number	O
of	O
proteins	O
that	O
co	O
-	O
immunoprecipitated	O
with	O
Enp1	O
(	O
43	O
)	O
.	O

These	O
proteins	O
included	O
Imp4	O
,	O
Kre31	O
,	O
Kre33	O
,	O
Mpp10	O
,	O
Nop1	O
,	O
Nop14	O
and	O
Sof1	O
,	O
all	O
of	O
which	O
have	O
been	O
implicated	O
in	O
18S	O
RNA	O
processing	O
or	O
40S	O
biogenesis	O
.	O

Very	O
recently	O
(	O
after	O
the	O
studies	O
in	O
this	O
manuscript	O
were	O
concluded	O
)	O
Grandi	O
et	O
al	O
.	O
published	O
an	O
analysis	O
of	O
components	O
of	O
the	O
90s	O
preribosomal	O
particle	O
,	O
which	O
include	O
the	O
35S	O
pre	O
-	O
rRNA	O
,	O
U3	O
snoRNP	O
and	O
rRNA	O
processing	O
factors	O
for	O
the	O
40S	O
subunit	O
(	O
44	O
)	O
.	O

In	O
agreement	O
with	O
our	O
findings	O
,	O
they	O
found	O
that	O
Enp1	O
is	O
a	O
component	O
of	O
this	O
90s	O
complex	O
and	O
also	O
of	O
a	O
smaller	O
complex	O
containing	O
the	O
20S	O
pre	O
-	O
rRNA	O
.	O

Surprisingly	O
,	O
none	O
of	O
the	O
other	O
proteins	O
involved	O
in	O
processing	O
of	O
pre	O
-	O
rRNAs	O
that	O
were	O
tested	O
associated	O
with	O
the	O
20S	O
rRNA	O
,	O
suggesting	O
that	O
those	O
proteins	O
,	O
but	O
not	O
Enp1	O
,	O
are	O
released	O
prior	O
to	O
20S	O
pre	O
-	O
rRNA	O
formation	O
(	O
44	O
)	O
.	O

The	O
authors	O
also	O
showed	O
co	O
-	O
precipitation	O
of	O
Enp1	O
with	O
dimethylated	O
20S	O
pre	O
-	O
rRNA	O
,	O
which	O
is	O
formed	O
after	O
export	O
of	O
20S	O
to	O
the	O
cytoplasm	O
.	O

These	O
results	O
of	O
Grandi	O
et	O
al	O
.	O
suggest	O
that	O
Enp1	O
may	O
also	O
be	O
involved	O
in	O
later	O
steps	O
of	O
processing	O
or	O
nuclear	O
export	O
.	O

A	O
previous	O
study	O
on	O
the	O
Enp1	O
human	S-Species
homolog	O
,	O
bystin	O
,	O
reported	O
that	O
the	O
protein	O
was	O
localized	O
in	O
the	O
cytoplasm	O
of	O
mammalian	O
cells	O
and	O
might	O
be	O
involved	O
in	O
cell	O
adhesion	O
(	O
19	O
)	O
.	O

Our	O
discovery	O
of	O
the	O
437	O
amino	O
acid	O
human	S-Species
Enp1	O
homolog	O
revealed	O
that	O
the	O
bystin	O
studied	O
previously	O
was	O
from	O
a	O
truncated	O
library	O
cDNA	O
encoding	O
only	O
the	O
C	O
-	O
terminal	O
306	O
amino	O
acids	O
.	O

Although	O
the	O
human	S-Species
homolog	O
of	O
Enp1	O
did	O
not	O
complement	O
a	O
yeast	S-Species
Delta	O
enp1	O
mutant	O
,	O
we	O
did	O
show	O
that	O
it	O
was	O
localized	O
to	O
the	O
nucleus	O
and	O
enriched	O
in	O
the	O
nucleolus	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
the	O
conserved	O
function	O
of	O
Enp1	O
is	O
in	O
rRNA	O
processing	O
.	O

The	O
cytoplasmic	O
localization	O
of	O
bystin	O
and	O
its	O
proposed	O
function	O
in	O
cell	O
adhesion	O
are	O
unlikely	O
to	O
reflect	O
the	O
actual	O
function	O
of	O
the	O
human	S-Species
Enp1	O
homolog	O
.	O

It	O
will	O
be	O
important	O
to	O
study	O
the	O
nature	O
of	O
the	O
associations	O
between	O
Enp1	O
and	O
U3	O
and	O
U14	O
snoRNPs	O
,	O
and	O
to	O
learn	O
more	O
about	O
the	O
exact	O
role	O
of	O
Enp1	O
in	O
ribosomal	O
RNA	O
processing	O
.	O

Piezoelectric	O
osteotomy	O
in	O
hand	O
surgery	O
:	O
first	O
experiences	O
with	O
a	O
new	O
technique	O

Abstract	O

Background	O

In	O
hand	O
and	O
spinal	O
surgery	O
nerve	O
lesions	O
are	O
feared	O
complications	O
with	O
the	O
use	O
of	O
standard	O
oscillating	O
saws	O
.	O

Oral	O
surgeons	O
have	O
started	O
using	O
a	O
newly	O
developed	O
ultrasound	O
bone	O
scalpel	O
when	O
performing	O
precise	O
osteotomies	O
.	O

By	O
using	O
a	O
frequency	O
of	O
25	O
-	O
29	O
kHz	O
only	O
mineralized	O
tissue	O
is	O
cut	O
,	O
sparing	O
the	O
soft	O
tissue	O
.	O

This	O
reduces	O
the	O
risk	O
of	O
nerve	O
lesions	O
.	O

As	O
there	O
is	O
a	O
lack	O
of	O
experience	O
with	O
this	O
technique	O
in	O
the	O
field	O
of	O
orthopaedic	O
bone	O
surgery	O
,	O
we	O
performed	O
the	O
first	O
ultrasound	O
osteotomy	O
in	O
hand	O
surgery	O
.	O

Method	O

While	O
performing	O
a	O
correctional	O
osteotomy	O
of	O
the	O
5th	O
metacarpal	O
bone	O
we	O
used	O
the	O
Piezosurgery	O
(R)	O
Device	O
from	O
Mectron	O
[	O
Italy	O
]	O
instead	O
of	O
the	O
usual	O
oscillating	O
saw	O
.	O

We	O
will	O
report	O
on	O
our	O
experience	O
with	O
one	O
case	O
,	O
with	O
a	O
follow	O
up	O
time	O
of	O
one	O
year	O
.	O

Results	O

The	O
cut	O
was	O
highly	O
precise	O
and	O
there	O
were	O
no	O
vibrations	O
of	O
the	O
bone	O
.	O

The	O
time	O
needed	O
for	O
the	O
operation	O
was	O
slightly	O
longer	O
than	O
the	O
time	O
needed	O
while	O
using	O
the	O
usual	O
saw	O
.	O

Bone	O
healing	O
was	O
good	O
and	O
at	O
no	O
point	O
were	O
there	O
any	O
neurovascular	O
disturbances	O
.	O

Conclusion	O

The	O
Piezosurgery	O
(R)	O
Device	O
is	O
useful	O
for	O
small	O
long	O
bone	O
osteotomies	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
curved	O
cutting	O
and	O
provides	O
an	O
opportunity	O
for	O
new	O
osteotomy	O
techniques	O
.	O

As	O
the	O
device	O
selectively	O
cuts	O
bone	O
we	O
feel	O
that	O
this	O
device	O
has	O
great	O
potential	O
in	O
the	O
field	O
of	O
hand	O
-	O
and	O
spinal	O
surgery	O
.	O

Background	O

For	O
osteotomies	O
of	O
the	O
hand	O
oscillating	O
saws	O
are	O
usually	O
used	O
[	O
1	O
]	O
.	O

Even	O
though	O
they	O
are	O
varied	O
in	O
size	O
,	O
they	O
are	O
not	O
very	O
precise	O
for	O
use	O
in	O
the	O
vicinity	O
of	O
nerves	O
and	O
arteries	O
.	O

They	O
also	O
pose	O
problems	O
while	O
being	O
used	O
in	O
conjunction	O
with	O
magnification	O
,	O
as	O
one	O
'	O
s	O
range	O
of	O
sight	O
and	O
focus	O
is	O
restricted	O
when	O
wearing	O
magnifying	O
glasses	O
.	O

For	O
that	O
reason	O
oral	O
surgeons	O
have	O
moved	O
to	O
using	O
the	O
newly	O
developed	O
piezoelectrical	O
bone	O
scalpel	O
when	O
operating	O
in	O
the	O
near	O
vicinity	O
of	O
nerves	O
or	O
arteries	O
.	O

The	O
tip	O
of	O
this	O
instrument	O
oscillates	O
in	O
the	O
frequency	O
of	O
ultrasound	O
[	O
2	O
]	O
.	O

The	O
mechanism	O
of	O
this	O
device	O
is	O
based	O
on	O
the	O
so	O
called	O
Piezo	O
-	O
Effect	O
.	O

French	O
Physicists	O
Jean	O
and	O
Marie	O
Curie	O
first	O
mentioned	O
the	O
direct	O
Piezo	O
-	O
Effect	O
1880	O
,	O
whereby	O
certain	O
crystals	O
produce	O
electrical	O
current	O
while	O
under	O
mechanical	O
pressure	O
.	O

The	O
reciprocal	O
effect	O
,	O
by	O
which	O
the	O
crystals	O
are	O
deformed	O
when	O
under	O
electrical	O
current	O
,	O
was	O
then	O
discovered	O
a	O
while	O
later	O
.	O

This	O
is	O
the	O
effect	O
being	O
used	O
by	O
the	O
Piezosurgery	O
Device	O
(R)	O
.	O

In	O
this	O
device	O
,	O
the	O
electrical	O
field	O
is	O
located	O
in	O
the	O
handle	O
of	O
the	O
saw	O
[	O
3	O
]	O
.	O

Due	O
to	O
the	O
deformation	O
caused	O
by	O
the	O
electrical	O
current	O
,	O
a	O
cutting	O
-	O
hammering	O
movement	O
is	O
produced	O
at	O
the	O
tip	O
of	O
the	O
instrument	O
.	O

These	O
micro	O
movements	O
are	O
in	O
the	O
frequency	O
range	O
of	O
25	O
to	O
29	O
kHz	O
and	O
,	O
depending	O
on	O
the	O
insert	O
,	O
with	O
an	O
amplitude	O
of	O
60	O
to	O
210	O
mu	O
m	O
.	O

This	O
way	O
only	O
mineralized	O
tissue	O
is	O
selectively	O
cut	O
.	O

Neurovascular	O
tissue	O
and	O
other	O
soft	O
tissue	O
would	O
only	O
be	O
cut	O
by	O
a	O
frequency	O
of	O
above	O
50	O
kHz	O
[	O
3	O
-	O
5	O
]	O
.	O

Depending	O
on	O
the	O
strength	O
of	O
the	O
bone	O
and	O
the	O
blade	O
geometry	O
,	O
the	O
efficiency	O
of	O
the	O
cutting	O
can	O
be	O
regulated	O
by	O
the	O
frequency	O
modulator	O
and	O
the	O
power	O
level	O
.	O

For	O
cooling	O
there	O
is	O
an	O
integrated	O
pump	O
with	O
five	O
different	O
working	O
levels	O
.	O

This	O
pump	O
automatically	O
washes	O
physiological	O
solution	O
to	O
the	O
area	O
being	O
cut	O
.	O

The	O
cost	O
of	O
the	O
device	O
is	O
about	O
7	O
.	O
000	O
USD	O
.	O

Additional	O
costs	O
per	O
operation	O
are	O
for	O
the	O
cooling	O
liquid	O
and	O
are	O
in	O
the	O
range	O
of	O
a	O
few	O
dollars	O
.	O

We	O
have	O
used	O
the	O
Piezosurgery	O
Device	O
(R)	O
by	O
Mectron	O
[	O
Italy	O
]	O
[	O
3	O
]	O
for	O
the	O
first	O
time	O
in	O
osteotomies	O
of	O
the	O
long	O
bone	O
in	O
the	O
field	O
of	O
hand	O
surgery	O
.	O

We	O
will	O
report	O
on	O
our	O
experience	O
with	O
one	O
case	O
,	O
with	O
a	O
follow	O
up	O
time	O
of	O
one	O
year	O
.	O

Method	O

The	O
correctional	O
osteotomy	O
was	O
performed	O
on	O
a	O
23	O
year	O
old	O
worker	O
who	O
suffered	O
a	O
malunited	O
metacarpal	O
bone	O
fracture	O
of	O
the	O
fifth	O
finger	O
on	O
his	O
dominant	O
hand	O
.	O

The	O
X	O
-	O
ray	O
revealed	O
a	O
45	O
degree	O
angular	O
deformity	O
of	O
the	O
fifth	O
metacarpal	O
neck	O
with	O
internal	O
rotation	O
.	O

(	O
Figure	O
1	O
)	O
.	O

The	O
operation	O
was	O
performed	O
under	O
regional	O
anesthesia	O
.	O

A	O
longitudinal	O
incision	O
was	O
made	O
over	O
the	O
fifth	O
metacarpal	O
.	O

The	O
tendon	O
of	O
the	O
extensor	O
digiti	O
minimi	O
was	O
found	O
and	O
on	O
its	O
radial	O
side	O
the	O
periosteum	O
of	O
metacarpal	O
five	O
was	O
reached	O
.	O

The	O
periosteum	O
was	O
opened	O
longitudinally	O
over	O
the	O
defect	O
as	O
usual	O
.	O

For	O
the	O
correction	O
of	O
the	O
defect	O
of	O
45	O
degrees	O
,	O
a	O
bone	O
wedge	O
was	O
excised	O
.	O

Instead	O
of	O
using	O
the	O
traditional	O
oscillating	O
saw	O
,	O
the	O
Piezosurgery	O
Device	O
(R)	O
[	O
3	O
]	O
was	O
used	O
(	O
Figure	O
2	O
)	O
.	O

We	O
used	O
a	O
sharp	O
hardened	O
saw	O
coated	O
with	O
titannitrid	O
(	O
Figure	O
3	O
)	O
.	O

For	O
most	O
of	O
the	O
surgery	O
the	O
highest	O
power	O
level	O
,	O
the	O
boosted	O
burst	O
c	O
,	O
was	O
used	O
.	O

We	O
set	O
the	O
automatic	O
cooling	O
of	O
the	O
area	O
with	O
water	O
to	O
its	O
highest	O
level	O
.	O

The	O
angulation	O
and	O
rotation	O
was	O
corrected	O
and	O
fixed	O
with	O
a	O
1	O
.	O
5	O
mm	O
titanium	O
five	O
-	O
hole	O
plate	O
and	O
four	O
screws	O
.	O

Closure	O
of	O
the	O
wound	O
was	O
done	O
in	O
layers	O
.	O

Mobilization	O
was	O
started	O
on	O
the	O
10th	O
postoperative	O
day	O
.	O

The	O
overall	O
time	O
of	O
observation	O
was	O
one	O
year	O
.	O

Results	O
and	O
discussion	O

The	O
Piezosurgery	O
(R)	O
Device	O
is	O
ideally	O
sized	O
for	O
hand	O
surgery	O
.	O

The	O
cutting	O
was	O
very	O
precise	O
.	O

The	O
edges	O
of	O
the	O
osteotomy	O
were	O
all	O
sharp	O
to	O
the	O
edge	O
,	O
there	O
was	O
no	O
need	O
to	O
split	O
the	O
bone	O
with	O
a	O
chisel	O
,	O
nor	O
was	O
there	O
the	O
danger	O
of	O
a	O
break	O
out	O
.	O

During	O
the	O
osteotomy	O
there	O
were	O
no	O
disturbing	O
vibrations	O
in	O
the	O
area	O
of	O
operation	O
.	O

This	O
absence	O
of	O
vibration	O
is	O
very	O
practical	O
for	O
operations	O
using	O
a	O
magnifier	O
.	O

Vercellotti	O
mentions	O
that	O
to	O
overcome	O
any	O
problems	O
during	O
surgery	O
,	O
instead	O
of	O
increasing	O
pressure	O
on	O
the	O
hand	O
piece	O
,	O
as	O
in	O
traditional	O
techniques	O
,	O
it	O
is	O
necessary	O
to	O
find	O
the	O
correct	O
pressure	O
to	O
achieve	O
the	O
desired	O
result	O
.	O

With	O
piezoelectric	O
surgery	O
,	O
increasing	O
the	O
working	O
pressure	O
above	O
a	O
certain	O
limit	O
impedes	O
the	O
vibrations	O
of	O
the	O
insert	O
[	O
4	O
]	O
.	O

We	O
have	O
also	O
experienced	O
this	O
in	O
our	O
study	O
.	O

The	O
instrument	O
can	O
be	O
moved	O
in	O
all	O
directions	O
comparable	O
to	O
a	O
pen	O
.	O

The	O
tip	O
of	O
the	O
instrument	O
is	O
exchangeable	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
multiplanar	O
as	O
well	O
as	O
curved	O
cutting	O
.	O

Because	O
of	O
the	O
automatic	O
water	O
cooling	O
during	O
the	O
whole	O
procedure	O
,	O
there	O
is	O
always	O
a	O
clear	O
view	O
onto	O
the	O
object	O
.	O

This	O
is	O
something	O
oral	O
surgeons	O
found	O
especially	O
useful	O
[	O
6	O
]	O
.	O

The	O
authors	O
mention	O
that	O
the	O
downside	O
of	O
the	O
device	O
is	O
the	O
relative	O
slow	O
sawing	O
process	O
.	O

We	O
needed	O
about	O
30	O
seconds	O
for	O
one	O
cut	O
of	O
the	O
relatively	O
small	O
bone	O
.	O

This	O
is	O
about	O
20	O
seconds	O
longer	O
than	O
the	O
time	O
needed	O
for	O
cutting	O
with	O
the	O
usual	O
saw	O
.	O

Although	O
the	O
power	O
can	O
be	O
regulated	O
with	O
the	O
power	O
box	O
and	O
the	O
use	O
of	O
different	O
scalpels	O
,	O
we	O
agree	O
with	O
other	O
authors	O
that	O
the	O
optimal	O
use	O
of	O
this	O
device	O
is	O
in	O
surgeries	O
of	O
small	O
bones	O
where	O
precise	O
and	O
soft	O
tissue	O
friendly	O
cutting	O
is	O
required	O
[	O
7	O
]	O
.	O

As	O
other	O
literature	O
has	O
shown	O
,	O
the	O
device	O
selectively	O
cuts	O
bone	O
while	O
sparing	O
nerves	O
and	O
other	O
soft	O
tissue	O
[	O
2	O
,	O
3	O
]	O
.	O

This	O
allows	O
for	O
minimal	O
invasive	O
surgeries	O
with	O
limited	O
retraction	O
of	O
soft	O
tissue	O
and	O
minimal	O
stripping	O
of	O
the	O
periosteum	O
,	O
saves	O
time	O
and	O
might	O
have	O
a	O
positive	O
effect	O
on	O
the	O
healing	O
process	O
.	O

Our	O
aim	O
of	O
the	O
first	O
time	O
use	O
of	O
the	O
Piezosurgery	O
(R)	O
Device	O
in	O
hand	O
surgery	O
was	O
to	O
check	O
its	O
usability	O
in	O
osteotomies	O
of	O
tubular	O
bones	O
.	O

The	O
preparation	O
of	O
the	O
bone	O
was	O
done	O
in	O
the	O
usual	O
manner	O
as	O
is	O
done	O
when	O
cutting	O
with	O
an	O
oscillating	O
saw	O
.	O

The	O
reason	O
for	O
this	O
was	O
to	O
fully	O
visualize	O
the	O
cutting	O
process	O
using	O
this	O
new	O
device	O
,	O
although	O
in	O
the	O
future	O
,	O
it	O
should	O
be	O
possible	O
to	O
minimize	O
the	O
bony	O
exposure	O
.	O

In	O
our	O
patient	S-Species
the	O
postoperative	O
healing	O
of	O
the	O
wound	O
and	O
the	O
bone	O
consolidation	O
(	O
Figure	O
4	O
)	O
were	O
smooth	O
.	O

The	O
duration	O
of	O
postoperative	O
sick	O
leave	O
was	O
four	O
weeks	O
which	O
is	O
more	O
rapid	O
than	O
the	O
usual	O
recovery	O
period	O
.	O

The	O
patient	S-Species
regained	O
full	O
use	O
of	O
his	O
finger	O
according	O
to	O
the	O
state	O
before	O
the	O
fracture	O
.	O

At	O
no	O
point	O
was	O
there	O
any	O
loss	O
of	O
sensitivity	O
.	O

The	O
patient	S-Species
as	O
well	O
as	O
the	O
surgeons	O
were	O
fully	O
satisfied	O
with	O
the	O
result	O
.	O

Conclusion	O

The	O
Piezosurgery	O
(R)	O
Device	O
is	O
a	O
useful	O
device	O
for	O
small	O
long	O
bone	O
osteotomies	O
.	O

We	O
feel	O
that	O
this	O
device	O
has	O
great	O
potential	O
in	O
the	O
field	O
of	O
hand	O
-	O
and	O
spinal	O
surgery	O
.	O

As	O
the	O
device	O
selectively	O
cuts	O
bone	O
,	O
considerable	O
nerve	O
lesions	O
can	O
be	O
avoided	O
and	O
minimal	O
invasive	O
surgeries	O
are	O
possible	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
curved	O
cutting	O
and	O
provides	O
an	O
opportunity	O
for	O
new	O
osteotomy	O
techniques	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

DJH	O
initiated	O
and	O
coordinated	O
the	O
new	O
application	O
of	O
Piezosurgery	O
(R)	O
device	O
and	O
wrote	O
the	O
publication	O
.	O

StSt	O
lead	O
the	O
osteotomy	O
as	O
he	O
was	O
experienced	O
with	O
this	O
tool	O
from	O
oral	O
surgery	O
.	O

He	O
played	O
a	O
major	O
part	O
in	O
writing	O
the	O
technical	O
aspects	O
.	O

OVK	O
was	O
the	O
treating	O
surgeon	O
,	O
performed	O
the	O
operation	O
and	O
evaluated	O
the	O
new	O
tool	O
.	O

SS	O
performed	O
a	O
literature	O
review	O
and	O
wrote	O
part	O
of	O
the	O
publication	O
.	O

PH	O
was	O
the	O
treating	O
chief	O
surgeon	O
,	O
evaluated	O
the	O
new	O
tool	O
and	O
lead	O
the	O
treatment	O
in	O
all	O
aspects	O
.	O

Consent	O

We	O
obtained	O
oral	O
consent	O
from	O
the	O
patient	S-Species
but	O
could	O
not	O
obtain	O
written	O
consent	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Molecular	O
cloning	O
of	O
four	O
novel	O
murine	S-Species
ribonuclease	O
genes	O
:	O
unusual	O
expansion	O
within	O
the	O
ribonuclease	O
A	O
gene	O
family	O
.	O

Abstract	O

We	O
have	O
characterized	O
four	O
novel	O
murine	S-Species
ribonuclease	O
genes	O
that	O
,	O
together	O
with	O
the	O
murine	S-Species
eosinophil	O
-	O
associated	O
ribonucleases	O
1	O
and	O
2	O
,	O
form	O
a	O
distinct	O
and	O
unusual	O
cluster	O
within	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

Three	O
of	O
these	O
genes	O
(	O
mR	O
-	O
3	O
,	O
mR	O
-	O
4	O
,	O
mR	O
-	O
5	O
)	O
include	O
complete	O
open	O
reading	O
frames	O
,	O
encoding	O
ribonucleases	O
with	O
eight	O
cysteines	O
and	O
appropriately	O
spaced	O
histidines	O
(	O
His11	O
and	O
His124	O
)	O
and	O
lysine	O
(	O
Lys35	O
)	O
that	O
are	O
characteristic	O
of	O
this	O
enlarging	O
protein	O
family	O
;	O
the	O
fourth	O
sequence	O
encodes	O
a	O
non	O
-	O
functional	O
pseudogene	O
(	O
mR	O
-	O
6P	O
)	O
.	O

Although	O
the	O
amino	O
acid	O
sequence	O
similarities	O
among	O
these	O
murine	S-Species
ribonucleases	O
varies	O
from	O
60	O
to	O
94	O
%	O
,	O
they	O
form	O
a	O
unique	O
cluster	O
,	O
as	O
each	O
sequence	O
is	O
found	O
to	O
be	O
more	O
closely	O
related	O
to	O
another	O
of	O
this	O
group	O
than	O
to	O
either	O
murine	S-Species
angiogenin	O
or	O
to	O
murine	S-Species
pancreatic	O
ribonuclease	O
.	O

Interestingly	O
,	O
the	O
relationship	O
between	O
the	O
six	O
genes	O
in	O
this	O
'	O
mR	O
cluster	O
'	O
and	O
the	O
defined	O
lineages	O
of	O
the	O
RNase	O
A	O
gene	O
family	O
could	O
not	O
be	O
determined	O
by	O
amino	O
acid	O
sequence	O
homology	O
,	O
suggesting	O
the	O
possibility	O
that	O
there	O
are	O
one	O
or	O
more	O
additional	O
ribonuclease	O
lineages	O
that	O
have	O
yet	O
to	O
be	O
defined	O
.	O

Although	O
the	O
nature	O
of	O
the	O
evolutionary	O
constraints	O
promoting	O
this	O
unusual	O
expansion	O
and	O
diversification	O
remain	O
unclear	O
,	O
the	O
implications	O
with	O
respect	O
to	O
function	O
are	O
intriguing	O
.	O

<FFFD>	O
1997	O
Oxford	O
University	O
Press	O

Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No	O
.	O
21	O

4235	O
<FFFD>	O
4239	O

Molecular	O
cloning	O
of	O
four	O
novel	O
murine	S-Species
ribonuclease	O
genes	O
:	O
unusual	O
expansion	O
within	O
the	O
Ribonuclease	O
A	O
gene	O
family	O
Dean	O
Batten	O
+	O
,	O
Kimberly	O
D	O
.	O
Dyer	O
,	O
Joseph	O
B	O
.	O
Domachowske	O
<FFFD>	O
and	O
Helene	O
F	O
.	O
Rosenberg	O
*	O
The	O
Laboratory	O
of	O
Host	O
Defenses	O
,	O
Building	O
10	O
,	O
Room	O
11N104	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
9000	O
Rockville	O
Pike	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
Received	O
August	O
4	O
,	O
1997	O
;	O
Revised	O
and	O
Accepted	O
September	O
17	O
,	O
1997	O
DDBJ	O
/	O
EMBL	O
/	O
GenBank	O
accession	O
numbers	O
:	O
U72031	O
,	O
U72032	O
,	O
AF017258	O
<FFFD>	O
AF017261	O

ABSTRACT	O
We	O
have	O
characterized	O
four	O
novel	O
murine	S-Species
ribonuclease	O
genes	O
that	O
,	O
together	O
with	O
the	O
murine	S-Species
eosinophilassociated	O
ribonucleases	O
1	O
and	O
2	O
,	O
form	O
a	O
distinct	O
and	O
unusual	O
cluster	O
within	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

Three	O
of	O
these	O
genes	O
(	O
mR	O
-	O
3	O
,	O
mR	O
-	O
4	O
,	O
mR	O
-	O
5	O
)	O
include	O
complete	O
open	O
reading	O
frames	O
,	O
encoding	O
ribonucleases	O
with	O
eight	O
cysteines	O
and	O
appropriately	O
spaced	O
histidines	O
(	O
His11	O
and	O
His124	O
)	O
and	O
lysine	O
(	O
Lys35	O
)	O
that	O
are	O
characteristic	O
of	O
this	O
enlarging	O
protein	O
family	O
;	O
the	O
fourth	O
sequence	O
encodes	O
a	O
non	O
-	O
functional	O
pseudogene	O
(	O
mR	O
-	O
6P	O
)	O
.	O

Although	O
the	O
amino	O
acid	O
sequence	O
similarities	O
among	O
these	O
murine	S-Species
ribonucleases	O
varies	O
from	O
60	O
to	O
94	O
%	O
,	O
they	O
form	O
a	O
unique	O
cluster	O
,	O
as	O
each	O
sequence	O
is	O
found	O
to	O
be	O
more	O
closely	O
related	O
to	O
another	O
of	O
this	O
group	O
than	O
to	O
either	O
murine	S-Species
angiogenin	O
or	O
to	O
murine	S-Species
pancreatic	O
ribonuclease	O
.	O

Interestingly	O
,	O
the	O
relationship	O
between	O
the	O
six	O
genes	O
in	O
this	O
`	O
mR	O
cluster	O
'	O
and	O
the	O
defined	O
lineages	O
of	O
the	O
RNase	O
A	O
gene	O
family	O
could	O
not	O
be	O
determined	O
by	O
amino	O
acid	O
sequence	O
homology	O
,	O
suggesting	O
the	O
possibility	O
that	O
there	O
are	O
one	O
or	O
more	O
additional	O
ribonuclease	O
lineages	O
that	O
have	O
yet	O
to	O
be	O
defined	O
.	O

Although	O
the	O
nature	O
of	O
the	O
evolutionary	O
constraints	O
promoting	O
this	O
unusual	O
expansion	O
and	O
diversification	O
remain	O
unclear	O
,	O
the	O
implications	O
with	O
respect	O
to	O
function	O
are	O
intriguing	O
.	O

INTRODUCTION	O
Ribonuclease	O
A	O
(	O
RNase	O
A	O
,	O
bovine	S-Species
pancreatic	O
ribonuclease	O
)	O
is	O
the	O
prototype	O
of	O
an	O
enlarging	O
family	O
of	O
proteins	O
defined	O
by	O
distinctive	O
elements	O
of	O
conserved	O
primary	O
structure	O
and	O
enzymatic	O
activity	O
(	O
1	O
,	O
2	O
)	O
.	O

The	O
features	O
shared	O
by	O
all	O
members	O
of	O
the	O
RNase	O
A	O
family	O
include	O
six	O
to	O
eight	O
cysteines	O
and	O
specific	O
histidine	O
and	O
lysine	O
residues	O
that	O
form	O
the	O
ribonuclease	O
active	O
site	O
.	O

To	O
date	O
,	O
several	O
distinct	O
lineages	O
within	O
the	O
RNase	O
A	O
superfamily	O
have	O
been	O
identified	O
.	O

Pancreatic	O
ribonucleases	O
(	O
RNases	O
1	O
)	O
have	O
been	O
isolated	O
from	O
an	O
extensive	O
array	O
of	O
mammalian	O
species	O
(	O
3	O
,	O
4	O
)	O
,	O
and	O
mRNA	O
encoding	O
human	S-Species
pancreatic	O
ribonuclease	O
has	O
been	O
detected	O
in	O

numerous	O
somatic	O
tissues	O
in	O
addition	O
to	O
pancreas	O
(	O
5	O
)	O
.	O

RNases	O
2	O
and	O
3	O
,	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
)	O
and	O
eosinophil	O
cationic	O
protein	O
(	O
ECP	O
)	O
,	O
respectively	O
,	O
have	O
been	O
characterized	O
primarily	O
with	O
respect	O
to	O
eosinophil	O
function	O
(	O
6	O
,	O
7	O
)	O
,	O
although	O
expression	O
of	O
EDN	O
[	O
also	O
known	O
as	O
RNase	O
Us	O
(	O
8	O
)	O
or	O
human	S-Species
liver	O
ribonuclease	O
(	O
9	O
)	O
]	O
is	O
also	O
widespread	O
(	O
5	O
)	O
.	O

Angiogenin	O
(	O
RNase	O
5	O
)	O
,	O
a	O
structurally	O
atypical	O
member	O
of	O
this	O
family	O
,	O
was	O
originally	O
identified	O
as	O
an	O
agent	O
promoting	O
blood	O
vessel	O
growth	O
and	O
development	O
(	O
10	O
,	O
11	O
)	O
.	O

RNase	O
4	O
(	O
12	O
,	O
13	O
)	O
and	O
RNase	O
k6	O
(	O
14	O
)	O
are	O
also	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
,	O
although	O
their	O
functions	O
are	O
currently	O
obscure	O
.	O

Recently	O
,	O
Larson	O
and	O
colleagues	O
(	O
15	O
)	O
described	O
cDNAs	O
encoding	O
two	O
highly	O
homologous	O
murine	S-Species
ribonucleases	O
,	O
the	O
murine	S-Species
eosinophil	O
-	O
associated	O
ribonucleases	O
(	O
mEAR	O
)	O
1	O
and	O
2	O
,	O
which	O
were	O
cloned	O
and	O
identified	O
via	O
tryptic	O
peptides	O
isolated	O
from	O
murine	S-Species
eosinophil	O
proteins	O
.	O

Although	O
Southern	O
analysis	O
demonstrated	O
that	O
multiple	O
copies	O
of	O
sequence	O
homologous	O
to	O
mEAR	O
-	O
1	O
and	O
mEAR	O
-	O
2	O
were	O
present	O
in	O
murine	S-Species
genomic	O
DNA	O
,	O
the	O
precise	O
nature	O
of	O
these	O
copies	O
-	O
-	O
as	O
pseudogenes	O
,	O
polymorphisms	O
,	O
or	O
distinct	O
functional	O
genes	O
-	O
-	O
was	O
unclear	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
identified	O
four	O
of	O
these	O
homologous	O
sequences	O
,	O
three	O
encoding	O
novel	O
ribonucleases	O
,	O
and	O
one	O
encoding	O
a	O
pseudogene	O
.	O

Together	O
with	O
mEAR	O
-	O
1	O
and	O
mEAR	O
-	O
2	O
,	O
these	O
six	O
ribonuclease	O
genes	O
form	O
an	O
`	O
mR	O
cluster	O
,	O
'	O
whose	O
members	O
are	O
more	O
closely	O
related	O
to	O
one	O
another	O
than	O
they	O
are	O
to	O
other	O
murine	S-Species
ribonucleases	O
,	O
yet	O
whose	O
position	O
with	O
respect	O
to	O
the	O
defined	O
RNase	O
A	O
lineages	O
remains	O
unclear	O
.	O

MATERIALS	O
AND	O
METHODS	O
Isolation	O
of	O
genomic	O
fragments	O
encoding	O
murine	S-Species
ribonucleases	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
cells	O
of	O
the	O
murine	S-Species
3T3	O
fibroblast	O
cell	O
line	O
.	O

The	O
mR	O
-	O
3	O
,	O
mR	O
-	O
5	O
and	O
mR	O
-	O
6P	O
sequences	O
were	O
amplified	O
using	O
oligonucleotide	O
primers	O
derived	O
from	O
the	O
published	O
coding	O
sequence	O
of	O
mEAR	O
-	O
1	O
as	O
follows	O
:	O
5	O
-	O
CAA	O
ACC	O
CTT	O
TCC	O
CAG	O
AAG	O
TTT	O
GCC	O
-	O
3	O
(	O
amino	O
acids	O
28	O
<FFFD>	O
33	O
)	O
;	O
5	O
-	O
AAA	O
TGT	O
CCC	O
ATC	O
CAA	O
GTG	O
AAC	O
TGG	O
ACC	O
-	O
3	O
(	O
amino	O
acids	O
156	O
<FFFD>	O
148	O
)	O
(	O
15	O
)	O
.	O

The	O
PCR	O
reactions	O
were	O
performed	O
as	O
described	O
previously	O
(	O
14	O
)	O
,	O
and	O
the	O
multiple	O
products	O
present	O
in	O
the	O
single	O
400	O
bp	O
product	O
were	O
identified	O
by	O
dideoxy	O

*	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
.	O

Tel	O
:	O
+	O
1	O
301	O
402	O
9131	O
;	O
Fax	O
:	O
+	O
1	O
301	O
402	O
4369	O
;	O
Email	O
:	O
hr2k	O
@	O
nih	O
.	O
gov	O
Present	O
addresses	O
:	O
+	O
Duke	O
University	O
School	O
of	O
Medicine	O
,	O
Durham	O
,	O
NC	O
27701	O
,	O
USA	O
and	O
<FFFD>	O
Department	O
of	O
Pediatrics	O
,	O
State	O
University	O
of	O
New	O
York	O
-	O
Health	O
Sciences	O
Center	O
at	O
Syracuse	O
,	O
Syracuse	O
,	O
NY	O
13210	O
,	O
USA	O

4236	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No	O
.	O
21	O

Figure	O
1	O
.	O

(	O
A	O
)	O
Alignment	O
of	O
amino	O
acid	O
sequences	O
encoded	O
by	O
six	O
related	O
murine	S-Species
ribonuclease	O
genes	O
.	O

Regions	O
of	O
amino	O
acid	O
sequence	O
identity	O
among	O
the	O
five	O
functional	O
genes	O
are	O
enclosed	O
in	O
boxes	O
;	O
the	O
boxes	O
enclosing	O
the	O
active	O
site	O
residues	O
(	O
His11	O
,	O
Lys35	O
,	O
His124	O
)	O
and	O
eight	O
cysteines	O
conserved	O
in	O
all	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
are	O
shaded	O
.	O

(	O
B	O
)	O
Percent	O
similarities	O
between	O
amino	O
acid	O
sequences	O
determined	O
via	O
the	O
BESTFIT	O
algorithm	O
of	O
the	O
Wisconsin	O
Genetics	O
Computer	O
Group	O
(	O
WGCG	O
)	O
program	O
on	O
-	O
line	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

GenBank	O
accession	O
numbers	O
:	O
mEAR	O
(	O
murine	S-Species
eosinophil	O
-	O
associated	O
ribonuclease	O
)	O
-	O
1	O
,	O
U72032	O
;	O
mEAR	O
-	O
2	O
,	O
U72031	O
;	O
mR	O
(	O
murine	S-Species
ribonuclease	O
)	O
-	O
3	O
,	O
AF017258	O
;	O
mR	O
-	O
4	O
,	O
AF017259	O
;	O
mR	O
-	O
5	O
,	O
AF017260	O
;	O
mR	O
-	O
6P	O
(	O
pseudogene	O
)	O
,	O
AF017261	O
.	O

sequencing	O
of	O
individual	O
plasmids	O
after	O
subcloning	O
into	O
the	O
pCR	O
II	O
TA	O
cloning	O
vector	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
complete	O
open	O
reading	O
frames	O
were	O
obtained	O
by	O
extension	O
in	O
both	O
5	O
and	O
3	O
directions	O
by	O
uni	O
-	O
directional	O
PCR	O
(	O
Genome	O
Walker	O
kit	O
,	O
Clontech	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
,	O
involving	O
two	O
amplifications	O
with	O
nested	O
primers	O
and	O
Tth	O
polymerase	O
as	O
described	O
previously	O
(	O
14	O
)	O
.	O

The	O
nested	O
gene	O
-	O
specific	O
primer	O
pairs	O
were	O
as	O
follows	O
:	O
for	O
5	O
extension	O
of	O
mR	O
-	O
3	O
,	O
5	O
-	O
CTG	O
GAA	O
CCA	O
CTG	O
GAT	O
ACG	O
TGG	O
GAC	O
TGT	O
CCT	O
-	O
3	O
and	O
5	O
-	O
ACG	O
TGG	O
GAC	O
TGT	O
CCT	O
GTG	O
GAG	O
TTC	O
TGG	O
GTT	O
-	O
3	O
;	O
for	O
3	O
extension	O
of	O
mR	O
-	O
3	O
,	O
5	O
-	O
ATG	O
CTG	O
TTG	O
GTG	O
TGT	O
GTG	O
GAA	O
ATC	O
CAA	O
GTG	O
-	O
3	O
and	O
5	O
-	O
GCT	O
TGT	O
GCA	O
GTG	O
ACA	O
ATA	O
TAA	O
GTC	O
AAA	O
ACT	O
-	O
3	O
;	O
for	O
5	O
extension	O
of	O
mR	O
-	O
5	O
,	O
5	O
-	O
GGT	O
GGG	O
ACG	O
GTC	O
CTT	O
TGG	O
AGT	O
TCT	O
GGG	O
GTT	O
ACA	O
-	O
3	O
and	O
5	O
-	O
GGG	O
GTT	O
ACA	O
GGC	O
AAC	O
TGT	O
GTA	O
GGA	O
CTT	O
CTT	O
TCC	O
-	O
3	O
;	O
for	O
3	O
extension	O
of	O
mR	O
-	O
5	O
,	O
5	O
-	O
GAT	O
GTT	O
GTC	O
CGT	O
GTG	O
TGT	O
CAC	O
AAT	O
CCA	O
CCC	O
-	O
3	O
and	O
5	O
-	O
AAG	O
ACT	O
TGC	O
AAA	O
GAC	O
GGG	O
ACA	O
AGT	O
CCA	O
AAT	O
-	O
3	O
;	O
for	O
5	O
extension	O
of	O
mR	O
-	O
6P	O
,	O
5	O
-	O
TTG	O
TTG	O
TTT	O
TGC	O
ATC	O
TGC	O
ATT	O
GTG	O
CAT	O
AAC	O
TGC	O
-	O
3	O
and	O
5	O
-	O
TTC	O
TGC	O
ATA	O
ACT	O
GCT	O
TGC	O
TGA	O
ACT	O
TGT	O
GAG	O
TGA	O
-	O
3	O
;	O
for	O
3	O
extension	O
of	O
mR	O
-	O
6P	O
,	O
5	O
-	O
ATG	O
TGA	O
TAA	O
TGC	O
AAT	O
GCT	O
GTC	O
TCT	O
TAG	O
CAG	O
TTA	O
-	O
3	O
and	O
5	O
-	O
TAC	O
AAG	O

AGT	O
ATG	O
TAA	O
GCC	O
ATT	O
GAA	O
TCA	O
TTT	O
TCT	O
-	O
3	O
.	O

The	O
products	O
of	O
these	O
reactions	O
were	O
likewise	O
subcloned	O
into	O
the	O
PCR	O
II	O
TA	O
vector	O
and	O
evaluated	O
by	O
dideoxy	O
-	O
sequencing	O
.	O

The	O
mR	O
-	O
4	O
sequence	O
was	O
amplified	O
with	O
a	O
36	O
bp	O
primer	O
derived	O
from	O
sequence	O
encoding	O
the	O
amino	O
-	O
terminal	O
signal	O
sequence	O
of	O
mEAR	O
-	O
1	O
;	O
5	O
-	O
ATG	O
GGT	O
CCG	O
AAG	O
CTG	O
CTT	O
GAG	O
TCC	O
CGA	O
CTT	O
TGT	O
CTC	O
-	O
3	O
with	O
the	O
carboxy	O
-	O
primer	O
described	O
above	O
.	O

Northern	O
analysis	O
The	O
murine	S-Species
multi	O
-	O
tissue	O
Northern	O
blot	O
was	O
purchased	O
from	O
Clontech	O
,	O
and	O
pre	O
-	O
hybridized	O
and	O
hybridized	O
as	O
per	O
manufacturer	O
'	O
s	O
instructions	O
with	O
radiolabelled	O
oligonucleotide	O
probes	O
.	O

The	O
membrane	O
was	O
washed	O
with	O
5	O
<FFFD>	O
SSPE	O
with	O
0	O
.	O
1	O
%	O
SDS	O
for	O
1	O
h	O
at	O
37	O
_	O
C	O
and	O
the	O
autoradiogram	O
developed	O
after	O
exposure	O
to	O
film	O
at	O
<FFFD>	O
80	O
_	O
C	O
.	O

The	O
mEAR	O
-	O
1	O
/	O
mEAR	O
-	O
2	O
/	O
mR	O
-	O
3	O
probe	O
:	O
5	O
-	O
CTC	O
TTG	O
TCA	O
CTG	O
CAC	O
AAG	O
CCA	O
CTT	O
GGA	O
TTT	O
CC	O
-	O
3	O
,	O
the	O
mR	O
-	O
5	O
probe	O
:	O
5	O
-	O
GTC	O
CCG	O
TCT	O
TTG	O
CAA	O
GTC	O
TTG	O
GGT	O
GGA	O
TTG	O
TG	O
-	O
3	O
,	O
and	O
the	O
actin	O
probe	O
:	O
5	O
-	O
GCA	O
CAT	O
GCC	O
GGA	O
GCC	O
GTT	O
GTC	O
GAC	O
GAC	O
GAG	O
CGC	O
GGC	O
GAT	O
ATC	O
ATC	O
ATC	O
-	O
3	O
(	O
16	O
)	O
.	O

4237	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No	O
.	O

Nucleic	O
Acids	O
Research	O
,	O
1994	O
,	O
Vol	O
.	O

22	O
,	O
No	O
.	O
121	O
4237	O

Figure	O
2	O
.	O

(	O
A	O
)	O
Dendrogram	O
depicting	O
relationships	O
among	O
the	O
eight	O
characterized	O
murine	S-Species
ribonucleases	O
as	O
determined	O
by	O
a	O
modified	O
UPGMA	O
method	O
(	O
17	O
)	O
.	O

Abbreviations	O
are	O
as	O
in	O
Figure	O
1A	O
,	O
also	O
mPR	O
(	O
murine	S-Species
pancreatic	O
ribonuclease	O
,	O
sw	O
:	O
rnp	O
_	O
mouse	S-Species
)	O
,	O
mANG	O
(	O
murine	S-Species
angiogenin	O
,	O
U72672	O
)	O
,	O
hEDN	O
(	O
human	S-Species
eosinophil	O
-	O
derived	O
neurotoxin	O
,	O
M24157	O
)	O
,	O
hECP	O
(	O
human	S-Species
eosinophil	O
cationic	O
protein	O
,	O
X15161	O
)	O
,	O
hRK6	O
(	O
human	S-Species
ribonuclease	O
k6	O
,	O
U64998	O
)	O
,	O
pRK6	O
(	O
porcine	O
kidney	O
ribonuclease	O
(	O
24	O
)	O
,	O
and	O
bRK6	O
(	O
bovine	S-Species
kidney	O
ribonuclease	O
,	O
sw	O
:	O
rnkd	O
_	O
bovin	O
)	O
.	O

(	O
B	O
)	O
Calculated	O
isoelectric	O
points	O
from	O
amino	O
acid	O
sequences	O
in	O
(	O
A	O
)	O
as	O
determined	O
via	O
the	O
PEPTIDESORT	O
algorithm	O
of	O
WGCG	O
.	O

Table	O
1	O
.	O

Amino	O
acid	O
sequence	O
comparisons	O
of	O
murine	S-Species
and	O
human	S-Species
ribonucleases	O

Sequence	O
analysis	O
All	O
DNA	O
sequence	O
analysis	O
and	O
comparisons	O
were	O
performed	O
with	O
the	O
assistance	O
of	O
the	O
Wisconsin	O
Genetics	O
Computer	O
Group	O
and	O
Sequencher	O
(	O
Gene	O
Codes	O
Corporation	O
)	O
programs	O
available	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

The	O
dendrogram	O
in	O
Figure	O
2A	O
was	O
constructed	O
by	O
a	O
modified	O
version	O
of	O
the	O
unweighted	O
pair	O
group	O
method	O
with	O
arithmetic	O
mean	O
(	O
UPGMA	O
)	O
(	O
17	O
)	O
,	O
constructed	O
using	O
four	O
initial	O
pairings	O
,	O
mEAR	O
-	O
2	O
to	O
mR	O
-	O
3	O
,	O
mR	O
-	O
5	O
to	O
mR	O
-	O
6P	O
,	O
hEDN	O
to	O
hECP	O
and	O
bRK6	O
to	O
pRK6	O
.	O

RESULTS	O
Isolation	O
of	O
genomic	O
fragments	O
encoding	O
novel	O
murine	S-Species
ribonucleases	O
The	O
alignment	O
in	O
Figure	O
1A	O
displays	O
the	O
amino	O
acid	O
sequences	O
encoded	O
by	O
the	O
six	O
related	O
ribonuclease	O
genes	O
.	O

Murine	S-Species
eosinophil	O
-	O
associated	O
ribonucleases	O
-	O
1	O
and	O
-	O
2	O
(	O
mEAR	O
-	O
1	O
and	O
mEAR	O
-	O
2	O
)	O
are	O
the	O
predicted	O
amino	O
acid	O
sequences	O
from	O
two	O
genes	O
described	O
previously	O
by	O
Larson	O
and	O
colleagues	O
(	O
15	O
)	O
;	O
murine	S-Species
ribonucleases	O
3	O
,	O
4	O
,	O
5	O
and	O
6	O
-	O
pseudogene	O
(	O
mR	O
-	O
3	O
,	O
mR	O
-	O
4	O
,	O
mR	O
-	O
5	O
and	O
mR	O
-	O
6P	O
)	O
,	O
are	O
the	O
predicted	O
amino	O
acid	O
sequences	O
encoded	O
by	O
novel	O
DNA	O

hEDN	O
mEAR	O
-	O
1	O
mEAR	O
-	O
2	O
mR	O
-	O
3	O
mR	O
-	O
4	O
mR	O
-	O
5	O
mANG	O
mPR	O
56	O
56	O
54	O
60	O
60	O
43	O
53	O

hECP	O
59	O
59	O
57	O
59	O
58	O
49	O
52	O

hRK6	O
58	O
59	O
59	O
53	O
56	O
49	O
59	O

hPR	O
47	O
48	O
49	O
48	O
57	O
55	O
79	O

hR4	O
50	O
53	O
51	O
52	O
54	O
57	O
66	O

hANG	O
49	O
48	O
51	O
47	O
47	O
80	O
60	O

Values	O
are	O
expressed	O
as	O
percent	O
similarity	O
between	O
pairs	O
of	O
amino	O
acid	O
sequences	O
as	O
determined	O
by	O
the	O
BESTFIT	O
algorithm	O
of	O
the	O
Wisconsin	O
Genetics	O
Computer	O
Group	O
program	O
on	O
-	O
line	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

Value	O
representing	O
the	O
highest	O
degree	O
of	O
sequence	O
homology	O
in	O
each	O
row	O
is	O
indicated	O
in	O
boldface	O
.	O

Abbreviations	O
are	O
as	O
defined	O
in	O
Figures	O
1	O
and	O
2	O
,	O
and	O
also	O
include	O
hR4	O
(	O
human	S-Species
ribonuclease	O
4	O
,	O
sw	O
:	O
rnl4	O
_	O
human	S-Species
)	O
,	O
hANG	O
(	O
human	S-Species
angiogenin	O
,	O
M11567	O
)	O
,	O
and	O
hPR	O
(	O
human	S-Species
pancreatic	O
ribonuclease	O
,	O
X62946	O
)	O
.	O

4238	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No	O
.	O
21	O
fragments	O
amplified	O
from	O
murine	S-Species
genomic	O
DNA	O
.	O

All	O
five	O
functional	O
genes	O
encode	O
amino	O
acid	O
sequences	O
with	O
eight	O
cysteines	O
and	O
appropriately	O
spaced	O
catalytic	O
histidines	O
and	O
lysine	O
that	O
are	O
conserved	O
among	O
the	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
.	O

The	O
predicted	O
coding	O
sequence	O
of	O
the	O
non	O
-	O
functional	O
pseudogene	O
(	O
mR	O
-	O
6P	O
)	O
includes	O
two	O
aberrant	O
stop	O
codons	O
(	O
positions	O
19	O
and	O
100	O
)	O
as	O
well	O
as	O
a	O
point	O
mutation	O
resulting	O
in	O
the	O
destruction	O
of	O
the	O
cysteine	O
at	O
position	O
78	O
.	O

Each	O
genomic	O
fragment	O
also	O
encodes	O
a	O
28	O
residue	O
amino	O
terminal	O
signal	O
sequence	O
(	O
not	O
shown	O
)	O
.	O

The	O
amino	O
acid	O
sequences	O
are	O
displayed	O
in	O
order	O
of	O
decreasing	O
similarity	O
to	O
mEAR	O
-	O
1	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Genomic	O
fragments	O
encoding	O
mEAR	O
-	O
1	O
and	O
mEAR	O
-	O
2	O
were	O
also	O
detected	O
.	O

Relationships	O
among	O
the	O
murine	S-Species
ribonucleases	O
A	O
dendrogram	O
depicting	O
the	O
relationships	O
among	O
several	O
of	O
the	O
murine	S-Species
and	O
human	S-Species
ribonucleases	O
is	O
shown	O
in	O
Figure	O
2A	O
.	O

The	O
mEAR	O
-	O
1	O
,	O
mEAR	O
-	O
2	O
,	O
and	O
mR	O
-	O
3	O
sequences	O
form	O
a	O
closely	O
related	O
sub	O
-	O
group	O
,	O
with	O
only	O
nine	O
amino	O
acid	O
sequence	O
differences	O
noted	O
between	O
mEAR	O
-	O
2	O
and	O
mR	O
-	O
3	O
,	O
and	O
12	O
and	O
17	O
between	O
these	O
two	O
and	O
mEAR	O
-	O
1	O
,	O
respectively	O
.	O

The	O
mR	O
-	O
4	O
,	O
mR	O
-	O
5	O
,	O
and	O
mR	O
-	O
6P	O
sequences	O
diverge	O
from	O
this	O
subgroup	O
and	O
from	O
one	O
another	O
as	O
well	O
.	O

These	O
six	O
sequences	O
are	O
more	O
closely	O
related	O
to	O
one	O
another	O
than	O
they	O
are	O
to	O
either	O
murine	S-Species
pancreatic	O
ribonuclease	O
(	O
mPR	O
)	O
or	O
to	O
murine	S-Species
angiogenin	O
(	O
mANG	O
)	O
or	O
to	O
any	O
of	O
the	O
three	O
human	S-Species
ribonucleases	O
shown	O
(	O
hEDN	O
,	O
hECP	O
or	O
hRK6	O
)	O
.	O

Isoelectric	O
points	O
The	O
isoelectric	O
points	O
of	O
all	O
six	O
related	O
ribonucleases	O
range	O
from	O
8	O
<FFFD>	O
11	O
,	O
as	O
is	O
typical	O
for	O
members	O
of	O
the	O
RNase	O
A	O
superfamily	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Interestingly	O
,	O
the	O
isoelectric	O
points	O
within	O
the	O
mEAR	O
-	O
1	O
/	O
mEAR	O
-	O
2	O
/	O
mR	O
-	O
3	O
subgroup	O
vary	O
by	O
a	O
full	O
1	O
.	O
0	O
unit	O
(	O
mEAR	O
-	O
1	O
at	O
9	O
.	O
2	O
to	O
mEAR	O
-	O
2	O
at	O
10	O
.	O
2	O
)	O
in	O
response	O
to	O
only	O
12	O
discrepancies	O
in	O
amino	O
acid	O
sequence	O
.	O

As	O
increased	O
charge	O
has	O
been	O
associated	O
with	O
increased	O
toxicity	O
in	O
other	O
branches	O
of	O
the	O
RNase	O
A	O
gene	O
family	O
(	O
18	O
)	O
,	O
this	O
finding	O
has	O
potential	O
consequences	O
with	O
respect	O
to	O
the	O
function	O
of	O
these	O
proteins	O
(	O
see	O
Discussion	O
)	O
.	O

Northern	O
analysis	O
Tissue	O
-	O
specific	O
expression	O
of	O
mRNA	O
encoding	O
these	O
murine	S-Species
ribonucleases	O
is	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
probe	O
complementary	O
to	O
all	O
three	O
sequences	O
of	O
the	O
mEAR	O
-	O
1	O
/	O
mEAR	O
-	O
2	O
/	O
mR	O
-	O
3	O
subgroup	O
hybridizes	O
to	O
an	O
1	O
.	O
4	O
kb	O
mRNA	O
isolated	O
from	O
renal	O
tissue	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

As	O
the	O
probe	O
cannot	O
distinguish	O
among	O
the	O
three	O
genes	O
,	O
it	O
is	O
not	O
possible	O
to	O
conclude	O
whether	O
the	O
band	O
detected	O
represents	O
mRNA	O
encoding	O
one	O
,	O
two	O
,	O
or	O
all	O
three	O
of	O
the	O
ribonucleases	O
of	O
this	O
subgroup	O
.	O

In	O
contrast	O
,	O
the	O
probe	O
complementary	O
to	O
the	O
mR	O
-	O
5	O
genomic	O
fragment	O
hybridizes	O
to	O
two	O
prominent	O
mRNA	O
species	O
in	O
hepatic	O
tissue	O
,	O
one	O
at	O
1	O
.	O
4	O
kb	O
,	O
and	O
a	O
second	O
at	O
2	O
.	O
0	O
kb	O
.	O

A	O
prominent	O
mRNA	O
of	O
1	O
.	O
8	O
kb	O
was	O
also	O
detected	O
in	O
mRNA	O
isolated	O
from	O
murine	S-Species
testicular	O
tissue	O
;	O
fainter	O
hybridizing	O
mRNAs	O
of	O
varying	O
size	O
were	O
detected	O
in	O
lung	O
and	O
skeletal	O
muscle	O
.	O

The	O
size	O
variation	O
may	O
represent	O
differential	O
splicing	O
of	O
the	O
mR	O
-	O
5	O
-	O
encoding	O
mRNA	O
,	O
or	O
may	O
represent	O
mRNAs	O
encoding	O
one	O
or	O
more	O
as	O
yet	O
undiscovered	O
murine	S-Species
ribonucleases	O
that	O
are	O
more	O
closely	O
related	O
to	O
mR	O
-	O
5	O
than	O
those	O
whose	O
sequences	O
are	O
reported	O
here	O
.	O

Figure	O
3	O
.	O

(	O
A	O
)	O
Murine	S-Species
RNA	O
probed	O
with	O
a	O
32	O
bp	O
oligonucleotide	O
complementary	O
to	O
mEAR	O
-	O
1	O
,	O
mEAR	O
-	O
2	O
and	O
mR	O
-	O
3	O
coding	O
sequences	O
.	O

Tissue	O
source	O
of	O
each	O
RNA	O
is	O
indicated	O
above	O
each	O
lane	O
.	O

(	O
B	O
)	O
Same	O
as	O
in	O
(	O
A	O
)	O
,	O
probed	O
with	O
a	O
32	O
bp	O
oligonucleotide	O
complementary	O
to	O
mR	O
-	O
5	O
.	O

(	O
C	O
)	O
Same	O
as	O
in	O
(	O
A	O
)	O
,	O
probed	O
with	O
a	O
48	O
bp	O
oligonucleotide	O
complementary	O
to	O
human	S-Species
actin	O
(	O
16	O
)	O
,	O
demonstrating	O
relative	O
loading	O
of	O
each	O
lane	O
.	O

Relationship	O
to	O
human	S-Species
ribonucleases	O
The	O
data	O
in	O
Table	O
1	O
denote	O
the	O
amino	O
acid	O
sequence	O
similarity	O
between	O
pairs	O
of	O
murine	S-Species
and	O
human	S-Species
ribonucleases	O
of	O
the	O
RNase	O
A	O
superfamily	O
.	O

Overall	O
,	O
the	O
similarities	O
within	O
the	O
identified	O
cluster	O
range	O
from	O
47	O
to	O
60	O
%	O
,	O
with	O
remarkably	O
little	O
variation	O
among	O
the	O
pairs	O
.	O

Although	O
the	O
sequences	O
of	O
the	O
mEAR	O
-	O
1	O
/	O
mEAR	O
-	O
2	O
/	O
mR	O
-	O
3	O
subgroup	O
are	O
slightly	O
more	O
similar	O
to	O
ECP	O
and	O
RNase	O
k6	O
,	O
and	O
mR	O
-	O
4	O
and	O
mR	O
-	O
5	O
,	O
to	O
EDN	O
and	O
ECP	O
,	O
the	O
orthologous	O
relationships	O
of	O
these	O
murine	S-Species
ribonucleases	O
cannot	O
be	O
discerned	O
from	O
these	O
data	O
.	O

This	O
stands	O
in	O
direct	O
contrast	O
to	O
mPR	O
and	O
mANG	O
,	O
whose	O
human	S-Species
orthologs	O
can	O
be	O
clearly	O
distinguished	O
on	O
the	O
basis	O
of	O
their	O
amino	O
acid	O
sequence	O
homologies	O
.	O

DISCUSSION	O
In	O
this	O
work	O
,	O
we	O
have	O
identified	O
four	O
novel	O
murine	S-Species
ribonuclease	O
genes	O
that	O
,	O
together	O
with	O
mEAR	O
-	O
1	O
and	O
mEAR	O
-	O
2	O
defined	O
by	O
Larson	O
and	O
colleagues	O
(	O
15	O
)	O
,	O
form	O
an	O
unusual	O
cluster	O
within	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

The	O
six	O
genes	O
within	O
this	O
cluster	O
have	O
varying	O
amino	O
acid	O
sequence	O
homologies	O
to	O
one	O
another	O
,	O
but	O
are	O
clearly	O
more	O
closely	O
related	O
to	O
one	O
another	O
than	O
to	O
either	O
murine	S-Species
pancreatic	O
ribonuclease	O
(	O
mPR	O
)	O
or	O
angiogenin	O
(	O
mANG	O
)	O
,	O
or	O
to	O
any	O
of	O
the	O
human	S-Species
ribonucleases	O
of	O
the	O
RNase	O
A	O
family	O
.	O

These	O
results	O
suggest	O
that	O
the	O
`	O
mR	O
cluster	O
'	O
emerged	O
via	O
multiple	O
duplications	O
of	O
a	O
gene	O
that	O
had	O
already	O
diverged	O
from	O
those	O
encoding	O
the	O
other	O
murine	S-Species
ribonucleases	O
.	O

Although	O
this	O
type	O
of	O
expansion	O
is	O
unusual	O
in	O
this	O
gene	O
family	O
,	O
it	O
is	O
actually	O
not	O
unique	O
;	O
similar	O
expansion	O
has	O
occurred	O
in	O
bovine	S-Species
species	O
,	O
with	O
gene	O
duplication	O
resulting	O
in	O
the	O
three	O
closely	O
-	O
related	O
bovine	S-Species
pancreatic	O
,	O
bovine	S-Species
brain	O
(	O
19	O
,	O
20	O
)	O
and	O
bovine	S-Species
seminal	O
(	O
21	O
)	O
ribonucleases	O
.	O

One	O
interesting	O
feature	O
of	O
the	O
mR	O
cluster	O
is	O
that	O
its	O
relationship	O
to	O
any	O
of	O
to	O
the	O
six	O
known	O
human	S-Species
RNase	O
A	O
-	O
type	O
genes	O
cannot	O
be	O

4239	O
Nucleic	O
Acids	O
Research	O
,	O
1997	O
,	O
Vol	O
.	O

25	O
,	O
No	O
.	O

Nucleic	O
Acids	O
Research	O
,	O
1994	O
,	O
Vol	O
.	O

22	O
,	O
No	O
.	O
121	O
determined	O
from	O
their	O
respective	O
amino	O
acid	O
sequence	O
homologies	O
.	O

Although	O
the	O
amino	O
acid	O
sequences	O
encoded	O
by	O
mEAR	O
-	O
1	O
and	O
mEAR	O
-	O
2	O
match	O
those	O
of	O
tryptic	O
peptides	O
derived	O
from	O
murine	S-Species
eosinophil	O
proteins	O
(	O
15	O
)	O
,	O
the	O
homology	O
data	O
do	O
not	O
stand	O
in	O
overwhelming	O
support	O
of	O
a	O
unique	O
relationship	O
between	O
any	O
of	O
the	O
mR	O
cluster	O
ribonucleases	O
and	O
the	O
human	S-Species
eosinophil	O
ribonucleases	O
EDN	O
and	O
ECP	O
.	O

The	O
existence	O
of	O
an	O
additional	O
,	O
as	O
yet	O
unidentified	O
human	S-Species
ribonuclease	O
(	O
or	O
ribonucleases	O
)	O
more	O
closely	O
related	O
to	O
those	O
of	O
the	O
mR	O
cluster	O
cannot	O
be	O
ruled	O
out	O
.	O

Perhaps	O
the	O
most	O
important	O
issue	O
raised	O
by	O
this	O
work	O
is	O
the	O
question	O
of	O
why	O
so	O
much	O
evolutionary	O
energy	O
has	O
been	O
devoted	O
to	O
enlarging	O
and	O
diversifying	O
the	O
RNase	O
A	O
gene	O
superfamily	O
.	O

To	O
date	O
,	O
this	O
superfamily	O
now	O
includes	O
several	O
distinct	O
lineages	O
,	O
two	O
species	O
-	O
limited	O
clusters	O
,	O
and	O
the	O
two	O
most	O
rapidly	O
evolving	O
functional	O
coding	O
sequences	O
known	O
among	O
primates	O
(	O
22	O
)	O
.	O

The	O
question	O
of	O
evolutionary	O
energy	O
takes	O
on	O
particular	O
significance	O
here	O
,	O
where	O
five	O
functional	O
ribonucleases	O
have	O
emerged	O
in	O
what	O
appears	O
to	O
be	O
a	O
remarkably	O
short	O
period	O
of	O
evolutionary	O
time	O
(	O
15	O
)	O
.	O

It	O
is	O
conceivable	O
that	O
each	O
of	O
these	O
ribonucleases	O
might	O
serve	O
a	O
unique	O
but	O
related	O
function	O
.	O

On	O
this	O
point	O
,	O
a	O
number	O
of	O
studies	O
have	O
suggested	O
a	O
distinct	O
role	O
for	O
the	O
human	S-Species
ribonuclease	O
ECP	O
in	O
eosinophil	O
-	O
mediated	O
host	O
defense	O
(	O
6	O
,	O
7	O
)	O
;	O
in	O
addition	O
,	O
we	O
have	O
recently	O
shown	O
that	O
eosinophil	O
ribonucleases	O
can	O
inhibit	O
retroviral	O
transduction	O
of	O
human	S-Species
target	O
cells	O
(	O
23	O
)	O
.	O

The	O
possibility	O
that	O
certain	O
ribonucleases	O
have	O
diverged	O
to	O
promote	O
distinct	O
and	O
specific	O
host	O
defense	O
-	O
related	O
activities	O
remains	O
an	O
intriguing	O
hypothesis	O
.	O

ACKNOWLEDGEMENTS	O
We	O
would	O
like	O
to	O
thank	O
Dr	O
Jianzhi	O
Zhang	O
for	O
helpful	O
discussions	O
,	O
and	O
Drs	O
Harry	O
L	O
.	O
Malech	O
and	O
John	O
I	O
.	O
Gallin	O
for	O
their	O
ongoing	O
suppport	O
of	O
the	O
work	O
in	O
our	O
laboratory	O
.	O

D	O
.	O
B	O
.	O

is	O
a	O
Howard	O
Hughes	O
Medical	O
Institute	O
-	O
National	O
Institutes	O
of	O
Health	O
Research	O
Scholar	O
REFERENCES	O
1	O
D	O
'	O
Alessio	O
,	O
G	O
.	O
and	O
Riordan	O
,	O
J	O
.	O
F	O
.	O

(	O
1997	O
)	O
In	O
D	O
'	O
Alessio	O
,	O
G	O
.	O
and	O
Riordan	O
,	O
J	O
.	O
F	O
.	O

(	O
eds	O
)	O
Ribonucleases	O
:	O
structure	O
and	O
function	O
.	O

Academic	O
Press	O
,	O
Inc	O
.	O
,	O
New	O
York	O
,	O
NY	O
.	O

2	O
Sorrentino	O
,	O
S	O
.	O
and	O
Libonati	O
,	O
M	O
.	O

(	O
1997	O
)	O
FEBS	O
Lett	O
.	O

404	O
,	O
1	O
<FFFD>	O
5	O
.	O

21	O
22	O
23	O
24	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O

4239	O

Beintema	O
,	O
J	O
.	O
J	O
.	O
,	O
Breukelman	O
,	O
H	O
.	O
J	O
,	O
Carsana	O
,	O
A	O
.	O
,	O
and	O
Furia	O
,	O
A	O
.	O

(	O
1997	O
)	O
In	O
D	O
'	O
Alessio	O
,	O
G	O
.	O
and	O
Riordan	O
,	O
J	O
.	O
F	O
.	O

(	O
eds	O
)	O
Ribonucleases	O
:	O
structure	O
and	O
function	O
.	O

Academic	O
Press	O
,	O
Inc	O
.	O
,	O
New	O
York	O
,	O
NY	O
.	O

Confalone	O
,	O
E	O
.	O
,	O
Beintema	O
,	O
J	O
.	O
J	O
.	O
,	O
Sasso	O
,	O
M	O
.	O
P	O
.	O

Carsana	O
,	O
A	O
.	O
,	O
Palmieria	O
,	O
M	O
.	O
,	O
Vento	O
,	O
M	O
.	O
T	O
.	O
and	O
Furia	O
A	O
.	O

(	O
1995	O
)	O
J	O
.	O

Mol	O
.	O

Evol	O
.	O

41	O
,	O
850	O
<FFFD>	O
858	O
.	O

Futami	O
,	O
J	O
.	O
,	O
Tsushima	O
,	O
Y	O
.	O
,	O
Murato	O
,	O
U	O
,	O
Tada	O
,	O
H	O
.	O
,	O
Sasaki	O
,	O
J	O
.	O
,	O
Seno	O
,	O
M	O
.	O
,	O
and	O
Yamada	O
,	O
H	O
.	O

(	O
1997	O
)	O
DNA	O
Cell	O
Biol	O
.	O

16	O
,	O
413	O
<FFFD>	O
419	O
.	O

Ackerman	O
,	O
S	O
.	O
J	O
.	O

(	O
1993	O
)	O
In	O
Makino	O
,	O
S	O
.	O
and	O
Fukuda	O
,	O
T	O
.	O

(	O
eds	O
)	O
Eosinophils	O
:	O
biological	O
and	O
clinical	O
aspects	O
.	O

CRC	O
Press	O
,	O
Inc	O
.	O
,	O
Boca	O
Raton	O
,	O
FL	O
Spry	O
,	O
C	O
.	O
J	O
.	O
F	O
.	O

(	O
1988	O
)	O
Eosinophils	O
:	O
a	O
comprehensive	O
review	O
and	O
guide	O
to	O
the	O
scientific	O
and	O
medical	O
literature	O
.	O

Oxford	O
University	O
Press	O
,	O
Oxford	O
,	O
UK	O
.	O

Beintema	O
,	O
J	O
.	O
J	O
.	O
,	O
Hofsteenge	O
,	O
J	O
.	O
,	O
Iwama	O
,	O
M	O
.	O
,	O
Morita	O
,	O
T	O
.	O
,	O
Ohgi	O
,	O
K	O
.	O
,	O
Irie	O
,	O
M	O
.	O
,	O
Sugiyama	O
,	O
R	O
.	O
H	O
.	O
,	O
Schieven	O
G	O
.	O
L	O
.	O
,	O
Dekker	O
,	O
C	O
.	O
A	O
.	O
,	O
and	O
Glitz	O
,	O
D	O
.	O
G	O
.	O

(	O
1988	O
)	O
Biochemistry	O
27	O
,	O
4530	O
<FFFD>	O
4538	O
.	O

Sorrentino	O
,	O
S	O
.	O
,	O
Tucker	O
,	O
G	O
.	O
K	O
.	O
,	O
and	O
Glitz	O
,	O
D	O
.	O
G	O
.	O

(	O
1988	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

263	O
,	O
16125	O
<FFFD>	O
16131	O
.	O

Vallee	O
,	O
B	O
.	O
L	O
.	O
and	O
Riordan	O
,	O
J	O
.	O
F	O
.	O

(	O
1988	O
)	O
Adv	O
.	O

Exp	O
.	O

Med	O
.	O

Biol	O
.	O

234	O
,	O
41	O
<FFFD>	O
53	O
.	O

Moroianu	O
,	O
J	O
.	O
and	O
Riordan	O
,	O
J	O
.	O
F	O
.	O

(	O
1994	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
91	O
,	O
1677	O
<FFFD>	O
1681	O
.	O

Seno	O
,	O
M	O
.	O
,	O
Futami	O
,	O
J	O
.	O
,	O
Tsushima	O
,	O
Y	O
.	O
,	O
Akutagawa	O
,	O
K	O
.	O
,	O
Kosaka	O
,	O
M	O
.	O
,	O
Tada	O
,	O
H	O
.	O
and	O
Yamada	O
,	O
H	O
.	O

(	O
1995	O
)	O
Bioch	O
.	O

Biophys	O
.	O

Acta	O
1261	O
,	O
424	O
<FFFD>	O
426	O
.	O

Rosenberg	O
,	O
H	O
.	O
F	O
.	O
and	O
Dyer	O
,	O
K	O
.	O
D	O
.	O

(	O
1995	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

23	O
,	O
4290	O
<FFFD>	O
4295	O
.	O

Rosenberg	O
,	O
H	O
.	O
F	O
.	O
and	O
Dyer	O
,	O
K	O
.	O
D	O
.	O

(	O
1996	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

24	O
,	O
3507	O
<FFFD>	O
3513	O
.	O

Larson	O
,	O
K	O
.	O
A	O
.	O
,	O
Olson	O
,	O
E	O
.	O
V	O
.	O
,	O
Madden	O
,	O
B	O
.	O
J	O
.	O
,	O
Gleich	O
,	O
G	O
.	O
J	O
.	O
,	O
Lee	O
,	O
N	O
.	O
A	O
.	O
and	O
Lee	O
,	O
J	O
.	O
J	O
.	O

(	O
1997	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
93	O
,	O
12370	O
<FFFD>	O
12375	O
.	O

Nakajima	O
-	O
Iyima	O
,	O
S	O
.	O
,	O
Hamada	O
,	O
H	O
.	O
,	O
Reddy	O
,	O
P	O
.	O
and	O
Kakanaga	O
,	O
T	O
.	O

(	O
1985	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
82	O
,	O
6133	O
<FFFD>	O
6137	O
.	O

Li	O
,	O
W	O
.	O
-	O
H	O
.	O
and	O
Graur	O
,	O
D	O
.	O

(	O
1991	O
)	O
Fundamentals	O
of	O
Molecular	O
Evolution	O
.	O

Sinauer	O
Associates	O
,	O
Sunderland	O
,	O
MA	O
.	O

Rosenberg	O
,	O
H	O
.	O
F	O
.	O
and	O
Dyer	O
,	O
K	O
.	O
D	O
.	O

(	O
1995	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

270	O
,	O
21539	O
<FFFD>	O
21544	O
.	O

Watanabe	O
,	O
H	O
.	O
,	O
Katoh	O
,	O
H	O
,	O
Ishii	O
,	O
M	O
.	O
,	O
Komoda	O
,	O
Y	O
.	O
,	O
Sanda	O
,	O
A	O
.	O
,	O
Takizawa	O
,	O
Y	O
.	O
,	O
Ohgi	O
,	O
K	O
.	O
and	O
Irie	O
,	O
M	O
.	O

(	O
1988	O
)	O
J	O
.	O

Biochem	O
.	O

104	O
,	O
939	O
<FFFD>	O
945	O
.	O

Sasso	O
,	O
M	O
.	O
P	O
.	O
,	O
Carsana	O
,	O
A	O
.	O
,	O
Confalone	O
,	O
E	O
.	O
,	O
Cosi	O
,	O
C	O
.	O
,	O
Sorrentino	O
,	O
S	O
.	O
,	O
Viola	O
,	O
M	O
.	O
,	O
Palmieri	O
,	O
M	O
.	O
,	O
Russo	O
,	O
E	O
.	O
and	O
Furia	O
,	O
A	O
.	O

(	O
1991	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

19	O
,	O
6469	O
<FFFD>	O
6474	O
.	O

Palmieri	O
,	O
M	O
.	O
,	O
Carsana	O
,	O
A	O
.	O
,	O
Furia	O
,	O
A	O
.	O
and	O
Libonati	O
,	O
M	O
.	O

(	O
1985	O
)	O
Eur	O
.	O

J	O
.	O

Biochem	O
.	O

152	O
,	O
275	O
<FFFD>	O
277	O
.	O

Rosenberg	O
,	O
H	O
.	O
F	O
.	O
,	O
Dyer	O
,	O
K	O
.	O
D	O
.	O
,	O
Tiffany	O
,	O
H	O
.	O
L	O
.	O
and	O
Gonzalez	O
,	O
M	O
.	O

(	O
1995	O
)	O
Nature	O
Genet	O
.	O

10	O
,	O
219	O
<FFFD>	O
223	O
.	O

Domachowske	O
,	O
J	O
.	O
B	O
.	O
and	O
Rosenberg	O
,	O
H	O
.	O
F	O
.	O

(	O
1997	O
)	O
J	O
.	O

Leukoc	O
.	O

Biol	O
.	O
,	O
62	O
,	O
363	O
<FFFD>	O
368	O
.	O

Iwama	O
,	O
M	O
.	O
,	O
Sanda	O
,	O
A	O
.	O
,	O
Ohgi	O
,	O
K	O
.	O
,	O
Hofsteenge	O
,	O
J	O
.	O
,	O
and	O
Irie	O
,	O
M	O
.	O

(	O
1993	O
)	O
Biosci	O
.	O

Biotech	O
.	O

Biochem	O
.	O

57	O
,	O
2133	O
<FFFD>	O
2138	O
.	O

Physiological	O
and	O
chemical	O
characterization	O
of	O
cyanobacterial	S-Species
metallothioneins	O
.	O

Abstract	O

Techniques	O
have	O
been	O
developed	O
for	O
detection	O
,	O
quantitation	O
,	O
and	O
isolation	O
of	O
bacterial	O
metallothioneins	O
(	O
MTs	O
)	O
from	O
cyanobacterial	O
species	O
.	O

These	O
methods	O
involve	O
differential	O
pulse	O
polarography	O
and	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
have	O
allowed	O
detection	O
of	O
picomole	O
quantities	O
of	O
these	O
high	O
sulfhydryl	O
content	O
proteins	O
.	O

The	O
prokaryotic	O
molecule	O
was	O
found	O
to	O
be	O
induced	O
in	O
the	O
presence	O
of	O
Cd	O
or	O
Zn	O
salts	O
with	O
regulation	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Cu	O
was	O
not	O
found	O
to	O
induce	O
synthesis	O
of	O
the	O
prokaryotic	O
MT	O
.	O

Exposure	O
to	O
the	O
former	O
metals	O
resulted	O
in	O
a	O
growth	O
lag	O
followed	O
by	O
simultaneous	O
induction	O
of	O
MT	O
synthesis	O
and	O
onset	O
of	O
growth	O
.	O

Amino	O
acid	O
analysis	O
and	O
N	O
-	O
terminal	O
sequence	O
analysis	O
indicated	O
that	O
the	O
bacterial	O
MTs	O
from	O
cyanobacteria	O
are	O
unique	O
,	O
having	O
many	O
aromatic	O
and	O
aliphatic	O
residues	O
and	O
no	O
apparent	O
association	O
of	O
hydroxylated	O
or	O
basic	O
amino	O
acids	O
with	O
cysteines	O
.	O

Although	O
the	O
characteristic	O
Cys	O
-	O
X	O
-	O
Cys	O
sequences	O
were	O
present	O
,	O
no	O
apparent	O
amino	O
acid	O
sequence	O
homology	O
with	O
the	O
eukaryotic	O
MTs	O
was	O
found	O
in	O
the	O
first	O
42	O
residues	O
.	O

Environmental	O
Health	O
Perspectives	O
Vol	O
.	O

65	O
,	O
pp	O
.	O

71	O
-	O
75	O
,	O
1986	O

Physiological	O
and	O
Chemical	O

Characterization	O
of	O
Cyanobacterial	O
Metallothioneins	O

by	O
Robert	O
W	O
.	O
Olafson	O
*	O

Techniques	O
have	O
been	O
developed	O
for	O
detection	O
,	O
quantitation	O
,	O
and	O
isolation	O
of	O
bacterial	O
metallothioneins	O
(	O
MTs	O
)	O
from	O
cyanobacterial	O
species	O
.	O

These	O
methods	O
involve	O
differential	O
pulse	O
polarography	O
and	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
have	O
allowed	O
detection	O
of	O
picomole	O
quantities	O
of	O
these	O
high	O
sulfhydryl	O
content	O
proteins	O
.	O

The	O
prokaryotic	O
molecule	O
was	O
found	O
to	O
be	O
induced	O
in	O
the	O
presence	O
of	O
Cd	O
or	O
Zn	O
salts	O
with	O
regulation	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Cu	O
was	O
not	O
found	O
to	O
induce	O
synthesis	O
of	O
the	O
prokaryotic	O
MT	O
.	O

Exposure	O
to	O
the	O
former	O
metals	O
resulted	O
in	O
a	O
growth	O
lag	O
followed	O
by	O
simultaneous	O
induction	O
of	O
MT	O
synthesis	O
and	O
onset	O
of	O
growth	O
.	O

Amino	O
acid	O
analysis	O
and	O
N	O
-	O
terminal	O
sequence	O
analysis	O
indicated	O
that	O
the	O
bacterial	O
MTs	O
from	O
cyanobacteria	O
are	O
unique	O
,	O
having	O
many	O
aromatic	O
and	O
aliphatic	O
residues	O
and	O
no	O
apparent	O
association	O
of	O
hydroxylated	O
or	O
basic	O
amino	O
acids	O
with	O
cysteines	O
.	O

Although	O
the	O
characteristic	O
CysX	O
-	O
Cys	O
sequences	O
were	O
present	O
,	O
no	O
apparent	O
amino	O
acid	O
sequence	O
homology	O
with	O
the	O
eukaryotic	O
MTs	O
was	O
found	O
in	O
the	O
first	O
42	O
residues	O
.	O

Introduction	O

Metallothioneins	O
have	O
now	O
been	O
isolated	O
and	O
characterized	O
from	O
a	O
large	O
variety	O
of	O
eukaryotic	O
organisms	O
(	O
1	O
)	O
and	O
shown	O
to	O
be	O
involved	O
in	O
heavy	O
metal	O
detoxification	O
and	O
/	O
or	O
homeostasis	O
(	O
2	O
-	O
4	O
)	O
.	O

These	O
proteins	O
are	O
highly	O
homologous	O
with	O
respect	O
to	O
amino	O
acid	O
sequence	O
and	O
complex	O
metals	O
in	O
characteristic	O
metal	O
-	O
thiolate	O
cluster	O
arrangements	O
,	O
the	O
structures	O
of	O
which	O
have	O
been	O
recently	O

investigated	O
by	O
113Cd	O
-	O
NMR	O
(	O
6	O
)	O
.	O

Although	O
metallothionein	O
(	O
MT	O
)	O
is	O
found	O
throughout	O
the	O
eukaryotic	O
world	O
,	O
few	O
reports	O
of	O
the	O
presence	O
of	O
this	O
type	O
of	O
high	O
sulfhydryl	O
content	O
metal	O
-	O
binding	O
protein	O
exist	O
for	O
prokaryotes	O
.	O

We	O
earlier	O
reported	O
the	O
presence	O
of	O
a	O
prokaryotic	O
MT	O
in	O
cyanobacteria	O
(	O
7	O
,	O
8	O
)	O
and	O
have	O
recently	O
provided	O
primary	O
sequence	O
evidence	O
substantiating	O
these	O
data	O
.	O

This	O
manuscript	O
is	O
intended	O
to	O
summarize	O
the	O
present	O
state	O
of	O
knowledge	O
regarding	O
the	O
physiological	O
and	O
chemical	O
characterization	O
of	O
these	O
bacterial	O
MTs	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
techniques	O
employed	O
in	O
such	O
studies	O
.	O

Analytical	O
Procedure	O

In	O
order	O
to	O
facilitate	O
rapid	O
detection	O
,	O
isolation	O
,	O
and	O
quantitation	O
of	O
MT	O
from	O
various	O
sources	O
,	O
we	O
have	O
routinely	O
employed	O
a	O
differential	O
pulse	O
polarographic	O
tech	O

*	O
Department	O
of	O
Biochemistry	O
and	O
Microbiology	O
,	O
University	O
of	O
Victoria	O
,	O
Victoria	O
,	O
British	O
Columbia	O
V8W	O
2Y2	O
,	O
Canada	O
.	O

nique	O
first	O
described	O
by	O
Brdicka	O
(	O
9	O
-	O
11	O
)	O
.	O

This	O
procedure	O
avoids	O
use	O
of	O
radioisotopes	O
and	O
circumvents	O
problems	O
such	O
as	O
species	O
specificity	O
and	O
metal	O
stoichiometric	O
assumptions	O
associated	O
with	O
radioimmunoassays	O
and	O
metal	O
binding	O
assays	O
.	O

Figure	O
1	O
shows	O
a	O
typical	O
polarographic	O
wave	O
for	O
MT	O
using	O
the	O
Brdicka	O
procedure	O
.	O

Measurement	O
of	O
the	O
wave	O
height	O
can	O
be	O
performed	O
from	O
either	O
the	O

0	O
.	O
20	O

glJ	O
MT	O
-	O
1	O

O	O
0	O
.	O
15	O

E	O

0	O
0	O
.	O
10	O
0	O

E	O
0	O
.	O
05	O
_	O
_	O

-	O
1	O
.	O
35	O
-	O
1	O
.	O
45	O
-	O
1	O
.	O
55	O
-	O
1	O
.	O
65	O

V	O
vs	O
Agt	O
/	O
AgC1	O

FIGURE	O
1	O
.	O

Differential	O
pulse	O
polarographic	O
wave	O
for	O
murine	S-Species
MT	O
-	O
1	O
.	O

Wave	O
heights	O
were	O
calculated	O
from	O
the	O
broken	O
tangent	O
line	O
between	O
minima	O
rather	O
than	O
the	O
supporting	O
electrolyte	O
baseline	O
at	O
the	O
bottom	O
of	O
the	O
figure	O
.	O

R	O
.	O

W	O
OLAFSON	O

supporting	O
electrolyte	O
baseline	O
or	O
a	O
tangent	O
to	O
the	O
minima	O
as	O
shown	O
in	O
the	O
preceding	O
figure	O
.	O

In	O
the	O
cobalt	O
hexaminechloride	O
supporting	O
electrolyte	O
,	O
the	O
half	O
-	O
wave	O
potential	O
for	O
all	O
MTs	O
studied	O
to	O
date	O
is	O
approximately	O
-	O
1	O
.	O
45	O
V	O
versus	O
a	O
Ag	O
/	O
AgCl	O
reference	O
electrode	O
.	O

This	O
electrochemical	O
reaction	O
results	O
in	O
highly	O
reproducible	O
and	O
linear	O
current	O
responses	O
which	O
can	O
be	O
used	O
with	O
samples	O
containing	O
picomole	O
levels	O
of	O
MT	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Since	O
this	O
is	O
an	O
exceedingly	O
sensitive	O
instrument	O
,	O
attention	O
to	O
detail	O
is	O
particularly	O
important	O
for	O
successful	O
use	O
of	O
the	O
Brdicka	O
procedure	O
(	O
11	O
)	O
.	O

Routine	O
use	O
of	O
a	O
reference	O
standard	O
MT	O
is	O
highly	O
recommended	O
to	O
compensate	O
for	O
small	O
day	O
-	O
today	O
variations	O
in	O
response	O
.	O

For	O
absolute	O
values	O
,	O
standards	O
must	O
be	O
identical	O
to	O
the	O
species	O
of	O
protein	O
quantitated	O
;	O
otherwise	O
commercially	O
available	O
standard	O
is	O
adequate	O
.	O

Although	O
certain	O
tissues	O
and	O
cellular	O
types	O
can	O
be	O
shown	O
to	O
have	O
no	O
other	O
polarographically	O
active	O
material	O
other	O
than	O
MT	O
,	O
with	O
samples	O
from	O
new	O
species	O
,	O
it	O
is	O
necessary	O
to	O
evaluate	O
this	O
potential	O
problem	O
by	O
gelperneation	O
chromatography	O
and	O
,	O
if	O
necessary	O
,	O
take	O
steps	O
to	O
remove	O
contaminants	O
before	O
assaying	O
.	O

In	O
most	O
cases	O
,	O

0	O

E	O
i	O

m	O
0	O

0	O
E	O

0	O
.	O
31	O

0	O
.	O
11	O

O	O
0	O
.	O
1	O
0	O
.	O
3	O
0	O
.	O
5	O

MT	O
(	O
nanomoles	O
)	O

FIGURE	O
2	O
.	O

Standard	O
curve	O
for	O
polarographic	O
determination	O
of	O
me	O

tallothionein	O
.	O

FIGURE	O
3	O
.	O

Cyclic	O
voltamogram	O
obtained	O
by	O
equilibration	O
at	O
-	O
1	O
.	O
0	O
V	O

for	O
4	O
min	O
followed	O
by	O
cyclic	O
scanning	O
to	O
OV	O
and	O
-	O
1	O
.	O
4	O
V	O
at	O
a	O
scan	O
rate	O
of	O
200	O
mV	O
/	O
sec	O
with	O
a	O
PAR	O
Model	O
303	O
static	O
mercury	O
drop	O
electrode	O
in	O
the	O
hanging	O
drop	O
mode	O
.	O

The	O
mercury	O
drop	O
electrode	O
was	O
set	O
in	O
the	O
large	O
drop	O
position	O
producing	O
a	O
drop	O
of	O
0	O
.	O
0226	O
cm3	O
.	O

The	O
supporting	O
electrolyte	O
was	O
20	O
mM	O
HEPES	O
buffer	O
,	O
pH	O
7	O
.	O
3	O
.	O

The	O
dotted	O
line	O
is	O
the	O
equilibrium	O
trace	O
.	O

Adapted	O
Olafson	O
and	O
Sim	O
(	O
10	O
)	O
.	O

this	O
is	O
easily	O
managed	O
by	O
heat	O
denaturation	O
,	O
if	O
care	O
is	O
taken	O
to	O
assess	O
the	O
degree	O
of	O
MT	O
losses	O
due	O
to	O
coprecipitation	O
.	O

Such	O
losses	O
later	O
can	O
usually	O
be	O
minimized	O
to	O
less	O
than	O
10	O
%	O
by	O
adjustment	O
of	O
the	O
tissue	O
homogenate	O
density	O
prior	O
to	O
denaturation	O
.	O

It	O
should	O
be	O
indicated	O
that	O
additional	O
utility	O
can	O
be	O
found	O
with	O
a	O
polarographic	O
analyzer	O
beyond	O
application	O
of	O
the	O
Brdicka	O
procedure	O
.	O

For	O
example	O
,	O
metal	O
levels	O
can	O
be	O
readily	O
determined	O
by	O
using	O
differential	O
pulse	O
or	O
anodic	O
stripping	O
voltametry	O
procedures	O
(	O
10	O
)	O
,	O
while	O
Figure	O
3	O
shows	O
a	O
cyclic	O
voltamogram	O
of	O
bacterial	O
MT	O
.	O

The	O
latter	O
technique	O
is	O
potentially	O
useful	O
in	O
assessing	O
metal	O
speciation	O
and	O
integrity	O
of	O
the	O
protein	O
tertiary	O
structure	O
near	O
metal	O
clusters	O
,	O
particularly	O
after	O
metal	O
reconstitution	O
studies	O
.	O

E	O

'	O
C2A	O
-	O
E	O
24	O

0	O
30	O
40	O
E0	O

*	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O

o	O
C	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
C	O

Fraction	O
Number	O
(	O
18ml	O
)	O

FIGURE	O
4	O
.	O

Sephadex	O
G	O
-	O
75	O
chromatography	O
profile	O
of	O
bacterial	O
cell	O

lysate	O
applied	O
to	O
a	O
5	O
x	O
100	O
cm	O
column	O
and	O
eluted	O
with	O
10	O
mM	O
anunoium	O
bicarbonate	O
,	O
5	O
mM	O
mercaptoethanol	O
(	O
7	O
)	O
.	O

Elution	O
Time	O
(	O
min	O
)	O

FIGURE	O
5	O
.	O

Reverse	O
-	O
phase	O
high	O
-	O
performance	O
chromatography	O
profile	O

of	O
Sephadex	O
G	O
-	O
75	O
fractionated	O
bacterial	O
MT	O
.	O

The	O
300	O
A	O
pore	O
size	O
propyl	O
column	O
was	O
eluted	O
with	O
20	O
mM	O
triethylamine	O
phosphate	O
,	O
pH	O
7	O
.	O
0	O
,	O
by	O
using	O
an	O
acetonitrile	O
organic	O
modifier	O
(	O
phase	O
B	O
)	O
.	O

Column	O
effluent	O
was	O
monitored	O
at	O
250	O
nm	O
with	O
a	O
sensitivity	O
of	O
1	O
.	O
0	O
AUFS	O
(	O
12	O
)	O
.	O

72	O

CYANOBACTERIAL	S-Species
METALLOTHIONEINS	O

Isolation	O
of	O
Cyanobacterial	O
MT	O

Synechococcus	B-Species
strain	I-Species
Tx	I-Species
-	I-Species
20	E-Species
cyanobacteria	O
were	O
maintained	O
in	O
axenic	O
culture	O
on	O
BG	O
-	O
11	O
medium	O
(	O
7	O
)	O
and	O
harvested	O
from	O
aerated	O
20	O
L	O
cultures	O
grown	O
at	O
280C	O
under	O
fluorescent	O
light	O
.	O

Cells	O
were	O
broken	O
in	O
a	O
French	O
pressure	O
cell	O
at	O
0	O
?	O
C	O
in	O
0	O
.	O
5	O
M	O
Tris	O
-	O
HCI	O
,	O
pH	O
8	O
.	O
6	O
,	O
and	O
the	O
lysate	O
exposed	O
to	O
10	O
,	O
uCi	O
of	O
109CdCl	O
.	O

The	O
40	O
,	O
000g	O
supernatant	O
was	O
applied	O
to	O
a	O
Sephadex	O
G	O
-	O
75	O
column	O
developed	O
with	O
10	O
mM	O
ammonium	O
bicarbonate	O
and	O
5	O
mM	O
mercaptoethanol	O
resulting	O
in	O
the	O
profile	O
shown	O
in	O
Figure	O
4	O
.	O

Polarographic	O
activity	O
and	O
radionuclide	O
binding	O
were	O
coincident	O
with	O
a	O
10	O
,	O
000	O
MW	O
ultraviolet	O
absorbing	O
fraction	O
.	O

Further	O
purification	O
of	O
this	O
material	O
could	O
be	O
undertaken	O
by	O
DEAE	O
-	O
cellulose	O
chromatography	O
or	O
isoelectric	O
focusing	O
but	O
maximum	O
resolution	O
of	O
isoproteins	O
was	O
best	O
attained	O
by	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatogra	O

0	O
5	O

DAYS	O

I0	O

5	O

phy	O
.	O

Figure	O
5	O
shows	O
such	O
a	O
separation	O
performed	O
on	O
a	O
300	O
A	O
pore	O
size	O
C	O
-	O
3	O
column	O
(	O
Beckman	O
Instruments	O
)	O
.	O

Four	O
baseline	O
resolved	O
MT	O
peaks	O
appear	O
between	O
40	O
and	O
70	O
min	O
.	O

Peaks	O
eluting	O
at	O
80	O
min	O
contain	O
at	O
least	O
four	O
additional	O
MT	O
components	O
resolvable	O
by	O
adjustment	O
of	O
the	O
applied	O
organic	O
modifier	O
ramp	O
.	O

Preliminary	O
evidence	O
indicates	O
that	O
these	O
isoproteins	O
are	O
microheterogeneous	O
with	O
respect	O
to	O
both	O
amino	O
acid	O
composition	O
and	O
metal	O
speciation	O
resulting	O
in	O
the	O
observed	O
reverse	O
-	O
phase	O
separation	O
.	O

Physiological	O
Characteristics	O
of	O
Cyanobacterial	O
MT	O

Using	O
the	O
Brdicka	O
polarographic	O
procedure	O
,	O
it	O
is	O
possible	O
to	O
measure	O
basal	O
MT	O
levels	O
in	O
Synechococcus	O
strain	O

5	O

DAYS	O

10	O

15	O

FIGURE	O
6	O
.	O

Cell	O
numbers	O
and	O
MT	O
concentrations	O
as	O
a	O
function	O
of	O
time	O
after	O
inoculation	O
of	O
wild	O
-	O
type	O
cyanobacteria	O
in	O
the	O
presence	O
and	O
absence	O

of	O
(	O
A	O
)	O
22	O
.	O
5	O
,	O
uM	O
CdCl2	O
;	O
(	O
B	O
)	O
control	O
;	O
(	O
C	O
)	O
50	O
,	O
uM	O
ZnSO4	O
;	O
(	O
D	O
)	O
50	O
,	O
uM	O
CuCl2	O
(	O
8	O
)	O
.	O

73	O

74	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
R	O
.	O

W	O
OLAFSON	O

Table	O
1	O
.	O

Amino	O
acid	O
compositions	O
of	O
cyanobacterial	O

metallothioneins	O
compared	O
with	O
eukaryotic	O
metallothioneins	O
.	O

Nearest	O
integer	O
residues	O
per	O
molecule	O
Human	S-Species
(	O
MT	O
-	O
2	O
)	O
Crab	O
(	O
MT	O
-	O
2	O
)	O
Tx	O
-	O
20t	O
CysA	O
20	O
18	O
9	O
.	O
5	O
Asx	O
4	O
6	O
5	O
.	O
7	O
Thr	O
2	O
3	O
4	O
.	O
8	O
Ser	O
8	O
5	O
3	O
.	O
8	O
Glx	O
2	O
5	O
2	O
.	O
0	O
Gly	O
5	O
3	O
8	O
.	O
0	O
Ala	O
7	O
1	O
4	O
.	O
0	O
Val	O
1	O
-	O
2	O
.	O
3	O
Met	O
1	O
-	O

Ile	O
1	O
-	O
1	O
.	O
1	O

Leu	O
Tyr	O
Phe	O
His	O
Lys	O
Arg	O
Pro	O

8	O
2	O

8	O
2	O
6	O

2	O
.	O
9	O
2	O
.	O
3	O

2	O
.	O
8	O
2	O
.	O
6	O
1	O
.	O
0	O
1	O
.	O
9	O

RRIMP	O
NI	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
added	O
metal	O
,	O
as	O
shown	O
in	O
Figure	O
6B	O
(	O
8	O
)	O
.	O

Comparison	O
with	O
cultures	O
exposed	O
to	O
cadmium	O
chloride	O
(	O
Fig	O
.	O
6A	O
)	O
or	O
zinc	O
sulfate	O
(	O
Fig	O
.	O
6C	O
)	O
showed	O
that	O
introduction	O
of	O
metal	O
salts	O
resulted	O
in	O
a	O
growth	O
lag	O
and	O
that	O
resumption	O
of	O
growth	O
occurred	O
coincident	O
with	O
an	O
increase	O
in	O
cellular	O
levels	O
of	O
MT	O
.	O

In	O
addition	O
,	O
it	O
should	O
be	O
noted	O
that	O
,	O
like	O
mammalian	O
MT	O
,	O
cadmium	O
appears	O
to	O
be	O
a	O
more	O
potent	O
inducer	O
than	O
zinc	O
.	O

Twice	O
as	O
much	O
cadmium	O
-	O
thionein	O
was	O
synthesized	O
on	O
exposure	O
to	O
half	O
as	O
much	O
metal	O
as	O
was	O
used	O
in	O
the	O
zinc	O
induction	O
experiment	O
.	O

A	O
further	O
interesting	O
finding	O
was	O
that	O
copper	O
exposure	O
resulted	O
in	O
an	O
even	O
greater	O
growth	O
lag	O
than	O
observed	O
with	O
cadmium	O
,	O
but	O
on	O
resumption	O
of	O
growth	O
in	O
the	O
presence	O
copper	O
,	O
MT	O
synthesis	O
was	O
not	O
noted	O
(	O
Fig	O
.	O
6D	O
)	O
.	O

Recent	O
results	O
suggest	O
that	O
this	O
copper	O
resistance	O
is	O
manifest	O
via	O
a	O
membrane	O
exclusion	O
mechanism	O
(	O
unpublished	O
results	O
)	O
.	O

HOURS	O

FIGURE	O
7	O
.	O

Inhibition	O
of	O
cadmium	O
induced	O
synthesis	O
by	O
actinomycin	O

D	O
(	O
hatched	O
bar	O
)	O
and	O
chloramphenicol	O
(	O
solid	O
bar	O
)	O
.	O

Control	O
cells	O
are	O
shown	O
by	O
unmarked	O
bars	O
.	O

In	O
order	O
that	O
the	O
level	O
of	O
regulation	O
of	O
metal	O
induction	O
be	O
determined	O
for	O
cyanobacteria	O
,	O
logarithmically	O
growing	O
cultures	O
were	O
exposed	O
to	O
cadmium	O
and	O
MT	O
concentrations	O
measured	O
at	O
several	O
time	O
intervals	O
thereafter	O
.	O

Two	O
cultures	O
were	O
exposed	O
to	O
either	O
chloramphenicol	O
or	O
actinomycin	O
D	O
30	O
min	O
prior	O
to	O
introduction	O
of	O
metal	O
,	O
while	O
a	O
third	O
culture	O
was	O
used	O
as	O
a	O
control	O
.	O

The	O
results	O
of	O
this	O
experiment	O
are	O
shown	O
in	O
Figure	O
7	O
and	O
indicate	O
induction	O
at	O
the	O
level	O
of	O
transcription	O
,	O
as	O
was	O
found	O
in	O
eukaryotic	O
organisms	O
.	O

The	O
assumption	O
at	O
this	O
stage	O
in	O
these	O
investigations	O
was	O
that	O
the	O
growth	O
lag	O
observed	O
in	O
cultures	O
exposed	O
to	O

Table	O
2	O
.	O

Amino	O
acid	O
sequence	O
analysis	O
.	O

Amino	O
acid	O

1	O
10	O
20	O
30	O
Cyanobacteria	O
T	O
S	O
T	O
T	O
L	O
V	O
K	O
C	O
A	O
C	O
E	O
P	O
C	O
L	O
C	O
N	O
V	O
D	O
P	O
S	O
K	O
A	O
I	O
D	O
R	O
N	O
G	O
L	O
Y	O
Y	O
Scylla	O
P	O
DP	O
C	O
C	O
NDK	O
C	O
DC	O
K	O
EG	O
EC	O
KT	O
GC	O
K	O
CT	O
S	O
C	O
Human	S-Species
Ac	O
MD	O
P	O
NC	O
S	O
C	O
AA	O
G	O
DS	O
CT	O
C	O
AG	O
S	O
C	O
KC	O
KE	O
C	O
KC	O
T	O
S	O
C	O

Neurospora	O

G	O
D	O
C	O
G	O
C	O
S	O
G	O
A	O
S	O
S	O
C	O
N	O
C	O
G	O
S	O
G	O
C	O
S	O
C	O
S	O
N	O

C	O
G	O
S	O
K	O

Table	O
2	O
.	O

Continued	O
.	O

Amino	O
acid	O

40	O
50	O
60	O
C	O
C	O
EAC	O
A	O
H	O
GHT	O
G	O
G	O

R	O
CP	O
PC	O
EQ	O
C	O
S	O
SGC	O
K	O
CA	O
NK	O
E	O
DC	O
RK	O
TC	O
SK	O
PC	O
SCC	O
P	O
K	O
K	O
SCC	O
S	O
CCP	O
V	O
GC	O
A	O
KCA	O
Q	O
BC	O
I	O
C	O
K	O
GA	O
SDK	O
C	O
S	O
CC	O
A	O

74	O

I	O

II	O

I	O
I	O

CYANOBACTERIAL	S-Species
METALLOTHIONEINS	O
75	O

cadmium	O
or	O
zinc	O
was	O
due	O
to	O
a	O
rather	O
protracted	O
time	O
of	O
MT	O
induction	O
,	O
perhaps	O
associated	O
with	O
toxic	O
burden	O
.	O

If	O
the	O
above	O
cadmium	O
-	O
resistant	O
cells	O
were	O
transferred	O
into	O
fresh	O
media	O
in	O
the	O
absence	O
of	O
cadmium	O
and	O
allowed	O
to	O
grow	O
up	O
between	O
three	O
successive	O
transfers	O
,	O
levels	O
of	O
MT	O
dropped	O
to	O
near	O
basal	O
values	O
as	O
synthesis	O
was	O
repressed	O
in	O
the	O
absence	O
of	O
metal	O
.	O

However	O
,	O
when	O
these	O
cells	O
were	O
now	O
transferred	O
into	O
cadmium	O
-	O
containing	O
media	O
,	O
instead	O
of	O
the	O
predicted	O
growth	O
lag	O
,	O
they	O
grew	O
immediately	O
.	O

Thus	O
,	O
these	O
cells	O
were	O
truly	O
cadmium	O
resistant	O
.	O

Since	O
50	O
tubes	O
of	O
wild	O
-	O
type	O
cells	O
at	O
a	O
dilution	O
of	O
104	O
grew	O
,	O
after	O
the	O
usual	O
lag	O
on	O
exposure	O
to	O
cadmium	O
-	O
containing	O
media	O
,	O
the	O
acquisition	O
of	O
cadmium	O
resistance	O
in	O
this	O
strain	O
of	O
Synechococcus	O
was	O
therefore	O
considered	O
unlikely	O
to	O
be	O
related	O
to	O
a	O
chromosomal	O
mutational	O
event	O
.	O

Such	O
a	O
mutation	O
frequency	O
would	O
be	O
unreasonably	O
high	O
.	O

Although	O
no	O
direct	O
evidence	O
exists	O
at	O
this	O
time	O
,	O
this	O
metal	O
resistance	O
phenomenon	O
is	O
best	O
explained	O
by	O
the	O
amplification	O
of	O
an	O
extrachromosomal	O
gene	O
,	O
especially	O
since	O
this	O
strain	O
is	O
known	O
to	O
have	O
plasmids	O
.	O

Structure	O
of	O
Cyanobacterial	O
MT	O

The	O
structural	O
determination	O
of	O
cyanobacterial	S-Species
MT	O
is	O
not	O
yet	O
complete	O
,	O
although	O
a	O
substantial	O
amount	O
of	O
information	O
is	O
now	O
known	O
.	O

For	O
example	O
,	O
Table	O
1	O
compares	O
the	O
amino	O
acid	O
composition	O
of	O
a	O
Synechococcus	B-Species
TX	I-Species
-	I-Species
20	E-Species
isoprotein	O
with	O
two	O
eukaryotic	O
MTs	O
.	O

These	O
data	O
indicate	O
that	O
the	O
bacterial	O
form	O
is	O
unique	O
.	O

While	O
cysteine	O
was	O
still	O
the	O
predominant	O
amino	O
acid	O
in	O
this	O
protein	O
,	O
levels	O
of	O
the	O
amino	O
acid	O
were	O
half	O
that	O
seen	O
in	O
the	O
eukaryotes	O
.	O

In	O
addition	O
,	O
the	O
bacterial	O
protein	O
had	O
two	O
tyrosines	O
,	O
three	O
histidines	O
,	O
and	O
five	O
long	O
-	O
chain	O
aliphatics	O
-	O
all	O
residues	O
rarely	O
found	O
in	O
eukaryotic	O
MTs	O
.	O

Thus	O
,	O
the	O
amino	O
acid	O
composition	O
indicates	O
that	O
prokaryotic	O
MTs	O
are	O
not	O
as	O
structurally	O
homologous	O
with	O
eukaryotes	O
as	O
they	O
are	O
physiologically	O
homologous	O
.	O

This	O
was	O
further	O
exemplified	O
on	O
amino	O
terminal	O
amino	O
acid	O
sequence	O
analysis	O
(	O
12	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
typical	O
Cys	O
-	O
X	O
-	O
Cys	O
sequences	O
,	O
the	O
first	O
42	O
residues	O
of	O
the	O
prokaryotic	O
MT	O
were	O
essentially	O
without	O
homology	O
on	O
comparison	O
with	O
the	O
crab	S-Species
(	O
Scylla	S-Species
)	O
,	O
human	S-Species
,	O
or	O
Neurospora	B-Species
crassa	E-Species
MTs	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
above	O
-	O
mentioned	O
uncommon	O
MT	O
residues	O
,	O
two	O
tyrosines	O
were	O
found	O
together	O
in	O
positions	O
29	O
and	O
30	O
,	O
all	O
five	O
of	O
the	O
long	O
-	O
chain	O
aliphatic	O
amino	O
acids	O
were	O
located	O
in	O
the	O
first	O
28	O
residues	O
,	O
and	O
two	O
histidines	O
were	O
situated	O
at	O
positions	O
37	O
and	O
39	O
.	O

Perhaps	O
of	O
greater	O
interest	O
was	O
the	O
complete	O
lack	O
of	O
association	O
of	O
basic	O
residues	O
or	O
hydroxylated	O
residues	O
with	O
cysteines	O
,	O
as	O
is	O
found	O
in	O
eukaryotes	O
(	O
11	O
)	O
.	O

Instead	O
,	O
a	O
block	O
of	O
four	O
hydroxylated	O
amino	O
acids	O
was	O
found	O
at	O
the	O
amino	O
terminus	O
.	O

The	O
sequence	O
of	O
this	O
unique	O
MT	O
is	O
now	O
nearing	O
completion	O
,	O
opening	O
the	O
way	O
for	O
an	O
X	O
-	O
ray	O
crystallographic	O
investigation	O
.	O

However	O
,	O
the	O
degree	O
of	O
similarity	O
between	O
the	O
metal	O
cluster	O
arrangement	O
of	O
these	O
bacterial	O
molecules	O
with	O
the	O
eukaryotic	O
structures	O
will	O
initially	O
be	O
undertaken	O
spectroscopically	O
.	O

Reliable	O
interpretation	O
of	O
the	O
113Cd	O
-	O
NMR	O
data	O
for	O
this	O
molecule	O
will	O
be	O
dependent	O
upon	O
adequate	O
isolation	O
of	O
isoproteins	O
using	O
RP	O
-	O
HPLC	O
and	O
assessment	O
of	O
conformational	O
integrity	O
of	O
metal	O
reconstituted	O
molecules	O
,	O
using	O
procedures	O
such	O
as	O
cyclic	O
voltametry	O
.	O

Studies	O
along	O
these	O
lines	O
are	O
presently	O
underway	O
in	O
this	O
laboratory	O

The	O
author	O
gratefully	O
acknowledges	O
the	O
financial	O
support	O
of	O
the	O
Australian	O
Institute	O
of	O
Marine	O
Science	O
and	O
the	O
National	O
Science	O
and	O
Engineering	O
Research	O
Council	O
of	O
Canada	O
.	O

Excellent	O
technical	O
assistance	O
was	O
provided	O
by	O
R	O
.	O

G	O
.	O

Sim	O
and	O
S	O
.	O

Kielland	O
in	O
carrying	O
out	O
the	O
polarographic	O
and	O
sequence	O
analyses	O
,	O
respectively	O
.	O

REFERENCES	O

1	O
.	O

Kagi	O
,	O
J	O
.	O

H	O
.	O

R	O
.	O
,	O
and	O
Nordberg	O
,	O
M	O
.	O

(	O
Eds	O
.	O
)	O
.	O

Metallothionein	O
.	O

Birk	O

hauser	O
Verlag	O
,	O
Basel	O
,	O
1979	O
,	O
pp	O
.	O

5	O
-	O
55	O
.	O

2	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
Differential	O
pulse	O
polarographic	O
determination	O
of	O

murine	S-Species
metallothionein	O
induction	O
kinetics	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

256	O
:	O
12631268	O
(	O
1981	O
)	O
.	O

3	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
Intestinal	O
metallothionein	O
:	O
effect	O
of	O
parenteral	O
and	O

enteral	O
zinc	O
exposure	O
on	O
tissue	O
levels	O
of	O
mice	S-Species
on	O
controlled	O
zinc	O
diets	O
.	O

J	O
.	O

Nutr	O
.	O

113	O
:	O
268	O
-	O
275	O
(	O
1983	O
)	O
.	O

4	O
.	O

McCarter	O
,	O
J	O
.	O
A	O
.	O
,	O
and	O
Roch	O
,	O
M	O
.	O

Chronic	O
exposure	O
of	O
Coho	B-Species
salmon	E-Species

to	O
sublethal	O
concentrations	O
of	O
copper	O
.	O

III	O
.	O

Kinetics	O
of	O
metabolism	O
of	O
metallothionein	O
.	O

Comp	O
.	O

Biochem	O
.	O

Physiol	O
.	O

77C	O
:	O
83	O
-	O
87	O
(	O
1984	O
)	O
.	O

5	O
.	O

Lerch	O
,	O
K	O
.	O
,	O
Ammer	O
,	O
D	O
.	O
,	O
and	O
Olafson	O
,	O
R	O
.	O

W	O
Crab	O
metallothionein	O

primary	O
structures	O
of	O
metallothioneins	O
1	O
and	O
2	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

257	O
:	O
2420	O
-	O
2426	O
(	O
1982	O
)	O
.	O

6	O
.	O

Otvos	O
,	O
J	O
.	O

D	O
.	O
,	O
Olafson	O
,	O
R	O
.	O
W	O
,	O
and	O
Armitage	O
,	O
I	O
.	O

M	O
.	O

Structure	O
of	O
an	O

invertebrate	O
metallothionein	O
from	O
Scylla	B-Species
serrata	E-Species
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

257	O
:	O
2427	O
-	O
2431	O
(	O
1982	O
)	O
.	O

7	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
,	O
Abel	O
,	O
K	O
.	O
,	O
and	O
Sim	O
,	O
R	O
.	O

G	O
.	O

Prokaryotic	O
metallothi	O

onein	O
:	O
preliminary	O
characteristics	O
of	O
a	O
blue	O
-	O
green	O
alga	O
heavy	O
metalbinding	O
protein	O
.	O

Biochem	O
.	O

Biophys	O
.	O

Res	O
.	O

Commun	O
.	O

89	O
:	O
36	O
-	O
40	O
(	O
1979	O
)	O
.	O

8	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
,	O
Loya	O
,	O
S	O
.	O
,	O
and	O
Sim	O
,	O
R	O
.	O

G	O
.	O

Physiological	O
parameters	O

of	O
prokaryotic	O
metallothionein	O
induction	O
.	O

Biochem	O
.	O

Biophys	O
.	O

Res	O
.	O

Commun	O
.	O

95	O
:	O
1495	O
-	O
1503	O
(	O
1980	O
)	O
.	O

9	O
.	O

Brdicka	O
,	O
R	O
.	O

Pblarographic	O
studies	O
with	O
the	O
dropping	O
mercury	O
ka	O

thode	O
.	O
-	O
Part	O
XXXI	O
.	O
-	O
A	O
new	O
test	O
for	O
proteins	O
in	O
the	O
presence	O
of	O
cobalt	O
salts	O
in	O
ammoniacal	O
solutions	O
of	O
ammonium	O
chloride	O
.	O

Collect	O
.	O

Czech	O
.	O

Chem	O
.	O

Commun	O
.	O

5	O
:	O
112	O
-	O
128	O
(	O
1933	O
)	O
.	O

10	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
,	O
and	O
Sim	O
,	O
R	O
.	O

G	O
.	O

An	O
electrochemical	O
approach	O
to	O

quantitation	O
and	O
characterization	O
of	O
metallothionein	O
.	O

Anal	O
.	O

Biochem	O
.	O

100	O
:	O
343	O
-	O
351	O
(	O
1979	O
)	O
.	O

11	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
Differential	O
pulse	O
polarographic	O
determination	O
of	O

murine	S-Species
metallothionein	O
induction	O
kinetics	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

256	O
:	O
12631268	O
(	O
1981	O
)	O
.	O

12	O
.	O

Olafson	O
,	O
R	O
.	O

W	O
Prokaryotic	O
metallothionein	O
:	O
amino	O
terminal	O
se	O

quence	O
analysis	O
of	O
a	O
unique	O
metallothionein	O
.	O

Int	O
.	O

J	O
.	O

Peptide	O
Protein	O
Res	O
.	O

24	O
:	O
303	O
-	O
308	O
(	O
1984	O
)	O
.	O

Peculiarities	O
of	O
carcinogenesis	O
under	O
simultaneous	O
oral	O
administration	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
o	O
-	O
cresol	O
in	O
mice	S-Species
.	O

Abstract	O

A	O
modifying	O
influence	O
of	O
ortho	O
-	O
cresol	O
(	O
o	O
-	O
cresol	O
)	O
on	O
the	O
carcinogenic	O
effect	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
with	O
combined	O
oral	O
administration	O
to	O
CC57Br	O
mice	S-Species
had	O
been	O
found	O
.	O

During	O
simultaneous	O
administration	O
of	O
o	O
-	O
cresol	O
(	O
1	O
mg	O
)	O
and	O
BaP	O
(	O
1	O
mg	O
)	O
,	O
the	O
incidence	O
of	O
tumors	O
,	O
the	O
multiplicity	O
of	O
tumors	O
,	O
and	O
the	O
degree	O
of	O
malignancy	O
all	O
increased	O
,	O
but	O
the	O
latency	O
was	O
shortened	O
.	O

When	O
o	O
-	O
cresol	O
was	O
administered	O
before	O
or	O
after	O
BaP	O
(	O
in	O
identical	O
doses	O
)	O
,	O
the	O
carcinogenic	O
effect	O
was	O
weakened	O
.	O

When	O
o	O
-	O
cresol	O
(	O
10	O
mg	O
)	O
and	O
BaP	O
(	O
5	O
mg	O
)	O
were	O
administered	O
simultaneously	O
,	O
the	O
incidence	O
of	O
malignant	O
tumors	O
was	O
similar	O
to	O
controls	O
receiving	O
BaP	O
only	O
(	O
13	O
.	O
8	O
%	O
)	O
,	O
indicating	O
inhibition	O
of	O
carcinogenesis	O
.	O

Environnmental	O
Health	O
Perspectives	O
Supplements	O
Vol	O
.	O

101	O
(	O
Suppl	O
.	O
3	O
)	O
:	O
341	O
-	O
344	O
(	O
1993	O
)	O

Peculiarities	O
of	O
Carcinogenesis	O
under	O
Simultaneous	O
Oral	O
Administration	O
of	O

Benzo	O
(	O
a	O
)	O
Pyrene	O
and	O
o	O
-	O
Cresol	O
in	O
Mice	S-Species

by	O
N	O
.	O

Ya	O
.	O

Yanysheva	O
,	O
'	O
N	O
.	O

V	O
.	O

Balenko	O
,	O
1	O
.	O

A	O
.	O

Chernichenko	O
,	O
1	O
and	O
V	O
.	O

F	O
.	O

Babiy	O
'	O

A	O
modifying	O
influence	O
of	O
ortho	O
-	O
cresol	O
(	O
o	O
-	O
cresol	O
)	O
on	O
the	O
carcinogenic	O
effect	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
with	O
combined	O
oral	O
administration	O
to	O
CC57Br	O
mice	S-Species
had	O
been	O
found	O
.	O

During	O
simultaneous	O
administration	O
of	O
o	O
-	O
cresol	O
(	O
1	O
mg	O
)	O
and	O
BaP	O
(	O
1	O
mg	O
)	O
,	O
the	O
incidence	O
of	O
tumors	O
,	O
the	O
multiplicity	O
of	O
tumors	O
,	O
and	O
the	O
degree	O
of	O
malignancy	O
all	O
increased	O
,	O
but	O
the	O
latency	O
was	O
shortened	O
.	O

When	O
o	O
-	O
cresol	O
was	O
administered	O
before	O
or	O
after	O
BaP	O
(	O
in	O
identical	O
doses	O
)	O
,	O
the	O
carcinogenic	O
effect	O
was	O
weakened	O
.	O

When	O
o	O
-	O
cresol	O
(	O
10	O
mg	O
)	O
and	O
BaP	O
(	O
5	O
mg	O
)	O
were	O
administered	O
simultaneously	O
,	O
the	O
incidence	O
of	O
malignant	O
tumors	O
was	O
similar	O
to	O
controls	O
receiving	O
BaP	O
only	O
(	O
13	O
.	O
8	O
%	O
)	O
,	O
indicating	O
inhibition	O
of	O
carcinogenesis	O
.	O

Introduction	O

Numerous	O
experiments	O
have	O
shown	O
a	O
modifying	O
influence	O
of	O
different	O
chemicals	O
on	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
induced	O
carcinogenic	O
effects	O
.	O

Both	O
enhancing	O
or	O
weakening	O
effects	O
have	O
been	O
seen	O
(	O
1	O
-	O
12	O
)	O
.	O

In	O
some	O
experiments	O
ubiquitious	O
environmental	O
carcinogenic	O
and	O
toxic	O
chemical	O
pollutants	O
were	O
used	O
(	O
13	O
-	O
17	O
)	O
.	O

The	O
stimulating	O
effect	O
of	O
phenol	O
,	O
nitrogen	O
oxides	O
,	O
and	O
sulfur	O
dioxide	O
upon	O
BaP	O
'	O
s	O
blastogenic	O
action	O
on	O
the	O
respiratory	O
tract	O
and	O
phenol	O
on	O
the	O
digestive	O
tract	O
(	O
forestomach	O
)	O
have	O
been	O
reported	O
(	O
12	O
-	O
18	O
)	O
.	O

We	O
have	O
established	O
the	O
relationship	O
between	O
the	O
doses	O
of	O
carcinogenic	O
and	O
toxic	O
agents	O
and	O
their	O
modifying	O
effects	O
(	O
17	O
,	O
18	O
)	O
.	O

The	O
maximal	O
enhancing	O
effect	O
was	O
observed	O
after	O
BaP	O
(	O
2	O
.	O
5	O
mg	O
)	O
and	O
NO2	O
(	O
0	O
.	O
87	O
mg	O
/	O
m3	O
)	O
were	O
exposed	O
to	O
rat	S-Species
respiratory	O
tract	O
.	O

The	O
effect	O
weakened	O
with	O
decreasing	O
dose	O
.	O

At	O
concentrations	O
at	O
the	O
MPC	O
level	O
(	O
MPC	O
BaP	O
,	O
1	O
ng	O
/	O
m3	O
,	O
MPC	O
NO2	O
,	O
0	O
.	O
04	O
mg	O
/	O
m3	O
)	O
no	O
effect	O
was	O
seen	O
.	O

Phenol	O
at	O
1	O
mg	O
orally	O
to	O
CC57Br	O
mice	S-Species
enhanced	O
the	O
BaP	O
(	O
1	O
mg	O
)	O
effect	O
,	O
but	O
no	O
effect	O
was	O
seen	O
at	O
0	O
.	O
02	O
mg	O
.	O

Phenolic	O
compounds	O
showed	O
either	O
enhancing	O
or	O
inhibiting	O
effects	O
on	O
carcinogenesis	O
depending	O
on	O
their	O
chemical	O
structure	O
(	O
16	O
,	O
18	O
-	O
25	O
)	O
.	O

This	O
report	O
presents	O
the	O
results	O
of	O
combined	O
oral	O
administration	O
of	O
BaP	O
and	O
artho	O
-	O
cresol	O
(	O
o	O
-	O
cresol	O
)	O
in	O
mice	S-Species
,	O

'	O
Ukrainian	O
State	O
Medical	O
Center	O
for	O
Environmental	O
Health	O
,	O
Kiev	O
,	O
Ukraine	O
.	O

Address	O
reprint	O
requests	O
to	O
N	O
.	O

Y	O
.	O

Yanysheva	O
,	O
Ukrainian	O
State	O
Medical	O
Center	O
for	O
Environmental	O
Health	O
,	O
Popudrenko	O
St	O
.	O

50	O
,	O
253660	O
Kiev	O
-	O
94	O
,	O
Ukraine	O
.	O

chemicals	O
commonly	O
found	O
in	O
ambient	O
water	O
because	O
of	O
their	O
industrial	O
use	O
(	O
coke	O
chemistry	O
,	O
oil	O
processing	O
,	O
shale	O
processing	O
,	O
and	O
other	O
industries	O
)	O
(	O
27	O
-	O
30	O
)	O
.	O

Materials	O
and	O
Methods	O

The	O
experiment	O
was	O
conducted	O
on	O
CC57Br	O
female	O
mice	S-Species
weighing	O
12	O
-	O
14	O
g	O
.	O

Animals	O
were	O
divided	O
in	O
15	O
groups	O
.	O

This	O
experiment	O
included	O
three	O
types	O
of	O
sequential	O
combinations	O
for	O
the	O
introduction	O
of	O
compounds	O
:	O
a	O
)	O
simultaneous	O
BaP	O
and	O
o	O
-	O
cresol	O
administration	O
;	O
b	O
)	O
BaP	O
after	O
o	O
-	O
cresol	O
(	O
stage	O
1	O
)	O
;	O
and	O
c	O
)	O
BaP	O
before	O
o	O
-	O
cresol	O
(	O
stage	O
2	O
)	O
.	O

Appropriate	O
controls	O
were	O
included	O
(	O
Table	O
1	O
)	O
.	O

The	O
chemicals	O
were	O
administered	O
twice	O
per	O
week	O
(	O
for	O
a	O
total	O
of	O
10	O
,	O
20	O
,	O
and	O
40	O
doses	O
)	O
using	O
a	O
syringe	O
and	O
a	O
needle	O
with	O
a	O
soldered	O
olive	O
on	O
its	O
tip	O
.	O

BaP	O
(	O
1	O
or	O
5	O
mg	O
)	O
or	O
o	O
-	O
cresol	O
(	O
0	O
.	O
02	O
,	O
1	O
,	O
or	O
10	O
mg	O
)	O
was	O
placed	O
in	O
triethylene	O
glycol	O
(	O
TEG	O
)	O
and	O
administered	O
as	O
0	O
.	O
1	O
-	O
mL	O
water	O
solutions	O
.	O

The	O
evaluation	O
of	O
o	O
-	O
cresol	O
'	O
s	O
modifying	O
effect	O
on	O
the	O
incidence	O
of	O
tumors	O
,	O
especially	O
malignant	O
tumors	O
,	O
the	O
tumor	O
latency	O
period	O
(	O
tl	O
)	O
,	O
and	O
the	O
average	O
time	O
(	O
ta	O
)	O
of	O
the	O
appearance	O
of	O
tumors	O
,	O
as	O
well	O
as	O
the	O
multiplicity	O
index	O
,	O
M	O
(	O
the	O
average	O
number	O
of	O
tumors	O
per	O
animal	O
for	O
tumor	O
-	O
bearing	O
animals	O
)	O
was	O
recorded	O
.	O

Because	O
the	O
M	O
could	O
be	O
identified	O
at	O
the	O
initial	O
stage	O
of	O
carcinogenesis	O
by	O
the	O
third	O
month	O
after	O
the	O
beginning	O
of	O
the	O
trial	O
when	O
neoplasms	O
began	O
to	O
emerge	O
,	O
moribund	O
animals	O
were	O
killed	O
by	O
ether	O
inhalation	O
if	O
they	O
did	O
not	O
die	O
spontaneously	O
.	O

The	O
experiments	O
with	O
large	O
chemical	O
doses	O
(	O
BaP	O
,	O
5	O
mg	O
;	O
o	O
-	O
cresol	O
,	O
10	O
mg	O
)	O
lasted	O
for	O
30	O
weeks	O
.	O

Some	O
animals	O
were	O
killed	O
after	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
,	O
and	O
10th	O
procedures	O
for	O
the	O

YANYSHEVA	O
ET	O
AL	O
.	O

evaluation	O
of	O
initial	O
stages	O
of	O
carcinogenesis	O
;	O
others	O
were	O
killed	O
at	O
26	O
and	O
30	O
weeks	O
.	O

The	O
stomachs	O
were	O
distended	O
with	O
formalin	O
solution	O
and	O
the	O
mucosa	O
examined	O
macroscopically	O
.	O

All	O
tumors	O
>	O
1	O
mm	O
in	O
diameter	O
were	O
recorded	O
.	O

Organs	O
and	O
tissues	O
were	O
fised	O
in	O
10	O
%	O
neutral	O
formalin	O
solution	O
,	O
embedded	O
in	O
paraffin	O
and	O
routine	O
histological	O
slides	O
prepared	O
.	O

Microscopic	O
data	O
were	O
processed	O
according	O
to	O
Mostkovoy	O
(	O
30	O
)	O
.	O

Results	O

The	O
data	O
from	O
this	O
study	O
demonstrate	O
the	O
modifying	O
influence	O
of	O
o	O
-	O
cresol	O
on	O
BaP	O
-	O
induced	O
carcinogenesis	O
with	O
combined	O
oral	O
exposure	O
.	O

The	O
combined	O
exposure	O
and	O
BaP	O
alone	O
caused	O
benign	O
and	O
malignant	O
epithelial	O
tumors	O
of	O
the	O
forestomach	O
.	O

The	O
benign	O
neoplasms	O
were	O
papillomas	O
,	O
and	O
the	O
malignant	O
neoplasms	O
were	O
invasive	O
carcinomas	O
.	O

The	O
combined	O
administration	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
showed	O
different	O
results	O
depending	O
on	O
doses	O
and	O
sequential	O
combinations	O
of	O
both	O
chemicals	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
the	O
simultaneous	O
administration	O
of	O
BaP	O
(	O
1	O
mg	O
)	O
and	O
o	O
-	O
cresol	O
(	O
1	O
mg	O
)	O
affected	O
all	O
parameters	O
of	O
carcinogenesis	O
that	O
were	O
measured	O
.	O

This	O
included	O
a	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
tumors	O
,	O
shortening	O
of	O
the	O
time	O
to	O
the	O
appearance	O
of	O
the	O
first	O
tumor	O
,	O
and	O
the	O
mean	O
time	O
of	O
tumor	O

development	O
as	O
compared	O
to	O
animals	O
that	O
received	O
1	O
mg	O
of	O
BaP	O
alone	O
and	O
had	O
tumors	O
.	O

One	O
hundred	O
percent	O
of	O
the	O
mice	S-Species
that	O
received	O
5	O
mg	O
of	O
BaP	O
alone	O
had	O
tumors	O
.	O

Shortening	O
of	O
the	O
time	O
to	O
appearance	O
of	O
malignant	O
tumors	O
was	O
also	O
observed	O
:	O
the	O
mice	S-Species
with	O
forestomach	O
cancer	O
died	O
between	O
23	O
and	O
26	O
.	O
2	O
weeks	O
after	O
the	O
beginning	O
of	O
experiment	O
,	O
but	O
the	O
controls	O
survived	O
to	O
58	O
.	O
5	O
weeks	O
.	O

Muliple	O
small	O
metastases	O
in	O
the	O
lungs	O
and	O
mediastinum	O
were	O
found	O
in	O
42	O
.	O
8	O
%	O
of	O
mice	S-Species
,	O
which	O
signifies	O
a	O
high	O
degree	O
of	O
malignancy	O
.	O

o	O
-	O
Cresol	O
at	O
0	O
.	O
02	O
mg	O
did	O
not	O
modify	O
carcinogenesis	O
in	O
comparison	O
to	O
the	O
control	O
.	O

o	O
-	O
Cresol	O
administration	O
before	O
or	O
after	O
BaP	O
did	O
not	O
modify	O
tumor	O
incidence	O
or	O
the	O
multiplicity	O
index	O
as	O
compared	O
to	O
control	O
,	O
but	O
the	O
latency	O
period	O
was	O
longer	O
(	O
Table	O
2	O
)	O
.	O

When	O
o	O
-	O
cresol	O
was	O
administered	O
after	O
BaP	O
(	O
stage	O
2	O
)	O
,	O
there	O
was	O
an	O
absence	O
of	O
malignant	O
tumors	O
.	O

Besides	O
the	O
quantitative	O
aspects	O
,	O
other	O
peculiarities	O
of	O
carcinogenesis	O
in	O
mice	S-Species
simultaneously	O
administered	O
BaP	O
and	O
o	O
-	O
cresol	O
should	O
be	O
noted	O
.	O

The	O
combined	O
chemical	O
administration	O
resulted	O
in	O
diffuse	O
verrucosa	O
vegetations	O
over	O
the	O
forestomach	O
surface	O
,	O
especially	O
near	O
the	O
greater	O
curvature	O
.	O

Highly	O
aggressive	O
malignant	O
neoplasms	O
developed	O
earlier	O
with	O
more	O
metastases	O
as	O
compared	O
to	O
control	O
.	O

Many	O
mice	S-Species
were	O
emaciated	O
,	O
and	O
the	O
tumors	O
could	O
be	O

Table	O
1	O
.	O

Scheme	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
combined	O
action	O
under	O
different	O
regimes	O
of	O
oral	O
administration	O
.	O

Theatmenta	O

No	O
.	O
of	O
mice	S-Species
Stage	O
1	O
Stage	O
2	O

Groups	O
of	O
in	O
each	O
No	O
.	O
of	O
No	O
.	O
of	O

animals	O
group	O
Substances	O
Dose	O
,	O
mg	O
applications	O
Substances	O
Dose	O
,	O
mg	O
applications	O

1	O
55	O
BaP	O
,	O
o	O
-	O
cresol	O
5	O
+	O
10	O
10	O
-	O
-	O
2	O
45	O
BaP	O
5	O
10	O
-	O
-	O
3	O
40	O
TEG	O
la	O
10	O
-	O
-	O
4	O
45	O
TEG	O
,	O
o	O
-	O
cresol	O
1b	O
+	O
10	O
10	O
-	O
-	O
5	O
30	O
BaP	O
,	O
o	O
-	O
cresol	O
1	O
+	O
1	O
20	O
-	O
-	O
6	O
30	O
BaP	O
,	O
o	O
-	O
cresol	O
1	O
+	O
0	O
.	O
02	O
20	O
-	O
-	O
7	O
30	O
o	O
-	O
Cresol	O
1	O
20	O
BaP	O
1	O
20	O
8	O
30	O
BaP	O
1	O
20	O
o	O
-	O
Cresol	O
1	O
20	O
9	O
30	O
BaP	O
1	O
20	O
-	O
10	O
30	O
-	O
-	O
-	O
BaP	O
1	O
20	O
11	O
30	O
o	O
-	O
Cresol	O
1	O
20	O
-	O
12	O
30	O
-	O
-	O
-	O
o	O
-	O
Cresol	O
1	O
20	O
13	O
30	O
o	O
-	O
Cresol	O
+	O
TEG	O
1	O
+	O
2	O
'	O
20	O
-	O
14	O
30	O
o	O
-	O
Cresol	O
+	O
TEG	O
0	O
.	O
02	O
+	O
2b	O
20	O

15	O
30	O
TEG	O
2b	O
20	O
-	O
-	O
Abbreviations	O
:	O
BaP	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
;	O
TEG	O
,	O
triethylene	O
glycol	O
.	O

Table	O
2	O
.	O

Occurrence	O
of	O
forestomach	O
tumors	O
in	O
CC57Br	O
mice	S-Species
after	O
combined	O
oral	O
administration	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
.	O

Number	O
of	O
animals	O
with	O
forestomach	O
tumors	O

Order	O
of	O
administration	O
of	O
substances	O
Total	O
Benign	O
Malignant	O

(	O
dose	O
,	O
mg	O
)	O
Absolute	O
%	O
%	O
M	O
t	O
,	O
ta	O
%	O
t	O
,	O
ta	O
BaP	O
(	O
5	O
)	O
,	O
o	O
-	O
cresol	O
(	O
10	O
)	O
29	O
100	O
.	O
0	O
86	O
.	O
2	O
ND	O
ND	O
ND	O
13	O
.	O
8	O
ND	O
ND	O
BaP	O
(	O
1	O
)	O
,	O
o	O
-	O
cresol	O
(	O
1	O
)	O
19	O
95	O
.	O
0	O
60	O
.	O
0	O
9	O
.	O
6	O
10	O
.	O
7	O
16	O
.	O
3	O
35	O
.	O
0	O
23	O
.	O
0	O
25	O
.	O
2	O
BaP	O
(	O
1	O
)	O
,	O
o	O
-	O
cresol	O
(	O
0	O
.	O
02	O
)	O
7	O
35	O
.	O
0	O
30	O
.	O
0	O
1	O
.	O
6	O
13	O
.	O
5	O
19	O
.	O
8	O
5	O
.	O
0	O
56	O
.	O
8	O
56	O
.	O
8	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
1	O
,	O
o	O
-	O
cresol	O
(	O
1	O
)	O
,	O
stage	O
2	O
7	O
31	O
.	O
8	O
31	O
.	O
8	O
1	O
.	O
4	O
16	O
.	O
2	O
31	O
.	O
1	O
0	O
0	O
0	O

BaP	O
(	O
1	O
)	O
,	O
stage	O
2	O
6	O
35	O
.	O
3	O
29	O
.	O
4	O
2	O
.	O
8	O
15	O
.	O
8	O
41	O
.	O
2	O
5	O
.	O
9	O
24	O
.	O
8	O
24	O
.	O
8	O
BaP	O
(	O
5	O
)	O
,	O
stage	O
1	O
18	O
100	O
.	O
0	O
50	O
.	O
0	O
ND	O
ND	O
ND	O
50	O
.	O
0	O
ND	O
ND	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
1	O
8	O
33	O
.	O
3	O
28	O
.	O
7	O
1	O
.	O
4	O
14	O
.	O
0	O
21	O
.	O
3	O
4	O
.	O
6	O
58	O
.	O
5	O
58	O
.	O
5	O
BaP	O
(	O
1	O
)	O
,	O
stage	O
2	O
7	O
36	O
.	O
8	O
31	O
.	O
6	O
2	O
.	O
8	O
10	O
.	O
0	O
13	O
.	O
3	O
5	O
.	O
2	O
55	O
.	O
7	O
55	O
.	O
7	O

Abbreviations	O
:	O
BaP	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
;	O
0	O
,	O
not	O
observed	O
;	O
ND	O
,	O
not	O
determined	O
;	O
t1	O
,	O
time	O
of	O
the	O
first	O
tumor	O
appearance	O
in	O
weeks	O
;	O
ta	O
,	O
mean	O
time	O
of	O
tumor	O
development	O
in	O
weeks	O
;	O
M	O
,	O
multiplicity	O
.	O

342	O

CARCINOGENESIS	O
OF	O
BaP	O
AND	O
o	O
-	O
CRESOL	O
343	O

palpated	O
through	O
the	O
abdominal	O
wall	O
.	O

At	O
autopsy	O
,	O
enlargement	O
of	O
the	O
stomach	O
with	O
tuberculous	O
white	O
superficial	O
vegetations	O
were	O
observed	O
.	O

The	O
forestomach	O
and	O
glandular	O
part	O
of	O
the	O
stomach	O
was	O
often	O
obliterated	O
by	O
tumor	O
masses	O
.	O

The	O
stomach	O
was	O
often	O
adhered	O
to	O
the	O
pancreas	O
,	O
liver	O
,	O
and	O
mesentery	O
.	O

Hemmorrhage	O
and	O
inflammation	O
were	O
found	O
in	O
tumors	O
foci	O
.	O

When	O
o	O
-	O
cresol	O
was	O
introduced	O
before	O
BaP	O
,	O
the	O
tumors	O
were	O
more	O
frequently	O
found	O
closer	O
to	O
the	O
small	O
curvature	O
of	O
the	O
stomach	O
between	O
the	O
forestomach	O
and	O
esophageal	O
entrance	O
.	O

Over	O
the	O
large	O
curvature	O
less	O
prominent	O
mucosal	O
folds	O
were	O
observed	O
.	O

Microscopically	O
,	O
a	O
decrease	O
in	O
mucosa	O
papillae	O
,	O
epithelial	O
atrophy	O
(	O
one	O
to	O
two	O
cullular	O
layers	O
)	O
,	O
decreased	O
keratonization	O
,	O
and	O
nuclear	O
pycnosis	O
were	O
observed	O
.	O

With	O
the	O
simultaneous	O
administration	O
of	O
large	O
doses	O
of	O
o	O
-	O
cresol	O
and	O
BaP	O
,	O
the	O
final	O
carcinogenic	O
effect	O
(	O
30	O
weeks	O
after	O
the	O
first	O
dose	O
)	O
was	O
similar	O
to	O
BaP	O
alone	O
but	O
differences	O
were	O
observed	O
at	O
the	O
earlier	O
stages	O
(	O
after	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
,	O
and	O
10th	O
exposures	O
)	O
.	O

In	O
the	O
BaP	O
control	O
,	O
multiple	O
forestomach	O
epithelial	O
proliferative	O
and	O
hyperplastic	O
changes	O
were	O
found	O
after	O
the	O
third	O
dose	O
.	O

Multiple	O
papillomas	O
occurred	O
(	O
9	O
-	O
15	O
in	O
each	O
mouse	S-Species
)	O
.	O

The	O
stomach	O
'	O
s	O
mucosal	O
folds	O
appeared	O
thickened	O
diffusely	O
,	O
then	O
papillomas	O
appeared	O
and	O
finally	O
merged	O
together	O
.	O

Approximately	O
half	O
of	O
the	O
tumors	O
were	O
malignant	O
.	O

The	O
neoplasms	O
filled	O
almost	O
the	O
whole	O
forestomach	O
cavity	O
and	O
infiltrated	O
the	O
wall	O
with	O
tuberculous	O
vegetations	O
,	O
which	O
were	O
visible	O
on	O
the	O
serosal	O
surface	O
.	O

Thmor	O
infiltration	O
in	O
the	O
liver	O
,	O
pancreas	O
,	O
and	O
wide	O
dissemination	O
of	O
peritoneum	O
were	O
also	O
observed	O
.	O

In	O
mice	S-Species
simultaneously	O
administered	O
BaP	O
and	O
o	O
-	O
cresol	O
,	O
the	O
proliferative	O
alterations	O
of	O
forestomach	O
epithelium	O
were	O
seen	O
after	O
the	O
third	O
dose	O
.	O

However	O
,	O
they	O
occurred	O
as	O
the	O
single	O
foci	O
at	O
damaged	O
mucosa	O
and	O
even	O
in	O
the	O
later	O
stages	O
were	O
not	O
diffuse	O
.	O

Adjacent	O
to	O
the	O
hyperplastic	O
foci	O
,	O
the	O
mucosa	O
was	O
atrophied	O
with	O
decreased	O
keratonization	O
.	O

The	O
epithelial	O
cells	O
also	O
showed	O
cytoplasm	O
coagulation	O
and	O
nuclear	O
pycnosis	O
.	O

Edema	O
,	O
inflammation	O
of	O
the	O
mucosa	O
,	O
submucosa	O
microabscesses	O
,	O
and	O
erosion	O
were	O
seen	O
.	O

There	O
were	O
fewer	O
papillomas	O
per	O
mouse	S-Species
(	O
four	O
to	O
eight	O
in	O
each	O
mouse	S-Species
)	O
than	O
in	O
the	O
control	O
group	O
.	O

Even	O
in	O
the	O
late	O
stages	O
the	O
papillomas	O
were	O
isolated	O
and	O
elevated	O
on	O
the	O
atrophied	O
mucosal	O
folds	O
.	O

In	O
the	O
final	O
experiment	O
the	O
papillomas	O
prevailed	O
as	O
compared	O
to	O
the	O
previous	O
experiments	O
.	O

Only	O
4	O
out	O
of	O
29	O
mice	S-Species
(	O
13	O
.	O
8	O
%	O
)	O
developed	O
malignant	O
tumors	O
.	O

Neoplasms	O
were	O
smaller	O
and	O
appeared	O
as	O
single	O
verrucosa	O
vegetations	O
5	O
-	O
10	O
mm	O
in	O
diameter	O
.	O

Thus	O
,	O
the	O
toxic	O
dose	O
of	O
o	O
-	O
cresol	O
inhibits	O
the	O
carcinogenic	O
process	O
of	O
induced	O
forestomach	O
tumors	O
by	O
decreasing	O
multiplicity	O
,	O
frequency	O
,	O
and	O
percentage	O
of	O
malignant	O
tumors	O
.	O

Discussion	O

Our	O
results	O
and	O
the	O
literature	O
suggest	O
a	O
hypothesis	O
on	O
modifying	O
carcinogenesis	O
mechanisms	O
.	O

The	O
primary	O
effect	O
of	O
the	O
toxic	O
agents	O
,	O
including	O
carcinogenic	O
agents	O
,	O
may	O
relate	O
to	O
cellular	O
membrane	O
damage	O
with	O
the	O
subsequent	O
increased	O
permeability	O
(	O
31	O
-	O
35	O
)	O
,	O
which	O
may	O
be	O
the	O
mechanism	O
of	O
the	O
o	O
-	O
cresol	O
.	O

With	O
simultaneous	O
introduction	O
of	O
o	O
-	O
cresol	O
at	O
low	O
toxic	O
doses	O
and	O
BaP	O
there	O
may	O
be	O
increased	O
carcinogen	O
penetration	O
to	O
the	O
target	O
cells	O
.	O

In	O
addition	O
,	O
membrane	O
damage	O
may	O
alter	O
other	O
cellular	O
systems	O
responsible	O
for	O
energy	O
and	O
xenobiotic	O
detoxication	O
.	O

Damage	O
of	O
these	O
processes	O
may	O
activate	O
free	O
-	O
radical	O
reactions	O
,	O
glycolysis	O
,	O
or	O
alter	O
carcinogenic	O
metabolism	O
,	O
which	O
promotes	O
the	O
oncogenic	O
effect	O
.	O

The	O
o	O
-	O
cresol	O
effect	O
on	O
these	O
systems	O
was	O
confirmed	O
by	O
our	O
previous	O
investigations	O
on	O
cytochrome	O
P450	O
,	O
ferrosulfuric	O
nonhemic	O
proteins	O
,	O
and	O
semiquinon	O
radical	O
content	O
affected	O
by	O
the	O
combined	O
action	O
of	O
BaP	O
and	O
o	O
-	O
cresol	O
(	O
36	O
)	O
.	O

Another	O
effect	O
was	O
obtained	O
with	O
BaP	O
exposure	O
after	O
o	O
-	O
cresol	O
.	O

The	O
atrophic	O
alterations	O
in	O
the	O
stomach	O
induced	O
by	O
2	O
.	O
5	O
months	O
of	O
o	O
-	O
cresol	O
administration	O
might	O
decrease	O
the	O
natural	O
conditions	O
of	O
retention	O
(	O
muscosal	O
folds	O
,	O
frontier	O
torn	O
)	O
,	O
and	O
thus	O
shorten	O
the	O
contact	O
of	O
BaP	O
with	O
the	O
forestomach	O
.	O

In	O
our	O
opinion	O
,	O
this	O
explains	O
the	O
decreased	O
carcinogenic	O
effect	O
seen	O
after	O
o	O
-	O
cresol	O
exposure	O
.	O

Considering	O
the	O
toxic	O
effect	O
of	O
o	O
-	O
cresol	O
at	O
low	O
toxic	O
doses	O
(	O
1	O
mg	O
)	O
after	O
BaP	O
and	O
the	O
effect	O
of	O
a	O
super	O
toxic	O
dose	O
(	O
10	O
mg	O
)	O
simultaneously	O
with	O
BaP	O
administration	O
,	O
it	O
is	O
possible	O
that	O
the	O
inhibition	O
of	O
carcinogenesis	O
in	O
both	O
trials	O
was	O
related	O
to	O
the	O
toxic	O
effects	O
of	O
o	O
-	O
cresol	O
.	O

Cytotoxicity	O
may	O
not	O
only	O
hamper	O
tumor	O
growth	O
,	O
but	O
also	O
promote	O
the	O
regression	O
of	O
inducible	O
and	O
spontaneous	O
neoplasms	O
(	O
37	O
-	O
39	O
)	O
.	O

There	O
is	O
also	O
a	O
possibility	O
that	O
BaP	O
damages	O
metabolic	O
systems	O
and	O
decreases	O
resistance	O
to	O
carcinogenesis	O
.	O

Conclusions	O

The	O
data	O
obtained	O
demonstrate	O
that	O
simultaneous	O
administration	O
of	O
BaP	O
modifies	O
the	O
induced	O
carcinogenesis	O
depending	O
on	O
the	O
dose	O
and	O
the	O
sequence	O
of	O
administration	O
.	O

Administered	O
with	O
BaP	O
(	O
1	O
mg	O
)	O
,	O
a	O
low	O
toxic	O
o	O
-	O
cresol	O
dose	O
(	O
about	O
minimally	O
effective	O
)	O
produces	O
an	O
enhanced	O
cocarcinogenic	O
effect	O
reflected	O
in	O
the	O
incidence	O
,	O
frequency	O
,	O
multiplicity	O
,	O
and	O
degree	O
of	O
malignancy	O
of	O
forestomach	O
tumors	O
.	O

o	O
-	O
Cresol	O
administration	O
at	O
low	O
toxic	O
doses	O
before	O
or	O
after	O
BaP	O
at	O
the	O
same	O
dose	O
level	O
(	O
1	O
mg	O
)	O
and	O
its	O
administration	O
at	O
super	O
toxic	O
doses	O
(	O
10	O
mg	O
)	O
with	O
the	O
BaP	O
optimal	O
dose	O
(	O
5	O
mg	O
)	O
may	O
inhibit	O
carcinogenesis	O
.	O

Simultaneous	O
introduction	O
of	O
a	O
noneffective	O
o	O
-	O
cresol	O
dose	O
(	O
0	O
.	O
02	O
mg	O
)	O
with	O
the	O
BaP	O
(	O
1	O
mg	O
)	O
does	O
not	O
change	O
its	O
carcinogenic	O
activity	O
.	O

Controlling	O
both	O
chemicals	O
in	O
the	O
environment	O
is	O
the	O
most	O
effective	O
measure	O
of	O
preventing	O
potential	O
risk	O
and	O
is	O
undoubtedly	O
of	O
paramount	O
significance	O
.	O

REFERENCES	O

1	O
.	O

Bingham	O
,	O
E	O
.	O
,	O
and	O
Falk	O
,	O
H	O
.	O

L	O
.	O

Environmental	O
carcinogenesis	O
.	O

The	O

modifying	O
effect	O
of	O
cocarcinogens	O
on	O
the	O
threshold	O
response	O
.	O

Arch	O
.	O

Environ	O
.	O

Health	O
19	O
:	O
779	O
-	O
783	O
(	O
1969	O
)	O
.	O

2	O
.	O

Goldschmidt	O
,	O
B	O
.	O

M	O
.	O
,	O
Katz	O
,	O
C	O
.	O
,	O
and	O
Van	O
Duuren	O
,	O
B	O
.	O

L	O
.	O

The	O
cocar	O

cinogenic	O
activity	O
of	O
non	O
-	O
carcinogenic	O
aromatic	O
hydrocarbons	O
.	O

Proc	O
.	O

Am	O
.	O

Assoc	O
.	O

Cancer	O
Res	O
.	O

17	O
:	O
84	O
(	O
1973	O
)	O
.	O

3	O
.	O

Kaufman	O
,	O
D	O
.	O

C	O
.	O
,	O
and	O
Madison	O
,	O
R	O
.	O

M	O
.	O

Synergistic	O
effects	O
of	O

benzo	O
(	O
a	O
)	O
pyrene	O
and	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
respirators	O
carcinogenesis	O
in	O
Syrian	B-Species
golden	I-Species
hamsters	E-Species
.	O

In	O
:	O
Proceedings	O
of	O
the	O
Sym	O

344	O
YANYSHEVA	O
ET	O
AL	O
.	O

posium	O
on	O
Epithelial	O
Respiratory	O
Carcinogenesis	O
and	O
Bioassays	O
.	O

Batelle	O
Seattle	O
Research	O
Center	O
,	O
Seattle	O
,	O
WA	O
,	O
1974	O
,	O
p	O
.	O

17	O
.	O

4	O
.	O

Montesano	O
,	O
R	O
.	O
,	O
Saffiotti	O
,	O
U	O
,	O
Ferrero	O
,	O
A	O
,	O
and	O
Kaufman	O
,	O
D	O
.	O

Synergistic	O

effects	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
diethylnitrosamine	O
on	O
respiratory	O
carcinogenesis	O
in	O
hamsters	O
.	O

J	O
.	O

Natl	O
.	O

Cancer	O
.	O

Inst	O
.	O

5	O
:	O
1395	O
-	O
1397	O
(	O
1974	O
)	O
.	O

5	O
.	O

Pfeiffer	O
,	O
E	O
.	O

H	O
.	O

Investigations	O
of	O
the	O
carcinogenic	O
burden	O
by	O
air	O

pollution	O
in	O
man	S-Species
.	O

VII	O
.	O

Studies	O
on	O
the	O
ontogenetic	O
interaction	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
.	O

Zbl	O
.	O

Bakteriol	O
.	O

Parasitenk	O
.	O

Infektion	O
.	O

Hyg	O
.	O

Abt	O
.	O

B	O
158	O
(	O
1	O
)	O
:	O
69	O
-	O
83	O
(	O
1973	O
)	O
.	O

6	O
.	O

Slaga	O
,	O
T	O
.	O

J	O
.	O
,	O
Jecker	O
,	O
L	O
.	O
,	O
Bracken	O
,	O
W	O
.	O

M	O
.	O
,	O
and	O
Weeks	O
,	O
C	O
.	O

E	O
.	O

The	O
effects	O
of	O

weak	O
or	O
non	O
-	O
carcinogenic	O
polycyclic	O
hydrocarbons	O
on	O
7	O
,	O
12	O
-	O
dimethylbenz	O
(	O
a	O
)	O
anthracene	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
skin	O
tumor	O
-	O
initiation	O
.	O

Cancer	O
Lett	O
.	O

7	O
:	O
51	O
-	O
59	O
(	O
1979	O
)	O
.	O

7	O
.	O

Topping	O
,	O
D	O
.	O

C	O
.	O
,	O
Martin	O
,	O
D	O
.	O

H	O
.	O
,	O
and	O
Nettesheim	O
,	O
P	O
.	O

Determination	O
of	O

cocarcinogenic	O
activity	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
for	O
respiratory	O
tract	O
mucosa	O
.	O

Cancer	O
Lett	O
.	O

11	O
:	O
315	O
-	O
321	O
(	O
1981	O
)	O
.	O

8	O
.	O

Ilnitsky	O
,	O
A	O
.	O

P	O
.	O
,	O
Voronin	O
,	O
V	O
.	O

M	O
.	O
,	O
and	O
Solenova	O
,	O
M	O
.	O

G	O
.	O

Carcinogenic	O
effect	O

of	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
its	O
combinations	O
with	O
other	O
carbohydrates	O
at	O
their	O
oral	O
intake	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

10	O
:	O
71	O
-	O
75	O
(	O
1974	O
)	O
.	O

9	O
.	O

Kurljandsky	O
,	O
B	O
.	O

A	O
.	O
,	O
Medvedovsky	O
,	O
A	O
.	O

G	O
.	O
,	O
and	O
Mashbits	O
,	O
F	O
.	O

D	O
.	O

On	O

cocarcinogenic	O
effect	O
of	O
toxic	O
factors	O
of	O
low	O
intensity	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

10	O
:	O
83	O
-	O
85	O
(	O
1972	O
)	O
.	O

10	O
.	O

Thrusov	O
,	O
V	O
.	O

S	O
.	O
,	O
and	O
Andrianov	O
,	O
L	O
.	O

A	O
.	O

On	O
combined	O
effect	O
on	O
the	O
skin	O
of	O

single	O
application	O
of	O
7	O
,	O
12	O
-	O
dimethylbenz	O
(	O
a	O
)	O
anthracene	O
and	O
repeated	O
applications	O
of	O
benz	O
(	O
a	O
)	O
pyrene	O
[	O
in	O
Russian	O
]	O
.	O

Bull	O
.	O

Eksper	O
.	O

Biol	O
.	O

Med	O
.	O

3	O
:	O
80	O
-	O
83	O
(	O
1972	O
)	O
.	O

11	O
.	O

Yanysheva	O
,	O
N	O
.	O

Ya	O
.	O
,	O
Chernichenko	O
,	O
I	O
.	O

A	O
.	O
,	O
Balenko	O
,	O
N	O
.	O

V	O
,	O
and	O
Kireeva	O
,	O

I	O
.	O

S	O
.	O

Carcinogenic	O
substances	O
and	O
their	O
hygienic	O
standardization	O
in	O
the	O
environment	O
[	O
in	O
Russian	O
]	O
.	O

Zdorovja	O
,	O
Kiev	O
,	O
1977	O
.	O

12	O
.	O

Laskin	O
,	O
S	O
.	O
,	O
Kushner	O
,	O
M	O
.	O
,	O
and	O
Drew	O
,	O
R	O
.	O

T	O
.	O

Studies	O
in	O
pulmonary	O

careinogenesis	O
.	O

In	O
:	O
Inhalation	O
Carcinogenesis	O
(	O
M	O
.	O
G	O
.	O
Hanna	O
,	O
P	O
.	O
Nettesheim	O
,	O
and	O
J	O
.	O
R	O
.	O
Gillbert	O
,	O
Eds	O
.	O
)	O
U	O
.	O
S	O
.	O

Atomic	O
Energy	O
Commission	O
Symposium	O
,	O
Series	O
18	O
,	O
1970	O
,	O
p	O
.	O

321	O
.	O

13	O
.	O

Laskin	O
,	O
S	O
.	O
,	O
Kuschner	O
,	O
M	O
.	O
,	O
and	O
Drew	O
,	O
R	O
.	O

T	O
.	O

Inhalation	O
exposure	O
to	O

sulphur	O
dioxide	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
.	O

Oak	O
Ridge	O
National	O
Laboratory	O
,	O
Gatlinburg	O
,	O
TN	O
,	O
1970	O
,	O
pp	O
.	O

322	O
-	O
351	O
.	O

14	O
.	O

Kuschner	O
,	O
M	O
.	O
,	O
and	O
Laskin	O
,	O
S	O
.	O

Experimental	O
models	O
in	O
environmental	O

carcinogenesis	O
.	O

Am	O
.	O

J	O
.	O

Pathol	O
.	O

1	O
:	O
183	O
-	O
196	O
(	O
1971	O
)	O
.	O

15	O
.	O

Komine	O
,	O
T	O
.	O

Influences	O
of	O
sulfur	O
dioxide	O
and	O
3	O
,	O
4	O
-	O
benzpyrene	O
on	O
the	O

respiratory	O
organ	O
of	O
rats	S-Species
.	O

Hokkaido	O
Igaku	O
Zasshi	O
3	O
:	O
189	O
-	O
203	O
(	O
1977	O
)	O
.	O

16	O
.	O

Skvortsova	O
,	O
N	O
.	O

N	O
.	O

Role	O
of	O
some	O
common	O
atmospheric	O
pollutions	O
in	O

lung	O
blastomogenesis	O
[	O
in	O
Russian	O
]	O
.	O

In	O
:	O
Handbook	O
of	O
Hygiene	O
of	O
Atmospheric	O
Air	O
(	O
K	O
.	O
A	O
.	O
Bushtueva	O
,	O
Ed	O
.	O
)	O
,	O
Meditsina	O
,	O
Moscow	O
,	O
1976	O
,	O
pp	O
.	O

384	O
-	O
391	O
.	O

17	O
.	O

Yanysheva	O
,	O
N	O
.	O

Ya	O
.	O
,	O
Balenko	O
,	O
N	O
.	O

V	O
,	O
Chernichenko	O
,	O
I	O
.	O

A	O
,	O
and	O
Babiy	O
,	O
V	O
.	O

F	O
.	O

Quantitation	O
of	O
modified	O
effects	O
of	O
nitrogen	O
oxides	O
on	O
carcinogenicity	O
of	O
benz	O
(	O
a	O
)	O
pyrene	O
effect	O
[	O
in	O
Rusian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

7	O
:	O
7	O
-	O
9	O
(	O
1986	O
)	O
.	O

18	O
.	O

Yanysheva	O
,	O
N	O
.	O

Ya	O
.	O
,	O
Balenko	O
,	O
N	O
.	O

V	O
.	O
,	O
Chernichenko	O
,	O
I	O
.	O

A	O
.	O
,	O
Babiy	O
,	O
V	O
.	O

F	O
.	O
,	O

Bakanova	O
,	O
G	O
.	O

N	O
.	O
,	O
and	O
Lemeshko	O
,	O
L	O
.	O

P	O
.	O

Peculiarities	O
of	O
manifestation	O
of	O
carcinogenesis	O
at	O
combined	O
effect	O
of	O
benz	O
(	O
a	O
)	O
pyrene	O
and	O
phenol	O
depending	O
on	O
regimen	O
of	O
intake	O
into	O
the	O
organism	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

4	O
:	O
29	O
-	O
33	O
(	O
1988	O
)	O
.	O

19	O
.	O

Van	O
Duuren	O
,	O
B	O
.	O

L	O
.	O
,	O
Katz	O
,	O
C	O
.	O
,	O
and	O
Goldschmidt	O
,	O
B	O
.	O

M	O
.	O

Brief	O
communica	O

tion	O
:	O
cocarcinogenic	O
agents	O
in	O
tobacco	S-Species
carcinogenesis	O
.	O

J	O
.	O

Natl	O
.	O

Cancer	O
Inst	O
.	O

51	O
:	O
703	O
-	O
705	O
(	O
1973	O
)	O
.	O

20	O
.	O

Van	O
Duuren	O
,	O
B	O
.	O

L	O
.	O
,	O
and	O
Goldschmidt	O
,	O
B	O
.	O

M	O
.	O

Cocarcinogenic	O
and	O

tumor	O
-	O
promoting	O
agents	O
in	O
tobacco	S-Species
carcinogenesis	O
.	O

J	O
.	O

Natl	O
.	O

Cancer	O
Inst	O
.	O

56	O
:	O
1237	O
-	O
1242	O
(	O
1976	O
)	O
.	O

21	O
.	O

Wattenberg	O
,	O
L	O
.	O

W	O
.	O
,	O
Coccia	O
,	O
J	O
.	O

B	O
.	O
,	O
and	O
Lam	O
,	O
L	O
.	O

K	O
.	O

Inhibitory	O
effects	O
of	O

phenolic	O
compounds	O
on	O
benzo	O
(	O
a	O
)	O
pyrene	O
-	O
induced	O
neoplasia	O
.	O

Cancer	O
Res	O
.	O

8	O
:	O
2820	O
-	O
2823	O
(	O
1980	O
)	O
.	O

22	O
.	O

Bogovski	O
,	O
P	O
.	O

A	O
,	O
and	O
Mirme	O
,	O
H	O
.	O

Yu	O
.	O

Cocarcinogenicity	O
of	O
phenols	O
from	O

Estonian	O
shale	O
tars	O
(	O
oils	O
)	O
.	O

Environ	O
.	O

Health	O
Perspect	O
.	O

30	O
:	O
177	O
-	O
178	O
(	O
1979	O
)	O
.	O

23	O
.	O

Gubergritz	O
,	O
M	O
.	O

Ya	O
.	O
,	O
and	O
Kirso	O
,	O
U	O
.	O

E	O
.	O

Carcinogenic	O
properties	O
,	O
struc	O

ture	O
and	O
reactive	O
capacity	O
of	O
phenols	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

8	O
:	O
96	O
-	O
100	O
(	O
1970	O
)	O
.	O

24	O
.	O

Mirme	O
,	O
H	O
.	O

Yu	O
.	O

Modifying	O
effect	O
of	O
water	O
-	O
soluble	O
shale	O
phenols	O
upon	O

carcinogenesis	O
[	O
in	O
Russian	O
]	O
.	O

In	O
:	O
Problems	O
of	O
Prevention	O
of	O
Pollution	O
of	O
Environment	O
by	O
Carcinogenic	O
Substances	O
(	O
M	O
.	O
M	O
.	O
Shabad	O
,	O
Ed	O
.	O
)	O
,	O
Tallinn	O
,	O
Valgus	O
,	O
1972	O
,	O
pp	O
.	O

16	O
-	O
18	O
.	O

25	O
.	O

Kirso	O
,	O
U	O
.	O

E	O
.	O
,	O
Pashin	O
,	O
Yu	O
.	O

V	O
.	O
,	O
Bakhitova	O
,	O
L	O
.	O

M	O
.	O
,	O
and	O
Kjung	O
,	O
A	O
.	O

I	O
.	O

Effect	O

of	O
antioxidants	O
on	O
carcinogenic	O
and	O
mutagenic	O
activity	O
of	O
benzo	O
(	O
a	O
)	O
pyrene	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

4	O
:	O
70	O
-	O
75	O
(	O
1985	O
)	O
.	O

26	O
.	O

Veldre	O
,	O
I	O
.	O

A	O
.	O

Comparative	O
assessment	O
of	O
toxic	O
effect	O
of	O
some	O
water	O

soluble	O
phenols	O
[	O
in	O
Russian	O
]	O
.	O

In	O
:	O
Proceedings	O
of	O
the	O
Scientific	O
Conference	O
on	O
Urgent	O
Problems	O
Related	O
with	O
Decrease	O
of	O
Infectious	O
Diseases	O
Morbidity	O
and	O
with	O
Hygienic	O
Problems	O
.	O

Tallinn	O
,	O
1968	O
,	O
pp	O
.	O

200	O
-	O
202	O
.	O

27	O
.	O

Substances	O
possessing	O
cocarcinogenic	O
effect	O
.	O

In	O
:	O
Carcinogenic	O
Sub	O

stances	O
in	O
the	O
Environment	O
of	O
Man	S-Species
(	O
L	O
.	O
M	O
.	O
Shabad	O
and	O
A	O
.	O
P	O
.	O
Ilnitsky	O
,	O
Eds	O
.	O
)	O
,	O
Budapest	O
,	O
1979	O
,	O
pp	O
.	O

111	O
-	O
113	O
.	O

28	O
.	O

Djatlovitskaya	O
,	O
F	O
.	O

G	O
.	O
,	O
and	O
Maktas	O
,	O
E	O
.	O

D	O
.	O

Separate	O
determination	O
of	O
fly	O

phenols	O
in	O
water	O
using	O
thin	O
-	O
layer	O
chromatography	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

6	O
:	O
60	O
-	O
63	O
(	O
1965	O
)	O
.	O

29	O
.	O

Kostovetsky	O
,	O
Ya	O
.	O

I	O
.	O
,	O
and	O
Zholdakova	O
,	O
Z	O
.	O

I	O
.	O

About	O
hygienic	O
rate	O
setting	O

of	O
phenol	O
in	O
the	O
water	O
of	O
waterpools	O
[	O
in	O
Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

7	O
:	O
7	O
-	O
10	O
(	O
1971	O
)	O
.	O

30	O
.	O

Mostkovoy	O
,	O
M	O
.	O

I	O
.	O

Practicum	O
on	O
variational	O
-	O
statistical	O
processing	O
of	O

clinical	O
material	O
[	O
in	O
Russian	O
]	O
.	O

Ashkhabad	O
,	O
1954	O
,	O
p	O
.	O

132	O
.	O

31	O
.	O

Weinstein	O
,	O
I	O
.	O

B	O
.	O

The	O
scientific	O
basis	O
for	O
carcinogen	O
detection	O
and	O

primary	O
cancer	O
prevention	O
.	O

Cancer	O
47	O
:	O
1133	O
-	O
1141	O
(	O
1981	O
)	O
.	O

32	O
.	O

Merkulov	O
,	O
A	O
.	O

I	O
,	O
and	O
Skvortsova	O
,	O
R	O
.	O

I	O
.	O

About	O
toxic	O
effect	O
of	O
phenol	O
[	O
in	O

Russian	O
]	O
.	O

Gig	O
.	O

Sanit	O
.	O

1	O
:	O
79	O
-	O
80	O
(	O
1984	O
)	O
.	O

33	O
.	O

Weinstein	O
,	O
I	O
.	O

B	O
.	O
,	O
Mufson	O
,	O
R	O
.	O

A	O
.	O
,	O
Lee	O
,	O
L	O
.	O

S	O
.	O
,	O
et	O
al	O
.	O

Membrane	O
and	O
other	O

biochemical	O
effects	O
of	O
the	O
phorbol	O
esters	O
and	O
their	O
relevance	O
to	O
tumor	O
promotion	O
.	O

In	O
:	O
Carcinogenesis	O
.	O

Fundamental	O
Mechanisms	O
and	O
Environmental	O
Effects	O
.	O

London	O
,	O
1980	O
,	O
pp	O
.	O

543	O
-	O
563	O
.	O

34	O
.	O

Yamasaki	O
,	O
H	O
.	O
,	O
and	O
Weinstein	O
,	O
I	O
.	O

B	O
.	O

Cellular	O
and	O
molecular	O
mecha	O

nisms	O
of	O
tumor	O
promotion	O
and	O
their	O
implications	O
for	O
risk	O
assessment	O
.	O

In	O
:	O
Methods	O
for	O
Estimating	O
Risk	O
of	O
Chemical	O
Injury	O
:	O
Human	S-Species
and	O
Non	O
-	O
human	S-Species
Biota	O
and	O
Ecosystems	O
(	O
V	O
.	O
B	O
.	O
Vouk	O
,	O
G	O
.	O
C	O
.	O
Butler	O
,	O
D	O
.	O
G	O
.	O
Hoel	O
,	O
and	O
D	O
.	O
B	O
.	O
Peakall	O
,	O
Eds	O
.	O
)	O
,	O
SCOPE	O
,	O
1985	O
,	O
pp	O
.	O

155	O
-	O
180	O
.	O

35	O
.	O

Karu	O
,	O
T	O
,	O
Kirso	O
,	O
U	O
.	O

E	O
.	O
,	O
and	O
Andrianov	O
,	O
L	O
.	O

A	O
.	O

Dynamics	O
of	O
resorption	O
of	O

3	O
,	O
4	O
-	O
benzpyrene	O
with	O
phenols	O
from	O
mouse	S-Species
skin	O
[	O
in	O
Russian	O
]	O
.	O

Voprosy	O
Onkol	O
.	O

5	O
:	O
80	O
-	O
84	O
(	O
1973	O
)	O
.	O

36	O
.	O

Yanysheva	O
,	O
N	O
.	O

Ya	O
.	O
,	O
Yurkovskaya	O
,	O
T	O
.	O

N	O
.	O
,	O
Beregovskaya	O
,	O
N	O
.	O

N	O
.	O
,	O
et	O
al	O
.	O

Metalloenzymic	O
complexes	O
of	O
energetic	O
and	O
detoxicating	O
systems	O
of	O
cell	O
during	O
benz	O
(	O
a	O
)	O
pyrene	O
-	O
induced	O
carcinogenesis	O
.	O

In	O
:	O
Proceedings	O
of	O
the	O
4th	O
National	O
Congress	O
of	O
Oncology	O
with	O
International	O
Participation	O
.	O

Sofia	O
,	O
1985	O
,	O
p	O
.	O

102	O
.	O

37	O
.	O

Mizell	O
,	O
M	O
.	O

Anuran	O
(	O
Lucke	O
)	O
tumor	O
breakdown	O
in	O
regenerating	O
anuran	O

tadpole	O
tails	O
.	O

Anat	O
.	O

Res	O
.	O

137	O
:	O
382	O
-	O
383	O
(	O
1960	O
)	O
.	O

38	O
.	O

Sheremetieva	O
,	O
E	O
.	O

N	O
.	O

Spontaneous	O
melanoma	O
in	O
regenerating	O
tails	O
of	O

axolotis	O
.	O

J	O
.	O

Exp	O
.	O

Zool	O
.	O

158	O
:	O
101	O
-	O
122	O
(	O
1965	O
)	O
.	O

39	O
.	O

Tsonis	O
,	O
P	O
.	O

A	O
,	O
and	O
Eguchi	O
,	O
G	O
.	O

Carcinogens	O
on	O
regeneration	O
.	O

Effects	O
on	O

N	O
-	O
methyl	O
-	O
N	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
and	O
4	O
-	O
nitrogninoline	O
-	O
1	O
-	O
oxide	O
on	O
limb	O
regeneration	O
in	O
adult	O
newts	O
.	O

Differentiation	O
20	O
:	O
52	O
-	O
60	O
(	O
1981	O
)	O
.	O

B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
)	O
isoforms	O
in	O
systemic	O
lupus	O
erythematosus	O
:	O
disease	O
activity	O
correlates	O
better	O
with	O
blood	O
leukocyte	O
BLyS	O
mRNA	O
levels	O
than	O
with	O
plasma	O
BLyS	O
protein	O
levels	O

Abstract	O

Considerable	O
evidence	O
points	O
to	O
a	O
role	O
for	O
B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
)	O
overproduction	O
in	O
murine	S-Species
and	O
human	S-Species
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

Nevertheless	O
,	O
the	O
correlation	O
between	O
circulating	O
levels	O
of	O
BLyS	O
protein	O
and	O
disease	O
activity	O
in	O
human	S-Species
SLE	O
is	O
modest	O
at	O
best	O
.	O

This	O
may	O
be	O
due	O
to	O
an	O
inadequacy	O
of	O
the	O
former	O
to	O
reflect	O
endogenous	O
BLyS	O
overproduction	O
faithfully	O
,	O
in	O
that	O
steady	O
-	O
state	O
protein	O
levels	O
are	O
affected	O
not	O
just	O
by	O
production	O
rates	O
but	O
also	O
by	O
rates	O
of	O
peripheral	O
utilization	O
and	O
excretion	O
.	O

Increased	O
levels	O
of	O
BLyS	O
mRNA	O
may	O
better	O
reflect	O
increased	O
in	O
vivo	O
BLyS	O
production	O
,	O
and	O
therefore	O
they	O
may	O
correlate	O
better	O
with	O
biologic	O
and	O
clinical	O
sequelae	O
of	O
BLyS	O
overexpression	O
than	O
do	O
circulating	O
levels	O
of	O
BLyS	O
protein	O
.	O

Accordingly	O
,	O
we	O
assessed	O
peripheral	O
blood	O
leukocyte	O
levels	O
of	O
BLyS	O
mRNA	O
isoforms	O
(	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
)	O
and	O
plasma	O
BLyS	O
protein	O
levels	O
in	O
patients	S-Species
with	O
SLE	O
,	O
and	O
correlated	O
these	O
levels	O
with	O
laboratory	O
and	O
clinical	O
features	O
.	O

BLyS	O
protein	O
,	O
full	O
-	O
length	O
BLyS	O
mRNA	O
,	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
were	O
greater	O
in	O
SLE	O
patients	S-Species
(	O
n	O
=	O
60	O
)	O
than	O
in	O
rheumatoid	O
arthritis	O
patients	S-Species
(	O
n	O
=	O
60	O
)	O
or	O
normal	O
control	O
individuals	O
(	O
n	O
=	O
30	O
)	O
.	O

Although	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
correlated	O
significantly	O
with	O
BLyS	O
protein	O
levels	O
in	O
the	O
SLE	O
cohort	O
,	O
BLyS	O
mRNA	O
levels	O
were	O
more	O
closely	O
associated	O
with	O
serum	O
immunoglobulin	O
levels	O
and	O
SLE	O
Disease	O
Activity	O
Index	O
scores	O
than	O
were	O
BLyS	O
protein	O
levels	O
.	O

Moreover	O
,	O
changes	O
in	O
SLE	O
Disease	O
Activity	O
Index	O
scores	O
were	O
more	O
closely	O
associated	O
with	O
changes	O
in	O
BLyS	O
mRNA	O
levels	O
than	O
with	O
changes	O
in	O
BLyS	O
protein	O
levels	O
among	O
the	O
37	O
SLE	O
patients	S-Species
from	O
whom	O
repeat	O
blood	O
samples	O
were	O
obtained	O
.	O

Thus	O
,	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
are	O
elevated	O
in	O
SLE	O
and	O
are	O
more	O
closely	O
associated	O
with	O
disease	O
activity	O
than	O
are	O
BLyS	O
protein	O
levels	O
.	O

BLyS	O
mRNA	O
levels	O
may	O
be	O
a	O
helpful	O
biomarker	O
in	O
the	O
clinical	O
monitoring	O
of	O
SLE	O
patients	S-Species
.	O

Introduction	O

B	O
lymphocyte	O
stimulator	O
(	O
BLyS	O
;	O
a	O
trademark	O
of	O
Human	S-Species
Genome	O
Sciences	O
,	O
Inc	O
.	O
,	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
is	O
a	O
285	O
-	O
amino	O
-	O
acid	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
ligand	O
superfamily	O
[	O
1	O
-	O
3	O
]	O
.	O

A	O
causal	O
relation	O
between	O
constitutive	O
overproduction	O
of	O
BLyS	O
and	O
development	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
-	O
like	O
illness	O
has	O
incontrovertibly	O
been	O
established	O
in	O
mice	S-Species
.	O

BLyS	O
-	O
transgenic	O
mice	S-Species
often	O
develop	O
SLE	O
-	O
like	O
features	O
as	O
they	O
age	O
[	O
3	O
-	O
5	O
]	O
,	O
and	O
SLE	O
-	O
prone	O
(	O
NZB	O
x	O
NZW	O
)	O
F1	O
(	O
BWF1	O
)	O
and	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	S-Species
respond	O
clinically	O
to	O
treatment	O
with	O
BLyS	O
antagonists	O
(	O
decreased	O
disease	O
progression	O
and	O
improved	O
survival	O
)	O
[	O
3	O
,	O
6	O
]	O
.	O

Considerable	O
inferential	O
evidence	O
points	O
to	O
a	O
role	O
for	O
BLyS	O
overproduction	O
in	O
human	S-Species
SLE	O
as	O
well	O
.	O

Cross	O
-	O
sectional	O
studies	O
have	O
demonstrated	O
elevated	O
circulating	O
levels	O
of	O
BLyS	O
in	O
20	O
-	O
30	O
%	O
of	O
human	S-Species
SLE	O
patients	S-Species
tested	O
at	O
a	O
single	O
point	O
in	O
time	O
[	O
7	O
,	O
8	O
]	O
.	O

Moreover	O
,	O
a	O
12	O
-	O
month	O
longitudinal	O
study	O
documented	O
persistently	O
elevated	O
serum	O
BLyS	O
levels	O
in	O
about	O
25	O
%	O
of	O
SLE	O
patients	S-Species
and	O
intermittently	O
elevated	O
serum	O
BLyS	O
levels	O
in	O
an	O
additional	O
25	O
%	O
of	O
patients	S-Species
[	O
9	O
]	O
.	O

Remarkably	O
,	O
circulating	O
BLyS	O
levels	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
(	O
measured	O
using	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
[	O
SLEDAI	O
]	O
)	O
in	O
these	O
cross	O
-	O
sectional	O
or	O
longitudinal	O
studies	O
[	O
7	O
-	O
9	O
]	O
.	O

Although	O
a	O
statistically	O
significant	O
correlation	O
between	O
circulating	O
BLyS	O
levels	O
and	O
SLEDAI	O
has	O
been	O
appreciated	O
in	O
a	O
more	O
recent	O
24	O
-	O
month	O
longitudinal	O
study	O
of	O
245	O
SLE	O
patients	S-Species
(	O
with	O
>	O
1	O
,	O
700	O
plasma	O
samples	O
analyzed	O
)	O
[	O
10	O
]	O
,	O
the	O
correlation	O
remains	O
weak	O
.	O

The	O
limited	O
correlation	O
between	O
circulating	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
in	O
these	O
studies	O
may	O
have	O
exposed	O
an	O
inadequacy	O
of	O
the	O
former	O
to	O
reflect	O
faithfully	O
endogenous	O
BLyS	O
overproduction	O
.	O

In	O
addition	O
to	O
the	O
rate	O
of	O
BLyS	O
protein	O
production	O
,	O
several	O
other	O
factors	O
(	O
for	O
example	O
,	O
utilization	O
and	O
excretion	O
)	O
can	O
affect	O
circulating	O
BLyS	O
protein	O
levels	O
.	O

Although	O
there	O
are	O
no	O
practicable	O
means	O
of	O
directly	O
measuring	O
in	O
vivo	O
BLyS	O
production	O
per	O
se	O
in	O
humans	S-Species
,	O
the	O
level	O
of	O
BLyS	O
mRNA	O
may	O
serve	O
as	O
a	O
better	O
surrogate	O
marker	O
of	O
in	O
vivo	O
BLyS	O
production	O
than	O
does	O
the	O
level	O
of	O
BLyS	O
protein	O
.	O

Candidate	O
BLyS	O
mRNA	O
isoforms	O
include	O
the	O
full	O
-	O
length	O
BLyS	O
mRNA	O
isoform	O
,	O
which	O
encodes	O
the	O
full	O
-	O
length	O
protein	O
,	O
and	O
the	O
alternatively	O
spliced	O
Delta	O
BLyS	O
mRNA	O
isoform	O
,	O
which	O
encodes	O
a	O
protein	O
with	O
a	O
small	O
peptide	O
deletion	O
[	O
11	O
]	O
.	O

(	O
Delta	O
BLyS	O
does	O
not	O
bind	O
to	O
cells	O
expressing	O
BLyS	O
receptors	O
,	O
and	O
therefore	O
it	O
has	O
no	O
agonistic	O
activity	O
.	O
Moreover	O
,	O
Delta	O
BLyS	O
can	O
form	O
heterotrimers	O
with	O
full	O
-	O
length	O
BLyS	O
,	O
thereby	O
actually	O
functioning	O
as	O
a	O
dominant	O
-	O
negative	O
antagonist	O
of	O
BLyS	O
activity	O
.	O
)	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
peripheral	O
blood	O
leukocytes	O
from	O
SLE	O
patients	S-Species
express	O
elevated	O
mRNA	O
levels	O
of	O
both	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
relative	O
to	O
those	O
levels	O
expressed	O
by	O
patients	S-Species
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
or	O
by	O
normal	O
control	O
individuals	O
.	O

In	O
the	O
SLE	O
patients	S-Species
,	O
both	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
are	O
more	O
closely	O
associated	O
with	O
disease	O
activity	O
(	O
SLEDAI	O
)	O
than	O
are	O
BLyS	O
protein	O
levels	O
.	O

Accordingly	O
,	O
BLyS	O
mRNA	O
levels	O
may	O
be	O
a	O
helpful	O
biomarker	O
in	O
the	O
clinical	O
monitoring	O
of	O
SLE	O
patients	S-Species
.	O

Materials	O
and	O
methods	O

General	O
details	O

This	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
of	O
the	O
University	O
of	O
Southern	O
California	O
and	O
the	O
Scripps	O
Research	O
Institute	O
.	O

All	O
participants	S-Species
gave	O
their	O
written	O
informed	O
consent	O
before	O
participation	O
in	O
this	O
study	O
.	O

Participants	S-Species

Patients	S-Species
receiving	O
outpatient	O
medical	O
care	O
at	O
the	O
rheumatology	O
clinics	O
of	O
the	O
Los	O
Angeles	O
County	O
+	O
University	O
of	O
Southern	O
California	O
Medical	O
Center	O
were	O
recruited	O
into	O
the	O
study	O
.	O

Diagnoses	O
of	O
SLE	O
(	O
n	O
=	O
60	O
)	O
or	O
RA	O
(	O
n	O
=	O
60	O
)	O
were	O
based	O
on	O
established	O
clinical	O
criteria	O
[	O
12	O
]	O
.	O

Healthy	O
control	O
individuals	O
(	O
n	O
=	O
30	O
)	O
were	O
recruited	O
from	O
Los	O
Angeles	O
County	O
+	O
University	O
of	O
Southern	O
California	O
Medical	O
Center	O
and	O
University	O
of	O
Southern	O
California	O
Keck	O
School	O
of	O
Medicine	O
personnel	O
.	O

No	O
exclusions	O
were	O
made	O
on	O
any	O
basis	O
other	O
than	O
an	O
inability	O
to	O
give	O
informed	O
consent	O
.	O

Each	O
patient	S-Species
'	O
s	O
sex	O
,	O
race	O
,	O
age	O
,	O
and	O
medications	O
at	O
the	O
time	O
of	O
the	O
phlebotomy	O
were	O
recorded	O
(	O
Table	O
1	O
)	O
.	O

Based	O
solely	O
on	O
the	O
patient	S-Species
'	O
s	O
willingness	O
to	O
donate	O
a	O
second	O
blood	O
sample	O
,	O
repeat	O
blood	O
samples	O
were	O
collected	O
from	O
37	O
of	O
the	O
SLE	O
patients	S-Species
147	O
-	O
511	O
days	O
(	O
median	O
371	O
days	O
)	O
after	O
collection	O
of	O
the	O
first	O
samples	O
.	O

These	O
patients	S-Species
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
any	O
demographic	O
,	O
clinical	O
,	O
or	O
laboratory	O
feature	O
.	O

Clinical	O
disease	O
activity	O
for	O
the	O
SLE	O
patients	S-Species
was	O
assessed	O
using	O
the	O
SLEDAI	O
[	O
13	O
]	O
and	O
using	O
a	O
modified	O
SLEDAI	O
that	O
excludes	O
the	O
contribution	O
of	O
anti	O
-	O
double	O
-	O
stranded	O
DNA	O
(	O
anti	O
-	O
dsDNA	O
)	O
antibodies	O
from	O
the	O
total	O
score	O
.	O

Each	O
patient	S-Species
'	O
s	O
medical	O
chart	O
was	O
reviewed	O
for	O
results	O
of	O
standard	O
clinical	O
laboratory	O
tests	O
within	O
the	O
previous	O
or	O
subsequent	O
1	O
-	O
month	O
period	O
.	O

Plasma	O
BLyS	O
determination	O

Whole	O
venous	O
blood	O
was	O
centrifuged	O
to	O
yield	O
plasma	O
and	O
a	O
buffy	O
coat	O
.	O

The	O
plasma	O
was	O
harvested	O
,	O
stored	O
at	O
-	O
70	O
degrees	O
C	O
,	O
and	O
assayed	O
for	O
BLyS	O
levels	O
by	O
ELISA	O
[	O
8	O
,	O
14	O
]	O
using	O
Fab	O
fragments	O
of	O
the	O
capture	O
antibody	O
rather	O
than	O
the	O
whole	O
antibody	O
to	O
reduce	O
assay	O
interference	O
by	O
rheumatoid	O
factor	O
.	O

The	O
lower	O
limit	O
of	O
detection	O
in	O
this	O
assay	O
is	O
0	O
.	O
3	O
ng	O
/	O
ml	O
.	O

For	O
statistical	O
purposes	O
,	O
plasma	O
samples	O
with	O
BLyS	O
concentrations	O
below	O
the	O
lower	O
limit	O
of	O
detection	O
were	O
assigned	O
a	O
value	O
of	O
0	O
.	O
25	O
ng	O
/	O
ml	O
.	O

Blood	O
BLyS	O
mRNA	O
determination	O

The	O
buffy	O
coat	O
from	O
centrifuged	O
whole	O
blood	O
was	O
harvested	O
,	O
added	O
to	O
RNAlater	O
(TM)	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
,	O
USA	O
)	O
at	O
a	O
1	O
:	O
4	O
vol	O
/	O
vol	O
ratio	O
for	O
RNA	O
stabilization	O
,	O
stored	O
at	O
-	O
70	O
degrees	O
C	O
,	O
and	O
assayed	O
for	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Total	O
RNA	O
was	O
purified	O
from	O
buffy	O
coat	O
samples	O
using	O
RNAeasy	O
miniprep	O
kits	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
contaminating	O
genomic	O
DNA	O
was	O
removed	O
by	O
DNAse	O
-	O
I	O
digestion	O
.	O

One	O
-	O
tenth	O
volume	O
of	O
total	O
RNA	O
was	O
used	O
as	O
template	O
in	O
the	O
first	O
-	O
strand	O
cDNA	O
reaction	O
using	O
oligo	O
-	O
dT	O
and	O
the	O
Superscript	O
III	O
first	O
-	O
strand	O
synthesis	O
system	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Duplicate	O
samples	O
of	O
cDNA	O
were	O
amplified	O
with	O
primers	O
against	O
beta	O
-	O
actin	O
,	O
full	O
-	O
length	O
BLyS	O
,	O
or	O
Delta	O
BLyS	O
:	O
beta	O
-	O
actin	O
sense	O
5	O
'	O
-	O
CGAGAAGATGACCCAGATCATGT	O
-	O
3	O
'	O
;	O
beta	O
-	O
actin	O
anti	O
-	O
sense	O
5	O
'	O
-	O
GGCATACCCCTCGTAGATGG	O
-	O
3	O
'	O
;	O
full	O
-	O
length	O
BLyS	O
sense	O
5	O
'	O
-	O
GCAGACAGTGAAACACCAACTATAC	O
-	O
3	O
'	O
;	O
Delta	O
BLyS	O
sense	O
5	O
'	O
-	O
CAGAAGAAACAGGATCTTACACAT	O
-	O
3	O
'	O
;	O
and	O
full	O
-	O
length	O
BLyS	O
/	O
Delta	O
BLyS	O
anti	O
-	O
sense	O
5	O
'	O
-	O
TGCCAGCTGAATAGCAGGAATTAT	O
-	O
3	O
'	O
.	O

A	O
165	O
bp	O
amplicon	O
for	O
beta	O
-	O
actin	O
was	O
PCR	O
-	O
amplified	O
using	O
the	O
7900	O
HT	O
ABI	O
Prism	O
machine	O
(	O
Qiagen	O
)	O
with	O
annealing	O
at	O
65	O
degrees	O
C	O
.	O

A	O
296	O
bp	O
amplicon	O
for	O
full	O
-	O
length	O
BLyS	O
was	O
PCR	O
-	O
amplified	O
,	O
with	O
annealing	O
at	O
64	O
degrees	O
C	O
.	O

A	O
270	O
bp	O
amplicon	O
for	O
Delta	O
BLyS	O
was	O
PCR	O
-	O
amplified	O
with	O
annealing	O
at	O
61	O
degrees	O
C	O
.	O

The	O
annealing	O
conditions	O
for	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
were	O
determined	O
so	O
that	O
each	O
primer	O
set	O
remained	O
specific	O
to	O
the	O
respective	O
BLyS	O
isoform	O
and	O
yielded	O
a	O
PCR	O
efficiency	O
similar	O
to	O
those	O
of	O
cloned	O
cDNA	O
standards	O
.	O

Melting	O
curve	O
analysis	O
revealed	O
a	O
single	O
peak	O
for	O
each	O
gene	O
amplified	O
.	O

The	O
threshold	O
cycle	O
(	O
Ct	O
)	O
values	O
for	O
each	O
reaction	O
were	O
determined	O
using	O
Sequence	O
Detection	O
System	O
software	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Results	O
are	O
presented	O
as	O
ratios	O
of	O
full	O
-	O
length	O
BLyS	O
or	O
Delta	O
BLyS	O
mRNA	O
to	O
beta	O
-	O
actin	O
mRNA	O
,	O
which	O
were	O
calculated	O
using	O
the	O
following	O
formulae	O
:	O

2	O
exp	O
(	O
Ct	O
beta	O
-	O
actin	O
-	O
Ctfull	O
-	O
length	O
BLyS	O
)	O

2	O
exp	O
(	O
Ct	O
beta	O
-	O
actin	O
-	O
Ct	O
Delta	O
BLyS	O
)	O

Determination	O
of	O
anti	O
-	O
BLyS	O
autoantibodies	O

BLyS	O
was	O
bound	O
to	O
microtiter	O
plates	O
by	O
first	O
coating	O
the	O
plates	O
with	O
streptavidin	O
and	O
then	O
adding	O
biotinylated	O
recombinant	O
BLyS	O
.	O

Using	O
these	O
plates	O
as	O
the	O
capture	O
reagent	O
,	O
plasma	O
samples	O
were	O
incubated	O
,	O
and	O
horseradish	S-Species
peroxidase	O
-	O
conjugated	O
anti	O
-	O
human	S-Species
IgA	O
/	O
IgM	O
/	O
IgG	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Birmingham	O
,	O
AL	O
,	O
USA	O
;	O
1	O
:	O
20	O
,	O
000	O
final	O
dilution	O
)	O
or	O
horseradish	S-Species
peroxidase	O
-	O
conjugated	O
anti	O
-	O
human	S-Species
IgG	O
(	O
Southern	O
Biotechnology	O
;	O
1	O
:	O
10	O
,	O
000	O
final	O
dilution	O
)	O
were	O
used	O
as	O
the	O
detector	O
reagents	O
.	O

Statistical	O
analysis	O

All	O
analyses	O
were	O
performed	O
using	O
SigmaStat	O
software	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Results	O
that	O
did	O
not	O
follow	O
a	O
normal	O
distribution	O
were	O
log	O
-	O
transformed	O
to	O
achieve	O
normality	O
.	O

Parametric	O
testing	O
between	O
two	O
matched	O
or	O
unmatched	O
groups	O
was	O
performed	O
using	O
the	O
paired	O
or	O
unpaired	O
t	O
test	O
,	O
respectively	O
.	O

Parametric	O
testing	O
among	O
three	O
or	O
more	O
groups	O
was	O
performed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
.	O

When	O
log	O
-	O
transformation	O
failed	O
to	O
generate	O
normally	O
distributed	O
data	O
or	O
the	O
equal	O
variance	O
test	O
was	O
not	O
satisfied	O
,	O
nonparametric	O
testing	O
was	O
performed	O
using	O
the	O
Mann	O
-	O
Whitney	O
rank	O
sum	O
test	O
between	O
two	O
groups	O
and	O
by	O
Kruskal	O
-	O
Wallis	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
on	O
ranks	O
among	O
three	O
or	O
more	O
groups	O
.	O

Correlations	O
were	O
determined	O
using	O
Pearson	O
product	O
moment	O
correlation	O
for	O
interval	O
data	O
and	O
using	O
Spearman	O
rank	O
order	O
correlation	O
for	O
ordinal	O
data	O
or	O
for	O
interval	O
data	O
that	O
did	O
not	O
follow	O
a	O
normal	O
distribution	O
.	O

Nominal	O
data	O
were	O
analyzed	O
using	O
chi	O
2	O
analysis	O
-	O
of	O
-	O
contingency	O
tables	O
.	O

Results	O

Elevated	O
plasma	O
BLyS	O
levels	O
and	O
blood	O
levels	O
of	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
isoforms	O
in	O
systemic	O
lupus	O
erythematosus	O
patients	S-Species

Previous	O
reports	O
of	O
elevated	O
circulating	O
BLyS	O
levels	O
in	O
SLE	O
patients	S-Species
were	O
based	O
on	O
a	O
BLyS	O
ELISA	O
that	O
utilized	O
a	O
whole	O
(	O
unfragmented	O
)	O
capture	O
anti	O
-	O
BLyS	O
monoclonal	O
antibody	O
[	O
7	O
-	O
9	O
]	O
.	O

Since	O
the	O
publication	O
of	O
these	O
reports	O
,	O
it	O
has	O
been	O
recognized	O
that	O
the	O
presence	O
of	O
rheumatoid	O
factor	O
can	O
potentially	O
interfere	O
with	O
the	O
assay	O
and	O
lead	O
to	O
spurious	O
overestimation	O
of	O
the	O
true	O
circulating	O
BLyS	O
levels	O
(	O
Human	S-Species
Genome	O
Sciences	O
,	O
Inc	O
.	O
;	O
unpublished	O
observations	O
)	O
.	O

To	O
mitigate	O
potential	O
interference	O
from	O
rheumatoid	O
factor	O
,	O
the	O
BLyS	O
ELISA	O
has	O
been	O
modified	O
and	O
the	O
capture	O
anti	O
-	O
BLyS	O
monoclonal	O
antibody	O
is	O
now	O
utilized	O
as	O
a	O
Fab	O
fragment	O
.	O

Despite	O
the	O
changes	O
in	O
the	O
ELISA	O
format	O
,	O
our	O
findings	O
are	O
entirely	O
consistent	O
with	O
those	O
of	O
the	O
previous	O
reports	O
.	O

Plasma	O
BLyS	O
levels	O
were	O
significantly	O
greater	O
in	O
the	O
SLE	O
group	O
than	O
in	O
either	O
RA	O
or	O
normal	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
Figure	O
1a	O
)	O
.	O

Arbitrary	O
assignment	O
of	O
the	O
95th	O
percentile	O
value	O
among	O
the	O
normal	O
control	O
individuals	O
as	O
the	O
upper	O
limit	O
of	O
'	O
normal	O
'	O
revealed	O
that	O
two	O
of	O
the	O
30	O
normal	O
control	O
individuals	O
,	O
15	O
of	O
the	O
60	O
RA	O
patients	S-Species
,	O
and	O
29	O
of	O
the	O
60	O
SLE	O
patients	S-Species
harbored	O
elevated	O
plasma	O
BLyS	O
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Overexpression	O
of	O
BLyS	O
in	O
SLE	O
patients	S-Species
was	O
also	O
established	O
by	O
measuring	O
BLyS	O
mRNA	O
levels	O
normalized	O
to	O
beta	O
-	O
actin	O
mRNA	O
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
buffy	O
coats	O
)	O
.	O

The	O
geometric	O
mean	O
full	O
-	O
length	O
BLyS	O
mRNA	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
among	O
the	O
SLE	O
patients	S-Species
were	O
each	O
significantly	O
greater	O
than	O
those	O
among	O
the	O
RA	O
patients	S-Species
and	O
normal	O
control	O
individuals	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
for	O
each	O
;	O
Figure	O
1b	O
,	O
c	O
)	O
.	O

Arbitrary	O
assignment	O
of	O
the	O
95th	O
percentile	O
values	O
for	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
among	O
the	O
normal	O
control	O
individuals	O
as	O
the	O
upper	O
limits	O
of	O
'	O
normal	O
'	O
revealed	O
that	O
two	O
of	O
the	O
30	O
normal	O
control	O
individuals	O
,	O
four	O
of	O
the	O
60	O
RA	O
patients	S-Species
,	O
and	O
20	O
of	O
the	O
60	O
SLE	O
patients	S-Species
had	O
elevated	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
that	O
two	O
of	O
the	O
30	O
normal	O
control	O
individuals	O
,	O
three	O
of	O
the	O
60	O
RA	O
patients	S-Species
,	O
and	O
19	O
of	O
the	O
60	O
SLE	O
patients	S-Species
had	O
elevated	O
Delta	O
BLyS	O
mRNA	O
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Levels	O
of	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
strongly	O
correlated	O
with	O
each	O
other	O
(	O
r	O
=	O
0	O
.	O
703	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
SLE	O
cohort	O
,	O
and	O
plasma	O
BLyS	O
levels	O
also	O
correlated	O
significantly	O
with	O
levels	O
of	O
each	O
BLyS	O
isoform	O
(	O
r	O
=	O
0	O
.	O
429	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
and	O
r	O
=	O
0	O
.	O
290	O
,	O
P	O
=	O
0	O
.	O
024	O
,	O
respectively	O
)	O
.	O

Among	O
these	O
SLE	O
patients	S-Species
,	O
none	O
of	O
the	O
measured	O
BLyS	O
parameters	O
correlated	O
with	O
patient	S-Species
age	O
,	O
sex	O
,	O
race	O
,	O
or	O
daily	O
dose	O
of	O
corticosteroids	O
(	O
data	O
not	O
shown	O
)	O
.	O

Because	O
the	O
racial	O
composition	O
of	O
the	O
normal	O
cohort	O
was	O
not	O
as	O
predominantly	O
Hispanic	O
as	O
were	O
those	O
of	O
the	O
RA	O
and	O
SLE	O
cohorts	O
,	O
we	O
assessed	O
the	O
BLyS	O
parameters	O
in	O
the	O
respective	O
Hispanic	O
subpopulations	O
.	O

As	O
for	O
the	O
entire	O
populations	O
,	O
values	O
for	O
SLE	O
were	O
significantly	O
greater	O
than	O
those	O
for	O
either	O
RA	O
or	O
normal	O
controls	O
(	O
P	O
<=	O
0	O
.	O
004	O
;	O
data	O
not	O
shown	O
)	O
.	O

Correlations	O
between	O
BLyS	O
parameters	O
and	O
plasma	O
immunoglobulin	O
levels	O

BLyS	O
is	O
a	O
potent	O
B	O
cell	O
survival	O
factor	O
[	O
15	O
-	O
21	O
]	O
,	O
and	O
administration	O
of	O
exogenous	O
BLyS	O
to	O
mice	S-Species
leads	O
to	O
B	O
cell	O
expansion	O
and	O
hypergammaglobulinemia	O
[	O
1	O
]	O
.	O

Previous	O
studies	O
with	O
numbers	O
of	O
SLE	O
patients	S-Species
greater	O
than	O
were	O
included	O
in	O
the	O
present	O
study	O
documented	O
a	O
modest	O
but	O
significant	O
correlation	O
between	O
serum	O
levels	O
of	O
BLyS	O
and	O
IgG	O
[	O
8	O
,	O
10	O
]	O
.	O

In	O
our	O
SLE	O
cohort	O
of	O
limited	O
size	O
,	O
plasma	O
BLyS	O
levels	O
failed	O
to	O
show	O
significant	O
correlations	O
with	O
plasma	O
levels	O
of	O
total	O
immunoglobulin	O
,	O
IgG	O
,	O
or	O
IgA	O
.	O

In	O
contrast	O
,	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
correlated	O
significantly	O
with	O
each	O
(	O
Figure	O
2	O
)	O
.	O

(	O
None	O
of	O
the	O
BLyS	O
parameters	O
correlated	O
with	O
plasma	O
IgM	O
levels	O
.	O
)	O
The	O
absence	O
of	O
significant	O
correlation	O
between	O
plasma	O
BLyS	O
levels	O
and	O
the	O
immunoglobulin	O
parameters	O
also	O
persisted	O
when	O
just	O
the	O
53	O
patients	S-Species
with	O
detectable	O
plasma	O
BLyS	O
levels	O
were	O
considered	O
(	O
r	O
=	O
-	O
0	O
.	O
133	O
,	O
P	O
=	O
0	O
.	O
346	O
for	O
total	O
immunoglobulin	O
;	O
r	O
=	O
-	O
0	O
.	O
048	O
,	O
P	O
=	O
0	O
.	O
734	O
for	O
IgG	O
;	O
and	O
r	O
=	O
0	O
.	O
033	O
,	O
P	O
=	O
0	O
.	O
817	O
for	O
IgA	O
)	O
.	O

Correlations	O
between	O
BLyS	O
parameters	O
and	O
disease	O
activity	O

Previous	O
studies	O
either	O
have	O
failed	O
to	O
demonstrate	O
a	O
significant	O
correlation	O
between	O
disease	O
activity	O
and	O
circulating	O
BLyS	O
levels	O
[	O
7	O
-	O
9	O
]	O
or	O
have	O
detected	O
only	O
a	O
weak	O
correlation	O
between	O
the	O
two	O
[	O
10	O
]	O
.	O

Consonant	O
with	O
those	O
studies	O
,	O
we	O
identified	O
no	O
significant	O
correlation	O
between	O
plasma	O
BLyS	O
levels	O
and	O
SLEDAI	O
in	O
our	O
cohort	O
of	O
60	O
SLE	O
patients	S-Species
(	O
Figure	O
3a	O
)	O
.	O

The	O
failure	O
to	O
demonstrate	O
a	O
significant	O
correlation	O
cannot	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
results	O
by	O
the	O
patients	S-Species
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
below	O
the	O
limit	O
of	O
detection	O
,	O
because	O
no	O
significant	O
correlation	O
was	O
detected	O
among	O
the	O
53	O
SLE	O
patients	S-Species
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
in	O
the	O
detectable	O
range	O
(	O
r	O
=	O
0	O
.	O
185	O
,	O
P	O
=	O
0	O
.	O
183	O
)	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
correlation	O
between	O
SLEDAI	O
and	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
was	O
readily	O
discernible	O
(	O
Figure	O
3b	O
)	O
.	O

A	O
trend	O
toward	O
a	O
correlation	O
between	O
SLEDAI	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
was	O
also	O
observed	O
,	O
although	O
it	O
did	O
not	O
achieve	O
statistical	O
significance	O
(	O
Figure	O
3c	O
)	O
.	O

A	O
component	O
of	O
the	O
SLEDAI	O
is	O
the	O
presence	O
of	O
circulating	O
anti	O
-	O
dsDNA	O
antibodies	O
.	O

Because	O
circulating	O
BLyS	O
levels	O
may	O
affect	O
the	O
presence	O
and	O
/	O
or	O
titers	O
of	O
circulating	O
anti	O
-	O
dsDNA	O
antibodies	O
[	O
7	O
-	O
10	O
]	O
,	O
we	O
assessed	O
correlations	O
between	O
the	O
individual	O
BLyS	O
parameters	O
and	O
a	O
modified	O
SLEDAI	O
that	O
excludes	O
any	O
consideration	O
of	O
anti	O
-	O
dsDNA	O
antibodies	O
.	O

As	O
with	O
the	O
unmodified	O
SLEDAI	O
,	O
the	O
modified	O
SLEDAI	O
did	O
not	O
correlate	O
with	O
plasma	O
BLyS	O
levels	O
(	O
Figure	O
3d	O
)	O
either	O
among	O
the	O
SLE	O
cohort	O
overall	O
or	O
among	O
the	O
53	O
patients	S-Species
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
in	O
the	O
detectable	O
range	O
(	O
r	O
=	O
0	O
.	O
160	O
,	O
P	O
=	O
0	O
.	O
252	O
)	O
,	O
but	O
it	O
significantly	O
correlated	O
with	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
(	O
Figure	O
3e	O
)	O
and	O
exhibited	O
a	O
trend	O
toward	O
correlation	O
with	O
Delta	O
BLyS	O
mRNA	O
levels	O
(	O
Figure	O
3f	O
)	O
.	O

Thus	O
,	O
the	O
stronger	O
correlations	O
between	O
BLyS	O
mRNA	O
levels	O
and	O
disease	O
activity	O
cannot	O
solely	O
be	O
explained	O
by	O
any	O
effects	O
that	O
BLyS	O
may	O
have	O
on	O
anti	O
-	O
dsDNA	O
antibodies	O
per	O
se	O
.	O

Moreover	O
,	O
among	O
the	O
37	O
SLE	O
patients	S-Species
who	O
were	O
evaluated	O
on	O
two	O
separate	O
occasions	O
,	O
trends	O
toward	O
correlation	O
were	O
appreciated	O
between	O
changes	O
in	O
the	O
unmodified	O
or	O
modified	O
SLEDAI	O
and	O
changes	O
in	O
full	O
-	O
length	O
BLyS	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
but	O
not	O
changes	O
in	O
plasma	O
BLyS	O
levels	O
(	O
Figure	O
4	O
)	O
.	O

These	O
results	O
cannot	O
be	O
ascribed	O
to	O
changes	O
in	O
medications	O
taken	O
by	O
the	O
patients	S-Species
,	O
because	O
changes	O
in	O
neither	O
disease	O
activity	O
nor	O
in	O
any	O
of	O
the	O
BLyS	O
parameters	O
correlated	O
with	O
changes	O
in	O
the	O
doses	O
of	O
corticosteroids	O
or	O
cytotoxics	O
taken	O
by	O
the	O
patients	S-Species
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
failure	O
to	O
demonstrate	O
a	O
meaningful	O
association	O
between	O
changes	O
in	O
SLEDAI	O
score	O
and	O
changes	O
in	O
plasma	O
BLyS	O
protein	O
levels	O
cannot	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
results	O
by	O
the	O
patients	S-Species
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
below	O
the	O
limit	O
of	O
detection	O
,	O
because	O
the	O
absence	O
of	O
association	O
between	O
the	O
two	O
persisted	O
among	O
the	O
27	O
SLE	O
patients	S-Species
in	O
whom	O
plasma	O
BLyS	O
levels	O
were	O
in	O
the	O
detectable	O
range	O
in	O
both	O
samples	O
(	O
r	O
=	O
-	O
0	O
.	O
069	O
,	O
P	O
=	O
0	O
.	O
727	O
for	O
plasma	O
BLyS	O
versus	O
unmodified	O
SLEDAI	O
;	O
r	O
=	O
-	O
0	O
.	O
020	O
,	O
P	O
=	O
0	O
.	O
919	O
for	O
plasma	O
BLyS	O
versus	O
modified	O
SLEDAI	O
)	O
.	O

Lack	O
of	O
correlation	O
between	O
levels	O
of	O
BLyS	O
mRNA	O
isoforms	O
and	O
percentages	O
of	O
individual	O
leukocyte	O
cell	O
types	O

Among	O
cells	O
in	O
peripheral	O
blood	O
,	O
BLyS	O
is	O
predominantly	O
expressed	O
by	O
cells	O
of	O
the	O
myeloid	O
lineage	O
(	O
monocytes	O
and	O
neutrophils	O
)	O
[	O
1	O
,	O
14	O
,	O
22	O
,	O
23	O
]	O
.	O

Accordingly	O
,	O
a	O
shift	O
in	O
the	O
differential	O
leukocyte	O
count	O
away	O
from	O
lymphocytes	O
to	O
monocytes	O
and	O
/	O
or	O
neutrophils	O
could	O
substantially	O
alter	O
BLyS	O
mRNA	O
results	O
.	O

Because	O
of	O
the	O
limited	O
amount	O
of	O
blood	O
we	O
were	O
permitted	O
to	O
obtain	O
from	O
the	O
SLE	O
patients	S-Species
(	O
consequent	O
to	O
the	O
high	O
prevalence	O
of	O
anemia	O
among	O
these	O
patients	S-Species
)	O
,	O
we	O
were	O
unable	O
to	O
purify	O
the	O
individual	O
leukocyte	O
populations	O
for	O
BLyS	O
mRNA	O
analysis	O
.	O

Nevertheless	O
,	O
to	O
demonstrate	O
that	O
the	O
elevated	O
BLyS	O
mRNA	O
levels	O
in	O
SLE	O
did	O
not	O
simply	O
reflect	O
a	O
shift	O
in	O
differential	O
leukocyte	O
count	O
,	O
we	O
assessed	O
the	O
correlations	O
between	O
the	O
individual	O
BLyS	O
parameters	O
on	O
the	O
one	O
hand	O
and	O
the	O
percentages	O
of	O
blood	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
lymphocytes	O
on	O
the	O
other	O
.	O

No	O
correlations	O
were	O
appreciated	O
(	O
Figure	O
5	O
)	O
.	O

Presence	O
of	O
anti	O
-	O
BLyS	O
autoantibodies	O
in	O
patients	S-Species
with	O
systemic	O
lupus	O
erythematosus	O

The	O
poorer	O
correlation	O
between	O
plasma	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
compared	O
with	O
that	O
between	O
BLyS	O
mRNA	O
levels	O
and	O
disease	O
activity	O
was	O
striking	O
.	O

Patients	S-Species
with	O
SLE	O
frequently	O
develop	O
autoantibodies	O
against	O
self	O
-	O
antigens	O
,	O
and	O
so	O
some	O
of	O
the	O
SLE	O
patients	S-Species
might	O
have	O
harbored	O
autoantibodies	O
to	O
BLyS	O
.	O

Such	O
autoantibodies	O
could	O
have	O
complexed	O
with	O
BLyS	O
and	O
enhanced	O
its	O
clearance	O
,	O
thereby	O
masking	O
BLyS	O
overproduction	O
.	O

Alternatively	O
,	O
such	O
autoantibodies	O
might	O
have	O
sterically	O
blocked	O
the	O
epitopes	O
recognized	O
by	O
the	O
detecting	O
antibodies	O
in	O
the	O
in	O
vitro	O
ELISA	O
.	O

In	O
this	O
case	O
,	O
measured	O
BLyS	O
levels	O
would	O
have	O
been	O
spuriously	O
reduced	O
,	O
again	O
masking	O
BLyS	O
overproduction	O
.	O

In	O
our	O
cohort	O
,	O
IgA	O
/	O
IgM	O
/	O
IgG	O
anti	O
-	O
BLyS	O
antibodies	O
were	O
detected	O
in	O
six	O
out	O
of	O
the	O
60	O
SLE	O
patients	S-Species
.	O

Such	O
autoantibodies	O
were	O
also	O
detected	O
in	O
two	O
out	O
of	O
60	O
RA	O
patients	S-Species
and	O
in	O
one	O
out	O
of	O
30	O
normal	O
control	O
individuals	O
,	O
demonstrating	O
that	O
anti	O
-	O
BLyS	O
autoantibodies	O
are	O
not	O
restricted	O
to	O
SLE	O
patients	S-Species
.	O

IgG	O
anti	O
-	O
BLyS	O
autoantibodies	O
were	O
detected	O
in	O
3	O
SLE	O
patients	S-Species
but	O
in	O
no	O
RA	O
patients	S-Species
or	O
normal	O
control	O
individuals	O
.	O

Discussion	O

Elevated	O
blood	O
levels	O
of	O
BLyS	O
protein	O
and	O
mRNA	O
are	O
well	O
described	O
features	O
of	O
human	S-Species
SLE	O
[	O
7	O
-	O
9	O
]	O
.	O

We	O
confirmed	O
these	O
observations	O
in	O
our	O
study	O
and	O
extended	O
them	O
by	O
documenting	O
increases	O
not	O
just	O
in	O
levels	O
of	O
full	O
-	O
length	O
BLyS	O
mRNA	O
but	O
also	O
in	O
levels	O
of	O
Delta	O
BLyS	O
mRNA	O
(	O
Figure	O
1	O
)	O
.	O

Of	O
note	O
,	O
BLyS	O
mRNA	O
levels	O
were	O
elevated	O
in	O
SLE	O
but	O
not	O
in	O
RA	O
,	O
raising	O
the	O
possibility	O
that	O
BLyS	O
overproduction	O
in	O
SLE	O
is	O
systemic	O
whereas	O
BLyS	O
overproduction	O
in	O
RA	O
may	O
be	O
more	O
focused	O
to	O
the	O
affected	O
arthritic	O
joints	O
[	O
24	O
]	O
.	O

The	O
modestly	O
elevated	O
plasma	O
BLyS	O
protein	O
levels	O
in	O
RA	O
patients	S-Species
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
release	O
of	O
locally	O
overproduced	O
BLyS	O
into	O
the	O
circulation	O
.	O

The	O
relationship	O
between	O
circulating	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
was	O
addressed	O
in	O
several	O
previous	O
studies	O
,	O
but	O
significant	O
correlations	O
between	O
the	O
two	O
measures	O
did	O
not	O
emerge	O
[	O
7	O
-	O
9	O
]	O
.	O

In	O
the	O
largest	O
study	O
to	O
date	O
,	O
a	O
2	O
-	O
year	O
longitudinal	O
study	O
of	O
245	O
patients	S-Species
in	O
which	O
more	O
than	O
1	O
,	O
700	O
plasma	O
samples	O
were	O
analyzed	O
,	O
a	O
significant	O
but	O
weak	O
correlation	O
between	O
the	O
two	O
was	O
appreciated	O
[	O
10	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
significant	O
correlation	O
between	O
plasma	O
BLyS	O
protein	O
levels	O
and	O
disease	O
activity	O
was	O
again	O
not	O
realized	O
(	O
Figure	O
3a	O
,	O
d	O
)	O
.	O

The	O
weak	O
,	O
at	O
best	O
,	O
correlation	O
between	O
circulating	O
BLyS	O
levels	O
and	O
disease	O
activity	O
is	O
seemingly	O
rather	O
surprising	O
.	O

There	O
is	O
a	O
clear	O
-	O
cut	O
association	O
in	O
BlyS	O
transgenic	O
mice	S-Species
between	O
BLyS	O
overexpression	O
and	O
development	O
of	O
SLE	O
-	O
like	O
features	O
[	O
3	O
-	O
5	O
]	O
,	O
and	O
treatment	O
of	O
SLE	O
-	O
prone	O
mice	S-Species
with	O
BLyS	O
antagonists	O
retards	O
the	O
progression	O
of	O
disease	O
and	O
improves	O
survival	O
[	O
3	O
,	O
6	O
]	O
.	O

Moreover	O
,	O
development	O
of	O
precocious	O
glomerular	O
pathology	O
in	O
autoimmune	O
-	O
prone	O
mice	S-Species
correlates	O
strongly	O
with	O
circulating	O
BLyS	O
levels	O
[	O
25	O
]	O
.	O

The	O
likely	O
explanation	O
for	O
the	O
weak	O
correlation	O
between	O
circulating	O
BLyS	O
levels	O
and	O
disease	O
activity	O
in	O
human	S-Species
SLE	O
is	O
not	O
that	O
disease	O
activity	O
in	O
SLE	O
patients	S-Species
is	O
insensitive	O
to	O
the	O
degree	O
of	O
BLyS	O
overproduction	O
.	O

Rather	O
,	O
a	O
more	O
tenable	O
explanation	O
is	O
that	O
circulating	O
BLyS	O
levels	O
in	O
human	S-Species
SLE	O
do	O
not	O
always	O
accurately	O
reflect	O
excessive	O
endogenous	O
BLyS	O
production	O
.	O

We	O
can	O
identify	O
at	O
least	O
three	O
nonmutually	O
exclusive	O
mechanisms	O
to	O
explain	O
a	O
dissociation	O
between	O
the	O
two	O
.	O

First	O
,	O
SLE	O
patients	S-Species
frequently	O
develop	O
autoantibodies	O
to	O
a	O
myriad	O
of	O
self	O
-	O
targets	O
(	O
for	O
example	O
,	O
erythrocytes	O
,	O
lymphocytes	O
)	O
.	O

Indeed	O
,	O
we	O
detected	O
circulating	O
IgA	O
/	O
IgM	O
/	O
IgG	O
anti	O
-	O
BLyS	O
autoantibodies	O
in	O
10	O
%	O
(	O
6	O
/	O
60	O
)	O
of	O
the	O
tested	O
SLE	O
patients	S-Species
,	O
and	O
we	O
detected	O
circulating	O
IgG	O
anti	O
-	O
BLyS	O
autoantibodies	O
in	O
5	O
%	O
(	O
3	O
/	O
60	O
)	O
.	O

These	O
percentages	O
may	O
be	O
underestimates	O
of	O
the	O
true	O
prevalence	O
of	O
anti	O
-	O
BLyS	O
autoantibodies	O
,	O
because	O
some	O
of	O
these	O
autoantibodies	O
may	O
be	O
saturated	O
in	O
vivo	O
with	O
circulating	O
BLyS	O
,	O
rendering	O
them	O
incapable	O
of	O
binding	O
to	O
BLyS	O
in	O
the	O
in	O
vitro	O
detection	O
assay	O
.	O

We	O
do	O
not	O
yet	O
know	O
whether	O
the	O
anti	O
-	O
BLyS	O
autoantibodies	O
are	O
functionally	O
neutralizing	O
but	O
,	O
regardless	O
,	O
such	O
autoantibodies	O
could	O
enhance	O
the	O
clearance	O
of	O
BLyS	O
and	O
/	O
or	O
interfere	O
with	O
in	O
vitro	O
detection	O
of	O
BLyS	O
,	O
thereby	O
masking	O
endogenous	O
BLyS	O
overproduction	O
.	O

Second	O
,	O
increased	O
urinary	O
excretion	O
of	O
BLyS	O
has	O
been	O
reported	O
in	O
SLE	O
patients	S-Species
,	O
especially	O
among	O
those	O
with	O
clinically	O
overt	O
renal	O
involvement	O
[	O
26	O
]	O
.	O

At	O
least	O
four	O
of	O
the	O
patients	S-Species
we	O
studied	O
manifested	O
nephrotic	O
-	O
range	O
proteinuria	O
(	O
>=	O
3	O
g	O
/	O
24	O
hours	O
)	O
,	O
and	O
so	O
urinary	O
loss	O
of	O
BLyS	O
was	O
probably	O
substantial	O
in	O
at	O
least	O
these	O
patients	S-Species
.	O

A	O
validated	O
assay	O
for	O
urinary	O
BLyS	O
detection	O
has	O
not	O
yet	O
been	O
developed	O
so	O
we	O
were	O
unable	O
to	O
quantify	O
urinary	O
BLyS	O
levels	O
.	O

Once	O
an	O
assay	O
for	O
urinary	O
BLyS	O
levels	O
is	O
validated	O
,	O
we	O
should	O
be	O
able	O
to	O
assess	O
the	O
effect	O
of	O
urinary	O
BLyS	O
excretion	O
on	O
circulating	O
BLyS	O
levels	O
.	O

Third	O
,	O
BLyS	O
promotes	O
in	O
vivo	O
expansion	O
of	O
B	O
cells	O
[	O
1	O
]	O
.	O

Freshly	O
isolated	O
SLE	O
B	O
cells	O
,	O
despite	O
intact	O
surface	O
expression	O
of	O
BLyS	O
receptors	O
,	O
bind	O
less	O
biotinylated	O
BLyS	O
ex	O
vivo	O
than	O
do	O
freshly	O
isolated	O
normal	O
B	O
cells	O
[	O
27	O
]	O
.	O

Although	O
other	O
interpretations	O
are	O
possible	O
,	O
the	O
most	O
likely	O
explanation	O
is	O
that	O
BLyS	O
receptors	O
on	O
B	O
cells	O
in	O
SLE	O
patients	S-Species
are	O
occupied	O
in	O
vivo	O
by	O
soluble	O
BLyS	O
.	O

Accordingly	O
,	O
it	O
is	O
likely	O
that	O
BLyS	O
receptors	O
expressed	O
by	O
the	O
expanded	O
B	O
cell	O
population	O
do	O
bind	O
BLyS	O
and	O
remove	O
it	O
from	O
the	O
circulation	O
,	O
resulting	O
in	O
a	O
homeostatic	O
pathway	O
that	O
modulates	O
the	O
effects	O
of	O
BLyS	O
overproduction	O
on	O
circulating	O
BLyS	O
levels	O
.	O

Indeed	O
,	O
circulating	O
levels	O
of	O
BLyS	O
rise	O
with	O
peripheral	O
blood	O
B	O
cell	O
depletion	O
and	O
fall	O
with	O
re	O
-	O
emergence	O
of	O
peripheral	O
blood	O
B	O
cells	O
in	O
rituximab	O
-	O
treated	O
RA	O
or	O
SLE	O
patients	S-Species
[	O
28	O
,	O
29	O
]	O
,	O
highlighting	O
this	O
inverse	O
relationship	O
between	O
circulating	O
BLyS	O
levels	O
and	O
B	O
cell	O
load	O
.	O

Moreover	O
,	O
one	O
of	O
the	O
hallmarks	O
of	O
active	O
disease	O
in	O
human	S-Species
SLE	O
is	O
the	O
increased	O
percentages	O
of	O
activated	O
B	O
cells	O
and	O
plasma	O
cells	O
in	O
peripheral	O
blood	O
[	O
30	O
-	O
34	O
]	O
,	O
probably	O
reflecting	O
increased	O
systemic	O
numbers	O
of	O
activated	O
B	O
cells	O
and	O
plasma	O
cells	O
.	O

Although	O
not	O
yet	O
formally	O
tested	O
,	O
differential	O
BLyS	O
receptor	O
expression	O
by	O
these	O
cells	O
compared	O
with	O
expression	O
by	O
nonactivated	O
B	O
cells	O
may	O
result	O
in	O
increased	O
peripheral	O
BLyS	O
utilization	O
,	O
further	O
dampening	O
the	O
effects	O
of	O
BLyS	O
overproduction	O
on	O
circulating	O
protein	O
levels	O
.	O

To	O
circumvent	O
these	O
confounding	O
processes	O
,	O
we	O
used	O
BLyS	O
mRNA	O
levels	O
as	O
a	O
surrogate	O
marker	O
of	O
endogenous	O
BLyS	O
production	O
.	O

Overall	O
,	O
the	O
correlations	O
between	O
disease	O
activity	O
and	O
either	O
full	O
-	O
length	O
BLyS	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
were	O
much	O
stronger	O
than	O
that	O
between	O
disease	O
activity	O
and	O
BLyS	O
protein	O
levels	O
(	O
Figures	O
3	O
and	O
4	O
)	O
.	O

This	O
was	O
the	O
case	O
regardless	O
of	O
whether	O
we	O
used	O
the	O
standard	O
SLEDAI	O
or	O
the	O
modified	O
SLEDAI	O
as	O
a	O
measure	O
of	O
disease	O
activity	O
.	O

These	O
correlations	O
were	O
not	O
spurious	O
ones	O
consequent	O
to	O
shifts	O
in	O
percentages	O
of	O
leukocyte	O
subpopulations	O
in	O
peripheral	O
blood	O
,	O
because	O
BLyS	O
mRNA	O
levels	O
did	O
not	O
correlate	O
with	O
percentages	O
of	O
blood	O
neutrophils	O
,	O
monocytes	O
,	O
or	O
lymphocytes	O
(	O
Figure	O
5	O
)	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
between	O
plasma	O
immunoglobulin	O
levels	O
and	O
the	O
BLyS	O
parameters	O
,	O
with	O
plasma	O
levels	O
of	O
total	O
immunoglobulin	O
,	O
IgG	O
,	O
and	O
IgA	O
correlating	O
significantly	O
with	O
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
mRNA	O
levels	O
but	O
not	O
with	O
plasma	O
BLyS	O
levels	O
(	O
Figure	O
2	O
)	O
.	O

These	O
significant	O
correlations	O
between	O
full	O
-	O
length	O
BLyS	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
and	O
plasma	O
immunoglobulin	O
levels	O
again	O
highlight	O
the	O
greater	O
ability	O
of	O
BLyS	O
mRNA	O
levels	O
,	O
compared	O
with	O
plasma	O
BLyS	O
protein	O
levels	O
,	O
to	O
reflect	O
ongoing	O
BLyS	O
overproduction	O
.	O

At	O
present	O
,	O
it	O
is	O
not	O
known	O
whether	O
soluble	O
Delta	O
BLyS	O
protein	O
is	O
present	O
in	O
the	O
circulation	O
of	O
SLE	O
patients	S-Species
or	O
of	O
normal	O
individuals	O
.	O

Although	O
full	O
-	O
length	O
BLyS	O
protein	O
is	O
readily	O
cleaved	O
and	O
released	O
from	O
cells	O
transfected	O
with	O
a	O
vector	O
containing	O
murine	S-Species
full	O
-	O
length	O
BLyS	O
,	O
Delta	O
BLyS	O
protein	O
is	O
not	O
cleaved	O
or	O
released	O
from	O
murine	S-Species
Delta	O
BLyS	O
transfectants	O
[	O
11	O
]	O
.	O

Given	O
the	O
strong	O
similarities	O
between	O
murine	S-Species
and	O
human	S-Species
full	O
-	O
length	O
BLyS	O
and	O
Delta	O
BLyS	O
,	O
it	O
is	O
likely	O
that	O
human	S-Species
soluble	O
Delta	O
BLyS	O
protein	O
is	O
also	O
not	O
cleaved	O
from	O
the	O
cell	O
surface	O
and	O
released	O
into	O
the	O
circulation	O
.	O

Moreover	O
,	O
soluble	O
Delta	O
BLyS	O
protein	O
is	O
not	O
released	O
from	O
cells	O
transfected	O
with	O
a	O
vector	O
containing	O
just	O
the	O
extracellular	O
domain	O
of	O
human	S-Species
Delta	O
BLyS	O
(	O
which	O
encodes	O
the	O
soluble	O
protein	O
;	O
A	O
.	O
L	O
.	O
Gavin	O
,	O
unpublished	O
observations	O
)	O
.	O

Whether	O
this	O
reflects	O
rapid	O
intracellular	O
degradation	O
of	O
soluble	O
Delta	O
BLyS	O
or	O
some	O
other	O
impediment	O
to	O
its	O
release	O
remains	O
unknown	O
.	O

Regardless	O
,	O
if	O
the	O
inability	O
to	O
release	O
soluble	O
Delta	O
BLyS	O
in	O
vitro	O
faithfully	O
recapitulates	O
in	O
vivo	O
biology	O
,	O
then	O
the	O
stronger	O
associations	O
between	O
SLE	O
disease	O
activity	O
and	O
full	O
-	O
length	O
BLyS	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
compared	O
with	O
that	O
between	O
SLE	O
disease	O
activity	O
and	O
BLyS	O
protein	O
levels	O
could	O
not	O
be	O
attributable	O
to	O
interference	O
by	O
biologically	O
inactive	O
(	O
inhibitory	O
)	O
Delta	O
BLyS	O
protein	O
in	O
the	O
BLyS	O
protein	O
detection	O
ELISA	O
.	O

Importantly	O
,	O
even	O
if	O
soluble	O
Delta	O
BLyS	O
protein	O
is	O
present	O
in	O
the	O
circulation	O
and	O
is	O
detected	O
by	O
the	O
BLyS	O
protein	O
detection	O
ELISA	O
,	O
then	O
the	O
stronger	O
correlations	O
between	O
SLE	O
disease	O
activity	O
and	O
full	O
-	O
length	O
BLyS	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
than	O
that	O
between	O
disease	O
activity	O
and	O
total	O
BLyS	O
(	O
including	O
Delta	O
BLyS	O
)	O
protein	O
levels	O
suggest	O
that	O
full	O
-	O
length	O
BLyS	O
and	O
/	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
may	O
operationally	O
serve	O
as	O
useful	O
biomarkers	O
of	O
disease	O
activity	O
in	O
SLE	O
.	O

Although	O
the	O
complexity	O
and	O
labor	O
intensiveness	O
associated	O
with	O
quantitative	O
real	O
-	O
time	O
PCR	O
may	O
render	O
measurement	O
of	O
BLyS	O
mRNA	O
levels	O
impracticable	O
for	O
routine	O
clinical	O
practice	O
,	O
such	O
measurement	O
could	O
readily	O
be	O
incorporated	O
into	O
clinical	O
trials	O
and	O
yield	O
valuable	O
information	O
.	O

Longitudinal	O
observations	O
in	O
large	O
numbers	O
of	O
SLE	O
patients	S-Species
will	O
be	O
necessary	O
to	O
establish	O
or	O
refute	O
the	O
utility	O
of	O
full	O
-	O
length	O
BLyS	O
and	O
/	O
or	O
Delta	O
BLyS	O
mRNA	O
to	O
subserve	O
this	O
clinically	O
vital	O
function	O
.	O

Although	O
expression	O
of	O
the	O
two	O
major	O
BLyS	O
isoforms	O
was	O
highly	O
coordinate	O
among	O
SLE	O
patients	S-Species
,	O
there	O
were	O
several	O
patients	S-Species
in	O
whom	O
Delta	O
BLyS	O
mRNA	O
levels	O
were	O
markedly	O
greater	O
than	O
or	O
less	O
than	O
the	O
expected	O
values	O
based	O
on	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
dysregulation	O
of	O
Delta	O
BLyS	O
may	O
contribute	O
to	O
overall	O
BLyS	O
dysregulation	O
in	O
at	O
least	O
some	O
SLE	O
patients	S-Species
.	O

It	O
is	O
known	O
that	O
interferon	O
-	O
gamma	O
,	O
interleukin	O
-	O
10	O
,	O
interferon	O
-	O
alpha	O
,	O
and	O
CD154	O
can	O
upregulate	O
full	O
-	O
length	O
BLyS	O
mRNA	O
levels	O
[	O
14	O
,	O
22	O
,	O
35	O
]	O
,	O
but	O
it	O
is	O
not	O
known	O
what	O
effects	O
these	O
or	O
other	O
cytokines	O
/	O
cell	O
-	O
surface	O
structures	O
have	O
on	O
Delta	O
BLyS	O
expression	O
.	O

Further	O
investigation	O
of	O
the	O
regulation	O
of	O
Delta	O
BLyS	O
and	O
the	O
differential	O
expression	O
of	O
BLyS	O
isoforms	O
is	O
certainly	O
warranted	O
.	O

Although	O
the	O
associations	O
between	O
full	O
-	O
length	O
BLyS	O
and	O
/	O
or	O
Delta	O
BLyS	O
mRNA	O
levels	O
and	O
disease	O
activity	O
in	O
SLE	O
were	O
usually	O
strong	O
when	O
the	O
SLE	O
cohort	O
was	O
analyzed	O
in	O
aggregate	O
,	O
there	O
were	O
several	O
SLE	O
patients	S-Species
in	O
whom	O
BLyS	O
mRNA	O
levels	O
were	O
quite	O
high	O
despite	O
little	O
objective	O
ongoing	O
disease	O
activity	O
,	O
and	O
there	O
were	O
several	O
SLE	O
patients	S-Species
in	O
whom	O
BLyS	O
mRNA	O
levels	O
were	O
low	O
despite	O
considerable	O
ongoing	O
disease	O
activity	O
.	O

One	O
must	O
recognize	O
that	O
the	O
bulk	O
of	O
the	O
pathogenic	O
autoimmune	O
responses	O
probably	O
takes	O
place	O
in	O
the	O
spleen	O
and	O
lymph	O
nodes	O
,	O
rather	O
than	O
in	O
the	O
peripheral	O
blood	O
,	O
where	O
myeloid	O
lineage	O
cells	O
(	O
for	O
example	O
,	O
dendritic	O
cells	O
)	O
produce	O
BLyS	O
and	O
support	O
B	O
cell	O
survival	O
and	O
expansion	O
[	O
36	O
]	O
.	O

Local	O
BLyS	O
production	O
in	O
the	O
secondary	O
lymphoid	O
tissues	O
will	O
be	O
more	O
important	O
to	O
the	O
development	O
and	O
maintenance	O
of	O
an	O
autoimmune	O
response	O
than	O
will	O
remote	O
BLyS	O
levels	O
in	O
the	O
circulation	O
.	O

Because	O
at	O
least	O
some	O
autoreactive	O
B	O
cells	O
may	O
be	O
more	O
sensitive	O
to	O
BLyS	O
-	O
mediated	O
survival	O
signals	O
than	O
non	O
-	O
autoreactive	O
B	O
cells	O
[	O
37	O
,	O
38	O
]	O
,	O
local	O
increases	O
in	O
BLyS	O
production	O
could	O
preferentially	O
promote	O
expansion	O
of	O
autoreactive	O
B	O
cells	O
.	O

These	O
cells	O
,	O
in	O
turn	O
,	O
could	O
activate	O
autoreactive	O
T	O
cells	O
by	O
presenting	O
autoantigen	O
to	O
them	O
,	O
and	O
some	O
of	O
the	O
autoreactive	O
B	O
cells	O
would	O
respond	O
to	O
T	O
cell	O
derived	O
signals	O
and	O
mature	O
into	O
(	O
pathogenic	O
)	O
autoantibody	O
secreting	O
plasma	O
cells	O
.	O

In	O
contrast	O
to	O
murine	S-Species
studies	O
,	O
in	O
which	O
investigators	O
can	O
readily	O
harvest	O
and	O
analyze	O
lymphoid	O
and	O
myeloid	O
lineage	O
cells	O
from	O
any	O
site	O
(	O
for	O
example	O
,	O
spleen	O
,	O
bone	O
marrow	O
)	O
,	O
such	O
is	O
not	O
the	O
case	O
for	O
human	S-Species
studies	O
.	O

Peripheral	O
blood	O
is	O
the	O
only	O
site	O
readily	O
accessible	O
for	O
human	S-Species
studies	O
,	O
and	O
it	O
is	O
possible	O
that	O
,	O
at	O
least	O
in	O
some	O
patients	S-Species
,	O
BLyS	O
mRNA	O
levels	O
in	O
circulating	O
leukocytes	O
do	O
not	O
reflect	O
local	O
BLyS	O
production	O
in	O
the	O
secondary	O
lymphoid	O
tissues	O
.	O

One	O
must	O
also	O
recognize	O
that	O
disease	O
activity	O
in	O
SLE	O
is	O
not	O
solely	O
driven	O
by	O
B	O
cells	O
.	O

Systemic	O
inflammation	O
and	O
SLE	O
flares	O
can	O
be	O
triggered	O
via	O
B	O
cell	O
independent	O
means	O
.	O

Not	O
all	O
SLE	O
patients	S-Species
treated	O
with	O
a	O
B	O
cell	O
depleting	O
course	O
of	O
rituximab	O
experience	O
clinical	O
remission	O
[	O
39	O
]	O
,	O
strongly	O
pointing	O
to	O
the	O
importance	O
of	O
non	O
-	O
B	O
cells	O
in	O
disease	O
pathogenesis	O
/	O
maintenance	O
.	O

Conversely	O
,	O
not	O
all	O
pathogenic	O
B	O
cells	O
necessarily	O
require	O
high	O
levels	O
of	O
BLyS	O
to	O
effect	O
their	O
pathogenicity	O
.	O

Murine	O
studies	O
have	O
unequivocally	O
documented	O
B	O
cell	O
subpopulations	O
that	O
do	O
not	O
depend	O
upon	O
BLyS	O
for	O
their	O
survival	O
[	O
40	O
-	O
42	O
]	O
.	O

Although	O
mice	S-Species
completely	O
devoid	O
of	O
BLyS	O
have	O
reduced	O
numbers	O
of	O
mature	O
B	O
cells	O
and	O
harbor	O
reduced	O
levels	O
of	O
immunoglobulin	O
,	O
these	O
reductions	O
are	O
incomplete	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
some	O
SLE	O
patients	S-Species
harbor	O
pathogenic	O
B	O
cells	O
that	O
are	O
relatively	O
insensitive	O
to	O
BLyS	O
and	O
could	O
drive	O
considerable	O
disease	O
activity	O
even	O
in	O
the	O
context	O
of	O
low	O
endogenous	O
BLyS	O
production	O
.	O

Conversely	O
,	O
patients	S-Species
with	O
high	O
BLyS	O
mRNA	O
levels	O
may	O
be	O
those	O
patients	S-Species
whose	O
disease	O
is	O
strongly	O
driven	O
by	O
BLyS	O
and	O
may	O
be	O
especially	O
helped	O
by	O
BLyS	O
antagonist	O
therapy	O
.	O

Future	O
clinical	O
trials	O
should	O
be	O
able	O
to	O
establish	O
whether	O
the	O
BLyS	O
mRNA	O
levels	O
are	O
good	O
predictors	O
of	O
response	O
to	O
such	O
agents	O
.	O

Conclusion	O

Plasma	O
total	O
immunoglobulin	O
,	O
IgG	O
,	O
and	O
IgA	O
levels	O
and	O
disease	O
activity	O
(	O
as	O
measured	O
by	O
SLEDAI	O
)	O
in	O
SLE	O
patients	S-Species
correlate	O
more	O
closely	O
with	O
peripheral	O
blood	O
leukocyte	O
levels	O
of	O
BLyS	O
mRNA	O
than	O
with	O
plasma	O
levels	O
of	O
BLyS	O
protein	O
.	O

These	O
findings	O
suggest	O
that	O
BLyS	O
mRNA	O
levels	O
better	O
reflect	O
in	O
vivo	O
BLyS	O
production	O
than	O
do	O
circulating	O
BLyS	O
protein	O
levels	O
,	O
and	O
may	O
be	O
a	O
useful	O
biomarker	O
in	O
the	O
clinical	O
monitoring	O
of	O
SLE	O
patients	S-Species
.	O

These	O
findings	O
also	O
support	O
the	O
premise	O
that	O
BLyS	O
overexpression	O
not	O
only	O
promotes	O
development	O
of	O
disease	O
but	O
also	O
actively	O
contributes	O
to	O
the	O
ongoing	O
maintenance	O
of	O
disease	O
in	O
SLE	O
patients	S-Species
.	O

This	O
reinforces	O
the	O
rationale	O
underlying	O
clinical	O
trials	O
with	O
BLyS	O
antagonists	O
in	O
SLE	O
.	O

Abbreviations	O

anti	O
-	O
dsDNA	O
=	O
anti	O
-	O
double	O
-	O
stranded	O
DNA	O
;	O
BLyS	O
=	O
B	O
lymphocyte	O
stimulator	O
;	O
bp	O
=	O
base	O
pairs	O
;	O
Ct	O
=	O
threshold	O
cycle	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
PCR	O
=	O
polymerase	O
chain	O
reaction	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
;	O
SLE	O
=	O
systemic	O
lupus	O
erythematosus	O
;	O
SLEDAI	O
=	O
SLE	O
Disease	O
Activity	O
Index	O
.	O

Competing	O
interests	O

TSM	O
and	O
DMH	O
were	O
employees	O
of	O
Human	S-Species
Genome	O
Sciences	O
(	O
HGS	O
)	O
at	O
the	O
time	O
the	O
investigation	O
was	O
conducted	O
.	O

(	O
DMH	O
has	O
since	O
left	O
the	O
company	O
.	O
)	O
WS	O
has	O
received	O
research	O
support	O
from	O
HGS	O
and	O
has	O
served	O
as	O
a	O
consultant	O
to	O
HGS	O
(	O
<	O
$	O
10	O
,	O
000	O
)	O
.	O

CEC	O
,	O
ALG	O
,	O
and	O
DN	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

CEC	O
identified	O
and	O
recruited	O
all	O
participants	S-Species
;	O
collected	O
all	O
the	O
blood	O
samples	O
and	O
reviewed	O
all	O
the	O
medical	O
charts	O
;	O
and	O
wrote	O
the	O
initial	O
working	O
draft	O
of	O
this	O
manuscript	O
.	O

ALG	O
developed	O
and	O
performed	O
all	O
the	O
real	O
-	O
time	O
PCR	O
assays	O
and	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

TSM	O
performed	O
the	O
plasma	O
BLyS	O
protein	O
and	O
anti	O
-	O
BLyS	O
assays	O
and	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

DMH	O
assisted	O
in	O
the	O
design	O
in	O
the	O
study	O
,	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
,	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

DN	O
assisted	O
in	O
the	O
design	O
in	O
the	O
study	O
,	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
,	O
and	O
in	O
writing	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

WS	O
conceived	O
the	O
study	O
,	O
supervised	O
the	O
recruitment	O
of	O
participants	S-Species
,	O
performed	O
the	O
statistical	O
analyses	O
,	O
assisted	O
in	O
the	O
interpretation	O
of	O
the	O
results	O
,	O
and	O
supervised	O
the	O
editing	O
of	O
the	O
manuscript	O
to	O
its	O
final	O
form	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
version	O
.	O

Travel	O
-	O
Related	O
Venous	O
Thrombosis	O
:	O
Results	O
from	O
a	O
Large	O
Population	O
-	O
Based	O
Case	O
Control	O
Study	O
(	O
MEGA	O
Study	O
)	O

Abstract	O

Background	O

Recent	O
studies	O
have	O
indicated	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
after	O
air	O
travel	O
.	O

Nevertheless	O
,	O
questions	O
on	O
the	O
magnitude	O
of	O
risk	O
,	O
the	O
underlying	O
mechanism	O
,	O
and	O
modifying	O
factors	O
remain	O
unanswered	O
.	O

Methods	O
and	O
Findings	O

We	O
studied	O
the	O
effect	O
of	O
various	O
modes	O
and	O
duration	O
of	O
travel	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
in	O
a	O
large	O
ongoing	O
case	O
-	O
control	O
study	O
on	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
in	O
an	O
unselected	O
population	O
(	O
MEGA	O
study	O
)	O
.	O

We	O
also	O
assessed	O
the	O
combined	O
effect	O
of	O
travel	O
and	O
prothrombotic	O
mutations	O
,	O
body	O
mass	O
index	O
,	O
height	O
,	O
and	O
oral	O
contraceptive	O
use	O
.	O

Since	O
March	O
1999	O
,	O
consecutive	O
patients	S-Species
younger	O
than	O
70	O
y	O
with	O
a	O
first	O
venous	O
thrombosis	O
have	O
been	O
invited	O
to	O
participate	O
in	O
the	O
study	O
,	O
with	O
their	O
partners	O
serving	O
as	O
matched	O
control	O
individuals	O
.	O

Information	O
has	O
been	O
collected	O
on	O
acquired	O
and	O
genetic	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

Of	O
1	O
,	O
906	O
patients	S-Species
,	O
233	O
had	O
traveled	O
for	O
more	O
than	O
4	O
h	O
in	O
the	O
8	O
wk	O
preceding	O
the	O
event	O
.	O

Traveling	O
in	O
general	O
was	O
found	O
to	O
increase	O
the	O
risk	O
of	O
venous	O
thrombosis	O
2	O
-	O
fold	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
2	O
.	O
1	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
5	O
-	O
3	O
.	O
0	O
)	O
.	O

The	O
risk	O
of	O
flying	O
was	O
similar	O
to	O
the	O
risks	O
of	O
traveling	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
.	O

The	O
risk	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
traveling	O
.	O

Travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
led	O
to	O
a	O
high	O
relative	O
risk	O
of	O
thrombosis	O
in	O
individuals	O
with	O
factor	O
V	O
Leiden	O
(	O
OR	O
8	O
.	O
1	O
;	O
95	O
%	O
CI	O
2	O
.	O
7	O
-	O
24	O
.	O
7	O
)	O
,	O
in	O
those	O
who	O
had	O
a	O
body	O
mass	O
index	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
(	O
OR	O
9	O
.	O
9	O
;	O
95	O
%	O
CI	O
3	O
.	O
6	O
-	O
27	O
.	O
6	O
)	O
,	O
in	O
those	O
who	O
were	O
more	O
than	O
1	O
.	O
90	O
m	O
tall	O
(	O
OR	O
4	O
.	O
7	O
;	O
95	O
%	O
CI	O
1	O
.	O
4	O
-	O
15	O
.	O
4	O
)	O
,	O
and	O
in	O
those	O
who	O
used	O
oral	O
contraceptives	O
(	O
estimated	O
OR	O
>	O
20	O
)	O
.	O

For	O
air	O
travel	O
these	O
synergistic	O
findings	O
were	O
more	O
apparent	O
,	O
while	O
people	S-Species
shorter	O
than	O
1	O
.	O
60	O
m	O
had	O
an	O
increased	O
risk	O
of	O
thrombosis	O
after	O
air	O
travel	O
(	O
OR	O
4	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
9	O
-	O
25	O
.	O
6	O
)	O
as	O
well	O
.	O

Conclusions	O

The	O
risk	O
of	O
venous	O
thrombosis	O
after	O
travel	O
is	O
moderately	O
increased	O
for	O
all	O
modes	O
of	O
travel	O
.	O

Subgroups	O
exist	O
in	O
which	O
the	O
risk	O
is	O
highly	O
increased	O
.	O

Background	O
.	O

Recently	O
there	O
has	O
been	O
increasing	O
concern	O
that	O
blood	O
clots	O
(	O
thromboses	O
)	O
in	O
the	O
leg	O
or	O
lungs	O
occur	O
with	O
greater	O
frequency	O
after	O
air	O
travel	O
.	O

Several	O
theories	O
have	O
been	O
put	O
forward	O
to	O
explain	O
why	O
this	O
increase	O
might	O
happen	O
,	O
including	O
the	O
fact	O
that	O
air	O
passengers	O
tend	O
to	O
not	O
move	O
around	O
much	O
,	O
or	O
possibly	O
that	O
reduced	O
amounts	O
of	O
oxygen	O
in	O
the	O
blood	O
make	O
the	O
blood	O
more	O
likely	O
to	O
clot	O
.	O

Understanding	O
what	O
causes	O
such	O
clots	O
is	O
important	O
as	O
it	O
would	O
help	O
us	O
come	O
up	O
with	O
suggestions	O
of	O
ways	O
to	O
prevent	O
them	O
.	O

Why	O
Was	O
This	O
Study	O
Done	O
?	O

It	O
is	O
not	O
possible	O
to	O
test	O
in	O
a	O
controlled	O
trial	O
whether	O
travel	O
causes	O
an	O
increase	O
in	O
blood	O
clots	O
,	O
so	O
the	O
next	O
best	O
way	O
of	O
studying	O
this	O
problem	O
is	O
to	O
do	O
a	O
case	O
-	O
control	O
study	O
,	O
in	O
which	O
people	S-Species
with	O
blood	O
clots	O
(	O
cases	O
)	O
are	O
compared	O
with	O
similar	O
people	S-Species
who	O
don	O
'	O
t	O
have	O
a	O
blood	O
clot	O
(	O
controls	O
--	O
in	O
this	O
case	O
,	O
the	O
partners	O
of	O
the	O
cases	O
)	O
,	O
and	O
the	O
differences	O
in	O
a	O
number	O
of	O
contributing	O
factors	O
are	O
assessed	O
.	O

What	O
Did	O
the	O
Researchers	O
Do	O
and	O
Find	O
?	O

Since	O
1999	O
,	O
the	O
MEGA	O
(	O
Multiple	O
Environmental	O
and	O
Genetic	O
Assessment	O
of	O
Risk	O
Factors	O
for	O
Venous	O
Thrombosis	O
)	O
study	O
has	O
aimed	O
to	O
identify	O
all	O
people	S-Species
in	O
an	O
area	O
of	O
the	O
Netherlands	O
who	O
develop	O
a	O
blood	O
clot	O
for	O
the	O
first	O
time	O
,	O
by	O
seeking	O
out	O
people	S-Species
who	O
receive	O
treatment	O
for	O
blood	O
clots	O
.	O

At	O
the	O
time	O
of	O
this	O
report	O
,	O
1	O
,	O
906	O
people	S-Species
with	O
clots	O
had	O
been	O
found	O
;	O
of	O
these	O
,	O
233	O
had	O
traveled	O
for	O
more	O
than	O
four	O
hours	O
in	O
the	O
eight	O
weeks	O
preceding	O
the	O
event	O
.	O

Traveling	O
in	O
general	O
was	O
found	O
to	O
increase	O
the	O
risk	O
of	O
clots	O
two	O
-	O
fold	O
,	O
and	O
the	O
risk	O
was	O
highest	O
in	O
the	O
week	O
after	O
traveling	O
.	O

The	O
risk	O
of	O
flying	O
was	O
similar	O
to	O
the	O
risk	O
of	O
traveling	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
,	O
and	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
traveling	O
.	O

Certain	O
other	O
factors	O
increased	O
the	O
risk	O
of	O
a	O
blood	O
clot	O
even	O
more	O
,	O
such	O
as	O
having	O
a	O
particular	O
mutation	O
(	O
known	O
as	O
factor	O
V	O
Leiden	O
)	O
in	O
a	O
gene	O
involved	O
in	O
blood	O
clotting	O
,	O
having	O
a	O
body	O
mass	O
index	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
(	O
over	O
30	O
kg	O
/	O
m2	O
is	O
defined	O
as	O
being	O
obese	O
)	O
,	O
being	O
more	O
than	O
1	O
.	O
90	O
meters	O
tall	O
,	O
and	O
using	O
oral	O
contraceptives	O
.	O

All	O
these	O
factors	O
made	O
the	O
risk	O
of	O
clots	O
especially	O
after	O
air	O
travel	O
worse	O
;	O
in	O
addition	O
,	O
people	S-Species
shorter	O
than	O
1	O
.	O
60	O
meters	O
also	O
had	O
an	O
increased	O
risk	O
of	O
thrombosis	O
after	O
air	O
travel	O
.	O

However	O
,	O
it	O
should	O
be	O
borne	O
in	O
mind	O
that	O
the	O
number	O
of	O
cases	O
in	O
each	O
of	O
these	O
various	O
groups	O
was	O
quite	O
small	O
,	O
and	O
the	O
overall	O
risk	O
of	O
getting	O
a	O
thrombosis	O
is	O
still	O
low	O
.	O

What	O
Do	O
These	O
Findings	O
Mean	O
?	O

Since	O
the	O
risks	O
of	O
thrombosis	O
are	O
increased	O
for	O
all	O
types	O
of	O
long	O
travel	O
,	O
it	O
seems	O
that	O
the	O
main	O
factor	O
causing	O
the	O
thrombosis	O
is	O
immobility	O
.	O

However	O
,	O
since	O
the	O
risk	O
is	O
even	O
higher	O
for	O
air	O
travel	O
,	O
the	O
relative	O
lack	O
of	O
oxygen	O
may	O
also	O
play	O
a	O
part	O
.	O

One	O
interesting	O
aspect	O
of	O
this	O
study	O
is	O
that	O
the	O
researchers	O
used	O
partners	O
as	O
controls	O
;	O
in	O
order	O
to	O
be	O
sure	O
that	O
doing	O
this	O
did	O
not	O
make	O
the	O
results	O
invalid	O
,	O
the	O
researchers	O
had	O
to	O
carefully	O
adjust	O
for	O
differences	O
between	O
the	O
cases	O
and	O
controls	O
,	O
such	O
as	O
the	O
fact	O
that	O
partners	O
were	O
generally	O
of	O
the	O
opposite	O
sex	O
.	O

In	O
a	O
related	O
Perspective	O
(	O
DOI	O
:	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pmed	O
.	O
0030300	O
)	O
,	O
Kenneth	O
Rothman	O
discusses	O
the	O
study	O
further	O
.	O

Additional	O
Information	O
.	O

Please	O
access	O
these	O
Web	O
sites	O
via	O
the	O
online	O
version	O
of	O
this	O
summary	O
at	O
http	O
:	O
/	O
/	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pmed	O
.	O
0030307	O
.	O

Introduction	O

Interest	O
in	O
the	O
role	O
of	O
air	O
travel	O
in	O
the	O
pathogenesis	O
of	O
venous	O
thrombosis	O
has	O
heightened	O
in	O
the	O
past	O
5	O
y	O
[	O
1	O
-	O
5	O
]	O
.	O

Venous	O
thrombosis	O
was	O
first	O
linked	O
to	O
air	O
travel	O
in	O
1954	O
[	O
6	O
]	O
,	O
and	O
as	O
air	O
travel	O
has	O
become	O
more	O
and	O
more	O
common	O
,	O
many	O
case	O
reports	O
and	O
case	O
series	O
have	O
been	O
published	O
since	O
.	O

Several	O
clinical	O
studies	O
have	O
shown	O
an	O
association	O
between	O
air	O
travel	O
and	O
the	O
risk	O
of	O
venous	O
thrombosis	O
.	O

In	O
a	O
series	O
of	O
individuals	O
who	O
died	O
suddenly	O
at	O
Heathrow	O
Airport	O
,	O
death	O
occurred	O
far	O
more	O
often	O
in	O
the	O
arrival	O
than	O
in	O
the	O
departure	O
area	O
[	O
7	O
]	O
.	O

Two	O
similar	O
studies	O
described	O
a	O
"	O
dose	O
-	O
response	O
"	O
relation	O
:	O
the	O
risk	O
of	O
pulmonary	O
embolism	O
in	O
air	O
travelers	O
increased	O
with	O
the	O
distance	O
traveled	O
[	O
5	O
,	O
8	O
]	O
.	O

A	O
number	O
of	O
case	O
-	O
control	O
studies	O
,	O
however	O
,	O
have	O
shown	O
conflicting	O
results	O
[	O
9	O
-	O
11	O
]	O
.	O

More	O
recently	O
,	O
a	O
2	O
-	O
fold	O
increased	O
risk	O
in	O
patients	S-Species
who	O
had	O
traveled	O
by	O
air	O
was	O
described	O
in	O
a	O
case	O
-	O
control	O
study	O
among	O
210	O
patients	S-Species
and	O
210	O
controls	O
[	O
3	O
]	O
.	O

A	O
case	O
-	O
crossover	O
study	O
based	O
on	O
record	O
linking	O
in	O
Australia	O
described	O
a	O
4	O
-	O
fold	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
in	O
the	O
first	O
2	O
wk	O
after	O
a	O
long	O
-	O
haul	O
flight	O
[	O
1	O
]	O
.	O

In	O
terms	O
of	O
absolute	O
risk	O
,	O
two	O
studies	O
found	O
similar	O
results	O
:	O
one	O
performed	O
in	O
New	O
Zealand	O
found	O
a	O
frequency	O
of	O
1	O
%	O
of	O
venous	O
thrombosis	O
in	O
878	O
individuals	O
who	O
had	O
traveled	O
by	O
air	O
for	O
at	O
least	O
10	O
h	O
[	O
2	O
]	O
,	O
and	O
a	O
German	O
study	O
found	O
venous	O
thrombotic	O
events	O
in	O
2	O
.	O
8	O
%	O
of	O
964	O
individuals	O
who	O
had	O
traveled	O
for	O
more	O
than	O
8	O
h	O
in	O
an	O
airplane	O
,	O
as	O
compared	O
to	O
1	O
%	O
in	O
1	O
,	O
213	O
controls	O
[	O
4	O
]	O
.	O

The	O
events	O
in	O
both	O
studies	O
were	O
mostly	O
asymptomatic	O
.	O

The	O
available	O
evidence	O
suggests	O
that	O
the	O
overall	O
risk	O
of	O
venous	O
thrombosis	O
is	O
moderately	O
increased	O
after	O
air	O
travel	O
.	O

Nevertheless	O
,	O
many	O
questions	O
remain	O
unanswered	O
:	O
the	O
exact	O
underlying	O
mechanism	O
is	O
still	O
unknown	O
,	O
and	O
,	O
related	O
to	O
this	O
,	O
it	O
is	O
not	O
clear	O
whether	O
the	O
risk	O
is	O
increased	O
after	O
air	O
travel	O
only	O
or	O
after	O
long	O
-	O
distance	O
travel	O
in	O
general	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
the	O
combination	O
of	O
other	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
and	O
travel	O
has	O
not	O
yet	O
been	O
systematically	O
studied	O
,	O
with	O
the	O
exception	O
of	O
a	O
study	O
by	O
Martinelli	O
et	O
al	O
.	O
,	O
who	O
found	O
an	O
additionally	O
increased	O
risk	O
in	O
patients	S-Species
with	O
thrombophilia	O
and	O
patients	S-Species
who	O
used	O
oral	O
contraceptives	O
[	O
3	O
]	O
.	O

The	O
Multiple	O
Environmental	O
and	O
Genetic	O
Assessment	O
(	O
MEGA	O
)	O
study	O
of	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
is	O
a	O
large	O
ongoing	O
case	O
-	O
control	O
study	O
aimed	O
at	O
assessing	O
the	O
combined	O
effect	O
of	O
genetic	O
and	O
acquired	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

Cases	O
and	O
control	O
individuals	O
are	O
questioned	O
about	O
--	O
among	O
many	O
other	O
items	O
--	O
travel	O
that	O
occurred	O
shortly	O
before	O
the	O
event	O
.	O

This	O
provides	O
an	O
opportunity	O
to	O
assess	O
the	O
effect	O
of	O
travel	O
on	O
the	O
risk	O
of	O
thrombosis	O
in	O
an	O
unselected	O
population	O
,	O
as	O
well	O
as	O
the	O
effect	O
of	O
the	O
combination	O
of	O
travel	O
with	O
several	O
other	O
risk	O
factors	O
for	O
thrombosis	O
.	O

Methods	O

Study	O
Design	O

Since	O
March	O
1999	O
,	O
consecutive	O
patients	S-Species
younger	O
than	O
70	O
y	O
with	O
a	O
first	O
deep	O
-	O
vein	O
thrombosis	O
(	O
DVT	O
)	O
or	O
pulmonary	O
embolism	O
(	O
PE	O
)	O
have	O
been	O
identified	O
at	O
six	O
regional	O
anticoagulation	O
clinics	O
in	O
the	O
Netherlands	O
.	O

Anticoagulant	O
clinics	O
monitor	O
the	O
anticoagulant	O
therapy	O
of	O
all	O
patients	S-Species
in	O
a	O
well	O
-	O
defined	O
geographical	O
area	O
,	O
allowing	O
us	O
to	O
identify	O
consecutive	O
and	O
unselected	O
patients	S-Species
with	O
thrombosis	O
.	O

Patients	S-Species
who	O
were	O
unable	O
to	O
fill	O
in	O
the	O
questionnaire	O
(	O
because	O
of	O
language	O
or	O
severe	O
psychiatric	O
problems	O
)	O
,	O
as	O
well	O
as	O
those	O
who	O
died	O
soon	O
after	O
the	O
venous	O
thrombosis	O
or	O
who	O
were	O
in	O
the	O
end	O
stage	O
of	O
a	O
disease	O
and	O
for	O
that	O
reason	O
did	O
not	O
participate	O
,	O
were	O
not	O
included	O
.	O

All	O
others	O
were	O
considered	O
eligible	O
.	O

Partners	O
of	O
these	O
patients	S-Species
were	O
invited	O
as	O
control	O
individuals	O
,	O
and	O
the	O
same	O
exclusion	O
criteria	O
were	O
applied	O
.	O

All	O
participants	S-Species
filled	O
in	O
a	O
detailed	O
standardized	O
questionnaire	O
on	O
general	O
demographic	O
and	O
anthropomorphic	O
characteristics	O
,	O
as	O
well	O
as	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

The	O
questionnaire	O
was	O
sent	O
to	O
all	O
participants	S-Species
within	O
a	O
few	O
weeks	O
after	O
the	O
event	O
and	O
covered	O
the	O
period	O
of	O
1	O
y	O
prior	O
to	O
the	O
date	O
of	O
the	O
thrombotic	O
event	O
(	O
index	O
date	O
)	O
.	O

When	O
the	O
participant	S-Species
was	O
unable	O
to	O
fill	O
in	O
the	O
questionnaire	O
we	O
asked	O
questions	O
by	O
phone	O
,	O
using	O
a	O
standardized	O
mini	O
-	O
questionnaire	O
.	O

Three	O
months	O
after	O
the	O
patients	S-Species
had	O
discontinued	O
their	O
oral	O
anticoagulant	O
therapy	O
,	O
they	O
were	O
invited	O
with	O
their	O
partners	O
to	O
the	O
anticoagulation	O
clinic	O
for	O
a	O
blood	O
sample	O
.	O

In	O
those	O
patients	S-Species
who	O
continued	O
to	O
take	O
oral	O
anticoagulant	O
therapy	O
for	O
more	O
than	O
1	O
y	O
after	O
the	O
event	O
,	O
blood	O
was	O
drawn	O
during	O
therapy	O
.	O

If	O
participants	S-Species
were	O
unable	O
to	O
come	O
to	O
the	O
clinic	O
,	O
a	O
buccal	O
swab	O
was	O
sent	O
by	O
mail	O
to	O
replace	O
the	O
blood	O
sample	O
for	O
DNA	O
extraction	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Leiden	O
University	O
Medical	O
Center	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	S-Species
[	O
12	O
]	O
.	O

Validation	O
Study	O
of	O
Thrombosis	O
Diagnosis	O

Discharge	O
letters	O
or	O
diagnostic	O
reports	O
of	O
the	O
venous	O
thrombotic	O
event	O
were	O
obtained	O
for	O
a	O
sample	O
of	O
742	O
patients	S-Species
who	O
had	O
their	O
first	O
thrombosis	O
between	O
March	O
1999	O
and	O
March	O
2000	O
.	O

The	O
diagnostic	O
management	O
of	O
the	O
patients	S-Species
was	O
compared	O
to	O
the	O
diagnostic	O
procedure	O
as	O
described	O
in	O
the	O
Dutch	O
consensus	O
[	O
13	O
]	O
.	O

Diagnosis	O
of	O
clinically	O
suspected	O
DVT	O
of	O
the	O
leg	O
is	O
based	O
on	O
a	O
clinical	O
score	O
,	O
serial	O
compression	O
ultrasonography	O
,	O
and	O
D	O
-	O
dimer	O
assay	O
.	O

Objective	O
testing	O
of	O
clinically	O
suspected	O
pulmonary	O
embolism	O
is	O
based	O
on	O
perfusion	O
and	O
ventilation	O
scintigraphy	O
,	O
ultrasonography	O
of	O
the	O
leg	O
veins	O
,	O
pulmonary	O
angiography	O
,	O
or	O
helical	O
computed	O
tomography	O
.	O

Out	O
of	O
395	O
patients	S-Species
with	O
DVT	O
of	O
the	O
leg	O
,	O
384	O
(	O
97	O
%	O
)	O
were	O
objectively	O
diagnosed	O
,	O
while	O
out	O
of	O
347	O
patients	S-Species
with	O
PE	O
,	O
271	O
(	O
78	O
%	O
)	O
were	O
confirmed	O
with	O
objective	O
testing	O
as	O
certainly	O
having	O
PE	O
.	O

Since	O
the	O
diagnosis	O
appears	O
to	O
be	O
made	O
by	O
objective	O
methods	O
in	O
virtually	O
all	O
cases	O
of	O
DVT	O
,	O
while	O
being	O
more	O
ambiguous	O
for	O
PE	O
,	O
we	O
also	O
analyzed	O
these	O
two	O
manifestations	O
of	O
venous	O
thrombosis	O
separately	O
.	O

Current	O
Analysis	O

For	O
the	O
current	O
analysis	O
we	O
were	O
interested	O
in	O
the	O
effects	O
of	O
travel	O
,	O
and	O
its	O
combined	O
effect	O
with	O
other	O
common	O
risk	O
factors	O
for	O
venous	O
thrombosis	O
.	O

Patients	S-Species
with	O
a	O
solitary	O
arm	O
thrombosis	O
were	O
excluded	O
from	O
this	O
analysis	O
.	O

Of	O
3	O
,	O
902	O
eligible	O
cases	O
,	O
diagnosed	O
up	O
to	O
May	O
2002	O
,	O
656	O
did	O
not	O
participate	O
for	O
various	O
reasons	O
(	O
such	O
as	O
not	O
willing	O
or	O
not	O
reachable	O
)	O
,	O
leading	O
to	O
a	O
response	O
of	O
83	O
%	O
.	O

A	O
further	O
3	O
%	O
responded	O
only	O
to	O
the	O
mini	O
-	O
questionnaire	O
,	O
taken	O
by	O
phone	O
,	O
which	O
did	O
not	O
contain	O
questions	O
about	O
travel	O
.	O

Of	O
the	O
remaining	O
3	O
,	O
111	O
cases	O
,	O
78	O
%	O
had	O
a	O
partner	O
,	O
77	O
%	O
of	O
whom	O
were	O
willing	O
to	O
participate	O
,	O
which	O
left	O
1	O
,	O
867	O
couples	O
.	O

Additionally	O
,	O
229	O
partners	O
were	O
identified	O
for	O
whom	O
the	O
corresponding	O
patient	S-Species
originally	O
participated	O
but	O
was	O
later	O
found	O
not	O
to	O
be	O
eligible	O
(	O
aged	O
over	O
70	O
y	O
,	O
or	O
not	O
a	O
first	O
thrombotic	O
event	O
)	O
.	O

These	O
control	O
individuals	O
were	O
matched	O
on	O
sex	O
and	O
5	O
-	O
y	O
age	O
groups	O
to	O
one	O
of	O
the	O
557	O
patients	S-Species
whose	O
partner	O
did	O
not	O
want	O
to	O
participate	O
,	O
so	O
an	O
extra	O
229	O
pairs	O
were	O
included	O
,	O
making	O
a	O
total	O
of	O
4	O
,	O
192	O
participants	S-Species
(	O
2	O
,	O
096	O
pairs	O
)	O
.	O

As	O
part	O
of	O
the	O
general	O
questionnaire	O
,	O
questions	O
had	O
been	O
asked	O
about	O
whether	O
or	O
not	O
respondents	O
had	O
traveled	O
for	O
more	O
than	O
4	O
h	O
in	O
the	O
3	O
mo	O
before	O
the	O
index	O
date	O
,	O
about	O
the	O
travel	O
date	O
,	O
and	O
about	O
mode	O
and	O
duration	O
of	O
travel	O
.	O

We	O
assessed	O
the	O
occurrence	O
of	O
thrombosis	O
in	O
relation	O
to	O
the	O
period	O
of	O
time	O
that	O
had	O
passed	O
since	O
traveling	O
.	O

Travel	O
was	O
defined	O
in	O
the	O
analysis	O
as	O
at	O
least	O
one	O
journey	O
with	O
a	O
duration	O
of	O
at	O
least	O
four	O
uninterrupted	O
hours	O
during	O
the	O
8	O
-	O
wk	O
period	O
before	O
the	O
event	O
.	O

During	O
the	O
analysis	O
it	O
appeared	O
that	O
some	O
individuals	O
had	O
provided	O
dates	O
of	O
travel	O
after	O
the	O
event	O
instead	O
of	O
before	O
.	O

As	O
there	O
was	O
only	O
one	O
opportunity	O
to	O
fill	O
in	O
such	O
a	O
date	O
,	O
we	O
had	O
no	O
information	O
about	O
the	O
period	O
before	O
the	O
event	O
.	O

This	O
was	O
the	O
case	O
in	O
88	O
cases	O
and	O
146	O
controls	O
.	O

We	O
excluded	O
these	O
individuals	O
and	O
their	O
partners	O
,	O
which	O
left	O
3	O
,	O
812	O
participants	S-Species
(	O
1	O
,	O
906	O
pairs	O
)	O
for	O
the	O
analysis	O
.	O

Because	O
we	O
selected	O
the	O
partners	O
of	O
the	O
cases	O
as	O
control	O
individuals	O
,	O
and	O
because	O
it	O
turned	O
out	O
,	O
as	O
expected	O
,	O
that	O
couples	O
tend	O
to	O
travel	O
together	O
,	O
we	O
performed	O
a	O
conditional	O
logistic	O
regression	O
analysis	O
to	O
calculate	O
odds	O
ratios	O
(	O
ORs	O
)	O
for	O
the	O
relation	O
between	O
travel	O
and	O
venous	O
thrombosis	O
.	O

This	O
method	O
fully	O
takes	O
this	O
matching	O
into	O
account	O
,	O
and	O
leads	O
to	O
unbiased	O
estimates	O
,	O
with	O
adjustment	O
for	O
all	O
factors	O
in	O
which	O
cases	O
and	O
controls	O
tend	O
to	O
be	O
similar	O
,	O
e	O
.	O
g	O
.	O
,	O
socioeconomic	O
class	O
[	O
14	O
]	O
.	O

Details	O
of	O
this	O
method	O
can	O
be	O
found	O
in	O
Protocol	O
S1	O
.	O

The	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
derived	O
from	O
the	O
model	O
.	O

We	O
assessed	O
the	O
combined	O
effect	O
of	O
traveling	O
and	O
the	O
following	O
risk	O
factors	O
for	O
thrombosis	O
:	O
factor	O
V	O
Leiden	O
mutation	O
,	O
prothrombin	O
G20210A	O
mutation	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
,	O
as	O
kg	O
/	O
m2	O
)	O
,	O
and	O
height	O
.	O

We	O
were	O
also	O
interested	O
in	O
the	O
combined	O
effect	O
of	O
oral	O
contraceptive	O
use	O
and	O
travel	O
.	O

However	O
,	O
as	O
the	O
control	O
individuals	O
were	O
nearly	O
always	O
of	O
the	O
opposite	O
sex	O
(	O
partners	O
of	O
the	O
cases	O
were	O
recruited	O
as	O
controls	O
)	O
,	O
it	O
was	O
not	O
possible	O
to	O
perform	O
a	O
matched	O
analysis	O
for	O
the	O
combination	O
of	O
oral	O
contraceptive	O
use	O
and	O
travel	O
.	O

Therefore	O
,	O
we	O
performed	O
a	O
case	O
-	O
only	O
analysis	O
[	O
15	O
]	O
.	O

This	O
method	O
allows	O
one	O
to	O
examine	O
the	O
association	O
between	O
two	O
exposures	O
among	O
case	O
individuals	O
only	O
.	O

ORs	O
are	O
interpreted	O
as	O
a	O
synergy	O
index	O
(	O
SI	O
)	O
on	O
a	O
multiplicative	O
scale	O
,	O
with	O
independence	O
assumed	O
between	O
the	O
exposures	O
.	O

As	O
this	O
analysis	O
depends	O
only	O
on	O
cases	O
,	O
it	O
was	O
possible	O
to	O
perform	O
it	O
in	O
all	O
consecutive	O
cases	O
,	O
therefore	O
also	O
including	O
those	O
without	O
a	O
partner	O
.	O

Laboratory	O
Measurements	O

Blood	O
was	O
collected	O
from	O
the	O
antecubital	O
vein	O
into	O
vacuum	O
tubes	O
containing	O
0	O
.	O
106	O
mol	O
/	O
l	O
trisodium	O
citrate	O
.	O

High	O
molecular	O
weight	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
using	O
a	O
standard	O
salting	O
-	O
out	O
procedure	O
[	O
16	O
]	O
and	O
stored	O
at	O
-	O
20	O
degrees	O
C	O
.	O

When	O
a	O
blood	O
sample	O
was	O
not	O
available	O
,	O
DNA	O
was	O
extracted	O
from	O
buccal	O
swabs	O
.	O

Three	O
large	O
cotton	S-Species
swabs	O
in	O
a	O
total	O
of	O
6	O
ml	O
of	O
SDS	O
-	O
proteinase	O
K	O
solution	O
(	O
100	O
mM	O
NaCl	O
,	O
10	O
mM	O
EDTA	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
8	O
.	O
0	O
]	O
,	O
0	O
.	O
5	O
%	O
SDS	O
,	O
0	O
.	O
1	O
mg	O
/	O
ml	O
proteinase	O
K	O
)	O
were	O
obtained	O
.	O

Upon	O
arrival	O
,	O
the	O
proteinase	O
K	O
concentration	O
was	O
raised	O
to	O
0	O
.	O
2	O
mg	O
/	O
ml	O
,	O
and	O
the	O
sample	O
was	O
incubated	O
for	O
2	O
h	O
at	O
65	O
degrees	O
C	O
.	O

Subsequently	O
,	O
the	O
solute	O
was	O
recovered	O
by	O
centrifugation	O
.	O

Potassium	O
acetate	O
was	O
added	O
to	O
the	O
supernatant	O
to	O
a	O
final	O
concentration	O
of	O
1	O
.	O
6	O
M	O
.	O

After	O
15	O
min	O
incubation	O
on	O
ice	O
,	O
proteins	O
were	O
removed	O
using	O
chloroform	O
/	O
isomylalcohol	O
(	O
24	O
:	O
1	O
)	O
treatment	O
.	O

The	O
DNA	O
in	O
the	O
water	O
phase	O
was	O
subsequently	O
ethanol	O
precipitated	O
.	O

After	O
centrifugation	O
,	O
the	O
pellet	O
was	O
resuspended	O
in	O
200	O
mu	O
l	O
of	O
10	O
mM	O
Tris	O
-	O
HCl	O
and	O
10	O
mM	O
EDTA	O
(	O
pH	O
8	O
.	O
0	O
)	O
,	O
and	O
frozen	O
at	O
-	O
20	O
degrees	O
C	O
until	O
further	O
analysis	O
.	O

The	O
factor	O
V	O
Leiden	O
mutation	O
(	O
G1691A	O
)	O
and	O
the	O
prothrombin	O
mutation	O
(	O
G20210A	O
)	O
were	O
simultaneously	O
detected	O
by	O
duplex	O
polymerase	O
chain	O
reaction	O
[	O
17	O
,	O
18	O
]	O
.	O

The	O
technician	O
was	O
blinded	O
concerning	O
the	O
origin	O
of	O
the	O
sample	O
,	O
i	O
.	O
e	O
.	O
,	O
whether	O
it	O
was	O
from	O
a	O
patient	S-Species
or	O
from	O
a	O
control	O
individual	O
.	O

Results	O

Venous	O
Thrombosis	O
in	O
Relation	O
to	O
Travel	O

Table	O
1	O
shows	O
general	O
characteristics	O
of	O
the	O
1	O
,	O
906	O
patients	S-Species
.	O

They	O
ranged	O
in	O
age	O
from	O
18	O
to	O
69	O
y	O
(	O
median	O
50	O
.	O
4	O
y	O
)	O
;	O
51	O
%	O
were	O
men	S-Species
.	O

Diagnosis	O
was	O
DVT	O
in	O
57	O
%	O
of	O
the	O
cases	O
,	O
PE	O
in	O
32	O
%	O
,	O
and	O
both	O
in	O
11	O
%	O
.	O

As	O
partners	O
of	O
the	O
cases	O
were	O
included	O
as	O
control	O
individuals	O
,	O
the	O
sex	O
distribution	O
of	O
the	O
control	O
individuals	O
was	O
the	O
opposite	O
;	O
the	O
age	O
distribution	O
differed	O
only	O
trivially	O
.	O

Of	O
the	O
patients	S-Species
,	O
233	O
individuals	O
(	O
12	O
%	O
)	O
had	O
traveled	O
for	O
at	O
least	O
4	O
h	O
by	O
air	O
,	O
bus	O
,	O
car	O
,	O
or	O
train	O
within	O
the	O
8	O
wk	O
preceding	O
the	O
index	O
date	O
,	O
as	O
compared	O
to	O
182	O
of	O
the	O
control	O
individuals	O
(	O
9	O
.	O
5	O
%	O
)	O
.	O

As	O
the	O
cases	O
and	O
control	O
individuals	O
were	O
selected	O
as	O
couples	O
,	O
many	O
pairs	O
(	O
135	O
)	O
had	O
traveled	O
together	O
and	O
were	O
uninformative	O
:	O
as	O
a	O
consequence	O
,	O
145	O
pairs	O
in	O
which	O
either	O
the	O
patient	S-Species
(	O
98	O
)	O
or	O
the	O
control	O
(	O
47	O
)	O
had	O
traveled	O
could	O
be	O
used	O
for	O
the	O
matched	O
analysis	O
(	O
Table	O
2	O
)	O
.	O

This	O
analysis	O
showed	O
a	O
2	O
-	O
fold	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
for	O
all	O
modes	O
of	O
travel	O
combined	O
(	O
OR	O
2	O
.	O
1	O
;	O
95	O
%	O
CI	O
1	O
.	O
5	O
-	O
3	O
.	O
0	O
)	O
compared	O
to	O
not	O
traveling	O
.	O

For	O
air	O
travel	O
alone	O
,	O
49	O
individuals	O
(	O
31	O
cases	O
and	O
18	O
controls	O
)	O
had	O
traveled	O
without	O
their	O
partner	O
,	O
and	O
the	O
analysis	O
yielded	O
an	O
OR	O
of	O
1	O
.	O
7	O
(	O
95	O
%	O
CI	O
1	O
.	O
0	O
-	O
3	O
.	O
1	O
)	O
.	O

For	O
the	O
other	O
modes	O
of	O
travel	O
(	O
car	O
,	O
bus	O
,	O
and	O
train	O
)	O
the	O
relative	O
risks	O
were	O
essentially	O
similar	O
to	O
each	O
other	O
and	O
to	O
that	O
of	O
air	O
travel	O
(	O
Table	O
2	O
)	O
.	O

The	O
risk	O
of	O
venous	O
thrombosis	O
was	O
not	O
clearly	O
related	O
to	O
increased	O
duration	O
of	O
travel	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
233	O
events	O
that	O
occurred	O
within	O
8	O
wk	O
after	O
traveling	O
,	O
68	O
(	O
29	O
%	O
)	O
were	O
diagnosed	O
in	O
the	O
first	O
week	O
,	O
after	O
which	O
the	O
incidence	O
gradually	O
decreased	O
(	O
Figure	O
1	O
)	O
.	O

The	O
Effect	O
of	O
Other	O
Risk	O
Factors	O
Combined	O
with	O
Travel	O

Prothrombotic	O
mutations	O
.	O

Information	O
on	O
the	O
factor	O
V	O
Leiden	O
mutation	O
and	O
prothrombin	O
G20210A	O
genotype	O
was	O
available	O
for	O
1	O
,	O
713	O
patients	S-Species
(	O
90	O
%	O
)	O
and	O
for	O
1	O
,	O
629	O
of	O
the	O
control	O
individuals	O
(	O
85	O
%	O
)	O
.	O

Factor	O
V	O
Leiden	O
was	O
present	O
in	O
259	O
cases	O
(	O
14	O
%	O
)	O
and	O
84	O
control	O
individuals	O
(	O
4	O
%	O
)	O
(	O
OR	O
3	O
.	O
1	O
;	O
95	O
%	O
CI	O
2	O
.	O
4	O
-	O
4	O
.	O
1	O
)	O
.	O

The	O
risk	O
of	O
venous	O
thrombosis	O
was	O
8	O
-	O
fold	O
increased	O
in	O
people	S-Species
with	O
factor	O
V	O
Leiden	O
who	O
had	O
traveled	O
by	O
bus	O
,	O
car	O
,	O
or	O
train	O
(	O
modes	O
combined	O
)	O
as	O
compared	O
to	O
noncarriers	O
who	O
did	O
not	O
travel	O
(	O
OR	O
8	O
.	O
1	O
;	O
95	O
%	O
CI	O
2	O
.	O
7	O
-	O
24	O
.	O
7	O
)	O
.	O

For	O
the	O
combined	O
effect	O
of	O
air	O
travel	O
and	O
factor	O
V	O
Leiden	O
,	O
the	O
risk	O
seemed	O
even	O
slightly	O
higher	O
(	O
OR	O
13	O
.	O
6	O
;	O
95	O
%	O
CI	O
2	O
.	O
9	O
-	O
64	O
.	O
2	O
)	O
.	O

The	O
prothrombin	O
G20210A	O
mutation	O
was	O
found	O
in	O
83	O
cases	O
(	O
4	O
%	O
)	O
and	O
in	O
29	O
control	O
individuals	O
(	O
2	O
%	O
)	O
(	O
OR	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
1	O
.	O
7	O
-	O
4	O
.	O
2	O
)	O
.	O

The	O
risk	O
in	O
individuals	O
with	O
this	O
mutation	O
who	O
had	O
traveled	O
was	O
difficult	O
to	O
interpret	O
because	O
of	O
the	O
small	O
numbers	O
but	O
appeared	O
not	O
to	O
increase	O
more	O
than	O
additively	O
(	O
Table	O
3	O
)	O
.	O

BMI	O
.	O

The	O
effect	O
of	O
BMI	O
was	O
studied	O
by	O
dividing	O
individuals	O
into	O
three	O
categories	O
with	O
the	O
following	O
BMI	O
values	O
:	O
<	O
25	O
,	O
25	O
-	O
30	O
,	O
and	O
>	O
30	O
kg	O
/	O
m2	O
[	O
19	O
]	O
.	O

A	O
BMI	O
of	O
25	O
-	O
30	O
kg	O
/	O
m2	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
(	O
OR	O
1	O
.	O
4	O
;	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
)	O
,	O
and	O
the	O
risk	O
was	O
slightly	O
higher	O
in	O
patients	S-Species
with	O
a	O
BMI	O
of	O
30	O
kg	O
/	O
m2	O
or	O
more	O
(	O
OR	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
1	O
.	O
4	O
-	O
2	O
.	O
1	O
)	O
.	O

The	O
combined	O
effect	O
of	O
a	O
higher	O
BMI	O
and	O
travel	O
was	O
the	O
sum	O
of	O
the	O
individual	O
risks	O
(	O
Table	O
3	O
)	O
,	O
with	O
the	O
exception	O
of	O
people	S-Species
with	O
a	O
BMI	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
who	O
traveled	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
,	O
for	O
whom	O
the	O
risk	O
was	O
10	O
-	O
fold	O
increased	O
(	O
OR	O
9	O
.	O
9	O
;	O
95	O
%	O
CI	O
3	O
.	O
6	O
-	O
27	O
.	O
6	O
)	O
.	O

This	O
increase	O
in	O
risk	O
was	O
not	O
found	O
in	O
people	S-Species
who	O
traveled	O
by	O
air	O
.	O

Height	O
.	O

Particularly	O
short	O
or	O
tall	O
people	S-Species
may	O
be	O
subjected	O
during	O
travel	O
to	O
even	O
more	O
unnatural	O
sitting	O
positions	O
than	O
individuals	O
with	O
average	O
height	O
.	O

Therefore	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
extremes	O
of	O
heights	O
in	O
combination	O
with	O
travel	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
by	O
comparing	O
short	O
(	O
less	O
than	O
1	O
.	O
60	O
m	O
)	O
and	O
tall	O
individuals	O
(	O
more	O
than	O
1	O
.	O
90	O
m	O
)	O
with	O
people	S-Species
of	O
average	O
height	O
(	O
1	O
.	O
60	O
-	O
1	O
.	O
90	O
m	O
)	O
.	O

Compared	O
to	O
people	S-Species
of	O
average	O
height	O
,	O
the	O
risk	O
of	O
venous	O
thrombosis	O
was	O
lower	O
for	O
short	O
people	S-Species
(	O
OR	O
0	O
.	O
7	O
;	O
95	O
%	O
CI	O
0	O
.	O
5	O
-	O
0	O
.	O
9	O
)	O
and	O
did	O
not	O
differ	O
for	O
very	O
tall	O
individuals	O
(	O
OR	O
0	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
)	O
.	O

The	O
risk	O
was	O
found	O
to	O
be	O
increased	O
in	O
people	S-Species
of	O
more	O
than	O
1	O
.	O
90	O
m	O
who	O
traveled	O
(	O
OR	O
4	O
.	O
7	O
;	O
95	O
%	O
CI	O
1	O
.	O
4	O
-	O
15	O
.	O
4	O
for	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
;	O
OR	O
6	O
.	O
8	O
;	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
60	O
.	O
6	O
for	O
air	O
travel	O
)	O
compared	O
to	O
non	O
-	O
traveling	O
people	S-Species
of	O
average	O
height	O
.	O

Interestingly	O
,	O
the	O
risk	O
of	O
venous	O
thrombosis	O
was	O
also	O
increased	O
in	O
short	O
people	S-Species
but	O
only	O
after	O
air	O
travel	O
(	O
OR	O
4	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
9	O
-	O
25	O
.	O
6	O
)	O
,	O
not	O
after	O
other	O
modes	O
of	O
travel	O
(	O
OR	O
1	O
.	O
0	O
;	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
2	O
.	O
8	O
,	O
all	O
relative	O
to	O
non	O
-	O
traveling	O
people	S-Species
of	O
average	O
height	O
)	O
.	O

Oral	O
contraception	O
.	O

To	O
study	O
the	O
association	O
between	O
oral	O
contraceptive	O
use	O
,	O
travel	O
,	O
and	O
the	O
risk	O
of	O
venous	O
thrombosis	O
,	O
we	O
performed	O
a	O
case	O
-	O
only	O
analysis	O
in	O
all	O
female	O
patients	S-Species
who	O
were	O
less	O
than	O
50	O
y	O
of	O
age	O
.	O

As	O
we	O
needed	O
only	O
cases	O
,	O
it	O
was	O
also	O
possible	O
to	O
include	O
women	S-Species
without	O
a	O
partner	O
for	O
this	O
analysis	O
,	O
which	O
led	O
to	O
a	O
total	O
of	O
1	O
,	O
025	O
women	S-Species
aged	O
under	O
50	O
.	O

Non	O
-	O
users	O
who	O
did	O
not	O
travel	O
were	O
used	O
as	O
the	O
reference	O
group	O
.	O

The	O
case	O
-	O
only	O
estimate	O
of	O
the	O
SI	O
for	O
women	S-Species
who	O
traveled	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
was	O
2	O
.	O
4	O
(	O
95	O
%	O
CI	O
1	O
.	O
5	O
-	O
3	O
.	O
7	O
)	O
.	O

This	O
indicates	O
that	O
the	O
OR	O
for	O
the	O
combination	O
of	O
travel	O
and	O
oral	O
contraceptive	O
use	O
is	O
2	O
.	O
4	O
times	O
the	O
product	O
of	O
the	O
separate	O
ORs	O
.	O

As	O
oral	O
contraceptive	O
use	O
generally	O
increases	O
the	O
risk	O
of	O
venous	O
thrombosis	O
about	O
4	O
-	O
fold	O
[	O
20	O
]	O
,	O
the	O
combination	O
with	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
would	O
lead	O
to	O
an	O
estimated	O
OR	O
of	O
about	O
20	O
(	O
4	O
x	O
2	O
x	O
2	O
.	O
4	O
)	O
.	O

A	O
clearly	O
stronger	O
interaction	O
of	O
travel	O
by	O
air	O
with	O
oral	O
contraceptive	O
use	O
was	O
found	O
:	O
the	O
case	O
-	O
only	O
estimate	O
of	O
the	O
SI	O
was	O
4	O
.	O
9	O
(	O
95	O
%	O
CI	O
2	O
.	O
1	O
-	O
11	O
.	O
4	O
)	O
,	O
which	O
would	O
result	O
in	O
an	O
OR	O
of	O
about	O
40	O
(	O
4	O
x	O
2	O
x	O
4	O
.	O
9	O
)	O
.	O

Effect	O
of	O
Risk	O
Factors	O
in	O
DVT	O
Patients	S-Species
Only	O

Of	O
the	O
1	O
,	O
906	O
cases	O
,	O
1	O
,	O
082	O
were	O
diagnosed	O
with	O
DVT	O
.	O

As	O
the	O
diagnosis	O
was	O
more	O
unambiguous	O
in	O
these	O
patients	S-Species
(	O
97	O
%	O
objectively	O
diagnosed	O
as	O
compared	O
to	O
78	O
%	O
of	O
the	O
PE	O
patients	S-Species
)	O
,	O
we	O
repeated	O
the	O
analysis	O
in	O
these	O
patients	S-Species
only	O
.	O

In	O
this	O
analysis	O
,	O
the	O
overall	O
effect	O
of	O
travel	O
on	O
the	O
risk	O
of	O
DVT	O
was	O
equal	O
to	O
the	O
effect	O
on	O
all	O
venous	O
thrombosis	O
(	O
DVT	O
and	O
PE	O
combined	O
)	O
.	O

However	O
,	O
here	O
we	O
found	O
a	O
stronger	O
risk	O
for	O
travel	O
by	O
air	O
(	O
OR	O
3	O
.	O
0	O
;	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
7	O
.	O
1	O
)	O
then	O
for	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
(	O
OR	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
3	O
.	O
2	O
)	O
(	O
Table	O
4	O
)	O
.	O

Also	O
,	O
the	O
analysis	O
of	O
the	O
combination	O
of	O
other	O
risk	O
factors	O
with	O
travel	O
resulted	O
in	O
more	O
clear	O
-	O
cut	O
effects	O
,	O
despite	O
the	O
smaller	O
number	O
of	O
cases	O
:	O
the	O
risk	O
of	O
DVT	O
was	O
still	O
clearly	O
synergistically	O
increased	O
in	O
patients	S-Species
with	O
factor	O
V	O
Leiden	O
who	O
traveled	O
,	O
whereas	O
the	O
prothrombin	O
G20210A	O
mutation	O
did	O
not	O
further	O
increase	O
the	O
risk	O
of	O
travel	O
(	O
Table	O
4	O
)	O
.	O

Furthermore	O
,	O
a	O
BMI	O
of	O
more	O
than	O
30	O
kg	O
/	O
m2	O
in	O
combination	O
with	O
travel	O
yielded	O
high	O
ORs	O
for	O
DVT	O
both	O
in	O
people	S-Species
who	O
traveled	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
and	O
in	O
those	O
who	O
flew	O
.	O

Being	O
more	O
than	O
1	O
.	O
90	O
m	O
tall	O
in	O
combination	O
with	O
travel	O
resulted	O
in	O
higher	O
ORs	O
for	O
DVT	O
;	O
the	O
risk	O
for	O
short	O
people	S-Species
was	O
more	O
increased	O
after	O
travel	O
by	O
air	O
(	O
OR	O
6	O
.	O
8	O
;	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
43	O
.	O
5	O
)	O
(	O
Table	O
4	O
)	O
.	O

The	O
effect	O
of	O
oral	O
contraceptive	O
use	O
in	O
combination	O
with	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
on	O
the	O
risk	O
of	O
DVT	O
was	O
studied	O
in	O
589	O
women	S-Species
and	O
was	O
somewhat	O
lower	O
than	O
the	O
effect	O
on	O
the	O
risk	O
of	O
all	O
venous	O
thrombosis	O
(	O
SI	O
1	O
.	O
9	O
;	O
95	O
%	O
CI	O
0	O
.	O
9	O
-	O
4	O
.	O
2	O
)	O
.	O

In	O
those	O
who	O
traveled	O
by	O
air	O
it	O
was	O
also	O
a	O
bit	O
lower	O
(	O
SI	O
3	O
.	O
4	O
;	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
8	O
.	O
8	O
)	O
,	O
but	O
still	O
indicative	O
of	O
a	O
strong	O
synergistic	O
effect	O
.	O

Discussion	O

In	O
this	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
long	O
-	O
distance	O
traveling	O
increased	O
the	O
risk	O
of	O
venous	O
thrombosis	O
2	O
-	O
fold	O
.	O

Travel	O
by	O
air	O
increased	O
the	O
risk	O
to	O
the	O
same	O
extent	O
as	O
travel	O
by	O
car	O
,	O
bus	O
,	O
or	O
train	O
.	O

The	O
risk	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
traveling	O
.	O

As	O
venous	O
thrombosis	O
is	O
a	O
disease	O
in	O
which	O
many	O
factors	O
(	O
genetic	O
and	O
acquired	O
)	O
interact	O
[	O
21	O
]	O
,	O
we	O
identified	O
groups	O
with	O
additional	O
risk	O
factors	O
in	O
which	O
the	O
risk	O
was	O
further	O
increased	O
.	O

This	O
was	O
the	O
case	O
for	O
individuals	O
with	O
factor	O
V	O
Leiden	O
,	O
obese	O
people	S-Species
(	O
BMI	O
>	O
30	O
kg	O
/	O
m2	O
)	O
,	O
and	O
short	O
(	O
only	O
for	O
travel	O
by	O
air	O
)	O
and	O
tall	O
people	S-Species
,	O
as	O
well	O
as	O
for	O
women	S-Species
using	O
oral	O
contraceptives	O
.	O

Some	O
of	O
these	O
synergistic	O
effects	O
were	O
more	O
apparent	O
for	O
air	O
travel	O
.	O

Although	O
the	O
studies	O
that	O
have	O
been	O
published	O
so	O
far	O
have	O
not	O
yielded	O
entirely	O
consistent	O
results	O
,	O
those	O
that	O
did	O
report	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
in	O
air	O
travelers	O
showed	O
similar	O
risk	O
estimates	O
of	O
a	O
2	O
-	O
to	O
3	O
-	O
fold	O
increased	O
risk	O
(	O
even	O
in	O
one	O
with	O
asymptomatic	O
events	O
only	O
[	O
4	O
]	O
)	O
.	O

The	O
occurrence	O
of	O
venous	O
thrombosis	O
was	O
highest	O
in	O
the	O
first	O
week	O
after	O
travel	O
,	O
and	O
slowly	O
declined	O
afterwards	O
,	O
a	O
pattern	O
that	O
was	O
also	O
described	O
in	O
a	O
recent	O
record	O
-	O
linking	O
study	O
from	O
Australia	O
[	O
1	O
]	O
,	O
supporting	O
a	O
causal	O
relation	O
.	O

As	O
a	O
possible	O
mechanism	O
for	O
an	O
extra	O
risk	O
in	O
travelers	O
who	O
fly	O
,	O
an	O
effect	O
of	O
hypobaric	O
hypoxia	O
on	O
the	O
coagulation	O
system	O
was	O
postulated	O
,	O
which	O
has	O
already	O
been	O
studied	O
a	O
number	O
of	O
times	O
,	O
mainly	O
in	O
hypobaric	O
chambers	O
,	O
with	O
unclear	O
results	O
so	O
far	O
.	O

Our	O
study	O
showed	O
an	O
increased	O
risk	O
in	O
all	O
types	O
of	O
travel	O
,	O
which	O
suggests	O
that	O
the	O
increased	O
risk	O
of	O
flying	O
is	O
caused	O
mainly	O
by	O
immobilization	O
.	O

Additionally	O
,	O
the	O
risk	O
is	O
further	O
increased	O
in	O
short	O
and	O
tall	O
people	S-Species
,	O
who	O
are	O
likely	O
to	O
experience	O
more	O
immobilization	O
and	O
venous	O
compression	O
than	O
other	O
travelers	O
.	O

However	O
,	O
as	O
some	O
of	O
our	O
findings	O
were	O
more	O
pronounced	O
for	O
air	O
travel	O
,	O
we	O
cannot	O
exclude	O
an	O
additional	O
effect	O
of	O
hypobaric	O
hypoxia	O
,	O
possibly	O
in	O
risk	O
groups	O
only	O
.	O

This	O
possibility	O
is	O
supported	O
by	O
a	O
recent	O
study	O
of	O
our	O
group	O
[	O
22	O
]	O
in	O
which	O
we	O
found	O
that	O
thrombin	O
generation	O
occurred	O
in	O
some	O
healthy	O
volunteers	O
after	O
flying	O
for	O
8	O
h	O
but	O
happened	O
to	O
a	O
far	O
lesser	O
extent	O
after	O
being	O
immobilized	O
for	O
8	O
h	O
in	O
a	O
cinema	O
.	O

The	O
high	O
response	O
in	O
the	O
fliers	O
was	O
associated	O
with	O
the	O
presence	O
of	O
risk	O
factors	O
for	O
thrombosis	O
,	O
i	O
.	O
e	O
.	O
,	O
oral	O
contraceptive	O
use	O
,	O
the	O
factor	O
V	O
Leiden	O
mutation	O
,	O
and	O
the	O
combination	O
of	O
the	O
two	O
.	O

This	O
finding	O
indicates	O
an	O
effect	O
of	O
an	O
additional	O
factor	O
in	O
an	O
airplane	O
,	O
such	O
as	O
hypobaric	O
hypoxia	O
,	O
to	O
which	O
mainly	O
individuals	O
with	O
risk	O
factors	O
respond	O
.	O

None	O
of	O
the	O
studies	O
published	O
so	O
far	O
have	O
systematically	O
studied	O
the	O
effect	O
of	O
traveling	O
in	O
combination	O
with	O
other	O
risk	O
factors	O
,	O
with	O
the	O
exception	O
of	O
the	O
study	O
by	O
Martinelli	O
et	O
al	O
.	O

[	O
3	O
]	O
.	O

In	O
an	O
analysis	O
of	O
210	O
patients	S-Species
,	O
they	O
found	O
a	O
16	O
-	O
fold	O
increased	O
risk	O
for	O
patients	S-Species
who	O
traveled	O
by	O
air	O
and	O
had	O
some	O
form	O
of	O
thrombophilia	O
,	O
as	O
well	O
as	O
a	O
14	O
-	O
fold	O
increased	O
risk	O
in	O
women	S-Species
who	O
flew	O
and	O
used	O
oral	O
contraceptives	O
,	O
findings	O
that	O
confirm	O
both	O
the	O
results	O
of	O
the	O
present	O
study	O
and	O
our	O
finding	O
of	O
activated	O
coagulation	O
in	O
individuals	O
with	O
risk	O
factors	O
after	O
flying	O
[	O
22	O
]	O
.	O

The	O
finding	O
that	O
taller	O
and	O
shorter	O
people	S-Species
had	O
an	O
increased	O
risk	O
of	O
venous	O
thrombosis	O
after	O
traveling	O
should	O
be	O
interpreted	O
with	O
some	O
caution	O
,	O
as	O
the	O
numbers	O
were	O
small	O
in	O
these	O
strata	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
is	O
biologically	O
plausible	O
:	O
very	O
tall	O
people	S-Species
are	O
subjected	O
to	O
even	O
more	O
cramped	O
seating	O
than	O
average	O
-	O
height	O
individuals	O
,	O
and	O
very	O
short	O
people	S-Species
'	O
s	O
feet	O
may	O
not	O
touch	O
the	O
floor	O
,	O
which	O
would	O
lead	O
to	O
extra	O
compression	O
of	O
the	O
popliteal	O
veins	O
.	O

Interestingly	O
,	O
the	O
increased	O
risk	O
for	O
short	O
people	S-Species
was	O
only	O
found	O
in	O
people	S-Species
who	O
traveled	O
by	O
air	O
.	O

This	O
may	O
have	O
to	O
do	O
with	O
the	O
fact	O
that	O
seats	O
in	O
cars	O
are	O
generally	O
lower	O
,	O
and	O
more	O
individually	O
adjustable	O
,	O
than	O
those	O
in	O
airplanes	O
.	O

As	O
the	O
diagnosis	O
of	O
DVT	O
is	O
usually	O
more	O
unambiguous	O
than	O
that	O
of	O
PE	O
[	O
23	O
]	O
,	O
as	O
was	O
the	O
case	O
in	O
our	O
study	O
population	O
as	O
well	O
,	O
we	O
repeated	O
the	O
analysis	O
using	O
only	O
DVT	O
as	O
the	O
outcome	O
of	O
interest	O
(	O
97	O
%	O
objectively	O
diagnosed	O
)	O
.	O

In	O
this	O
analysis	O
,	O
despite	O
using	O
smaller	O
numbers	O
,	O
most	O
findings	O
were	O
either	O
similar	O
or	O
appeared	O
more	O
evident	O
,	O
and	O
inconsistencies	O
that	O
were	O
found	O
when	O
using	O
both	O
DVT	O
and	O
PE	O
as	O
endpoints	O
disappeared	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
in	O
which	O
the	O
effect	O
of	O
travel	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
has	O
been	O
studied	O
.	O

Because	O
the	O
control	O
individuals	O
were	O
closely	O
matched	O
,	O
being	O
partners	O
of	O
the	O
cases	O
,	O
and	O
couples	O
tend	O
to	O
travel	O
together	O
,	O
only	O
the	O
cases	O
and	O
control	O
individuals	O
who	O
had	O
not	O
traveled	O
together	O
could	O
be	O
used	O
for	O
the	O
analysis	O
.	O

Also	O
because	O
of	O
this	O
design	O
,	O
the	O
effect	O
of	O
sex	O
and	O
age	O
could	O
not	O
be	O
studied	O
.	O

It	O
has	O
to	O
be	O
noted	O
,	O
however	O
,	O
that	O
for	O
all	O
other	O
research	O
questions	O
on	O
the	O
effect	O
of	O
genetic	O
and	O
acquired	O
risk	O
factors	O
on	O
the	O
risk	O
of	O
venous	O
thrombosis	O
,	O
this	O
design	O
has	O
no	O
limitations	O
and	O
the	O
close	O
matching	O
of	O
cases	O
and	O
controls	O
renders	O
confounding	O
by	O
,	O
for	O
instance	O
,	O
lifestyle	O
and	O
socioeconomic	O
class	O
less	O
likely	O
than	O
in	O
previous	O
unmatched	O
studies	O
(	O
see	O
also	O
Protocol	O
S1	O
)	O
.	O

Another	O
advantage	O
of	O
this	O
approach	O
is	O
the	O
minimization	O
of	O
recall	O
bias	O
,	O
as	O
the	O
cases	O
and	O
controls	O
would	O
generally	O
fill	O
in	O
the	O
questionnaire	O
together	O
.	O

Many	O
questions	O
are	O
still	O
left	O
unanswered	O
that	O
necessitate	O
more	O
research	O
.	O

First	O
of	O
all	O
,	O
our	O
study	O
results	O
apply	O
only	O
to	O
people	S-Species
younger	O
than	O
70	O
y	O
of	O
age	O
.	O

Furthermore	O
,	O
it	O
is	O
likely	O
that	O
other	O
characteristics	O
exist	O
that	O
also	O
increase	O
the	O
risk	O
--	O
person	S-Species
-	O
specific	O
(	O
e	O
.	O
g	O
.	O
,	O
other	O
drug	O
use	O
)	O
,	O
behavioral	O
(	O
e	O
.	O
g	O
.	O
,	O
use	O
of	O
sleeping	O
pills	O
or	O
alcohol	O
consumption	O
)	O
,	O
and	O
flight	O
-	O
specific	O
(	O
e	O
.	O
g	O
.	O
,	O
class	O
or	O
seating	O
)	O
--	O
that	O
need	O
to	O
be	O
identified	O
.	O

These	O
further	O
variables	O
are	O
part	O
of	O
our	O
ongoing	O
study	O
as	O
part	O
of	O
the	O
World	O
Health	O
Organization	O
Research	O
Initiative	O
into	O
the	O
Global	O
Hazards	O
of	O
Travel	O
(	O
WRIGHT	O
study	O
)	O
.	O

For	O
those	O
who	O
have	O
an	O
increased	O
risk	O
,	O
such	O
as	O
oral	O
contraceptive	O
users	O
and	O
individuals	O
with	O
factor	O
V	O
Leiden	O
,	O
prevention	O
may	O
be	O
warranted	O
.	O

Prevention	O
may	O
vary	O
from	O
simple	O
measures	O
,	O
such	O
as	O
exercises	O
during	O
the	O
flight	O
,	O
to	O
measures	O
that	O
carry	O
a	O
risk	O
themselves	O
,	O
such	O
as	O
anticoagulants	O
.	O

Specific	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
efficacy	O
of	O
these	O
measures	O
and	O
their	O
risk	O
-	O
benefit	O
ratio	O
.	O

It	O
can	O
be	O
concluded	O
that	O
the	O
risk	O
of	O
venous	O
thrombosis	O
is	O
2	O
-	O
fold	O
increased	O
for	O
all	O
travelers	O
and	O
to	O
the	O
same	O
extent	O
for	O
all	O
modes	O
of	O
travel	O
.	O

In	O
individuals	O
who	O
use	O
oral	O
contraceptives	O
,	O
are	O
carriers	O
of	O
the	O
factor	O
V	O
Leiden	O
mutation	O
,	O
or	O
are	O
particularly	O
tall	O
,	O
short	O
,	O
or	O
obese	O
,	O
this	O
risk	O
is	O
considerably	O
higher	O
,	O
to	O
such	O
an	O
extent	O
that	O
studies	O
into	O
the	O
efficacy	O
of	O
prophylactic	O
measures	O
are	O
required	O
.	O

Supporting	O
Information	O

The	O
role	O
of	O
the	O
muscarinic	O
system	O
in	O
regulating	O
estradiol	O
secretion	O
varies	O
during	O
the	O
estrous	O
cycle	O
:	O
the	O
hemiovariectomized	O
rat	S-Species
model	O

Abstract	O

There	O
is	O
evidence	O
that	O
one	O
gonad	O
has	O
functional	O
predominance	O
.	O

The	O
present	O
study	O
analyzed	O
the	O
acute	O
effects	O
of	O
unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
and	O
blocking	O
the	O
cholinergic	O
system	O
,	O
by	O
injecting	O
atropine	O
sulfate	O
(	O
ATR	O
)	O
,	O
on	O
estradiol	O
(	O
E2	O
)	O
serum	O
concentrations	O
during	O
the	O
estrous	O
cycle	O
.	O

The	O
results	O
indicate	O
that	O
ULO	O
effects	O
on	O
E2	O
concentrations	O
are	O
asymmetric	O
,	O
vary	O
during	O
the	O
estrous	O
cycle	O
,	O
and	O
partially	O
depend	O
on	O
the	O
cholinergic	O
innervation	O
.	O

Background	O

Estradiol	O
secretion	O
is	O
regulated	O
by	O
pituitary	O
[	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
luteinizing	O
hormones	O
(	O
LH	O
)	O
,	O
prolactin	O
,	O
and	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
]	O
.	O

The	O
effects	O
of	O
these	O
hormones	O
are	O
modulated	O
by	O
neurotransmitters	O
released	O
by	O
the	O
intrinsic	O
ovarian	O
innervation	O
near	O
the	O
follicular	O
wall	O
.	O

Acetylcholine	O
produced	O
by	O
the	O
follicle	O
may	O
be	O
one	O
of	O
the	O
neurotransmitters	O
participating	O
in	O
modulating	O
the	O
effects	O
of	O
pituitary	O
hormones	O
on	O
the	O
follicle	O
[	O
1	O
-	O
3	O
]	O
.	O

Evidence	O
suggesting	O
that	O
one	O
gonad	O
has	O
functional	O
predominance	O
in	O
mammals	O
and	O
birds	O
have	O
been	O
published	O
[	O
1	O
,	O
4	O
-	O
8	O
]	O
.	O

In	O
previous	O
studies	O
we	O
have	O
shown	O
that	O
unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
modifies	O
progesterone	O
and	O
/	O
or	O
testosterone	O
serum	O
concentrations	O
,	O
and	O
that	O
the	O
effects	O
of	O
ULO	O
depend	O
on	O
both	O
,	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
ULO	O
was	O
performed	O
and	O
the	O
ovary	O
(	O
left	O
or	O
right	O
)	O
remaining	O
in	O
situ	O
[	O
9	O
-	O
11	O
]	O
.	O

Asymmetry	O
in	O
ovarian	O
functions	O
has	O
been	O
explained	O
by	O
differences	O
in	O
the	O
ovarian	O
innervation	O
participating	O
in	O
modulating	O
the	O
effects	O
of	O
gonadotropin	O
on	O
the	O
ovarian	O
follicles	O
[	O
1	O
,	O
6	O
]	O
.	O

Kawakami	O
et	O
al	O
[	O
12	O
]	O
showed	O
that	O
electrical	O
stimulation	O
of	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
,	O
the	O
ventro	O
-	O
medial	O
hypothalamus	O
,	O
and	O
the	O
areas	O
in	O
the	O
mesencephalon	O
of	O
hypophysectomized	O
and	O
adrenalectomized	O
female	O
rats	S-Species
resulted	O
in	O
a	O
significant	O
increase	O
of	O
estradiol	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
P4	O
)	O
plasma	O
concentrations	O
in	O
the	O
contra	O
-	O
lateral	O
ovarian	O
venous	O
blood	O
.	O

In	O
turn	O
,	O
stimulating	O
the	O
dorsal	O
hippocampus	O
,	O
the	O
lateral	O
amygdala	O
,	O
and	O
the	O
mesencephalic	O
areas	O
resulted	O
in	O
lower	O
E2	O
and	O
P4	O
concentrations	O
.	O

Ovarian	O
denervation	O
of	O
rats	S-Species
in	O
proestrus	O
stage	O
blocks	O
E2	O
secretion	O
induced	O
by	O
stimulating	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
.	O

In	O
addition	O
,	O
the	O
electrochemical	O
stimulation	O
in	O
proestrus	O
day	O
of	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
of	O
untreated	O
rats	S-Species
increased	O
E2	O
and	O
P4	O
concentrations	O
in	O
serum	O
.	O

This	O
effect	O
was	O
not	O
observed	O
when	O
stimulation	O
was	O
applied	O
to	O
the	O
pre	O
-	O
optic	O
supra	O
-	O
chiasmatic	O
area	O
.	O

According	O
to	O
the	O
authors	O
'	O
interpretation	O
of	O
the	O
results	O
,	O
the	O
efferent	O
neural	O
system	O
connecting	O
the	O
brain	O
and	O
the	O
ovaries	O
is	O
supplementary	O
to	O
the	O
brain	O
-	O
pituitary	O
-	O
ovarian	O
hormonal	O
mechanisms	O
regulating	O
ovarian	O
steroid	O
secretion	O
,	O
and	O
the	O
system	O
may	O
be	O
required	O
for	O
adjusting	O
ovarian	O
responsiveness	O
and	O
sensitivity	O
to	O
gonadotropins	O
[	O
12	O
,	O
13	O
]	O
.	O

Gerendai	O
et	O
al	O
.	O

[	O
14	O
]	O
described	O
a	O
multi	O
-	O
synaptic	O
neural	O
pathway	O
between	O
the	O
central	O
nervous	O
system	O
and	O
the	O
ovaries	O
,	O
with	O
the	O
vagus	O
nerve	O
being	O
one	O
of	O
the	O
main	O
neural	O
pathways	O
.	O

In	O
ULO	O
treated	O
rats	S-Species
,	O
bi	O
-	O
lateral	O
sectioning	O
the	O
vagus	O
nerve	O
(	O
ventral	O
or	O
dorsal	O
)	O
results	O
in	O
lower	O
compensatory	O
ovarian	O
hypertrophy	O
.	O

The	O
effects	O
of	O
sectioning	O
the	O
left	O
vagus	O
nerve	O
depend	O
on	O
the	O
remaining	O
ovary	O
in	O
situ	O
:	O
rats	S-Species
with	O
the	O
left	O
ovary	O
in	O
situ	O
had	O
a	O
larger	O
proportion	O
of	O
ovulating	O
animals	O
,	O
compensatory	O
ovarian	O
hypertrophy	O
and	O
number	O
of	O
ova	O
shed	O
.	O

In	O
turn	O
,	O
rats	S-Species
with	O
the	O
right	O
ovary	O
in	O
situ	O
showed	O
a	O
decrease	O
in	O
all	O
parameters	O
studied	O
[	O
15	O
]	O
.	O

Based	O
on	O
available	O
information	O
,	O
the	O
present	O
study	O
aims	O
to	O
analyze	O
if	O
changes	O
in	O
E2	O
secretion	O
by	O
the	O
left	O
and	O
right	O
ovaries	O
vary	O
during	O
the	O
estrous	O
cycle	O
,	O
using	O
the	O
unilateral	O
ovariectomized	O
animal	O
as	O
a	O
model	O
of	O
study	O
.	O

We	O
also	O
investigated	O
if	O
,	O
throughout	O
estrous	O
cycle	O
diestrus	O
1	O
(	O
D1	O
)	O
,	O
diestrus	O
2	O
(	O
D2	O
)	O
and	O
proestrus	O
(	O
P	O
)	O
,	O
the	O
cholinergic	O
system	O
modulates	O
E2	O
secretion	O
in	O
an	O
asymmetric	O
way	O
.	O

For	O
this	O
purpose	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
injecting	O
ATR	O
at	O
13	O
.	O
00	O
h	O
to	O
rats	S-Species
on	O
D1	O
,	O
D2	O
or	O
P	O
with	O
or	O
without	O
unilateral	O
or	O
bilateral	O
ovariectomy	O
.	O

Materials	O
and	O
methods	O

The	O
study	O
was	O
performed	O
with	O
virgin	O
adult	O
female	O
rats	S-Species
(	O
195	O
-	O
225	O
-	O
g	O
body	O
weight	O
)	O
of	O
the	O
CIIZ	O
-	O
V	O
strain	O
from	O
our	O
own	O
stock	O
.	O

Animals	O
were	O
kept	O
under	O
controlled	O
lighting	O
conditions	O
(	O
lights	O
on	O
from	O
05	O
:	O
00	O
to	O
19	O
:	O
00	O
h	O
)	O
,	O
with	O
free	O
access	O
to	O
food	O
(	O
Purina	O
S	O
.	O
A	O
.	O
,	O
Mexico	O
)	O
and	O
tap	O
water	O
;	O
following	O
NIH	O
Guide	O
parameters	O
for	O
the	O
care	O
of	O
laboratory	O
animals	O
.	O

The	O
Committee	O
of	O
the	O
Facultad	O
de	O
Estudios	O
Superiores	O
Zaragoza	O
approved	O
the	O
experimental	O
protocols	O
.	O

Estrous	O
cycles	O
were	O
monitored	O
by	O
daily	O
vaginal	O
smears	O
.	O

Only	O
rats	S-Species
showing	O
at	O
least	O
two	O
consecutive	O
4	O
-	O
day	O
cycles	O
were	O
used	O
in	O
the	O
experiment	O
.	O

All	O
surgeries	O
were	O
performed	O
under	O
ether	O
anesthesia	O
,	O
between	O
13	O
:	O
00	O
-	O
13	O
:	O
15	O
hours	O
.	O

Rats	S-Species
were	O
sacrificed	O
by	O
decapitation	O
one	O
hour	O
after	O
treatment	O
.	O

Experimental	O
groups	O

Rats	S-Species
were	O
randomly	O
allotted	O
to	O
one	O
of	O
the	O
experimental	O
groups	O
described	O
below	O
.	O

Animals	O
from	O
different	O
experimental	O
groups	O
were	O
treated	O
simultaneously	O
and	O
sacrificed	O
one	O
hour	O
after	O
surgery	O
.	O

The	O
number	O
of	O
animals	O
used	O
in	O
each	O
experimental	O
group	O
is	O
presented	O
in	O
Tables	O
1	O
,	O
2	O
and	O
3	O
.	O

Control	O
group	O
(	O
N	O
=	O
48	O
)	O
.	O

Non	O
-	O
treated	O
cyclic	O
rats	S-Species
sacrificed	O
at	O
14	O
:	O
00	O
h	O
on	O
D1	O
(	O
17	O
rats	S-Species
)	O
,	O
D2	O
(	O
19	O
rats	S-Species
)	O
and	O
P	O
(	O
12	O
rats	S-Species
)	O
.	O

Ether	O
anesthesia	O
(	O
N	O
=	O
24	O
)	O
:	O
Groups	O
of	O
rats	S-Species
,	O
on	O
specific	O
stages	O
(	O
D1	O
,	O
D2	O
or	O
P	O
)	O
of	O
the	O
estrous	O
cycle	O
,	O
were	O
anesthetized	O
for	O
10	O
min	O
and	O
sacrificed	O
one	O
hour	O
later	O
.	O

Unilateral	O
peritoneal	O
perforation	O
(	O
sham	O
operation	O
)	O
(	O
N	O
=	O
53	O
)	O
:	O
A	O
unilateral	O
incision	O
was	O
performed	O
2	O
-	O
cm	O
below	O
the	O
last	O
rib	O
;	O
affecting	O
skin	O
,	O
muscle	O
,	O
and	O
peritoneum	O
.	O

The	O
ovaries	O
were	O
not	O
injured	O
or	O
manipulated	O
.	O

After	O
surgical	O
procedures	O
the	O
wound	O
was	O
sealed	O
.	O

Bilateral	O
peritoneal	O
perforation	O
(	O
sham	O
operation	O
2	O
)	O
(	O
N	O
=	O
27	O
)	O
.	O

A	O
bilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
,	O
was	O
performed	O
.	O

The	O
ovaries	O
were	O
not	O
injured	O
or	O
manipulated	O
.	O

After	O
surgical	O
procedures	O
the	O
wound	O
was	O
sealed	O
.	O

Unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
(	O
N	O
=	O
50	O
)	O
:	O
A	O
unilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
was	O
performed	O
,	O
and	O
the	O
right	O
or	O
left	O
ovary	O
was	O
extirpated	O
.	O

The	O
wound	O
was	O
subsequently	O
sealed	O
.	O

Bilateral	O
ovariectomy	O
(	O
N	O
=	O
23	O
)	O
:	O
A	O
bilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
was	O
performed	O
,	O
and	O
the	O
ovaries	O
removed	O
.	O

The	O
wound	O
was	O
subsequently	O
sealed	O
.	O

Blocking	O
the	O
cholinergic	O
system	O

To	O
analyze	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
,	O
groups	O
of	O
animals	O
were	O
injected	O
with	O
atropine	O
sulfate	O
(	O
ATR	O
,	O
Sigma	O
Chem	O
.	O
Co	O
.	O
St	O
.	O
Louis	O
,	O
Mo	O
.	O
)	O
.	O

ATR	O
was	O
injected	O
one	O
hour	O
before	O
surgery	O
at	O
doses	O
known	O
to	O
block	O
ovulation	O
:	O
in	O
D1	O
,	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
b	O
.	O
w	O
.	O
)	O
;	O
in	O
D2	O
,	O
300	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
;	O
and	O
in	O
P	O
,	O
700	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O

[	O
16	O
]	O
.	O

One	O
hour	O
after	O
ATR	O
treatment	O
,	O
rats	S-Species
were	O
randomly	O
allotted	O
to	O
one	O
of	O
the	O
following	O
treatments	O
:	O
unilateral	O
peritoneal	O
perforation	O
,	O
bilateral	O
peritoneal	O
perforation	O
,	O
ULO	O
,	O
or	O
bilateral	O
ovariectomy	O
.	O

All	O
animals	O
were	O
sacrificed	O
one	O
hour	O
after	O
surgery	O
.	O

For	O
control	O
purposes	O
,	O
untreated	O
rats	S-Species
,	O
on	O
D1	O
,	O
D2	O
or	O
P	O
,	O
were	O
injected	O
with	O
ATR	O
in	O
the	O
same	O
dose	O
as	O
in	O
their	O
corresponding	O
treatment	O
group	O
.	O

The	O
animals	O
were	O
sacrificed	O
two	O
hours	O
after	O
treatment	O
.	O

Autopsy	O
procedures	O

Animals	O
were	O
sacrificed	O
by	O
decapitation	O
.	O

The	O
blood	O
of	O
the	O
trunk	O
was	O
collected	O
in	O
a	O
test	O
tube	O
,	O
allowed	O
to	O
clot	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
and	O
centrifuged	O
at	O
3	O
,	O
000	O
rpm	O
for	O
15	O
minutes	O
.	O

Serum	O
was	O
stored	O
at	O
-	O
20	O
degrees	O
C	O
,	O
until	O
E2	O
concentrations	O
were	O
measured	O
.	O

Hormone	O
assay	O

Concentrations	O
of	O
E2	O
in	O
serum	O
were	O
measured	O
by	O
Radio	O
-	O
Immuno	O
-	O
Assay	O
(	O
RIA	O
)	O
;	O
using	O
kits	O
purchased	O
from	O
Diagnostic	O
Products	O
(	O
Los	O
Angeles	O
,	O
CA	O
)	O
.	O

Results	O
are	O
expressed	O
in	O
pg	O
/	O
ml	O
.	O

The	O
Intra	O
-	O
and	O
inter	O
-	O
assay	O
variation	O
coefficients	O
were	O
6	O
.	O
9	O
%	O
and	O
10	O
.	O
8	O
%	O
,	O
respectively	O
.	O

Statistics	O

Data	O
on	O
hormonal	O
concentrations	O
in	O
serum	O
were	O
analyzed	O
using	O
multivariate	O
analysis	O
of	O
variance	O
(	O
MANOVA	O
)	O
followed	O
by	O
Tukey	O
'	O
s	O
test	O
.	O

Differences	O
in	O
serum	O
hormone	O
concentrations	O
between	O
two	O
groups	O
were	O
analyzed	O
by	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

A	O
probability	O
value	O
of	O
less	O
than	O
5	O
%	O
was	O
considered	O
significant	O
.	O

Results	O

Effects	O
of	O
ether	O
anesthesia	O
and	O
unilateral	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O

In	O
the	O
control	O
group	O
,	O
animals	O
sacrificed	O
on	O
P	O
showed	O
significantly	O
higher	O
E2	O
serum	O
concentration	O
than	O
animals	O
sacrificed	O
on	O
D1	O
or	O
D2	O
(	O
D1	O
:	O
55	O
.	O
3	O
+/-	O
8	O
.	O
0	O
;	O
D2	O
:	O
59	O
.	O
1	O
+/-	O
7	O
.	O
9	O
;	O
P	O
:	O
158	O
.	O
4	O
+/-	O
1	O
.	O
8	O
)	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
ether	O
anesthesia	O
treatment	O
did	O
not	O
modify	O
E2	O
serum	O
concentrations	O
(	O
D1	O
:	O
62	O
.	O
9	O
+/-	O
8	O
.	O
4	O
;	O
D2	O
:	O
69	O
.	O
5	O
+/-	O
12	O
.	O
0	O
;	O
P	O
:	O
164	O
.	O
1	O
+/-	O
17	O
.	O
6	O
)	O
.	O

Since	O
ether	O
anesthesia	O
did	O
not	O
modify	O
E2	O
serum	O
concentrations	O
,	O
treatment	O
results	O
are	O
compared	O
to	O
their	O
respective	O
control	O
group	O
.	O

The	O
effects	O
on	O
E2	O
serum	O
concentrations	O
of	O
unilaterally	O
or	O
bilaterally	O
perforating	O
the	O
peritoneum	O
depended	O
on	O
the	O
side	O
of	O
the	O
peritoneum	O
and	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
perforation	O
surgery	O
was	O
performed	O
.	O

Perforating	O
the	O
left	O
peritoneum	O
on	O
D1	O
resulted	O
in	O
lower	O
E2	O
serum	O
concentrations	O
(	O
55	O
%	O
)	O
,	O
while	O
bilateral	O
perforation	O
,	O
or	O
perforating	O
the	O
right	O
side	O
of	O
the	O
peritoneum	O
,	O
had	O
no	O
apparent	O
effects	O
(	O
Table	O
1	O
)	O
.	O

Perforating	O
the	O
right	O
side	O
of	O
the	O
peritoneum	O
on	O
D2	O
day	O
resulted	O
in	O
E2	O
concentration	O
increases	O
(	O
184	O
%	O
)	O
,	O
while	O
perforating	O
the	O
left	O
side	O
resulted	O
in	O
a	O
decrease	O
(	O
51	O
%	O
)	O
of	O
E2	O
serum	O
concentrations	O
.	O

Bilateral	O
perforation	O
had	O
no	O
apparent	O
effects	O
on	O
hormone	O
concentrations	O
.	O

Perforating	O
the	O
peritoneum	O
on	O
P	O
phase	O
(	O
left	O
,	O
right	O
or	O
bilateral	O
)	O
resulted	O
in	O
hormone	O
serum	O
concentration	O
decreases	O
(	O
Left	O
30	O
%	O
;	O
Right	O
50	O
%	O
;	O
Bilateral	O
41	O
%	O
)	O
.	O

Results	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Effects	O
of	O
unilateral	O
or	O
bilateral	O
ovariectomy	O

When	O
surgery	O
was	O
performed	O
on	O
D1	O
,	O
no	O
significant	O
differences	O
in	O
E2	O
serum	O
concentrations	O
were	O
observed	O
between	O
rats	S-Species
with	O
ULO	O
(	O
animals	O
with	O
intact	O
left	O
or	O
right	O
ovary	O
in	O
situ	O
)	O
or	O
perforation	O
of	O
the	O
peritoneum	O
(	O
Figure	O
1	O
)	O
.	O

Animals	O
with	O
the	O
left	O
intact	O
ovary	O
in	O
situ	O
showed	O
significantly	O
higher	O
E2	O
serum	O
concentrations	O
than	O
animals	O
with	O
the	O
right	O
intact	O
ovary	O
in	O
situ	O
(	O
61	O
.	O
5	O
+/-	O
9	O
.	O
4	O
vs	O
.	O
17	O
.	O
3	O
+/-	O
4	O
.	O
3	O
,	O
p	O
<	O
0	O
.	O
05	O
Student	O
'	O
s	O
t	O
test	O
)	O
.	O

Compared	O
to	O
animals	O
with	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
animals	O
with	O
right	O
ULO	O
(	O
left	O
ovary	O
in	O
situ	O
)	O
performed	O
on	O
D2	O
had	O
lower	O
E2	O
serum	O
concentrations	O
(	O
55	O
%	O
)	O
.	O

Such	O
differences	O
were	O
not	O
observed	O
in	O
rats	S-Species
with	O
left	O
ULO	O
(	O
Figure	O
1	O
)	O
.	O

As	O
in	O
rats	S-Species
treated	O
on	O
D1	O
,	O
E2	O
serum	O
concentrations	O
were	O
significantly	O
higher	O
in	O
animals	O
treated	O
on	O
D2	O
with	O
the	O
left	O
ovary	O
in	O
situ	O
(	O
right	O
ULO	O
)	O
than	O
in	O
animals	O
with	O
the	O
right	O
ovary	O
in	O
situ	O
(	O
49	O
.	O
5	O
+/-	O
10	O
.	O
8	O
vs	O
.	O
26	O
.	O
0	O
+/-	O
6	O
.	O
9	O
)	O
.	O

In	O
animals	O
treated	O
on	O
P	O
,	O
right	O
ULO	O
(	O
left	O
ovary	O
in	O
situ	O
)	O
resulted	O
in	O
higher	O
E2	O
(	O
180	O
%	O
)	O
serum	O
concentrations	O
than	O
in	O
animals	O
with	O
unilateral	O
peritoneum	O
perforation	O
.	O

ULO	O
performed	O
on	O
the	O
left	O
side	O
(	O
right	O
ovary	O
in	O
situ	O
)	O
,	O
resulted	O
in	O
significantly	O
lower	O
(	O
45	O
%	O
)	O
E2	O
serum	O
concentrations	O
compared	O
to	O
rats	S-Species
with	O
a	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
(	O
Figure	O
1	O
)	O
.	O

As	O
observed	O
in	O
rats	S-Species
treated	O
on	O
D1	O
or	O
D2	O
,	O
when	O
the	O
intact	O
left	O
ovary	O
remains	O
in	O
situ	O
,	O
estradiol	O
serum	O
concentrations	O
were	O
significantly	O
higher	O
than	O
in	O
animals	O
with	O
the	O
intact	O
right	O
ovary	O
in	O
situ	O
(	O
142	O
.	O
0	O
+/-	O
14	O
.	O
1	O
vs	O
.	O
61	O
.	O
5	O
+/-	O
6	O
.	O
0	O
)	O
.	O

Compared	O
to	O
animals	O
with	O
a	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
bilateral	O
ovariectomy	O
resulted	O
in	O
significantly	O
lower	O
E2	O
serum	O
concentrations	O
,	O
regardless	O
of	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
surgery	O
performed	O
(	O
D1	O
74	O
%	O
;	O
D2	O
73	O
%	O
;	O
P	O
84	O
%	O
)	O
.	O

Results	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

Effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O

Injecting	O
ATR	O
on	O
D1	O
or	O
P	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
decreases	O
(	O
84	O
%	O
and	O
67	O
%	O
,	O
respectively	O
)	O
,	O
and	O
had	O
no	O
apparent	O
effects	O
on	O
E2	O
serum	O
concentrations	O
when	O
injected	O
on	O
D2	O
(	O
Table	O
3	O
)	O
.	O

Figure	O
2	O
shows	O
that	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
of	O
rats	S-Species
with	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
depended	O
on	O
both	O
,	O
the	O
side	O
(	O
left	O
or	O
right	O
)	O
and	O
the	O
phase	O
of	O
the	O
estrous	O
when	O
surgery	O
was	O
performed	O
.	O

Injecting	O
ATR	O
on	O
D1	O
or	O
D2	O
resulted	O
in	O
a	O
significant	O
drop	O
in	O
E2	O
serum	O
concentrations	O
in	O
animals	O
with	O
sham	O
treatment	O
on	O
the	O
right	O
side	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
of	O
rats	S-Species
with	O
left	O
side	O
peritoneum	O
perforation	O
on	O
D1	O
or	O
P	O
resulted	O
in	O
a	O
drop	O
in	O
E2	O
serum	O
concentrations	O
(	O
52	O
%	O
;	O
47	O
%	O
,	O
respectively	O
)	O
,	O
while	O
the	O
same	O
treatment	O
performed	O
on	O
D2	O
resulted	O
in	O
a	O
significant	O
E2	O
concentrations	O
increase	O
(	O
157	O
%	O
)	O
.	O

Figure	O
3	O
shows	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
of	O
rats	S-Species
with	O
ULO	O
.	O

ATR	O
treatment	O
on	O
D1	O
or	O
P	O
stages	O
performed	O
on	O
rats	S-Species
with	O
the	O
left	O
ovary	O
in	O
situ	O
resulted	O
in	O
a	O
significant	O
drop	O
of	O
E2	O
serum	O
concentrations	O
(	O
65	O
%	O
;	O
62	O
%	O
respectively	O
)	O
.	O

Such	O
effects	O
were	O
not	O
observed	O
in	O
rats	S-Species
treated	O
on	O
D2	O
.	O

When	O
ATR	O
treatment	O
was	O
performed	O
on	O
rats	S-Species
with	O
the	O
right	O
ovary	O
in	O
situ	O
on	O
D1	O
,	O
E2	O
serum	O
concentrations	O
were	O
lower	O
(	O
48	O
%	O
)	O
than	O
in	O
ULO	O
animals	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
on	O
D2	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
increase	O
(	O
159	O
%	O
)	O
.	O

When	O
the	O
treatment	O
was	O
performed	O
on	O
P	O
,	O
no	O
significant	O
differences	O
in	O
E2	O
serum	O
concentrations	O
were	O
observed	O
.	O

Compared	O
to	O
bilateral	O
treatment	O
,	O
perforation	O
of	O
the	O
peritoneum	O
or	O
bilateral	O
ovariectomy	O
,	O
ATR	O
treatment	O
on	O
D1	O
resulted	O
in	O
significant	O
E2	O
serum	O
concentrations	O
decreases	O
,	O
90	O
%	O
in	O
bilateral	O
peritoneal	O
perforation	O
and	O
60	O
%	O
in	O
bilateral	O
ovariectomized	O
animals	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
on	O
D2	O
,	O
to	O
rats	S-Species
with	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
or	O
bilateral	O
ovariectomy	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
increases	O
(	O
159	O
%	O
and	O
253	O
%	O
respectively	O
)	O
,	O
while	O
injecting	O
ATR	O
to	O
animals	O
treated	O
on	O
P	O
had	O
no	O
apparent	O
effects	O
(	O
Figure	O
4	O
)	O
.	O

Discussion	O

The	O
results	O
obtained	O
in	O
the	O
present	O
study	O
suggest	O
that	O
the	O
ability	O
to	O
compensate	O
the	O
secretion	O
of	O
E2	O
by	O
the	O
missing	O
ovary	O
is	O
different	O
between	O
the	O
right	O
and	O
left	O
ovaries	O
and	O
varies	O
during	O
the	O
estrous	O
cycle	O
.	O

Similarly	O
,	O
our	O
results	O
suggest	O
that	O
the	O
cholinergic	O
system	O
participates	O
in	O
regulating	O
E2	O
secretion	O
by	O
the	O
ovary	O
,	O
and	O
that	O
such	O
participation	O
varies	O
depending	O
on	O
the	O
ovary	O
remaining	O
in	O
situ	O
and	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
the	O
surgical	O
procedure	O
was	O
performed	O
.	O

Previously	O
,	O
we	O
suggested	O
the	O
existence	O
of	O
a	O
neural	O
pathway	O
arising	O
from	O
the	O
peritoneum	O
that	O
participates	O
in	O
regulating	O
E2	O
[	O
9	O
]	O
,	O
P4	O
[	O
10	O
]	O
and	O
testosterone	O
secretion	O
[	O
11	O
]	O
.	O

In	O
the	O
rat	S-Species
,	O
the	O
sensory	O
information	O
arising	O
from	O
the	O
peritoneum	O
is	O
sent	O
to	O
the	O
nucleus	O
tractus	O
solitarius	O
and	O
stimulates	O
neurokinine	O
-	O
B	O
receptors	O
[	O
17	O
]	O
.	O

Since	O
perforating	O
the	O
peritoneum	O
unilaterally	O
on	O
each	O
day	O
of	O
the	O
estrous	O
cycle	O
changed	O
E2	O
serum	O
concentrations	O
,	O
we	O
think	O
that	O
each	O
side	O
of	O
the	O
peritoneum	O
sends	O
different	O
neural	O
information	O
through	O
the	O
superior	O
ovarian	O
nerve	O
(	O
SON	O
)	O
to	O
the	O
ovary	O
and	O
the	O
central	O
nervous	O
system	O
,	O
perhaps	O
reaching	O
nuclei	O
related	O
to	O
the	O
vagus	O
nerve	O
.	O

A	O
study	O
analyzing	O
the	O
distribution	O
of	O
sensory	O
neurons	O
innervating	O
the	O
peritoneum	O
showed	O
that	O
when	O
tracer	O
was	O
placed	O
on	O
the	O
area	O
where	O
the	O
peritoneum	O
covers	O
the	O
abdominal	O
wall	O
,	O
labeled	O
neurons	O
were	O
observed	O
only	O
in	O
the	O
ipsilateral	O
dorsal	O
root	O
ganglia	O
[	O
18	O
]	O
.	O

The	O
authors	O
suggest	O
that	O
most	O
of	O
the	O
parietal	O
peritoneum	O
receives	O
sensory	O
nerves	O
from	O
dorsal	O
root	O
ganglia	O
,	O
and	O
visceral	O
peritoneum	O
from	O
both	O
,	O
the	O
spinal	O
and	O
vagus	O
nerves	O
.	O

According	O
to	O
Stener	O
-	O
Victorin	O
et	O
al	O
.	O

(	O
19	O
)	O
repeated	O
electro	O
-	O
acupunture	O
treatments	O
in	O
rats	S-Species
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCO	O
)	O
,	O
induced	O
by	O
a	O
single	O
injection	O
of	O
estradiol	O
valerate	O
,	O
resulted	O
in	O
lower	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
concentrations	O
at	O
the	O
ovarian	O
level	O
than	O
in	O
non	O
-	O
electro	O
-	O
acupunture	O
treated	O
PCO	O
rats	S-Species
.	O

In	O
our	O
experiments	O
,	O
perforating	O
the	O
peritoneum	O
affected	O
the	O
same	O
somatic	O
segments	O
employed	O
by	O
Stener	O
-	O
Victorin	O
et	O
.	O

al	O
.	O

[	O
19	O
]	O
.	O

We	O
presume	O
that	O
peritoneum	O
surgery	O
resulted	O
in	O
an	O
increase	O
of	O
NGF	O
concentrations	O
at	O
the	O
ovarian	O
level	O
,	O
which	O
in	O
turn	O
induced	O
hyper	O
-	O
androgenism	O
,	O
as	O
observed	O
in	O
women	O
with	O
PCO	O
[	O
20	O
]	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
results	O
in	O
a	O
significant	O
increase	O
in	O
testosterone	O
serum	O
concentrations	O
[	O
11	O
]	O
.	O

Because	O
E2	O
serum	O
concentrations	O
did	O
not	O
increase	O
after	O
left	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
we	O
suppose	O
that	O
the	O
neural	O
information	O
originating	O
from	O
the	O
peritoneum	O
inhibits	O
the	O
mechanisms	O
regulating	O
aromatase	O
activity	O
within	O
the	O
follicle	O
.	O

One	O
of	O
the	O
ovaries	O
'	O
sources	O
of	O
catecholamines	O
arrives	O
through	O
the	O
SON	O
.	O

In	O
the	O
ovary	O
,	O
the	O
SON	O
fibers	O
are	O
mainly	O
distributed	O
in	O
the	O
peri	O
-	O
follicular	O
theca	O
layer	O
,	O
and	O
in	O
close	O
relation	O
with	O
the	O
cells	O
of	O
the	O
theca	O
interna	O
[	O
21	O
,	O
22	O
]	O
.	O

Sectioning	O
the	O
SON	O
of	O
rats	S-Species
in	O
P	O
results	O
in	O
a	O
sudden	O
drop	O
of	O
P4	O
and	O
E2	O
concentrations	O
in	O
the	O
ovarian	O
vein	O
effluent	O
[	O
23	O
]	O
,	O
while	O
the	O
same	O
procedure	O
on	O
estrus	O
did	O
not	O
modify	O
E2	O
concentrations	O
[	O
24	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
perforating	O
the	O
peritoneum	O
modifies	O
the	O
type	O
and	O
/	O
or	O
rate	O
of	O
information	O
arriving	O
to	O
the	O
ovary	O
via	O
the	O
SON	O
.	O

Another	O
possibility	O
is	O
that	O
perforating	O
the	O
left	O
side	O
of	O
the	O
peritoneum	O
results	O
in	O
an	O
increase	O
release	O
of	O
ovarian	O
gamma	O
amino	O
butyric	O
acid	O
(	O
GABA	O
)	O
,	O
and	O
a	O
subsequent	O
increase	O
of	O
E2	O
concentrations	O
.	O

According	O
to	O
Erd	O
o	O
,	O
et	O
.	O

al	O
.	O

[	O
25	O
]	O
and	O
Laszlo	O
,	O
et	O
.	O

al	O
.	O

[	O
26	O
]	O
,	O
injecting	O
GABA	O
into	O
pseudo	O
-	O
pregnant	O
rats	S-Species
increases	O
E2	O
concentration	O
in	O
the	O
blood	O
.	O

Present	O
results	O
indicate	O
that	O
injecting	O
ATR	O
,	O
before	O
unilateral	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
to	O
rats	S-Species
in	O
D1	O
or	O
P	O
,	O
results	O
in	O
lower	O
E2serum	O
concentrations	O
;	O
leading	O
us	O
to	O
think	O
that	O
some	O
of	O
the	O
neural	O
fibers	O
present	O
in	O
the	O
peritoneum	O
are	O
muscarinic	O
.	O

It	O
is	O
also	O
possible	O
that	O
blocking	O
the	O
cholinergic	O
innervation	O
,	O
by	O
ATR	O
treatment	O
,	O
results	O
in	O
lower	O
adrenaline	O
and	O
norepinephrine	O
release	O
by	O
the	O
adrenal	O
medulla	O
.	O

Our	O
results	O
,	O
and	O
those	O
of	O
others	O
,	O
suggest	O
that	O
stimulating	O
on	O
D2	O
the	O
sensory	O
receptors	O
located	O
on	O
the	O
left	O
side	O
of	O
the	O
peritoneum	O
triggers	O
an	O
E2	O
secretion	O
inhibitory	O
mechanism	O
,	O
that	O
the	O
sensory	O
pathway	O
arising	O
from	O
the	O
right	O
side	O
has	O
a	O
stimulatory	O
effect	O
,	O
and	O
that	O
both	O
are	O
mediated	O
by	O
the	O
cholinergic	O
muscarinic	O
system	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
injecting	O
ATR	O
to	O
rats	S-Species
in	O
D2	O
results	O
in	O
increases	O
of	O
P4	O
serum	O
concentrations	O
originating	O
from	O
the	O
adrenals	O
[	O
8	O
]	O
,	O
without	O
having	O
apparent	O
effects	O
on	O
testosterone	O
serum	O
concentrations	O
[	O
11	O
]	O
.	O

Since	O
P4	O
and	O
androgens	O
are	O
precursors	O
in	O
the	O
synthesis	O
of	O
E2	O
,	O
we	O
presume	O
that	O
this	O
mechanism	O
may	O
explain	O
the	O
increase	O
in	O
E2	O
serum	O
concentrations	O
observed	O
in	O
rats	S-Species
with	O
peritoneum	O
perforation	O
previously	O
injected	O
with	O
ATR	O
.	O

Another	O
possibility	O
explaining	O
the	O
differences	O
on	O
E2	O
secretion	O
regulation	O
during	O
the	O
estrous	O
cycle	O
is	O
that	O
the	O
effects	O
of	O
the	O
cholinergic	O
system	O
take	O
place	O
through	O
changes	O
at	O
the	O
celiac	O
ganglion	O
level	O
.	O

According	O
to	O
Aguado	O
and	O
Ojeda	O
[	O
23	O
]	O
,	O
acetylcholine	O
inhibits	O
P4	O
secretion	O
in	O
the	O
celiac	O
ganglion	O
-	O
SON	O
-	O
ovary	O
preparation	O
obtained	O
from	O
rats	S-Species
in	O
D1	O
or	O
D2	O
,	O
while	O
the	O
preparation	O
obtained	O
from	O
rats	S-Species
in	O
P	O
resulted	O
in	O
only	O
a	O
moderate	O
stimulation	O
.	O

Since	O
there	O
is	O
evidence	O
that	O
fibers	O
from	O
the	O
vagus	O
nerve	O
innervate	O
neurons	O
in	O
the	O
celiac	O
ganglion	O
[	O
27	O
]	O
,	O
we	O
presume	O
that	O
the	O
cholinergic	O
system	O
modulates	O
the	O
sympathetic	O
post	O
-	O
ganglionar	O
activity	O
and	O
the	O
secretory	O
ability	O
of	O
the	O
ovaries	O
through	O
the	O
SON	O
.	O

Conclusion	O

Based	O
on	O
the	O
differences	O
in	O
E2	O
serum	O
concentrations	O
in	O
rats	S-Species
with	O
ULO	O
,	O
present	O
results	O
suggest	O
that	O
the	O
capacity	O
to	O
release	O
E2	O
by	O
the	O
left	O
and	O
right	O
ovaries	O
varies	O
during	O
the	O
estrous	O
cycle	O
.	O

We	O
presume	O
that	O
the	O
left	O
ovary	O
releases	O
more	O
E2	O
than	O
the	O
right	O
one	O
.	O

As	O
previously	O
proposed	O
,	O
another	O
possibility	O
is	O
that	O
neural	O
communication	O
between	O
the	O
ovaries	O
modulates	O
E2	O
secretion	O
.	O

Case	O
report	O
:	O
rapidly	O
fatal	O
bowel	O
ischaemia	O
on	O
clozapine	O
treatment	O

Abstract	O

Background	O

There	O
have	O
been	O
previous	O
reported	O
deaths	O
due	O
to	O
clozapine	O
-	O
induced	O
constipation	O
.	O

In	O
all	O
these	O
cases	O
patients	S-Species
have	O
experienced	O
prior	O
abdominal	O
symptoms	O
over	O
a	O
period	O
of	O
weeks	O
or	O
months	O
.	O

Case	O
presentation	O

We	O
report	O
the	O
sudden	O
death	O
due	O
to	O
constipation	O
of	O
a	O
healthy	O
young	O
male	O
patient	S-Species
on	O
clozapine	O
without	O
any	O
known	O
history	O
of	O
prior	O
abdominal	O
symptoms	O
.	O

Conclusion	O

Psychiatrists	O
need	O
to	O
be	O
alert	O
to	O
the	O
medical	O
emergencies	O
which	O
can	O
occur	O
in	O
the	O
context	O
of	O
clozapine	O
treatment	O
and	O
also	O
need	O
to	O
make	O
other	O
clinicians	O
who	O
may	O
have	O
contact	O
with	O
their	O
patients	S-Species
aware	O
of	O
these	O
.	O

Background	O

There	O
have	O
been	O
six	O
previously	O
published	O
cases	O
of	O
death	O
secondary	O
to	O
clozapine	O
-	O
induced	O
constipation	O
[	O
1	O
-	O
3	O
]	O
.	O

Of	O
these	O
,	O
two	O
patients	S-Species
died	O
from	O
faecal	O
peritonitis	O
,	O
two	O
from	O
aspiration	O
of	O
faeculent	O
vomitus	O
as	O
a	O
result	O
of	O
bowel	O
obstruction	O
and	O
two	O
from	O
bowel	O
necrosis	O
.	O

In	O
all	O
these	O
cases	O
there	O
had	O
been	O
prior	O
complaints	O
of	O
constipation	O
and	O
/	O
or	O
other	O
abdominal	O
symptoms	O
for	O
weeks	O
to	O
months	O
before	O
the	O
fatal	O
event	O
.	O

Here	O
we	O
describe	O
a	O
case	O
of	O
constipation	O
,	O
presumably	O
clozapine	O
-	O
induced	O
,	O
where	O
death	O
from	O
bowel	O
ischaemia	O
occured	O
within	O
2	O
days	O
from	O
the	O
first	O
complaint	O
of	O
constipation	O
and	O
without	O
any	O
prior	O
reported	O
abdominal	O
symptoms	O
which	O
might	O
have	O
provided	O
a	O
warning	O
to	O
the	O
clinicians	O
involved	O
.	O

Case	O
presentation	O

A	O
20	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
year	O
long	O
history	O
of	O
schizophrenia	O
which	O
had	O
been	O
unresponsive	O
to	O
trials	O
of	O
two	O
atypical	O
antipsychotic	O
drugs	O
was	O
commenced	O
on	O
clozapine	O
.	O

The	O
dose	O
was	O
titrated	O
over	O
the	O
next	O
year	O
to	O
900	O
mg	O
daily	O
.	O

Due	O
to	O
persisting	O
negative	O
symptoms	O
amisulpiride	O
400	O
mg	O
twice	O
daily	O
was	O
added	O
with	O
good	O
response	O
after	O
one	O
month	O
.	O

The	O
patient	S-Species
was	O
reviewed	O
regularly	O
over	O
the	O
next	O
year	O
,	O
continued	O
to	O
improve	O
and	O
did	O
not	O
report	O
any	O
side	O
effects	O
to	O
members	O
of	O
the	O
multidisciplinary	O
mental	O
health	O
team	O
working	O
to	O
support	O
him	O
in	O
the	O
community	O
.	O

He	O
appeared	O
to	O
be	O
fit	O
and	O
healthy	O
.	O

Although	O
he	O
usually	O
lived	O
in	O
supported	O
accommodation	O
he	O
was	O
staying	O
temporarily	O
with	O
his	O
family	O
and	O
from	O
their	O
account	O
he	O
complained	O
of	O
having	O
constipation	O
for	O
2	O
days	O
before	O
presenting	O
to	O
his	O
GP	O
with	O
severe	O
abdominal	O
pain	O
.	O

He	O
was	O
prescribed	O
medication	O
and	O
returned	O
home	O
but	O
his	O
condition	O
deteriorated	O
further	O
and	O
a	O
few	O
hours	O
later	O
an	O
ambulance	O
was	O
called	O
.	O

He	O
collapsed	O
and	O
died	O
before	O
reaching	O
hospital	O
.	O

Post	O
mortem	O
examination	O
revealed	O
that	O
he	O
had	O
impacted	O
faeces	O
which	O
had	O
pressed	O
against	O
the	O
bowel	O
wall	O
causing	O
ischaemia	O
.	O

This	O
had	O
led	O
to	O
infarction	O
of	O
this	O
part	O
of	O
the	O
bowel	O
.	O

Conclusion	O

This	O
case	O
demonstrates	O
that	O
death	O
can	O
occur	O
over	O
a	O
very	O
short	O
time	O
course	O
from	O
constipation	O
,	O
in	O
this	O
case	O
presumably	O
induced	O
by	O
clozapine	O
.	O

Death	O
from	O
constipation	O
and	O
subsequent	O
bowel	O
infarction	O
is	O
relatively	O
common	O
in	O
elderly	O
patients	S-Species
and	O
infarction	O
causes	O
a	O
far	O
more	O
rapid	O
and	O
dangerous	O
deterioration	O
than	O
does	O
intestinal	O
obstruction	O
.	O

In	O
the	O
present	O
case	O
this	O
meant	O
that	O
this	O
patient	S-Species
did	O
not	O
have	O
any	O
contact	O
with	O
psychiatric	O
services	O
between	O
the	O
onset	O
of	O
his	O
symptoms	O
and	O
his	O
rapid	O
demise	O
,	O
in	O
spite	O
of	O
regular	O
follow	O
-	O
up	O
.	O

Although	O
the	O
risk	O
of	O
neutropenia	O
is	O
relatively	O
well	O
-	O
known	O
,	O
it	O
should	O
be	O
borne	O
in	O
mind	O
that	O
clozapine	O
is	O
reported	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
other	O
syndromes	O
which	O
may	O
be	O
rapidly	O
fatal	O
including	O
not	O
only	O
constipation	O
and	O
obstruction	O
but	O
also	O
cardiovascular	O
collapse	O
,	O
seizures	O
and	O
ketoacidosis	O
.	O

Psychiatrists	O
working	O
with	O
such	O
patients	S-Species
should	O
not	O
only	O
themselves	O
be	O
vigilant	O
regarding	O
such	O
complications	O
but	O
should	O
take	O
steps	O
to	O
see	O
that	O
other	O
clinicians	O
to	O
whom	O
the	O
patient	S-Species
may	O
present	O
are	O
also	O
aware	O
of	O
them	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

Both	O
authors	O
were	O
equally	O
involved	O
in	O
the	O
preparation	O
of	O
this	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

A	O
disease	O
-	O
specific	O
measure	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
for	O
use	O
in	O
adults	O
with	O
immune	O
thrombocytopenic	O
purpura	O
:	O
Its	O
development	O
and	O
validation	O

Abstract	O

Background	O

No	O
validated	O
disease	O
-	O
specific	O
measures	O
are	O
available	O
to	O
assess	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
in	O
adult	O
subjects	O
with	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
develop	O
and	O
validate	O
the	O
ITP	O
-	O
Patient	S-Species
Assessment	O
Questionnaire	O
(	O
ITP	O
-	O
PAQ	O
)	O
for	O
adult	O
subjects	O
with	O
ITP	O
.	O

Methods	O

Information	O
from	O
literature	O
reviews	O
,	O
focus	O
groups	O
with	O
subjects	O
,	O
and	O
clinicians	O
were	O
used	O
to	O
develop	O
50	O
ITP	O
-	O
PAQ	O
items	O
.	O

Factor	O
analyses	O
were	O
conducted	O
to	O
develop	O
the	O
scale	O
structure	O
and	O
reduce	O
the	O
number	O
of	O
items	O
.	O

The	O
final	O
44	O
-	O
item	O
ITP	O
-	O
PAQ	O
,	O
which	O
includes	O
ten	O
scales	O
[	O
Symptoms	O
(	O
S	O
)	O
,	O
Bother	O
-	O
Physical	O
Health	O
(	O
B	O
)	O
,	O
Fatigue	O
/	O
Sleep	O
(	O
FT	O
)	O
,	O
Activity	O
(	O
A	O
)	O
,	O
Fear	O
(	O
FR	O
)	O
,	O
Psychological	O
Health	O
(	O
PH	O
)	O
,	O
Work	O
(	O
W	O
)	O
,	O
Social	O
Activity	O
(	O
SA	O
)	O
,	O
Women	S-Species
'	O
s	O
Reproductive	O
Health	O
(	O
RH	O
)	O
,	O
and	O
Overall	O
(	O
QoL	O
)	O
]	O
,	O
was	O
self	O
-	O
administered	O
to	O
adult	O
ITP	O
subjects	O
at	O
baseline	O
and	O
7	O
-	O
10	O
days	O
later	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
internal	O
consistency	O
reliability	O
,	O
construct	O
and	O
known	O
groups	O
validity	O
of	O
the	O
final	O
ITP	O
-	O
PAQ	O
were	O
evaluated	O
.	O

Results	O

Seventy	O
-	O
three	O
subjects	O
with	O
ITP	O
completed	O
the	O
questionnaire	O
twice	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
as	O
measured	O
by	O
the	O
intra	O
-	O
class	O
correlation	O
,	O
ranged	O
from	O
0	O
.	O
52	O
-	O
0	O
.	O
90	O
.	O

Internal	O
consistency	O
reliability	O
was	O
demonstrated	O
with	O
Cronbach	O
'	O
s	O
alpha	O
for	O
all	O
scales	O
above	O
the	O
acceptable	O
level	O
of	O
0	O
.	O
70	O
(	O
range	O
:	O
0	O
.	O
71	O
-	O
0	O
.	O
92	O
)	O
,	O
except	O
for	O
RH	O
(	O
0	O
.	O
66	O
)	O
.	O

Construct	O
validity	O
,	O
assessed	O
by	O
correlating	O
ITP	O
-	O
PAQ	O
scales	O
with	O
established	O
measures	O
(	O
Short	O
Form	O
-	O
36	O
v	O
.	O
1	O
,	O
SF	O
-	O
36	O
and	O
Center	O
for	O
Epidemiologic	O
Studies	O
Depression	O
Scale	O
,	O
CES	O
-	O
D	O
)	O
,	O
was	O
demonstrated	O
through	O
moderate	O
correlations	O
between	O
the	O
ITP	O
-	O
PAQ	O
SA	O
and	O
SF	O
-	O
36	O
Social	O
Function	O
scales	O
(	O
r	O
=	O
0	O
.	O
67	O
)	O
,	O
and	O
between	O
ITP	O
-	O
PAQ	O
PH	O
and	O
SF	O
-	O
36	O
Mental	O
Health	O
Scales	O
(	O
r	O
=	O
0	O
.	O
63	O
)	O
.	O

Moderate	O
to	O
strong	O
inter	O
-	O
scale	O
correlations	O
were	O
reported	O
between	O
ITP	O
-	O
PAQ	O
scales	O
and	O
the	O
CES	O
-	O
D	O
,	O
except	O
for	O
the	O
RH	O
scale	O
.	O

Known	O
groups	O
validity	O
was	O
evaluated	O
by	O
comparing	O
mean	O
scores	O
for	O
groups	O
that	O
differed	O
clinically	O
.	O

Statistically	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
observed	O
when	O
subjects	O
were	O
categorized	O
by	O
treatment	O
status	O
[	O
S	O
,	O
FT	O
,	O
B	O
,	O
A	O
,	O
PH	O
,	O
and	O
QoL	O
,	O
perceived	O
effectiveness	O
of	O
ITP	O
treatment	O
[	O
S	O
]	O
,	O
and	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
[	O
PH	O
]	O
.	O

Conclusion	O

Results	O
provide	O
preliminary	O
evidence	O
of	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
ITP	O
-	O
PAQ	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Further	O
work	O
should	O
be	O
conducted	O
to	O
assess	O
the	O
responsiveness	O
and	O
to	O
estimate	O
the	O
minimal	O
clinical	O
important	O
difference	O
of	O
the	O
ITP	O
-	O
PAQ	O
to	O
more	O
fully	O
understand	O
the	O
impact	O
of	O
ITP	O
and	O
its	O
treatments	O
on	O
HRQoL	O
.	O

Background	O

Immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
is	O
a	O
disorder	O
characterized	O
by	O
autoimmune	O
-	O
mediated	O
platelet	O
destruction	O
and	O
suboptimal	O
platelet	O
production	O
[	O
1	O
-	O
3	O
]	O
that	O
results	O
in	O
a	O
decrease	O
in	O
the	O
number	O
of	O
circulating	O
platelets	O
and	O
increases	O
the	O
risk	O
of	O
bleeding	O
events	O
.	O

The	O
estimated	O
prevalence	O
rate	O
for	O
ITP	O
in	O
the	O
United	O
States	O
is	O
9	O
.	O
5	O
/	O
100	O
,	O
000	O
[	O
4	O
]	O
.	O

Adult	O
women	S-Species
are	O
disproportionately	O
affected	O
by	O
the	O
disorder	O
,	O
with	O
a	O
female	O
to	O
male	O
ratio	O
of	O
nearly	O
two	O
to	O
one	O
[	O
5	O
]	O
.	O

The	O
disorder	O
rarely	O
remits	O
spontaneously	O
in	O
adult	O
subjects	O
[	O
1	O
]	O
.	O

The	O
mortality	O
rate	O
is	O
relatively	O
low	O
(	O
<	O
1	O
%	O
)	O
[	O
6	O
]	O
in	O
adults	O
less	O
than	O
65	O
years	O
of	O
age	O
.	O

Morbidity	O
increases	O
above	O
age	O
65	O
,	O
primarily	O
as	O
a	O
result	O
of	O
an	O
increase	O
in	O
age	O
-	O
related	O
major	O
bleeding	O
events	O
[	O
7	O
]	O
.	O

Initial	O
therapy	O
for	O
ITP	O
consists	O
of	O
some	O
combination	O
of	O
glucocorticoids	O
,	O
intravenous	O
immune	O
globulin	O
(	O
IVIg	O
)	O
or	O
anti	O
-	O
D	O
[	O
8	O
]	O
.	O

Splenectomy	O
is	O
often	O
considered	O
if	O
these	O
therapies	O
fail	O
.	O

Approximately	O
two	O
-	O
thirds	O
of	O
patients	S-Species
treated	O
with	O
splenectomy	O
achieve	O
a	O
sustained	O
remission	O
[	O
1	O
,	O
5	O
,	O
9	O
]	O
.	O

Patients	S-Species
who	O
fail	O
splenectomy	O
are	O
treated	O
with	O
a	O
wide	O
variety	O
of	O
agents	O
including	O
corticosteroids	O
,	O
danazol	O
,	O
and	O
chemotherapeutic	O
agents	O
.	O

Morbidity	O
and	O
mortality	O
in	O
these	O
refractory	O
patients	S-Species
are	O
substantial	O
[	O
1	O
,	O
6	O
,	O
8	O
]	O
.	O

Patient	S-Species
-	O
reported	O
outcomes	O
(	O
PRO	O
)	O
,	O
including	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
measures	O
,	O
are	O
critical	O
components	O
for	O
evaluating	O
and	O
understanding	O
treatment	O
effects	O
from	O
the	O
subject	O
'	O
s	O
perspective	O
.	O

The	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
indicates	O
that	O
PRO	O
measures	O
are	O
important	O
to	O
assess	O
because	O
they	O
may	O
:	O
1	O
)	O
detect	O
treatment	O
effects	O
known	O
only	O
to	O
the	O
subject	O
;	O
2	O
)	O
understand	O
the	O
subject	O
'	O
s	O
perspective	O
regarding	O
treatment	O
effect	O
;	O
or	O
3	O
)	O
provide	O
information	O
not	O
included	O
in	O
a	O
clinician	O
'	O
s	O
subject	O
notes	O
[	O
10	O
]	O
.	O

Furthermore	O
,	O
the	O
Committee	O
for	O
Medicinal	O
Products	O
for	O
Human	S-Species
Use	O
of	O
the	O
European	O
Medicines	O
Agency	O
defines	O
HRQoL	O
as	O
"	O
the	O
subject	O
'	O
s	O
subjective	O
perception	O
of	O
the	O
impact	O
of	O
his	O
disease	O
and	O
its	O
treatment	O
(	O
s	O
)	O
on	O
his	O
daily	O
life	O
,	O
physical	O
,	O
psychological	O
and	O
social	O
functioning	O
and	O
well	O
-	O
being	O
"	O
[	O
11	O
]	O
.	O

Currently	O
,	O
limited	O
data	O
are	O
available	O
on	O
the	O
assessment	O
of	O
the	O
impact	O
of	O
symptoms	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Symptoms	O
of	O
ITP	O
,	O
such	O
as	O
spontaneous	O
bruising	O
,	O
menorrhagia	O
,	O
mucosal	O
bleeding	O
and	O
prolonged	O
bleeding	O
with	O
injury	O
,	O
may	O
significantly	O
affect	O
HRQoL	O
in	O
ITP	O
subjects	O
[	O
12	O
]	O
.	O

Treatments	O
for	O
chronic	O
ITP	O
can	O
also	O
be	O
associated	O
with	O
substantial	O
side	O
effects	O
[	O
5	O
,	O
8	O
]	O
.	O

In	O
addition	O
,	O
subjects	O
who	O
are	O
resistant	O
to	O
current	O
therapies	O
are	O
likely	O
to	O
experience	O
an	O
even	O
greater	O
decrement	O
to	O
their	O
HRQoL	O
than	O
responders	O
to	O
treatment	O
.	O

Thus	O
,	O
restoring	O
and	O
/	O
or	O
maintaining	O
quality	O
of	O
life	O
should	O
be	O
an	O
important	O
goal	O
of	O
treatment	O
.	O

While	O
the	O
primary	O
markers	O
for	O
ITP	O
include	O
hematologic	O
measures	O
such	O
as	O
platelet	O
counts	O
,	O
clinical	O
measures	O
typically	O
do	O
not	O
assess	O
a	O
subject	O
'	O
s	O
functioning	O
and	O
well	O
-	O
being	O
.	O

Therefore	O
,	O
subjects	O
and	O
physicians	O
may	O
want	O
to	O
weigh	O
the	O
impact	O
of	O
ITP	O
therapies	O
on	O
HRQoL	O
endpoints	O
when	O
making	O
treatment	O
decisions	O
.	O

Previously	O
,	O
no	O
validated	O
disease	O
-	O
specific	O
measures	O
were	O
available	O
to	O
evaluate	O
quality	O
of	O
life	O
in	O
adult	O
ITP	O
subjects	O
;	O
however	O
,	O
two	O
disease	O
-	O
specific	O
HRQoL	O
questionnaires	O
have	O
been	O
developed	O
for	O
use	O
in	O
children	S-Species
with	O
ITP	O
[	O
13	O
,	O
14	O
]	O
.	O

Thus	O
,	O
we	O
sought	O
to	O
develop	O
a	O
questionnaire	O
that	O
would	O
be	O
appropriate	O
to	O
assess	O
the	O
impact	O
of	O
ITP	O
symptoms	O
and	O
its	O
treatments	O
on	O
HRQoL	O
in	O
adult	O
subjects	O
.	O

The	O
objective	O
of	O
this	O
current	O
manuscript	O
is	O
to	O
describe	O
the	O
development	O
and	O
initial	O
validation	O
of	O
a	O
newly	O
developed	O
HRQoL	O
questionnaire	O
for	O
use	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Methods	O

Overview	O

A	O
newly	O
developed	O
questionnaire	O
,	O
which	O
assesses	O
issues	O
of	O
importance	O
to	O
ITP	O
subjects	O
,	O
was	O
developed	O
based	O
on	O
available	O
published	O
literature	O
,	O
existing	O
questionnaires	O
,	O
expert	O
clinical	O
opinion	O
,	O
and	O
input	O
from	O
subjects	O
with	O
ITP	O
.	O

Subjects	O
and	O
Procedures	O

To	O
develop	O
the	O
questionnaire	O
,	O
three	O
focus	O
groups	O
with	O
ITP	O
subjects	O
were	O
conducted	O
in	O
geographically	O
diverse	O
locations	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
New	O
York	O
,	O
NY	O
,	O
and	O
Oklahoma	O
City	O
,	O
OK	O
)	O
.	O

Each	O
of	O
the	O
three	O
sites	O
recruited	O
a	O
convenience	O
sample	O
of	O
five	O
to	O
eight	O
ITP	O
subjects	O
who	O
were	O
being	O
treated	O
on	O
an	O
outpatient	O
basis	O
.	O

To	O
be	O
eligible	O
,	O
subjects	O
were	O
required	O
to	O
have	O
active	O
disease	O
and	O
be	O
>=	O
18	O
years	O
of	O
age	O
.	O

Although	O
platelet	O
count	O
data	O
were	O
not	O
required	O
for	O
participation	O
in	O
the	O
focus	O
groups	O
,	O
clinicians	O
at	O
each	O
site	O
considered	O
the	O
subjects	O
to	O
have	O
active	O
disease	O
,	O
usually	O
an	O
indication	O
that	O
platelet	O
levels	O
have	O
dropped	O
below	O
120	O
x	O
109L	O
and	O
the	O
subject	O
requires	O
treatment	O
and	O
/	O
or	O
more	O
frequent	O
monitoring	O
.	O

In	O
total	O
,	O
23	O
ITP	O
subjects	O
participated	O
in	O
the	O
focus	O
groups	O
after	O
providing	O
their	O
informed	O
consent	O
.	O

To	O
validate	O
the	O
questionnaire	O
,	O
a	O
convenience	O
sample	O
of	O
subjects	O
was	O
recruited	O
from	O
the	O
same	O
three	O
clinical	O
sites	O
in	O
New	O
York	O
,	O
NY	O
,	O
Oklahoma	O
City	O
,	O
OK	O
,	O
and	O
La	O
Jolla	O
,	O
CA	O
.	O

Subjects	O
were	O
eligible	O
if	O
they	O
were	O
>=	O
18	O
years	O
of	O
age	O
,	O
had	O
active	O
disease	O
,	O
and	O
were	O
willing	O
to	O
complete	O
a	O
self	O
-	O
administered	O
questionnaire	O
at	O
two	O
time	O
points	O
.	O

Target	O
enrollment	O
was	O
roughly	O
72	O
subjects	O
(	O
24	O
subjects	O
from	O
each	O
site	O
)	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
a	O
local	O
institutional	O
review	O
board	O
at	O
each	O
site	O
and	O
was	O
carried	O
out	O
in	O
accordance	O
with	O
Good	O
Clinical	O
Practice	O
and	O
International	O
Conference	O
on	O
Harmonization	O
guidelines	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
prior	O
to	O
enrollment	O
.	O

Creation	O
of	O
Questionnaire	O
/	O
Item	O
Selection	O

A	O
trained	O
moderator	O
led	O
all	O
focus	O
groups	O
using	O
a	O
detailed	O
discussion	O
guide	O
.	O

Subjects	O
discussed	O
their	O
ITP	O
history	O
,	O
treatment	O
,	O
ITP	O
symptoms	O
,	O
and	O
the	O
impact	O
of	O
ITP	O
on	O
daily	O
activities	O
.	O

Each	O
focus	O
group	O
lasted	O
approximately	O
three	O
hours	O
,	O
and	O
subjects	O
were	O
provided	O
with	O
an	O
honorarium	O
for	O
their	O
time	O
.	O

Following	O
the	O
focus	O
group	O
session	O
,	O
all	O
subjects	O
completed	O
a	O
questionnaire	O
which	O
included	O
the	O
SF	O
-	O
36	O
v1	O
[	O
15	O
]	O
and	O
ITP	O
-	O
specific	O
questions	O
.	O

The	O
ITP	O
-	O
specific	O
items	O
were	O
developed	O
based	O
on	O
clinical	O
input	O
[	O
12	O
,	O
16	O
-	O
18	O
]	O
.	O

The	O
ITP	O
-	O
specific	O
items	O
assessed	O
the	O
impact	O
of	O
ITP	O
on	O
the	O
subject	O
'	O
s	O
overall	O
quality	O
of	O
life	O
,	O
relationships	O
,	O
ability	O
to	O
sleep	O
,	O
menstruation	O
/	O
gynecological	O
history	O
,	O
and	O
sexual	O
activity	O
.	O

The	O
ITP	O
-	O
specific	O
questions	O
also	O
assessed	O
the	O
subject	O
'	O
s	O
response	O
to	O
ITP	O
treatments	O
and	O
any	O
side	O
effects	O
.	O

Transcripts	O
of	O
the	O
focus	O
groups	O
were	O
summarized	O
and	O
reviewed	O
by	O
the	O
study	O
team	O
.	O

The	O
initial	O
draft	O
of	O
the	O
ITP	O
Subject	O
Assessment	O
Questionnaire	O
(	O
ITP	O
-	O
PAQ	O
)	O
was	O
developed	O
after	O
reviewing	O
information	O
from	O
the	O
literature	O
searches	O
,	O
existing	O
questionnaires	O
,	O
expert	O
opinion	O
,	O
focus	O
group	O
transcripts	O
,	O
and	O
the	O
questionnaire	O
responses	O
from	O
the	O
focus	O
group	O
subjects	O
.	O

The	O
initial	O
ITP	O
-	O
PAQ	O
consisted	O
of	O
50	O
items	O
that	O
assesses	O
the	O
impact	O
of	O
ITP	O
in	O
the	O
areas	O
of	O
physical	O
health	O
,	O
mental	O
health	O
,	O
work	O
,	O
social	O
activity	O
,	O
reproductive	O
health	O
(	O
relevant	O
for	O
women	S-Species
only	O
)	O
,	O
and	O
overall	O
quality	O
of	O
life	O
.	O

Factor	O
analyses	O
were	O
conducted	O
which	O
yielded	O
six	O
unique	O
domains	O
.	O

The	O
impact	O
of	O
ITP	O
on	O
physical	O
health	O
was	O
measured	O
by	O
four	O
scales	O
that	O
evaluated	O
ITP	O
-	O
related	O
symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
and	O
Activity	O
.	O

Its	O
impact	O
on	O
mental	O
health	O
was	O
measured	O
by	O
two	O
scales	O
that	O
evaluated	O
psychological	O
distress	O
and	O
fear	O
.	O

A	O
copy	O
of	O
the	O
questionnaire	O
can	O
be	O
obtained	O
by	O
contacting	O
Janet	O
L	O
.	O
Nichol	O
and	O
sample	O
items	O
are	O
included	O
Table	O
2	O
.	O

Statistical	O
Analyses	O

A	O
validation	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
the	O
newly	O
developed	O
ITP	O
-	O
PAQ	O
questionnaire	O
so	O
that	O
it	O
could	O
be	O
used	O
to	O
measure	O
the	O
impact	O
of	O
ITP	O
in	O
adult	O
subjects	O
in	O
future	O
studies	O
.	O

Standard	O
psychometric	O
methods	O
were	O
used	O
to	O
evaluate	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
questionnaire	O
[	O
19	O
,	O
20	O
]	O
.	O

Eligible	O
subjects	O
completed	O
the	O
baseline	O
questionnaire	O
at	O
the	O
site	O
or	O
by	O
mail	O
after	O
providing	O
telephone	O
consent	O
.	O

An	O
informed	O
consent	O
form	O
and	O
baseline	O
questionnaire	O
was	O
mailed	O
to	O
those	O
subjects	O
who	O
gave	O
their	O
initial	O
consent	O
via	O
telephone	O
.	O

These	O
completed	O
documents	O
were	O
returned	O
by	O
mail	O
to	O
the	O
investigators	O
.	O

At	O
follow	O
up	O
,	O
each	O
subject	O
was	O
mailed	O
the	O
same	O
questionnaire	O
and	O
asked	O
to	O
complete	O
it	O
a	O
second	O
time	O
(	O
for	O
evaluating	O
test	O
-	O
retest	O
reliability	O
)	O
approximately	O
two	O
weeks	O
later	O
.	O

Additionally	O
,	O
subjects	O
completed	O
the	O
SF	O
-	O
36	O
and	O
the	O
CES	O
-	O
D	O
[	O
21	O
]	O
for	O
validation	O
purposes	O
at	O
both	O
assessments	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
also	O
solicited	O
in	O
order	O
to	O
more	O
fully	O
describe	O
the	O
study	O
population	O
.	O

Each	O
study	O
subject	O
received	O
an	O
honorarium	O
for	O
completing	O
the	O
questionnaires	O
.	O

Scale	O
creation	O
and	O
confirmatory	O
factor	O
analysis	O

Confirmatory	O
factor	O
analyses	O
were	O
conducted	O
to	O
test	O
the	O
hypothesized	O
structure	O
of	O
the	O
scales	O
.	O

Two	O
models	O
using	O
LISREL	O
version	O
8	O
were	O
tested	O
[	O
22	O
]	O
.	O

The	O
first	O
model	O
consisted	O
of	O
all	O
50	O
HRQoL	O
items	O
and	O
10	O
factors	O
,	O
whereas	O
the	O
second	O
model	O
consisted	O
of	O
a	O
subset	O
of	O
the	O
50	O
-	O
item	O
correlation	O
matrix	O
.	O

Only	O
women	S-Species
respond	O
to	O
the	O
six	O
items	O
comprising	O
the	O
Reproductive	O
Health	O
scale	O
,	O
so	O
the	O
items	O
were	O
not	O
included	O
in	O
the	O
second	O
LISREL	O
model	O
to	O
avoid	O
estimation	O
biases	O
.	O

The	O
remaining	O
44	O
items	O
were	O
analyzed	O
.	O

Model	O
fit	O
was	O
evaluated	O
using	O
the	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
GFI	O
)	O
,	O
the	O
normed	O
fit	O
index	O
(	O
NFI	O
)	O
,	O
the	O
non	O
-	O
normed	O
fit	O
index	O
(	O
NNFI	O
)	O
,	O
the	O
comparative	O
fit	O
index	O
(	O
CIF	O
)	O
,	O
and	O
the	O
root	O
mean	O
square	O
error	O
of	O
approximation	O
(	O
RMSEA	O
)	O
.	O

For	O
the	O
confirmatory	O
models	O
,	O
index	O
values	O
greater	O
than	O
0	O
.	O
95	O
indicate	O
better	O
fit	O
,	O
and	O
RMSEA	O
values	O
less	O
than	O
0	O
.	O
05	O
are	O
considered	O
evidence	O
of	O
adequate	O
fit	O
[	O
23	O
]	O
.	O

Reliability	O
and	O
stability	O

Two	O
forms	O
of	O
reliability	O
were	O
assessed	O
:	O
test	O
-	O
retest	O
reliability	O
and	O
internal	O
consistency	O
reliability	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
a	O
measure	O
of	O
the	O
degree	O
to	O
which	O
the	O
questionnaire	O
yields	O
stable	O
scores	O
over	O
a	O
short	O
period	O
of	O
time	O
(	O
assuming	O
there	O
is	O
no	O
underlying	O
change	O
)	O
,	O
was	O
measured	O
by	O
the	O
intra	O
-	O
class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
[	O
24	O
,	O
25	O
]	O
.	O

An	O
ICC	O
of	O
>=	O
0	O
.	O
70	O
was	O
considered	O
acceptable	O
[	O
26	O
]	O
.	O

Internal	O
consistency	O
reliability	O
,	O
the	O
extent	O
to	O
which	O
items	O
within	O
each	O
scale	O
correlate	O
with	O
each	O
other	O
to	O
form	O
a	O
multi	O
-	O
item	O
scale	O
,	O
was	O
assessed	O
using	O
Cronbach	O
'	O
s	O
alpha	O
[	O
25	O
,	O
27	O
]	O
.	O

Data	O
from	O
both	O
assessments	O
were	O
used	O
to	O
evaluate	O
internal	O
consistency	O
reliability	O
.	O

An	O
alpha	O
coefficient	O
of	O
>=	O
0	O
.	O
70	O
was	O
considered	O
acceptable	O
,	O
which	O
is	O
the	O
commonly	O
accepted	O
minimal	O
standard	O
for	O
reliability	O
coefficients	O
endorsed	O
by	O
the	O
Scientific	O
Advisory	O
Committee	O
of	O
the	O
Medical	O
Outcomes	O
Trust	O
[	O
26	O
]	O
.	O

Construct	O
Validity	O

Construct	O
validity	O
was	O
assessed	O
by	O
examining	O
the	O
inter	O
-	O
scale	O
correlations	O
between	O
the	O
ITP	O
-	O
PAQ	O
and	O
the	O
CES	O
-	O
D	O
and	O
the	O
ITP	O
-	O
PAQ	O
with	O
the	O
SF	O
-	O
36	O
and	O
by	O
examining	O
the	O
strength	O
of	O
the	O
within	O
ITP	O
-	O
PAQ	O
scale	O
correlations	O
[	O
25	O
,	O
28	O
]	O
.	O

For	O
both	O
inter	O
-	O
scale	O
and	O
intra	O
-	O
scale	O
correlations	O
,	O
we	O
made	O
a	O
priori	O
hypotheses	O
about	O
the	O
directionality	O
and	O
magnitude	O
of	O
the	O
correlation	O
and	O
observed	O
the	O
extent	O
to	O
which	O
hypothesized	O
relationships	O
held	O
.	O

For	O
example	O
,	O
we	O
hypothesized	O
that	O
the	O
scales	O
of	O
the	O
ITP	O
-	O
PAQ	O
would	O
be	O
negatively	O
correlated	O
with	O
the	O
CES	O
-	O
D	O
and	O
positively	O
correlated	O
with	O
those	O
of	O
the	O
SF	O
-	O
36	O
.	O

We	O
expected	O
the	O
Pearson	O
correlations	O
to	O
be	O
moderate	O
in	O
size	O
.	O

Known	O
Groups	O

Known	O
groups	O
validity	O
evaluates	O
the	O
ability	O
of	O
the	O
measure	O
to	O
discriminate	O
between	O
groups	O
known	O
to	O
be	O
clinically	O
different	O
[	O
28	O
]	O
.	O

We	O
only	O
collected	O
patient	S-Species
-	O
reported	O
information	O
using	O
the	O
questionnaire	O
and	O
did	O
not	O
collect	O
clinical	O
information	O
such	O
as	O
platelet	O
counts	O
.	O

Therefore	O
,	O
the	O
following	O
four	O
criteria	O
were	O
identified	O
as	O
proxies	O
for	O
severity	O
:	O

*	O
Currently	O
on	O
treatment	O

*	O
Splenectomy	O
status	O

*	O
Subjects	O
'	O
self	O
-	O
perception	O
of	O
the	O
effectiveness	O
of	O
current	O
medication	O

*	O
Length	O
of	O
time	O
since	O
diagnosis	O

It	O
was	O
hypothesized	O
that	O
subjects	O
not	O
being	O
treated	O
,	O
who	O
did	O
not	O
have	O
a	O
splenectomy	O
,	O
who	O
perceived	O
their	O
medication	O
to	O
be	O
more	O
effective	O
,	O
and	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
a	O
longer	O
time	O
would	O
be	O
healthier	O
and	O
therefore	O
report	O
higher	O
HRQoL	O
scores	O
.	O

In	O
contrast	O
,	O
subjects	O
on	O
any	O
treatment	O
,	O
who	O
had	O
received	O
a	O
splenectomy	O
,	O
who	O
perceived	O
their	O
medication	O
to	O
be	O
less	O
effective	O
,	O
and	O
who	O
were	O
diagnosed	O
more	O
recently	O
would	O
report	O
worse	O
HRQoL	O
.	O

In	O
addition	O
,	O
subjects	O
were	O
also	O
categorized	O
by	O
gender	O
.	O

Subjects	O
were	O
categorized	O
into	O
two	O
groups	O
for	O
each	O
of	O
the	O
analyses	O
:	O
female	O
vs	O
.	O
male	O
,	O
intact	O
spleen	O
vs	O
.	O
removed	O
spleen	O
,	O
currently	O
on	O
ITP	O
treatment	O
vs	O
.	O
not	O
currently	O
on	O
ITP	O
treatment	O
,	O
subject	O
'	O
s	O
perception	O
of	O
the	O
effectiveness	O
of	O
their	O
current	O
ITP	O
medication	O
(	O
extremely	O
/	O
moderately	O
effective	O
vs	O
.	O
not	O
at	O
all	O
effective	O
)	O
,	O
and	O
ITP	O
diagnosis	O
less	O
than	O
one	O
year	O
ago	O
vs	O
.	O
ITP	O
diagnosis	O
more	O
than	O
one	O
year	O
ago	O
.	O

Results	O

Demographics	O
and	O
clinical	O
characteristics	O

Table	O
1	O
describes	O
the	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
73	O
subjects	O
included	O
in	O
the	O
validation	O
analyses	O
.	O

The	O
majority	O
were	O
female	O
(	O
77	O
%	O
)	O
and	O
Caucasian	O
(	O
84	O
%	O
)	O
.	O

The	O
mean	O
age	O
was	O
45	O
years	O
(	O
SD	O
=	O
15	O
.	O
7	O
)	O
,	O
and	O
most	O
of	O
the	O
subjects	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
at	O
least	O
five	O
years	O
(	O
57	O
%	O
)	O
.	O

Fifty	O
-	O
two	O
percent	O
of	O
the	O
subjects	O
reported	O
that	O
they	O
were	O
currently	O
taking	O
medications	O
for	O
their	O
ITP	O
.	O

Furthermore	O
,	O
58	O
%	O
indicated	O
that	O
they	O
had	O
a	O
splenectomy	O
.	O

Among	O
the	O
42	O
subjects	O
who	O
had	O
a	O
splenectomy	O
,	O
55	O
%	O
reported	O
that	O
the	O
removal	O
of	O
their	O
spleen	O
did	O
not	O
cure	O
their	O
ITP	O
.	O

With	O
one	O
exception	O
,	O
the	O
remaining	O
subjects	O
did	O
not	O
provide	O
a	O
response	O
.	O

Confirmatory	O
factor	O
analysis	O

The	O
first	O
confirmatory	O
factor	O
analysis	O
of	O
the	O
50	O
-	O
item	O
and	O
ten	O
factors	O
model	O
converged	O
in	O
28	O
iterations	O
.	O

However	O
,	O
neither	O
the	O
inter	O
-	O
item	O
correlation	O
matrix	O
nor	O
the	O
inter	O
-	O
factor	O
correlation	O
matrix	O
was	O
positive	O
-	O
definite	O
,	O
which	O
suggests	O
that	O
the	O
proposed	O
model	O
is	O
wrong	O
for	O
the	O
data	O
or	O
the	O
data	O
are	O
inadequate	O
for	O
the	O
model	O
[	O
22	O
]	O
.	O

The	O
chi	O
-	O
square	O
value	O
of	O
the	O
model	O
was	O
316	O
.	O
64	O
with	O
1129	O
degrees	O
of	O
freedom	O
(	O
p	O
=	O
1	O
.	O
0	O
)	O
,	O
which	O
does	O
not	O
support	O
the	O
hypothesized	O
scale	O
structure	O
of	O
the	O
initial	O
ITP	O
-	O
PAQ	O
.	O

The	O
confirmatory	O
analysis	O
of	O
this	O
LISREL	O
model	O
indicate	O
that	O
computing	O
domain	O
scores	O
for	O
the	O
Physical	O
Health	O
and	O
Mental	O
Health	O
domains	O
is	O
not	O
appropriate	O
for	O
the	O
ITP	O
-	O
PAQ	O
.	O

The	O
second	O
LISREL	O
model	O
was	O
analyzed	O
to	O
confirm	O
the	O
scale	O
structure	O
,	O
excluding	O
the	O
Reproductive	O
Health	O
scale	O
.	O

For	O
this	O
model	O
,	O
126	O
parameters	O
were	O
estimated	O
:	O
46	O
factor	O
loadings	O
,	O
44	O
error	O
terms	O
,	O
and	O
36	O
inter	O
-	O
factor	O
correlations	O
.	O

The	O
model	O
converged	O
in	O
39	O
iterations	O
,	O
with	O
a	O
chi	O
-	O
square	O
value	O
of	O
1043	O
.	O
10	O
with	O
864	O
degrees	O
of	O
freedom	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
Goodness	O
of	O
Fit	O
Index	O
(	O
GFI	O
)	O
,	O
Normed	O
Fit	O
Index	O
(	O
NFI	O
)	O
,	O
Non	O
-	O
normed	O
Fit	O
Index	O
(	O
NNFI	O
)	O
,	O
and	O
Comparative	O
Fit	O
Index	O
(	O
CFI	O
)	O
was	O
0	O
.	O
60	O
,	O
0	O
.	O
63	O
,	O
0	O
.	O
91	O
,	O
and	O
0	O
.	O
92	O
,	O
respectively	O
,	O
and	O
the	O
RMSEA	O
was	O
0	O
.	O
05	O
[	O
90	O
%	O
CI	O
,	O
0	O
.	O
04	O
-	O
0	O
.	O
065	O
]	O
.	O

Furthermore	O
,	O
the	O
inter	O
-	O
factor	O
correlations	O
ranged	O
form	O
0	O
.	O
33	O
between	O
the	O
Symptoms	O
and	O
Work	O
scales	O
to	O
0	O
.	O
96	O
between	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Overall	O
QoL	O
scales	O
.	O

In	O
addition	O
to	O
the	O
confirmatory	O
factor	O
analyses	O
,	O
Cronbach	O
'	O
s	O
alphas	O
and	O
item	O
-	O
to	O
-	O
total	O
correlations	O
were	O
used	O
for	O
item	O
reduction	O
.	O

Items	O
with	O
low	O
factor	O
loadings	O
and	O
item	O
-	O
to	O
-	O
total	O
correlations	O
that	O
reduced	O
the	O
internal	O
consistency	O
were	O
eliminated	O
.	O

Although	O
initial	O
factor	O
analyses	O
identified	O
six	O
domains	O
for	O
future	O
use	O
,	O
the	O
final	O
version	O
of	O
the	O
ITP	O
-	O
PAQ	O
contained	O
44	O
items	O
that	O
included	O
the	O
following	O
ten	O
scales	O
:	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Activity	O
,	O
Fear	O
,	O
Psychological	O
Health	O
,	O
Work	O
,	O
Social	O
Activity	O
,	O
Women	S-Species
'	O
s	O
Reproductive	O
Health	O
,	O
and	O
Overall	O
QoL	O
.	O

Table	O
2	O
provides	O
information	O
on	O
the	O
number	O
of	O
items	O
,	O
item	O
variability	O
and	O
sample	O
items	O
from	O
each	O
scale	O
of	O
the	O
questionnaire	O
.	O

Each	O
scale	O
is	O
scored	O
from	O
0	O
to	O
100	O
,	O
with	O
higher	O
scores	O
representing	O
better	O
quality	O
of	O
life	O
.	O

Test	O
-	O
retest	O
reliability	O

Of	O
the	O
73	O
subjects	O
who	O
completed	O
the	O
first	O
administration	O
of	O
the	O
questionnaire	O
,	O
most	O
of	O
the	O
subjects	O
completed	O
the	O
second	O
questionnaire	O
within	O
a	O
15	O
-	O
day	O
period	O
(	O
75	O
%	O
)	O
,	O
during	O
which	O
subjects	O
were	O
expected	O
to	O
remain	O
clinically	O
stable	O
.	O

However	O
,	O
20	O
%	O
of	O
the	O
73	O
subjects	O
completed	O
the	O
questionnaire	O
within	O
three	O
weeks	O
following	O
the	O
first	O
administration	O
.	O

The	O
remaining	O
5	O
%	O
of	O
subjects	O
completed	O
it	O
between	O
four	O
and	O
nine	O
weeks	O
after	O
the	O
first	O
"	O
test	O
.	O
"	O
ICC	O
'	O
s	O
were	O
computed	O
for	O
the	O
entire	O
sample	O
(	O
n	O
=	O
73	O
)	O
and	O
for	O
a	O
sub	O
-	O
sample	O
of	O
respondents	O
who	O
completed	O
the	O
second	O
questionnaire	O
within	O
three	O
weeks	O
(	O
n	O
=	O
69	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
,	O
all	O
scales	O
had	O
acceptable	O
test	O
-	O
retest	O
reliability	O
(	O
ICC	O
>=	O
0	O
.	O
70	O
)	O
as	O
measured	O
by	O
the	O
ICC	O
(	O
Table	O
3	O
)	O
.	O

For	O
the	O
entire	O
sample	O
,	O
ICC	O
values	O
ranged	O
from	O
0	O
.	O
52	O
-	O
0	O
.	O
90	O
,	O
while	O
ICC	O
values	O
for	O
the	O
sub	O
-	O
sample	O
ranged	O
from	O
0	O
.	O
56	O
-	O
0	O
.	O
89	O
.	O

Internal	O
consistency	O
reliability	O

Internal	O
consistency	O
reliability	O
,	O
measured	O
by	O
Cronbach	O
'	O
s	O
alpha	O
,	O
ranged	O
from	O
0	O
.	O
66	O
to	O
0	O
.	O
92	O
(	O
Table	O
3	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
,	O
Cronbach	O
'	O
s	O
alpha	O
coefficients	O
exceeded	O
the	O
acceptable	O
level	O
of	O
0	O
.	O
70	O
.	O

Cronbach	O
'	O
s	O
alpha	O
for	O
the	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
ranged	O
from	O
0	O
.	O
71	O
-	O
0	O
.	O
89	O
,	O
while	O
Cronbach	O
'	O
s	O
alpha	O
for	O
the	O
Psychological	O
Health	O
and	O
Fear	O
scales	O
ranged	O
from	O
0	O
.	O
87	O
-	O
0	O
.	O
92	O
.	O

Additionally	O
,	O
Cronbach	O
'	O
s	O
alphas	O
for	O
the	O
Social	O
Activity	O
,	O
Work	O
,	O
Reproductive	O
Health	O
,	O
and	O
Overall	O
QoL	O
scales	O
were	O
0	O
.	O
72	O
,	O
0	O
.	O
86	O
,	O
0	O
.	O
66	O
,	O
and	O
0	O
.	O
89	O
,	O
respectively	O
.	O

Construct	O
validity	O

Table	O
4	O
displays	O
the	O
results	O
of	O
inter	O
-	O
scale	O
Pearson	O
correlation	O
coefficients	O
for	O
the	O
initial	O
test	O
administration	O
of	O
the	O
ITP	O
-	O
PAQ	O
.	O

As	O
expected	O
,	O
the	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
were	O
moderately	O
to	O
strongly	O
inter	O
-	O
correlated	O
based	O
on	O
the	O
data	O
from	O
the	O
initial	O
administration	O
(	O
correlation	O
coefficients	O
ranged	O
from	O
0	O
.	O
56	O
-	O
0	O
.	O
75	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
Overall	O
QoL	O
scale	O
was	O
moderately	O
to	O
strongly	O
correlated	O
with	O
the	O
other	O
ITP	O
-	O
PAQ	O
scales	O
,	O
with	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
.	O

In	O
addition	O
to	O
examining	O
the	O
correlations	O
within	O
the	O
ITP	O
-	O
PAQ	O
scales	O
,	O
construct	O
validity	O
was	O
also	O
assessed	O
by	O
comparing	O
the	O
ITP	O
-	O
PAQ	O
scale	O
scores	O
with	O
those	O
of	O
the	O
CES	O
-	O
D	O
and	O
the	O
SF	O
-	O
36	O
.	O

The	O
CES	O
-	O
D	O
was	O
negatively	O
correlated	O
with	O
all	O
ITP	O
-	O
PAQ	O
scales	O
,	O
except	O
for	O
the	O
Reproductive	O
Health	O
scale	O
.	O

Other	O
than	O
the	O
Reproductive	O
Health	O
scale	O
,	O
Pearson	O
correlations	O
ranged	O
from	O
-	O
0	O
.	O
37	O
to	O
-	O
0	O
.	O
70	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
moderately	O
correlated	O
with	O
the	O
SF	O
-	O
36	O
scales	O
;	O
however	O
,	O
the	O
Reproductive	O
Health	O
scale	O
was	O
not	O
significantly	O
correlated	O
with	O
any	O
of	O
the	O
SF	O
-	O
36	O
scales	O
.	O

The	O
mean	O
SF	O
-	O
36	O
scores	O
of	O
the	O
subjects	O
with	O
ITP	O
were	O
compared	O
to	O
those	O
of	O
the	O
general	O
U	O
.	O
S	O
.	O
population	O
norms	O
[	O
15	O
]	O
.	O

Results	O
from	O
t	O
-	O
tests	O
indicate	O
that	O
there	O
were	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
SF	O
-	O
36	O
mean	O
scores	O
between	O
subjects	O
with	O
ITP	O
(	O
range	O
,	O
43	O
.	O
04	O
-	O
72	O
.	O
86	O
)	O
and	O
the	O
general	O
U	O
.	O
S	O
.	O
population	O
(	O
range	O
,	O
60	O
.	O
86	O
-	O
84	O
.	O
15	O
)	O
.	O

Subjects	O
with	O
ITP	O
reported	O
lower	O
scores	O
on	O
each	O
SF	O
-	O
36	O
scale	O
compared	O
to	O
the	O
US	O
norm	O
(	O
data	O
not	O
shown	O
)	O
.	O

Known	O
groups	O
validity	O

Subjects	O
were	O
categorized	O
into	O
two	O
groups	O
according	O
to	O
gender	O
,	O
splenectomy	O
status	O
,	O
current	O
ITP	O
treatment	O
status	O
,	O
subject	O
'	O
s	O
perception	O
of	O
the	O
effectiveness	O
of	O
ITP	O
treatment	O
,	O
and	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
.	O

When	O
subjects	O
were	O
grouped	O
according	O
to	O
gender	O
or	O
splenectomy	O
status	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
observed	O
for	O
any	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
who	O
were	O
currently	O
receiving	O
treatment	O
for	O
ITP	O
reported	O
lower	O
scores	O
on	O
all	O
ITP	O
-	O
PAQ	O
scales	O
compared	O
to	O
subjects	O
who	O
were	O
not	O
currently	O
receiving	O
treatment	O
.	O

Statistically	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
reported	O
for	O
the	O
following	O
ITP	O
-	O
PAQ	O
scales	O
when	O
subjects	O
were	O
categorized	O
by	O
treatment	O
status	O
:	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Activity	O
,	O
Psychological	O
Health	O
,	O
and	O
Overall	O
QoL	O
(	O
Figure	O
1	O
)	O
.	O

When	O
subjects	O
were	O
categorized	O
by	O
effectiveness	O
of	O
ITP	O
treatment	O
,	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
for	O
the	O
Symptoms	O
and	O
Activity	O
scales	O
(	O
Figure	O
1	O
)	O
,	O
while	O
statistically	O
significant	O
differences	O
were	O
only	O
found	O
for	O
the	O
Psychological	O
Health	O
scale	O
when	O
subjects	O
were	O
categorized	O
according	O
to	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
<	O
1	O
year	O
had	O
a	O
lower	O
mean	O
score	O
on	O
the	O
Psychological	O
Health	O
scale	O
compared	O
to	O
subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
at	O
least	O
one	O
year	O
(	O
50	O
.	O
38	O
vs	O
.	O
66	O
.	O
46	O
,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Discussion	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
undertake	O
initial	O
validation	O
analyses	O
of	O
the	O
ITP	O
-	O
PAQ	O
as	O
a	O
tool	O
for	O
measuring	O
HRQoL	O
specifically	O
related	O
to	O
adult	O
subjects	O
with	O
ITP	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
preliminary	O
evidence	O
of	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
ITP	O
-	O
PAQ	O
in	O
this	O
population	O
.	O

The	O
results	O
indicate	O
that	O
,	O
with	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
,	O
the	O
questionnaire	O
has	O
good	O
internal	O
consistency	O
.	O

The	O
Reproductive	O
Health	O
scale	O
may	O
not	O
have	O
reached	O
an	O
acceptable	O
level	O
because	O
the	O
items	O
could	O
in	O
fact	O
be	O
measuring	O
slightly	O
different	O
concepts	O
.	O

For	O
example	O
,	O
the	O
Reproductive	O
Health	O
scale	O
includes	O
items	O
that	O
assess	O
symptom	O
bother	O
related	O
to	O
menstruation	O
in	O
addition	O
to	O
items	O
that	O
ask	O
how	O
ITP	O
impacts	O
reproductive	O
choices	O
,	O
such	O
as	O
becoming	O
pregnant	O
,	O
giving	O
birth	O
,	O
and	O
adopting	O
children	S-Species
.	O

Perhaps	O
,	O
the	O
symptom	O
bother	O
items	O
in	O
this	O
scale	O
may	O
fit	O
more	O
appropriately	O
with	O
the	O
Bother	O
-	O
Physical	O
Health	O
scale	O
,	O
and	O
the	O
reproductive	O
choice	O
items	O
could	O
comprise	O
a	O
separate	O
scale	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
also	O
demonstrated	O
acceptable	O
test	O
-	O
retest	O
reliability	O
,	O
even	O
though	O
the	O
time	O
interval	O
between	O
test	O
and	O
retest	O
administrations	O
of	O
the	O
questionnaire	O
exceeded	O
the	O
targeted	O
time	O
interval	O
of	O
seven	O
to	O
ten	O
days	O
.	O

However	O
,	O
two	O
scales	O
,	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
,	O
reported	O
ICC	O
values	O
below	O
the	O
acceptable	O
value	O
of	O
0	O
.	O
70	O
.	O

In	O
addition	O
to	O
the	O
lag	O
between	O
the	O
two	O
administrations	O
of	O
the	O
questionnaire	O
,	O
subjects	O
may	O
have	O
experienced	O
an	O
increase	O
in	O
bother	O
and	O
/	O
or	O
a	O
decrease	O
in	O
activity	O
due	O
to	O
ITP	O
during	O
the	O
extended	O
time	O
interval	O
.	O

Additionally	O
,	O
the	O
comparatively	O
low	O
ICC	O
values	O
of	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
relatively	O
low	O
number	O
of	O
items	O
contained	O
in	O
each	O
of	O
these	O
scales	O
(	O
four	O
and	O
two	O
items	O
,	O
respectively	O
)	O
compared	O
to	O
the	O
Symptoms	O
scale	O
which	O
contains	O
six	O
items	O
.	O

In	O
general	O
,	O
the	O
construct	O
validity	O
of	O
the	O
questionnaire	O
was	O
supported	O
by	O
inter	O
-	O
scale	O
correlations	O
.	O

As	O
expected	O
,	O
the	O
Bother	O
-	O
Physical	O
Health	O
,	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
were	O
more	O
strongly	O
correlated	O
to	O
one	O
another	O
than	O
with	O
other	O
scales	O
.	O

However	O
,	O
the	O
Reproductive	O
Health	O
scale	O
had	O
a	O
lower	O
internal	O
consistency	O
reliability	O
and	O
it	O
was	O
weakly	O
correlated	O
with	O
the	O
ITP	O
-	O
PAQ	O
scales	O
,	O
the	O
SF	O
-	O
36	O
,	O
and	O
the	O
CES	O
-	O
D	O
,	O
possibly	O
due	O
to	O
the	O
differing	O
concepts	O
measured	O
by	O
the	O
items	O
within	O
this	O
scale	O
or	O
the	O
all	O
-	O
female	O
sample	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
moderately	O
correlated	O
with	O
the	O
SF	O
-	O
36	O
scales	O
and	O
the	O
CES	O
-	O
D	O
;	O
however	O
,	O
correlations	O
between	O
some	O
of	O
the	O
scales	O
were	O
<	O
0	O
.	O
40	O
(	O
e	O
.	O
g	O
.	O
,	O
Fear	O
and	O
SF	O
-	O
36	O
Mental	O
Health	O
,	O
0	O
.	O
30	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
low	O
correlation	O
could	O
be	O
due	O
to	O
the	O
ITP	O
-	O
PAQ	O
assessing	O
fear	O
associated	O
with	O
ITP	O
(	O
e	O
.	O
g	O
.	O
,	O
fear	O
of	O
having	O
a	O
bleeding	O
episode	O
)	O
,	O
while	O
the	O
SF	O
-	O
36	O
provides	O
a	O
more	O
general	O
assessment	O
of	O
mental	O
health	O
issues	O
(	O
e	O
.	O
g	O
.	O
,	O
felt	O
downhearted	O
and	O
blue	O
)	O
.	O

The	O
known	O
-	O
groups	O
validity	O
results	O
indicate	O
that	O
some	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
(	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Activity	O
,	O
Psychological	O
Health	O
,	O
and	O
Overall	O
QoL	O
scales	O
)	O
were	O
able	O
to	O
differentiate	O
ITP	O
subjects	O
who	O
were	O
currently	O
receiving	O
ITP	O
treatment	O
from	O
those	O
who	O
were	O
not	O
receiving	O
treatment	O
for	O
ITP	O
,	O
providing	O
preliminary	O
evidence	O
of	O
the	O
ITP	O
-	O
PAQ	O
'	O
s	O
ability	O
to	O
distinguish	O
between	O
groups	O
known	O
to	O
be	O
different	O
.	O

However	O
,	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
generally	O
unable	O
to	O
distinguish	O
between	O
subjects	O
when	O
they	O
were	O
grouped	O
by	O
gender	O
,	O
splenectomy	O
status	O
,	O
perceived	O
effectiveness	O
of	O
treatment	O
and	O
length	O
of	O
time	O
since	O
ITP	O
diagnosis	O
.	O

The	O
ITP	O
-	O
PAQ	O
may	O
not	O
be	O
able	O
to	O
differentiate	O
between	O
female	O
and	O
male	O
subjects	O
because	O
the	O
disorder	O
may	O
affect	O
females	O
and	O
males	O
similarly	O
.	O

Additionally	O
,	O
significant	O
differences	O
may	O
not	O
have	O
been	O
observed	O
between	O
subjects	O
who	O
have	O
undergone	O
splenectomy	O
and	O
subjects	O
who	O
have	O
not	O
because	O
55	O
%	O
of	O
subjects	O
who	O
had	O
a	O
splenectomy	O
indicated	O
that	O
it	O
did	O
not	O
cure	O
their	O
ITP	O
.	O

Specifically	O
,	O
the	O
known	O
-	O
groups	O
could	O
be	O
defined	O
as	O
'	O
subjects	O
without	O
a	O
splenectomy	O
'	O
versus	O
'	O
subjects	O
with	O
a	O
failed	O
splenectomy	O
'	O
(	O
for	O
whom	O
QoL	O
likely	O
worsened	O
)	O
versus	O
'	O
subjects	O
with	O
a	O
successful	O
splenectomy	O
'	O
(	O
for	O
whom	O
QoL	O
may	O
have	O
improved	O
)	O
.	O

In	O
the	O
future	O
,	O
to	O
assess	O
whether	O
the	O
ITP	O
-	O
PAQ	O
scales	O
can	O
differentiate	O
between	O
groups	O
of	O
subjects	O
,	O
it	O
may	O
be	O
worthwhile	O
to	O
categorize	O
subjects	O
by	O
a	O
more	O
clinically	O
relevant	O
measure	O
,	O
such	O
as	O
platelet	O
count	O
.	O

Several	O
limitations	O
should	O
be	O
considered	O
when	O
interpreting	O
our	O
findings	O
.	O

Subjects	O
were	O
drawn	O
from	O
a	O
convenience	O
sample	O
.	O

The	O
study	O
population	O
was	O
fairly	O
homogeneous	O
,	O
comprised	O
primarily	O
of	O
Caucasian	O
female	O
subjects	O
.	O

The	O
data	O
was	O
validated	O
using	O
only	O
patient	S-Species
-	O
reported	O
data	O
collected	O
via	O
questionnaire	O
.	O

The	O
lack	O
of	O
clinical	O
data	O
in	O
this	O
initial	O
validation	O
study	O
will	O
be	O
addressed	O
in	O
on	O
-	O
going	O
pivotal	O
trials	O
that	O
will	O
collect	O
clinical	O
data	O
such	O
as	O
platelet	O
counts	O
and	O
platelet	O
response	O
.	O

In	O
addition	O
,	O
the	O
time	O
interval	O
between	O
the	O
initial	O
and	O
retest	O
administration	O
of	O
the	O
questionnaire	O
may	O
have	O
been	O
too	O
lengthy	O
to	O
properly	O
evaluate	O
the	O
test	O
-	O
retest	O
reliability	O
.	O

Because	O
25	O
%	O
of	O
subjects	O
did	O
not	O
complete	O
the	O
questionnaire	O
within	O
the	O
targeted	O
fifteen	O
day	O
interval	O
,	O
those	O
subjects	O
may	O
have	O
undergone	O
clinical	O
changes	O
that	O
may	O
have	O
affected	O
their	O
responses	O
.	O

In	O
future	O
validation	O
studies	O
platelet	O
counts	O
or	O
type	O
of	O
platelet	O
response	O
should	O
be	O
used	O
to	O
identify	O
a	O
stable	O
cohort	O
for	O
the	O
test	O
-	O
retest	O
analyses	O
.	O

Furthermore	O
,	O
the	O
criteria	O
used	O
to	O
categorize	O
the	O
subjects	O
for	O
the	O
known	O
groups	O
validity	O
evaluation	O
may	O
not	O
have	O
been	O
sufficient	O
to	O
allow	O
for	O
the	O
ITP	O
-	O
PAQ	O
scales	O
to	O
detect	O
differences	O
between	O
groups	O
.	O

Grouping	O
the	O
subjects	O
by	O
a	O
different	O
criterion	O
,	O
such	O
as	O
a	O
relevant	O
clinical	O
measure	O
,	O
may	O
bolster	O
the	O
findings	O
for	O
its	O
known	O
groups	O
validity	O
.	O

Conclusion	O

The	O
primary	O
goal	O
of	O
this	O
manuscript	O
was	O
to	O
describe	O
the	O
development	O
of	O
a	O
new	O
ITP	O
-	O
specific	O
HRQoL	O
questionnaire	O
for	O
adults	O
with	O
ITP	O
and	O
to	O
present	O
our	O
initial	O
findings	O
on	O
the	O
psychometric	O
properties	O
of	O
this	O
questionnaire	O
.	O

The	O
results	O
of	O
this	O
initial	O
validation	O
study	O
indicate	O
that	O
the	O
questionnaire	O
generally	O
has	O
acceptable	O
reliability	O
and	O
validity	O
.	O

We	O
plan	O
to	O
conduct	O
additional	O
analyses	O
using	O
more	O
objective	O
clinical	O
measures	O
such	O
as	O
platelet	O
counts	O
as	O
a	O
criterion	O
for	O
known	O
groups	O
validity	O
.	O

Further	O
validation	O
work	O
should	O
also	O
be	O
conducted	O
to	O
assess	O
its	O
responsiveness	O
and	O
to	O
estimate	O
its	O
minimal	O
clinical	O
important	O
difference	O
value	O
so	O
that	O
it	O
can	O
become	O
a	O
more	O
widely	O
used	O
HRQoL	O
measure	O
in	O
the	O
ITP	O
population	O
.	O

Competing	O
interests	O

The	O
validation	O
study	O
design	O
,	O
analysis	O
,	O
interpretation	O
of	O
results	O
,	O
and	O
the	O
writing	O
of	O
the	O
manuscript	O
represent	O
the	O
joint	O
collaboration	O
of	O
all	O
authors	O
of	O
this	O
study	O
,	O
which	O
was	O
funded	O
solely	O
by	O
Amgen	O
,	O
Inc	O
,	O
Thousand	O
Oaks	O
,	O
California	O
,	O
USA	O
.	O

Ovation	O
Research	O
Group	O
provided	O
no	O
additional	O
funding	O
for	O
this	O
study	O
.	O

The	O
decision	O
to	O
submit	O
this	O
manuscript	O
for	O
publication	O
was	O
subject	O
to	O
the	O
approval	O
of	O
Amgen	O
,	O
Inc	O
.	O
and	O
all	O
authors	O
.	O

Gary	O
Okano	O
and	O
Janet	O
Nichol	O
are	O
employees	O
of	O
Amgen	O
,	O
Inc	O
.	O

James	O
Bussel	O
is	O
an	O
employee	O
of	O
Weill	O
Cornell	O
Medical	O
Center	O
.	O

James	O
George	O
is	O
employed	O
by	O
the	O
University	O
of	O
Oklahoma	O
Health	O
Sciences	O
Center	O
.	O

Robert	O
McMillan	O
is	O
a	O
Professor	O
Emeritus	O
of	O
the	O
Scripps	O
Research	O
Institute	O
.	O

Susan	O
Mathias	O
is	O
an	O
employee	O
of	O
Ovation	O
Research	O
Group	O
.	O

Authors	O
'	O
contributions	O

SDM	O
supervised	O
the	O
interpretation	O
of	O
the	O
results	O
from	O
the	O
validation	O
study	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

JBB	O
,	O
JNG	O
,	O
RM	O
,	O
and	O
JLN	O
provided	O
clinical	O
expertise	O
in	O
the	O
development	O
of	O
the	O
questionnaire	O
,	O
and	O
participated	O
in	O
the	O
design	O
and	O
execution	O
of	O
the	O
study	O
.	O

GJO	O
assisted	O
in	O
interpreting	O
the	O
results	O
and	O
drafting	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Estrogen	O
receptor	O
alpha	O
(	O
ER	O
alpha	O
)	O
mRNA	O
copy	O
numbers	O
in	O
immunohistochemically	O
ER	O
alpha	O
-	O
positive	O
-	O
,	O
and	O
negative	O
breast	O
cancer	O
tissues	O

Abstract	O

Background	O

The	O
presence	O
of	O
ER	O
alpha	O
is	O
the	O
basis	O
for	O
treating	O
breast	O
cancer	O
patients	S-Species
with	O
targeted	O
molecular	O
therapies	O
that	O
block	O
estrogen	O
stimulation	O
of	O
breast	O
cancer	O
cell	O
division	O
.	O

To	O
select	O
patients	S-Species
for	O
the	O
above	O
therapies	O
,	O
currently	O
,	O
the	O
ER	O
alpha	O
presence	O
in	O
breast	O
cancer	O
tissues	O
is	O
determined	O
in	O
clinical	O
laboratories	O
by	O
microscopically	O
scoring	O
the	O
slides	O
subjected	O
to	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

This	O
method	O
is	O
not	O
quantitative	O
,	O
highly	O
subjective	O
and	O
requires	O
large	O
amount	O
of	O
tumor	O
tissue	O
,	O
therefore	O
,	O
cannot	O
be	O
applied	O
to	O
sterotactic	O
and	O
ultrasound	O
guided	O
biopsy	O
samples	O
.	O

To	O
circumvent	O
these	O
problems	O
,	O
we	O
previously	O
developed	O
quantitative	O
real	O
-	O
time	O
PCR	O
based	O
molecular	O
assay	O
that	O
can	O
be	O
applied	O
to	O
determine	O
mRNA	O
copies	O
of	O
ER	O
alpha	O
in	O
picogram	O
amounts	O
of	O
total	O
RNA	O
from	O
tumor	O
samples	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
how	O
the	O
mRNA	O
copy	O
numbers	O
correlate	O
to	O
IHC	O
positive	O
and	O
negative	O
status	O
.	O

Methods	O

In	O
the	O
current	O
study	O
we	O
determined	O
the	O
copy	O
numbers	O
of	O
ER	O
alpha	O
mRNA	O
by	O
Q	O
RTPCR	O
in	O
breast	O
cancer	O
tissues	O
that	O
were	O
graded	O
as	O
ER	O
alpha	O
-	O
positive	O
and	O
negative	O
by	O
1	O
)	O
IHC	O
and	O
2	O
)	O
functional	O
estrogen	O
binding	O
assay	O
and	O
statistically	O
analyzed	O
the	O
data	O
.	O

Results	O

We	O
demonstrate	O
here	O
that	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
are	O
not	O
significantly	O
different	O
in	O
tissues	O
that	O
are	O
graded	O
as	O
positive	O
by	O
IHC	O
and	O
ligand	O
binding	O
assays	O
.	O

We	O
establish	O
here	O
a	O
cut	O
of	O
value	O
of	O
5	O
x	O
106	O
copies	O
per	O
1010	O
mRNA	O
copies	O
of	O
GAPDH	O
with	O
an	O
Odds	O
Radio	O
of	O
39	O
.	O
4	O
,	O
Sensitivity	O
of	O
0	O
.	O
81	O
and	O
Specificity	O
of	O
0	O
.	O
90	O
in	O
breast	O
cancer	O
tissues	O
that	O
are	O
negative	O
for	O
ER	O
alpha	O
protein	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
.	O

ROC	O
analysis	O
of	O
the	O
data	O
gave	O
an	O
area	O
of	O
0	O
.	O
8967	O
under	O
the	O
curve	O
.	O

Conclusion	O

We	O
expect	O
that	O
the	O
cut	O
off	O
values	O
determined	O
here	O
will	O
be	O
highly	O
significant	O
for	O
applying	O
molecular	O
assay	O
in	O
the	O
place	O
of	O
IHC	O
in	O
clinical	O
laboratories	O
for	O
evaluating	O
the	O
presence	O
of	O
ER	O
alpha	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
.	O

Background	O

Breast	O
cancer	O
is	O
the	O
most	O
diagnosed	O
and	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
deaths	O
for	O
women	S-Species
in	O
the	O
United	O
States	O
striking	O
about	O
300	O
,	O
000	O
and	O
killing	O
about	O
40	O
,	O
000	O
women	S-Species
a	O
year	O
[	O
1	O
]	O
.	O

A	O
substantial	O
body	O
of	O
epidemiological	O
,	O
experimental	O
and	O
clinical	O
evidence	O
indicated	O
that	O
unopposed	O
stimulation	O
of	O
breast	O
epithelial	O
cells	O
by	O
the	O
natural	O
hormone	O
,	O
estrogen	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
progression	O
of	O
breast	O
cancers	O
[	O
2	O
]	O
.	O

Because	O
endogenous	O
estrogens	O
directly	O
promote	O
the	O
growth	O
of	O
breast	O
cancer	O
cells	O
,	O
estrogen	O
deprivation	O
either	O
by	O
inhibiting	O
its	O
biosynthesis	O
(	O
aromatase	O
inhibitors	O
)	O
or	O
blocking	O
estrogen	O
-	O
mediated	O
gene	O
transcription	O
(	O
tamoxifen	O
)	O
through	O
its	O
high	O
affinity	O
receptor	O
,	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ER	O
alpha	O
)	O
,	O
are	O
the	O
primary	O
lines	O
of	O
therapy	O
for	O
breast	O
cancer	O
patients	S-Species
.	O

In	O
most	O
cases	O
,	O
the	O
efficacy	O
of	O
the	O
above	O
treatments	O
has	O
correlated	O
with	O
the	O
presence	O
of	O
ER	O
alpha	O
in	O
the	O
tumor	O
tissues	O
.	O

Currently	O
,	O
only	O
those	O
patients	S-Species
who	O
express	O
ER	O
alpha	O
in	O
their	O
tumors	O
are	O
chosen	O
for	O
aromatase	O
inhibitor	O
or	O
tamoxifen	O
therapies	O
.	O

In	O
addition	O
to	O
being	O
a	O
therapeutic	O
target	O
,	O
ER	O
alpha	O
was	O
also	O
shown	O
to	O
be	O
the	O
most	O
important	O
factor	O
to	O
predict	O
breast	O
cancer	O
prognosis	O
.	O

The	O
patients	S-Species
who	O
express	O
ER	O
alpha	O
in	O
their	O
tumors	O
have	O
an	O
overall	O
longer	O
cancer	O
-	O
free	O
survival	O
and	O
lower	O
recurrence	O
rates	O
than	O
patients	S-Species
who	O
do	O
not	O
express	O
this	O
receptor	O
[	O
3	O
]	O
.	O

To	O
predict	O
prognosis	O
and	O
identify	O
patients	S-Species
for	O
the	O
above	O
two	O
anti	O
-	O
estrogen	O
therapies	O
,	O
every	O
breast	O
cancer	O
tissue	O
is	O
currently	O
screened	O
for	O
the	O
presence	O
of	O
ER	O
alpha	O
before	O
a	O
treatment	O
regimen	O
is	O
selected	O
for	O
any	O
breast	O
cancer	O
patient	S-Species
.	O

The	O
presence	O
of	O
ER	O
alpha	O
in	O
breast	O
tumors	O
was	O
originally	O
determined	O
in	O
clinical	O
labs	O
by	O
estrogen	O
binding	O
assay	O
for	O
about	O
20	O
years	O
.	O

However	O
,	O
when	O
the	O
tumors	O
were	O
detected	O
at	O
comparatively	O
smaller	O
sizes	O
and	O
highly	O
specific	O
monoclonal	O
antibodies	O
were	O
developed	O
that	O
could	O
detect	O
ER	O
alpha	O
both	O
in	O
the	O
fresh	O
frozen	O
as	O
well	O
as	O
formalin	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
the	O
clinical	O
labs	O
switched	O
to	O
immunohistochemistry	O
(	O
IHC	O
)	O
from	O
estrogen	O
binding	O
assay	O
for	O
determining	O
the	O
presence	O
of	O
ER	O
alpha	O
.	O

Currently	O
ER	O
alpha	O
is	O
determined	O
in	O
the	O
clinical	O
laboratories	O
from	O
rough	O
estimates	O
yielded	O
by	O
microscopically	O
scoring	O
the	O
slides	O
subjected	O
to	O
IHC	O
technique	O
using	O
antibodies	O
against	O
the	O
N	O
-	O
terminal	O
A	O
/	O
B	O
region	O
of	O
ER	O
alpha	O
.	O

Although	O
this	O
procedure	O
is	O
used	O
for	O
over	O
ten	O
years	O
,	O
it	O
has	O
several	O
limitations	O
including	O
not	O
quantitative	O
,	O
highly	O
subjective	O
,	O
variations	O
due	O
to	O
antibody	O
preparations	O
,	O
variations	O
from	O
one	O
clinical	O
lab	O
to	O
other	O
and	O
comparatively	O
large	O
sample	O
size	O
requirement	O
.	O

In	O
recent	O
times	O
,	O
due	O
to	O
increased	O
awareness	O
and	O
substantially	O
improved	O
screening	O
methods	O
,	O
breast	O
cancers	O
are	O
detected	O
at	O
very	O
early	O
stages	O
and	O
excised	O
,	O
in	O
a	O
large	O
majority	O
of	O
cases	O
,	O
by	O
stereotactic	O
and	O
ultrasound	O
guided	O
techniques	O
.	O

In	O
these	O
cases	O
the	O
limited	O
amount	O
of	O
tumor	O
tissue	O
that	O
remains	O
after	O
histological	O
testing	O
restricts	O
determining	O
ER	O
alpha	O
status	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
by	O
IHC	O
.	O

In	O
many	O
cases	O
,	O
ER	O
alpha	O
status	O
is	O
not	O
determined	O
due	O
to	O
insufficient	O
amount	O
of	O
tumor	O
tissue	O
.	O

For	O
these	O
reasons	O
there	O
is	O
an	O
urgent	O
need	O
to	O
switch	O
to	O
a	O
procedure	O
that	O
can	O
detect	O
ER	O
alpha	O
in	O
a	O
very	O
small	O
amount	O
of	O
tumor	O
tissue	O
obtained	O
by	O
the	O
above	O
methods	O
.	O

There	O
is	O
a	O
general	O
consensus	O
that	O
ER	O
alpha	O
mRNA	O
quantification	O
is	O
a	O
more	O
suited	O
technique	O
for	O
detecting	O
its	O
presence	O
in	O
tumor	O
tissues	O
.	O

Several	O
PCR	O
based	O
approaches	O
have	O
been	O
described	O
for	O
detecting	O
the	O
presence	O
of	O
ER	O
alpha	O
in	O
breast	O
cancer	O
tissues	O
[	O
4	O
,	O
5	O
]	O
.	O

We	O
recently	O
developed	O
a	O
highly	O
sensitive	O
real	O
-	O
time	O
PCR	O
based	O
quantitative	O
molecular	O
assay	O
that	O
can	O
detect	O
and	O
quantify	O
as	O
low	O
as	O
50	O
-	O
100	O
copies	O
of	O
ER	O
alpha	O
mRNA	O
from	O
as	O
small	O
as	O
40	O
picograms	O
of	O
total	O
RNA	O
from	O
breast	O
cancer	O
tissues	O
.	O

Because	O
quantitative	O
real	O
-	O
time	O
PCR	O
is	O
a	O
high	O
through	O
-	O
put	O
method	O
,	O
it	O
could	O
be	O
automated	O
to	O
apply	O
in	O
clinical	O
laboratories	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
how	O
the	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
correlate	O
to	O
ER	O
alpha	O
positivity	O
and	O
negativity	O
by	O
IHC	O
assay	O
.	O

Establishing	O
a	O
cut	O
off	O
value	O
in	O
IHC	O
negative	O
tissues	O
is	O
required	O
for	O
the	O
application	O
of	O
molecular	O
assay	O
in	O
the	O
place	O
of	O
IHC	O
assay	O
.	O

To	O
determine	O
the	O
cut	O
off	O
value	O
,	O
we	O
have	O
profiled	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
in	O
breast	O
cancer	O
tissues	O
which	O
have	O
been	O
graded	O
as	O
ER	O
alpha	O
positive	O
and	O
negative	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
.	O

We	O
demonstrate	O
here	O
that	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
are	O
not	O
significantly	O
different	O
in	O
tissues	O
that	O
were	O
graded	O
as	O
positive	O
by	O
IHC	O
and	O
ligand	O
binding	O
assays	O
.	O

However	O
,	O
ER	O
alpha	O
positive	O
tissues	O
,	O
either	O
by	O
IHC	O
or	O
estrogen	O
binding	O
assays	O
,	O
express	O
significantly	O
higher	O
mRNA	O
copy	O
numbers	O
than	O
the	O
negative	O
tissues	O
.	O

We	O
have	O
determined	O
the	O
cut	O
off	O
values	O
of	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
by	O
molecular	O
assay	O
that	O
correlate	O
to	O
ER	O
alpha	O
negativity	O
by	O
both	O
IHC	O
and	O
ligand	O
binding	O
assays	O
using	O
CART	O
program	O
(	O
Classification	O
And	O
Regression	O
Tree	O
)	O
.	O

We	O
expect	O
that	O
the	O
cut	O
off	O
values	O
determined	O
here	O
will	O
be	O
highly	O
significant	O
for	O
applying	O
molecular	O
assay	O
in	O
the	O
place	O
of	O
IHC	O
in	O
clinical	O
laboratories	O
for	O
determining	O
the	O
ER	O
alpha	O
status	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
.	O

Methods	O

All	O
the	O
primers	O
used	O
in	O
the	O
current	O
study	O
were	O
synthesized	O
by	O
Gibco	O
-	O
BRL	O
Life	O
Technologies	O
.	O

TaqMan	O
Universal	O
PCR	O
Master	O
Mix	O
(	O
Cat	O
#	O
4304437	O
)	O
was	O
from	O
Applied	O
Biosystems	O
.	O

5	O
'	O
FAM	O
and	O
3	O
'	O
TAMARA	O
labeled	O
oligonucleotide	O
probes	O
were	O
synthesized	O
by	O
Applied	O
Biosystems	O
and	O
available	O
from	O
previous	O
studies	O
.	O

PCR	O
quality	O
water	O
and	O
Tris	O
-	O
EDTA	O
buffer	O
were	O
from	O
BioWhittaker	O
.	O

Breast	O
tumor	O
samples	O

Breast	O
cancer	O
tissues	O
with	O
known	O
ER	O
alpha	O
status	O
by	O
IHC	O
and	O
ligand	O
binding	O
assay	O
were	O
available	O
from	O
previous	O
studies	O
[	O
6	O
-	O
9	O
]	O
.	O

Briefly	O
,	O
the	O
tumor	O
samples	O
were	O
collected	O
from	O
either	O
biopsy	O
or	O
mastectomies	O
immediately	O
after	O
surgery	O
and	O
stored	O
at	O
-	O
80	O
degrees	O
C	O
until	O
use	O
.	O

Fresh	O
tumor	O
tissue	O
samples	O
for	O
ER	O
alpha	O
quantification	O
were	O
routinely	O
harvested	O
immediately	O
adjacent	O
to	O
the	O
histologic	O
/	O
diagnostic	O
sections	O
and	O
considered	O
to	O
be	O
representative	O
of	O
the	O
tissue	O
used	O
for	O
diagnosis	O
.	O

All	O
the	O
samples	O
were	O
examined	O
by	O
a	O
pathologist	O
and	O
tissues	O
containing	O
>	O
80	O
%	O
cancer	O
cells	O
were	O
excised	O
and	O
used	O
for	O
ER	O
alpha	O
mRNA	O
quantification	O
.	O

The	O
ER	O
alpha	O
-	O
status	O
for	O
the	O
samples	O
used	O
in	O
this	O
study	O
was	O
determined	O
either	O
by	O
IHC	O
using	O
monoclonal	O
antibodies	O
against	O
NH2	O
-	O
terminal	O
portion	O
of	O
the	O
molecule	O
at	O
Oncotech	O
Laboratories	O
,	O
Irwine	O
,	O
CA	O
,	O
or	O
by	O
ligand	O
binding	O
assay	O
as	O
described	O
[	O
10	O
]	O
.	O

The	O
tumor	O
tissues	O
were	O
considered	O
positive	O
for	O
ER	O
alpha	O
by	O
IHC	O
if	O
>	O
5	O
%	O
of	O
cancer	O
cells	O
showed	O
positive	O
nuclear	O
staining	O
.	O

The	O
tumor	O
tissues	O
that	O
were	O
diagnosed	O
as	O
ER	O
alpha	O
positive	O
by	O
estrogen	O
binding	O
assay	O
had	O
>	O
3	O
fmol	O
of	O
ER	O
/	O
mg	O
of	O
total	O
tissue	O
extract	O
.	O

A	O
total	O
of	O
70	O
samples	O
positive	O
by	O
IHC	O
,	O
33	O
positive	O
by	O
estrogen	O
binding	O
assay	O
,	O
43	O
negative	O
by	O
IHC	O
and	O
20	O
negative	O
by	O
estrogen	O
binding	O
assay	O
were	O
included	O
in	O
the	O
current	O
study	O
(	O
Tables	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
respectively	O
)	O
.	O

The	O
tumor	O
tissues	O
were	O
processed	O
to	O
isolate	O
total	O
RNA	O
and	O
cDNAs	O
prepared	O
as	O
previously	O
described	O
[	O
6	O
-	O
9	O
]	O
.	O

Howard	O
University	O
Institutional	O
Review	O
Board	O
granted	O
the	O
ethical	O
approval	O
of	O
Tumor	O
collection	O
procedures	O
for	O
the	O
study	O
.	O

Absolute	O
quantification	O
of	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O

Absolute	O
quantification	O
of	O
ER	O
alpha	O
transcript	O
copy	O
numbers	O
was	O
achieved	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
in	O
ABI	O
Prism	O
GeneAmp	O
7900	O
HT	O
Sequence	O
Detection	O
System	O
as	O
described	O
previously	O
(	O
9	O
)	O
.	O

Briefly	O
,	O
a	O
typical	O
real	O
-	O
time	O
PCR	O
reaction	O
mixture	O
contained	O
cDNA	O
prepared	O
from	O
reverse	O
transcription	O
of	O
0	O
.	O
5	O
-	O
5	O
nanograms	O
of	O
tumor	O
tissue	O
total	O
RNA	O
,	O
0	O
.	O
04	O
micromolar	O
each	O
of	O
sense	O
and	O
anti	O
-	O
sense	O
primers	O
,	O
0	O
.	O
05	O
micromolar	O
5	O
'	O
FAM	O
and	O
3	O
'	O
TAMARA	O
labeled	O
oligonucleotide	O
probe	O
and	O
1	O
x	O
Taqman	O
Universal	O
PCR	O
Mix	O
in	O
a	O
total	O
volume	O
of	O
25	O
mu	O
l	O
.	O

PCR	O
conditions	O
were	O
initial	O
hold	O
at	O
50	O
degrees	O
C	O
for	O
two	O
minutes	O
,	O
followed	O
by	O
denaturation	O
for	O
ten	O
minutes	O
at	O
95	O
degrees	O
C	O
,	O
and	O
denaturation	O
for	O
15	O
seconds	O
at	O
95	O
degrees	O
C	O
in	O
the	O
subsequent	O
cycles	O
and	O
annealing	O
and	O
extension	O
for	O
1	O
min	O
at	O
60	O
degrees	O
C	O
for	O
40	O
cycles	O
.	O

The	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
in	O
tumor	O
tissues	O
were	O
determined	O
in	O
comparison	O
with	O
a	O
standard	O
graph	O
constructed	O
simultaneously	O
using	O
102	O
,	O
103	O
,	O
104	O
,	O
105	O
,	O
106	O
,	O
107	O
,	O
108	O
,	O
and	O
109	O
copies	O
of	O
reverse	O
transcribed	O
cRNA	O
of	O
ER	O
alpha	O
.	O

All	O
the	O
samples	O
were	O
amplified	O
in	O
triplicate	O
and	O
real	O
-	O
time	O
PCRs	O
were	O
repeated	O
four	O
times	O
.	O

The	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
in	O
tumor	O
tissues	O
were	O
normalized	O
to	O
mRNA	O
copy	O
numbers	O
of	O
the	O
house	O
keeping	O
gene	O
,	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
.	O

GAPDH	O
copy	O
numbers	O
were	O
determined	O
as	O
previously	O
described	O
[	O
11	O
,	O
12	O
]	O
.	O

The	O
sense	O
,	O
and	O
anti	O
-	O
sense	O
primers	O
and	O
probe	O
for	O
quantifying	O
the	O
mRNA	O
copy	O
numbers	O
of	O
ER	O
alpha	O
were	O
5	O
'	O
caagcccgctcatgatcaa	O
3	O
'	O
(	O
position	O
,	O
exon	O
4	O
,	O
bp	O
1110	O
-	O
1128	O
)	O
,	O
5	O
'	O
ctgatcatggagggtcaaatccac3	O
'	O
(	O
position	O
,	O
exon	O
5	O
,	O
bp	O
1358	O
-	O
1338	O
)	O
and	O
FAM	O
5	O
'	O
agaacagcctggccttgtccctg3	O
'	O
TAMARA	O
(	O
position	O
,	O
exon	O
4	O
,	O
bp	O
1140	O
-	O
1162	O
)	O
respectively	O
.	O

The	O
sense	O
and	O
anti	O
-	O
sense	O
primers	O
and	O
probe	O
for	O
quantifying	O
GAPDH	O
mRNA	O
copy	O
numbers	O
were	O
5	O
'	O
ttccagg	O
agcgag	O
atccct3	O
'	O
(	O
position	O
,	O
bp	O
304	O
-	O
322	O
)	O
,	O
5	O
'	O
ggctgttgtcatacttctcatgg3	O
'	O
(	O
position	O
,	O
bp	O
483	O
-	O
505	O
)	O
and	O
FAM	O
5	O
'	O
tgctggcgctgagtacgtcgtg3	O
'	O
TAMARA	O
(	O
position	O
,	O
bp	O
342	O
-	O
363	O
)	O
respectively	O
.	O

Primer	O
positions	O
of	O
ER	O
alpha	O
and	O
GAPDH	O
nucleotide	O
sequences	O
were	O
as	O
described	O
[	O
13	O
,	O
14	O
]	O
.	O

Statistical	O
analysis	O

Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
and	O
standard	O
two	O
-	O
sample	O
t	O
-	O
test	O
were	O
used	O
to	O
determine	O
whether	O
the	O
mRNA	O
copy	O
numbers	O
were	O
significantly	O
different	O
in	O
breast	O
cancer	O
tissues	O
that	O
were	O
1	O
)	O
ER	O
alpha	O
-	O
positive	O
and	O
ER	O
alpha	O
-	O
negative	O
by	O
IHC	O
,	O
2	O
)	O
ER	O
alpha	O
-	O
positive	O
and	O
ER	O
alpha	O
-	O
negative	O
by	O
estrogen	O
binding	O
assays	O
,	O
3	O
)	O
ER	O
alpha	O
positive	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
,	O
and	O
4	O
)	O
ER	O
alpha	O
-	O
negative	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
.	O

Test	O
results	O
were	O
considered	O
significant	O
if	O
P	O
<=	O
0	O
.	O

05	O
.	O

To	O
determine	O
the	O
cut	O
-	O
off	O
value	O
/	O
maximum	O
level	O
of	O
mRNA	O
copy	O
numbers	O
in	O
the	O
samples	O
which	O
were	O
negative	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
,	O
we	O
used	O
CART	O
(	O
Classification	O
Regression	O
Tree	O
)	O
[	O
15	O
,	O
16	O
]	O
program	O
.	O

The	O
data	O
consisting	O
of	O
103	O
ER	O
alpha	O
positive	O
and	O
63	O
ER	O
alpha	O
negative	O
samples	O
which	O
had	O
a	O
predictive	O
variable	O
,	O
mRNA	O
copy	O
numbers	O
,	O
were	O
partitioned	O
into	O
two	O
groups	O
using	O
CART	O
program	O
.	O

This	O
program	O
determines	O
the	O
best	O
cut	O
-	O
off	O
value	O
copy	O
numbers	O
in	O
the	O
sense	O
that	O
the	O
OR	O
(	O
Odds	O
Ratio	O
,	O
ER	O
alpha	O
positive	O
to	O
ER	O
alpha	O
negative	O
in	O
our	O
case	O
)	O
of	O
the	O
two	O
groups	O
(	O
with	O
copy	O
number	O
greater	O
than	O
the	O
cut	O
-	O
off	O
value	O
in	O
one	O
group	O
and	O
less	O
or	O
equal	O
to	O
the	O
cut	O
-	O
off	O
value	O
in	O
the	O
other	O
)	O
is	O
maximized	O
.	O

Receiver	O
Operating	O
Characteristic	O
(	O
ROC	O
)	O
analysis	O
was	O
performed	O
to	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
RNA	O
based	O
molecular	O
assay	O
.	O

The	O
ROC	O
curves	O
were	O
generated	O
by	O
connecting	O
all	O
the	O
points	O
determined	O
by	O
the	O
copy	O
numbers	O
in	O
all	O
the	O
samples	O
in	O
an	O
increasing	O
order	O
.	O

Since	O
data	O
on	O
IHC	O
grading	O
as	O
percent	O
positive	O
cells	O
were	O
available	O
on	O
some	O
of	O
the	O
samples	O
,	O
the	O
correlation	O
between	O
the	O
IHC	O
grading	O
and	O
the	O
mRNA	O
copy	O
number	O
was	O
determined	O
both	O
in	O
the	O
original	O
scale	O
and	O
in	O
logarithmic	O
transformations	O
scale	O
using	O
S	O
-	O
PLUS	O
software	O
.	O

Results	O

We	O
have	O
undertaken	O
the	O
current	O
study	O
to	O
determine	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
in	O
breast	O
cancer	O
tissues	O
that	O
were	O
positive	O
and	O
negative	O
by	O
two	O
conventional	O
methods	O
of	O
assaying	O
ER	O
alpha	O
protein	O
,	O
IHC	O
and	O
estrogen	O
binding	O
.	O

The	O
rational	O
for	O
undertaking	O
this	O
study	O
is	O
that	O
once	O
we	O
establish	O
a	O
threshold	O
value	O
in	O
IHC	O
negative	O
tissues	O
,	O
then	O
the	O
molecular	O
assay	O
could	O
be	O
applied	O
in	O
clinical	O
laboratories	O
in	O
the	O
place	O
of	O
currently	O
used	O
IHC	O
assay	O
for	O
determining	O
the	O
status	O
of	O
ER	O
alpha	O
for	O
prognostic	O
and	O
therapeutic	O
purposes	O
.	O

Our	O
rational	O
for	O
establishing	O
a	O
cut	O
off	O
value	O
is	O
that	O
any	O
patient	S-Species
who	O
expresses	O
above	O
the	O
cut	O
off	O
level	O
could	O
be	O
selected	O
as	O
a	O
candidate	O
for	O
anti	O
-	O
estrogen	O
therapies	O
and	O
could	O
be	O
considered	O
to	O
have	O
good	O
prognosis	O
.	O

We	O
first	O
profiled	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
in	O
70	O
samples	O
positive	O
by	O
IHC	O
,	O
43	O
negative	O
by	O
IHC	O
,	O
33	O
positive	O
by	O
estrogen	O
binding	O
assay	O
and	O
20	O
negative	O
by	O
estrogen	O
binding	O
assay	O
.	O

The	O
data	O
are	O
presented	O
in	O
Tables	O
1	O
,	O
3	O
,	O
2	O
and	O
4	O
respectively	O
.	O

A	O
box	O
plot	O
drawn	O
for	O
the	O
copy	O
numbers	O
(	O
logarithm	O
base	O
2	O
scale	O
)	O
in	O
the	O
four	O
groups	O
(	O
positive	O
and	O
negative	O
by	O
IHC	O
and	O
by	O
estrogen	O
binding	O
assay	O
)	O
using	O
S	O
-	O
PLUS	O
software	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

We	O
next	O
compared	O
the	O
quantitative	O
data	O
on	O
mRNA	O
copy	O
numbers	O
among	O
samples	O
as	O
described	O
below	O
.	O

1	O
)	O
We	O
tested	O
whether	O
the	O
two	O
conventional	O
assays	O
,	O
the	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
,	O
correlate	O
in	O
terms	O
of	O
mRNA	O
copy	O
numbers	O
in	O
70	O
and	O
33	O
positive	O
tissues	O
(	O
Tables	O
1	O
and	O
2	O
respectively	O
)	O
using	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
and	O
standard	O
two	O
-	O
sample	O
t	O
-	O
tests	O
.	O

By	O
these	O
two	O
tests	O
,	O
we	O
did	O
not	O
find	O
significant	O
differences	O
in	O
the	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
in	O
samples	O
that	O
were	O
ER	O
alpha	O
positive	O
by	O
IHC	O
and	O
estrogen	O
binding	O
assays	O
(	O
p	O
>	O
0	O
.	O
28	O
by	O
both	O
tests	O
)	O
.	O

2	O
)	O
We	O
also	O
compared	O
the	O
mRNA	O
copy	O
numbers	O
in	O
43	O
samples	O
negative	O
by	O
IHC	O
with	O
20	O
samples	O
negative	O
by	O
estrogen	O
binding	O
assay	O
and	O
did	O
not	O
find	O
significant	O
differences	O
(	O
Tables	O
3	O
and	O
4	O
respectively	O
)	O
(	O
p	O
>	O
0	O
.	O
25	O
by	O
the	O
above	O
two	O
tests	O
)	O
.	O

However	O
,	O
3	O
)	O
we	O
found	O
significant	O
differences	O
in	O
mRNA	O
copy	O
numbers	O
in	O
the	O
breast	O
tumors	O
that	O
were	O
IHC	O
positive	O
from	O
those	O
which	O
were	O
IHC	O
negative	O
(	O
Tables	O
1	O
and	O
3	O
respectively	O
)	O
(	O
p	O
=	O
1	O
.	O
3e	O
-	O
6	O
by	O
standard	O
two	O
-	O
sample	O
t	O
-	O
test	O
and	O
p	O
=	O
2	O
.	O
7e	O
-	O
18	O
by	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
)	O
.	O

And	O
4	O
)	O
we	O
also	O
found	O
significant	O
differences	O
in	O
the	O
samples	O
that	O
were	O
positive	O
and	O
negative	O
by	O
estrogen	O
binding	O
assay	O
(	O
Tables	O
2	O
and	O
4	O
respectively	O
)	O
(	O
p	O
=	O
7	O
.	O
6e	O
-	O
3	O
by	O
standard	O
two	O
-	O
sample	O
t	O
-	O
test	O
and	O
p	O
=	O
3	O
.	O
6e	O
-	O
7	O
by	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
)	O
.	O

After	O
establishing	O
that	O
ER	O
alpha	O
-	O
positive	O
tissues	O
express	O
significantly	O
higher	O
levels	O
of	O
mRNA	O
copy	O
numbers	O
compared	O
to	O
negative	O
tumor	O
samples	O
,	O
we	O
next	O
determined	O
the	O
maximum	O
level	O
of	O
expression	O
in	O
ER	O
alpha	O
-	O
negative	O
samples	O
using	O
CART	O
program	O
.	O

By	O
using	O
this	O
program	O
,	O
we	O
found	O
the	O
maximum	O
level	O
of	O
expression	O
of	O
mRNA	O
copy	O
numbers	O
/	O
cut	O
-	O
off	O
value	O
to	O
be	O
5	O
x	O
106	O
per	O
1010copies	O
of	O
GAPDH	O
mRNA	O
.	O

Of	O
the	O
total	O
106	O
positive	O
(	O
70	O
by	O
IHC	O
and	O
33	O
by	O
estrogen	O
binding	O
assay	O
)	O
samples	O
in	O
our	O
study	O
,	O
83	O
samples	O
showed	O
higher	O
level	O
of	O
expression	O
than	O
5	O
x	O
106	O
copies	O
per	O
1010	O
copies	O
of	O
GAPDH	O
.	O

It	O
is	O
possible	O
that	O
the	O
samples	O
that	O
showed	O
less	O
than	O
the	O
above	O
cut	O
off	O
value	O
copy	O
numbers	O
could	O
be	O
due	O
to	O
false	O
positivity	O
by	O
the	O
above	O
methods	O
.	O

In	O
a	O
total	O
of	O
63	O
negative	O
samples	O
(	O
43	O
by	O
IHC	O
and	O
20	O
by	O
estrogen	O
binding	O
assay	O
)	O
only	O
6	O
samples	O
showed	O
higher	O
expression	O
than	O
5	O
x	O
106	O
copies	O
per	O
1010GAPDH	O
copies	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
samples	O
that	O
showed	O
higher	O
than	O
the	O
cut	O
off	O
copy	O
numbers	O
could	O
be	O
false	O
negative	O
.	O

The	O
OR	O
(	O
Odds	O
Ratio	O
)	O
in	O
the	O
two	O
groups	O
is	O
about	O
39	O
.	O
4	O
,	O
an	O
extremely	O
high	O
OR	O
value	O
.	O

The	O
counts	O
of	O
the	O
ER	O
alpha	O
-	O
positive	O
(	O
80	O
,	O
23	O
)	O
and	O
ER	O
alpha	O
-	O
negative	O
(	O
6	O
,	O
66	O
)	O
in	O
the	O
two	O
groups	O
produce	O
a	O
chi	O
-	O
square	O
value	O
of	O
88	O
.	O
2544	O
with	O
1	O
degree	O
of	O
freedom	O
,	O
which	O
is	O
consistent	O
with	O
our	O
T	O
-	O
test	O
and	O
Wilcoxon	O
-	O
rank	O
-	O
sum	O
test	O
results	O
.	O

We	O
applied	O
the	O
above	O
cut	O
off	O
value	O
and	O
determined	O
the	O
Sensitivity	O
(	O
percentage	O
of	O
samples	O
that	O
showed	O
higher	O
copy	O
numbers	O
than	O
the	O
cut	O
off	O
value	O
of	O
5	O
x	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
in	O
IHC	O
positive	O
tissues	O
)	O
and	O
Specificity	O
(	O
percentage	O
of	O
samples	O
that	O
showed	O
less	O
than	O
5	O
x	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
in	O
IHC	O
negative	O
tissues	O
)	O
and	O
the	O
values	O
obtained	O
were	O
0	O
.	O
81	O
and	O
0	O
.	O
90	O
respectively	O
.	O

We	O
also	O
determined	O
Receiver	O
Operating	O
Characteristics	O
using	O
S	O
-	O
PLUS	O
software	O
and	O
the	O
ROC	O
curve	O
generated	O
is	O
shown	O
in	O
Figure	O
2	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curve	O
,	O
0	O
.	O
89675	O
,	O
shows	O
that	O
the	O
molecular	O
assay	O
clearly	O
distinguishes	O
the	O
positives	O
by	O
IHC	O
or	O
estrogen	O
binding	O
from	O
the	O
negative	O
tissues	O
.	O

Since	O
we	O
have	O
the	O
grading	O
score	O
as	O
percent	O
positive	O
cells	O
for	O
about	O
50	O
samples	O
(	O
Table	O
1	O
)	O
,	O
we	O
tested	O
if	O
a	O
correlation	O
exits	O
between	O
the	O
percent	O
positive	O
cells	O
by	O
IHC	O
and	O
the	O
mRNA	O
copy	O
numbers	O
using	O
S	O
-	O
PLUS	O
software	O
.	O

We	O
obtained	O
a	O
correlation	O
coefficient	O
of	O
0	O
.	O
02	O
.	O

When	O
we	O
used	O
the	O
logarithmic	O
transformations	O
scale	O
,	O
we	O
obtained	O
a	O
correlation	O
coefficient	O
of	O
0	O
.	O
037	O
.	O

These	O
results	O
indicated	O
that	O
there	O
is	O
no	O
correlation	O
between	O
the	O
percent	O
positive	O
cells	O
and	O
the	O
level	O
of	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
.	O

These	O
observations	O
could	O
be	O
due	O
to	O
qualitative	O
nature	O
of	O
IHC	O
assay	O
.	O

The	O
IHC	O
data	O
only	O
show	O
the	O
number	O
of	O
positive	O
cells	O
but	O
not	O
quantitative	O
to	O
determine	O
the	O
level	O
of	O
ER	O
alpha	O
expression	O
.	O

The	O
molecular	O
assay	O
based	O
on	O
RNA	O
is	O
quantitative	O
to	O
determine	O
the	O
level	O
of	O
ER	O
alpha	O
expression	O
.	O

Discussion	O
and	O
conclusion	O

Previously	O
ER	O
alpha	O
mRNA	O
levels	O
in	O
immunohistochemically	O
positive	O
and	O
negative	O
tissues	O
were	O
evaluated	O
in	O
breast	O
cancer	O
tissues	O
by	O
several	O
groups	O
using	O
conventional	O
RT	O
PCR	O
.	O

Cullen	O
et	O
al	O
[	O
17	O
]	O
determined	O
mRNA	O
levels	O
by	O
conventional	O
PCR	O
in	O
107	O
breast	O
cancer	O
tissues	O
.	O

They	O
reported	O
that	O
ER	O
alpha	O
mRNA	O
was	O
more	O
frequently	O
detected	O
in	O
ER	O
alpha	O
protein	O
positive	O
tissues	O
than	O
ER	O
alpha	O
protein	O
negative	O
tissues	O
.	O

Jarzabek	O
et	O
al	O
[	O
18	O
]	O
studied	O
ER	O
alpha	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
41	O
primary	O
breast	O
cancer	O
tissues	O
.	O

They	O
reported	O
the	O
presence	O
of	O
ER	O
alpha	O
mRNA	O
in	O
all	O
the	O
tissues	O
,	O
where	O
as	O
the	O
protein	O
was	O
present	O
only	O
in	O
70	O
%	O
of	O
tumor	O
tissues	O
by	O
Western	O
blotting	O
and	O
67	O
%	O
showed	O
positive	O
by	O
immunohistochemistry	O
.	O

They	O
concluded	O
that	O
lack	O
of	O
ER	O
alpha	O
protein	O
is	O
not	O
due	O
to	O
lack	O
of	O
ER	O
alpha	O
gene	O
expression	O
or	O
methylation	O
of	O
its	O
promoter	O
,	O
but	O
may	O
be	O
due	O
to	O
post	O
-	O
transcriptional	O
or	O
post	O
-	O
translational	O
mechanisms	O
.	O

Alkarain	O
et	O
al	O
[	O
19	O
]	O
reported	O
the	O
presence	O
of	O
ER	O
alpha	O
mRNA	O
in	O
immunohistochemically	O
ER	O
alpha	O
-	O
negative	O
tissues	O
.	O

However	O
,	O
none	O
of	O
the	O
above	O
studies	O
has	O
evaluated	O
the	O
threshold	O
levels	O
of	O
ER	O
alpha	O
mRNA	O
levels	O
in	O
immunohistochemically	O
negative	O
tissues	O
or	O
those	O
negative	O
by	O
ligand	O
binding	O
assays	O
.	O

Our	O
quantitative	O
analysis	O
of	O
ER	O
alpha	O
mRNA	O
copy	O
numbers	O
demonstrate	O
that	O
breast	O
cancer	O
tissues	O
that	O
are	O
negative	O
by	O
both	O
IHC	O
and	O
ligand	O
binding	O
express	O
significant	O
levels	O
of	O
ER	O
alpha	O
mRNA	O
.	O

The	O
reasons	O
why	O
the	O
mRNA	O
is	O
not	O
translated	O
to	O
detectable	O
protein	O
are	O
not	O
clear	O
.	O

Our	O
previous	O
studies	O
on	O
ER	O
beta	O
mRNA	O
copy	O
numbers	O
[	O
9	O
]	O
in	O
breast	O
cancer	O
tissues	O
have	O
shown	O
that	O
at	O
the	O
5	O
x	O
106	O
copies	O
per	O
1010	O
mRNA	O
copies	O
of	O
GAPDH	O
levels	O
ER	O
beta	O
protein	O
is	O
translated	O
.	O

It	O
is	O
possible	O
that	O
either	O
ER	O
alpha	O
mRNA	O
is	O
not	O
translated	O
or	O
the	O
translated	O
protein	O
is	O
degraded	O
to	O
undetectable	O
levels	O
in	O
these	O
tissues	O
.	O

The	O
results	O
and	O
the	O
analysis	O
presented	O
above	O
clearly	O
demonstrate	O
that	O
the	O
ER	O
alpha	O
positive	O
tissues	O
by	O
IHC	O
or	O
estrogen	O
binding	O
assay	O
express	O
significantly	O
higher	O
mRNA	O
copy	O
numbers	O
than	O
5	O
x	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
.	O

An	O
extremely	O
high	O
Odds	O
Ratio	O
,	O
high	O
sensitivity	O
and	O
specificity	O
demonstrate	O
that	O
the	O
molecular	O
assay	O
could	O
be	O
used	O
in	O
the	O
place	O
of	O
currently	O
used	O
IHC	O
in	O
the	O
clinical	O
laboratories	O
.	O

Based	O
on	O
our	O
data	O
above	O
any	O
patient	S-Species
who	O
has	O
more	O
than	O
5	O
x	O
106	O
copies	O
per	O
1010	O
GAPDH	O
copies	O
in	O
her	O
tumor	O
tissue	O
could	O
be	O
considered	O
positive	O
for	O
ER	O
alpha	O
,	O
could	O
be	O
selected	O
for	O
anti	O
-	O
estrogen	O
therapies	O
and	O
considered	O
to	O
have	O
good	O
prognosis	O
.	O

However	O
,	O
the	O
above	O
described	O
approach	O
has	O
some	O
limitations	O
in	O
that	O
it	O
needs	O
to	O
be	O
verified	O
on	O
a	O
defined	O
set	O
of	O
biopsy	O
samples	O
and	O
with	O
reference	O
to	O
another	O
house	O
keeping	O
gene	O
.	O

Therefore	O
,	O
the	O
results	O
should	O
be	O
interpreted	O
with	O
caution	O
and	O
undoubtedly	O
will	O
require	O
confirmation	O
by	O
a	O
larger	O
prospective	O
multi	O
-	O
centered	O
clinical	O
study	O
with	O
a	O
more	O
accurate	O
design	O
to	O
bring	O
the	O
technology	O
to	O
the	O
clinic	O
.	O

The	O
current	O
study	O
is	O
a	O
first	O
step	O
in	O
that	O
direction	O
.	O

We	O
expect	O
that	O
the	O
cost	O
effective	O
,	O
extremely	O
sensitive	O
,	O
high	O
though	O
-	O
put	O
molecular	O
assay	O
which	O
requires	O
only	O
a	O
few	O
cancer	O
cells	O
could	O
be	O
an	O
assay	O
of	O
choice	O
to	O
replace	O
IHC	O
in	O
clinical	O
labs	O
for	O
determining	O
ER	O
alpha	O
status	O
in	O
breast	O
cancer	O
tissues	O
once	O
established	O
in	O
a	O
multi	O
-	O
centered	O
prospective	O
clinical	O
study	O
.	O

Abbreviations	O

FAM	O
,	O
carboxy	O
-	O
fluorescein	O
;	O
TAMARA	O
,	O
6	O
-	O
carboxy	O
tetraethyl	O
-	O
rhodamine	O
;	O
GAPDH	O
,	O
Glyceraldehyde	O
-	O
3	O
phosphate	O
dehydrogenase	O
;	O
ER	O
alpha	O
,	O
estrogen	O
receptor	O
alpha	O
;	O
IHC	O
,	O
Immunohistochemistry	O
;	O
CART	O
,	O
Classification	O
And	O
Regression	O
Tree	O
;	O
and	O
OR	O
,	O
Odds	O
Ratio	O
and	O
ROC	O
,	O
Receiver	O
Operating	O
Characteristics	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

I	O
.	O

P	O
conceived	O
the	O
study	O
,	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
the	O
real	O
-	O
time	O
PCR	O
quantifications	O
of	O
ERalph	O
mRNA	O
copy	O
numbers	O
and	O
drafted	O
the	O
manuscript	O
.	O

Q	O
.	O
Y	O
participated	O
in	O
performing	O
the	O
statistical	O
analysis	O
of	O
the	O
data	O
.	O

Both	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Molecular	O
Basis	O
for	O
a	O
Lack	O
of	O
Correlation	O
between	O
Viral	O
Fitness	O
and	O
Cell	O
Killing	O
Capacity	O

Abstract	O

The	O
relationship	O
between	O
parasite	O
fitness	O
and	O
virulence	O
has	O
been	O
the	O
object	O
of	O
experimental	O
and	O
theoretical	O
studies	O
often	O
with	O
conflicting	O
conclusions	O
.	O

Here	O
,	O
we	O
provide	O
direct	O
experimental	O
evidence	O
that	O
viral	O
fitness	O
and	O
virulence	O
,	O
both	O
measured	O
in	O
the	O
same	O
biological	O
environment	O
provided	O
by	O
host	O
cells	O
in	O
culture	O
,	O
can	O
be	O
two	O
unrelated	O
traits	O
.	O

A	O
biological	O
clone	O
of	O
foot	B-Species
-	I-Species
and	I-Species
-	I-Species
mouth	I-Species
disease	I-Species
virus	E-Species
acquired	O
high	O
fitness	O
and	O
virulence	O
(	O
cell	O
killing	O
capacity	O
)	O
upon	O
large	O
population	O
passages	O
in	O
cell	O
culture	O
.	O

However	O
,	O
subsequent	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
resulted	O
in	O
profound	O
fitness	O
loss	O
,	O
but	O
only	O
a	O
minimal	O
decrease	O
of	O
virulence	O
.	O

While	O
fitness	O
-	O
decreasing	O
mutations	O
have	O
been	O
mapped	O
throughout	O
the	O
genome	O
,	O
virulence	O
determinants	O
--	O
studied	O
here	O
with	O
mutant	O
and	O
chimeric	O
viruses	O
--	O
were	O
multigenic	O
,	O
but	O
concentrated	O
on	O
some	O
genomic	O
regions	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
model	O
in	O
which	O
viral	O
virulence	O
is	O
more	O
robust	O
to	O
mutation	O
than	O
viral	O
fitness	O
.	O

As	O
a	O
consequence	O
,	O
depending	O
on	O
the	O
passage	O
regime	O
,	O
viral	O
fitness	O
and	O
virulence	O
can	O
follow	O
different	O
evolutionary	O
trajectories	O
.	O

This	O
lack	O
of	O
correlation	O
is	O
relevant	O
to	O
current	O
models	O
of	O
attenuation	O
and	O
virulence	O
in	O
that	O
virus	O
de	O
-	O
adaptation	O
need	O
not	O
entail	O
a	O
decrease	O
of	O
virulence	O
.	O

Virulence	O
expresses	O
the	O
harm	O
that	O
parasites	O
inflict	O
upon	O
their	O
hosts	O
.	O

Many	O
studies	O
have	O
addressed	O
the	O
basis	O
of	O
virulence	O
and	O
its	O
effect	O
on	O
host	O
and	O
parasite	O
survival	O
.	O

It	O
has	O
generally	O
been	O
accepted	O
that	O
one	O
of	O
the	O
components	O
of	O
parasite	O
virulence	O
is	O
fitness	O
,	O
or	O
the	O
capacity	O
of	O
the	O
parasite	O
to	O
multiply	O
in	O
its	O
host	O
.	O

Some	O
models	O
have	O
equated	O
virulence	O
with	O
fitness	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
use	O
foot	B-Species
-	I-Species
and	I-Species
-	I-Species
mouth	I-Species
disease	I-Species
virus	E-Species
(	O
FMDV	S-Species
)	O
to	O
document	O
that	O
virulence	O
and	O
fitness	O
--	O
measured	O
in	O
the	O
same	O
biological	O
environment	O
provided	O
by	O
cells	O
in	O
culture	O
--	O
can	O
be	O
unrelated	O
traits	O
.	O

This	O
has	O
been	O
achieved	O
by	O
multiplying	O
the	O
virus	O
in	O
a	O
manner	O
that	O
mutations	O
accumulated	O
in	O
its	O
genome	O
.	O

Mutations	O
decreased	O
fitness	O
dramatically	O
,	O
but	O
not	O
virulence	O
.	O

Chimeric	O
and	O
mutant	O
viruses	O
were	O
constructed	O
to	O
show	O
that	O
virulence	O
is	O
influenced	O
by	O
only	O
some	O
of	O
the	O
FMDV	S-Species
genes	O
,	O
while	O
fitness	O
is	O
influenced	O
by	O
the	O
entire	O
genome	O
.	O

For	O
this	O
reason	O
,	O
virulence	O
is	O
more	O
robust	O
(	O
"	O
resistant	O
"	O
)	O
than	O
fitness	O
to	O
the	O
effects	O
of	O
deleterious	O
mutations	O
.	O

The	O
fact	O
that	O
virulence	O
can	O
be	O
unrelated	O
to	O
fitness	O
has	O
implications	O
for	O
the	O
design	O
of	O
anti	O
-	O
viral	O
vaccines	O
because	O
it	O
suggests	O
that	O
it	O
may	O
be	O
possible	O
to	O
design	O
high	O
fitness	O
,	O
low	O
virulence	O
strains	O
to	O
stimulate	O
the	O
host	O
immune	O
response	O
.	O

Furthermore	O
,	O
in	O
modelling	O
studies	O
it	O
cannot	O
be	O
assumed	O
that	O
virulence	O
is	O
equal	O
to	O
fitness	O
.	O

Introduction	O

The	O
relationship	O
between	O
fitness	O
and	O
virulence	O
is	O
an	O
unsettled	O
question	O
,	O
and	O
sometimes	O
fitness	O
is	O
considered	O
a	O
component	O
of	O
the	O
virulence	O
phenotype	O
of	O
parasites	O
.	O

RNA	O
viruses	O
are	O
ideal	O
systems	O
to	O
address	O
this	O
important	O
question	O
because	O
of	O
their	O
high	O
mutability	O
and	O
fecundity	O
,	O
which	O
result	O
in	O
a	O
potential	O
for	O
rapid	O
evolution	O
,	O
and	O
also	O
because	O
of	O
the	O
availability	O
of	O
quantitative	O
fitness	O
and	O
virulence	O
assays	O
.	O

RNA	O
viruses	O
replicate	O
as	O
complex	O
and	O
dynamic	O
mutant	O
spectra	O
,	O
termed	O
viral	O
quasispecies	O
.	O

Key	O
to	O
quasispecies	O
dynamics	O
are	O
mutation	O
rates	O
in	O
the	O
range	O
of	O
10	O
-	O
3	O
to	O
10	O
-	O
5	O
substitutions	O
per	O
nucleotide	O
copied	O
,	O
and	O
competition	O
among	O
continuously	O
arising	O
variant	O
genomes	O
[	O
1	O
-	O
4	O
]	O
,	O
which	O
prompt	O
rapid	O
movements	O
in	O
sequence	O
space	O
,	O
with	O
corresponding	O
changes	O
of	O
position	O
in	O
the	O
fitness	O
landscape	O
[	O
5	O
]	O
.	O

Indeed	O
,	O
large	O
population	O
passages	O
of	O
RNA	O
viruses	O
in	O
cell	O
culture	O
permit	O
competitive	O
optimization	O
of	O
mutant	O
distributions	O
that	O
generally	O
result	O
in	O
fitness	O
gain	O
[	O
6	O
,	O
7	O
]	O
,	O
while	O
repeated	O
bottleneck	O
events	O
(	O
experimentally	O
realized	O
as	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
)	O
lead	O
to	O
random	O
accumulation	O
of	O
deleterious	O
mutations	O
(	O
operation	O
of	O
Muller	O
'	O
s	O
ratchet	O
[	O
8	O
]	O
)	O
and	O
result	O
in	O
average	O
fitness	O
decreases	O
[	O
9	O
-	O
13	O
]	O
.	O

Fitness	O
recovery	O
of	O
low	O
fitness	O
foot	B-Species
-	I-Species
and	I-Species
-	I-Species
mouth	I-Species
disease	I-Species
virus	E-Species
(	O
FMDV	S-Species
)	O
clones	O
occurs	O
mainly	O
with	O
introduction	O
of	O
mutations	O
along	O
the	O
genome	O
,	O
with	O
very	O
few	O
true	O
reversions	O
.	O

An	O
understanding	O
of	O
the	O
consequences	O
of	O
fitness	O
variation	O
for	O
viral	O
virulence	O
is	O
a	O
key	O
question	O
for	O
viral	O
pathogenesis	O
and	O
evolution	O
.	O

Here	O
,	O
we	O
approach	O
this	O
issue	O
with	O
FMDV	S-Species
,	O
an	O
important	O
viral	O
pathogen	O
in	O
veterinary	O
medicine	O
[	O
14	O
]	O
,	O
and	O
one	O
that	O
fully	O
participates	O
of	O
quasispecies	O
dynamics	O
.	O

Our	O
laboratory	O
has	O
characterized	O
multiple	O
FMDV	S-Species
variants	O
that	O
derive	O
from	O
one	O
original	O
biological	O
clone	O
,	O
and	O
that	O
occupy	O
widely	O
different	O
fitness	O
levels	O
when	O
replicating	O
in	O
a	O
defined	O
environment	O
in	O
cell	O
culture	O
.	O

We	O
define	O
fitness	O
as	O
the	O
replication	O
capacity	O
of	O
a	O
mutant	O
FMDV	S-Species
,	O
relative	O
to	O
a	O
reference	O
FMDV	S-Species
,	O
in	O
direct	O
growth	O
-	O
competition	O
upon	O
coinfection	O
of	O
baby	O
hamster	S-Species
kidney	O
21	O
(	O
BHK	O
-	O
21	O
)	O
cells	O
[	O
15	O
-	O
17	O
]	O
.	O

Fitness	O
of	O
FMDV	S-Species
in	O
BHK	O
-	O
21	O
cells	O
is	O
a	O
multigenic	O
trait	O
[	O
7	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
define	O
virulence	O
of	O
FMDV	S-Species
as	O
the	O
capacity	O
of	O
the	O
virus	O
to	O
kill	O
BHK	O
-	O
21	O
cells	O
under	O
a	O
standard	O
set	O
of	O
cell	O
culture	O
conditions	O
[	O
18	O
]	O
.	O

Thus	O
,	O
the	O
FMDV	S-Species
-	O
BHK	O
-	O
21	O
system	O
offered	O
a	O
means	O
to	O
investigate	O
in	O
a	O
direct	O
and	O
comparative	O
fashion	O
the	O
relationship	O
between	O
fitness	O
and	O
virulence	O
of	O
a	O
virus	O
,	O
measured	O
in	O
the	O
same	O
biological	O
environment	O
provided	O
by	O
BHK	O
-	O
21	O
cells	O
.	O

We	O
describe	O
the	O
behavior	O
of	O
an	O
FMDV	S-Species
clone	O
(	O

)	O
,	O
which	O
has	O
a	O
history	O
of	O
repeated	O
serial	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
in	O
BHK	O
-	O
21	O
cells	O
[	O
11	O
]	O
,	O
that	O
attained	O
a	O
very	O
low	O
fitness	O
value	O
relative	O
to	O
its	O
parental	O
reference	O
virus	O
(	O
C	O
-	O
S8c1	O
)	O
,	O
and	O
yet	O
,	O
its	O
virulence	O
for	O
BHK	O
-	O
21	O
cells	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
C	O
-	O
S8c1	O
.	O

A	O
comparative	O
study	O
of	O
the	O
capacity	O
to	O
kill	O
BHK	O
-	O
21	O
cells	O
of	O
chimeric	O
FMDVs	S-Species
constructed	O
with	O
cDNA	O
copies	O
of	O
the	O
two	O
parental	O
FMDVs	S-Species
indicates	O
that	O
the	O
enhanced	O
virulence	O
for	O
BHK	O
-	O
21	O
cells	O
of	O
the	O
low	O
fitness	O
clone	O
is	O
a	O
polygenic	O
trait	O
,	O
with	O
participation	O
of	O
the	O
regions	O
encoding	O
capsid	O
proteins	O
and	O
non	O
-	O
structural	O
proteins	O
2A	O
,	O
2B	O
,	O
and	O
2C	O
as	O
virulence	O
determinants	O
.	O

Three	O
specific	O
amino	O
acid	O
replacements	O
in	O
2C	O
have	O
been	O
identified	O
as	O
redundant	O
virulence	O
determinants	O
of	O
FMDV	S-Species
for	O
BHK	O
-	O
21	O
cells	O
.	O

Thus	O
,	O
while	O
large	O
population	O
passages	O
of	O
the	O
virus	O
resulted	O
in	O
a	O
gain	O
of	O
both	O
fitness	O
and	O
virulence	O
,	O
subsequent	O
bottleneck	O
passages	O
resulted	O
in	O
a	O
decrease	O
of	O
fitness	O
but	O
not	O
of	O
virulence	O
.	O

The	O
results	O
suggest	O
that	O
fitness	O
is	O
very	O
vulnerable	O
to	O
mutation	O
in	O
any	O
genomic	O
region	O
.	O

In	O
contrast	O
,	O
because	O
of	O
the	O
involvement	O
of	O
several	O
(	O
but	O
not	O
all	O
)	O
viral	O
genes	O
in	O
virulence	O
,	O
and	O
the	O
redundant	O
effect	O
of	O
three	O
2C	O
substitutions	O
,	O
virulence	O
is	O
a	O
more	O
robust	O
phenotypic	O
trait	O
than	O
fitness	O
,	O
and	O
less	O
vulnerable	O
to	O
accumulation	O
of	O
mutations	O
.	O

Therefore	O
,	O
we	O
provide	O
direct	O
evidence	O
that	O
viral	O
fitness	O
and	O
capacity	O
to	O
kill	O
cells	O
can	O
(	O
in	O
some	O
cases	O
)	O
be	O
unrelated	O
traits	O
.	O

Furthermore	O
,	O
the	O
relationship	O
between	O
fitness	O
and	O
virulence	O
,	O
of	O
being	O
either	O
linked	O
or	O
unrelated	O
traits	O
,	O
depends	O
on	O
the	O
evolutionary	O
history	O
of	O
the	O
virus	O
.	O

This	O
observation	O
has	O
implications	O
for	O
viral	O
pathogenesis	O
,	O
and	O
sheds	O
light	O
on	O
models	O
of	O
virulence	O
proposed	O
on	O
the	O
basis	O
of	O
theoretical	O
and	O
experimental	O
studies	O
with	O
cellular	O
organisms	O
.	O

Results	O

Inability	O
of	O
FMDV	S-Species

to	O
Establish	O
a	O
Persistent	O
Infection	O
in	O
BHK	O
-	O
21	O
Cells	O

Several	O
biological	O
clones	O
and	O
populations	O
were	O
obtained	O
by	O
passaging	O
FMDV	S-Species
biological	O
clone	O
C	O
-	O
S8c1	O
[	O
19	O
-	O
22	O
]	O
in	O
BHK	O
-	O
21	O
cells	O
,	O
either	O
as	O
large	O
population	O
passages	O
or	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
(	O
Figure	O
1	O
)	O
.	O

The	O
biological	O
clones	O
and	O
populations	O
differed	O
up	O
to	O
236	O
-	O
fold	O
in	O
relative	O
fitness	O
(	O
Table	O
1	O
)	O
.	O

The	O
fitness	O
differences	O
found	O
are	O
expected	O
from	O
previous	O
results	O
on	O
fitness	O
gain	O
upon	O
large	O
population	O
passages	O
of	O
RNA	O
viruses	O
[	O
6	O
,	O
7	O
]	O
and	O
fitness	O
decrease	O
upon	O
plaque	O
-	O
to	O
-	O
plaque	O
(	O
bottleneck	O
)	O
transfers	O
[	O
9	O
-	O
13	O
]	O
.	O

The	O
initial	O
experiment	O
was	O
aimed	O
at	O
testing	O
whether	O

,	O
because	O
of	O
its	O
low	O
fitness	O
(	O
0	O
.	O
11	O
times	O
that	O
of	O
its	O
parental	O
C	O
-	O
S8c1	O
[	O
12	O
,	O
23	O
,	O
24	O
]	O
[	O
Table	O
1	O
]	O
)	O
,	O
had	O
an	O
advantage	O
in	O
establishing	O
a	O
persistent	O
non	O
-	O
cytopathic	O
infection	O
in	O
BHK	O
-	O
21	O
cells	O
as	O
compared	O
with	O
its	O
parental	O
clone	O
,	O
C	O
-	O
S8c1	O
(	O
Figure	O
1	O
)	O
.	O

A	O
persistent	O
FMDV	S-Species
infection	O
is	O
established	O
by	O
growing	O
the	O
cells	O
that	O
survive	O
a	O
standard	O
cytolytic	O
infection	O
with	O
FMDV	S-Species
[	O
25	O
]	O
.	O

Confluent	O
monolayers	O
of	O
BHK	O
-	O
21	O
cells	O
were	O
infected	O
either	O
with	O
C	O
-	O
S8c1	O
or	O
with	O

at	O
a	O
multiplicity	O
of	O
infection	O
(	O
MOI	O
)	O
of	O
0	O
.	O
02	O
-	O
0	O
.	O
1	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)	O
/	O
cell	O
(	O
2	O
x	O
106	O
cells	O
infected	O
with	O
4	O
x	O
104	O
-	O
2	O
x	O
105	O
PFU	O
)	O
.	O

Unexpectedly	O
,	O
at	O
24	O
h	O
postinfection	O
,	O
the	O
cells	O
infected	O
with	O

showed	O
extensive	O
cytopathology	O
,	O
and	O
at	O
48	O
h	O
postinfection	O
,	O
no	O
surviving	O
cells	O
were	O
observed	O
.	O

The	O
frequency	O
of	O
surviving	O
cells	O
in	O
parallel	O
infections	O
with	O
C	O
-	O
S8c1	O
was	O
5	O
x	O
10	O
-	O
3	O
-	O
9	O
x	O
10	O
-	O
3	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
determinations	O
[	O
25	O
]	O
.	O

No	O
persistently	O
infected	O
BHK	O
-	O
21	O
cell	O
cultures	O
could	O
be	O
established	O
with	O

,	O
despite	O
several	O
attempts	O
.	O

Thus	O
,	O
C	O
-	O
S8c1	O
,	O
which	O
displays	O
a	O
9	O
-	O
fold	O
higher	O
relative	O
fitness	O
than	O

in	O
BHK	O
-	O
21	O
cells	O
,	O
showed	O
a	O
capacity	O
to	O
kill	O
BHK	O
-	O
21	O
cells	O
that	O
was	O
at	O
least	O
103	O
-	O
fold	O
lower	O
than	O
the	O
killing	O
capacity	O
of	O

in	O
the	O
infectivity	O
assay	O
intended	O
to	O
establish	O
a	O
persistent	O
FMDV	S-Species
infection	O
.	O

FMDV	S-Species
Fitness	O
and	O
Capacity	O
to	O
Kill	O
BHK	O
-	O
21	O
Cells	O
May	O
Not	O
Be	O
Positively	O
Correlated	O

The	O
capacity	O
of	O

to	O
kill	O
BHK	O
-	O
21	O
cells	O
despite	O
its	O
low	O
fitness	O
in	O
BHK	O
-	O
21	O
cells	O
led	O
us	O
to	O
quantitatively	O
examine	O
the	O
relationship	O
between	O
fitness	O
of	O
FMDV	S-Species
and	O
its	O
capacity	O
to	O
kill	O
BHK	O
-	O
21	O
cells	O
.	O

To	O
this	O
aim	O
,	O
FMDV	S-Species
clones	O
or	O
populations	O
were	O
compared	O
in	O
a	O
cell	O
killing	O
assay	O
,	O
consisting	O
in	O
determining	O
the	O
time	O
required	O
to	O
kill	O
104	O
BHK	O
-	O
21	O
cells	O
as	O
a	O
function	O
of	O
the	O
PFU	O
added	O
(	O
described	O
in	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
results	O
(	O
Figure	O
2A	O
)	O
indicate	O
that	O
over	O
the	O
time	O
range	O
of	O
12	O
h	O
to	O
48	O
h	O
postinfection	O
,	O
the	O
number	O
of	O
PFUs	O
needed	O
to	O
kill	O
104	O
BHK	O
-	O
21	O
cells	O
varied	O
logarithmically	O
as	O
a	O
function	O
of	O
time	O
.	O

Similar	O
quantifications	O
of	O
relative	O
virulence	O
were	O
obtained	O
by	O
measuring	O
the	O
PFU	O
needed	O
to	O
kill	O
104	O
cells	O
in	O
24	O
h	O
,	O
and	O
then	O
by	O
extrapolating	O
the	O
PFU	O
values	O
to	O
0	O
h	O
postinfection	O
(	O
Tables	O
1	O
and	O
S1	O
)	O
.	O

Virulence	O
of	O

was	O
29	O
to	O
35	O
times	O
higher	O
than	O
virulence	O
of	O
C	O
-	O
S8c1	O
,	O
despite	O
the	O
latter	O
displaying	O
a	O
9	O
-	O
fold	O
higher	O
fitness	O
(	O
Tables	O
1	O
and	O
S1	O
)	O
.	O

The	O
high	O
virulence	O
of	O

was	O
not	O
due	O
to	O
the	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
,	O
since	O
a	O
high	O
virulence	O
was	O
also	O
quantitated	O
for	O
its	O
parental	O
clone	O
,	O

,	O
and	O
for	O
population	O
C	O
-	O
S8p113	O
(	O
Figure	O
2B	O
;	O
Tables	O
1	O
,	O
2	O
,	O
and	O
S1	O
)	O
.	O

deviated	O
from	O
a	O
line	O
that	O
correlated	O
relative	O
fitness	O
of	O
FMDV	S-Species
and	O
the	O
logarithm	O
of	O
cell	O
killing	O
capacity	O
,	O
as	O
reflected	O
in	O
the	O
decrease	O
of	O
the	O
regression	O
coefficient	O
(	O
R2	O
)	O
(	O
inset	O
in	O
Figure	O
2A	O
)	O
.	O

Probably	O
,	O
this	O
deviation	O
is	O
due	O
to	O
the	O
fact	O
that	O

lost	O
fitness	O
due	O
to	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
,	O
and	O
the	O
other	O
viruses	O
were	O
not	O
subjected	O
to	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
.	O

On	O
the	O
other	O
hand	O
,	O
virulence	O
determinants	O
were	O
acquired	O
during	O
the	O
large	O
population	O
passages	O
done	O
between	O
C	O
-	O
S8c1	O
and	O
C	O
-	O
S8c1p113	O
.	O

The	O
29	O
-	O
to	O
35	O
-	O
fold	O
higher	O
virulence	O
of	O

with	O
respect	O
to	O
C	O
-	O
S8c1	O
(	O
Tables	O
1	O
and	O
S1	O
)	O
,	O
despite	O
its	O
low	O
fitness	O
,	O
indicates	O
that	O
viral	O
fitness	O
and	O
virulence	O
can	O
be	O
two	O
unrelated	O
traits	O
.	O

Mapping	O
Virulence	O
Determinants	O
in	O
the	O

Genome	O

The	O
comparison	O
of	O
the	O
consensus	O
nucleotide	O
sequence	O
of	O
the	O

genome	O
with	O
that	O
of	O
C	O
-	O
S8c1	O
revealed	O
a	O
total	O
of	O
47	O
mutations	O
(	O
Table	O
S2	O
)	O
,	O
leading	O
to	O
21	O
amino	O
acid	O
replacements	O
affecting	O
structural	O
and	O
non	O
-	O
structural	O
proteins	O
(	O
Figure	O
3	O
)	O
.	O

To	O
identify	O
the	O
genomic	O
regions	O
associated	O
with	O
the	O
increased	O
virulence	O
of	O

with	O
respect	O
to	O
C	O
-	O
S8c1	O
,	O
we	O
measured	O
the	O
BHK	O
-	O
21	O
cell	O
killing	O
capacity	O
of	O
nine	O
chimeric	O
viruses	O
rescued	O
from	O
constructs	O
obtained	O
by	O
introducing	O
fragments	O
of	O
cDNA	O
of	O
the	O

genome	O
into	O
plasmid	O
pMT28	O
,	O
which	O
encodes	O
infectious	O
C	O
-	O
S8c1	O
RNA	O
[	O
21	O
]	O
(	O
Figure	O
4	O
)	O
.	O

The	O
results	O
(	O
Figure	O
5	O
;	O
Tables	O
2	O
and	O
S1	O
)	O
show	O
that	O
several	O
genomic	O
regions	O
contribute	O
to	O
the	O
virulence	O
of	O

for	O
BHK	O
-	O
21	O
cells	O
,	O
and	O
that	O
the	O
major	O
contributors	O
map	O
within	O
genomic	O
positions	O
2046	O
to	O
3760	O
(	O
residues	O
encoding	O
part	O
of	O
VP2	O
,	O
VP3	O
,	O
and	O
part	O
of	O
VP1	O
,	O
Figure	O
5A	O
)	O
and	O
3760	O
to	O
5839	O
(	O
residues	O
encoding	O
2A	O
,	O
2B	O
,	O
2C	O
,	O
and	O
3A	O
,	O
Figure	O
5B	O
)	O
.	O

The	O
results	O
exclude	O
the	O
internal	O
ribosome	O
entry	O
site	O
and	O
the	O
3C	O
-	O
and	O
3D	O
-	O
coding	O
regions	O
as	O
significant	O
virulence	O
determinants	O
of	O

for	O
BHK	O
-	O
21	O
cells	O
(	O
virulence	O
of	O
the	O
relevant	O
chimeric	O
viruses	O
<=	O
2	O
.	O
5	O
,	O
relative	O
to	O
C	O
-	O
S8c1	O
;	O
Tables	O
2	O
and	O
S1	O
)	O
.	O

Infectious	O
progeny	O
production	O
by	O
each	O
chimeric	O
virus	O
was	O
intermediate	O
between	O
the	O
production	O
of	O
the	O
parental	O
viruses	O
pMT28	O
and	O

,	O
with	O
no	O
significant	O
differences	O
that	O
could	O
be	O
correlated	O
with	O
virulence	O
(	O
Table	O
2	O
)	O
.	O

Non	O
-	O
Structural	O
Protein	O
2C	O
Is	O
a	O
Determinant	O
of	O
the	O
Virulence	O
of	O
FMDV	S-Species
for	O
BHK	O
-	O
21	O
Cells	O

Amino	O
acid	O
substitutions	O
in	O
human	B-Species
rhinovirus	E-Species
protein	O
2C	O
promoted	O
cytopathology	O
for	O
mouse	S-Species
L	O
cells	O
[	O
26	O
]	O
.	O

Remarkably	O
,	O

shares	O
with	O
other	O
FMDV	S-Species
clones	O
and	O
populations	O
,	O
notably	O
,	O
MARLS	O
and	O
C	O
-	O
S8p260p3d	O
(	O
the	O
two	O
viruses	O
showing	O
the	O
highest	O
virulence	O
for	O
BHK	O
-	O
21	O
cells	O
;	O
Figure	O
2A	O
;	O
Tables	O
1	O
and	O
S1	O
)	O
,	O
three	O
amino	O
acid	O
substitutions	O
in	O
2C	O
:	O
S80N	O
,	O
T256A	O
,	O
and	O
Q263H	O
.	O

In	O
addition	O
,	O
MARLS	O
and	O
CS8p260p3d	O
include	O
replacement	O
M283V	O
in	O
2C	O
,	O
relative	O
to	O
C	O
-	O
S8c1	O
[	O
27	O
,	O
28	O
]	O
.	O

To	O
test	O
whether	O
any	O
(	O
or	O
a	O
combination	O
)	O
of	O
the	O
three	O
shared	O
amino	O
acid	O
substitutions	O
in	O
2C	O
contributed	O
to	O
the	O
increased	O
virulence	O
of	O
FMDV	S-Species
,	O
each	O
of	O
the	O
mutations	O
was	O
introduced	O
individually	O
into	O
plasmid	O
pMT28	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Transcripts	O
of	O
the	O
three	O
mutants	O
,	O
termed	O
pMT28	O
(	O
SN	O
)	O
,	O
pMT28	O
(	O
TA	O
)	O
,	O
and	O
pMT28	O
(	O
QH	O
)	O
(	O
Figure	O
4	O
)	O
,	O
were	O
used	O
to	O
transfect	O
BHK	O
-	O
21	O
cells	O
,	O
and	O
the	O
viruses	O
obtained	O
were	O
tested	O
with	O
the	O
BHK	O
-	O
21	O
cell	O
killing	O
assay	O
.	O

Viruses	O
having	O
any	O
of	O
the	O
substitutions	O
in	O
2C	O
have	O
a	O
virulence	O
intermediate	O
between	O
that	O
of	O
C	O
-	O
S8c1	O
and	O

(	O
Figure	O
6A	O
)	O
.	O

To	O
test	O
whether	O
the	O
combination	O
of	O
the	O
three	O
substitutions	O
in	O
2C	O
could	O
produce	O
an	O
additional	O
increase	O
of	O
virulence	O
,	O
the	O
three	O
mutations	O
were	O
introduced	O
in	O
pMT28	O
to	O
rescue	O
the	O
triple	O
mutant	O
pMT28	O
(	O
SN	O
,	O
TA	O
,	O
QH	O
)	O
(	O
Figure	O
4	O
)	O
.	O

The	O
results	O
(	O
Figure	O
6B	O
)	O
show	O
that	O
the	O
virulence	O
of	O
the	O
triple	O
2C	O
mutant	O
is	O
similar	O
to	O
the	O
virulence	O
of	O
the	O
individual	O
2C	O
mutants	O
.	O

The	O
2C	O
mutations	O
did	O
not	O
significantly	O
affect	O
the	O
infectious	O
progeny	O
production	O
(	O
Table	O
2	O
)	O
.	O

A	O
testable	O
prediction	O
of	O
this	O
result	O
is	O
that	O
the	O
introduction	O
of	O
the	O
wild	O
-	O
type	O
2C	O
-	O
3A	O
-	O
coding	O
region	O
in	O
the	O
genetic	O
background	O
of	O

should	O
produce	O
a	O
virus	O
with	O
lower	O
virulence	O
than	O

.	O
Indeed	O
,	O
the	O
results	O
with	O
such	O
a	O
chimeric	O
virus	O
(	O
Figure	O
5D	O
)	O
indicate	O
that	O
the	O
presence	O
of	O
the	O
2C	O
-	O
and	O
3A	O
-	O
coding	O
region	O
as	O
the	O
only	O
genetic	O
region	O
of	O
the	O
pMT28	O
in	O
the	O
genetic	O
background	O
of	O

resulted	O
in	O
an	O
FMDV	S-Species
with	O
a	O
2	O
.	O
4	O
-	O
to	O
4	O
.	O
8	O
-	O
fold	O
lower	O
virulence	O
than	O

.	O
We	O
conclude	O
that	O
mutations	O
in	O
2C	O
contribute	O
to	O
virulence	O
of	O
FMDV	S-Species
for	O
BHK	O
-	O
21	O
cells	O
.	O

Thus	O
,	O
a	O
virus	O
that	O
evolves	O
towards	O
low	O
fitness	O
levels	O
due	O
to	O
the	O
operation	O
of	O
Muller	O
'	O
s	O
ratchet	O
may	O
nevertheless	O
maintain	O
its	O
capacity	O
to	O
kill	O
the	O
same	O
cells	O
in	O
which	O
it	O
displays	O
low	O
fitness	O
.	O

In	O
FMDV	S-Species
,	O
the	O
enhanced	O
capacity	O
to	O
kill	O
BHK	O
-	O
21	O
cells	O
was	O
multigenic	O
,	O
including	O
participation	O
of	O
non	O
-	O
structural	O
protein	O
2C	O
with	O
three	O
amino	O
acid	O
substitutions	O
acting	O
in	O
a	O
redundant	O
fashion	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
provide	O
a	O
molecular	O
interpretation	O
of	O
why	O
fitness	O
and	O
virulence	O
of	O
an	O
animal	O
virus	O
can	O
follow	O
disparate	O
evolutionary	O
trajectories	O
,	O
culminating	O
in	O
two	O
unrelated	O
traits	O
.	O

Discussion	O

The	O
capacity	O
of	O
a	O
virus	O
to	O
kill	O
cells	O
is	O
probably	O
influenced	O
by	O
several	O
steps	O
in	O
the	O
virus	O
life	O
cycle	O
,	O
including	O
receptor	O
affinity	O
(	O
which	O
may	O
trigger	O
signalling	O
pathways	O
and	O
alter	O
cell	O
functions	O
)	O
and	O
intracellular	O
viral	O
replication	O
that	O
may	O
lead	O
to	O
metabolic	O
alterations	O
such	O
as	O
transcriptional	O
or	O
translational	O
shut	O
-	O
off	O
[	O
29	O
]	O
.	O

A	O
parallel	O
increase	O
of	O
virulence	O
and	O
fitness	O
as	O
a	O
virus	O
improves	O
its	O
adaptation	O
to	O
a	O
host	O
cell	O
type	O
is	O
expected	O
,	O
since	O
a	O
key	O
parameter	O
that	O
should	O
contribute	O
to	O
the	O
fitness	O
level	O
of	O
a	O
cytophatic	O
virus	O
is	O
the	O
accumulation	O
of	O
infectious	O
particles	O
and	O
its	O
release	O
from	O
cells	O
,	O
which	O
are	O
events	O
often	O
associated	O
with	O
cell	O
killing	O
.	O

This	O
expectation	O
was	O
fulfilled	O
in	O
our	O
experiments	O
(	O
increase	O
of	O
both	O
fitness	O
and	O
cell	O
killing	O
following	O
large	O
population	O
passages	O
of	O
C	O
-	O
S8c1	O
[	O
Figure	O
2	O
]	O
)	O
,	O
and	O
also	O
in	O
other	O
virus	O
-	O
host	O
systems	O
.	O

In	O
a	O
comparison	O
of	O
two	O
genetically	O
divergent	O
isolates	O
of	O
the	O
whispovirus	O
white	O
spot	O
syndrome	O
virus	O
,	O
whose	O
virulence	O
for	O
the	O
shrimp	S-Species
host	O
Penaeus	B-Species
monodon	E-Species
was	O
measured	O
by	O
in	O
vivo	O
cumulative	O
mortality	O
rates	O
,	O
virulence	O
correlated	O
with	O
competitive	O
fitness	O
in	O
vivo	O
[	O
30	O
]	O
.	O

The	O
onset	O
of	O
type	O
1	O
diabetes	O
by	O
coxsackievirus	O
B	O
strains	O
was	O
linked	O
to	O
the	O
viral	O
replication	O
rate	O
and	O
to	O
the	O
infectious	O
dose	O
[	O
31	O
]	O
.	O

In	O
engineered	O
alphavirus	O
replicons	O
,	O
a	O
direct	O
correlation	O
between	O
the	O
level	O
of	O
RNA	O
replication	O
and	O
cytopathogenicity	O
was	O
observed	O
[	O
32	O
]	O
.	O

At	O
an	O
epidemiological	O
level	O
,	O
a	O
greater	O
replicative	O
fitness	O
of	O
historical	O
versus	O
current	O
human	B-Species
immunodeficiency	I-Species
virus	I-Species
type	I-Species
1	E-Species
(	O
HIV	B-Species
-	I-Species
1	E-Species
)	O
isolates	O
was	O
taken	O
as	O
evidence	O
of	O
HIV	B-Species
-	I-Species
1	E-Species
attenuation	O
over	O
time	O
,	O
assuming	O
a	O
direct	O
connection	O
between	O
fitness	O
and	O
virulence	O
[	O
33	O
]	O
.	O

In	O
vivo	O
,	O
viral	O
fitness	O
may	O
vary	O
among	O
specific	O
organs	O
,	O
and	O
virulence	O
may	O
be	O
affected	O
only	O
when	O
fitness	O
for	O
some	O
specific	O
target	O
tissues	O
is	O
affected	O
[	O
34	O
]	O
.	O

Replicative	O
fitness	O
is	O
,	O
however	O
,	O
but	O
one	O
of	O
several	O
factors	O
which	O
influence	O
the	O
progression	O
of	O
a	O
viral	O
infection	O
in	O
vivo	O
.	O

In	O
a	O
comparative	O
analysis	O
,	O
R5	O
-	O
tropic	O
and	O
X4	O
-	O
tropic	O
clones	O
of	O
HIV	B-Species
-	I-Species
1	E-Species
showed	O
similar	O
replication	O
capacity	O
in	O
mitogen	O
-	O
activated	O
T	O
cells	O
.	O

However	O
,	O
X4	O
clones	O
were	O
transferred	O
more	O
efficiently	O
than	O
R5	O
clones	O
from	O
dendritic	O
cells	O
to	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
,	O
a	O
fact	O
that	O
can	O
contribute	O
to	O
the	O
competitive	O
advantage	O
of	O
X4	O
viruses	O
in	O
AIDS	O
patients	S-Species
[	O
35	O
]	O
.	O

Simian	B-Species
immunodeficiency	I-Species
virus	E-Species
SIVmac239	S-Species
infects	O
both	O
the	O
sooty	B-Species
mangabey	E-Species
and	O
the	O
rhesus	B-Species
macaque	E-Species
,	O
reaching	O
high	O
viral	O
loads	O
in	O
both	O
hosts	O
,	O
yet	O
it	O
is	O
only	O
virulent	O
for	O
the	O
rhesus	B-Species
macaque	E-Species
[	O
36	O
]	O
.	O

Deviations	O
of	O
a	O
positive	O
correlation	O
between	O
viral	O
fitness	O
and	O
virulence	O
were	O
observed	O
also	O
in	O
the	O
plant	O
viruses	O
cucumber	B-Species
mosaic	I-Species
virus	E-Species
[	O
37	O
]	O
and	O
barley	B-Species
stripe	I-Species
mosaic	I-Species
virus	E-Species
[	O
38	O
]	O
.	O

A	O
study	O
of	O
the	O
effect	O
of	O
lysis	O
timing	O
on	O
bacteriophage	S-Species
fitness	O
revealed	O
that	O
a	O
strain	O
with	O
an	O
intermediate	O
lysis	O
time	O
had	O
the	O
highest	O
fitness	O
[	O
39	O
]	O
.	O

The	O
time	O
of	O
transmission	O
may	O
also	O
affect	O
virulence	O
.	O

Nuclear	O
polyhedrosis	O
virus	O
transmitted	O
early	O
to	O
its	O
host	O
,	O
the	O
moth	O
Lymantria	B-Species
dispar	E-Species
,	O
was	O
more	O
virulent	O
than	O
virus	O
transmitted	O
late	O
,	O
although	O
the	O
latter	O
was	O
more	O
productive	O
because	O
the	O
virus	O
could	O
use	O
more	O
host	O
tissue	O
for	O
replication	O
[	O
40	O
]	O
.	O

In	O
a	O
study	O
of	O
the	O
susceptibility	O
of	O
North	O
American	O
and	O
non	O
-	O
North	O
American	O
breeds	O
of	O
Lymantria	O
to	O
several	O
isolates	O
of	O
the	O
fungus	O
Entomaphaga	B-Species
maimaiga	E-Species
,	O
mortality	O
was	O
scored	O
in	O
all	O
cases	O
.	O

However	O
,	O
virulence	O
of	O
the	O
fungus	O
,	O
quantitated	O
by	O
the	O
time	O
of	O
death	O
of	O
Lymantria	O
,	O
was	O
,	O
in	O
some	O
cases	O
,	O
inversely	O
proportional	O
to	O
fitness	O
,	O
quantitated	O
by	O
fungal	O
reproduction	O
in	O
the	O
moth	S-Species
[	O
41	O
]	O
.	O

In	O
all	O
these	O
cases	O
,	O
the	O
molecular	O
basis	O
of	O
the	O
lack	O
of	O
positive	O
correlation	O
between	O
fitness	O
and	O
virulence	O
is	O
not	O
understood	O
.	O

Model	O
for	O
a	O
Lack	O
of	O
Correlation	O
between	O
Viral	O
Fitness	O
and	O
Virulence	O

The	O
results	O
with	O
FMDV	S-Species
clones	O
H5	O
have	O
documented	O
that	O
both	O
fitness	O
-	O
enhancing	O
and	O
virulence	O
-	O
enhancing	O
mutations	O
can	O
be	O
incorporated	O
in	O
the	O
viral	O
genome	O
in	O
such	O
a	O
fashion	O
that	O
subsequent	O
fitness	O
-	O
decreasing	O
mutations	O
associated	O
with	O
bottleneck	O
(	O
plaque	O
-	O
to	O
-	O
plaque	O
)	O
transfers	O
produce	O
only	O
minimal	O
effects	O
on	O
virulence	O
(	O
Figure	O
2	O
)	O
.	O

The	O
dissection	O
of	O
accompanying	O
molecular	O
events	O
,	O
achieved	O
through	O
quantification	O
of	O
virulence	O
of	O
recombinant	O
and	O
mutant	O
genomes	O
(	O
Tables	O
2	O
and	O
S1	O
)	O
,	O
provides	O
an	O
interpretation	O
of	O
the	O
lack	O
of	O
positive	O
correlation	O
between	O
virulence	O
and	O
fitness	O
.	O

Multiple	O
fitness	O
-	O
decreasing	O
mutations	O
occur	O
in	O
the	O
course	O
of	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
,	O
distributed	O
throughout	O
the	O
FMDV	S-Species
genome	O
[	O
11	O
]	O
.	O

In	O
contrast	O
,	O
determinants	O
of	O
virulence	O
for	O
BHK	O
-	O
21	O
cells	O
are	O
multigenic	O
,	O
but	O
concentrated	O
mainly	O
in	O
some	O
FMDV	S-Species
genomic	O
regions	O
.	O

Similar	O
multigenic	O
but	O
discrete	O
virulence	O
determinants	O
have	O
been	O
described	O
also	O
in	O
other	O
virus	O
-	O
host	O
systems	O
[	O
42	O
,	O
43	O
]	O
.	O

To	O
decrease	O
virulence	O
,	O
mutations	O
occurring	O
randomly	O
in	O
the	O
course	O
of	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
should	O
affect	O
specific	O
genomic	O
sites	O
,	O
and	O
this	O
will	O
occur	O
with	O
a	O
lower	O
probability	O
than	O
fitness	O
-	O
decreasing	O
mutations	O
,	O
which	O
can	O
hit	O
any	O
of	O
the	O
multifunctional	O
picornaviral	O
proteins	O
and	O
regulatory	O
regions	O
[	O
11	O
]	O
.	O

This	O
model	O
is	O
reinforced	O
by	O
the	O
observation	O
that	O
three	O
amino	O
acid	O
substitutions	O
in	O
2C	O
(	O
S80N	O
,	O
T256A	O
,	O
and	O
Q263H	O
)	O
had	O
a	O
similar	O
effect	O
in	O
enhancing	O
FMDV	S-Species
virulence	O
,	O
and	O
the	O
three	O
mutations	O
in	O
the	O
same	O
genome	O
had	O
an	O
effect	O
comparable	O
to	O
each	O
mutation	O
individually	O
(	O
Figure	O
6	O
;	O
Tables	O
2	O
and	O
S1	O
)	O
.	O

It	O
is	O
not	O
clear	O
what	O
the	O
basis	O
of	O
the	O
contribution	O
of	O
2C	O
to	O
virulence	O
for	O
BHK	O
-	O
21	O
could	O
be	O
.	O

2C	O
is	O
involved	O
in	O
RNA	O
synthesis	O
and	O
contains	O
a	O
nucleotide	O
-	O
binding	O
domain	O
,	O
although	O
none	O
of	O
the	O
substitutions	O
found	O
in	O

and	O

lie	O
within	O
such	O
a	O
domain	O
.	O

An	O
unlikely	O
triple	O
reversion	O
would	O
be	O
required	O
to	O
eliminate	O
the	O
virulence	O
-	O
enhancing	O
effect	O
of	O
the	O
three	O
mutations	O
in	O
2C	O
.	O

We	O
propose	O
that	O
a	O
higher	O
robustness	O
of	O
the	O
FMDV	S-Species
genome	O
with	O
regard	O
to	O
virulence	O
for	O
BHK	O
-	O
21	O
cells	O
,	O
rather	O
than	O
to	O
replicative	O
fitness	O
in	O
the	O
same	O
cells	O
,	O
underlies	O
the	O
different	O
trajectories	O
followed	O
by	O
fitness	O
and	O
virulence	O
upon	O
subjecting	O
the	O
virus	O
to	O
repeated	O
bottleneck	O
transfers	O
.	O

Obviously	O
,	O
we	O
cannot	O
exclude	O
that	O
parameters	O
of	O
the	O
virus	O
life	O
cycle	O
,	O
other	O
than	O
fitness	O
as	O
measured	O
in	O
our	O
experiments	O
,	O
could	O
correlate	O
with	O
virulence	O
for	O
BHK	O
-	O
21	O
.	O

The	O
comparative	O
analysis	O
of	O
FMDV	S-Species
clones	O
and	O
populations	O
shows	O
that	O
shifts	O
in	O
virulence	O
can	O
occur	O
even	O
through	O
the	O
evolution	O
of	O
a	O
single	O
viral	O
clone	O
(	O
C	O
-	O
S8c1	O
)	O
,	O
with	O
its	O
restricted	O
genetic	O
diversity	O
prompted	O
by	O
different	O
replication	O
regimes	O
in	O
the	O
same	O
host	O
cells	O
,	O
which	O
also	O
have	O
a	O
clonal	O
origin	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

We	O
conjecture	O
that	O
the	O
demonstration	O
that	O
fitness	O
and	O
virulence	O
can	O
follow	O
different	O
evolutionary	O
courses	O
has	O
been	O
possible	O
thanks	O
to	O
the	O
consequences	O
of	O
the	O
extreme	O
passage	O
regimes	O
to	O
which	O
the	O
viral	O
populations	O
were	O
subjected	O
:	O
competitive	O
evolution	O
of	O
an	O
ample	O
mutant	O
spectra	O
during	O
repeated	O
large	O
population	O
passages	O
,	O
and	O
accumulation	O
of	O
deleterious	O
(	O
with	O
regard	O
to	O
fitness	O
,	O
but	O
not	O
with	O
regard	O
to	O
virulence	O
)	O
mutations	O
upon	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
(	O
predominance	O
of	O
genetic	O
drift	O
and	O
operation	O
of	O
Muller	O
'	O
s	O
ratchet	O
)	O
[	O
12	O
,	O
15	O
]	O
.	O

Implications	O
for	O
Models	O
of	O
Virulence	O

It	O
must	O
be	O
emphasized	O
that	O
fitness	O
and	O
virulence	O
are	O
relative	O
values	O
that	O
pertain	O
to	O
a	O
defined	O
physical	O
and	O
biological	O
environment	O
.	O

Virulence	O
determinants	O
of	O
FMDV	S-Species
,	O
identified	O
here	O
for	O
BHK	O
-	O
21	O
cells	O
,	O
need	O
not	O
apply	O
to	O
virulence	O
for	O
the	O
natural	O
animal	O
hosts	O
of	O
FMDV	S-Species
[	O
44	O
]	O
.	O

However	O
,	O
the	O
observation	O
of	O
a	O
lack	O
of	O
correlation	O
between	O
fitness	O
and	O
virulence	O
in	O
a	O
FMDV	S-Species
clone	O
is	O
relevant	O
to	O
current	O
models	O
of	O
attenuation	O
and	O
virulence	O
,	O
since	O
it	O
shows	O
that	O
more	O
virulent	O
forms	O
of	O
a	O
virus	O
need	O
not	O
have	O
a	O
reproductive	O
advantage	O
,	O
and	O
that	O
viral	O
virulence	O
is	O
not	O
necessarily	O
a	O
byproduct	O
of	O
viral	O
fitness	O
.	O

Even	O
if	O
virulence	O
is	O
regarded	O
as	O
an	O
unavoidable	O
consequence	O
of	O
parasite	O
adaptation	O
[	O
45	O
]	O
,	O
virus	O
de	O
-	O
adaptation	O
(	O
fitness	O
loss	O
)	O
need	O
not	O
entail	O
a	O
decrease	O
of	O
virulence	O
.	O

Most	O
current	O
definitions	O
of	O
virulence	O
include	O
both	O
the	O
ability	O
of	O
the	O
pathogen	O
to	O
multiply	O
and	O
to	O
cause	O
harm	O
to	O
its	O
host	O
;	O
some	O
authors	O
,	O
however	O
,	O
assume	O
a	O
direct	O
relationship	O
between	O
fitness	O
and	O
capacity	O
to	O
produce	O
disease	O
[	O
46	O
-	O
48	O
]	O
.	O

In	O
relating	O
the	O
results	O
with	O
FMDV	S-Species
to	O
general	O
models	O
of	O
virulence	O
in	O
host	O
-	O
parasite	O
systems	O
,	O
it	O
must	O
be	O
considered	O
that	O
in	O
the	O
FMDV	S-Species
system	O
,	O
evolution	O
of	O
the	O
host	O
BHK	O
-	O
21	O
cells	O
could	O
not	O
influence	O
FMDV	S-Species
evolution	O
,	O
because	O
clonal	O
cell	O
populations	O
with	O
a	O
controlled	O
passage	O
history	O
were	O
supplied	O
in	O
constant	O
numbers	O
at	O
each	O
infection	O
event	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

Therefore	O
,	O
changes	O
in	O
host	O
density	O
,	O
or	O
mobility	O
,	O
as	O
well	O
as	O
pathogen	O
survival	O
in	O
the	O
external	O
environment	O
,	O
all	O
of	O
which	O
are	O
relevant	O
parameters	O
in	O
virulence	O
models	O
[	O
48	O
,	O
49	O
]	O
,	O
cannot	O
play	O
a	O
role	O
in	O
our	O
system	O
.	O

A	O
consistent	O
finding	O
in	O
serial	O
passage	O
experiments	O
is	O
that	O
virulence	O
of	O
a	O
parasite	O
increases	O
with	O
passage	O
number	O
in	O
a	O
new	O
host	O
[	O
50	O
]	O
.	O

The	O
results	O
with	O
FMDV	S-Species
infecting	O
BHK	O
-	O
21	O
cells	O
cytolytically	O
imply	O
that	O
the	O
increase	O
of	O
virulence	O
can	O
be	O
conditioned	O
to	O
the	O
history	O
of	O
passage	O
regimes	O
undergone	O
by	O
a	O
virus	O
.	O

The	O
invariance	O
of	O
BHK	O
-	O
21	O
cells	O
in	O
the	O
course	O
of	O
serial	O
cytolytic	O
passages	O
of	O
FMDV	S-Species
is	O
in	O
contrast	O
with	O
the	O
parallel	O
system	O
consisting	O
of	O
BHK	O
-	O
21	O
cells	O
persistently	O
infected	O
with	O
FMDV	S-Species
C	O
-	O
S8c1	O
[	O
25	O
]	O
,	O
in	O
which	O
the	O
cells	O
are	O
passaged	O
and	O
coevolve	O
with	O
the	O
resident	O
virus	O
[	O
51	O
]	O
.	O

Host	O
-	O
virus	O
coevolution	O
has	O
generally	O
favored	O
a	O
decrease	O
of	O
viral	O
virulence	O
in	O
the	O
field	O
,	O
a	O
classical	O
example	O
being	O
myxoma	B-Species
virus	E-Species
and	O
myxomatosis	O
in	O
rabbits	S-Species
[	O
52	O
]	O
.	O

Our	O
comparison	O
of	O
FMDV	S-Species
clones	O
did	O
not	O
provide	O
evidence	O
of	O
clones	O
with	O
high	O
fitness	O
and	O
low	O
virulence	O
,	O
which	O
,	O
with	O
regard	O
to	O
natural	O
hosts	O
,	O
is	O
an	O
aim	O
of	O
biomedicine	O
to	O
obtain	O
vaccine	O
strains	O
.	O

Yet	O
,	O
the	O
existence	O
of	O
specific	O
mutations	O
that	O
differentially	O
affect	O
fitness	O
and	O
virulence	O
opens	O
the	O
way	O
to	O
engineer	O
candidate	O
vaccine	O
strains	O
unable	O
to	O
kill	O
the	O
host	O
,	O
while	O
maintaining	O
replicative	O
competence	O
.	O

Virulence	O
is	O
,	O
however	O
,	O
a	O
feature	O
of	O
the	O
host	O
-	O
parasite	O
relationship	O
[	O
46	O
]	O
,	O
and	O
the	O
mutations	O
needed	O
to	O
impair	O
virulence	O
are	O
expected	O
to	O
be	O
host	O
-	O
dependent	O
[	O
53	O
,	O
54	O
]	O
.	O

Materials	O
and	O
Methods	O

Cells	O
,	O
viruses	O
,	O
and	O
infections	O
.	O

The	O
BHK	O
-	O
21	O
cells	O
used	O
in	O
the	O
present	O
study	O
were	O
cloned	O
by	O
end	O
-	O
point	O
dilution	O
,	O
followed	O
by	O
preparation	O
of	O
a	O
cell	O
stock	O
from	O
a	O
single	O
cell	O
;	O
they	O
were	O
passaged	O
a	O
maximum	O
of	O
30	O
times	O
before	O
being	O
used	O
for	O
FMDV	S-Species
infection	O
[	O
25	O
,	O
51	O
]	O
.	O

Procedures	O
for	O
cell	O
growth	O
,	O
infection	O
of	O
BHK	O
-	O
21	O
cell	O
monolayers	O
with	O
FMDV	S-Species
in	O
liquid	O
medium	O
,	O
and	O
plaque	O
assays	O
in	O
semi	O
-	O
solid	O
agar	O
medium	O
were	O
carried	O
out	O
as	O
previously	O
described	O
[	O
11	O
,	O
19	O
,	O
25	O
,	O
27	O
]	O
.	O

Mock	O
-	O
infected	O
cells	O
were	O
handled	O
in	O
parallel	O
in	O
all	O
infectivity	O
and	O
plaque	O
assays	O
to	O
monitor	O
absence	O
of	O
viral	O
contamination	O
.	O

The	O
FMDVs	S-Species
used	O
in	O
the	O
present	O
study	O
(	O
Figure	O
1	O
)	O
are	O
(	O
i	O
)	O
the	O
reference	O
clone	O
C	O
-	O
S8c1	O
,	O
which	O
has	O
been	O
assigned	O
a	O
relative	O
fitness	O
of	O
1	O
.	O
0	O
[	O
11	O
]	O
.	O

(	O
ii	O
)	O
MARLS	O
,	O
a	O
monoclonal	O
antibody	O
escape	O
mutant	O
isolated	O
from	O
population	O
C	O
-	O
S8c1p213	O
[	O
55	O
]	O
;	O
MARLS	O
has	O
a	O
fitness	O
of	O
25	O
relative	O
to	O
C	O
-	O
S8c1	O
[	O
24	O
]	O
.	O

(	O
iii	O
)	O
C	O
-	O
S8p260p3d	O
,	O
a	O
standard	O
FMDV	S-Species
virus	O
rescued	O
by	O
low	O
MOI	O
passage	O
of	O
C	O
-	O
S8p260	O
.	O

The	O
latter	O
is	O
a	O
virus	O
that	O
evolved	O
by	O
passage	O
of	O
C	O
-	O
S8c1	O
at	O
a	O
high	O
MOI	O
,	O
which	O
resulted	O
in	O
dominance	O
of	O
two	O
defective	O
FMDV	S-Species
genomes	O
(	O
both	O
including	O
internal	O
deletions	O
)	O
that	O
were	O
infectious	O
by	O
complementation	O
,	O
in	O
the	O
absence	O
of	O
standard	O
virus	O
[	O
22	O
,	O
24	O
,	O
28	O
]	O
;	O
C	O
-	O
S8p260p3d	O
has	O
a	O
relative	O
fitness	O
of	O
20	O
[	O
24	O
]	O
.	O

(	O
iv	O
)	O
REDpt60	O
,	O
obtained	O
after	O
60	O
successive	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
of	O
RED	O
(	O
a	O
monoclonal	O
antibody	O
escape	O
mutant	O
isolated	O
from	O
population	O
C	O
-	O
S8c1p100	O
)	O
[	O
20	O
]	O
;	O
REDpt60	O
has	O
a	O
fitness	O
of	O
1	O
.	O
9	O
relative	O
to	O
C	O
-	O
S8c1	O
.	O

(	O
v	O
)	O
C	O
-	O
S8c1p113	O
,	O
a	O
viral	O
population	O
obtained	O
after	O
113	O
serial	O
cytolytic	O
passages	O
of	O
C	O
-	O
S8c1	O
at	O
a	O
high	O
MOI	O
in	O
BHK	O
-	O
21	O
cells	O
(	O
2	O
x	O
106	O
BHK	O
-	O
21	O
cells	O
infected	O
with	O
the	O
virus	O
contained	O
in	O
200	O
mu	O
l	O
of	O
the	O
supernatant	O
from	O
the	O
previous	O
infection	O
)	O
.	O

(	O
vi	O
)	O
Clone	O

,	O
a	O
biological	O
clone	O
isolated	O
from	O
population	O
C	O
-	O
S8c1p113	O
[	O
11	O
]	O
;	O
its	O
relative	O
fitness	O
is	O
26	O
(	O
unpublished	O
data	O
)	O
.	O

(	O
vii	O
)	O
Clone	O

,	O
obtained	O
after	O
95	O
successive	O
plaque	O
-	O
to	O
-	O
plaque	O
transfers	O
of	O

[	O
11	O
]	O
;	O
its	O
relative	O
fitness	O
is	O
0	O
.	O
11	O
[	O
23	O
]	O
.	O

Cell	O
killing	O
assay	O
.	O

The	O
capacity	O
of	O
FMDV	S-Species
to	O
kill	O
BHK	O
-	O
21	O
cells	O
was	O
measured	O
as	O
previously	O
described	O
[	O
18	O
,	O
22	O
]	O
.	O

The	O
assay	O
consists	O
in	O
determining	O
the	O
minimum	O
number	O
of	O
PFU	O
required	O
to	O
kill	O
104	O
BHK	O
-	O
21	O
cells	O
after	O
variable	O
times	O
of	O
infection	O
.	O

The	O
assay	O
was	O
performed	O
in	O
M96	O
multiwell	O
plates	O
with	O
monolayers	O
of	O
104	O
BHK	O
-	O
21	O
cells	O
per	O
well	O
infected	O
with	O
serial	O
dilutions	O
of	O
virus	O
.	O

At	O
different	O
times	O
postinfection	O
,	O
cells	O
were	O
fixed	O
with	O
2	O
%	O
formaldehyde	O
and	O
stained	O
with	O
2	O
%	O
crystal	O
violet	O
in	O
2	O
%	O
formaldehyde	O
.	O

Results	O
are	O
expressed	O
as	O
the	O
logarithm	O
of	O
the	O
number	O
of	O
PFUs	O
needed	O
for	O
complete	O
cell	O
killing	O
(	O
as	O
judged	O
by	O
cell	O
staining	O
with	O
crystal	O
violet	O
,	O
with	O
series	O
of	O
control	O
wells	O
with	O
known	O
numbers	O
of	O
cells	O
)	O
as	O
a	O
function	O
of	O
time	O
postinfection	O
[	O
18	O
,	O
22	O
]	O
.	O

Determination	O
of	O
relative	O
fitness	O
of	O

.	O

The	O
relative	O
fitness	O
of	O
FMDV	S-Species

was	O
determined	O
by	O
growth	O
competition	O
in	O
BHK	O
-	O
21	O
cells	O
as	O
previously	O
described	O
[	O
7	O
,	O
10	O
,	O
11	O
,	O
24	O
,	O
56	O
]	O
.	O

FMDV	S-Species

was	O
mixed	O
with	O
appropriate	O
proportions	O
of	O

,	O
which	O
was	O
used	O
as	O
reference	O
virus	O
.	O

This	O
virus	O
has	O
a	O
fitness	O
8	O
.	O
5	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
reference	O
clone	O
of	O
C	O
-	O
S8c1	O
in	O
BHK	O
-	O
21	O
cells	O
[	O
7	O
,	O
10	O
,	O
11	O
,	O
24	O
,	O
56	O
]	O
.	O

Four	O
serial	O
infections	O
were	O
carried	O
out	O
at	O
MOI	O
of	O
0	O
.	O
1	O
PFU	O
/	O
cell	O
.	O

The	O
proportion	O
of	O
the	O
two	O
competing	O
genomes	O
at	O
different	O
passages	O
was	O
determined	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
,	O
employing	O
primers	O
5531wtnew	O
and	O

,	O
which	O
are	O
able	O
to	O
discriminate	O
FMDV	S-Species

RNA	O
from	O

RNA	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
primers	O
will	O
be	O
provided	O
upon	O
request	O
.	O

The	O
fitness	O
vector	O
obtained	O
for	O

corresponded	O
to	O
the	O
equation	O
y	O
=	O
0	O
,	O
0206e1	O
,	O
1074x	O
;	O
R2	O
=	O
0	O
.	O
9507	O
.	O

The	O
antilogarithm	O
(	O
base	O
e	O
)	O
of	O
the	O
vector	O
slope	O
is	O
the	O
fitness	O
of	O
the	O
assayed	O
virus	O
relative	O
to	O
the	O
reference	O
virus	O
[	O
56	O
]	O
.	O

cDNA	O
synthesis	O
,	O
molecular	O
cloning	O
,	O
and	O
nucleotide	O
sequencing	O
.	O

Viral	O
RNA	O
was	O
extracted	O
by	O
treatment	O
with	O
Trizol	O
as	O
previously	O
described	O
[	O
57	O
]	O
.	O

Reverse	O
transcription	O
of	O
FMDV	S-Species
RNA	O
was	O
carried	O
out	O
with	O
avian	B-Species
myeloblastosis	I-Species
virus	E-Species
reverse	O
transcriptase	O
(	O
Promega	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
promega	O
.	O
com	O
)	O
or	O
Transcriptor	O
reverse	O
transcriptase	O
(	O
Roche	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
roche	O
.	O
com	O
)	O
,	O
and	O
PCR	O
amplification	O
was	O
performed	O
by	O
using	O
either	O
Ampli	O
-	O
Taq	O
polymerase	O
(	O
PerkinElmer	O
,	O
http	O
:	O
/	O
/	O
las	O
.	O
perkinelmer	O
.	O
com	O
)	O
or	O
an	O
Expand	O
High	O
Fidelity	O
polymerase	O
system	O
(	O
Roche	O
)	O
,	O
as	O
instructed	O
by	O
the	O
manufacturers	O
.	O

The	O
FMDV	S-Species
genome	O
-	O
specific	O
oligonucleotide	O
primers	O
used	O
have	O
been	O
previously	O
described	O
[	O
22	O
,	O
58	O
]	O
.	O

In	O
all	O
RT	O
-	O
PCR	O
amplifications	O
,	O
negative	O
amplification	O
controls	O
,	O
including	O
all	O
reaction	O
components	O
except	O
template	O
RNA	O
,	O
were	O
run	O
in	O
parallel	O
to	O
monitor	O
absence	O
of	O
contamination	O
.	O

Chimeric	O
viruses	O
containing	O
selected	O
regions	O
of	O

in	O
the	O
genetic	O
background	O
of	O
C	O
-	O
S8c1	O
(	O
Figure	O
4	O
)	O
were	O
obtained	O
by	O
replacing	O
the	O
corresponding	O
DNA	O
fragment	O
of	O
pMT28	O
by	O
a	O
cDNA	O
copy	O
of	O

RNA	O
,	O
using	O
specific	O
restriction	O
sites	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
436	O
-	O
2046	O
)	O
,	O
a	O
chimera	O
that	O
included	O
nucleotides	O
436	O
to	O
2046	O
of	O

(	O
the	O
residue	O
numbering	O
of	O
the	O
FMDV	S-Species
genome	O
is	O
as	O
in	O
[	O
11	O
]	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
NR2	O
and	O
JH2	O
,	O
and	O
the	O
cDNA	O
was	O
digested	O
with	O
Hpa	O
I	O
(	O
position	O
436	O
)	O
and	O
Xba	O
I	O
(	O
2046	O
)	O
,	O
and	O
ligated	O
into	O
pMT28	O
DNA	O
digested	O
with	O
the	O
same	O
enzymes	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
2046	O
-	O
3760	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
2R1New	O
and	O
pU	O
,	O
and	O
then	O
the	O
cDNA	O
was	O
digested	O
with	O
Xba	O
I	O
(	O
2046	O
)	O
and	O
Avr	O
II	O
(	O
3760	O
)	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
3760	O
-	O
5839	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
3R2New	O
and	O
3CD1	O
,	O
and	O
then	O
the	O
cDNA	O
was	O
digested	O
with	O
Avr	O
II	O
(	O
3760	O
)	O
and	O
Rsr	O
II	O
(	O
5839	O
)	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
5839	O
-	O
7427	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
5531	O
wt	O
new	O
and	O
C	O
-	O
Not	O
-	O
Pol	O
,	O
and	O
then	O
the	O
cDNA	O
was	O
digested	O
with	O
Rsr	O
II	O
(	O
5839	O
)	O
and	O
Bam	O
HI	O
(	O
7427	O
)	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
436	O
-	O
3760	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
NR2	O
and	O
JH2	O
,	O
and	O
then	O
the	O
cDNA	O
was	O
digested	O
with	O
Hpa	O
I	O
(	O
position	O
436	O
)	O
and	O
Xba	O
I	O
(	O
2046	O
)	O
,	O
and	O
ligated	O
into	O
pMT28	O
/	O

(	O
2046	O
-	O
3760	O
)	O
DNA	O
digested	O
with	O
the	O
same	O
enzymes	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
3760	O
-	O
7427	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
3R2New	O
and	O
3CD1	O
,	O
and	O
then	O
the	O
cDNA	O
was	O
digested	O
with	O
Avr	O
II	O
(	O
3760	O
)	O
and	O
Rsr	O
II	O
(	O
5839	O
)	O
,	O
and	O
ligated	O
into	O
pMT28	O
/	O

(	O
5839	O
-	O
7427	O
)	O
DNA	O
digested	O
with	O
the	O
same	O
enzymes	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
2046	O
-	O
7427	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
2R1New	O
and	O
pU	O
,	O
and	O
then	O
the	O
cDNA	O
was	O
digested	O
with	O
Xba	O
I	O
(	O
2046	O
)	O
and	O
Avr	O
II	O
(	O
3760	O
)	O
,	O
and	O
ligated	O
into	O
pMT28	O
/	O

(	O
3760	O
-	O
7427	O
)	O
DNA	O
digested	O
with	O
the	O
same	O
enzymes	O
.	O

To	O
obtain	O
pMT28	O
/	O

(	O
436	O
-	O
7427	O
)	O
,	O

RNA	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
primers	O
NR2	O
and	O
JH2	O
;	O
the	O
cDNA	O
was	O
digested	O
with	O
Hpa	O
I	O
(	O
position	O
436	O
)	O
and	O
Xba	O
I	O
(	O
2046	O
)	O
,	O
and	O
ligated	O
into	O
pMT28	O
/	O

(	O
2046	O
-	O
7427	O
)	O
DNA	O
digested	O
with	O
the	O
same	O
enzymes	O
.	O

To	O
obtain	O

/	O
2C	O
-	O
3A	O
(	O
pMT28	O
)	O
,	O
pMT28	O
was	O
digested	O
with	O
Bgl	O
II	O
(	O
4201	O
)	O
and	O
Rsr	O
II	O
(	O
5839	O
)	O
,	O
and	O
a	O
DNA	O
fragment	O
including	O
wild	O
-	O
type	O
2C	O
-	O
3A	O
-	O
coding	O
region	O
was	O
inserted	O
into	O
pMT28	O
/	O

(	O
436	O
-	O
7427	O
)	O
DNA	O
digested	O
with	O
the	O
same	O
enzymes	O
.	O

DNA	O
ligation	O
,	O
transformation	O
of	O
Escherichia	B-Species
coli	E-Species
DH5	O
alpha	O
,	O
isolation	O
of	O
DNA	O
from	O
bacterial	O
colonies	O
,	O
and	O
characterization	O
of	O
DNA	O
by	O
restriction	O
enzyme	O
digestion	O
were	O
performed	O
by	O
standard	O
procedures	O
[	O
59	O
]	O
.	O

The	O
primers	O
used	O
for	O
molecular	O
cloning	O
and	O
site	O
-	O
directed	O
mutagenesis	O
are	O
described	O
in	O
Table	O
S3	O
.	O

To	O
obtain	O
FMDV	S-Species
C	O
-	O
S8c1	O
containing	O
the	O
mutations	O
found	O
in	O
gene	O
2C	O
of	O

,	O
plasmid	O
pMT28	O
was	O
subjected	O
to	O
site	O
-	O
directed	O
mutagenesis	O
using	O
an	O
oligonucleotide	O
including	O
the	O
required	O
nucleotide	O
replacement	O
,	O
and	O
3R2New	O
or	O
3CD1	O
as	O
external	O
oligonucleotide	O
primer	O
(	O
Table	O
S3	O
;	O
Figure	O
4	O
)	O
.	O

A	O
DNA	O
fragment	O
termed	O
A	O
was	O
obtained	O
by	O
subjecting	O
plasmid	O
pMT28	O
to	O
site	O
-	O
directed	O
mutagenesis	O
using	O
primers	O
(	O
reverse	O
)	O
mutSNu	O
,	O
mutTAu	O
,	O
and	O
mutQHu	O
(	O
to	O
introduce	O
mutations	O
S80N	O
,	O
T256A	O
,	O
and	O
Q263H	O
,	O
respectively	O
)	O
and	O
an	O
external	O
oligonucleotide	O
primer	O
(	O
3R2New	O
,	O
forward	O
)	O
.	O

A	O
DNA	O
fragment	O
termed	O
B	O
was	O
obtained	O
amplifying	O
pMT28	O
with	O
primers	O
(	O
forward	O
)	O
mutSNd	O
,	O
mutTAd	O
,	O
and	O
mutQHd	O
(	O
to	O
introduce	O
mutations	O
S80N	O
,	O
T256A	O
,	O
and	O
Q263H	O
,	O
respectively	O
)	O
and	O
an	O
external	O
oligonucleotide	O
primer	O
(	O
3CD1	O
,	O
reverse	O
)	O
.	O

DNA	O
fragments	O
A	O
and	O
B	O
,	O
including	O
the	O
desired	O
mutations	O
,	O
were	O
recombined	O
by	O
shuffling	O
PCR	O
using	O
equimolar	O
amounts	O
of	O
DNA	O
fragments	O
and	O
two	O
external	O
primers	O
(	O
3R2New	O
and	O
3CD1	O
)	O
.	O

The	O
DNA	O
with	O
the	O
desired	O
mutation	O
(	O
s	O
)	O
in	O
the	O
2C	O
gene	O
was	O
digested	O
with	O
Avr	O
II	O
(	O
genomic	O
position	O
3760	O
)	O
and	O
Rsr	O
II	O
(	O
position	O
5839	O
)	O
,	O
and	O
cloned	O
into	O
pMT28	O
to	O
generate	O
pMT28	O
(	O
SN	O
)	O
,	O
pMT28	O
(	O
TA	O
)	O
,	O
and	O
pMT28	O
(	O
QH	O
)	O
.	O

To	O
obtain	O
pMT28	O
(	O
SN	O
,	O
TA	O
,	O
QH	O
)	O
,	O
plasmid	O
pMT28	O
(	O
SN	O
)	O
was	O
subjected	O
to	O
site	O
-	O
directed	O
mutagenesis	O
to	O
introduce	O
mutation	O
T256A	O
in	O
a	O
similar	O
way	O
as	O
described	O
above	O
,	O
and	O
then	O
,	O
plasmid	O
pMT28	O
(	O
SN	O
,	O
TA	O
)	O
was	O
subjected	O
to	O
site	O
-	O
directed	O
mutagenesis	O
to	O
introduce	O
mutation	O
Q263H	O
.	O

All	O
chimeric	O
viruses	O
and	O
mutants	O
were	O
analyzed	O
by	O
nucleotide	O
sequencing	O
using	O
Big	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
kit	O
(	O
Abi	O
Prism	O
;	O
PerkinElmer	O
)	O
and	O
sequencer	O
ABI373	O
as	O
previously	O
described	O
[	O
58	O
]	O
.	O

Sequences	O
were	O
analyzed	O
using	O
DNASTAR	O
4	O
.	O
0	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
dnastar	O
.	O
com	O
)	O
,	O
GeneDoc	O
,	O
and	O
GCC	O
(	O
University	O
of	O
Wisconsin	O
)	O
.	O

Each	O
sequence	O
was	O
determined	O
at	O
least	O
twice	O
,	O
with	O
products	O
obtained	O
using	O
different	O
oligonucleotide	O
primers	O
.	O

DNA	O
from	O
pMT28	O
or	O
its	O
recombinant	O
and	O
mutant	O
derivatives	O
was	O
linearized	O
with	O
Nde	O
I	O
and	O
transcribed	O
with	O
SP6	O
RNA	O
polymerase	O
as	O
previously	O
described	O
[	O
22	O
,	O
27	O
]	O
.	O

Transcript	O
RNA	O
integrity	O
and	O
concentration	O
were	O
estimated	O
by	O
agarose	O
gel	O
electrophoresis	O
,	O
in	O
parallel	O
runs	O
with	O
known	O
amounts	O
of	O
standard	O
C	O
-	O
S8c1	O
RNA	O
.	O

BHK	O
-	O
21	O
cell	O
monolayers	O
(	O
70	O
%	O
confluent	O
,	O
about	O
1	O
x	O
106	O
cells	O
)	O
were	O
transfected	O
with	O
RNA	O
transcripts	O
(	O
1	O
mu	O
g	O
RNA	O
)	O
using	O
lipofectin	O
as	O
previously	O
described	O
[	O
59	O
]	O
.	O

Virus	O
was	O
collected	O
from	O
the	O
culture	O
supernatant	O
at	O
72	O
h	O
post	O
-	O
transfection	O
.	O

The	O
virus	O
obtained	O
by	O
transfection	O
was	O
passaged	O
twice	O
before	O
using	O
it	O
in	O
biological	O
studies	O
.	O

RNA	O
was	O
extracted	O
and	O
sequenced	O
to	O
ascertain	O
that	O
the	O
virus	O
maintained	O
the	O
genomic	O
structure	O
and	O
mutations	O
of	O
the	O
initial	O
transcript	O
.	O

Consensus	O
genomic	O
nucleotide	O
sequences	O
of	O
FMDV	S-Species
clones	O
were	O
obtained	O
by	O
RT	O
-	O
PCR	O
amplification	O
of	O
virion	O
RNA	O
using	O
specific	O
primers	O
[	O
7	O
,	O
22	O
,	O
28	O
]	O
.	O

Supporting	O
Information	O

Accession	O
Numbers	O

The	O
GenBank	O
accession	O
numbers	O
for	O
the	O
C	O
-	O
S8c1	O
,	O

,	O

,	O
CS8p260p3d	O
,	O
and	O
MARLS	O
genomic	O
sequences	O
are	O
AJ133357	O
,	O
AM409190	O
,	O
AM409325	O
,	O
DQ409185	O
,	O
and	O
AF274010	O
,	O
respectively	O
.	O

Nucleotide	O
and	O
amino	O
acid	O
sequences	O
for	O
picornaviruses	O
can	O
be	O
found	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
iah	O
.	O
bbsrc	O
.	O
ac	O
.	O
uk	O
/	O
virus	O
/	O
picornaviridae	O
/	O
SequenceDatabase	O
/	O
3Ddatabase	O
/	O
3D	O
.	O
HTM	O
.	O

Human	S-Species
growth	O
hormone	O
(	O
GH1	O
)	O
gene	O
polymorphism	O
map	O
in	O
a	O
normal	O
-	O
statured	O
adult	O
population	O

Abstract	O

Objective	O

GH1	O
gene	O
presents	O
a	O
complex	O
map	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
entire	O
promoter	O
,	O
coding	O
and	O
noncoding	O
regions	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
establish	O
the	O
complete	O
map	O
of	O
GH1	O
gene	O
SNPs	O
in	O
our	O
control	O
normal	O
population	O
and	O
to	O
analyse	O
its	O
association	O
with	O
adult	O
height	O
.	O

Design	O
,	O
subjects	O
and	O
measurements	O

A	O
systematic	O
GH1	O
gene	O
analysis	O
was	O
designed	O
in	O
a	O
control	O
population	O
of	O
307	O
adults	O
of	O
both	O
sexes	O
with	O
height	O
normally	O
distributed	O
within	O
normal	O
range	O
for	O
the	O
same	O
population	O
:	O
-	O
2	O
standard	O
deviation	O
scores	O
(	O
SDS	O
)	O
to	O
+	O
2	O
SDS	O
.	O

An	O
analysis	O
was	O
performed	O
on	O
individual	O
and	O
combined	O
genotype	O
associations	O
with	O
adult	O
height	O
.	O

Results	O

Twenty	O
-	O
five	O
SNPs	O
presented	O
a	O
frequency	O
over	O
1	O
%	O
:	O
11	O
in	O
the	O
promoter	O
(	O
P1	O
to	O
P11	O
)	O
,	O
three	O
in	O
the	O
5	O
'	O
UTR	O
region	O
(	O
P12	O
to	O
P14	O
)	O
,	O
one	O
in	O
exon	O
1	O
(	O
P15	O
)	O
,	O
three	O
in	O
intron	O
1	O
(	O
P16	O
to	O
P18	O
)	O
,	O
two	O
in	O
intron	O
2	O
(	O
P19	O
and	O
P20	O
)	O
,	O
two	O
in	O
exon	O
4	O
(	O
P21	O
and	O
P22	O
)	O
and	O
three	O
in	O
intron	O
4	O
(	O
P23	O
to	O
P25	O
)	O
.	O

Twenty	O
-	O
nine	O
additional	O
changes	O
with	O
frequencies	O
under	O
1	O
%	O
were	O
found	O
in	O
29	O
subjects	O
.	O

P8	O
,	O
P19	O
,	O
P20	O
and	O
P25	O
had	O
not	O
been	O
previously	O
described	O
.	O

P6	O
,	O
P12	O
,	O
P17	O
and	O
P25	O
accounted	O
for	O
6	O
.	O
2	O
%	O
of	O
the	O
variation	O
in	O
adult	O
height	O
(	O
P	O
=	O
0	O
.	O
0007	O
)	O
in	O
this	O
population	O
with	O
genotypes	O
A	O
/	O
G	O
at	O
P6	O
,	O
G	O
/	O
G	O
at	O
P6	O
and	O
A	O
/	O
G	O
at	O
P12	O
decreasing	O
height	O
SDS	O
(	O
-	O
0	O
.	O
063	O
+/-	O
0	O
.	O
031	O
,	O
-	O
0	O
.	O
693	O
+/-	O
0	O
.	O
350	O
and	O
-	O
0	O
.	O
489	O
+/-	O
0	O
.	O
265	O
,	O
Mean	O
+/-	O
SE	O
)	O
and	O
genotypes	O
A	O
/	O
T	O
at	O
P17	O
and	O
T	O
/	O
G	O
at	O
P25	O
increasing	O
height	O
SDS	O
(	O
+	O
1	O
.	O
094	O
+/-	O
0	O
.	O
456	O
and	O
+	O
1	O
.	O
184	O
+/-	O
0	O
.	O
432	O
)	O
.	O

Conclusions	O

This	O
study	O
established	O
the	O
GH1	O
gene	O
sequence	O
variation	O
map	O
in	O
a	O
normal	O
adult	O
height	O
control	O
population	O
confirming	O
the	O
high	O
density	O
of	O
SNPs	O
in	O
a	O
relatively	O
small	O
gene	O
.	O

Our	O
study	O
shows	O
that	O
the	O
more	O
frequent	O
SNPs	O
did	O
not	O
significantly	O
contribute	O
to	O
height	O
determination	O
,	O
while	O
only	O
one	O
promoter	O
and	O
two	O
intronic	O
SNPs	O
contributed	O
significantly	O
to	O
it	O
.	O

Studies	O
in	O
larger	O
populations	O
will	O
have	O
to	O
confirm	O
the	O
associations	O
and	O
in	O
vitro	O
functional	O
studies	O
will	O
elucidate	O
the	O
mechanisms	O
involved	O
.	O

Systematic	O
GH1	O
gene	O
analysis	O
in	O
patients	S-Species
with	O
growth	O
delay	O
and	O
suspected	O
GH	O
deficiency	O
/	O
insufficiency	O
will	O
clarify	O
whether	O
different	O
SNP	O
frequencies	O
and	O
/	O
or	O
the	O
presence	O
of	O
different	O
sequence	O
changes	O
may	O
be	O
associated	O
with	O
phenotypes	O
in	O
them	O
.	O

Introduction	O

Human	S-Species
skeletal	O
growth	O
and	O
final	O
height	O
attainment	O
are	O
a	O
result	O
of	O
a	O
multifactorial	O
regulation	O
involving	O
systemic	O
and	O
local	O
hormones	O
,	O
growth	O
and	O
nutritional	O
factors	O
,	O
lifestyle	O
and	O
genetic	O
factors	O
.	O

Heritability	O
estimates1	O
and	O
genome	O
-	O
wide	O
linkage	O
analysis2	O
have	O
shown	O
that	O
genetic	O
factors	O
play	O
a	O
major	O
role	O
in	O
determining	O
stature	O
.	O

Among	O
these	O
factors	O
,	O
the	O
GH	O
-	O
IGF	O
-	O
I	O
axis	O
plays	O
an	O
important	O
role	O
during	O
postnatal	O
life	O
,	O
and	O
associations	O
between	O
structural	O
variations	O
in	O
its	O
genes	O
and	O
height	O
are	O
currently	O
under	O
study	O
.	O
3	O
Although	O
growth	O
hormone	O
(	O
GH	O
)	O
deficiency	O
is	O
a	O
well	O
-	O
known	O
cause	O
of	O
growth	O
retardation	O
,	O
which	O
responds	O
to	O
GH	O
replacement	O
therapy	O
,	O
the	O
diagnosis	O
and	O
physiopathological	O
mechanisms	O
for	O
the	O
so	O
-	O
called	O
'	O
idiopathic	O
isolated	O
GH	O
deficiency	O
'	O
(	O
IIGHD	O
)	O
require	O
further	O
clarification	O
.	O

In	O
addition	O
,	O
GH	O
secretion	O
levels	O
and	O
markers	O
of	O
GH	O
biological	O
activity	O
have	O
been	O
demonstrated	O
to	O
be	O
specific	O
and	O
sensitive	O
only	O
in	O
major	O
deficiency	O
states	O
.	O
4	O
,	O
5	O
Genetic	O
causes	O
of	O
GH	O
deficiency	O
within	O
the	O
GH1	O
gene	O
have	O
been	O
established	O
;	O
however	O
,	O
they	O
are	O
rarely	O
recognized	O
and	O
only	O
sought	O
in	O
major	O
GH	O
deficiency	O
states	O
during	O
childhood	O
and	O
in	O
family	O
studies	O
.	O
3	O
GH1	O
gene	O
,	O
located	O
at	O
17q22	O
-	O
24	O
,	O
is	O
a	O
component	O
of	O
the	O
GH	O
gene	O
cluster	O
in	O
which	O
five	O
genes	O
evolving	O
from	O
a	O
common	O
ancestor	O
are	O
91	O
-	O
99	O
%	O
sequence	O
conserved	O
(	O
paralogues	O
)	O
.	O
6	O
GH1	O
is	O
more	O
abundantly	O
expressed	O
in	O
pituitary	O
cells	O
,	O
while	O
the	O
other	O
four	O
genes	O
are	O
expressed	O
in	O
placental	O
tissue	O
.	O

Large	O
deletions	O
within	O
the	O
GH1	O
gene	O
cluster	O
were	O
described	O
first	O
followed	O
by	O
point	O
mutations	O
,	O
the	O
majority	O
of	O
which	O
affect	O
introns	O
3	O
or	O
4	O
,	O
provoke	O
skipping	O
of	O
exon	O
3	O
product	O
and	O
exert	O
a	O
dominant	O
effect	O
.	O
3	O
,	O
7	O
,	O
8	O
More	O
recently	O
,	O
the	O
presence	O
of	O
single	O
nucleotide	O
polymorphic	O
points	O
(	O
SNPs	O
)	O
in	O
the	O
promoter	O
region	O
or	O
in	O
intron	O
4	O
of	O
the	O
GH1	O
gene	O
have	O
been	O
described9	O
-	O
12	O
and	O
associations	O
with	O
promoter	O
allele	O
activities	O
or	O
with	O
GH	O
secretion	O
efficacy	O
and	O
circulating	O
IGF	O
-	O
I	O
levels	O
in	O
growth	O
-	O
retarded	O
patients	S-Species
have	O
also	O
been	O
described	O
.	O
11	O
,	O
12	O
Other	O
studies	O
have	O
analysed	O
several	O
GH1	O
gene	O
SNP	O
genotypes	O
as	O
related	O
to	O
the	O
incidence	O
of	O
neoplasia	O
,	O
with	O
a	O
positive	O
association	O
with	O
colorectal	O
neoplasia	O
for	O
intron	O
4	O
SNP	O
,	O
13	O
a	O
negative	O
result	O
for	O
breast	O
carcinoma14	O
,	O
15	O
or	O
a	O
positive	O
one	O
for	O
breast	O
cancer	O
risk	O
.	O
16	O
,	O
17	O
In	O
addition	O
,	O
a	O
recent	O
study	O
in	O
a	O
cohort	O
of	O
adults	O
over	O
ages	O
60	O
years	O
detected	O
a	O
significant	O
association	O
between	O
genotypes	O
at	O
one	O
SNP	O
in	O
the	O
GH1	O
gene	O
promoter	O
region	O
and	O
at	O
the	O
intron	O
4	O
SNP	O
described	O
by	O
Hasegawa	O
et	O
al	O
.	O
11	O
with	O
baseline	O
bone	O
density	O
and	O
accelerated	O
bone	O
loss	O
together	O
with	O
an	O
interaction	O
with	O
weight	O
at	O
1	O
year	O
.	O
18	O
Intron	O
4	O
SNP	O
described	O
by	O
Hasegawa	O
et	O
al	O
.	O
11	O
has	O
also	O
been	O
associated	O
,	O
in	O
women	S-Species
,	O
with	O
shorter	O
body	O
height	O
and	O
reduced	O
mortality	O
,	O
19	O
whereas	O
another	O
intron	O
4	O
SNP	O
(	O
T1169A	O
)	O
has	O
been	O
associated	O
in	O
both	O
sexes	O
with	O
a	O
favourable	O
metabolic	O
profile	O
.	O
20	O
A	O
systematic	O
SNP	O
study	O
was	O
conducted	O
by	O
Adkins	O
et	O
al	O
.	O
21	O
in	O
GH1	O
promoter	O
,	O
coding	O
and	O
noncoding	O
regions	O
in	O
DNAs	O
from	O
placental	O
tissues	O
,	O
and	O
analysis	O
of	O
associations	O
between	O
genotypes	O
and	O
birth	O
weight	O
revealed	O
an	O
association	O
between	O
an	O
alternate	O
nucleotide	O
at	O
-	O
1	O
and	O
+	O
3	O
of	O
translation	O
initiation	O
site	O
and	O
fetal	O
growth	O
restriction	O
.	O

However	O
,	O
no	O
systematic	O
GH1	O
gene	O
analysis	O
in	O
the	O
entire	O
promoter	O
,	O
coding	O
and	O
noncoding	O
regions	O
has	O
been	O
conducted	O
in	O
adults	O
to	O
establish	O
the	O
map	O
of	O
structural	O
variation	O
and	O
its	O
possible	O
association	O
with	O
height	O
.	O

The	O
relatively	O
short	O
size	O
of	O
the	O
entire	O
gene	O
permits	O
a	O
complete	O
analysis	O
which	O
is	O
,	O
nevertheless	O
,	O
hampered	O
by	O
the	O
need	O
to	O
avoid	O
amplification	O
of	O
any	O
other	O
of	O
the	O
GH	O
cluster	O
genes	O
(	O
paralogues	O
)	O
and	O
the	O
high	O
density	O
of	O
sequence	O
variations	O
.	O

To	O
obtain	O
normative	O
data	O
for	O
subsequent	O
analysis	O
of	O
GH1	O
gene	O
contribution	O
to	O
IIGHD	O
in	O
children	S-Species
,	O
a	O
systematic	O
GH1	O
gene	O
structural	O
analysis	O
was	O
designed	O
in	O
a	O
normal	O
adult	O
control	O
population	O
to	O
establish	O
the	O
GH1	O
gene	O
SNP	O
map	O
in	O
adults	O
from	O
our	O
population	O
with	O
heights	O
within	O
the	O
normal	O
range	O
,	O
determine	O
the	O
genotype	O
frequencies	O
and	O
analyse	O
possible	O
associations	O
between	O
individual	O
and	O
combined	O
SNPs	O
with	O
height	O
.	O

Subjects	O
and	O
methods	O

Subjects	O

A	O
total	O
of	O
307	O
adult	O
subjects	O
of	O
both	O
sexes	O
(	O
164	O
women	S-Species
and	O
143	O
men	S-Species
)	O
were	O
recruited	O
from	O
hospital	O
personnel	O
and	O
parents	O
of	O
patients	S-Species
with	O
no	O
history	O
of	O
growth	O
retardation	O
.	O

Subjects	O
had	O
to	O
fulfil	O
the	O
following	O
criteria	O
:	O
Iberian	O
Peninsular	O
(	O
except	O
Basque	O
)	O
family	O
origin	O
and	O
no	O
family	O
history	O
of	O
pathological	O
short	O
stature	O
.	O

A	O
single	O
subject	O
per	O
family	O
was	O
included	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
Hospital	O
Vall	O
d	O
'	O
Hebron	O
Ethics	O
Committee	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	S-Species
.	O

Height	O
standard	O
deviation	O
scores	O
(	O
height	O
SDS	O
)	O
were	O
calculated	O
according	O
to	O
sex	O
-	O
specific	O
reference	O
growth	O
charts	O
for	O
the	O
Spanish	O
population	O
(	O
Carrascosa	O
et	O
al	O
.	O
22	O
charts	O
were	O
used	O
for	O
subjects	O
under	O
ages	O
30	O
years	O
and	O
Hern	O
a	O
ndez	O
et	O
al	O
.	O
23	O
for	O
subjects	O
aged	O
30	O
-	O
50	O
years	O
)	O
.	O

Only	O
individuals	O
with	O
height	O
SDS	O
between	O
-	O
2	O
and	O
+	O
2	O
SDS	O
were	O
included	O
in	O
the	O
study	O
(	O
mean	O
-	O
0	O
.	O
016	O
;	O
32	O
women	S-Species
and	O
28	O
men	S-Species
between	O
-	O
2	O
.	O
000	O
and	O
-	O
1	O
.	O
010	O
;	O
99	O
women	S-Species
and	O
80	O
men	S-Species
between	O
-	O
1	O
.	O
000	O
and	O
+	O
0	O
.	O
910	O
;	O
33	O
women	S-Species
and	O
35	O
men	S-Species
between	O
+	O
1	O
.	O
010	O
and	O
+	O
1	O
.	O
980	O
)	O
and	O
sample	O
size	O
was	O
adjusted	O
for	O
normal	O
sex	O
and	O
height	O
SDS	O
distribution	O
.	O

Height	O
and	O
weight	O
were	O
recorded	O
in	O
the	O
morning	O
by	O
a	O
single	O
observer	O
.	O

Height	O
was	O
measured	O
with	O
a	O
Harpenden	O
stadiometer	O
.	O

Four	O
millilitres	O
of	O
peripheral	O
venous	O
blood	O
were	O
drawn	O
into	O
EDTA	O
-	O
containing	O
tubes	O
for	O
molecular	O
genetic	O
analysis	O
.	O

Genomic	O
DNA	O
study	O

Genomic	O
DNA	O
was	O
obtained	O
from	O
peripheral	O
blood	O
following	O
the	O
method	O
described	O
by	O
Lahiri	O
and	O
Nurnberger	O
.	O
24	O
DNA	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
a	O
nested	O
strategy	O
.	O

Briefly	O
,	O
50	O
ng	O
of	O
genomic	O
DNA	O
were	O
added	O
to	O
a	O
10	O
micro	O
l	O
reaction	O
mixture	O
of	O
1	O
mm	O
Mg	O
(	O
OAc	O
)	O
2	O
,	O
0	O
.	O
6	O
mm	O
dNTPs	O
,	O
0	O
.	O
3	O
micro	O
m	O
of	O
each	O
primer	O
,	O
and	O
0	O
.	O
4	O
U	O
r	O
Tth	O
DNA	O
polymerase	O
XL	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
sense	O
and	O
antisense	O
primers	O
used	O
corresponded	O
to	O
nucleotides	O
4156	O
-	O
5	O
'	O
ACGGTCCGCCACTACGCCCAGC	O
-	O
3	O
'	O
and	O
the	O
complement	O
of	O
6948	O
-	O
5	O
'	O
TGCAGTGAGCCAAGATTGTGCC	O
-	O
3	O
'	O
of	O
the	O
GH	O
gene	O
cluster	O
.	O
6	O
The	O
PCR	O
reaction	O
mix	O
was	O
denatured	O
for	O
5	O
min	O
at	O
94	O
degrees	O
C	O
and	O
cycled	O
40	O
times	O
(	O
94	O
degrees	O
C	O
,	O
1	O
min	O
;	O
72	O
degrees	O
C	O
,	O
3	O
min	O
30	O
s	O
)	O
followed	O
by	O
a	O
7	O
-	O
min	O
extension	O
at	O
72	O
degrees	O
C	O
.	O

The	O
resulting	O
GH1	O
PCR	O
products	O
(	O
2893	O
bp	O
)	O
were	O
used	O
as	O
templates	O
for	O
five	O
nested	O
reactions	O
(	O
AN	O
,	O
BL	O
,	O
CK	O
,	O
DI	O
,	O
FP	O
)	O
,	O
carried	O
out	O
as	O
follows	O
:	O
1	O
micro	O
l	O
of	O
each	O
GH1	O
PCR	O
product	O
was	O
added	O
to	O
a	O
20	O
micro	O
l	O
reaction	O
mixture	O
of	O
1	O
.	O
5	O
mm	O
MgCl2	O
,	O
0	O
.	O
2	O
mm	O
dNTPs	O
,	O
0	O
.	O
3	O
micro	O
m	O
of	O
each	O
primer	O
and	O
0	O
.	O
4	O
U	O
Eco	O
Taq	O
DNA	O
polymerase	O
(	O
Ecogen	O
S	O
.	O
R	O
.	O
L	O
.	O
,	O
Barcelona	O
,	O
Spain	O
)	O
.	O

Reaction	O
mixtures	O
were	O
denatured	O
for	O
5	O
min	O
at	O
94	O
degrees	O
C	O
,	O
cycled	O
40	O
times	O
(	O
94	O
degrees	O
C	O
,	O
1	O
min	O
;	O
58	O
degrees	O
C	O
,	O
1	O
min	O
;	O
and	O
72	O
degrees	O
C	O
,	O
1	O
min	O
)	O
,	O
followed	O
by	O
a	O
7	O
-	O
min	O
extension	O
at	O
72	O
degrees	O
C	O
.	O

Sense	O
and	O
antisense	O
primers	O
were	O
as	O
follows	O
:	O

Sequencing	O
from	O
both	O
ends	O
was	O
performed	O
by	O
the	O
dideoxy	O
method	O
using	O
ABI	O
PRISM	O
BigDye	O
Terminator	O
version	O
3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

GH1	O
gene	O
nucleotide	O
sequence	O
published	O
by	O
Chen	O
et	O
al	O
.	O
6	O
was	O
used	O
as	O
control	O
.	O

For	O
each	O
DNA	O
,	O
the	O
five	O
segments	O
from	O
the	O
nested	O
PCR	O
were	O
assembled	O
with	O
the	O
SeqEscape	O
programme	O
(	O
Applied	O
Biosystems	O
)	O
and	O
interpretation	O
was	O
made	O
visually	O
and	O
simultaneously	O
by	O
two	O
observers	O
.	O

Antisense	O
sequencing	O
was	O
performed	O
to	O
confirm	O
each	O
nucleotide	O
sequence	O
change	O
up	O
to	O
the	O
establishment	O
of	O
the	O
more	O
frequent	O
SNP	O
map	O
(	O
frequency	O
over	O
1	O
%	O
)	O
,	O
whereas	O
less	O
frequent	O
single	O
or	O
multiple	O
nucleotide	O
changes	O
were	O
reconfirmed	O
in	O
each	O
DNA	O
by	O
antisense	O
sequence	O
and	O
resequencing	O
after	O
a	O
new	O
nested	O
PCR	O
from	O
original	O
DNA	O
was	O
performed	O
.	O

Single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
genotyping	O

The	O
sequences	O
for	O
the	O
five	O
genes	O
of	O
the	O
GH	O
cluster	O
identified	O
by	O
Chen	O
et	O
al	O
.	O
6	O
and	O
reported	O
as	O
the	O
GI	O
sequence	O
183148	O
were	O
aligned	O
using	O
the	O
Multalin	O
program	O
.	O
25	O
SNPs	O
and	O
other	O
sequence	O
changes	O
identified	O
were	O
indicated	O
using	O
their	O
position	O
corresponding	O
to	O
GH1	O
.	O

Genotypes	O
were	O
deduced	O
by	O
the	O
combination	O
of	O
genetic	O
variation	O
at	O
the	O
polymorphic	O
positions	O
.	O

Statistical	O
analysis	O

Standardized	O
height	O
was	O
investigated	O
for	O
normal	O
distribution	O
(	O
Kolmogorov	O
-	O
Smirnov	O
test	O
:	O
c2	O
=	O
2	O
.	O
882	O
,	O
P	O
=	O
0	O
.	O
4733	O
)	O
.	O

Hardy	O
-	O
Weinberg	O
equilibrium	O
was	O
tested	O
for	O
SNPs	O
presenting	O
three	O
alternate	O
genotypes	O
according	O
to	O
standard	O
procedures	O
using	O
chi	O
2	O
-	O
analysis	O
.	O
anova	O
test	O
was	O
applied	O
to	O
investigate	O
individual	O
and	O
combined	O
SNP	O
association	O
with	O
adult	O
height	O
SDS	O
;	O
significance	O
assessment	O
was	O
adjusted	O
for	O
multiple	O
testing	O
using	O
Fisher	O
'	O
s	O
PLSD	O
test	O
setting	O
Pcritical	O
=	O
0	O
.	O
05	O
or	O
the	O
Bonferroni	O
-	O
Dunn	O
test	O
setting	O
Pcritical	O
=	O
0	O
.	O
05	O
/	O
n	O
(	O
n	O
=	O
number	O
of	O
comparisons	O
carried	O
out	O
)	O
.	O

Stepwise	O
regression	O
analysis	O
was	O
applied	O
to	O
predict	O
the	O
contribution	O
of	O
SNPs	O
to	O
adult	O
height	O
SDS	O
.	O

Statview	O
4	O
.	O
5	O
program	O
(	O
Abacus	O
Concepts	O
Inc	O
.	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
for	O
statistical	O
analyses	O
.	O

Results	O

GH1	O
gene	O
sequence	O
variation	O

GH1	O
gene	O
sequence	O
comparison	O
with	O
the	O
GI	O
-	O
183148	O
sequence	O
published	O
by	O
Chen	O
et	O
al	O
.	O
6	O
yielded	O
a	O
total	O
of	O
54	O
single	O
or	O
multiple	O
nucleotide	O
changes	O
.	O

Twenty	O
-	O
five	O
SNPs	O
presented	O
a	O
frequency	O
over	O
1	O
%	O
(	O
genotypes	O
and	O
frequencies	O
are	O
listed	O
in	O
Table	O
1	O
)	O
.	O

SNPs	O
which	O
presented	O
the	O
three	O
alternate	O
genotypes	O
(	O
P2	O
to	O
P4	O
,	O
P6	O
,	O
P7	O
,	O
P10	O
and	O
P24	O
)	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
(	O
data	O
not	O
shown	O
)	O
.	O

Twenty	O
-	O
nine	O
additional	O
changes	O
were	O
found	O
with	O
a	O
frequency	O
under	O
1	O
%	O
or	O
involving	O
more	O
than	O
one	O
nucleotide	O
and	O
thus	O
could	O
be	O
considered	O
as	O
rare	O
variant	O
SNPs	O
(	O
R1	O
to	O
R29	O
)	O
(	O
Table	O
2	O
)	O
.	O

These	O
changes	O
were	O
found	O
in	O
29	O
of	O
307	O
subjects	O
(	O
9	O
.	O
4	O
%	O
)	O
,	O
all	O
in	O
heterozygosity	O
.	O

GH1	O
-	O
paralogue	O
alignment	O

A	O
sequence	O
alignment	O
was	O
performed	O
to	O
study	O
possible	O
sequence	O
recombinations	O
among	O
paralogues	O
of	O
the	O
five	O
GH1	O
-	O
gene	O
cluster	O
(	O
Fig	O
.	O
1	O
)	O
.	O

This	O
alignment	O
showed	O
that	O
9	O
of	O
25	O
SNPs	O
(	O
36	O
%	O
)	O
in	O
the	O
GH1	O
gene	O
did	O
not	O
correspond	O
to	O
any	O
of	O
the	O
paralogues	O
.	O

Among	O
the	O
29	O
rare	O
SNPs	O
found	O
,	O
six	O
(	O
20	O
.	O
7	O
%	O
)	O
did	O
not	O
correspond	O
to	O
any	O
of	O
the	O
paralogues	O
:	O
two	O
were	O
located	O
in	O
the	O
5	O
'	O
UTR	O
region	O
(	O
R9	O
and	O
R10	O
)	O
,	O
two	O
in	O
intron	O
1	O
(	O
positions	O
5300	O
=	O
R14	O
and	O
5302	O
=	O
R17	O
)	O
,	O
one	O
in	O
intron	O
2	O
(	O
position	O
5679	O
=	O
R21	O
)	O
and	O
one	O
in	O
intron	O
4	O
(	O
position	O
6344	O
=	O
R23	O
)	O
(	O
Table	O
2	O
)	O
.	O

Equivalence	O
with	O
previously	O
reported	O
GH1	O
changes	O

Equivalence	O
with	O
changes	O
and	O
SNPs	O
previously	O
reported	O
by	O
other	O
authors	O
are	O
shown	O
in	O
Table	O
3	O
.	O

The	O
majority	O
found	O
a	O
high	O
density	O
of	O
SNPs	O
in	O
the	O
promoter	O
and	O
5	O
'	O
UTR	O
regions	O
in	O
control	O
populations	O
.	O
10	O
,	O
12	O
,	O
21	O
Several	O
sequence	O
changes	O
have	O
been	O
reported	O
in	O
patients	S-Species
with	O
familial	O
or	O
idiopathic	O
short	O
stature	O
,	O
11	O
,	O
26	O
,	O
27	O
whereas	O
P8	O
,	O
P19	O
,	O
P20	O
and	O
P25	O
(	O
at	O
positions	O
5165	O
,	O
5681	O
,	O
5686	O
and	O
6358	O
,	O
respectively	O
,	O
in	O
the	O
Genebank	O
accession	O
GI	O
183148	O
)	O
located	O
in	O
the	O
promoter	O
,	O
intron	O
2	O
and	O
intron	O
4	O
regions	O
,	O
respectively	O
,	O
had	O
not	O
been	O
previously	O
described	O
.	O

GH1	O
genotypes	O
and	O
associations	O
with	O
height	O
SDS	O

Associations	O
between	O
genotypes	O
and	O
standardized	O
height	O
were	O
first	O
studied	O
in	O
the	O
subpopulation	O
of	O
278	O
controls	O
carrying	O
only	O
the	O
25	O
most	O
frequent	O
SNPs	O
in	O
the	O
GH1	O
gene	O
(	O
c2	O
=	O
2	O
.	O
59	O
;	O
P	O
=	O
0	O
.	O
5458	O
for	O
normality	O
of	O
height	O
distribution	O
)	O
.	O

Three	O
individual	O
SNPs	O
showed	O
a	O
statistically	O
significant	O
association	O
with	O
height	O
SDS	O
:	O
at	O
positions	O
5286	O
(	O
P16	O
)	O
,	O
5290	O
(	O
P17	O
)	O
and	O
6358	O
(	O
P25	O
)	O
.	O

Subjects	O
with	O
heterozygous	O
genotypes	O
presented	O
statistically	O
significant	O
taller	O
stature	O
than	O
the	O
corresponding	O
homozygous	O
genotypes	O
(	O
P	O
=	O
0	O
.	O
016	O
for	O
P16	O
,	O
P	O
=	O
0	O
.	O
015	O
for	O
P17	O
and	O
P	O
=	O
0	O
.	O
023	O
for	O
P25	O
)	O
(	O
Fig	O
.	O
2a	O
,	O
b	O
,	O
c	O
)	O
.	O

P16	O
and	O
P17	O
were	O
in	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
(	O
r2	O
=	O
0	O
.	O
831	O
)	O
,	O
while	O
P25	O
was	O
carried	O
by	O
six	O
subjects	O
homozygous	O
at	O
P16	O
and	O
P17	O
.	O

GH1	O
gene	O
genotypes	O
were	O
defined	O
by	O
genetic	O
variation	O
in	O
the	O
25	O
polymorphic	O
positions	O
.	O

We	O
found	O
163	O
different	O
combinations	O
.	O

Only	O
two	O
genotypes	O
presented	O
a	O
frequency	O
over	O
5	O
%	O
(	O
Table	O
4	O
)	O
.	O

Height	O
SDS	O
in	O
the	O
two	O
more	O
frequent	O
genotypes	O
did	O
not	O
differ	O
significantly	O
and	O
covered	O
the	O
whole	O
height	O
range	O
.	O

Genotype	O
1	O
presented	O
four	O
heterozygous	O
variations	O
and	O
Genotype	O
2	O
was	O
the	O
corresponding	O
homozygous	O
genotype	O
.	O

Heterozygous	O
positions	O
corresponded	O
to	O
SNPs	O
with	O
the	O
highest	O
frequency	O
variation	O
(	O
4886	O
(	O
P4	O
)	O
,	O
5107	O
(	O
P7	O
)	O
,	O
5157	O
(	O
P10	O
)	O
and	O
6331	O
(	O
P24	O
)	O
)	O
.	O

In	O
addition	O
,	O
DNAs	O
exhibited	O
a	O
different	O
genotype	O
in	O
each	O
of	O
129	O
subjects	O
(	O
46	O
.	O
4	O
%	O
)	O
.	O

The	O
11	O
SNPs	O
found	O
in	O
the	O
promoter	O
region	O
(	O
Table	O
1	O
)	O
were	O
grouped	O
in	O
94	O
genotypes	O
and	O
analysed	O
for	O
association	O
with	O
adult	O
height	O
SDS	O
.	O

The	O
four	O
more	O
frequent	O
combinations	O
are	O
listed	O
in	O
Table	O
4	O
:	O
height	O
SDS	O
of	O
these	O
four	O
genotypes	O
did	O
not	O
differ	O
statistically	O
although	O
Genotype	O
3	O
tended	O
to	O
have	O
a	O
shorter	O
height	O
.	O

Genotype	O
3	O
differed	O
from	O
Genotype	O
1	O
in	O
the	O
SNP	O
located	O
at	O
position	O
5089	O
(	O
P6	O
)	O
,	O
corresponding	O
to	O
Pit	O
1	O
proximal	O
responsive	O
element	O
for	O
GH1	O
gene	O
promoter	O
.	O

Genotype	O
4	O
is	O
heterozygous	O
at	O
positions	O
4856	O
(	O
P2	O
)	O
,	O
4863	O
(	O
P3	O
)	O
and	O
5107	O
(	O
P7	O
)	O
.	O

In	O
addition	O
,	O
19	O
%	O
of	O
cases	O
exhibited	O
a	O
genotype	O
in	O
the	O
promoter	O
region	O
carried	O
by	O
only	O
one	O
subject	O
.	O

Combination	O
of	O
the	O
three	O
SNPs	O
in	O
the	O
5	O
'	O
UTR	O
region	O
of	O
GH1	O
gene	O
resulted	O
in	O
five	O
different	O
genotypes	O
.	O

SNPs	O
at	O
positions	O
5178	O
(	O
P12	O
)	O
and	O
5187	O
(	O
P13	O
)	O
were	O
in	O
LD	O
(	O
r2	O
=	O
0	O
.	O
88	O
)	O
.	O

Mean	O
height	O
SDS	O
comparison	O
among	O
these	O
genotypes	O
was	O
not	O
statistically	O
significant	O
,	O
although	O
mean	O
height	O
SDS	O
of	O
alternate	O
nucleotide	O
carriers	O
at	O
position	O
5178	O
(	O
P12	O
)	O
tended	O
to	O
be	O
shorter	O
(	O
Table	O
4	O
)	O
.	O

An	O
anova	O
analysis	O
was	O
conducted	O
to	O
investigate	O
the	O
interaction	O
between	O
two	O
or	O
more	O
SNPs	O
and	O
height	O
SDS	O
.	O

SNPs	O
at	O
positions	O
5286	O
(	O
P16	O
)	O
and	O
5290	O
(	O
P17	O
)	O
were	O
in	O
LD	O
(	O
r2	O
=	O
0	O
.	O
83	O
)	O
:	O
the	O
heterozygous	O
genotype	O
AG	O
/	O
AT	O
for	O
these	O
SNPs	O
was	O
associated	O
with	O
taller	O
stature	O
(	O
shown	O
above	O
)	O
.	O

SNP	O
at	O
position	O
6358	O
(	O
P25	O
)	O
increased	O
the	O
expected	O
height	O
SDS	O
for	O
individual	O
carriers	O
of	O
the	O
G	O
allele	O
at	O
5089	O
(	O
P6	O
)	O
SNP	O
as	O
shown	O
in	O
Fig	O
.	O

2	O
(	O
d	O
)	O
:	O
subjects	O
heterozygous	O
at	O
6358	O
(	O
P25	O
)	O
were	O
taller	O
than	O
the	O
mean	O
,	O
and	O
mean	O
height	O
SDS	O
of	O
subjects	O
with	O
GG	O
/	O
TG	O
combined	O
genotype	O
was	O
significantly	O
higher	O
than	O
the	O
corresponding	O
GG	O
/	O
TT	O
genotype	O
(	O
P	O
=	O
0	O
.	O
0021	O
)	O
,	O
suggesting	O
an	O
interaction	O
between	O
these	O
two	O
SNPs	O
as	O
they	O
were	O
not	O
in	O
LD	O
.	O

Analysis	O
of	O
height	O
SDS	O
association	O
with	O
the	O
most	O
frequent	O
single	O
and	O
combined	O
SNPs	O
and	O
with	O
rare	O
variant	O
SNPs	O
was	O
performed	O
in	O
the	O
29	O
individuals	O
carrying	O
the	O
rare	O
SNPs	O
(	O
Table	O
2	O
)	O
.	O

None	O
of	O
them	O
carried	O
any	O
of	O
the	O
three	O
SNPs	O
(	O
P16	O
,	O
P17	O
and	O
P25	O
)	O
related	O
to	O
taller	O
stature	O
in	O
the	O
population	O
of	O
278	O
controls	O
with	O
only	O
the	O
frequent	O
SNPs	O
.	O

In	O
these	O
29	O
,	O
mean	O
height	O
SDS	O
(	O
0	O
.	O
000	O
+/-	O
0	O
.	O
987	O
,	O
from	O
-	O
1	O
.	O
930	O
to	O
+	O
1	O
.	O
870	O
)	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
278	O
controls	O
(	O
-	O
0	O
.	O
018	O
+/-	O
1	O
.	O
041	O
,	O
from	O
-	O
2	O
.	O
000	O
to	O
+	O
1	O
.	O
980	O
)	O
.	O

Analysis	O
of	O
associations	O
between	O
individual	O
SNP	O
genotypes	O
and	O
height	O
SDS	O
revealed	O
that	O
SNPs	O
at	O
positions	O
5089	O
(	O
P6	O
)	O
,	O
5178	O
(	O
P12	O
)	O
and	O
5187	O
(	O
P13	O
)	O
were	O
associated	O
with	O
significantly	O
shorter	O
stature	O
(	O
Fig	O
.	O
2e	O
)	O
.	O

Only	O
two	O
sequence	O
changes	O
considered	O
as	O
rare	O
SNPs	O
were	O
carried	O
by	O
individuals	O
in	O
the	O
lower	O
normal	O
height	O
range	O
(	O
between	O
-	O
1	O
.	O
500	O
and	O
-	O
2	O
.	O
000	O
SDS	O
)	O
(	O
Table	O
2	O
)	O
:	O
R4	O
(	O
4979	O
C	O
>	O
T	O
)	O
in	O
the	O
promoter	O
region	O
and	O
R14	O
(	O
5300	O
C	O
>	O
T	O
)	O
in	O
intron	O
1	O
.	O

Predicted	O
single	O
amino	O
acid	O
changes	O
located	O
in	O
exon	O
5	O
(	O
R25	O
to	O
R27	O
)	O
were	O
not	O
associated	O
with	O
short	O
stature	O
.	O

In	O
the	O
entire	O
population	O
of	O
307	O
controls	O
,	O
stepwise	O
regression	O
analysis	O
between	O
height	O
SDS	O
and	O
genotypes	O
at	O
the	O
25	O
SNPs	O
showed	O
that	O
genotypes	O
at	O
5089	O
(	O
P6	O
)	O
,	O
5178	O
(	O
P12	O
)	O
,	O
5290	O
(	O
P17	O
)	O
and	O
6358	O
(	O
P25	O
)	O
were	O
significantly	O
correlated	O
with	O
height	O
SDS	O
(	O
r2	O
=	O
0	O
.	O
062	O
,	O
P	O
=	O
0	O
.	O
0007	O
)	O
with	O
genotypes	O
A	O
/	O
G	O
at	O
P6	O
,	O
G	O
/	O
G	O
at	O
P6	O
and	O
A	O
/	O
G	O
at	O
P12	O
decreasing	O
height	O
SDS	O
(	O
-	O
0	O
.	O
063	O
+/-	O
0	O
.	O
031	O
,	O
-	O
0	O
.	O
693	O
+/-	O
0	O
.	O
350	O
and	O
-	O
0	O
.	O
489	O
+/-	O
0	O
.	O
265	O
,	O
respectively	O
,	O
Mean	O
+/-	O
SE	O
)	O
and	O
genotypes	O
A	O
/	O
T	O
at	O
P17	O
and	O
T	O
/	O
G	O
at	O
P25	O
increasing	O
height	O
SDS	O
(	O
+	O
1	O
.	O
094	O
+/-	O
0	O
.	O
456	O
and	O
+	O
1	O
.	O
184	O
+/-	O
0	O
.	O
432	O
,	O
respectively	O
)	O
.	O

Discussion	O

Genetic	O
variations	O
within	O
human	S-Species
GH1	O
gene	O
have	O
been	O
described	O
by	O
several	O
authors	O
.	O
9	O
-	O
12	O
,	O
21	O
The	O
populations	O
described	O
to	O
date	O
comprised	O
small	O
numbers	O
of	O
normal	O
-	O
stature	O
individuals	O
,	O
9	O
male	O
adults	O
with	O
narrow	O
height	O
range12	O
or	O
growth	O
-	O
retarded	O
patients	S-Species
with	O
/	O
without	O
GHD	O
before	O
achievement	O
of	O
adult	O
height	O
.	O
9	O
,	O
11	O
,	O
12	O
Our	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
GH1	O
gene	O
sequence	O
variation	O
in	O
individuals	O
within	O
the	O
whole	O
range	O
of	O
normal	O
adult	O
height	O
(	O
between	O
-	O
2	O
and	O
+	O
2	O
SDS	O
)	O
according	O
to	O
the	O
standards	O
for	O
our	O
population	O
.	O

Height	O
was	O
normally	O
distributed	O
,	O
both	O
sexes	O
were	O
equally	O
represented	O
and	O
the	O
GI	O
-	O
183148	O
homozygous	O
sequence6	O
was	O
used	O
for	O
comparison	O
.	O

A	O
nested	O
PCR	O
with	O
specific	O
primers	O
for	O
GH1	O
gene	O
was	O
designed	O
,	O
thus	O
avoiding	O
amplification	O
of	O
any	O
other	O
GH	O
gene	O
paralogue	O
of	O
the	O
GH	O
gene	O
cluster	O
.	O

Our	O
results	O
establish	O
a	O
map	O
of	O
25	O
SNPs	O
as	O
present	O
in	O
over	O
1	O
%	O
of	O
individuals	O
,	O
whereas	O
29	O
other	O
sequence	O
changes	O
(	O
single	O
or	O
multiple	O
nucleotide	O
)	O
are	O
present	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
.	O

More	O
than	O
50	O
%	O
(	O
n	O
=	O
14	O
)	O
of	O
SNPs	O
are	O
located	O
in	O
the	O
promoter	O
and	O
5	O
'	O
UTR	O
regions	O
,	O
thus	O
confirming	O
previous	O
reports	O
:	O
Giordano	O
et	O
al	O
.	O
9	O
reported	O
eight	O
SNPs	O
in	O
the	O
promoter	O
and	O
5	O
'	O
UTR	O
regions	O
,	O
Wagner	O
et	O
al	O
.	O
10	O
16	O
SNPs	O
from	O
the	O
promoter	O
to	O
intron	O
1	O
and	O
Horan	O
et	O
al	O
.	O
12	O
identified	O
36	O
haplotypes	O
in	O
control	O
subjects	O
of	O
the	O
British	O
population	O
,	O
which	O
would	O
result	O
from	O
the	O
combination	O
of	O
15	O
of	O
the	O
previously	O
reported	O
SNPs	O
.	O

Our	O
results	O
confirm	O
the	O
presence	O
of	O
13	O
of	O
those	O
points	O
;	O
SNP	O
at	O
5165	O
(	O
R11	O
in	O
the	O
present	O
study	O
and	O
+	O
3	O
in	O
references9	O
,	O
12	O
)	O
was	O
present	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
and	O
a	O
new	O
SNP	O
is	O
described	O
(	O
P8	O
at	O
5116	O
in	O
the	O
VDR	O
/	O
RA	O
/	O
T3	O
responsive	O
element	O
sequence	O
)	O
.	O

The	O
remaining	O
SNPs	O
(	O
from	O
P15	O
to	O
P25	O
,	O
n	O
=	O
11	O
)	O
are	O
distributed	O
in	O
introns	O
1	O
,	O
2	O
and	O
4	O
,	O
and	O
among	O
coding	O
regions	O
only	O
exon	O
1	O
and	O
exon	O
4	O
bear	O
a	O
total	O
of	O
three	O
SNPs	O
,	O
two	O
of	O
which	O
predict	O
an	O
amino	O
acid	O
change	O
(	O
P15	O
and	O
P21	O
)	O
.	O

These	O
two	O
latter	O
SNPs	O
had	O
been	O
described	O
by	O
Millar	O
et	O
al	O
.	O
26	O
and	O
the	O
more	O
frequent	O
SNP	O
in	O
intron	O
4	O
(	O
P24	O
)	O
has	O
been	O
described	O
by	O
Hasegawa	O
et	O
al	O
.	O
11	O
together	O
with	O
the	O
two	O
more	O
frequent	O
SNPs	O
in	O
the	O
promoter	O
region	O
(	O
P4	O
and	O
P7	O
in	O
our	O
map	O
)	O
.	O

Three	O
new	O
SNPs	O
are	O
described	O
(	O
P19	O
and	O
P20	O
in	O
intron	O
2	O
and	O
P25	O
in	O
intron	O
4	O
)	O
,	O
all	O
outside	O
the	O
splice	O
sites	O
.	O

Only	O
SNPs	O
presenting	O
high	O
frequency	O
are	O
present	O
in	O
homozygous	O
alternate	O
state	O
and	O
this	O
accounts	O
mostly	O
for	O
the	O
majority	O
of	O
the	O
promoter	O
and	O
5	O
'	O
UTR	O
SNPs	O
and	O
in	O
the	O
intron	O
4	O
more	O
frequent	O
SNP	O
(	O
P24	O
)	O
described	O
by	O
Hasegawa	O
et	O
al	O
.	O
11	O
In	O
conclusion	O
,	O
in	O
the	O
entire	O
coding	O
and	O
noncoding	O
GH1	O
gene	O
sequence	O
,	O
only	O
P24	O
is	O
present	O
in	O
homozygous	O
alternate	O
state	O
.	O

Our	O
results	O
show	O
that	O
the	O
GI	O
183148	O
homozygous	O
sequence	O
is	O
present	O
in	O
our	O
population	O
except	O
for	O
SNP	O
P14	O
in	O
the	O
5	O
'	O
UTR	O
region	O
which	O
is	O
only	O
present	O
as	O
the	O
alternate	O
nucleotide	O
in	O
homozygous	O
or	O
heterozygous	O
states	O
.	O

As	O
described	O
by	O
several	O
authors9	O
,	O
10	O
,	O
12	O
,	O
21	O
several	O
promoter	O
SNPs	O
affected	O
functional	O
sequences	O
and	O
P6	O
is	O
located	O
in	O
the	O
Pit	O
1	O
proximal	O
responsive	O
element	O
,	O
P7	O
and	O
P8	O
in	O
the	O
VDR	O
/	O
RA	O
/	O
T3	O
responsive	O
element	O
and	O
P9	O
(	O
G	O
del	O
)	O
in	O
the	O
TATA	O
box	O
.	O

The	O
mechanisms	O
by	O
which	O
the	O
high	O
density	O
of	O
SNPs	O
in	O
the	O
GH1	O
gene	O
is	O
generated	O
has	O
been	O
proposed	O
to	O
be	O
recombination	O
and	O
gene	O
conversion	O
with	O
any	O
other	O
(	O
s	O
)	O
of	O
the	O
GH	O
cluster	O
genes	O
.	O
9	O
,	O
12	O
,	O
28	O
Alignment	O
of	O
the	O
25	O
SNPs	O
with	O
the	O
other	O
GH1	O
gene	O
paralogues	O
demonstrated	O
in	O
our	O
results	O
that	O
this	O
mechanism	O
is	O
possible	O
for	O
64	O
%	O
of	O
SNPs	O
.	O

Familial	O
SNP	O
transmission	O
pattern	O
analysis	O
will	O
be	O
of	O
interest	O
to	O
support	O
the	O
hypothesis	O
of	O
GH	O
gene	O
recombination	O
.	O

In	O
addition	O
,	O
29	O
of	O
307	O
individuals	O
(	O
9	O
.	O
4	O
%	O
)	O
bore	O
additional	O
GH1	O
sequence	O
changes	O
with	O
frequencies	O
under	O
1	O
%	O
.	O

As	O
for	O
SNPs	O
,	O
they	O
are	O
located	O
along	O
the	O
whole	O
gene	O
with	O
higher	O
density	O
in	O
the	O
promoter	O
and	O
5	O
'	O
UTR	O
regions	O
.	O

Interestingly	O
,	O
intron	O
3	O
and	O
exon	O
5	O
present	O
several	O
of	O
these	O
less	O
frequent	O
changes	O
.	O

Intron	O
3	O
has	O
been	O
shown	O
to	O
carry	O
the	O
majority	O
of	O
single	O
nucleotide	O
mutations	O
causing	O
the	O
dominant	O
form	O
of	O
GH	O
deficiency	O
.	O
3	O
The	O
two	O
single	O
nucleotide	O
changes	O
detected	O
in	O
intron	O
3	O
(	O
R15	O
at	O
6056	O
and	O
R16	O
at	O
6061	O
)	O
are	O
in	O
perfect	O
LD	O
(	O
r2	O
=	O
1	O
.	O
0	O
)	O
and	O
located	O
within	O
the	O
enhancer	O
splice	O
site	O
element	O
(	O
ESE	O
)	O
described	O
by	O
Ryther	O
et	O
al	O
.	O
29	O
,	O
30	O
Studies	O
in	O
additional	O
normal	O
or	O
growth	O
-	O
retarded	O
populations	O
will	O
permit	O
description	O
of	O
their	O
possible	O
clinical	O
implications	O
.	O

Five	O
single	O
nucleotide	O
changes	O
are	O
located	O
in	O
exon	O
5	O
;	O
of	O
these	O
five	O
,	O
three	O
predict	O
an	O
amino	O
acid	O
change	O
,	O
and	O
one	O
of	O
the	O
three	O
(	O
Ile179Met	O
)	O
has	O
been	O
described	O
by	O
Lewis	O
et	O
al	O
.	O
27	O
in	O
a	O
paediatric	O
patient	S-Species
with	O
familial	O
short	O
stature	O
and	O
the	O
other	O
two	O
,	O
as	O
yet	O
undescribed	O
,	O
are	O
contiguous	O
in	O
a	O
single	O
individual	O
(	O
Pro133Hys	O
and	O
Arg134Leu	O
)	O
.	O

Polynucleotide	O
changes	O
are	O
mostly	O
located	O
in	O
the	O
promoter	O
region	O
corresponding	O
to	O
the	O
VDR	O
/	O
RA	O
/	O
T3	O
response	O
element	O
.	O

As	O
for	O
frequent	O
SNPs	O
,	O
the	O
majority	O
of	O
the	O
sequence	O
changes	O
with	O
frequencies	O
under	O
1	O
%	O
may	O
have	O
been	O
generated	O
by	O
recombination	O
within	O
the	O
GH	O
gene	O
cluster	O
as	O
19	O
of	O
24	O
(	O
79	O
%	O
)	O
may	O
correspond	O
to	O
one	O
or	O
more	O
of	O
the	O
GH1	O
gene	O
paralogues	O
.	O

Our	O
results	O
now	O
show	O
the	O
diversity	O
and	O
complexity	O
of	O
SNP	O
genotypes	O
,	O
as	O
previously	O
highlighted	O
by	O
other	O
authors9	O
,	O
10	O
,	O
12	O
,	O
21	O
in	O
a	O
normal	O
adult	O
height	O
control	O
population	O
.	O

Our	O
initial	O
aim	O
when	O
designing	O
the	O
present	O
study	O
was	O
to	O
establish	O
the	O
map	O
of	O
GH1	O
gene	O
SNPs	O
in	O
our	O
adult	O
control	O
population	O
with	O
heights	O
normally	O
distributed	O
within	O
the	O
entire	O
normal	O
range	O
for	O
further	O
comparison	O
with	O
genotypes	O
in	O
our	O
paediatric	O
population	O
with	O
growth	O
delay	O
,	O
variable	O
response	O
to	O
GH	O
secretion	O
tests	O
and	O
adequate	O
response	O
to	O
GH	O
therapy	O
.	O

Analysis	O
of	O
SNP	O
association	O
with	O
adult	O
height	O
was	O
subsequently	O
performed	O
to	O
establish	O
a	O
body	O
of	O
knowledge	O
useful	O
for	O
comparing	O
patient	S-Species
genotypes	O
and	O
phenotypes	O
.	O

This	O
analysis	O
was	O
first	O
performed	O
in	O
controls	O
bearing	O
only	O
frequent	O
SNPs	O
(	O
90	O
.	O
5	O
%	O
of	O
the	O
total	O
population	O
)	O
.	O

We	O
demonstrate	O
that	O
the	O
four	O
SNPs	O
with	O
the	O
highest	O
allelic	O
variation	O
frequencies	O
(	O
P4	O
,	O
P7	O
,	O
P10	O
and	O
P24	O
)	O
do	O
not	O
significantly	O
contribute	O
to	O
adult	O
height	O
determination	O
,	O
with	O
the	O
heterozygous	O
genotype	O
being	O
the	O
most	O
frequent	O
followed	O
by	O
the	O
corresponding	O
homozygous	O
genotype	O
in	O
the	O
whole	O
sequence	O
,	O
and	O
heights	O
are	O
normally	O
distributed	O
over	O
the	O
entire	O
height	O
range	O
.	O

The	O
third	O
most	O
frequent	O
combined	O
genotype	O
in	O
the	O
promoter	O
region	O
in	O
our	O
population	O
presented	O
,	O
in	O
addition	O
,	O
in	O
heterozygosity	O
,	O
the	O
SNP	O
at	O
P6	O
in	O
the	O
sequence	O
regulated	O
by	O
Pit	O
1	O
and	O
although	O
mean	O
height	O
of	O
individuals	O
(	O
6	O
.	O
1	O
%	O
)	O
bearing	O
this	O
genotype	O
was	O
around	O
-	O
0	O
.	O
5	O
SDS	O
,	O
this	O
was	O
not	O
statistically	O
significant	O
.	O

Analysis	O
of	O
single	O
SNP	O
genotype	O
association	O
with	O
adult	O
height	O
yielded	O
few	O
clues	O
as	O
to	O
the	O
contribution	O
of	O
GH1	O
gene	O
variation	O
to	O
adult	O
height	O
determination	O
.	O

Only	O
three	O
SNPs	O
(	O
P16	O
,	O
P17	O
and	O
P25	O
)	O
,	O
present	O
with	O
low	O
frequency	O
and	O
only	O
in	O
heterozygous	O
state	O
,	O
were	O
individually	O
significantly	O
associated	O
with	O
taller	O
stature	O
and	O
none	O
was	O
individually	O
associated	O
with	O
shorter	O
stature	O
.	O

P16	O
and	O
P17	O
(	O
in	O
LD	O
,	O
r2	O
=	O
0	O
.	O
83	O
)	O
are	O
located	O
in	O
intron	O
1	O
and	O
P25	O
in	O
intron	O
4	O
.	O

The	O
resulting	O
sequence	O
for	O
the	O
presence	O
of	O
P16	O
and	O
P17	O
corresponded	O
to	O
the	O
paralogue	O
GH2	O
and	O
generated	O
a	O
responsive	O
element	O
for	O
a	O
core	O
-	O
binding	O
protein	O
(	O
Matinspector	O
Programme	O
,	O
Geometrix	O
Software	O
GmbH	O
,	O
M	O
u	O
nchen	O
,	O
Germany	O
)	O
with	O
three	O
Kruppel	O
-	O
type	O
zinc	O
fingers	O
which	O
could	O
increase	O
the	O
efficacy	O
of	O
GH1	O
gene	O
transcription	O
;	O
31	O
,	O
32	O
moreover	O
,	O
Kruppel	O
-	O
like	O
proteins	O
have	O
recently	O
been	O
described	O
in	O
the	O
brain	O
.	O
33	O
Stepwise	O
regression	O
analysis	O
demonstrated	O
that	O
P17	O
and	O
P25	O
contribute	O
,	O
separately	O
,	O
to	O
an	O
increase	O
of	O
almost	O
1	O
.	O
0	O
height	O
SDS	O
.	O

P16	O
and	O
P17	O
had	O
been	O
described	O
by	O
Adkins	O
et	O
al	O
.	O
21	O
although	O
they	O
found	O
no	O
association	O
with	O
fetal	O
growth	O
,	O
whereas	O
P25	O
had	O
not	O
previously	O
been	O
described	O
.	O

The	O
mechanisms	O
by	O
which	O
they	O
may	O
determine	O
taller	O
final	O
height	O
should	O
be	O
established	O
by	O
in	O
vitro	O
studies	O
analysing	O
GH1	O
gene	O
transcription	O
and	O
GH	O
protein	O
translation	O
efficiencies	O
.	O

Analysis	O
of	O
interaction	O
effect	O
between	O
SNPs	O
detected	O
that	O
variation	O
at	O
P25	O
masked	O
an	O
effect	O
of	O
P6	O
.	O

Individuals	O
homozygous	O
at	O
P25	O
(	O
TT	O
)	O
present	O
a	O
significant	O
association	O
between	O
P6	O
genotype	O
and	O
height	O
with	O
the	O
homozygous	O
alternate	O
genotype	O
at	O
P6	O
(	O
GG	O
)	O
being	O
associated	O
with	O
shorter	O
stature	O
.	O

This	O
was	O
further	O
confirmed	O
in	O
the	O
subpopulation	O
of	O
29	O
individuals	O
bearing	O
rare	O
SNPs	O
who	O
,	O
in	O
the	O
absence	O
of	O
heterozygous	O
change	O
at	O
P25	O
,	O
presented	O
significantly	O
shorter	O
stature	O
in	O
the	O
heterozygous	O
alternate	O
nucleotide	O
change	O
at	O
P6	O
(	O
AG	O
)	O
.	O

P6	O
,	O
located	O
at	O
Pit	O
1	O
proximal	O
responsive	O
element	O
of	O
the	O
GH1	O
gene	O
promoter	O
,	O
was	O
first	O
described	O
by	O
Wagner	O
et	O
al	O
.	O
10	O
and	O
Giordano	O
et	O
al	O
.	O
9	O
and	O
further	O
by	O
Horan	O
et	O
al	O
.	O
12	O
Six	O
of	O
nine	O
GH1	O
gene	O
promoter	O
haplotypes	O
bearing	O
the	O
alternate	O
G	O
at	O
P6	O
presented	O
lower	O
transcriptional	O
activities	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
detected	O
differential	O
protein	O
binding	O
strength	O
,	O
although	O
in	O
vitro	O
studies	O
were	O
unable	O
to	O
identify	O
this	O
SNP	O
as	O
a	O
major	O
determinant	O
of	O
GH1	O
gene	O
expression	O
level	O
.	O
12	O
A	O
recent	O
study	O
from	O
Giordano	O
et	O
al	O
.	O
34	O
has	O
shown	O
a	O
twofold	O
reduced	O
luciferase	O
activity	O
for	O
the	O
G	O
nucleotide	O
bearing	O
promoter	O
haplotype	O
in	O
transfected	O
rat	S-Species
pituitary	O
cells	O
.	O

Genotypes	O
at	O
P6	O
had	O
also	O
been	O
associated	O
with	O
decreased	O
breast	O
cancer	O
risk	O
through	O
its	O
association	O
with	O
lower	O
GH	O
secretion	O
and	O
IGF	O
-	O
I	O
circulating	O
levels	O
.	O
16	O
,	O
17	O

In	O
our	O
results	O
,	O
GH1	O
gene	O
polymorphic	O
structural	O
variation	O
accounted	O
for	O
only	O
6	O
.	O
2	O
%	O
of	O
adult	O
height	O
determination	O
in	O
the	O
entire	O
adult	O
population	O
studied	O
and	O
genome	O
-	O
wide	O
linkage	O
analysis	O
of	O
stature	O
in	O
multiple	O
populations	O
revealed	O
no	O
linkage	O
with	O
chromosome	O
17	O
GH	O
gene	O
cluster	O
.	O
2	O
,	O
35	O
As	O
only	O
some	O
of	O
the	O
less	O
frequent	O
SNPs	O
are	O
statistically	O
associated	O
with	O
height	O
,	O
and	O
in	O
view	O
of	O
the	O
high	O
density	O
of	O
SNPs	O
,	O
our	O
study	O
may	O
be	O
hampered	O
by	O
selection	O
bias36	O
and	O
would	O
ideally	O
have	O
required	O
a	O
wider	O
sampling	O
of	O
some	O
2	O
000	O
individuals	O
;	O
however	O
,	O
this	O
was	O
a	O
highly	O
laborious	O
strategy	O
when	O
the	O
complete	O
sequencing	O
technique	O
is	O
applied	O
.	O

The	O
high	O
density	O
of	O
SNPs	O
and	O
their	O
proximity	O
hamper	O
other	O
genotyping	O
strategies	O
for	O
rapid	O
determination	O
of	O
the	O
complete	O
GH1	O
SNP	O
map	O
in	O
large	O
control	O
and	O
patient	S-Species
populations	O
.	O

Individual	O
SNP	O
associations	O
with	O
height	O
or	O
other	O
GH	O
secretion	O
-	O
related	O
phenotypic	O
traits	O
will	O
require	O
further	O
confirmation	O
by	O
studies	O
in	O
larger	O
populations	O
and	O
by	O
in	O
vitro	O
functional	O
studies	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
established	O
the	O
GH1	O
gene	O
sequence	O
variation	O
map	O
in	O
an	O
adult	O
control	O
population	O
with	O
heights	O
normally	O
distributed	O
within	O
the	O
normal	O
range	O
.	O

SNPs	O
and	O
other	O
sequence	O
change	O
contributions	O
to	O
skeletal	O
growth	O
as	O
observed	O
at	O
adult	O
height	O
demonstrated	O
that	O
,	O
despite	O
the	O
high	O
frequency	O
of	O
variation	O
and	O
diversity	O
and	O
complexity	O
of	O
combinations	O
,	O
only	O
some	O
of	O
the	O
less	O
frequent	O
SNPs	O
were	O
associated	O
with	O
taller	O
stature	O
(	O
P17	O
in	O
intron	O
1	O
and	O
P25	O
in	O
intron	O
4	O
)	O
,	O
even	O
masking	O
the	O
SNP	O
contribution	O
to	O
a	O
shorter	O
one	O
(	O
P6	O
in	O
the	O
promoter	O
and	O
P12	O
in	O
the	O
5	O
'	O
UTR	O
regions	O
,	O
respectively	O
)	O
.	O

Systematic	O
GH1	O
gene	O
analysis	O
in	O
patients	S-Species
with	O
growth	O
delay	O
and	O
suspected	O
GH	O
deficiency	O
/	O
insufficiency	O
will	O
clarify	O
whether	O
different	O
SNP	O
frequencies	O
and	O
/	O
or	O
the	O
presence	O
of	O
different	O
sequence	O
changes	O
may	O
be	O
associated	O
with	O
phenotypes	O
in	O
them	O
.	O

Elevated	O
Blood	O
Lead	O
Levels	O
of	O
Children	S-Species
in	O
Guiyu	O
,	O
an	O
Electronic	O
Waste	O
Recycling	O
Town	O
in	O
China	O

Abstract	O

Background	O

Electronic	O
waste	O
(	O
e	O
-	O
waste	O
)	O
recycling	O
has	O
remained	O
primitive	O
in	O
Guiyu	O
,	O
China	O
,	O
and	O
thus	O
may	O
contribute	O
to	O
the	O
elevation	O
of	O
blood	O
lead	O
levels	O
(	O
BLLs	O
)	O
in	O
children	S-Species
living	O
in	O
the	O
local	O
environment	O
.	O

Objectives	O

We	O
compared	O
the	O
BLLs	O
in	O
children	S-Species
living	O
in	O
the	O
e	O
-	O
waste	O
recycling	O
town	O
of	O
Guiyu	O
with	O
those	O
living	O
in	O
the	O
neighboring	O
town	O
of	O
Chendian	O
.	O

Methods	O

We	O
observed	O
the	O
processing	O
of	O
e	O
-	O
waste	O
recycling	O
in	O
Guiyu	O
and	O
studied	O
BLLs	O
in	O
a	O
cluster	O
sample	O
of	O
226	O
children	S-Species
<	O
6	O
years	O
of	O
age	O
who	O
lived	O
in	O
Guiyu	O
and	O
Chendian	O
.	O

BLLs	O
were	O
determined	O
with	O
atomic	O
absorption	O
spectrophotometry	O
.	O

Hemoglobin	O
(	O
Hgb	O
)	O
and	O
physical	O
indexes	O
(	O
height	O
and	O
weight	O
,	O
head	O
and	O
chest	O
circumferences	O
)	O
were	O
also	O
measured	O
.	O

Results	O

BLLs	O
in	O
165	O
children	S-Species
of	O
Guiyu	O
ranged	O
from	O
4	O
.	O
40	O
to	O
32	O
.	O
67	O
mu	O
g	O
/	O
dL	O
with	O
a	O
mean	O
of	O
15	O
.	O
3	O
mu	O
g	O
/	O
dL	O
,	O
whereas	O
BLLs	O
in	O
61	O
children	S-Species
of	O
Chendian	O
were	O
from	O
4	O
.	O
09	O
to	O
23	O
.	O
10	O
mu	O
g	O
/	O
dL	O
with	O
a	O
mean	O
of	O
9	O
.	O
94	O
mu	O
g	O
/	O
dL	O
.	O

Statistical	O
analyses	O
showed	O
that	O
children	S-Species
living	O
in	O
Guiyu	O
had	O
significantly	O
higher	O
BLLs	O
compared	O
with	O
those	O
living	O
in	O
Chendian	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Of	O
children	S-Species
in	O
Guiyu	O
,	O
81	O
.	O
8	O
%	O
(	O
135	O
of	O
165	O
)	O
had	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
,	O
compared	O
with	O
37	O
.	O
7	O
%	O
of	O
children	S-Species
(	O
23	O
of	O
61	O
)	O
in	O
Chendian	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
addition	O
,	O
we	O
observed	O
a	O
significant	O
increasing	O
trend	O
in	O
BLLs	O
with	O
increasing	O
age	O
in	O
Guiyu	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

It	O
appeared	O
that	O
there	O
was	O
correlation	O
between	O
the	O
BLLs	O
in	O
children	S-Species
and	O
numbers	O
of	O
e	O
-	O
waste	O
workshops	O
.	O

However	O
,	O
no	O
significant	O
difference	O
in	O
Hgb	O
level	O
or	O
physical	O
indexes	O
was	O
found	O
between	O
the	O
two	O
towns	O
.	O

Conclusions	O

The	O
primitive	O
e	O
-	O
waste	O
recycling	O
activities	O
may	O
contribute	O
to	O
the	O
elevated	O
BLLs	O
in	O
children	S-Species
living	O
in	O
Guiyu	O
.	O

Disposal	O
of	O
electronic	O
waste	O
,	O
or	O
e	O
-	O
waste	O
,	O
is	O
an	O
emerging	O
global	O
environmental	O
issue	O
,	O
as	O
these	O
wastes	O
have	O
become	O
the	O
most	O
rapidly	O
growing	O
segment	O
of	O
the	O
municipal	O
waste	O
stream	O
in	O
the	O
world	O
[	O
Dahl	O
2002	O
;	O
Halluite	O
et	O
al	O
.	O
2005	O
;	O
Jang	O
and	O
Townsend	O
2003	O
;	O
Schmidt	O
2002	O
;	O
Silicon	O
Valley	O
Toxics	O
Coalition	O
(	O
SVTC	O
)	O
2001	O
]	O
.	O

It	O
is	O
reported	O
that	O
approximately	O
500	O
million	O
computers	O
became	O
obsolete	O
between	O
1997	O
and	O
2007	O
in	O
the	O
United	O
States	O
(	O
National	O
Safety	O
Council	O
1999	O
)	O
.	O

Up	O
to	O
80	O
%	O
of	O
e	O
-	O
waste	O
from	O
the	O
United	O
States	O
has	O
seeped	O
into	O
Asia	O
and	O
Africa	O
(	O
Johnson	O
2006	O
;	O
Puckett	O
et	O
al	O
.	O
2002	O
;	O
Schmidt	O
2002	O
,	O
2006	O
;	O
SVTC	O
2001	O
)	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
United	O
States	O
is	O
the	O
only	O
developed	O
country	O
today	O
that	O
has	O
not	O
ratified	O
the	O
United	O
Nations	O
Basel	O
Convention	O
,	O
which	O
bans	O
the	O
export	O
of	O
hazardous	O
wastes	O
to	O
developing	O
countries	O
(	O
United	O
Nations	O
Environment	O
Programme	O
1992	O
,	O
2006	O
;	O
USA	O
Today	O
2002	O
)	O
.	O

Together	O
with	O
New	O
Delhi	O
in	O
India	O
,	O
Guiyu	O
in	O
Shantou	O
,	O
Guangdong	O
Province	O
,	O
China	O
(	O
Figure	O
1	O
)	O
,	O
is	O
one	O
of	O
the	O
popular	O
destinations	O
of	O
e	O
-	O
waste	O
(	O
Brigden	O
et	O
al	O
.	O
2005	O
;	O
Puckett	O
et	O
al	O
.	O
2002	O
)	O
.	O

Within	O
a	O
total	O
area	O
of	O
52	O
km2	O
and	O
local	O
population	O
of	O
132	O
,	O
000	O
(	O
in	O
2003	O
)	O
,	O
Guiyu	O
has	O
accommodated	O
millions	O
of	O
tons	O
of	O
e	O
-	O
waste	O
from	O
overseas	O
and	O
domestic	O
a	O
year	O
.	O

Nearly	O
60	O
-	O
80	O
%	O
of	O
families	O
in	O
the	O
town	O
have	O
engaged	O
in	O
e	O
-	O
waste	O
recycling	O
operations	O
conducted	O
by	O
small	O
scale	O
family	O
-	O
run	O
workshops	O
,	O
with	O
approximately	O
100	O
,	O
000	O
migrant	O
workers	O
employed	O
in	O
processing	O
e	O
-	O
waste	O
.	O

Because	O
the	O
implementation	O
of	O
a	O
clean	O
and	O
safe	O
high	O
-	O
tech	O
recovery	O
process	O
was	O
very	O
expensive	O
(	O
Allsopp	O
et	O
al	O
.	O
2006	O
)	O
,	O
the	O
processes	O
and	O
techniques	O
used	O
during	O
the	O
recycling	O
activities	O
in	O
Guiyu	O
were	O
very	O
primitive	O
.	O

The	O
result	O
was	O
that	O
many	O
tons	O
of	O
e	O
-	O
waste	O
material	O
and	O
process	O
residues	O
were	O
dumped	O
in	O
workshops	O
,	O
yards	O
,	O
roadsides	O
,	O
open	O
fields	O
,	O
irrigation	O
canals	O
,	O
riverbanks	O
,	O
ponds	O
,	O
and	O
rivers	O
.	O

Hazardous	O
chemicals	O
can	O
be	O
released	O
from	O
e	O
-	O
wastes	O
through	O
disposal	O
or	O
recycling	O
processes	O
,	O
threatening	O
the	O
health	O
of	O
local	O
residents	O
.	O

Several	O
studies	O
have	O
reported	O
the	O
soaring	O
levels	O
of	O
toxic	O
heavy	O
metals	O
and	O
organic	O
contaminants	O
in	O
samples	O
of	O
dust	O
,	O
soil	O
,	O
river	O
sediment	O
,	O
surface	O
water	O
,	O
and	O
groundwater	O
of	O
Guiyu	O
(	O
Brigden	O
et	O
al	O
.	O
2005	O
;	O
Puckett	O
et	O
al	O
.	O
2002	O
;	O
Wang	O
and	O
Guo	O
2006	O
;	O
Wang	O
et	O
al	O
.	O
2005	O
;	O
Wong	O
et	O
al	O
.	O
2006	O
;	O
Yu	O
et	O
al	O
.	O
2006	O
)	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
the	O
residents	O
in	O
Guiyu	O
had	O
high	O
incidence	O
of	O
skin	O
damage	O
,	O
headaches	O
,	O
vertigo	O
,	O
nausea	O
,	O
chronic	O
gastritis	O
,	O
and	O
gastric	O
and	O
duodenal	O
ulcers	O
,	O
all	O
of	O
which	O
may	O
be	O
caused	O
by	O
the	O
primitive	O
recycling	O
processing	O
of	O
e	O
-	O
waste	O
(	O
Qiu	O
et	O
al	O
.	O
2004	O
)	O
.	O

Of	O
many	O
toxic	O
heavy	O
metals	O
,	O
lead	O
is	O
the	O
most	O
widely	O
used	O
in	O
electronic	O
devices	O
for	O
various	O
purposes	O
,	O
resulting	O
in	O
a	O
variety	O
of	O
health	O
hazards	O
due	O
to	O
environmental	O
contamination	O
(	O
Jang	O
and	O
Townsend	O
2003	O
;	O
Musson	O
et	O
al	O
.	O
2006	O
;	O
Vann	O
et	O
al	O
.	O
2006	O
)	O
.	O

Lead	O
enters	O
biological	O
systems	O
via	O
food	O
,	O
water	O
,	O
air	O
,	O
and	O
soil	O
.	O

Children	S-Species
are	O
particularly	O
vulnerable	O
to	O
lead	O
poisoning	O
--	O
more	O
so	O
than	O
adults	O
because	O
they	O
absorb	O
more	O
lead	O
from	O
their	O
environments	O
(	O
Baghurst	O
et	O
al	O
.	O
1992	O
;	O
Grigg	O
2004	O
;	O
Guilarte	O
et	O
al	O
.	O
2003	O
;	O
Jain	O
and	O
Hu	O
2006	O
;	O
Needleman	O
2004	O
;	O
Safi	O
et	O
al	O
.	O
2006	O
;	O
Wasserman	O
et	O
al	O
.	O
1998	O
)	O
.	O

The	O
U	O
.	O
S	O
.	O

Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
defined	O
elevated	O
blood	O
lead	O
levels	O
(	O
BLLs	O
)	O
as	O
those	O
>=	O
10	O
mu	O
g	O
/	O
dL	O
in	O
children	S-Species
<=	O
6	O
years	O
of	O
age	O
(	O
CDC	O
1991	O
)	O
.	O

Nevertheless	O
,	O
studies	O
have	O
increasingly	O
shown	O
that	O
low	O
blood	O
lead	O
concentrations	O
,	O
even	O
<	O
10	O
mu	O
g	O
/	O
dL	O
,	O
were	O
inversely	O
associated	O
with	O
children	S-Species
'	O
s	O
IQ	O
scores	O
and	O
academic	O
skills	O
(	O
Canfield	O
et	O
al	O
.	O
2003	O
;	O
Lanphear	O
et	O
al	O
.	O
2000	O
,	O
2005	O
;	O
Nevin	O
2000	O
;	O
Schnaas	O
et	O
al	O
.	O
2006	O
)	O
.	O

Therefore	O
,	O
no	O
safety	O
margin	O
at	O
existing	O
exposures	O
has	O
been	O
identified	O
(	O
Chiodo	O
et	O
al	O
.	O
2004	O
;	O
Koller	O
et	O
al	O
.	O
2004	O
)	O
.	O

Considering	O
the	O
potential	O
heavy	O
metal	O
contamination	O
in	O
the	O
local	O
living	O
environment	O
of	O
Guiyu	O
,	O
we	O
hypothesized	O
that	O
children	S-Species
living	O
in	O
Guiyu	O
may	O
have	O
elevated	O
BLLs	O
and	O
thus	O
their	O
physical	O
and	O
mental	O
development	O
may	O
have	O
been	O
affected	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
mean	O
BLLs	O
in	O
children	S-Species
1	O
-	O
6	O
years	O
of	O
age	O
living	O
in	O
Guiyu	O
and	O
compared	O
them	O
with	O
those	O
living	O
in	O
the	O
neighboring	O
town	O
of	O
Chendian	O
,	O
where	O
no	O
e	O
-	O
waste	O
processing	O
was	O
taken	O
.	O

Materials	O
and	O
Methods	O

Geographic	O
location	O
and	O
site	O
description	O

There	O
are	O
28	O
villages	O
with	O
a	O
total	O
area	O
of	O
52	O
km2	O
and	O
a	O
resident	O
population	O
of	O
132	O
,	O
000	O
and	O
around	O
100	O
,	O
000	O
migrant	O
workers	O
in	O
Guiyu	O
(	O
Figure	O
1	O
)	O
.	O

We	O
chose	O
four	O
villages	O
for	O
their	O
differences	O
in	O
the	O
scale	O
and	O
type	O
of	O
e	O
-	O
waste	O
processing	O
.	O

Beilin	O
village	O
has	O
dense	O
e	O
-	O
waste	O
workshops	O
mainly	O
involved	O
in	O
equipment	O
dismantling	O
,	O
circuit	O
board	O
baking	O
,	O
and	O
acid	O
baths	O
;	O
Dutou	O
village	O
specializes	O
in	O
plastics	O
sorting	O
,	O
including	O
manually	O
stripping	O
plastic	O
materials	O
from	O
electronic	O
products	O
and	O
then	O
crudely	O
classifying	O
them	O
;	O
Huamei	O
village	O
had	O
workshops	O
similar	O
to	O
those	O
of	O
Beilin	O
,	O
but	O
they	O
are	O
fewer	O
and	O
scattered	O
;	O
and	O
Longgang	O
village	O
was	O
involved	O
in	O
plastic	O
reprocessing	O
in	O
which	O
plastics	O
collected	O
from	O
Dutou	O
and	O
other	O
villages	O
were	O
washed	O
and	O
smashed	O
into	O
tiny	O
pieces	O
of	O
recycled	O
plastic	O
.	O

We	O
used	O
the	O
neighboring	O
town	O
of	O
Chendian	O
as	O
a	O
control	O
because	O
the	O
local	O
residents	O
work	O
mainly	O
in	O
the	O
textiles	O
industry	O
,	O
not	O
in	O
e	O
-	O
waste	O
processing	O
.	O

The	O
population	O
,	O
traffic	O
density	O
,	O
lifestyle	O
,	O
and	O
socioeconomic	O
status	O
were	O
very	O
similar	O
to	O
those	O
of	O
Guiyu	O
.	O

Study	O
population	O

The	O
study	O
population	O
was	O
composed	O
of	O
children	S-Species
<=	O
6	O
years	O
of	O
age	O
.	O

No	O
children	S-Species
involved	O
in	O
the	O
study	O
had	O
any	O
occupational	O
exposure	O
to	O
e	O
-	O
waste	O
.	O

A	O
cluster	O
sample	O
of	O
165	O
children	S-Species
with	O
a	O
median	O
age	O
of	O
5	O
.	O
0	O
years	O
lived	O
in	O
the	O
four	O
villages	O
of	O
Guiyu	O
(	O
Figure	O
1	O
)	O
.	O

Sixty	O
-	O
one	O
children	S-Species
with	O
a	O
median	O
age	O
of	O
4	O
.	O
0	O
years	O
resided	O
in	O
Chendian	O
were	O
included	O
in	O
the	O
study	O
for	O
comparison	O
.	O

After	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
parents	O
or	O
guardians	O
,	O
blood	O
samples	O
were	O
collected	O
from	O
the	O
children	S-Species
at	O
village	O
kindergartens	O
.	O

To	O
facilitate	O
the	O
counseling	O
process	O
,	O
advice	O
on	O
dietary	O
and	O
eating	O
habits	O
to	O
minimize	O
lead	O
exposure	O
were	O
provided	O
to	O
the	O
local	O
residents	O
.	O

All	O
children	S-Species
found	O
to	O
have	O
high	O
BLLs	O
were	O
advised	O
to	O
get	O
further	O
hospital	O
treatment	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Human	O
Ethics	O
Committee	O
of	O
Shantou	O
University	O
Medical	O
College	O
.	O

Measurement	O
of	O
BLLs	O
and	O
hemoglobin	O

Venipuncture	O
blood	O
samples	O
were	O
obtained	O
from	O
each	O
volunteer	O
at	O
the	O
kindergarten	O
,	O
and	O
collected	O
in	O
lead	O
-	O
free	O
tubes	O
by	O
trained	O
nurses	O
.	O

Lead	O
in	O
total	O
blood	O
was	O
analyzed	O
by	O
graphite	O
furnace	O
atomic	O
absorption	O
spectrometry	O
(	O
GFAAS	O
)	O
,	O
which	O
consisted	O
of	O
a	O
Shimadzu	O
AA	O
-	O
660	O
AAS	O
and	O
GFA	O
-	O
4B	O
graphite	O
furnace	O
atomizer	O
and	O
an	O
ACS	O
-	O
60G	O
autosampler	O
(	O
Shimadzu	O
Corporation	O
,	O
Kyoto	O
,	O
Japan	O
)	O
.	O

The	O
main	O
parameters	O
used	O
for	O
the	O
determination	O
were	O
a	O
wavelength	O
of	O
283	O
.	O
3	O
nm	O
,	O
current	O
of	O
8	O
mA	O
,	O
a	O
slit	O
width	O
of	O
1	O
.	O
00	O
nm	O
,	O
drying	O
at	O
150	O
degrees	O
C	O
,	O
ashing	O
at	O
325	O
degrees	O
C	O
,	O
and	O
atomization	O
at	O
1	O
,	O
400	O
degrees	O
C	O
.	O

The	O
accuracy	O
of	O
the	O
method	O
was	O
controlled	O
by	O
recoveries	O
between	O
95	O
%	O
and	O
107	O
%	O
from	O
the	O
spiked	O
blood	O
samples	O
.	O

Repeated	O
analyses	O
of	O
standard	O
solutions	O
confirmed	O
the	O
method	O
'	O
s	O
precision	O
.	O

The	O
BLLs	O
were	O
expressed	O
in	O
micrograms	O
per	O
deciliter	O
(	O
1	O
mu	O
g	O
/	O
dL	O
=	O
0	O
.	O
0484	O
mu	O
mol	O
/	O
L	O
)	O
.	O

Meanwhile	O
,	O
we	O
assessed	O
hemoglobin	O
(	O
Hgb	O
)	O
levels	O
by	O
hemoglobin	O
cyanide	O
method	O
with	O
hemoglobinometer	O
(	O
XK	O
-	O
2	O
,	O
JiangSu	O
,	O
China	O
)	O
.	O

Evaluation	O
of	O
physical	O
developmental	O
indexes	O

Children	S-Species
'	O
s	O
physical	O
growth	O
and	O
development	O
,	O
such	O
as	O
body	O
height	O
,	O
weight	O
,	O
and	O
head	O
and	O
chest	O
circumferences	O
were	O
measured	O
when	O
blood	O
samples	O
were	O
collected	O
.	O

Weight	O
and	O
height	O
were	O
measured	O
using	O
a	O
weighing	O
and	O
height	O
scale	O
(	O
TZ120	O
;	O
Yuyao	O
Balance	O
Instrument	O
Factory	O
,	O
Yuyao	O
,	O
China	O
)	O
with	O
maximum	O
weight	O
of	O
120	O
kg	O
(	O
minimum	O
scale	O
,	O
50	O
g	O
)	O
and	O
minimum	O
height	O
of	O
70	O
cm	O
(	O
minimum	O
scale	O
,	O
0	O
.	O
5	O
cm	O
)	O
.	O

Head	O
and	O
chest	O
circumferences	O
were	O
measured	O
using	O
graduated	O
anthropometric	O
tapes	O
.	O

Statistical	O
analyses	O

We	O
performed	O
statistical	O
analyses	O
using	O
SPSS	O
version	O
10	O
.	O
0	O
software	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

We	O
used	O
independent	O
sample	O
t	O
-	O
tests	O
or	O
covariance	O
analyses	O
for	O
comparisons	O
of	O
mean	O
,	O
chi	O
-	O
square	O
analyses	O
for	O
test	O
of	O
frequency	O
data	O
,	O
and	O
linear	O
regression	O
analysis	O
for	O
the	O
association	O
between	O
BLLs	O
and	O
age	O
.	O

Differences	O
were	O
considered	O
significant	O
with	O
a	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
.	O

Results	O

Observation	O
of	O
e	O
-	O
waste	O
processing	O

The	O
primitive	O
e	O
-	O
waste	O
recycling	O
procedures	O
in	O
Guiyu	O
were	O
mainly	O
as	O
follows	O
:	O
a	O
)	O
Old	O
electronic	O
equipment	O
was	O
dismantled	O
(	O
Figure	O
2	O
)	O
with	O
electric	O
drill	O
,	O
cutter	O
,	O
hammer	O
,	O
and	O
screwdriver	O
into	O
component	O
parts	O
such	O
as	O
monitor	O
,	O
hard	O
drive	O
,	O
CD	O
driver	O
,	O
wires	O
,	O
cables	O
,	O
circuit	O
boards	O
,	O
transformer	O
,	O
charger	O
,	O
battery	O
,	O
and	O
plastic	O
or	O
metal	O
frame	O
that	O
are	O
sold	O
for	O
reuse	O
or	O
to	O
other	O
workshops	O
for	O
further	O
recycling	O
.	O

b	O
)	O
Circuit	O
boards	O
(	O
Figure	O
3	O
)	O
of	O
computers	O
and	O
other	O
large	O
appliances	O
were	O
heated	O
over	O
coal	O
fires	O
to	O
melt	O
the	O
solder	O
to	O
release	O
valuable	O
electronic	O
components	O
,	O
such	O
as	O
diodes	O
,	O
resistors	O
,	O
and	O
microchips	O
.	O

c	O
)	O
Circuit	O
boards	O
of	O
cell	O
phones	O
and	O
other	O
hand	O
-	O
held	O
devices	O
were	O
taken	O
apart	O
by	O
a	O
electrothermal	O
machine	O
(	O
Figure	O
4	O
)	O
,	O
which	O
was	O
a	O
particular	O
environmental	O
and	O
human	S-Species
health	O
concern	O
in	O
the	O
processing	O
of	O
e	O
-	O
waste	O
in	O
Guiyu	O
.	O

d	O
)	O
In	O
acid	O
baths	O
(	O
Figure	O
5	O
)	O
,	O
some	O
microchips	O
and	O
computer	O
parts	O
were	O
soaked	O
to	O
extract	O
precious	O
gold	O
and	O
palladium	O
,	O
from	O
which	O
the	O
waste	O
acids	O
were	O
discharged	O
into	O
nearby	O
fields	O
and	O
streams	O
.	O

e	O
)	O
Wires	O
and	O
cables	O
were	O
stripped	O
or	O
simply	O
burnt	O
in	O
open	O
air	O
to	O
recover	O
metals	O
.	O

f	O
)	O
Printer	O
cartridges	O
were	O
ripped	O
apart	O
for	O
their	O
toner	O
and	O
recyclable	O
aluminum	O
,	O
steel	O
,	O
and	O
plastic	O
parts	O
.	O

g	O
)	O
Plastic	O
[	O
e	O
.	O
g	O
.	O
,	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
,	O
acrylonitrile	O
butadiene	O
styrene	O
copolymer	O
(	O
ABS	O
)	O
,	O
high	O
-	O
density	O
polyethylene	O
(	O
HDPE	O
)	O
]	O
was	O
sorted	O
by	O
workers	O
according	O
to	O
rigidity	O
,	O
color	O
,	O
and	O
luster	O
.	O

Plastic	O
scraps	O
that	O
cannot	O
be	O
sorted	O
visually	O
must	O
be	O
burned	O
and	O
classified	O
by	O
burning	O
odor	O
.	O

Another	O
way	O
to	O
sort	O
different	O
plastics	O
was	O
gravitational	O
separation	O
into	O
ceramic	O
jugs	O
with	O
brine	O
(	O
Figure	O
6	O
)	O
,	O
after	O
which	O
the	O
pieces	O
were	O
spread	O
on	O
the	O
sidewalk	O
to	O
dry	O
;	O
h	O
)	O
For	O
reprocessing	O
,	O
after	O
sorting	O
plastic	O
scraps	O
were	O
fed	O
into	O
grinders	O
that	O
spit	O
out	O
tiny	O
pieces	O
of	O
plastic	O
.	O

i	O
)	O
For	O
metals	O
sorting	O
and	O
reprocessing	O
,	O
transformers	O
,	O
chargers	O
,	O
batteries	O
,	O
and	O
cathode	O
-	O
ray	O
tubes	O
were	O
separated	O
and	O
hammered	O
open	O
for	O
recycling	O
metals	O
such	O
as	O
copper	O
,	O
steel	O
,	O
silver	O
,	O
aluminum	O
,	O
which	O
were	O
then	O
reprocessed	O
to	O
raw	O
material	O
.	O

Although	O
the	O
methods	O
for	O
processing	O
e	O
-	O
waste	O
were	O
primitive	O
,	O
the	O
coordination	O
of	O
e	O
-	O
waste	O
recycling	O
in	O
Guiyu	O
was	O
very	O
well	O
organized	O
into	O
specific	O
tasks	O
.	O

Workshops	O
specializing	O
in	O
dismantled	O
equipment	O
would	O
not	O
conduct	O
circuit	O
board	O
baking	O
or	O
plastics	O
and	O
metals	O
reprocessing	O
.	O

The	O
chain	O
of	O
recycling	O
components	O
from	O
each	O
type	O
of	O
e	O
-	O
waste	O
was	O
well	O
established	O
in	O
the	O
town	O
.	O

BLLs	O
in	O
children	S-Species

We	O
collected	O
blood	O
from	O
165	O
children	S-Species
in	O
Guiyu	O
and	O
61	O
children	S-Species
in	O
Chendian	O
and	O
measured	O
the	O
BLLs	O
in	O
these	O
children	S-Species
.	O

Table	O
1	O
shows	O
that	O
the	O
BLLs	O
corresponded	O
to	O
the	O
children	S-Species
'	O
s	O
age	O
,	O
sex	O
,	O
and	O
town	O
of	O
residence	O
.	O

As	O
expected	O
,	O
BLLs	O
among	O
Guiyu	O
children	S-Species
were	O
much	O
higher	O
than	O
those	O
in	O
the	O
children	S-Species
of	O
Chendian	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Among	O
Guiyu	O
children	S-Species
,	O
135	O
(	O
81	O
.	O
8	O
%	O
)	O
had	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
,	O
whereas	O
23	O
(	O
37	O
.	O
7	O
%	O
)	O
in	O
Chendian	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
had	O
high	O
levels	O
.	O

Among	O
135	O
(	O
81	O
.	O
8	O
%	O
)	O
Guiyu	O
children	S-Species
with	O
elevated	O
BLLs	O
,	O
61	O
.	O
8	O
%	O
and	O
20	O
%	O
had	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
and	O
20	O
mu	O
g	O
/	O
dL	O
respectively	O
,	O
but	O
lead	O
levels	O
>	O
45	O
mu	O
g	O
/	O
dL	O
were	O
not	O
found	O
.	O

And	O
BLLs	O
of	O
Guiyu	O
increased	O
somewhat	O
with	O
age	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
;	O
older	O
children	S-Species
tended	O
to	O
have	O
higher	O
BLLs	O
than	O
younger	O
ones	O
.	O

We	O
found	O
no	O
evidence	O
for	O
the	O
association	O
in	O
lead	O
concentrations	O
or	O
prevalence	O
of	O
elevated	O
BLLs	O
differentiated	O
by	O
sex	O
(	O
both	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Table	O
2	O
presents	O
BLLs	O
for	O
165	O
exposed	O
children	S-Species
in	O
the	O
four	O
villages	O
.	O

The	O
findings	O
showed	O
that	O
BLLs	O
from	O
different	O
villages	O
were	O
in	O
the	O
following	O
descending	O
order	O
:	O
Beilin	O
,	O
19	O
.	O
34	O
mu	O
g	O
/	O
dL	O
>	O
Dutou	O
,	O
17	O
.	O
86	O
mu	O
g	O
/	O
dL	O
>	O
Huamei	O
,	O
14	O
.	O
23	O
mu	O
g	O
/	O
dL	O
>	O
Longgang	O
,	O
13	O
.	O
13	O
mu	O
g	O
/	O
dL	O
(	O
Table	O
2	O
)	O
.	O

Children	S-Species
living	O
in	O
Beilin	O
,	O
where	O
the	O
number	O
of	O
e	O
-	O
waste	O
workshops	O
specializing	O
in	O
equipment	O
dismantling	O
,	O
circuit	O
board	O
baking	O
,	O
and	O
acid	O
baths	O
,	O
had	O
the	O
highest	O
BLLs	O
.	O

Dutou	O
,	O
which	O
had	O
many	O
workshops	O
specializing	O
in	O
plastics	O
sorting	O
,	O
including	O
strip	O
plastic	O
materials	O
from	O
e	O
-	O
waste	O
,	O
had	O
the	O
second	O
highest	O
BLLs	O
in	O
children	S-Species
.	O

Huamei	O
had	O
e	O
-	O
waste	O
workshops	O
similar	O
to	O
those	O
of	O
Beilin	O
,	O
but	O
fewer	O
and	O
less	O
centralized	O
;	O
the	O
BLLs	O
of	O
Huamei	O
children	S-Species
were	O
much	O
lower	O
than	O
those	O
of	O
Beilin	O
and	O
Dutou	O
.	O

Longgang	O
,	O
a	O
village	O
specializing	O
in	O
reprocessing	O
plastics	O
collected	O
from	O
other	O
villages	O
that	O
had	O
no	O
workshops	O
directly	O
processing	O
e	O
-	O
waste	O
,	O
had	O
the	O
lowest	O
BLLs	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
BLLs	O
among	O
the	O
children	S-Species
of	O
the	O
four	O
villages	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
Beilin	O
and	O
Dutou	O
,	O
88	O
.	O
8	O
%	O
and	O
100	O
%	O
children	S-Species
had	O
elevated	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
,	O
respectively	O
.	O

As	O
far	O
as	O
physical	O
indexes	O
and	O
Hgb	O
levels	O
were	O
concerned	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
Guiyu	O
and	O
Chendian	O
(	O
p	O
>	O
0	O
.	O
05	O
,	O
Table	O
3	O
)	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
the	O
processing	O
of	O
e	O
-	O
waste	O
in	O
Guiyu	O
was	O
very	O
primitive	O
and	O
the	O
recycling	O
industry	O
depended	O
mainly	O
on	O
manual	O
processing	O
methods	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
coordination	O
of	O
the	O
e	O
-	O
waste	O
recycling	O
is	O
well	O
organized	O
in	O
family	O
-	O
based	O
small	O
business	O
units	O
,	O
the	O
manual	O
processing	O
methods	O
and	O
the	O
deposition	O
of	O
the	O
e	O
-	O
waste	O
have	O
contributed	O
to	O
the	O
contamination	O
by	O
heavy	O
metals	O
in	O
the	O
living	O
environment	O
.	O

Examination	O
of	O
the	O
possible	O
impact	O
of	O
the	O
e	O
-	O
waste	O
industry	O
on	O
the	O
BLLs	O
of	O
children	S-Species
living	O
in	O
Guiyu	O
revealed	O
that	O
Guiyu	O
children	S-Species
had	O
significantly	O
higher	O
BLLs	O
than	O
Chendian	O
children	S-Species
.	O

Of	O
children	S-Species
tested	O
in	O
Guiyu	O
,	O
81	O
.	O
8	O
%	O
had	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
,	O
indicating	O
a	O
correlation	O
between	O
the	O
BLLs	O
in	O
children	S-Species
and	O
the	O
numbers	O
of	O
e	O
-	O
waste	O
workshops	O
.	O

We	O
speculated	O
that	O
the	O
elevated	O
BLLs	O
in	O
Guiyu	O
children	S-Species
may	O
be	O
directly	O
caused	O
by	O
the	O
contamination	O
of	O
the	O
lead	O
during	O
e	O
-	O
waste	O
recycling	O
.	O

However	O
,	O
further	O
study	O
should	O
be	O
conducted	O
to	O
determine	O
the	O
relationship	O
between	O
BLLs	O
in	O
Children	S-Species
and	O
the	O
actual	O
lead	O
contamination	O
in	O
the	O
environment	O
.	O

Lead	O
is	O
considered	O
one	O
of	O
the	O
major	O
heavy	O
metal	O
contaminants	O
during	O
the	O
process	O
of	O
e	O
-	O
waste	O
recycling	O
.	O

A	O
cathode	O
ray	O
tube	O
inside	O
a	O
television	O
set	O
or	O
a	O
computer	O
monitor	O
contains	O
an	O
average	O
of	O
4	O
-	O
8	O
lb	O
lead	O
;	O
monitor	O
glass	O
contains	O
about	O
20	O
%	O
lead	O
by	O
weight	O
;	O
a	O
typical	O
battery	O
weighs	O
36	O
lb	O
and	O
contains	O
about	O
18	O
lb	O
of	O
lead	O
.	O

For	O
decades	O
,	O
lead	O
as	O
a	O
major	O
component	O
of	O
solders	O
has	O
been	O
used	O
to	O
attach	O
electronic	O
components	O
to	O
printed	O
circuit	O
boards	O
.	O

Lead	O
compounds	O
have	O
also	O
been	O
used	O
as	O
stabilizers	O
in	O
some	O
PVC	O
cables	O
and	O
other	O
products	O
.	O

Our	O
study	O
demonstrated	O
in	O
Guiyu	O
a	O
significant	O
increasing	O
trend	O
in	O
BLLs	O
with	O
increasing	O
age	O
;	O
older	O
children	S-Species
tended	O
to	O
have	O
higher	O
BLLs	O
than	O
younger	O
ones	O
.	O

This	O
might	O
be	O
the	O
result	O
of	O
increasing	O
exposure	O
risk	O
because	O
older	O
children	S-Species
might	O
have	O
more	O
outdoor	O
activities	O
.	O

In	O
addition	O
,	O
it	O
may	O
also	O
be	O
attributed	O
to	O
the	O
fact	O
that	O
the	O
heaviest	O
lead	O
-	O
contaminated	O
zone	O
in	O
air	O
after	O
the	O
burning	O
of	O
the	O
e	O
-	O
waste	O
was	O
75	O
-	O
100	O
cm	O
above	O
the	O
ground	O
(	O
Wang	O
and	O
Zhang	O
2006	O
)	O
,	O
which	O
was	O
the	O
height	O
range	O
for	O
normal	O
Chinese	O
children	S-Species
5	O
-	O
6	O
years	O
of	O
age	O
.	O

In	O
China	O
,	O
the	O
mean	O
BLL	O
of	O
children	S-Species
was	O
9	O
.	O
29	O
mu	O
g	O
/	O
dL	O
,	O
and	O
33	O
.	O
8	O
%	O
of	O
the	O
subjects	O
had	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
;	O
boys	S-Species
'	O
mean	O
BLL	O
was	O
9	O
.	O
64	O
mu	O
g	O
/	O
dL	O
,	O
significantly	O
higher	O
than	O
the	O
girls	S-Species
'	O
mean	O
BLL	O
of	O
8	O
.	O
94	O
mu	O
g	O
/	O
dL	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
Wang	O
and	O
Zhang	O
2006	O
)	O
.	O

Generally	O
in	O
China	O
,	O
BLLs	O
of	O
children	S-Species
living	O
in	O
industrial	O
and	O
urban	O
areas	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
children	S-Species
in	O
suburbs	O
and	O
rural	O
areas	O
(	O
Wang	O
and	O
Zhang	O
2006	O
)	O
.	O

In	O
Guiyu	O
,	O
the	O
BLLs	O
of	O
children	S-Species
were	O
higher	O
than	O
the	O
mean	O
level	O
in	O
China	O
,	O
and	O
there	O
were	O
no	O
significant	O
different	O
between	O
boys	S-Species
and	O
girls	S-Species
.	O

Although	O
Guiyu	O
is	O
rural	O
,	O
the	O
children	S-Species
'	O
s	O
BLLs	O
were	O
nearly	O
double	O
those	O
of	O
a	O
nearby	O
urban	O
area	O
,	O
Shantou	O
City	O
(	O
7	O
.	O
9	O
mu	O
g	O
/	O
dL	O
;	O
Luo	O
et	O
al	O
.	O
2003	O
)	O
.	O

Compared	O
with	O
results	O
from	O
studies	O
conducted	O
in	O
some	O
other	O
part	O
of	O
Guangdong	O
province	O
,	O
such	O
as	O
Zhongshan	O
City	O
(	O
7	O
.	O
45	O
mu	O
g	O
/	O
dL	O
;	O
Huang	O
et	O
al	O
.	O
2003	O
)	O
and	O
Shenzhen	O
City	O
(	O
9	O
.	O
06	O
mu	O
g	O
/	O
dL	O
;	O
Wang	O
et	O
al	O
.	O
2003	O
)	O
,	O
we	O
observed	O
higher	O
BLLs	O
not	O
only	O
in	O
Guiyu	O
children	S-Species
,	O
but	O
also	O
in	O
Chendian	O
children	S-Species
(	O
9	O
.	O
94	O
mu	O
g	O
/	O
dL	O
)	O
.	O

The	O
lead	O
contamination	O
may	O
have	O
spread	O
from	O
Guiyu	O
to	O
nearby	O
Chendian	O
by	O
dust	O
,	O
river	O
,	O
and	O
air	O
and	O
contributed	O
to	O
the	O
elevation	O
of	O
Chendian	O
children	S-Species
'	O
s	O
BLLs	O
.	O

In	O
conclusion	O
,	O
elevated	O
BLLs	O
in	O
Guiyu	O
children	S-Species
are	O
common	O
as	O
a	O
result	O
of	O
exposure	O
to	O
lead	O
contamination	O
caused	O
by	O
primitive	O
e	O
-	O
waste	O
recycling	O
activities	O
.	O

Lead	O
contamination	O
from	O
e	O
-	O
waste	O
processing	O
appears	O
to	O
have	O
reached	O
the	O
level	O
considered	O
to	O
be	O
a	O
serious	O
threat	O
to	O
children	S-Species
'	O
s	O
health	O
around	O
the	O
e	O
-	O
waste	O
recycling	O
area	O
.	O

Based	O
on	O
these	O
threats	O
,	O
it	O
is	O
necessary	O
to	O
increase	O
public	O
awareness	O
about	O
the	O
effects	O
of	O
exposure	O
to	O
lead	O
from	O
e	O
-	O
waste	O
and	O
arouse	O
local	O
governments	O
'	O
interest	O
in	O
public	O
health	O
and	O
safety	O
,	O
so	O
that	O
an	O
infrastructure	O
for	O
safe	O
management	O
of	O
e	O
-	O
waste	O
can	O
be	O
established	O
.	O

More	O
important	O
,	O
responsible	O
management	O
strategies	O
should	O
be	O
undertaken	O
to	O
minimize	O
e	O
-	O
waste	O
production	O
and	O
make	O
e	O
-	O
waste	O
components	O
more	O
easily	O
recycled	O
and	O
reused	O
.	O

Correction	O

In	O
the	O
Abstract	O
and	O
Discussion	O
,	O
the	O
percentage	O
of	O
Guiyu	O
children	S-Species
with	O
BLLs	O
>	O
10	O
mu	O
g	O
/	O
dL	O
has	O
been	O
corrected	O
from	O
88	O
%	O
in	O
the	O
original	O
manuscript	O
published	O
online	O
to	O
81	O
.	O
8	O
%	O
.	O

Dynein	O
Modifiers	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
:	O
Light	O
Chains	O
Suppress	O
Conditional	O
Heavy	O
Chain	O
Mutants	O

Abstract	O

Cytoplasmic	O
dynein	O
is	O
a	O
microtubule	O
-	O
dependent	O
motor	O
protein	O
that	O
functions	O
in	O
mitotic	O
cells	O
during	O
centrosome	O
separation	O
,	O
metaphase	O
chromosome	O
congression	O
,	O
anaphase	O
spindle	O
elongation	O
,	O
and	O
chromosome	O
segregation	O
.	O

Dynein	O
is	O
also	O
utilized	O
during	O
interphase	O
for	O
vesicle	O
transport	O
and	O
organelle	O
positioning	O
.	O

While	O
numerous	O
cellular	O
processes	O
require	O
cytoplasmic	O
dynein	O
,	O
the	O
mechanisms	O
that	O
target	O
and	O
regulate	O
this	O
microtubule	O
motor	O
remain	O
largely	O
unknown	O
.	O

By	O
screening	O
a	O
conditional	O
Caenorhabditis	B-Species
elegans	E-Species
cytoplasmic	O
dynein	O
heavy	O
chain	O
mutant	O
at	O
a	O
semipermissive	O
temperature	O
with	O
a	O
genome	O
-	O
wide	O
RNA	O
interference	O
library	O
to	O
reduce	O
gene	O
functions	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
twenty	O
dynein	O
-	O
specific	O
suppressor	O
genes	O
.	O

When	O
reduced	O
in	O
function	O
,	O
these	O
genes	O
suppress	O
dynein	O
mutants	O
but	O
not	O
other	O
conditionally	O
mutant	O
loci	O
,	O
and	O
twelve	O
of	O
the	O
20	O
specific	O
suppressors	O
do	O
not	O
exhibit	O
sterile	O
or	O
lethal	O
phenotypes	O
when	O
their	O
function	O
is	O
reduced	O
in	O
wild	O
-	O
type	O
worms	S-Species
.	O

Many	O
of	O
the	O
suppressor	O
proteins	O
,	O
including	O
two	O
dynein	O
light	O
chains	O
,	O
localize	O
to	O
subcellular	O
sites	O
that	O
overlap	O
with	O
those	O
reported	O
by	O
others	O
for	O
the	O
dynein	O
heavy	O
chain	O
.	O

Furthermore	O
,	O
knocking	O
down	O
any	O
one	O
of	O
four	O
putative	O
dynein	O
accessory	O
chains	O
suppresses	O
the	O
conditional	O
heavy	O
chain	O
mutants	O
,	O
suggesting	O
that	O
some	O
accessory	O
chains	O
negatively	O
regulate	O
heavy	O
chain	O
function	O
.	O

We	O
also	O
identified	O
29	O
additional	O
genes	O
that	O
,	O
when	O
reduced	O
in	O
function	O
,	O
suppress	O
conditional	O
mutations	O
not	O
only	O
in	O
dynein	O
but	O
also	O
in	O
loci	O
required	O
for	O
unrelated	O
essential	O
processes	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
twenty	O
genes	O
that	O
in	O
many	O
cases	O
are	O
not	O
essential	O
themselves	O
but	O
are	O
conserved	O
and	O
when	O
reduced	O
in	O
function	O
can	O
suppress	O
conditionally	O
lethal	O
C	B-Species
.	I-Species
elegans	E-Species
cytoplasmic	O
dynein	O
heavy	O
chain	O
mutants	O
.	O

We	O
conclude	O
that	O
conserved	O
but	O
nonessential	O
genes	O
contribute	O
to	O
dynein	O
function	O
during	O
the	O
essential	O
process	O
of	O
mitosis	O
.	O

Microtubules	O
and	O
microtubule	O
-	O
dependent	O
motor	O
proteins	O
segregate	O
chromosomes	O
during	O
mitosis	O
and	O
also	O
promote	O
cellular	O
organization	O
in	O
nondividing	O
cells	O
.	O

An	O
essential	O
motor	O
protein	O
complex	O
called	O
cytoplasmic	O
dynein	O
powers	O
many	O
aspects	O
of	O
microtubule	O
-	O
dependent	O
transport	O
,	O
but	O
it	O
is	O
currently	O
unclear	O
how	O
dynein	O
is	O
regulated	O
such	O
that	O
it	O
can	O
execute	O
different	O
processes	O
.	O

We	O
have	O
performed	O
a	O
genome	O
-	O
wide	O
screen	O
to	O
isolate	O
genes	O
that	O
are	O
involved	O
in	O
dynein	O
-	O
dependent	O
processes	O
.	O

We	O
determined	O
that	O
20	O
of	O
the	O
49	O
genes	O
we	O
identified	O
specifically	O
influenced	O
the	O
viability	O
of	O
dynein	O
mutant	O
strains	O
but	O
not	O
the	O
viability	O
of	O
other	O
C	B-Species
.	I-Species
elegans	E-Species
mutants	O
.	O

Many	O
of	O
the	O
proteins	O
that	O
specifically	O
influence	O
dynein	O
localized	O
to	O
subcellular	O
sites	O
where	O
the	O
dynein	O
heavy	O
chain	O
has	O
been	O
reported	O
by	O
others	O
to	O
be	O
found	O
.	O

Additionally	O
,	O
we	O
identified	O
four	O
dynein	O
components	O
that	O
appear	O
to	O
negatively	O
regulate	O
the	O
force	O
-	O
generating	O
dynein	O
heavy	O
chain	O
.	O

The	O
identification	O
and	O
initial	O
characterization	O
of	O
this	O
group	O
of	O
genes	O
represents	O
a	O
route	O
to	O
identify	O
genes	O
that	O
are	O
not	O
themselves	O
essential	O
but	O
do	O
participate	O
in	O
essential	O
processes	O
.	O

Introduction	O

The	O
microtubule	O
motor	O
called	O
cytoplasmic	O
dynein	O
has	O
roles	O
in	O
diverse	O
cellular	O
processes	O
including	O
meiotic	O
and	O
mitotic	O
spindle	O
assembly	O
and	O
function	O
,	O
neuronal	O
transport	O
,	O
and	O
organelle	O
positioning	O
[	O
1	O
]	O
.	O

Cytoplasmic	O
dynein	O
is	O
composed	O
of	O
a	O
dimer	O
of	O
heavy	O
chains	O
(	O
HCs	O
)	O
,	O
along	O
with	O
several	O
accessory	O
chains	O
(	O
ACs	O
:	O
intermediate	O
,	O
light	O
intermediate	O
,	O
and	O
light	O
chains	O
)	O
.	O

Other	O
dynein	O
-	O
interacting	O
proteins	O
,	O
such	O
as	O
dynactin	O
and	O
LIS1	O
,	O
are	O
likely	O
present	O
at	O
substoichiometric	O
levels	O
and	O
further	O
modulate	O
dynein	O
function	O
.	O

The	O
HCs	O
contain	O
both	O
ATPase	O
and	O
microtubule	O
binding	O
activities	O
and	O
are	O
sufficient	O
for	O
microtubule	O
-	O
based	O
motility	O
in	O
vitro	O
,	O
moving	O
toward	O
the	O
minus	O
,	O
or	O
slow	O
-	O
growing	O
,	O
end	O
of	O
microtubules	O
[	O
2	O
]	O
.	O

The	O
dynein	O
ACs	O
provide	O
cargo	O
docking	O
sites	O
and	O
often	O
are	O
encoded	O
by	O
multigene	O
families	O
in	O
any	O
one	O
species	O
[	O
reviewed	O
in	O
1	O
,	O
3	O
]	O
.	O

In	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
a	O
single	O
gene	O
called	O
dhc	O
-	O
1	O
encodes	O
a	O
cytoplasmic	O
dynein	O
1	O
HC	O
,	O
while	O
11	O
other	O
genes	O
encode	O
five	O
classes	O
of	O
predicted	O
dynein	O
ACs	O
[	O
3	O
,	O
4	O
]	O
.	O

The	O
early	O
C	B-Species
.	I-Species
elegans	E-Species
embryo	O
is	O
an	O
excellent	O
system	O
for	O
investigating	O
gene	O
contributions	O
for	O
essential	O
cellular	O
processes	O
,	O
including	O
cytoskeletal	O
functions	O
[	O
5	O
]	O
.	O

The	O
C	B-Species
.	I-Species
elegans	E-Species
dynein	O
HC	O
DHC	O
-	O
1	O
is	O
essential	O
and	O
required	O
for	O
multiple	O
microtubule	O
-	O
dependent	O
events	O
during	O
early	O
embryogenesis	O
[	O
6	O
-	O
9	O
]	O
.	O

Depletion	O
of	O
DHC	O
-	O
1	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
in	O
early	O
C	B-Species
.	I-Species
elegans	E-Species
embryos	O
produces	O
defects	O
in	O
female	O
meiotic	O
divisions	O
,	O
migration	O
of	O
the	O
oocyte	O
and	O
sperm	O
pronuclei	O
after	O
fertilization	O
,	O
and	O
centrosome	O
separation	O
during	O
mitotic	O
spindle	O
assembly	O
[	O
6	O
]	O
.	O

Analysis	O
of	O
fast	O
-	O
acting	O
dhc	O
-	O
1	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutants	O
has	O
further	O
revealed	O
that	O
dynein	O
is	O
required	O
for	O
chromosome	O
congression	O
to	O
the	O
metaphase	O
plate	O
during	O
mitosis	O
,	O
as	O
well	O
as	O
for	O
mitotic	O
spindle	O
positioning	O
[	O
10	O
]	O
.	O

While	O
many	O
requirements	O
for	O
cytoplasmic	O
dynein	O
are	O
known	O
,	O
our	O
knowledge	O
of	O
the	O
molecular	O
mechanisms	O
that	O
target	O
and	O
regulate	O
dynein	O
remains	O
limited	O
.	O

Clearly	O
,	O
the	O
multiple	O
ACs	O
can	O
couple	O
the	O
dynein	O
HC	O
to	O
particular	O
substrates	O
[	O
11	O
]	O
,	O
including	O
vesicles	O
,	O
nuclei	O
,	O
viruses	O
,	O
kinetochores	O
,	O
and	O
rhodopsin	O
[	O
see	O
table	O
in	O
1	O
]	O
.	O

However	O
,	O
reducing	O
the	O
function	O
of	O
only	O
four	O
of	O
the	O
eleven	O
dynein	O
ACs	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
produces	O
lethal	O
phenotypes	O
[	O
12	O
]	O
.	O

Thus	O
,	O
it	O
remains	O
unclear	O
how	O
ACs	O
influence	O
the	O
different	O
essential	O
requirements	O
for	O
dynein	O
.	O

Another	O
potential	O
route	O
for	O
dynein	O
regulation	O
involves	O
the	O
phosphorylation	O
state	O
of	O
the	O
different	O
dynein	O
chains	O
,	O
which	O
in	O
some	O
cases	O
confers	O
distinctive	O
functional	O
properties	O
to	O
the	O
motor	O
.	O

While	O
many	O
examples	O
of	O
dynein	O
phosphorylation	O
exist	O
,	O
and	O
cell	O
cycle	O
dependent	O
changes	O
in	O
phosphorylation	O
have	O
been	O
described	O
[	O
13	O
-	O
15	O
]	O
,	O
few	O
if	O
any	O
studies	O
have	O
demonstrated	O
a	O
requirement	O
for	O
such	O
modification	O
during	O
mitosis	O
.	O

Large	O
-	O
scale	O
forward	O
genetic	O
screens	O
have	O
identified	O
genes	O
with	O
requirements	O
similar	O
to	O
those	O
for	O
dynein	O
,	O
but	O
many	O
of	O
these	O
encode	O
core	O
components	O
of	O
the	O
microtubule	O
cytoskeleton	O
and	O
few	O
are	O
known	O
to	O
directly	O
influence	O
dynein	O
itself	O
[	O
12	O
,	O
16	O
]	O
.	O

Genes	O
that	O
do	O
influence	O
dynein	O
function	O
might	O
also	O
have	O
other	O
essential	O
roles	O
,	O
leading	O
to	O
pleiotropic	O
mutant	O
phenotypes	O
that	O
obscure	O
their	O
relationship	O
to	O
dynein	O
[	O
17	O
-	O
19	O
]	O
.	O

Moreover	O
,	O
redundancy	O
within	O
the	O
multigene	O
dynein	O
subunit	O
families	O
,	O
and	O
also	O
perhaps	O
between	O
the	O
different	O
ACs	O
,	O
may	O
complicate	O
the	O
identification	O
of	O
single	O
gene	O
requirements	O
that	O
are	O
important	O
for	O
dynein	O
function	O
.	O

Thus	O
far	O
,	O
reducing	O
the	O
function	O
of	O
individual	O
genes	O
has	O
not	O
provided	O
substantial	O
insight	O
into	O
the	O
mechanisms	O
that	O
regulate	O
and	O
mediate	O
the	O
many	O
different	O
requirements	O
for	O
cytoplasmic	O
dynein	O
during	O
mitosis	O
.	O

To	O
identify	O
potential	O
regulators	O
of	O
cytoplasmic	O
dynein	O
,	O
we	O
have	O
used	O
a	O
sensitized	O
genetic	O
background	O
to	O
conduct	O
a	O
genome	O
-	O
wide	O
screen	O
for	O
modifiers	O
of	O
dynein	O
function	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
.	O

Other	O
groups	O
have	O
successfully	O
used	O
RNAi	O
modifier	O
screens	O
to	O
identify	O
genes	O
that	O
function	O
in	O
particular	O
pathways	O
[	O
20	O
-	O
23	O
]	O
;	O
we	O
have	O
used	O
RNAi	O
to	O
screen	O
for	O
genes	O
that	O
,	O
when	O
reduced	O
in	O
function	O
,	O
suppress	O
the	O
embryonic	O
lethality	O
associated	O
with	O
a	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
allele	O
of	O
the	O
dhc	O
-	O
1	O
dynein	O
HC	O
gene	O
.	O

Using	O
the	O
dhc	O
-	O
1ts	O
genetic	O
background	O
,	O
we	O
found	O
49	O
genes	O
that	O
,	O
when	O
depleted	O
,	O
suppress	O
the	O
partial	O
loss	O
of	O
HC	O
function	O
.	O

Twenty	O
of	O
these	O
genes	O
suppress	O
conditional	O
dynein	O
HC	O
mutants	O
but	O
not	O
other	O
conditional	O
mutants	O
with	O
unrelated	O
defects	O
.	O

Finally	O
,	O
we	O
show	O
that	O
some	O
of	O
these	O
dynein	O
-	O
specific	O
suppressors	O
encode	O
proteins	O
that	O
may	O
overlap	O
with	O
the	O
dynein	O
HC	O
in	O
subcellular	O
localization	O
.	O

Results	O

To	O
identify	O
dynein	O
suppressors	O
,	O
we	O
used	O
three	O
different	O
conditional	O
and	O
recessive	O
dhc	O
-	O
1	O
mutants	O
that	O
were	O
identified	O
previously	O
[	O
7	O
]	O
.	O

These	O
ts	O
alleles	O
of	O
dhc	O
-	O
1	O
(	O
or195	O
,	O
or283	O
,	O
and	O
or352	O
)	O
produce	O
similar	O
defects	O
at	O
the	O
restrictive	O
temperature	O
of	O
26	O
degrees	O
C	O
,	O
including	O
incomplete	O
mitotic	O
spindle	O
assembly	O
in	O
one	O
-	O
cell	O
embryos	O
and	O
embryonic	O
lethality	O
[	O
7	O
]	O
.	O

We	O
sequenced	O
the	O
dhc	O
-	O
1	O
locus	O
in	O
the	O
three	O
mutants	O
.	O

The	O
independently	O
isolated	O
or195	O
and	O
or283	O
alleles	O
each	O
change	O
a	O
conserved	O
serine	O
to	O
leucine	O
at	O
codon	O
3200	O
,	O
within	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
the	O
microtubule	O
-	O
binding	O
stalk	O
domain	O
(	O
Figure	O
1A	O
and	O
1C	O
)	O
.	O

The	O
or352	O
allele	O
replaces	O
a	O
conserved	O
glycine	O
with	O
aspartic	O
acid	O
at	O
codon	O
2158	O
,	O
in	O
the	O
ATP	O
-	O
binding	O
walker	O
A	O
motif	O
of	O
the	O
second	O
AAA	O
ATPase	O
domain	O
(	O
Figure	O
1B	O
and	O
1C	O
)	O
.	O

As	O
both	O
missense	O
mutations	O
affect	O
conserved	O
residues	O
,	O
they	O
may	O
prove	O
useful	O
for	O
engineering	O
ts	O
alleles	O
in	O
other	O
organisms	O
.	O

The	O
temperature	O
versus	O
viability	O
curves	O
of	O
the	O
dynein	O
ts	O
mutants	O
feature	O
a	O
steep	O
central	O
transition	O
zone	O
ideal	O
for	O
modifier	O
screening	O
because	O
subtle	O
changes	O
in	O
temperature	O
produce	O
large	O
changes	O
in	O
embryonic	O
viability	O
(	O
Figure	O
2A	O
)	O
.	O

To	O
identify	O
genes	O
that	O
,	O
when	O
reduced	O
in	O
function	O
,	O
can	O
suppress	O
conditional	O
dhc	O
-	O
1	O
mutants	O
,	O
we	O
developed	O
a	O
high	O
-	O
throughput	O
RNAi	O
-	O
based	O
screen	O
(	O
Figure	O
2B	O
)	O
.	O

To	O
reduce	O
gene	O
function	O
we	O
used	O
a	O
library	O
of	O
16	O
,	O
757	O
bacterial	O
strains	O
that	O
each	O
express	O
a	O
dsRNA	O
corresponding	O
to	O
exon	O
-	O
rich	O
gene	O
sequences	O
[	O
17	O
,	O
19	O
]	O
.	O

We	O
then	O
tested	O
over	O
99	O
%	O
of	O
the	O
bacterial	O
strains	O
in	O
this	O
library	O
for	O
RNAi	O
-	O
mediated	O
suppression	O
of	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
embryonic	O
lethality	O
at	O
23	O
degrees	O
C	O
,	O
after	O
raising	O
synchronized	O
L1	O
larvae	O
to	O
adulthood	O
on	O
dsRNA	O
-	O
expressing	O
bacterial	O
lawns	O
in	O
48	O
-	O
well	O
agar	O
plates	O
.	O

This	O
screening	O
procedure	O
should	O
work	O
to	O
identify	O
nonessential	O
and	O
essential	O
suppressor	O
genes	O
,	O
because	O
RNAi	O
does	O
not	O
always	O
fully	O
reduce	O
gene	O
function	O
[	O
24	O
,	O
25	O
]	O
,	O
and	O
even	O
if	O
RNAi	O
does	O
produce	O
lethality	O
,	O
cosuppression	O
could	O
restore	O
viability	O
.	O

Nevertheless	O
,	O
essential	O
genes	O
may	O
be	O
missed	O
due	O
to	O
earlier	O
requirements	O
that	O
produce	O
strong	O
larval	O
arrest	O
,	O
sterile	O
,	O
or	O
embryonic	O
lethal	O
phenotypes	O
.	O

Using	O
this	O
screening	O
procedure	O
,	O
we	O
identified	O
49	O
bacterial	O
clones	O
that	O
consistently	O
increased	O
embryonic	O
viability	O
at	O
the	O
semipermissive	O
temperature	O
.	O

The	O
dsRNA	O
-	O
producing	O
plasmids	O
were	O
then	O
sequenced	O
to	O
verify	O
gene	O
identity	O
.	O

Quantification	O
of	O
embryonic	O
viability	O
using	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
animals	O
showed	O
that	O
the	O
RNAi	O
-	O
mediated	O
depletion	O
of	O
suppressor	O
gene	O
function	O
increased	O
viability	O
to	O
5	O
%	O
-	O
100	O
%	O
,	O
compared	O
to	O
less	O
than	O
2	O
%	O
in	O
unsuppressed	O
controls	O
(	O
Figure	O
3A	O
;	O
Table	O
S1	O
)	O
.	O

The	O
proteins	O
encoded	O
by	O
the	O
suppressor	O
genes	O
we	O
identified	O
are	O
summarized	O
in	O
Figure	O
4	O
.	O

As	O
a	O
more	O
direct	O
assay	O
for	O
dynein	O
activity	O
in	O
the	O
suppressed	O
dhc	O
-	O
1	O
embryos	O
,	O
we	O
measured	O
spindle	O
length	O
and	O
cytokinesis	O
success	O
:	O
dhc	O
-	O
1	O
mutant	O
embryos	O
have	O
severe	O
spindle	O
assembly	O
defects	O
and	O
subsequent	O
cytokinesis	O
failures	O
[	O
6	O
,	O
7	O
,	O
10	O
]	O
.	O

We	O
shifted	O
dhc	O
-	O
1	O
adult	O
hermaphrodites	O
from	O
23	O
degrees	O
C	O
to	O
the	O
fully	O
restrictive	O
temperature	O
of	O
26	O
degrees	O
C	O
for	O
3	O
-	O
5	O
hours	O
and	O
made	O
time	O
-	O
lapse	O
video	O
micrographs	O
using	O
Nomarski	O
optics	O
to	O
monitor	O
the	O
first	O
embryonic	O
cell	O
division	O
.	O

This	O
procedure	O
results	O
in	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
embryos	O
with	O
P0	O
spindles	O
30	O
%	O
the	O
length	O
of	O
wild	O
-	O
type	O
spindles	O
(	O
Figure	O
S1	O
)	O
.	O

In	O
the	O
suppressed	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
backgrounds	O
,	O
spindle	O
lengths	O
ranged	O
from	O
30	O
%	O
-	O
83	O
%	O
of	O
wild	O
-	O
type	O
lengths	O
(	O
Figure	O
S1	O
)	O
.	O

Similarly	O
,	O
cytokinesis	O
failed	O
in	O
unsuppressed	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
embryos	O
89	O
%	O
of	O
the	O
time	O
,	O
but	O
most	O
of	O
the	O
suppressors	O
rescued	O
this	O
phenotype	O
(	O
Figure	O
S1	O
)	O
.	O

These	O
results	O
indicate	O
that	O
most	O
of	O
the	O
suppressors	O
influence	O
dynein	O
-	O
dependent	O
cellular	O
processes	O
,	O
as	O
expected	O
given	O
their	O
ability	O
to	O
restore	O
viability	O
when	O
reduced	O
in	O
function	O
.	O

Specificity	O
of	O
Suppression	O

Because	O
RNAi	O
can	O
reduce	O
the	O
function	O
of	O
unintended	O
targets	O
(	O
so	O
-	O
called	O
"	O
off	O
-	O
target	O
effects	O
"	O
[	O
26	O
,	O
27	O
]	O
)	O
,	O
we	O
also	O
used	O
available	O
mutations	O
in	O
some	O
of	O
the	O
suppressor	O
genes	O
we	O
identified	O
to	O
reduce	O
their	O
function	O
.	O

We	O
constructed	O
double	O
mutant	O
strains	O
using	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
and	O
viable	O
deletion	O
alleles	O
for	O
two	O
suppressor	O
genes	O
,	O
dylt	O
-	O
1	O
(	O
ok417	O
)	O
and	O
ufd	O
-	O
2	O
(	O
tm1380	O
)	O
,	O
and	O
examined	O
embryonic	O
viability	O
(	O
Figure	O
3B	O
)	O
.	O

The	O
deletion	O
alleles	O
of	O
dylt	O
-	O
1	O
(	O
encoding	O
a	O
Tctex1	O
-	O
type	O
dynein	O
light	O
chain	O
)	O
,	O
and	O
ufd	O
-	O
2	O
(	O
encoding	O
a	O
ubiquitin	O
conjugating	O
enzyme	O
)	O
both	O
recapitulated	O
the	O
suppression	O
produced	O
by	O
RNAi	O
knockdown	O
(	O
Figure	O
3B	O
)	O
.	O

The	O
dpy	O
-	O
3	O
(	O
e27	O
)	O
and	O
dpy	O
-	O
10	O
(	O
e128	O
)	O
point	O
mutation	O
alleles	O
[	O
28	O
]	O
also	O
suppressed	O
embryonic	O
lethality	O
in	O
double	O
mutants	O
(	O
Figure	O
3B	O
)	O
.	O

Based	O
on	O
this	O
small	O
sampling	O
,	O
and	O
because	O
RNAi	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
appears	O
to	O
be	O
highly	O
gene	O
specific	O
in	O
the	O
absence	O
of	O
close	O
paralogs	O
[	O
12	O
,	O
19	O
]	O
,	O
we	O
conclude	O
that	O
many	O
of	O
the	O
suppressors	O
we	O
have	O
identified	O
will	O
prove	O
to	O
be	O
suppressor	O
locus	O
specific	O
.	O

The	O
dsRNA	O
-	O
expressing	O
bacterial	O
clones	O
we	O
used	O
to	O
deplete	O
two	O
of	O
the	O
dynein	O
suppressors	O
(	O
tag	O
-	O
300	O
and	O
ZK1127	O
.	O
10	O
)	O
probably	O
also	O
knock	O
down	O
expression	O
of	O
one	O
close	O
paralog	O
for	O
each	O
locus	O
[	O
29	O
]	O
.	O

We	O
next	O
asked	O
whether	O
the	O
suppressors	O
are	O
specific	O
for	O
dynein	O
function	O
or	O
if	O
their	O
depletion	O
more	O
generally	O
stabilizes	O
ts	O
proteins	O
.	O

We	O
tested	O
for	O
specificity	O
using	O
two	O
conditional	O
mutants	O
with	O
cell	O
fate	O
patterning	O
defects	O
unrelated	O
to	O
dynein	O
function	O
,	O
lit	O
-	O
1	O
(	O
or131	O
)	O
and	O
spn	O
-	O
4	O
(	O
or191	O
)	O
.	O

The	O
lit	O
-	O
1	O
gene	O
encodes	O
a	O
MAP	O
kinase	O
-	O
related	O
protein	O
[	O
30	O
]	O
,	O
while	O
spn	O
-	O
4	O
encodes	O
a	O
protein	O
with	O
an	O
RNA	O
binding	O
motif	O
[	O
31	O
]	O
.	O

We	O
found	O
that	O
ten	O
of	O
the	O
dhc	O
-	O
1	O
-	O
interacting	O
genes	O
significantly	O
increased	O
embryonic	O
viability	O
in	O
both	O
lit	O
-	O
1	O
and	O
spn	O
-	O
4	O
mutants	O
,	O
while	O
18	O
others	O
suppressed	O
one	O
or	O
the	O
other	O
of	O
these	O
two	O
conditional	O
mutants	O
when	O
reduced	O
in	O
function	O
using	O
the	O
same	O
RNAi	O
protocol	O
as	O
that	O
used	O
for	O
dhc	O
-	O
1ts	O
mutants	O
(	O
Figure	O
4	O
,	O
right	O
two	O
columns	O
;	O
Table	O
S1	O
)	O
.	O

Therefore	O
,	O
about	O
half	O
of	O
the	O
suppressors	O
appear	O
to	O
act	O
nonspecifically	O
on	O
multiple	O
ts	O
mutants	O
to	O
restore	O
embryonic	O
viability	O
.	O

From	O
here	O
on	O
,	O
we	O
will	O
refer	O
to	O
the	O
suppressors	O
that	O
only	O
acted	O
on	O
dhc	O
-	O
1	O
,	O
and	O
not	O
on	O
lit	O
-	O
1	O
and	O
spn	O
-	O
4	O
ts	O
mutants	O
,	O
as	O
dynein	O
-	O
specific	O
suppressors	O
.	O

Because	O
many	O
ts	O
mutations	O
exert	O
their	O
effect	O
via	O
protein	O
assembly	O
or	O
unfolding	O
mechanisms	O
[	O
32	O
]	O
,	O
suppressor	O
genes	O
reduced	O
in	O
function	O
by	O
RNAi	O
might	O
not	O
be	O
expected	O
to	O
exhibit	O
allele	O
specificity	O
with	O
most	O
ts	O
mutations	O
.	O

To	O
determine	O
if	O
the	O
dynein	O
suppressors	O
are	O
either	O
allele	O
or	O
strain	O
specific	O
,	O
we	O
tested	O
the	O
two	O
other	O
conditional	O
dhc	O
-	O
1	O
strains	O
(	O
containing	O
the	O
or283	O
and	O
or352	O
alleles	O
)	O
.	O

Although	O
the	O
or283	O
allele	O
is	O
identical	O
to	O
or195	O
,	O
it	O
provides	O
a	O
useful	O
control	O
for	O
the	O
presence	O
of	O
background	O
mutations	O
because	O
the	O
two	O
strains	O
were	O
isolated	O
independently	O
.	O

In	O
most	O
cases	O
,	O
depletion	O
of	O
the	O
dynein	O
-	O
specific	O
suppressors	O
also	O
restored	O
viability	O
to	O
the	O
other	O
two	O
ts	O
dhc	O
-	O
1	O
alleles	O
.	O

Y40B1B	O
.	O
5	O
,	O
a	O
putative	O
translation	O
initiation	O
factor	O
,	O
suppressed	O
only	O
one	O
conditional	O
dhc	O
-	O
1	O
strain	O
,	O
and	O
we	O
consider	O
this	O
as	O
an	O
example	O
of	O
a	O
nonspecific	O
interaction	O
(	O
Figure	O
4	O
,	O
left	O
three	O
columns	O
;	O
Table	O
S1	O
)	O
.	O

Two	O
dsRNAs	O
that	O
do	O
not	O
suppress	O
lit	O
-	O
1	O
or	O
spn	O
-	O
4	O
mutants	O
produced	O
suppression	O
in	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
and	O
dhc	O
-	O
1	O
(	O
or283	O
)	O
strains	O
,	O
but	O
not	O
in	O
the	O
dhc	O
-	O
1	O
(	O
or352	O
)	O
strain	O
,	O
perhaps	O
indicating	O
allele	O
specificity	O
or	O
variability	O
in	O
the	O
RNAi	O
treatments	O
.	O

We	O
conclude	O
that	O
strain	O
background	O
differences	O
are	O
relatively	O
rare	O
,	O
and	O
that	O
the	O
majority	O
of	O
the	O
suppressors	O
are	O
allele	O
-	O
independent	O
.	O

To	O
summarize	O
,	O
we	O
have	O
identified	O
20	O
genes	O
that	O
when	O
reduced	O
in	O
function	O
specifically	O
suppress	O
multiple	O
dynein	O
ts	O
strains	O
but	O
not	O
unrelated	O
ts	O
loci	O
.	O

Survey	O
of	O
Putative	O
Dynein	O
Accessory	O
Chains	O

We	O
were	O
surprised	O
to	O
discover	O
that	O
depleting	O
two	O
predicted	O
dynein	O
ACs	O
specifically	O
suppressed	O
the	O
partial	O
loss	O
of	O
HC	O
function	O
,	O
because	O
most	O
dynein	O
accessory	O
subunits	O
are	O
presumed	O
to	O
promote	O
dynein	O
function	O
by	O
aiding	O
dynein	O
complex	O
formation	O
or	O
mediating	O
cargo	O
attachment	O
[	O
3	O
,	O
11	O
,	O
33	O
]	O
.	O

Depletion	O
of	O
either	O
dylt	O
-	O
1	O
(	O
encoding	O
a	O
Tctex1	O
-	O
type	O
light	O
chain	O
)	O
or	O
dyrb	O
-	O
1	O
(	O
encoding	O
a	O
roadblock	O
-	O
type	O
light	O
chain	O
)	O
suppressed	O
embryonic	O
lethality	O
in	O
all	O
three	O
ts	O
dynein	O
HC	O
mutant	O
strains	O
(	O
Figure	O
4	O
)	O
.	O

To	O
extend	O
this	O
observation	O
,	O
we	O
surveyed	O
all	O
genes	O
encoding	O
predicted	O
dynein	O
components	O
for	O
suppression	O
of	O
the	O
three	O
ts	O
dhc	O
-	O
1	O
mutants	O
(	O
Figure	O
5A	O
;	O
Table	O
S2	O
)	O
.	O

We	O
reasoned	O
that	O
some	O
dynein	O
subunit	O
genes	O
could	O
have	O
been	O
missed	O
in	O
the	O
primary	O
screening	O
and	O
several	O
dynein	O
AC	O
genes	O
were	O
not	O
represented	O
in	O
the	O
E	B-Species
.	I-Species
coli	E-Species
RNAi	O
library	O
.	O

After	O
using	O
RNAi	O
to	O
reduce	O
their	O
function	O
,	O
we	O
found	O
that	O
one	O
of	O
three	O
Tctex1	O
homologs	O
(	O
dylt	O
-	O
1	O
)	O
,	O
one	O
of	O
four	O
LC8	O
homologs	O
(	O
dlc	O
-	O
1	O
)	O
,	O
one	O
of	O
two	O
light	O
intermediate	O
chains	O
(	O
dli	O
-	O
1	O
)	O
,	O
as	O
well	O
as	O
the	O
sole	O
roadblock	O
homolog	O
(	O
dyrb	O
-	O
1	O
)	O
each	O
strongly	O
suppressed	O
the	O
three	O
conditional	O
dynein	O
mutants	O
.	O

Lower	O
-	O
level	O
suppression	O
was	O
also	O
seen	O
for	O
the	O
second	O
light	O
intermediate	O
chain	O
,	O
xbx	O
-	O
1	O
,	O
when	O
its	O
function	O
was	O
reduced	O
.	O

Thus	O
,	O
one	O
gene	O
of	O
each	O
of	O
four	O
subunit	O
classes	O
restores	O
viability	O
to	O
the	O
three	O
dhc	O
-	O
1	O
mutant	O
strains	O
when	O
depleted	O
by	O
RNAi	O
.	O

The	O
only	O
subunit	O
class	O
not	O
found	O
to	O
suppress	O
was	O
the	O
intermediate	O
chain	O
,	O
encoded	O
by	O
a	O
single	O
gene	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
dyci	O
-	O
1	O
.	O

When	O
reduced	O
in	O
function	O
by	O
RNAi	O
,	O
dyci	O
-	O
1	O
produces	O
a	O
larval	O
arrest	O
phenotype	O
like	O
that	O
observed	O
for	O
dhc	O
-	O
1	O
(	O
RNAi	O
)	O
;	O
this	O
phenotype	O
precludes	O
any	O
suppression	O
of	O
the	O
conditional	O
embryonic	O
lethality	O
(	O
shown	O
as	O
"	O
la	O
"	O
in	O
Figure	O
5A	O
)	O
.	O

In	O
contrast	O
,	O
knockdown	O
of	O
either	O
dlc	O
-	O
1	O
or	O
dli	O
-	O
1	O
suppresses	O
embryonic	O
lethality	O
in	O
the	O
dhc	O
-	O
1ts	O
mutants	O
,	O
even	O
though	O
reducing	O
their	O
function	O
in	O
otherwise	O
wild	O
-	O
type	O
embryos	O
produces	O
dhc	O
-	O
1	O
-	O
like	O
defects	O
,	O
including	O
embryonic	O
lethality	O
[	O
12	O
,	O
34	O
]	O
(	O
see	O
Figure	O
5B	O
and	O
Discussion	O
)	O
.	O

The	O
suppressing	O
cytoplasmic	O
dynein	O
subunits	O
and	O
DYCI	O
-	O
1	O
are	O
shown	O
in	O
a	O
putative	O
complex	O
in	O
Figure	O
5E	O
.	O

We	O
performed	O
several	O
genetic	O
assays	O
to	O
better	O
understand	O
how	O
the	O
suppressor	O
genes	O
may	O
be	O
operating	O
.	O

First	O
,	O
suppression	O
of	O
dhc	O
-	O
1	O
lethality	O
by	O
reducing	O
AC	O
function	O
may	O
indicate	O
that	O
our	O
dhc	O
-	O
1	O
alleles	O
express	O
a	O
neomorphic	O
and	O
toxic	O
DHC	O
-	O
1	O
protein	O
:	O
if	O
the	O
suppressor	O
dynein	O
AC	O
subunits	O
positively	O
function	O
in	O
dynein	O
processes	O
,	O
depleting	O
them	O
might	O
suppress	O
any	O
neomorphic	O
effects	O
.	O

This	O
explanation	O
is	O
perhaps	O
unlikely	O
,	O
because	O
the	O
dhc	O
-	O
1ts	O
alleles	O
are	O
all	O
recessive	O
,	O
but	O
remained	O
a	O
possibility	O
in	O
dhc	O
-	O
1	O
homozygotes	O
.	O

We	O
therefore	O
reduced	O
dynein	O
function	O
using	O
RNAi	O
in	O
animals	O
that	O
had	O
passed	O
through	O
the	O
larval	O
arrest	O
points	O
for	O
dhc	O
-	O
1	O
(	O
RNAi	O
)	O
and	O
dyci	O
-	O
1	O
(	O
RNAi	O
)	O
.	O

Specifically	O
,	O
we	O
transferred	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
L4	O
hermaphrodites	O
to	O
plates	O
with	O
bacteria	O
expressing	O
dhc	O
-	O
1	O
or	O
dyci	O
-	O
1	O
dsRNA	O
.	O

As	O
control	O
we	O
performed	O
dylt	O
-	O
1	O
(	O
RNAi	O
)	O
using	O
the	O
same	O
procedure	O
.	O

We	O
observed	O
substantial	O
suppression	O
with	O
dylt	O
-	O
1	O
in	O
this	O
assay	O
,	O
but	O
we	O
saw	O
no	O
suppression	O
with	O
the	O
heavy	O
or	O
intermediate	O
chains	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
suggests	O
that	O
the	O
DHC	O
-	O
1ts	O
protein	O
is	O
not	O
toxic	O
and	O
that	O
dyci	O
-	O
1	O
acts	O
more	O
like	O
dhc	O
-	O
1	O
than	O
the	O
other	O
suppressing	O
ACs	O
because	O
it	O
does	O
not	O
suppress	O
the	O
heavy	O
chain	O
mutant	O
.	O

To	O
further	O
examine	O
the	O
nature	O
of	O
the	O
AC	O
suppression	O
,	O
we	O
asked	O
if	O
depletion	O
of	O
the	O
suppressor	O
chains	O
could	O
bypass	O
the	O
requirement	O
for	O
dhc	O
-	O
1	O
.	O

We	O
transferred	O
wild	O
-	O
type	O
L4	O
larvae	O
to	O
plates	O
with	O
bacteria	O
expressing	O
dsRNA	O
corresponding	O
to	O
both	O
the	O
suppressor	O
ACs	O
and	O
dhc	O
-	O
1	O
.	O

We	O
did	O
not	O
observe	O
any	O
suppression	O
in	O
these	O
double	O
RNAi	O
assays	O
(	O
Figure	O
5D	O
)	O
,	O
suggesting	O
that	O
dhc	O
-	O
1ts	O
suppression	O
requires	O
the	O
residual	O
activity	O
of	O
the	O
defective	O
DHC	O
-	O
1	O
protein	O
.	O

We	O
conclude	O
that	O
the	O
dynein	O
AC	O
suppressors	O
inhibit	O
or	O
somehow	O
oppose	O
the	O
function	O
of	O
the	O
DHC	O
-	O
1ts	O
protein	O
,	O
and	O
that	O
the	O
dhc	O
-	O
1	O
(	O
or195ts	O
)	O
mutation	O
does	O
not	O
produce	O
a	O
toxic	O
gene	O
product	O
but	O
simply	O
reduces	O
DHC	O
-	O
1	O
activity	O
to	O
a	O
low	O
,	O
but	O
non	O
-	O
null	O
,	O
level	O
.	O

Localization	O
of	O
the	O
Dynein	O
Suppressor	O
Proteins	O

To	O
further	O
explore	O
how	O
the	O
suppressor	O
proteins	O
function	O
,	O
we	O
examined	O
the	O
subcellular	O
localization	O
of	O
nine	O
of	O
them	O
as	O
stably	O
expressed	O
N	O
-	O
terminal	O
GFP	O
:	O
:	O
S	O
fusions	O
.	O

We	O
chose	O
to	O
first	O
focus	O
on	O
the	O
suppressor	O
genes	O
that	O
were	O
conserved	O
but	O
poorly	O
characterized	O
in	O
any	O
system	O
,	O
or	O
were	O
conserved	O
but	O
uncharacterized	O
during	O
early	O
C	B-Species
.	I-Species
elegans	E-Species
embryogenesis	O
.	O

Prior	O
dynein	O
immunocytochemistry	O
-	O
based	O
localization	O
studies	O
serve	O
as	O
a	O
comparison	O
[	O
6	O
,	O
10	O
,	O
35	O
]	O
.	O

As	O
in	O
other	O
species	O
,	O
C	B-Species
.	I-Species
elegans	E-Species
DHC	O
-	O
1	O
is	O
associated	O
with	O
mitotic	O
spindles	O
,	O
centrosomes	O
,	O
the	O
nuclear	O
envelope	O
,	O
the	O
cell	O
cortex	O
,	O
the	O
midbody	O
,	O
and	O
throughout	O
the	O
cytoplasm	O
.	O

Most	O
of	O
the	O
suppressor	O
proteins	O
we	O
examined	O
localized	O
to	O
sites	O
where	O
DHC	O
-	O
1	O
is	O
known	O
to	O
act	O
or	O
localize	O
(	O
Figure	O
6	O
)	O
.	O

However	O
,	O
the	O
nearly	O
ubiquitous	O
distribution	O
of	O
DHC	O
-	O
1	O
in	O
early	O
embryonic	O
cells	O
makes	O
colocalization	O
likely	O
but	O
not	O
necessarily	O
meaningful	O
,	O
and	O
biochemical	O
studies	O
are	O
needed	O
to	O
conclusively	O
address	O
any	O
direct	O
or	O
indirect	O
physical	O
associations	O
.	O

Four	O
suppressor	O
GFP	O
fusion	O
proteins	O
localized	O
to	O
nuclear	O
membranes	O
and	O
to	O
spindle	O
poles	O
or	O
pericentrosomal	O
regions	O
.	O

The	O
DYLT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
dynein	O
light	O
chains	O
were	O
associated	O
with	O
nuclear	O
envelopes	O
and	O
centrosomes	O
,	O
as	O
well	O
as	O
meiotic	O
and	O
mitotic	O
spindle	O
poles	O
(	O
Figure	O
6A	O
-	O
6H	O
;	O
Videos	O
S1	O
and	O
S2	O
)	O
.	O

The	O
potential	O
coiled	O
-	O
coil	O
protein	O
K04F10	O
.	O
3	O
was	O
present	O
on	O
the	O
nuclear	O
envelope	O
and	O
in	O
a	O
pericentrosomal	O
position	O
during	O
mitosis	O
,	O
similar	O
to	O
endoplasmic	O
reticulum	O
proteins	O
[	O
36	O
]	O
(	O
Figure	O
6I	O
-	O
6L	O
;	O
Video	O
S3	O
)	O
.	O

K04F10	O
.	O
3	O
was	O
also	O
highly	O
enriched	O
at	O
meiotic	O
spindle	O
poles	O
(	O
Figure	O
6I	O
)	O
,	O
which	O
has	O
been	O
observed	O
for	O
other	O
endoplasmic	O
reticulum	O
proteins	O
[	O
36	O
]	O
.	O

The	O
NPP	O
-	O
22	O
transmembrane	O
nucleoporin	O
was	O
found	O
at	O
nuclear	O
envelopes	O
(	O
Figure	O
6M	O
-	O
6P	O
;	O
Video	O
S4	O
)	O
,	O
as	O
previously	O
reported	O
for	O
later	O
stage	O
embryos	O
[	O
37	O
]	O
,	O
and	O
it	O
also	O
surrounded	O
centrosomes	O
during	O
mitosis	O
.	O

Two	O
splice	O
isoforms	O
of	O
the	O
pleckstrin	O
homology	O
domain	O
-	O
containing	O
EFA	O
-	O
6	O
/	O
Y55D9A	O
.	O
1	O
,	O
an	O
ARF	O
guanine	O
nucleotide	O
exchange	O
factor	O
,	O
were	O
enriched	O
cortically	O
both	O
in	O
the	O
anterior	O
portion	O
of	O
the	O
one	O
-	O
cell	O
zygote	O
and	O
at	O
the	O
blastomere	O
boundary	O
in	O
two	O
-	O
cell	O
embryos	O
(	O
Figure	O
6Q	O
-	O
6T	O
;	O
Videos	O
S5	O
and	O
S6	O
)	O
.	O

The	O
conserved	O
Mo25	O
homolog	O
MOP	O
-	O
25	O
.	O
2	O
/	O
Y53C12A	O
.	O
4	O
was	O
found	O
enriched	O
in	O
a	O
single	O
spot	O
after	O
cytokinesis	O
that	O
appears	O
to	O
correspond	O
to	O
the	O
midbody	O
(	O
Figure	O
6U	O
-	O
6X	O
;	O
Video	O
S7	O
)	O
.	O

F10E7	O
.	O
8	O
,	O
a	O
highly	O
conserved	O
ortholog	O
of	O
S	B-Species
.	I-Species
cerevisiae	E-Species
Far11	O
,	O
appears	O
nuclear	O
(	O
Figure	O
6Y	O
-	O
6B	O
'	O
and	O
Video	O
S8	O
)	O
.	O

Finally	O
,	O
the	O
nonspecific	O
suppressor	O
protein	O
STAR	O
-	O
2	O
,	O
a	O
predicted	O
RNA	O
binding	O
protein	O
,	O
appears	O
to	O
be	O
associated	O
with	O
P	O
-	O
granules	O
(	O
like	O
its	O
homolog	O
GLD	O
-	O
1	O
)	O
,	O
where	O
dynein	O
is	O
neither	O
localized	O
nor	O
known	O
to	O
function	O
(	O
Figure	O
6C	O
'	O
-	O
6F	O
'	O
)	O
.	O

DLYT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
:	O
Dynein	O
Light	O
Chain	O
Localization	O

The	O
C	B-Species
.	I-Species
elegans	E-Species
dynein	O
HC	O
protein	O
weakly	O
localizes	O
to	O
spindle	O
poles	O
during	O
early	O
embryonic	O
cell	O
cycles	O
[	O
6	O
,	O
10	O
]	O
,	O
and	O
so	O
did	O
DYRB	O
-	O
1	O
and	O
DYLT	O
-	O
1	O
(	O
Videos	O
S9	O
and	O
S10	O
)	O
.	O

However	O
,	O
ts	O
mutant	O
forms	O
of	O
the	O
DHC	O
-	O
1	O
protein	O
(	O
including	O
DHC	O
-	O
1	O
encoded	O
by	O
the	O
or195	O
allele	O
)	O
strongly	O
localize	O
to	O
centrosomes	O
when	O
shifted	O
to	O
the	O
non	O
-	O
permissive	O
temperature	O
[	O
10	O
]	O
.	O

The	O
mechanism	O
underlying	O
this	O
enhanced	O
localization	O
is	O
not	O
known	O
,	O
but	O
it	O
may	O
represent	O
trapping	O
of	O
the	O
defective	O
protein	O
at	O
a	O
normally	O
transient	O
location	O
.	O

We	O
exploited	O
this	O
behavior	O
of	O
the	O
mutant	O
DHC	O
-	O
1	O
protein	O
to	O
determine	O
whether	O
redistribution	O
of	O
the	O
putative	O
DYRB	O
-	O
1	O
and	O
DYLT	O
-	O
1	O
dynein	O
light	O
chains	O
also	O
occurred	O
in	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
background	O
.	O

We	O
found	O
that	O
the	O
cellular	O
distributions	O
of	O
DYRB	O
-	O
1	O
and	O
DYLT	O
-	O
1	O
were	O
dramatically	O
altered	O
in	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
mutant	O
embryos	O
.	O

After	O
shifting	O
the	O
parental	O
worms	S-Species
to	O
the	O
restrictive	O
temperature	O
for	O
3	O
-	O
5	O
h	O
prior	O
to	O
collecting	O
embryos	O
,	O
these	O
two	O
proteins	O
were	O
prominently	O
localized	O
to	O
centrosomes	O
and	O
to	O
spindle	O
poles	O
that	O
did	O
not	O
separate	O
in	O
one	O
-	O
cell	O
stage	O
embryos	O
(	O
Figure	O
7	O
;	O
Videos	O
S11	O
and	O
S12	O
)	O
.	O

The	O
spindle	O
pole	O
to	O
cytoplasmic	O
fluorescence	O
ratio	O
during	O
late	O
anaphase	O
was	O
5	O
-	O
fold	O
higher	O
in	O
both	O
of	O
the	O
dhc	O
-	O
1	O
homozygous	O
mutant	O
strains	O
when	O
compared	O
to	O
wild	O
-	O
type	O
embryos	O
expressing	O
the	O
GFP	O
fusions	O
.	O

We	O
also	O
assayed	O
localization	O
of	O
the	O
two	O
putative	O
dynein	O
light	O
chains	O
after	O
short	O
temperature	O
shifts	O
to	O
the	O
nonpermissive	O
temperature	O
in	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
mutant	O
background	O
,	O
which	O
yields	O
mitotic	O
spindles	O
with	O
an	O
overall	O
wild	O
-	O
type	O
appearance	O
and	O
function	O
.	O

These	O
short	O
temperature	O
shifts	O
also	O
resulted	O
in	O
robust	O
localization	O
of	O
these	O
two	O
dynein	O
light	O
chains	O
to	O
centrosomes	O
(	O
unpublished	O
data	O
)	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
localization	O
of	O
GFP	O
:	O
:	O
DYRB	O
-	O
1	O
and	O
GFP	O
:	O
:	O
DYLT	O
-	O
1	O
in	O
embryos	O
from	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
-	O
/	O
+	O
worms	S-Species
grown	O
at	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
permissive	O
temperature	O
of	O
15	O
degrees	O
C	O
.	O

Even	O
though	O
embryos	O
from	O
mothers	O
heterozygous	O
for	O
this	O
recessive	O
mutation	O
are	O
viable	O
and	O
develop	O
normally	O
,	O
even	O
at	O
26	O
degrees	O
C	O
[	O
7	O
]	O
,	O
we	O
observed	O
a	O
substantial	O
increase	O
in	O
both	O
GFP	O
fusion	O
proteins	O
at	O
the	O
mitotic	O
spindle	O
poles	O
in	O
early	O
embryos	O
(	O
Figure	O
7	O
;	O
Videos	O
S13	O
and	O
S14	O
)	O
.	O

Importantly	O
,	O
localization	O
of	O
DYLT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
to	O
centrosomes	O
does	O
not	O
occur	O
in	O
embryos	O
depleted	O
for	O
DHC	O
-	O
1	O
with	O
RNAi	O
(	O
our	O
unpublished	O
results	O
)	O
,	O
indicating	O
that	O
these	O
proteins	O
require	O
the	O
mutant	O
DHC	O
-	O
1	O
polypeptide	O
for	O
centrosomal	O
targeting	O
in	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
embryos	O
.	O

In	O
summary	O
,	O
the	O
DYRB	O
-	O
1	O
and	O
DYLT	O
-	O
1	O
proteins	O
localize	O
to	O
sites	O
where	O
the	O
DHC	O
-	O
1	O
HC	O
is	O
also	O
found	O
in	O
wild	O
-	O
type	O
embryos	O
,	O
and	O
all	O
three	O
proteins	O
respond	O
similarly	O
to	O
mutational	O
alterations	O
in	O
DHC	O
-	O
1	O
.	O

Genetic	O
Characterization	O
of	O
the	O
DYLT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
Dynein	O
Light	O
Chains	O

We	O
obtained	O
putative	O
null	O
alleles	O
to	O
determine	O
if	O
dylt	O
-	O
1	O
and	O
dyrb	O
-	O
1	O
function	O
in	O
dynein	O
-	O
dependent	O
processes	O
.	O

DYLT	O
-	O
1	O
is	O
40	O
%	O
identical	O
to	O
human	S-Species
DYNLT3	O
and	O
38	O
%	O
identical	O
to	O
Drosophila	S-Species
Dlc90F	O
(	O
see	O
alignment	O
in	O
Figure	O
8A	O
)	O
.	O

Two	O
other	O
C	B-Species
.	I-Species
elegans	E-Species
genes	O
,	O
dylt	O
-	O
2	O
and	O
dylt	O
-	O
3	O
,	O
encode	O
more	O
divergent	O
members	O
of	O
this	O
protein	O
family	O
.	O

DYRB	O
-	O
1	O
is	O
49	O
%	O
identical	O
to	O
both	O
human	S-Species
DYNLRB1	O
and	O
Drosophila	S-Species
Robl	O
(	O
see	O
alignment	O
in	O
Figure	O
8A	O
)	O
.	O

There	O
do	O
not	O
appear	O
to	O
be	O
other	O
Roadblock	O
genes	O
in	O
the	O
C	B-Species
.	I-Species
elegans	E-Species
genome	O
[	O
3	O
]	O
.	O

Deletion	O
alleles	O
for	O
both	O
dylt	O
-	O
1	O
and	O
dyrb	O
-	O
1	O
have	O
been	O
isolated	O
(	O
Figure	O
8B	O
)	O
.	O

The	O
dylt	O
-	O
1	O
(	O
ok417	O
)	O
deletion	O
removes	O
the	O
entire	O
DYLT	O
-	O
1	O
open	O
reading	O
frame	O
and	O
does	O
not	O
affect	O
adjacent	O
coding	O
regions	O
.	O

The	O
dyrb	O
-	O
1	O
(	O
tm2645	O
)	O
deletion	O
removes	O
69	O
%	O
of	O
the	O
dyrb	O
-	O
1	O
coding	O
region	O
,	O
leaving	O
29	O
predicted	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
and	O
does	O
not	O
affect	O
adjacent	O
coding	O
regions	O
.	O

Both	O
deletions	O
are	O
currently	O
annotated	O
as	O
homozygous	O
viable	O
[	O
29	O
]	O
.	O

However	O
,	O
we	O
found	O
that	O
the	O
dyrb	O
-	O
1	O
(	O
tm2645	O
)	O
strain	O
was	O
in	O
fact	O
heterozygous	O
for	O
the	O
deletion	O
and	O
that	O
most	O
embryos	O
produced	O
by	O
dyrb	O
-	O
1	O
(	O
tm2645	O
)	O
homozygous	O
animals	O
failed	O
to	O
hatch	O
(	O
Figure	O
8C	O
)	O
.	O

Homozygous	O
dyrb	O
-	O
1	O
(	O
tm2645	O
)	O
worms	S-Species
also	O
showed	O
an	O
egg	O
-	O
laying	O
defect	O
and	O
produced	O
small	O
broods	O
(	O
unpublished	O
data	O
)	O
.	O

To	O
determine	O
if	O
the	O
dyrb	O
-	O
1	O
deletion	O
was	O
responsible	O
for	O
the	O
embryonic	O
lethality	O
,	O
we	O
crossed	O
the	O
GFP	O
:	O
:	O
dyrb	O
-	O
1	O
transgene	O
into	O
the	O
deletion	O
background	O
.	O

The	O
presence	O
of	O
the	O
transgene	O
fully	O
rescued	O
the	O
embryonic	O
lethality	O
(	O
Figure	O
8C	O
)	O
,	O
but	O
not	O
the	O
egg	O
-	O
laying	O
defect	O
:	O
the	O
transgene	O
is	O
driven	O
from	O
a	O
germline	O
-	O
specific	O
promoter	O
and	O
so	O
would	O
not	O
be	O
expected	O
to	O
rescue	O
zygotic	O
phenotypes	O
.	O

The	O
embryonic	O
lethality	O
exhibited	O
by	O
dyrb	O
-	O
1	O
(	O
tm2645	O
)	O
mutants	O
is	O
consistent	O
with	O
RNAi	O
studies	O
performed	O
by	O
injection	O
or	O
soaking	O
[	O
12	O
,	O
38	O
]	O
.	O

In	O
contrast	O
,	O
homozygous	O
dylt	O
-	O
1	O
deletion	O
mutants	O
did	O
not	O
exhibit	O
any	O
larval	O
or	O
embryonic	O
lethality	O
(	O
Figure	O
8C	O
)	O
.	O

To	O
determine	O
if	O
these	O
dynein	O
light	O
chain	O
mutants	O
exhibit	O
dynein	O
HC	O
-	O
like	O
phenotypes	O
,	O
we	O
observed	O
the	O
completion	O
of	O
meiotic	O
polar	O
body	O
extrusion	O
and	O
the	O
first	O
two	O
mitotic	O
cell	O
divisions	O
in	O
mutant	O
embryos	O
(	O
Figure	O
8D	O
)	O
.	O

The	O
dylt	O
-	O
1	O
embryos	O
appeared	O
wild	O
type	O
for	O
completion	O
of	O
meiosis	O
,	O
pronuclear	O
migration	O
,	O
and	O
spindle	O
assembly	O
and	O
function	O
.	O

However	O
,	O
the	O
dyrb	O
-	O
1	O
embryos	O
occasionally	O
contained	O
extra	O
female	O
pronuclei	O
(	O
observed	O
in	O
four	O
of	O
12	O
recordings	O
,	O
Figure	O
8D	O
)	O
,	O
suggesting	O
that	O
polar	O
body	O
extrusion	O
was	O
defective	O
,	O
and	O
pronuclear	O
migration	O
was	O
often	O
slow	O
compared	O
to	O
wild	O
-	O
type	O
embryos	O
.	O

Once	O
formed	O
,	O
spindles	O
appeared	O
functional	O
using	O
Nomarski	O
optics	O
,	O
although	O
they	O
were	O
frequently	O
positioned	O
improperly	O
and	O
had	O
large	O
spindle	O
poles	O
,	O
as	O
has	O
also	O
been	O
observed	O
after	O
RNAi	O
knockdown	O
[	O
12	O
]	O
.	O

Thus	O
,	O
these	O
two	O
genes	O
are	O
not	O
strictly	O
essential	O
,	O
but	O
the	O
DYRB	O
-	O
1	O
protein	O
clearly	O
is	O
required	O
for	O
dynein	O
-	O
dependent	O
processes	O
.	O

Discussion	O

By	O
using	O
the	O
suppressor	O
screening	O
method	O
outlined	O
in	O
Figure	O
2B	O
,	O
we	O
have	O
isolated	O
and	O
characterized	O
49	O
genes	O
that	O
when	O
reduced	O
in	O
function	O
can	O
suppress	O
a	O
partial	O
loss	O
of	O
dynein	O
HC	O
function	O
.	O

This	O
screening	O
procedure	O
takes	O
advantage	O
of	O
sensitized	O
genetic	O
backgrounds	O
using	O
conditional	O
mutants	O
,	O
can	O
be	O
completed	O
for	O
one	O
mutant	O
in	O
less	O
than	O
5	O
wk	O
,	O
and	O
is	O
scalable	O
so	O
that	O
many	O
mutants	O
can	O
be	O
screened	O
in	O
parallel	O
.	O

In	O
fact	O
,	O
we	O
have	O
performed	O
15	O
such	O
screens	O
in	O
different	O
sensitized	O
backgrounds	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
using	O
three	O
dhc	O
-	O
1ts	O
mutant	O
strains	O
,	O
we	O
found	O
that	O
strain	O
background	O
differences	O
and	O
allele	O
specificity	O
are	O
minimal	O
because	O
most	O
of	O
these	O
genes	O
suppress	O
all	O
three	O
dynein	O
mutants	O
when	O
reduced	O
in	O
function	O
using	O
RNAi	O
.	O

Furthermore	O
,	O
by	O
using	O
two	O
unrelated	O
ts	O
mutants	O
to	O
assay	O
for	O
specificity	O
,	O
we	O
found	O
that	O
57	O
%	O
of	O
the	O
suppressor	O
genes	O
suppress	O
multiple	O
unrelated	O
mutant	O
loci	O
.	O

Thus	O
,	O
it	O
is	O
clear	O
that	O
assaying	O
the	O
specificity	O
of	O
suppression	O
is	O
critical	O
for	O
evaluating	O
the	O
functional	O
significance	O
of	O
these	O
RNAi	O
interactions	O
.	O

Eliminating	O
the	O
analysis	O
of	O
these	O
nonspecific	O
genes	O
in	O
future	O
screens	O
will	O
save	O
time	O
and	O
resources	O
.	O

Most	O
of	O
the	O
specific	O
suppressor	O
proteins	O
we	O
examined	O
appear	O
to	O
overlap	O
in	O
subcellular	O
localization	O
with	O
the	O
dynein	O
HC	O
,	O
based	O
on	O
previous	O
studies	O
of	O
DHC	O
-	O
1	O
,	O
while	O
one	O
nonspecific	O
suppressor	O
protein	O
,	O
STAR	O
-	O
2	O
,	O
localized	O
to	O
germline	O
P	O
-	O
granules	O
,	O
where	O
dynein	O
is	O
not	O
known	O
to	O
function	O
.	O

Many	O
of	O
the	O
20	O
genes	O
that	O
specifically	O
suppress	O
multiple	O
dhc	O
-	O
1ts	O
alleles	O
are	O
nonessential	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
but	O
well	O
conserved	O
nonetheless	O
.	O

Six	O
of	O
eight	O
deletion	O
alleles	O
available	O
for	O
the	O
20	O
specific	O
suppressor	O
genes	O
are	O
homozygous	O
viable	O
,	O
and	O
six	O
additional	O
specific	O
genes	O
do	O
not	O
display	O
lethal	O
phenotypes	O
when	O
reduced	O
in	O
function	O
by	O
RNAi	O
in	O
wild	O
-	O
type	O
worms	S-Species
[	O
29	O
]	O
.	O

Thus	O
,	O
our	O
genetic	O
screening	O
has	O
identified	O
roles	O
in	O
an	O
essential	O
process	O
for	O
at	O
least	O
12	O
apparently	O
nonessential	O
genes	O
.	O

Fourteen	O
of	O
the	O
specific	O
dynein	O
suppressor	O
genes	O
have	O
human	S-Species
orthologs	O
as	O
determined	O
by	O
best	O
reciprocal	O
BLAST	O
hits	O
(	O
Table	O
1	O
)	O
,	O
while	O
mop	O
-	O
25	O
.	O
2	O
has	O
a	O
conserved	O
human	S-Species
homolog	O
but	O
also	O
a	O
paralog	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
.	O

Eleven	O
of	O
these	O
conserved	O
genes	O
are	O
nonessential	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
.	O

Interestingly	O
,	O
eight	O
of	O
the	O
conserved	O
genes	O
in	O
Table	O
1	O
have	O
been	O
implicated	O
in	O
human	S-Species
disease	O
etiology	O
,	O
with	O
three	O
of	O
them	O
identified	O
as	O
the	O
causative	O
gene	O
[	O
39	O
-	O
41	O
]	O
.	O

Thus	O
,	O
using	O
sensitized	O
genetic	O
backgrounds	O
for	O
genome	O
-	O
wide	O
modifier	O
screens	O
can	O
identify	O
roles	O
for	O
nonessential	O
but	O
conserved	O
genes	O
and	O
thereby	O
provide	O
insights	O
into	O
human	S-Species
disease	O
.	O

Nonspecific	O
Suppression	O
of	O
Conditional	O
Mutants	O

We	O
examined	O
the	O
predicted	O
molecular	O
functions	O
of	O
the	O
suppressor	O
proteins	O
to	O
better	O
understand	O
the	O
basis	O
for	O
the	O
nonspecific	O
suppression	O
phenomenon	O
.	O

Strikingly	O
,	O
many	O
of	O
the	O
nonspecific	O
suppressor	O
genes	O
encode	O
proteins	O
with	O
predicted	O
roles	O
in	O
mitochondrial	O
,	O
ribosomal	O
,	O
and	O
collagen	O
function	O
(	O
18	O
of	O
29	O
genes	O
,	O
or	O
62	O
%	O
)	O
,	O
while	O
only	O
two	O
such	O
genes	O
appeared	O
to	O
specifically	O
suppress	O
dhc	O
-	O
1	O
(	O
2	O
of	O
20	O
genes	O
or	O
10	O
%	O
)	O
.	O

It	O
is	O
possible	O
that	O
stress	O
produced	O
by	O
RNAi	O
knockdown	O
of	O
these	O
suppressor	O
genes	O
triggers	O
the	O
activity	O
of	O
molecular	O
chaperones	O
that	O
can	O
generally	O
restore	O
function	O
to	O
ts	O
proteins	O
.	O

Indeed	O
,	O
mutation	O
of	O
dpy	O
-	O
10	O
is	O
known	O
to	O
suppress	O
three	O
other	O
ts	O
mutants	O
:	O
glp	O
-	O
1	O
,	O
emb	O
-	O
5	O
,	O
and	O
mup	O
-	O
1	O
[	O
42	O
-	O
44	O
]	O
.	O

Furthermore	O
,	O
RNAi	O
reduction	O
of	O
dpy	O
-	O
10	O
,	O
star	O
-	O
2	O
,	O
osr	O
-	O
1	O
,	O
or	O
C50D2	O
.	O
1	O
(	O
all	O
suppressors	O
of	O
dhc	O
-	O
1	O
,	O
lit	O
-	O
1	O
,	O
and	O
spn	O
-	O
4	O
ts	O
alleles	O
)	O
induces	O
the	O
glycerol	O
biosynthetic	O
gene	O
gpdh	O
-	O
2	O
,	O
while	O
dpy	O
-	O
10	O
and	O
osr	O
-	O
1	O
mutants	O
exhibit	O
increased	O
glycerol	O
levels	O
,	O
a	O
condition	O
that	O
promotes	O
protein	O
stability	O
[	O
45	O
]	O
.	O

We	O
suggest	O
that	O
partial	O
loss	O
of	O
central	O
metabolic	O
processes	O
can	O
invoke	O
stress	O
responses	O
that	O
nonspecifically	O
alleviate	O
protein	O
-	O
folding	O
problems	O
in	O
ts	O
proteins	O
.	O

Filtering	O
out	O
these	O
nonspecific	O
interactions	O
by	O
testing	O
unrelated	O
conditional	O
mutants	O
increases	O
the	O
likelihood	O
that	O
the	O
remaining	O
suppressor	O
genes	O
are	O
more	O
directly	O
involved	O
with	O
dynein	O
function	O
.	O

However	O
,	O
ts	O
mutants	O
likely	O
differ	O
in	O
their	O
susceptibility	O
to	O
nonspecific	O
suppression	O
mechanisms	O
,	O
and	O
some	O
apparently	O
unrelated	O
ts	O
mutants	O
might	O
share	O
common	O
cofactors	O
such	O
that	O
both	O
mutants	O
are	O
suppressed	O
by	O
depletion	O
of	O
the	O
same	O
cofactor	O
.	O

Nevertheless	O
,	O
we	O
expect	O
that	O
more	O
extensive	O
testing	O
for	O
specificity	O
will	O
prove	O
very	O
useful	O
for	O
judging	O
the	O
significance	O
of	O
modifier	O
interactions	O
.	O

Possible	O
Relevance	O
of	O
Suppressor	O
Proteins	O
to	O
Dynein	O
Function	O

We	O
examined	O
the	O
localization	O
of	O
a	O
number	O
of	O
GFP	O
fusions	O
to	O
suppressor	O
proteins	O
to	O
gain	O
insight	O
into	O
their	O
functional	O
relationship	O
to	O
dynein	O
.	O

In	O
several	O
cases	O
,	O
the	O
subcellular	O
distribution	O
of	O
the	O
suppressor	O
proteins	O
overlapped	O
in	O
different	O
ways	O
with	O
the	O
known	O
and	O
nearly	O
ubiquitous	O
distribution	O
of	O
cytoplasmic	O
dynein	O
in	O
the	O
early	O
C	B-Species
.	I-Species
elegans	E-Species
embryo	O
.	O

In	O
fact	O
,	O
the	O
only	O
specific	O
suppressor	O
that	O
did	O
not	O
display	O
dynein	O
-	O
like	O
localization	O
was	O
F10E7	O
.	O
8	O
,	O
a	O
homolog	O
of	O
yeast	S-Species
Far11	O
of	O
unknown	O
function	O
[	O
46	O
]	O
,	O
which	O
was	O
nuclear	O
.	O

The	O
one	O
nonspecific	O
suppressor	O
protein	O
we	O
examined	O
did	O
not	O
show	O
any	O
dynein	O
-	O
like	O
localization	O
patterns	O
.	O

The	O
subcellular	O
localizations	O
of	O
the	O
GFP	O
:	O
:	O
suppressor	O
protein	O
fusions	O
are	O
intriguing	O
.	O

However	O
,	O
given	O
the	O
nearly	O
ubiquitous	O
distribution	O
of	O
dynein	O
in	O
early	O
embryonic	O
cells	O
,	O
biochemical	O
tests	O
for	O
direct	O
association	O
are	O
needed	O
to	O
address	O
the	O
significance	O
of	O
any	O
colocalization	O
detected	O
using	O
light	O
microscopy	O
.	O

We	O
are	O
particularly	O
interested	O
in	O
suppressor	O
proteins	O
that	O
localize	O
to	O
mitotic	O
spindle	O
poles	O
:	O
the	O
association	O
of	O
the	O
DYLT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
predicted	O
dynein	O
light	O
chains	O
with	O
centrosomes	O
and	O
spindle	O
poles	O
suggests	O
that	O
they	O
may	O
be	O
components	O
of	O
cytoplasmic	O
dynein	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
.	O

Localization	O
of	O
cytoplasmic	O
dynein	O
to	O
centrosomes	O
and	O
spindle	O
poles	O
is	O
well	O
established	O
[	O
47	O
,	O
48	O
]	O
,	O
and	O
the	O
inhibition	O
of	O
dynein	O
function	O
prevents	O
centrosome	O
separation	O
,	O
centrosome	O
attachment	O
to	O
nuclei	O
,	O
and	O
the	O
formation	O
of	O
bipolar	O
spindles	O
[	O
6	O
,	O
10	O
,	O
49	O
,	O
50	O
]	O
.	O

Moreover	O
,	O
the	O
centrosomal	O
localization	O
of	O
DHC	O
-	O
1	O
,	O
DYLT	O
-	O
1	O
,	O
and	O
DYRB	O
-	O
1	O
are	O
all	O
greatly	O
enhanced	O
in	O
dhc	O
-	O
1ts	O
mutant	O
embryos	O
:	O
this	O
dependence	O
of	O
the	O
light	O
chain	O
distribution	O
on	O
the	O
HC	O
further	O
suggests	O
they	O
reside	O
in	O
the	O
same	O
motor	O
complex	O
(	O
Figure	O
7	O
and	O
[	O
10	O
]	O
)	O
.	O

Furthermore	O
,	O
roadblock	O
light	O
chains	O
are	O
well	O
-	O
established	O
components	O
of	O
dynein	O
,	O
and	O
all	O
of	O
the	O
roadblock	O
protein	O
in	O
mammalian	O
liver	O
extracts	O
is	O
dynein	O
associated	O
[	O
51	O
,	O
52	O
]	O
.	O

Finally	O
,	O
a	O
DYLT	O
-	O
1	O
homolog	O
in	O
vertebrates	O
is	O
a	O
stoichiometric	O
subunit	O
of	O
cytoplasmic	O
dynein	O
[	O
53	O
]	O
.	O

The	O
presence	O
of	O
these	O
two	O
light	O
chains	O
in	O
a	O
dynein	O
complex	O
is	O
consistent	O
with	O
them	O
having	O
either	O
positive	O
or	O
negative	O
roles	O
in	O
the	O
regulation	O
of	O
HC	O
function	O
(	O
see	O
below	O
)	O
.	O

Cytoplasmic	O
dynein	O
is	O
found	O
on	O
the	O
nuclear	O
envelope	O
where	O
it	O
is	O
thought	O
to	O
regulate	O
nuclear	O
membrane	O
breakdown	O
during	O
mitosis	O
[	O
54	O
]	O
,	O
and	O
dynein	O
plays	O
roles	O
during	O
the	O
trafficking	O
of	O
endoplasmic	O
reticulum	O
components	O
[	O
55	O
,	O
56	O
]	O
.	O

Therefore	O
,	O
the	O
nuclear	O
envelope	O
/	O
endoplasmic	O
reticulum	O
proteins	O
NPP	O
-	O
22	O
and	O
K04F10	O
.	O
3	O
could	O
couple	O
dynein	O
activity	O
to	O
either	O
of	O
these	O
structures	O
.	O

The	O
anc	O
-	O
1	O
gene	O
was	O
also	O
isolated	O
in	O
our	O
screening	O
and	O
ANC	O
-	O
1	O
is	O
localized	O
to	O
the	O
nuclear	O
envelope	O
where	O
it	O
maintains	O
nuclear	O
positioning	O
in	O
postembryonic	O
cells	O
[	O
57	O
]	O
.	O

Reducing	O
the	O
function	O
of	O
these	O
three	O
genes	O
may	O
suppress	O
partial	O
loss	O
of	O
dynein	O
HC	O
mutants	O
by	O
reducing	O
the	O
need	O
for	O
dynein	O
during	O
nuclear	O
envelope	O
breakdown	O
,	O
through	O
constitutive	O
partial	O
destabilization	O
of	O
the	O
nuclear	O
envelope	O
.	O

The	O
distribution	O
of	O
the	O
cytoplasmic	O
dynein	O
HC	O
includes	O
sites	O
other	O
than	O
spindle	O
poles	O
and	O
nuclear	O
envelopes	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
for	O
example	O
,	O
at	O
the	O
cell	O
cortex	O
and	O
at	O
the	O
cell	O
division	O
remnant	O
called	O
the	O
midbody	O
[	O
6	O
,	O
10	O
]	O
.	O

The	O
MOP	O
-	O
25	O
.	O
2	O
protein	O
was	O
found	O
at	O
the	O
midbody	O
and	O
faintly	O
at	O
spindle	O
poles	O
.	O

The	O
MOP	O
-	O
25	O
.	O
2	O
ortholog	O
in	O
S	B-Species
.	I-Species
pombe	E-Species
,	O
Pmo25	O
,	O
is	O
also	O
present	O
at	O
the	O
cell	O
division	O
site	O
and	O
on	O
spindle	O
poles	O
[	O
58	O
]	O
.	O

Mammalian	O
MOP	O
-	O
25	O
.	O
2	O
homologs	O
stimulate	O
the	O
kinase	O
activity	O
of	O
the	O
LKB1	O
tumor	O
suppressor	O
(	O
the	O
C	B-Species
.	I-Species
elegans	E-Species
ortholog	O
is	O
PAR	O
-	O
4	O
)	O
,	O
which	O
in	O
turn	O
activates	O
MARK	O
microtubule	O
-	O
destabilizing	O
kinases	O
[	O
59	O
,	O
60	O
]	O
.	O

The	O
C	B-Species
.	I-Species
elegans	E-Species
MARK	O
ortholog	O
,	O
PAR	O
-	O
1	O
,	O
controls	O
cell	O
polarity	O
during	O
embryogenesis	O
,	O
and	O
orthologs	O
have	O
been	O
implicated	O
in	O
regulation	O
of	O
microtubule	O
dynamics	O
from	O
yeast	S-Species
to	O
humans	S-Species
[	O
61	O
-	O
64	O
]	O
.	O

Lastly	O
,	O
the	O
two	O
splice	O
isoforms	O
of	O
EFA	O
-	O
6	O
were	O
associated	O
with	O
the	O
anterior	O
cell	O
cortex	O
in	O
late	O
one	O
-	O
cell	O
embryos	O
.	O

Cortically	O
localized	O
dynein	O
may	O
have	O
important	O
roles	O
in	O
applying	O
forces	O
to	O
astral	O
microtubules	O
that	O
influence	O
mitotic	O
spindle	O
positioning	O
and	O
chromosome	O
separation	O
during	O
anaphase	O
[	O
10	O
,	O
65	O
,	O
66	O
]	O
.	O

EFA6	O
ARF	O
guanine	O
nucleotide	O
exchange	O
factors	O
require	O
their	O
pleckstrin	O
homology	O
domain	O
for	O
cortical	O
targeting	O
,	O
and	O
are	O
known	O
to	O
regulate	O
cortical	O
actin	O
dynamics	O
in	O
vertebrate	O
cells	O
by	O
promoting	O
guanine	O
nucleotide	O
exchange	O
on	O
ARF6	O
[	O
67	O
,	O
68	O
]	O
.	O

Our	O
results	O
identifying	O
efa	O
-	O
6	O
as	O
a	O
dynein	O
HC	O
suppressor	O
suggest	O
a	O
functional	O
linkage	O
of	O
the	O
actin	O
and	O
microtubule	O
cytoskeletons	O
at	O
the	O
cell	O
cortex	O
.	O

Interestingly	O
,	O
two	O
yeast	S-Species
pleckstrin	O
homology	O
domain	O
proteins	O
,	O
Num1	O
and	O
mcp5	O
+	O
,	O
localize	O
to	O
the	O
cell	O
cortex	O
and	O
direct	O
astral	O
microtubule	O
and	O
dynein	O
function	O
,	O
although	O
they	O
do	O
not	O
contain	O
a	O
Sec7	O
domain	O
like	O
EFA	O
-	O
6	O
does	O
[	O
69	O
-	O
71	O
]	O
.	O

Function	O
of	O
Dynein	O
Intermediate	O
,	O
Light	O
Intermediate	O
,	O
and	O
Light	O
Chains	O

The	O
dynein	O
chains	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
exhibit	O
strikingly	O
different	O
functional	O
requirements	O
.	O

The	O
DYRB	O
-	O
1	O
roadblock	O
light	O
chain	O
is	O
required	O
for	O
completion	O
of	O
meiosis	O
and	O
pronuclear	O
migration	O
,	O
but	O
an	O
at	O
least	O
partially	O
functional	O
mitotic	O
spindle	O
forms	O
in	O
the	O
absence	O
of	O
DYRB	O
-	O
1	O
(	O
Figure	O
8	O
)	O
.	O

The	O
DLI	O
-	O
1	O
light	O
intermediate	O
chain	O
is	O
required	O
for	O
multiple	O
dynein	O
-	O
dependent	O
functions	O
:	O
pronuclear	O
migration	O
,	O
centrosome	O
separation	O
,	O
and	O
meiotic	O
and	O
mitotic	O
spindle	O
function	O
[	O
12	O
,	O
34	O
]	O
.	O

DLI	O
-	O
1	O
may	O
promote	O
nuclear	O
envelope	O
targeting	O
of	O
both	O
centrosomes	O
and	O
DHC	O
-	O
1	O
by	O
interacting	O
with	O
the	O
nuclear	O
envelope	O
protein	O
ZYG	O
-	O
12	O
[	O
35	O
]	O
.	O

The	O
second	O
worm	O
light	O
intermediate	O
chain	O
gene	O
,	O
xbx	O
-	O
1	O
,	O
is	O
required	O
for	O
cilia	O
function	O
but	O
not	O
early	O
embryonic	O
development	O
[	O
12	O
,	O
72	O
]	O
.	O

RNAi	O
knockdown	O
of	O
DLC	O
-	O
1	O
,	O
one	O
of	O
three	O
LC8	O
proteins	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
produces	O
defects	O
similar	O
to	O
dli	O
-	O
1	O
but	O
knockdown	O
of	O
the	O
other	O
two	O
LC8	O
-	O
related	O
genes	O
does	O
not	O
result	O
in	O
any	O
phenotypes	O
[	O
12	O
]	O
.	O

RNAi	O
depletion	O
of	O
dyci	O
-	O
1	O
results	O
in	O
severe	O
meiotic	O
,	O
pronuclear	O
migration	O
,	O
and	O
mitotic	O
spindle	O
assembly	O
defects	O
[	O
12	O
]	O
and	O
in	O
our	O
feeding	O
RNAi	O
regimen	O
dyci	O
-	O
1	O
(	O
RNAi	O
)	O
produces	O
a	O
larval	O
arrest	O
phenotype	O
similar	O
to	O
that	O
observed	O
for	O
dhc	O
-	O
1	O
.	O

Finally	O
,	O
the	O
three	O
Tctex1	O
proteins	O
in	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
DYLT	O
-	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
are	O
not	O
essential	O
for	O
dynein	O
-	O
related	O
functions	O
[	O
12	O
]	O
.	O

As	O
the	O
dyrb	O
-	O
1	O
,	O
dlc	O
-	O
1	O
,	O
and	O
dli	O
-	O
1	O
dynein	O
AC	O
genes	O
display	O
some	O
dhc	O
-	O
1	O
-	O
like	O
requirements	O
,	O
they	O
positively	O
influence	O
dynein	O
function	O
.	O

However	O
,	O
because	O
reducing	O
their	O
function	O
suppresses	O
dhc	O
-	O
1ts	O
mutants	O
,	O
they	O
may	O
also	O
exert	O
negative	O
regulation	O
(	O
along	O
with	O
dylt	O
-	O
1	O
)	O
on	O
the	O
heavy	O
chain	O
.	O

Negative	O
Regulation	O
of	O
Dynein	O
HC	O
by	O
Light	O
Chain	O
Subunits	O

Finding	O
that	O
reducing	O
the	O
function	O
of	O
light	O
and	O
light	O
intermediate	O
dynein	O
chains	O
suppressed	O
the	O
partial	O
loss	O
of	O
HC	O
function	O
was	O
a	O
striking	O
result	O
.	O

One	O
member	O
of	O
each	O
of	O
four	O
subunit	O
classes	O
can	O
suppress	O
the	O
embryonic	O
lethality	O
associated	O
with	O
three	O
dhc	O
-	O
1	O
ts	O
mutants	O
(	O
Figure	O
5	O
)	O
.	O

We	O
have	O
considered	O
two	O
different	O
models	O
to	O
explain	O
how	O
RNAi	O
-	O
mediated	O
depletion	O
of	O
these	O
dynein	O
ACs	O
can	O
suppress	O
reduced	O
HC	O
function	O
.	O

First	O
,	O
these	O
dynein	O
subunits	O
could	O
be	O
in	O
functional	O
complexes	O
with	O
,	O
and	O
exert	O
negative	O
regulation	O
on	O
,	O
the	O
DHC	O
-	O
1	O
HC	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
suppression	O
mechanism	O
in	O
this	O
case	O
proposes	O
that	O
removal	O
of	O
the	O
suppressing	O
ACs	O
increases	O
residual	O
mutant	O
DHC	O
-	O
1	O
activity	O
.	O

The	O
other	O
,	O
nonsuppressing	O
,	O
accessory	O
subunits	O
might	O
then	O
function	O
in	O
nonmitotic	O
cellular	O
processes	O
such	O
as	O
neuronal	O
transport	O
or	O
organelle	O
positioning	O
.	O

In	O
support	O
of	O
this	O
view	O
,	O
physical	O
removal	O
of	O
the	O
intermediate	O
chains	O
of	O
rat	S-Species
cytoplasmic	O
dynein	O
increased	O
HC	O
ATPase	O
activity	O
by	O
about	O
4	O
-	O
fold	O
(	O
light	O
chains	O
were	O
not	O
monitored	O
in	O
this	O
study	O
but	O
were	O
likely	O
removed	O
as	O
well	O
)	O
[	O
73	O
]	O
.	O

Thus	O
,	O
at	O
least	O
with	O
respect	O
to	O
ATPase	O
activity	O
,	O
some	O
dynein	O
ACs	O
do	O
act	O
as	O
biochemical	O
negative	O
regulators	O
of	O
HC	O
function	O
.	O

An	O
Assortment	O
of	O
Essential	O
and	O
Nonessential	O
Dynein	O
Complexes	O

Alternatively	O
,	O
an	O
assortment	O
of	O
dynein	O
complexes	O
(	O
with	O
different	O
ACs	O
)	O
could	O
coexist	O
within	O
early	O
embryonic	O
cells	O
,	O
with	O
only	O
a	O
subset	O
required	O
for	O
the	O
essential	O
mitotic	O
functions	O
that	O
require	O
DHC	O
-	O
1	O
.	O

In	O
this	O
case	O
,	O
suppression	O
might	O
result	O
from	O
the	O
release	O
of	O
DHC	O
-	O
1	O
HCs	O
from	O
less	O
essential	O
motor	O
complexes	O
,	O
allowing	O
more	O
of	O
the	O
functionally	O
compromised	O
HCs	O
to	O
participate	O
in	O
the	O
essential	O
process	O
of	O
mitosis	O
.	O

We	O
currently	O
disfavor	O
this	O
hypothesis	O
because	O
two	O
of	O
the	O
suppressing	O
light	O
chains	O
(	O
DYLT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
)	O
can	O
indeed	O
localize	O
to	O
meiotic	O
and	O
mitotic	O
spindles	O
(	O
Figures	O
6	O
and	O
7	O
)	O
,	O
sites	O
where	O
DHC	O
-	O
1	O
has	O
been	O
shown	O
by	O
others	O
to	O
localize	O
and	O
function	O
.	O

Furthermore	O
,	O
the	O
distribution	O
of	O
DYRB	O
-	O
1	O
and	O
DYLT	O
-	O
1	O
closely	O
resembles	O
the	O
distribution	O
of	O
the	O
HC	O
in	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
embryos	O
,	O
suggesting	O
that	O
these	O
two	O
light	O
chains	O
associate	O
with	O
the	O
HC	O
during	O
mitosis	O
(	O
Figure	O
7	O
and	O
[	O
10	O
]	O
)	O
.	O

Finally	O
,	O
dhc	O
-	O
1	O
-	O
like	O
phenotypes	O
result	O
from	O
mutation	O
or	O
RNAi	O
knockdown	O
of	O
three	O
suppressing	O
ACs	O
in	O
otherwise	O
wild	O
-	O
type	O
worms	S-Species
,	O
indicating	O
that	O
they	O
share	O
at	O
least	O
some	O
common	O
and	O
essential	O
requirements	O
.	O

Regardless	O
of	O
the	O
suppression	O
mechanism	O
,	O
our	O
identification	O
of	O
ACs	O
that	O
genetically	O
interact	O
with	O
the	O
DHC	O
-	O
1	O
HC	O
provides	O
a	O
basis	O
for	O
functionally	O
classifying	O
the	O
paralogs	O
of	O
these	O
dynein	O
subunit	O
gene	O
families	O
,	O
and	O
for	O
further	O
investigation	O
of	O
dynein	O
composition	O
and	O
function	O
.	O

Nonessential	O
Dynein	O
Subunits	O
and	O
Negative	O
Regulation	O
of	O
the	O
HC	O

Some	O
ACs	O
are	O
nonessential	O
,	O
supporting	O
the	O
view	O
that	O
some	O
cytoplasmic	O
dynein	O
subunits	O
could	O
function	O
by	O
exerting	O
negative	O
regulation	O
on	O
the	O
HC	O
,	O
rather	O
than	O
positively	O
influencing	O
essential	O
HC	O
function	O
.	O

For	O
example	O
,	O
DYRB	O
-	O
1	O
is	O
not	O
absolutely	O
required	O
for	O
viability	O
because	O
worms	S-Species
lacking	O
this	O
protein	O
can	O
be	O
propagated	O
,	O
although	O
they	O
are	O
extremely	O
sick	O
and	O
do	O
exhibit	O
two	O
dhc	O
-	O
1	O
-	O
like	O
phenotypes	O
(	O
Figure	O
8	O
)	O
.	O

Also	O
,	O
homozygous	O
dylt	O
-	O
1	O
deletion	O
mutants	O
appear	O
fully	O
viable	O
(	O
Figure	O
8	O
)	O
.	O

The	O
two	O
additional	O
Tctex1	O
C	B-Species
.	I-Species
elegans	E-Species
genes	O
could	O
be	O
functionally	O
redundant	O
with	O
DYLT	O
-	O
1	O
,	O
but	O
simultaneously	O
reducing	O
the	O
function	O
of	O
DYLT	O
-	O
2	O
and	O
DYLT	O
-	O
3	O
by	O
RNAi	O
in	O
the	O
dylt	O
-	O
1	O
deletion	O
strain	O
did	O
not	O
cause	O
lethality	O
(	O
unpublished	O
data	O
)	O
.	O

Because	O
RNAi	O
does	O
not	O
always	O
completely	O
reduce	O
function	O
,	O
the	O
question	O
of	O
redundancy	O
in	O
the	O
Tctex1	O
C	B-Species
.	I-Species
elegans	E-Species
gene	O
family	O
remains	O
unresolved	O
.	O

However	O
,	O
Drosophila	S-Species
contains	O
only	O
a	O
single	O
Tctex1	O
gene	O
,	O
Dlc90F	O
[	O
74	O
,	O
75	O
]	O
.	O

A	O
Dlc90F	O
null	O
allele	O
that	O
deletes	O
80	O
%	O
of	O
the	O
open	O
reading	O
frame	O
is	O
essential	O
only	O
for	O
sperm	O
production	O
but	O
not	O
for	O
viability	O
of	O
male	O
or	O
female	O
flies	O
,	O
despite	O
the	O
wild	O
-	O
type	O
protein	O
being	O
incorporated	O
into	O
dynein	O
motors	O
and	O
expressed	O
in	O
various	O
Drosophila	S-Species
tissues	O
[	O
74	O
]	O
.	O

Thus	O
,	O
at	O
least	O
in	O
Drosophila	S-Species
,	O
the	O
Tctex1	O
dynein	O
light	O
chain	O
family	O
is	O
not	O
required	O
for	O
cell	O
division	O
processes	O
like	O
the	O
HC	O
is	O
.	O

Interestingly	O
,	O
budding	O
yeast	S-Species
does	O
not	O
possess	O
genes	O
for	O
the	O
Tctex1	O
or	O
roadblock	O
ACs	O
,	O
indicating	O
that	O
functional	O
cytoplasmic	O
dynein	O
does	O
not	O
require	O
these	O
subunits	O
that	O
are	O
conserved	O
in	O
many	O
other	O
organisms	O
.	O

The	O
AC	O
genes	O
that	O
yeast	S-Species
does	O
posses	O
are	O
not	O
required	O
for	O
HC	O
motility	O
in	O
vitro	O
because	O
dynein	O
purified	O
from	O
yeast	S-Species
with	O
mutations	O
in	O
these	O
genes	O
remains	O
fully	O
active	O
[	O
2	O
]	O
.	O

Thus	O
,	O
dynein	O
function	O
in	O
several	O
contexts	O
does	O
not	O
require	O
AC	O
subunits	O
,	O
and	O
we	O
suggest	O
that	O
in	O
some	O
cases	O
they	O
may	O
have	O
negative	O
regulatory	O
roles	O
.	O

Negative	O
regulation	O
of	O
cytoplasmic	O
dynein	O
may	O
be	O
redundant	O
with	O
other	O
modes	O
of	O
HC	O
regulation	O
or	O
only	O
required	O
during	O
special	O
circumstances	O
.	O

Further	O
studies	O
of	O
subunit	O
localization	O
,	O
and	O
in	O
vitro	O
studies	O
of	O
C	B-Species
.	I-Species
elegans	E-Species
dynein	O
motility	O
,	O
may	O
provide	O
further	O
insight	O
into	O
the	O
modes	O
of	O
AC	O
regulation	O
and	O
function	O
.	O

Materials	O
and	O
Methods	O

C	B-Species
.	I-Species
elegans	E-Species
strains	O
and	O
culture	O
.	O

Strains	O
were	O
cultured	O
according	O
to	O
standard	O
procedures	O
[	O
28	O
]	O
.	O

ts	O
mutants	O
were	O
maintained	O
at	O
15	O
degrees	O
C	O
and	O
GFP	O
-	O
expressing	O
strains	O
in	O
a	O
wild	O
-	O
type	O
background	O
were	O
maintained	O
in	O
a	O
23	O
degrees	O
C	O
incubator	O
.	O

dhc	O
-	O
1	O
(	O
or195	O
)	O
was	O
outcrossed	O
six	O
times	O
to	O
the	O
N2	O
Bristol	O
wild	O
-	O
type	O
strain	O
and	O
the	O
or283	O
and	O
or352	O
dhc	O
-	O
1	O
mutants	O
were	O
each	O
outcrossed	O
four	O
times	O
with	O
N2	O
.	O

For	O
sequencing	O
mutant	O
dhc	O
-	O
1	O
loci	O
,	O
genomic	O
DNA	O
was	O
amplified	O
as	O
overlapping	O
~	O
1	O
-	O
kb	O
fragments	O
from	O
the	O
start	O
codon	O
to	O
the	O
stop	O
codon	O
and	O
sequenced	O
at	O
the	O
University	O
of	O
Oregon	O
DNA	O
sequencing	O
laboratory	O
.	O

For	O
double	O
mutant	O
constructions	O
,	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
mutation	O
was	O
monitored	O
by	O
sequencing	O
or	O
by	O
assaying	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
caused	O
by	O
the	O
mutation	O
with	O
Hpy188I	O
(	O
New	O
England	O
Biolabs	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
neb	O
.	O
com	O
)	O
,	O
following	O
PCR	O
amplification	O
of	O
the	O
mutated	O
region	O
.	O

The	O
dylt	O
-	O
1	O
(	O
ok417	O
)	O
and	O
ufd	O
-	O
2	O
(	O
tm1380	O
)	O
alleles	O
were	O
monitored	O
by	O
PCR	O
amplification	O
of	O
genomic	O
sequence	O
encompassing	O
the	O
deletions	O
and	O
assaying	O
product	O
size	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

GFP	O
imaging	O
.	O

Visualization	O
of	O
GFP	O
fusion	O
protein	O
localization	O
was	O
accomplished	O
by	O
mounting	O
embryos	O
on	O
M9	O
+	O
3	O
%	O
agarose	O
pads	O
on	O
microscope	O
slides	O
covered	O
with	O
a	O
coverslip	O
.	O

Time	O
-	O
lapse	O
videos	O
were	O
obtained	O
on	O
a	O
spinning	O
disk	O
Nikon	O
Eclipse	O
TE2000	O
-	O
U	O
microscope	O
(	O
Nikon	O
Instruments	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
nikon	O
.	O
com	O
)	O
fitted	O
with	O
an	O
ORCA	O
-	O
ER	O
digital	O
camera	O
(	O
Hamamatsu	O
Photonics	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
hamamatsu	O
.	O
com	O
)	O
using	O
a	O
Nikon	O
60	O
x	O
,	O
1	O
.	O
4	O
NA	O
Plan	O
Apo	O
oil	O
objective	O
lens	O
.	O

Videos	O
were	O
adjusted	O
for	O
contrast	O
in	O
ImageJ	O
(	O
National	O
Institutes	O
of	O
Health	O
,	O
http	O
:	O
/	O
/	O
rsb	O
.	O
info	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
/	O
)	O
[	O
76	O
]	O
,	O
images	O
were	O
adjusted	O
for	O
levels	O
in	O
Adobe	O
Photoshop	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
adobe	O
.	O
com	O
/	O
)	O
.	O

RNAi	O
screening	O
.	O

After	O
obtaining	O
the	O
E	B-Species
.	I-Species
coli	E-Species
RNAi	O
library	O
from	O
the	O
MRC	O
Geneservice	O
(	O
Cambridge	O
,	O
UK	O
)	O
[	O
17	O
,	O
19	O
]	O
,	O
we	O
rearrayed	O
it	O
into	O
a	O
48	O
-	O
well	O
microplate	O
format	O
using	O
a	O
liquid	O
-	O
handling	O
Qiagen	O
BioRobot	O
8000	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
qiagen	O
.	O
com	O
)	O
.	O

E	B-Species
.	I-Species
coli	E-Species
strains	O
were	O
thawed	O
from	O
-	O
80	O
degrees	O
C	O
storage	O
and	O
inoculated	O
into	O
1	O
ml	O
of	O
LB	O
+	O
100	O
mg	O
/	O
ml	O
ampicillin	O
-	O
containing	O
96	O
-	O
well	O
growth	O
plates	O
(	O
Whatman	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
whatman	O
.	O
com	O
)	O
and	O
covered	O
with	O
microporous	O
sealing	O
film	O
(	O
USA	O
Scientific	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
usascientific	O
.	O
com	O
)	O
.	O

Only	O
48	O
wells	O
of	O
the	O
96	O
-	O
well	O
growth	O
plates	O
were	O
filled	O
with	O
media	O
,	O
corresponding	O
to	O
the	O
rearrayed	O
E	B-Species
.	I-Species
coli	E-Species
library	O
.	O

After	O
overnight	O
shaking	O
incubation	O
at	O
37	O
degrees	O
C	O
,	O
20	O
mu	O
l	O
of	O
the	O
cultures	O
were	O
dispensed	O
with	O
a	O
24	O
-	O
channel	O
electronic	O
repeating	O
pipette	O
(	O
Rainin	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
rainin	O
.	O
com	O
)	O
onto	O
48	O
-	O
well	O
plates	O
(	O
Nunc	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
nuncbrand	O
.	O
com	O
/	O
)	O
containing	O
NGM	O
agar	O
,	O
100	O
mu	O
g	O
/	O
ml	O
ampicillin	O
,	O
and	O
1	O
mM	O
IPTG	O
and	O
allowed	O
to	O
dry	O
and	O
induce	O
dsRNA	O
at	O
37	O
degrees	O
C	O
overnight	O
.	O

The	O
48	O
-	O
well	O
agar	O
plates	O
were	O
filled	O
with	O
a	O
Wheaton	O
Unispense	O
peristaltic	O
pump	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
wheaton	O
.	O
com	O
)	O
equipped	O
with	O
a	O
custom	O
-	O
made	O
adaptor	O
(	O
University	O
of	O
Oregon	O
Technical	O
Science	O
Administration	O
)	O
that	O
allowed	O
simultaneous	O
filling	O
of	O
eight	O
wells	O
with	O
the	O
agar	O
solution	O
.	O

Approximately	O
15	O
hypochlorite	O
-	O
synchronized	O
L1	O
mutant	O
larvae	O
were	O
pipetted	O
into	O
each	O
well	O
of	O
the	O
48	O
-	O
well	O
plates	O
with	O
a	O
multichannel	O
pipette	O
and	O
allowed	O
to	O
produce	O
broods	O
.	O

Screening	O
for	O
F1	O
viability	O
was	O
performed	O
by	O
visual	O
examination	O
with	O
a	O
dissecting	O
microscope	O
.	O

Phenotypes	O
were	O
recorded	O
on	O
an	O
Excel	O
spreadsheet	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
microsoft	O
.	O
com	O
)	O
and	O
organized	O
in	O
a	O
FileMaker	O
Pro	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
filemaker	O
.	O
com	O
)	O
database	O
.	O

We	O
qualitatively	O
identified	O
295	O
initial	O
positive	O
suppressing	O
E	B-Species
.	I-Species
coli	E-Species
strains	O
,	O
for	O
which	O
we	O
repeated	O
the	O
assay	O
on	O
60	O
-	O
mm	O
plates	O
with	O
E	B-Species
.	I-Species
coli	E-Species
again	O
thawed	O
from	O
the	O
library	O
(	O
not	O
streak	O
purified	O
)	O
.	O

If	O
the	O
observed	O
phenotypes	O
reproduced	O
,	O
the	O
assay	O
was	O
performed	O
with	O
three	O
streak	O
-	O
purified	O
E	B-Species
.	I-Species
coli	E-Species
colonies	O
,	O
and	O
a	O
single	O
isolate	O
that	O
again	O
displayed	O
the	O
interaction	O
was	O
kept	O
for	O
further	O
analysis	O
.	O

Embryonic	O
viability	O
quantitation	O
methods	O
.	O

To	O
quantitate	O
embryonic	O
viability	O
we	O
used	O
the	O
following	O
procedure	O
.	O

Cultures	O
of	O
dsRNA	O
-	O
producing	O
bacteria	O
were	O
grown	O
overnight	O
in	O
LB	O
+	O
100	O
mu	O
g	O
/	O
ml	O
ampicillin	O
.	O

Cultures	O
(	O
0	O
.	O
2	O
ml	O
)	O
were	O
seeded	O
onto	O
60	O
-	O
mm	O
NGM	O
agar	O
plates	O
containing	O
100	O
mu	O
g	O
/	O
ml	O
ampicillin	O
and	O
1	O
mM	O
IPTG	O
and	O
allowed	O
to	O
induce	O
dsRNAs	O
overnight	O
at	O
room	O
temperature	O
.	O

The	O
L4440	O
control	O
vector	O
-	O
containing	O
strain	O
was	O
used	O
as	O
the	O
bacterial	O
lawn	O
for	O
the	O
experiments	O
shown	O
in	O
Figures	O
2A	O
and	O
3B	O
.	O

Approximately	O
80	O
synchronized	O
L1	O
larvae	O
(	O
obtained	O
from	O
hypochlorite	O
-	O
treated	O
worms	S-Species
)	O
were	O
pipetted	O
onto	O
the	O
plates	O
and	O
allowed	O
to	O
grow	O
to	O
young	O
adulthood	O
.	O

Five	O
gravid	O
worms	S-Species
were	O
transferred	O
to	O
prepared	O
NGM	O
agar	O
plates	O
supplemented	O
with	O
100	O
mu	O
g	O
/	O
ml	O
ampicillin	O
and	O
1	O
mM	O
IPTG	O
containing	O
a	O
small	O
RNAi	O
bacterial	O
lawn	O
produced	O
from	O
~	O
5	O
mu	O
l	O
of	O
overnight	O
E	B-Species
.	I-Species
coli	E-Species
culture	O
.	O

After	O
producing	O
broods	O
,	O
the	O
adult	O
worms	S-Species
were	O
removed	O
and	O
the	O
embryos	O
were	O
allowed	O
to	O
develop	O
for	O
at	O
least	O
24	O
h	O
.	O

Embryos	O
and	O
larvae	O
were	O
then	O
counted	O
immediately	O
or	O
after	O
storage	O
at	O
4	O
degrees	O
C	O
.	O

We	O
considered	O
only	O
suppressor	O
dsRNAs	O
that	O
increased	O
embryonic	O
viability	O
greater	O
than	O
3	O
-	O
fold	O
above	O
the	O
background	O
viability	O
observed	O
with	O
the	O
L4440	O
control	O
vector	O
(	O
in	O
the	O
dhc	O
-	O
1	O
(	O
or195	O
)	O
)	O
screen	O
to	O
be	O
significant	O
enough	O
for	O
continued	O
study	O
.	O

Molecular	O
biology	O
.	O

We	O
introduced	O
a	O
polylinker	O
site	O
containing	O
six	O
unique	O
restriction	O
enzyme	O
recognition	O
sites	O
into	O
the	O
pIC26	O
GFP	O
-	O
S	O
protein	O
plasmid	O
by	O
using	O
phosphorylated	O
and	O
PAGE	O
-	O
purified	O
synthetic	O
oligonucleotides	O
[	O
77	O
]	O
.	O

Following	O
ligation	O
,	O
the	O
new	O
plasmid	O
was	O
sequence	O
verified	O
.	O

The	O
modified	O
vector	O
,	O
pSO26	O
,	O
allows	O
the	O
use	O
of	O
additional	O
restriction	O
enzymes	O
and	O
directional	O
cloning	O
for	O
inserting	O
genes	O
of	O
interest	O
(	O
Figure	O
S2	O
)	O
.	O

The	O
SpeI	O
site	O
was	O
recreated	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
polylinker	O
but	O
not	O
at	O
the	O
3	O
'	O
end	O
.	O

We	O
amplified	O
N2	O
genomic	O
DNA	O
or	O
cDNA	O
(	O
Invitrogen	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
with	O
Pfu	O
Turbo	O
polymerase	O
(	O
Stratagene	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
stratagene	O
.	O
com	O
)	O
,	O
and	O
cloned	O
A	O
-	O
tailed	O
PCR	O
products	O
into	O
either	O
pGEM	O
-	O
T	O
or	O
pGEM	O
-	O
T	O
-	O
easy	O
shuttle	O
vectors	O
(	O
Promega	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
promega	O
.	O
com	O
)	O
.	O

Inserted	O
genes	O
were	O
sequence	O
verified	O
at	O
the	O
University	O
of	O
Oregon	O
DNA	O
sequencing	O
laboratory	O
prior	O
to	O
cleavage	O
and	O
ligation	O
to	O
pSO26	O
(	O
see	O
Table	O
S3	O
for	O
restriction	O
sites	O
and	O
primer	O
sequences	O
used	O
)	O
.	O

All	O
of	O
the	O
constructs	O
used	O
in	O
this	O
study	O
were	O
cloned	O
as	O
SpeI	O
-	O
AsiSI	O
or	O
AscI	O
-	O
AsiSI	O
fragments	O
,	O
except	O
for	O
the	O
STAR	O
-	O
2	O
gene	O
,	O
which	O
was	O
amplified	O
as	O
a	O
SpeI	O
fragment	O
and	O
cloned	O
into	O
pIC26	O
.	O

To	O
construct	O
dynein	O
subunit	O
dsRNA	O
-	O
expressing	O
plasmids	O
not	O
available	O
in	O
the	O
RNAi	O
library	O
,	O
gene	O
fragments	O
were	O
amplified	O
from	O
N2	O
genomic	O
DNA	O
with	O
the	O
following	O
primers	O
:	O
F41G4	O
.	O
1	O
:	O
5	O
'	O
-	O
AAGATATCACCCAAAATGGTCCAAAACAAAG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CGGATATCTCGACTGAAGCTGGTTCTGA	O
-	O
3	O
'	O
,	O
xbx	O
-	O
1	O
:	O
5	O
'	O
-	O
AAGATATCTACGACGATGGAAGTTTGAAG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CGGATATCCGTGCCTCTGCAGC	O
-	O
3	O
'	O
,	O
dlc	O
-	O
3	O
:	O
5	O
'	O
-	O
AAGATATCAATTTCAGGTGGACACTGGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CGGATATCAGCACACTTGCATCATCTGAA	O
-	O
3	O
'	O
.	O

The	O
PCR	O
products	O
were	O
cut	O
with	O
EcoRV	O
,	O
ligated	O
to	O
EcoRV	O
-	O
digested	O
L4440	O
,	O
and	O
sequence	O
verified	O
.	O

Isolation	O
of	O
transgenic	O
worms	S-Species
.	O

GFP	O
fusion	O
plasmids	O
were	O
bombarded	O
into	O
unc	O
-	O
119	O
(	O
ed3	O
)	O
worms	S-Species
as	O
previously	O
described	O
except	O
with	O
the	O
following	O
two	O
changes	O
[	O
78	O
]	O
.	O

Three	O
milligrams	O
of	O
gold	O
particles	O
were	O
used	O
per	O
hepta	O
adaptor	O
bombardment	O
.	O

Also	O
,	O
we	O
briefly	O
sonicated	O
the	O
gold	O
particles	O
(	O
prior	O
to	O
DNA	O
coating	O
and	O
while	O
suspended	O
in	O
50	O
%	O
glycerol	O
)	O
with	O
a	O
Branson	O
sonifier	O
450	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
sonifier	O
.	O
com	O
/	O
)	O
fitted	O
with	O
a	O
small	O
tip	O
set	O
to	O
power	O
level	O
1	O
,	O
to	O
disrupt	O
gold	O
aggregates	O
.	O

Non	O
-	O
Unc	O
worms	S-Species
were	O
picked	O
to	O
new	O
plates	O
and	O
allowed	O
to	O
produce	O
broods	O
,	O
which	O
were	O
assayed	O
for	O
GFP	O
fluorescence	O
with	O
a	O
Zeiss	O
axioskop	O
microscope	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
zeiss	O
.	O
com	O
/	O
)	O
fitted	O
with	O
an	O
X	O
-	O
Cite	O
120	O
illumination	O
system	O
(	O
EXFO	O
life	O
sciences	O
,	O
Mississauga	O
,	O
Ontario	O
,	O
Canada	O
)	O
.	O

For	O
each	O
fluorescent	O
line	O
,	O
12	O
GFP	O
-	O
positive	O
worms	S-Species
were	O
singled	O
to	O
new	O
plates	O
to	O
determine	O
if	O
the	O
constructs	O
were	O
integrated	O
or	O
were	O
carried	O
as	O
extrachromosomal	O
arrays	O
.	O

Supporting	O
Information	O

Accession	O
Numbers	O

The	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
gquery	O
/	O
gquery	O
.	O
fcgi	O
?	O
itool	O
=	O
toolbar	O
)	O
accession	O
numbers	O
for	O
the	O
dhc	O
-	O
1	O
homologs	O
discussed	O
in	O
this	O
paper	O
are	O
C	B-Species
.	I-Species
elegans	E-Species
,	O
NP	O
_	O
491363	O
;	O
Dictyostelium	B-Species
discoideum	E-Species
,	O
XP	O
_	O
643185	O
;	O
Drosophila	B-Species
melanogaster	E-Species
,	O
AAA60323	O
;	O
Homo	B-Species
sapiens	E-Species
,	O
NP	O
_	O
001367	O
;	O
Mus	B-Species
musculus	E-Species
,	O
NP	O
_	O
084514	O
;	O
Saccharomyces	B-Species
cerevisiae	E-Species
,	O
NP	O
_	O
012980	O
;	O
and	O
Schizosaccharomyces	B-Species
pombe	E-Species
,	O
NP	O
_	O
001018285	O
.	O

The	O
NCBI	O
accession	O
numbers	O
for	O
the	O
Drosophila	S-Species
and	O
human	S-Species
DYLT	O
-	O
1	O
and	O
DYRB	O
-	O
1	O
protein	O
homologues	O
,	O
respectively	O
,	O
are	O
Dlc90F	O
,	O
NP	O
_	O
477356	O
;	O
DYNLT3	O
,	O
NP	O
_	O
006511	O
;	O
DYNLRB1	O
,	O
NP	O
_	O
054902	O
;	O
and	O
robl	O
,	O
NP	O
_	O
523771	O
.	O

Identification	O
of	O
Two	O
Independent	O
Risk	O
Factors	O
for	O
Lupus	O
within	O
the	O
MHC	O
in	O
United	O
Kingdom	O
Families	O

Abstract	O

The	O
association	O
of	O
the	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
with	O
SLE	O
is	O
well	O
established	O
yet	O
the	O
causal	O
variants	O
arising	O
from	O
this	O
region	O
remain	O
to	O
be	O
identified	O
,	O
largely	O
due	O
to	O
inadequate	O
study	O
design	O
and	O
the	O
strong	O
linkage	O
disequilibrium	O
demonstrated	O
by	O
genes	O
across	O
this	O
locus	O
.	O

The	O
majority	O
of	O
studies	O
thus	O
far	O
have	O
identified	O
strong	O
association	O
with	O
classical	O
class	O
II	O
alleles	O
,	O
in	O
particular	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

Additional	O
associations	O
have	O
been	O
reported	O
with	O
class	O
III	O
alleles	O
;	O
specifically	O
,	O
complement	O
C4	O
null	O
alleles	O
and	O
a	O
tumor	O
necrosis	O
factor	O
promoter	O
SNP	O
(	O
TNF	O
-	O
308G	O
/	O
A	O
)	O
.	O

However	O
,	O
the	O
relative	O
effects	O
of	O
these	O
class	O
II	O
and	O
class	O
III	O
variants	O
have	O
not	O
been	O
determined	O
.	O

We	O
have	O
thus	O
used	O
a	O
family	O
-	O
based	O
approach	O
to	O
map	O
association	O
signals	O
across	O
the	O
MHC	O
class	O
II	O
and	O
class	O
III	O
regions	O
in	O
a	O
cohort	O
of	O
314	O
complete	O
United	O
Kingdom	O
Caucasian	O
SLE	O
trios	O
by	O
typing	O
tagging	O
SNPs	O
together	O
with	O
classical	O
typing	O
of	O
the	O
HLA	O
-	O
DRB1	O
locus	O
.	O

Using	O
TDT	O
and	O
conditional	O
regression	O
analyses	O
,	O
we	O
have	O
demonstrated	O
the	O
presence	O
of	O
two	O
distinct	O
and	O
independent	O
association	O
signals	O
in	O
SLE	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
nominal	O
p	O
=	O
4	O
.	O
9	O
x	O
10	O
-	O
8	O
,	O
permuted	O
p	O
<	O
0	O
.	O
0001	O
,	O
OR	O
=	O
2	O
.	O
3	O
)	O
and	O
the	O
T	O
allele	O
of	O
SNP	O
rs419788	O
(	O
nominal	O
p	O
=	O
4	O
.	O
3	O
x	O
10	O
-	O
8	O
,	O
permuted	O
p	O
<	O
0	O
.	O
0001	O
,	O
OR	O
=	O
2	O
.	O
0	O
)	O
in	O
intron	O
6	O
of	O
the	O
class	O
III	O
region	O
gene	O
SKIV2L	O
.	O

Assessment	O
of	O
genotypic	O
risk	O
demonstrates	O
a	O
likely	O
dominant	O
model	O
of	O
inheritance	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
while	O
rs419788	O
-	O
T	O
confers	O
susceptibility	O
in	O
an	O
additive	O
manner	O
.	O

Furthermore	O
,	O
by	O
comparing	O
transmitted	O
and	O
untransmitted	O
parental	O
chromosomes	O
,	O
we	O
have	O
delimited	O
our	O
class	O
II	O
signal	O
to	O
a	O
180	O
kb	O
region	O
encompassing	O
the	O
alleles	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0501	O
-	O
HLA	O
-	O
DQB1	O
*	O
0201	O
alone	O
.	O

Our	O
class	O
III	O
signal	O
importantly	O
excludes	O
independent	O
association	O
at	O
the	O
TNF	O
promoter	O
polymorphism	O
,	O
TNF	O
-	O
308G	O
/	O
A	O
,	O
in	O
our	O
SLE	O
cohort	O
and	O
provides	O
a	O
potentially	O
novel	O
locus	O
for	O
future	O
genetic	O
and	O
functional	O
studies	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
/	O
lupus	O
)	O
is	O
a	O
complex	O
autoimmune	O
disease	O
in	O
which	O
the	O
body	O
'	O
s	O
immune	O
system	O
attacks	O
its	O
own	O
tissues	O
,	O
causing	O
inflammation	O
in	O
a	O
variety	O
of	O
different	O
organs	O
such	O
as	O
the	O
skin	O
,	O
joints	O
,	O
and	O
kidneys	O
.	O

The	O
cause	O
of	O
lupus	O
is	O
not	O
known	O
,	O
but	O
genes	O
play	O
a	O
significant	O
role	O
in	O
the	O
predisposition	O
to	O
disease	O
.	O

The	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
on	O
Chromosome	O
6	O
contains	O
at	O
least	O
100	O
different	O
genes	O
that	O
affect	O
the	O
immune	O
system	O
,	O
including	O
the	O
genes	O
with	O
the	O
strongest	O
effect	O
on	O
lupus	O
susceptibility	O
.	O

Despite	O
the	O
importance	O
of	O
the	O
MHC	O
in	O
SLE	O
,	O
the	O
identity	O
of	O
the	O
actual	O
genes	O
in	O
the	O
MHC	O
region	O
that	O
cause	O
SLE	O
has	O
remained	O
elusive	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
latest	O
set	O
of	O
genetic	O
markers	O
present	O
at	O
the	O
MHC	O
in	O
lupus	O
families	O
to	O
identify	O
the	O
actual	O
genes	O
that	O
affect	O
the	O
disease	O
.	O

To	O
our	O
knowledge	O
,	O
we	O
have	O
shown	O
for	O
the	O
first	O
time	O
that	O
two	O
separate	O
groups	O
of	O
genes	O
are	O
involved	O
in	O
SLE	O
.	O

One	O
group	O
of	O
genes	O
alters	O
how	O
the	O
immune	O
system	O
may	O
inappropriately	O
target	O
its	O
own	O
tissues	O
in	O
the	O
disease	O
.	O

How	O
the	O
second	O
set	O
of	O
genes	O
predisposes	O
to	O
SLE	O
is	O
the	O
subject	O
of	O
ongoing	O
study	O
.	O

Introduction	O

Since	O
the	O
early	O
1970s	O
,	O
the	O
human	S-Species
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
,	O
inflammatory	O
,	O
and	O
infectious	O
diseases	O
,	O
and	O
it	O
continues	O
to	O
be	O
the	O
focus	O
of	O
intense	O
research	O
[	O
1	O
]	O
.	O

The	O
recently	O
defined	O
extended	O
MHC	O
(	O
xMHC	O
)	O
encompasses	O
7	O
.	O
6	O
Mb	O
of	O
genome	O
on	O
6p21	O
.	O
3	O
and	O
is	O
divided	O
into	O
five	O
subregions	O
from	O
telomere	O
to	O
centromere	O
:	O
extended	O
class	O
I	O
,	O
classical	O
class	O
I	O
,	O
classical	O
class	O
III	O
,	O
classical	O
class	O
II	O
,	O
and	O
extended	O
class	O
II	O
.	O

In	O
addition	O
,	O
the	O
MHC	O
contains	O
two	O
hypervariable	O
regions	O
,	O
the	O
RCCX	O
module	O
in	O
class	O
III	O
(	O
spanning	O
complement	O
C4	O
)	O
and	O
the	O
HLA	O
-	O
DRB	O
genes	O
in	O
class	O
II	O
,	O
that	O
both	O
exhibit	O
copy	O
number	O
polymorphism	O
.	O

Examination	O
of	O
the	O
sequence	O
across	O
the	O
extended	O
MHC	O
reveals	O
the	O
presence	O
of	O
421	O
genes	O
,	O
and	O
over	O
252	O
(	O
60	O
%	O
)	O
are	O
thought	O
to	O
be	O
expressed	O
[	O
2	O
]	O
.	O

Around	O
40	O
%	O
of	O
genes	O
expressed	O
within	O
the	O
classical	O
MHC	O
encode	O
proteins	O
with	O
putative	O
immunomodulatory	O
function	O
[	O
3	O
]	O
.	O

The	O
classical	O
class	O
I	O
and	O
class	O
II	O
loci	O
encode	O
the	O
human	S-Species
leucocyte	O
antigen	O
(	O
HLA	O
)	O
proteins	O
involved	O
in	O
antigen	O
presentation	O
to	O
T	O
cells	O
,	O
initiating	O
the	O
adaptive	O
immune	O
response	O
.	O

The	O
class	O
III	O
region	O
contains	O
the	O
greatest	O
density	O
of	O
genes	O
in	O
the	O
genome	O
(	O
58	O
expressed	O
genes	O
)	O
,	O
which	O
are	O
often	O
found	O
in	O
functionally	O
related	O
clusters	O
[	O
2	O
]	O
.	O

A	O
major	O
obstacle	O
in	O
the	O
identification	O
of	O
disease	O
-	O
specific	O
causal	O
variants	O
within	O
the	O
MHC	O
has	O
been	O
the	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
exhibited	O
by	O
certain	O
alleles	O
in	O
this	O
region	O
,	O
resulting	O
in	O
the	O
existence	O
of	O
long	O
-	O
range	O
,	O
conserved	O
,	O
extended	O
haplotypes	O
[	O
4	O
]	O
,	O
also	O
known	O
as	O
ancestral	O
haplotypes	O
[	O
5	O
]	O
,	O
sometimes	O
spanning	O
more	O
than	O
2	O
Mb	O
[	O
6	O
]	O
.	O

Thus	O
,	O
for	O
many	O
MHC	O
-	O
associated	O
diseases	O
,	O
it	O
has	O
only	O
been	O
possible	O
to	O
delimit	O
association	O
signals	O
to	O
a	O
particular	O
extended	O
haplotype	O
or	O
segment	O
of	O
one	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
/	O
lupus	O
,	O
[	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	S-Species
152700	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
sites	O
/	O
entrez	O
?	O
db	O
=	O
OMIM	O
&	O
TabCmd	O
=	O
Limits	O
]	O
)	O
is	O
a	O
chronic	O
,	O
multi	O
-	O
system	O
autoimmune	O
disease	O
affecting	O
young	O
women	S-Species
ten	O
times	O
more	O
commonly	O
than	O
men	S-Species
.	O

The	O
worldwide	O
prevalence	O
of	O
SLE	O
is	O
estimated	O
at	O
between	O
12	O
and	O
124	O
cases	O
per	O
100	O
,	O
000	O
individuals	O
[	O
7	O
]	O
.	O

SLE	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
pathogenic	O
autoantibodies	O
to	O
nuclear	O
and	O
cell	O
-	O
surface	O
antigens	O
that	O
show	O
affinity	O
maturation	O
.	O

The	O
consequent	O
immune	O
complexes	O
deposit	O
in	O
tissues	O
,	O
causing	O
inflammation	O
and	O
damage	O
.	O

It	O
is	O
well	O
established	O
that	O
there	O
is	O
a	O
complex	O
genetic	O
component	O
to	O
lupus	O
aetiology	O
,	O
with	O
hormonal	O
and	O
environmental	O
influences	O
also	O
contributing	O
to	O
disease	O
susceptibility	O
[	O
8	O
,	O
9	O
]	O
.	O

The	O
MHC	O
has	O
been	O
the	O
most	O
consistently	O
confirmed	O
genetic	O
risk	O
factor	O
for	O
SLE	O
,	O
and	O
multiple	O
different	O
genes	O
within	O
the	O
region	O
have	O
been	O
significantly	O
implicated	O
with	O
disease	O
susceptibility	O
.	O

For	O
example	O
,	O
hereditary	O
and	O
acquired	O
deficiencies	O
of	O
the	O
early	O
classical	O
complement	O
component	O
C4	O
,	O
located	O
within	O
the	O
MHC	O
class	O
III	O
locus	O
,	O
leads	O
to	O
a	O
lupus	O
-	O
like	O
syndrome	O
.	O

A	O
role	O
for	O
another	O
class	O
III	O
gene	O
,	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
,	O
in	O
SLE	O
was	O
suggested	O
following	O
the	O
observation	O
that	O
the	O
lupus	O
-	O
prone	O
New	O
Zealand	O
F1	O
mouse	S-Species
hybrid	O
exhibits	O
constitutively	O
low	O
TNF	O
expression	O
[	O
10	O
]	O
.	O

Recently	O
,	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
in	O
patients	S-Species
treated	O
with	O
TNF	O
antagonists	O
has	O
also	O
stimulated	O
interest	O
in	O
the	O
possible	O
role	O
of	O
TNF	O
in	O
SLE	O
[	O
11	O
-	O
13	O
]	O
.	O

Murine	O
and	O
human	S-Species
candidate	O
gene	O
studies	O
,	O
together	O
with	O
genome	O
-	O
wide	O
linkage	O
screens	O
,	O
provide	O
further	O
support	O
that	O
multiple	O
genetic	O
loci	O
,	O
including	O
the	O
mouse	S-Species
MHC	O
complex	O
H2	O
and	O
the	O
human	S-Species
MHC	O
locus	O
,	O
contribute	O
to	O
disease	O
susceptibility	O
[	O
14	O
-	O
17	O
]	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
human	S-Species
MHC	O
was	O
first	O
associated	O
with	O
SLE	O
in	O
1971	O
,	O
when	O
studies	O
demonstrated	O
that	O
lupus	O
probands	O
were	O
enriched	O
for	O
the	O
class	O
I	O
alleles	O
HL	O
-	O
A8	O
(	O
now	O
known	O
as	O
HLA	O
-	O
B8	O
)	O
and	O
HLA	O
-	O
W15	O
(	O
now	O
known	O
as	O
HLA	O
-	O
B15	O
)	O
when	O
compared	O
with	O
healthy	O
controls	O
[	O
18	O
,	O
19	O
]	O
.	O

Further	O
case	O
control	O
association	O
studies	O
were	O
small	O
,	O
performed	O
in	O
ethnically	O
diverse	O
populations	O
,	O
and	O
tested	O
only	O
a	O
small	O
number	O
of	O
the	O
classical	O
HLA	O
and	O
complement	O
C4	O
alleles	O
.	O

The	O
most	O
consistent	O
findings	O
reported	O
to	O
date	O
are	O
associations	O
with	O
the	O
class	O
II	O
alleles	O
HLA	O
-	O
DR2	O
(	O
DRB1	O
*	O
1501	O
)	O
and	O
HLA	O
-	O
DR3	O
(	O
DRB1	O
*	O
0301	O
)	O
and	O
their	O
respective	O
haplotypes	O
in	O
Caucasian	O
populations	O
.	O

The	O
complement	O
C4A	O
null	O
allele	O
(	O
C4A	O
*	O
Q0	O
)	O
has	O
shown	O
inconsistent	O
association	O
with	O
lupus	O
in	O
a	O
number	O
of	O
studies	O
--	O
a	O
situation	O
that	O
may	O
reflect	O
genetic	O
heterogeneity	O
in	O
disease	O
susceptibility	O
[	O
20	O
-	O
23	O
]	O
.	O

In	O
addition	O
,	O
a	O
recent	O
study	O
has	O
demonstrated	O
that	O
low	O
C4A	O
copy	O
number	O
is	O
a	O
risk	O
factor	O
for	O
lupus	O
in	O
a	O
European	O
American	O
cohort	O
[	O
24	O
]	O
.	O

However	O
,	O
the	O
C4A	O
null	O
allele	O
lies	O
on	O
the	O
lupus	O
-	O
associated	O
DR3	O
"	O
autoimmune	O
"	O
extended	O
haplotype	O
(	O
AH8	O
.	O
1	O
)	O
,	O
which	O
exhibits	O
extremely	O
strong	O
LD	O
[	O
6	O
]	O
.	O

It	O
therefore	O
remains	O
to	O
be	O
definitively	O
established	O
whether	O
this	O
locus	O
constitutes	O
a	O
distinct	O
susceptibility	O
allele	O
to	O
that	O
of	O
the	O
class	O
II	O
association	O
or	O
is	O
merely	O
in	O
LD	O
with	O
it	O
.	O

Similarly	O
,	O
certain	O
TNF	O
promoter	O
polymorphisms	O
,	O
including	O
the	O
much	O
-	O
studied	O
SNP	O
TNF	O
-	O
308G	O
/	O
A	O
,	O
have	O
shown	O
association	O
with	O
SLE	O
;	O
but	O
again	O
,	O
many	O
of	O
these	O
variants	O
are	O
carried	O
on	O
the	O
highly	O
conserved	O
8	O
.	O
1	O
ancestral	O
haplotype	O
,	O
thus	O
restricting	O
interpretation	O
of	O
these	O
data	O
.	O

In	O
2002	O
,	O
a	O
family	O
-	O
based	O
study	O
employing	O
microsatellites	O
as	O
surrogate	O
markers	O
for	O
HLA	O
-	O
DRB1	O
haplotypes	O
in	O
Caucasian	O
lupus	O
families	O
demonstrated	O
association	O
with	O
DR3	O
-	O
,	O
DR2	O
-	O
,	O
and	O
DR8	O
(	O
DRB1	O
*	O
0801	O
)	O
-	O
containing	O
haplotypes	O
.	O

In	O
that	O
study	O
,	O
Graham	O
and	O
colleagues	O
reported	O
that	O
,	O
taking	O
advantage	O
of	O
recombinant	O
chromosomes	O
,	O
the	O
disease	O
risk	O
region	O
could	O
be	O
limited	O
to	O
a	O
1	O
Mb	O
region	O
encompassing	O
classical	O
class	O
II	O
and	O
class	O
III	O
[	O
25	O
]	O
.	O

We	O
have	O
performed	O
a	O
medium	O
resolution	O
association	O
mapping	O
study	O
of	O
the	O
MHC	O
in	O
lupus	O
families	O
,	O
utilizing	O
a	O
combination	O
of	O
SNPs	O
and	O
four	O
-	O
digit	O
typing	O
at	O
the	O
HLA	O
-	O
DRB1	O
locus	O
in	O
order	O
to	O
anchor	O
haplotypes	O
.	O

Sixty	O
-	O
eight	O
SNPs	O
were	O
successfully	O
genotyped	O
across	O
a	O
2	O
.	O
4	O
Mb	O
region	O
of	O
the	O
MHC	O
,	O
from	O
the	O
class	O
I	O
locus	O
KIAA1949	O
to	O
the	O
class	O
II	O
gene	O
HLA	O
-	O
DPB2	O
,	O
in	O
314	O
UK	O
Caucasian	O
SLE	O
trios	O
.	O

We	O
used	O
these	O
data	O
to	O
perform	O
a	O
family	O
-	O
based	O
association	O
study	O
in	O
an	O
attempt	O
to	O
distinguish	O
the	O
relative	O
effects	O
of	O
the	O
class	O
II	O
and	O
class	O
III	O
regions	O
of	O
the	O
MHC	O
in	O
lupus	O
susceptibility	O
.	O

In	O
addition	O
,	O
we	O
employed	O
the	O
long	O
-	O
range	O
haplotype	O
test	O
to	O
search	O
for	O
the	O
presence	O
of	O
high	O
-	O
frequency	O
,	O
extended	O
haplotypes	O
indicative	O
of	O
recent	O
positive	O
selection	O
[	O
26	O
]	O
.	O

We	O
have	O
also	O
used	O
family	O
-	O
based	O
and	O
case	O
-	O
control	O
strategies	O
to	O
examine	O
genotypic	O
risk	O
at	O
HLA	O
-	O
DRB1	O
and	O
rs419788	O
.	O

Results	O

Association	O
Testing	O
of	O
HLA	O
-	O
DRB1	O
and	O
MHC	O
Region	O
SNPs	O

In	O
order	O
to	O
define	O
the	O
causal	O
variation	O
within	O
the	O
MHC	O
region	O
,	O
we	O
typed	O
314	O
complete	O
SLE	O
trios	O
for	O
the	O
HLA	O
-	O
DRB1	O
gene	O
as	O
well	O
as	O
for	O
86	O
SNPs	O
across	O
a	O
2	O
.	O
4	O
Mb	O
region	O
encompassing	O
the	O
HLA	O
class	O
I	O
locus	O
HLA	O
-	O
B	O
to	O
HLA	O
-	O
DPB2	O
.	O

High	O
-	O
quality	O
genotype	O
data	O
was	O
obtained	O
for	O
HLA	O
-	O
DRB1	O
and	O
68	O
MHC	O
SNPs	O
(	O
see	O
Table	O
S1	O
for	O
quality	O
control	O
data	O
)	O
.	O

Association	O
testing	O
of	O
the	O
HLA	O
-	O
DRB1	O
gene	O
revealed	O
a	O
significant	O
association	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
nominal	O
p	O
=	O
4	O
.	O
9	O
x	O
10	O
-	O
8	O
,	O
permuted	O
p	O
<	O
0	O
.	O
0001	O
,	O
T	O
:	O
U	O
=	O
129	O
:	O
55	O
)	O
in	O
our	O
lupus	O
cohort	O
(	O
Table	O
1	O
)	O
.	O

There	O
was	O
also	O
a	O
trend	O
for	O
under	O
transmission	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0701	O
allele	O
(	O
nominal	O
p	O
=	O
0	O
.	O
0013	O
,	O
T	O
:	O
U	O
42	O
:	O
77	O
)	O
;	O
however	O
,	O
this	O
association	O
was	O
no	O
longer	O
significant	O
after	O
correction	O
for	O
multiple	O
testing	O
as	O
determined	O
by	O
10	O
,	O
000	O
permutations	O
of	O
the	O
dataset	O
(	O
permuted	O
p	O
=	O
0	O
.	O
09	O
)	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
find	O
evidence	O
of	O
association	O
with	O
HLA	O
-	O
DRB1	O
*	O
1501	O
(	O
nominal	O
p	O
=	O
1	O
.	O
0	O
,	O
T	O
:	O
U	O
70	O
:	O
70	O
)	O
or	O
HLA	O
-	O
DRB1	O
*	O
0801	O
(	O
nominal	O
p	O
=	O
1	O
.	O
0	O
,	O
T	O
:	O
U	O
=	O
11	O
:	O
11	O
)	O
in	O
our	O
cohort	O
(	O
see	O
Table	O
S2	O
for	O
complete	O
HLA	O
-	O
DRB1	O
association	O
data	O
)	O
;	O
alleles	O
previously	O
suggested	O
by	O
microsatellite	O
typing	O
of	O
a	O
US	O
lupus	O
cohort	O
[	O
25	O
]	O
.	O

Association	O
testing	O
of	O
the	O
MHC	O
region	O
SNPs	O
also	O
identified	O
significant	O
evidence	O
of	O
association	O
to	O
SLE	O
(	O
Table	O
1	O
for	O
associated	O
markers	O
and	O
Table	O
S3	O
for	O
all	O
MHC	O
SNPs	O
)	O
.	O

The	O
SNP	O
with	O
the	O
most	O
significant	O
association	O
,	O
rs419788	O
(	O
nominal	O
p	O
=	O
4	O
.	O
3	O
x	O
10	O
-	O
8	O
,	O
permuted	O
p	O
<	O
0	O
.	O
0001	O
)	O
was	O
of	O
similar	O
strength	O
to	O
that	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
,	O
with	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
of	O
2	O
.	O
0	O
(	O
1	O
.	O
6	O
-	O
2	O
.	O
6	O
)	O
and	O
2	O
.	O
3	O
(	O
1	O
.	O
7	O
-	O
3	O
.	O
2	O
)	O
,	O
respectively	O
.	O

This	O
SNP	O
is	O
located	O
within	O
intron	O
6	O
of	O
the	O
class	O
III	O
gene	O
,	O
superkiller	O
viralicidic	O
activity	O
2	O
-	O
like	O
(	O
Saccharomyces	B-Species
cerevisiae	E-Species
)	O
(	O
SKIV2L	O
)	O
,	O
and	O
is	O
located	O
approximately	O
500	O
kb	O
telomeric	O
to	O
the	O
HLA	O
-	O
DRB1	O
gene	O
.	O

Of	O
the	O
other	O
12	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
SLE	O
(	O
nominal	O
p	O
=	O
4	O
.	O
0	O
x	O
10	O
-	O
4	O
to	O
2	O
.	O
5	O
x	O
10	O
-	O
7	O
;	O
permuted	O
p	O
=	O
0	O
.	O
03	O
to	O
<	O
0	O
.	O
0001	O
)	O
,	O
one	O
was	O
located	O
in	O
the	O
class	O
I	O
region	O
between	O
HLA	O
-	O
B	O
and	O
MICA	O
,	O
seven	O
were	O
located	O
in	O
the	O
class	O
III	O
region	O
,	O
and	O
four	O
were	O
situated	O
in	O
the	O
class	O
II	O
region	O
(	O
Table	O
1	O
;	O
Figure	O
S1	O
)	O
.	O

Specifically	O
,	O
the	O
seven	O
associated	O
class	O
III	O
SNPs	O
were	O
located	O
in	O
or	O
close	O
to	O
the	O
following	O
genes	O
:	O
the	O
TNF	O
promoter	O
,	O
BAT3	O
,	O
SLC44A4	O
,	O
EHMT2	O
,	O
TNXB	O
,	O
GPSM3	O
,	O
and	O
NOTCH4	O
.	O

One	O
of	O
the	O
four	O
class	O
II	O
associated	O
SNPs	O
was	O
close	O
to	O
HLA	O
-	O
DRA	O
,	O
two	O
were	O
between	O
HLA	O
-	O
DRB1	O
and	O
HLA	O
-	O
DQA1	O
and	O
one	O
was	O
in	O
intron	O
1	O
of	O
HLA	O
-	O
DQA1	O
.	O

The	O
correlation	O
between	O
all	O
68	O
SNPs	O
and	O
HLA	O
-	O
DRB1	O
in	O
our	O
UK	O
SLE	O
cohort	O
is	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
markers	O
showing	O
significant	O
association	O
are	O
highlighted	O
.	O

Conditional	O
Analyses	O
Identify	O
Two	O
Independent	O
Association	O
Signals	O
in	O
the	O
MHC	O

In	O
order	O
to	O
establish	O
whether	O
the	O
two	O
most	O
associated	O
signals	O
identified	O
in	O
this	O
association	O
-	O
mapping	O
experiment	O
are	O
likely	O
to	O
represent	O
a	O
single	O
causal	O
allele	O
or	O
independent	O
risk	O
factors	O
,	O
we	O
first	O
examined	O
the	O
association	O
data	O
conditioned	O
upon	O
the	O
presence	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
.	O

We	O
found	O
that	O
four	O
of	O
the	O
13	O
associated	O
SNPs	O
showed	O
evidence	O
of	O
signals	O
independent	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
our	O
dataset	O
,	O
the	O
strongest	O
of	O
which	O
was	O
rs419788	O
(	O
Table	O
1	O
)	O
.	O

We	O
therefore	O
conditioned	O
the	O
three	O
remaining	O
SNPs	O
(	O
rs2523589	O
,	O
rs1052486	O
,	O
and	O
rs605203	O
)	O
on	O
rs419788	O
to	O
assess	O
whether	O
these	O
signals	O
are	O
truly	O
independent	O
of	O
each	O
other	O
or	O
show	O
association	O
due	O
to	O
LD	O
with	O
rs419788	O
.	O

In	O
addition	O
,	O
we	O
included	O
HLA	O
-	O
DRB1	O
in	O
stepwise	O
conditional	O
regression	O
analyses	O
performed	O
on	O
the	O
SNPs	O
showing	O
association	O
independent	O
of	O
HLA	O
-	O
DRB1	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
analyses	O
demonstrated	O
that	O
the	O
observed	O
association	O
signals	O
at	O
rs2523589	O
,	O
rs1052486	O
,	O
and	O
rs605203	O
were	O
predominantly	O
dependent	O
upon	O
the	O
association	O
at	O
rs419788	O
,	O
and	O
suggested	O
that	O
there	O
are	O
two	O
major	O
independent	O
association	O
signals	O
in	O
the	O
MHC	O
in	O
UK	O
SLE	O
:	O
HLA	O
-	O
DRB1	O
and	O
rs419788	O
.	O

The	O
independence	O
of	O
the	O
association	O
signals	O
at	O
HLA	O
-	O
DRB1	O
and	O
rs419788	O
is	O
further	O
supported	O
by	O
the	O
observation	O
that	O
there	O
is	O
only	O
modest	O
LD	O
between	O
these	O
two	O
(	O
r2	O
=	O
0	O
.	O
24	O
)	O
.	O

There	O
was	O
no	O
association	O
with	O
any	O
other	O
HLA	O
-	O
DRB1	O
allele	O
and	O
the	O
four	O
SNPs	O
independent	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
TRANSMIT	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
association	O
of	O
the	O
tumour	O
necrosis	O
factor	O
gene	O
promoter	O
SNP	O
TNF	O
-	O
308G	O
/	O
A	O
with	O
SLE	O
is	O
lost	O
after	O
conditioning	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
our	O
cohort	O
.	O

If	O
we	O
perform	O
the	O
reverse	O
analysis	O
and	O
condition	O
HLA	O
-	O
DRB1	O
*	O
0301	O
on	O
the	O
presence	O
of	O
the	O
TNF	O
promoter	O
SNP	O
,	O
we	O
find	O
that	O
the	O
association	O
remains	O
,	O
confirming	O
that	O
our	O
TNF	O
association	O
is	O
secondary	O
to	O
that	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

Genotypic	O
Risk	O
for	O
Class	O
II	O
and	O
Class	O
III	O
Association	O
Signals	O

Having	O
established	O
independent	O
association	O
at	O
the	O
allelic	O
level	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
rs419788	O
-	O
T	O
in	O
our	O
UK	O
SLE	O
cohort	O
,	O
we	O
wanted	O
to	O
further	O
determine	O
the	O
genotypic	O
risk	O
conferred	O
by	O
these	O
variants	O
and	O
hence	O
gain	O
insight	O
into	O
their	O
underlying	O
mode	O
of	O
inheritance	O
in	O
lupus	O
.	O

We	O
used	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
analyses	O
to	O
assess	O
genotypic	O
risk	O
at	O
HLA	O
-	O
DRB1	O
,	O
while	O
the	O
family	O
-	O
based	O
test	O
alone	O
was	O
used	O
for	O
rs419788	O
.	O

Common	O
family	O
-	O
based	O
tests	O
of	O
LD	O
,	O
such	O
as	O
those	O
used	O
in	O
this	O
study	O
(	O
Genehunter	O
)	O
,	O
measure	O
transmission	O
distortion	O
based	O
on	O
allele	O
counts	O
rather	O
than	O
genotype	O
counts	O
;	O
the	O
former	O
has	O
been	O
shown	O
to	O
be	O
more	O
powerful	O
under	O
additive	O
models	O
,	O
while	O
the	O
latter	O
has	O
greater	O
power	O
under	O
recessive	O
or	O
dominant	O
genetic	O
models	O
[	O
27	O
]	O
.	O

The	O
genotype	O
-	O
pedigree	O
disequilibrium	O
test	O
(	O
geno	O
-	O
PDT	O
)	O
determines	O
LD	O
between	O
a	O
locus	O
genotype	O
and	O
disease	O
by	O
comparing	O
genotypes	O
that	O
are	O
transmitted	O
from	O
parent	O
to	O
proband	O
with	O
those	O
that	O
are	O
not	O
[	O
27	O
]	O
.	O

We	O
used	O
the	O
geno	O
-	O
PDT	O
to	O
assess	O
genotypic	O
risk	O
for	O
our	O
class	O
II	O
and	O
class	O
III	O
association	O
signals	O
:	O
HLA	O
-	O
DRB1	O
and	O
the	O
SNP	O
rs419788	O
.	O

In	O
the	O
case	O
-	O
control	O
analysis	O
for	O
HLA	O
-	O
DRB1	O
,	O
ORs	O
with	O
95	O
%	O
CI	O
were	O
calculated	O
and	O
Fisher	O
'	O
s	O
exact	O
test	O
employed	O
to	O
assess	O
statistically	O
significant	O
differences	O
between	O
HLA	O
-	O
DRB1	O
genotypes	O
in	O
lupus	O
probands	O
and	O
healthy	O
controls	O
.	O

For	O
HLA	O
-	O
DRB1	O
,	O
the	O
alleles	O
were	O
coded	O
as	O
follows	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
HLA	O
-	O
DRB1	O
*	O
1501	O
,	O
HLA	O
-	O
DRB1	O
*	O
X	O
where	O
X	O
represents	O
all	O
HLA	O
-	O
DRB1	O
alleles	O
other	O
than	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
and	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

We	O
included	O
HLA	O
-	O
DRB1	O
*	O
1501	O
in	O
the	O
analysis	O
,	O
even	O
though	O
we	O
find	O
no	O
allelic	O
association	O
in	O
our	O
cohort	O
,	O
because	O
previous	O
studies	O
have	O
shown	O
a	O
greater	O
risk	O
for	O
lupus	O
in	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
and	O
HLA	O
-	O
DRB1	O
*	O
1501	O
-	O
containing	O
haplotypes	O
[	O
25	O
,	O
28	O
]	O
.	O

Overall	O
the	O
results	O
are	O
consistent	O
with	O
a	O
dominant	O
effect	O
from	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
Table	O
2	O
)	O
and	O
a	O
dose	O
-	O
dependent	O
(	O
additive	O
)	O
effect	O
from	O
rs419788	O
-	O
T	O
(	O
Table	O
3	O
)	O
.	O

Specifically	O
,	O
both	O
case	O
-	O
control	O
and	O
geno	O
-	O
PDT	O
demonstrate	O
that	O
there	O
is	O
no	O
dose	O
-	O
dependent	O
increase	O
in	O
disease	O
risk	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

Rather	O
,	O
it	O
appears	O
that	O
the	O
presence	O
of	O
a	O
single	O
copy	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
alone	O
is	O
sufficient	O
to	O
increase	O
susceptibility	O
to	O
disease	O
.	O

Moreover	O
the	O
0301	O
/	O
X	O
genotypes	O
constitute	O
the	O
greatest	O
risk	O
in	O
our	O
cohort	O
rather	O
than	O
the	O
0301	O
/	O
1501	O
heterozygotes	O
.	O

Genotypes	O
containing	O
HLA	O
-	O
DRB1	O
*	O
1501	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
revealed	O
no	O
significant	O
association	O
in	O
our	O
cohort	O
.	O

All	O
three	O
rs419788	O
genotypes	O
demonstrated	O
significant	O
association	O
in	O
our	O
lupus	O
families	O
(	O
Table	O
3	O
)	O
.	O

The	O
common	O
CC	O
genotype	O
was	O
significantly	O
under	O
transmitted	O
,	O
while	O
the	O
rare	O
T	O
allele	O
displayed	O
dose	O
-	O
dependent	O
over	O
transmission	O
to	O
lupus	O
probands	O
.	O

Characterization	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
Risk	O
Haplotype	O

Next	O
,	O
we	O
wanted	O
to	O
further	O
delimit	O
the	O
MHC	O
class	O
II	O
association	O
signal	O
that	O
we	O
have	O
detected	O
at	O
HLA	O
-	O
DRB1	O
.	O

We	O
used	O
phased	O
parental	O
genotype	O
data	O
to	O
compare	O
the	O
allelic	O
composition	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
bearing	O
haplotypes	O
that	O
were	O
transmitted	O
(	O
T	O
)	O
to	O
affected	O
probands	O
to	O
those	O
that	O
were	O
not	O
transmitted	O
(	O
or	O
untransmitted	O
,	O
UT	O
)	O
with	O
the	O
aim	O
of	O
identifying	O
differences	O
that	O
could	O
delineate	O
the	O
lupus	O
susceptibility	O
interval	O
(	O
s	O
)	O
arising	O
from	O
this	O
haplotype	O
(	O
summarized	O
in	O
Figures	O
2A	O
,	O
2B	O
,	O
and	O
S2	O
)	O
.	O

We	O
observed	O
a	O
striking	O
difference	O
between	O
transmitted	O
and	O
untransmitted	O
chromosomes	O
within	O
the	O
class	O
II	O
region	O
:	O
nearly	O
all	O
transmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
(	O
99	O
%	O
)	O
are	O
identical	O
across	O
a	O
180	O
kb	O
region	O
defined	O
by	O
eight	O
SNPs	O
,	O
whereas	O
the	O
corresponding	O
region	O
within	O
untransmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
exhibits	O
significant	O
recombination	O
.	O

These	O
data	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
risk	O
haplotype	O
that	O
,	O
interestingly	O
,	O
contains	O
only	O
three	O
expressed	O
genes	O
:	O
HLA	O
-	O
DRB1	O
,	O
HLA	O
-	O
DQA1	O
,	O
and	O
HLA	O
-	O
DQB1	O
.	O

Furthermore	O
,	O
we	O
can	O
confidently	O
define	O
the	O
allelic	O
composition	O
of	O
this	O
risk	O
haplotype	O
,	O
as	O
these	O
three	O
genes	O
are	O
in	O
strong	O
LD	O
and	O
occur	O
in	O
one	O
common	O
haplotype	O
in	O
Caucasians	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0501	O
-	O
HLA	O
-	O
DQB1	O
*	O
0201	O
.	O

Thus	O
,	O
we	O
hypothesize	O
that	O
the	O
specific	O
combination	O
of	O
all	O
three	O
alleles	O
is	O
required	O
to	O
confer	O
disease	O
risk	O
in	O
lupus	O
or	O
that	O
disease	O
susceptibility	O
lies	O
with	O
either	O
HLA	O
-	O
DRB1	O
*	O
0301	O
or	O
the	O
HLA	O
-	O
DQ	O
alleles	O
.	O

We	O
do	O
not	O
have	O
sufficient	O
numbers	O
of	O
recombinant	O
chromosomes	O
in	O
this	O
risk	O
region	O
to	O
further	O
delimit	O
this	O
signal	O
:	O
2	O
/	O
176	O
(	O
1	O
.	O
1	O
%	O
)	O
transmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
are	O
recombinant	O
at	O
HLA	O
-	O
DQA1	O
-	O
HLA	O
-	O
DQB1	O
;	O
3	O
/	O
178	O
(	O
1	O
.	O
7	O
%	O
)	O
transmitted	O
haplotypes	O
identical	O
across	O
HLA	O
-	O
DQA1	O
-	O
HLA	O
-	O
DQB1	O
do	O
not	O
possess	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

The	O
composite	O
relative	O
extended	O
haplotype	O
homozygosity	O
(	O
REHH	O
)	O
versus	O
frequency	O
plot	O
for	O
UK	O
SLE	O
;	O
Utah	O
residents	O
with	O
ancestry	O
from	O
northern	O
and	O
western	O
Europe	O
(	O
CEPH	O
)	O
;	O
and	O
Yoruba	O
in	O
Ibadan	O
,	O
Nigeria	O
(	O
Yoruba	O
)	O
populations	O
is	O
shown	O
in	O
Figure	O
3A	O
.	O

We	O
can	O
only	O
comment	O
on	O
evidence	O
for	O
positive	O
selection	O
in	O
CEPH	O
individuals	O
,	O
as	O
we	O
have	O
used	O
this	O
population	O
alone	O
to	O
assess	O
background	O
variation	O
on	O
Chromosome	O
6	O
.	O

The	O
SLE	O
and	O
Yoruba	O
cohorts	O
are	O
shown	O
for	O
comparative	O
purposes	O
.	O

We	O
find	O
no	O
evidence	O
of	O
positive	O
selection	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
the	O
CEPH	O
population	O
.	O

However	O
,	O
this	O
allele	O
is	O
enriched	O
in	O
our	O
lupus	O
cohort	O
(	O
21	O
%	O
of	O
parental	O
chromosomes	O
)	O
and	O
displays	O
greater	O
extended	O
homozygosity	O
when	O
compared	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
bearing	O
haplotypes	O
in	O
CEPH	O
and	O
Yoruba	O
.	O

Hence	O
,	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
in	O
lupus	O
is	O
observed	O
as	O
an	O
outlier	O
on	O
the	O
plot	O
when	O
compared	O
to	O
background	O
variation	O
in	O
CEPH	O
.	O

These	O
data	O
support	O
our	O
previous	O
observations	O
(	O
outlined	O
above	O
)	O
of	O
the	O
highly	O
conserved	O
nature	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotypes	O
in	O
lupus	O
.	O

In	O
addition	O
,	O
the	O
haplotype	O
bifurcation	O
plots	O
centered	O
on	O
HLA	O
-	O
DRB1	O
*	O
0301	O
for	O
UK	O
SLE	O
,	O
CEPH	O
,	O
and	O
Yoruba	O
populations	O
in	O
Figure	O
3B	O
illustrate	O
preservation	O
of	O
the	O
common	O
HLA	O
-	O
DRB1	O
*	O
0301	O
haplotype	O
in	O
CEPH	O
and	O
UK	O
SLE	O
,	O
while	O
that	O
seen	O
in	O
the	O
Yoruba	O
is	O
significantly	O
different	O
.	O

The	O
class	O
II	O
regions	O
of	O
all	O
three	O
populations	O
are	O
essentially	O
identical	O
across	O
our	O
chosen	O
SNPs	O
;	O
the	O
main	O
differences	O
lie	O
in	O
class	O
III	O
.	O

The	O
difference	O
in	O
African	O
populations	O
in	O
the	O
class	O
III	O
region	O
is	O
one	O
possible	O
explanation	O
for	O
the	O
lack	O
of	O
evidence	O
for	O
an	O
association	O
between	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
SLE	O
in	O
African	O
or	O
African	O
American	O
populations	O
.	O

However	O
,	O
HLA	O
-	O
DRB1	O
*	O
0301	O
has	O
a	O
lower	O
frequency	O
(	O
~	O
7	O
%	O
-	O
10	O
%	O
)	O
in	O
African	O
populations	O
compared	O
with	O
Europeans	O
(	O
~	O
13	O
%	O
)	O
,	O
and	O
the	O
number	O
of	O
HLA	O
association	O
studies	O
conducted	O
in	O
African	O
populations	O
is	O
very	O
limited	O
.	O

Characterization	O
of	O
Class	O
III	O
Region	O
Risk	O
Haplotype	O

Our	O
data	O
reveal	O
a	O
second	O
independent	O
signal	O
at	O
the	O
MHC	O
in	O
SLE	O
arising	O
from	O
the	O
T	O
allele	O
of	O
SNP	O
rs419788	O
in	O
intron	O
6	O
of	O
the	O
class	O
III	O
gene	O
,	O
SKIV2L	O
.	O

Further	O
evidence	O
supporting	O
the	O
independence	O
of	O
the	O
rs419788	O
-	O
T	O
and	O
HLA	O
-	O
DRB1	O
*	O
0301	O
alleles	O
is	O
provided	O
by	O
the	O
moderate	O
LD	O
between	O
these	O
two	O
variants	O
(	O
r2	O
=	O
0	O
.	O
24	O
)	O
coupled	O
with	O
our	O
data	O
demonstrating	O
that	O
only	O
47	O
%	O
of	O
rs419788	O
-	O
T	O
allele	O
-	O
bearing	O
haplotypes	O
contain	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

The	O
structure	O
and	O
composition	O
of	O
T	O
and	O
UT	O
haplotypes	O
anchored	O
at	O
rs419788	O
-	O
T	O
were	O
essentially	O
identical	O
(	O
Figures	O
2C	O
,	O
2D	O
,	O
and	O
S2	O
)	O
,	O
and	O
hence	O
not	O
informative	O
in	O
delimiting	O
our	O
class	O
III	O
signal	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
LD	O
structure	O
around	O
our	O
associated	O
class	O
III	O
SNP	O
to	O
better	O
define	O
our	O
disease	O
risk	O
interval	O
.	O

In	O
our	O
lupus	O
dataset	O
the	O
rs419788	O
-	O
T	O
allele	O
resides	O
on	O
three	O
of	O
seven	O
haplotypes	O
present	O
within	O
a	O
large	O
block	O
of	O
six	O
SNPs	O
exhibiting	O
strong	O
LD	O
.	O

This	O
haplotype	O
block	O
encompasses	O
roughly	O
270	O
kb	O
containing	O
class	O
III	O
genes	O
from	O
SLC44A4	O
to	O
AGER	O
,	O
including	O
the	O
RCCX	O
module	O
.	O

Next	O
,	O
we	O
analyzed	O
the	O
haplotype	O
block	O
structure	O
of	O
this	O
region	O
in	O
CEPH	O
families	O
using	O
SNP	O
data	O
dumped	O
from	O
the	O
International	O
HapMap	O
Project	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hapmap	O
.	O
org	O
/	O
)	O
.	O

The	O
greater	O
density	O
of	O
SNP	O
typing	O
available	O
in	O
the	O
HapMap	O
CEPH	O
population	O
compared	O
to	O
our	O
current	O
UK	O
SLE	O
map	O
allowed	O
us	O
to	O
potentially	O
refine	O
our	O
signal	O
by	O
exploring	O
correlations	O
between	O
our	O
associated	O
SNP	O
and	O
those	O
surrounding	O
it	O
.	O

Analysis	O
of	O
these	O
data	O
(	O
Figure	O
4	O
)	O
suggests	O
the	O
presence	O
of	O
short	O
-	O
range	O
LD	O
around	O
our	O
associated	O
variant	O
,	O
rs419788	O
,	O
in	O
CEPH	O
families	O
,	O
encompassing	O
approximately	O
40	O
kb	O
of	O
the	O
genome	O
which	O
includes	O
the	O
five	O
genes	O
:	O
complement	O
factor	O
B	O
(	O
CFB	O
)	O
,	O
RD	O
RNA	O
binding	O
protein	O
(	O
RDBP	O
)	O
,	O
SKIV2L	O
,	O
dom	O
-	O
3	O
homolg	O
Z	O
(	O
C	B-Species
.	I-Species
elegans	E-Species
)	O
(	O
DOM3Z	O
)	O
,	O
and	O
serine	O
/	O
threonine	O
kinase	O
19	O
(	O
STK19	O
)	O
,	O
and	O
does	O
not	O
include	O
the	O
complement	O
C4	O
locus	O
.	O

Furthermore	O
,	O
assessment	O
of	O
marker	O
association	O
in	O
our	O
lupus	O
dataset	O
demonstrates	O
that	O
after	O
conditioning	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
the	O
only	O
markers	O
that	O
retain	O
association	O
signals	O
are	O
telomeric	O
of	O
SKIV2L	O
,	O
suggesting	O
that	O
complement	O
C4	O
,	O
which	O
is	O
centromeric	O
to	O
this	O
gene	O
,	O
may	O
not	O
be	O
responsible	O
for	O
our	O
independent	O
class	O
III	O
signal	O
.	O

Subphenotype	O
Analysis	O

In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
disease	O
pathogenesis	O
,	O
we	O
examined	O
common	O
lupus	O
subphenotypes	O
.	O

Such	O
subsets	O
are	O
more	O
homogeneous	O
than	O
lupus	O
per	O
se	O
and	O
thus	O
maybe	O
enriched	O
for	O
specific	O
predisposing	O
variants	O
.	O

In	O
addition	O
,	O
one	O
might	O
expect	O
a	O
close	O
association	O
between	O
MHC	O
class	O
II	O
alleles	O
and	O
autoantibody	O
subsets	O
in	O
lupus	O
if	O
these	O
are	O
indeed	O
causal	O
variants	O
,	O
given	O
their	O
role	O
in	O
antigen	O
presentation	O
and	O
subsequent	O
humoral	O
immunity	O
.	O

We	O
therefore	O
tested	O
our	O
two	O
main	O
MHC	O
association	O
signals	O
,	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
rs419788	O
,	O
for	O
association	O
with	O
renal	O
disease	O
and	O
autoantibody	O
subsets	O
in	O
our	O
lupus	O
cohort	O
.	O

We	O
found	O
that	O
HLA	O
-	O
DRB1	O
*	O
0301	O
was	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
Ro	O
and	O
anti	O
-	O
La	O
antibodies	O
in	O
our	O
UK	O
SLE	O
cohort	O
,	O
with	O
the	O
latter	O
showing	O
the	O
greatest	O
evidence	O
of	O
association	O
(	O
anti	O
-	O
La	O
nominal	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
anti	O
-	O
Ro	O
nominal	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

We	O
found	O
no	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
with	O
renal	O
disease	O
or	O
any	O
other	O
autoantibody	O
subsets	O
in	O
our	O
dataset	O
(	O
see	O
Table	O
S4	O
for	O
detailed	O
results	O
)	O
.	O

Genotypes	O
of	O
the	O
SNP	O
rs419788	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
tested	O
lupus	O
subphenotypes	O
after	O
controlling	O
for	O
the	O
effect	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
unpublished	O
data	O
)	O
.	O

Discussion	O

We	O
present	O
the	O
first	O
family	O
-	O
based	O
SNP	O
association	O
study	O
of	O
the	O
MHC	O
in	O
SLE	O
.	O

We	O
have	O
genotyped	O
69	O
markers	O
(	O
HLA	O
-	O
DRB1	O
and	O
68	O
SNPs	O
)	O
across	O
2	O
.	O
4	O
Mb	O
of	O
the	O
MHC	O
,	O
encompassing	O
class	O
III	O
and	O
class	O
II	O
,	O
in	O
a	O
cohort	O
of	O
314	O
UK	O
Caucasian	O
SLE	O
trios	O
.	O

Transmission	O
disequilibrium	O
testing	O
of	O
these	O
data	O
has	O
shown	O
predominant	O
association	O
with	O
the	O
alleles	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
rs419788	O
-	O
T	O
,	O
together	O
with	O
12	O
other	O
MHC	O
SNPs	O
.	O

Moreover	O
,	O
using	O
conditional	O
analyses	O
,	O
we	O
have	O
shown	O
that	O
the	O
two	O
primary	O
signals	O
of	O
association	O
at	O
the	O
MHC	O
are	O
independent	O
of	O
each	O
other	O
.	O

Specifically	O
,	O
one	O
signal	O
arises	O
from	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
class	O
II	O
and	O
the	O
other	O
from	O
the	O
T	O
allele	O
of	O
SNP	O
rs419788	O
in	O
the	O
class	O
III	O
gene	O
SKIV2L	O
.	O

Examination	O
of	O
bifurcation	O
plots	O
for	O
T	O
and	O
UT	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
containing	O
haplotypes	O
has	O
enabled	O
delineation	O
of	O
our	O
class	O
II	O
association	O
signal	O
to	O
a	O
180	O
kb	O
region	O
encompassing	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0501	O
-	O
HLA	O
-	O
DQB1	O
*	O
0201	O
.	O

These	O
data	O
substantially	O
refine	O
that	O
previously	O
published	O
by	O
Graham	O
et	O
al	O
.	O
in	O
2002	O
[	O
25	O
]	O
,	O
where	O
the	O
lupus	O
susceptibility	O
interval	O
within	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
containing	O
haplotypes	O
could	O
only	O
be	O
delimited	O
to	O
a	O
1	O
Mb	O
region	O
encompassing	O
class	O
II	O
and	O
class	O
III	O
.	O

The	O
precise	O
causal	O
variant	O
(	O
s	O
)	O
within	O
this	O
region	O
remains	O
to	O
be	O
determined	O
,	O
as	O
the	O
three	O
implicated	O
alleles	O
exhibit	O
strong	O
LD	O
with	O
few	O
recombination	O
events	O
separating	O
them	O
(	O
two	O
out	O
of	O
176	O
transmitted	O
HLA	O
-	O
DRB1	O
*	O
0301	O
chromosomes	O
in	O
our	O
dataset	O
)	O
.	O

However	O
,	O
all	O
three	O
allelic	O
variants	O
represent	O
attractive	O
functional	O
candidates	O
in	O
lupus	O
susceptibility	O
for	O
their	O
role	O
in	O
antigen	O
presentation	O
and	O
stimulation	O
of	O
the	O
adaptive	O
immune	O
response	O
.	O

Our	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
with	O
lupus	O
concurs	O
with	O
published	O
data	O
in	O
Caucasian	O
cohorts	O
and	O
is	O
well	O
established	O
[	O
16	O
]	O
.	O

While	O
our	O
lack	O
of	O
association	O
with	O
HLA	O
-	O
DRB1	O
*	O
1501	O
and	O
HLA	O
-	O
DRB1	O
*	O
0801	O
is	O
consistent	O
with	O
previous	O
data	O
from	O
the	O
UK	O
[	O
29	O
]	O
,	O
Spain	O
[	O
30	O
]	O
,	O
the	O
Netherlands	O
[	O
31	O
]	O
,	O
Sweden	O
[	O
32	O
]	O
,	O
Mexico	O
[	O
33	O
]	O
,	O
and	O
the	O
US	O
[	O
34	O
]	O
,	O
it	O
conflicts	O
with	O
that	O
of	O
other	O
US	O
groups	O
[	O
25	O
,	O
35	O
]	O
.	O

Interestingly	O
,	O
we	O
demonstrate	O
a	O
trend	O
,	O
though	O
not	O
statistically	O
significant	O
,	O
for	O
undertransmission	O
of	O
HLA	O
-	O
DRB1	O
*	O
0701	O
--	O
a	O
result	O
also	O
observed	O
in	O
prior	O
UK	O
and	O
Canadian	O
lupus	O
studies	O
[	O
29	O
,	O
36	O
]	O
.	O

Moreover	O
,	O
a	O
negative	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0701	O
has	O
been	O
reported	O
in	O
other	O
autoimmune	O
diseases	O
including	O
Graves	O
disease	O
[	O
37	O
,	O
38	O
]	O
,	O
type	O
1	O
diabetes	O
[	O
39	O
]	O
,	O
and	O
rheumatoid	O
arthritis	O
[	O
40	O
]	O
.	O

It	O
appears	O
that	O
the	O
conflicting	O
results	O
between	O
UK	O
SLE	O
and	O
previous	O
US	O
(	O
Minnesota	O
[	O
MN	O
]	O
)	O
[	O
25	O
]	O
SLE	O
data	O
stem	O
from	O
differences	O
in	O
HLA	O
-	O
DRB1	O
allele	O
frequency	O
in	O
the	O
probands	O
of	O
each	O
cohort	O
.	O

The	O
reason	O
for	O
this	O
is	O
unclear	O
.	O

A	O
comparison	O
between	O
UK	O
and	O
MN	O
SLE	O
cohorts	O
(	O
Table	O
4	O
)	O
reveals	O
that	O
UK	O
SLE	O
cases	O
are	O
enriched	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
but	O
not	O
HLA	O
-	O
DRB1	O
*	O
0801	O
or	O
HLA	O
-	O
DRB1	O
*	O
1501	O
when	O
compared	O
to	O
a	O
UK	O
control	O
population	O
.	O

In	O
contrast	O
,	O
MN	O
SLE	O
cases	O
are	O
enriched	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
DQB1	O
*	O
0201	O
,	O
DRB1	O
*	O
0801	O
-	O
DQB1	O
*	O
0402	O
,	O
and	O
DRB1	O
*	O
1501	O
-	O
DQB1	O
*	O
0602	O
inferred	O
haplotypes	O
when	O
compared	O
to	O
MN	O
controls	O
[	O
25	O
]	O
.	O

There	O
is	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
aforementioned	O
HLA	O
class	O
II	O
alleles	O
/	O
haplotypes	O
between	O
UK	O
and	O
MN	O
control	O
populations	O
that	O
could	O
account	O
for	O
the	O
disparity	O
seen	O
in	O
the	O
respective	O
lupus	O
cohorts	O
.	O

Differences	O
in	O
disease	O
severity	O
and	O
subphenotype	O
frequency	O
between	O
the	O
two	O
populations	O
could	O
account	O
for	O
the	O
observed	O
discrepancy	O
.	O

From	O
the	O
limited	O
data	O
available	O
we	O
found	O
that	O
the	O
presence	O
of	O
renal	O
disease	O
appears	O
to	O
be	O
similar	O
in	O
both	O
cohorts	O
(	O
UK	O
SLE	O
36	O
%	O
compared	O
with	O
MN	O
SLE	O
40	O
%	O
)	O
,	O
while	O
the	O
gender	O
ratios	O
are	O
significantly	O
different	O
(	O
female	O
:	O
male	O
UK	O
SLE	O
11	O
:	O
1	O
compared	O
with	O
MN	O
SLE	O
57	O
:	O
1	O
,	O
Chi	O
square	O
p	O
value	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
were	O
unable	O
to	O
compare	O
other	O
lupus	O
subphenotypes	O
.	O

Furthermore	O
,	O
closer	O
inspection	O
of	O
these	O
data	O
reveals	O
that	O
microsatellite	O
-	O
inference	O
of	O
HLA	O
-	O
DRB1	O
alleles	O
in	O
the	O
MN	O
SLE	O
dataset	O
may	O
underestimate	O
the	O
frequency	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
and	O
overestimate	O
that	O
of	O
HLA	O
-	O
DRB1	O
*	O
1501	O
,	O
thus	O
diminishing	O
the	O
effect	O
of	O
the	O
former	O
and	O
enhancing	O
that	O
of	O
the	O
latter	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
MN	O
SLE	O
cohort	O
shows	O
greater	O
racial	O
heterogeneity	O
in	O
comparison	O
to	O
our	O
UK	O
SLE	O
cohort	O
,	O
despite	O
both	O
being	O
characterized	O
as	O
Caucasian	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
increased	O
risk	O
for	O
lupus	O
in	O
individuals	O
carrying	O
particular	O
combinations	O
of	O
microsatellite	O
-	O
inferred	O
HLA	O
-	O
DRB1	O
-	O
HLA	O
-	O
DQB1	O
haplotypes	O
[	O
25	O
,	O
28	O
]	O
.	O

The	O
highest	O
risk	O
genotype	O
was	O
found	O
to	O
be	O
the	O
compound	O
heterozygote	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
DQB1	O
*	O
0201	O
/	O
HLA	O
-	O
DRB1	O
*	O
1501	O
-	O
DQB1	O
*	O
0602	O
,	O
while	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
DQB1	O
*	O
0201	O
-	O
containing	O
genotypes	O
demonstrated	O
a	O
dose	O
-	O
dependent	O
effect	O
in	O
increasing	O
lupus	O
susceptibility	O
[	O
25	O
,	O
28	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
examined	O
genotypic	O
risk	O
at	O
the	O
classically	O
typed	O
HLA	O
-	O
DRB1	O
locus	O
and	O
in	O
contrast	O
to	O
the	O
aforementioned	O
data	O
of	O
Graham	O
et	O
al	O
.	O

[	O
25	O
,	O
28	O
]	O
we	O
have	O
shown	O
a	O
likely	O
dominant	O
effect	O
of	O
the	O
associated	O
allele	O
,	O
HLA	O
-	O
DRB1	O
*	O
0301	O
.	O

The	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
analyses	O
for	O
HLA	O
-	O
DRB1	O
also	O
show	O
the	O
greater	O
power	O
of	O
the	O
former	O
to	O
detect	O
significant	O
association	O
(	O
Table	O
2	O
)	O
.	O

Specifically	O
,	O
all	O
genotypes	O
containing	O
HLA	O
-	O
DRB1	O
*	O
0301	O
show	O
increased	O
transmission	O
to	O
lupus	O
probands	O
;	O
however	O
,	O
homozygotes	O
show	O
no	O
greater	O
risk	O
compared	O
with	O
heterozygotes	O
,	O
as	O
would	O
be	O
expected	O
under	O
additive	O
or	O
multiplicative	O
models	O
.	O

Thus	O
,	O
a	O
dominant	O
model	O
of	O
inheritance	O
,	O
requiring	O
the	O
presence	O
of	O
a	O
single	O
copy	O
of	O
the	O
disease	O
-	O
predisposing	O
variant	O
alone	O
,	O
likely	O
underlies	O
the	O
susceptibility	O
conferred	O
by	O
HLA	O
-	O
DRB1	O
*	O
0301	O
in	O
UK	O
SLE	O
.	O

Such	O
a	O
model	O
would	O
fit	O
an	O
antigen	O
presentation	O
hypothesis	O
where	O
susceptible	O
individuals	O
carrying	O
an	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
are	O
able	O
to	O
present	O
auto	O
-	O
antigens	O
to	O
CD4	O
+	O
lymphocytes	O
,	O
thus	O
stimulating	O
an	O
autoimmune	O
response	O
.	O

The	O
differences	O
between	O
our	O
UK	O
SLE	O
and	O
the	O
previously	O
published	O
US	O
SLE	O
data	O
may	O
reflect	O
disease	O
,	O
ethnic	O
,	O
and	O
haplotypic	O
heterogeneity	O
.	O

Interestingly	O
,	O
analysis	O
of	O
genotypic	O
risk	O
at	O
the	O
associated	O
class	O
III	O
marker	O
,	O
rs419788	O
,	O
suggests	O
an	O
additive	O
(	O
dose	O
-	O
dependent	O
)	O
pattern	O
of	O
inheritance	O
for	O
the	O
rare	O
T	O
allele	O
,	O
where	O
one	O
copy	O
confers	O
a	O
low	O
risk	O
of	O
disease	O
and	O
two	O
copies	O
results	O
in	O
greater	O
susceptibility	O
.	O

The	O
different	O
inheritance	O
patterns	O
for	O
our	O
class	O
II	O
and	O
class	O
III	O
association	O
signals	O
provide	O
further	O
evidence	O
for	O
their	O
independence	O
.	O

A	O
variety	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DQ	O
alleles	O
have	O
been	O
associated	O
with	O
autoantibody	O
subsets	O
in	O
ethnically	O
diverse	O
populations	O
of	O
lupus	O
.	O

The	O
strongest	O
associations	O
have	O
been	O
demonstrated	O
between	O
anti	O
-	O
Ro	O
and	O
anti	O
-	O
La	O
antibodies	O
and	O
HLA	O
-	O
DR3	O
and	O
HLA	O
-	O
DQ2	O
(	O
HLA	O
-	O
DQB1	O
*	O
0201	O
)	O
,	O
which	O
are	O
in	O
strong	O
LD	O
[	O
41	O
-	O
45	O
]	O
in	O
case	O
-	O
control	O
studies	O
.	O

Here	O
,	O
we	O
confirm	O
the	O
association	O
of	O
HLA	O
-	O
DRB1	O
*	O
0301	O
with	O
anti	O
-	O
Ro	O
and	O
anti	O
-	O
La	O
antibody	O
production	O
in	O
our	O
family	O
-	O
based	O
cohort	O
.	O

Examination	O
of	O
LD	O
structure	O
around	O
our	O
second	O
independent	O
association	O
,	O
rs419788	O
-	O
T	O
in	O
class	O
III	O
,	O
coupled	O
with	O
the	O
results	O
of	O
our	O
conditional	O
analysis	O
,	O
suggests	O
that	O
this	O
signal	O
could	O
also	O
be	O
delimited	O
to	O
a	O
relatively	O
narrow	O
genomic	O
interval	O
of	O
about	O
40	O
kb	O
given	O
further	O
SNP	O
mapping	O
in	O
our	O
cohort	O
.	O

This	O
region	O
includes	O
the	O
genes	O
CFB	O
,	O
RDBP	O
,	O
SKIV2L	O
,	O
DOM3Z	O
,	O
and	O
STK19	O
,	O
but	O
does	O
not	O
include	O
complement	O
C4	O
.	O

Thus	O
,	O
complement	O
C4	O
null	O
alleles	O
,	O
which	O
have	O
been	O
implicated	O
in	O
lupus	O
pathogenesis	O
,	O
may	O
not	O
be	O
responsible	O
for	O
our	O
class	O
III	O
signal	O
.	O

We	O
conclude	O
,	O
therefore	O
,	O
that	O
our	O
family	O
-	O
based	O
mapping	O
study	O
has	O
potentially	O
revealed	O
a	O
hitherto	O
unknown	O
lupus	O
susceptibility	O
interval	O
in	O
the	O
class	O
III	O
region	O
of	O
the	O
MHC	O
.	O

However	O
,	O
we	O
cannot	O
conclusively	O
exclude	O
association	O
at	O
complement	O
C4	O
/	O
RCCX	O
without	O
direct	O
determination	O
of	O
C4	O
polymorphism	O
/	O
copy	O
number	O
in	O
our	O
cohort	O
.	O

With	O
respect	O
to	O
the	O
genes	O
implicated	O
in	O
our	O
study	O
,	O
CFB	O
is	O
a	O
vital	O
component	O
of	O
the	O
alternate	O
complement	O
pathway	O
and	O
disregulation	O
may	O
clearly	O
affect	O
the	O
inflammatory	O
response	O
[	O
46	O
]	O
.	O

RD	O
and	O
Skiv2l	O
are	O
proteins	O
potentially	O
involved	O
in	O
RNA	O
processing	O
.	O

The	O
RD	O
protein	O
forms	O
part	O
of	O
a	O
negative	O
elongation	O
factor	O
(	O
NELF	O
)	O
complex	O
that	O
represses	O
RNA	O
polymerase	O
II	O
transcript	O
elongation	O
,	O
while	O
Skiv2l	O
is	O
a	O
DEAD	O
box	O
protein	O
with	O
possible	O
function	O
as	O
an	O
RNA	O
helicase	O
.	O

The	O
function	O
of	O
Dom3z	O
is	O
currently	O
unknown	O
,	O
although	O
the	O
homologous	O
yeast	S-Species
protein	O
binds	O
nuclear	O
exoribonuclease	O
.	O

Moreover	O
,	O
its	O
ubiquitous	O
expression	O
suggests	O
a	O
housekeeping	O
role	O
.	O

STK19	O
is	O
a	O
protein	O
kinase	O
of	O
unknown	O
function	O
with	O
primary	O
nuclear	O
localization	O
[	O
47	O
]	O
.	O

Interestingly	O
,	O
RDBP	O
and	O
SKIV2L	O
are	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
B	O
lymphocytes	O
,	O
and	O
dendritic	O
cells	O
(	O
SymAtlas	O
,	O
http	O
:	O
/	O
/	O
symatlas	O
.	O
gnf	O
.	O
org	O
/	O
SymAtlas	O
/	O
)	O
.	O

A	O
number	O
of	O
studies	O
have	O
demonstrated	O
conflicting	O
evidence	O
for	O
and	O
against	O
association	O
with	O
various	O
TNF	O
locus	O
polymorphisms	O
in	O
SLE	O
[	O
48	O
]	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
of	O
the	O
TNF	O
-	O
308G	O
/	O
A	O
promoter	O
polymorphism	O
in	O
SLE	O
[	O
48	O
]	O
revealed	O
evidence	O
of	O
association	O
for	O
the	O
minor	O
allele	O
(	O
A	O
)	O
in	O
European	O
populations	O
;	O
however	O
,	O
this	O
study	O
did	O
not	O
account	O
for	O
LD	O
with	O
class	O
II	O
alleles	O
.	O

On	O
conditioning	O
our	O
dataset	O
for	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
we	O
find	O
that	O
the	O
TNF	O
promoter	O
signal	O
is	O
lost	O
,	O
suggesting	O
that	O
this	O
association	O
is	O
not	O
independent	O
and	O
is	O
due	O
to	O
LD	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
(	O
or	O
another	O
variant	O
in	O
LD	O
with	O
HLA	O
-	O
DRB1	O
*	O
0301	O
)	O
.	O

In	O
summary	O
,	O
we	O
have	O
found	O
association	O
with	O
two	O
distinct	O
and	O
independent	O
variants	O
within	O
the	O
class	O
II	O
(	O
HLA	O
-	O
DRB1	O
*	O
0301	O
)	O
and	O
class	O
III	O
(	O
SKIV2L	O
)	O
regions	O
of	O
the	O
MHC	O
in	O
UK	O
SLE	O
trios	O
.	O

We	O
can	O
delimit	O
our	O
class	O
II	O
signal	O
in	O
lupus	O
to	O
three	O
genetic	O
variants	O
(	O
HLA	O
-	O
DRB1	O
*	O
0301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0501	O
-	O
HLA	O
-	O
DQB1	O
*	O
0201	O
)	O
that	O
may	O
confer	O
disease	O
risk	O
in	O
combination	O
or	O
as	O
separate	O
signals	O
.	O

Our	O
class	O
III	O
signal	O
importantly	O
excludes	O
independent	O
association	O
at	O
the	O
TNF	O
promoter	O
polymorphism	O
TNF	O
-	O
308G	O
/	O
A	O
and	O
potentially	O
provides	O
a	O
novel	O
locus	O
for	O
further	O
study	O
.	O

Materials	O
and	O
Methods	O

Study	O
cohorts	O
.	O

SLE	O
families	O
.	O

The	O
cohort	O
comprises	O
314	O
complete	O
SLE	O
trios	O
(	O
that	O
is	O
,	O
mother	O
,	O
father	O
,	O
and	O
affected	O
lupus	O
proband	O
)	O
collected	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

All	O
study	O
participants	S-Species
are	O
European	O
Caucasian	O
on	O
the	O
basis	O
of	O
grandparental	O
origin	O
.	O

All	O
314	O
lupus	O
probands	O
(	O
288	O
female	O
,	O
26	O
male	O
)	O
fulfill	O
the	O
revised	O
American	O
College	O
of	O
Rheumatology	O
(	O
ACR	O
)	O
criteria	O
for	O
SLE	O
[	O
50	O
]	O
,	O
36	O
%	O
of	O
whom	O
have	O
a	O
diagnosis	O
of	O
lupus	O
nephritis	O
.	O

Written	O
consent	O
was	O
obtained	O
from	O
all	O
study	O
participants	S-Species
and	O
ethical	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
the	O
Multi	O
-	O
Centre	O
Research	O
Ethics	O
Committee	O
(	O
MREC	O
2	O
June	O
1998	O
)	O
.	O

Healthy	O
controls	O
.	O

The	O
control	O
population	O
for	O
the	O
HLA	O
-	O
DRB1	O
genotypic	O
risk	O
case	O
-	O
control	O
analysis	O
constitutes	O
1	O
,	O
667	O
healthy	O
males	O
of	O
Northern	O
European	O
origin	O
.	O

The	O
individuals	O
are	O
potential	O
hematopoietic	O
stem	O
cell	O
donors	O
and	O
were	O
typed	O
to	O
four	O
digits	O
for	O
HLA	O
-	O
DRB1	O
at	O
the	O
Anthony	O
Nolan	O
Trust	O
,	O
UK	O
for	O
this	O
purpose	O
.	O

The	O
level	O
of	O
resolution	O
used	O
for	O
the	O
typing	O
of	O
HLA	O
-	O
DRB1	O
*	O
15	O
alleles	O
in	O
these	O
healthy	O
controls	O
resulted	O
in	O
the	O
ambiguous	O
allele	O
string	O
HLA	O
-	O
DRB1	O
*	O
1501	O
/	O
1502	O
/	O
1504	O
/	O
1506	O
.	O

However	O
,	O
it	O
is	O
likely	O
that	O
the	O
great	O
majority	O
are	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

There	O
is	O
no	O
gender	O
bias	O
in	O
HLA	O
-	O
DRB1	O
allele	O
frequencies	O
,	O
so	O
although	O
we	O
have	O
used	O
a	O
male	O
control	O
cohort	O
,	O
the	O
frequencies	O
would	O
be	O
expected	O
to	O
be	O
the	O
same	O
in	O
a	O
similar	O
female	O
cohort	O
(	O
Steven	O
Marsh	O
,	O
personal	O
communication	O
)	O
.	O

SNP	O
genotyping	O
.	O

Eighty	O
-	O
six	O
SNPs	O
were	O
chosen	O
for	O
genotyping	O
in	O
our	O
mapping	O
study	O
.	O

Specifically	O
,	O
we	O
selected	O
40	O
MHC	O
class	O
II	O
and	O
class	O
III	O
haplotype	O
tagging	O
SNPs	O
from	O
a	O
preliminary	O
MHC	O
SNP	O
map	O
[	O
51	O
]	O
that	O
had	O
previously	O
shown	O
robust	O
genotyping	O
efficacy	O
.	O

In	O
addition	O
,	O
we	O
typed	O
36	O
MHC	O
class	O
II	O
tag	O
SNPs	O
from	O
a	O
subsequent	O
high	O
-	O
resolution	O
MHC	O
study	O
[	O
52	O
]	O
.	O

We	O
also	O
included	O
the	O
TNF	O
-	O
308G	O
/	O
A	O
promoter	O
SNP	O
,	O
together	O
with	O
nine	O
further	O
SNPs	O
in	O
the	O
region	O
of	O
HLA	O
-	O
B	O
and	O
MICA	O
obtained	O
from	O
the	O
database	O
,	O
dbSNP	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
projects	O
/	O
SNP	O
/	O
)	O
.	O

The	O
latter	O
SNPs	O
had	O
not	O
been	O
well	O
characterized	O
.	O

All	O
variants	O
were	O
typed	O
in	O
the	O
entire	O
cohort	O
(	O
n	O
=	O
942	O
)	O
.	O

The	O
SNPs	O
span	O
approximately	O
2	O
.	O
4	O
Mb	O
of	O
the	O
MHC	O
from	O
the	O
class	O
I	O
gene	O
,	O
KIAA1949	O
to	O
the	O
class	O
II	O
pseudogene	O
,	O
HLA	O
-	O
DPB2	O
and	O
thus	O
encompass	O
MHC	O
class	O
III	O
and	O
class	O
II	O
.	O

SNP	O
genotyping	O
was	O
performed	O
at	O
the	O
Broad	O
Institute	O
of	O
MIT	O
and	O
Harvard	O
and	O
at	O
Imperial	O
College	O
London	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionisation	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
using	O
the	O
Sequenom	O
MassARRAY	O
platform	O
as	O
previously	O
described	O
[	O
53	O
]	O
.	O

SNPs	O
that	O
failed	O
Sequenom	O
typing	O
were	O
retyped	O
by	O
KBiosciences	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
kbioscience	O
.	O
co	O
.	O
uk	O
/	O
)	O
using	O
their	O
in	O
-	O
house	O
SNP	O
genotyping	O
methodology	O
,	O
KASPar	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
kbioscience	O
.	O
co	O
.	O
uk	O
/	O
genotyping	O
/	O
index	O
.	O
htm	O
)	O
,	O
a	O
competitive	O
allele	O
-	O
specific	O
PCR	O
technique	O
.	O

HLA	O
-	O
DRB1	O
genotyping	O
.	O

HLA	O
-	O
DRB1	O
typing	O
was	O
performed	O
at	O
the	O
Anthony	O
Nolan	O
Trust	O
,	O
UK	O
.	O

All	O
samples	O
(	O
n	O
=	O
942	O
UK	O
SLE	O
trios	O
and	O
n	O
=	O
1	O
,	O
667	O
controls	O
)	O
were	O
genotyped	O
using	O
LABType	O
SSO	O
(	O
sequence	O
-	O
specific	O
oligonucleotide	O
)	O
typing	O
technology	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
written	O
recommendations	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
onelambda	O
.	O
com	O
)	O
.	O

Briefly	O
,	O
a	O
locus	O
-	O
specific	O
biotinylated	O
PCR	O
amplicon	O
is	O
produced	O
,	O
denatured	O
,	O
and	O
rehybridized	O
to	O
complementary	O
oligonucleotide	O
probes	O
conjugated	O
to	O
fluorescently	O
coded	O
beads	O
.	O

The	O
bound	O
biotinylated	O
PCR	O
product	O
can	O
be	O
detected	O
using	O
R	O
-	O
phycoerythrin	O
-	O
conjugated	O
streptavidin	O
.	O

A	O
flow	O
analyzer	O
identifies	O
the	O
fluorescent	O
intensity	O
of	O
phycoerythrin	O
on	O
each	O
bead	O
.	O

The	O
assignment	O
of	O
HLA	O
type	O
is	O
based	O
on	O
the	O
reaction	O
pattern	O
compared	O
to	O
patterns	O
associated	O
with	O
known	O
sequences	O
.	O

High	O
resolution	O
testing	O
was	O
performed	O
using	O
the	O
Dynal	O
AllSet	O
+	O
SSP	O
(	O
sequence	O
-	O
specific	O
primers	O
)	O
DRB1	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Invitrogen	O
)	O
for	O
SLE	O
families	O
only	O
.	O

The	O
presence	O
or	O
absence	O
of	O
PCR	O
amplification	O
was	O
detected	O
in	O
a	O
gel	O
electrophoresis	O
step	O
using	O
visualization	O
by	O
ethidium	O
bromide	O
incorporation	O
.	O

Genotypes	O
were	O
determined	O
using	O
SSPTool	O
software	O
.	O

Samples	O
that	O
could	O
not	O
be	O
resolved	O
to	O
four	O
digits	O
using	O
SSO	O
and	O
PCR	O
-	O
SSP	O
were	O
analyzed	O
by	O
DNA	O
sequencing	O
of	O
exon	O
2	O
of	O
HLA	O
-	O
DRB1	O
.	O

Primers	O
,	O
reagents	O
,	O
and	O
protocols	O
were	O
provided	O
by	O
The	O
Anthony	O
Nolan	O
Trust	O
,	O
UK	O
(	O
primer	O
sequences	O
are	O
available	O
on	O
request	O
)	O
.	O

Specific	O
HLA	O
-	O
DRB1	O
alleles	O
were	O
assigned	O
by	O
comparing	O
the	O
resultant	O
sequence	O
with	O
reference	O
sequence	O
from	O
the	O
IMGT	O
/	O
HLA	O
Database	O
[	O
54	O
]	O
.	O

Data	O
analysis	O
.	O

Mendelian	O
inconsistencies	O
were	O
removed	O
using	O
PedCheck	O
[	O
55	O
]	O
.	O

Families	O
in	O
which	O
more	O
than	O
eight	O
markers	O
demonstrated	O
Mendel	O
errors	O
were	O
removed	O
from	O
further	O
analysis	O
.	O

Markers	O
with	O
less	O
than	O
80	O
%	O
genotyping	O
efficiency	O
and	O
markers	O
where	O
more	O
than	O
eight	O
families	O
showed	O
Mendel	O
errors	O
were	O
also	O
excluded	O
from	O
analysis	O
.	O

Two	O
markers	O
located	O
within	O
the	O
SLE	O
associated	O
class	O
II	O
region	O
(	O
rs2239802	O
in	O
intron	O
4	O
of	O
HLA	O
-	O
DRA	O
and	O
rs6457594	O
in	O
the	O
region	O
between	O
HLA	O
-	O
DRB9	O
and	O
HLA	O
-	O
DRB5	O
)	O
show	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
(	O
HWE	O
)	O
,	O
which	O
may	O
reflect	O
an	O
undetected	O
SLE	O
association	O
or	O
systematic	O
genotyping	O
error	O
.	O

HWE	O
was	O
assessed	O
in	O
parental	O
samples	O
in	O
our	O
cohort	O
.	O

There	O
is	O
currently	O
no	O
uniform	O
opinion	O
in	O
the	O
community	O
regarding	O
the	O
inclusion	O
or	O
exclusion	O
of	O
SNPs	O
that	O
show	O
deviation	O
from	O
HWE	O
,	O
hence	O
we	O
elected	O
to	O
include	O
these	O
markers	O
in	O
the	O
final	O
analysis	O
.	O

Sixty	O
-	O
eight	O
out	O
of	O
the	O
total	O
86	O
SNPs	O
passed	O
our	O
quality	O
-	O
control	O
measures	O
(	O
see	O
Table	O
S1	O
for	O
details	O
)	O
.	O

In	O
summary	O
,	O
one	O
SNP	O
was	O
monomorphic	O
in	O
our	O
dataset	O
,	O
four	O
SNPs	O
yielded	O
low	O
genotyping	O
efficiency	O
,	O
and	O
13	O
SNPs	O
were	O
excluded	O
for	O
unacceptable	O
Mendel	O
error	O
rate	O
.	O

The	O
mean	O
call	O
rate	O
for	O
all	O
markers	O
post	O
-	O
quality	O
control	O
was	O
94	O
%	O
(	O
range	O
83	O
%	O
to	O
99	O
%	O
)	O
.	O

Family	O
-	O
based	O
association	O
testing	O
was	O
performed	O
using	O
Genehunter	O
TDT	O
(	O
version	O
2	O
.	O
1	O
)	O
[	O
56	O
]	O
and	O
TRANSMIT	O
(	O
version	O
2	O
.	O
5	O
)	O
[	O
57	O
]	O
.	O

Haplotypes	O
were	O
constructed	O
and	O
permutation	O
testing	O
performed	O
using	O
Haploview	O
(	O
version	O
3	O
.	O
32	O
)	O
[	O
58	O
]	O
.	O

Significance	O
of	O
association	O
signals	O
in	O
all	O
analyses	O
was	O
based	O
on	O
permutation	O
testing	O
(	O
10	O
,	O
000	O
permutations	O
)	O
.	O

The	O
data	O
are	O
represented	O
both	O
as	O
nominal	O
and	O
permuted	O
p	O
values	O
.	O

ORs	O
with	O
95	O
%	O
CI	O
for	O
family	O
-	O
based	O
analyses	O
were	O
calculated	O
in	O
PLINK	O
(	O
http	O
:	O
/	O
/	O
pngu	O
.	O
mgh	O
.	O
harvard	O
.	O
edu	O
/	O
purcell	O
/	O
plink	O
/	O
)	O
[	O
59	O
]	O
.	O

Conditional	O
regression	O
analyses	O
were	O
undertaken	O
using	O
WHAP	O
[	O
60	O
]	O
.	O

The	O
geno	O
-	O
PDT	O
was	O
performed	O
using	O
PDT	O
version	O
5	O
.	O
1	O
with	O
default	O
settings	O
[	O
27	O
]	O
.	O

The	O
HLA	O
-	O
DRB1	O
alleles	O
were	O
coded	O
into	O
three	O
groups	O
for	O
the	O
geno	O
-	O
PDT	O
and	O
the	O
case	O
-	O
control	O
analysis	O
:	O
HLA	O
-	O
DRB1	O
*	O
0301	O
,	O
HLA	O
-	O
DRB1	O
*	O
1501	O
and	O
HLA	O
-	O
DRX	O
where	O
HLA	O
-	O
DRX	O
includes	O
all	O
HLA	O
-	O
DRB1	O
alleles	O
other	O
than	O
HLA	O
-	O
DRB1	O
*	O
0301	O
or	O
HLA	O
-	O
DRB1	O
*	O
1501	O
.	O

The	O
HLA	O
-	O
DRB1	O
*	O
1501	O
code	O
in	O
the	O
healthy	O
controls	O
represents	O
the	O
allele	O
string	O
HLA	O
-	O
DRB1	O
*	O
1501	O
/	O
1502	O
/	O
1504	O
/	O
1506	O
,	O
as	O
described	O
previously	O
.	O

The	O
HLA	O
-	O
DRB1	O
*	O
1501	O
code	O
in	O
the	O
lupus	O
probands	O
represents	O
the	O
alleles	O
HLA	O
-	O
DRB1	O
*	O
1501	O
(	O
84	O
out	O
of	O
91	O
*	O
1501	O
and	O
*	O
1502	O
alleles	O
)	O
and	O
HLA	O
-	O
DRB1	O
*	O
1502	O
(	O
7	O
/	O
91	O
*	O
1501	O
and	O
*	O
1502	O
alleles	O
)	O
,	O
as	O
*	O
1504	O
and	O
*	O
1506	O
were	O
not	O
present	O
in	O
this	O
population	O
.	O

Fisher	O
'	O
s	O
exact	O
test	O
was	O
used	O
to	O
assess	O
significance	O
of	O
association	O
in	O
the	O
case	O
-	O
control	O
analysis	O
.	O

Subphenotype	O
analysis	O
.	O

We	O
looked	O
for	O
association	O
of	O
the	O
HLA	O
-	O
DRB1	O
*	O
0301	O
allele	O
with	O
autoantibody	O
subsets	O
and	O
renal	O
disease	O
in	O
our	O
cohort	O
using	O
the	O
Chi	O
-	O
square	O
test	O
.	O

We	O
compared	O
cases	O
with	O
and	O
without	O
the	O
subphenotype	O
of	O
interest	O
with	O
DRB1	O
*	O
0301	O
homozygosity	O
,	O
heterozygosity	O
,	O
combined	O
homozygosity	O
and	O
heterozygosity	O
,	O
and	O
non	O
-	O
DRB1	O
*	O
0301	O
status	O
.	O

We	O
performed	O
the	O
same	O
analyses	O
for	O
homozygous	O
and	O
heterozygous	O
genotypes	O
of	O
the	O
associated	O
SNP	O
rs419788	O
.	O

The	O
autoantibody	O
subsets	O
compared	O
were	O
anti	O
-	O
C1q	O
,	O
IgG	O
,	O
and	O
IgM	O
anti	O
-	O
cardiolipin	O
antibodies	O
(	O
ACLG	O
and	O
ACLM	O
)	O
,	O
anti	O
-	O
Ro	O
,	O
anti	O
-	O
La	O
,	O
anti	O
-	O
RNP	O
,	O
anti	O
-	O
Sm	O
,	O
and	O
anti	O
-	O
dsDNA	O
.	O

Delineation	O
of	O
associated	O
MHC	O
haplotypes	O
and	O
evidence	O
for	O
positive	O
selection	O
.	O

We	O
looked	O
for	O
positively	O
selected	O
alleles	O
in	O
our	O
dataset	O
using	O
the	O
long	O
-	O
range	O
haplotype	O
test	O
as	O
measured	O
by	O
extended	O
haplotype	O
homozygosity	O
(	O
EHH	O
)	O
,	O
previously	O
described	O
by	O
Sabeti	O
et	O
al	O
.	O

[	O
26	O
]	O
.	O

Essentially	O
,	O
such	O
an	O
analysis	O
allows	O
assessment	O
of	O
positive	O
selection	O
by	O
mining	O
datasets	O
for	O
high	O
frequency	O
extended	O
haplotypes	O
in	O
comparison	O
to	O
the	O
other	O
core	O
haplotypes	O
at	O
a	O
locus	O
.	O

EHH	O
is	O
defined	O
as	O
the	O
probability	O
that	O
two	O
randomly	O
chosen	O
chromosomes	O
carrying	O
the	O
core	O
haplotype	O
of	O
interest	O
will	O
be	O
identical	O
by	O
descent	O
(	O
homozygosity	O
at	O
all	O
SNPs	O
)	O
for	O
the	O
entire	O
interval	O
from	O
the	O
core	O
to	O
a	O
distance	O
x	O
.	O

The	O
REHH	O
is	O
the	O
ratio	O
of	O
the	O
EHH	O
on	O
the	O
tested	O
core	O
haplotype	O
compared	O
with	O
the	O
combined	O
EHH	O
of	O
all	O
the	O
other	O
core	O
haplotypes	O
at	O
the	O
region	O
excluding	O
the	O
tested	O
core	O
;	O
as	O
such	O
,	O
REHH	O
accounts	O
for	O
local	O
variation	O
in	O
recombination	O
rate	O
while	O
EHH	O
does	O
not	O
[	O
26	O
]	O
.	O

The	O
program	O
emphase	O
was	O
employed	O
to	O
assign	O
the	O
phase	O
of	O
parental	O
genotype	O
data	O
and	O
reconstruct	O
missing	O
information	O
.	O

Emphase	O
is	O
a	O
simple	O
phaser	O
similar	O
to	O
the	O
phaser	O
of	O
Excoffier	O
and	O
Slatkin	O
[	O
61	O
]	O
.	O

It	O
is	O
very	O
fast	O
,	O
especially	O
on	O
large	O
datasets	O
,	O
and	O
sufficiently	O
accurate	O
for	O
most	O
genetic	O
applications	O
.	O

EHH	O
analysis	O
was	O
performed	O
on	O
the	O
phased	O
parental	O
data	O
using	O
the	O
software	O
program	O
SWEEP	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
broad	O
.	O
mit	O
.	O
edu	O
/	O
mpg	O
/	O
sweep	O
/	O
index	O
.	O
html	O
)	O
.	O

Haplotype	O
bifurcation	O
plots	O
.	O

We	O
represent	O
the	O
breakdown	O
of	O
LD	O
on	O
core	O
haplotypes	O
using	O
haplotype	O
bifurcation	O
diagrams	O
generated	O
in	O
the	O
program	O
TREE	O
[	O
62	O
]	O
(	O
also	O
explained	O
in	O
[	O
52	O
]	O
)	O
.	O

REHH	O
versus	O
frequency	O
plots	O
.	O

Fifty	O
-	O
three	O
SNPs	O
(	O
identified	O
in	O
Figure	O
1	O
)	O
are	O
common	O
to	O
our	O
dataset	O
and	O
the	O
CEPH	O
and	O
Yoruba	O
HapMap	O
[	O
63	O
]	O
populations	O
.	O

These	O
three	O
datasets	O
,	O
together	O
with	O
CEPH	O
SNP	O
data	O
for	O
Chromosome	O
6	O
in	O
its	O
entirety	O
,	O
were	O
used	O
to	O
generate	O
separate	O
REHH	O
versus	O
frequency	O
plots	O
in	O
SWEEP	O
.	O

The	O
plots	O
from	O
the	O
four	O
cohorts	O
were	O
combined	O
for	O
visual	O
,	O
not	O
statistical	O
,	O
comparison	O
.	O

Evidence	O
for	O
positive	O
selection	O
was	O
quantitatively	O
assessed	O
in	O
CEPH	O
individuals	O
,	O
as	O
this	O
population	O
alone	O
was	O
used	O
to	O
assess	O
background	O
variation	O
on	O
Chromosome	O
6	O
.	O

The	O
UK	O
SLE	O
and	O
Yoruba	O
cohort	O
data	O
are	O
shown	O
for	O
comparison	O
.	O

The	O
95th	O
percentile	O
based	O
on	O
total	O
CEPH	O
Chromosome	O
6	O
SNP	O
data	O
is	O
shown	O
.	O

Supporting	O
Information	O

Accession	O
Numbers	O

The	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	S-Species
(	O
OMIM	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
sites	O
/	O
entrez	O
?	O
db	O
=	O
omim	O
)	O
accession	O
numbers	O
for	O
the	O
genes	O
described	O
in	O
this	O
study	O
are	O
as	O
follows	O
:	O
AGER	O
,	O
600214	O
;	O
BAT3	O
,	O
142590	O
;	O
C4A	O
,	O
120810	O
;	O
C4B	O
,	O
120820	O
;	O
CFB	O
,	O
138470	O
;	O
DOM3Z	O
,	O
605996	O
;	O
DOM3Z	O
,	O
605996	O
;	O
EHMT2	O
,	O
604599	O
;	O
HLA	O
-	O
B	O
,	O
142830	O
;	O
HLA	O
-	O
DPB2	O
,	O
120290	O
;	O
HLA	O
-	O
DQA1	O
,	O
146880	O
;	O
HLA	O
-	O
DQB1	O
,	O
604305	O
;	O
HLA	O
-	O
DRA	O
,	O
142860	O
;	O
HLA	O
-	O
DRB1	O
,	O
142857	O
;	O
KIAA1949	O
,	O
610990	O
;	O
MICA	O
,	O
600169	O
;	O
NOTCH4	O
,	O
164951	O
;	O
RDBP	O
,	O
154040	O
;	O
RDBP	O
,	O
154040	O
;	O
SKIV2L	O
,	O
600478	O
;	O
SLC44A4	O
,	O
606107	O
;	O
STK19	O
,	O
604977	O
;	O
STK19	O
,	O
604977	O
;	O
TNF	O
,	O
191160	O
;	O
and	O
TNXB	O
,	O
600985	O
.	O

SuperCAT	O
:	O
a	O
supertree	O
database	O
for	O
combined	O
and	O
integrative	O
multilocus	O
sequence	O
typing	O
analysis	O
of	O
the	O
Bacillus	B-Species
cereus	I-Species
group	E-Species
of	O
bacteria	O
(	O
including	O
B	B-Species
.	I-Species
cereus	E-Species
,	O
B	B-Species
.	I-Species
anthracis	E-Species
and	O
B	B-Species
.	I-Species
thuringiensis	E-Species
)	O

Abstract	O

The	O
Bacillus	B-Species
cereus	I-Species
group	E-Species
of	O
bacteria	O
is	O
an	O
important	O
group	O
including	O
mammalian	O
and	O
insect	O
pathogens	O
,	O
such	O
as	O
B	B-Species
.	I-Species
anthracis	E-Species
,	O
the	O
anthrax	S-Species
bacterium	O
,	O
B	B-Species
.	I-Species
thuringiensis	E-Species
,	O
used	O
as	O
a	O
biological	O
pesticide	O
and	O
B	B-Species
.	I-Species
cereus	E-Species
,	O
often	O
involved	O
in	O
food	O
poisoning	O
incidents	O
.	O

To	O
characterize	O
the	O
population	O
structure	O
and	O
epidemiology	O
of	O
these	O
bacteria	O
,	O
five	O
separate	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
schemes	O
have	O
been	O
developed	O
,	O
which	O
makes	O
results	O
difficult	O
to	O
compare	O
.	O

Therefore	O
,	O
we	O
have	O
developed	O
a	O
database	O
that	O
compiles	O
and	O
integrates	O
MLST	O
data	O
from	O
all	O
five	O
schemes	O
for	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
,	O
accessible	O
at	O
http	O
:	O
/	O
/	O
mlstoslo	O
.	O
uio	O
.	O
no	O
/	O
.	O

Supertree	O
techniques	O
were	O
used	O
to	O
combine	O
the	O
phylogenetic	O
information	O
from	O
analysis	O
of	O
all	O
schemes	O
and	O
datasets	O
,	O
in	O
order	O
to	O
produce	O
an	O
integrated	O
view	O
of	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
population	O
.	O

The	O
database	O
currently	O
contains	O
strain	O
information	O
and	O
sequence	O
data	O
for	O
1029	O
isolates	O
and	O
26	O
housekeeping	O
gene	O
fragments	O
,	O
which	O
can	O
be	O
searched	O
by	O
keywords	O
,	O
MLST	O
scheme	O
,	O
or	O
sequence	O
similarity	O
.	O

Supertrees	O
can	O
be	O
browsed	O
according	O
to	O
various	O
criteria	O
such	O
as	O
species	O
,	O
isolate	O
source	O
,	O
or	O
genetic	O
distance	O
,	O
and	O
subtrees	O
containing	O
strains	O
of	O
interest	O
can	O
be	O
extracted	O
.	O

Besides	O
analysis	O
of	O
the	O
available	O
data	O
,	O
the	O
user	O
has	O
the	O
possibility	O
to	O
enter	O
her	O
/	O
his	O
own	O
sequences	O
and	O
compare	O
them	O
to	O
the	O
database	O
and	O
/	O
or	O
include	O
them	O
into	O
the	O
supertree	O
reconstructions	O
.	O

INTRODUCTION	O

Multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
is	O
a	O
tool	O
that	O
is	O
widely	O
used	O
for	O
phylogenetic	O
typing	O
of	O
bacteria	O
.	O

MLST	O
is	O
based	O
on	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
internal	O
fragments	O
of	O
usually	O
seven	O
essential	O
or	O
housekeeping	O
genes	O
spread	O
around	O
the	O
bacterial	O
chromosome	O
.	O

The	O
genetic	O
relatedness	O
among	O
isolates	O
is	O
then	O
determined	O
by	O
comparison	O
of	O
the	O
nucleotide	O
sequence	O
types	O
(	O
1	O
,	O
2	O
)	O
.	O

MLST	O
is	O
thus	O
a	O
method	O
that	O
is	O
unambiguous	O
and	O
truly	O
portable	O
among	O
laboratories	O
.	O

Since	O
the	O
initial	O
development	O
of	O
this	O
technique	O
for	O
Neisseria	B-Species
meningitidis	E-Species
in	O
1998	O
,	O
MLST	O
schemes	O
have	O
been	O
developed	O
for	O
about	O
30	O
species	O
including	O
some	O
of	O
the	O
most	O
important	O
bacterial	O
pathogens	O
,	O
e	O
.	O
g	O
.	O
Streptococcus	B-Species
pneumoniae	E-Species
,	O
Streptococcus	B-Species
pyogenes	E-Species
,	O
Haemophilus	B-Species
influenzae	E-Species
,	O
Staphylococcus	B-Species
aureus	E-Species
,	O
Campylobacter	B-Species
jejuni	E-Species
,	O
Enterococcus	B-Species
faecium	E-Species
,	O
Burkholderia	B-Species
pseudomallei	E-Species
,	O
Escherichia	B-Species
coli	E-Species
,	O
Salmonella	B-Species
enterica	E-Species
and	O
the	O
Bacillus	B-Species
cereus	I-Species
group	E-Species
(	O
see	O
(	O
1	O
)	O
for	O
a	O
recent	O
review	O
)	O
.	O

These	O
MLST	O
schemes	O
have	O
been	O
used	O
successfully	O
to	O
explore	O
the	O
population	O
structure	O
of	O
bacteria	O
,	O
to	O
study	O
the	O
evolution	O
of	O
their	O
virulence	O
properties	O
,	O
to	O
identify	O
antibiotic	O
-	O
resistant	O
strains	O
and	O
epidemic	O
clones	O
,	O
and	O
for	O
epidemiological	O
surveillance	O
.	O

The	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
includes	O
bacterial	O
species	O
that	O
are	O
of	O
medical	O
and	O
/	O
or	O
economic	O
importance	O
,	O
such	O
as	O
B	B-Species
.	I-Species
anthracis	E-Species
,	O
an	O
obligate	O
mammalian	O
pathogen	O
causing	O
the	O
lethal	O
disease	O
anthrax	S-Species
,	O
B	B-Species
.	I-Species
cereus	E-Species
,	O
an	O
opportunistic	O
human	S-Species
pathogen	O
involved	O
in	O
food	O
-	O
poisoning	O
incidents	O
and	O
contaminations	O
in	O
hospitals	O
,	O
B	B-Species
.	I-Species
thuringiensis	E-Species
,	O
an	O
insect	O
pathogen	O
and	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
widely	O
used	O
biopesticide	O
and	O
B	B-Species
.	I-Species
weihenstephanensis	E-Species
,	O
a	O
cold	O
-	O
tolerant	O
species	O
known	O
for	O
contaminating	O
dairies	O
.	O

These	O
species	O
are	O
genetically	O
very	O
closely	O
related	O
and	O
may	O
be	O
considered	O
as	O
one	O
species	O
based	O
on	O
genetic	O
and	O
genomic	O
evidence	O
(	O
3	O
-	O
5	O
)	O
.	O

Unlike	O
other	O
bacterial	O
species	O
that	O
are	O
typed	O
using	O
a	O
single	O
MLST	O
scheme	O
,	O
five	O
separate	O
schemes	O
have	O
been	O
developed	O
for	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
,	O
based	O
on	O
different	O
sets	O
of	O
genes	O
and	O
isolates	O
(	O
5	O
-	O
10	O
)	O
.	O

The	O
Priest	O
scheme	O
(	O
8	O
)	O
is	O
currently	O
the	O
most	O
widely	O
used	O
.	O

Studies	O
with	O
the	O
various	O
schemes	O
have	O
independently	O
indicated	O
that	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
population	O
is	O
divided	O
into	O
three	O
main	O
phylogenetic	O
clusters	O
and	O
that	O
species	O
are	O
usually	O
intermixed	O
within	O
the	O
groups	O
.	O

One	O
cluster	O
contains	O
the	O
monomorphic	O
B	B-Species
.	I-Species
anthracis	E-Species
isolates	O
and	O
a	O
number	O
of	O
B	B-Species
.	I-Species
cereus	E-Species
and	O
B	B-Species
.	I-Species
thuringiensis	E-Species
strains	O
,	O
many	O
of	O
which	O
are	O
from	O
clinical	O
sources	O
.	O

A	O
second	O
heterogeneous	O
cluster	O
includes	O
B	B-Species
.	I-Species
cereus	E-Species
and	O
B	B-Species
.	I-Species
thuringiensis	E-Species
isolates	O
from	O
various	O
origins	O
,	O
while	O
cold	O
-	O
tolerant	O
B	B-Species
.	I-Species
weihenstephanensis	E-Species
and	O
B	B-Species
.	I-Species
cereus	E-Species
isolates	O
belong	O
to	O
the	O
third	O
group	O
.	O

The	O
separate	O
MLST	O
analyses	O
have	O
also	O
revealed	O
that	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
population	O
is	O
weakly	O
clonal	O
overall	O
due	O
to	O
numerous	O
clinical	O
and	O
virulent	O
isolates	O
emerging	O
from	O
different	O
phylogenetic	O
positions	O
(	O
5	O
-	O
8	O
,	O
11	O
-	O
14	O
)	O
,	O
with	O
the	O
exception	O
of	O
the	O
'	O
cold	O
-	O
tolerant	O
'	O
cluster	O
that	O
seems	O
to	O
exhibit	O
a	O
panmictic	O
(	O
or	O
sexual	O
)	O
population	O
structure	O
,	O
i	O
.	O
e	O
.	O
with	O
frequent	O
genetic	O
exchanges	O
between	O
strains	O
(	O
9	O
)	O
.	O

Despite	O
the	O
overall	O
congruence	O
between	O
the	O
various	O
MLST	O
studies	O
,	O
the	O
use	O
of	O
separate	O
schemes	O
with	O
no	O
gene	O
overlap	O
and	O
very	O
little	O
strain	O
overlap	O
has	O
produced	O
a	O
confusing	O
situation	O
and	O
makes	O
the	O
results	O
difficult	O
to	O
compare	O
directly	O
.	O

Therefore	O
,	O
we	O
recently	O
proposed	O
a	O
combined	O
scheme	O
based	O
on	O
genes	O
taken	O
from	O
three	O
of	O
the	O
four	O
schemes	O
available	O
by	O
then	O
and	O
for	O
which	O
we	O
created	O
a	O
web	O
-	O
based	O
database	O
accessible	O
at	O
the	O
University	O
of	O
Oslo	O
'	O
s	O
MLST	O
server	O
,	O
http	O
:	O
/	O
/	O
mlstoslo	O
.	O
uio	O
.	O
no	O
/	O
(	O
5	O
)	O
.	O

Here	O
,	O
in	O
order	O
to	O
provide	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
research	O
community	O
with	O
a	O
common	O
MLST	O
resource	O
,	O
we	O
have	O
developed	O
on	O
the	O
same	O
website	O
a	O
database	O
,	O
SuperCAT	O
,	O
that	O
compiles	O
and	O
integrates	O
MLST	O
data	O
from	O
all	O
the	O
published	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
schemes	O
.	O

In	O
addition	O
,	O
we	O
applied	O
supertree	O
reconstruction	O
methods	O
to	O
build	O
an	O
integrated	O
view	O
of	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
population	O
and	O
phylogeny	O
.	O

Below	O
we	O
describe	O
the	O
content	O
and	O
main	O
features	O
of	O
the	O
new	O
database	O
as	O
well	O
as	O
the	O
process	O
of	O
supertree	O
building	O
.	O

DATABASE	O
CONTENT	O
AND	O
IMPLEMENTATION	O

The	O
SuperCAT	O
database	O
provides	O
information	O
,	O
sequence	O
and	O
phylogenetic	O
data	O
for	O
all	O
bacterial	O
isolates	O
that	O
have	O
been	O
typed	O
using	O
any	O
of	O
the	O
five	O
published	O
MLST	O
schemes	O
for	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
(	O
Table	O
1	O
)	O
.	O

Strain	O
information	O
,	O
when	O
known	O
,	O
includes	O
isolate	O
description	O
,	O
source	O
and	O
geographical	O
location	O
of	O
isolation	O
,	O
and	O
the	O
scheme	O
(	O
s	O
)	O
used	O
for	O
typing	O
.	O

The	O
sequence	O
data	O
include	O
the	O
nucleotide	O
sequences	O
of	O
the	O
MLST	O
loci	O
examined	O
in	O
a	O
given	O
strain	O
.	O

SuperCAT	O
also	O
contains	O
the	O
phylogenetic	O
supertree	O
of	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
reconstructed	O
by	O
combining	O
the	O
sequence	O
data	O
from	O
all	O
five	O
schemes	O
,	O
as	O
well	O
as	O
supertrees	O
built	O
for	O
individual	O
schemes	O
.	O

Information	O
and	O
sequences	O
for	O
isolates	O
typed	O
by	O
the	O
Priest	O
and	O
Tourasse	O
-	O
Helgason	O
schemes	O
were	O
retrieved	O
from	O
the	O
databases	O
devoted	O
to	O
these	O
schemes	O
at	O
http	O
:	O
/	O
/	O
pubmlst	O
.	O
org	O
/	O
bcereus	O
and	O
http	O
:	O
/	O
/	O
mlstoslo	O
.	O
uio	O
.	O
no	O
/	O
,	O
respectively	O
.	O

MLST	O
data	O
for	O
additional	O
strains	O
not	O
available	O
in	O
the	O
pubmlst	O
.	O
org	O
repository	O
(	O
strains	O
from	O
(	O
15	O
)	O
are	O
missing	O
therein	O
)	O
and	O
for	O
the	O
Helgason	O
,	O
Ko	O
,	O
and	O
Candelon	O
-	O
Sorokin	O
schemes	O
were	O
taken	O
from	O
the	O
published	O
literature	O
and	O
the	O
Genbank	O
nucleotide	O
sequence	O
database	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
sequences	O
of	O
all	O
MLST	O
loci	O
were	O
extracted	O
from	O
the	O
complete	O
genomes	O
of	O
the	O
21	O
sequenced	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
strains	O
available	O
in	O
Genbank	O
.	O

Altogether	O
,	O
SuperCAT	O
currently	O
contains	O
data	O
for	O
1029	O
isolates	O
and	O
26	O
gene	O
fragments	O
from	O
25	O
different	O
genes	O
.	O

However	O
,	O
since	O
most	O
strains	O
have	O
been	O
typed	O
using	O
only	O
6	O
or	O
7	O
of	O
the	O
26	O
loci	O
,	O
about	O
one	O
-	O
third	O
of	O
the	O
complete	O
set	O
of	O
sequences	O
are	O
included	O
.	O

The	O
26	O
loci	O
,	O
only	O
available	O
for	O
the	O
completely	O
sequenced	O
strains	O
,	O
sum	O
up	O
to	O
10	O
619	O
bp	O
.	O

All	O
these	O
genes	O
are	O
located	O
on	O
the	O
chromosome	O
,	O
thus	O
the	O
database	O
provides	O
no	O
information	O
about	O
extrachromosomal	O
plasmids	O
even	O
though	O
most	O
of	O
the	O
strains	O
do	O
carry	O
one	O
or	O
several	O
small	O
and	O
/	O
or	O
large	O
plasmids	O
.	O

Unlike	O
scheme	O
-	O
specific	O
MLST	O
databases	O
,	O
SuperCAT	O
does	O
not	O
contain	O
allele	O
and	O
sequence	O
type	O
(	O
ST	O
)	O
numbers	O
.	O

Since	O
isolates	O
in	O
SuperCAT	O
have	O
been	O
typed	O
by	O
different	O
subsets	O
of	O
loci	O
,	O
complete	O
allelic	O
profiles	O
are	O
unavailable	O
and	O
therefore	O
STs	O
cannot	O
be	O
assigned	O
for	O
most	O
strains	O
,	O
except	O
the	O
fully	O
sequenced	O
ones	O
.	O

Table	O
1	O
.	O
The	O
five	O
MLST	O
schemes	O
designed	O
for	O
typing	O
bacteria	O
of	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
groupSchemeGenesTotal	E-Species
sequence	O
length	O
(	O
bp	O
)	O
Total	O
number	O
of	O
isolateseUsed	O
in	O
(	O
references	O
)	O
Helgasonadk	O
,	O
ccpA	O
,	O
ftsA	O
,	O
glpT	O
,	O
pyre	O
,	O
recF	O
and	O
sucC2	O
938120	O
(	O
6	O
,	O
12	O
,	O
46	O
)	O
Candelon	O
-	O
Sorokina	O
,	O
cclpC	O
,	O
dinB	O
,	O
gdpD	O
,	O
panC	O
,	O
purF	O
and	O
yhfL2	O
850149	O
(	O
9	O
,	O
10	O
)	O
Kob	O
,	O
cgyrB	O
,	O
mbl	O
,	O
mdh	O
,	O
mutS	O
,	O
pycA	O
(	O
1	O
)	O
and	O
rpoB2	O
00265	O
(	O
7	O
)	O
Priesta	O
,	O
bglpF	O
,	O
gmk	O
,	O
ilvD	O
,	O
pta	O
,	O
purH	O
,	O
pycA	O
(	O
2	O
)	O
and	O
tpi2	O
829721	O
(	O
8	O
,	O
11	O
,	O
13	O
-	O
15	O
,	O
46	O
-	O
48	O
)	O
Tourasse	O
-	O
Helgasona	O
,	O
b	O
,	O
dadk	O
,	O
ccpA	O
,	O
glpF	O
,	O
glpT	O
,	O
panC	O
,	O
pta	O
and	O
pycA	O
(	O
2	O
)	O
2	O
658172	O
(	O
5	O
)	O
aSpecific	O
databases	O
for	O
the	O
Priest	O
and	O
Tourasse	O
-	O
Helgason	O
schemes	O
are	O
accessible	O
at	O
http	O
:	O
/	O
/	O
pubmlst	O
.	O
org	O
/	O
bcereus	O
/	O
and	O
http	O
:	O
/	O
/	O
mlstoslo	O
.	O
uio	O
.	O
no	O
/	O
,	O
respectively	O
.	O

A	O
BLAST	O
database	O
for	O
the	O
Candelon	O
-	O
Sorokin	O
scheme	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
spock	O
.	O
jouy	O
.	O
inra	O
.	O
fr	O
/	O
cgi	O
-	O
bin	O
/	O
bacilliMLSopen	O
.	O
cgi	O
.	O
bWhile	O
the	O
Tourasse	O
-	O
Helgason	O
and	O
Priest	O
schemes	O
use	O
the	O
same	O
gene	O
fragment	O
for	O
the	O
pycA	O
gene	O
,	O
the	O
Ko	O
scheme	O
is	O
based	O
on	O
a	O
different	O
and	O
non	O
-	O
overlapping	O
gene	O
region	O
.	O
cThe	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
-	O
specific	O
transcriptional	O
regulator	O
plcR	O
was	O
originally	O
included	O
in	O
the	O
Candelon	O
-	O
Sorokin	O
and	O
Ko	O
schemes	O
.	O

However	O
,	O
plcR	O
follows	O
a	O
phylogeny	O
different	O
from	O
the	O
other	O
MLST	O
loci	O
(	O
7	O
,	O
10	O
)	O
and	O
is	O
no	O
longer	O
used	O
for	O
MLST	O
;	O
therefore	O
,	O
it	O
is	O
not	O
included	O
in	O
SuperCAT	O
.	O
dThe	O
Tourasse	O
-	O
Helgason	O
scheme	O
is	O
a	O
combined	O
scheme	O
based	O
on	O
3	O
genes	O
from	O
the	O
Helgason	O
scheme	O
(	O
adk	O
,	O
ccpA	O
,	O
and	O
glpT	O
)	O
,	O
3	O
genes	O
from	O
the	O
Priest	O
scheme	O
(	O
glpF	O
,	O
pta	O
and	O
pycA	O
(	O
2	O
)	O
)	O
,	O
and	O
the	O
panC	O
gene	O
from	O
the	O
Candelon	O
-	O
Sorokin	O
scheme	O
.	O
eIncluding	O
strains	O
with	O
fully	O
sequenced	O
genomes	O
.	O

SuperCAT	O
is	O
built	O
as	O
a	O
relational	O
database	O
using	O
the	O
PostgreSQL	O
management	O
system	O
,	O
and	O
data	O
are	O
accessible	O
through	O
a	O
graphical	O
web	O
interface	O
.	O

User	O
queries	O
and	O
results	O
pages	O
are	O
processed	O
and	O
created	O
on	O
-	O
the	O
-	O
fly	O
via	O
a	O
highly	O
modified	O
version	O
of	O
the	O
mlstdbNet	O
software	O
(	O
16	O
)	O
written	O
in	O
PERL	O
and	O
based	O
on	O
the	O
DataBase	O
Interface	O
(	O
DBI	O
)	O
and	O
Common	O
Gateway	O
Interface	O
(	O
CGI	O
)	O
modules	O
.	O

The	O
database	O
is	O
implemented	O
on	O
a	O
Linux	O
Apache	O
web	O
server	O
maintained	O
through	O
the	O
facilities	O
and	O
support	O
provided	O
by	O
the	O
Norwegian	O
EMBnet	O
node	O
.	O

Some	O
large	O
supertree	O
computations	O
are	O
run	O
on	O
a	O
Linux	O
supercomputer	O
at	O
the	O
University	O
of	O
Oslo	O
.	O

The	O
ATV	O
(	O
A	O
Tree	O
Viewer	O
)	O
Java	O
applet	O
is	O
used	O
for	O
phylogenetic	O
tree	O
display	O
(	O
17	O
)	O
.	O

ATV	O
notably	O
supports	O
horizontal	O
and	O
vertical	O
zooming	O
capabilities	O
that	O
are	O
suitable	O
for	O
browsing	O
large	O
trees	O
.	O

The	O
Jalview	O
editor	O
Java	O
applet	O
is	O
also	O
implemented	O
in	O
SuperCAT	O
for	O
advanced	O
multiple	O
sequence	O
alignment	O
display	O
(	O
18	O
)	O
.	O

SUPERTREE	O
RECONSTRUCTION	O

Supertree	O
techniques	O
allow	O
to	O
combine	O
the	O
phylogenetic	O
information	O
from	O
different	O
datasets	O
into	O
a	O
common	O
phylogenetic	O
tree	O
and	O
several	O
studies	O
have	O
shown	O
that	O
meaningful	O
supertrees	O
can	O
be	O
obtained	O
even	O
when	O
taxon	O
overlap	O
is	O
very	O
sparse	O
(	O
see	O
(	O
19	O
,	O
20	O
)	O
for	O
reviews	O
)	O
.	O

Supertree	O
analysis	O
has	O
thus	O
become	O
increasingly	O
popular	O
for	O
taking	O
advantage	O
and	O
combining	O
the	O
massive	O
amount	O
of	O
sequence	O
data	O
available	O
in	O
public	O
databases	O
for	O
reconstructing	O
large	O
-	O
scale	O
organismal	O
phylogenies	O
with	O
the	O
ultimate	O
goal	O
of	O
building	O
the	O
tree	O
of	O
life	O
(	O
21	O
-	O
24	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
21	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
strains	O
that	O
have	O
been	O
completely	O
sequenced	O
,	O
and	O
for	O
which	O
the	O
sequences	O
at	O
all	O
26	O
MLST	O
loci	O
are	O
thus	O
available	O
,	O
can	O
be	O
used	O
to	O
join	O
all	O
five	O
schemes	O
and	O
provide	O
the	O
strain	O
overlap	O
necessary	O
for	O
supertree	O
analysis	O
.	O

The	O
global	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
supertree	O
,	O
containing	O
1029	O
isolates	O
,	O
was	O
reconstructed	O
according	O
to	O
the	O
widely	O
used	O
matrix	O
representation	O
by	O
parsimony	O
(	O
MRP	O
)	O
procedure	O
(	O
Figure	O
1	O
;	O
(	O
19	O
,	O
25	O
,	O
26	O
)	O
)	O
.	O

Scheme	O
-	O
specific	O
supertrees	O
were	O
also	O
reconstructed	O
for	O
each	O
of	O
the	O
five	O
MLST	O
schemes	O
by	O
the	O
same	O
technique	O
.	O

Briefly	O
,	O
a	O
phylogenetic	O
tree	O
is	O
built	O
for	O
every	O
gene	O
separately	O
by	O
the	O
maximum	O
likelihood	O
method	O
with	O
the	O
PHYML	O
_	O
aLRT	O
program	O
(	O
27	O
)	O
.	O

Then	O
,	O
each	O
gene	O
tree	O
is	O
recoded	O
into	O
a	O
binary	O
matrix	O
representing	O
the	O
branching	O
order	O
(	O
i	O
.	O
e	O
.	O
the	O
phylogenetic	O
groupings	O
)	O
following	O
standard	O
MRP	O
coding	O
using	O
the	O
SuperMRP	O
.	O
pl	O
script	O
(	O
28	O
)	O
.	O

All	O
gene	O
tree	O
matrices	O
are	O
concatenated	O
into	O
a	O
supermatrix	O
,	O
in	O
which	O
isolates	O
missing	O
from	O
a	O
particular	O
tree	O
are	O
coded	O
using	O
the	O
'	O
?	O
'	O
character	O
representing	O
unknown	O
data	O
.	O

In	O
this	O
supermatrix	O
,	O
the	O
sequence	O
of	O
0	O
'	O
s	O
,	O
1	O
'	O
s	O
and	O
?	O
'	O
s	O
defines	O
the	O
branching	O
profile	O
of	O
a	O
strain	O
.	O

Closely	O
related	O
strains	O
have	O
similar	O
branching	O
profiles	O
.	O

Supertrees	O
are	O
then	O
generated	O
from	O
the	O
supermatrix	O
by	O
the	O
maximum	O
parsimony	O
technique	O
using	O
the	O
program	O
MIX	O
from	O
the	O
PHYLIP	O
package	O
(	O
29	O
)	O
run	O
with	O
default	O
parameters	O
.	O

The	O
maximum	O
parsimony	O
step	O
infers	O
the	O
trees	O
that	O
would	O
require	O
the	O
minimum	O
number	O
of	O
changes	O
between	O
the	O
branching	O
profiles	O
of	O
all	O
isolates	O
,	O
where	O
the	O
unknown	O
characters	O
can	O
take	O
any	O
of	O
the	O
two	O
possible	O
states	O
0	O
or	O
1	O
(	O
they	O
are	O
not	O
treated	O
as	O
missing	O
gaps	O
)	O
.	O

As	O
many	O
trees	O
were	O
equally	O
parsimonious	O
,	O
the	O
final	O
supertree	O
was	O
taken	O
as	O
the	O
strict	O
consensus	O
of	O
all	O
parsimony	O
trees	O
with	O
the	O
CONSENSE	O
program	O
of	O
PHYLIP	O
.	O

In	O
order	O
to	O
obtain	O
branch	O
lengths	O
that	O
are	O
proportional	O
to	O
the	O
amount	O
of	O
nucleotide	O
changes	O
,	O
we	O
added	O
an	O
additional	O
step	O
in	O
which	O
branch	O
lengths	O
and	O
statistical	O
support	O
for	O
groupings	O
are	O
estimated	O
from	O
the	O
concatenated	O
sequences	O
by	O
the	O
maximum	O
likelihood	O
method	O
employing	O
approximate	O
likelihood	O
-	O
ratio	O
tests	O
(	O
aLRTs	O
)	O
for	O
branches	O
using	O
PHYML	O
_	O
aLRT	O
with	O
Shimodaira	O
-	O
Hasegawa	O
-	O
like	O
support	O
values	O
(	O
27	O
,	O
30	O
)	O
.	O

aLRTs	O
provide	O
a	O
fast	O
way	O
of	O
testing	O
branch	O
support	O
without	O
requirement	O
of	O
multiple	O
replicates	O
like	O
traditional	O
bootstrap	O
procedures	O
.	O

The	O
Felsenstein	O
-	O
1984	O
nucleotide	O
substitution	O
model	O
supplemented	O
with	O
a	O
gamma	O
distribution	O
(	O
F84	O
+	O
Gamma	O
)	O
was	O
used	O
in	O
maximum	O
likelihood	O
computations	O
for	O
individual	O
gene	O
trees	O
and	O
the	O
supertree	O
(	O
31	O
)	O
.	O

This	O
model	O
allows	O
for	O
unequal	O
base	O
frequencies	O
,	O
transition	O
/	O
transversion	O
rate	O
bias	O
,	O
and	O
gamma	O
-	O
distributed	O
substitution	O
rate	O
variation	O
among	O
sites	O
.	O

It	O
was	O
empirically	O
chosen	O
as	O
a	O
consensus	O
from	O
exploratory	O
model	O
testing	O
using	O
ModelTest	O
(	O
32	O
,	O
33	O
)	O
,	O
which	O
indicated	O
that	O
models	O
including	O
these	O
three	O
factors	O
were	O
most	O
appropriate	O
for	O
the	O
MLST	O
loci	O
studied	O
,	O
although	O
models	O
for	O
individual	O
loci	O
differed	O
slightly	O
.	O

Note	O
that	O
the	O
maximum	O
likelihood	O
technique	O
also	O
allows	O
for	O
uneven	O
rates	O
of	O
nucleotide	O
substitution	O
between	O
strains	O
,	O
which	O
allows	O
to	O
accommodate	O
slow	O
-	O
and	O
fast	O
-	O
evolving	O
isolates	O
.	O

To	O
reduce	O
the	O
size	O
of	O
the	O
binary	O
supermatrix	O
and	O
speed	O
up	O
computations	O
,	O
individual	O
gene	O
trees	O
and	O
the	O
supertree	O
were	O
built	O
using	O
only	O
one	O
representative	O
from	O
a	O
set	O
of	O
strains	O
having	O
identical	O
sequences	O
.	O

The	O
remaining	O
identical	O
isolates	O
were	O
graphically	O
added	O
to	O
the	O
tree	O
afterwards	O
when	O
drawing	O
the	O
final	O
supertree	O
.	O

Figure	O
1	O
.	O
Schematic	O
overview	O
of	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
supertree	O
reconstruction	O
procedure	O
using	O
Matrix	O
Representation	O
by	O
Parsimony	O
(	O
MRP	O
)	O
.	O

See	O
text	O
for	O
details	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
global	O
1029	O
-	O
strain	O
supertree	O
retains	O
the	O
phylogenetic	O
signals	O
from	O
the	O
individual	O
schemes	O
and	O
contains	O
the	O
three	O
main	O
clusters	O
of	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
population	O
described	O
in	O
the	O
section	O
'	O
Introduction	O
'	O
.	O

The	O
integrated	O
SuperCAT	O
system	O
may	O
also	O
allow	O
to	O
infer	O
new	O
relationships	O
between	O
strains	O
that	O
were	O
analyzed	O
with	O
different	O
gene	O
sets	O
.	O

Even	O
though	O
the	O
26	O
loci	O
sequences	O
are	O
available	O
for	O
only	O
21	O
isolates	O
,	O
they	O
apparently	O
provide	O
enough	O
overlap	O
information	O
for	O
building	O
the	O
main	O
branches	O
of	O
the	O
supertree	O
.	O

These	O
21	O
isolates	O
cover	O
all	O
three	O
clusters	O
,	O
although	O
the	O
majority	O
of	O
them	O
are	O
B	B-Species
.	I-Species
anthracis	E-Species
strains	O
or	O
clinical	O
strains	O
closely	O
related	O
to	O
B	B-Species
.	I-Species
anthracis	E-Species
due	O
to	O
the	O
focus	O
of	O
genome	O
sequencing	O
projects	O
,	O
making	O
the	O
part	O
of	O
the	O
supertree	O
containing	O
these	O
isolates	O
likely	O
to	O
be	O
more	O
accurate	O
than	O
the	O
rest	O
of	O
the	O
tree	O
.	O

Furthermore	O
,	O
111	O
other	O
isolates	O
have	O
been	O
typed	O
by	O
10	O
genes	O
or	O
more	O
,	O
providing	O
additional	O
overlap	O
(	O
see	O
the	O
'	O
Gene	O
Distribution	O
'	O
page	O
)	O
.	O

Although	O
about	O
two	O
-	O
thirds	O
of	O
the	O
sequence	O
data	O
are	O
missing	O
overall	O
,	O
it	O
has	O
been	O
shown	O
for	O
other	O
organisms	O
that	O
relevant	O
supertrees	O
could	O
be	O
reconstructed	O
with	O
datasets	O
containing	O
more	O
than	O
90	O
%	O
of	O
missing	O
data	O
,	O
especially	O
when	O
the	O
characters	O
that	O
are	O
present	O
are	O
informative	O
(	O
20	O
,	O
22	O
,	O
23	O
,	O
34	O
)	O
.	O

Empirical	O
and	O
simulation	O
studies	O
have	O
indicated	O
that	O
this	O
behavior	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
characters	O
which	O
are	O
present	O
are	O
more	O
important	O
for	O
the	O
tree	O
-	O
building	O
process	O
than	O
those	O
which	O
are	O
absent	O
(	O
see	O
(	O
20	O
,	O
34	O
)	O
and	O
references	O
therein	O
)	O
.	O

Precise	O
within	O
-	O
cluster	O
groupings	O
may	O
contain	O
more	O
uncertainty	O
,	O
as	O
indicated	O
by	O
the	O
large	O
number	O
of	O
unresolved	O
multifurcations	O
in	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
supertree	O
.	O

Finally	O
,	O
it	O
is	O
also	O
worth	O
mentioning	O
that	O
the	O
branching	O
orders	O
of	O
the	O
scheme	O
-	O
specific	O
MRP	O
supertrees	O
are	O
highly	O
correlated	O
to	O
those	O
of	O
the	O
published	O
trees	O
built	O
with	O
concatenated	O
sequences	O
and	O
other	O
phylogenetic	O
algorithms	O
.	O

DATA	O
ACCESS	O
AND	O
MANIPULATION	O

The	O
complete	O
list	O
of	O
isolates	O
included	O
in	O
SuperCAT	O
(	O
currently	O
1029	O
)	O
with	O
strain	O
description	O
,	O
source	O
and	O
country	O
of	O
origin	O
is	O
available	O
at	O
the	O
database	O
home	O
page	O
.	O

By	O
default	O
all	O
isolates	O
in	O
the	O
database	O
are	O
used	O
in	O
the	O
analysis	O
tools	O
provided	O
,	O
but	O
the	O
user	O
can	O
select	O
strains	O
of	O
interest	O
by	O
keywords	O
,	O
MLST	O
scheme	O
,	O
entering	O
a	O
list	O
of	O
strain	O
identifiers	O
,	O
or	O
choosing	O
isolates	O
individually	O
via	O
checkboxes	O
.	O

All	O
subsequent	O
analyses	O
will	O
be	O
based	O
on	O
the	O
selected	O
strain	O
subset	O
and	O
their	O
loci	O
.	O

The	O
keyword	O
search	O
will	O
look	O
for	O
matches	O
in	O
any	O
of	O
the	O
strain	O
,	O
description	O
,	O
source	O
,	O
location	O
and	O
scheme	O
fields	O
.	O

Complex	O
keyword	O
queries	O
with	O
several	O
logical	O
operators	O
can	O
be	O
formulated	O
in	O
the	O
'	O
advanced	O
search	O
'	O
page	O
.	O

Note	O
that	O
many	O
isolates	O
were	O
referred	O
by	O
alternative	O
names	O
in	O
different	O
MLST	O
schemes	O
and	O
publications	O
,	O
therefore	O
synonyms	O
have	O
been	O
included	O
in	O
the	O
strain	O
descriptions	O
that	O
allow	O
a	O
particular	O
isolate	O
to	O
be	O
looked	O
up	O
using	O
any	O
of	O
its	O
alternative	O
identifiers	O
.	O

A	O
sequence	O
search	O
is	O
also	O
possible	O
using	O
BLASTN	O
(	O
35	O
)	O
,	O
in	O
order	O
to	O
select	O
isolates	O
that	O
have	O
allele	O
sequences	O
identical	O
to	O
user	O
-	O
entered	O
query	O
sequences	O
.	O

Throughout	O
SuperCAT	O
,	O
clicking	O
on	O
a	O
strain	O
name	O
will	O
pop	O
up	O
an	O
isolate	O
-	O
specific	O
window	O
showing	O
all	O
relevant	O
information	O
and	O
giving	O
access	O
to	O
the	O
nucleotide	O
sequences	O
of	O
individual	O
loci	O
for	O
that	O
isolate	O
.	O

Detailed	O
information	O
about	O
the	O
MLST	O
schemes	O
(	O
e	O
.	O
g	O
.	O
loci	O
names	O
and	O
lengths	O
,	O
genomic	O
coordinates	O
,	O
literature	O
references	O
)	O
and	O
their	O
overlap	O
,	O
the	O
distribution	O
of	O
available	O
loci	O
among	O
the	O
isolates	O
,	O
and	O
the	O
supertree	O
reconstruction	O
procedure	O
can	O
be	O
obtained	O
by	O
clicking	O
the	O
relevant	O
links	O
in	O
the	O
header	O
line	O
present	O
at	O
the	O
top	O
of	O
every	O
page	O
.	O

Apart	O
from	O
the	O
basic	O
functions	O
for	O
selecting	O
and	O
accessing	O
strain	O
information	O
and	O
sequence	O
data	O
for	O
all	O
five	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
MLST	O
schemes	O
,	O
the	O
main	O
features	O
of	O
SuperCAT	O
relate	O
to	O
the	O
manipulation	O
of	O
the	O
supertrees	O
constructed	O
by	O
the	O
MRP	O
approach	O
.	O

The	O
global	O
supertree	O
based	O
on	O
the	O
combination	O
of	O
all	O
five	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
MLST	O
schemes	O
as	O
well	O
as	O
the	O
five	O
scheme	O
-	O
specific	O
supertrees	O
can	O
be	O
browsed	O
according	O
to	O
various	O
user	O
-	O
chosen	O
criteria	O
(	O
Figure	O
2	O
)	O
.	O

Isolates	O
in	O
the	O
supertrees	O
can	O
be	O
colored	O
by	O
species	O
or	O
source	O
of	O
isolation	O
.	O

It	O
is	O
also	O
possible	O
to	O
specifically	O
mark	O
in	O
red	O
the	O
current	O
subset	O
of	O
strains	O
that	O
has	O
been	O
selected	O
by	O
the	O
user	O
and	O
to	O
extract	O
from	O
the	O
supertrees	O
the	O
subtree	O
containing	O
only	O
those	O
isolates	O
.	O

In	O
the	O
case	O
of	O
the	O
multi	O
-	O
scheme	O
supertree	O
highlighting	O
of	O
the	O
strains	O
can	O
be	O
based	O
on	O
genetic	O
distance	O
.	O

With	O
this	O
option	O
the	O
user	O
can	O
mark	O
on	O
and	O
/	O
or	O
extract	O
from	O
the	O
tree	O
the	O
isolates	O
that	O
are	O
genetically	O
closely	O
related	O
to	O
strains	O
of	O
her	O
/	O
his	O
choice	O
.	O

The	O
user	O
can	O
either	O
select	O
strains	O
that	O
share	O
one	O
or	O
several	O
identical	O
allele	O
sequences	O
with	O
her	O
/	O
his	O
query	O
isolate	O
(	O
s	O
)	O
or	O
that	O
are	O
at	O
a	O
specified	O
genetic	O
distance	O
.	O

Distances	O
between	O
isolates	O
are	O
computed	O
by	O
summing	O
up	O
the	O
lengths	O
of	O
the	O
branches	O
(	O
in	O
average	O
number	O
of	O
nucleotide	O
substitutions	O
per	O
site	O
)	O
connecting	O
the	O
isolates	O
in	O
the	O
supertree	O
(	O
known	O
as	O
patristic	O
distances	O
;	O
(	O
36	O
)	O
)	O
.	O

The	O
genetic	O
relatedness	O
search	O
functions	O
are	O
also	O
available	O
in	O
a	O
separate	O
page	O
for	O
the	O
user	O
to	O
find	O
closely	O
related	O
isolates	O
without	O
tree	O
manipulation	O
.	O

SuperCAT	O
allows	O
to	O
compare	O
the	O
scheme	O
-	O
specific	O
MLST	O
supertrees	O
with	O
each	O
other	O
and	O
with	O
the	O
global	O
supertree	O
by	O
using	O
the	O
subset	O
of	O
isolates	O
that	O
are	O
common	O
to	O
all	O
selected	O
schemes	O
.	O

Common	O
isolates	O
can	O
either	O
be	O
highlighted	O
in	O
red	O
or	O
be	O
extracted	O
as	O
subtrees	O
from	O
each	O
supertree	O
,	O
which	O
can	O
be	O
used	O
for	O
comparing	O
the	O
positions	O
of	O
the	O
common	O
strains	O
in	O
the	O
various	O
MLST	O
trees	O
.	O

For	O
all	O
supertree	O
-	O
related	O
options	O
,	O
detailed	O
tree	O
navigation	O
can	O
be	O
achieved	O
using	O
the	O
various	O
functions	O
in	O
the	O
ATV	O
tree	O
window	O
when	O
the	O
trees	O
are	O
displayed	O
(	O
17	O
)	O
.	O

Figure	O
2	O
.	O
Examples	O
of	O
supertree	O
browsing	O
and	O
manipulation	O
in	O
SuperCAT	O
.	O

A	O
,	O
supertree	O
colored	O
by	O
species	O
;	O
B	O
,	O
specific	O
highlighting	O
of	O
user	O
-	O
selected	O
strains	O
(	O
in	O
red	O
)	O
;	O
C	O
,	O
extracted	O
subtree	O
containing	O
only	O
the	O
strains	O
highlighted	O
in	O
B	O
.	O

Trees	O
are	O
displayed	O
using	O
ATV	O
(	O
17	O
)	O
.	O

Besides	O
the	O
manipulation	O
of	O
the	O
precomputed	O
supertrees	O
,	O
SuperCAT	O
offers	O
the	O
user	O
the	O
possibility	O
to	O
compute	O
new	O
supertrees	O
by	O
MRP	O
using	O
any	O
combination	O
of	O
strains	O
,	O
schemes	O
and	O
genes	O
.	O

Supertree	O
computations	O
may	O
be	O
extremely	O
time	O
consuming	O
,	O
ranging	O
from	O
a	O
few	O
minutes	O
to	O
2	O
-	O
3	O
days	O
with	O
the	O
complete	O
database	O
.	O

Users	O
are	O
therefore	O
requested	O
to	O
enter	O
their	O
e	O
-	O
mail	O
addresses	O
and	O
will	O
receive	O
a	O
notification	O
containing	O
a	O
link	O
to	O
the	O
results	O
page	O
when	O
the	O
supertree	O
is	O
ready	O
.	O

Note	O
that	O
when	O
building	O
a	O
supertree	O
for	O
a	O
user	O
-	O
selected	O
subset	O
of	O
strains	O
,	O
the	O
computation	O
will	O
first	O
include	O
all	O
database	O
isolates	O
.	O

A	O
subtree	O
containing	O
only	O
the	O
user	O
-	O
selected	O
isolates	O
will	O
then	O
be	O
extracted	O
from	O
the	O
supertree	O
of	O
all	O
strains	O
.	O

Although	O
more	O
time	O
consuming	O
,	O
this	O
strategy	O
allows	O
:	O
(	O
i	O
)	O
to	O
avoid	O
sampling	O
artefacts	O
as	O
phylogenies	O
built	O
with	O
different	O
isolate	O
sets	O
may	O
vary	O
and	O
(	O
ii	O
)	O
to	O
obtain	O
relationships	O
even	O
if	O
the	O
selected	O
isolates	O
have	O
been	O
typed	O
using	O
non	O
-	O
overlapping	O
gene	O
sets	O
,	O
as	O
the	O
supertree	O
of	O
all	O
isolates	O
can	O
always	O
be	O
built	O
owing	O
to	O
the	O
completely	O
sequenced	O
strains	O
that	O
are	O
common	O
to	O
all	O
schemes	O
.	O

Another	O
main	O
feature	O
of	O
the	O
SuperCAT	O
database	O
is	O
that	O
the	O
user	O
can	O
enter	O
her	O
/	O
his	O
own	O
private	O
sequences	O
and	O
conduct	O
several	O
sequence	O
analyses	O
(	O
Figure	O
3	O
)	O
.	O

These	O
analyses	O
include	O
:	O
(	O
a	O
)	O
building	O
new	O
supertrees	O
containing	O
user	O
isolates	O
and	O
sequences	O
;	O
(	O
b	O
)	O
finding	O
database	O
isolates	O
having	O
sequences	O
most	O
similar	O
to	O
the	O
user	O
'	O
s	O
query	O
sequences	O
using	O
an	O
on	O
-	O
line	O
BLASTN	O
(	O
35	O
)	O
service	O
;	O
and	O
(	O
c	O
)	O
aligning	O
user	O
sequences	O
to	O
database	O
genes	O
using	O
the	O
multiple	O
sequence	O
alignment	O
program	O
CLUSTALW	O
(	O
37	O
)	O
.	O

For	O
the	O
last	O
option	O
,	O
the	O
Jalview	O
editor	O
(	O
18	O
)	O
is	O
provided	O
for	O
advanced	O
multiple	O
alignment	O
display	O
.	O

All	O
user	O
-	O
entered	O
data	O
must	O
be	O
in	O
FASTA	O
format	O
and	O
can	O
be	O
either	O
copied	O
and	O
pasted	O
into	O
the	O
query	O
forms	O
or	O
uploaded	O
from	O
text	O
files	O
stored	O
locally	O
on	O
the	O
user	O
'	O
s	O
computer	O
.	O

Figure	O
3	O
.	O
Examples	O
of	O
query	O
results	O
in	O
SuperCAT	O
.	O

A	O
,	O
multi	O
-	O
scheme	O
BLAST	O
search	O
with	O
sequence	O
alignment	O
;	O
B	O
,	O
multi	O
-	O
scheme	O
genetic	O
search	O
showing	O
the	O
list	O
of	O
isolates	O
sharing	O
one	O
or	O
more	O
sequences	O
with	O
a	O
query	O
strain	O
;	O
C	O
,	O
multiple	O
sequence	O
alignment	O
using	O
Jalview	O
(	O
18	O
)	O
.	O

All	O
strain	O
information	O
data	O
,	O
sequences	O
and	O
phylogenetic	O
trees	O
,	O
including	O
user	O
-	O
made	O
supertrees	O
and	O
extracted	O
subtrees	O
,	O
can	O
be	O
saved	O
and	O
downloaded	O
freely	O
from	O
the	O
database	O
.	O

Users	O
wishing	O
to	O
have	O
their	O
MLST	O
data	O
included	O
as	O
part	O
of	O
the	O
SuperCAT	O
release	O
(	O
and	O
/	O
or	O
the	O
Tourasse	O
-	O
Helgason	O
scheme	O
-	O
specific	O
database	O
)	O
are	O
welcome	O
to	O
contact	O
N	O
.	O
J	O
.	O
T	O
.	O
or	O
A	O
.	O
-	O
B	O
.	O
K	O
.	O
at	O
the	O
e	O
-	O
mail	O
addresses	O
given	O
on	O
the	O
Oslo	O
MLST	O
server	O
front	O
page	O
.	O

DISCUSSION	O
AND	O
FUTURE	O
DEVELOPMENTS	O

SuperCAT	O
is	O
a	O
newly	O
created	O
database	O
devoted	O
to	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
of	O
bacteria	O
whose	O
main	O
objectives	O
are	O
to	O
provide	O
a	O
common	O
MLST	O
repository	O
and	O
means	O
for	O
building	O
a	O
comprehensive	O
genetic	O
analysis	O
of	O
the	O
group	O
that	O
has	O
been	O
typed	O
by	O
five	O
separate	O
schemes	O
.	O

The	O
database	O
is	O
publicly	O
and	O
freely	O
available	O
at	O
http	O
:	O
/	O
/	O
mlstoslo	O
.	O
uio	O
.	O
no	O
/	O
,	O
along	O
with	O
the	O
database	O
specific	O
for	O
the	O
combined	O
scheme	O
of	O
(	O
5	O
)	O
.	O

We	O
plan	O
to	O
update	O
SuperCAT	O
quarterly	O
.	O

Future	O
developments	O
of	O
the	O
database	O
may	O
deal	O
with	O
refining	O
the	O
supertree	O
-	O
building	O
procedure	O
.	O

In	O
particular	O
,	O
a	O
new	O
improved	O
method	O
has	O
recently	O
been	O
developed	O
for	O
taking	O
into	O
account	O
both	O
nucleotide	O
substitutions	O
and	O
recombination	O
events	O
in	O
phylogenies	O
,	O
as	O
part	O
of	O
the	O
ClonalFrame	O
software	O
,	O
which	O
has	O
been	O
applied	O
to	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
and	O
the	O
Priest	O
scheme	O
(	O
38	O
)	O
.	O

It	O
would	O
therefore	O
be	O
of	O
interest	O
to	O
examine	O
the	O
suitability	O
of	O
ClonalFrame	O
in	O
the	O
supertree	O
context	O
.	O

It	O
is	O
also	O
tempting	O
to	O
extend	O
the	O
supertree	O
analysis	O
beyond	O
MLST	O
data	O
,	O
by	O
incorporating	O
the	O
phylogenies	O
obtained	O
previously	O
from	O
large	O
-	O
scale	O
multilocus	O
enzyme	O
electrophoresis	O
(	O
MLEE	O
;	O
(	O
3	O
,	O
39	O
-	O
41	O
)	O
)	O
and	O
amplified	O
fragment	O
length	O
polymorphism	O
(	O
AFLP	O
;	O
(	O
42	O
-	O
45	O
)	O
)	O
studies	O
.	O

The	O
MRP	O
framework	O
is	O
ideal	O
since	O
it	O
allows	O
to	O
integrate	O
trees	O
that	O
can	O
be	O
built	O
from	O
different	O
methods	O
and	O
data	O
.	O

As	O
MLEE	O
,	O
AFLP	O
and	O
MLST	O
have	O
different	O
levels	O
of	O
resolution	O
,	O
one	O
can	O
hope	O
that	O
combining	O
them	O
might	O
provide	O
an	O
even	O
more	O
robust	O
supertree	O
for	O
the	O
B	B-Species
.	I-Species
cereus	I-Species
group	E-Species
.	O

Discovery	O
of	O
genes	O
implicated	O
in	O
whirling	O
disease	O
infection	O
and	O
resistance	O
in	O
rainbow	B-Species
trout	E-Species
using	O
genome	O
-	O
wide	O
expression	O
profiling	O

Abstract	O

Background	O

Whirling	O
disease	O
,	O
caused	O
by	O
the	O
pathogen	O
Myxobolus	B-Species
cerebralis	E-Species
,	O
afflicts	O
several	O
salmonid	O
species	O
.	O

Rainbow	B-Species
trout	E-Species
are	O
particularly	O
susceptible	O
and	O
may	O
suffer	O
high	O
mortality	O
rates	O
.	O

The	O
disease	O
is	O
persistent	O
and	O
spreading	O
in	O
hatcheries	O
and	O
natural	O
waters	O
of	O
several	O
countries	O
,	O
including	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
,	O
and	O
the	O
economic	O
losses	O
attributed	O
to	O
whirling	O
disease	O
are	O
substantial	O
.	O

In	O
this	O
study	O
,	O
genome	O
-	O
wide	O
expression	O
profiling	O
using	O
cDNA	O
microarrays	O
was	O
conducted	O
for	O
resistant	O
Hofer	O
and	O
susceptible	O
Trout	O
Lodge	O
rainbow	B-Species
trout	E-Species
strains	O
following	O
pathogen	O
exposure	O
with	O
the	O
primary	O
objective	O
of	O
identifying	O
specific	O
genes	O
implicated	O
in	O
whirling	O
disease	O
resistance	O
.	O

Results	O

Several	O
genes	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
skin	O
following	O
pathogen	O
exposure	O
for	O
both	O
the	O
resistant	O
and	O
susceptible	O
rainbow	B-Species
trout	E-Species
strains	O
.	O

For	O
both	O
strains	O
,	O
response	O
to	O
infection	O
appears	O
to	O
be	O
linked	O
with	O
the	O
interferon	O
system	O
.	O

Expression	O
profiles	O
for	O
three	O
genes	O
identified	O
with	O
microarrays	O
were	O
confirmed	O
with	O
qRT	O
-	O
PCR	O
.	O

Ubiquitin	O
-	O
like	O
protein	O
1	O
was	O
up	O
-	O
regulated	O
over	O
100	O
fold	O
and	O
interferon	O
regulating	O
factor	O
1	O
was	O
up	O
-	O
regulated	O
over	O
15	O
fold	O
following	O
pathogen	O
exposure	O
for	O
both	O
strains	O
.	O

Expression	O
of	O
metallothionein	O
B	O
,	O
which	O
has	O
known	O
roles	O
in	O
inflammation	O
and	O
immune	O
response	O
,	O
was	O
up	O
-	O
regulated	O
over	O
5	O
fold	O
in	O
the	O
resistant	O
Hofer	O
strain	O
but	O
was	O
unchanged	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
following	O
pathogen	O
exposure	O
.	O

Conclusion	O

The	O
present	O
study	O
has	O
provided	O
an	O
initial	O
view	O
into	O
the	O
genetic	O
basis	O
underlying	O
immune	O
response	O
and	O
resistance	O
of	O
rainbow	B-Species
trout	E-Species
to	O
the	O
whirling	O
disease	O
parasite	O
.	O

The	O
identified	O
genes	O
have	O
allowed	O
us	O
to	O
gain	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
implicated	O
in	O
salmonid	O
immune	O
response	O
and	O
resistance	O
to	O
whirling	O
disease	O
infection	O
.	O

Background	O

Whirling	O
disease	O
was	O
first	O
described	O
among	O
farmed	O
rainbow	B-Species
trout	E-Species
(	O
Oncorhynchus	B-Species
mykiss	E-Species
)	O
,	O
a	O
native	O
North	O
American	O
salmonid	O
species	O
,	O
introduced	O
to	O
Germany	O
as	O
a	O
food	O
fish	O
in	O
the	O
late	O
1800s	O
[	O
1	O
]	O
.	O

Whirling	O
disease	O
is	O
associated	O
with	O
systemic	O
infections	O
by	O
the	O
myxozoan	O
Myxobolus	B-Species
cerebralis	E-Species
,	O
a	O
parasite	O
with	O
presumed	O
origins	O
among	O
salmonid	O
fish	O
in	O
Eurasia	O
[	O
2	O
,	O
3	O
]	O
.	O

Rainbow	B-Species
trout	E-Species
are	O
highly	O
susceptible	O
to	O
whirling	O
disease	O
and	O
the	O
introduction	O
of	O
the	O
parasite	O
to	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
in	O
the	O
1950s	O
had	O
immediate	O
economic	O
impacts	O
on	O
salmonid	O
hatcheries	O
in	O
both	O
eastern	O
and	O
western	O
states	O
[	O
2	O
]	O
.	O

The	O
parasite	O
has	O
a	O
broad	O
worldwide	O
distribution	O
and	O
has	O
been	O
identified	O
in	O
25	O
states	O
in	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
where	O
salmonid	O
fish	O
are	O
present	O
[	O
4	O
]	O
.	O

Salmonid	O
hatcheries	O
throughout	O
the	O
U	O
.	O
S	O
.	O
A	O
have	O
suffered	O
drastic	O
economic	O
losses	O
due	O
to	O
whirling	O
disease	O
outbreaks	O
.	O

The	O
disease	O
has	O
more	O
recently	O
been	O
recognized	O
as	O
the	O
principal	O
cause	O
of	O
major	O
population	O
declines	O
among	O
wild	O
rainbow	B-Species
trout	E-Species
populations	O
in	O
the	O
intermountain	O
region	O
of	O
the	O
U	O
.	O
S	O
.	O
A	O
with	O
serious	O
negative	O
impacts	O
on	O
sportfishing	O
and	O
allied	O
industries	O
[	O
5	O
-	O
7	O
]	O
.	O

Additionally	O
,	O
concerns	O
continue	O
over	O
the	O
potential	O
negative	O
ecologic	O
impacts	O
of	O
whirling	O
disease	O
on	O
wild	O
salmonid	O
populations	O
,	O
particularly	O
threatened	O
or	O
endangered	O
salmonids	O
such	O
as	O
bull	B-Species
trout	E-Species
(	O
Salvelinus	B-Species
confluentus	E-Species
)	O
,	O
cutthroat	B-Species
trout	E-Species
(	O
Oncorhynchus	B-Species
clarki	E-Species
)	O
,	O
and	O
steelhead	S-Species
(	O
Oncorhynchus	B-Species
mykiss	E-Species
)	O
[	O
8	O
,	O
9	O
]	O
.	O

Myxobolus	B-Species
cerebralis	E-Species
has	O
a	O
complex	O
life	O
cycle	O
that	O
includes	O
two	O
alternate	O
hosts	O
,	O
a	O
salmonid	O
fish	O
and	O
an	O
oligochaete	O
worm	O
,	O
Tubifex	B-Species
tubifex	E-Species
[	O
10	O
,	O
11	O
]	O
.	O

Infection	O
in	O
the	O
salmonid	O
host	O
begins	O
when	O
microscopic	O
waterborne	O
actinospore	O
stages	O
of	O
M	B-Species
.	I-Species
cerebralis	E-Species
are	O
released	O
from	O
the	O
worm	O
and	O
contact	O
the	O
skin	O
of	O
the	O
fish	O
host	O
.	O

Actinospores	O
,	O
also	O
referred	O
to	O
as	O
triactinomyxons	O
for	O
M	B-Species
.	I-Species
cerebralis	E-Species
,	O
attach	O
preferentially	O
to	O
fins	O
and	O
the	O
buccal	O
cavity	O
where	O
they	O
release	O
one	O
or	O
more	O
of	O
three	O
coiled	O
polar	O
filaments	O
which	O
penetrate	O
and	O
then	O
anchor	O
them	O
to	O
the	O
epidermis	O
[	O
12	O
]	O
.	O

Within	O
minutes	O
the	O
sporoplasm	O
,	O
which	O
contains	O
64	O
internal	O
cells	O
,	O
migrates	O
from	O
the	O
triactinomxyon	O
to	O
deeper	O
layers	O
of	O
the	O
epidermis	O
,	O
an	O
action	O
that	O
may	O
be	O
facilitated	O
by	O
parasite	O
proteases	O
[	O
13	O
-	O
15	O
]	O
.	O

Aggregates	O
and	O
single	O
cells	O
from	O
the	O
sporoplasm	O
then	O
begin	O
mitotic	O
replication	O
within	O
two	O
h	O
of	O
initial	O
infection	O
,	O
alternating	O
between	O
inter	O
and	O
intracellular	O
locations	O
,	O
a	O
process	O
that	O
may	O
also	O
depend	O
upon	O
parasite	O
coded	O
protease	O
activity	O
[	O
15	O
,	O
16	O
]	O
.	O

Over	O
the	O
next	O
10	O
h	O
at	O
water	O
temperatures	O
of	O
15	O
degrees	O
C	O
,	O
parasites	O
within	O
host	O
epithelial	O
cells	O
further	O
divide	O
by	O
the	O
process	O
of	O
endogeny	O
or	O
cell	O
within	O
cell	O
replication	O
prior	O
to	O
release	O
and	O
then	O
penetration	O
of	O
new	O
host	O
cells	O
.	O

Between	O
12	O
and	O
20	O
h	O
post	O
infection	O
,	O
the	O
number	O
of	O
parasite	O
cells	O
present	O
in	O
the	O
epidermis	O
steadily	O
declines	O
until	O
new	O
stages	O
are	O
observed	O
in	O
the	O
subcutis	O
at	O
48	O
h	O
.	O

Degenerative	O
stages	O
observed	O
in	O
the	O
epidermis	O
between	O
12	O
and	O
20	O
h	O
are	O
suspected	O
to	O
be	O
a	O
result	O
of	O
the	O
action	O
of	O
the	O
host	O
immune	O
response	O
,	O
although	O
the	O
cellular	O
and	O
or	O
humoral	O
factors	O
involved	O
are	O
not	O
currently	O
known	O
.	O

After	O
a	O
brief	O
residence	O
in	O
the	O
subcutis	O
,	O
parasite	O
stages	O
are	O
presumed	O
to	O
migrate	O
to	O
proximal	O
nervous	O
tissues	O
,	O
initially	O
in	O
peripheral	O
and	O
then	O
more	O
central	O
locations	O
[	O
16	O
]	O
.	O

Migration	O
and	O
potential	O
replication	O
of	O
parasite	O
stages	O
in	O
nervous	O
tissue	O
ensues	O
over	O
the	O
next	O
16	O
d	O
with	O
the	O
first	O
parasites	O
exiting	O
to	O
invade	O
cartilage	O
observed	O
at	O
20	O
d	O
post	O
infection	O
[	O
16	O
]	O
.	O

Feeding	O
on	O
cartilage	O
may	O
induce	O
a	O
host	O
inflammatory	O
response	O
that	O
constricts	O
the	O
spinal	O
cord	O
,	O
brain	O
stem	O
,	O
and	O
caudal	O
nerves	O
resulting	O
in	O
the	O
erratic	O
swimming	O
behavior	O
(	O
whirling	O
)	O
and	O
black	O
tail	O
observed	O
among	O
fish	O
with	O
acute	O
whirling	O
disease	O
[	O
17	O
]	O
.	O

An	O
additional	O
impact	O
of	O
cartilage	O
destruction	O
are	O
permanent	O
deformities	O
to	O
the	O
skeletal	O
system	O
that	O
may	O
increase	O
vulnerability	O
to	O
predation	O
and	O
impair	O
ability	O
to	O
forage	O
for	O
food	O
[	O
1	O
]	O
.	O

The	O
final	O
developmental	O
stages	O
of	O
the	O
parasite	O
in	O
the	O
fish	O
are	O
environmentally	O
resistant	O
spore	O
stages	O
(	O
myxospores	O
)	O
which	O
remained	O
trapped	O
in	O
cartilage	O
or	O
bone	O
[	O
18	O
]	O
.	O

Death	O
of	O
infected	O
fish	O
or	O
ingestion	O
by	O
fish	O
or	O
avian	O
predators	O
releases	O
myxospores	O
from	O
the	O
fish	O
tissues	O
and	O
they	O
may	O
be	O
ingested	O
by	O
the	O
second	O
host	O
,	O
the	O
benthic	O
dwelling	O
oligochaete	O
T	B-Species
.	I-Species
tubifex	E-Species
[	O
19	O
]	O
.	O

A	O
second	O
developmental	O
cycle	O
then	O
occurs	O
under	O
the	O
mucosal	O
lining	O
of	O
the	O
intestine	O
that	O
results	O
in	O
the	O
release	O
of	O
thousands	O
of	O
the	O
actinospore	O
(	O
triactinomyxon	O
)	O
stages	O
potentially	O
over	O
the	O
entire	O
lifetime	O
of	O
the	O
individual	O
oligochaete	O
[	O
20	O
]	O
.	O

Susceptibility	O
to	O
whirling	O
disease	O
in	O
U	O
.	O
S	O
.	O
rainbow	B-Species
trout	E-Species
strains	O
is	O
pervasive	O
with	O
only	O
two	O
of	O
the	O
tested	O
native	O
strains	O
displaying	O
any	O
degree	O
of	O
resistance	O
,	O
which	O
may	O
be	O
inconsistent	O
and	O
relatively	O
moderate	O
[	O
21	O
,	O
22	O
]	O
.	O

Hatchery	O
rainbow	B-Species
trout	E-Species
in	O
Germany	O
(	O
Hofer	O
strain	O
)	O
,	O
however	O
,	O
have	O
acquired	O
a	O
degree	O
of	O
resistance	O
to	O
whirling	O
disease	O
that	O
is	O
consistently	O
much	O
higher	O
than	O
any	O
domestic	O
rainbow	O
strains	O
and	O
comparable	O
to	O
that	O
of	O
brown	B-Species
trout	E-Species
(	O
Salmon	B-Species
trutta	E-Species
)	O
,	O
which	O
are	O
native	O
to	O
Europe	O
and	O
typically	O
asymptomatic	O
following	O
infection	O
[	O
23	O
]	O
.	O

Laboratory	O
tests	O
comparing	O
rainbow	B-Species
trout	E-Species
strains	O
under	O
the	O
same	O
environmental	O
conditions	O
and	O
pathogen	O
exposure	O
indicate	O
that	O
the	O
Hofer	O
strain	O
'	O
s	O
ability	O
to	O
combat	O
M	B-Species
.	I-Species
cerebralis	E-Species
infection	O
has	O
a	O
genetic	O
basis	O
.	O

Recently	O
,	O
controlled	O
crosses	O
of	O
the	O
Hofer	O
strain	O
and	O
a	O
susceptible	O
strain	O
(	O
Colorado	O
River	O
rainbow	B-Species
trout	E-Species
[	O
CRR	O
]	O
)	O
demonstrated	O
that	O
resistance	O
to	O
whirling	O
disease	O
was	O
inherited	O
by	O
progeny	O
[	O
24	O
]	O
and	O
heritability	O
estimates	O
are	O
currently	O
underway	O
.	O

The	O
discovery	O
of	O
the	O
resistant	O
Hofer	O
strain	O
allowed	O
us	O
to	O
conduct	O
an	O
intraspecific	O
comparison	O
of	O
susceptible	O
and	O
resistant	O
rainbow	B-Species
trout	E-Species
in	O
order	O
to	O
gain	O
insight	O
into	O
the	O
genetic	O
basis	O
underlying	O
whirling	O
disease	O
susceptibility	O
for	O
this	O
species	O
.	O

Gene	O
expression	O
profiling	O
,	O
through	O
the	O
use	O
of	O
microarrays	O
,	O
is	O
an	O
extremely	O
high	O
-	O
throughput	O
method	O
to	O
discover	O
specific	O
genes	O
and	O
pathways	O
involved	O
in	O
a	O
disease	O
phenotype	O
without	O
the	O
bias	O
of	O
a	O
candidate	O
gene	O
approach	O
.	O

In	O
this	O
study	O
,	O
microarray	O
analysis	O
was	O
used	O
to	O
examine	O
expression	O
changes	O
in	O
a	O
resistant	O
and	O
susceptible	O
strain	O
of	O
rainbow	B-Species
trout	E-Species
following	O
exposure	O
to	O
M	B-Species
.	I-Species
cerebralis	E-Species
,	O
the	O
pathogen	O
causing	O
whirling	O
disease	O
.	O

We	O
have	O
found	O
several	O
genes	O
significantly	O
up	O
-	O
regulated	O
in	O
both	O
the	O
resistant	O
and	O
susceptible	O
strain	O
that	O
appear	O
to	O
be	O
involved	O
in	O
host	O
response	O
to	O
infection	O
.	O

We	O
have	O
also	O
found	O
a	O
gene	O
which	O
is	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
but	O
remains	O
unchanged	O
in	O
the	O
susceptible	O
rainbow	B-Species
trout	E-Species
strain	O
following	O
pathogen	O
exposure	O
that	O
is	O
a	O
likely	O
candidate	O
gene	O
for	O
involvement	O
in	O
conferring	O
whirling	O
disease	O
resistance	O
.	O

Results	O
and	O
Discussion	O

Quantitative	O
PCR	O
conducted	O
on	O
caudal	O
fin	O
tissues	O
at	O
two	O
hours	O
post	O
exposure	O
to	O
M	B-Species
.	I-Species
cerebralis	E-Species
demonstrated	O
each	O
fish	O
strain	O
had	O
similar	O
initial	O
pathogen	O
loads	O
,	O
although	O
there	O
was	O
substantial	O
variation	O
between	O
individual	O
fish	O
within	O
each	O
strain	O
.	O

The	O
mean	O
parasite	O
copy	O
numbers	O
per	O
host	O
cell	O
were	O
1	O
.	O
20	O
x	O
106	O
(	O
SD	O
1	O
.	O
53	O
x	O
106	O
)	O
for	O
the	O
Hofer	O
and	O
1	O
.	O
04	O
x	O
106	O
(	O
SD	O
0	O
.	O
91	O
x	O
106	O
)	O
for	O
the	O
Trout	O
Lodge	O
.	O

These	O
mean	O
values	O
and	O
standard	O
deviations	O
are	O
similar	O
to	O
those	O
obtained	O
in	O
additional	O
studies	O
of	O
susceptible	O
rainbow	B-Species
trout	E-Species
when	O
examined	O
at	O
early	O
time	O
points	O
post	O
TAM	O
exposure	O
(	O
unpublished	O
data	O
)	O
.	O

In	O
order	O
to	O
study	O
genes	O
involved	O
in	O
whirling	O
disease	O
response	O
,	O
resistant	O
and	O
susceptible	O
rainbow	B-Species
trout	E-Species
strains	O
were	O
exposed	O
to	O
M	B-Species
.	I-Species
cerebralis	E-Species
and	O
RNA	O
from	O
skin	O
tissue	O
was	O
converted	O
to	O
cDNA	O
and	O
hybridized	O
onto	O
microarrays	O
.	O

Relative	O
gene	O
expression	O
for	O
exposed	O
and	O
unexposed	O
controls	O
for	O
each	O
strain	O
was	O
compared	O
and	O
the	O
list	O
of	O
differentially	O
expressed	O
genes	O
for	O
both	O
strains	O
is	O
found	O
in	O
Table	O
1	O
.	O

A	O
combined	O
total	O
of	O
17	O
genes	O
or	O
features	O
(	O
14	O
annotated	O
genes	O
,	O
3	O
unknown	O
features	O
)	O
were	O
differentially	O
expressed	O
in	O
one	O
or	O
both	O
strains	O
following	O
pathogen	O
exposure	O
and	O
are	O
involved	O
with	O
rainbow	B-Species
trout	E-Species
infection	O
response	O
to	O
whirling	O
disease	O
exposure	O
.	O

Several	O
of	O
these	O
genes	O
were	O
found	O
in	O
different	O
locations	O
on	O
the	O
array	O
as	O
unique	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
clones	O
and	O
their	O
repeated	O
presence	O
on	O
the	O
significance	O
gene	O
lists	O
provides	O
additional	O
support	O
for	O
their	O
involvement	O
in	O
the	O
whirling	O
disease	O
phenotype	O
.	O

The	O
small	O
number	O
of	O
genes	O
found	O
potentially	O
indicates	O
that	O
only	O
a	O
few	O
genes	O
contribute	O
to	O
the	O
phenotypic	O
differences	O
found	O
between	O
resistant	O
Hofer	O
and	O
susceptible	O
Trout	O
Lodge	O
,	O
at	O
least	O
in	O
terms	O
of	O
differential	O
gene	O
expression	O
,	O
during	O
early	O
disease	O
progression	O
in	O
the	O
skin	O
.	O

In	O
the	O
microarray	O
statistical	O
analysis	O
,	O
when	O
the	O
delta	O
value	O
was	O
adjusted	O
even	O
slightly	O
lower	O
,	O
the	O
FDR	O
estimate	O
increases	O
from	O
0	O
%	O
to	O
~	O
78	O
%	O
.	O

Since	O
increasing	O
the	O
FDR	O
cut	O
-	O
off	O
to	O
such	O
a	O
high	O
percentage	O
would	O
dramatically	O
reduce	O
power	O
,	O
we	O
chose	O
to	O
leave	O
the	O
gene	O
list	O
small	O
with	O
an	O
estimated	O
FDR	O
of	O
0	O
%	O
.	O

This	O
type	O
of	O
dramatic	O
increase	O
in	O
FDR	O
estimation	O
is	O
additional	O
support	O
that	O
there	O
are	O
not	O
many	O
genes	O
differentially	O
expressed	O
in	O
response	O
to	O
whirling	O
disease	O
infection	O
for	O
our	O
chosen	O
tissue	O
and	O
time	O
points	O
.	O

Different	O
salmonid	O
microarray	O
platforms	O
,	O
such	O
as	O
those	O
available	O
from	O
Oregon	O
State	O
University	O
and	O
Michigan	O
State	O
University	O
,	O
or	O
different	O
tissues	O
and	O
time	O
points	O
may	O
produce	O
additional	O
candidate	O
genes	O
.	O

A	O
recent	O
time	O
course	O
study	O
used	O
a	O
candidate	O
gene	O
approach	O
to	O
identify	O
four	O
genes	O
(	O
TGF	O
-	O
beta	O
,	O
IL	O
-	O
1	O
beta	O
1	O
,	O
IL	O
-	O
1	O
beta	O
2	O
,	O
and	O
COX	O
-	O
2	O
)	O
that	O
were	O
significantly	O
up	O
-	O
regulated	O
by	O
both	O
Hofer	O
and	O
Trout	O
Lodge	O
in	O
response	O
to	O
whirling	O
disease	O
infection	O
[	O
25	O
]	O
.	O

These	O
genes	O
and	O
their	O
downstream	O
effectors	O
were	O
not	O
identified	O
in	O
the	O
current	O
microarray	O
study	O
,	O
likely	O
due	O
to	O
many	O
differences	O
in	O
experimental	O
design	O
between	O
the	O
two	O
studies	O
(	O
e	O
.	O
g	O
.	O
,	O
pathogen	O
exposure	O
levels	O
,	O
tissue	O
types	O
,	O
water	O
temperatures	O
,	O
age	O
of	O
fish	O
at	O
exposure	O
,	O
etc	O
.	O
)	O
.	O

While	O
downstream	O
effectors	O
of	O
these	O
genes	O
were	O
present	O
on	O
the	O
microarray	O
,	O
only	O
one	O
of	O
the	O
four	O
genes	O
(	O
COX	O
-	O
2	O
)	O
was	O
actually	O
present	O
on	O
the	O
microarray	O
.	O

It	O
is	O
our	O
hope	O
that	O
future	O
genome	O
sequencing	O
will	O
enable	O
the	O
construction	O
of	O
more	O
comprehensive	O
microarray	O
platforms	O
for	O
economically	O
important	O
aquaculture	O
species	O
,	O
such	O
as	O
Atlantic	B-Species
salmon	E-Species
and	O
rainbow	B-Species
trout	E-Species
.	O

All	O
significant	O
genes	O
identified	O
by	O
the	O
current	O
microarray	O
study	O
were	O
up	O
-	O
regulated	O
following	O
pathogen	O
exposure	O
for	O
one	O
or	O
both	O
strains	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
both	O
strains	O
are	O
undergoing	O
transcriptional	O
activation	O
to	O
defend	O
against	O
whirling	O
disease	O
infection	O
and	O
thus	O
,	O
are	O
exclusively	O
employing	O
positive	O
regulation	O
for	O
the	O
genes	O
examined	O
in	O
skin	O
during	O
early	O
disease	O
progression	O
.	O

The	O
normal	O
caveats	O
that	O
apply	O
for	O
microarray	O
studies	O
(	O
gene	O
discovery	O
is	O
limited	O
by	O
transcripts	O
on	O
arrays	O
,	O
differences	O
at	O
transcriptional	O
level	O
may	O
not	O
cause	O
phenotypic	O
differences	O
,	O
results	O
are	O
dependent	O
upon	O
tissue	O
type	O
and	O
time	O
point	O
chosen	O
,	O
etc	O
.	O
)	O
apply	O
for	O
this	O
study	O
.	O

Additionally	O
,	O
the	O
comparison	O
of	O
two	O
rainbow	B-Species
trout	E-Species
strains	O
(	O
i	O
.	O
e	O
.	O
,	O
resistant	O
versus	O
susceptible	O
)	O
added	O
another	O
layer	O
of	O
complexity	O
to	O
the	O
analysis	O
.	O

We	O
chose	O
to	O
not	O
directly	O
compare	O
the	O
two	O
strains	O
because	O
there	O
could	O
be	O
expression	O
differences	O
between	O
them	O
,	O
due	O
to	O
divergence	O
following	O
strain	O
isolation	O
,	O
that	O
are	O
unrelated	O
to	O
the	O
whirling	O
disease	O
phenotype	O
.	O

With	O
that	O
in	O
mind	O
,	O
the	O
two	O
strains	O
were	O
first	O
compared	O
entirely	O
separately	O
from	O
each	O
other	O
to	O
discover	O
expression	O
differences	O
in	O
response	O
to	O
pathogen	O
exposure	O
for	O
each	O
strain	O
.	O

Only	O
the	O
genes	O
responding	O
to	O
infection	O
,	O
and	O
therefore	O
implicated	O
in	O
the	O
whirling	O
disease	O
phenotype	O
,	O
were	O
compared	O
between	O
the	O
two	O
strains	O
for	O
differential	O
gene	O
expression	O
(	O
Figure	O
1	O
)	O
.	O

A	O
limitation	O
of	O
this	O
approach	O
to	O
our	O
study	O
is	O
that	O
constitutively	O
expressed	O
transcripts	O
which	O
are	O
differentially	O
expressed	O
between	O
the	O
two	O
strains	O
that	O
contribute	O
to	O
the	O
whirling	O
disease	O
phenotype	O
cannot	O
be	O
identified	O
.	O

Microarray	O
analysis	O
of	O
genes	O
differentially	O
expressed	O
in	O
the	O
resistant	O
Hofer	O
strain	O
in	O
response	O
to	O
pathogen	O
exposure	O

A	O
total	O
of	O
16	O
genes	O
or	O
features	O
(	O
13	O
annotated	O
genes	O
,	O
3	O
unknown	O
features	O
)	O
were	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
following	O
pathogen	O
exposure	O
.	O

All	O
13	O
annotated	O
genes	O
have	O
been	O
previously	O
implicated	O
in	O
host	O
immune	O
response	O
for	O
other	O
infectious	O
diseases	O
.	O

Viral	B-Species
Hemorrhagic	I-Species
Septicemia	I-Species
Virus	E-Species
(	O
VHSV	S-Species
)	O
induced	O
protein	O
and	O
neighbor	O
of	O
COX	O
-	O
4	O
are	O
the	O
only	O
annotated	O
genes	O
without	O
known	O
molecular	O
functions	O
.	O

A	O
common	O
link	O
between	O
the	O
majority	O
of	O
annotated	O
genes	O
with	O
known	O
molecular	O
functions	O
is	O
an	O
involvement	O
in	O
the	O
interferon	O
system	O
.	O

The	O
interferon	O
system	O
is	O
one	O
of	O
the	O
first	O
lines	O
of	O
host	O
defense	O
against	O
invading	O
pathogens	O
for	O
vertebrates	O
(	O
for	O
review	O
see	O
[	O
26	O
]	O
)	O
,	O
including	O
teleost	B-Species
fish	E-Species
(	O
for	O
review	O
see	O
[	O
27	O
]	O
)	O
.	O

Other	O
economically	O
important	O
salmonid	O
pathogens	O
,	O
such	O
as	O
infectious	B-Species
pancreatic	I-Species
necrosis	I-Species
virus	E-Species
and	O
infectious	B-Species
salmon	I-Species
anaemia	I-Species
virus	E-Species
have	O
been	O
found	O
to	O
activate	O
both	O
type	O
I	O
and	O
type	O
II	O
interferon	O
(	O
IFN	O
)	O
responses	O
in	O
the	O
Atlantic	B-Species
salmon	E-Species
host	O
following	O
infection	O
[	O
28	O
]	O
.	O

Interferons	O
are	O
cytokine	O
proteins	O
that	O
are	O
secreted	O
following	O
infection	O
and	O
play	O
a	O
critical	O
role	O
in	O
both	O
innate	O
and	O
adaptive	O
immunity	O
.	O

The	O
IFN	O
system	O
has	O
been	O
most	O
widely	O
researched	O
in	O
mammals	O
and	O
studies	O
have	O
found	O
that	O
type	O
I	O
IFN	O
(	O
mammalian	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
are	O
secreted	O
by	O
the	O
pathogen	O
-	O
infected	O
cells	O
as	O
part	O
of	O
a	O
rapid	O
initial	O
immune	O
response	O
while	O
Type	O
II	O
IFN	O
(	O
mammalian	O
IFN	O
-	O
gamma	O
)	O
is	O
secreted	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
T	O
cells	O
and	O
plays	O
a	O
more	O
central	O
role	O
in	O
the	O
second	O
wave	O
of	O
immune	O
response	O
.	O

To	O
cope	O
with	O
the	O
myriad	O
of	O
host	O
infections	O
,	O
the	O
interferon	O
system	O
is	O
highly	O
complex	O
and	O
involves	O
the	O
regulation	O
of	O
hundreds	O
of	O
genes	O
[	O
29	O
,	O
30	O
]	O
.	O

Specifically	O
,	O
type	O
I	O
IFN	O
acts	O
to	O
increase	O
MHC	O
class	O
I	O
expression	O
for	O
antigen	O
presentation	O
[	O
31	O
]	O
,	O
promote	O
T	O
cell	O
survival	O
[	O
32	O
]	O
,	O
inhibit	O
cell	O
proliferation	O
[	O
33	O
]	O
,	O
mediate	O
apoptosis	O
[	O
26	O
]	O
,	O
and	O
increase	O
NK	O
cell	O
activity	O
[	O
34	O
]	O
.	O

Type	O
II	O
IFN	O
acts	O
to	O
increase	O
both	O
MHC	O
class	O
I	O
and	O
II	O
expression	O
for	O
antigen	O
presentation	O
[	O
29	O
]	O
,	O
stimulate	O
macrophages	O
to	O
kill	O
engulfed	O
pathogens	O
[	O
35	O
]	O
,	O
induce	O
apoptosis	O
[	O
36	O
]	O
,	O
and	O
regulate	O
leukocyte	O
-	O
endothelium	O
interactions	O
[	O
37	O
]	O
in	O
addition	O
to	O
many	O
other	O
immune	O
-	O
related	O
activities	O
.	O

It	O
is	O
informative	O
to	O
examine	O
the	O
functional	O
roles	O
of	O
each	O
gene	O
'	O
s	O
encoded	O
protein	O
specifically	O
to	O
better	O
understand	O
the	O
part	O
each	O
plays	O
,	O
both	O
individually	O
and	O
as	O
interconnected	O
components	O
,	O
in	O
host	O
immune	O
response	O
.	O

Expression	O
of	O
the	O
interferon	O
-	O
induced	O
35	O
kDa	O
protein	O
is	O
induced	O
by	O
IFN	O
and	O
it	O
is	O
involved	O
in	O
cytokine	O
signalling	O
[	O
38	O
]	O
.	O

Interferon	O
regulatory	O
factor	O
1	O
(	O
IRF	O
-	O
1	O
)	O
and	O
interferon	O
regulatory	O
factor	O
7	O
(	O
IRF	O
-	O
7	O
)	O
are	O
transcription	O
factors	O
that	O
induce	O
expression	O
of	O
IFN	O
responsive	O
genes	O
[	O
39	O
,	O
40	O
]	O
.	O

Additionally	O
,	O
IRF	O
-	O
1	O
is	O
involved	O
in	O
apoptosis	O
and	O
cell	O
cycle	O
regulation	O
related	O
to	O
tumor	O
suppression	O
[	O
41	O
]	O
.	O

Similarly	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
inhibitor	O
B	O
(	O
p15	O
-	O
INK4b	O
)	O
plays	O
a	O
role	O
in	O
apoptosis	O
[	O
42	O
]	O
,	O
cell	O
cycle	O
regulation	O
[	O
42	O
]	O
,	O
and	O
tumor	O
suppression	O
[	O
43	O
]	O
and	O
can	O
be	O
induced	O
by	O
the	O
cytokine	O
TGF	O
-	O
beta	O
[	O
44	O
]	O
.	O

Gig2	O
is	O
an	O
interferon	O
-	O
inducible	O
protein	O
that	O
is	O
likely	O
part	O
of	O
the	O
JAK	O
-	O
STAT	O
signal	O
transduction	O
pathway	O
[	O
45	O
]	O
.	O

Ubiquitin	O
and	O
the	O
proteasome	O
subunit	O
beta	O
type	O
8	O
precursor	O
are	O
both	O
members	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
system	O
(	O
for	O
review	O
see	O
[	O
26	O
]	O
)	O
,	O
which	O
serves	O
to	O
degrade	O
proteins	O
via	O
proteolysis	O
.	O

These	O
degraded	O
proteins	O
can	O
originate	O
from	O
an	O
invading	O
pathogen	O
and	O
are	O
displayed	O
on	O
MHC	O
class	O
I	O
proteins	O
.	O

The	O
beta	O
-	O
2	O
-	O
microglobulin	O
is	O
an	O
integral	O
component	O
of	O
MHC	O
class	O
I	O
proteins	O
and	O
is	O
therefore	O
involved	O
in	O
antigen	O
processing	O
and	O
presentation	O
to	O
cytotoxic	O
T	O
cells	O
[	O
46	O
]	O
.	O

Haptoglobin	O
binds	O
hemoglobin	O
and	O
limits	O
its	O
availability	O
to	O
infectious	O
bacteria	O
,	O
thus	O
preventing	O
bacterial	O
proliferation	O
in	O
a	O
wound	O
[	O
47	O
]	O
.	O

The	O
PPAR	O
-	O
alpha	O
-	O
interacting	O
complex	O
protein	O
285	O
is	O
a	O
transcriptional	O
co	O
-	O
activator	O
with	O
helicase	O
activity	O
[	O
48	O
]	O
and	O
has	O
sequence	O
similarity	O
to	O
a	O
rainbow	B-Species
trout	E-Species
VHSV	S-Species
-	O
induced	O
protein	O
.	O

Gene	O
expression	O
of	O
metallothionein	O
B	O
(	O
MT	O
-	O
B	O
)	O
is	O
induced	O
by	O
several	O
metal	O
ions	O
[	O
49	O
]	O
,	O
cytokines	O
[	O
50	O
-	O
52	O
]	O
,	O
and	O
stress	O
hormones	O
[	O
53	O
-	O
55	O
]	O
.	O

MT	O
proteins	O
are	O
believed	O
to	O
play	O
diverse	O
functional	O
roles	O
in	O
inflammation	O
,	O
immune	O
response	O
,	O
apoptosis	O
,	O
tumor	O
suppression	O
,	O
and	O
detoxification	O
(	O
for	O
reviews	O
see	O
[	O
55	O
,	O
56	O
]	O
)	O
.	O

Microarray	O
analysis	O
of	O
genes	O
differentially	O
expressed	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
in	O
response	O
to	O
pathogen	O
exposure	O

A	O
total	O
of	O
six	O
genes	O
or	O
features	O
(	O
five	O
annotated	O
genes	O
,	O
one	O
unknown	O
feature	O
)	O
were	O
up	O
-	O
regulated	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
following	O
pathogen	O
exposure	O
.	O

Only	O
one	O
of	O
the	O
significant	O
genes	O
for	O
Trout	O
Lodge	O
,	O
which	O
has	O
sequence	O
similarity	O
to	O
CC	O
chemokine	O
SCYA113	O
,	O
was	O
not	O
also	O
differentially	O
expressed	O
in	O
Hofer	O
in	O
response	O
to	O
pathogen	O
exposure	O
.	O

The	O
CC	O
chemokine	O
SCYA113	O
gene	O
is	O
a	O
member	O
of	O
the	O
CC	O
chemokine	O
family	O
,	O
which	O
guides	O
leukocytes	O
to	O
sites	O
of	O
infection	O
and	O
inflammation	O
(	O
for	O
review	O
see	O
[	O
57	O
]	O
)	O
.	O

The	O
fewer	O
number	O
of	O
significant	O
genes	O
found	O
for	O
Trout	O
Lodge	O
relative	O
to	O
Hofer	O
may	O
indicate	O
a	O
decrease	O
in	O
transcriptional	O
activation	O
for	O
this	O
susceptible	O
strain	O
.	O

There	O
is	O
,	O
however	O
,	O
likely	O
some	O
degree	O
of	O
overlap	O
in	O
both	O
strains	O
'	O
response	O
to	O
pathogen	O
exposure	O
due	O
to	O
the	O
fact	O
that	O
several	O
genes	O
were	O
up	O
-	O
regulated	O
in	O
both	O
Hofer	O
and	O
Trout	O
Lodge	O
(	O
i	O
.	O
e	O
.	O
,	O
ubiquitin	O
-	O
like	O
protein	O
1	O
,	O
IRF	O
-	O
1	O
,	O
and	O
PPAR	O
-	O
alpha	O
-	O
interacting	O
protein	O
Gig2	O
)	O
.	O

A	O
critical	O
phase	O
in	O
the	O
early	O
stages	O
of	O
M	B-Species
.	I-Species
cerebralis	E-Species
infection	O
in	O
trout	O
is	O
invasion	O
and	O
intracellular	O
replication	O
,	O
processes	O
that	O
begin	O
as	O
early	O
as	O
one	O
hour	O
post	O
exposure	O
to	O
triactinomyxons	O
[	O
16	O
]	O
.	O

A	O
role	O
for	O
accumulated	O
ubiquinated	O
proteins	O
in	O
the	O
lysosome	O
in	O
the	O
killing	O
of	O
Mycobacterium	B-Species
tuberculosis	E-Species
has	O
recently	O
been	O
described	O
that	O
has	O
implications	O
for	O
a	O
range	O
of	O
intracellular	O
infections	O
[	O
58	O
]	O
and	O
some	O
similar	O
responses	O
to	O
infection	O
may	O
be	O
occurring	O
for	O
both	O
resistant	O
and	O
susceptible	O
strains	O
.	O

Microarray	O
analysis	O
of	O
genes	O
differentially	O
expressed	O
between	O
resistant	O
and	O
susceptible	O
strains	O
in	O
response	O
to	O
pathogen	O
exposure	O

Of	O
the	O
genes	O
differentially	O
expressed	O
in	O
response	O
to	O
pathogen	O
exposure	O
for	O
both	O
strains	O
,	O
only	O
metallothionein	O
B	O
shows	O
a	O
statistically	O
significant	O
difference	O
in	O
expression	O
between	O
the	O
two	O
strains	O
(	O
Table	O
2	O
)	O
.	O

MT	O
-	O
B	O
was	O
found	O
to	O
be	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
following	O
pathogen	O
exposure	O
but	O
remained	O
unchanged	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
.	O

As	O
previously	O
noted	O
,	O
metallothionein	O
has	O
been	O
implicated	O
in	O
a	O
broad	O
range	O
of	O
functional	O
capacities	O
,	O
including	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Several	O
cytokines	O
can	O
induce	O
metallothionein	O
expression	O
including	O
IFN	O
[	O
59	O
-	O
61	O
]	O
,	O
interleukin	O
-	O
1	O
[	O
50	O
]	O
,	O
interleukin	O
-	O
6	O
[	O
51	O
]	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
[	O
52	O
]	O
.	O

Metallothionein	O
has	O
been	O
shown	O
to	O
mediate	O
leukocyte	O
chemotaxis	O
and	O
has	O
been	O
hypothesized	O
to	O
serve	O
as	O
an	O
early	O
"	O
danger	O
signal	O
"	O
during	O
times	O
of	O
stress	O
or	O
infection	O
to	O
activate	O
an	O
immune	O
response	O
[	O
62	O
]	O
.	O

The	O
functional	O
similarities	O
between	O
metallothionein	O
and	O
CC	O
chemokine	O
SCYA113	O
,	O
at	O
least	O
in	O
terms	O
of	O
leukocyte	O
chemotaxis	O
,	O
are	O
certainly	O
of	O
interest	O
since	O
these	O
genes	O
displayed	O
quite	O
distinct	O
expression	O
profiles	O
.	O

Metallothionein	O
was	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
and	O
CC	O
chemokine	O
SCYA113	O
was	O
up	O
-	O
regulated	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
strain	O
(	O
although	O
CC	O
chemokine	O
SCYA113	O
did	O
not	O
pass	O
the	O
significance	O
cut	O
-	O
off	O
to	O
be	O
considered	O
differentially	O
expressed	O
between	O
the	O
two	O
strains	O
)	O
.	O

This	O
distinction	O
between	O
two	O
genes	O
,	O
capable	O
of	O
similar	O
biological	O
roles	O
,	O
may	O
indicate	O
that	O
leukocyte	O
movements	O
to	O
,	O
and	O
their	O
activities	O
once	O
at	O
,	O
the	O
infection	O
site	O
are	O
key	O
factors	O
in	O
determining	O
resistance	O
versus	O
susceptibility	O
to	O
whirling	O
disease	O
.	O

Evaluations	O
by	O
light	O
microscopy	O
and	O
qPCR	O
for	O
M	B-Species
.	I-Species
cerebralis	E-Species
genomic	O
DNA	O
of	O
Hofer	O
and	O
Trout	O
Lodge	O
rainbow	B-Species
trout	E-Species
exposed	O
to	O
triactinomyxons	O
demonstrates	O
Hofer	O
more	O
efficiently	O
eliminates	O
invading	O
parasites	O
in	O
the	O
skin	O
(	O
M	O
.	O
Adkison	O
,	O
pers	O
.	O
comm	O
.	O
)	O
.	O

While	O
the	O
parasite	O
effectively	O
penetrates	O
the	O
epidermis	O
in	O
both	O
strains	O
,	O
significantly	O
fewer	O
parasites	O
survive	O
the	O
migration	O
from	O
the	O
skin	O
to	O
the	O
nerves	O
as	O
evaluated	O
at	O
10	O
d	O
post	O
exposure	O
.	O

A	O
role	O
for	O
host	O
immune	O
factors	O
in	O
the	O
elimination	O
of	O
invading	O
parasites	O
,	O
even	O
in	O
susceptible	O
rainbow	B-Species
trout	E-Species
strains	O
,	O
is	O
suggested	O
by	O
several	O
prior	O
light	O
and	O
electron	O
microscopy	O
studies	O
that	O
demonstrate	O
an	O
increase	O
in	O
degenerative	O
stages	O
in	O
the	O
skin	O
beginning	O
as	O
early	O
as	O
12	O
h	O
and	O
then	O
their	O
elimination	O
by	O
24	O
h	O
post	O
-	O
exposure	O
to	O
triactinomyxons	O
[	O
12	O
,	O
16	O
,	O
63	O
]	O
.	O

The	O
difference	O
in	O
metallothionein	O
expression	O
may	O
be	O
due	O
to	O
an	O
alternative	O
immune	O
response	O
pathway	O
since	O
the	O
protein	O
has	O
known	O
involvement	O
in	O
diverse	O
functional	O
capacities	O
.	O

For	O
instance	O
,	O
metallothionein	O
'	O
s	O
role	O
as	O
a	O
zinc	O
-	O
finger	O
transcriptional	O
regulator	O
[	O
64	O
]	O
may	O
dramatically	O
alter	O
the	O
expression	O
profiles	O
between	O
resistant	O
and	O
susceptible	O
rainbow	B-Species
trout	E-Species
.	O

All	O
biological	O
roles	O
of	O
this	O
diverse	O
protein	O
should	O
be	O
considered	O
when	O
examining	O
the	O
complexities	O
of	O
host	O
immune	O
response	O
.	O

Additionally	O
,	O
upstream	O
regulators	O
of	O
metallothionein	O
expression	O
could	O
be	O
the	O
true	O
underlying	O
cause	O
of	O
the	O
whirling	O
disease	O
phenotype	O
since	O
a	O
gene	O
expression	O
study	O
alone	O
cannot	O
determine	O
if	O
a	O
gene	O
is	O
directly	O
contributing	O
to	O
a	O
phenotype	O
(	O
i	O
.	O
e	O
.	O
,	O
cause	O
versus	O
downstream	O
effect	O
)	O
.	O

Validation	O
of	O
microarray	O
results	O
by	O
qRT	O
-	O
PCR	O

Quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
confirmed	O
the	O
microarrays	O
results	O
for	O
two	O
of	O
the	O
genes	O
up	O
-	O
regulated	O
in	O
both	O
Hofer	O
and	O
Trout	O
Lodge	O
following	O
infection	O
,	O
ubiquitin	O
and	O
IRF	O
-	O
1	O
,	O
and	O
the	O
metallothionein	O
gene	O
(	O
MT	O
-	O
B	O
)	O
,	O
which	O
was	O
up	O
-	O
regulated	O
in	O
Hofer	O
but	O
remained	O
unchanged	O
in	O
Trout	O
Lodge	O
following	O
infection	O
(	O
Figure	O
2	O
)	O
.	O

The	O
qRT	O
-	O
PCR	O
results	O
for	O
IRF	O
-	O
1	O
and	O
metallothionein	O
were	O
quite	O
similar	O
to	O
the	O
microarray	O
results	O
for	O
each	O
gene	O
,	O
in	O
terms	O
of	O
relative	O
expression	O
changes	O
in	O
response	O
to	O
infection	O
.	O

MT	O
-	O
B	O
was	O
found	O
to	O
once	O
again	O
be	O
significantly	O
up	O
-	O
regulated	O
in	O
the	O
resistant	O
Hofer	O
strain	O
following	O
pathogen	O
exposure	O
but	O
remained	O
unchanged	O
in	O
the	O
susceptible	O
Trout	O
Lodge	O
.	O

This	O
difference	O
in	O
MT	O
-	O
B	O
gene	O
expression	O
between	O
the	O
two	O
strains	O
was	O
statistically	O
significant	O
(	O
P	O
~	O
0	O
.	O
001	O
)	O
.	O

The	O
relative	O
degree	O
of	O
up	O
-	O
regulation	O
for	O
ubiquitin	O
following	O
pathogen	O
exposure	O
was	O
considerably	O
higher	O
in	O
the	O
qRT	O
-	O
PCR	O
(	O
~	O
9	O
-	O
17	O
fold	O
greater	O
up	O
-	O
regulation	O
in	O
qRT	O
-	O
PCR	O
versus	O
microarrays	O
)	O
.	O

Many	O
other	O
studies	O
have	O
also	O
observed	O
this	O
pattern	O
of	O
greater	O
sensitivity	O
in	O
qRT	O
-	O
PCR	O
versus	O
microarray	O
results	O
(	O
for	O
examples	O
see	O
[	O
65	O
,	O
66	O
]	O
,	O
which	O
is	O
often	O
attributed	O
to	O
the	O
more	O
gene	O
-	O
specific	O
optimized	O
conditions	O
of	O
the	O
qRT	O
-	O
PCR	O
approach	O
.	O

Given	O
the	O
high	O
degree	O
of	O
statistical	O
support	O
and	O
biological	O
relevance	O
of	O
the	O
candidate	O
genes	O
,	O
we	O
believe	O
this	O
study	O
provides	O
initial	O
insight	O
into	O
rainbow	B-Species
trout	E-Species
genes	O
and	O
pathways	O
responding	O
to	O
whirling	O
disease	O
infection	O
and	O
identifies	O
the	O
first	O
candidate	O
genes	O
for	O
whirling	O
disease	O
resistance	O
.	O

Potential	O
future	O
studies	O

While	O
the	O
interferon	O
system	O
appears	O
to	O
be	O
a	O
likely	O
candidate	O
system	O
for	O
further	O
study	O
,	O
many	O
of	O
the	O
significant	O
genes	O
are	O
found	O
in	O
alternative	O
pathways	O
and	O
have	O
distinct	O
roles	O
and	O
functions	O
in	O
other	O
systems	O
.	O

Furthermore	O
,	O
it	O
is	O
increasingly	O
apparent	O
that	O
epistatic	O
interactions	O
and	O
the	O
interplay	O
between	O
pathways	O
/	O
networks	O
previously	O
classified	O
as	O
discrete	O
can	O
have	O
enormous	O
phenotypic	O
effects	O
on	O
quantitative	O
traits	O
[	O
67	O
]	O
.	O

Multiple	O
avenues	O
of	O
research	O
should	O
be	O
examined	O
in	O
future	O
studies	O
,	O
using	O
the	O
candidate	O
genes	O
presented	O
here	O
as	O
an	O
initial	O
guide	O
,	O
due	O
to	O
the	O
complex	O
relationships	O
between	O
hosts	O
and	O
pathogens	O
.	O

For	O
instance	O
,	O
the	O
migration	O
of	O
leukocytes	O
and	O
their	O
subsequent	O
activity	O
in	O
the	O
skin	O
are	O
likely	O
a	O
critical	O
part	O
of	O
the	O
early	O
immune	O
and	O
inflammatory	O
host	O
response	O
after	O
pathogen	O
infection	O
.	O

Additionally	O
,	O
it	O
is	O
quite	O
feasible	O
that	O
the	O
difference	O
in	O
metallothionein	O
expression	O
is	O
due	O
to	O
an	O
alternative	O
immune	O
response	O
pathway	O
since	O
the	O
protein	O
has	O
known	O
involvement	O
in	O
diverse	O
functional	O
capacities	O
.	O

For	O
instance	O
,	O
metallothionein	O
'	O
s	O
role	O
as	O
a	O
zinc	O
-	O
finger	O
transcriptional	O
regulator	O
[	O
64	O
]	O
may	O
dramatically	O
alter	O
the	O
expression	O
profiles	O
between	O
resistant	O
and	O
susceptible	O
rainbow	B-Species
trout	E-Species
.	O

All	O
biological	O
roles	O
of	O
this	O
diverse	O
protein	O
should	O
be	O
considered	O
when	O
examining	O
the	O
complexities	O
of	O
host	O
immune	O
response	O
.	O

Finally	O
,	O
upstream	O
regulators	O
of	O
metallothionein	O
expression	O
could	O
be	O
the	O
true	O
underlying	O
cause	O
of	O
the	O
whirling	O
disease	O
phenotype	O
since	O
a	O
gene	O
expression	O
study	O
alone	O
cannot	O
determine	O
if	O
a	O
gene	O
is	O
directly	O
contributing	O
to	O
a	O
phenotype	O
(	O
i	O
.	O
e	O
.	O
,	O
cause	O
versus	O
downstream	O
effect	O
)	O
.	O

The	O
expression	O
profiles	O
of	O
a	O
variety	O
of	O
metallothionein	O
upstream	O
regulators	O
,	O
such	O
as	O
cytokines	O
and	O
metal	O
transcription	O
factor	O
(	O
MTF	O
-	O
1	O
)	O
,	O
could	O
be	O
evaluated	O
in	O
a	O
time	O
course	O
study	O
during	O
early	O
disease	O
progression	O
to	O
identify	O
additional	O
candidate	O
genes	O
.	O

A	O
QTL	O
mapping	O
approach	O
could	O
also	O
be	O
used	O
to	O
identify	O
particular	O
chromosomal	O
regions	O
directly	O
contributing	O
to	O
the	O
disease	O
phenotype	O
.	O

Conclusion	O

The	O
present	O
study	O
has	O
provided	O
the	O
first	O
examination	O
into	O
the	O
genetic	O
basis	O
underlying	O
rainbow	B-Species
trout	E-Species
'	O
s	O
immune	O
response	O
and	O
resistance	O
to	O
the	O
whirling	O
disease	O
pathogen	O
.	O

Several	O
genes	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
skin	O
following	O
pathogen	O
exposure	O
for	O
both	O
the	O
resistant	O
Hofer	O
and	O
susceptible	O
Trout	O
Lodge	O
rainbow	B-Species
trout	E-Species
strains	O
.	O

For	O
both	O
strains	O
,	O
response	O
to	O
infection	O
appears	O
to	O
be	O
linked	O
with	O
the	O
interferon	O
system	O
.	O

Metallothionein	O
B	O
is	O
differentially	O
expressed	O
between	O
the	O
resistant	O
and	O
susceptible	O
strains	O
and	O
is	O
a	O
good	O
candidate	O
for	O
future	O
whirling	O
disease	O
resistance	O
studies	O
.	O

The	O
identified	O
genes	O
have	O
allowed	O
us	O
to	O
gain	O
initial	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
a	O
salmonid	O
host	O
'	O
s	O
immune	O
response	O
and	O
resistance	O
to	O
whirling	O
disease	O
infection	O
.	O

Methods	O

Animal	O
care	O
,	O
pathogen	O
exposure	O
,	O
and	O
RNA	O
preparation	O

Hofer	O
and	O
Trout	O
Lodge	O
rainbow	B-Species
trout	E-Species
strains	O
were	O
reared	O
in	O
35	O
gallon	O
aquaria	O
with	O
15	O
degrees	O
C	O
flow	O
-	O
through	O
well	O
water	O
for	O
nine	O
weeks	O
post	O
-	O
hatch	O
,	O
with	O
each	O
fish	O
weighing	O
approximately	O
6	O
.	O
5	O
grams	O
prior	O
to	O
pathogen	O
exposure	O
.	O

Individuals	O
from	O
each	O
strain	O
(	O
n	O
=	O
60	O
)	O
were	O
exposed	O
to	O
2	O
,	O
000	O
triactinomyxons	O
(	O
TAMs	O
)	O
per	O
fish	O
for	O
one	O
hour	O
.	O

Additional	O
fish	O
(	O
n	O
=	O
60	O
)	O
from	O
both	O
strains	O
served	O
as	O
unexposed	O
controls	O
,	O
which	O
were	O
treated	O
identically	O
to	O
exposed	O
fish	O
at	O
all	O
experimental	O
stages	O
other	O
than	O
their	O
lack	O
of	O
pathogen	O
exposure	O
.	O

Fish	O
were	O
then	O
kept	O
under	O
standard	O
aquaculture	O
conditions	O
until	O
euthanized	O
.	O

TaqMan	O
PCR	O
for	O
the	O
quantitative	O
evaluation	O
of	O
genomic	O
parasite	O
DNA	O
was	O
employed	O
to	O
confirm	O
that	O
fish	O
in	O
both	O
the	O
Hofer	O
and	O
Trout	O
Lodge	O
groups	O
received	O
equal	O
amounts	O
of	O
parasite	O
exposure	O
.	O

At	O
two	O
hours	O
post	O
TAM	O
exposure	O
,	O
6	O
fish	O
in	O
each	O
exposed	O
group	O
were	O
removed	O
and	O
euthanized	O
with	O
an	O
overdose	O
of	O
benzocaine	O
at	O
a	O
concentration	O
of	O
500	O
mg	O
/	O
L	O
.	O

Caudal	O
fins	O
were	O
removed	O
posterior	O
to	O
the	O
peduncle	O
and	O
used	O
as	O
the	O
tissue	O
for	O
a	O
quantiative	O
TaqMan	O
assay	O
following	O
procedures	O
described	O
by	O
Kelley	O
et	O
al	O
.	O

[	O
68	O
]	O
.	O

Microarray	O
studies	O
examining	O
skin	O
four	O
hours	O
after	O
pathogen	O
exposure	O
did	O
not	O
identify	O
any	O
genes	O
differentially	O
expressed	O
between	O
Trout	O
Lodge	O
and	O
Hofer	O
strains	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
we	O
chose	O
a	O
later	O
time	O
point	O
(	O
24	O
hours	O
after	O
exposure	O
)	O
so	O
that	O
early	O
host	O
immune	O
response	O
was	O
more	O
likely	O
to	O
be	O
fully	O
underway	O
and	O
significant	O
expression	O
changes	O
could	O
be	O
detected	O
.	O

After	O
the	O
24	O
hour	O
incubation	O
period	O
,	O
all	O
fish	O
were	O
euthanized	O
with	O
an	O
overdose	O
of	O
benzocaine	O
at	O
a	O
concentration	O
of	O
500	O
mg	O
/	O
L	O
.	O

Each	O
fish	O
was	O
euthanized	O
individually	O
and	O
the	O
caudal	O
fin	O
(	O
largely	O
comprised	O
of	O
skin	O
tissue	O
)	O
was	O
removed	O
posterior	O
to	O
the	O
peduncle	O
.	O

The	O
fin	O
was	O
immediately	O
placed	O
into	O
2	O
x	O
Nucleic	O
Acid	O
Purification	O
Lysis	O
Solution	O
supplied	O
with	O
ABI	O
'	O
s	O
TransPrep	O
Chemistry	O
kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
to	O
stop	O
further	O
gene	O
expression	O
changes	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
fin	O
of	O
each	O
individual	O
using	O
the	O
ABI	O
Prism	O
(TM)	O
TransPrep	O
system	O
with	O
the	O
ABI	O
Prism	O
(TM)	O
6100	O
Nucleic	O
Acid	O
PrepStation	O
according	O
to	O
manufacturer	O
instructions	O
.	O

RNA	O
quality	O
was	O
assessed	O
by	O
agarose	O
gel	O
electrophoresis	O
and	O
RNA	O
concentrations	O
were	O
measured	O
using	O
a	O
ND	O
-	O
1000	O
spectrophotometer	O
(	O
NanoDrop	O
Technologies	O
,	O
Wilmington	O
,	O
DE	O
)	O
.	O

Starting	O
total	O
RNA	O
yields	O
were	O
not	O
sufficient	O
for	O
microarray	O
hybridizations	O
due	O
to	O
the	O
small	O
amount	O
of	O
caudal	O
fin	O
tissue	O
present	O
on	O
these	O
young	O
fish	O
.	O

Therefore	O
,	O
250	O
-	O
1000	O
ng	O
of	O
total	O
RNA	O
was	O
used	O
as	O
the	O
starting	O
material	O
to	O
create	O
amplified	O
RNA	O
(	O
aRNA	O
)	O
indirectly	O
labeled	O
with	O
Cy3	O
or	O
Cy5	O
fluorescent	O
dyes	O
(	O
GE	O
Healthcare	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
using	O
the	O
Amino	O
Allyl	O
MessageAmp	O
(TM)	O
II	O
aRNA	O
Amplification	O
kit	O
according	O
to	O
manufacturer	O
instructions	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Microarray	O
hybridization	O
and	O
data	O
analysis	O

Salmonid	O
cDNA	O
microarrays	O
(	O
GRASP16k	O
v2	O
.	O
0	O
)	O
were	O
obtained	O
from	O
consortium	O
for	O
Genomic	O
Research	O
on	O
Atlantic	O
Salmon	O
(	O
cGRASP	O
)	O
and	O
details	O
of	O
microarray	O
development	O
and	O
fabrication	O
can	O
be	O
found	O
in	O
von	O
Schalburg	O
et	O
al	O
.	O

[	O
69	O
]	O
.	O

These	O
arrays	O
contain	O
13	O
,	O
421	O
Atlantic	B-Species
salmon	E-Species
and	O
2	O
,	O
576	O
rainbow	B-Species
trout	E-Species
cDNA	O
features	O
and	O
have	O
been	O
successfully	O
used	O
for	O
several	O
previous	O
rainbow	B-Species
trout	E-Species
gene	O
expression	O
studies	O
[	O
70	O
-	O
73	O
]	O
.	O

For	O
each	O
rainbow	B-Species
trout	E-Species
strain	O
,	O
competitive	O
hybridization	O
was	O
conducted	O
on	O
every	O
array	O
using	O
equal	O
amounts	O
(	O
8	O
mu	O
g	O
)	O
of	O
differentially	O
labeled	O
aRNA	O
from	O
one	O
control	O
fish	O
and	O
one	O
exposed	O
fish	O
.	O

Four	O
biological	O
replicates	O
were	O
performed	O
for	O
each	O
experimental	O
condition	O
and	O
dye	O
-	O
sample	O
coupling	O
was	O
swapped	O
between	O
biological	O
replicates	O
in	O
a	O
balanced	O
block	O
design	O
.	O

Prehybridization	O
washes	O
for	O
all	O
microarrays	O
included	O
:	O
2	O
x	O
5	O
min	O
in	O
0	O
.	O
1	O
%	O
SDS	O
,	O
5	O
x	O
1	O
min	O
in	O
NANOpure	O
H2O	O
with	O
0	O
.	O
5	O
mM	O
dithiothreotol	O
,	O
1	O
min	O
in	O
near	O
boiling	O
nanopure	O
H2O	O
,	O
centrifugation	O
for	O
2	O
min	O
at	O
1500	O
RPM	O
.	O

To	O
reduce	O
background	O
,	O
the	O
microarrays	O
were	O
next	O
incubated	O
for	O
90	O
min	O
in	O
5	O
x	O
SSC	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
3	O
%	O
BSA	O
(	O
Fraction	O
V	O
)	O
at	O
49	O
degrees	O
C	O
,	O
washed	O
3	O
x	O
20	O
s	O
in	O
nanopure	O
H2O	O
,	O
and	O
dried	O
by	O
centrifugation	O
for	O
5	O
min	O
at	O
1500	O
RPM	O
.	O

The	O
labeled	O
aRNA	O
samples	O
were	O
competitively	O
hybridized	O
to	O
microarrays	O
prewarmed	O
to	O
49	O
degrees	O
C	O
for	O
16	O
hours	O
in	O
a	O
formamide	O
-	O
based	O
buffer	O
(	O
Genisphere	O
,	O
Hatfield	O
,	O
PA	O
)	O
with	O
LNA	O
dT	O
blocker	O
(	O
Genisphere	O
)	O
.	O

Posthybridization	O
washes	O
for	O
all	O
microarrays	O
included	O
:	O
1	O
x	O
10	O
min	O
in	O
2	O
x	O
SSC	O
,	O
0	O
.	O
1	O
%	O
SDS	O
prewarmed	O
to	O
49	O
degrees	O
C	O
,	O
2	O
x	O
5	O
min	O
in	O
2	O
x	O
SSC	O
,	O
0	O
.	O
1	O
%	O
SDS	O
at	O
room	O
temperature	O
,	O
2	O
x	O
5	O
min	O
1	O
x	O
SSC	O
at	O
room	O
temperature	O
,	O
2	O
x	O
5	O
min	O
0	O
.	O
1	O
x	O
SSC	O
at	O
room	O
temperature	O
.	O

Slides	O
were	O
then	O
dried	O
by	O
centrifugation	O
and	O
immediately	O
scanned	O
using	O
an	O
Agilent	O
G2565BA	O
Microarray	O
Scanner	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Data	O
underwent	O
local	O
background	O
subtraction	O
and	O
LOWESS	O
normalization	O
using	O
Agilent	O
'	O
s	O
Feature	O
Extraction	O
software	O
.	O

Raw	O
and	O
processed	O
gene	O
expression	O
data	O
have	O
been	O
deposited	O
into	O
the	O
NCBI	O
Gene	O
Expression	O
Omnibus	O
[	O
74	O
]	O
(	O
series	O
GSE8631	O
)	O
and	O
are	O
in	O
compliance	O
with	O
MIAME	O
guidelines	O
.	O

The	O
Significance	O
Analysis	O
of	O
Microarrays	O
(	O
SAM	O
)	O
software	O
package	O
[	O
75	O
]	O
was	O
used	O
to	O
identify	O
differentially	O
expressed	O
genes	O
between	O
exposed	O
and	O
unexposed	O
control	O
fish	O
for	O
each	O
rainbow	B-Species
trout	E-Species
strain	O
.	O

Both	O
a	O
Wilcoxon	O
rank	O
sum	O
and	O
a	O
modified	O
t	O
-	O
test	O
were	O
conducted	O
with	O
1	O
,	O
000	O
permutations	O
and	O
the	O
minimum	O
fold	O
change	O
cut	O
-	O
off	O
was	O
set	O
to	O
2	O
.	O
0	O
up	O
-	O
or	O
down	O
-	O
regulated	O
.	O

A	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
of	O
0	O
.	O
00	O
%	O
was	O
estimated	O
for	O
both	O
strains	O
.	O

To	O
determine	O
statistically	O
significant	O
differences	O
between	O
the	O
Hofer	O
and	O
Trout	O
Lodge	O
strains	O
,	O
a	O
Welch	O
'	O
s	O
t	O
-	O
test	O
(	O
P	O
-	O
value	O
<	O
0	O
.	O
01	O
)	O
was	O
implemented	O
in	O
Microsoft	O
Excel	O
between	O
the	O
log	O
ratios	O
(	O
exposed	O
/	O
control	O
)	O
for	O
each	O
strain	O
for	O
all	O
genes	O
that	O
were	O
significant	O
for	O
at	O
least	O
one	O
strain	O
in	O
the	O
SAM	O
program	O
.	O

Quantitative	O
RT	O
-	O
PCR	O

Microarray	O
expression	O
results	O
were	O
validated	O
by	O
qRT	O
-	O
PCR	O
for	O
several	O
identified	O
genes	O
.	O

Prior	O
to	O
qRT	O
-	O
PCR	O
,	O
80	O
ng	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
from	O
each	O
biological	O
replicate	O
used	O
for	O
the	O
microarray	O
study	O
along	O
with	O
two	O
additional	O
samples	O
(	O
total	O
n	O
=	O
6	O
per	O
experimental	O
condition	O
)	O
using	O
the	O
QuantiScript	O
Reverse	O
Transcriptase	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
according	O
to	O
manufacturer	O
instructions	O
.	O

In	O
contrast	O
to	O
the	O
microarray	O
experiments	O
,	O
the	O
template	O
RNA	O
was	O
not	O
amplified	O
before	O
cDNA	O
synthesis	O
.	O

EST	O
clone	O
sequences	O
from	O
the	O
cGRASP	O
microarray	O
were	O
used	O
to	O
design	O
primers	O
for	O
genes	O
undergoing	O
validation	O
,	O
along	O
with	O
a	O
beta	O
-	O
actin	O
reference	O
gene	O
used	O
for	O
normalization	O
,	O
with	O
Primer3	O
software	O
[	O
76	O
]	O
and	O
the	O
sequence	O
for	O
each	O
primer	O
pair	O
is	O
shown	O
in	O
Table	O
3	O
.	O

The	O
Quantitect	O
(TM)	O
SYBR	O
(R)	O
Green	O
RT	O
-	O
PCR	O
kit	O
(	O
Qiagen	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
except	O
the	O
final	O
PCR	O
volume	O
was	O
reduced	O
to	O
25	O
mu	O
l	O
.	O

The	O
PCR	O
conditions	O
used	O
on	O
a	O
Chromo4	O
Real	O
Time	O
PCR	O
Detection	O
System	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
were	O
as	O
follows	O
:	O
HotStarTaq	O
DNA	O
polymerase	O
activation	O
at	O
95	O
degrees	O
C	O
for	O
15	O
min	O
,	O
45	O
cycles	O
of	O
15	O
s	O
denaturation	O
at	O
94	O
degrees	O
C	O
,	O
30	O
s	O
annealing	O
at	O
58	O
degrees	O
C	O
,	O
30	O
s	O
extension	O
at	O
72	O
degrees	O
C	O
,	O
followed	O
by	O
a	O
melting	O
curve	O
to	O
ensure	O
that	O
a	O
single	O
PCR	O
product	O
was	O
produced	O
for	O
each	O
reaction	O
.	O

For	O
each	O
gene	O
,	O
the	O
relative	O
amount	O
of	O
gene	O
expression	O
was	O
calculated	O
using	O
the	O
Delta	O
Delta	O
CT	O
method	O
[	O
77	O
]	O
and	O
significance	O
was	O
determined	O
using	O
a	O
nonparametric	O
Mann	O
-	O
Whitney	O
U	O
test	O
and	O
multiple	O
linear	O
regression	O
in	O
JMP	O
.	O

Authors	O
'	O
contributions	O

MRB	O
participated	O
in	O
study	O
conception	O
and	O
design	O
,	O
conducted	O
gene	O
expression	O
experiments	O
and	O
data	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

ABW	O
participated	O
in	O
study	O
design	O
,	O
data	O
analysis	O
,	O
and	O
manuscript	O
revision	O
.	O

RPH	O
and	O
BPM	O
participated	O
in	O
study	O
conception	O
and	O
design	O
,	O
supervision	O
of	O
research	O
activities	O
,	O
and	O
manuscript	O
revision	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
comparative	O
analysis	O
of	O
statistics	O
,	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
,	O
in	O
the	O
automated	O
annotation	O
problem	O

Abstract	O

Background	O

This	O
paper	O
discusses	O
the	O
problem	O
of	O
automated	O
annotation	O
.	O

It	O
is	O
a	O
continuation	O
of	O
the	O
previous	O
work	O
on	O
the	O
A4	O
-	O
algorithm	O
(	O
Adaptive	O
algorithm	O
of	O
automated	O
annotation	O
)	O
developed	O
by	O
Leontovich	O
and	O
others	O
.	O

Results	O

A	O
number	O
of	O
new	O
statistics	O
for	O
the	O
automated	O
annotation	O
of	O
biological	O
sequences	O
is	O
introduced	O
.	O

All	O
these	O
statistics	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
.	O

Conclusion	O

Some	O
of	O
the	O
statistics	O
yield	O
a	O
prediction	O
quality	O
that	O
is	O
significantly	O
higher	O
(	O
up	O
to	O
1	O
.	O
5	O
times	O
higher	O
)	O
in	O
comparison	O
with	O
the	O
results	O
obtained	O
with	O
the	O
A4	O
-	O
procedure	O
.	O

Background	O

Many	O
biological	O
databanks	O
,	O
both	O
dealing	O
with	O
protein	O
sequences	O
(	O
e	O
.	O
g	O
.	O
,	O
SWISS	O
-	O
PROT	O
)	O
and	O
nucleotide	O
sequences	O
(	O
e	O
.	O
g	O
.	O
,	O
GeneBank	O
)	O
,	O
contain	O
not	O
only	O
primary	O
structures	O
of	O
sequences	O
(	O
i	O
.	O
e	O
.	O
,	O
sequences	O
of	O
letters	O
-	O
amino	O
acids	O
or	O
nucleotides	O
)	O
,	O
but	O
also	O
information	O
about	O
functions	O
and	O
properties	O
of	O
these	O
sequences	O
.	O

This	O
information	O
is	O
stored	O
in	O
so	O
called	O
description	O
fields	O
of	O
the	O
sequences	O
.	O

There	O
exist	O
different	O
types	O
of	O
description	O
fields	O
-	O
KW	O
(	O
KeyWords	O
)	O
,	O
DE	O
(	O
Descriptions	O
)	O
,	O
.	O
.	O
.	O
,	O
FT	O
(	O
Feature	O
Table	O
)	O
,	O
.	O
.	O
.	O
;	O
elements	O
of	O
description	O
fields	O
are	O
referred	O
to	O
as	O
words	O
.	O

Words	O
from	O
KW	O
,	O
DE	O
,	O
.	O
.	O
.	O
fields	O
describe	O
a	O
sequence	O
as	O
a	O
whole	O
,	O
while	O
words	O
from	O
FT	O
fields	O
correspond	O
to	O
certain	O
positions	O
(	O
letters	O
)	O
of	O
a	O
sequence	O
.	O

The	O
automated	O
annotation	O
problem	O
can	O
be	O
described	O
as	O
follows	O
.	O

Consider	O
a	O
biological	O
sequence	O
(	O
referred	O
to	O
as	O
a	O
query	O
sequence	O
)	O
with	O
known	O
primary	O
structure	O
(	O
i	O
.	O
e	O
.	O
letter	O
sequence	O
)	O
but	O
unknown	O
properties	O
and	O
functions	O
(	O
i	O
.	O
e	O
.	O
,	O
description	O
fields	O
)	O
.	O

The	O
task	O
is	O
to	O
determine	O
functions	O
and	O
properties	O
of	O
this	O
sequence	O
(	O
in	O
other	O
words	O
,	O
to	O
restore	O
its	O
description	O
fields	O
)	O
on	O
the	O
basis	O
of	O
the	O
primary	O
structure	O
.	O

The	O
annotation	O
should	O
be	O
fully	O
automated	O
.	O

This	O
is	O
the	O
subject	O
of	O
the	O
current	O
paper	O
.	O

There	O
are	O
two	O
main	O
approaches	O
to	O
the	O
solution	O
of	O
this	O
problem	O
.	O

In	O
the	O
first	O
approach	O
(	O
it	O
can	O
be	O
called	O
a	O
static	O
one	O
)	O
a	O
certain	O
fixed	O
protein	O
classification	O
(	O
grouping	O
proteins	O
according	O
to	O
similarity	O
in	O
structure	O
and	O
/	O
or	O
functions	O
)	O
,	O
specified	O
beforehand	O
,	O
is	O
used	O
:	O
for	O
a	O
query	O
protein	O
the	O
search	O
of	O
a	O
relative	O
group	O
(	O
super	O
family	O
)	O
is	O
performed	O
on	O
the	O
basis	O
of	O
primary	O
structures	O
,	O
and	O
properties	O
/	O
functions	O
of	O
this	O
group	O
are	O
extended	O
to	O
the	O
query	O
protein	O
.	O

An	O
example	O
of	O
this	O
approach	O
is	O
described	O
in	O
the	O
paper	O
by	O
W	O
.	O

Fleischmann	O
et	O
al	O
.	O

[	O
1	O
]	O
,	O
it	O
uses	O
the	O
protein	O
classification	O
(	O
more	O
than	O
1000	O
families	O
)	O
,	O
stored	O
in	O
the	O
Prosite	O
databank	O
.	O

The	O
second	O
approach	O
(	O
it	O
can	O
be	O
called	O
a	O
dynamic	O
or	O
an	O
adaptive	O
one	O
)	O
does	O
not	O
use	O
protein	O
classification	O
.	O

Instead	O
,	O
a	O
"	O
dynamic	O
"	O
collection	O
of	O
bank	O
sequences	O
that	O
are	O
similar	O
to	O
a	O
query	O
sequence	O
is	O
generated	O
,	O
and	O
then	O
common	O
properties	O
/	O
functions	O
of	O
these	O
bank	O
sequences	O
are	O
extended	O
to	O
the	O
query	O
sequence	O
.	O

One	O
of	O
the	O
first	O
examples	O
of	O
this	O
approach	O
was	O
described	O
by	O
M	O
.	O
A	O
.	O

Andrade	O
et	O
al	O
.	O

[	O
2	O
]	O
.	O

In	O
this	O
paper	O
the	O
prediction	O
was	O
based	O
on	O
so	O
called	O
word	O
reliability	O
function	O
-	O
a	O
function	O
depending	O
on	O
the	O
degree	O
of	O
similarity	O
between	O
a	O
query	O
sequence	O
and	O
corresponding	O
bank	O
sequences	O
.	O

In	O
other	O
examples	O
of	O
annotation	O
procedures	O
based	O
on	O
the	O
dynamic	O
approach	O
prediction	O
was	O
performed	O
in	O
a	O
"	O
naive	O
"	O
way	O
-	O
all	O
properties	O
/	O
functions	O
of	O
similar	O
proteins	O
were	O
extended	O
to	O
a	O
query	O
protein	O
,	O
or	O
using	O
stochastic	O
methods	O
-	O
only	O
properties	O
/	O
functions	O
that	O
are	O
most	O
frequent	O
for	O
the	O
collection	O
of	O
similar	O
proteins	O
were	O
extended	O
(	O
see	O
[	O
3	O
,	O
4	O
]	O
)	O
.	O

The	O
current	O
paper	O
uses	O
the	O
dynamic	O
approach	O
.	O

This	O
paper	O
is	O
a	O
sequel	O
to	O
paper	O
[	O
5	O
]	O
that	O
describes	O
the	O
A4	O
algorithm	O
(	O
the	O
Adaptive	O
Algorithm	O
of	O
Automated	O
Annotation	O
)	O
,	O
so	O
results	O
of	O
the	O
paper	O
[	O
5	O
]	O
are	O
constantly	O
used	O
here	O
.	O

The	O
A4	O
algorithm	O
is	O
based	O
on	O
a	O
stochastic	O
approach	O
.	O

More	O
precisely	O
,	O
it	O
is	O
based	O
on	O
the	O
notion	O
of	O
transfer	O
probabilities	O
.	O

Transfer	O
probabilities	O
are	O
the	O
probabilities	O
of	O
word	O
transfer	O
(	O
extension	O
)	O
from	O
description	O
fields	O
of	O
one	O
sequence	O
to	O
description	O
fields	O
of	O
another	O
sequence	O
;	O
they	O
depend	O
on	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
.	O

Transfer	O
probabilities	O
are	O
evaluated	O
on	O
the	O
basis	O
of	O
word	O
transfer	O
frequencies	O
in	O
the	O
found	O
collection	O
of	O
sequences	O
similar	O
to	O
a	O
query	O
sequence	O
.	O

For	O
each	O
word	O
from	O
description	O
fields	O
of	O
sequences	O
included	O
in	O
the	O
collection	O
the	O
prediction	O
of	O
the	O
fact	O
that	O
this	O
word	O
belongs	O
(	O
or	O
does	O
not	O
belong	O
)	O
to	O
the	O
description	O
field	O
of	O
a	O
query	O
sequence	O
is	O
performed	O
;	O
this	O
prediction	O
is	O
based	O
on	O
transfer	O
probabilities	O
.	O

In	O
the	O
current	O
paper	O
we	O
introduce	O
and	O
analyze	O
a	O
number	O
of	O
new	O
statistics	O
for	O
the	O
prediction	O
.	O

All	O
of	O
them	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
[	O
6	O
]	O
(	O
which	O
is	O
the	O
most	O
powerful	O
criterion	O
)	O
.	O

As	O
in	O
[	O
5	O
]	O
,	O
all	O
these	O
statistics	O
are	O
evaluated	O
using	O
transfer	O
probabilities	O
.	O

Two	O
approaches	O
to	O
statistics	O
definition	O
are	O
introduced	O
:	O
a	O
"	O
discrete	O
"	O
approach	O
and	O
a	O
"	O
continuous	O
"	O
approach	O
.	O

A	O
detailed	O
analysis	O
and	O
comparison	O
of	O
introduced	O
statistics	O
are	O
performed	O
and	O
the	O
best	O
statistics	O
are	O
selected	O
.	O

The	O
emphasis	O
is	O
on	O
a	O
precise	O
description	O
of	O
the	O
way	O
these	O
statistics	O
can	O
be	O
constructed	O
using	O
well	O
-	O
known	O
concepts	O
from	O
statistical	O
decision	O
theory	O
.	O

The	O
current	O
A4	O
algorithm	O
uses	O
SPKW	O
as	O
a	O
language	O
of	O
annotation	O
.	O

Of	O
course	O
,	O
it	O
is	O
possible	O
to	O
use	O
GO	O
terms	O
in	O
A4	O
as	O
well	O
.	O

That	O
would	O
facilitate	O
comparison	O
with	O
other	O
approaches	O
.	O

However	O
,	O
at	O
the	O
current	O
stage	O
of	O
our	O
research	O
we	O
test	O
and	O
choose	O
"	O
the	O
best	O
decision	O
making	O
algorithm	O
"	O
,	O
not	O
"	O
the	O
best	O
annotation	O
terminology	O
"	O
.	O

Obviously	O
,	O
which	O
annotation	O
is	O
used	O
hardly	O
matters	O
for	O
the	O
problem	O
of	O
finding	O
the	O
optimal	O
"	O
decision	O
making	O
algorithm	O
"	O

Results	O

Algorithm	O
description	O

Generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O

First	O
,	O
we	O
introduce	O
some	O
notation	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
we	O
write	O
"	O
a	O
word	O
omega	O
belongs	O
to	O
a	O
sequence	O
pi	O
"	O
instead	O
of	O
"	O
a	O
word	O
omega	O
belongs	O
to	O
description	O
fields	O
of	O
a	O
sequence	O
pi	O
"	O
.	O

If	O
omega	O
is	O
a	O
KW	O
-	O
type	O
word	O
(	O
to	O
be	O
definite	O
,	O
further	O
in	O
the	O
paper	O
we	O
consider	O
only	O
amino	O
-	O
acid	O
sequences	O
and	O
KW	O
-	O
type	O
words	O
)	O
,	O
we	O
write	O
omega	O
in	O
KW	O
[	O
pi	O
]	O
.	O

The	O
application	O
of	O
an	O
annotation	O
procedure	O
to	O
an	O
unannotated	O
amino	O
-	O
acid	O
query	O
sequence	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
prediction	O
of	O
description	O
fields	O
)	O
starts	O
with	O
generating	O
a	O
collection	O
of	O
sequences	O
similar	O
to	O
this	O
query	O
sequence	O
with	O
known	O
description	O
fields	O
.	O

These	O
similar	O
sequences	O
are	O
selected	O
from	O
a	O
certain	O
databank	O
that	O
contains	O
annotated	O
amino	O
-	O
acid	O
sequences	O
,	O
e	O
.	O
g	O
.	O
,	O
SWISS	O
-	O
PROT	O
.	O

There	O
exist	O
different	O
approaches	O
to	O
the	O
generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
(	O
see	O
[	O
7	O
]	O
)	O
.	O

This	O
collections	O
can	O
be	O
generated	O
on	O
the	O
basis	O
of	O
global	O
alignments	O
between	O
a	O
query	O
sequence	O
and	O
bank	O
sequences	O
(	O
global	O
alignments	O
can	O
be	O
constructed	O
,	O
e	O
.	O
g	O
.	O
,	O
by	O
CLUSTAL	O
procedure	O
)	O
using	O
an	O
identity	O
percentage	O
or	O
,	O
more	O
generally	O
,	O
a	O
similarity	O
percentage	O
as	O
a	O
similarity	O
measure	O
.	O

Another	O
variant	O
is	O
to	O
use	O
local	O
alignments	O
(	O
i	O
.	O
e	O
.	O
,	O
alignments	O
of	O
most	O
similar	O
fragments	O
of	O
compared	O
sequences	O
,	O
see	O
[	O
7	O
]	O
)	O
instead	O
of	O
global	O
alignments	O
.	O

Local	O
alignments	O
can	O
be	O
constructed	O
,	O
for	O
example	O
,	O
by	O
a	O
well	O
-	O
known	O
BLAST	O
procedure	O
[	O
7	O
,	O
8	O
]	O
,	O
in	O
which	O
sum	O
of	O
weights	O
or	O
a	O
corresponding	O
e	O
-	O
value	O
serves	O
as	O
a	O
measure	O
of	O
similarity	O
between	O
fragments	O
(	O
and	O
thus	O
between	O
compared	O
sequences	O
)	O
.	O

Other	O
alignment	O
procedures	O
are	O
also	O
acceptable	O
;	O
alignment	O
procedure	O
selection	O
does	O
not	O
play	O
a	O
critical	O
role	O
.	O

Since	O
we	O
build	O
on	O
the	O
A4	O
procedure	O
,	O
we	O
briefly	O
summarize	O
that	O
approach	O
.	O

In	O
the	O
A4	O
procedure	O
a	O
collection	O
of	O
similar	O
sequences	O
is	O
generated	O
on	O
the	O
basis	O
of	O
local	O
alignments	O
of	O
a	O
special	O
type	O
.	O

These	O
alignments	O
are	O
constructed	O
by	O
the	O
DotHelix	O
procedure	O
(	O
[	O
9	O
]	O
)	O
,	O
in	O
which	O
the	O
"	O
power	O
"	O
(	O
sum	O
of	O
weights	O
divided	O
by	O
the	O
root	O
of	O
the	O
length	O
of	O
the	O
local	O
alignment	O
,	O
see	O
[	O
9	O
,	O
10	O
]	O
for	O
details	O
)	O
serves	O
as	O
a	O
similarity	O
measure	O
.	O

Each	O
local	O
alignment	O
constructed	O
by	O
DotHelix	O
procedure	O
is	O
a	O
chain	O
of	O
closely	O
located	O
gapless	O
local	O
alignments	O
.	O

Local	O
alignments	O
that	O
are	O
generated	O
during	O
the	O
construction	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
are	O
referred	O
to	O
as	O
primary	O
local	O
alignments	O
.	O

Each	O
sequence	O
from	O
a	O
collection	O
of	O
similar	O
sequences	O
pi	O
1	O
,	O
.	O
.	O
.	O
,	O
pi	O
n	O
can	O
have	O
several	O
corresponding	O
primary	O
local	O
alignments	O
,	O
but	O
for	O
the	O
sake	O
of	O
simplicity	O
we	O
assume	O
that	O
each	O
similar	O
sequence	O
pi	O
i	O
has	O
exactly	O
one	O
corresponding	O
primary	O
local	O
alignment	O
,	O
the	O
one	O
with	O
the	O
maximum	O
similarity	O
measure	O
.	O

Let	O
mu	O
i	O
denote	O
the	O
similarity	O
measure	O
(	O
power	O
)	O
of	O
a	O
primary	O
alignment	O
that	O
corresponds	O
to	O
pi	O
i	O
.	O

The	O
value	O
of	O
mu	O
i	O
characterizes	O
the	O
measure	O
of	O
similarity	O
between	O
fragments	O
that	O
constitute	O
this	O
alignment	O
;	O
at	O
the	O
same	O
time	O
mu	O
i	O
can	O
be	O
treated	O
as	O
a	O
measure	O
of	O
similarity	O
between	O
the	O
whole	O
query	O
sequence	O
pi	O
0	O
and	O
the	O
whole	O
similar	O
sequence	O
pi	O
i	O
.	O

We	O
assume	O
that	O
similar	O
sequences	O
are	O
ordered	O
in	O
such	O
a	O
way	O
that	O
mu	O
1	O
>=	O
mu	O
2	O
>=	O
.	O
.	O
.	O
>=	O
mu	O
n	O
.	O

The	O
exact	O
stochastic	O
formulation	O
of	O
the	O
problem	O

Let	O
pi	O
0	O
be	O
an	O
unannotated	O
amino	O
-	O
acid	O
query	O
sequence	O
,	O
pi	O
1	O
,	O
.	O
.	O
.	O
,	O
pi	O
n	O
be	O
a	O
collection	O
of	O
sequences	O
similar	O
to	O
pi	O
0	O
,	O
and	O
omega	O
be	O
a	O
word	O
that	O
belongs	O
to	O
some	O
similar	O
sequences	O
(	O
i	O
.	O
e	O
.	O
,	O
omega	O
in	O
KW	O
[	O
pi	O
i	O
]	O
.	O
for	O
at	O
least	O
one	O
similar	O
sequence	O
pi	O
i	O
)	O
.	O

The	O
task	O
is	O
to	O
predict	O
whether	O
this	O
word	O
omega	O
belongs	O
to	O
the	O
query	O
sequence	O
pi	O
0	O
or	O
not	O
.	O

Let	O
us	O
put	O

xi	O
i	O
=	O
1	O
,	O
if	O
omega	O
in	O
KW	O
[	O
pi	O
i	O
]	O
,	O
and	O
xi	O
i	O
=	O
0	O
,	O
if	O
omega	O
not-in	O
KW	O
[	O
pi	O
i	O
]	O
(	O
i	O
=	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O
)	O
.	O

we	O
also	O
put	O

xi	O
0	O
=	O
1	O
,	O
if	O
omega	O
in	O
KW	O
[	O
pi	O
0	O
]	O
,	O
and	O
xi	O
0	O
=	O
0	O
,	O
if	O
omega	O
not-in	O
KW	O
[	O
pi	O
0	O
]	O
.	O

Variables	O
xi	O
i	O
can	O
be	O
treated	O
as	O
random	O
variates	O
Actually	O
,	O
they	O
depend	O
on	O
omega	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
we	O
write	O
xi	O
i	O
instead	O
of	O
xi	O
i	O
(	O
omega	O
)	O
.	O

In	O
this	O
notation	O
the	O
problem	O
can	O
be	O
stated	O
as	O
follows	O
.	O

Measures	O
of	O
similarity	O
mu	O
i	O
between	O
the	O
query	O
sequence	O
pi	O
0	O
and	O
similar	O
sequences	O
pi	O
i	O
and	O
values	O
of	O
random	O
variates	O
xi	O
i	O
,	O
i	O
=	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O
,	O
are	O
given	O
.	O

The	O
task	O
is	O
to	O
determine	O
whether	O
the	O
word	O
omega	O
belongs	O
to	O
the	O
query	O
sequence	O
pi	O
0	O
or	O
not	O
.	O

In	O
other	O
words	O
,	O
two	O
hypotheses	O
are	O
considered	O
,	O
H1	O
:	O
xi	O
0	O
=	O
1	O
(	O
i	O
.	O
e	O
.	O
,	O
omega	O
in	O
KW	O
[	O
pi	O
0	O
]	O
)	O
,	O
and	O
H0	O
:	O
xi	O
0	O
=	O
0	O
(	O
i	O
.	O
e	O
.	O
,	O
omega	O
not-in	O
KW	O
[	O
pi	O
0	O
]	O
)	O
,	O
and	O
the	O
task	O
is	O
to	O
construct	O
a	O
procedure	O
that	O
allows	O
to	O
decide	O
which	O
hypothesis	O
is	O
true	O
on	O
the	O
basis	O
of	O
xi	O
=	O
(	O
xi	O
1	O
,	O
.	O
.	O
.	O
,	O
xi	O
n	O
)	O
.	O

As	O
announced	O
in	O
the	O
introduction	O
,	O
we	O
base	O
our	O
procedures	O
on	O
the	O
likelihood	O
ratio	O
.	O

Let	O
us	O
recall	O
the	O
famous	O
Bayes	O
'	O
Theorem	O
that	O
can	O
be	O
written	O
as	O

P	O
{	O
H1	O
|	O
xi	O
}	O
P	O
{	O
H0	O
|	O
xi	O
}	O
=	O
P	O
{	O
xi	O
0	O
=	O
1	O
|	O
xi	O
}	O
P	O
{	O
xi	O
0	O
=	O
0	O
|	O
xi	O
}	O
=	O
P	O
{	O
xi	O
0	O
=	O
1	O
,	O
xi	O
}	O
/	O
P	O
{	O
xi	O
}	O
P	O
{	O
xi	O
0	O
=	O
0	O
,	O
xi	O
}	O
/	O
P	O
{	O
xi	O
}	O
=	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
1	O
}	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
0	O
}	O
.	O
P	O
{	O
xi	O
0	O
=	O
1	O
}	O
P	O
{	O
xi	O
0	O
=	O
0	O
}	O
.	O

Here	O
the	O
left	O
part	O
is	O
the	O
posterior	O
odds	O
,	O
that	O
is	O
the	O
ratio	O
of	O
a	O
posteriori	O
probabilities	O
of	O
hypotheses	O
H1	O
and	O
H0	O
(	O
a	O
posteriori	O
means	O
that	O
values	O
xi	O
1	O
,	O
.	O
.	O
.	O
,	O
xi	O
n	O
are	O
known	O
)	O
.	O

It	O
is	O
equal	O
to	O
the	O
product	O
of	O
the	O
likelihood	O
ratio	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
1	O
}	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
0	O
}	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
ratio	O
of	O
probabilities	O
that	O
the	O
set	O
of	O
values	O
xi	O
=	O
xi	O
(	O
omega	O
)	O
is	O
realized	O
for	O
the	O
word	O
omega	O
given	O
the	O
conditions	O
xi	O
0	O
=	O
1	O
and	O
xi	O
0	O
=	O
0	O
respectively	O
)	O
and	O
the	O
prior	O
odds	O
,	O
that	O
is	O
the	O
ratio	O
of	O
a	O
priori	O
probabilities	O
of	O
hypotheses	O
H1	O
and	O
H0	O
.	O

Statistical	O
decision	O
theory	O
tells	O
us	O
that	O
the	O
optimal	O
prediction	O
procedure	O
should	O
be	O
based	O
on	O
the	O
statistic	O
P	O
{	O
H1	O
|	O
xi	O
}	O
P	O
{	O
H0	O
|	O
xi	O
}	O
or	O
equivalently	O
on	O
the	O
likelihood	O
ratio	O
.	O

For	O
any	O
statistic	O
a	O
threshold	O
value	O
should	O
be	O
specified	O
for	O
the	O
procedure	O
:	O
if	O
the	O
value	O
of	O
the	O
statistic	O
is	O
greater	O
than	O
the	O
threshold	O
,	O
hypothesis	O
H1	O
is	O
accepted	O
,	O
otherwise	O
hypothesis	O
H0	O
is	O
accepted	O
.	O

The	O
threshold	O
value	O
should	O
be	O
selected	O
in	O
such	O
a	O
way	O
that	O
the	O
total	O
number	O
of	O
incorrect	O
predictions	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
sum	O
of	O
the	O
number	O
of	O
type	O
1	O
errors	O
and	O
the	O
number	O
of	O
type	O
2	O
errors	O
)	O
would	O
be	O
minimal	O
.	O

It	O
is	O
clear	O
that	O
if	O
the	O
prior	O
odds	O
are	O
equal	O
to	O
1	O
,	O
then	O
a	O
threshold	O
value	O
of	O
one	O
should	O
be	O
selected	O
for	O
the	O
likelihood	O
ratio	O
;	O
total	O
number	O
of	O
errors	O
would	O
(	O
theoretically	O
)	O
be	O
minimal	O
for	O
this	O
threshold	O
.	O

Surely	O
,	O
the	O
assumption	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
equals	O
1	O
does	O
not	O
seem	O
to	O
be	O
natural	O
.	O

Indeed	O
,	O
the	O
number	O
of	O
considered	O
words	O
that	O
do	O
not	O
belong	O
to	O
a	O
query	O
sequence	O
is	O
much	O
greater	O
(	O
approximately	O
8	O
times	O
greater	O
)	O
than	O
the	O
number	O
of	O
considered	O
words	O
that	O
belong	O
to	O
a	O
query	O
sequence	O
.	O

But	O
statistics	O
that	O
are	O
obtained	O
from	O
the	O
assumption	O
that	O
this	O
a	O
priori	O
ratio	O
equals	O
1	O
,	O
and	O
the	O
assumption	O
that	O
this	O
a	O
priori	O
ratio	O
does	O
not	O
equal	O
1	O
,	O
but	O
is	O
constant	O
(	O
i	O
.	O
e	O
.	O
,	O
it	O
does	O
not	O
depend	O
on	O
a	O
word	O
omega	O
)	O
are	O
equivalent	O
.	O

Essentially	O
these	O
are	O
the	O
same	O
statistics	O
(	O
only	O
the	O
threshold	O
value	O
should	O
be	O
changed	O
:	O
a	O
value	O
P	O
{	O
xi	O
0	O
=	O
0	O
}	O
P	O
{	O
xi	O
0	O
=	O
1	O
}	O
should	O
be	O
taken	O
instead	O
of	O
1	O
;	O
as	O
it	O
was	O
noted	O
,	O
this	O
value	O
approximately	O
equals	O
8	O
in	O
our	O
data	O
)	O
.	O

Therefore	O
,	O
we	O
assume	O
from	O
now	O
on	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
equals	O
1	O
.	O

Thus	O
all	O
considered	O
statistics	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O

(	O
1	O
)	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
1	O
}	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
0	O
}	O

Assumption	O
of	O
independence	O
of	O
variables	O
xi	O
i	O
.	O

Transfer	O
probabilities	O

By	O
virtue	O
of	O
equation	O
(	O
1	O
)	O
we	O
need	O
to	O
estimate	O
conditional	O
probabilities	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
epsilon	O
}	O
,	O
where	O
epsilon	O
=	O
1	O
or	O
0	O
in	O
order	O
to	O
calculate	O
the	O
likelihood	O
ratio	O
.	O

Our	O
derivation	O
of	O
these	O
estimates	O
uses	O
the	O
assumption	O
that	O
variables	O
xi	O
i	O
,	O
i	O
=	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O
,	O
are	O
independent	O
in	O
the	O
aggregate	O
.	O

Surely	O
,	O
this	O
assumption	O
is	O
false	O
.	O

In	O
reality	O
variables	O
xi	O
i	O
are	O
dependent	O
,	O
and	O
the	O
dependence	O
is	O
considerably	O
strong	O
.	O

Nevertheless	O
,	O
in	O
our	O
definition	O
of	O
the	O
likelihood	O
ratio	O
statistic	O
(	O
and	O
the	O
statistic	O
that	O
is	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
)	O
we	O
use	O
the	O
independence	O
assumption	O
.	O

Since	O
variables	O
xi	O
i	O
are	O
not	O
independent	O
,	O
one	O
can	O
not	O
assert	O
that	O
the	O
obtained	O
statistics	O
are	O
the	O
most	O
powerful	O
,	O
but	O
these	O
statistics	O
can	O
be	O
still	O
quite	O
good	O
.	O

In	O
decision	O
theory	O
,	O
this	O
approach	O
is	O
known	O
as	O
the	O
naive	O
Bayes	O
procedure	O
.	O

The	O
independence	O
of	O
variables	O
xi	O
i	O
implies	O
the	O
equality	O

(	O
2	O
)	O
P	O
{	O
xi	O
|	O
xi	O
0	O
=	O
epsilon	O
}	O
=	O
product	O
i	O
=	O
1nP	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
epsilon	O
}	O
,	O
epsilon	O
=	O
1	O
,	O
0	O

Each	O
variable	O
xi	O
i	O
has	O
exactly	O
two	O
possible	O
values	O
:	O
1	O
and	O
0	O
.	O

Thus	O
,	O
everything	O
is	O
reduced	O
to	O
the	O
following	O
four	O
conditional	O
probabilities	O
:	O

(	O
3	O
)	O
P	O
{	O
xi	O
i	O
=	O
1	O
|	O
xi	O
0	O
=	O
1	O
}	O
,	O
P	O
{	O
xi	O
i	O
=	O
0	O
|	O
xi	O
0	O
=	O
1	O
}	O
,	O
P	O
{	O
xi	O
i	O
=	O
1	O
|	O
xi	O
0	O
=	O
0	O
}	O
,	O
P	O
{	O
xi	O
i	O
=	O
0	O
|	O
xi	O
0	O
=	O
0	O
}	O
.	O

In	O
addition	O
,	O
it	O
is	O
clear	O
that	O

(	O
4	O
)	O
P	O
{	O
xi	O
i	O
=	O
1	O
|	O
xi	O
0	O
=	O
1	O
}	O
+	O
P	O
{	O
xi	O
i	O
=	O
0	O
|	O
xi	O
0	O
=	O
1	O
}	O
=	O
1	O
,	O
P	O
{	O
xi	O
i	O
=	O
1	O
|	O
xi	O
0	O
=	O
0	O
}	O
+	O
P	O
{	O
xi	O
i	O
=	O
0	O
|	O
xi	O
0	O
=	O
0	O
}	O
=	O
1	O
,	O

so	O
actually	O
everything	O
is	O
reduced	O
to	O
two	O
conditional	O
probabilities	O

P	O
{	O
xi	O
i	O
=	O
1	O
|	O
xi	O
0	O
=	O
1	O
}	O
,	O
P	O
{	O
xi	O
i	O
=	O
1	O
|	O
xi	O
0	O
=	O
0	O
}	O
.	O

Conditional	O
probabilities	O
(	O
3	O
)	O
are	O
a	O
special	O
case	O
of	O
conditional	O
probabilities	O
of	O
the	O
type	O

P	O
{	O
xi	O
i	O
=	O
epsilon	O
1	O
|	O
xi	O
j	O
=	O
epsilon	O
2	O
}	O
,	O
where	O
epsilon	O
1	O
,	O
epsilon	O
2	O
=	O
1	O
or	O
0	O
,	O
i	O
,	O
j	O
=	O
0	O
,	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O

(	O
above	O
special	O
case	O
corresponds	O
to	O
j	O
=	O
0	O
)	O
.	O

We	O
call	O
all	O
this	O
conditional	O
probabilities	O
transfer	O
probabilities	O
and	O
denote	O
them	O
by	O

P	O
{	O
xi	O
i	O
=	O
epsilon	O
1	O
|	O
xi	O
j	O
=	O
epsilon	O
2	O
}	O
=	O
p	O
epsilon	O
1	O
|	O
epsilon	O
2	O
.	O

Transfer	O
probabilities	O
depend	O
on	O
i	O
,	O
j	O
(	O
and	O
certainly	O
on	O
the	O
word	O
omega	O
)	O
:	O

p	O
epsilon	O
1	O
|	O
epsilon	O
2	O
=	O
p	O
epsilon	O
1	O
|	O
epsilon	O
2	O
(	O
i	O
,	O
j	O
;	O
omega	O
)	O
.	O

Conditional	O
probabilities	O
play	O
a	O
central	O
role	O
in	O
our	O
procedure	O
.	O

According	O
to	O
equation	O
(	O
4	O
)	O
,	O
it	O
suffices	O
to	O
explain	O
how	O
transfer	O
probabilities	O
p1	O
|	O
1	O
,	O
p1	O
|	O
0	O
are	O
evaluated	O
.	O

We	O
suppose	O
that	O
transfer	O
probabilities	O
satisfy	O
the	O
following	O
assumptions	O
(	O
"	O
axioms	O
"	O
)	O
(	O
the	O
sense	O
of	O
these	O
assumptions	O
is	O
obvious	O
)	O
.	O

Assumption	O
1	O
)	O
For	O
a	O
fixed	O
word	O
omega	O
and	O
for	O
sequences	O
pi	O
0	O
,	O
pi	O
1	O
,	O
.	O
.	O
.	O
,	O
pi	O
n	O
(	O
i	O
.	O
e	O
.	O
,	O
for	O
the	O
sequence	O
pi	O
0	O
and	O
sequences	O
similar	O
to	O
pi	O
0	O
)	O
transfer	O
probabilities	O
depend	O
only	O
on	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
.	O

Thus	O
,	O
we	O
have	O
:	O

p1	O
|	O
1	O
=	O
p1	O
|	O
1	O
(	O
i	O
,	O
j	O
;	O
omega	O
)	O
=	O
p1	O
|	O
1	O
(	O
mu	O
ij	O
;	O
omega	O
)	O
=	O
p1	O
|	O
1	O
(	O
mu	O
ij	O
)	O
=	O
1	O
-	O
p0	O
|	O
1	O
(	O
mu	O
ij	O
)	O
,	O

p1	O
|	O
0	O
=	O
p1	O
|	O
0	O
(	O
i	O
,	O
j	O
;	O
omega	O
)	O
=	O
p1	O
|	O
0	O
(	O
mu	O
ij	O
;	O
omega	O
)	O
=	O
p1	O
|	O
0	O
(	O
mu	O
ij	O
)	O
=	O
1	O
-	O
p0	O
|	O
0	O
(	O
mu	O
ij	O
)	O
,	O

where	O
mu	O
ij	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
pi	O
i	O
,	O
pi	O
j	O
(	O
i	O
,	O
j	O
=	O
0	O
,	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O
)	O
.	O

Particularly	O
,	O
if	O
one	O
of	O
these	O
sequences	O
is	O
the	O
query	O
sequence	O
pi	O
0	O
and	O
mu	O
j	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
pi	O
j	O
,	O
pi	O
0	O
,	O
we	O
have	O

(	O
5	O
)	O
P	O
{	O
xi	O
j	O
=	O
1	O
|	O
xi	O
0	O
=	O
1	O
}	O
=	O
p1	O
|	O
1	O
(	O
mu	O
j	O
)	O
,	O
P	O
{	O
xi	O
j	O
=	O
1	O
|	O
xi	O
0	O
=	O
0	O
}	O
=	O
p1	O
|	O
0	O
(	O
mu	O
j	O
)	O
.	O

Assumption	O
2	O
)	O
Transfer	O
probabilities	O
(	O
for	O
an	O
arbitrary	O
fixed	O
word	O
omega	O
)	O
depend	O
on	O
similarity	O
measure	O
mu	O
monotonically	O
:	O
the	O
probability	O
p1	O
|	O
1	O
(	O
mu	O
)	O
increases	O
(	O
does	O
not	O
decrease	O
)	O
and	O
the	O
probability	O
p1	O
|	O
0	O
(	O
mu	O
)	O
decreases	O
(	O
does	O
not	O
increase	O
)	O
as	O
mu	O
increases	O
.	O

Assumption	O
3	O
)	O
The	O
inequality	O

(	O
6	O
)	O
p1	O
|	O
1	O
(	O
mu	O
)	O
>	O
p1	O
|	O
0	O
(	O
mu	O
)	O

always	O
holds	O
(	O
if	O
mu	O
>	O
0	O
)	O
.	O

Transfer	O
probabilities	O
are	O
evaluated	O
on	O
the	O
basis	O
of	O
the	O
measure	O
of	O
similarity	O
between	O
similar	O
sequences	O
for	O
which	O
it	O
is	O
known	O
whether	O
omega	O
in	O
KW	O
[	O
pi	O
i	O
]	O
using	O
the	O
so	O
called	O
isotonic	O
regression	O
procedure	O
(	O
see	O
[	O
11	O
]	O
)	O
.	O

(	O
In	O
[	O
5	O
]	O
this	O
procedure	O
was	O
referred	O
to	O
as	O
monotonization	O
procedure	O
)	O
.	O

Results	O
of	O
this	O
procedure	O
are	O
piecewise	O
-	O
constant	O
monotonous	O
functions	O
of	O
the	O
similarity	O
measure	O
mu	O
that	O
increase	O
(	O
do	O
not	O
decrease	O
)	O
for	O
probabilities	O
p1	O
|	O
1	O
(	O
mu	O
)	O
and	O
decrease	O
(	O
do	O
not	O
increase	O
)	O
for	O
probabilities	O
p1	O
|	O
0	O
(	O
mu	O
)	O
.	O

We	O
briefly	O
recall	O
the	O
isotonic	O
regression	O
problem	O
.	O

Let	O
one	O
have	O
two	O
number	O
sets	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
set	O
of	O
points	O
in	O
the	O
plain	O
)	O
xi	O
,	O
yi	O
,	O
i	O
=	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O
,	O
for	O
which	O
x1	O
<=	O
x2	O
<=	O
.	O
.	O
.	O
<=	O
xn	O
.	O

The	O
task	O
is	O
to	O
find	O
values	O
z1	O
,	O
z2	O
,	O
.	O
.	O
.	O
,	O
zn	O
,	O
z1	O
<=	O
z2	O
<=	O
.	O
.	O
.	O
<=	O
zn	O
,	O
that	O
minimize	O
the	O
deviation	O
sum	O
i	O
=	O
1n	O
(	O
zi	O
-	O
yi	O
)	O
2	O
.	O

This	O
is	O
the	O
monotone	O
-	O
increasing	O
isotonic	O
regression	O
problem	O
.	O

The	O
monotone	O
-	O
decreasing	O
isotonic	O
regression	O
problem	O
is	O
similar	O
;	O
the	O
only	O
difference	O
is	O
that	O
here	O
z1	O
>=	O
z2	O
>=	O
.	O
.	O
.	O
>=	O
zn	O
.	O

The	O
isotonic	O
regression	O
procedure	O
constructs	O
a	O
monotonic	O
number	O
sequence	O
z1	O
,	O
.	O
.	O
.	O
,	O
zn	O
(	O
while	O
in	O
linear	O
regression	O
values	O
of	O
zi	O
are	O
linearly	O
expressed	O
in	O
terms	O
of	O
xi	O
:	O
zi	O
=	O
alpha	O
xi	O
+	O
beta	O
)	O
.	O

An	O
algorithm	O
for	O
the	O
solution	O
of	O
isotonic	O
regression	O
problem	O
can	O
be	O
easily	O
constructed	O
.	O

We	O
do	O
not	O
describe	O
it	O
here	O
.	O

We	O
only	O
note	O
that	O
each	O
zi	O
is	O
the	O
mean	O
value	O
of	O
{	O
yj	O
}	O
over	O
a	O
window	O
of	O
variable	O
length	O
:	O
Li	O
:	O
zi	O
=	O
(	O
sum	O
j	O
=	O
t	O
(	O
i	O
)	O
t	O
(	O
i	O
)	O
+	O
L	O
(	O
i	O
)	O
-	O
1yi	O
)	O
/	O
Li	O
.	O

For	O
different	O
indices	O
these	O
windows	O
either	O
coincide	O
or	O
do	O
not	O
overlap	O
,	O
and	O
the	O
i	O
-	O
th	O
window	O
contains	O
i	O
.	O

We	O
also	O
note	O
that	O
the	O
values	O
of	O
xi	O
are	O
not	O
essential	O
in	O
the	O
isotonic	O
regression	O
problem	O
,	O
only	O
the	O
order	O
of	O
values	O
of	O
yi	O
is	O
essential	O
.	O

To	O
obtain	O
the	O
transfer	O
probabilities	O
using	O
isotonic	O
regression	O
we	O
proceed	O
as	O
follows	O
.	O

For	O
the	O
evaluation	O
of	O
p1	O
|	O
1	O
we	O
consider	O
pairs	O
of	O
similar	O
sequences	O
pi	O
i	O
,	O
pi	O
j	O
that	O
satisfy	O
the	O
condition	O
omega	O
in	O
KW	O
[	O
pi	O
i	O
]	O
.	O

Let	O
mu	O
ij	O
denote	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
pi	O
i	O
,	O
pi	O
j	O
.	O

We	O
put	O
xi	O
ij	O
=	O
1	O
if	O
the	O
word	O
omega	O
belongs	O
to	O
the	O
sequence	O
pi	O
j	O
,	O
and	O
put	O
xi	O
ij	O
=	O
0	O
if	O
omega	O
does	O
not	O
belong	O
to	O
pi	O
j	O
(	O
recall	O
that	O
the	O
word	O
omega	O
belongs	O
to	O
pi	O
i	O
)	O
.	O

Then	O
we	O
apply	O
the	O
monotone	O
-	O
increasing	O
isotonic	O
regression	O
procedure	O
to	O
the	O
collection	O
of	O
points	O
(	O
mu	O
ij	O
,	O
xi	O
ij	O
)	O
,	O
where	O
mu	O
ij	O
are	O
in	O
ascending	O
order	O
.	O

The	O
resulting	O
values	O
are	O
the	O
estimates	O
of	O
the	O
transfer	O
probabilities	O
p1	O
|	O
1	O
(	O
mu	O
ij	O
)	O
.	O

Similarly	O
,	O
applying	O
the	O
monotone	O
-	O
decreasing	O
isotonic	O
regression	O
procedure	O
to	O
the	O
collection	O
of	O
points	O
(	O
mu	O
ij	O
,	O
xi	O
ij	O
)	O
that	O
correspond	O
to	O
pairs	O
of	O
similar	O
sequences	O
pi	O
i	O
,	O
pi	O
j	O
for	O
which	O
omega	O
does	O
not	O
belong	O
to	O
pi	O
i	O
,	O
we	O
obtain	O
values	O
of	O
the	O
transfer	O
probabilities	O
p1	O
|	O
0	O
(	O
mu	O
ij	O
)	O
.	O

As	O
we	O
noted	O
,	O
the	O
probabilities	O
p1	O
|	O
1	O
,	O
p1	O
|	O
0	O
are	O
supposed	O
to	O
satisfy	O
condition	O
(	O
6	O
)	O
.	O

Therefore	O
,	O
if	O
it	O
turns	O
out	O
that	O
functions	O
p1	O
|	O
1	O
(	O
mu	O
)	O
,	O
p1	O
|	O
0	O
(	O
mu	O
)	O
obtained	O
after	O
the	O
application	O
of	O
isotonic	O
regression	O
procedure	O
do	O
not	O
satisfy	O
this	O
condition	O
for	O
some	O
values	O
of	O
mu	O
,	O
then	O
we	O
consider	O
that	O
probabilities	O
p1	O
|	O
1	O
,	O
p1	O
|	O
0	O
are	O
not	O
defined	O
for	O
these	O
values	O
of	O
mu	O
.	O

Hence	O
,	O
it	O
is	O
possible	O
that	O
transfer	O
probabilities	O
are	O
defined	O
only	O
for	O
sufficiently	O
large	O
values	O
of	O
mu	O
,	O
but	O
not	O
for	O
all	O
mu	O
.	O

In	O
particular	O
,	O
it	O
is	O
possible	O
that	O
for	O
some	O
words	O
there	O
are	O
no	O
values	O
of	O
mu	O
such	O
that	O
inequality	O
(	O
6	O
)	O
holds	O
.	O

These	O
words	O
are	O
referred	O
to	O
as	O
degenerate	O
words	O
.	O

Statistics	O
description	O

All	O
statistics	O
considered	O
in	O
this	O
paper	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
,	O
that	O
is	O
on	O
formula	O
(	O
1	O
)	O
under	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
xi	O
i	O
(	O
formula	O
(	O
2	O
)	O
)	O
.	O

Two	O
approaches	O
are	O
used	O
in	O
the	O
definitions	O
of	O
these	O
statistics	O
.	O

One	O
of	O
them	O
can	O
be	O
called	O
a	O
"	O
discrete	O
"	O
approach	O
;	O
the	O
other	O
can	O
be	O
called	O
a	O
"	O
continuous	O
"	O
approach	O
.	O

The	O
discrete	O
approach	O
is	O
based	O
directly	O
on	O
formulae	O
(	O
1	O
)	O
,	O
(	O
2	O
)	O
and	O
the	O
definition	O
of	O
transfer	O
probabilities	O
.	O

It	O
follows	O
from	O
(	O
5	O
)	O
that	O
the	O
following	O
formulae	O
for	O
conditional	O
probabilities	O
hold	O
:	O

P	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
1	O
}	O
=	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
,	O
if	O
xi	O
i	O
=	O
1	O
,	O

P	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
1	O
}	O
=	O
p0	O
|	O
1	O
(	O
mu	O
i	O
)	O
=	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
,	O
if	O
xi	O
i	O
=	O
0	O
,	O

and	O
hence	O

(	O
7	O
)	O
P	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
1	O
}	O
=	O
(	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
)	O
.	O
(	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
)	O
)	O
xi	O
i	O
.	O

Similarly	O
,	O

(	O
8	O
)	O
P	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
0	O
}	O
=	O
(	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
)	O
.	O
(	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
)	O
xi	O
i	O
.	O

Relations	O
(	O
7	O
)	O
,	O
(	O
8	O
)	O
together	O
with	O
(	O
1	O
)	O
,	O
(	O
2	O
)	O
imply	O
the	O
following	O
formula	O
for	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
:	O

(	O
9	O
)	O
T	O
(	O
1	O
)	O
(	O
xi	O
;	O
omega	O
)	O
=	O
T	O
(	O
1	O
)	O
(	O
xi	O
)	O
=	O
ln	O
(	O
product	O
i	O
=	O
1nP	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
1	O
}	O
P	O
{	O
xi	O
i	O
|	O
xi	O
0	O
=	O
0	O
}	O
)	O
=	O
alpha	O
0	O
+	O
sum	O
i	O
=	O
1n	O
alpha	O
i	O
.	O
xi	O
i	O
,	O

where	O

(	O
10	O
)	O
alpha	O
0	O
=	O
sum	O
i	O
=	O
1n	O
alpha	O
0i	O
,	O
alpha	O
0i	O
=	O
ln	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
<	O
0	O

(	O
11	O
)	O
alpha	O
i	O
=	O
ln	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
(	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
)	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
(	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
)	O
>	O
0	O
.	O

One	O
can	O
see	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
can	O
be	O
expressed	O
as	O
a	O
linear	O
combination	O
of	O
the	O
xi	O
i	O
.	O

As	O
we	O
noted	O
,	O
theoretically	O
the	O
best	O
threshold	O
value	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
equal	O
to	O
1n1	O
=	O
0	O
.	O

However	O
,	O
that	O
is	O
only	O
theoretical	O
.	O

As	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
xi	O
i	O
is	O
incorrect	O
and	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
only	O
a	O
rough	O
estimate	O
of	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
,	O
the	O
best	O
threshold	O
value	O
is	O
not	O
necessarily	O
equal	O
to	O
zero	O
(	O
and	O
this	O
threshold	O
does	O
not	O
really	O
equal	O
zero	O
in	O
practice	O
)	O
.	O

Let	O
us	O
put	O
eta	O
=	O
eta	O
(	O
omega	O
)	O
=	O
T	O
(	O
1	O
)	O
-	O
alpha	O
0	O
sum	O
i	O
=	O
1n	O
alpha	O
i	O
.	O

From	O
the	O
definition	O
of	O
eta	O
and	O
relations	O
(	O
9	O
)	O
-	O
(	O
11	O
)	O
it	O
follows	O
that	O

(	O
12	O
)	O
eta	O
=	O
sum	O
i	O
=	O
1na	O
^	O
i	O
xi	O
i	O
,	O

where	O

(	O
13	O
)	O
a	O
^	O
i	O
=	O
ln	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
(	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
)	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
(	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
)	O
sum	O
i	O
=	O
1nln	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
(	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
)	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
(	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
)	O
>	O
0	O
.	O

We	O
note	O
that	O

(	O
14	O
)	O
sum	O
i	O
=	O
1na	O
^	O
i	O
=	O
1	O
.	O

The	O
variable	O
eta	O
(	O
omega	O
)	O
can	O
be	O
treated	O
as	O
a	O
second	O
statistic	O
.	O

Its	O
values	O
lie	O
between	O
0	O
and	O
1	O
.	O

Statistics	O
T	O
(	O
1	O
)	O
and	O
eta	O
are	O
linearly	O
dependent	O
,	O
and	O
hence	O
for	O
a	O
fixed	O
word	O
omega	O
these	O
statistics	O
are	O
equivalent	O
.	O

However	O
,	O
the	O
coefficients	O
alpha	O
0	O
and	O
alpha	O
i	O
(	O
i	O
=	O
1	O
,	O
.	O
.	O
.	O
,	O
n	O
)	O
are	O
different	O
for	O
different	O
words	O
omega	O
,	O
so	O
the	O
relation	O
between	O
thresholds	O
,	O
used	O
in	O
the	O
prediction	O
,	O
is	O
different	O
for	O
different	O
words	O
;	O
consequently	O
,	O
the	O
statistics	O
T	O
(	O
1	O
)	O
and	O
eta	O
are	O
not	O
equivalent	O
for	O
the	O
whole	O
totality	O
of	O
words	O
(	O
We	O
will	O
see	O
later	O
that	O
if	O
thresholds	O
are	O
well	O
-	O
chosen	O
,	O
then	O
eta	O
leads	O
to	O
better	O
results	O
than	O
T	O
(	O
1	O
)	O
)	O
.	O

The	O
other	O
approach	O
to	O
the	O
definition	O
of	O
statistics	O
,	O
used	O
in	O
the	O
annotation	O
procedure	O
,	O
starts	O
from	O
a	O
linear	O
combination	O
eta	O
=	O
sum	O
i	O
=	O
1nai	O
xi	O
i	O
of	O
the	O
xi	O
i	O
as	O
in	O
formula	O
(	O
12	O
)	O
.	O

Here	O
coefficients	O
alpha	O
i	O
are	O
not	O
necessarily	O
given	O
by	O
(	O
13	O
)	O
,	O
but	O
should	O
be	O
positive	O
and	O
satisfy	O
the	O
relation	O
(	O
14	O
)	O
.	O

This	O
approach	O
uses	O
the	O
assumption	O
that	O
eta	O
has	O
the	O
normal	O
distribution	O
.	O

Certainly	O
this	O
assumption	O
is	O
not	O
correct	O
(	O
at	O
least	O
because	O
the	O
inequality	O
0	O
<=	O
eta	O
<=	O
1	O
always	O
holds	O
)	O
.	O

Nevertheless	O
,	O
we	O
use	O
this	O
assumption	O
(	O
and	O
,	O
similarly	O
to	O
the	O
discrete	O
approach	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
xi	O
i	O
(	O
omega	O
)	O
)	O
.	O

(	O
As	O
the	O
normal	O
distribution	O
is	O
continuous	O
,	O
this	O
approach	O
can	O
be	O
called	O
"	O
continuous	O
"	O
)	O
.	O

Thus	O
,	O
we	O
consider	O
a	O
random	O
variable	O

(	O
15	O
)	O
eta	O
=	O
sum	O
i	O
=	O
1nai	O
xi	O
i	O

and	O
assume	O
that	O
it	O
has	O
a	O
normal	O
distribution	O
.	O

Denote	O
by	O

M1	O
eta	O
=	O
M	O
(	O
eta	O
|	O
xi	O
0	O
=	O
1	O
)	O
,	O
D1	O
eta	O
=	O
D	O
(	O
eta	O
|	O
xi	O
0	O
=	O
1	O
)	O
=	O
sigma	O
12	O
,	O
M0	O
eta	O
=	O
M	O
(	O
eta	O
|	O
xi	O
0	O
=	O
0	O
)	O
,	O
D0	O
eta	O
=	O
D	O
(	O
eta	O
|	O
xi	O
0	O
=	O
0	O
)	O
=	O
sigma	O
02	O

the	O
conditional	O
expectations	O
and	O
dispersions	O
of	O
eta	O
given	O
that	O
xi	O
0	O
=	O
1	O
or	O
0	O
respectively	O
.	O

We	O
have	O

M1	O
eta	O
=	O
sum	O
aiM	O
(	O
xi	O
i	O
|	O
xi	O
0	O
=	O
1	O
)	O
=	O
sum	O
aip1	O
|	O
1	O
(	O
mu	O
i	O
)	O
,	O
M0	O
eta	O
=	O
sum	O
aip1	O
|	O
0	O
(	O
mu	O
i	O
)	O
.	O

Further	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
xi	O
i	O
(	O
omega	O
)	O
implies	O
that	O

D1	O
eta	O
=	O
sigma	O
12	O
=	O
sum	O
iai2	O
.	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
.	O
(	O
1	O
-	O
p1	O
|	O
1	O
(	O
mu	O
i	O
)	O
)	O
,	O
D0	O
eta	O
=	O
sigma	O
02	O
=	O
sum	O
iai2	O
.	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
.	O
(	O
1	O
-	O
p1	O
|	O
0	O
(	O
mu	O
i	O
)	O
)	O
.	O

(	O
We	O
note	O
that	O
it	O
is	O
the	O
only	O
place	O
where	O
the	O
independence	O
of	O
xi	O
i	O
is	O
used	O
;	O
therefore	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
xi	O
i	O
is	O
not	O
as	O
essential	O
in	O
this	O
approach	O
as	O
it	O
was	O
in	O
the	O
definition	O
of	O
the	O
statistic	O
T	O
(	O
1	O
)	O
)	O
.	O

It	O
follows	O
from	O
the	O
assumption	O
of	O
a	O
normal	O
distribution	O
that	O
in	O
cases	O
xi	O
0	O
=	O
1	O
and	O
0	O
the	O
variables	O

(	O
16	O
)	O
eta	O
-	O
M1	O
eta	O
sigma	O
1	O
and	O
eta	O
-	O
M0	O
eta	O
sigma	O
0	O
have	O
standard	O
normal	O
distribution	O
N	O
(	O
0	O
,	O
1	O
)	O

As	O
above	O
,	O
we	O
use	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
as	O
a	O
statistic	O
and	O
in	O
addition	O
assume	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
is	O
equal	O
to	O
1	O
.	O

Let	O
us	O
denote	O
this	O
statistic	O
by	O
T	O
(	O
2	O
)	O
.	O

Relation	O
(	O
16	O
)	O
implies	O
that	O

T	O
(	O
2	O
)	O
(	O
lambda	O
)	O
=	O
ln	O
P	O
{	O
lambda	O
<=	O
eta	O
<=	O
lambda	O
+	O
d	O
lambda	O
|	O
xi	O
0	O
=	O
1	O
}	O
P	O
{	O
lambda	O
<=	O
eta	O
<=	O
lambda	O
+	O
d	O
lambda	O
|	O
xi	O
0	O
=	O
0	O
}	O
=	O
ln	O
(	O
1	O
/	O
2	O
pi	O
.	O
sigma	O
1	O
)	O
.	O
exp	O
{	O
-	O
12	O
.	O
(	O
(	O
lambda	O
-	O
M1	O
eta	O
)	O
/	O
sigma	O
1	O
)	O
2	O
}	O
(	O
1	O
/	O
2	O
pi	O
.	O
sigma	O
0	O
)	O
.	O
exp	O
{	O
12	O
.	O
(	O
(	O
lambda	O
-	O
M0	O
eta	O
)	O
/	O
sigma	O
0	O
)	O
2	O
}	O
=	O
12	O
.	O
{	O
(	O
(	O
lambda	O
-	O
M0	O
eta	O
)	O
/	O
sigma	O
0	O
)	O
2	O
-	O
(	O
(	O
lambda	O
-	O
M1	O
eta	O
)	O
/	O
sigma	O
1	O
)	O
2	O
}	O
+	O
ln	O
(	O
sigma	O
0	O
/	O
sigma	O
1	O
)	O
.	O

Another	O
variant	O
of	O
this	O
statistic	O
-	O
statistic	O
T	O
^	O
(	O
2	O
)	O
-	O
was	O
used	O
in	O
the	O
paper	O
[	O
5	O
]	O
.	O

The	O
statistic	O
T	O
^	O
(	O
2	O
)	O
is	O
the	O
ratio	O
of	O
type	O
1	O
error	O
to	O
type	O
2	O
error	O
:	O

(	O
17	O
)	O
T	O
^	O
(	O
2	O
)	O
(	O
lambda	O
)	O
=	O
ln	O
P	O
(	O
1	O
)	O
(	O
lambda	O
)	O
P	O
(	O
2	O
)	O
(	O
lambda	O
)	O
=	O
ln	O
Phi	O
(	O
(	O
lambda	O
-	O
M1	O
eta	O
)	O
/	O
sigma	O
1	O
)	O
1	O
-	O
Phi	O
(	O
(	O
lambda	O
-	O
M0	O
eta	O
)	O
/	O
sigma	O
0	O
)	O
,	O

where	O
Phi	O
(	O
x	O
)	O
is	O
the	O
cumulative	O
normal	O
distribution	O
function	O
:	O
Phi	O
(	O
x	O
)	O
=	O
12	O
pi	O
integral	O
-	O
infinity	O
xe	O
-	O
z22dz	O
.	O

The	O
statistics	O
eta	O
and	O
T	O
^	O
(	O
2	O
)	O
are	O
equivalent	O
for	O
an	O
arbitrary	O
fixed	O
word	O
omega	O
(	O
although	O
not	O
equivalent	O
for	O
the	O
whole	O
totality	O
of	O
words	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
statistics	O
eta	O
and	O
T	O
(	O
2	O
)	O
are	O
not	O
necessarily	O
equivalent	O
,	O
as	O
the	O
dependence	O
of	O
T	O
(	O
2	O
)	O
on	O
eta	O
may	O
turn	O
out	O
to	O
be	O
not	O
monotonic	O
.	O

Moreover	O
,	O
it	O
is	O
never	O
monotonic	O
for	O
all	O
values	O
of	O
eta	O
.	O

However	O
,	O
we	O
are	O
interested	O
only	O
in	O
values	O
0	O
<=	O
eta	O
<=	O
1	O
,	O
and	O
usually	O
(	O
though	O
not	O
always	O
)	O
the	O
dependence	O
of	O
T	O
(	O
2	O
)	O
on	O
eta	O
is	O
monotonous	O
for	O
these	O
values	O
of	O
eta	O
,	O
and	O
in	O
this	O
case	O
the	O
statistics	O
eta	O
and	O
T	O
(	O
2	O
)	O
are	O
equivalent	O
(	O
for	O
a	O
fixed	O
word	O
omega	O
)	O
.	O

Furthermore	O
,	O
even	O
in	O
the	O
case	O
where	O
the	O
dependence	O
is	O
not	O
monotonic	O
,	O
the	O
monotonicity	O
is	O
violated	O
only	O
for	O
the	O
values	O
of	O
eta	O
close	O
either	O
to	O
0	O
or	O
to	O
1	O
,	O
and	O
the	O
lack	O
of	O
monotonicity	O
can	O
be	O
disregarded	O
.	O

We	O
still	O
have	O
to	O
discuss	O
the	O
question	O
of	O
the	O
choice	O
of	O
coefficients	O
ai	O
in	O
(	O
15	O
)	O
.	O

One	O
of	O
the	O
variants	O
was	O
described	O
above	O
:	O
formula	O
(	O
13	O
)	O
can	O
be	O
applied	O
.	O

Another	O
variant	O
was	O
introduced	O
in	O
[	O
5	O
]	O
.	O

This	O
variant	O
can	O
be	O
described	O
as	O
follows	O
.	O

As	O
above	O
,	O
we	O
assume	O
that	O
the	O
variate	O
eta	O
=	O
sum	O
ai	O
xi	O
i	O
has	O
a	O
normal	O
distribution	O
.	O

Each	O
set	O
of	O
coefficients	O
ai	O
and	O
each	O
threshold	O
value	O
lambda	O
have	O
corresponding	O
theoretical	O
frequencies	O
of	O
type	O
1	O
and	O
type	O
2	O
errors	O
P	O
(	O
1	O
)	O
(	O
lambda	O
)	O
,	O
P	O
(	O
2	O
)	O
(	O
lambda	O
)	O
.	O

The	O
idea	O
is	O
to	O
take	O
the	O
set	O
of	O
coefficients	O
{	O
ai	O
}	O
that	O
gives	O
the	O
minimum	O
sum	O
P	O
(	O
1	O
)	O
(	O
lambda	O
)	O
+	O
P	O
(	O
2	O
)	O
(	O
lambda	O
)	O
,	O
where	O
lambda	O
is	O
the	O
best	O
threshold	O
value	O
for	O
this	O
coefficient	O
set	O
.	O

However	O
,	O
analytically	O
it	O
is	O
very	O
cumbersome	O
,	O
so	O
the	O
following	O
simplification	O
was	O
implemented	O
.	O

For	O
a	O
fixed	O
set	O
of	O
coefficients	O
{	O
ai	O
}	O
we	O
select	O
the	O
threshold	O
value	O
lambda	O
such	O
that	O
the	O
frequency	O
of	O
type	O
1	O
errors	O
is	O
equal	O
to	O
the	O
frequency	O
of	O
type	O
2	O
errors	O
:	O
P	O
(	O
1	O
)	O
(	O
lambda	O
)	O
=	O
P	O
(	O
2	O
)	O
(	O
lambda	O
)	O
.	O

Then	O
we	O
find	O
the	O
set	O
of	O
coefficients	O
that	O
minimizes	O
these	O
frequencies	O
P	O
(	O
1	O
)	O
(	O
lambda	O
)	O
=	O
P	O
(	O
2	O
)	O
(	O
lambda	O
)	O
.	O

Here	O
the	O
search	O
of	O
the	O
coefficient	O
set	O
can	O
be	O
reduced	O
to	O
a	O
conditional	O
extremum	O
problem	O
.	O

The	O
A4	O
algorithm	O
uses	O
an	O
iterated	O
procedure	O
for	O
the	O
solution	O
of	O
this	O
problem	O
(	O
see	O
[	O
5	O
]	O
)	O
.	O

In	O
order	O
to	O
optimize	O
the	O
automated	O
annotation	O
procedure	O
,	O
that	O
is	O
to	O
increase	O
the	O
prediction	O
quality	O
,	O
certain	O
modifications	O
of	O
the	O
procedure	O
were	O
introduced	O
.	O

For	O
each	O
statistic	O
(	O
eta	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O
)	O
many	O
variants	O
(	O
up	O
to	O
36	O
)	O
,	O
including	O
the	O
variant	O
that	O
was	O
described	O
above	O
,	O
were	O
considered	O
-	O
each	O
variant	O
corresponds	O
to	O
a	O
certain	O
combination	O
of	O
these	O
modifications	O
.	O

Some	O
variants	O
really	O
turned	O
out	O
to	O
be	O
better	O
than	O
the	O
variants	O
described	O
above	O
.	O

A	O
simplified	O
scheme	O
of	O
modifications	O
(	O
and	O
thereby	O
of	O
statistic	O
variants	O
)	O
can	O
be	O
described	O
as	O
follows	O
.	O

1	O
)	O
What	O
primary	O
local	O
alignments	O
are	O
considered	O
?	O

In	O
the	O
described	O
variant	O
of	O
statistics	O
only	O
one	O
primary	O
local	O
alignment	O
(	O
the	O
one	O
with	O
the	O
maximum	O
power	O
)	O
was	O
considered	O
.	O

Meanwhile	O
,	O
all	O
constructed	O
local	O
alignments	O
with	O
sufficiently	O
high	O
power	O
can	O
be	O
considered	O
,	O
as	O
it	O
was	O
done	O
in	O
[	O
5	O
]	O
.	O

In	O
this	O
case	O
indices	O
i	O
in	O
(	O
9	O
)	O
,	O
(	O
12	O
)	O
,	O
(	O
15	O
)	O
correspond	O
not	O
to	O
individual	O
similar	O
sequences	O
,	O
but	O
to	O
primary	O
local	O
alignments	O
of	O
this	O
sequences	O
.	O

2	O
)	O
Are	O
the	O
lengths	O
of	O
primary	O
local	O
alignments	O
taken	O
into	O
consideration	O
?	O

In	O
the	O
described	O
variant	O
lengths	O
of	O
primary	O
local	O
alignments	O
were	O
not	O
taken	O
into	O
consideration	O
,	O
but	O
these	O
lengths	O
can	O
be	O
considered	O
as	O
well	O
.	O

In	O
this	O
case	O
indices	O
i	O
in	O
(	O
9	O
)	O
,	O
(	O
12	O
)	O
,	O
(	O
15	O
)	O
correspond	O
not	O
to	O
similar	O
sequences	O
or	O
primary	O
local	O
alignments	O
,	O
but	O
to	O
individual	O
positions	O
of	O
these	O
primary	O
local	O
alignments	O
(	O
as	O
in	O
case	O
of	O
FT	O
-	O
type	O
words	O
)	O
.	O

In	O
this	O
case	O
the	O
total	O
number	O
of	O
variates	O
xi	O
i	O
is	O
equal	O
to	O
the	O
overall	O
length	O
of	O
all	O
primary	O
local	O
alignments	O
.	O

For	O
these	O
variants	O
of	O
statistics	O
long	O
local	O
alignments	O
turn	O
out	O
to	O
be	O
more	O
significant	O
than	O
short	O
local	O
alignments	O
with	O
the	O
same	O
power	O
.	O

3	O
)	O
How	O
are	O
the	O
coefficients	O
ai	O
calculated	O
?	O

The	O
coefficients	O
ai	O
in	O
(	O
15	O
)	O
can	O
be	O
calculated	O
using	O
different	O
methods	O
-	O
either	O
formula	O
(	O
13	O
)	O
can	O
be	O
used	O
,	O
or	O
an	O
iterative	O
method	O
(	O
described	O
in	O
[	O
5	O
]	O
)	O
can	O
be	O
applied	O
.	O

(	O
For	O
the	O
statistic	O
T	O
(	O
1	O
)	O
the	O
coefficients	O
ai	O
are	O
always	O
calculated	O
using	O
formula	O
(	O
13	O
)	O
)	O
.	O

As	O
there	O
are	O
3	O
modifications	O
,	O
the	O
total	O
number	O
of	O
basic	O
variants	O
(	O
in	O
the	O
described	O
simplified	O
scheme	O
)	O
equals	O
23	O
=	O
8	O
(	O
and	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
it	O
equals	O
4	O
)	O
.	O

So	O
,	O
variants	O
of	O
the	O
statistics	O
eta	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O
are	O
considered	O
in	O
this	O
paper	O
.	O

Moreover	O
,	O
for	O
the	O
purpose	O
of	O
comparison	O
(	O
as	O
in	O
the	O
paper	O
[	O
5	O
]	O
)	O
the	O
simple	O
statistic	O

(	O
18	O
)	O
q	O
=	O
q	O
(	O
omega	O
)	O
=	O
sum	O
in	O
xi	O
in	O

(	O
the	O
frequency	O
of	O
occurrence	O
of	O
a	O
word	O
omega	O
in	O
the	O
collection	O
of	O
similar	O
sequences	O
)	O
is	O
also	O
considered	O
.	O

Finally	O
we	O
quote	O
a	O
scheme	O
of	O
the	O
A4	O
algorithm	O
in	O
Figure	O
1	O
(	O
this	O
scheme	O
is	O
essentially	O
taken	O
from	O
[	O
5	O
]	O
)	O
.	O

A	O
short	O
description	O
of	O
each	O
stage	O
can	O
be	O
found	O
in	O
[	O
5	O
]	O
.	O

Here	O
we	O
only	O
note	O
that	O
the	O
most	O
time	O
-	O
consuming	O
stage	O
is	O
the	O
first	O
one	O
-	O
the	O
generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
.	O

We	O
also	O
note	O
that	O
in	O
the	O
current	O
investigation	O
regions	O
were	O
not	O
determined	O
,	O
and	O
the	O
prediction	O
was	O
performed	O
for	O
the	O
whole	O
query	O
sequence	O
.	O

Testing	O
results	O

Testing	O
scheme	O

A	O
collection	O
of	O
518	O
sequences	O
,	O
randomly	O
selected	O
from	O
SWISS	O
-	O
PROT	O
databank	O
,	O
was	O
generated	O
.	O

Note	O
that	O
only	O
initially	O
annotated	O
sequences	O
(	O
i	O
.	O
e	O
.	O
,	O
sequences	O
whose	O
description	O
fields	O
were	O
not	O
obtained	O
by	O
the	O
extension	O
from	O
similar	O
sequences	O
)	O
were	O
selected	O
.	O

The	O
prediction	O
was	O
performed	O
for	O
KW	O
-	O
type	O
words	O
.	O

All	O
selected	O
sequences	O
were	O
divided	O
into	O
two	O
groups	O
.	O

The	O
first	O
group	O
contained	O
210	O
sequences	O
.	O

This	O
group	O
was	O
used	O
during	O
the	O
"	O
learning	O
stage	O
"	O
:	O
the	O
procedure	O
was	O
applied	O
to	O
all	O
sequences	O
from	O
the	O
group	O
,	O
and	O
values	O
of	O
procedure	O
parameters	O
(	O
including	O
optimal	O
threshold	O
values	O
)	O
that	O
minimize	O
the	O
total	O
number	O
of	O
errors	O
for	O
the	O
first	O
group	O
were	O
selected	O
.	O

The	O
remaining	O
308	O
sequences	O
were	O
used	O
for	O
the	O
"	O
main	O
testing	O
"	O
that	O
was	O
performed	O
using	O
parameter	O
values	O
obtained	O
on	O
the	O
basis	O
of	O
"	O
learning	O
"	O
results	O
.	O

A	O
list	O
of	O
all	O
these	O
308	O
sequences	O
is	O
given	O
in	O
Additional	O
file	O
1	O
.	O

The	O
total	O
number	O
of	O
KW	O
-	O
type	O
words	O
in	O
the	O
description	O
fields	O
of	O
308	O
selected	O
sequences	O
,	O
used	O
as	O
query	O
sequences	O
,	O
was	O
equal	O
to	O
1176	O
(	O
the	O
positive	O
prediction	O
was	O
preferable	O
for	O
these	O
words	O
)	O
.	O

As	O
it	O
was	O
noted	O
,	O
a	O
collection	O
of	O
similar	O
sequences	O
was	O
generated	O
for	O
each	O
query	O
sequence	O
;	O
the	O
number	O
of	O
sequences	O
in	O
these	O
collections	O
equaled	O
100	O
.	O

Then	O
the	O
list	O
of	O
all	O
KW	O
-	O
type	O
words	O
from	O
description	O
fields	O
of	O
similar	O
sequences	O
was	O
formed	O
.	O

The	O
majority	O
of	O
these	O
words	O
belonged	O
only	O
to	O
one	O
similar	O
sequence	O
.	O

All	O
such	O
words	O
are	O
degenerate	O
,	O
transfer	O
probabilities	O
are	O
not	O
defined	O
for	O
them	O
.	O

At	O
the	O
same	O
time	O
nearly	O
all	O
these	O
words	O
did	O
not	O
belong	O
to	O
the	O
query	O
sequence	O
.	O

Hence	O
it	O
was	O
sensible	O
to	O
perform	O
prediction	O
only	O
for	O
words	O
that	O
belonged	O
to	O
at	O
least	O
two	O
similar	O
sequences	O
.	O

For	O
all	O
these	O
words	O
transfer	O
probabilities	O
were	O
evaluated	O
,	O
non	O
-	O
degenerate	O
words	O
(	O
i	O
.	O
e	O
.	O
,	O
words	O
with	O
defined	O
transfer	O
probabilities	O
)	O
were	O
determined	O
,	O
and	O
the	O
prediction	O
was	O
performed	O
(	O
for	O
both	O
degenerate	O
and	O
non	O
-	O
degenerate	O
words	O
)	O
.	O

Table	O
1	O
shows	O
certain	O
characteristics	O
of	O
sequences	O
used	O
for	O
the	O
testing	O
.	O

The	O
average	O
number	O
of	O
words	O
considered	O
per	O
query	O
sequence	O
equals	O
30	O
and	O
the	O
entire	O
range	O
was	O
from	O
3	O
to	O
67	O
.	O

Final	O
results	O

Testing	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O

The	O
table	O
contains	O
testing	O
results	O
for	O
the	O
basic	O
statistics	O
eta	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O
as	O
well	O
as	O
for	O
the	O
statistics	O
q	O
and	O
SAnd	O
,	O
included	O
into	O
the	O
table	O
for	O
the	O
purpose	O
of	O
comparison	O
(	O
See	O
the	O
Discussion	O
section	O
)	O
.	O

Each	O
line	O
of	O
the	O
table	O
corresponds	O
to	O
a	O
certain	O
variant	O
of	O
studied	O
statistics	O
.	O

The	O
first	O
column	O
shows	O
which	O
statistic	O
and	O
which	O
variant	O
of	O
this	O
statistic	O
corresponds	O
to	O
a	O
line	O
.	O

Variants	O
are	O
given	O
in	O
square	O
brackets	O
:	O
the	O
first	O
number	O
equals	O
0	O
if	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
not	O
considered	O
,	O
and	O
1	O
otherwise	O
;	O
the	O
second	O
number	O
equals	O
0	O
if	O
the	O
coefficients	O
ai	O
are	O
calculated	O
using	O
formula	O
(	O
13	O
)	O
,	O
and	O
1	O
if	O
the	O
coefficients	O
ai	O
are	O
calculated	O
using	O
the	O
iterative	O
procedure	O
(	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
the	O
second	O
number	O
is	O
always	O
0	O
)	O
.	O

The	O
second	O
column	O
contains	O
the	O
number	O
N1	O
of	O
type	O
1	O
errors	O
(	O
i	O
.	O
e	O
.	O
,	O
number	O
of	O
cases	O
when	O
the	O
prediction	O
for	O
a	O
word	O
that	O
belongs	O
to	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
is	O
negative	O
)	O
.	O

The	O
third	O
column	O
contains	O
the	O
number	O
N2	O
of	O
type	O
2	O
errors	O
(	O
i	O
.	O
e	O
.	O
,	O
number	O
of	O
cases	O
when	O
the	O
prediction	O
for	O
a	O
word	O
that	O
does	O
not	O
belong	O
to	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
is	O
positive	O
)	O
.	O

The	O
forth	O
column	O
contains	O
the	O
total	O
number	O
of	O
errors	O
Nall	O
=	O
N1	O
+	O
N2	O
.	O

The	O
next	O
columns	O
contain	O
sums	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
and	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
+	O
)	O
,	O
where	O
P	O
(	O
1	O
)	O
is	O
the	O
proportion	O
of	O
type	O
1	O
errors	O
,	O
P	O
(	O
2	O
)	O
is	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
,	O
and	O
P	O
(	O
+	O
)	O
is	O
the	O
ratio	O
of	O
false	O
positive	O
predictions	O
to	O
the	O
total	O
number	O
of	O
predictions	O
:	O
P	O
(	O
1	O
)	O
=	O
N1nq	O
,	O
P	O
(	O
2	O
)	O
=	O
N2nall	O
-	O
nq	O
,	O
P	O
(	O
+	O
)	O
=	O
N2n	O
+	O
(	O
nall	O
is	O
the	O
total	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
is	O
performed	O
,	O
i	O
.	O
e	O
.	O
,	O
total	O
number	O
of	O
KW	O
-	O
type	O
words	O
in	O
description	O
fields	O
of	O
all	O
sequences	O
,	O
similar	O
to	O
at	O
least	O
one	O
query	O
sequence	O
,	O
nq	O
is	O
the	O
number	O
of	O
words	O
(	O
from	O
the	O
list	O
of	O
these	O
nall	O
words	O
)	O
that	O
belong	O
to	O
query	O
sequences	O
,	O
n	O
+	O
is	O
the	O
total	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
is	O
positive	O
;	O
here	O
nall	O
=	O
9236	O
,	O
nq	O
=	O
1176	O
,	O
nall	O
-	O
nq	O
=	O
8060	O
;	O
the	O
value	O
of	O
n	O
+	O
of	O
depends	O
on	O
the	O
threshold	O
evaluated	O
for	O
the	O
given	O
version	O
of	O
statistic	O
at	O
the	O
"	O
learning	O
stage	O
"	O
)	O
.	O

Lines	O
are	O
ordered	O
according	O
to	O
the	O
prediction	O
quality	O
:	O
higher	O
lines	O
correspond	O
to	O
statistic	O
variants	O
with	O
lower	O
total	O
number	O
of	O
errors	O
.	O

For	O
a	O
fixed	O
statistic	O
,	O
lines	O
that	O
correspond	O
to	O
the	O
best	O
variant	O
of	O
this	O
statistic	O
(	O
i	O
.	O
e	O
.	O
,	O
for	O
the	O
variant	O
that	O
leads	O
to	O
the	O
lowest	O
total	O
number	O
of	O
errors	O
)	O
are	O
marked	O
.	O

Recall	O
that	O
the	O
statistic	O
T	O
^	O
(	O
2	O
)	O
[	O
1	O
,	O
0	O
]	O
is	O
exactly	O
the	O
statistic	O
that	O
was	O
considered	O
in	O
[	O
5	O
]	O
(	O
note	O
that	O
it	O
is	O
the	O
best	O
variant	O
for	O
the	O
statistic	O
T	O
^	O
(	O
2	O
)	O
)	O
.	O

The	O
results	O
could	O
also	O
have	O
been	O
presented	O
as	O
a	O
confusion	O
table	O
as	O
laid	O
out	O
in	O
Table	O
3	O
,	O
but	O
doing	O
so	O
for	O
all	O
variants	O
would	O
take	O
a	O
lot	O
of	O
space	O
.	O

The	O
testing	O
results	O
showed	O
that	O
the	O
first	O
modification	O
(	O
consideration	O
of	O
all	O
primary	O
local	O
alignments	O
or	O
only	O
one	O
primary	O
local	O
alignment	O
with	O
the	O
maximum	O
power	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
prediction	O
quality	O
,	O
so	O
results	O
are	O
only	O
presented	O
for	O
one	O
case	O
(	O
all	O
local	O
alignments	O
are	O
considered	O
,	O
similarly	O
to	O
[	O
5	O
]	O
)	O
.	O

Note	O
that	O
the	O
results	O
presented	O
in	O
the	O
Table	O
correspond	O
to	O
the	O
whole	O
totality	O
of	O
words	O
including	O
degenerate	O
words	O
(	O
though	O
statistics	O
eta	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O
,	O
T	O
(	O
nik	O
)	O
were	O
evaluated	O
only	O
for	O
non	O
-	O
degenerate	O
words	O
,	O
for	O
degenerate	O
words	O
the	O
prediction	O
was	O
performed	O
on	O
the	O
basis	O
of	O
the	O
statistic	O
q	O
,	O
i	O
.	O
e	O
.	O
,	O
on	O
the	O
basis	O
of	O
word	O
frequency	O
)	O
.	O

In	O
particular	O
,	O
the	O
total	O
number	O
of	O
errors	O
includes	O
errors	O
for	O
degenerate	O
words	O
.	O

It	O
is	O
worth	O
noticing	O
that	O
the	O
total	O
number	O
of	O
errors	O
for	O
degenerate	O
words	O
in	O
case	O
of	O
the	O
best	O
choice	O
of	O
threshold	O
q0	O
for	O
the	O
frequency	O
q	O
(	O
omega	O
)	O
turned	O
out	O
to	O
be	O
surprisingly	O
small	O
:	O
only	O
13	O
(	O
whereas	O
the	O
number	O
of	O
errors	O
for	O
the	O
whole	O
totality	O
of	O
words	O
was	O
220	O
)	O
;	O
these	O
errors	O
included	O
twelve	O
type	O
1	O
errors	O
and	O
one	O
type	O
2	O
error	O
(	O
recall	O
that	O
the	O
prediction	O
was	O
performed	O
for	O
2029	O
degenerate	O
words	O
,	O
and	O
the	O
prediction	O
was	O
incorrect	O
only	O
in	O
13	O
cases	O
)	O
.	O

Such	O
a	O
small	O
number	O
of	O
errors	O
can	O
seemingly	O
be	O
explained	O
by	O
the	O
fact	O
that	O
for	O
degenerate	O
words	O
the	O
frequency	O
q	O
(	O
omega	O
)	O
is	O
nearly	O
always	O
close	O
either	O
to	O
1	O
or	O
to	O
0	O
,	O
otherwise	O
in	O
almost	O
all	O
cases	O
transfer	O
probabilities	O
p1	O
|	O
1	O
,	O
p1	O
|	O
0	O
can	O
be	O
defined	O
for	O
at	O
least	O
some	O
values	O
of	O
similarity	O
measure	O
mu	O
and	O
hence	O
a	O
word	O
omega	O
turns	O
out	O
to	O
be	O
non	O
-	O
degenerate	O
.	O

We	O
also	O
note	O
that	O
along	O
with	O
type	O
1	O
and	O
type	O
2	O
errors	O
other	O
errors	O
can	O
occur	O
,	O
as	O
it	O
is	O
possible	O
that	O
some	O
words	O
from	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
do	O
not	O
belong	O
to	O
description	O
fields	O
of	O
similar	O
sequences	O
and	O
hence	O
the	O
prediction	O
is	O
not	O
performed	O
for	O
these	O
words	O
at	O
all	O
.	O

However	O
,	O
we	O
used	O
a	O
large	O
number	O
of	O
similar	O
sequences	O
(	O
100	O
)	O
for	O
the	O
prediction	O
,	O
so	O
such	O
errors	O
were	O
extremely	O
rare	O
(	O
only	O
two	O
words	O
for	O
the	O
whole	O
test	O
set	O
of	O
518	O
sequences	O
,	O
whereas	O
the	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
was	O
performed	O
equaled	O
9236	O
)	O
.	O

Hence	O
,	O
in	O
our	O
case	O
these	O
errors	O
can	O
be	O
disregarded	O
.	O

Statistical	O
analysis	O
showed	O
that	O
the	O
precision	O
of	O
the	O
evaluation	O
of	O
N1	O
,	O
N2	O
,	O
Nall	O
is	O
reasonable	O
:	O
it	O
can	O
be	O
checked	O
that	O
the	O
relative	O
precision	O
of	O
Nall	O
(	O
the	O
standard	O
error	O
of	O
ln	O
(	O
Nall	O
)	O
)	O
is	O
in	O
the	O
order	O
of	O
7	O
-	O
10	O
%	O
which	O
is	O
in	O
line	O
with	O
the	O
relative	O
precision	O
of	O
a	O
Poisson	O
random	O
variable	O
that	O
is	O
given	O
by	O
1	O
/	O
Nall	O
.	O

However	O
,	O
since	O
the	O
"	O
methods	O
"	O
(	O
the	O
statistics	O
and	O
their	O
variants	O
)	O
are	O
compared	O
on	O
the	O
same	O
sequences	O
,	O
the	O
standard	O
error	O
for	O
the	O
comparison	O
between	O
methods	O
is	O
much	O
smaller	O
due	O
to	O
the	O
high	O
correlation	O
of	O
results	O
for	O
the	O
same	O
sequence	O
and	O
is	O
in	O
the	O
order	O
of	O
2	O
-	O
4	O
%	O
.	O

This	O
implies	O
that	O
"	O
methods	O
"	O
for	O
which	O
Nall	O
differ	O
by	O
more	O
than	O
10	O
%	O
can	O
considered	O
to	O
be	O
significantly	O
different	O
.	O

This	O
shows	O
that	O
size	O
of	O
the	O
experiment	O
with	O
210	O
randomly	O
selected	O
sequences	O
in	O
the	O
learning	O
stage	O
and	O
308	O
sequences	O
in	O
the	O
testing	O
stage	O
is	O
large	O
enough	O
to	O
obtain	O
valid	O
statements	O
about	O
the	O
accuracy	O
of	O
the	O
proposed	O
methodology	O
and	O
allows	O
statistical	O
comparisons	O
of	O
different	O
statistics	O
and	O
variants	O
.	O

When	O
the	O
set	O
of	O
tested	O
sequences	O
is	O
fixed	O
,	O
the	O
total	O
number	O
of	O
errors	O
Nall	O
is	O
an	O
objective	O
characteristic	O
of	O
prediction	O
quality	O
,	O
and	O
the	O
optimal	O
threshold	O
values	O
(	O
selected	O
during	O
the	O
"	O
learning	O
stage	O
"	O
)	O
provide	O
exactly	O
the	O
minimum	O
of	O
the	O
total	O
number	O
of	O
errors	O
.	O

However	O
,	O
if	O
different	O
testing	O
results	O
(	O
based	O
on	O
different	O
sets	O
of	O
query	O
sequences	O
)	O
are	O
compared	O
,	O
then	O
absolute	O
numbers	O
of	O
errors	O
can	O
not	O
be	O
treated	O
as	O
a	O
procedure	O
quality	O
measure	O
,	O
and	O
relative	O
quantities	O
(	O
proportions	O
)	O
should	O
be	O
considered	O
instead	O
of	O
absolute	O
quantities	O
.	O

Usually	O
a	O
sum	O
of	O
the	O
proportion	O
of	O
type	O
1	O
errors	O
and	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
is	O
used	O
as	O
a	O
quality	O
measure	O
;	O
values	O
of	O
this	O
sum	O
are	O
presented	O
in	O
the	O
fifth	O
column	O
of	O
Table	O
2	O
.	O

However	O
,	O
in	O
our	O
situation	O
the	O
number	O
of	O
words	O
nall	O
-	O
nq	O
that	O
do	O
not	O
belong	O
to	O
query	O
sequences	O
is	O
much	O
larger	O
than	O
nq	O
,	O
and	O
for	O
the	O
majority	O
of	O
these	O
words	O
it	O
is	O
obvious	O
that	O
they	O
do	O
not	O
belong	O
to	O
a	O
query	O
sequence	O
.	O

Consequently	O
,	O
in	O
case	O
of	O
optimal	O
parameter	O
values	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
P	O
(	O
2	O
)	O
is	O
small	O
,	O
it	O
is	O
considerably	O
smaller	O
than	O
P	O
(	O
1	O
)	O
.	O

Thus	O
the	O
quantity	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
is	O
not	O
representative	O
in	O
our	O
case	O
(	O
see	O
[	O
5	O
]	O
)	O
.	O

The	O
ratio	O
P	O
(	O
+	O
)	O
of	O
the	O
number	O
of	O
wrong	O
positive	O
predictions	O
to	O
the	O
total	O
number	O
of	O
positive	O
predictions	O
is	O
more	O
representative	O
than	O
P	O
(	O
2	O
)	O
.	O

Hence	O
,	O
it	O
is	O
natural	O
to	O
measure	O
procedure	O
quality	O
by	O
the	O
sum	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
+	O
)	O
.	O

Exactly	O
this	O
procedure	O
quality	O
measure	O
was	O
used	O
in	O
[	O
5	O
]	O
.	O

In	O
medical	O
decision	O
making	O
(	O
diagnostic	O
testing	O
)	O
the	O
terms	O
sensitivity	O
(	O
sens	O
=	O
1	O
-	O
P	O
(	O
1	O
)	O
)	O
and	O
specificity	O
(	O
spec	O
=	O
1	O
-	O
P	O
(	O
2	O
)	O
)	O
are	O
frequently	O
used	O
to	O
quantify	O
the	O
accuracy	O
of	O
a	O
procedure	O
,	O
while	O
the	O
quantity	O
1	O
-	O
P	O
(	O
+	O
)	O
is	O
known	O
as	O
the	O
positive	O
predictive	O
value	O
.	O

Alternative	O
terminology	O
is	O
discussed	O
in	O
[	O
12	O
]	O
.	O

The	O
ROC	O
curve	O
plotting	O
sens	O
against	O
1	O
-	O
spec	O
is	O
a	O
popular	O
way	O
of	O
showing	O
the	O
overall	O
performance	O
of	O
a	O
diagnostic	O
test	O
without	O
specification	O
of	O
a	O
cut	O
off	O
value	O
.	O

It	O
is	O
also	O
used	O
and	O
discussed	O
in	O
[	O
12	O
]	O
,	O
but	O
with	O
different	O
labels	O
for	O
the	O
axes	O
.	O

Figure	O
2	O
contains	O
ROC	O
curves	O
for	O
the	O
best	O
variants	O
of	O
the	O
statistics	O
(	O
i	O
.	O
e	O
.	O
,	O
for	O
variants	O
that	O
were	O
marked	O
in	O
Table	O
2	O
)	O
applied	O
to	O
the	O
non	O
-	O
degenerate	O
words	O
.	O

Discussion	O

Overall	O
comparison	O
of	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
eta	O
,	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O

Mean	O
values	O
of	O
Nall	O
(	O
where	O
averaging	O
is	O
performed	O
over	O
all	O
variants	O
presented	O
in	O
Table	O
2	O
)	O
for	O
different	O
statistics	O
are	O
the	O
following	O
:	O
241	O
for	O
eta	O
,	O
310	O
for	O
T	O
(	O
1	O
)	O
,	O
320	O
for	O
T	O
(	O
2	O
)	O
,	O
and	O
356	O
for	O
T	O
^	O
(	O
2	O
)	O
(	O
recall	O
that	O
differences	O
in	O
the	O
order	O
of	O
10	O
%	O
can	O
be	O
considered	O
to	O
be	O
significant	O
)	O
.	O

These	O
numbers	O
show	O
that	O
the	O
statistics	O
can	O
clearly	O
be	O
ordered	O
with	O
respect	O
to	O
the	O
prediction	O
quality	O
:	O
the	O
best	O
statistic	O
is	O
eta	O
,	O
then	O
comes	O
T	O
(	O
1	O
)	O
,	O
then	O
T	O
(	O
2	O
)	O
,	O
and	O
finally	O
T	O
^	O
(	O
2	O
)	O
.	O

For	O
the	O
comparison	O
of	O
the	O
statistics	O
eta	O
,	O
T	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
for	O
the	O
comparison	O
of	O
statistics	O
the	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O
this	O
conclusion	O
is	O
obvious	O
.	O

For	O
the	O
comparison	O
of	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
it	O
seems	O
to	O
be	O
less	O
obvious	O
,	O
but	O
the	O
consideration	O
of	O
variants	O
in	O
which	O
the	O
calculation	O
of	O
coefficients	O
ai	O
is	O
performed	O
using	O
formula	O
(	O
13	O
)	O
(	O
i	O
.	O
e	O
.	O
,	O
variants	O
[	O
0	O
,	O
0	O
]	O
and	O
[	O
1	O
,	O
0	O
]	O
;	O
recall	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
has	O
only	O
such	O
variants	O
)	O
clearly	O
shows	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
considerably	O
better	O
than	O
T	O
(	O
2	O
)	O
.	O

The	O
same	O
conclusion	O
can	O
be	O
drawn	O
from	O
the	O
comparison	O
of	O
ROC	O
curves	O
presented	O
in	O
Fig	O
.	O

2	O
.	O

Testing	O
results	O
show	O
that	O
the	O
prediction	O
quality	O
for	O
the	O
best	O
variant	O
of	O
the	O
statistic	O
eta	O
(	O
see	O
the	O
first	O
line	O
of	O
Table	O
2	O
)	O
is	O
much	O
higher	O
(	O
higher	O
by	O
50	O
%	O
)	O
in	O
comparison	O
with	O
results	O
of	O
[	O
5	O
]	O
(	O
see	O
the	O
line	O
of	O
Table	O
2	O
that	O
corresponds	O
to	O
T	O
^	O
(	O
2	O
)	O
[	O
0	O
,	O
1	O
]	O
)	O
.	O

That	O
is	O
the	O
most	O
striking	O
finding	O
of	O
the	O
current	O
paper	O
.	O

It	O
is	O
interesting	O
to	O
see	O
that	O
the	O
statistic	O
eta	O
turned	O
out	O
to	O
be	O
better	O
than	O
T	O
(	O
1	O
)	O
:	O
the	O
latter	O
would	O
be	O
expected	O
to	O
be	O
better	O
as	O
it	O
equals	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
(	O
in	O
reality	O
,	O
it	O
does	O
not	O
equal	O
this	O
logarithm	O
because	O
the	O
xi	O
i	O
are	O
not	O
independent	O
)	O
.	O

We	O
suppose	O
that	O
this	O
fact	O
can	O
be	O
explained	O
as	O
follows	O
.	O

Recall	O
that	O
T	O
(	O
1	O
)	O
and	O
eta	O
are	O
equivalent	O
for	O
an	O
arbitrary	O
fixed	O
word	O
omega	O
.	O

These	O
statistics	O
turn	O
out	O
to	O
be	O
not	O
equivalent	O
only	O
if	O
they	O
are	O
compared	O
on	O
the	O
whole	O
totality	O
of	O
words	O
.	O

It	O
is	O
worth	O
noting	O
that	O
the	O
variation	O
of	O
the	O
values	O
of	O
the	O
statistic	O
T	O
(	O
1	O
)	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
difference	O
between	O
values	O
of	O
T	O
(	O
1	O
)	O
in	O
cases	O
xi	O
1	O
=	O
.	O
.	O
.	O
.	O
=	O
xi	O
n	O
=	O
0	O
and	O
xi	O
1	O
=	O
.	O
.	O
.	O
.	O
=	O
xi	O
n	O
=	O
1	O
)	O
significantly	O
depends	O
on	O
a	O
word	O
omega	O
:	O
for	O
some	O
words	O
these	O
values	O
vary	O
from	O
-	O
700	O
to	O
700	O
,	O
for	O
some	O
other	O
from	O
-	O
0	O
.	O
01	O
to	O
0	O
.	O
01	O
.	O

In	O
principle	O
,	O
the	O
optimal	O
threshold	O
value	O
is	O
different	O
for	O
different	O
words	O
.	O

As	O
the	O
ranges	O
of	O
T	O
(	O
1	O
)	O
values	O
essentially	O
vary	O
,	O
then	O
it	O
is	O
probable	O
that	O
optimal	O
thresholds	O
also	O
essentially	O
vary	O
.	O

The	O
optimal	O
threshold	O
for	O
the	O
whole	O
totality	O
of	O
words	O
is	O
a	O
certain	O
mean	O
value	O
of	O
thresholds	O
over	O
individual	O
words	O
omega	O
.	O

Since	O
the	O
optimal	O
thresholds	O
are	O
significantly	O
different	O
for	O
different	O
words	O
,	O
the	O
quality	O
of	O
the	O
mean	O
is	O
low	O
:	O
for	O
certain	O
words	O
(	O
e	O
.	O
g	O
.	O
,	O
words	O
with	O
small	O
variation	O
of	O
T	O
(	O
1	O
)	O
)	O
this	O
mean	O
is	O
completely	O
unrepresentative	O
.	O

In	O
the	O
same	O
time	O
,	O
the	O
range	O
of	O
values	O
of	O
eta	O
is	O
the	O
same	O
for	O
all	O
words	O
(	O
these	O
values	O
lie	O
between	O
0	O
and	O
1	O
)	O
.	O

Consequently	O
,	O
the	O
difference	O
between	O
optimal	O
thresholds	O
for	O
individual	O
words	O
is	O
probably	O
not	O
so	O
significant	O
,	O
and	O
the	O
mean	O
gives	O
better	O
quality	O
for	O
individual	O
words	O
in	O
comparison	O
with	O
T	O
(	O
1	O
)	O
.	O

From	O
the	O
point	O
of	O
view	O
of	O
prediction	O
quality	O
the	O
statistic	O
T	O
(	O
2	O
)	O
turned	O
out	O
to	O
be	O
worse	O
than	O
T	O
(	O
1	O
)	O
.	O

It	O
is	O
not	O
surprising	O
,	O
because	O
during	O
the	O
derivation	O
of	O
the	O
formula	O
for	O
T	O
(	O
2	O
)	O
along	O
with	O
the	O
incorrect	O
assumption	O
of	O
independence	O
of	O
xi	O
i	O
we	O
also	O
made	O
the	O
incorrect	O
assumption	O
of	O
the	O
normal	O
distribution	O
of	O
eta	O
.	O

This	O
consideration	O
is	O
applicable	O
to	O
T	O
^	O
(	O
2	O
)	O
as	O
well	O
.	O

Since	O
the	O
cut	O
-	O
off	O
points	O
for	O
these	O
statistics	O
are	O
determined	O
empirically	O
in	O
the	O
test	O
set	O
and	O
validated	O
in	O
the	O
training	O
set	O
,	O
the	O
violation	O
of	O
the	O
normality	O
assumption	O
does	O
not	O
invalidate	O
the	O
procedures	O
as	O
such	O
,	O
but	O
might	O
affect	O
their	O
performance	O
.	O

Effect	O
of	O
procedure	O
modifications	O

The	O
next	O
issue	O
is	O
the	O
dependence	O
of	O
prediction	O
quality	O
on	O
procedure	O
modifications	O
.	O

One	O
can	O
see	O
that	O
for	O
a	O
fixed	O
statistic	O
the	O
prediction	O
quality	O
significantly	O
depends	O
on	O
the	O
choice	O
of	O
the	O
variant	O
.	O

Thus	O
,	O
the	O
introduction	O
of	O
modifications	O
turned	O
out	O
to	O
be	O
effective	O
.	O

It	O
is	O
interesting	O
that	O
all	O
statistics	O
for	O
which	O
coefficients	O
aj	O
can	O
be	O
calculated	O
in	O
different	O
ways	O
(	O
these	O
are	O
the	O
statistics	O
eta	O
,	O
T	O
(	O
2	O
)	O
T	O
^	O
(	O
2	O
)	O
)	O
prediction	O
quality	O
was	O
better	O
in	O
case	O
when	O
these	O
coefficients	O
were	O
calculated	O
using	O
the	O
iterative	O
procedure	O
.	O

At	O
the	O
same	O
time	O
the	O
dependence	O
of	O
prediction	O
quality	O
on	O
the	O
modification	O
related	O
to	O
the	O
consideration	O
of	O
lengths	O
of	O
primary	O
local	O
alignments	O
is	O
more	O
intricate	O
:	O
for	O
the	O
statistic	O
eta	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
for	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
the	O
results	O
are	O
better	O
if	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
considered	O
,	O
but	O
for	O
the	O
statistic	O
T	O
^	O
(	O
2	O
)	O
results	O
are	O
better	O
when	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
not	O
considered	O
.	O

Currently	O
reasons	O
of	O
this	O
fact	O
are	O
not	O
clear	O
for	O
us	O
.	O

As	O
it	O
was	O
noted	O
,	O
the	O
dependence	O
of	O
results	O
on	O
modifications	O
dealing	O
with	O
the	O
number	O
of	O
considered	O
primary	O
local	O
alignments	O
for	O
similar	O
sequences	O
is	O
not	O
essential	O
.	O

(	O
However	O
,	O
we	O
note	O
that	O
for	O
nearly	O
all	O
variants	O
that	O
were	O
described	O
above	O
as	O
well	O
as	O
variants	O
that	O
were	O
not	O
described	O
,	O
prediction	O
quality	O
is	O
better	O
in	O
case	O
when	O
all	O
primary	O
local	O
alignments	O
are	O
considered	O
)	O
.	O

Comparison	O
with	O
other	O
procedures	O

For	O
the	O
purpose	O
of	O
comparison	O
we	O
compared	O
our	O
findings	O
with	O
the	O
simple	O
statistic	O
q	O
(	O
omega	O
)	O
(	O
the	O
frequency	O
of	O
word	O
occurrence	O
in	O
the	O
list	O
of	O
similar	O
sequences	O
,	O
see	O
(	O
18	O
)	O
)	O
was	O
also	O
considered	O
,	O
using	O
a	O
threshold	O
of	O
q	O
=	O
0	O
.	O
422	O
.	O

As	O
expected	O
,	O
q	O
(	O
omega	O
)	O
gave	O
essentially	O
worse	O
results	O
in	O
comparison	O
with	O
T	O
(	O
1	O
)	O
,	O
eta	O
,	O
T	O
(	O
2	O
)	O
,	O
T	O
^	O
(	O
2	O
)	O
(	O
see	O
Table	O
2	O
)	O
.	O

Furthermore	O
,	O
we	O
compared	O
our	O
results	O
with	O
the	O
results	O
,	O
which	O
predicts	O
all	O
of	O
the	O
words	O
for	O
which	O
there	O
is	O
among	O
similar	O
sequences	O
at	O
least	O
one	O
sequence	O
with	O
a	O
power	O
above	O
a	O
certain	O
threshold	O
.	O

Such	O
an	O
approach	O
was	O
used	O
by	O
Andrade	O
M	O
.	O

et	O
al	O
.	O

[	O
2	O
]	O
.	O

This	O
is	O
the	O
statistics	O
SAnd	O
as	O
already	O
mentioned	O
in	O
Table	O
2	O
.	O

It	O
is	O
defined	O
as	O
SAnd	O
(	O
omega	O
)	O
=	O
max	O
mu	O
j	O
,	O
where	O
mu	O
j	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
pi	O
0	O
,	O
pi	O
j	O
,	O
and	O
the	O
maximum	O
is	O
taken	O
on	O
the	O
j	O
for	O
which	O
xi	O
j	O
(	O
omega	O
)	O
=	O
1	O
(	O
i	O
.	O
e	O
.	O
the	O
word	O
belongs	O
to	O
these	O
sequences	O
)	O
.	O

In	O
our	O
application	O
similarity	O
is	O
measured	O
by	O
the	O
power	O
value	O
(	O
see	O
[	O
9	O
,	O
10	O
]	O
)	O
as	O
used	O
in	O
the	O
other	O
statistics	O
in	O
this	O
paper	O
and	O
mentioned	O
before	O
,	O
while	O
[	O
2	O
]	O
used	O
the	O
E	O
-	O
value	O
.	O

That	O
makse	O
the	O
cut	O
-	O
offs	O
hard	O
to	O
compare	O
.	O

The	O
results	O
for	O
these	O
statistics	O
are	O
given	O
in	O
the	O
same	O
Table	O
2	O
.	O

The	O
results	O
were	O
better	O
than	O
in	O
the	O
statistics	O
q	O
(	O
omega	O
)	O
,	O
but	O
worse	O
than	O
in	O
any	O
of	O
our	O
statistics	O
.	O

Surprisingly	O
,	O
it	O
turned	O
out	O
that	O
the	O
prediction	O
quality	O
is	O
better	O
when	O
only	O
some	O
similar	O
sequences	O
(	O
e	O
.	O
g	O
.	O
,	O
10	O
from	O
100	O
)	O
are	O
used	O
for	O
the	O
evaluation	O
of	O
a	O
statistic	O
(	O
but	O
not	O
for	O
the	O
evaluation	O
of	O
transfer	O
probabilities	O
!	O
)	O
.	O

It	O
means	O
that	O
a	O
large	O
part	O
of	O
similar	O
sequences	O
only	O
leads	O
to	O
an	O
increase	O
of	O
"	O
noise	O
"	O
.	O

(	O
See	O
[	O
13	O
]	O
for	O
details	O
.	O
)	O

We	O
would	O
also	O
like	O
to	O
mention	O
the	O
work	O
[	O
14	O
]	O
on	O
FunCat	O
categories	O
containing	O
a	O
set	O
of	O
about	O
7	O
,	O
500	O
well	O
annotated	O
proteins	O
and	O
providing	O
a	O
benchmarking	O
for	O
different	O
methods	O
of	O
automated	O
annotation	O
.	O

It	O
would	O
be	O
interesting	O
to	O
apply	O
our	O
procedure	O
to	O
this	O
database	O
,	O
but	O
that	O
has	O
not	O
been	O
realized	O
yet	O
.	O

We	O
did	O
not	O
attempt	O
at	O
this	O
stage	O
to	O
apply	O
our	O
approach	O
to	O
the	O
GO	O
annotation	O
.	O

It	O
would	O
be	O
interesting	O
further	O
research	O
to	O
switch	O
to	O
GO	O
data	O
and	O
to	O
compare	O
our	O
approach	O
with	O
other	O
approaches	O
in	O
the	O
literature	O
.	O

There	O
is	O
a	O
similarity	O
with	O
the	O
approach	O
of	O
Kajan	O
et	O
al	O
.	O

[	O
15	O
]	O
.	O

They	O
also	O
base	O
their	O
procedures	O
on	O
the	O
likelihood	O
ratio	O
,	O
but	O
use	O
approximations	O
based	O
on	O
maximal	O
similarity	O
(	O
or	O
minimal	O
distance	O
)	O
,	O
while	O
we	O
attempt	O
to	O
estimate	O
the	O
likelihood	O
ratio	O
from	O
pairwise	O
comparisons	O
within	O
the	O
set	O
of	O
similar	O
sequences	O
.	O

There	O
is	O
also	O
an	O
interesting	O
relation	O
with	O
the	O
GOPET	O
tool	O
presented	O
in	O
[	O
16	O
]	O
based	O
on	O
earlier	O
work	O
by	O
the	O
same	O
authors	O
[	O
17	O
]	O
.	O

These	O
authors	O
use	O
a	O
number	O
of	O
characteristics	O
of	O
the	O
set	O
of	O
found	O
similar	O
sequences	O
for	O
term	O
(	O
word	O
)	O
,	O
such	O
as	O
maximal	O
e	O
-	O
value	O
,	O
frequency	O
of	O
the	O
term	O
etc	O
.	O
,	O
as	O
a	O
coordinates	O
of	O
decision	O
making	O
space	O
.	O

They	O
use	O
more	O
features	O
while	O
we	O
concentrate	O
on	O
the	O
similarity	O
.	O

That	O
might	O
be	O
an	O
advantage	O
for	O
their	O
method	O
.	O

On	O
the	O
other	O
hand	O
we	O
try	O
to	O
use	O
the	O
information	O
from	O
all	O
similar	O
sequences	O
in	O
an	O
optimal	O
way	O
relying	O
on	O
statistical	O
decision	O
theory	O
by	O
means	O
of	O
the	O
use	O
of	O
transfer	O
probabilities	O
and	O
the	O
concept	O
of	O
likelihood	O
ratio	O
.	O

It	O
is	O
an	O
interesting	O
topic	O
of	O
further	O
research	O
to	O
compare	O
the	O
two	O
methods	O
.	O

So	O
far	O
we	O
only	O
predicted	O
the	O
presence	O
of	O
a	O
key	O
word	O
.	O

It	O
is	O
quite	O
a	O
challenge	O
to	O
obtain	O
a	O
true	O
prediction	O
of	O
function	O
.	O

Conclusion	O

The	O
main	O
conclusion	O
of	O
the	O
paper	O
is	O
that	O
the	O
introduction	O
of	O
the	O
concept	O
of	O
likelihood	O
ratio	O
coming	O
from	O
statistical	O
decision	O
theory	O
is	O
very	O
helpful	O
in	O
the	O
development	O
of	O
automated	O
annotation	O
procedures	O
.	O

We	O
obtained	O
a	O
substantial	O
improvement	O
when	O
compared	O
with	O
our	O
previous	O
results	O
.	O

We	O
are	O
sure	O
that	O
there	O
is	O
room	O
for	O
further	O
improvement	O
.	O

Issues	O
for	O
further	O
research	O
are	O
the	O
size	O
of	O
the	O
set	O
of	O
similar	O
sequences	O
and	O
the	O
combination	O
of	O
different	O
statistics	O
into	O
a	O
"	O
super	O
-	O
predictor	O
"	O
.	O

Authors	O
'	O
contributions	O

A	O
.	O
M	O
.	O

Leontovich	O
and	O
H	O
.	O
C	O
.	O
van	O
Houwelingen	O
developed	O
the	O
approach	O
.	O

A	O
.	O
M	O
.	O

Leontovich	O
developed	O
the	O
methodology	O
and	O
the	O
algorithms	O
in	O
cooperation	O
with	O
K	O
.	O
Y	O
.	O

Tokmachev	O
and	O
H	O
.	O
C	O
.	O
van	O
Houwelingen	O
.	O

K	O
.	O
Y	O
.	O

Tokmachev	O
carried	O
out	O
all	O
computations	O
.	O

Supplementary	O
Material	O

Borrelia	B-Species
burgdorferi	E-Species
membranes	O
are	O
the	O
primary	O
targets	O
of	O
reactive	O
oxygen	O
species	O

Abstract	O

Spirochetes	O
living	O
in	O
an	O
oxygen	O
-	O
rich	O
environment	O
or	O
when	O
challenged	O
by	O
host	O
immune	O
cells	O
are	O
exposed	O
to	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

These	O
species	O
can	O
harm	O
/	O
destroy	O
cysteinyl	O
residues	O
,	O
iron	O
-	O
sulphur	O
clusters	O
,	O
DNA	O
and	O
polyunsaturated	O
lipids	O
,	O
leading	O
to	O
inhibition	O
of	O
growth	O
or	O
cell	O
death	O
.	O

Because	O
Borrelia	B-Species
burgdorferi	E-Species
contains	O
no	O
intracellular	O
iron	O
,	O
DNA	O
is	O
most	O
likely	O
not	O
a	O
major	O
target	O
for	O
ROS	O
via	O
Fenton	O
reaction	O
.	O

In	O
support	O
of	O
this	O
,	O
growth	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
in	O
the	O
presence	O
of	O
5	O
mM	O
H2O2	O
had	O
no	O
effect	O
on	O
the	O
DNA	O
mutation	O
rate	O
(	O
spontaneous	O
coumermycin	O
A1	O
resistance	O
)	O
,	O
and	O
cells	O
treated	O
with	O
10	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
or	O
10	O
mM	O
H2O2	O
show	O
no	O
increase	O
in	O
DNA	O
damage	O
.	O

Unlike	O
most	O
bacteria	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
incorporates	O
ROS	O
-	O
susceptible	O
polyunsaturated	O
fatty	O
acids	O
from	O
the	O
environment	O
into	O
their	O
membranes	O
.	O

Analysis	O
of	O
lipoxidase	O
-	O
treated	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
by	O
Electron	O
Microscopy	O
showed	O
significant	O
irregularities	O
indicative	O
of	O
membrane	O
damage	O
.	O

Fatty	O
acid	O
analysis	O
of	O
cells	O
treated	O
with	O
lipoxidase	O
indicated	O
that	O
host	O
-	O
derived	O
linoleic	O
acid	O
had	O
been	O
dramatically	O
reduced	O
(	O
50	O
-	O
fold	O
)	O
in	O
these	O
cells	O
,	O
with	O
a	O
corresponding	O
increase	O
in	O
the	O
levels	O
of	O
malondialdehyde	O
by	O
-	O
product	O
(	O
fourfold	O
)	O
.	O

These	O
data	O
suggest	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
membrane	O
lipids	O
are	O
targets	O
for	O
attack	O
by	O
ROS	O
encountered	O
in	O
the	O
various	O
stages	O
of	O
the	O
infective	O
cycle	O
.	O

Introduction	O

Borrelia	B-Species
burgdorferi	E-Species
,	O
the	O
causative	O
agent	O
of	O
Lyme	O
disease	O
,	O
survives	O
and	O
proliferates	O
in	O
distinctly	O
different	O
niches	O
,	O
including	O
its	O
arthropod	O
vector	O
and	O
various	O
mammalian	O
hosts	O
.	O

These	O
'	O
micro	O
'	O
environments	O
provide	O
their	O
own	O
distinct	O
sets	O
of	O
advantages	O
and	O
challenges	O
to	O
B	B-Species
.	I-Species
burgdorferi	E-Species
.	O

For	O
example	O
,	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
the	O
mammalian	O
host	O
,	O
immune	O
cells	O
attempt	O
to	O
prevent	O
B	B-Species
.	I-Species
burgdorferi	E-Species
from	O
establishing	O
an	O
infection	O
using	O
several	O
systems	O
including	O
those	O
generating	O
bacteriocidal	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
[	O
e	O
.	O
g	O
.	O
superoxide	O
radicals	O
(	O
O2	O
-	O
)	O
,	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
and	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
]	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	O
)	O
[	O
e	O
.	O
g	O
.	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
peroxynitrite	O
]	O
(	O
Storz	O
and	O
Imlay	O
,	O
1999	O
)	O
.	O

In	O
order	O
for	O
B	B-Species
.	I-Species
burgdorferi	E-Species
to	O
successfully	O
colonize	O
a	O
new	O
host	O
and	O
cause	O
disease	O
,	O
they	O
must	O
overcome	O
the	O
challenges	O
posed	O
by	O
the	O
innate	O
immune	O
system	O
including	O
the	O
deleterious	O
effects	O
of	O
ROS	O
/	O
RNS	O
compounds	O
.	O

The	O
effects	O
of	O
ROS	O
/	O
RNS	O
on	O
cells	O
have	O
been	O
extensively	O
investigated	O
.	O

These	O
highly	O
reactive	O
compounds	O
have	O
been	O
shown	O
to	O
damage	O
cellular	O
macromolecules	O
including	O
DNA	O
,	O
proteins	O
and	O
cellular	O
membranes	O
.	O

The	O
damage	O
to	O
membranes	O
can	O
arise	O
through	O
either	O
lipid	O
or	O
membrane	O
protein	O
damage	O
.	O

In	O
eukaryotes	O
,	O
membrane	O
lipids	O
are	O
a	O
major	O
target	O
of	O
ROS	O
.	O

Free	O
radicals	O
attack	O
polyunsaturated	O
fatty	O
acids	O
in	O
membranes	O
and	O
initiate	O
lipid	O
peroxidation	O
.	O

A	O
primary	O
effect	O
of	O
this	O
is	O
a	O
decrease	O
in	O
membrane	O
fluidity	O
which	O
affects	O
the	O
physical	O
properties	O
of	O
the	O
membrane	O
altering	O
the	O
function	O
of	O
membrane	O
-	O
associated	O
proteins	O
.	O

Once	O
lipid	O
peroxides	O
form	O
,	O
they	O
react	O
with	O
adjacent	O
polyunsaturated	O
lipids	O
causing	O
an	O
amplification	O
of	O
the	O
damage	O
.	O

Lipid	O
peroxides	O
undergo	O
further	O
oxidation	O
to	O
a	O
variety	O
of	O
products	O
,	O
including	O
aldehydes	O
,	O
which	O
subsequently	O
react	O
with	O
and	O
damage	O
membrane	O
proteins	O
.	O

However	O
,	O
in	O
bacteria	O
,	O
it	O
is	O
assumed	O
that	O
lipids	O
are	O
not	O
subject	O
to	O
the	O
oxidative	O
damage	O
observed	O
in	O
eukaryotic	O
cells	O
.	O

Only	O
certain	O
polyunsaturated	O
lipids	O
,	O
such	O
as	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
,	O
are	O
susceptible	O
to	O
oxidation	O
(	O
Gutteridge	O
and	O
Halliwell	O
,	O
1990	O
)	O
,	O
and	O
it	O
is	O
clear	O
that	O
most	O
bacteria	O
do	O
not	O
synthesize	O
or	O
incorporate	O
these	O
types	O
of	O
lipids	O
in	O
their	O
cell	O
membrane	O
.	O

Two	O
notable	O
exceptions	O
are	O
the	O
photosynthetic	O
bacteria	O
which	O
synthesize	O
and	O
incorporate	O
significant	O
levels	O
of	O
linoleic	O
acid	O
in	O
their	O
membrane	O
(	O
Tasaka	O
et	O
al	O
.	O
,	O
1996	O
)	O
and	O
Helicobacter	B-Species
pylori	E-Species
membranes	O
which	O
contain	O
between	O
0	O
.	O
5	O
%	O
and	O
3	O
%	O
linoleic	O
acid	O
(	O
Ursini	O
and	O
Bindoli	O
,	O
1987	O
)	O
.	O

Instead	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
most	O
damaging	O
effects	O
of	O
ROS	O
in	O
bacteria	O
result	O
from	O
the	O
interactions	O
of	O
H2O2	O
with	O
'	O
free	O
'	O
Fe2	O
+	O
(	O
Imlay	O
,	O
2003	O
)	O
,	O
generating	O
very	O
reactive	O
OH	O
(	O
Fenton	O
reaction	O
)	O
.	O

Because	O
of	O
this	O
reactivity	O
,	O
the	O
effect	O
on	O
any	O
given	O
biomolecule	O
will	O
depend	O
largely	O
upon	O
proximity	O
to	O
the	O
target	O
.	O

Because	O
Fe2	O
+	O
localizes	O
along	O
the	O
phosphodiester	O
backbone	O
of	O
nucleic	O
acid	O
,	O
DNA	O
is	O
a	O
major	O
target	O
of	O
OH	O
.	O

This	O
reactive	O
species	O
can	O
pull	O
electrons	O
from	O
either	O
the	O
base	O
or	O
sugar	O
moieties	O
,	O
producing	O
a	O
variety	O
of	O
lesions	O
including	O
single	O
-	O
and	O
double	O
-	O
stranded	O
breaks	O
in	O
the	O
backbone	O
and	O
chemical	O
cross	O
-	O
links	O
to	O
other	O
molecules	O
.	O

These	O
strand	O
breaks	O
and	O
other	O
lesions	O
block	O
DNA	O
replication	O
and	O
contribute	O
to	O
OH	O
toxicity	O
and	O
cell	O
death	O
.	O

Other	O
base	O
damage	O
,	O
which	O
does	O
not	O
hinder	O
replication	O
,	O
may	O
result	O
in	O
a	O
significant	O
increase	O
in	O
mutation	O
rates	O
.	O

The	O
intracellular	O
biochemistry	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
suggests	O
that	O
the	O
primary	O
cellular	O
target	O
of	O
ROS	O
may	O
be	O
distinct	O
from	O
that	O
described	O
in	O
other	O
bacteria	O
such	O
as	O
Escherichia	B-Species
coli	E-Species
.	O

In	O
E	B-Species
.	I-Species
coli	E-Species
,	O
the	O
extent	O
of	O
DNA	O
damage	O
due	O
to	O
H2O2	O
and	O
Fenton	O
chemistry	O
is	O
directly	O
proportional	O
to	O
Fe	O
metabolism	O
and	O
the	O
free	O
Fe	O
concentration	O
within	O
the	O
cell	O
(	O
10	O
micro	O
M	O
)	O
(	O
Keyer	O
and	O
Imlay	O
,	O
1996	O
)	O
.	O

As	O
the	O
intracellular	O
Fe	O
concentrations	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
are	O
estimated	O
to	O
be	O
<	O
10	O
atoms	O
per	O
cell	O
(	O
Posey	O
and	O
Gherardini	O
,	O
2000	O
)	O
,	O
it	O
seems	O
unlikely	O
that	O
DNA	O
is	O
a	O
primary	O
target	O
for	O
ROS	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
biochemical	O
effects	O
of	O
ROS	O
on	O
B	B-Species
.	I-Species
burgdorferi	E-Species
,	O
including	O
growth	O
effects	O
and	O
biological	O
/	O
physical	O
damage	O
.	O

Results	O

Effect	O
of	O
ROS	O
on	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O

In	O
order	O
to	O
determine	O
what	O
the	O
cellular	O
targets	O
of	O
ROS	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
are	O
,	O
we	O
first	O
needed	O
to	O
determine	O
the	O
sensitivity	O
of	O
Borrelia	O
cells	O
to	O
various	O
oxidants	O
.	O

Microaerobic	O
cultures	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B31A3	O
were	O
grown	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
,	O
treated	O
with	O
varying	O
concentrations	O
of	O
H2O2	O
(	O
0	O
-	O
50	O
mM	O
)	O
or	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
0	O
-	O
50	O
mM	O
)	O
and	O
the	O
number	O
of	O
surviving	O
cells	O
determined	O
by	O
plating	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
.	O

1	O
.	O

When	O
cells	O
were	O
exposed	O
to	O
10	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
approximately	O
50	O
%	O
of	O
the	O
cells	O
survive	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

In	O
contrast	O
,	O
when	O
E	B-Species
.	I-Species
coli	E-Species
cells	O
were	O
exposed	O
to	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
approximately	O
1	O
%	O
of	O
the	O
cells	O
survive	O
.	O

B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
were	O
much	O
more	O
resistant	O
to	O
t	O
-	O
butyl	O
hydroperoxide	O
than	O
E	B-Species
.	I-Species
coli	E-Species
cells	O
,	O
with	O
a	O
survival	O
rate	O
of	O
approximately	O
100	O
%	O
at	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
.	O

This	O
trend	O
was	O
observed	O
when	O
cells	O
were	O
exposed	O
to	O
H2O2	O
.	O

E	B-Species
.	I-Species
coli	E-Species
cells	O
exposed	O
to	O
1	O
mM	O
H2O2	O
have	O
approximately	O
10	O
%	O
survivability	O
,	O
while	O
100	O
%	O
of	O
the	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
survive	O
at	O
this	O
concentration	O
,	O
and	O
approximately	O
80	O
%	O
survive	O
when	O
exposed	O
to	O
10	O
mM	O
H2O2	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
cells	O
were	O
exposed	O
in	O
HN	O
(	O
Hepes	O
-	O
NaCl	O
)	O
buffer	O
,	O
suggesting	O
that	O
the	O
high	O
-	O
level	O
resistance	O
to	O
ROS	O
was	O
not	O
due	O
to	O
the	O
interaction	O
of	O
ROS	O
with	O
components	O
of	O
Barbour	O
-	O
Stoenner	O
-	O
Kelly	O
(	O
BSK	O
-	O
II	O
)	O
growth	O
medium	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B31A3	O
was	O
highly	O
resistant	O
to	O
exposure	O
to	O
both	O
t	O
-	O
butyl	O
peroxide	O
and	O
H2O2	O
.	O

Borrelia	B-Species
burgdorferi	E-Species
DNA	O
is	O
not	O
the	O
primary	O
target	O
of	O
ROS	O

For	O
most	O
bacteria	O
,	O
DNA	O
is	O
the	O
major	O
target	O
of	O
ROS	O
causing	O
a	O
wide	O
variety	O
of	O
DNA	O
lesions	O
.	O

This	O
is	O
in	O
part	O
due	O
to	O
the	O
localization	O
of	O
'	O
free	O
'	O
Fe2	O
+	O
along	O
the	O
phosphodiester	O
backbone	O
of	O
nucleic	O
acids	O
,	O
putting	O
the	O
DNA	O
in	O
close	O
proximity	O
to	O
the	O
active	O
species	O
formed	O
via	O
the	O
Fenton	O
reaction	O
.	O

However	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
has	O
been	O
shown	O
to	O
harbour	O
few	O
genes	O
encoding	O
orthologues	O
of	O
known	O
iron	O
-	O
containing	O
proteins	O
,	O
does	O
not	O
require	O
Fe	O
for	O
growth	O
and	O
has	O
intracellular	O
Fe	O
concentrations	O
estimated	O
to	O
be	O
<	O
10	O
atoms	O
per	O
cell	O
(	O
Posey	O
and	O
Gherardini	O
,	O
2000	O
)	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
strongly	O
suggest	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
is	O
not	O
a	O
major	O
target	O
for	O
ROS	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
different	O
techniques	O
were	O
used	O
to	O
measure	O
DNA	O
damage	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
after	O
exposure	O
to	O
ROS	O
.	O

One	O
reliable	O
indicator	O
of	O
DNA	O
damage	O
by	O
ROS	O
in	O
a	O
cell	O
is	O
an	O
increase	O
in	O
the	O
spontaneous	O
mutation	O
rate	O
.	O

In	O
B	B-Species
.	I-Species
burgdorferi	E-Species
,	O
mutations	O
that	O
confer	O
resistance	O
to	O
coumermycin	O
A1	O
,	O
which	O
targets	O
the	O
beta	O
subunit	O
of	O
DNA	O
gyrase	O
,	O
have	O
been	O
mapped	O
to	O
gyrB	O
,	O
the	O
gene	O
encoding	O
DNA	O
gyrase	O
B	O
(	O
Samuels	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

In	O
each	O
case	O
,	O
a	O
single	O
point	O
mutation	O
correlated	O
with	O
this	O
drug	O
resistance	O
.	O

To	O
determine	O
if	O
exposure	O
to	O
oxidants	O
increases	O
DNA	O
damage	O
by	O
increasing	O
point	O
mutations	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
B31A3	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
5	O
mM	O
H2O2	O
and	O
plated	O
in	O
the	O
presence	O
and	O
absence	O
of	O
250	O
ng	O
ml	O
-	O
1	O
coumermycin	O
A1	O
.	O

The	O
mutation	O
frequency	O
was	O
calculated	O
as	O
the	O
number	O
of	O
colonies	O
that	O
are	O
CouR	O
per	O
total	O
number	O
of	O
cells	O
plated	O
.	O

The	O
spontaneous	O
resistance	O
frequency	O
of	O
treated	O
cells	O
was	O
approximately	O
equivalent	O
to	O
that	O
of	O
untreated	O
cells	O
,	O
8	O
.	O
8	O
x	O
10	O
-	O
8	O
and	O
1	O
.	O
33	O
x	O
10	O
-	O
7	O
,	O
respectively	O
,	O
indicating	O
no	O
increase	O
in	O
the	O
number	O
of	O
point	O
mutations	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Also	O
,	O
no	O
increase	O
in	O
point	O
mutations	O
was	O
observed	O
when	O
cells	O
were	O
treated	O
with	O
higher	O
concentrations	O
of	O
H2O2	O
(	O
10	O
mM	O
)	O
or	O
when	O
treated	O
with	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
5	O
and	O
10	O
mM	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Another	O
effective	O
way	O
to	O
determine	O
DNA	O
damage	O
is	O
by	O
measuring	O
the	O
number	O
of	O
apurinic	O
/	O
apyrimidinic	O
sites	O
(	O
AP	O
)	O
.	O

AP	O
sites	O
in	O
DNA	O
,	O
where	O
the	O
DNA	O
base	O
is	O
lost	O
,	O
can	O
be	O
generated	O
spontaneously	O
under	O
physiological	O
conditions	O
by	O
hydrolysis	O
of	O
the	O
N	O
-	O
glycosylic	O
bond	O
,	O
or	O
can	O
also	O
be	O
formed	O
by	O
DNA	O
-	O
damaging	O
agents	O
(	O
Lindahl	O
and	O
Nyberg	O
,	O
1972	O
)	O
,	O
such	O
as	O
UV	O
,	O
alkylating	O
agents	O
or	O
OH	O
.	O

They	O
are	O
also	O
intermediates	O
in	O
the	O
base	O
excision	O
repair	O
pathway	O
(	O
BER	O
)	O
(	O
Weiss	O
and	O
Grossman	O
,	O
1987	O
;	O
Friedberg	O
and	O
Hanawalt	O
,	O
1988	O
;	O
Wallace	O
,	O
1988	O
)	O
.	O

Thus	O
,	O
the	O
cellular	O
steady	O
state	O
level	O
of	O
AP	O
sites	O
would	O
increase	O
as	O
a	O
consequence	O
of	O
base	O
modifications	O
and	O
their	O
subsequent	O
repair	O
.	O

As	O
AP	O
sites	O
are	O
bypassed	O
inefficiently	O
by	O
DNA	O
polymerase	O
in	O
bacterial	O
cells	O
,	O
DNA	O
lesions	O
can	O
result	O
in	O
a	O
significant	O
block	O
in	O
DNA	O
replication	O
.	O

Therefore	O
,	O
the	O
number	O
of	O
AP	O
sites	O
can	O
serve	O
as	O
a	O
sensitive	O
indicator	O
of	O
DNA	O
damage	O
resulting	O
from	O
oxidative	O
stress	O
(	O
Kubo	O
et	O
al	O
.	O
,	O
1992	O
)	O
.	O

To	O
determine	O
whether	O
ROS	O
can	O
damage	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
,	O
strain	O
B31A3	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
H2O2	O
(	O
1	O
or	O
10	O
mM	O
)	O
,	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
1	O
or	O
10	O
mM	O
)	O
or	O
lipoxidase	O
(	O
an	O
enzyme	O
which	O
specifically	O
catalyses	O
the	O
hydroperoxidation	O
of	O
lipids	O
containing	O
a	O
cis	O
,	O
cis	O
-	O
pentadiene	O
structure	O
,	O
such	O
as	O
linoleic	O
acid	O
)	O
.	O

The	O
DNA	O
was	O
isolated	O
and	O
assayed	O
for	O
AP	O
sites	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
.	O

2B	O
.	O

In	O
all	O
cases	O
,	O
the	O
numbers	O
of	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
were	O
equivalent	O
,	O
indicating	O
that	O
the	O
addition	O
of	O
oxidants	O
did	O
not	O
increase	O
the	O
number	O
of	O
DNA	O
base	O
lesions	O
.	O

In	O
contrast	O
,	O
when	O
E	B-Species
.	I-Species
coli	E-Species
strain	O
TA4315	O
cells	O
(	O
ahpCF	O
)	O
(	O
Storz	O
et	O
al	O
.	O
,	O
1989	O
)	O
were	O
treated	O
with	O
100	O
micro	O
M	O
H2O2	O
,	O
the	O
number	O
of	O
AP	O
sites	O
increased	O
~	O
10	O
-	O
fold	O
over	O
untreated	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
was	O
not	O
a	O
major	O
target	O
for	O
oxidative	O
damage	O
under	O
these	O
conditions	O
.	O

It	O
is	O
of	O
note	O
to	O
mention	O
that	O
the	O
total	O
number	O
of	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
is	O
approximately	O
10	O
-	O
fold	O
higher	O
in	O
untreated	O
Borrelia	O
B31A3	O
DNA	O
than	O
in	O
untreated	O
E	B-Species
.	I-Species
coli	E-Species
DNA	O
.	O

The	O
Borrelia	O
genome	O
consists	O
of	O
a	O
linear	O
chromosome	O
and	O
multiple	O
linear	O
and	O
circular	O
plasmids	O
.	O

Numerous	O
observations	O
indicate	O
that	O
functional	O
telomeres	O
require	O
interaction	O
with	O
DNA	O
damage	O
repair	O
proteins	O
,	O
suggesting	O
that	O
the	O
DNA	O
damage	O
repair	O
machinery	O
,	O
including	O
the	O
BER	O
,	O
is	O
involved	O
in	O
replication	O
of	O
telomeres	O
and	O
protection	O
of	O
functional	O
chromosome	O
ends	O
(	O
Verdun	O
and	O
Karlseder	O
,	O
2007	O
)	O
.	O

An	O
important	O
intermediate	O
in	O
BER	O
is	O
the	O
apurinic	O
or	O
abasic	O
site	O
.	O

Therefore	O
,	O
it	O
was	O
possible	O
that	O
the	O
higher	O
numbers	O
of	O
AP	O
sites	O
in	O
untreated	O
Borrelia	O
DNA	O
was	O
due	O
to	O
the	O
number	O
of	O
telomeres	O
present	O
in	O
the	O
genome	O
.	O

The	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B31A3	O
harbours	O
11	O
linear	O
plasmids	O
and	O
a	O
linear	O
chromosome	O
with	O
~	O
100	O
unpaired	O
bases	O
in	O
the	O
telomere	O
loops	O
per	O
genome	O
or	O
10	O
bases	O
per	O
105	O
bp	O
DNA	O
(	O
Hinnebusch	O
and	O
Barbour	O
,	O
1991	O
;	O
Chaconas	O
,	O
2005	O
)	O
.	O

Untreated	O
Borrelia	O
B31A3	O
contains	O
11	O
+/-	O
3	O
.	O
8	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
,	O
suggesting	O
that	O
the	O
elevated	O
number	O
of	O
AP	O
sites	O
in	O
Borrelia	O
was	O
due	O
to	O
the	O
number	O
of	O
telomeres	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
AP	O
sites	O
were	O
measured	O
in	O
DNA	O
isolated	O
from	O
untreated	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B314	O
which	O
harbours	O
no	O
linear	O
plasmids	O
(	O
Sadziene	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

The	O
number	O
of	O
unpaired	O
bases	O
in	O
the	O
telomere	O
loops	O
per	O
genome	O
was	O
estimated	O
to	O
be	O
10	O
,	O
which	O
corresponds	O
to	O
1	O
base	O
per	O
105	O
bp	O
DNA	O
,	O
and	O
only	O
3	O
.	O
6	O
+/-	O
0	O
.	O
2	O
AP	O
sites	O
per	O
105	O
bp	O
DNA	O
were	O
detected	O
,	O
supporting	O
the	O
hypothesis	O
that	O
the	O
high	O
number	O
of	O
AP	O
sites	O
in	O
untreated	O
Borrelia	O
DNA	O
was	O
due	O
to	O
the	O
number	O
of	O
unpaired	O
bases	O
in	O
the	O
telomeres	O
.	O

The	O
analyses	O
of	O
the	O
AP	O
sites	O
strongly	O
suggested	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
was	O
not	O
the	O
major	O
target	O
for	O
oxidative	O
damage	O
.	O

In	O
addition	O
to	O
the	O
generation	O
of	O
abasic	O
sites	O
,	O
oxygen	O
radicals	O
often	O
damage	O
DNA	O
through	O
the	O
formation	O
of	O
8	O
-	O
oxoguanine	O
lesions	O
(	O
Nakamura	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

8	O
-	O
Oxoguanine	O
,	O
through	O
its	O
ability	O
to	O
mispair	O
with	O
bases	O
other	O
than	O
cytosine	O
,	O
likely	O
plays	O
a	O
role	O
in	O
DNA	O
mutagenesis	O
.	O

Consequently	O
,	O
8	O
-	O
oxoguanine	O
is	O
often	O
used	O
as	O
a	O
marker	O
of	O
oxidized	O
DNA	O
damage	O
.	O

To	O
determine	O
whether	O
ROS	O
can	O
damage	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
and	O
cause	O
8	O
-	O
oxoguanine	O
lesions	O
,	O
strain	O
B31A3	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
H2O2	O
(	O
5	O
or	O
10	O
mM	O
)	O
,	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
5	O
or	O
10	O
mM	O
)	O
or	O
lipoxidase	O
.	O

The	O
DNA	O
was	O
isolated	O
and	O
assayed	O
for	O
8	O
-	O
oxoguanine	O
using	O
an	O
Enzyme	O
-	O
Linked	O
ImmunoSorbent	O
Assay	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
.	O

2C	O
.	O

In	O
all	O
cases	O
,	O
the	O
amount	O
of	O
8	O
-	O
oxoguanine	O
in	O
Borrelia	O
cells	O
was	O
below	O
the	O
detection	O
limit	O
of	O
the	O
assay	O
.	O

In	O
contrast	O
,	O
when	O
a	O
MutM	O
(	O
the	O
specific	O
glycosylase	O
that	O
removes	O
the	O
8	O
-	O
oxoguanine	O
)	O
-	O
deficient	O
E	B-Species
.	I-Species
coli	E-Species
strain	O
was	O
treated	O
with	O
100	O
micro	O
M	O
H2O2	O
,	O
the	O
amount	O
of	O
8	O
-	O
oxoguanine	O
sites	O
increased	O
~	O
fivefold	O
over	O
untreated	O
cells	O
.	O

It	O
is	O
important	O
to	O
point	O
out	O
that	O
no	O
MutM	O
homologue	O
has	O
been	O
identified	O
in	O
the	O
genome	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
was	O
not	O
a	O
major	O
target	O
for	O
oxidative	O
damage	O
under	O
these	O
conditions	O
.	O

The	O
membranes	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
are	O
targeted	O
during	O
oxidative	O
stress	O

In	O
eukaryotes	O
,	O
membrane	O
lipids	O
are	O
a	O
major	O
target	O
of	O
ROS	O
.	O

Free	O
radicals	O
can	O
attack	O
polyunsaturated	O
fatty	O
acids	O
,	O
such	O
as	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
,	O
in	O
membranes	O
and	O
initiate	O
lipid	O
peroxidation	O
.	O

This	O
reaction	O
can	O
cascade	O
throughout	O
the	O
membrane	O
to	O
adjacent	O
polyunsaturated	O
fatty	O
acids	O
,	O
decreasing	O
membrane	O
fluidity	O
and	O
generating	O
more	O
toxic	O
products	O
such	O
as	O
aldehydes	O
(	O
Imlay	O
,	O
2003	O
)	O
.	O

Because	O
most	O
bacterial	O
membranes	O
contain	O
saturated	O
and	O
monounsaturated	O
fatty	O
acids	O
rather	O
than	O
'	O
reactive	O
'	O
polyunsaturated	O
lipids	O
,	O
peroxidation	O
of	O
lipids	O
in	O
bacterial	O
membranes	O
is	O
not	O
considered	O
a	O
problem	O
.	O

As	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cannot	O
synthesize	O
their	O
own	O
lipids	O
,	O
they	O
must	O
instead	O
scavenge	O
them	O
.	O

Therefore	O
,	O
it	O
seems	O
likely	O
that	O
their	O
membrane	O
composition	O
would	O
reflect	O
the	O
host	O
'	O
s	O
lipid	O
profile	O
or	O
that	O
of	O
their	O
growth	O
medium	O
(	O
Barbour	O
,	O
1984	O
;	O
Fraser	O
et	O
al	O
.	O
,	O
1997	O
)	O
and	O
would	O
contain	O
some	O
polyunsaturated	O
fatty	O
acids	O
.	O

To	O
determine	O
if	O
B	B-Species
.	I-Species
burgdorferi	E-Species
contains	O
polyunsaturated	O
lipids	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B31A3	O
was	O
grown	O
under	O
anaerobic	O
conditions	O
and	O
analysed	O
for	O
fatty	O
acid	O
composition	O
by	O
Lipid	O
Technologies	O
(	O
Austin	O
,	O
MN	O
)	O
.	O

The	O
results	O
are	O
shown	O
in	O
Table	O
1	O
and	O
are	O
reported	O
as	O
percentage	O
of	O
total	O
fatty	O
acid	O
content	O
.	O

Linoleic	O
acid	O
comprised	O
~	O
10	O
%	O
of	O
the	O
total	O
lipid	O
content	O
and	O
the	O
linolenic	O
acid	O
content	O
was	O
measured	O
to	O
be	O
~	O
1	O
%	O
,	O
indicating	O
that	O
Borrelia	O
cells	O
do	O
contain	O
lipids	O
that	O
are	O
susceptible	O
to	O
ROS	O
damage	O
.	O

The	O
amount	O
of	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
present	O
in	O
Borrelia	O
reflected	O
the	O
amount	O
present	O
in	O
the	O
media	O
.	O

Therefore	O
,	O
these	O
results	O
suggested	O
that	O
the	O
amount	O
of	O
these	O
fatty	O
acids	O
in	O
the	O
membranes	O
would	O
vary	O
as	O
availability	O
varies	O
.	O

To	O
determine	O
if	O
Borrelia	O
polyunsaturated	O
lipids	O
can	O
undergo	O
lipid	O
peroxidation	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
B31A3	O
cells	O
grown	O
microaerobically	O
were	O
treated	O
with	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
or	O
250	O
mg	O
of	O
lipoxidase	O
,	O
and	O
the	O
cell	O
pellets	O
were	O
analysed	O
for	O
fatty	O
acid	O
composition	O
(	O
Industrial	O
Laboratory	O
)	O
.	O

The	O
results	O
are	O
shown	O
in	O
Table	O
2	O
and	O
are	O
reported	O
as	O
the	O
percentage	O
of	O
total	O
cell	O
mass	O
.	O

The	O
per	O
cent	O
of	O
linoleic	O
acid	O
in	O
the	O
total	O
cell	O
mass	O
decreased	O
with	O
treatment	O
,	O
while	O
the	O
levels	O
of	O
oleic	O
acid	O
(	O
c18	O
:	O
1n9	O
)	O
and	O
pentadecanoic	O
acid	O
(	O
c15	O
:	O
0	O
)	O
remained	O
relatively	O
constant	O
.	O

Untreated	O
cells	O
contained	O
0	O
.	O
04	O
%	O
linoleic	O
acid	O
,	O
while	O
cells	O
treated	O
with	O
t	O
-	O
butyl	O
hydroperoxide	O
contained	O
10	O
-	O
fold	O
less	O
(	O
0	O
.	O
004	O
%	O
)	O
linoleic	O
acid	O
and	O
cells	O
treated	O
with	O
lipoxidase	O
had	O
no	O
detectable	O
linoleic	O
acid	O
present	O
in	O
the	O
sample	O
.	O

These	O
data	O
indicated	O
that	O
the	O
linoleic	O
acid	O
present	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
membranes	O
can	O
be	O
oxidized	O
by	O
ROS	O
.	O

Malondialdehyde	O
(	O
MDA	O
)	O
is	O
generated	O
as	O
a	O
relatively	O
stable	O
end	O
-	O
product	O
from	O
the	O
oxidative	O
degradation	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O

MDA	O
has	O
thus	O
been	O
used	O
as	O
an	O
indicator	O
of	O
lipid	O
peroxidation	O
(	O
Gutteridge	O
and	O
Halliwell	O
,	O
1990	O
;	O
Esterbauer	O
et	O
al	O
.	O
,	O
1991	O
)	O
.	O

To	O
further	O
demonstrate	O
that	O
Borrelia	O
lipids	O
can	O
undergo	O
lipid	O
peroxidation	O
,	O
B31A3	O
cells	O
grown	O
microaerobically	O
were	O
treated	O
with	O
5	O
mM	O
AAPH	O
(	O
free	O
radical	O
generator	O
)	O
or	O
250	O
mg	O
of	O
lipoxidase	O
and	O
MDA	O
measured	O
(	O
Seljeskog	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
.	O

3	O
.	O

Untreated	O
cells	O
contained	O
~	O
16	O
.	O
5	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
.	O

When	O
the	O
cells	O
were	O
treated	O
with	O
AAPH	O
or	O
lipoxidase	O
,	O
the	O
amount	O
of	O
MDA	O
increased	O
~	O
1	O
.	O
5	O
-	O
fold	O
(	O
27	O
.	O
3	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
and	O
approximately	O
twofold	O
(	O
33	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
respectively	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

As	O
a	O
control	O
,	O
eukaryotic	O
cells	O
(	O
mouse	S-Species
myeloma	O
cells	O
SP2	O
)	O
were	O
treated	O
with	O
AAPH	O
and	O
MDA	O
measured	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Mouse	S-Species
myeloma	O
cells	O
have	O
been	O
used	O
as	O
a	O
model	O
system	O
for	O
the	O
determination	O
of	O
phospholipid	O
hydroperoxides	O
(	O
Chotimarkorn	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

In	O
this	O
case	O
,	O
the	O
amount	O
of	O
MDA	O
increased	O
approximately	O
threefold	O
(	O
36	O
.	O
3	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
in	O
the	O
treated	O
cells	O
versus	O
untreated	O
cells	O
(	O
11	O
.	O
7	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
,	O
like	O
eukaryotic	O
membranes	O
,	O
Borrelia	O
membrane	O
lipids	O
were	O
capable	O
of	O
undergoing	O
lipid	O
peroxidation	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

3A	O
,	O
there	O
is	O
a	O
measurable	O
quantity	O
of	O
MDA	O
present	O
even	O
in	O
untreated	O
cells	O
,	O
suggesting	O
that	O
the	O
membrane	O
lipids	O
are	O
damaged	O
without	O
the	O
addition	O
of	O
exogenous	O
ROS	O
.	O

Oxidative	O
damage	O
is	O
an	O
unavoidable	O
by	O
-	O
product	O
of	O
growth	O
in	O
an	O
oxygen	O
environment	O
because	O
superoxide	O
anions	O
and	O
H2O2	O
are	O
formed	O
whenever	O
molecular	O
oxygen	O
chemically	O
oxidizes	O
electron	O
carriers	O
.	O

To	O
determine	O
if	O
the	O
Borrelia	O
lipids	O
are	O
damaged	O
from	O
growth	O
in	O
an	O
oxygen	O
environment	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
B31A3	O
cells	O
were	O
grown	O
under	O
anaerobic	O
,	O
microaerobic	O
and	O
aerobic	O
conditions	O
and	O
MDA	O
measured	O
.	O

Figure	O
3C	O
demonstrates	O
that	O
as	O
the	O
oxygen	O
concentration	O
increased	O
,	O
the	O
amount	O
of	O
MDA	O
increased	O
.	O

Cells	O
grown	O
under	O
anaerobic	O
conditions	O
contained	O
the	O
lowest	O
amount	O
of	O
MDA	O
(	O
7	O
.	O
6	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
,	O
approximately	O
twofold	O
less	O
than	O
the	O
measured	O
amount	O
in	O
microaerobic	O
cells	O
(	O
16	O
.	O
5	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
.	O

Aerobically	O
grown	O
cells	O
contained	O
the	O
highest	O
amount	O
of	O
MDA	O
,	O
~	O
1	O
.	O
5	O
-	O
fold	O
greater	O
than	O
that	O
observed	O
in	O
microaerobic	O
cells	O
(	O
28	O
.	O
8	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
)	O
and	O
~	O
3	O
.	O
7	O
-	O
fold	O
greater	O
than	O
that	O
observed	O
in	O
anaerobically	O
grown	O
cells	O
.	O

These	O
data	O
suggested	O
that	O
Borrelia	O
lipids	O
can	O
be	O
damaged	O
during	O
aerobic	O
growth	O
.	O

Our	O
High	O
Performance	O
Liquid	O
Chromatography	O
analyses	O
of	O
the	O
MDA	O
present	O
in	O
anaerobically	O
grown	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
showed	O
a	O
small	O
peak	O
with	O
a	O
retention	O
time	O
similar	O
to	O
that	O
of	O
the	O
MDA	O
standard	O
.	O

This	O
was	O
puzzling	O
as	O
little	O
or	O
no	O
lipid	O
peroxidation	O
should	O
occur	O
under	O
these	O
conditions	O
.	O

To	O
further	O
characterize	O
this	O
'	O
MDA	O
'	O
peak	O
,	O
a	O
three	O
-	O
dimensional	O
diode	O
array	O
spectra	O
was	O
generated	O
by	O
scanning	O
each	O
sample	O
during	O
the	O
elution	O
of	O
the	O
peak	O
(	O
Fig	O
.	O
4	O
,	O
lower	O
sections	O
)	O
.	O

An	O
authentic	O
MDA	O
standard	O
was	O
also	O
scanned	O
as	O
a	O
control	O
(	O
Fig	O
.	O
4A	O
,	O
lower	O
section	O
)	O
.	O

In	O
the	O
anaerobically	O
grown	O
cells	O
,	O
the	O
spectrum	O
shows	O
that	O
two	O
compounds	O
with	O
different	O
absorbance	O
maximums	O
(	O
Fig	O
.	O
4B	O
,	O
lower	O
section	O
)	O
comprised	O
the	O
single	O
retention	O
time	O
peak	O
from	O
the	O
HPLC	O
chromatogram	O
(	O
Fig	O
.	O
4B	O
,	O
upper	O
section	O
)	O
.	O

Based	O
on	O
this	O
spectrum	O
,	O
the	O
amount	O
of	O
actual	O
MDA	O
contributed	O
<	O
15	O
%	O
of	O
the	O
total	O
amount	O
of	O
material	O
detected	O
in	O
the	O
HPLC	O
peak	O
while	O
the	O
second	O
contaminating	O
peak	O
contributed	O
>	O
85	O
%	O
.	O

Therefore	O
,	O
the	O
amount	O
of	O
MDA	O
in	O
untreated	O
anaerobically	O
grown	O
cells	O
was	O
considerably	O
less	O
than	O
the	O
7	O
.	O
6	O
micro	O
M	O
of	O
MDA	O
per	O
mg	O
of	O
protein	O
actually	O
measured	O
.	O

However	O
,	O
in	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
,	O
the	O
MDA	O
peak	O
contributed	O
more	O
to	O
the	O
overall	O
retention	O
time	O
peak	O
when	O
compared	O
with	O
the	O
anaerobic	O
spectrum	O
,	O
while	O
the	O
second	O
contaminating	O
peak	O
stays	O
relatively	O
constant	O
(	O
Fig	O
.	O
4C	O
,	O
lower	O
section	O
)	O
.	O

These	O
spectra	O
demonstrated	O
that	O
the	O
increase	O
in	O
the	O
MDA	O
retention	O
time	O
peak	O
between	O
anaerobically	O
and	O
aerobically	O
grown	O
cells	O
was	O
due	O
to	O
the	O
increase	O
in	O
the	O
amount	O
of	O
authentic	O
MDA	O
present	O
.	O

The	O
fluorescent	O
probe	O
diphenyl	O
-	O
1	O
-	O
pyrenylphophine	O
(	O
DPPP	O
)	O
has	O
been	O
used	O
for	O
detection	O
of	O
lipid	O
hydroperoxides	O
in	O
cell	O
membranes	O
(	O
Okimoto	O
et	O
al	O
.	O
,	O
2000	O
;	O
Takahashi	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

In	O
this	O
method	O
,	O
the	O
hydroperoxides	O
are	O
reduced	O
with	O
DPPP	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
the	O
fluorescent	O
arylphosphine	O
oxide	O
.	O

To	O
visualize	O
the	O
lipid	O
hydroperoxides	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
B31A3	O
cells	O
were	O
labelled	O
with	O
DPPP	O
and	O
observed	O
by	O
fluorescence	O
microscopy	O
(	O
Fig	O
.	O
5B	O
)	O
.	O

E	B-Species
.	I-Species
coli	E-Species
Top10	O
cells	O
and	O
mouse	S-Species
myeloma	O
SP2	O
cells	O
were	O
also	O
labelled	O
and	O
visualized	O
to	O
serve	O
as	O
negative	O
and	O
positive	O
controls	O
respectively	O
(	O
Fig	O
.	O
5A	O
and	O
C	O
)	O
.	O

Red	O
Fluorescent	O
dye	O
was	O
used	O
to	O
visualize	O
the	O
cell	O
membranes	O
.	O

A	O
strong	O
fluorescence	O
of	O
DPPP	O
was	O
observed	O
for	O
B31A3	O
cells	O
(	O
Fig	O
.	O
5B	O
)	O
and	O
for	O
the	O
mouse	S-Species
myeloma	O
cells	O
(	O
Fig	O
.	O
5C	O
)	O
,	O
but	O
not	O
for	O
the	O
E	B-Species
.	I-Species
coli	E-Species
cells	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

An	O
overlay	O
of	O
the	O
two	O
dyes	O
demonstrates	O
that	O
the	O
DPPP	O
fluorescence	O
of	O
both	O
the	O
Borrelia	O
and	O
myeloma	O
cells	O
corresponds	O
to	O
the	O
areas	O
of	O
red	O
fluorescence	O
.	O

This	O
indicated	O
that	O
lipid	O
hydroperoxides	O
were	O
present	O
on	O
the	O
Borrelia	O
cell	O
membranes	O
and	O
suggested	O
that	O
the	O
membranes	O
were	O
damaged	O
.	O

To	O
further	O
demonstrate	O
Borrelia	O
membrane	O
damage	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
B31A3	O
cells	O
were	O
grown	O
under	O
anaerobic	O
and	O
microaerobic	O
conditions	O
and	O
visualized	O
by	O
negative	O
stain	O
using	O
an	O
electron	O
microscope	O
.	O

Additionally	O
,	O
cells	O
grown	O
under	O
microaerobic	O
conditions	O
were	O
treated	O
with	O
250	O
mg	O
of	O
lipoxidase	O
and	O
visualized	O
by	O
Electron	O
Microscopy	O
.	O

Intact	O
membranes	O
were	O
observed	O
in	O
cultures	O
of	O
B31A3	O
grown	O
under	O
anaerobic	O
and	O
microaerobic	O
conditions	O
(	O
Fig	O
.	O
6A	O
and	O
B	O
respectively	O
)	O
.	O

However	O
,	O
in	O
cultures	O
treated	O
with	O
lipoxidase	O
(	O
Fig	O
.	O
6C	O
)	O
,	O
a	O
significant	O
number	O
of	O
membrane	O
blebs	O
were	O
seen	O
surrounding	O
the	O
spirochetes	O
,	O
indicating	O
membrane	O
damage	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
Borrelia	O
membranes	O
were	O
a	O
target	O
for	O
oxidative	O
stress	O
.	O

Discussion	O

Most	O
bacterial	O
pathogens	O
are	O
faced	O
with	O
the	O
challenge	O
of	O
overcoming	O
ROS	O
generated	O
by	O
the	O
host	O
immune	O
system	O
.	O

These	O
radicals	O
can	O
cause	O
a	O
great	O
deal	O
of	O
damage	O
to	O
biological	O
molecules	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
potential	O
cellular	O
targets	O
for	O
ROS	O
damage	O
in	O
bacteria	O
include	O
DNA	O
,	O
RNA	O
,	O
proteins	O
and	O
lipids	O
,	O
and	O
extensive	O
work	O
has	O
been	O
done	O
to	O
determine	O
the	O
cellular	O
targets	O
of	O
ROS	O
that	O
affect	O
bacterial	O
survival	O
.	O

To	O
date	O
,	O
the	O
most	O
definitive	O
work	O
has	O
been	O
done	O
on	O
E	B-Species
.	I-Species
coli	E-Species
.	O

It	O
seems	O
clear	O
from	O
several	O
studies	O
that	O
the	O
most	O
physiologically	O
relevant	O
target	O
of	O
ROS	O
in	O
E	B-Species
.	I-Species
coli	E-Species
is	O
DNA	O
.	O

The	O
exposure	O
to	O
micro	O
M	O
concentrations	O
of	O
ROS	O
(	O
i	O
.	O
e	O
.	O
H2O2	O
)	O
is	O
sufficient	O
to	O
cause	O
DNA	O
damage	O
,	O
inhibit	O
DNA	O
replication	O
,	O
increase	O
the	O
mutation	O
rate	O
and	O
often	O
lead	O
to	O
cell	O
death	O
.	O

This	O
process	O
leading	O
to	O
DNA	O
damage	O
begins	O
with	O
formation	O
of	O
O2	O
-	O
and	O
H2O2	O
from	O
the	O
oxidation	O
of	O
flavoproteins	O
and	O
/	O
or	O
the	O
diffusion	O
of	O
these	O
reactive	O
species	O
from	O
the	O
extracellular	O
milieu	O
.	O

The	O
subsequent	O
oxidation	O
of	O
Fe	O
-	O
S	O
proteins	O
by	O
ROS	O
(	O
e	O
.	O
g	O
.	O
O2	O
-	O
)	O
leads	O
to	O
an	O
increase	O
in	O
intracellular	O
'	O
free	O
'	O
Fe2	O
+	O
which	O
triggers	O
the	O
reduction	O
of	O
H2O2	O
to	O
OH	O
(	O
Fenton	O
reaction	O
)	O
.	O

The	O
highly	O
reactive	O
nature	O
of	O
OH	O
limits	O
its	O
diffusion	O
so	O
that	O
it	O
generally	O
reacts	O
with	O
molecules	O
in	O
close	O
proximity	O
to	O
its	O
origin	O
(	O
e	O
.	O
g	O
.	O
the	O
Fe2	O
+	O
associated	O
with	O
DNA	O
)	O
.	O

In	O
DNA	O
,	O
OH	O
oxidizes	O
sugar	O
and	O
base	O
moieties	O
,	O
producing	O
radicals	O
which	O
ultimately	O
generate	O
lesions	O
,	O
including	O
base	O
modifications	O
,	O
strand	O
breaks	O
and	O
chemical	O
cross	O
-	O
links	O
to	O
other	O
molecules	O
.	O

Base	O
modifications	O
lead	O
to	O
mismatching	O
and	O
increased	O
mutation	O
frequencies	O
while	O
more	O
severe	O
damage	O
,	O
such	O
as	O
strand	O
breaks	O
,	O
prevents	O
DNA	O
replication	O
,	O
contributing	O
to	O
OH	O
toxicity	O
and	O
cell	O
death	O
.	O

Critical	O
to	O
this	O
chemical	O
process	O
in	O
vivo	O
is	O
the	O
presence	O
of	O
iron	O
.	O

No	O
other	O
metal	O
or	O
non	O
-	O
metal	O
electron	O
carrier	O
appears	O
to	O
be	O
able	O
to	O
univalently	O
reduce	O
H2O2	O
to	O
OH	O
in	O
vivo	O
(	O
Macomber	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

These	O
observations	O
are	O
critical	O
in	O
beginning	O
to	O
understand	O
the	O
oxidative	O
damage	O
/	O
targets	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
.	O

It	O
has	O
been	O
shown	O
in	O
E	B-Species
.	I-Species
coli	E-Species
that	O
the	O
free	O
-	O
iron	O
pool	O
size	O
determines	O
the	O
rate	O
of	O
oxidative	O
DNA	O
damage	O
.	O

For	O
example	O
,	O
in	O
wild	O
-	O
type	O
E	B-Species
.	I-Species
coli	E-Species
,	O
free	O
iron	O
levels	O
are	O
estimated	O
to	O
be	O
10	O
micro	O
M	O
,	O
yet	O
H2O2	O
is	O
only	O
mildly	O
genotoxic	O
(	O
Keyer	O
and	O
Imlay	O
,	O
1996	O
)	O
.	O

However	O
,	O
in	O
E	B-Species
.	I-Species
coli	E-Species
Fur	O
-	O
mutants	O
,	O
intracellular	O
iron	O
concentration	O
increases	O
eightfold	O
while	O
survival	O
is	O
10	O
-	O
fold	O
lower	O
when	O
cells	O
are	O
exposed	O
to	O
H2O2	O
.	O

Because	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
do	O
not	O
contain	O
detectable	O
levels	O
of	O
intracellular	O
Fe	O
,	O
it	O
seems	O
unlikely	O
that	O
DNA	O
is	O
a	O
major	O
target	O
for	O
damage	O
via	O
the	O
Fenton	O
reaction	O
in	O
this	O
bacterium	O
(	O
Posey	O
and	O
Gherardini	O
,	O
2000	O
)	O
.	O

The	O
experimental	O
data	O
present	O
in	O
this	O
report	O
suggested	O
that	O
this	O
was	O
the	O
case	O
.	O

When	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
were	O
exposed	O
to	O
high	O
concentrations	O
of	O
ROS	O
(	O
e	O
.	O
g	O
.	O
H2O2	O
)	O
,	O
there	O
was	O
no	O
effect	O
on	O
the	O
spontaneous	O
mutation	O
rate	O
(	O
Fig	O
.	O
2A	O
)	O
or	O
the	O
number	O
of	O
DNA	O
lesions	O
(	O
AP	O
sites	O
or	O
8	O
-	O
oxoguanine	O
)	O
(	O
Fig	O
.	O
2B	O
and	O
C	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
in	O
these	O
experiments	O
,	O
a	O
wild	O
-	O
type	O
strain	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
was	O
used	O
and	O
presumably	O
all	O
of	O
the	O
endogenous	O
oxidative	O
stress	O
enzymes	O
were	O
expressed	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
no	O
DNA	O
damage	O
was	O
observed	O
because	O
these	O
enzymes	O
are	O
capable	O
of	O
detoxifying	O
the	O
cell	O
and	O
protecting	O
nucleic	O
acids	O
from	O
oxidation	O
via	O
the	O
Fenton	O
reaction	O
.	O

However	O
,	O
we	O
do	O
not	O
believe	O
this	O
to	O
be	O
the	O
case	O
as	O
the	O
concentration	O
of	O
oxidants	O
used	O
in	O
these	O
experiments	O
were	O
significantly	O
higher	O
than	O
concentrations	O
known	O
to	O
cause	O
DNA	O
damage	O
in	O
E	B-Species
.	I-Species
coli	E-Species
and	O
other	O
pathogenic	O
bacteria	O
.	O

The	O
lack	O
of	O
detectable	O
DNA	O
damage	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
under	O
the	O
conditions	O
tested	O
could	O
be	O
the	O
result	O
of	O
very	O
efficient	O
DNA	O
repair	O
systems	O
.	O

Bacteria	O
,	O
such	O
as	O
E	B-Species
.	I-Species
coli	E-Species
,	O
harbour	O
genes	O
encoding	O
repair	O
enzymes	O
(	O
i	O
.	O
e	O
.	O
MutM	O
,	O
MutY	O
,	O
Ung	O
,	O
AlkA	O
,	O
MutS	O
,	O
MutL	O
,	O
ExoIII	O
,	O
EndoVIII	O
,	O
PolI	O
,	O
RecJ	O
)	O
.	O

Key	O
enzymes	O
in	O
the	O
repair	O
of	O
8	O
-	O
oxoguanine	O
lesions	O
resulting	O
from	O
the	O
oxidation	O
of	O
DNA	O
are	O
the	O
bifunctional	O
glycosylases	O
,	O
such	O
as	O
MutM	O
,	O
MutY	O
or	O
EndoVIII	O
.	O

The	O
first	O
activity	O
of	O
these	O
enzymes	O
is	O
to	O
remove	O
oxidized	O
or	O
ring	O
-	O
saturated	O
bases	O
while	O
the	O
second	O
activity	O
is	O
to	O
remove	O
the	O
resulting	O
deoxyribose	O
residue	O
,	O
generating	O
a	O
3	O
'	O
-	O
phosphate	O
end	O
(	O
Krwawicz	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

This	O
3	O
'	O
-	O
P	O
is	O
converted	O
to	O
a	O
3	O
'	O
-	O
OH	O
by	O
various	O
enzymes	O
/	O
pathways	O
and	O
the	O
lesion	O
is	O
repaired	O
by	O
enzymes	O
(	O
e	O
.	O
g	O
.	O
ExoIII	O
,	O
PolI	O
,	O
LigI	O
etc	O
.	O
)	O
in	O
the	O
short	O
or	O
long	O
BER	O
pathways	O
(	O
S	O
-	O
BER	O
,	O
L	O
-	O
BER	O
)	O
.	O

Interestingly	O
,	O
the	O
B	B-Species
.	I-Species
burgdorferi	E-Species
genome	O
does	O
not	O
contain	O
genes	O
encoding	O
homologues	O
of	O
MutM	O
,	O
MutY	O
or	O
EndoVIII	O
,	O
suggesting	O
that	O
it	O
would	O
be	O
difficult	O
for	O
the	O
cells	O
to	O
efficiently	O
repair	O
8	O
-	O
oxoguanine	O
sites	O
using	O
this	O
pathway	O
.	O

B	B-Species
.	I-Species
burgdorferi	E-Species
does	O
harbour	O
the	O
genes	O
encoding	O
the	O
enzymes	O
Ung	O
(	O
monofunctional	O
gylcosylase	O
,	O
BB0053	O
)	O
,	O
MutS	O
(	O
BB0797	O
,	O
BB0098	O
)	O
,	O
MutL	O
(	O
BB0211	O
)	O
,	O
ExoIII	O
(	O
BB0114	O
)	O
,	O
PolI	O
(	O
BB0548	O
)	O
,	O
LigI	O
(	O
BB0552	O
)	O
and	O
RecJ	O
(	O
BB0254	O
)	O
(	O
Fraser	O
et	O
al	O
.	O
,	O
1997	O
)	O
which	O
are	O
involved	O
in	O
excision	O
and	O
repair	O
,	O
via	O
S	O
-	O
BER	O
or	O
L	O
-	O
BER	O
,	O
of	O
deaminated	O
,	O
alkylated	O
,	O
methylated	O
or	O
mismatched	O
bases	O
.	O

Clearly	O
,	O
these	O
repair	O
systems	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
do	O
not	O
seem	O
as	O
robust	O
at	O
defending	O
against	O
oxidation	O
of	O
DNA	O
as	O
those	O
described	O
in	O
E	B-Species
.	I-Species
coli	E-Species
.	O

The	O
lack	O
of	O
key	O
repair	O
enzymes	O
in	O
this	O
system	O
may	O
indicate	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
is	O
not	O
subjected	O
to	O
the	O
same	O
challenge	O
from	O
ROS	O
as	O
is	O
E	B-Species
.	I-Species
coli	E-Species
.	O

In	O
most	O
bacteria	O
,	O
ROS	O
-	O
mediated	O
damage	O
to	O
lipids	O
(	O
lipid	O
peroxidation	O
)	O
is	O
very	O
unlikely	O
because	O
of	O
the	O
lack	O
of	O
polyunsaturated	O
fatty	O
acids	O
(	O
e	O
.	O
g	O
.	O
linoleic	O
acid	O
)	O
(	O
Imlay	O
,	O
2003	O
)	O
.	O

When	O
it	O
does	O
occur	O
,	O
lipid	O
peroxidation	O
is	O
initiated	O
by	O
the	O
attack	O
of	O
free	O
radicals	O
on	O
polyunsaturated	O
fatty	O
acids	O
which	O
decreases	O
the	O
membrane	O
fluidity	O
and	O
,	O
if	O
these	O
reactions	O
propagate	O
,	O
lipid	O
peroxides	O
and	O
their	O
degradation	O
products	O
(	O
e	O
.	O
g	O
.	O
aldehydes	O
)	O
in	O
turn	O
could	O
damage	O
proteins	O
(	O
Gutteridge	O
and	O
Halliwell	O
,	O
1990	O
)	O
.	O

This	O
would	O
dramatically	O
affect	O
the	O
function	O
of	O
transmembrane	O
proteins	O
and	O
membrane	O
-	O
bound	O
lipoproteins	O
involved	O
in	O
the	O
maintenance	O
of	O
membrane	O
potential	O
and	O
solute	O
transport	O
,	O
decreasing	O
cell	O
survivability	O
.	O

In	O
contrast	O
to	O
most	O
bacteria	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
membranes	O
contained	O
significant	O
levels	O
of	O
unsaturated	O
fatty	O
acids	O
,	O
such	O
as	O
linoleic	O
acid	O
and	O
linolenic	O
acid	O
,	O
which	O
were	O
derived	O
from	O
the	O
growth	O
media	O
(	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
it	O
seemed	O
possible	O
that	O
lipids	O
and	O
/	O
or	O
proteins	O
rather	O
than	O
DNA	O
are	O
the	O
primary	O
targets	O
of	O
ROS	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
.	O

When	O
Borrelia	O
cells	O
are	O
treated	O
with	O
oxidants	O
,	O
the	O
levels	O
of	O
linoleic	O
acid	O
decreased	O
while	O
other	O
fatty	O
acids	O
remain	O
unaffected	O
(	O
Table	O
2	O
)	O
.	O

In	O
addition	O
,	O
HPLC	O
-	O
based	O
assays	O
demonstrated	O
that	O
,	O
as	O
linoleic	O
acid	O
concentrations	O
decrease	O
,	O
MDA	O
(	O
a	O
toxic	O
lipid	O
peroxide	O
intermediate	O
)	O
increased	O
(	O
Fig	O
.	O
3	O
)	O
.	O

When	O
these	O
cells	O
were	O
examined	O
by	O
electron	O
microscopy	O
,	O
damage	O
to	O
the	O
membranes	O
(	O
membrane	O
'	O
blebs	O
'	O
)	O
was	O
observed	O
(	O
Fig	O
.	O
6	O
)	O
.	O

These	O
data	O
indicated	O
that	O
unlike	O
most	O
other	O
bacteria	O
,	O
Borrelia	O
membranes	O
were	O
damaged	O
by	O
oxygen	O
radicals	O
.	O

As	O
B	B-Species
.	I-Species
burgdorferi	E-Species
may	O
be	O
exposed	O
to	O
potentially	O
harmful	O
oxygen	O
species	O
at	O
different	O
stages	O
of	O
the	O
infective	O
cycle	O
,	O
the	O
ability	O
to	O
protect	O
its	O
membrane	O
lipids	O
from	O
ROS	O
should	O
be	O
required	O
for	O
survival	O
in	O
the	O
different	O
host	O
environments	O
.	O

In	O
eukaryotic	O
cells	O
,	O
where	O
lipid	O
peroxidation	O
is	O
a	O
major	O
consequence	O
of	O
oxidative	O
attack	O
,	O
proteins	O
which	O
protect	O
membranes	O
have	O
been	O
well	O
studied	O
.	O

For	O
example	O
,	O
phospholipid	O
hydroperoxide	O
glutathione	O
peroxidase	O
,	O
a	O
member	O
of	O
the	O
glutathione	O
peroxidase	O
family	O
,	O
has	O
been	O
identified	O
in	O
a	O
variety	O
of	O
higher	O
organisms	O
.	O

These	O
enzymes	O
are	O
capable	O
of	O
reducing	O
an	O
assortment	O
of	O
hydroperoxy	O
lipids	O
,	O
including	O
oxidized	O
phospholipids	O
and	O
cholesterol	O
esters	O
(	O
Ursini	O
and	O
Bindoli	O
,	O
1987	O
)	O
,	O
and	O
protect	O
complex	O
membranes	O
from	O
oxidative	O
damage	O
.	O

Much	O
less	O
is	O
known	O
about	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
protecting	O
unsaturated	O
lipids	O
from	O
ROS	O
in	O
prokaryotes	O
.	O

In	O
H	B-Species
.	I-Species
pylori	E-Species
,	O
lipid	O
hydroperoxide	O
levels	O
in	O
ahpC	O
mutants	O
are	O
approximately	O
three	O
times	O
higher	O
than	O
in	O
wild	O
-	O
type	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
AhpC	O
in	O
reducing	O
organic	O
peroxides	O
(	O
Wang	O
et	O
al	O
.	O
,	O
2006a	O
,	O
b	O
)	O
.	O

In	O
addition	O
,	O
purified	O
AhpC	O
has	O
been	O
shown	O
to	O
reduce	O
linoleic	O
acid	O
hydroperoxide	O
in	O
vitro	O
(	O
Baker	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Because	O
these	O
antioxidant	O
enzymes	O
promote	O
the	O
in	O
vivo	O
survival	O
of	O
cells	O
when	O
challenged	O
with	O
ROS	O
,	O
enzymes	O
for	O
the	O
reduction	O
of	O
lipid	O
peroxides	O
in	O
Borrelia	O
need	O
to	O
be	O
identified	O
.	O

Interestingly	O
,	O
Borrelia	O
cells	O
grown	O
aerobically	O
showed	O
signs	O
of	O
membrane	O
damage	O
similar	O
to	O
those	O
observed	O
in	O
cells	O
exposed	O
to	O
various	O
oxidants	O
.	O

The	O
amount	O
of	O
MDA	O
in	O
untreated	O
aerobically	O
grown	O
cells	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
treated	O
cells	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Also	O
,	O
EM	O
indicated	O
that	O
cells	O
grown	O
microaerobically	O
or	O
aerobically	O
had	O
significantly	O
more	O
membrane	O
damage	O
than	O
cells	O
grown	O
anaerobically	O
(	O
Fig	O
.	O
6	O
)	O
.	O

This	O
indicated	O
that	O
Borrelia	O
membranes	O
can	O
be	O
damaged	O
simply	O
by	O
exposure	O
to	O
physiologically	O
relevant	O
concentrations	O
of	O
dissolved	O
oxygen	O
.	O

In	O
exponentially	O
growing	O
E	B-Species
.	I-Species
coli	E-Species
,	O
Imlay	O
and	O
Fridovich	O
(	O
1991	O
)	O
have	O
shown	O
that	O
both	O
O2	O
-	O
and	O
H2O2	O
are	O
generated	O
by	O
the	O
autoxidation	O
of	O
components	O
of	O
the	O
respiratory	O
chain	O
during	O
oxygen	O
metabolism	O
.	O

In	O
contrast	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
is	O
very	O
metabolically	O
limited	O
and	O
has	O
no	O
enzymes	O
for	O
the	O
TCA	O
cycle	O
or	O
respiration	O
.	O

Therefore	O
,	O
it	O
seems	O
more	O
likely	O
that	O
sources	O
of	O
ROS	O
are	O
exogenous	O
(	O
e	O
.	O
g	O
.	O
innate	O
immune	O
response	O
in	O
the	O
mammalian	O
host	O
)	O
rather	O
than	O
endogenous	O
.	O

In	O
addition	O
,	O
the	O
current	O
practice	O
of	O
growing	O
B	B-Species
.	I-Species
burgdorferi	E-Species
under	O
atmospheric	O
oxygen	O
could	O
itself	O
be	O
unintentionally	O
compromising	O
cell	O
integrity	O
during	O
in	O
vitro	O
manipulations	O
.	O

Analyses	O
of	O
the	O
B	B-Species
.	I-Species
burgdorferi	E-Species
genome	O
indicates	O
that	O
only	O
a	O
few	O
genes	O
encoding	O
putative	O
oxidative	O
stress	O
/	O
intracellular	O
redox	O
proteins	O
(	O
SodA	O
,	O
NapA	O
,	O
BosR	O
,	O
CoADR	O
,	O
Trx	O
and	O
TrxR	O
)	O
(	O
Fraser	O
et	O
al	O
.	O
,	O
1997	O
)	O
are	O
present	O
,	O
compared	O
with	O
other	O
bacterial	O
pathogens	O
,	O
including	O
other	O
pathogenic	O
spirochetes	O
(	O
e	O
.	O
g	O
.	O
Treponema	O
,	O
Leptospira	O
)	O
.	O

Despite	O
this	O
apparent	O
'	O
deficiency	O
'	O
in	O
the	O
number	O
of	O
ROS	O
-	O
protective	O
enzymes	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
cells	O
appear	O
to	O
be	O
able	O
to	O
cope	O
with	O
physiologically	O
relevant	O
levels	O
of	O
ROS	O
.	O

There	O
are	O
several	O
factors	O
that	O
would	O
contribute	O
to	O
this	O
phenomenon	O
:	O
(	O
i	O
)	O
as	O
B	B-Species
.	I-Species
burgdorferi	E-Species
does	O
not	O
harbour	O
the	O
genes	O
encoding	O
respiratory	O
enzymes	O
nor	O
metabolize	O
oxygen	O
,	O
it	O
seems	O
unlikely	O
that	O
significant	O
levels	O
of	O
ROS	O
are	O
generated	O
via	O
the	O
incomplete	O
reduction	O
of	O
O2	O
during	O
cellular	O
metabolism	O
.	O

This	O
would	O
suggest	O
that	O
potential	O
ROS	O
challenges	O
to	O
B	B-Species
.	I-Species
burgdorferi	E-Species
would	O
come	O
almost	O
completely	O
from	O
extracellular	O
sources	O
with	O
little	O
contribution	O
from	O
intracellularly	O
generated	O
ROS	O
;	O
(	O
ii	O
)	O
owing	O
to	O
a	O
lack	O
of	O
understanding	O
of	O
the	O
physiological	O
conditions	O
in	O
vector	O
and	O
host	O
tissues	O
infected	O
with	O
B	B-Species
.	I-Species
burgdorferi	E-Species
,	O
it	O
is	O
difficult	O
to	O
assess	O
the	O
levels	O
and	O
/	O
or	O
sites	O
of	O
the	O
potential	O
ROS	O
challenge	O
during	O
the	O
infective	O
cycle	O
and	O
(	O
iii	O
)	O
most	O
importantly	O
,	O
analyses	O
of	O
the	O
potential	O
targets	O
for	O
ROS	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strongly	O
suggested	O
that	O
the	O
major	O
targets	O
of	O
oxidative	O
damage	O
are	O
different	O
and	O
perhaps	O
less	O
extensive	O
in	O
this	O
bacterium	O
than	O
in	O
other	O
bacterial	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
E	B-Species
.	I-Species
coli	E-Species
)	O
.	O

Taken	O
together	O
,	O
this	O
suggests	O
that	O
B	B-Species
.	I-Species
burgdorferi	E-Species
would	O
be	O
innately	O
more	O
resistant	O
to	O
ROS	O
and	O
require	O
a	O
less	O
extensive	O
repertoire	O
of	O
enzymes	O
to	O
protect	O
the	O
cells	O
from	O
oxidative	O
damage	O
.	O

Experimental	O
procedures	O

Strains	O
,	O
growth	O
conditions	O
and	O
reagents	O

Borrelia	B-Species
burgdorferi	E-Species
strain	O
B31A3	O
and	O
strain	O
B314	O
(	O
Sadziene	O
et	O
al	O
.	O
,	O
1993	O
)	O
were	O
grown	O
in	O
modified	O
BSK	O
-	O
II	O
(	O
Barbour	O
,	O
1984	O
)	O
medium	O
at	O
34	O
degrees	O
C	O
under	O
an	O
atmosphere	O
of	O
0	O
-	O
20	O
%	O
O2	O
with	O
5	O
%	O
CO2	O
and	O
the	O
balance	O
N2	O
.	O

Cells	O
density	O
was	O
determined	O
using	O
a	O
dark	O
-	O
field	O
microscope	O
.	O

All	O
reagents	O
were	O
purchased	O
from	O
Sigma	O
Chemicals	O
,	O
St	O
.	O

Louis	O
,	O
MO	O
unless	O
stated	O
otherwise	O
.	O

E	B-Species
.	I-Species
coli	E-Species
strain	O
Top10	O
,	O
strain	O
TA4315	O
(	O
ahpCF	O
)	O
(	O
Storz	O
et	O
al	O
.	O
,	O
1989	O
)	O
and	O
CM1319	O
(	O
mutM	O
)	O
(	O
Bridges	O
et	O
al	O
.	O
,	O
1996	O
)	O
were	O
grown	O
in	O
Luria	O
-	O
Bertani	O
(	O
LB	O
)	O
at	O
37	O
degrees	O
C	O
with	O
shaking	O
.	O

Per	O
cent	O
survivability	O
assays	O

Borrelia	B-Species
burgdorferi	E-Species
strain	O
B31A3	O
was	O
grown	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
in	O
BSK	O
II	O
under	O
microaerobic	O
(	O
3	O
%	O
O2	O
)	O
conditions	O
,	O
the	O
culture	O
split	O
and	O
the	O
cells	O
treated	O
with	O
varying	O
concentrations	O
of	O
oxidants	O
(	O
0	O
-	O
50	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
or	O
H2O2	O
)	O
at	O
34	O
degrees	O
C	O
for	O
4	O
h	O
.	O

After	O
the	O
incubation	O
,	O
cells	O
were	O
diluted	O
in	O
fresh	O
BSK	O
II	O
,	O
plated	O
on	O
BSK	O
plates	O
and	O
incubated	O
7	O
-	O
14	O
days	O
at	O
34	O
degrees	O
C	O
.	O

Per	O
cent	O
survivability	O
was	O
calculated	O
as	O
the	O
number	O
of	O
colonies	O
on	O
the	O
treated	O
plates	O
versus	O
the	O
number	O
of	O
colonies	O
on	O
the	O
untreated	O
plates	O
.	O

Determination	O
of	O
the	O
spontaneous	O
mutation	O
rate	O

To	O
determine	O
spontaneous	O
resistance	O
to	O
coumermycin	O
A1	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
B31A3	O
cells	O
were	O
grown	O
under	O
microaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
and	O
treated	O
with	O
5	O
mM	O
H2O2	O
for	O
1	O
h	O
at	O
34	O
degrees	O
C	O
.	O

The	O
cells	O
were	O
plated	O
on	O
BSK	O
plates	O
containing	O
0	O
or	O
250	O
ng	O
ml	O
-	O
1	O
coumermycin	O
A1	O
and	O
incubated	O
7	O
-	O
14	O
days	O
at	O
34	O
degrees	O
C	O
.	O

The	O
resistance	O
frequency	O
was	O
calculated	O
as	O
the	O
number	O
of	O
colonies	O
that	O
are	O
CouR	O
per	O
total	O
number	O
of	O
cells	O
plated	O
.	O

Measurement	O
of	O
DNA	O
base	O
lesions	O

Borrelia	B-Species
burgdorferi	E-Species
B31A3	O
cells	O
were	O
grown	O
in	O
BSK	O
-	O
II	O
under	O
microaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
,	O
treated	O
with	O
various	O
oxidants	O
(	O
1	O
or	O
10	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
1	O
or	O
10	O
mM	O
H2O2	O
,	O
10	O
mM	O
paraquat	O
or	O
lipoxidase	O
)	O
for	O
4	O
h	O
and	O
total	O
DNA	O
was	O
isolated	O
using	O
Wizard	O
Genomic	O
DNA	O
Purification	O
Kit	O
(	O
Promega	O
Corp	O
.	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

The	O
number	O
of	O
base	O
lesions	O
was	O
determined	O
using	O
the	O
DNA	O
Damage	O
Quantification	O
Colorimetric	O
Assay	O
kit	O
(	O
Oxford	O
Biomedical	O
Research	O
,	O
Oxford	O
,	O
MI	O
)	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Briefly	O
,	O
500	O
ng	O
of	O
DNA	O
was	O
mixed	O
with	O
an	O
equal	O
volume	O
of	O
10	O
mM	O
biotinylated	O
aldehyde	O
reactive	O
probe	O
(	O
ARP	O
)	O
reagent	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

The	O
DNA	O
-	O
ARP	O
product	O
was	O
ethanol	O
-	O
precipitated	O
using	O
glycogen	O
as	O
a	O
carrier	O
,	O
washed	O
three	O
times	O
with	O
70	O
%	O
ethanol	O
and	O
resuspended	O
in	O
Tris	O
-	O
EDTA	O
to	O
give	O
a	O
final	O
concentration	O
of	O
0	O
.	O
5	O
micro	O
g	O
ml	O
-	O
1	O
.	O

The	O
DNA	O
-	O
ARP	O
product	O
was	O
allowed	O
to	O
bind	O
to	O
the	O
wells	O
of	O
96	O
-	O
well	O
microplate	O
overnight	O
at	O
37	O
degrees	O
C	O
.	O

After	O
the	O
binding	O
,	O
the	O
wells	O
were	O
washed	O
four	O
times	O
with	O
TPBS	O
(	O
137	O
mM	O
NaCl	O
,	O
2	O
.	O
7	O
mM	O
KCl	O
,	O
10	O
mM	O
Na3HPO4	O
,	O
2	O
mM	O
KH2PO4	O
,	O
0	O
.	O
5	O
%	O
Tween	O
20	O
,	O
pH	O
7	O
.	O
4	O
)	O
.	O

The	O
HRP	O
-	O
streptavidin	O
conjugate	O
was	O
diluted	O
to	O
0	O
.	O
5	O
micro	O
g	O
ml	O
-	O
1	O
in	O
Assay	O
Buffer	O
(	O
0	O
.	O
15	O
M	O
NaCl	O
,	O
10	O
mM	O
NasHPO4	O
,	O
1	O
.	O
5	O
mM	O
KH2PO4	O
,	O
2	O
.	O
5	O
mM	O
KCl	O
,	O
5	O
mg	O
ml	O
-	O
1	O
BSA	O
,	O
0	O
.	O
1	O
%	O
Tween	O
,	O
pH	O
7	O
.	O
5	O
)	O
,	O
100	O
micro	O
l	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
incubated	O
at	O
100	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
1	O
h	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
.	O

After	O
incubation	O
,	O
the	O
wells	O
were	O
washed	O
four	O
times	O
with	O
TPBS	O
,	O
100	O
micro	O
l	O
of	O
substrate	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

The	O
reaction	O
was	O
then	O
quenched	O
with	O
100	O
micro	O
l	O
of	O
1	O
M	O
sulphuric	O
acid	O
and	O
the	O
reaction	O
was	O
monitored	O
at	O
450	O
nm	O
.	O

The	O
number	O
of	O
aldehyde	O
reactive	O
probe	O
(	O
DNA	O
base	O
lesions	O
)	O
per	O
105	O
bp	O
DNA	O
was	O
determined	O
using	O
a	O
standard	O
curve	O
.	O

As	O
a	O
control	O
,	O
E	B-Species
.	I-Species
coli	E-Species
TA4315	O
cells	O
were	O
grown	O
in	O
minimal	O
media	O
to	O
OD600	O
of	O
0	O
.	O
4	O
,	O
treated	O
with	O
0	O
or	O
100	O
micro	O
M	O
H2O2	O
for	O
30	O
min	O
and	O
DNA	O
isolated	O
.	O

The	O
number	O
of	O
base	O
lesions	O
was	O
determined	O
as	O
described	O
above	O
.	O

B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B314	O
cells	O
were	O
grown	O
under	O
microaerobic	O
conditions	O
and	O
DNA	O
isolated	O
.	O

The	O
number	O
of	O
DNA	O
lesions	O
was	O
determined	O
as	O
described	O
.	O

To	O
determine	O
the	O
amount	O
of	O
8	O
-	O
oxoguanine	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
DNA	O
,	O
cells	O
were	O
grown	O
and	O
treated	O
as	O
described	O
above	O
and	O
DNA	O
isolated	O
.	O

The	O
DNA	O
was	O
converted	O
to	O
single	O
-	O
stranded	O
DNA	O
by	O
boiling	O
the	O
sample	O
for	O
5	O
min	O
followed	O
by	O
rapid	O
chill	O
on	O
ice	O
.	O

The	O
DNA	O
was	O
then	O
digested	O
with	O
nuclease	O
P1	O
for	O
2	O
h	O
and	O
then	O
treated	O
with	O
alkaline	O
phosphatase	O
for	O
1	O
h	O
following	O
manufacturer	O
'	O
s	O
protocols	O
.	O

The	O
resultant	O
mixture	O
was	O
then	O
centrifuged	O
for	O
5	O
min	O
at	O
6000	O
g	O
and	O
the	O
supernatant	O
used	O
for	O
the	O
8	O
-	O
oxoguanine	O
ELISA	O
assay	O
(	O
Oxford	O
Biomedical	O
Research	O
,	O
Oxford	O
,	O
MI	O
)	O
.	O

As	O
a	O
control	O
,	O
E	B-Species
.	I-Species
coli	E-Species
CM1319	O
(	O
mutM	O
)	O
cells	O
were	O
grown	O
in	O
LB	O
to	O
OD600	O
of	O
0	O
.	O
4	O
,	O
treated	O
with	O
0	O
or	O
100	O
micro	O
M	O
H2O2	O
for	O
1	O
h	O
and	O
DNA	O
isolated	O
.	O

The	O
concentration	O
of	O
8	O
-	O
oxoguanine	O
was	O
determined	O
as	O
above	O
.	O

Lipid	O
analyses	O

To	O
determine	O
fatty	O
acid	O
content	O
in	O
B	B-Species
.	I-Species
burgdorferi	E-Species
total	O
membranes	O
,	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B31A3	O
was	O
grown	O
under	O
anaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
,	O
harvested	O
by	O
centrifugation	O
(	O
5000	O
g	O
,	O
15	O
min	O
,	O
4	O
degrees	O
C	O
)	O
and	O
washed	O
two	O
times	O
with	O
HN	O
(	O
20	O
mM	O
NaCl	O
,	O
50	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
6	O
)	O
buffer	O
.	O

Cell	O
pellets	O
were	O
analysed	O
for	O
fatty	O
acid	O
composition	O
by	O
fatty	O
acid	O
methyl	O
ester	O
(	O
FAME	O
)	O
gas	O
chromatography	O
(	O
Lipid	O
Technologies	O
,	O
Austin	O
,	O
MN	O
)	O
and	O
results	O
are	O
reported	O
as	O
percentage	O
of	O
total	O
fatty	O
acid	O
content	O
.	O

To	O
determine	O
the	O
effects	O
of	O
oxidants	O
on	O
fatty	O
acid	O
composition	O
,	O
a	O
1	O
.	O
5	O
l	O
culture	O
of	O
B	B-Species
.	I-Species
burgdorferi	E-Species
strain	O
B31A3	O
was	O
grown	O
under	O
microaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
.	O

The	O
culture	O
was	O
split	O
into	O
500	O
ml	O
aliquots	O
,	O
the	O
first	O
was	O
treated	O
with	O
1	O
mM	O
t	O
-	O
butyl	O
hydroperoxide	O
,	O
the	O
second	O
with	O
0	O
.	O
25	O
mg	O
of	O
lipoxidase	O
(	O
17	O
700	O
units	O
)	O
and	O
the	O
third	O
was	O
untreated	O
.	O

All	O
cultures	O
were	O
incubated	O
for	O
12	O
h	O
at	O
34	O
degrees	O
C	O
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
5000	O
g	O
,	O
4	O
degrees	O
C	O
,	O
15	O
min	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

The	O
fatty	O
acids	O
present	O
in	O
the	O
cell	O
pellets	O
were	O
analysed	O
by	O
FAME	O
gas	O
chromatography	O
(	O
Industrial	O
Laboratory	O
,	O
Wheat	O
Ridge	O
,	O
CO	O
)	O
.	O

Fatty	O
acids	O
were	O
reported	O
as	O
percentage	O
of	O
total	O
cell	O
mass	O
.	O

Measurement	O
of	O
MDA	O

Borrelia	B-Species
burgdorferi	E-Species
strain	O
B31A3	O
was	O
grown	O
aerobically	O
,	O
microaerobically	O
and	O
anaerobically	O
as	O
described	O
above	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
.	O

The	O
microaerobic	O
culture	O
was	O
split	O
and	O
treated	O
with	O
either	O
5	O
mM	O
AAPH	O
[	O
2	O
,	O
2	O
'	O
-	O
azobis	O
(	O
2	O
-	O
methylpropionamidine	O
)	O
dihydrochloride	O
]	O
or	O
250	O
mg	O
of	O
lipoxidase	O
for	O
4	O
h	O
at	O
34	O
degrees	O
C	O
.	O

To	O
measure	O
the	O
amount	O
of	O
MDA	O
,	O
the	O
cells	O
were	O
derivatized	O
with	O
thiobarbituric	O
acid	O
and	O
analysed	O
by	O
HPLC	O
as	O
described	O
by	O
Seljeskog	O
et	O
al	O
.	O

(	O
2006	O
)	O
.	O

After	O
the	O
incubation	O
,	O
all	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
1000	O
g	O
,	O
5	O
min	O
,	O
4	O
degrees	O
C	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

Each	O
sample	O
was	O
resuspended	O
in	O
50	O
micro	O
l	O
of	O
HN	O
,	O
mixed	O
with	O
150	O
micro	O
l	O
of	O
0	O
.	O
1	O
N	O
perchloric	O
acid	O
,	O
150	O
micro	O
l	O
of	O
40	O
mM	O
thiobarbituric	O
acid	O
and	O
35	O
micro	O
l	O
of	O
20	O
%	O
SDS	O
,	O
vortexed	O
and	O
heated	O
at	O
97	O
degrees	O
C	O
for	O
60	O
min	O
.	O

After	O
cooling	O
at	O
-	O
20	O
degrees	O
C	O
for	O
20	O
min	O
,	O
300	O
micro	O
l	O
of	O
methanol	O
and	O
100	O
micro	O
l	O
of	O
20	O
%	O
trichloroacetic	O
acid	O
was	O
added	O
and	O
the	O
samples	O
were	O
mixed	O
vigorously	O
and	O
centrifuged	O
(	O
13	O
000	O
g	O
,	O
6	O
min	O
)	O
.	O

The	O
samples	O
(	O
10	O
micro	O
l	O
)	O
were	O
then	O
analysed	O
with	O
an	O
Agilent	O
Technologies	O
1200	O
series	O
HPLC	O
system	O
using	O
a	O
C18	O
4	O
.	O
6	O
x	O
150	O
mm	O
column	O
with	O
mobile	O
phase	O
72	O
:	O
17	O
:	O
11	O
(	O
50	O
mM	O
KPO4	O
,	O
pH	O
6	O
.	O
8	O
:	O
methanol	O
:	O
acetonitrile	O
)	O
.	O

Absorbance	O
was	O
monitored	O
at	O
532	O
nm	O
.	O

Pure	O
MDA	O
standards	O
(	O
0	O
-	O
10	O
micro	O
M	O
)	O
were	O
prepared	O
in	O
methanol	O
for	O
comparison	O
.	O

As	O
a	O
negative	O
control	O
,	O
E	B-Species
.	I-Species
coli	E-Species
Top10	O
cells	O
were	O
grown	O
to	O
OD600	O
of	O
0	O
.	O
4	O
,	O
treated	O
with	O
0	O
or	O
5	O
mM	O
AAPH	O
for	O
30	O
min	O
and	O
MDA	O
measured	O
as	O
above	O
.	O

As	O
a	O
positive	O
control	O
,	O
mouse	S-Species
myeloma	O
SP2	O
/	O
O	O
cells	O
were	O
cultured	O
with	O
HYQ	O
-	O
CCM1	O
(	O
HyClone	O
)	O
medium	O
at	O
37	O
degrees	O
C	O
in	O
a	O
humidified	O
5	O
%	O
CO2	O
atmosphere	O
,	O
treated	O
with	O
1	O
mM	O
AAPH	O
at	O
37	O
degrees	O
C	O
for	O
4	O
h	O
(	O
Chotimarkorn	O
et	O
al	O
.	O
,	O
2005	O
)	O
and	O
MDA	O
measured	O
as	O
above	O
.	O

Identification	O
of	O
lipid	O
damage	O
using	O
Diphenyl	O
-	O
1	O
-	O
pyrenylphosphine	O
fluorescent	O
stain	O

Borrelia	B-Species
burgdorferi	E-Species
strain	O
B31A3	O
cells	O
were	O
grown	O
microaerobically	O
as	O
described	O
above	O
until	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
was	O
obtained	O
.	O

The	O
culture	O
was	O
divided	O
into	O
two	O
equal	O
aliquots	O
and	O
the	O
cells	O
treated	O
with	O
5	O
mM	O
AAPH	O
for	O
4	O
h	O
at	O
34	O
degrees	O
C	O
.	O

After	O
the	O
incubation	O
,	O
all	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
1000	O
g	O
,	O
5	O
min	O
,	O
4	O
degrees	O
C	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

To	O
visualize	O
Borrelia	O
cells	O
,	O
the	O
cells	O
were	O
stained	O
with	O
PKH26	O
Red	O
Fluorescent	O
Cell	O
Linker	O
Dye	O
(	O
Sigma	O
Aldrich	O
)	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

To	O
visualize	O
the	O
lipid	O
hydroperoxides	O
in	O
the	O
cell	O
membrane	O
,	O
the	O
cells	O
were	O
counterstained	O
with	O
DPPP	O
(	O
Cayman	O
Chemicals	O
,	O
MI	O
)	O
(	O
Okimoto	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Briefly	O
,	O
after	O
cells	O
were	O
stained	O
with	O
the	O
Red	O
Fluorescent	O
dye	O
,	O
2	O
ml	O
of	O
rabbit	S-Species
serum	O
was	O
added	O
to	O
stop	O
the	O
reaction	O
and	O
the	O
mixture	O
incubated	O
for	O
1	O
min	O
at	O
RT	O
.	O

Next	O
,	O
4	O
ml	O
of	O
HN	O
buffer	O
was	O
added	O
,	O
the	O
cells	O
harvested	O
by	O
centrifugation	O
(	O
1000	O
g	O
,	O
10	O
min	O
,	O
RT	O
)	O
and	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

The	O
cells	O
were	O
then	O
resuspended	O
in	O
1	O
ml	O
of	O
HN	O
buffer	O
,	O
incubated	O
at	O
34	O
degrees	O
C	O
for	O
5	O
min	O
and	O
30	O
micro	O
l	O
of	O
2	O
.	O
5	O
mM	O
DPPP	O
was	O
added	O
.	O

The	O
incubation	O
was	O
then	O
continued	O
at	O
34	O
degrees	O
C	O
for	O
5	O
min	O
in	O
the	O
dark	O
.	O

After	O
incubation	O
,	O
the	O
mixture	O
was	O
centrifuged	O
(	O
1000	O
g	O
,	O
10	O
min	O
,	O
RT	O
)	O
and	O
the	O
cells	O
washed	O
three	O
times	O
with	O
HN	O
buffer	O
.	O

The	O
cells	O
were	O
then	O
resuspended	O
in	O
100	O
micro	O
l	O
HN	O
buffer	O
and	O
observed	O
by	O
fluorescence	O
microscopy	O
with	O
excitation	O
wavelengths	O
551	O
nm	O
(	O
Red	O
Fluorescent	O
)	O
and	O
351	O
nm	O
(	O
DPPP	O
)	O
,	O
and	O
emission	O
wavelengths	O
567	O
nm	O
(	O
Red	O
Fluorescent	O
)	O
and	O
380	O
nm	O
(	O
DPPP	O
)	O
.	O

As	O
a	O
positive	O
control	O
,	O
mouse	S-Species
myeloma	O
SP2	O
/	O
O	O
cells	O
were	O
cultured	O
with	O
HYQ	O
-	O
CCM1	O
(	O
HyClone	O
)	O
medium	O
at	O
37	O
degrees	O
C	O
in	O
a	O
humidified	O
5	O
%	O
CO2	O
atmosphere	O
,	O
treated	O
with	O
1	O
mM	O
AAPH	O
at	O
37	O
degrees	O
C	O
for	O
4	O
h	O
(	O
Chotimarkorn	O
et	O
al	O
.	O
,	O
2005	O
)	O
and	O
stained	O
as	O
described	O
above	O
.	O

As	O
a	O
negative	O
control	O
,	O
E	B-Species
.	I-Species
coli	E-Species
Top10	O
cells	O
were	O
grown	O
to	O
OD600	O
of	O
0	O
.	O
4	O
,	O
treated	O
with	O
0	O
or	O
5	O
mM	O
AAPH	O
for	O
30	O
min	O
and	O
stained	O
as	O
described	O
above	O
.	O

Electron	O
microscopy	O

Borrelia	B-Species
burgdorferi	E-Species
cells	O
were	O
grown	O
under	O
microaerobic	O
or	O
anaerobic	O
conditions	O
to	O
a	O
cell	O
density	O
of	O
5	O
x	O
107	O
cells	O
ml	O
-	O
1	O
.	O

The	O
microaerobic	O
cultures	O
were	O
split	O
and	O
treated	O
with	O
lipoxidase	O
for	O
4	O
h	O
at	O
34	O
degrees	O
C	O
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
5000	O
g	O
,	O
10	O
min	O
,	O
4	O
degrees	O
C	O
)	O
,	O
washed	O
and	O
resuspended	O
in	O
HBSS	O
(	O
Lonza	O
Group	O
Ltd	O
,	O
Switzerland	O
)	O
.	O

The	O
cells	O
were	O
fixed	O
with	O
Karnovsky	O
'	O
s	O
phosphate	O
for	O
5	O
min	O
at	O
RT	O
adsorbed	O
to	O
Formvar	O
/	O
carbon	O
-	O
coated	O
grids	O
(	O
Ted	O
Pella	O
,	O
Redding	O
,	O
CA	O
)	O
for	O
5	O
min	O
and	O
washed	O
three	O
times	O
in	O
H2O	O
.	O

The	O
grids	O
were	O
stained	O
with	O
1	O
%	O
ammonium	O
molybdate	O
and	O
allowed	O
to	O
air	O
-	O
dry	O
.	O

Samples	O
were	O
examined	O
using	O
a	O
Hitachi	O
H7500	O
electron	O
microscope	O
(	O
Hitachi	O
High	O
Technologies	O
America	O
,	O
Pleasanton	O
,	O
CA	O
)	O
.	O

Cytotoxic	O
Activity	O
of	O
Silyl	O
-	O
and	O
Germyl	O
-	O
Substituted	O
4	O
,	O
4	O
-	O
Dioxo	O
-	O
3a	O
,	O
6a	O
-	O
Dihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazolines	O
-	O
2	O

Abstract	O

The	O
[	O
2	O
+	O
3	O
]	O
dipolar	O
cycloaddition	O
of	O
nitrile	O
oxides	O
to	O
the	O
double	O
C	O
=	O
C	O
bonds	O
of	O
thiophene	O
-	O
1	O
,	O
1	O
-	O
dioxides	O
leads	O
to	O
formation	O
of	O
the	O
fused	O
isoxazolines	O
-	O
2	O
(	O
1	O
,	O
2	O
)	O
.	O

Tumor	O
growth	O
inhibition	O
of	O
these	O
compounds	O
strongly	O
depends	O
on	O
the	O
nature	O
of	O
group	O
IV	O
A	O
element	O
increasing	O
from	O
slightly	O
active	O
tert	O
-	O
butyl	O
derivatives	O
to	O
silicon	O
and	O
germanium	O
containing	O
analogues	O
.	O

The	O
products	O
of	O
benzonitrile	O
oxide	O
cycloaddition	O
have	O
greater	O
cytotoxic	O
effect	O
than	O
the	O
compounds	O
obtained	O
from	O
the	O
cycloaddition	O
reaction	O
of	O
2	O
,	O
5	O
-	O
disubstituted	O
thiophene	O
-	O
1	O
,	O
1	O
-	O
dioxides	O
with	O
acetonitrile	O
oxide	O
.	O

Fused	O
silyl	O
substituted	O
isoxazolines	O
-	O
2	O
are	O
stronger	O
NO	O
-	O
inducers	O
than	O
their	O
germyl	O
and	O
tert	O
-	O
butyl	O
analogues	O
.	O

CYTOTOXIC	O
ACTIVITY	O
OF	O
SILYL	O
-	O
AND	O
GERMYL	O
-	O
SUBSTITUTED	O
4	O
,	O
4	O
-	O
DIOXO	O
-	O
3a	O
,	O
6a	O
-	O
DIHYDROTHIENO	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
ISOXAZOLINES	O
-	O
2	O

E	O
.	O

Lukevics	O
*	O
,	O
P	O
.	O

Arsenyan	O
,	O
I	O
.	O

Shestakova	O
,	O
O	O
.	O

Zharkova	O
,	O
I	O
.	O

Kanepe	O
,	O
R	O
.	O

Mezapuke	O
,	O
and	O
O	O
.	O

Pudova	O
Latvian	O
Institute	O
of	O
Organic	O
Synthesis	O
,	O
Aizkraukles	O
21	O
,	O
Riga	O
,	O
LV	O
-	O
1006	O
,	O
Latvia	O

ABSTRACT	O
The	O
[	O
2	O
+	O
3	O
]	O
dipolar	O
cycloaddition	O
of	O
nitrile	O
oxides	O
to	O
the	O
double	O
(	O
3	O
=	O
(	O
3	O
bonds	O
of	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioides	O
leads	O
to	O
formation	O
of	O
the	O
fused	O
isoxazolines	O
-	O
2	O
(	O
1	O
,	O
2	O
)	O
.	O

Tumor	O
growth	O
inhibition	O
of	O
these	O
compounds	O
strongly	O
depends	O
on	O
the	O
nature	O
of	O
group	O
IV	O
A	O
element	O
increasing	O
from	O
slightly	O
active	O
ert	O
-	O
butyl	O
derivatives	O
to	O
silicon	O
and	O
germanium	O
containing	O
analogues	O
.	O

The	O
products	O
of	O
benzonitdle	O
oxide	O
cycloaddition	O
have	O
greater	O
cytotoic	O
effect	O
than	O
the	O
compounds	O
obtained	O
from	O
he	O
cycloaddition	O
reaction	O
of	O
2	O
,	O
5	O
-	O
disubstituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
with	O
acetonitrile	O
oxide	O
.	O

Fused	O
silyl	O
substituted	O
isoxazolines	O
-	O
2	O
are	O
stronger	O
NO	O
-	O
inducers	O
than	O
their	O
germyl	O
and	O
tert	O
-	O
butyl	O
analogues	O
.	O

INTRODUCTION	O
The	O
interest	O
in	O
silyl	O
substituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
stems	O
from	O
the	O
fact	O
that	O
they	O
are	O
useful	O
synthetic	O
intermediates	O
for	O
the	O
preparation	O
of	O
various	O
types	O
of	O
organic	O
compounds	O
by	O
Diels	O
-	O
Alder	O
cycloaddition	O
[	O
1	O
]	O
,	O
amine	O
induced	O
ring	O
-	O
opening	O
reaction	O
[	O
2	O
]	O
,	O
or	O
coupling	O
of	O
bromothiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
with	O
thienyl	O
stannanes	O
in	O
the	O
presence	O
of	O
a	O
palladium	O
(	O
0	O
)	O
catalyst	O
[	O
3	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
unsubstituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxide	O
prepared	O
in	O
situ	O
is	O
a	O
quite	O
reactive	O
dipolarophile	O
in	O
the	O
[	O
2	O
+	O
3	O
]	O
cycloaddition	O
reactions	O
with	O
N	O
,	O
o	O
-	O
diphenylnitrone	O
[	O
4	O
]	O
,	O
benzonitrile	O
[	O
4	O
,	O
5	O
]	O
and	O
mesitonitrile	O
[	O
4	O
,	O
5	O
]	O
oxides	O
yielding	O
mono	O
-	O
and	O
diisoxazolines	O
-	O
2	O
and	O
N	O
-	O
substituted	O
isoxazolidines	O
.	O

Moreover	O
,	O
our	O
recent	O
studies	O
indicate	O
that	O
silyl	O
-	O
and	O
germylcontaining	O
isoxazolines	O
have	O
gained	O
a	O
great	O
deal	O
of	O
attention	O
as	O
compounds	O
possessing	O
a	O
wide	O
spectrum	O
of	O
the	O
biological	O
properties	O
.	O

The	O
vasodilating	O
,	O
anticoagulant	O
and	O
cardioprotective	O
activity	O
of	O
5	O
-	O
Si	O
-	O
(	O
Ge	O
)	O
substituted	O
isoxazolines	O
-	O
2	O
has	O
been	O
studied	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
6	O
,	O
7	O
]	O
.	O

The	O
most	O
active	O
isoxazoline	O
-	O
3	O
-	O
(	O
5	O
"	O
-	O
triethylgermyl	O
-	O
3	O
"	O
-	O
isoxazolino	O
)	O
pyridine	O
hydrochloride	O
protected	O
the	O
heart	O
from	O
rhythm	O
disturbances	O
and	O
lethality	O
during	O
ischemiareperfusion	O
[	O
7	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
silylisoxazolines	O
-	O
2	O
are	O
more	O
potent	O
in	O
protection	O
against	O
hypoxia	O
and	O
corazole	O
convulsions	O
than	O
germanium	O
analogues	O
.	O

However	O
,	O
germylisoxazolines	O
-	O
2	O
are	O
stronger	O
tumor	O
growth	O
inhibitors	O
and	O
NO	O
-	O
inducers	O
than	O
their	O
silicon	O
analogue	O
[	O
8	O
]	O
.	O

This	O
work	O
presents	O
the	O
results	O
of	O
cytotoxic	O
activity	O
for	O
fused	O
isoxazolines	O
-	O
2	O
bearing	O
a	O
group	O
14	O
element	O
as	O
substituent	O
(	O
1	O
,	O
2	O
)	O
in	O
function	O
of	O
the	O
nature	O
of	O
the	O
group	O
14	O
element	O
.	O

M	O

e3M	O
.	O
CH3	O
N	O

-	O
0	O
\	O
R	O

O	O
\	O
M	O

e3M	O
S	O

N	O

02	O

02	O
2	O

1	O

MATERIALS	O
AND	O
METHODS	O
CHEMISTRY	O
Seven	O
tert	O
-	O
butyl	O
-	O
,	O
trimethylsilyl	O
-	O
,	O
and	O
trimethylgermyl	O
-	O
substituted	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3a	O
,	O
6adihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazoline	O
-	O
2	O
1	O
and	O
2	O
(	O
Table	O
1	O
)	O
were	O
prepared	O
by	O
the	O
[	O
2	O
+	O
3	O
]	O
dipolar	O
63	O

Vol	O
.	O

7	O
,	O
No	O
.	O
2	O
,	O
2000	O

Cytotoxic	O
Activity	O
ofSilyl	O
-	O
and	O
Germyl	O
-	O
Substituted	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3a	O
,	O
6a	O
-	O
Dihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
Isoxazolines	O
-	O
2	O

cycloaddition	O
of	O
aceto	O
-	O
and	O
benzonitrile	O
oxides	O
to	O
2	O
,	O
5	O
-	O
disubstituted	O
thiophene	O
-	O
l	O
,	O
l	O
-	O
dioxides	O
.	O

Their	O
synthesis	O
and	O
characterization	O
are	O
given	O
in	O
ref	O
.	O

[	O
9	O
]	O
.	O

_	O
,	O
,	O
/	O
0	O
\	O
N	O
Me3M	O
M	O
'	O
Me3	O

Me3M	O

02	O
M	O
,	O
M	O
'	O
=	O
C	O
,	O
Si	O
,	O
Ge	O
;	O
R	O
=	O
Me	O
,	O
Ph	O
;	O
R	O
'	O
=	O
H	O
,	O
Me3Ge	O
Table	O
1	O
.	O

Me3C	O
,	O
MeSi	O
,	O
Investigated	O
dihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazolines	O
-	O
2	O

02	O
Me3Ge	O
substituted	O

%	O
,	O
\	O
R	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3a	O
,	O
6a	O

Compound	O

'	O
Type	O
la	O

M	O

R	O
H	O
Me3Ge	O
Me3Ge	O

Yield	O

4	O
,	O
4	O
-	O
dioxo	O
-	O
3	O
methyl	O
"	O
5	O
-	O
tert	O
-	O
butyl	O
-	O
3a	O
,	O
6adihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazoline	O
-	O
2	O

(	O
3	O
'	O
C	O
Si	O

(	O
%	O
)	O
80	O

4	O
,	O
4	O
-	O
dioxo	O
-	O
3	O
-	O
methyl	O
-	O
3a	O
-	O
trimethylgermyl	O
-	O
5	O
-	O
tert	O
-	O
butyl3a	O
,	O
6a	O
-	O
d	O
ihyd	O
rothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazoli	O
ne	O
-	O
2	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3	O
-	O
methyl	O
-	O
3a	O
-	O
trimethyigermyl	O
-	O
5tri	O
methylsilyl	O
-	O
3a	O
,	O
6a	O
-	O
d	O
hyd	O
roth	O
ien	O
o	O
[	O
2	O
,	O
3d	O
]	O
isoxazoline	O
-	O
2	O
4	O
,	O
4	O
-	O
d	O
io	O
x	O
o	O
-	O
3	O
-	O
meth	O
y	O
I	O
-	O
3a	O
,	O
5	O
-	O
b	O
s	O
tri	O
m	O
ethy	O
Ig	O
e	O
rmy	O
I	O
)	O
3a	O
,	O
6a	O
-	O
d	O
hyd	O
rothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazo	O
ne	O
-	O
2	O
4	O
,	O
4	O
-	O
d	O
ioxo	O
-	O
3	O
-	O
ph	O
en	O
y	O
I	O
-	O
5	O
-	O
tert	O
-	O
b	O
uty	O
I	O
-	O
3a	O
,	O
6adihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazoline	O
-	O
2	O
4	O
,	O
4	O
-	O
d	O
ioxo	O
-	O
3	O
-	O
p	O
h	O
e	O
ny	O
I	O
-	O
5	O
-	O
tri	O
meth	O
y	O
si	O
ly	O
I	O
-	O
3a	O
,	O
6adihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazoline	O
-	O
2	O
4	O
,	O
4	O
-	O
d	O
ioxo	O
-	O
3	O
-	O
p	O
h	O
e	O
n	O
y	O
I	O
-	O
5	O
-	O
tri	O
methy	O
Ig	O
e	O
rmy	O
I	O
-	O
3a	O
,	O
6adi	O
,	O
hydr0thieno	O
[	O
2	O
,	O
3	O
,	O
d	O
]	O
isoxazoline	O
-	O
2	O

lb	O
lc	O

58	O
45	O
67	O
84	O

ld	O
2a	O
2b	O

Ge	O

Me3Ge	O

C	O
Si	O

77	O
85	O

2c	O

Ge	O

IN	O
VITRO	O
CYTOTOXITY	O
ASSAY	O
Monolayer	O
cells	O
lines	O
were	O
cultivated	O
for	O
72	O
h	O
in	O
DMEM	O
standard	O
medium	O
without	O
an	O
indicator	O
and	O
antibiotics	O
.	O

After	O
the	O
ampoule	O
was	O
defreezed	O
not	O
more	O
than	O
four	O
passa4ges	O
were	O
performed	O
.	O

The	O
control	O
cells	O
and	O
cells	O
with	O
tested	O
substances	O
in	O
the	O
range	O
of	O
2	O
-	O
5	O
10	O
cell	O
/	O
mL	O
concentration	O
(	O
depending	O
on	O
line	O
nature	O
)	O
were	O
placed	O
on	O
a	O
separate	O
96	O
wells	O
plates	O
.	O

Solutions	O
containing	O
test	O
compounds	O
were	O
diluted	O
and	O
added	O
in	O
wells	O
to	O
give	O
the	O
final	O
concentrations	O
of	O
50	O
,	O
25	O
,	O
12	O
.	O
5	O
,	O
and	O
6	O
.	O
25	O
#	O
g	O
/	O
mL	O
Control	O
cells	O
were	O
treated	O
in	O
the	O
same	O
manner	O
only	O
in	O
the	O
absence	O
of	O
test	O
compounds	O
.	O

Plates	O
were	O
cultivated	O
for	O
72	O
h	O
.	O

A	O
quantity	O
of	O
survived	O
cells	O
was	O
determined	O
using	O
crystal	O
violet	O
(	O
CV	O
)	O
or	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5diphenyltetrazolinium	O
bromide	O
(	O
MTT	O
)	O
coloration	O
which	O
was	O
assayed	O
by	O
multiscan	O
spectrofotometer	O
.	O

The	O
quantity	O
of	O
alive	O
cells	O
on	O
control	O
plate	O
was	O
taken	O
in	O
calculations	O
for	O
100	O
%	O
[	O
10	O
,	O
11	O
]	O
.	O

Concentration	O
of	O
NO	O
was	O
determined	O
according	O
to	O
[	O
10	O
]	O
.	O

RESULTS	O
AND	O
DISCUSSION	O
Potential	O
cytotoxic	O
activity	O
of	O
synthesized	O
fused	O
isoxazolines	O
1	O
and	O
2	O
was	O
tested	O
in	O
vitro	O
on	O
four	O
monolayer	O
tumor	O
cell	O
lines	O
:	O
MG	O
-	O
22A	O
(	O
mouse	S-Species
hepatoma	O
)	O
,	O
HT	O
-	O
1080	O
(	O
human	S-Species
fibroblastoma	O
)	O
,	O
B16	O
(	O
mouse	S-Species
melanoma	O
)	O
,	O
Neuro	O
2A	O
(	O
mouse	S-Species
neiroblastoma	O
)	O
.	O

Concentrations	O
providing	O
50	O
%	O
of	O
tumor	O
death	O
effect	O
were	O
determined	O
according	O
to	O
the	O
known	O
procedure	O
[	O
12	O
]	O
using	O
96	O
well	O
plates	O
.	O

The	O
experimental	O
evaluation	O
of	O
cytotoxicity	O
properties	O
is	O
presented	O
in	O
Table	O
2	O
.	O

A	O
preliminary	O
analysis	O
of	O
the	O
structure	O
-	O
activity	O
relationship	O
for	O
the	O
cytotoxic	O
action	O
clearly	O
indicates	O
the	O
strong	O
influence	O
of	O
the	O
MeM	O
(	O
M	O
=	O
C	O
,	O
Si	O
,	O
Ge	O
)	O
group	O
in	O
position	O
5	O
of	O
fused	O
isoxazolines	O
1	O
and	O
2	O
.	O

Derivatives	O
bearing	O
tert	O
-	O
butyl	O
substituent	O
(	O
la	O
,	O
b	O
and	O
2a	O
)	O
have	O
a	O
slight	O
cytotoxic	O
effect	O
(	O
>	O
10	O
#	O
g	O
/	O
mL	O
)	O
.	O

The	O
substitution	O
of	O
the	O
tert	O
-	O
butyl	O
group	O
by	O
trimethylsilyl	O
or	O
64	O

E	O
.	O

Lukevics	O
et	O
al	O
.	O

Metal	O
-	O
Based	O
Drugs	O

A	O

oO	O

{	O
D	O

0	O

0	O

65	O

Vol	O
.	O

7	O
,	O
No	O
.	O
2	O
,	O
2000	O

Cytotoxic	O
Activity	O
ofSilyl	O
-	O
and	O
Germyl	O
-	O
Substituted	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3a	O
,	O
6a	O
-	O
Dihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
Isoxazolines	O
-	O
2	O

trimethylgermyl	O
ones	O
leads	O
to	O
considerable	O
increase	O
of	O
cytotoxicity	O
.	O

It	O
must	O
be	O
noted	O
that	O
the	O
activity	O
of	O
silicon	O
-	O
and	O
germanium	O
-	O
containing	O
compounds	O
(	O
1	O
and	O
l	O
d	O
)	O
depends	O
on	O
the	O
tumor	O
type	O
.	O

5	O
-	O
Trimethylsilyl	O
-	O
substituted	O
fused	O
isoxazoline	O
le	O
is	O
more	O
active	O
than	O
the	O
germanium	O
analogue	O
l	O
d	O
in	O
tests	O
on	O
HP	O
-	O
1080	O
and	O
MG	O
-	O
22A	O
cell	O
lines	O
.	O

However	O
,	O
the	O
germanium	O
compound	O
ld	O
has	O
greater	O
cytotoxic	O
effect	O
on	O
Neuro	O
2A	O
and	O
B16	O
cell	O
lines	O
than	O
the	O
silicon	O
derivative	O
lc	O
.	O

Comparison	O
of	O
the	O
tumor	O
growth	O
inhibition	O
for	O
derivatives	O
1	O
and	O
2	O
shows	O
a	O
higher	O
activity	O
of	O
the	O
condensed	O
isoxazolines	O
2	O
containing	O
a	O
phenyl	O
group	O
in	O
position	O
3	O
with	O
respect	O
to	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3	O
-	O
methyl	O
-	O
3a	O
-	O
trimethylgermyl	O
-	O
5	O
-	O
MeM	O
-	O
3a	O
,	O
6a	O
-	O
dihyd	O
rothieno	O
[	O
2	O
,	O
3d	O
]	O
isoxazolines	O
l	O
b	O
-	O
d	O
.	O

Silyl	O
-	O
and	O
germyl	O
-	O
substituted	O
fused	O
isoxazolines	O
have	O
a	O
medium	O
NOinduction	O
ability	O
,	O
4	O
,	O
4	O
-	O
dioxo	O
-	O
3	O
-	O
phenyl	O
-	O
5	O
-	O
trimethylsilyl	O
-	O
3a	O
,	O
6a	O
-	O
dihydrothieno	O
[	O
2	O
,	O
3	O
-	O
d	O
]	O
isoxazoline	O
-	O
2	O
(	O
2b	O
)	O
being	O
the	O
most	O
active	O
(	O
250	O
%	O
in	O
the	O
MG	O
-	O
22A	O
test	O
)	O
.	O

ACKNOWLEGMENT	O
We	O
are	O
grateful	O
to	O
Latvian	O
Taiho	O
Foundation	O
for	O
financial	O
support	O
.	O

REFERENCES	O
1	O
.	O

A	O
.	O

R	O
.	O

M	O
.	O

Donovan	O
,	O
M	O
.	O

K	O
.	O

Shepherd	O
,	O
Tetrahedron	O
Lett	O
.	O
,	O
35	O
(	O
1994	O
)	O
4425	O
.	O

2	O
.	O

S	O
.	O

Gronowitz	O
,	O
A	O
.	O
-	O
B	O
.	O

H0rnfeldt	O
,	O
E	O
.	O

Lukevics	O
,	O
O	O
.	O

Pudova	O
,	O
Synthesis	O
,	O
(	O
1994	O
)	O
40	O
.	O

3	O
.	O

G	O
.	O

Barbarella	O
,	O
L	O
.	O

Favaretto	O
,	O
G	O
.	O

Sotgiu	O
,	O
M	O
.	O

Zambianchi	O
,	O
L	O
.	O

Antolini	O
,	O
O	O
.	O

Pudova	O
,	O
A	O
.	O

Bongini	O
,	O
J	O
.	O

Org	O
.	O

Chem	O
.	O
,	O
63	O
(	O
1998	O
)	O
5497	O
.	O

4	O
.	O

A	O
.	O

Bened	O
,	O
R	O
.	O

Durand	O
,	O
D	O
.	O

Pioch	O
,	O
P	O
.	O

Geneste	O
,	O
J	O
.	O

P	O
.	O

Declerq	O
,	O
G	O
.	O

Germain	O
,	O
J	O
.	O

Rambaud	O
,	O
R	O
.	O

Roques	O
,	O
J	O
.	O

Org	O
.	O

Chem	O
.	O
,	O
46	O
(	O
1981	O
)	O
3502	O
.	O

5	O
.	O

F	O
.	O

M	O
.	O

Albini	O
,	O
P	O
.	O

Ceva	O
,	O
A	O
.	O

Mascherpa	O
,	O
E	O
.	O

Albini	O
,	O
P	O
.	O

Caramella	O
,	O
Tetrahedron	O
,	O
38	O
(	O
1982	O
)	O

6	O
.	O

7	O
.	O

8	O
.	O

9	O
.	O

10	O
.	O

11	O
.	O

12	O
.	O

3629	O
.	O

E	O
.	O

Lukevics	O
,	O
M	O
.	O

Veveris	O
,	O
V	O
.	O

Dirnens	O
,	O
Appl	O
.	O

Organomet	O
.	O

Chem	O
.	O
,	O
11	O
(	O
1997	O
)	O
805	O
.	O

E	O
.	O

Lukevics	O
,	O
P	O
.	O

Arsenyan	O
,	O
M	O
.	O

Veveris	O
,	O
Metal	O
Based	O
Drugs	O
,	O
5	O
(	O
1998	O
)	O
251	O
.	O

E	O
.	O

Lukevics	O
,	O
P	O
.	O

Arsenyan	O
,	O
S	O
.	O

Germane	O
,	O
I	O
.	O

Shestakova	O
,	O
Applied	O
Organomet	O
.	O

Chem	O
.	O
,	O
13	O
(	O
1999	O
)	O
795	O
.	O

E	O
.	O

Lukevics	O
,	O
P	O
.	O

Arsenyan	O
,	O
S	O
.	O

Belyakov	O
,	O
J	O
.	O

Popelis	O
,	O
O	O
.	O

Pudova	O
,	O
Organometallics	O
,	O
18	O
(	O
1999	O
)	O
3187	O
.	O

D	O
.	O
J	O
.	O

Fast	O
,	O
R	O
.	O
C	O
.	O

Lynch	O
,	O
R	O
.	O
W	O
.	O

Leu	O
,	O
J	O
.	O

Leuckocyt	O
.	O

Biol	O
.	O
,	O
52	O
(	O
1992	O
)	O
255	O
.	O

P	O
.	O
J	O
.	O

Freshney	O
,	O
Culture	O
of	O
Animal	O
Cells	O
(	O
A	O
Manual	O
of	O
Basic	O
Technique	O
)	O
,	O
Wiley	O
-	O
Liss	O
,	O
New	O
York	O
,	O
1994	O
,	O
pp	O
.	O

296	O
-	O
297	O
.	O

R	O
.	O

J	O
.	O

Riddell	O
,	O
R	O
.	O

H	O
.	O

Clothier	O
,	O
M	O
.	O

Fd	O
.	O

Balls	O
,	O
Chem	O
.	O

Toxicol	O
.	O
,	O
24	O
(	O
1986	O
)	O
469	O
.	O

Received	O
:	O
January	O
21	O
,	O
2000	O
Accepted	O
:	O
February	O
1	O
,	O
2000	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format	O
"	O
February	O
2	O
,	O
2000	O

66	O

IL	O
-	O
5	O
drives	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
in	O
a	O
guinea	B-Species
-	I-Species
pig	E-Species
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O

Abstract	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
role	O
of	O
IL	O
-	O
5	O
in	O
eosinophil	O
migration	O
and	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
a	O
guinea	B-Species
-	I-Species
pig	E-Species
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
.	O

The	O
results	O
show	O
that	O
the	O
infection	O
of	O
animals	O
with	O
Toxocara	B-Species
canis	E-Species
induced	O
an	O
early	O
increase	O
in	O
serum	O
IL	O
-	O
5	O
levels	O
that	O
might	O
be	O
essential	O
for	O
eosinophil	O
differentiation	O
and	O
proliferation	O
and	O
for	O
the	O
development	O
of	O
eosinophilia	O
.	O

When	O
infected	O
guinea	B-Species
-	I-Species
pigs	E-Species
were	O
treated	O
with	O
mAb	O
anti	O
-	O
IL	O
-	O
5	O
(	O
TRFK	O
-	O
5	O
)	O
given	O
at	O
the	O
same	O
time	O
or	O
1	O
or	O
3	O
days	O
after	O
infection	O
,	O
there	O
was	O
a	O
high	O
percentage	O
of	O
reduction	O
of	O
eosinophil	O
counts	O
18	O
days	O
after	O
infection	O
.	O

However	O
,	O
when	O
the	O
mAb	O
was	O
administered	O
during	O
the	O
peak	O
of	O
eosinophilia	O
,	O
there	O
was	O
high	O
inhibition	O
in	O
blood	O
,	O
no	O
inhibition	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
or	O
peritoneum	O
and	O
an	O
increase	O
in	O
eosinophil	O
numbers	O
in	O
bone	O
marrow	O
.	O

Thus	O
,	O
a	O
basic	O
level	O
of	O
IL	O
-	O
5	O
may	O
be	O
essential	O
to	O
drive	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
,	O
and	O
for	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
infected	O
animals	O
.	O

We	O
may	O
also	O
conclude	O
that	O
when	O
eosinophils	O
have	O
already	O
migrated	O
to	O
the	O
lungs	O
,	O
TRFK	O
-	O
5	O
has	O
no	O
power	O
to	O
inhibit	O
eosinophilia	O
,	O
which	O
is	O
also	O
under	O
control	O
of	O
local	O
lung	O
cells	O
producing	O
IL	O
-	O
5	O
.	O

In	O
this	O
way	O
,	O
only	O
one	O
later	O
TRFK	O
-	O
5	O
treatment	O
may	O
not	O
be	O
sufficient	O
to	O
modify	O
the	O
lung	O
parenchyma	O
microenvironment	O
,	O
since	O
T	B-Species
.	I-Species
canis	E-Species
antigens	O
had	O
already	O
stimulated	O
some	O
cell	O
populations	O
to	O
produce	O
IL	O
-	O
5	O
.	O

Research	O
Paper	O
Mediators	O
of	O
Inflammation	O
5	O
,	O
24	O
-	O
31	O
(	O
1996	O
)	O

Tins	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
role	O
of	O
11	O
-	O
5	O
in	O
eosinophil	O
migration	O
and	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
a	O
guinea	B-Species
-	I-Species
pig	E-Species
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
.	O

The	O
results	O
show	O
that	O
the	O
infection	O
of	O
animals	O
with	O
Toxocara	B-Species
canis	E-Species
induced	O
an	O
early	O
increase	O
in	O
serum	O
11	O
-	O
5	O
levels	O
that	O
might	O
be	O
essential	O
for	O
eosi	O

IL	O
-	O
5	O
drives	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
in	O
a	O
guinea	B-Species
-	I-Species
pig	E-Species
model	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
L	O
.	O

H	O
.	O

Faccioli	O
,	O
1	O
"	O
cA	O
V	O
.	O

F	O
.	O

Mokwa	O
,	O
C	O
.	O

L	O
.	O

Silva	O
,	O
G	O
.	O

M	O
.	O

Rocha	O
,	O
J	O
.	O

I	O
.	O

Araujo	O
,	O
M	O
.	O

A	O
.	O

Nahori	O
2	O
and	O
B	O
.	O

B	O
.	O

Vargaftig	O
2	O

nophil	O
differentiation	O
and	O
proliferation	O
and	O
for	O
the	O
development	O
of	O
eosinophilia	O
.	O

When	O
infected	O
guinea	B-Species
-	I-Species
pigs	E-Species
were	O
treated	O
with	O
mAb	O
anti	O
-	O
11	O
-	O
5	O
(	O
TRFK	O
-	O
5	O
)	O
given	O
at	O
the	O
same	O
time	O
or	O
1	O
or	O
3	O
days	O
after	O
infection	O
,	O
there	O
was	O
a	O
high	O
percentage	O
of	O
reduction	O
of	O
eosinophil	O
counts	O
18	O
days	O
after	O
infection	O
.	O

However	O
,	O
when	O
the	O
mAb	O
was	O
administered	O
during	O
the	O
peak	O
of	O
eosinophilia	O
,	O
there	O
was	O
high	O
inhibition	O
in	O
blood	O
,	O
no	O
inhibition	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
or	O
peritoneum	O
and	O
an	O
increase	O
in	O
eosinophil	O
numbers	O
in	O
bone	O
marrow	O
.	O

Thus	O
,	O
a	O
basic	O
level	O
of	O
11	O
-	O
5	O
may	O
be	O
essential	O
to	O
drive	O
eosinophils	O
from	O
bone	O
marrow	O
to	O
blood	O
and	O
tissues	O
,	O
and	O
for	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
infected	O
animals	O
.	O

We	O
may	O
also	O
conclude	O
that	O
when	O
eosinophils	O
have	O
already	O
migrated	O
to	O
the	O
lungs	O
,	O
TRFK	O
-	O
5	O
has	O
no	O
power	O
to	O
inhibit	O
eosinophilia	O
,	O
which	O
is	O
also	O
under	O
control	O
of	O
local	O
lung	O
cells	O
producing	O
11	O
-	O
5	O
.	O

In	O
this	O
way	O
,	O
only	O
one	O
later	O
TRFK	O
-	O
5	O
treatment	O
may	O
not	O
be	O
sufficient	O
to	O
modify	O
the	O
lung	O
parenchyma	O
microenvironment	O
,	O
since	O
T	B-Species
.	I-Species
canis	E-Species
antigens	O
had	O
already	O
stimulated	O
some	O
cell	O
populations	O
to	O
produce	O
11	O
-	O
5	O
.	O

1Department	O
of	O
Parasitology	O
,	O
Microbiology	O
and	O
Immunology	O
,	O
School	O
of	O
Medicine	O
of	O
Ribeir	O
,	O
5o	O
Preto	O
,	O
14049	O
-	O
900	O
,	O
Ribeiro	O
Preto	O
,	O
SP	O
,	O
Brazil	O
.	O

Fax	O
:	O
(	O
+	O
55	O
)	O
16	O
633	O
6631	O
2Unit	O
de	O
Pharmacologie	O
Cellulaire	O
,	O
Unit	O
Associe	O
Institut	O
Pasteur	O
/	O
INSERM	O
n	O
.	O

285	O
,	O
Paris	O
,	O

France	O
.	O

CACorresponding	O
Author	O

Key	O
words	O
:	O
Eosinophil	O
,	O
Eosinophilia	O
by	O
Toxocara	B-Species
canis	E-Species
,	O
IL	O
-	O
5	O
in	O
eosinophilia	O
,	O
Toxocara	B-Species
canis	E-Species

Introduction	O

treatment	O
in	O
mice	S-Species
infected	O
with	O

Eosinophilia	O
has	O
been	O
associated	O
with	O
parasitic	O
diseases	O
,	O
particularly	O
when	O
the	O
parasites	O
invade	O
the	O
tissues	O
or	O
injure	O
the	O
mucosal	O
surfaces	O
.	O

Toxocara	B-Species
canis	E-Species
is	O
an	O
intestinal	O
parasite	O
of	O
dogs	S-Species
,	O
and	O
is	O
the	O
most	O
common	O
aetiologic	O
agent	O
of	O
visceral	O
larva	O
migrans	O
syndrome	O
(	O
VLMS	O
)	O
.	O

In	O
humans	S-Species
,	O
VLMS	O
results	O
from	O
the	O
ingestion	O
of	O
embryonated	O
eggs	O
of	O
T	B-Species
.	I-Species
canis	E-Species
,	O
that	O
eclode	O
in	O
the	O
small	O
intesfine	O
.	O

The	O
infective	O
larvae	O
invade	O
the	O
mucosa	O
,	O
move	O
into	O
the	O
liver	O
via	O
the	O
portal	O
circulation	O
,	O
and	O
from	O
there	O
to	O
the	O
lungs	O
.	O

2	O
Beaver	O
et	O
al	O
.	O
,	O
3	O
who	O
were	O
the	O
first	O
to	O
describe	O
this	O
syndrome	O
,	O
noted	O
the	O
intense	O
eosinophilia	O
which	O
reaches	O
more	O
than	O
90	O
%	O
of	O
total	O
leucocyte	O
counts	O
.	O

However	O
,	O
there	O
are	O
few	O
studies	O
regarding	O
the	O
mechanisms	O
involved	O
in	O
the	O
blood	O
and	O
tissue	O
eosinophilia	O
obseeeed	O
in	O
VLMS	O
.	O

Several	O
investigators	O
have	O
suggested	O
a	O
direct	O
correlation	O
between	O
eosinophilia	O
and	O
interleukin5	O
(	O
IL	O
-	O
5	O
)	O
in	O
human	S-Species
helminth	O
infections4	O
'	O
5	O
and	O
in	O
experimental	O
animal	O
models	O
.	O

67	O
Inhibition	O
of	O
eosinophilia	O
has	O
been	O
demonstrated	O
by	O
anti	O
-	O
IL	O
-	O
5	O
24	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O

brasiliensis	O
,	O
8	O
$	O
chistosoma	O
mansoni	O
,	O
Toxocara	B-Species
canis7	E-Species
and	O
Heligmosomoidespolygyrus	S-Species
.	O

1	O
IL	O
-	O
5	O
has	O
also	O
been	O
shown	O
to	O
support	O
the	O
terminal	O
differentiation	O
,	O
proliferation	O
of	O
eosinophil	O
precursors	O
11	O
'	O
12	O
and	O
eosinophil	O
activation	O
.	O

13	O
Although	O
IL	O
-	O
5	O
does	O
not	O
demonstrate	O
eosinophil	O
chemotactic	O
activity	O
in	O
vivo14	O
there	O
is	O
some	O
evidence	O
suggesting	O
that	O
this	O
cytokine	O
may	O
modulate	O
a	O
selective	O
eosinophil	O
accumulation	O
at	O
the	O
site	O
of	O
inflammation	O
.	O

Moreover	O
,	O
Sehmi	O
et	O
a	O
/	O
.	O
15	O
reported	O
that	O
IL	O
-	O
5	O
has	O
a	O
selective	O
priming	O
effect	O
on	O
eosinophil	O
migratory	O
response	O
to	O
nonselective	O
chemoattractant	O
mediators	O
in	O
vitro	O
.	O

Also	O
,	O
Moser	O
et	O
a	O
/	O
.	O

16	O
have	O
demonstrated	O
that	O
in	O
order	O
to	O
acquire	O
the	O
ability	O
to	O
transmigrate	O
,	O
eosinophils	O
must	O
be	O
primed	O
with	O
IL	O
-	O
5	O
,	O
IL	O
-	O
3	O
and	O
GM	O
-	O
CSF	O
.	O

Thus	O
,	O
the	O
involvement	O
of	O
IL	O
-	O
5	O
in	O
eosinophilia	O
is	O
not	O
fully	O
understood	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
used	O
a	O
guinea	B-Species
-	I-Species
pig	E-Species
model	O
of	O
VLMS	O
to	O
investigate	O
the	O
involvement	O
of	O
IL	O
-	O
5	O
in	O
eosinophil	O
migration	O
and	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
in	O
blood	O
,	O
bone	O
marrow	O
,	O
lung	O
and	O
peritoneal	O
cavity	O
.	O

(	O
C	O
)	O
1996	O
Rapid	O
Science	O
Publishers	O

Nipostrongylus	O

1996	O

IL	O
-	O
5	O
drives	O
eosinophils	O
in	O
guinea	B-Species
-	I-Species
pig	E-Species

Materials	O
and	O
Methods	O
Animals	O
:	O
Outbred	O
albino	O
weighing	O
300	O
-	O
400g	O
at	O
the	O
ments	O
were	O
obtained	O
from	O
the	O
School	O
of	O
Medicine	O
of	O
versity	O
of	O
So	O
Paulo	O
,	O
Brazil	O
.	O

female	O
guinea	B-Species
-	I-Species
pigs	E-Species
start	O
of	O
the	O
experi	O

were	O
routinely	O
processed	O
,	O
embedded	O
in	O
paraffin	O
,	O
sectioned	O
at	O
4	O
-	O
61	O
.	O
tm	O
,	O
and	O
stained	O
with	O
Chromothope	O
2R	O
and	O
haematoxylin	O
,	O
for	O
examination	O
by	O
light	O
microscopy	O
.	O

Determination	O
oflL	O
-	O
5	O
in	O
serum	O
:	O
The	O
IL	O
-	O
5	O
level	O
in	O
the	O
serum	O
of	O
guinea	B-Species
-	I-Species
pigs	E-Species
was	O
measured	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

Briefly	O
,	O
ELISA	O
plates	O
(	O
96	O
-	O
well	O
Immunoplate	O
MaxiSorp	O
,	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
were	O
coated	O
with	O
IL	O
-	O
5	O
-	O
specific	O
monoclonal	O
antibody	O
(	O
TRFK	O
-	O
5	O
,	O
5	O
lag	O
/	O
ml	O
in	O
phosphate	O
buffered	O
saline	O
,	O
pH	O
7	O
.	O
4	O
,	O
PBS	O
,	O
100	O
l	O
.	O
tl	O
/	O
well	O
)	O
.	O

After	O
2	O
h	O
of	O
incubation	O
at	O
37C	O
,	O
the	O
wells	O
were	O
washed	O
four	O
times	O
with	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
Tween	O
20	O
(	O
PBS	O
-	O
T	O
)	O
.	O

Then	O
,	O
100	O
btl	O
of	O
samples	O
or	O
recombinant	O
murine	S-Species
IL	O
-	O
5	O
standards	O
(	O
0	O
.	O
15	O
-	O
200ng	O
/	O
ml	O
)	O
in	O
PBS	O
-	O
T	O
and	O
2	O
%	O
BSA	O
(	O
PBSTBSA	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

After	O
incubation	O
for	O
l	O
h	O
at	O
37C	O
,	O
the	O
wells	O
were	O
washed	O
three	O
times	O
and	O
100	O
l	O
.	O
tl	O
of	O
biotinylated	O
rat	S-Species
anti	O
-	O
murine	S-Species
IL	O
-	O
5	O
(	O
biotinylated	O
-	O
TRFK	O
-	O
5	O
,	O
1	O
lag	O
/	O
ml	O
in	O
PBS	O
-	O
TBSA	O
)	O
was	O
added	O
.	O

After	O
incubation	O
for	O
1	O
h	O
at	O
37C	O
,	O
the	O
wells	O
were	O
washed	O
again	O
three	O
times	O
and	O
100	O
of	O
peroxidase	O
-	O
labelled	O
streptavidin	O
(	O
1	O
/	O
1000	O
,	O
Kirkegaard	O
&	O
Perry	O
Laboratories	O
Inc	O
.	O
,	O
Maryland	O
,	O
USA	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

Following	O
incubation	O
for	O
l	O
h	O
at	O
37C	O
and	O
further	O
washing	O
,	O
the	O
enzyme	O
was	O
developed	O
using	O
the	O
TMB	O
substrate	O
peroxidase	O
for	O
5	O
min	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
adding	O
501	O
.	O
tl	O
of	O
2	O
.	O
0	O
N	O
HCl	O
,	O
and	O
the	O
optical	O
densities	O
were	O
read	O
at	O
490nm	O
using	O
an	O
automated	O
plate	O
reader	O
.	O

The	O
sensitivity	O
of	O
the	O
assay	O
was	O
0	O
.	O
15	O
ng	O
/	O
ml	O
and	O
the	O
upper	O
limit	O
100ng	O
/	O
ml	O
.	O

the	O
animal	O
house	O
of	O
Ribeiro	O
Preto	O
,	O
Uni	O

Infection	O
of	O
animals	O
:	O
T	B-Species
.	I-Species
canis	E-Species
eggs	O
were	O
obtained	O
by	O
the	O
methods	O
of	O
Olson	O
and	O
Schulz	O
,	O
17	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
gravid	O
female	O
worms	O
were	O
recovered	O
from	O
dogs	S-Species
,	O
and	O
the	O
eggs	O
were	O
rescued	O
from	O
the	O
uterus	O
,	O
washed	O
and	O
allowed	O
to	O
develop	O
to	O
the	O
infective	O
stage	O
in	O
shallow	O
dishes	O
containing	O
0	O
.	O
5	O
%	O
formalin	O
at	O
37C	O
.	O

Under	O
light	O
ether	O
anaesthesia	O
,	O
the	O
animals	O
were	O
infected	O
with	O
I	O
ml	O
saline	O
containing	O
500	O
T	B-Species
.	I-Species
canis	E-Species
eggs	O
,	O
by	O
gastric	O
intubation	O
using	O
a	O
metal	O
cannula	O
.	O

Blood	O
cell	O
counts	O
:	O
Guinea	B-Species
-	I-Species
pigs	E-Species
were	O
anaesthetized	O
with	O
sodium	O
pentobarbitone	O
(	O
30mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
and	O
blood	O
samples	O
were	O
collected	O
by	O
cardiac	O
puncture	O
with	O
10	O
%	O
EDTA	O
.	O

Total	O
cell	O
counts	O
were	O
carried	O
out	O
using	O
diluting	O
fluid	O
in	O
a	O
Neubauer	O
chamber	O
.	O

Differential	O
countings	O
were	O
obtained	O
using	O
Rosenfeld	O
-	O
stained	O
cytocentrifuge	O
preparations	O
,	O

Bronchoalveolar	O
lavage	O
fluid	O
.	O

The	O
guinea	B-Species
-	I-Species
pigs	E-Species
were	O
killed	O
by	O
an	O
overdose	O
of	O
sodium	O
pentobarbitone	O
and	O
5ml	O
of	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
containing	O
0	O
.	O
5	O
%	O
sodium	O
citrate	O
(	O
PBS	O
/	O
SC	O
)	O
,	O
at	O
room	O
temperature	O
,	O
were	O
instilled	O
through	O
a	O
polyethylene	O
cannula	O
introduced	O
into	O
the	O
trachea	O
.	O

The	O
cells	O
present	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
recovered	O
immediately	O
.	O

The	O
procedure	O
was	O
repeated	O
once	O
.	O

The	O
leucocyte	O
counts	O
in	O
the	O
BAI	O
_	O
were	O
determined	O
as	O
described	O
above	O
,	O
Peritoneal	O
cells	O
:	O
The	O
cells	O
from	O
the	O
peritoneal	O
cavities	O
were	O
harvested	O
by	O
injection	O
of	O
10ml	O
of	O
PBS	O
/	O
SC	O
into	O
the	O
peritoneum	O
.	O

Only	O
5	O
-	O
8	O
ml	O
of	O
the	O

fluid	O
was	O
withdrawn	O
for	O
cell	O
counts	O
,	O
as	O
described	O
above	O
,	O

Monoclonal	O
antibodies	O
:	O
The	O
rat	S-Species
monoclonal	O
antibody	O
TRFK	O
-	O
5	O
was	O
a	O
generous	O
gift	O
from	O
Dr	O
P	O
.	O

Minoprio	O
,	O
Institut	O
Pasteur	O
,	O
Paris	O
.	O

The	O
neutralizing	O
antibody	O
was	O
purified	O
by	O
precipitation	O
with	O
ammonium	O
sulfate	O
(	O
45	O
%	O
)	O
from	O
ascites	O
prepared	O
in	O
CD1	O
nude	B-Species
mice	E-Species
(	O
Charles	O
River	O
,	O
St	O
Aubin	O
les	O
Elbeuf	O
,	O
France	O
)	O
inoculated	O
1	O
week	O
before	O
the	O
injection	O
of	O
hybridoma	O
cells	O
,	O
with	O
I	O
ml	O
of	O
pristane	O
(	O
Sigma	O
)	O
.	O

After	O
precipitation	O
and	O
dialysis	O
of	O
the	O
ascite	O
fluid	O
overnight	O
against	O
PBS	O
,	O
the	O
dialysate	O
was	O
further	O
purified	O
on	O
a	O
Protein	O
G1	O
column	O
(	O
HiTrapTM	O
,	O
Pharmacia	O
Upsala	O
,	O
Sweden	O
)	O
.	O

Bone	O
marrow	O
cells	O
:	O
Bone	O
marrow	O
cells	O
were	O
collected	O
by	O
flushing	O
the	O
contents	O
of	O
the	O
guinea	B-Species
-	I-Species
pig	E-Species
femur	O
with	O
10	O
ml	O
of	O
PBS	O
/	O
SC	O
.	O

Total	O
cell	O
numbers	O
were	O
determined	O
as	O
above	O
.	O

In	O
the	O
differential	O
cell	O
counts	O
the	O
cell	O
populations	O
were	O
divided	O
into	O
mature	O
neutrophils	O
,	O
mature	O
eosinophils	O
and	O
others	O
(	O
mainly	O
precursors	O
and	O
mononuclear	O

cells	O
)	O
,	O
Histopathological	O
studies	O
:	O
Tissues	O
were	O
removed	O
from	O
guinea	B-Species
-	I-Species
pigs	E-Species
at	O
various	O
times	O
post	O
-	O
infection	O
and	O
immediately	O
fixed	O
in	O
10	O
%	O
formalin	O
.	O

Tissues	O

Eosinophil	O
and	O
cytokine	O
depletion	O
:	O
Guinea	B-Species
-	I-Species
pigs	E-Species
were	O
injected	O
i	O
.	O
p	O
.	O
with	O
TRFK	O
-	O
5	O
or	O
with	O
the	O
irrelevant	O
antibody	O
(	O
rat	S-Species
IgG	O
against	O
total	O
anti	O
-	O
human	S-Species
IgG	O
)	O
once	O
,	O
2mg	O
/	O
animal	O
,	O
at	O
the	O
time	O
of	O
infection	O
or	O
at	O
different	O
intervals	O
(	O
1	O
,	O
3	O
,	O
12	O
or	O
17	O
days	O
)	O
thereafter	O
.	O

The	O
animals	O
in	O
this	O
group	O
were	O
sacririced	O
18	O
days	O
after	O
infection	O
.	O
liver	O
:	O
One	O
lobule	O
of	O
was	O
used	O
to	O
determine	O
the	O
larval	O
each	O
liver	O
counts	O
from	O
infected	O
guinea	B-Species
-	I-Species
pigs	E-Species
.	O

Larval	O
recovery	O

Recovery	O

of	O
larvae	O
from	O

Mediators	O
of	O
Inflammation	O
Vol	O
5	O

1996	O

25	O

L	O
.	O

H	O
.	O

Faccioli	O
et	O
al	O
.	O

was	O
evaluated	O
as	O
described	O
by	O
Kayes	O
and	O
Oaks	O
,	O
18	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
the	O
tissue	O
was	O
chopped	O
and	O
digested	O
with	O
pepsin	O
-	O
HC1	O
(	O
pH	O
1	O
.	O
5	O

1	O
.	O
8	O
)	O
for	O
2h	O
at	O
37C	O
.	O

Larval	O
counts	O
for	O
each	O
sample	O
were	O
performed	O
after	O
centrifugation	O
and	O
examination	O
of	O
three	O
100	O
-	O
l	O
.	O
tl	O
samples	O
under	O
the	O
light	O
microscope	O
.	O

Statistical	O
analysis	O
:	O
Data	O
are	O
presented	O
as	O
the	O
mean	O
_	O
+	O
S	O
.	O
E	O
.	O
M	O
.	O
and	O
were	O
analysed	O
statistically	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
for	O
unpaired	O
data	O
.	O

A	O
p	O
<	O
0	O
.	O
05	O
value	O
was	O
considered	O
to	O
be	O
statistically	O

significant	O
.	O

Results	O

of	O
eosinophil	O
counts	O
in	O
blood	O
bone	O
marrow	O
,	O
BALF	O
and	O
peritoneum	O
:	O
Guinea	B-Species
-	I-Species
pigs	E-Species
infected	O
with	O
T	B-Species
.	I-Species
canis	E-Species
eggs	O
showed	O
a	O
timedependent	O
blood	O
,	O
bone	O
-	O
marrow	O
,	O
BAUV	O
and	O
peritoneal	O
eosinophilia	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
results	O
represent	O
the	O
mean	O
of	O
nine	O
animals	O
obtained	O
in	O
three	O
different	O
experiments	O
.	O

The	O
eosinophil	O
number	O
Kinetics	O
16	O

increased	O
significantly	O
from	O
0	O
.	O
55	O
+	O
_	O
0	O
.	O
37	O
x	O
105	O
at	O
the	O
beginning	O
of	O
experiment	O
to	O
6	O
.	O
0	O
+	O
_	O
_	O
1	O
.	O
03	O
x	O
105	O
at	O
6	O
days	O
post	O
-	O
infection	O
,	O
peaked	O
at	O
day	O
18	O
(	O
12	O
.	O
0	O
_	O
+	O
2	O
.	O
31	O
x	O
105	O
)	O
,	O
and	O
decreased	O
by	O
day	O
24	O
(	O
8	O
.	O
11	O
2	O
.	O
85	O
x	O
105	O
)	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

A	O
rise	O
in	O
the	O
percentage	O
of	O
mature	O
eosinophils	O
in	O
bone	O
marrow	O
"	O
was	O
observed	O
12	O
days	O
after	O
infection	O
(	O
ranging	O
from	O
6	O
2	O
%	O
to	O
14	O
2	O
%	O
)	O
and	O
peaked	O
at	O
18	O
days	O
(	O
17	O
2	O
%	O
)	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

As	O
in	O
blood	O
,	O
the	O
number	O
of	O
eosinophils	O
in	O
BALF	O
increased	O
significantly	O
from	O
0	O
.	O
14	O
0	O
.	O
06	O
x	O
105	O
to	O
1	O
.	O
37	O
_	O
+	O
0	O
.	O
35	O
x	O
105	O
at	O
6	O
days	O
after	O
infection	O
,	O
reaching	O
a	O
peak	O
at	O
18	O
days	O
(	O
10	O
.	O
23	O
2	O
.	O
62	O
x	O
105	O
)	O
with	O
an	O
increase	O
in	O
relative	O
number	O
of	O
as	O
much	O
as	O
90	O
%	O
in	O
eosinophil	O
counts	O
in	O
relation	O
to	O
controls	O
,	O
and	O
was	O
still	O
elevated	O
at	O
day	O
24	O
(	O
9	O
.	O
07	O
_	O
_	O
_	O
3	O
.	O
47	O
x	O
10	O
s	O
)	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

The	O
remaining	O
cells	O
in	O
the	O
BALF	O
were	O
alveolar	O
macrophages	O
,	O
lymphocytes	O
,	O
mast	O
cells	O
and	O
ciliated	O
cells	O
.	O

In	O
contrast	O
to	O
blood	O
and	O
BALF	O
,	O
the	O
number	O
of	O
eosinophils	O
in	O
the	O
peritoneal	O
cavity	O
increased	O
significantl	O
only	O
at	O
day	O
12	O
post	O
-	O
infection	O
(	O
onset	O
,	O
2	O
.	O
06	O
1	O
.	O
04	O
x	O
105	O
;	O
day	O
6	O
,	O
3	O
.	O
68	O
_	O
+	O
0	O
.	O
82	O
x	O
105	O
;	O
day	O
12	O
,	O
5	O
.	O
77	O
+	O
_	O
1	O
.	O
12	O
x	O
10	O
>	O
;	O
and	O
increased	O
progres	O

_	O
_	O
_	O
_	O
_	O
.	O

(	O
B	O
)	O

(	O
AI	O
Blood	O

24	O
20	O
"	O

Bone	O
Marrow	O

1612	O
8	O

4	O
O0	O

3	O

6	O

9	O

12	O

15	O

111	O

21	O

24	O

16	O

(	O
c	O
)	O
BALF	O

16	O

ID	O
)	O
Peritoneum	O

12	O

_	O
_	O
o	O

12	O

8	O

4	O

0	O
3	O

O6	O
9	O

12	O

15	O

16	O

21	O

24	O

Days	O
postinfoction	O

FIG	O
.	O

1	O
.	O

Number	O
of	O
eosinophils	O
in	O
blood	O
,	O
BALF	O
and	O
peritoneal	O
cavity	O
,	O
and	O
percentage	O
,	O
of	O
eosinophils	O
in	O
bone	O
marrow	O
of	O
T	B-Species
.	I-Species
canisqnfected	E-Species
guinea	B-Species
-	I-Species
pigs	E-Species
.	O

Values	O
are	O
the	O
mean	O
-	O
t	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O

(	O
n	O
=	O
8	O
to	O
9	O
)	O
.	O

Asterisks	O
indicate	O
a	O
significant	O
difference	O
between	O
infected	O
and	O
noninfected	O
animals	O
(	O
n	O
5	O
6	O
)	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
and	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
.	O

26	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O

1996	O

IL	O
-	O
5	O
drives	O
eosinophils	O
in	O
guinea	B-Species
-	I-Species
pig	E-Species

sively	O
until	O
day	O
24	O
,	O
12	O
.	O
44	O
4	O
-	O
2	O
.	O
72	O
x	O
105	O
)	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

The	O
percentage	O
of	O
eosinophils	O
in	O
some	O
animals	O
reached	O
55	O
%	O
at	O
the	O
peak	O
of	O
infection	O
.	O

No	O
increase	O
in	O
the	O
number	O
of	O
mononuclear	O
cells	O
was	O
seen	O
in	O
any	O
compartment	O
analysed	O
.	O

Larval	O
counts	O
:	O
The	O
percentage	O
of	O
inoculated	O
T	B-Species
.	I-Species
canis	E-Species
larvae	O
recovered	O
by	O
peptic	O
digestion	O
of	O
the	O
liver	O
of	O
experimental	O
animals	O
4	O
h	O
and	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
9	O
,	O
12	O
and	O
18	O
days	O
after	O
inoculation	O
of	O
500	O
eggs	O
per	O
animal	O
is	O
shown	O
in	O
Fig	O
.	O

2	O
.	O

Most	O
of	O
the	O
larvae	O
were	O
recovered	O
2	O
to	O
4	O
days	O
after	O
infection	O
and	O
10	O
%	O
recovery	O
was	O
also	O
observed	O
on	O
day	O
18	O
in	O
the	O
liver	O
of	O
the	O
animals	O
.	O

150	O

120	O

IL	O
-	O
5	O
level	O
in	O
serum	O
of	O
infected	O
animals	O
:	O
IL	O
-	O
5	O
was	O
measured	O
in	O
the	O
serum	O
of	O
infected	O
and	O
normal	O
guinea	B-Species
-	I-Species
pigs	E-Species
.	O

Each	O
time	O
point	O
in	O
Fig	O
.	O

3	O
represents	O
the	O
mean	O
of	O
results	O
from	O
three	O
to	O
five	O
infected	O
animals	O
,	O
and	O
from	O
six	O
controls	O
.	O

Two	O
peaks	O
of	O
IL5	O
were	O
present	O
in	O
the	O
serum	O
of	O
infected	O
guineapigs	S-Species
1	O
day	O
after	O
infection	O
(	O
102	O
_	O
_	O
+	O
22	O
pg	O
/	O
ml	O
)	O
,	O
and	O
18	O
days	O
later	O
(	O
59	O
7	O
pg	O
/	O
ml	O
)	O
.	O

The	O
level	O
of	O
IL	O
-	O
5	O
in	O
the	O
controls	O
was	O
31	O
4	O
-	O
4	O
pg	O
/	O
ml	O
.	O

Eosinophil	O
numbers	O
in	O
infected	O
animals	O
treated	O
with	O
TRFK	O
-	O
5	O
:	O
When	O
guinea	B-Species
-	I-Species
pigs	E-Species
received	O
an	O
i	O
.	O
p	O
.	O
injection	O
of	O
TRFK	O
-	O
5	O
,	O
the	O
monoclonal	O
antibody	O
against	O
IL	O
-	O
5	O
,	O
at	O
the	O
time	O
of	O
egg	O
administration	O
or	O
1	O
day	O
later	O
,	O
the	O
number	O
of	O
eosinophils	O
in	O
blood	O
,	O
BALF	O
,	O
peritoneal	O
cavity	O
and	O
bone	O
marrow	O
was	O

_	O

30	O

0	O

0	O

3	O

6	O

12	O

18	O

Days	O
postinfection	O

FIG	O
.	O

3	O
.	O

IL	O
-	O
5	O
concentration	O
in	O
serum	O
of	O
T	B-Species
.	I-Species
caniinfected	E-Species
guineapigs	S-Species
(	O
n	O
3	O
-	O
5	O
)	O
.	O

Basal	O
IL	O
-	O
5	O
concentrations	O
were	O
of	O
31	O
4	O
pg	O
/	O
ml	O
(	O
n	O
=	O
12	O
)	O
.	O

_	O

24	O

60	O

50	O

40	O

0	O

"	O
T	O
"	O

1	O
"	O

0	O

3	O

6	O

9	O

12	O

15	O

18	O

21	O

24	O

Days	O
postinfection	O
FIG	O
.	O

2	O
.	O

Percentage	O
of	O
T	B-Species
.	I-Species
canis	E-Species
larvae	O
recovered	O
from	O
liver	O
of	O
guinea	B-Species
-	I-Species
pigs	E-Species
studied	O
at	O
various	O
times	O
post	O
-	O
infection	O
.	O

Data	O
obtained	O
from	O
five	O
animals	O
.	O

drastically	O
reduced	O
,	O
even	O
when	O
determined	O
18	O
days	O
after	O
infection	O
(	O
Table	O
1	O
)	O
.	O

No	O
inhibition	O
of	O
eosinophil	O
counts	O
was	O
observed	O
when	O
the	O
animals	O
were	O
inoculated	O
with	O
the	O
irrelevant	O
antibody	O
at	O
the	O
time	O
of	O
infection	O
(	O
Table	O
1	O
)	O
.	O

Fig	O
.	O

4	O
shows	O
the	O
comparative	O
results	O
of	O
eosinophilia	O
obtained	O
when	O
the	O
antibody	O
was	O
given	O
3	O
days	O
or	O
17	O
days	O
after	O
egg	O
inoculation	O
.	O

The	O
antibody	O
given	O
at	O
3	O
days	O
after	O
infection	O
induced	O
a	O
high	O
percentage	O
of	O
inhibition	O
in	O
eosinophil	O
counts	O
in	O
all	O
the	O
compartments	O
analysed	O
18	O
days	O
after	O
infection	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

However	O
,	O
when	O
TRFK	O
-	O
5	O
was	O
administered	O
to	O
the	O
infected	O
animals	O
on	O
day	O
17	O
post	O
-	O
infection	O
(	O
thus	O
1	O
day	O
before	O
sacrifice	O
)	O
,	O
a	O
significant	O
inhibition	O
in	O
number	O
and	O
percentage	O
of	O
eosinophils	O
was	O
observed	O
only	O
in	O
the	O
blood	O
(	O
p	O
=	O
0	O
.	O
030	O
)	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

A	O
small	O
non	O
-	O
significant	O
decrease	O
was	O
seen	O
in	O
BALF	O
(	O
p	O
0	O
.	O
790	O
)	O
and	O
peritoneum	O
(	O
p	O
=	O
0	O
.	O
222	O
)	O
.	O

Moreover	O
,	O
the	O
number	O
of	O
mature	O
eosinophils	O
in	O
bone	O
marrow	O
increased	O
by	O
140	O
%	O
(	O
p	O
0	O
.	O
038	O
)	O
.	O

As	O
demonstrated	O
in	O
Fig	O
.	O

4B	O
,	O
the	O
behaviour	O
of	O
eosinotShilia	O
in	O
BALF	O
was	O
completely	O
different	O
from	O
that	O
observed	O
in	O
blood	O
.	O

Thus	O
,	O
to	O
better	O
understand	O
the	O
eosinophilia	O
in	O
the	O
lungs	O
of	O
infected	O
animals	O
,	O
we	O
monitored	O
eosinophil	O
numbers	O
in	O
BALF	O
after	O
administration	O
of	O
TRFK	O
-	O
5	O
at	O
the	O
same	O
time	O
,	O
or	O
1	O
,	O
3	O
,	O
12	O
or	O
17	O
days	O
after	O
infection	O
.	O

The	O
animals	O
were	O
sacrificed	O
18	O
days	O
after	O
infection	O
.	O

In	O
another	O
group	O
,	O
TRFK	O
-	O
5	O
was	O
administered	O
18	O
days	O
post	O
-	O
infection	O
and	O
the	O
animals	O
were	O
sacrificed	O
6	O
days	O
later	O
.	O

When	O
the	O
mAb	O
was	O
administered	O
at	O
the	O
same	O
time	O
or	O
1	O
or	O
3	O
days	O
postinfection	O
there	O
was	O
a	O
significant	O
inhibition	O
in	O
the	O
number	O
of	O
eosinophils	O
(	O
Fig	O
.	O
5	O
)	O
.	O

These	O
data	O
show	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O

1996	O

27	O

L	O
.	O

H	O
.	O

Faccioli	O
et	O
al	O
.	O

Table	O
1	O
.	O

Eosinophils	O
in	O
T	O
.	O
caniinfected	O
guinea	B-Species
-	I-Species
pigs	E-Species
treated	O
or	O
untreated	O
with	O
TRFK	O
-	O
5	O
Compartment	O

Time	O
of	O
sacrifice	O

(	O
days	O
)	O

Non18	O
24	O
18	O
24	O
18	O
24	O
18	O
24	O

treated	O

Blood	O

12	O
.	O
18	O
5	O
.	O
28	O
10	O
.	O
08	O
-	O
t	O
-	O
2	O
.	O
85	O
16	O
.	O
50	O
4	O
.	O
42	O
6	O
.	O
57	O
+	O
_	O
_	O
1	O
.	O
68	O

BALF	O
Peritoneal	O
cavity	O

12	O
.	O
31	O
-	O
I	O
-	O
2	O
.	O
35	O
12	O
.	O
44	O
2	O
.	O
33	O
9	O
6	O

Bone	O
marrow	O

_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
Days	O
of	O
treatment	O
with	O
TRFK	O
-	O
5	O
after	O
egg	O
administration	O

Irrelevant	O
Ab	O
at	O
the	O
time	O
of	O
infection	O

0	O

3	O

12	O

17	O

18	O

(	O
n	O
6	O
)	O

(	O
n	O
=	O
4	O
)	O

(	O
n	O
=	O
4	O
)	O

(	O
n	O
5	O
)	O

(	O
n	O
5	O
)	O

(	O
n	O
=	O
4	O
)	O

0	O
.	O
14	O
-	O
t	O
-	O
0	O
.	O
14	O
"	O

0	O
.	O
26	O
0	O
.	O
79	O

0	O
.	O
26	O
*	O
0	O
.	O
24	O
*	O

0	O
.	O
17	O
_	O
-	O
t	O
-	O
0	O
.	O
17	O
"	O

0	O
.	O
15	O

0	O
.	O
15	O
"	O

2	O
.	O
59	O

0	O
.	O
80	O
*	O
4	O
.	O
36	O
2	O
.	O
21	O

13	O
.	O
32	O

4	O
.	O
54	O

O	O
.	O

15	O

0	O
.	O
15	O
*	O

0	O
.	O
36	O

0	O
.	O
10	O
"	O

1	O
.	O
22	O
-	O
t	O
-	O
0	O
.	O
50	O
*	O

7	O
.	O
07	O
-	O
t	O
-	O
2	O
.	O
39	O

15	O
.	O
24	O

29	O
.	O
31	O
_	O
+	O
15	O
.	O
90	O
16	O
.	O
09	O

10	O
.	O
33	O
_	O
+	O
4	O
.	O
10	O
3	O
.	O
79	O

1	O
.	O
47	O
-	O
t	O
-	O
0	O
.	O
76	O
*	O
3	O

0	O
.	O
48	O

_	O
+	O
0	O
.	O
35	O
*	O

0	O
.	O
46	O
2	O
.	O
6	O

0	O
.	O
27	O
*	O
1	O
.	O
3	O
"	O

2	O
.	O
89	O

0	O
.	O
94	O
*	O

10	O
.	O
42	O

4	O
.	O
00	O

1	O
.	O
58	O
"	O

-	O
+	O

1	O
"	O

1	O
.	O
25	O
-	O
I	O
-	O
0	O
.	O
25	O
*	O

+	O

5	O

15	O
-	O
t	O
-	O
2	O

9	O
_	O
+	O
1	O

2	O

0	O
.	O
7	O
*	O

In	O
blood	O
BALF	O
and	O
peritoneal	O
cavity	O
the	O
values	O
represent	O
mean	O
-	O
t	O
-	O
_	O
S	O
.	O
E	O
.	O
M	O
.	O

x	O
10	O
eosinophils	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
.	O

ml	O
-	O
1	O

and	O
in	O
bone	O
marrow	O
mean	O
-	O
t	O
-	O
_	O
S	O
.	O
E	O
.	O
M	O
.	O
of	O
the	O
percentage	O
of	O
mature	O

that	O
the	O
inhibition	O
of	O
the	O
first	O
peak	O
of	O
IL	O
-	O
5	O
which	O
appeared	O
at	O
1	O
to	O
3	O
days	O
after	O
infection	O
as	O
shown	O
in	O
Fig	O
.	O

3	O
,	O
is	O
also	O
very	O
important	O
for	O
the	O
establishment	O
of	O
eosinophilia	O
in	O
the	O
lungs	O
.	O

However	O
,	O
24	O
-	O
(	O
A	O
)	O

when	O
the	O
mAb	O
was	O
administered	O
12	O
,	O
17	O
or	O
18	O
days	O
after	O
infection	O
there	O
was	O
no	O
significant	O
inhibition	O
in	O
the	O
numbers	O
of	O
eosinophils	O
in	O
BALF	O
(	O
Fig	O
.	O
5	O
)	O
,	O
showing	O
that	O
once	O
established	O
,	O
the	O
eosi18	O

15x	O

16	O

12	O

.	O
_	O
.	O

0	O

12	O

o	O

BIo	O
o	O
d	O

BALF	O

P	O
e	O
rit	O
oneum	O

Bone	O
marrow	O

24	O
-	O
(	O
Is	O
)	O

1815	O

E	O
x	O

20	O

16	O

o	O

12	O
/	O
/	O
/	O
.	O

o	O
=	O
o	O

12	O

0	O
Blood	O

O	O
"	O

BALF	O

Peritoneum	O

Bone	O
marrow	O
FIG	O
.	O

4	O
.	O

Number	O
of	O
eosinophils	O
in	O
blood	O
,	O
BALF	O
and	O
peritoneum	O
and	O
percentage	O
of	O
eosinophils	O
in	O
bone	O
marrow	O
of	O
T	B-Species
.	I-Species
caniinfected	E-Species
guinea	B-Species
-	I-Species
pigs	E-Species
submitted	O
or	O
not	O
to	O
treatment	O
with	O
TRFK	O
-	O
5	O
.	O

(	O
A	O
)	O
2	O
mg	O
/	O
animal	O
at	O
3	O
days	O
post	O
-	O
infection	O
;	O
(	O
B	O
)	O
2	O
mg	O
/	O
animal	O
17	O
days	O
post	O
-	O
infection	O
.	O

The	O
treated	O
and	O
control	O
animals	O
were	O
sacrificed	O
18	O
days	O
after	O
infection	O
.	O

Asterisks	O
indicate	O
a	O
significant	O
difference	O
from	O
infected	O
controls	O
(	O
n	O
=	O
5	O
-	O
6	O
)	O
and	O
from	O
animals	O
treated	O
with	O
TRFK	O
-	O
5	O
(	O
n	O
=	O
4	O
-	O
5	O
)	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
and	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
.	O

28	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O

1996	O

IL	O
-	O
5	O
drives	O
eosinophils	O
in	O
guinea	B-Species
-	I-Species
pig	E-Species
24	O

E	O

20	O

heart	O
;	O
data	O
not	O
shown	O
)	O
and	O
muscle	O
,	O
as	O
reported	O
by	O
other	O
investigators	O
,	O
8	O
were	O
infiltrated	O
.	O

The	O
factors	O
responsible	O
for	O
in	O
vivo	O
eosinophil	O
accumulation	O
at	O
inflammatory	O
sites	O
have	O
been	O

0	O

TRFK	O
-	O
5	O
i	O
.	O
p	O
.	O

0	O

3	O

12	O
17	O

A	O

B	O

FIG	O
.	O

5	O
.	O

Number	O
of	O
eosinophils	O
in	O
BALF	O
of	O
T	O
.	O
caniinfected	O
guinea	B-Species
-	I-Species
pigs	E-Species
submitted	O
or	O
not	O
to	O
treatment	O
with	O
TRFK	O
-	O
5	O
.	O

(	O
A	O
)	O
animals	O
were	O
sacrificed	O
18	O
days	O
post	O
-	O
infection	O
and	O
(	O
B	O
)	O
24	O
days	O
after	O
infection	O
.	O

Asterisks	O
indicate	O
a	O
significant	O
difference	O
from	O
infected	O
control	O
and	O
from	O
animals	O
treated	O
with	O
TRFK	O
-	O
5	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

nophilia	O
persists	O
in	O
lungs	O
,	O
probably	O
by	O
the	O
secretion	O
of	O
IL	O
-	O
5	O
from	O
cells	O
localized	O
in	O
the	O
lung	O
microenvironment	O
,	O

Histopathological	O
analysis	O
:	O
The	O
treatment	O
of	O
T	B-Species
.	I-Species
canis	E-Species
-	O
infected	O
animals	O
with	O
irrelevant	O
antibody	O
showed	O
a	O
widespread	O
eosinophilic	O
infiltration	O
as	O
in	O
untreated	O
animals	O
(	O
Fig	O
.	O
6A	O
,	O
B	O
)	O
.	O

However	O
,	O
the	O
treatment	O
of	O
animals	O
with	O
TRFK	O
-	O
5	O
at	O
the	O
same	O
time	O
of	O
infection	O
,	O
or	O
1	O
day	O
or	O
3	O
days	O
later	O
ted	O
to	O
a	O
complete	O
inhibition	O
of	O
eosinophil	O
infiltration	O
in	O
the	O
lung	O
parenchyma	O
(	O
Fig	O
.	O
6C	O
)	O
.	O

By	O
contrast	O
,	O
the	O
mononuclear	O
cell	O
infiltration	O
in	O
the	O
lungs	O
was	O
not	O
modified	O
.	O

When	O
the	O
infected	O
guinea	B-Species
-	I-Species
pigs	E-Species
received	O
TRFK	O
-	O
5	O
1	O
day	O
before	O
sacrifice	O
(	O
or	O
17	O
days	O
post	O
-	O
infection	O
)	O
,	O
eosinophil	O
infiltration	O
in	O
the	O
lung	O
parenchyma	O
was	O
also	O
inhibited	O
(	O
Fig	O
.	O
6D	O
)	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
observed	O
in	O
the	O
group	O
receiving	O
TRFK	O
-	O
5	O
given	O
at	O
the	O
time	O
of	O
infection	O
or	O
3	O
days	O
later	O
.	O

Thus	O
,	O
the	O
histological	O
determination	O
of	O
eosinophil	O
infiltration	O
in	O
these	O
lungs	O
corroborates	O
a	O
reduction	O
but	O
not	O
a	O
sizeable	O
inhibition	O
of	O
eosinophil	O
numbers	O
as	O
observed	O
in	O
the	O
BALF	O
of	O
the	O
same	O
infected	O
animals	O
,	O

poorly	O
defined	O
,	O
although	O
T	O
lymphocytes	O
and	O
mast	O
cells	O
appear	O
to	O
be	O
involved	O
in	O
eosinophilia	O
.	O

9	O
'	O
2	O
IL	O
-	O
5	O
,	O
a	O
T	O
cell	O
-	O
derived	O
factor	O
that	O
regulates	O
B	O
cell	O
functions	O
,	O
is	O
an	O
eosinophil	O
differentiation	O
factor11	O
as	O
well	O
as	O
a	O
stimulating	O
and	O
survival	O
-	O
prolonging	O
factor	O
specific	O
for	O
eosinophils	O
in	O
vitro	O
.	O

2	O
Also	O
,	O
several	O
investigators	O
have	O
demonstrated	O
that	O
sTstemic	O
eosinophilia	O
in	O
mice	S-Species
infected	O
with	O
parasites	O
is	O
mediated	O
by	O
IL	O
-	O
5	O
produced	O
in	O
response	O
to	O
the	O
infection	O
.	O

2	O
'	O
22	O
In	O
the	O
present	O
study	O
,	O
the	O
i	O
.	O
p	O
.	O
administration	O
of	O
the	O
TRFK	O
-	O
5	O
antibody	O
markedly	O
inhibited	O
the	O
widespread	O
eosinophilia	O
observed	O
in	O
T	B-Species
.	I-Species
canis	E-Species
-	O
infected	O
guinea	B-Species
-	I-Species
pigs	E-Species
,	O
indicating	O
that	O
IL5	O
participated	O
in	O
a	O
guinea	B-Species
-	I-Species
pig	E-Species
model	O
of	O
VLMS	O
eosinophJlia	O
.	O

Most	O
of	O
the	O
T	B-Species
.	I-Species
canis	E-Species
larvae	O
which	O
penetrated	O
the	O
intestinal	O
wall	O
had	O
migrated	O
into	O
the	O
liver	O
within	O
72h	O
after	O
inoculation	O
as	O
demonstrated	O
here	O
and	O
elsewhere	O
.	O

2	O
It	O
is	O
apparently	O
during	O
this	O
interval	O
that	O
the	O
worm	O
provides	O
the	O
signals	O
to	O
cytokine	O
-	O
producing	O
cells	O
,	O
which	O
in	O
turn	O
trigger	O
increased	O
serum	O
levels	O
of	O
specific	O
cytokine	O
as	O
demonstrated	O
here	O
for	O
IL	O
-	O
5	O
,	O
24	O
to	O
72	O
h	O
after	O
infection	O
.	O

The	O
signals	O
may	O
be	O
provided	O
directly	O
by	O
the	O
invading	O
parasite	O
or	O
by	O
cells	O
in	O
response	O
to	O
the	O
parasite	O
.	O

The	O
cytokine	O
pattern	O
that	O
develops	O
at	O
this	O
early	O
stage	O
,	O
probably	O
induced	O
by	O
a	O
T	O
-	O
cell	O
independent	O
pathway	O
,	O
may	O
also	O
influence	O
the	O
pattern	O
of	O
T	O
cell	O
differentiation	O
into	O
a	O
Th2	O
type	O
,	O
which	O
may	O
be	O
responsible	O
for	O
the	O
second	O
peak	O
of	O
IL	O
-	O
5	O
observed	O
in	O
our	O
experimental	O
model	O
(	O
Fig	O
.	O
3	O
)	O
,	O
although	O
a	O
second	O
cycle	O
of	O
larval	O
invasion	O
(	O
Fig	O
.	O
2	O
)	O
with	O
a	O
rapid	O
peak	O
of	O
IL	O
-	O
5	O
liberation	O
cannot	O
be	O
ruled	O
out	O
.	O

Discussion	O
The	O
results	O
of	O
the	O
present	O
study	O
show	O
that	O
in	O
our	O
experimental	O
model	O
widespread	O
eosinophilia	O
follows	O
the	O
infection	O
of	O
guinea	B-Species
-	I-Species
pigs	E-Species
with	O
second	O
stage	O
eggs	O
from	O
T	B-Species
.	I-Species
canis	E-Species
,	O
as	O
also	O
noted	O
in	O
humans	S-Species
and	O
in	O
other	O
experimental	O
animals	O
.	O

7	O
'	O
7	O
T	B-Species
.	I-Species
canis	E-Species
is	O
a	O
potent	O
stimulus	O
for	O
systemic	O
eosinophilia	O
,	O
since	O
blood	O
,	O
BALF	O
,	O
peritoneum	O
and	O
all	O
tissues	O
examined	O
(	O
kidney	O
,	O
eyes	O
,	O
spleen	O
,	O
thymus	O
,	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
the	O
eosinophilia	O
against	O
helminth	O
larvae	O
may	O
be	O
initiated	O
by	O
the	O
release	O
of	O
IL	O
-	O
5	O
when	O
the	O
parasites	O
migrate	O
from	O
the	O
intestine	O
to	O
the	O
liver	O
by	O
stimulation	O
of	O
specific	O
cell	O
populations	O
.	O

Then	O
,	O
an	O
early	O
release	O
of	O
IL	O
-	O
5	O
quickly	O
induces	O
eosinophil	O
recruitment	O
,	O
probably	O
first	O
from	O
the	O
stored	O
mature	O
eosinophil	O
pool	O
from	O
vascular	O
endothelium	O
or	O
by	O
the	O
mobilization	O
of	O
eosinophils	O
from	O
extravascular	O
sites	O
to	O
the	O
blood	O
.	O

This	O
fact	O
could	O
explain	O
why	O
we	O
found	O
increased	O
eosinophils	O
first	O
in	O
blood	O
and	O
later	O
in	O
other	O
compartments	O
.	O

The	O
early	O
IL	O
-	O
5	O
release	O
may	O
also	O
serve	O
as	O
a	O
signal	O
for	O
eosinophil	O
differentiation	O
and	O
maturation	O
in	O
bone	O
marrow	O
.	O

The	O
time	O

inteeeal	O
observed	O
between	O
the	O
first	O
peak	O
of	O
IL	O
-	O
5	O
release	O
and	O
the	O
increase	O
of	O
eosinophils	O
in	O
blood	O
coincides	O
with	O
that	O
reported	O
to	O
be	O
necessary	O
for	O
eosinophil	O
differentiation	O
and	O
maturation	O
in	O
vitro	O
.	O

12Increased	O
eosinophil	O
production	O
and	O
liberation	O
into	O
blood	O
and	O
other	O
tissues	O
occurs	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O

1996	O

29	O

L	O
.	O

H	O
.	O

Faccioli	O
et	O
al	O
.	O

FIG	O
.	O

6	O
.	O

(	O
A	O
)	O
photomicrographs	O
of	O
lung	O
parenchyma	O
from	O
guinea	B-Species
-	I-Species
pigs	E-Species
infected	O
for	O
18	O
days	O
with	O
T	B-Species
.	I-Species
cani	E-Species
,	O
,	O
(	O
B	O
)	O
infected	O
animals	O
which	O
were	O
treated	O
with	O
irrelevant	O
antibody	O
at	O
the	O
time	O
of	O
infection	O
;	O
(	O
C	O
)	O
infected	O
animals	O
which	O
were	O
treated	O
with	O
the	O
mAb	O
TRFK	O
-	O
5	O
at	O
3	O
days	O
after	O
infection	O
;	O
(	O
D	O
)	O
mAb	O
administration	O
17	O
days	O
after	O
infection	O
.	O

The	O
animals	O
were	O
sacrificed	O
18	O
days	O
after	O
infection	O
.	O

Note	O
the	O
intense	O
eosinophil	O
infiltration	O
into	O
the	O
lung	O
in	O
A	O
and	O
B	O
,	O
the	O
inhibition	O
of	O
eosinophils	O
in	O
C	O
and	O
the	O
reduction	O
of	O
eosinophils	O
in	O
D	O
.	O

thereafter	O
.	O

Thus	O
,	O
early	O
and	O
later	O
IL	O
-	O
5	O
release	O
provides	O
a	O
necessary	O
level	O
of	O
this	O
cytokine	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
eosinophilia	O
.	O

We	O
may	O
assume	O
that	O
the	O
inhibition	O
of	O
the	O
first	O
peak	O
of	O
IL	O
-	O
5	O
release	O
by	O
TRFK	O
-	O
5	O
does	O
not	O
permit	O
the	O
subsequent	O
T	O
cell	O
stimulation	O
and	O
differentiation	O
.	O

This	O
may	O
explain	O
the	O
long	O
-	O
lasting	O
effect	O
of	O
TRFK5	O
treatment	O
observed	O
here	O
and	O
also	O
reported	O
by	O
others	O
.	O

8	O
In	O
agreement	O
with	O
our	O
results	O
,	O
there	O
is	O
an	O
important	O
observation	O
of	O
Svetic	O
et	O
al	O
.	O

24	O
showing	O
that	O
a	O
specific	O
and	O
highly	O
reproducible	O
IL	O
-	O
5	O
gene	O
expression	O
pattern	O
is	O
detectable	O
in	O
Peyer	O
'	O
s	O
patches	O
by	O
6	O
to	O
12h	O
after	O
Heligmosomoides	B-Species
polygyrus	E-Species
infection	O
.	O

The	O
early	O
increase	O
in	O
IL	O
-	O
5	O
gene	O
expression	O
after	O
infection	O
was	O
probably	O
T	O
cell	O
-	O
independent	O
,	O
inasmuch	O
as	O
it	O
was	O
obseeeed	O
in	O
Peyer	O
'	O
s	O
patches	O
of	O
congenitally	O
athymic	O
mice	S-Species
and	O
of	O
conventional	O
mice	S-Species
treated	O
with	O
anti	O
-	O
CD4	O
30	O
Mediators	O
of	O
Inflammation	O
Vol	O
5	O

and	O
anti	O
-	O
CD8	O
mAb	O
.	O

Moreover	O
,	O
Kusama	O
eta	O
/	O
.	O

25	O
have	O
observed	O
two	O
peaks	O
of	O
eosinophilia	O
in	O
normal	O
and	O
athymic	O
mice	S-Species
,	O
and	O
suggested	O
that	O
IL	O
-	O
5	O
observed	O
in	O
the	O
first	O
peak	O
was	O
produced	O
by	O
cells	O
other	O
than	O
CD4	O
T	O
cells	O
,	O
since	O
anti	O
-	O
CD4	O
and	O
anti	O
-	O
CD3	O
mAb	O
reduced	O
only	O
the	O
second	O
peak	O
of	O
eosinophilia	O
in	O
normal	O
mice	S-Species
and	O
slightly	O
reduced	O
the	O
first	O
peak	O
of	O
eosinophilia	O
in	O
both	O
normal	O
and	O
nu	O
/	O
nu	O
mice	S-Species
.	O

The	O
local	O
lung	O
cells	O
producing	O
IL	O
-	O
5	O
may	O
also	O
help	O
us	O
to	O
explain	O
the	O
reason	O
why	O
12	O
,	O
17	O
or	O
18	O
days	O
post	O
-	O
infection	O
TRFK	O
-	O
5	O
treatment	O
only	O
partially	O
inhibits	O
,	O
or	O
does	O
not	O
inhibit	O
eosinophil	O
infiltration	O
into	O
the	O
lungs	O
,	O
as	O
demonstrated	O
in	O
Figs	O
5	O
and	O
6	O
.	O

We	O
may	O
suggest	O
that	O
when	O
eosinophils	O
have	O
already	O
migrated	O
to	O
the	O
lungs	O
,	O
TRFK	O
-	O
5	O
has	O
no	O
power	O
to	O
inhibit	O
eosinophilia	O
,	O
which	O
is	O
also	O
under	O
control	O
of	O
local	O
lung	O
cells	O
producing	O
IL	O
-	O
5	O
.	O

In	O
this	O
way	O
,	O
only	O
one	O
later	O
TRFK	O

1996	O

IL	O
-	O
5	O
drives	O
eosinophils	O
in	O
guinea	B-Species
-	I-Species
pig	E-Species

5	O
treatment	O
may	O
not	O
be	O
sufficient	O
to	O
modify	O
the	O
lung	O
parenchyma	O
microenvironment	O
,	O
since	O
T	B-Species
.	I-Species
canis	E-Species
antigens	O
have	O
already	O
stimulated	O
some	O
cell	O
populations	O
to	O
produce	O
IL	O
-	O
5	O
,	O
as	O
demonstrated	O
by	O
Kusama	O
et	O
aL25These	O
results	O
suggest	O
that	O
eosinophilia	O
in	O
lungs	O
is	O
under	O
the	O
control	O
of	O
different	O
factors	O
when	O
compared	O
to	O
that	O
observed	O
in	O
blood	O
and	O
the	O
peritoneal	O
cavity	O
.	O

One	O
of	O
the	O
most	O
important	O
results	O
obtained	O
here	O
was	O
the	O
inhibition	O
of	O
circulating	O
eosinophil	O
numbers	O
by	O
the	O
different	O
mAb	O
treatments	O
,	O
even	O
when	O
the	O
antibody	O
was	O
given	O
at	O
the	O
peak	O
of	O
blood	O
eosinophilia	O
,	O
which	O
was	O
accompanied	O
by	O
an	O
increase	O
of	O
mature	O
eosinophils	O
in	O
bone	O
marrow	O
.	O

This	O
suggests	O
that	O
IL	O
-	O
5	O
,	O
apart	O
from	O
being	O
required	O
for	O
the	O
terminal	O
differentiation	O
of	O
eosinophils	O
in	O
bone	O
marrow	O
,	O
26	O
is	O
also	O
likely	O
to	O
drive	O
eosinophils	O
from	O
the	O
bone	O
marrow	O
to	O
the	O
blood	O
and	O
then	O
to	O
the	O
tissues	O
,	O
probably	O
by	O
upregulating	O
VLA	O
-	O
4	O
expression	O
in	O
eosinophils	O
.	O

Moser	O
et	O
aL	O
have	O
demonstrated	O
that	O
in	O
order	O
to	O
acquire	O
the	O
ability	O
to	O
transmigrate	O
,	O
eosinophils	O
must	O
be	O
primed	O
with	O
cytokines	O
such	O
as	O
IL	O
-	O
5	O
,	O
IL	O
-	O
3	O
or	O
GM	O
-	O
CSF	O
for	O
expression	O
of	O
adhesion	O
molecules	O
such	O
as	O
VI	O
-	O
4	O
.	O

Recently	O
,	O
Pretolani	O
et	O
al	O
.	O

27	O
have	O
indeed	O
shown	O
that	O
an	O
anti	O
-	O
VLA	O
-	O
4	O
antibody	O
suppresses	O
eosinophil	O
recruitment	O
to	O
lung	O
in	O
the	O
guinea	B-Species
-	I-Species
pig	E-Species
and	O
,	O
as	O
a	O
consequence	O
,	O
inhibits	O
the	O
accompanying	O
bronchopulmonary	O
hyperresponsiveness	O
.	O

tant	O
in	O
protective	O
immunity	O
to	O
a	O
gastrointestinal	O
nematode	O
infection	O
in	O
mice	S-Species
.	O

Proc	O
Natl	O
Acad	O
Sci	O
USA	O
1991	O
;	O
88	O
=	O
5513	O
-	O
5517	O
.	O

11	O
.	O

Yamaguchi	O
A	O
,	O
Suda	O
T	O
,	O
Suda	O
J	O
,	O
et	O
al	O
.	O

Purified	O
interleukin	O
(	O
IL	O
-	O
5	O
)	O
supports	O
the	O
terminal	O
differentiation	O
and	O
proliferation	O
of	O
murine	S-Species
eosinophilic	O

precursors	O
.	O

J	O
Exp	O
Med	O
1988	O
;	O
16	O
'	O
7	O
:	O
43	O
-	O
56	O
.	O

12	O
.	O

Yamaguchi	O
Y	O
,	O
Hayashi	O
Y	O
,	O
Sugama	O
Y	O
,	O
et	O
al	O
.	O

Highly	O
purified	O
murine	S-Species
interleukin	O
(	O
IL	O
-	O
5	O
)	O
stimulates	O
eosinophil	O
function	O
and	O
prolongs	O
in	O
vitro	O
survival	O
.	O

IL	O
-	O
5	O
as	O
an	O
eosinophil	O
chemotactic	O
factor	O
.	O

J	O
Exp	O
Med	O
1988	O
;	O
16	O
'	O
7	O
:	O
17371752	O
.	O

13	O
.	O

Rothenberg	O
ME	O
,	O
Petersen	O
J	O
,	O
Stevens	O
RL	O
,	O
Silberstein	O
DS	O
,	O
McKenzie	O
DT	O
,	O
Austen	O
KF	O
,	O
Owen	O
WF	O
.	O

IL	O
-	O
5	O
-	O
dependent	O
conversion	O
of	O
normodense	O
human	S-Species
eosinophils	O
to	O
the	O
hypodense	O
phenotype	O
uses	O
3T3	O
fibroblasts	O
for	O
enhanced	O
viability	O
,	O
accelerated	O
hypodensity	O
,	O
and	O
sustained	O
antibodydependent	O
cytotoxicity	O
.	O

J	O
Immuno11989	O
;	O
143	O
;	O
2311	O
-	O
2316	O
.	O

14	O
.	O

Collins	O
PD	O
,	O
Weg	O
VB	O
,	O
Faccioli	O
LH	O
,	O
Watson	O
ML	O
,	O
Moqbel	O
R	O
,	O
Williams	O
TJ	O
.	O

Eosinophil	O
accumulation	O
induced	O
by	O
human	S-Species
interleukin	O
-	O
8	O
in	O
the	O
guinea	B-Species
pig	E-Species
in	O
vivo	O
.	O

Immunology	O
1993	O
;	O
'	O
7	O
}	O
;	O
312	O
-	O
318	O
.	O

15	O
.	O

Sehmi	O
R	O
,	O
Wardlavo	O
AJ	O
,	O
Cromwell	O
O	O
,	O
Kurihara	O
K	O
,	O
Waltmann	O
P	O
,	O
Kay	O
AB	O
.	O

Interleukin	O
-	O
5	O
selectively	O
enhances	O
the	O
chemotactic	O
response	O
of	O
eosinophils	O
obtained	O
from	O
normal	O
but	O
not	O
eosinophilic	O
subjects	O
.	O

Blood	O
1992	O
;	O
'	O
79	O
;	O
2952	O
-	O
2959	O
.	O

16	O
.	O

Moser	O
R	O
,	O
Fehr	O
J	O
,	O
Bruijnzeel	O
PLB	O
.	O

IL	O
-	O
4	O
controls	O
the	O
selective	O
endotheliumdriven	O
transmigration	O
of	O
eosinophils	O
from	O
allergic	O
individuals	O
.	O

J	O
Immunol	O
1992	O
;	O
149	O
:	O
1432	O
-	O
1438	O
.	O

17	O
.	O

Olson	O
LJ	O
,	O
Schulz	O
CW	O
.	O

Nematode	O
induced	O
hypersensitivity	O
reactions	O
in	O
guinea	B-Species
pigs	E-Species
:	O
onset	O
of	O
eosinophilia	O
and	O
positive	O
Schultz	O
-	O
Dale	O
reactions	O
following	O
graded	O
infection	O
with	O
Toxocara	B-Species
canis	E-Species
.	O

Ann	O
N	O
Y	O
Acad	O
Sci	O
1963	O
;	O
113	O
;	O
440	O
-	O
455	O
.	O

18	O
.	O

Kayes	O
SG	O
,	O
Oaks	O

JA	O
.	O

Development	O

of	O
the	O
granulomatous	O
response	O
in	O

murine	S-Species
toxocariasis	O
.	O

I	O
.	O

Initial	O
events	O
.	O

Am	O
J	O
Patho11978	O
;	O
,	O
}	O
3	O
;	O

277	O
-	O
294	O
.	O

19	O
.	O

Basten	O
A	O
,	O
Beeson	O
PB	O
.	O

Mechanisms	O
of	O
eosinophilia	O
.	O

II	O
.	O

Role	O
of	O
the	O
lymphocyte	O
.	O

J	O
Exp	O
Med	O
1970	O
;	O
131	O
;	O
1288	O
-	O
1305	O
.	O

20	O
.	O

Plaut	O
M	O
,	O
Pierce	O
JH	O
,	O
Watson	O
CJ	O
,	O
Hanley	O
-	O
Hyde	O
J	O
,	O
Nordan	O
RP	O
,	O
Paul	O
WE	O
.	O

Mast	O
cell	O
lines	O
produce	O
lymphokines	O
in	O
response	O
to	O
cross	O
-	O
linkage	O
of	O
Fc	O
epsilon	O
RI	O
or	O
to	O
calcium	O
ionophoras	O
.	O

Nature	O
1989	O
;	O
339	O
:	O
64	O
-	O
67	O
.	O

is	O
21	O
.	O

Sher	O
A	O
,	O
Coffman	O
RL	O
,	O
Hieny	O
S	O
,	O
Scott	O
P	O
,	O
Cheever	O
AW	O
.	O

Interleukin	O
required	O
for	O
the	O
blood	O
and	O
tissue	O
eosinophilia	O
but	O
not	O
granuloma	O
formation	O
induced	O
by	O
infection	O
with	O
Schistosoma	B-Species
mansoni	E-Species
.	O

Proc	O
Natl	O
Acad	O
Sci	O
USA	O
1990	O
;	O
8	O
'	O
7	O
;	O
61	O
-	O
65	O
.	O

22	O
.	O

Herndon	O
FJ	O
,	O
Kayes	O
SG	O
.	O

Depletion	O
of	O
eosinophils	O
by	O
anti	O
-	O
IL	O
-	O
5	O
monoclonal	O
antibody	O
treatment	O
of	O
mice	S-Species
infected	O
with	O
Trichinella	B-Species
spiralis	E-Species
does	O
not	O
alter	O
parasite	O
burden	O
or	O
immunologic	O
resistance	O
to	O
reinfection	O
.	O

J	O
Immuno11992	O
;	O
149	O
:	O
3642	O
-	O
3647	O
.	O

23	O
.	O

Oshima	O
T	O
.	O
Standardization	O
of	O
techniques	O
for	O
infecting	O
mice	S-Species
with	O
Tox24	O
.	O
ocara	O
canis	O
and	O
observations	O
on	O
the	O
normal	O
migration	O
routes	O
of	O
the	O
larvae	O
.	O

J	O
Parasito11961	O
;	O
4	O
'	O
7	O
=	O
652	O
.	O

Svetic	O
A	O
,	O
Madden	O
KB	O
,	O
Zhou	O
XD	O
,	O
et	O
al	O
.	O

A	O
primary	O
intestinal	O
helminthic	O
infection	O
rapidly	O
induces	O
a	O
gut	O
-	O
associated	O
elevation	O
of	O
Th2	O
-	O
associated	O
cytokines	O
and	O
IL	O
-	O
3	O
.	O

J	O
Immuno11993	O
;	O
150	O
:	O
3434	O
-	O
3441	O
.	O

Kusama	O
Y	O
,	O
Takamoto	O
M	O
,	O
Kasahara	O
T	O
,	O
Takatsu	O
K	O
,	O
Nariuchi	O
H	O
,	O
Sugane	O
K	O
.	O
Mechanisms	O
of	O
eosinophilia	O
in	O
BALB	O
/	O
c	O
-	O
nu	O
/	O
+	O
and	O
congenitally	O
athymic	O
BALB	O
/	O
c	O
-	O
nu	O
/	O
nu	O
mice	S-Species
infected	O
with	O
Toxocara	B-Species
canis	E-Species
.	O

Immunology	O
1995	O
;	O
84	O
;	O
461	O
-	O
468	O
.	O

Rennick	O
DM	O
,	O
Thompson	O
-	O
Snipes	O
L	O
,	O
Coffman	O
RL	O
,	O
Seymour	O
BWP	O
,	O
Jackson	O
JD	O
,	O
Hudak	O
S	O
.	O

In	O
vivo	O
administration	O
of	O
antibody	O
to	O
interleukin	O
-	O
5	O
inhibits	O
increased	O
generation	O
of	O
eosinophils	O
and	O
their	O
progenitors	O
in	O
bone	O
marrow	O
of	O
parasitized	O
mice	S-Species
.	O

Blood	O
1990	O
;	O
'	O
76	O
:	O
312	O
-	O
316	O
.	O

Petrolani	O
M	O
,	O
Ruffle	O
C	O
,	O
Lapa	O
e	O
Silva	O
JR	O
,	O
Joseph	O
D	O
,	O
Lobb	O
RR	O
,	O
Boris	O
Vargaftig	O
B	O
.	O
Antibody	O
to	O
very	O
late	O
activation	O
antigen	O
4	O
prevents	O
antigen	O
-	O
induced	O
bronchial	O
hyperreactivity	O
and	O
cellular	O
infiltration	O
in	O
guinea	B-Species
pig	E-Species
airways	O
.	O

J	O
Exp	O
Med	O
1994	O
;	O
180	O
=	O
795	O
-	O
805	O
.	O

References	O
25	O
.	O

1	O
.	O

Nutman	O

2	O
.	O

3	O
.	O

4	O
.	O

5	O
.	O

6	O
.	O

7	O
.	O

8	O
.	O

9	O
.	O

TB	O
,	O
Ottesen	O
EA	O
,	O
Cohen	O
SG	O
.	O

The	O
eosinophil	O
,	O
eosinophilia	O
,	O
and	O
eosinophil	O
-	O
related	O
disorders	O
.	O

Allergy	O
Proc	O
1989	O
;	O
10	O
;	O
47	O
-	O
62	O
.	O

Glickman	O
LT	O
,	O
Schantz	O
PM	O
.	O

Epidemiology	O
and	O
pathogenesis	O
of	O
zoonotic	O
toxocariasis	O
.	O

Epidem	O
Rev	O
1981	O
;	O
3	O
=	O
230	O
-	O
250	O
.	O

Beaver	O
P	O
,	O
Snyder	O
H	O
,	O
Carrera	O
G	O
,	O
Dent	O
J	O
,	O
Lafferty	O
J	O
.	O
Chronic	O
eosinophilia	O
due	O
to	O
visceral	O
larva	O
migrans	O
.	O

Pediatrics	O
1952	O
;	O
9	O
:	O
7	O
-	O
19	O
.	O

Limaye	O
AP	O
,	O
Abrams	O
JS	O
,	O
Silver	O
JE	O
,	O
Ottesen	O
EA	O
,	O
Nutman	O
TB	O
.	O

Regulation	O
of	O
parasite	O
-	O
induced	O
eosinophilia	O
:	O
selectively	O
increased	O
interleukin	O
production	O
in	O
helminth	O
-	O
infected	O
patients	S-Species
.	O

J	O
Exp	O
Med	O
1990	O
;	O
l	O
'	O
7	O
:	O
a	O
;	O
399	O
-	O
402	O
.	O

Steel	O
C	O
,	O
Nutman	O
TB	O
.	O

Regulation	O
of	O
IL	O
-	O
5	O
in	O
onchocerciasis	O
:	O
a	O
critical	O
role	O
for	O
IL	O
-	O
2	O
.	O

J	O
Immuno11993	O
;	O
15	O
{	O
}	O
;	O
5511	O
-	O
5518	O
.	O

Yamaguchi	O
Y	O
,	O
Matsui	O
T	O
,	O
Kasahara	O
T	O
,	O
et	O
al	O
.	O

In	O
vivo	O
changes	O
of	O
hemapoietic	O
progenitors	O
and	O
the	O
expression	O
of	O
the	O
interleukin	O
gene	O
in	O
eosinophilic	O
mice	S-Species
infected	O
with	O
Toxocara	B-Species
canis	E-Species
.	O

Exp	O
Hemato11990	O
;	O
18	O
;	O
1152	O
-	O
1157	O
.	O

Parsons	O
JC	O
,	O
Coffman	O
RL	O
,	O
Grieve	O
RB	O
.	O

Antibody	O
to	O
interleukin	O
prevents	O
blood	O
and	O
tissue	O
eosinophilia	O
but	O
not	O
liver	O
trapping	O
in	O
murine	S-Species
larval	O
toxocariasis	O
.	O

Parasite	O
Immuno11993	O
;	O
15	O
:	O
501	O
-	O
508	O
.	O

Coffman	O
RL	O
,	O
Seymour	O
BWP	O
,	O
Hudak	O
S	O
,	O
Jackson	O
J	O
,	O
Rennick	O
D	O
.	O
Antibody	O
to	O
interleukin	O
-	O
5	O
inhibits	O
helminth	O
-	O
induced	O
eosinophilia	O
in	O
mice	S-Species
.	O

Science	O
1989	O
;	O
245	O
;	O
308	O
-	O
310	O
.	O

Sher	O
A	O
,	O
Coffman	O
RL	O
,	O
Hieny	O
S	O
,	O
Cheever	O
AW	O
.	O

Ablation	O
of	O
eosinophil	O
and	O
IgE	O
responses	O
with	O
anti	O
-	O
IL	O
-	O
5	O
or	O
anti	O
-	O
IL	O
-	O
4	O
antibodies	O
fails	O
to	O
affect	O
immunity	O
against	O
Schistosoma	B-Species
mansoni	E-Species
in	O
the	O
mouse	S-Species
.	O

J	O
Immuno11990	O
;	O
145	O
:	O
3911	O

26	O
.	O

27	O
.	O

ACKNOWLEDGEMENTS	O
.	O

This	O
work	O
was	O
funded	O
by	O
grant	O
300652	O
/	O
85	O
-	O
2	O
from	O
Conselho	O
Nacional	O
de	O
Desenvolvimento	O
Cientifico	O
e	O
Tecnol6gico	O
(	O
CNPq	O
)	O
and	O
Grant	O
92	O
/	O
5105	O
-	O
7	O
from	O
Fundago	O
de	O
Amparo	O
ft	O
Pesquisa	O
do	O
Estado	O
de	O
So	O
Paulo	O
(	O
FAPESP	O
)	O
.	O

We	O
wish	O
to	O
thank	O
Mrs	O
M	O
.	O
A	O
.	O

Fernandes	O
for	O
technical	O
assistance	O
,	O
Mrs	O
M	O
.	O
M	O
.	O
O	O
.	O

Rossi	O
for	O
the	O
histological	O
sections	O
,	O
M	O
.	O

Costa	O
Gongalves	O
for	O
the	O
photography	O
artwork	O
,	O
and	O
Dr	O
P	O
.	O

Minoprio	O
,	O
Institut	O
Pasteur	O
,	O
for	O
kindly	O
providing	O
TRFK	O
-	O
5	O
.	O

3916	O
.	O

10	O
.	O

Urban	O

Jr	O
JF	O
,	O

Katona	O
IM	O
,	O
Paul	O
WE	O
,	O
Finkelman	O
FD	O
.	O

Interleukin	O
4	O
is	O
impor	O

Received	O
12	O
October	O
1995	O
;	O
accepted	O
17	O
November	O
1995	O

Mediators	O
of	O
Inflammation	O
Vol	O
5	O

1996	O

31	O

Modeling	O
the	O
effect	O
of	O
PTPN22	O
in	O
rheumatoid	O
arthritis	O

Abstract	O

In	O
order	O
to	O
model	O
the	O
effect	O
of	O
PTPN22	O
on	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
we	O
determined	O
the	O
combination	O
of	O
single	O
-	O
nucleotide	O
-	O
polymorphisms	O
(	O
SNPs	O
)	O
showing	O
the	O
strongest	O
association	O
with	O
RA	O
.	O

Three	O
SNPs	O
(	O
rs2476601	O
-	O
rs12730735	O
-	O
rs11102685	O
)	O
were	O
selected	O
for	O
which	O
we	O
estimated	O
the	O
genotypic	O
relative	O
risks	O
(	O
GRRs	O
)	O
of	O
the	O
corresponding	O
genotypes	O
.	O

On	O
the	O
basis	O
of	O
these	O
GRRs	O
we	O
defined	O
four	O
at	O
-	O
risk	O
genotypic	O
classes	O
.	O

Relative	O
to	O
the	O
class	O
of	O
reference	O
risk	O
,	O
individuals	O
had	O
a	O
risk	O
approximately	O
multiplied	O
by	O
two	O
,	O
three	O
,	O
or	O
four	O
.	O

This	O
classification	O
was	O
confirmed	O
by	O
the	O
excess	O
of	O
identity	O
-	O
by	O
-	O
descent	O
(	O
IBD	O
)	O
sharing	O
(	O
IBD	O
=	O
2	O
)	O
for	O
the	O
sibs	O
of	O
an	O
index	O
in	O
the	O
high	O
-	O
risk	O
class	O
and	O
by	O
excess	O
of	O
non	O
-	O
IBD	O
sharing	O
(	O
IBD	O
=	O
0	O
)	O
when	O
the	O
index	O
belonged	O
to	O
the	O
low	O
-	O
risk	O
class	O
.	O

The	O
observed	O
data	O
could	O
not	O
be	O
explained	O
by	O
the	O
role	O
of	O
a	O
single	O
variant	O
but	O
were	O
compatible	O
either	O
with	O
a	O
joint	O
effect	O
of	O
the	O
three	O
typed	O
SNPs	O
of	O
PTPN22	O
on	O
RA	O
or	O
with	O
the	O
role	O
of	O
two	O
untyped	O
variants	O
.	O

Background	O

The	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
R620W	O
,	O
also	O
denoted	O
rs2476601	O
,	O
is	O
located	O
within	O
the	O
hematopoietic	O
-	O
specific	O
protein	O
tyrosine	O
phosphatase	O
gene	O
,	O
PTPN22	O
.	O

This	O
SNP	O
(	O
C	O
/	O
T	O
)	O
codes	O
for	O
an	O
amino	O
-	O
acid	O
change	O
and	O
the	O
frequency	O
of	O
its	O
minor	O
allele	O
T	O
has	O
been	O
recently	O
and	O
repeatedly	O
shown	O
to	O
be	O
increased	O
in	O
patients	S-Species
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
[	O
1	O
]	O
.	O

The	O
allele	O
T	O
confers	O
1	O
.	O
7	O
-	O
to	O
1	O
.	O
9	O
-	O
fold	O
increased	O
risk	O
to	O
heterozygote	O
and	O
higher	O
risks	O
to	O
homozygote	O
carriers	O
[	O
2	O
]	O
compared	O
to	O
the	O
non	O
-	O
carrier	O
individuals	O
.	O

This	O
variant	O
is	O
also	O
well	O
known	O
to	O
be	O
associated	O
with	O
several	O
other	O
autoimmune	O
diseases	O
[	O
3	O
]	O
,	O
such	O
as	O
systemic	O
lupus	O
erythematosus	O
and	O
type	O
1	O
diabetes	O
.	O

Recently	O
,	O
Carlton	O
et	O
al	O
.	O

[	O
2	O
]	O
studied	O
the	O
PTPN22	O
genetic	O
variations	O
in	O
the	O
North	O
American	O
Rheumatoid	O
Arthritis	O
Consortium	O
(	O
NARAC	O
)	O
data	O
.	O

Using	O
the	O
information	O
on	O
several	O
SNPs	O
typed	O
in	O
PTPN22	O
,	O
they	O
compared	O
the	O
haplotype	O
distributions	O
in	O
NARAC	O
patients	S-Species
and	O
controls	O
.	O

They	O
demonstrated	O
that	O
SNP	O
R620W	O
does	O
not	O
fully	O
explain	O
the	O
association	O
between	O
PTPN22	O
and	O
RA	O
and	O
suggested	O
the	O
effect	O
of	O
at	O
least	O
one	O
additional	O
variant	O
in	O
the	O
PTPN22	O
gene	O
.	O

We	O
propose	O
here	O
to	O
reanalyze	O
the	O
NARAC	O
data	O
using	O
both	O
association	O
and	O
linkage	O
information	O
for	O
modeling	O
the	O
role	O
of	O
PTPN22	O
in	O
RA	O
.	O

Methods	O

Data	O

We	O
selected	O
from	O
the	O
NARAC	O
data	O
the	O
511	O
families	O
with	O
affected	O
sib	O
pairs	O
typed	O
for	O
14	O
SNPs	O
of	O
PTPN22	O
,	O
and	O
1404	O
unrelated	O
controls	O
also	O
typed	O
for	O
all	O
these	O
SNPs	O
.	O

For	O
each	O
affected	O
sib	O
pair	O
we	O
considered	O
the	O
proband	O
as	O
an	O
index	O
RA	O
patient	S-Species
.	O

The	O
R620W	O
SNP	O
is	O
one	O
of	O
the	O
14	O
SNPs	O
in	O
PTPN22	O
.	O

It	O
is	O
located	O
at	O
the	O
ninth	O
position	O
,	O
so	O
it	O
will	O
be	O
subsequently	O
denoted	O
as	O
SNP	O
9	O
.	O

A	O
preliminary	O
study	O
of	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
among	O
the	O
14	O
SNPs	O
was	O
examined	O
in	O
the	O
1404	O
controls	O
.	O

The	O
LD	O
analysis	O
lead	O
us	O
to	O
exclude	O
3	O
SNPs	O
(	O
SNP	O
2	O
,	O
SNP	O
12	O
,	O
SNP	O
13	O
)	O
,	O
which	O
are	O
in	O
complete	O
LD	O
with	O
one	O
(	O
or	O
more	O
)	O
other	O
SNP	O
(	O
s	O
)	O
.	O

Selection	O
of	O
associated	O
SNPs	O

The	O
combination	O
test	O
[	O
4	O
]	O
was	O
used	O
on	O
the	O
11	O
remaining	O
SNPs	O
to	O
select	O
the	O
subset	O
of	O
SNPs	O
showing	O
a	O
significant	O
difference	O
in	O
the	O
genotypic	O
distribution	O
between	O
RA	O
index	O
patients	S-Species
and	O
controls	O
.	O

Its	O
principle	O
consists	O
in	O
testing	O
all	O
possible	O
combinations	O
of	O
SNPs	O
within	O
a	O
gene	O
.	O

Here	O
,	O
there	O
are	O
(	O
211	O
-	O
1	O
)	O
possible	O
combinations	O
.	O

Such	O
a	O
systematic	O
testing	O
of	O
all	O
SNPs	O
and	O
all	O
SNP	O
combinations	O
raises	O
the	O
problem	O
of	O
multiple	O
and	O
non	O
-	O
independent	O
tests	O
.	O

This	O
problem	O
is	O
generally	O
solved	O
by	O
the	O
implementation	O
of	O
a	O
permutation	O
procedure	O
that	O
allows	O
estimation	O
of	O
corrected	O
p	O
-	O
values	O
.	O

Here	O
,	O
associated	O
combinations	O
are	O
very	O
significant	O
and	O
the	O
number	O
of	O
permutations	O
necessary	O
to	O
discriminate	O
them	O
would	O
be	O
extremely	O
high	O
and	O
almost	O
unreachable	O
.	O

Nevertheless	O
,	O
the	O
chi	O
-	O
square	O
values	O
of	O
the	O
genotypic	O
association	O
test	O
are	O
so	O
high	O
that	O
even	O
the	O
conservative	O
Bonferroni	O
correction	O
can	O
be	O
used	O
.	O

We	O
selected	O
the	O
most	O
associated	O
and	O
parsimonious	O
subset	O
of	O
SNPs	O
by	O
nested	O
chi	O
-	O
square	O
tests	O
(	O
NCST	O
)	O
in	O
a	O
forward	O
procedure	O
.	O

The	O
NCST	O
compares	O
the	O
strength	O
of	O
association	O
between	O
nested	O
significant	O
subsets	O
.	O

Genotypic	O
relative	O
-	O
risk	O
estimation	O

For	O
the	O
selected	O
subset	O
of	O
SNPs	O
,	O
we	O
used	O
the	O
marker	O
association	O
segregation	O
chi	O
-	O
square	O
(	O
MASC	O
)	O
method	O
[	O
5	O
]	O
to	O
compute	O
the	O
genotypic	O
relative	O
risk	O
(	O
GRR	O
)	O
of	O
each	O
genotype	O
.	O

The	O
genotype	O
distributions	O
of	O
index	O
and	O
controls	O
was	O
conditional	O
on	O
the	O
fact	O
that	O
the	O
index	O
has	O
an	O
affected	O
sib	O
.	O

Stratified	O
sib	O
pair	O
IBD	O
estimation	O

Conditional	O
on	O
each	O
marker	O
genotype	O
of	O
the	O
index	O
cases	O
,	O
the	O
number	O
of	O
parental	O
alleles	O
identical	O
by	O
descent	O
(	O
IBD	O
)	O
shared	O
by	O
the	O
index	O
case	O
and	O
one	O
affected	O
sib	O
were	O
estimated	O
on	O
PTPN22	O
with	O
the	O
MERLIN	O
software	O
[	O
6	O
]	O
.	O

MERLIN	O
is	O
able	O
to	O
take	O
into	O
account	O
LD	O
between	O
SNPs	O
during	O
the	O
IBD	O
computation	O
.	O

So	O
the	O
estimated	O
IBD	O
distributions	O
are	O
computed	O
on	O
the	O
overall	O
set	O
of	O
SNPs	O
even	O
if	O
they	O
are	O
in	O
LD	O
.	O

The	O
fit	O
of	O
a	O
model	O
to	O
the	O
IBD	O
distributions	O
stratified	O
on	O
index	O
marker	O
genotypes	O
[	O
7	O
]	O
may	O
then	O
be	O
tested	O
by	O
the	O
MASC	O
method	O
.	O

Modeling	O
PTPN22	O
effect	O

We	O
applied	O
the	O
MASC	O
method	O
[	O
5	O
]	O
to	O
find	O
the	O
most	O
parsimonious	O
model	O
explaining	O
the	O
overall	O
observations	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
genotype	O
and	O
the	O
stratified	O
sib	O
-	O
pair	O
IBD	O
distributions	O
.	O

To	O
do	O
this	O
,	O
MASC	O
requires	O
the	O
haplotype	O
frequencies	O
in	O
the	O
general	O
population	O
,	O
which	O
were	O
estimated	O
on	O
the	O
unrelated	O
controls	O
by	O
the	O
MERLIN	O
software	O
.	O

The	O
MASC	O
method	O
computes	O
the	O
expected	O
genotype	O
marker	O
distribution	O
and	O
the	O
expected	O
sib	O
-	O
pair	O
IBD	O
distributions	O
stratified	O
on	O
marker	O
genotypes	O
for	O
a	O
given	O
genetic	O
model	O
.	O

Here	O
,	O
the	O
computation	O
of	O
the	O
genotypic	O
distribution	O
is	O
conditioned	O
on	O
the	O
fact	O
that	O
index	O
cases	O
have	O
an	O
affected	O
sib	O
.	O

The	O
global	O
expected	O
likelihood	O
of	O
the	O
genetic	O
model	O
given	O
the	O
observed	O
data	O
is	O
then	O
computed	O
as	O
the	O
product	O
of	O
the	O
likelihoods	O
of	O
each	O
expected	O
distribution	O
,	O
and	O
is	O
maximized	O
on	O
the	O
model	O
parameters	O
.	O

The	O
fit	O
of	O
the	O
model	O
to	O
the	O
observed	O
data	O
is	O
tested	O
by	O
a	O
likelihood	O
ratio	O
test	O
(	O
LRT	O
)	O
between	O
global	O
expected	O
likelihood	O
and	O
the	O
likelihood	O
of	O
the	O
saturated	O
model	O
.	O

Results	O

Selection	O
of	O
associated	O
SNPs	O

Many	O
subsets	O
of	O
SNPs	O
show	O
significant	O
associations	O
.	O

Table	O
1	O
presents	O
a	O
selection	O
of	O
the	O
most	O
associated	O
combinations	O
of	O
one	O
,	O
two	O
,	O
and	O
three	O
SNPs	O
.	O

When	O
considering	O
only	O
the	O
effect	O
of	O
a	O
single	O
SNP	O
,	O
the	O
only	O
significant	O
associated	O
one	O
after	O
correction	O
for	O
multiple	O
testing	O
is	O
SNP	O
9	O
.	O

The	O
combination	O
of	O
SNPs	O
9	O
-	O
10	O
is	O
the	O
one	O
which	O
,	O
among	O
the	O
combination	O
of	O
two	O
SNPs	O
,	O
best	O
improves	O
the	O
association	O
shown	O
by	O
the	O
SNP	O
9	O
alone	O
(	O
p	O
=	O
0	O
.	O
017	O
)	O
.	O

The	O
subset	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
(	O
rs2476601	O
-	O
rs12730735	O
-	O
rs11102685	O
)	O
is	O
the	O
only	O
one	O
that	O
improves	O
significantly	O
the	O
association	O
shown	O
by	O
the	O
SNPs	O
9	O
-	O
10	O
(	O
p	O
=	O
0	O
.	O
038	O
)	O
.	O

Adding	O
another	O
SNP	O
to	O
this	O
subset	O
does	O
not	O
significantly	O
improve	O
the	O
association	O
.	O

Consequently	O
,	O
all	O
the	O
subsequent	O
analyses	O
have	O
been	O
done	O
considering	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
and	O
their	O
ten	O
corresponding	O
genotypes	O
.	O

GRR	O
estimation	O

Table	O
2	O
displays	O
the	O
genotypes	O
and	O
the	O
corresponding	O
GRRs	O
for	O
SNP	O
9	O
taken	O
alone	O
(	O
columns	O
1	O
and	O
2	O
)	O
and	O
for	O
the	O
set	O
of	O
the	O
three	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
(	O
columns	O
3	O
and	O
4	O
)	O
.	O

The	O
GRRs	O
vary	O
from	O
1	O
to	O
2	O
.	O
7	O
when	O
considering	O
only	O
SNP	O
9	O
,	O
whereas	O
the	O
variation	O
ranges	O
from	O
1	O
to	O
4	O
.	O
7	O
when	O
the	O
information	O
on	O
the	O
three	O
SNPs	O
is	O
taken	O
into	O
account	O
.	O

Interestingly	O
,	O
the	O
CC	O
genotype	O
of	O
the	O
SNP	O
9	O
can	O
be	O
subdivided	O
in	O
several	O
genotypes	O
when	O
taking	O
into	O
account	O
the	O
genotypes	O
for	O
SNPs	O
10	O
and	O
11	O
(	O
rows	O
1	O
to	O
6	O
)	O
with	O
GRRs	O
ranging	O
from	O
1	O
(	O
CC	O
-	O
GG	O
-	O
AA	O
)	O
to	O
3	O
.	O
6	O
(	O
CC	O
-	O
AA	O
-	O
GG	O
)	O
.	O

This	O
observation	O
demonstrates	O
the	O
importance	O
of	O
using	O
the	O
additional	O
information	O
on	O
SNPs	O
10	O
-	O
11	O
.	O

Sib	O
pair	O
IBD	O
estimation	O

The	O
proportion	O
of	O
RA	O
sibs	O
sharing	O
0	O
,	O
1	O
,	O
or	O
2	O
parental	O
alleles	O
for	O
PTPN22	O
is	O
0	O
.	O
26	O
(	O
181	O
pairs	O
)	O
,	O
0	O
.	O
51	O
(	O
362	O
pairs	O
)	O
,	O
and	O
0	O
.	O
23	O
(	O
167	O
pairs	O
)	O
,	O
respectively	O
,	O
and	O
does	O
not	O
differ	O
from	O
the	O
IBD	O
distribution	O
0	O
.	O
25	O
;	O
0	O
.	O
5	O
;	O
0	O
.	O
25	O
expected	O
under	O
no	O
linkage	O
.	O

However	O
,	O
if	O
our	O
GRRs	O
correctly	O
reflect	O
the	O
differential	O
risk	O
of	O
RA	O
,	O
we	O
expect	O
to	O
see	O
differences	O
in	O
the	O
IBD	O
vectors	O
stratified	O
on	O
the	O
genotypes	O
of	O
the	O
subset	O
of	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
[	O
7	O
]	O
.	O

To	O
avoid	O
cells	O
with	O
small	O
numbers	O
of	O
individuals	O
we	O
pooled	O
sib	O
pairs	O
with	O
the	O
index	O
genotypes	O
(	O
SNP	O
9	O
-	O
10	O
-	O
11	O
)	O
that	O
have	O
similar	O
risk	O
.	O

We	O
thus	O
defined	O
four	O
arbitrary	O
at	O
risk	O
genotypic	O
classes	O
:	O
the	O
low	O
risk	O
class	O
(	O
L	O
;	O
GRR	O
=	O
1	O
;	O
19	O
pairs	O
)	O
,	O
the	O
intermediate	O
risk	O
class	O
1	O
(	O
I1	O
;	O
1	O
<	O
GRR	O
<=	O
2	O
;	O
295	O
pairs	O
)	O
,	O
the	O
intermediate	O
risk	O
class	O
2	O
(	O
I2	O
;	O
2	O
<	O
GRR	O
<=	O
3	O
;	O
157	O
pairs	O
)	O
,	O
and	O
the	O
high	O
risk	O
class	O
(	O
H	O
;	O
GRR	O
>	O
3	O
;	O
34	O
pairs	O
)	O
.	O

Table	O
3	O
shows	O
that	O
the	O
proportion	O
of	O
IBD	O
=	O
0	O
decreases	O
from	O
0	O
.	O
47	O
to	O
0	O
.	O
09	O
according	O
to	O
the	O
fact	O
that	O
the	O
index	O
belongs	O
to	O
class	O
L	O
or	O
class	O
H	O
and	O
conversely	O
,	O
the	O
proportion	O
of	O
IBD	O
=	O
2	O
increases	O
from	O
0	O
.	O
11	O
to	O
0	O
.	O
26	O
.	O

These	O
stratified	O
IBD	O
distributions	O
are	O
consistent	O
with	O
the	O
risk	O
genotypic	O
classes	O
.	O

In	O
contrast	O
,	O
the	O
IBD	O
sharing	O
distributions	O
stratified	O
only	O
on	O
SNP	O
9	O
genotypes	O
are	O
not	O
consistent	O
with	O
the	O
GRR	O
estimates	O
on	O
this	O
SNP	O
(	O
Table	O
4	O
)	O
.	O

Modeling	O
PTPN22	O
effect	O

We	O
apply	O
the	O
MASC	O
method	O
in	O
using	O
the	O
genotype	O
distribution	O
only	O
on	O
the	O
SNP	O
9	O
and	O
the	O
IBD	O
stratified	O
on	O
the	O
SNP	O
9	O
genotypes	O
.	O

In	O
that	O
case	O
,	O
the	O
single	O
and	O
causal	O
effect	O
of	O
the	O
SNP	O
9	O
is	O
not	O
rejected	O
(	O
p	O
=	O
0	O
.	O
29	O
)	O
.	O

Then	O
,	O
we	O
model	O
the	O
effect	O
of	O
PTPN22	O
using	O
the	O
four	O
genotypic	O
groups	O
of	O
risk	O
defined	O
on	O
the	O
genotypes	O
of	O
the	O
combination	O
of	O
the	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
and	O
the	O
IBD	O
information	O
stratified	O
on	O
them	O
.	O

In	O
this	O
case	O
,	O
we	O
reject	O
the	O
direct	O
effect	O
of	O
SNP	O
9	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

We	O
also	O
reject	O
the	O
effect	O
of	O
a	O
single	O
untyped	O
SNP	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O

However	O
,	O
we	O
do	O
not	O
reject	O
the	O
interactive	O
effect	O
of	O
the	O
3	O
SNPs	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
the	O
interactive	O
effect	O
of	O
two	O
untyped	O
SNPs	O
.	O

Discussion	O

The	O
involvement	O
of	O
PTPN22	O
and	O
HLA	O
in	O
RA	O
susceptibility	O
is	O
no	O
longer	O
disputed	O
.	O

However	O
,	O
as	O
shown	O
by	O
Carlton	O
et	O
al	O
.	O
and	O
confirmed	O
in	O
this	O
study	O
,	O
the	O
role	O
of	O
PTPN22	O
cannot	O
be	O
explained	O
only	O
by	O
the	O
R620W	O
SNP	O
.	O

A	O
correct	O
modeling	O
of	O
PTPN22	O
is	O
important	O
and	O
shows	O
that	O
the	O
genotypic	O
risk	O
varies	O
much	O
more	O
(	O
1	O
to	O
4	O
.	O
7	O
)	O
than	O
reported	O
in	O
the	O
literature	O
(	O
1	O
to	O
2	O
.	O
7	O
)	O
[	O
4	O
]	O
.	O

In	O
this	O
study	O
we	O
proposed	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
model	O
for	O
the	O
effect	O
of	O
PTPN22	O
,	O
taking	O
into	O
account	O
both	O
association	O
and	O
linkage	O
information	O
.	O

Another	O
method	O
,	O
called	O
LAMP	O
[	O
8	O
]	O
was	O
recently	O
proposed	O
for	O
joint	O
modeling	O
of	O
linkage	O
and	O
association	O
[	O
8	O
]	O
.	O

The	O
linkage	O
information	O
used	O
by	O
the	O
LAMP	O
method	O
is	O
the	O
global	O
IBD	O
sharing	O
of	O
affected	O
sib	O
pairs	O
.	O

However	O
,	O
it	O
is	O
very	O
important	O
to	O
note	O
that	O
the	O
power	O
of	O
model	O
discrimination	O
strongly	O
depends	O
on	O
the	O
association	O
and	O
linkage	O
information	O
that	O
is	O
used	O
.	O

As	O
shown	O
here	O
,	O
the	O
information	O
on	O
SNP	O
9	O
alone	O
and	O
on	O
the	O
global	O
IBD	O
is	O
very	O
poor	O
as	O
compared	O
with	O
that	O
of	O
the	O
three	O
SNPs	O
9	O
-	O
10	O
-	O
11	O
and	O
to	O
the	O
stratified	O
IBD	O
distributions	O
on	O
the	O
four	O
at	O
-	O
risk	O
genotype	O
groups	O
.	O

In	O
conclusion	O
,	O
we	O
applied	O
a	O
four	O
-	O
step	O
strategy	O
to	O
model	O
the	O
effect	O
of	O
a	O
candidate	O
gene	O
covered	O
by	O
several	O
SNPs	O
:	O
1	O
)	O
to	O
select	O
the	O
most	O
associated	O
set	O
of	O
SNPs	O
;	O
2	O
)	O
to	O
group	O
the	O
corresponding	O
genotypes	O
according	O
their	O
GRRs	O
;	O
3	O
)	O
to	O
stratify	O
IBD	O
sharing	O
information	O
on	O
the	O
at	O
-	O
risk	O
genotype	O
groups	O
;	O
4	O
)	O
to	O
model	O
the	O
effect	O
of	O
the	O
candidate	O
gene	O
while	O
taking	O
into	O
account	O
both	O
linkage	O
and	O
association	O
information	O
.	O

This	O
strategy	O
allowed	O
better	O
modeling	O
of	O
the	O
effect	O
of	O
PTPN22	O
in	O
RA	O
susceptibility	O
.	O

Recently	O
,	O
du	O
Montcel	O
et	O
al	O
.	O

[	O
9	O
]	O
refined	O
the	O
modeling	O
of	O
HLA	O
in	O
RA	O
susceptibility	O
.	O

A	O
next	O
step	O
will	O
be	O
to	O
use	O
simultaneously	O
the	O
PTPN22	O
and	O
HLA	O
information	O
to	O
evaluate	O
their	O
joint	O
effects	O
while	O
taking	O
into	O
account	O
important	O
covariables	O
such	O
as	O
age	O
and	O
gender	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Purinergic	O
signalling	O
in	O
the	O
subretinal	O
space	O
:	O
a	O
role	O
in	O
the	O
communication	O
between	O
the	O
retina	O
and	O
the	O
RPE	O

Abstract	O

The	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
is	O
separated	O
from	O
the	O
photoreceptor	O
outer	O
segments	O
by	O
the	O
subretinal	O
space	O
.	O

While	O
the	O
actual	O
volume	O
of	O
this	O
space	O
is	O
minimal	O
,	O
the	O
communication	O
that	O
occurs	O
across	O
this	O
microenvironment	O
is	O
important	O
to	O
the	O
visual	O
process	O
,	O
and	O
accumulating	O
evidence	O
suggests	O
the	O
purines	O
ATP	O
and	O
adenosine	O
contribute	O
to	O
this	O
communication	O
.	O

P1	O
and	O
P2	O
receptors	O
are	O
localized	O
to	O
membranes	O
on	O
both	O
the	O
photoreceptor	O
outer	O
segments	O
and	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
which	O
border	O
subretinal	O
space	O
.	O

ATP	O
is	O
released	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
into	O
this	O
space	O
in	O
response	O
to	O
various	O
triggers	O
including	O
glutamate	O
and	O
chemical	O
ischemia	O
.	O

This	O
ATP	O
is	O
dephosphorylated	O
into	O
adenosine	O
by	O
a	O
series	O
of	O
ectoenzymes	O
on	O
the	O
RPE	O
apical	O
membrane	O
.	O

Regulation	O
of	O
release	O
and	O
ectoenzyme	O
activity	O
in	O
response	O
to	O
light	O
-	O
sensitive	O
signals	O
can	O
alter	O
the	O
balance	O
of	O
purines	O
in	O
subretinal	O
space	O
,	O
and	O
thus	O
coordinate	O
communication	O
across	O
subretinal	O
space	O
with	O
the	O
visual	O
process	O
.	O

Introduction	O

The	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
lies	O
between	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptors	O
and	O
the	O
choroidal	O
blood	O
supply	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
RPE	O
combines	O
the	O
functions	O
of	O
epithelial	O
and	O
glial	O
cells	O
,	O
providing	O
a	O
barrier	O
while	O
also	O
supporting	O
the	O
neural	O
photoreceptors	O
and	O
modulating	O
their	O
function	O
.	O

Tight	O
communication	O
between	O
photoreceptors	O
and	O
the	O
RPE	O
is	O
critical	O
to	O
coordinate	O
the	O
multiple	O
levels	O
of	O
interaction	O
,	O
and	O
the	O
purinergic	O
contribution	O
to	O
this	O
communication	O
is	O
becoming	O
apparent	O
.	O

The	O
relevance	O
of	O
this	O
purinergic	O
input	O
is	O
emphasized	O
by	O
the	O
many	O
functional	O
effects	O
of	O
P1	O
and	O
P2	O
receptor	O
stimulation	O
and	O
by	O
the	O
multiple	O
mechanisms	O
in	O
place	O
to	O
regulate	O
subretinal	O
levels	O
of	O
purine	O
agonists	O
.	O

As	O
the	O
dynamics	O
of	O
ATP	O
release	O
and	O
extracellular	O
conversion	O
into	O
adenosine	O
will	O
modify	O
agonist	O
availability	O
,	O
the	O
modulation	O
of	O
these	O
processes	O
can	O
exert	O
a	O
temporal	O
control	O
on	O
purinergic	O
signaling	O
.	O

The	O
following	O
review	O
will	O
outline	O
the	O
main	O
interactions	O
between	O
the	O
RPE	O
and	O
photoreceptors	O
,	O
describe	O
the	O
effects	O
of	O
stimulating	O
purinergic	O
receptors	O
on	O
both	O
sides	O
of	O
subretinal	O
space	O
,	O
and	O
summarize	O
how	O
levels	O
of	O
ATP	O
,	O
ADP	O
,	O
and	O
adenosine	O
are	O
manipulated	O
in	O
this	O
microenvironment	O
.	O

Fig	O
.	O
1Schematic	O
illustration	O
of	O
the	O
key	O
components	O
of	O
purinergic	O
signaling	O
in	O
the	O
subretinal	O
microenvironment	O
.	O

Stimulation	O
of	O
P2	O
receptors	O
on	O
the	O
RPE	O
can	O
enhance	O
transepithelial	O
fluid	O
absorption	O
while	O
P1	O
receptors	O
can	O
modulate	O
phagocytosis	O
.	O

ATP	O
released	O
through	O
CFTR	O
and	O
other	O
Cl	O
-	O
channels	O
can	O
stimulate	O
P2	O
receptors	O
or	O
be	O
converted	O
to	O
ADP	O
,	O
AMP	O
,	O
and	O
adenosine	O
(	O
Ado	O
)	O
by	O
a	O
series	O
of	O
ectonucleotidases	O
present	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
.	O

By	O
controlling	O
the	O
balance	O
of	O
extracellular	O
purines	O
available	O
to	O
stimulate	O
these	O
receptors	O
these	O
mechanisms	O
can	O
control	O
levels	O
of	O
endogenous	O
purines	O
available	O
to	O
activate	O
the	O
receptors	O
.	O

While	O
theoretically	O
possible	O
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
these	O
subretinal	O
purines	O
can	O
actually	O
stimulate	O
photoreceptors	O

Purines	O
and	O
subretinal	O
space	O

RPE	O
-	O
photoreceptor	O
interactions	O
across	O
the	O
subretinal	O
space	O

The	O
outer	O
segments	O
of	O
the	O
rods	O
and	O
cones	O
are	O
responsible	O
for	O
the	O
initial	O
stages	O
of	O
vision	O
,	O
converting	O
photon	O
energy	O
into	O
a	O
series	O
of	O
enzymatic	O
reactions	O
that	O
close	O
the	O
light	O
-	O
sensitive	O
channels	O
on	O
the	O
photoreceptor	O
plasma	O
membrane	O
,	O
hyperpolarize	O
the	O
cells	O
,	O
and	O
reduce	O
the	O
release	O
of	O
glutamate	O
from	O
the	O
synaptic	O
terminals	O
[	O
1	O
,	O
2	O
]	O
.	O

Efficient	O
photoreceptor	O
function	O
depends	O
upon	O
both	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
support	O
from	O
the	O
RPE	O
.	O

The	O
critical	O
nature	O
of	O
these	O
interactions	O
is	O
evident	O
from	O
the	O
rapid	O
degeneration	O
of	O
photoreceptors	O
in	O
the	O
absence	O
of	O
a	O
healthy	O
RPE	O
layer	O
and	O
by	O
the	O
RPE	O
localization	O
of	O
defective	O
gene	O
product	O
in	O
some	O
forms	O
of	O
hereditary	O
photoreceptor	O
degeneration	O
[	O
3	O
]	O
.	O

The	O
apical	O
membrane	O
of	O
the	O
RPE	O
is	O
separated	O
from	O
the	O
plasma	O
membrane	O
of	O
the	O
outer	O
segments	O
by	O
an	O
extracellular	O
space	O
of	O
only	O
10	O
-	O
20	O
nm	O
[	O
4	O
]	O
.	O

Although	O
small	O
,	O
this	O
subretinal	O
space	O
contains	O
a	O
highly	O
structured	O
matrix	O
which	O
ensheathes	O
the	O
outer	O
segments	O
and	O
extends	O
to	O
the	O
RPE	O
[	O
5	O
,	O
6	O
]	O
.	O

The	O
presence	O
of	O
enzymes	O
within	O
this	O
interphotoreceptor	O
matrix	O
emphasizes	O
that	O
this	O
extracellular	O
space	O
itself	O
is	O
functionally	O
active	O
[	O
7	O
,	O
8	O
]	O
.	O

This	O
intimate	O
anatomical	O
relationship	O
between	O
photoreceptors	O
and	O
the	O
RPE	O
reflects	O
multiple	O
functional	O
interactions	O
.	O

For	O
example	O
,	O
the	O
RPE	O
accepts	O
,	O
recycles	O
,	O
and	O
exports	O
central	O
components	O
of	O
the	O
phototransduction	O
process	O
[	O
9	O
]	O
.	O

The	O
outer	O
segments	O
are	O
continuously	O
resynthesized	O
,	O
and	O
the	O
phagocytosis	O
,	O
degradation	O
,	O
and	O
processing	O
of	O
shed	O
outer	O
segment	O
tips	O
by	O
the	O
RPE	O
cells	O
is	O
central	O
to	O
this	O
renewal	O
[	O
10	O
]	O
.	O

The	O
ion	O
channels	O
and	O
transporters	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
help	O
regulate	O
the	O
ionic	O
composition	O
of	O
the	O
subretinal	O
space	O
[	O
11	O
]	O
.	O

As	O
extracellular	O
levels	O
of	O
ions	O
can	O
modify	O
the	O
ionic	O
driving	O
forces	O
across	O
the	O
photoreceptor	O
plasma	O
membrane	O
,	O
these	O
RPE	O
transporters	O
can	O
influence	O
the	O
state	O
of	O
neural	O
activity	O
.	O

The	O
transport	O
of	O
fluid	O
and	O
ions	O
from	O
the	O
apical	O
membrane	O
to	O
basolateral	O
membrane	O
of	O
the	O
RPE	O
is	O
also	O
one	O
of	O
the	O
main	O
forces	O
keeping	O
the	O
retina	O
attached	O
[	O
12	O
]	O
.	O

The	O
control	O
of	O
photoreceptor	O
activity	O
by	O
light	O
gives	O
a	O
rapid	O
temporal	O
dependence	O
to	O
some	O
interactions	O
between	O
the	O
photoreceptors	O
and	O
the	O
RPE	O
.	O

The	O
volume	O
of	O
subretinal	O
space	O
increases	O
in	O
response	O
to	O
light	O
[	O
13	O
]	O
,	O
linking	O
small	O
changes	O
in	O
the	O
ionic	O
composition	O
of	O
the	O
subretinal	O
space	O
with	O
activity	O
of	O
the	O
RPE	O
transport	O
mechanisms	O
which	O
maintain	O
this	O
volume	O
[	O
14	O
,	O
15	O
]	O
.	O

Other	O
processes	O
are	O
controlled	O
on	O
a	O
diurnal	O
cycle	O
.	O

The	O
shed	O
tips	O
of	O
the	O
outer	O
segments	O
are	O
phagocytosed	O
by	O
the	O
RPE	O
soon	O
after	O
the	O
onset	O
of	O
light	O
[	O
16	O
,	O
17	O
]	O
.	O

These	O
processes	O
can	O
both	O
be	O
modulated	O
by	O
purine	O
levels	O
in	O
subretinal	O
space	O
,	O
indicating	O
purinergic	O
regulation	O
is	O
important	O
over	O
multiple	O
time	O
scales	O
.	O

Purinergic	O
receptors	O
on	O
photoreceptors	O

A2	O
adenosine	O
receptors	O
were	O
localized	O
to	O
both	O
the	O
inner	O
and	O
outer	O
segments	O
of	O
photoreceptor	O
outer	O
segments	O
over	O
a	O
decade	O
ago	O
by	O
Blazynski	O
and	O
colleagues	O
[	O
18	O
]	O
,	O
with	O
more	O
recent	O
reports	O
emphasizing	O
their	O
functional	O
role	O
.	O

A2	O
agonists	O
inhibit	O
the	O
L	O
-	O
type	O
Ca2	O
+	O
channel	O
on	O
rod	O
outer	O
segments	O
[	O
19	O
]	O
and	O
can	O
inhibit	O
the	O
synaptic	O
release	O
of	O
glutamate	O
from	O
rods	O
,	O
suggesting	O
changes	O
in	O
adenosine	O
levels	O
in	O
subretinal	O
space	O
could	O
modulate	O
light	O
sensitivity	O
[	O
20	O
]	O
.	O

The	O
A2	O
agonist	O
DPMA	O
and	O
the	O
adenosine	O
deaminase	O
inhibitor	O
EHNA	O
reduce	O
mRNA	O
for	O
opsin	O
in	O
rods	O
,	O
suggesting	O
that	O
endogenous	O
levels	O
of	O
adenosine	O
can	O
downregulate	O
opsin	O
message	O
at	O
night	O
[	O
21	O
]	O
.	O

EHNA	O
and	O
the	O
A2A	O
receptor	O
agonist	O
CGS21680	O
also	O
increase	O
the	O
survival	O
of	O
chick	O
embryonic	O
photoreceptors	O
in	O
culture	O
[	O
22	O
]	O
,	O
indicating	O
a	O
long	O
-	O
term	O
neuroprotective	O
role	O
for	O
adenosine	O
.	O

P2	O
receptors	O
are	O
also	O
present	O
in	O
the	O
photoreceptors	O
.	O

mRNA	O
for	O
the	O
P2X2	O
receptor	O
is	O
expressed	O
in	O
the	O
photoreceptor	O
cell	O
bodies	O
,	O
with	O
immunohistochemical	O
localization	O
of	O
the	O
protein	O
to	O
outer	O
segments	O
[	O
23	O
]	O
.	O

In	O
situ	O
hybridization	O
indicates	O
the	O
photoreceptor	O
layer	O
has	O
the	O
highest	O
level	O
of	O
P2Y2	O
receptor	O
of	O
any	O
region	O
in	O
the	O
rabbit	S-Species
retina	O
,	O
although	O
staining	O
was	O
not	O
pronounced	O
in	O
monkey	O
[	O
24	O
]	O
.	O

P2X7	O
receptors	O
have	O
recently	O
been	O
localized	O
to	O
photoreceptor	O
synaptic	O
terminals	O
,	O
with	O
evidence	O
for	O
ecto	O
-	O
ATPase	O
activity	O
in	O
the	O
synapse	O
,	O
and	O
functional	O
evidence	O
suggesting	O
ATP	O
augments	O
transmission	O
of	O
the	O
light	O
response	O
by	O
rods	O
[	O
25	O
]	O
.	O

It	O
was	O
suggested	O
that	O
ATP	O
might	O
be	O
co	O
-	O
released	O
from	O
photoreceptors	O
with	O
glutamate	O
,	O
although	O
this	O
remains	O
to	O
be	O
tested	O
directly	O
.	O

Purinergic	O
receptors	O
on	O
the	O
RPE	O

Stimulation	O
of	O
P1	O
receptors	O
can	O
have	O
a	O
considerable	O
impact	O
on	O
RPE	O
cells	O
.	O

A2	O
receptors	O
have	O
been	O
recognized	O
on	O
cultured	O
and	O
fresh	O
RPE	O
cells	O
for	O
some	O
time	O
[	O
26	O
,	O
27	O
]	O
,	O
with	O
in	O
situ	O
hybridization	O
confirming	O
the	O
presence	O
of	O
A2A	O
receptors	O
in	O
rat	S-Species
RPE	O
[	O
28	O
]	O
.	O

Stimulation	O
of	O
A2	O
receptors	O
reduces	O
the	O
rate	O
of	O
rod	O
outer	O
segment	O
phagocytosis	O
by	O
RPE	O
cells	O
[	O
29	O
]	O
,	O
while	O
application	O
of	O
adenosine	O
to	O
the	O
apical	O
membrane	O
of	O
chick	O
RPE	O
cells	O
increases	O
the	O
basolateral	O
Cl	O
-	O
conductance	O
,	O
the	O
transepithelial	O
potential	O
,	O
and	O
the	O
c	O
-	O
wave	O
,	O
and	O
decreases	O
the	O
hyperpolarization	O
of	O
the	O
basal	O
membrane	O
in	O
response	O
to	O
light	O
[	O
30	O
]	O
.	O

Although	O
adenosine	O
alone	O
does	O
not	O
increase	O
intracellular	O
Ca2	O
+	O
levels	O
[	O
31	O
]	O
,	O
adenosine	O
acts	O
synergistically	O
with	O
ATP	O
to	O
elevate	O
Ca2	O
+	O
levels	O
in	O
human	S-Species
RPE	O
cells	O
by	O
stimulating	O
both	O
A1	O
and	O
A2A	O
receptors	O
[	O
32	O
,	O
33	O
]	O
.	O

Stimulation	O
of	O
A1	O
receptors	O
with	O
high	O
doses	O
of	O
NECA	O
increases	O
the	O
active	O
transport	O
of	O
fluorescein	O
across	O
the	O
RPE	O
,	O
while	O
activation	O
of	O
A2A	O
receptors	O
decreases	O
this	O
transport	O
,	O
and	O
by	O
extension	O
,	O
transport	O
of	O
the	O
ions	O
that	O
underlie	O
fluid	O
movement	O
[	O
34	O
]	O
.	O

Stimulation	O
of	O
A1	O
and	O
A2A	O
receptors	O
produces	O
analogous	O
increases	O
and	O
decreases	O
,	O
respectively	O
,	O
in	O
the	O
absorption	O
of	O
subretinal	O
fluid	O
blebs	O
.	O

This	O
is	O
consistent	O
with	O
the	O
negative	O
coupling	O
of	O
the	O
A1	O
receptor	O
and	O
the	O
positive	O
coupling	O
of	O
the	O
A2	O
receptors	O
to	O
adenylate	O
cyclase	O
,	O
as	O
increasing	O
cAMP	O
inhibits	O
the	O
transport	O
of	O
fluid	O
across	O
the	O
RPE	O
towards	O
the	O
choroid	O
[	O
35	O
-	O
37	O
]	O
.	O

The	O
agonist	O
2	O
-	O
Cl	O
adenosine	O
reverses	O
the	O
deficit	O
in	O
phosphoinositide	O
metabolism	O
found	O
in	O
diabetic	O
RPE	O
cells	O
[	O
38	O
]	O
,	O
suggesting	O
effects	O
on	O
metabolism	O
in	O
addition	O
to	O
transport	O
and	O
phagocytosis	O
.	O

Multiple	O
P2	O
receptors	O
have	O
been	O
localized	O
to	O
the	O
RPE	O
.	O

The	O
P2Y2	O
receptor	O
was	O
initially	O
characterized	O
in	O
cultured	O
human	S-Species
RPE	O
[	O
31	O
]	O
,	O
with	O
subsequent	O
reports	O
localizing	O
transcript	O
for	O
P2Y1	O
,	O
P2Y2	O
,	O
P2Y4	O
,	O
and	O
P2Y6	O
in	O
the	O
rat	S-Species
RPE	O
/	O
choroid	O
[	O
39	O
]	O
and	O
for	O
P2Y1	O
and	O
P2Y12	O
receptors	O
in	O
ARPE	O
-	O
19	O
cells	O
[	O
40	O
]	O
,	O
and	O
functionally	O
identifying	O
a	O
P2X	O
receptor	O
in	O
rat	S-Species
RPE	O
cells	O
[	O
41	O
]	O
.	O

ATP	O
,	O
ADP	O
,	O
and	O
UTP	O
induce	O
numerous	O
effects	O
on	O
RPE	O
physiology	O
[	O
32	O
,	O
33	O
,	O
42	O
,	O
43	O
]	O
.	O

While	O
these	O
effects	O
likely	O
involve	O
multiple	O
different	O
receptor	O
types	O
,	O
the	O
contributions	O
of	O
the	O
P2Y2	O
receptor	O
have	O
been	O
explored	O
in	O
most	O
detail	O
to	O
date	O
.	O

The	O
P2Y2	O
receptor	O
has	O
been	O
specifically	O
localized	O
to	O
the	O
apical	O
membrane	O
of	O
fresh	O
bovine	S-Species
RPE	O
cells	O
,	O
and	O
addition	O
of	O
ATP	O
to	O
this	O
membrane	O
transiently	O
elevates	O
Ca2	O
+	O
,	O
activates	O
a	O
basolateral	O
Cl	O
-	O
conductance	O
,	O
inhibits	O
an	O
apical	O
K	O
+	O
conductance	O
,	O
and	O
increases	O
the	O
apical	O
to	O
basolateral	O
flow	O
of	O
fluid	O
[	O
43	O
]	O
.	O

This	O
increased	O
absorption	O
of	O
fluid	O
from	O
the	O
subretinal	O
space	O
suggests	O
P2Y2	O
receptor	O
stimulation	O
could	O
reduce	O
the	O
excess	O
fluid	O
that	O
accumulates	O
in	O
retinal	O
edemas	O
,	O
and	O
several	O
reports	O
have	O
supported	O
this	O
theory	O
.	O

ATP	O
,	O
UTP	O
,	O
and	O
the	O
P2Y2	O
receptor	O
agonist	O
INS37217	O
decrease	O
the	O
size	O
of	O
subretinal	O
fluid	O
blebs	O
when	O
injected	O
into	O
subretinal	O
space	O
of	O
rats	S-Species
[	O
44	O
]	O
.	O

In	O
both	O
normal	O
and	O
rds	O
+	O
/	O
-	O
mice	S-Species
with	O
experimentally	O
induced	O
detachment	O
,	O
INS31217	O
improves	O
the	O
ERG	O
recovery	O
and	O
decreased	O
cell	O
death	O
[	O
45	O
]	O
.	O

INS37217	O
also	O
reduces	O
subretinal	O
blebs	O
in	O
rabbits	S-Species
[	O
46	O
]	O
.	O

Injection	O
of	O
another	O
P2Y2	O
agonist	O
,	O
INS542	O
,	O
increases	O
the	O
active	O
transport	O
of	O
fluorescein	O
across	O
the	O
RPE	O
,	O
consistent	O
with	O
this	O
upregulation	O
of	O
ion	O
and	O
fluid	O
transport	O
across	O
the	O
tissue	O
[	O
47	O
]	O
.	O

Together	O
these	O
experiments	O
emphasize	O
the	O
clinical	O
potential	O
of	O
treating	O
retinal	O
edema	O
with	O
P2Y2	O
agonists	O
.	O

Regulation	O
of	O
purine	O
levels	O
in	O
subretinal	O
space	O

While	O
synthesized	O
purinergic	O
agonists	O
may	O
prove	O
useful	O
in	O
treating	O
some	O
ocular	O
disorders	O
,	O
the	O
endogenous	O
activation	O
of	O
P1	O
and	O
P2	O
receptors	O
in	O
the	O
subretinal	O
microenvironment	O
will	O
ultimately	O
be	O
determined	O
by	O
availability	O
of	O
agonists	O
.	O

These	O
levels	O
are	O
largely	O
controlled	O
by	O
the	O
release	O
of	O
ATP	O
into	O
the	O
subretinal	O
space	O
,	O
its	O
conversion	O
into	O
other	O
purines	O
including	O
adenosine	O
,	O
and	O
the	O
manipulation	O
of	O
adenosine	O
by	O
enzymes	O
or	O
transporters	O
.	O

Recent	O
work	O
has	O
increased	O
our	O
understanding	O
of	O
both	O
the	O
stimuli	O
that	O
initiate	O
changes	O
in	O
subretinal	O
purine	O
levels	O
and	O
the	O
mechanisms	O
that	O
mediate	O
these	O
changes	O
.	O

Release	O
of	O
ATP	O
by	O
the	O
RPE	O

At	O
least	O
some	O
of	O
the	O
ATP	O
capable	O
of	O
stimulating	O
the	O
purinergic	O
receptors	O
on	O
RPE	O
cells	O
is	O
released	O
from	O
the	O
RPE	O
itself	O
.	O

The	O
resulting	O
autocrine	O
stimulation	O
ensures	O
local	O
delivery	O
,	O
and	O
control	O
,	O
of	O
purines	O
to	O
initiate	O
the	O
physiologic	O
changes	O
in	O
the	O
RPE	O
.	O

The	O
release	O
of	O
ATP	O
by	O
RPE	O
cells	O
is	O
triggered	O
by	O
multiple	O
stimuli	O
including	O
osmotic	O
stress	O
,	O
bFGF	O
,	O
UTP	O
,	O
NMDA	O
,	O
glutamate	O
,	O
and	O
ATP	O
[	O
39	O
,	O
40	O
,	O
48	O
-	O
51	O
]	O
.	O

The	O
ATP	O
release	O
following	O
activation	O
of	O
NMDA	O
receptors	O
by	O
glutamate	O
may	O
have	O
the	O
most	O
interesting	O
implications	O
for	O
communication	O
across	O
subretinal	O
space	O
,	O
given	O
that	O
glutamate	O
confers	O
the	O
light	O
signal	O
from	O
photoreceptors	O
to	O
the	O
rest	O
of	O
the	O
visual	O
system	O
.	O

Glutamate	O
and	O
the	O
specific	O
receptor	O
agonist	O
NMDA	O
triggers	O
ATP	O
release	O
from	O
ARPE	O
-	O
19	O
cells	O
,	O
with	O
the	O
release	O
inhibited	O
by	O
NMDA	O
antagonist	O
MK	O
-	O
801	O
,	O
and	O
by	O
DCKA	O
,	O
which	O
inhibits	O
the	O
glycine	O
B	O
binding	O
site	O
on	O
NMDA	O
receptors	O
[	O
51	O
,	O
52	O
]	O
.	O

Although	O
NMDA	O
raises	O
intracellular	O
Ca2	O
+	O
levels	O
,	O
this	O
increase	O
is	O
prevented	O
by	O
eliminating	O
ATP	O
with	O
apyrase	O
,	O
indicating	O
autostimulation	O
through	O
released	O
ATP	O
is	O
responsible	O
for	O
this	O
Ca2	O
+	O
signal	O
.	O

NMDA	O
also	O
triggers	O
a	O
release	O
of	O
ATP	O
when	O
applied	O
to	O
the	O
intact	O
bovine	S-Species
RPE	O
eyecup	O
[	O
51	O
]	O
.	O

The	O
NMDA	O
receptors	O
and	O
the	O
ATP	O
release	O
sites	O
have	O
been	O
functionally	O
identified	O
to	O
the	O
apical	O
membrane	O
of	O
the	O
bovine	S-Species
RPE	O
,	O
suggesting	O
the	O
neurotransmitter	O
interactions	O
could	O
amplify	O
the	O
signal	O
from	O
any	O
glutamate	O
reaching	O
subretinal	O
space	O
.	O

The	O
ability	O
of	O
both	O
UTP	O
and	O
ATP	O
to	O
stimulate	O
release	O
of	O
ATP	O
from	O
the	O
RPE	O
supports	O
the	O
theory	O
that	O
the	O
system	O
acts	O
to	O
amplify	O
signals	O
.	O

When	O
applied	O
at	O
greater	O
than	O
1	O
mu	O
M	O
,	O
ATP	O
triggers	O
a	O
secondary	O
release	O
of	O
ATP	O
peaking	O
10	O
min	O
after	O
the	O
initial	O
stimuli	O
[	O
40	O
]	O
.	O

UTP	O
also	O
initiates	O
a	O
release	O
in	O
extracellular	O
ATP	O
with	O
a	O
similar	O
delay	O
[	O
48	O
]	O
.	O

The	O
rise	O
in	O
ATP	O
triggered	O
by	O
UTP	O
is	O
inhibited	O
by	O
the	O
Cl	O
-	O
channel	O
blocker	O
NPPB	O
,	O
and	O
UDP	O
is	O
much	O
less	O
effective	O
at	O
triggering	O
release	O
than	O
UTP	O
;	O
both	O
observations	O
suggest	O
the	O
P2Y2	O
receptor	O
contributes	O
to	O
the	O
increase	O
in	O
ATP	O
more	O
than	O
diphosphokinase	O
,	O
although	O
influence	O
from	O
the	O
enzyme	O
cannot	O
be	O
ruled	O
out	O
[	O
53	O
]	O
.	O

Recent	O
evidence	O
suggests	O
that	O
ischemia	O
may	O
lead	O
to	O
the	O
release	O
of	O
ATP	O
from	O
RPE	O
cells	O
.	O

Chemical	O
ischemia	O
triggers	O
a	O
substantial	O
ATP	O
release	O
from	O
cardiac	O
myocytes	O
[	O
54	O
]	O
,	O
while	O
changes	O
in	O
oxygen	O
levels	O
trigger	O
ATP	O
release	O
in	O
central	O
chemoreceptors	O
[	O
55	O
]	O
.	O

We	O
found	O
that	O
exposure	O
to	O
sodium	O
cyanide	O
led	O
to	O
a	O
rapid	O
release	O
of	O
ATP	O
from	O
ARPE	O
-	O
19	O
cells	O
(	O
Fig	O
.	O
2	O
)	O
.	O

As	O
hypoxic	O
and	O
/	O
or	O
ischemic	O
challenge	O
may	O
lead	O
to	O
changes	O
in	O
the	O
expression	O
of	O
growth	O
factors	O
in	O
RPE	O
cells	O
during	O
certain	O
ocular	O
disorders	O
such	O
as	O
macular	O
degeneration	O
[	O
56	O
]	O
,	O
and	O
as	O
purines	O
can	O
induce	O
expression	O
of	O
VEGF	O
in	O
other	O
cells	O
[	O
57	O
]	O
,	O
this	O
ATP	O
release	O
may	O
contribute	O
to	O
growth	O
factor	O
signaling	O
by	O
the	O
diseased	O
RPE	O
.	O

Fig	O
.	O
2Chemical	O
ischemia	O
triggers	O
ATP	O
release	O
from	O
ARPE	O
-	O
19	O
cells	O
.	O

ATP	O
release	O
was	O
measured	O
in	O
the	O
bath	O
directly	O
from	O
cells	O
plated	O
in	O
96	O
-	O
well	O
plates	O
to	O
which	O
the	O
luciferin	O
-	O
luciferase	O
reaction	O
mixture	O
was	O
added	O
[	O
51	O
]	O
.	O

Left	O
Levels	O
of	O
ATP	O
in	O
the	O
bath	O
after	O
addition	O
of	O
5	O
mM	O
NaCN	O
to	O
the	O
cells	O
.	O

Measurement	O
began	O
1	O
min	O
after	O
addition	O
of	O
NaCN	O
or	O
control	O
solution	O
to	O
wells	O
.	O

Right	O
Levels	O
of	O
ATP	O
measured	O
at	O
the	O
peak	O
,	O
3	O
min	O
after	O
addition	O
of	O
NaCN	O
(	O
n	O
=	O
12	O
)	O
.	O

Levels	O
were	O
normalized	O
to	O
concurrent	O
levels	O
in	O
control	O
(	O
n	O
=	O
14	O
)	O
.	O

Symbols	O
and	O
bars	O
represent	O
mean	O
+/-	O
SE	O
,	O
*	O
p	O
<	O
0	O
.	O
001	O

The	O
particular	O
conduit	O
for	O
ATP	O
release	O
varies	O
with	O
the	O
stimuli	O
.	O

The	O
release	O
in	O
response	O
to	O
hypotonic	O
challenge	O
is	O
largely	O
dependent	O
upon	O
CFTR	O
,	O
as	O
it	O
was	O
prevented	O
by	O
the	O
specific	O
CFTR	O
inhibitor	O
CFTR172	O
in	O
addition	O
to	O
the	O
more	O
general	O
blocker	O
glybenclamide	O
[	O
50	O
]	O
.	O

While	O
the	O
precise	O
mechanisms	O
by	O
which	O
CFTR	O
contributes	O
to	O
this	O
release	O
are	O
not	O
yet	O
known	O
,	O
a	O
role	O
for	O
CFTR	O
in	O
ATP	O
release	O
into	O
subretinal	O
space	O
is	O
consistent	O
with	O
the	O
reduction	O
of	O
certain	O
ERG	O
components	O
in	O
cftr	O
-	O
/	O
-	O
mice	S-Species
[	O
58	O
]	O
and	O
with	O
the	O
ability	O
of	O
apical	O
ATP	O
to	O
activate	O
conductances	O
associated	O
with	O
these	O
ERG	O
components	O
[	O
43	O
]	O
.	O

The	O
release	O
of	O
ATP	O
is	O
also	O
largely	O
blocked	O
by	O
the	O
vesicular	O
transport	O
inhibitor	O
brefeldin	O
A	O
,	O
suggesting	O
the	O
two	O
processes	O
occurred	O
in	O
series	O
whereby	O
ATP	O
efflux	O
follows	O
the	O
insertion	O
of	O
vesicles	O
containing	O
CFTR	O
into	O
the	O
plasma	O
membrane	O
.	O

Although	O
the	O
Ca2	O
+	O
chelator	O
BAPTA	O
blocks	O
this	O
ATP	O
release	O
[	O
50	O
]	O
,	O
raising	O
Ca2	O
+	O
alone	O
with	O
ionophore	O
ionomycin	O
does	O
not	O
itself	O
initiate	O
release	O
[	O
48	O
]	O
.	O

This	O
necessary	O
but	O
not	O
sufficient	O
contribution	O
of	O
Ca2	O
+	O
also	O
supports	O
a	O
role	O
for	O
vesicular	O
insertion	O
.	O

In	O
contrast	O
to	O
the	O
release	O
following	O
hypotonic	O
challenge	O
,	O
the	O
ATP	O
release	O
in	O
response	O
to	O
NMDA	O
does	O
not	O
involve	O
CFTR	O
[	O
51	O
]	O
.	O

Release	O
is	O
blocked	O
by	O
NPPB	O
,	O
however	O
,	O
suggesting	O
another	O
type	O
of	O
anion	O
channel	O
could	O
serve	O
as	O
a	O
conduit	O
for	O
ATP	O
release	O
.	O

The	O
presence	O
of	O
parallel	O
mechanisms	O
coexisting	O
on	O
the	O
same	O
cell	O
for	O
ATP	O
release	O
triggered	O
by	O
either	O
agonists	O
or	O
by	O
cell	O
swelling	O
has	O
also	O
been	O
reported	O
in	O
astrocytes	O
[	O
59	O
]	O
and	O
may	O
reflect	O
the	O
multiple	O
roles	O
of	O
purinergic	O
signaling	O
within	O
a	O
given	O
tissue	O
.	O

As	O
both	O
stimuli	O
lead	O
to	O
release	O
across	O
the	O
apical	O
membrane	O
into	O
subretinal	O
space	O
,	O
both	O
are	O
expected	O
to	O
influence	O
signaling	O
in	O
the	O
microenvironment	O
.	O

Interconversion	O
of	O
purines	O
in	O
subretinal	O
space	O

The	O
interconversion	O
of	O
nucleotides	O
and	O
nucleosides	O
each	O
capable	O
of	O
stimulating	O
distinct	O
receptors	O
makes	O
the	O
purinergic	O
signaling	O
system	O
of	O
particular	O
interest	O
in	O
a	O
confined	O
region	O
such	O
as	O
the	O
subretinal	O
space	O
.	O

The	O
main	O
enzymes	O
responsible	O
for	O
dephosphorylating	O
extracellular	O
ATP	O
on	O
the	O
RPE	O
cells	O
have	O
been	O
analyzed	O
and	O
a	O
basic	O
understanding	O
of	O
their	O
regulation	O
has	O
begun	O
.	O

This	O
section	O
first	O
describes	O
the	O
enzymes	O
that	O
act	O
on	O
ATP	O
and	O
ADP	O
,	O
followed	O
by	O
enzymes	O
which	O
convert	O
AMP	O
into	O
adenosine	O
.	O

The	O
dephosphorylation	O
of	O
extracellular	O
ATP	O
by	O
RPE	O
cells	O
involves	O
enzymes	O
from	O
multiple	O
families	O
[	O
40	O
]	O
,	O
as	O
found	O
in	O
airway	O
epithelial	O
cells	O
[	O
60	O
]	O
.	O

Degradation	O
of	O
ATP	O
by	O
the	O
apical	O
membrane	O
of	O
the	O
fresh	O
bovine	S-Species
eyecup	O
and	O
by	O
ARPE	O
-	O
19	O
cells	O
is	O
inhibited	O
by	O
ARL67156	O
or	O
beta	O
gamma	O
mATP	O
.	O

Message	O
for	O
eNPP1	O
,	O
eNPP2	O
,	O
and	O
eNPP3	O
is	O
present	O
in	O
ARPE	O
-	O
19	O
cells	O
,	O
consistent	O
with	O
the	O
preference	O
of	O
beta	O
gamma	O
mATP	O
for	O
members	O
of	O
the	O
eNPP	O
family	O
[	O
61	O
]	O
.	O

The	O
cells	O
also	O
express	O
NTPDase2	O
,	O
and	O
NTPDase3	O
,	O
although	O
the	O
intermittent	O
presence	O
of	O
NTPDase1	O
likely	O
reflects	O
a	O
regulated	O
process	O
[	O
40	O
]	O
.	O

Ecto	O
-	O
alkaline	O
phosphatase	O
has	O
no	O
effect	O
on	O
ATP	O
degradation	O
in	O
RPE	O
cells	O
,	O
in	O
contrast	O
to	O
its	O
considerable	O
contribution	O
in	O
airway	O
epithelium	O
[	O
62	O
]	O
.	O

The	O
putative	O
contribution	O
from	O
diphosphokinases	O
to	O
interconversion	O
of	O
subretinal	O
purines	O
is	O
presently	O
unknown	O
.	O

Extracellular	O
AMP	O
is	O
rapidly	O
dephosphorylated	O
into	O
adenosine	O
in	O
subretinal	O
space	O
.	O

The	O
production	O
of	O
adenosine	O
from	O
ATP	O
at	O
the	O
apical	O
membrane	O
of	O
the	O
bovine	S-Species
RPE	O
eyecup	O
is	O
inhibited	O
by	O
the	O
ecto	O
-	O
5	O
'	O
-	O
nucleotidase	O
inhibitor	O
alpha	O
beta	O
mADP	O
,	O
confirming	O
a	O
role	O
for	O
this	O
enzyme	O
[	O
63	O
]	O
.	O

The	O
enzyme	O
is	O
localized	O
to	O
rat	S-Species
RPE	O
and	O
ARPE	O
-	O
19	O
cells	O
immunohistochemically	O
.	O

Degradation	O
of	O
5	O
'	O
AMP	O
is	O
highest	O
near	O
the	O
subretinal	O
space	O
of	O
rat	S-Species
retina	O
[	O
63	O
]	O
,	O
although	O
localization	O
in	O
mouse	S-Species
indicated	O
larger	O
amounts	O
of	O
ecto	O
-	O
5	O
'	O
-	O
nucleotidase	O
at	O
the	O
tips	O
of	O
adjacent	O
M	O
u	O
ller	O
cells	O
[	O
64	O
]	O
.	O

Levamisole	O
does	O
not	O
inhibit	O
the	O
dephosphorylation	O
of	O
5	O
'	O
AMP	O
by	O
the	O
RPE	O
,	O
consistent	O
with	O
the	O
absence	O
of	O
substantial	O
ecto	O
-	O
alkaline	O
phosphatase	O
in	O
subretinal	O
space	O
.	O

The	O
presence	O
of	O
light	O
may	O
alter	O
the	O
levels	O
of	O
adenosine	O
in	O
subretinal	O
space	O
.	O

Epinephrine	O
is	O
released	O
at	O
the	O
onset	O
of	O
light	O
[	O
65	O
]	O
and	O
stimulation	O
of	O
the	O
RPE	O
with	O
epinephrine	O
can	O
decrease	O
activity	O
of	O
ecto	O
-	O
5	O
'	O
-	O
nucleotidase	O
[	O
63	O
]	O
.	O

While	O
norepinephrine	O
and	O
phenylephrine	O
lead	O
to	O
similar	O
decreases	O
in	O
enzyme	O
activity	O
,	O
prazosin	O
and	O
corynanthine	O
block	O
the	O
effects	O
of	O
norepinephrine	O
,	O
implicating	O
the	O
alpha	O
1	O
epinephrine	O
receptor	O
in	O
the	O
inhibition	O
of	O
ecto	O
-	O
5	O
'	O
-	O
nucleotidase	O
[	O
63	O
]	O
.	O

The	O
kinetics	O
of	O
inhibition	O
are	O
consistent	O
with	O
cleavage	O
of	O
the	O
nucleotidase	O
from	O
its	O
GPI	O
anchor	O
.	O

The	O
phagocytosis	O
of	O
rod	O
outer	O
segments	O
is	O
maximal	O
shortly	O
after	O
light	O
onset	O
[	O
16	O
]	O
,	O
and	O
this	O
phagocytosis	O
is	O
inhibited	O
by	O
adenosine	O
[	O
29	O
]	O
.	O

The	O
ability	O
of	O
epinephrine	O
released	O
by	O
the	O
illuminated	O
retina	O
to	O
reduce	O
ecto	O
-	O
5	O
'	O
-	O
nucleotidase	O
activity	O
and	O
consequently	O
adenosine	O
levels	O
may	O
relieve	O
this	O
inhibition	O
and	O
enhance	O
the	O
rate	O
of	O
phagocytosis	O
at	O
light	O
onset	O
.	O

Physiologic	O
effects	O
of	O
subretinal	O
purines	O
on	O
the	O
RPE	O
and	O
photoreceptors	O

The	O
number	O
of	O
purinergic	O
receptors	O
on	O
both	O
photoreceptor	O
and	O
RPE	O
membranes	O
suggests	O
purines	O
make	O
multiple	O
contributions	O
to	O
the	O
physiology	O
of	O
the	O
outer	O
retina	O
.	O

Our	O
increased	O
understanding	O
of	O
how	O
agonist	O
levels	O
in	O
subretinal	O
space	O
are	O
controlled	O
has	O
begun	O
to	O
indicate	O
how	O
and	O
when	O
this	O
contribution	O
may	O
occur	O
.	O

Future	O
research	O
will	O
involve	O
applying	O
these	O
findings	O
from	O
isolated	O
systems	O
to	O
intact	O
RPE	O
-	O
photoreceptor	O
models	O
,	O
and	O
pursuing	O
the	O
role	O
of	O
defective	O
purinergic	O
regulation	O
in	O
ocular	O
disease	O
.	O

While	O
it	O
is	O
unlikely	O
that	O
ATP	O
released	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
can	O
diffuse	O
to	O
these	O
P2	O
receptors	O
in	O
the	O
outer	O
plexiform	O
layer	O
given	O
the	O
ecto	O
-	O
ATPase	O
activity	O
in	O
the	O
synaptic	O
clef	O
[	O
25	O
]	O
,	O
stimulation	O
of	O
receptors	O
elsewhere	O
on	O
the	O
photoreceptor	O
membrane	O
is	O
possible	O
.	O

It	O
would	O
be	O
interesting	O
to	O
determine	O
whether	O
ATP	O
released	O
from	O
the	O
RPE	O
and	O
converted	O
to	O
adenosine	O
by	O
ecto	O
-	O
nucleotidases	O
can	O
actually	O
modulate	O
the	O
response	O
to	O
light	O
by	O
stimulating	O
the	O
A2A	O
receptors	O
on	O
photoreceptor	O
outer	O
segments	O
.	O

The	O
impact	O
of	O
purinergic	O
signaling	O
on	O
chronic	O
ocular	O
diseases	O
is	O
also	O
of	O
interest	O
,	O
such	O
as	O
the	O
role	O
of	O
ischemia	O
-	O
driven	O
ATP	O
release	O
in	O
VEGF	O
production	O
.	O

While	O
the	O
small	O
size	O
of	O
subretinal	O
space	O
can	O
complicate	O
pharmacologic	O
manipulation	O
within	O
the	O
intact	O
RPE	O
-	O
photoreceptor	O
complex	O
,	O
molecular	O
approaches	O
may	O
provide	O
new	O
insight	O
into	O
how	O
endogenous	O
purines	O
in	O
subretinal	O
space	O
affect	O
the	O
physiology	O
,	O
and	O
pathophysiology	O
,	O
of	O
both	O
RPE	O
and	O
photoreceptors	O
.	O

Comparative	O
Genome	O
Analysis	O
of	O
Filamentous	O
Fungi	O
Reveals	O
Gene	O
Family	O
Expansions	O
Associated	O
with	O
Fungal	O
Pathogenesis	O

Abstract	O

Fungi	O
and	O
oomycetes	O
are	O
the	O
causal	O
agents	O
of	O
many	O
of	O
the	O
most	O
serious	O
diseases	O
of	O
plants	O
.	O

Here	O
we	O
report	O
a	O
detailed	O
comparative	O
analysis	O
of	O
the	O
genome	O
sequences	O
of	O
thirty	O
-	O
six	O
species	O
of	O
fungi	O
and	O
oomycetes	O
,	O
including	O
seven	O
plant	O
pathogenic	O
species	O
,	O
that	O
aims	O
to	O
explore	O
the	O
common	O
genetic	O
features	O
associated	O
with	O
plant	O
disease	O
-	O
causing	O
species	O
.	O

The	O
predicted	O
translational	O
products	O
of	O
each	O
genome	O
have	O
been	O
clustered	O
into	O
groups	O
of	O
potential	O
orthologues	O
using	O
Markov	O
Chain	O
Clustering	O
and	O
the	O
data	O
integrated	O
into	O
the	O
e	O
-	O
Fungi	O
object	O
-	O
oriented	O
data	O
warehouse	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
e	O
-	O
fungi	O
.	O
org	O
.	O
uk	O
/	O
)	O
.	O

Analysis	O
of	O
the	O
species	O
distribution	O
of	O
members	O
of	O
these	O
clusters	O
has	O
identified	O
proteins	O
that	O
are	O
specific	O
to	O
filamentous	O
fungal	O
species	O
and	O
a	O
group	O
of	O
proteins	O
found	O
only	O
in	O
plant	O
pathogens	O
.	O

By	O
comparing	O
the	O
gene	O
inventories	O
of	O
filamentous	O
,	O
ascomycetous	O
phytopathogenic	O
and	O
free	O
-	O
living	O
species	O
of	O
fungi	O
,	O
we	O
have	O
identified	O
a	O
set	O
of	O
gene	O
families	O
that	O
appear	O
to	O
have	O
expanded	O
during	O
the	O
evolution	O
of	O
phytopathogens	O
and	O
may	O
therefore	O
serve	O
important	O
roles	O
in	O
plant	O
disease	O
.	O

We	O
have	O
also	O
characterised	O
the	O
predicted	O
set	O
of	O
secreted	O
proteins	O
encoded	O
by	O
each	O
genome	O
and	O
identified	O
a	O
set	O
of	O
protein	O
families	O
which	O
are	O
significantly	O
over	O
-	O
represented	O
in	O
the	O
secretomes	O
of	O
plant	O
pathogenic	O
fungi	O
,	O
including	O
putative	O
effector	O
proteins	O
that	O
might	O
perturb	O
host	O
cell	O
biology	O
during	O
plant	O
infection	O
.	O

The	O
results	O
demonstrate	O
the	O
potential	O
of	O
comparative	O
genome	O
analysis	O
for	O
exploring	O
the	O
evolution	O
of	O
eukaryotic	O
microbial	O
pathogenesis	O
.	O

Introduction	O

Fungi	O
and	O
oomycetes	O
are	O
responsible	O
for	O
many	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
plant	O
diseases	O
including	O
late	O
blight	O
disease	O
of	O
potato	S-Species
,	O
caused	O
by	O
the	O
oomycete	O
pathogen	O
Phytophthora	B-Species
infestans	E-Species
and	O
rice	S-Species
blast	O
disease	O
caused	O
by	O
the	O
ascomycete	O
fungus	O
Magnaporthe	B-Species
grisea	E-Species
,	O
both	O
of	O
which	O
are	O
responsible	O
for	O
very	O
significant	O
harvest	O
losses	O
each	O
year	O
.	O

The	O
enormous	O
diversity	O
of	O
crop	O
diseases	O
caused	O
by	O
these	O
eukaryotic	O
micro	O
-	O
organisms	O
poses	O
a	O
difficult	O
challenge	O
to	O
the	O
development	O
of	O
durable	O
disease	O
control	O
strategies	O
.	O

Identifying	O
common	O
underlying	O
molecular	O
mechanisms	O
necessary	O
for	O
pathogenesis	O
in	O
a	O
wide	O
range	O
of	O
pathogenic	O
species	O
is	O
therefore	O
a	O
major	O
goal	O
of	O
current	O
research	O
.	O

Approximately	O
100	O
,	O
000	O
species	O
of	O
fungi	O
have	O
so	O
far	O
been	O
described	O
,	O
but	O
only	O
a	O
very	O
small	O
proportion	O
of	O
these	O
are	O
pathogenic	O
[	O
1	O
]	O
.	O

Phylogenetic	O
studies	O
have	O
,	O
meanwhile	O
,	O
shown	O
that	O
disease	O
-	O
causing	O
pathogens	O
are	O
not	O
necessarily	O
closely	O
-	O
related	O
to	O
each	O
other	O
,	O
and	O
in	O
fact	O
are	O
spread	O
throughout	O
all	O
taxonomic	O
groups	O
of	O
fungi	O
,	O
often	O
showing	O
a	O
close	O
evolutionary	O
relationship	O
to	O
non	O
-	O
pathogenic	O
species	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

It	O
therefore	O
seems	O
likely	O
that	O
phytopathogenicity	O
has	O
evolved	O
as	O
a	O
trait	O
many	O
times	O
during	O
fungal	O
and	O
oomycete	O
evolution	O
[	O
1	O
]	O
and	O
in	O
some	O
groups	O
may	O
be	O
ancestral	O
to	O
the	O
more	O
recent	O
emergence	O
of	O
saprotrophic	O
species	O
.	O

A	O
significant	O
effort	O
has	O
gone	O
into	O
the	O
identification	O
of	O
pathogenicity	O
determinants	O
-	O
individual	O
genes	O
that	O
are	O
essential	O
for	O
a	O
pathogen	O
to	O
invade	O
a	O
host	O
plant	O
successfully	O
,	O
but	O
which	O
are	O
dispensable	O
for	O
saprophytic	O
growth	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

However	O
,	O
far	O
from	O
being	O
novel	O
proteins	O
encoded	O
only	O
by	O
the	O
genomes	O
of	O
pathogenic	O
fungi	O
,	O
many	O
of	O
the	O
genes	O
identified	O
so	O
far	O
encode	O
components	O
of	O
conserved	O
signalling	O
pathways	O
that	O
are	O
found	O
in	O
all	O
species	O
of	O
fungi	O
,	O
such	O
as	O
the	O
mitogen	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
[	O
6	O
]	O
,	O
adenylate	O
cyclase	O
[	O
7	O
]	O
and	O
G	O
-	O
protein	O
subunits	O
[	O
8	O
]	O
.	O

The	O
MAP	O
kinase	O
pathways	O
,	O
for	O
example	O
,	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
budding	O
yeast	S-Species
Saccharomyces	B-Species
cerevisiae	E-Species
and	O
trigger	O
morphological	O
and	O
biochemical	O
changes	O
in	O
response	O
to	O
external	O
stimuli	O
such	O
as	O
starvation	O
stress	O
or	O
hyperosmotic	O
conditions	O
[	O
9	O
]	O
.	O

In	O
pathogenic	O
fungi	O
,	O
components	O
of	O
these	O
pathways	O
have	O
evolved	O
instead	O
to	O
regulate	O
the	O
morphological	O
changes	O
associated	O
with	O
plant	O
infection	O
.	O

For	O
example	O
,	O
appressorium	O
formation	O
in	O
the	O
rice	B-Species
blast	I-Species
fungus	E-Species
Magnaporthe	B-Species
grisea	E-Species
,	O
stimulated	O
by	O
hard	O
,	O
hydrophobic	O
surfaces	O
is	O
regulated	O
by	O
a	O
MAP	O
kinase	O
cascade	O
[	O
10	O
]	O
.	O

This	O
pathway	O
deploys	O
novel	O
classes	O
of	O
G	O
-	O
protein	O
coupled	O
receptors	O
not	O
found	O
in	O
the	O
genome	O
of	O
S	B-Species
.	I-Species
cerevisiae	E-Species
[	O
11	O
]	O
,	O
but	O
the	O
inductive	O
signal	O
is	O
transmitted	O
via	O
a	O
MAP	O
kinase	O
,	O
Pmk1	O
,	O
that	O
is	O
a	O
functional	O
homologue	O
of	O
the	O
yeast	S-Species
Fus3	O
MAP	O
kinase	O
where	O
it	O
serves	O
a	O
role	O
in	O
pheromone	O
signalling	O
[	O
10	O
]	O
.	O

Similarly	O
,	O
conserved	O
metabolic	O
pathways	O
such	O
as	O
the	O
glyoxylate	O
cycle	O
and	O
amino	O
acid	O
biosynthesis	O
are	O
also	O
important	O
for	O
pathogenesis	O
[	O
12	O
]	O
-	O
[	O
14	O
]	O
.	O

This	O
may	O
in	O
some	O
cases	O
reflect	O
the	O
nutritional	O
environment	O
the	O
pathogen	O
encounters	O
when	O
growing	O
in	O
the	O
host	O
plant	O
tissue	O
,	O
and	O
in	O
others	O
shows	O
the	O
importance	O
of	O
simple	O
metabolites	O
for	O
pathogenic	O
processes	O
,	O
such	O
as	O
the	O
role	O
of	O
glycerol	O
as	O
a	O
compatible	O
solute	O
for	O
generating	O
turgor	O
pressure	O
in	O
the	O
appressorium	O
of	O
M	B-Species
.	I-Species
grisea	E-Species
[	O
15	O
]	O
.	O

It	O
is	O
undoubtedly	O
the	O
case	O
,	O
however	O
,	O
that	O
identification	O
of	O
such	O
genes	O
has	O
also	O
been	O
a	O
consequence	O
of	O
the	O
manner	O
in	O
which	O
these	O
studies	O
have	O
been	O
carried	O
out	O
,	O
often	O
using	O
yeast	S-Species
as	O
a	O
model	O
organism	O
to	O
test	O
hypotheses	O
concerning	O
the	O
developmental	O
biology	O
and	O
biochemistry	O
of	O
plant	O
pathogenic	O
species	O
.	O

Other	O
pathogenicity	O
factors	O
identified	O
to	O
date	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
functions	O
associated	O
with	O
host	O
infection	O
,	O
such	O
as	O
plant	O
cell	O
wall	O
degradation	O
,	O
toxin	O
biosynthesis	O
and	O
protection	O
against	O
plant	O
defences	O
[	O
reviewed	O
in	O
5	O
]	O
.	O

Identification	O
of	O
a	O
pathogenicity	O
factor	O
generally	O
involves	O
making	O
a	O
mutant	O
fungal	O
strain	O
with	O
a	O
non	O
-	O
functioning	O
version	O
of	O
the	O
gene	O
by	O
targeted	O
gene	O
deletion	O
and	O
assaying	O
the	O
ability	O
of	O
the	O
mutant	O
to	O
cause	O
disease	O
.	O

Therefore	O
,	O
most	O
pathogenicity	O
factors	O
identified	O
so	O
far	O
,	O
have	O
been	O
validated	O
in	O
only	O
a	O
small	O
number	O
of	O
genetically	O
tractable	O
pathogenic	O
fungi	O
,	O
such	O
as	O
M	B-Species
.	I-Species
grisea	E-Species
and	O
the	O
corn	S-Species
smut	O
Ustilago	B-Species
maydis	E-Species
and	O
many	O
of	O
the	O
advances	O
in	O
understanding	O
the	O
developmental	O
biology	O
of	O
plant	O
infection	O
have	O
occurred	O
in	O
these	O
model	O
pathogens	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

However	O
,	O
there	O
are	O
severe	O
limitations	O
to	O
studying	O
pathogenicity	O
by	O
mutating	O
one	O
gene	O
at	O
a	O
time	O
and	O
working	O
predominantly	O
with	O
a	O
hypothesis	O
-	O
driven	O
,	O
reverse	O
genetics	O
approach	O
.	O

Many	O
virulence	O
-	O
associated	O
processes	O
,	O
for	O
instance	O
,	O
such	O
as	O
the	O
development	O
of	O
infection	O
structures	O
and	O
haustoria	O
,	O
are	O
likely	O
to	O
involve	O
a	O
large	O
number	O
of	O
gene	O
products	O
and	O
so	O
there	O
is	O
likely	O
to	O
be	O
redundancy	O
in	O
gene	O
function	O
.	O

One	O
example	O
of	O
this	O
is	O
cutinase	O
,	O
a	O
type	O
of	O
methyl	O
esterase	O
that	O
hydrolyses	O
the	O
protective	O
cutin	O
layer	O
present	O
on	O
the	O
outside	O
of	O
the	O
plant	O
epidermis	O
.	O

Cutinase	O
was	O
excluded	O
as	O
a	O
pathogencity	O
factor	O
for	O
M	B-Species
.	I-Species
grisea	E-Species
on	O
the	O
basis	O
that	O
a	O
mutant	O
strain	O
containing	O
a	O
non	O
-	O
functional	O
cutinase	O
-	O
encoding	O
gene	O
was	O
still	O
able	O
to	O
cause	O
rice	S-Species
blast	O
disease	O
[	O
18	O
]	O
.	O

However	O
,	O
sequencing	O
of	O
the	O
M	B-Species
.	I-Species
grisea	E-Species
genome	O
has	O
shown	O
the	O
presence	O
of	O
eight	O
potential	O
cutinase	O
-	O
encoding	O
genes	O
implicated	O
in	O
virulence	O
[	O
19	O
]	O
.	O

Additionally	O
,	O
targeted	O
gene	O
deletion	O
is	O
not	O
feasible	O
in	O
many	O
important	O
pathogens	O
and	O
the	O
normal	O
definition	O
of	O
fungal	O
pathogenicity	O
cannot	O
be	O
applied	O
in	O
the	O
case	O
of	O
obligate	O
biotrophs	O
,	O
such	O
as	O
the	O
powdery	O
mildew	O
fungus	O
Blumeria	B-Species
graminis	E-Species
,	O
which	O
cannot	O
be	O
cultured	O
away	O
from	O
living	O
host	O
plants	O
.	O

Therefore	O
,	O
new	O
approaches	O
are	O
needed	O
to	O
identify	O
genes	O
that	O
are	O
vital	O
for	O
the	O
process	O
of	O
pathogenicity	O
.	O

These	O
include	O
high	O
-	O
throughput	O
methods	O
such	O
as	O
microarray	O
analysis	O
,	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
,	O
insertional	O
mutagenesis	O
,	O
proteomics	O
and	O
metabolomics	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
and	O
are	O
dependent	O
on	O
the	O
availability	O
of	O
genome	O
sequence	O
information	O
.	O

After	O
the	O
initial	O
release	O
of	O
the	O
genome	O
of	O
the	O
budding	O
yeast	S-Species
S	B-Species
.	I-Species
cerevisiae	E-Species
in	O
1996	O
[	O
21	O
]	O
,	O
the	O
number	O
of	O
publicly	O
available	O
sequenced	O
fungal	O
genomes	O
has	O
recently	O
risen	O
very	O
quickly	O
.	O

A	O
large	O
number	O
of	O
fungal	O
genome	O
sequences	O
are	O
now	O
publicly	O
available	O
,	O
including	O
those	O
from	O
several	O
phytopathogenic	O
fungi	O
,	O
including	O
M	B-Species
.	I-Species
grisea	E-Species
[	O
22	O
]	O
,	O
Ustilago	B-Species
maydis	E-Species
[	O
23	O
]	O
,	O
Gibberella	B-Species
zeae	E-Species
[	O
24	O
]	O
(	O
the	O
causal	O
agent	O
of	O
head	O
blight	O
of	O
wheat	S-Species
and	O
barley	S-Species
)	O
,	O
Stagonospora	B-Species
nodorum	E-Species
[	O
25	O
]	O
(	O
the	O
causal	O
agent	O
of	O
glume	O
blotch	O
of	O
wheat	S-Species
)	O
,	O
the	O
grey	O
mould	O
fungus	O
Botrytis	B-Species
cinerea	E-Species
and	O
the	O
white	O
mould	O
fungus	O
Sclerotinia	B-Species
sclerotiorum	E-Species
[	O
reviewed	O
in	O
19	O
]	O
.	O

Comparison	O
of	O
gene	O
inventories	O
of	O
pathogenic	O
and	O
non	O
-	O
pathogenic	O
organisms	O
offers	O
the	O
most	O
direct	O
means	O
of	O
providing	O
new	O
information	O
concerning	O
the	O
mechanisms	O
involved	O
in	O
fungal	O
and	O
oomycete	O
pathogenicity	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
developed	O
and	O
utilized	O
the	O
e	O
-	O
Fungi	O
object	O
-	O
oriented	O
data	O
warehouse	O
[	O
26	O
]	O
,	O
which	O
contains	O
data	O
from	O
36	O
species	O
of	O
fungi	O
and	O
oomycetes	O
and	O
deploys	O
a	O
range	O
of	O
querying	O
tools	O
to	O
allow	O
interrogation	O
of	O
a	O
significant	O
amount	O
of	O
genome	O
data	O
in	O
unparalleled	O
detail	O
.	O

We	O
report	O
the	O
identification	O
of	O
new	O
gene	O
families	O
that	O
are	O
over	O
represented	O
in	O
the	O
genomes	O
of	O
filamentous	O
ascomycete	O
phytopathogens	O
and	O
define	O
gene	O
sets	O
that	O
are	O
specific	O
to	O
diverse	O
fungal	O
pathogen	O
species	O
.	O

We	O
also	O
report	O
the	O
putatively	O
secreted	O
protein	O
sets	O
which	O
are	O
produced	O
by	O
plant	O
pathogenic	O
fungi	O
and	O
which	O
may	O
play	O
significant	O
roles	O
in	O
plant	O
infection	O
.	O

Results	O

Identification	O
of	O
orthologous	O
gene	O
sets	O
from	O
fungal	O
and	O
oomcyete	O
genomes	O

Genome	O
sequences	O
and	O
sets	O
of	O
predicted	O
proteins	O
were	O
analysed	O
from	O
34	O
species	O
of	O
fungi	O
and	O
2	O
species	O
of	O
oomycete	O
(	O
Table	O
1	O
)	O
.	O

In	O
order	O
to	O
compare	O
such	O
a	O
large	O
number	O
of	O
genomes	O
,	O
an	O
object	O
-	O
oriented	O
data	O
warehouse	O
has	O
been	O
constructed	O
known	O
as	O
e	O
-	O
Fungi	O
[	O
26	O
]	O
which	O
integrates	O
genomic	O
data	O
with	O
a	O
variety	O
of	O
functional	O
data	O
and	O
has	O
a	O
powerful	O
set	O
of	O
queries	O
that	O
enables	O
sophisticated	O
,	O
whole	O
-	O
genome	O
comparisons	O
to	O
be	O
performed	O
.	O

To	O
compare	O
genome	O
inventories	O
,	O
the	O
entire	O
set	O
of	O
predicted	O
proteins	O
from	O
the	O
36	O
species	O
(	O
348	O
,	O
787	O
proteins	O
)	O
were	O
clustered	O
using	O
Markov	O
Chain	O
Clustering	O
[	O
27	O
]	O
as	O
described	O
previously	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

A	O
total	O
of	O
282	O
,	O
061	O
predicted	O
proteins	O
were	O
grouped	O
into	O
23	O
,	O
724	O
clusters	O
,	O
each	O
cluster	O
representing	O
a	O
group	O
of	O
putative	O
orthologues	O
.	O

The	O
remaining	O
66	O
,	O
934	O
sequences	O
were	O
singletons	O
,	O
the	O
products	O
of	O
unique	O
genes	O
.	O

A	O
total	O
of	O
165	O
clusters	O
contained	O
proteins	O
from	O
all	O
36	O
species	O
used	O
in	O
this	O
study	O
(	O
Table	O
S1	O
)	O
.	O

Not	O
surprisingly	O
,	O
they	O
included	O
many	O
proteins	O
involved	O
in	O
basic	O
cellular	O
processes	O
,	O
such	O
as	O
ribosomal	O
proteins	O
,	O
components	O
of	O
transcription	O
,	O
translation	O
and	O
DNA	O
replication	O
apparatus	O
,	O
cytoskeletal	O
proteins	O
,	O
histones	O
,	O
proteins	O
involved	O
in	O
the	O
secretory	O
pathway	O
,	O
protein	O
folding	O
,	O
protein	O
sorting	O
and	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
and	O
enzymes	O
involved	O
in	O
primary	O
metabolism	O
.	O

Only	O
16	O
clusters	O
contained	O
proteins	O
that	O
were	O
found	O
in	O
all	O
34	O
species	O
of	O
fungi	O
,	O
but	O
which	O
were	O
absent	O
from	O
the	O
two	O
species	O
of	O
oomycete	O
(	O
Table	O
S2	O
)	O
.	O

This	O
number	O
of	O
fungal	O
-	O
specific	O
clusters	O
is	O
surprisingly	O
low	O
considering	O
the	O
phylogenetic	O
distance	O
between	O
the	O
oomycetes	O
and	O
fungi	O
[	O
30	O
]	O
.	O

The	O
list	O
however	O
,	O
is	O
consistent	O
with	O
the	O
fundamental	O
differences	O
in	O
biology	O
between	O
fungi	O
and	O
oomycetes	O
and	O
included	O
proteins	O
involved	O
in	O
fungal	O
septation	O
,	O
glycosylation	O
,	O
transcriptional	O
regulation	O
,	O
cell	O
signalling	O
,	O
as	O
well	O
as	O
two	O
amino	O
-	O
acyl	O
tRNA	O
synthetases	O
.	O

The	O
obligate	O
mammalian	O
pathogen	O
Encephalitozoon	B-Species
cuniculi	E-Species
,	O
a	O
microsporidian	O
fungus	O
,	O
has	O
a	O
reduced	O
genome	O
that	O
codes	O
only	O
for	O
1	O
,	O
997	O
proteins	O
and	O
lacks	O
genes	O
encoding	O
enzymes	O
of	O
many	O
primary	O
metabolic	O
pathways	O
such	O
as	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
,	O
biosynthetic	O
enzymes	O
of	O
the	O
vast	O
majority	O
of	O
amino	O
acids	O
,	O
fatty	O
acids	O
and	O
nucleotides	O
,	O
as	O
well	O
as	O
components	O
of	O
the	O
respiratory	O
electron	O
transport	O
chain	O
and	O
F1	O
-	O
F0	O
ATP	O
synthase	O
.	O

It	O
also	O
lacks	O
mitochondria	O
and	O
peroxisomes	O
[	O
31	O
]	O
.	O

Therefore	O
,	O
we	O
reasoned	O
that	O
the	O
inclusion	O
of	O
this	O
species	O
in	O
the	O
analysis	O
of	O
MCL	O
clusters	O
is	O
likely	O
to	O
result	O
in	O
underestimation	O
of	O
the	O
number	O
of	O
groups	O
of	O
conserved	O
proteins	O
.	O

By	O
discarding	O
E	B-Species
.	I-Species
cuniculi	E-Species
,	O
there	O
are	O
377	O
clusters	O
that	O
contained	O
proteins	O
from	O
35	O
species	O
of	O
fungi	O
and	O
oomycetes	O
(	O
Table	O
S3	O
)	O
.	O

This	O
relatively	O
small	O
number	O
of	O
fungal	O
-	O
conserved	O
clusters	O
reflects	O
the	O
large	O
evolutionary	O
distance	O
between	O
members	O
of	O
the	O
fungal	O
kingdom	O
,	O
as	O
well	O
as	O
complex	O
patterns	O
of	O
gene	O
gains	O
and	O
losses	O
during	O
the	O
evolution	O
of	O
fungi	O
.	O

Basidiomycetes	O
and	O
ascomycetes	O
are	O
thought	O
to	O
have	O
diverged	O
nearly	O
1	O
,	O
000	O
million	O
years	O
ago	O
[	O
32	O
]	O
and	O
the	O
Saccharomycotina	O
alone	O
are	O
more	O
evolutionarily	O
diverged	O
than	O
the	O
Chordate	O
phylum	O
of	O
the	O
animal	O
kingdom	O
[	O
33	O
]	O
.	O

Since	O
the	O
divergence	O
of	O
Saccharomycotina	O
(	O
hemiascomycetes	O
)	O
and	O
Pezizomycotina	O
(	O
euascomycetes	O
)	O
,	O
the	O
genomes	O
of	O
the	O
latter	O
have	O
greatly	O
increased	O
in	O
size	O
,	O
partly	O
due	O
to	O
the	O
appearance	O
of	O
novel	O
genes	O
related	O
to	O
the	O
filamentous	O
lifestyle	O
.	O

Lineage	O
-	O
specific	O
gene	O
losses	O
have	O
also	O
been	O
shown	O
in	O
a	O
number	O
of	O
hemiascomycete	O
species	O
[	O
34	O
]	O
.	O

As	O
well	O
as	O
the	O
groups	O
of	O
proteins	O
mentioned	O
above	O
(	O
Table	O
S1	O
)	O
,	O
the	O
fungal	O
-	O
conserved	O
clusters	O
included	O
those	O
containing	O
enzymes	O
from	O
primary	O
metabolic	O
pathways	O
not	O
present	O
in	O
E	B-Species
.	I-Species
cuniculi	E-Species
,	O
such	O
as	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
amino	O
acid	O
metabolism	O
,	O
fatty	O
acid	O
biosynthesis	O
,	O
cholesterol	O
biosynthesis	O
and	O
nucleotide	O
metabolism	O
,	O
as	O
well	O
as	O
components	O
of	O
the	O
respiratory	O
electron	O
transport	O
chain	O
and	O
F1	O
-	O
F0	O
ATP	O
synthase	O
.	O

The	O
conserved	O
protein	O
clusters	O
also	O
include	O
a	O
number	O
of	O
transporters	O
(	O
including	O
mitochondrial	O
transporters	O
)	O
,	O
enzymes	O
involved	O
in	O
haem	O
biosynthesis	O
,	O
autophagy	O
-	O
related	O
proteins	O
,	O
those	O
involved	O
in	O
protein	O
targeting	O
to	O
the	O
peroxisome	O
and	O
vacuole	O
and	O
additional	O
groups	O
of	O
proteins	O
involved	O
in	O
signal	O
transduction	O
that	O
are	O
not	O
present	O
in	O
E	B-Species
.	I-Species
cuniculi	E-Species
(	O
including	O
those	O
involved	O
in	O
inosine	O
triphosphate	O
and	O
leukotriene	O
metabolism	O
)	O
.	O

The	O
analysis	O
also	O
showed	O
there	O
were	O
105	O
clusters	O
that	O
contained	O
proteins	O
from	O
33	O
species	O
of	O
fungi	O
(	O
excluding	O
E	B-Species
.	I-Species
cuniculi	E-Species
)	O
,	O
but	O
not	O
from	O
the	O
two	O
species	O
of	O
oomycete	O
(	O
see	O
Table	O
S4	O
)	O
.	O

As	O
well	O
as	O
those	O
mentioned	O
previously	O
(	O
Table	O
S2	O
)	O
,	O
the	O
group	O
includes	O
a	O
number	O
of	O
clusters	O
of	O
transporters	O
that	O
are	O
conserved	O
in	O
fungi	O
but	O
not	O
found	O
in	O
oomycetes	O
,	O
as	O
well	O
as	O
proteins	O
involved	O
in	O
fungal	O
cell	O
wall	O
synthesis	O
,	O
and	O
lipid	O
metabolism	O
.	O

It	O
may	O
be	O
the	O
case	O
that	O
the	O
genomes	O
of	O
oomycete	O
species	O
do	O
not	O
possess	O
orthologues	O
of	O
the	O
fungal	O
genes	O
in	O
these	O
clusters	O
,	O
or	O
alternatively	O
,	O
the	O
large	O
evolutionary	O
distance	O
between	O
the	O
oomycetes	O
and	O
fungi	O
mean	O
that	O
the	O
corresponding	O
orthologues	O
from	O
each	O
Kingdom	O
cluster	O
separately	O
.	O

Comparative	O
analysis	O
of	O
yeasts	O
and	O
filamentous	O
fungi	O

One	O
striking	O
difference	O
in	O
the	O
morphology	O
of	O
species	O
of	O
fungi	O
is	O
between	O
those	O
that	O
have	O
a	O
filamentous	O
,	O
multi	O
-	O
cellular	O
growth	O
habit	O
and	O
those	O
that	O
grow	O
as	O
single	O
yeast	S-Species
cells	O
.	O

There	O
is	O
some	O
overlap	O
between	O
these	O
two	O
groups	O
;	O
because	O
some	O
fungi	O
are	O
dimorphic	O
or	O
even	O
pleiomorphic	O
,	O
switching	O
between	O
different	O
growth	O
forms	O
depending	O
on	O
environmental	O
conditions	O
or	O
the	O
stage	O
of	O
their	O
life	O
cycle	O
.	O

For	O
example	O
,	O
the	O
corn	S-Species
-	O
smut	O
fungus	O
Ustilago	B-Species
maydis	E-Species
can	O
exist	O
saprophytically	O
as	O
haploid	O
yeast	S-Species
-	O
like	O
cells	O
,	O
but	O
needs	O
to	O
form	O
a	O
dikaryotic	O
filamentous	O
growth	O
form	O
in	O
order	O
to	O
infect	O
the	O
host	O
plant	O
[	O
23	O
]	O
.	O

Generally	O
the	O
genomes	O
of	O
the	O
filamentous	O
fungi	O
contain	O
more	O
protein	O
-	O
encoding	O
genes	O
(	O
9	O
,	O
000	O
-	O
17	O
,	O
000	O
)	O
than	O
those	O
from	O
unicellular	O
yeasts	O
(	O
5	O
,	O
000	O
-	O
7	O
,	O
000	O
)	O
,	O
perhaps	O
reflecting	O
their	O
greater	O
morphological	O
complexity	O
and	O
secondary	O
metabolic	O
capacity	O
.	O

U	B-Species
.	I-Species
maydis	E-Species
,	O
however	O
,	O
has	O
6	O
,	O
522	O
protein	O
encoding	O
genes	O
,	O
perhaps	O
reflecting	O
its	O
lack	O
of	O
extensive	O
secondary	O
metabolic	O
pathways	O
and	O
its	O
potential	O
usefulness	O
in	O
defining	O
the	O
minimal	O
gene	O
sets	O
associated	O
with	O
biotrophic	O
growth	O
[	O
23	O
]	O
.	O

The	O
increase	O
in	O
proteome	O
size	O
in	O
filamentous	O
ascomycetes	O
may	O
be	O
due	O
to	O
the	O
expansion	O
of	O
certain	O
gene	O
families	O
or	O
the	O
presence	O
of	O
novel	O
genes	O
that	O
are	O
essential	O
for	O
the	O
filamentous	O
lifestyle	O
.	O

For	O
the	O
purposes	O
of	O
this	O
study	O
,	O
the	O
filamentous	O
fungi	O
were	O
defined	O
as	O
the	O
filamentous	O
ascomycetes	O
(	O
subphylum	O
Pezizomycotina	O
)	O
,	O
basidiomycetes	O
and	O
zygomycetes	O
and	O
the	O
unicellular	O
fungi	O
were	O
defined	O
as	O
the	O
budding	O
yeasts	O
(	O
order	O
Saccharomycetales	O
)	O
,	O
the	O
archiascomycete	O
Schizosaccharomyces	B-Species
pombe	E-Species
and	O
the	O
microsporidian	O
fungus	O
Encephalitozoon	B-Species
cuniculi	E-Species
.	O

A	O
total	O
of	O
37	O
MCL	O
clusters	O
contained	O
proteins	O
from	O
all	O
species	O
of	O
filamentous	O
fungi	O
,	O
but	O
no	O
species	O
of	O
unicellular	O
fungi	O
(	O
Table	O
2	O
)	O
.	O

Interestingly	O
,	O
eight	O
of	O
these	O
clusters	O
also	O
contained	O
proteins	O
from	O
both	O
species	O
of	O
oomycete	O
represented	O
in	O
e	O
-	O
Fungi	O
.	O

The	O
filamentous	O
-	O
fungal	O
specific	O
clusters	O
included	O
a	O
number	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cytoskeletal	O
rearrangements	O
(	O
dedicator	O
of	O
cytokinesis	O
protein	O
,	O
integrin	O
beta	O
-	O
1	O
-	O
binding	O
protein	O
,	O
dynactin	O
p62	O
family	O
,	O
dynein	O
light	O
intermediate	O
chain	O
2	O
)	O
,	O
it	O
seems	O
likely	O
that	O
these	O
are	O
required	O
for	O
the	O
complex	O
morphological	O
changes	O
that	O
filamentous	O
fungi	O
undergo	O
during	O
their	O
lifecycle	O
and	O
the	O
production	O
of	O
differentiated	O
cells	O
,	O
such	O
as	O
spores	O
,	O
fruiting	O
bodies	O
and	O
infection	O
structures	O
.	O

The	O
results	O
also	O
suggest	O
that	O
filamentous	O
fungal	O
species	O
make	O
a	O
greater	O
use	O
of	O
lipids	O
as	O
signalling	O
molecules	O
than	O
yeast	S-Species
species	O
.	O

For	O
example	O
,	O
the	O
occurrence	O
of	O
filamentous	O
fungal	O
-	O
specific	O
clusters	O
representing	O
two	O
groups	O
of	O
lysophospholipases	O
,	O
as	O
well	O
as	O
ceramidases	O
that	O
are	O
involved	O
in	O
sphingolipid	O
signalling	O
[	O
35	O
]	O
and	O
linoleate	O
diol	O
synthases	O
that	O
can	O
catalyse	O
the	O
formation	O
of	O
leukotrienes	O
[	O
36	O
]	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
products	O
of	O
linoleate	O
diol	O
synthase	O
has	O
been	O
shown	O
to	O
be	O
a	O
sporulation	O
hormone	O
in	O
Aspergillus	B-Species
nidulans	E-Species
[	O
37	O
]	O
.	O

There	O
is	O
also	O
a	O
cluster	O
that	O
represents	O
homologues	O
of	O
a	O
novel	O
human	S-Species
gene	O
(	O
LRP16	O
)	O
that	O
acts	O
downstream	O
of	O
a	O
steroid	O
receptor	O
and	O
promotes	O
cell	O
proliferation	O
[	O
38	O
]	O
.	O

Two	O
clusters	O
of	O
filamentous	O
fungal	O
-	O
specific	O
proteins	O
represent	O
enzymes	O
involved	O
in	O
molypterin	O
biosynthesis	O
(	O
MCL2420	O
,	O
MCL2581	O
)	O
.	O

Molypterin	O
is	O
a	O
molybdenum	O
-	O
containing	O
co	O
-	O
factor	O
for	O
nitrate	O
reductase	O
,	O
an	O
enzyme	O
that	O
is	O
known	O
to	O
be	O
absent	O
from	O
the	O
species	O
of	O
yeast	S-Species
used	O
in	O
this	O
study	O
[	O
39	O
]	O
.	O

Both	O
these	O
clusters	O
are	O
also	O
found	O
in	O
oomycetes	O
.	O

There	O
are	O
other	O
clusters	O
representing	O
proteins	O
important	O
for	O
activities	O
specific	O
to	O
filamentous	O
fungi	O
,	O
such	O
as	O
homologues	O
of	O
Pro11	O
(	O
striatin	O
)	O
which	O
regulates	O
fruiting	O
body	O
formation	O
in	O
Sordaria	B-Species
macrospora	E-Species
[	O
40	O
]	O
,	O
the	O
vegetatible	O
incompatibility	O
protein	O
HET	O
-	O
E	O
-	O
1	O
,	O
which	O
prevents	O
the	O
formation	O
of	O
heterokaryons	O
between	O
incompatible	O
fungal	O
strains	O
in	O
Podospora	B-Species
anserina	E-Species
[	O
41	O
]	O
,	O
anucleate	O
primary	O
sterigmata	O
protein	O
A	O
from	O
Aspergillus	B-Species
nidulans	E-Species
,	O
which	O
is	O
essential	O
for	O
nuclear	O
migration	O
and	O
conidiophore	O
development	O
[	O
42	O
]	O
and	O
cytochrome	O
P450	O
and	O
polyketide	O
synthase	O
-	O
encoding	O
genes	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
a	O
number	O
of	O
secondary	O
metabolic	O
pathways	O
including	O
toxin	O
biosynthesis	O
[	O
43	O
]	O
.	O

Pathogenicity	O
-	O
associated	O
gene	O
functions	O
in	O
fungi	O

As	O
the	O
selected	O
set	O
of	O
fungi	O
includes	O
both	O
saprotrophic	O
and	O
pathogenic	O
species	O
,	O
this	O
allows	O
us	O
to	O
compare	O
the	O
gene	O
inventories	O
of	O
phytopathogenic	O
and	O
closely	O
related	O
non	O
-	O
pathogenic	O
fungi	O
to	O
look	O
for	O
genes	O
that	O
are	O
unique	O
to	O
phytopathogens	O
.	O

Analysis	O
of	O
MCL	O
clusters	O
showed	O
that	O
there	O
were	O
no	O
clusters	O
that	O
contained	O
proteins	O
from	O
all	O
species	O
of	O
fungal	O
phytopathogen	O
in	O
e	O
-	O
Fungi	O
(	O
namely	O
B	B-Species
.	I-Species
cinerea	E-Species
,	O
Eremothecium	B-Species
gossypii	E-Species
,	O
G	B-Species
.	I-Species
zeae	E-Species
,	O
M	B-Species
.	I-Species
grisea	E-Species
,	O
S	B-Species
.	I-Species
sclerotiorum	E-Species
,	O
S	B-Species
.	I-Species
nodorum	E-Species
and	O
U	B-Species
.	I-Species
maydis	E-Species
)	O
but	O
did	O
not	O
contain	O
proteins	O
from	O
non	O
-	O
pathogenic	O
species	O
.	O

There	O
were	O
,	O
however	O
,	O
four	O
clusters	O
that	O
were	O
exclusive	O
to	O
filamentous	O
ascomycete	O
phytopathogens	O
(	O
namely	O
B	B-Species
.	I-Species
cinerea	E-Species
,	O
G	B-Species
.	I-Species
zeae	E-Species
,	O
M	B-Species
.	I-Species
grisea	E-Species
,	O
S	B-Species
.	I-Species
sclerotiorum	E-Species
,	O
S	B-Species
.	I-Species
nodorum	E-Species
as	O
shown	O
in	O
Table	O
3	O
)	O
.	O

Significantly	O
,	O
none	O
of	O
the	O
members	O
of	O
these	O
clusters	O
had	O
homology	O
to	O
any	O
known	O
proteins	O
or	O
contained	O
motifs	O
from	O
the	O
Pfam	O
database	O
[	O
44	O
]	O
,	O
so	O
we	O
were	O
unable	O
to	O
predict	O
their	O
function	O
,	O
although	O
two	O
of	O
the	O
clusters	O
(	O
MCL4854	O
and	O
MCL8229	O
)	O
consisted	O
entirely	O
of	O
proteins	O
that	O
were	O
predicted	O
to	O
be	O
secreted	O
.	O

Taken	O
together	O
,	O
the	O
observations	O
indicate	O
that	O
a	O
battery	O
of	O
completely	O
novel	O
secreted	O
proteins	O
may	O
be	O
associated	O
with	O
ascomycete	O
fungal	O
pathogens	O
.	O

Pathogenicity	O
factors	O
have	O
been	O
defined	O
as	O
genes	O
that	O
are	O
essential	O
for	O
successful	O
completion	O
of	O
the	O
pathogen	O
lifecycle	O
but	O
dispensable	O
for	O
saprophytic	O
growth	O
[	O
4	O
]	O
.	O

This	O
is	O
an	O
experimental	O
definition	O
based	O
on	O
whether	O
null	O
mutations	O
of	O
a	O
given	O
gene	O
reduce	O
the	O
virulence	O
of	O
the	O
pathogen	O
on	O
its	O
host	O
.	O

We	O
wished	O
to	O
ascertain	O
whether	O
homologues	O
of	O
previously	O
characterised	O
and	O
experimentally	O
-	O
validated	O
pathogenicity	O
factors	O
were	O
limited	O
to	O
the	O
genomes	O
of	O
pathogenic	O
species	O
.	O

A	O
search	O
was	O
therefore	O
made	O
for	O
pathogenicity	O
factors	O
that	O
have	O
been	O
identified	O
experimentally	O
for	O
the	O
species	O
of	O
phytopathogens	O
represented	O
in	O
e	O
-	O
Fungi	O
using	O
PHI	O
-	O
base	O
,	O
the	O
plant	O
-	O
host	O
interaction	O
database	O
[	O
45	O
]	O
.	O

The	O
matching	O
locus	O
was	O
identified	O
for	O
each	O
pathogenicity	O
factor	O
in	O
the	O
corresponding	O
genome	O
sequence	O
by	O
comparing	O
a	O
published	O
protein	O
sequence	O
with	O
sets	O
of	O
predicted	O
proteins	O
for	O
each	O
genome	O
using	O
BLASTP	O
.	O

This	O
produced	O
a	O
list	O
of	O
105	O
pathogenicity	O
factors	O
,	O
although	O
corresponding	O
loci	O
could	O
not	O
be	O
found	O
in	O
genome	O
sequences	O
for	O
all	O
the	O
published	O
genes	O
(	O
see	O
Table	O
S5	O
)	O
.	O

MCL	O
clusters	O
containing	O
these	O
proteins	O
were	O
identified	O
(	O
76	O
unique	O
clusters	O
)	O
and	O
the	O
species	O
distribution	O
of	O
members	O
of	O
these	O
clusters	O
analysed	O
.	O

In	O
total	O
,	O
29	O
of	O
the	O
MCL	O
clusters	O
contained	O
pathogenicity	O
factors	O
with	O
members	O
from	O
at	O
least	O
34	O
of	O
the	O
36	O
species	O
represented	O
in	O
e	O
-	O
Fungi	O
(	O
Table	O
4	O
)	O
.	O

Not	O
surprisingly	O
,	O
many	O
of	O
these	O
clusters	O
contain	O
conserved	O
components	O
of	O
signalling	O
pathways	O
such	O
as	O
protein	O
kinases	O
,	O
adenylate	O
cyclases	O
,	O
G	O
-	O
proteins	O
and	O
cell	O
cycle	O
regulators	O
.	O

Cellular	O
morphogenesis	O
is	O
known	O
to	O
be	O
important	O
for	O
infection	O
of	O
the	O
host	O
plant	O
by	O
many	O
phytopathogens	O
,	O
for	O
example	O
,	O
in	O
appressorium	O
formation	O
in	O
Magnaporthe	B-Species
grisea	E-Species
[	O
46	O
]	O
or	O
the	O
switch	O
in	O
the	O
growth	O
form	O
of	O
Ustilago	B-Species
maydis	E-Species
from	O
yeast	S-Species
-	O
like	O
growth	O
to	O
filamentous	O
invasive	O
growth	O
[	O
47	O
]	O
.	O

Links	O
between	O
successful	O
plant	O
infection	O
and	O
cell	O
cycle	O
control	O
have	O
also	O
been	O
demonstrated	O
[	O
48	O
]	O
.	O

It	O
seems	O
likely	O
that	O
conserved	O
signalling	O
pathways	O
that	O
control	O
activities	O
,	O
such	O
as	O
mating	O
and	O
morphogenesis	O
in	O
all	O
fungi	O
,	O
have	O
evolved	O
to	O
control	O
processes	O
essential	O
for	O
pathogencity	O
in	O
phytopathogens	O
.	O

Other	O
conserved	O
pathogenicity	O
factors	O
encode	O
enzymes	O
of	O
metabolic	O
pathways	O
that	O
are	O
present	O
in	O
nearly	O
all	O
fungi	O
,	O
but	O
seem	O
to	O
be	O
important	O
for	O
the	O
life	O
cycle	O
of	O
particular	O
pathogenic	O
species	O
,	O
for	O
example	O
,	O
enzymes	O
involved	O
in	O
beta	O
-	O
oxidation	O
of	O
fatty	O
acids	O
,	O
the	O
glyoxylate	O
shunt	O
,	O
amino	O
acid	O
metabolism	O
and	O
the	O
utilisation	O
of	O
stored	O
sugars	O
.	O

When	O
considered	O
together	O
,	O
this	O
may	O
indicate	O
that	O
nutritional	O
conditions	O
which	O
fungi	O
encounter	O
when	O
invading	O
host	O
plant	O
tissue	O
require	O
mobilisation	O
of	O
stored	O
lipids	O
prior	O
to	O
nutrition	O
being	O
extracted	O
from	O
the	O
host	O
plant	O
.	O

Seventeen	O
of	O
the	O
MCL	O
clusters	O
containing	O
pathogenicity	O
factors	O
were	O
specific	O
to	O
filamentous	O
ascomycetes	O
(	O
Table	O
5	O
)	O
.	O

These	O
include	O
a	O
number	O
of	O
enzymes	O
involved	O
in	O
secondary	O
metabolism	O
,	O
such	O
as	O
those	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
fungal	O
toxin	O
trichothecene	O
in	O
G	B-Species
.	I-Species
zeae	E-Species
[	O
43	O
]	O
and	O
those	O
involved	O
in	O
melanin	O
biosynthesis	O
[	O
49	O
]	O
,	O
as	O
well	O
as	O
structural	O
proteins	O
,	O
some	O
of	O
which	O
are	O
components	O
of	O
differentiated	O
cell	O
types	O
not	O
seen	O
in	O
yeasts	O
,	O
for	O
example	O
,	O
hydrophobins	O
which	O
are	O
components	O
of	O
aerial	O
structures	O
such	O
as	O
fruiting	O
bodies	O
[	O
50	O
]	O
but	O
are	O
also	O
involved	O
in	O
pathogenicity	O
[	O
16	O
]	O
.	O

There	O
also	O
seems	O
to	O
be	O
a	O
number	O
of	O
filamentous	O
ascomycete	O
specific	O
receptor	O
proteins	O
(	O
transducin	O
beta	O
-	O
subunit	O
,	O
G	O
-	O
protein	O
coupled	O
receptor	O
,	O
tetraspanins	O
)	O
that	O
have	O
evolved	O
in	O
pathogens	O
to	O
be	O
used	O
in	O
sensing	O
environmental	O
cues	O
that	O
are	O
essential	O
for	O
successful	O
infection	O
of	O
the	O
host	O
[	O
51	O
]	O
.	O

The	O
Woronin	O
body	O
is	O
a	O
structure	O
found	O
only	O
in	O
filamentous	O
ascomycetes	O
,	O
and	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
pathogenicity	O
in	O
M	B-Species
.	I-Species
grisea	E-Species
[	O
52	O
]	O
.	O

A	O
major	O
constituent	O
of	O
the	O
woronin	O
body	O
,	O
encoded	O
by	O
MVP1	O
,	O
is	O
a	O
pathogenicity	O
factor	O
for	O
M	B-Species
.	I-Species
grisea	E-Species
,	O
but	O
also	O
has	O
homologues	O
in	O
nearly	O
all	O
species	O
of	O
filamentous	O
ascomycetes	O
.	O

Two	O
proteins	O
that	O
were	O
initially	O
discovered	O
as	O
being	O
highly	O
expressed	O
in	O
the	O
appressoria	O
of	O
M	B-Species
.	I-Species
grisea	E-Species
and	O
essential	O
for	O
pathogenicity	O
(	O
Mas1	O
and	O
Mas3	O
)	O
[	O
53	O
]	O
also	O
have	O
homologues	O
in	O
a	O
number	O
of	O
species	O
of	O
filamentous	O
fungi	O
(	O
Table	O
5	O
)	O
.	O

Thus	O
,	O
many	O
innovations	O
that	O
have	O
allowed	O
filamentous	O
ascomycetes	O
to	O
have	O
a	O
more	O
complex	O
morphology	O
than	O
unicellular	O
yeasts	O
have	O
also	O
evolved	O
to	O
be	O
essential	O
for	O
plant	O
infection	O
by	O
phytopathogenic	O
species	O
.	O

Interestingly	O
,	O
none	O
of	O
the	O
MCL	O
clusters	O
containing	O
known	O
pathogenicity	O
factors	O
contained	O
members	O
only	O
from	O
phytopathogenic	O
fungi	O
,	O
apart	O
from	O
those	O
that	O
were	O
restricted	O
to	O
just	O
one	O
species	O
.	O

These	O
are	O
therefore	O
likely	O
to	O
represent	O
highly	O
-	O
specialised	O
proteins	O
that	O
have	O
evolved	O
for	O
the	O
specific	O
lifecycle	O
of	O
just	O
one	O
species	O
of	O
phytopathogen	O
,	O
for	O
example	O
the	O
Pwl	O
proteins	O
involved	O
in	O
determining	O
host	O
range	O
of	O
different	O
strains	O
of	O
M	B-Species
.	I-Species
grisea	E-Species
[	O
54	O
]	O
.	O

Two	O
of	O
the	O
proteins	O
specific	O
to	O
M	B-Species
.	I-Species
grisea	E-Species
,	O
the	O
metallothionein	O
Mmt1	O
[	O
55	O
]	O
and	O
the	O
hydrophobin	O
Mpg1	O
[	O
56	O
]	O
are	O
small	O
polypeptides	O
and	O
are	O
members	O
of	O
highly	O
divergent	O
gene	O
families	O
,	O
other	O
members	O
of	O
which	O
do	O
not	O
cluster	O
together	O
using	O
BLASTP	O
.	O

Comparative	O
analysis	O
of	O
plant	O
-	O
pathogenic	O
and	O
saprotrophic	O
filamentous	O
ascomycetes	O

Based	O
on	O
the	O
analysis	O
reported	O
,	O
it	O
is	O
likely	O
that	O
in	O
general	O
there	O
are	O
a	O
large	O
number	O
of	O
differences	O
in	O
gene	O
inventories	O
between	O
filamentous	O
and	O
yeast	S-Species
-	O
like	O
fungi	O
.	O

Therefore	O
,	O
in	O
order	O
to	O
compare	O
the	O
genomes	O
of	O
phytopathogens	O
and	O
saprotrophs	O
,	O
we	O
focused	O
on	O
filamentous	O
ascomycetes	O
in	O
order	O
to	O
resolve	O
in	O
greater	O
detail	O
the	O
distinct	O
differences	O
in	O
gene	O
sets	O
between	O
these	O
two	O
ecologically	O
separate	O
groups	O
of	O
fungi	O
.	O

In	O
this	O
way	O
differences	O
due	O
to	O
phylogeny	O
between	O
the	O
species	O
would	O
be	O
minimised	O
.	O

We	O
compared	O
the	O
gene	O
inventories	O
of	O
the	O
phytopathogens	O
B	B-Species
.	I-Species
cinerea	E-Species
,	O
G	B-Species
.	I-Species
zeae	E-Species
,	O
M	B-Species
.	I-Species
grisea	E-Species
,	O
S	B-Species
.	I-Species
sclerotiorum	E-Species
,	O
S	B-Species
.	I-Species
nodorum	E-Species
with	O
the	O
non	O
-	O
pathogens	O
Aspergillus	B-Species
nidulans	E-Species
,	O
Chaetomium	B-Species
globosum	E-Species
,	O
Neurospora	B-Species
crassa	E-Species
and	O
Trichoderma	B-Species
reesei	E-Species
.	O

Phylogenetic	O
analysis	O
suggests	O
that	O
the	O
phytopathogenic	O
species	O
do	O
not	O
form	O
a	O
separate	O
clade	O
from	O
the	O
pathogenic	O
species	O
(	O
Figure	O
1	O
)	O
,	O
[	O
3	O
]	O
and	O
we	O
assumed	O
that	O
differences	O
in	O
gene	O
inventory	O
should	O
therefore	O
reflect	O
lifestyle	O
rather	O
than	O
evolutionary	O
distance	O
.	O

In	O
order	O
for	O
such	O
a	O
comparison	O
to	O
be	O
considered	O
valid	O
,	O
the	O
completeness	O
and	O
quality	O
of	O
the	O
fungal	O
genome	O
sequences	O
used	O
should	O
,	O
however	O
,	O
also	O
be	O
comparable	O
.	O

Table	O
S6	O
summarises	O
the	O
available	O
data	O
about	O
genome	O
sequence	O
coverage	O
,	O
genome	O
size	O
and	O
the	O
number	O
of	O
predicted	O
proteins	O
for	O
each	O
species	O
.	O

This	O
shows	O
that	O
the	O
genome	O
coverage	O
is	O
greater	O
than	O
5x	O
and	O
the	O
number	O
of	O
predicted	O
proteins	O
in	O
the	O
range	O
of	O
10	O
,	O
000	O
-	O
16	O
,	O
000	O
for	O
all	O
genomes	O
used	O
,	O
suggesting	O
a	O
high	O
level	O
of	O
equivalence	O
between	O
species	O
with	O
regard	O
to	O
sequence	O
quality	O
.	O

From	O
our	O
work	O
it	O
seems	O
unlikely	O
that	O
there	O
are	O
pathogenicity	O
factors	O
conserved	O
in	O
,	O
and	O
specific	O
to	O
,	O
all	O
species	O
of	O
phytopathogen	O
.	O

It	O
may	O
,	O
for	O
instance	O
,	O
be	O
the	O
case	O
that	O
differences	O
in	O
the	O
gene	O
inventories	O
are	O
due	O
to	O
the	O
expansion	O
of	O
certain	O
gene	O
families	O
in	O
the	O
genomes	O
of	O
phytopathogenic	O
species	O
associated	O
with	O
functions	O
necessary	O
for	O
pathogenesis	O
.	O

To	O
define	O
protein	O
families	O
,	O
we	O
used	O
the	O
Pfam	O
database	O
which	O
contains	O
protein	O
family	O
models	O
based	O
on	O
Hidden	O
Markov	O
Models	O
[	O
44	O
]	O
,	O
[	O
57	O
]	O
.	O

Sets	O
of	O
predicted	O
proteins	O
for	O
each	O
fungal	O
species	O
in	O
e	O
-	O
Fungi	O
were	O
analysed	O
for	O
the	O
occurrence	O
of	O
Pfam	O
motifs	O
and	O
the	O
number	O
of	O
proteins	O
containing	O
each	O
domain	O
across	O
fungal	O
species	O
ascertained	O
.	O

The	O
sets	O
of	O
predicted	O
protein	O
sequences	O
used	O
in	O
this	O
study	O
have	O
been	O
automatically	O
predicted	O
as	O
part	O
of	O
each	O
individual	O
genome	O
project	O
and	O
are	O
likely	O
to	O
contain	O
a	O
number	O
of	O
artefactual	O
sequences	O
.	O

The	O
use	O
of	O
Pfam	O
motifs	O
to	O
define	O
gene	O
families	O
in	O
this	O
study	O
reduces	O
the	O
likelihood	O
of	O
such	O
sequences	O
affecting	O
the	O
data	O
,	O
since	O
Pfam	O
motifs	O
are	O
based	O
on	O
multiple	O
sequence	O
alignments	O
of	O
well	O
-	O
studied	O
proteins	O
.	O

A	O
small	O
number	O
of	O
Pfam	O
motifs	O
were	O
not	O
found	O
in	O
the	O
proteomes	O
of	O
the	O
filamentous	O
ascomycete	O
non	O
-	O
pathogens	O
,	O
but	O
were	O
found	O
in	O
the	O
proteomes	O
of	O
at	O
least	O
three	O
species	O
of	O
filamentous	O
ascomycete	O
phytopathogens	O
(	O
Table	O
6	O
)	O
.	O

These	O
include	O
the	O
Cas1p	O
-	O
like	O
motif	O
(	O
PF07779	O
)	O
,	O
found	O
in	O
4	O
species	O
of	O
phytopathogen	O
,	O
including	O
five	O
copies	O
in	O
G	B-Species
.	I-Species
zeae	E-Species
,	O
and	O
the	O
Yeast	S-Species
cell	O
wall	O
synthesis	O
protein	O
KRE9	O
/	O
KNH1	O
motif	O
(	O
PF05390	O
)	O
,	O
which	O
was	O
found	O
in	O
three	O
species	O
of	O
phytopathogen	O
.	O

Cas1p	O
is	O
a	O
membrane	O
protein	O
necessary	O
for	O
the	O
O	O
-	O
acetylation	O
of	O
the	O
capsular	O
polysaccharide	O
of	O
the	O
basidiomycete	O
animal	O
pathogen	O
Cryptococcus	B-Species
neoformans	E-Species
[	O
58	O
]	O
.	O

KRE9	O
and	O
KNH1	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
cell	O
surface	O
polysaccharides	O
in	O
S	B-Species
.	I-Species
cerevisiae	E-Species
[	O
59	O
]	O
.	O

Taken	O
together	O
this	O
suggests	O
that	O
synthesis	O
of	O
cell	O
surface	O
polysaccharides	O
is	O
important	O
for	O
phytopathogens	O
,	O
perhaps	O
helping	O
to	O
shroud	O
the	O
fungus	O
from	O
plant	O
defences	O
.	O

The	O
function	O
of	O
the	O
YDG	O
/	O
SRA	O
domain	O
motif	O
(	O
PF02182	O
)	O
is	O
unknown	O
,	O
but	O
is	O
found	O
in	O
a	O
novel	O
mouse	S-Species
cell	O
proliferation	O
protein	O
Np95	O
,	O
in	O
which	O
the	O
domain	O
is	O
important	O
both	O
for	O
the	O
interaction	O
with	O
histones	O
and	O
for	O
chromatin	O
binding	O
in	O
vivo	O
[	O
60	O
]	O
.	O

As	O
well	O
as	O
domains	O
of	O
unknown	O
function	O
,	O
the	O
list	O
of	O
phytopathogen	O
-	O
specific	O
Pfam	O
motifs	O
includes	O
Allophanate	O
hydrolase	O
(	O
PF02682	O
)	O
which	O
is	O
found	O
in	O
an	O
enzyme	O
involved	O
in	O
the	O
ATP	O
-	O
dependent	O
urea	O
degradation	O
pathway	O
[	O
61	O
]	O
,	O
a	O
peptidase	O
motif	O
,	O
an	O
opioid	O
growth	O
receptor	O
motif	O
(	O
PF04664	O
)	O
and	O
Mnd1	O
(	O
PF03962	O
)	O
,	O
which	O
is	O
involved	O
in	O
recombination	O
and	O
meiotic	O
nuclear	O
division	O
[	O
62	O
]	O
.	O

To	O
detect	O
potential	O
gene	O
family	O
expansion	O
,	O
we	O
decided	O
to	O
identify	O
Pfam	O
motifs	O
that	O
were	O
present	O
in	O
both	O
phytopathogenic	O
and	O
non	O
-	O
pathogenic	O
species	O
of	O
filamentous	O
ascomycetes	O
,	O
but	O
that	O
were	O
more	O
common	O
in	O
the	O
genomes	O
of	O
the	O
former	O
.	O

The	O
Pfam	O
motifs	O
were	O
ranked	O
on	O
the	O
ratio	O
of	O
the	O
mean	O
number	O
of	O
proteins	O
containing	O
each	O
motif	O
in	O
phytopathogens	O
,	O
when	O
compared	O
to	O
non	O
-	O
pathogens	O
(	O
Table	O
7	O
)	O
.	O

The	O
tables	O
only	O
show	O
ratios	O
of	O
greater	O
than	O
or	O
equal	O
to	O
2	O
.	O
5	O
.	O

Pfam	O
motifs	O
that	O
were	O
more	O
common	O
in	O
the	O
proteomes	O
of	O
pathogens	O
,	O
include	O
some	O
found	O
in	O
enzymes	O
involved	O
in	O
secondary	O
metabolic	O
pathways	O
.	O

These	O
include	O
novel	O
enzymes	O
that	O
have	O
only	O
previously	O
been	O
studied	O
in	O
non	O
-	O
fungal	O
species	O
,	O
such	O
as	O
the	O
chalcone	O
synthases	O
;	O
type	O
III	O
polyketide	O
synthases	O
involved	O
in	O
the	O
biosynthesis	O
of	O
flavonoids	O
in	O
plants	O
[	O
63	O
]	O
and	O
lipoxygenases	O
;	O
components	O
of	O
metabolic	O
pathways	O
resulting	O
in	O
the	O
synthesis	O
of	O
physiologically	O
-	O
active	O
compounds	O
such	O
as	O
eicosanoids	O
in	O
mammals	O
[	O
64	O
]	O
and	O
jasmonic	O
acid	O
in	O
plants	O
[	O
65	O
]	O
as	O
well	O
as	O
antibiotic	O
synthesis	O
monooxygenases	O
.	O

It	O
seems	O
likely	O
that	O
secondary	O
metabolism	O
is	O
essential	O
in	O
phytopathogenic	O
species	O
for	O
the	O
synthesis	O
of	O
mycotoxins	O
,	O
antibiotics	O
,	O
siderophores	O
and	O
pigments	O
[	O
66	O
]	O
,	O
but	O
it	O
may	O
also	O
offer	O
fungal	O
pathogens	O
a	O
distinct	O
alternative	O
means	O
of	O
perturbing	O
host	O
metabolism	O
,	O
cell	O
signalling	O
or	O
plant	O
defence	O
,	O
in	O
contrast	O
to	O
bacterial	O
pathogens	O
that	O
rely	O
on	O
protein	O
secretion	O
to	O
achieve	O
this	O
.	O

There	O
also	O
seems	O
to	O
be	O
number	O
of	O
protease	O
and	O
peptidase	O
domains	O
that	O
are	O
more	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
as	O
well	O
as	O
domains	O
from	O
two	O
classes	O
of	O
cell	O
-	O
wall	O
degrading	O
enzymes	O
:	O
namely	O
cutinase	O
(	O
PF01083	O
)	O
and	O
Glycosyl	O
hydrolase	O
family	O
53	O
(	O
PF07745	O
)	O
which	O
is	O
found	O
in	O
arabinogalactan	O
endo	O
-	O
1	O
,	O
4	O
-	O
beta	O
-	O
galactosidases	O
that	O
hydrolyze	O
the	O
galactan	O
side	O
chains	O
that	O
form	O
part	O
of	O
the	O
complex	O
carbohydrate	O
structure	O
of	O
pectin	O
[	O
67	O
]	O
.	O

Two	O
other	O
domains	O
found	O
in	O
enzymes	O
involved	O
in	O
pectin	O
degradation	O
,	O
pectinesterase	O
(	O
PF01095	O
)	O
and	O
Glycosyl	O
hydrolases	O
family	O
28	O
(	O
PF00295	O
)	O
are	O
both	O
more	O
than	O
twice	O
as	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
than	O
saprotrophs	O
.	O

In	O
contrast	O
,	O
domains	O
found	O
in	O
cellulases	O
have	O
fairly	O
equal	O
distribution	O
between	O
the	O
proteomes	O
of	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
for	O
phytopathogens	O
the	O
most	O
essential	O
enzymes	O
for	O
pathogenesis	O
may	O
well	O
be	O
those	O
that	O
allow	O
the	O
fungus	O
to	O
penetrate	O
the	O
protective	O
cutin	O
layer	O
of	O
the	O
plant	O
epidermis	O
and	O
disrupt	O
the	O
pectin	O
matrix	O
of	O
the	O
plant	O
cell	O
wall	O
in	O
which	O
cellulose	O
fibrils	O
are	O
embedded	O
.	O

Pectin	O
-	O
degrading	O
enzymes	O
have	O
already	O
been	O
shown	O
to	O
be	O
pathogenicity	O
factors	O
in	O
a	O
number	O
of	O
fungi	O
[	O
68	O
]	O
.	O

NPP1	O
motifs	O
are	O
characteristic	O
of	O
a	O
group	O
of	O
proteins	O
called	O
NLPs	O
(	O
Nep1	O
-	O
like	O
proteins	O
)	O
that	O
trigger	O
defence	O
responses	O
,	O
necrosis	O
and	O
cell	O
death	O
in	O
plants	O
and	O
may	O
act	O
as	O
virulence	O
factors	O
[	O
69	O
]	O
.	O

The	O
NLPs	O
are	O
more	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogenic	O
,	O
when	O
compared	O
to	O
non	O
-	O
pathogenic	O
ascomycetes	O
,	O
but	O
are	O
even	O
more	O
numerous	O
in	O
the	O
proteomes	O
of	O
the	O
oomycetes	O
(	O
64	O
proteins	O
in	O
Phytophthora	B-Species
ramorum	E-Species
and	O
75	O
in	O
Phytophthora	B-Species
sojae	E-Species
)	O
.	O

Proteins	O
containing	O
the	O
Chitin	O
recognition	O
protein	O
domain	O
(	O
PF00187	O
)	O
are	O
also	O
very	O
common	O
in	O
the	O
proteomes	O
of	O
phytopathogens	O
(	O
18	O
in	O
M	B-Species
.	I-Species
grisea	E-Species
and	O
16	O
in	O
S	B-Species
.	I-Species
nodorum	E-Species
)	O
.	O

A	O
role	O
for	O
chitin	O
-	O
binding	O
proteins	O
has	O
been	O
proposed	O
in	O
protecting	O
the	O
fungal	O
cell	O
wall	O
from	O
chitinases	O
produced	O
by	O
host	O
plants	O
[	O
70	O
]	O
.	O

There	O
are	O
also	O
two	O
other	O
Pfam	O
motifs	O
,	O
which	O
are	O
more	O
common	O
in	O
the	O
proteomes	O
of	O
phytopathogens	O
,	O
that	O
are	O
found	O
in	O
enzymes	O
involved	O
in	O
the	O
catabolism	O
of	O
toxic	O
compounds	O
,	O
namely	O
arylesterase	O
(	O
PF01731	O
)	O
and	O
EthD	O
protein	O
(	O
PF07110	O
)	O
which	O
breakdown	O
organophosphorus	O
esters	O
[	O
71	O
]	O
and	O
ethyl	O
tert	O
-	O
butyl	O
ether	O
[	O
72	O
]	O
,	O
respectively	O
.	O

Comparative	O
secretome	O
analysis	O
of	O
phytopathogenic	O
and	O
saprotrophic	O
filamentous	O
ascomycetes	O

Studies	O
in	O
bacterial	O
pathogens	O
and	O
oomycetes	O
have	O
shown	O
that	O
a	O
range	O
of	O
secreted	O
proteins	O
known	O
as	O
effectors	O
are	O
important	O
for	O
establishing	O
infection	O
of	O
the	O
host	O
plant	O
[	O
73	O
]	O
,	O
[	O
74	O
]	O
.	O

These	O
secreted	O
proteins	O
may	O
disable	O
plant	O
defences	O
and	O
subvert	O
cellular	O
processes	O
to	O
suit	O
the	O
needs	O
of	O
invading	O
pathogens	O
.	O

Therefore	O
,	O
we	O
decided	O
also	O
to	O
compare	O
gene	O
family	O
size	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
.	O

There	O
are	O
a	O
number	O
of	O
programs	O
available	O
that	O
predict	O
whether	O
a	O
protein	O
is	O
likely	O
to	O
be	O
secreted	O
,	O
although	O
the	O
predictions	O
they	O
give	O
significantly	O
differ	O
from	O
each	O
other	O
.	O

Therefore	O
we	O
defined	O
the	O
secretome	O
of	O
each	O
fungal	O
species	O
based	O
on	O
those	O
proteins	O
that	O
are	O
predicted	O
to	O
be	O
secreted	O
by	O
two	O
different	O
programs	O
:	O
SignalP	O
3	O
.	O
0	O
[	O
75	O
]	O
and	O
WoLFPSORT	O
[	O
76	O
]	O
.	O

The	O
size	O
of	O
each	O
secretome	O
is	O
summarised	O
in	O
Figure	O
2	O
.	O

Even	O
when	O
using	O
two	O
programs	O
,	O
the	O
sizes	O
of	O
predicted	O
secretomes	O
can	O
vary	O
greatly	O
.	O

For	O
example	O
,	O
a	O
similar	O
analysis	O
for	O
M	B-Species
.	I-Species
grisea	E-Species
using	O
SignalP	O
and	O
ProtComp	O
(	O
www	O
.	O
Softberry	O
.	O
com	O
)	O
predicted	O
only	O
739	O
secreted	O
proteins	O
(	O
out	O
of	O
a	O
proteome	O
of	O
11	O
,	O
109	O
)	O
compared	O
to	O
our	O
prediction	O
of	O
1	O
,	O
546	O
secreted	O
proteins	O
(	O
out	O
of	O
a	O
proteome	O
of	O
12	O
,	O
841	O
)	O
[	O
22	O
]	O
.	O

The	O
size	O
of	O
the	O
secretomes	O
for	O
each	O
species	O
varied	O
from	O
5	O
%	O
-	O
12	O
%	O
of	O
the	O
total	O
proteome	O
.	O

Overall	O
,	O
the	O
size	O
of	O
the	O
secretomes	O
from	O
phytopathogens	O
did	O
not	O
differ	O
greatly	O
from	O
that	O
of	O
non	O
-	O
pathogens	O
.	O

Table	O
8	O
shows	O
a	O
list	O
of	O
Pfam	O
motifs	O
,	O
not	O
found	O
in	O
the	O
secretomes	O
of	O
non	O
-	O
pathogenic	O
filamentous	O
ascomycetes	O
,	O
that	O
were	O
present	O
in	O
at	O
least	O
three	O
phytopathogenic	O
fungal	O
species	O
.	O

The	O
Isochorismatase	O
motif	O
(	O
PF00857	O
)	O
was	O
found	O
in	O
the	O
secretomes	O
of	O
all	O
five	O
species	O
of	O
phytopathogen	O
.	O

Isochorismatase	O
catalyses	O
the	O
conversion	O
of	O
isochorismate	O
to	O
2	O
,	O
3	O
-	O
dihydroxybenzoate	O
and	O
pyruvate	O
.	O

It	O
has	O
been	O
implicated	O
in	O
the	O
synthesis	O
of	O
the	O
anti	O
-	O
microbial	O
compound	O
phenazine	O
by	O
Pseudomonas	B-Species
aeruginosa	E-Species
[	O
77	O
]	O
and	O
the	O
siderophore	O
,	O
enterobactin	O
,	O
by	O
Escherichia	B-Species
coli	E-Species
[	O
78	O
]	O
.	O

The	O
isochorismatase	O
motif	O
is	O
also	O
found	O
in	O
a	O
number	O
of	O
hydrolases	O
,	O
such	O
as	O
nicotinamidase	O
that	O
converts	O
nicotinamide	O
to	O
nicotinic	O
acid	O
[	O
79	O
]	O
.	O

Members	O
of	O
this	O
family	O
are	O
found	O
in	O
all	O
filamentous	O
ascomycetes	O
,	O
but	O
interestingly	O
they	O
are	O
only	O
secreted	O
in	O
phytopathogens	O
.	O

Salicylic	O
acid	O
is	O
synthesised	O
in	O
plants	O
in	O
response	O
to	O
pathogen	O
attack	O
and	O
mediates	O
plant	O
defences	O
.	O

As	O
isochorismate	O
is	O
a	O
precursor	O
of	O
salicyclic	O
acid	O
[	O
80	O
]	O
,	O
it	O
may	O
be	O
worth	O
speculating	O
that	O
isochorismatases	O
secreted	O
by	O
fungi	O
could	O
act	O
to	O
reduce	O
salicylic	O
acid	O
accumulation	O
in	O
response	O
to	O
pathogen	O
attack	O
and	O
thus	O
inhibit	O
plant	O
defence	O
responses	O
.	O

The	O
secreted	O
isochorismatases	O
(	O
apart	O
from	O
one	O
of	O
the	O
proteins	O
from	O
S	B-Species
.	I-Species
nodorum	E-Species
)	O
all	O
show	O
sequence	O
similarity	O
to	O
ycaC	O
from	O
E	B-Species
.	I-Species
coli	E-Species
,	O
an	O
octameric	O
hydrolase	O
of	O
unknown	O
function	O
[	O
81	O
]	O
.	O

Pfam	O
motifs	O
found	O
in	O
the	O
secretomes	O
of	O
at	O
least	O
three	O
species	O
of	O
phytopathogens	O
,	O
but	O
not	O
in	O
any	O
of	O
the	O
non	O
-	O
pathogens	O
also	O
include	O
those	O
found	O
in	O
enzymes	O
potentially	O
involved	O
in	O
detoxification	O
,	O
such	O
as	O
arylesterase	O
and	O
amidohydrolase	O
,	O
and	O
also	O
beta	O
-	O
ketoacyl	O
synthase	O
,	O
which	O
catalyses	O
the	O
condensation	O
of	O
malonyl	O
-	O
ACP	O
with	O
a	O
growing	O
fatty	O
acid	O
chain	O
and	O
is	O
found	O
as	O
a	O
component	O
of	O
a	O
number	O
of	O
enzyme	O
systems	O
,	O
including	O
fatty	O
acid	O
synthases	O
and	O
polyketide	O
synthases	O
[	O
82	O
]	O
,	O
[	O
83	O
]	O
.	O

Table	O
9	O
shows	O
a	O
list	O
of	O
Pfam	O
motifs	O
that	O
are	O
more	O
common	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
as	O
compared	O
to	O
saprotrophs	O
.	O

These	O
include	O
a	O
number	O
of	O
secreted	O
proteases	O
,	O
transcription	O
factors	O
and	O
components	O
of	O
signal	O
transduction	O
pathways	O
.	O

The	O
Kelch	O
domain	O
(	O
PF01344	O
)	O
shows	O
the	O
most	O
striking	O
difference	O
in	O
distribution	O
between	O
phytopathogenic	O
and	O
non	O
-	O
pathogenic	O
genomes	O
.	O

This	O
50	O
-	O
residue	O
domain	O
is	O
found	O
in	O
a	O
number	O
of	O
actin	O
-	O
binding	O
proteins	O
[	O
84	O
]	O
,	O
as	O
well	O
as	O
enzymes	O
such	O
as	O
galactose	O
oxidase	O
and	O
neuraminidase	O
.	O

The	O
putative	O
function	O
of	O
each	O
secreted	O
Kelch	O
domain	O
-	O
containing	O
protein	O
was	O
ascertained	O
by	O
performing	O
a	O
BLAST	O
search	O
against	O
the	O
NCBI	O
non	O
-	O
redundant	O
protein	O
database	O
(	O
Table	O
10	O
)	O
.	O

A	O
number	O
of	O
these	O
seem	O
to	O
be	O
galactose	O
oxidases	O
,	O
enzymes	O
which	O
catalyse	O
the	O
oxidation	O
of	O
a	O
range	O
of	O
primary	O
alcohols	O
,	O
including	O
galactose	O
,	O
to	O
the	O
corresponding	O
aldehyde	O
with	O
the	O
concomitant	O
reduction	O
of	O
oxygen	O
to	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
[	O
85	O
]	O
.	O

Galactose	O
oxidase	O
shares	O
a	O
copper	O
radical	O
oxidase	O
motif	O
with	O
the	O
hydrogen	O
peroxide	O
-	O
generating	O
glyoxal	O
oxidases	O
involved	O
in	O
lignin	O
-	O
degradation	O
in	O
Phanerochaete	B-Species
chrysosporium	E-Species
[	O
86	O
]	O
.	O

H2O2	O
-	O
producing	O
copper	O
oxidases	O
have	O
been	O
shown	O
to	O
have	O
roles	O
in	O
morphogenesis	O
,	O
in	O
the	O
corn	S-Species
-	O
smut	O
fungus	O
Ustilago	B-Species
maydis	E-Species
for	O
example	O
,	O
a	O
glyoxal	O
oxidase	O
is	O
required	O
for	O
filamentous	O
growth	O
and	O
pathogenicity	O
[	O
87	O
]	O
and	O
a	O
galactose	O
oxidase	O
is	O
involved	O
in	O
fruiting	O
body	O
formation	O
in	O
the	O
gram	O
-	O
negative	O
bacterium	O
Stigmatella	B-Species
aurantiaca	E-Species
[	O
88	O
]	O
.	O

Interestingly	O
,	O
the	O
list	O
of	O
Pfam	O
motifs	O
more	O
common	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
also	O
includes	O
those	O
found	O
in	O
copper	O
amine	O
oxidases	O
,	O
H2O2	O
-	O
generating	O
enzymes	O
that	O
catalyse	O
the	O
oxidative	O
deamination	O
of	O
primary	O
amines	O
to	O
the	O
corresponding	O
aldehydes	O
[	O
89	O
]	O
and	O
peroxidases	O
,	O
haem	O
-	O
containing	O
enzymes	O
that	O
use	O
hydrogen	O
peroxide	O
as	O
the	O
electron	O
acceptor	O
to	O
catalyse	O
a	O
number	O
of	O
oxidative	O
reactions	O
.	O

Secreted	O
fungal	O
peroxidases	O
include	O
enzymes	O
involved	O
in	O
lignin	O
breakdown	O
by	O
the	O
white	O
rot	O
fungus	O
Phanerochaete	B-Species
chrysosporium	E-Species
[	O
90	O
]	O
,	O
but	O
in	O
plants	O
they	O
generate	O
reactive	O
oxygen	O
species	O
and	O
are	O
involved	O
in	O
defence	O
responses	O
and	O
growth	O
induction	O
[	O
91	O
]	O
.	O

A	O
number	O
of	O
other	O
secreted	O
Kelch	O
domain	O
-	O
containing	O
proteins	O
have	O
similarity	O
to	O
proteins	O
of	O
unknown	O
function	O
from	O
species	O
of	O
the	O
bacterial	O
phytopathogen	O
Xanthomonas	O
.	O

Many	O
Kelch	O
domain	O
-	O
containing	O
proteins	O
are	O
involved	O
in	O
cytoskeletal	O
rearrangement	O
and	O
cell	O
morphology	O
[	O
92	O
]	O
,	O
[	O
93	O
]	O
.	O

It	O
may	O
be	O
worth	O
speculating	O
that	O
secreted	O
Kelch	O
domain	O
-	O
containing	O
proteins	O
could	O
act	O
as	O
effectors	O
,	O
causing	O
changes	O
in	O
the	O
arrangement	O
of	O
the	O
cytoskeleton	O
of	O
infected	O
plants	O
to	O
aid	O
the	O
proliferation	O
of	O
fungal	O
hyphae	O
.	O

It	O
has	O
recently	O
been	O
shown	O
,	O
for	O
example	O
,	O
that	O
M	B-Species
.	I-Species
grisea	E-Species
co	O
-	O
opts	O
plasmodesmata	O
to	O
move	O
from	O
cell	O
to	O
cell	O
in	O
infected	O
rice	S-Species
leaves	O
[	O
94	O
]	O
and	O
would	O
therefore	O
need	O
to	O
peturb	O
cytoskeletal	O
organisation	O
in	O
rice	S-Species
epidermal	O
cells	O
.	O

There	O
are	O
other	O
Pfam	O
domains	O
that	O
are	O
more	O
common	O
in	O
the	O
secretomes	O
of	O
phytopathogens	O
that	O
may	O
potentially	O
be	O
found	O
in	O
effectors	O
such	O
as	O
the	O
PAN	O
domain	O
(	O
PF00024	O
)	O
,	O
that	O
mediates	O
protein	O
-	O
protein	O
and	O
protein	O
-	O
carbohydrate	O
interactions	O
[	O
95	O
]	O
and	O
the	O
F5	O
/	O
8	O
type	O
C	O
domain	O
(	O
PF00754	O
)	O
,	O
found	O
in	O
the	O
discoidin	O
family	O
of	O
proteins	O
involved	O
in	O
cell	O
-	O
adhesion	O
or	O
developmental	O
processes	O
[	O
96	O
]	O
.	O

Discussion	O

One	O
of	O
the	O
most	O
fundamental	O
aims	O
in	O
plant	O
pathology	O
research	O
is	O
to	O
define	O
precisely	O
the	O
difference	O
between	O
pathogenic	O
and	O
non	O
-	O
pathogenic	O
microorganisms	O
.	O

The	O
answer	O
cannot	O
be	O
one	O
of	O
simple	O
phylogeny	O
,	O
because	O
phytopathogenic	O
species	O
are	O
found	O
in	O
all	O
taxonomic	O
divisions	O
of	O
fungi	O
and	O
are	O
often	O
closely	O
related	O
to	O
non	O
-	O
pathogenic	O
species	O
[	O
3	O
]	O
.	O

Before	O
the	O
availability	O
of	O
genomic	O
sequences	O
and	O
high	O
throughput	O
approaches	O
to	O
study	O
gene	O
function	O
[	O
20	O
]	O
,	O
research	O
was	O
concentrated	O
on	O
the	O
search	O
for	O
single	O
pathogenicity	O
factors	O
;	O
genes	O
that	O
are	O
dispensable	O
for	O
saprophytic	O
growth	O
but	O
essential	O
for	O
successful	O
infection	O
of	O
the	O
host	O
plant	O
[	O
4	O
]	O
,	O
[	O
97	O
]	O
.	O

However	O
,	O
rather	O
than	O
encoding	O
novel	O
proteins	O
found	O
only	O
in	O
phytopathogens	O
,	O
the	O
majority	O
of	O
pathogenicity	O
factors	O
discovered	O
in	O
this	O
way	O
have	O
been	O
found	O
to	O
be	O
involved	O
in	O
signalling	O
cascades	O
and	O
metabolic	O
pathways	O
and	O
hence	O
are	O
conserved	O
in	O
most	O
species	O
of	O
fungi	O
[	O
5	O
]	O
.	O

Components	O
of	O
signalling	O
cascades	O
that	O
in	O
the	O
budding	O
yeast	S-Species
S	B-Species
.	I-Species
cerevisiae	E-Species
are	O
responsible	O
for	O
responses	O
to	O
pheromones	O
,	O
nutritional	O
starvation	O
and	O
osmotic	O
stress	O
[	O
9	O
]	O
have	O
in	O
many	O
cases	O
evolved	O
different	O
roles	O
in	O
the	O
life	O
cycle	O
of	O
pathogens	O
,	O
such	O
as	O
controlling	O
appressorium	O
formation	O
,	O
dimorphism	O
and	O
growth	O
[	O
10	O
]	O
.	O

Although	O
the	O
central	O
components	O
of	O
signalling	O
are	O
conserved	O
between	O
phytopathogens	O
and	O
S	B-Species
.	I-Species
cerevisiae	E-Species
,	O
the	O
receptors	O
are	O
often	O
different	O
,	O
reflecting	O
the	O
different	O
environmental	O
cues	O
to	O
which	O
the	O
pathogen	O
needs	O
to	O
respond	O
[	O
11	O
]	O
,	O
[	O
98	O
]	O
.	O

Analysis	O
of	O
all	O
available	O
genome	O
sequences	O
from	O
a	O
wider	O
range	O
of	O
fungal	O
species	O
has	O
for	O
the	O
first	O
time	O
allowed	O
us	O
to	O
address	O
the	O
differences	O
between	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
at	O
a	O
whole	O
genome	O
level	O
.	O

For	O
this	O
purpose	O
,	O
the	O
e	O
-	O
Fungi	O
data	O
warehouse	O
provides	O
a	O
means	O
to	O
interrogate	O
the	O
vast	O
amounts	O
of	O
genomic	O
and	O
functional	O
data	O
available	O
in	O
a	O
simple	O
integrated	O
manner	O
[	O
26	O
]	O
.	O

Previous	O
research	O
,	O
in	O
which	O
EST	O
datasets	O
were	O
compared	O
with	O
genomic	O
sequences	O
,	O
suggested	O
that	O
the	O
expressed	O
gene	O
inventories	O
of	O
phytopathogenic	O
species	O
were	O
not	O
significantly	O
more	O
similar	O
to	O
one	O
another	O
than	O
to	O
those	O
of	O
saprotrophic	O
filamentous	O
fungi	O
[	O
99	O
]	O
.	O

We	O
clustered	O
sets	O
of	O
predicted	O
proteins	O
from	O
36	O
different	O
species	O
of	O
fungi	O
and	O
oomycetes	O
into	O
groups	O
of	O
potential	O
orthologues	O
and	O
the	O
species	O
distribution	O
of	O
members	O
of	O
each	O
cluster	O
was	O
ascertained	O
.	O

There	O
were	O
no	O
clusters	O
that	O
were	O
completely	O
specific	O
to	O
phytopathogenic	O
species	O
across	O
both	O
fungi	O
and	O
oomycetes	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
novel	O
,	O
universal	O
pathogenicity	O
factors	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
is	O
unlikely	O
.	O

This	O
was	O
confirmed	O
by	O
looking	O
at	O
clusters	O
containing	O
empirically	O
defined	O
pathogenicity	O
factors	O
,	O
where	O
homologues	O
of	O
many	O
of	O
these	O
were	O
found	O
in	O
all	O
species	O
studied	O
and	O
none	O
were	O
conserved	O
in	O
the	O
genomes	O
only	O
of	O
phytopathogens	O
.	O

A	O
small	O
number	O
were	O
only	O
found	O
in	O
a	O
single	O
species	O
of	O
fungus	O
and	O
probably	O
represented	O
proteins	O
that	O
are	O
highly	O
specialised	O
for	O
a	O
particular	O
role	O
in	O
a	O
specific	O
pathogenic	O
species	O
,	O
for	O
example	O
in	O
host	O
-	O
plant	O
recognition	O
[	O
54	O
]	O
.	O

Previous	O
research	O
also	O
suggested	O
that	O
the	O
gene	O
inventories	O
of	O
filamentous	O
fungi	O
were	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
those	O
of	O
unicellular	O
yeasts	O
[	O
99	O
]	O
.	O

Analysis	O
of	O
the	O
clusters	O
of	O
similar	O
proteins	O
show	O
some	O
clusters	O
that	O
are	O
found	O
in	O
all	O
species	O
of	O
filamentous	O
fungi	O
(	O
including	O
ascomycetes	O
,	O
basidiomycetes	O
and	O
zygomycetes	O
)	O
but	O
are	O
not	O
present	O
in	O
the	O
genomes	O
of	O
yeasts	O
,	O
consistent	O
with	O
the	O
original	O
conclusion	O
.	O

These	O
contain	O
a	O
number	O
of	O
proteins	O
that	O
are	O
likely	O
to	O
be	O
involved	O
in	O
morphological	O
changes	O
associated	O
with	O
the	O
more	O
complex	O
filamentous	O
lifestyle	O
,	O
as	O
well	O
those	O
involved	O
in	O
secondary	O
metabolism	O
and	O
signalling	O
cascades	O
that	O
are	O
not	O
found	O
in	O
yeasts	O
.	O

In	O
particular	O
,	O
our	O
results	O
suggest	O
that	O
filamentous	O
fungi	O
use	O
a	O
wider	O
variety	O
of	O
lipid	O
molecules	O
for	O
the	O
purpose	O
of	O
signalling	O
.	O

Some	O
of	O
these	O
may	O
act	O
as	O
pheromones	O
,	O
or	O
hormones	O
-	O
chemical	O
messengers	O
diffusing	O
from	O
one	O
cell	O
to	O
another	O
to	O
elicit	O
a	O
physiological	O
or	O
developmental	O
response	O
[	O
37	O
]	O
.	O

A	O
number	O
of	O
these	O
innovations	O
to	O
the	O
filamentous	O
lifestyle	O
may	O
serve	O
important	O
roles	O
in	O
pathogenesis	O
as	O
well	O
,	O
because	O
homologues	O
of	O
a	O
number	O
of	O
pathogenicity	O
factors	O
are	O
found	O
only	O
in	O
filamentous	O
ascomycetes	O
.	O

The	O
distribution	O
of	O
filamentous	O
fungi	O
-	O
specific	O
proteins	O
,	O
such	O
as	O
involved	O
in	O
those	O
cytoskeletal	O
rearrangements	O
and	O
fruiting	O
body	O
formation	O
,	O
throughout	O
the	O
fungal	O
kingdom	O
(	O
and	O
in	O
some	O
cases	O
in	O
oomycetes	O
as	O
well	O
)	O
,	O
suggests	O
that	O
the	O
last	O
common	O
ancestral	O
fungus	O
may	O
well	O
have	O
been	O
multi	O
-	O
cellular	O
and	O
the	O
evolution	O
of	O
uni	O
-	O
cellular	O
fungi	O
was	O
likely	O
associated	O
with	O
massive	O
gene	O
loss	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
early	O
in	O
ascomycete	O
evolution	O
there	O
was	O
a	O
proliferation	O
of	O
subtilase	O
-	O
type	O
protease	O
-	O
encoding	O
genes	O
that	O
have	O
been	O
retained	O
in	O
some	O
filamentous	O
ascomycete	O
lineages	O
,	O
but	O
lost	O
in	O
the	O
yeast	S-Species
lineage	O
[	O
100	O
]	O
.	O

It	O
has	O
previously	O
been	O
speculated	O
that	O
the	O
evolution	O
of	O
phytopathogenesis	O
was	O
associated	O
with	O
the	O
expansion	O
of	O
certain	O
gene	O
families	O
[	O
1	O
]	O
.	O

Duplication	O
of	O
an	O
ancestral	O
gene	O
,	O
followed	O
by	O
mutation	O
allows	O
members	O
of	O
the	O
family	O
to	O
take	O
on	O
new	O
functions	O
[	O
101	O
]	O
.	O

For	O
example	O
,	O
genomes	O
of	O
the	O
filamentous	O
ascomycetes	O
studied	O
here	O
have	O
between	O
40	O
and	O
140	O
cytochrome	O
P450	O
-	O
encoding	O
genes	O
(	O
data	O
not	O
shown	O
)	O
that	O
are	O
involved	O
in	O
toxin	O
biosynthesis	O
,	O
lipid	O
metabolism	O
,	O
alkane	O
assimilation	O
and	O
detoxification	O
[	O
102	O
]	O
and	O
which	O
probably	O
arose	O
via	O
gene	O
duplication	O
and	O
functional	O
diversification	O
.	O

In	O
contrast	O
,	O
the	O
genome	O
of	O
the	O
budding	O
yeast	S-Species
S	B-Species
.	I-Species
cerevisiae	E-Species
has	O
only	O
three	O
cytochrome	O
P450	O
-	O
encoding	O
enzymes	O
.	O

We	O
have	O
shown	O
here	O
that	O
there	O
are	O
likely	O
to	O
be	O
large	O
differences	O
in	O
the	O
gene	O
inventories	O
of	O
filamentous	O
fungi	O
compared	O
to	O
unicellular	O
yeasts	O
.	O

To	O
study	O
the	O
differences	O
between	O
phytopathogenic	O
and	O
saprophytic	O
fungi	O
,	O
we	O
concentrated	O
on	O
the	O
filamentous	O
ascomycetes	O
where	O
there	O
are	O
a	O
number	O
of	O
phytopathogenic	O
species	O
genomes	O
have	O
been	O
sequenced	O
along	O
with	O
closely	O
related	O
non	O
-	O
pathogens	O
.	O

Protein	O
families	O
were	O
defined	O
using	O
Pfam	O
motifs	O
[	O
57	O
]	O
and	O
the	O
predicted	O
protein	O
sets	O
for	O
each	O
species	O
analysed	O
in	O
order	O
to	O
identify	O
domains	O
that	O
were	O
specific	O
to	O
or	O
more	O
common	O
in	O
the	O
genomes	O
of	O
phytopathogens	O
.	O

Not	O
surprisingly	O
,	O
many	O
of	O
the	O
protein	O
families	O
we	O
identified	O
are	O
likely	O
to	O
be	O
associated	O
with	O
pathogenic	O
processes	O
such	O
as	O
plant	O
cell	O
wall	O
degradation	O
,	O
toxin	O
biosynthesis	O
,	O
formation	O
of	O
reactive	O
oxygen	O
species	O
and	O
detoxification	O
[	O
5	O
]	O
.	O

Studies	O
of	O
bacterial	O
phytopathogens	O
have	O
shown	O
the	O
importance	O
of	O
effectors	O
,	O
secreted	O
proteins	O
that	O
disable	O
plant	O
defences	O
and	O
subvert	O
metabolic	O
and	O
morphological	O
processes	O
for	O
the	O
benefit	O
of	O
the	O
invading	O
pathogen	O
and	O
which	O
require	O
delivery	O
via	O
a	O
type	O
III	O
secretion	O
system	O
that	O
are	O
often	O
deployed	O
during	O
pathogenesis	O
[	O
73	O
]	O
.	O

Bacterial	O
type	O
III	O
secreted	O
effectors	O
(	O
T3SEs	O
)	O
have	O
been	O
shown	O
to	O
target	O
salicyclic	O
acid	O
and	O
abscisic	O
acid	O
-	O
dependent	O
defences	O
,	O
host	O
vesicle	O
trafficking	O
,	O
transcription	O
and	O
RNA	O
metabolism	O
,	O
and	O
several	O
components	O
of	O
the	O
plant	O
defence	O
signalling	O
networks	O
[	O
103	O
]	O
.	O

Very	O
recently	O
,	O
potential	O
effector	O
-	O
encoding	O
genes	O
have	O
been	O
identified	O
in	O
the	O
genomes	O
of	O
several	O
species	O
of	O
oomycete	O
pathogens	O
and	O
are	O
defined	O
by	O
the	O
presence	O
of	O
a	O
conserved	O
RXLR	O
-	O
EER	O
motif	O
downstream	O
of	O
the	O
signal	O
peptide	O
sequence	O
[	O
74	O
]	O
.	O

The	O
RXLR	O
-	O
EER	O
motif	O
is	O
necessary	O
for	O
delivery	O
of	O
effector	O
proteins	O
into	O
host	O
plant	O
cells	O
and	O
is	O
therefore	O
critical	O
to	O
their	O
biological	O
activity	O
[	O
74	O
]	O
.	O

To	O
identify	O
potential	O
fungal	O
effectors	O
,	O
we	O
compared	O
Pfam	O
motif	O
frequency	O
between	O
the	O
secretomes	O
of	O
phytopathogens	O
and	O
non	O
-	O
pathogens	O
.	O

This	O
analysis	O
identified	O
potential	O
effector	O
-	O
encoding	O
genes	O
,	O
including	O
secreted	O
proteases	O
,	O
transcription	O
factors	O
and	O
proteins	O
that	O
may	O
be	O
involved	O
in	O
cytoskeletal	O
rearrangements	O
(	O
such	O
as	O
Kelch	O
-	O
domain	O
containing	O
proteins	O
)	O
and	O
protein	O
-	O
protein	O
interactions	O
,	O
as	O
well	O
as	O
a	O
group	O
of	O
pathogen	O
-	O
specific	O
secreted	O
isochorisimatases	O
that	O
potentially	O
could	O
suppress	O
salicyclic	O
acid	O
-	O
dependent	O
host	O
plant	O
defences	O
.	O

Bacterial	O
T3SEs	O
are	O
injected	O
directly	O
into	O
the	O
host	O
cytoplasm	O
via	O
the	O
type	O
III	O
secretion	O
injection	O
apparatus	O
[	O
73	O
]	O
.	O

In	O
contrast	O
,	O
the	O
potential	O
fungal	O
effectors	O
identified	O
in	O
this	O
study	O
appear	O
to	O
be	O
secreted	O
by	O
the	O
normal	O
cellular	O
secretory	O
pathway	O
via	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
mechanism	O
by	O
which	O
fungal	O
effectors	O
might	O
be	O
taken	O
up	O
by	O
plant	O
cells	O
and	O
enter	O
into	O
the	O
host	O
cytoplasm	O
is	O
currently	O
unknown	O
.	O

Although	O
the	O
evolution	O
of	O
phytopathogenicity	O
is	O
likely	O
to	O
have	O
happened	O
several	O
times	O
and	O
the	O
lifestyles	O
of	O
these	O
fungi	O
are	O
diverse	O
,	O
a	O
comparison	O
of	O
gene	O
inventories	O
of	O
a	O
number	O
of	O
species	O
using	O
a	O
powerful	O
resource	O
,	O
such	O
as	O
e	O
-	O
Fungi	O
,	O
has	O
allowed	O
us	O
to	O
pinpoint	O
new	O
gene	O
families	O
that	O
may	O
serve	O
important	O
roles	O
in	O
the	O
virulence	O
of	O
phytopathogens	O
,	O
allowing	O
their	O
selection	O
for	O
gene	O
functional	O
studies	O
,	O
that	O
are	O
currently	O
in	O
progress	O
.	O

The	O
analyses	O
deployed	O
here	O
may	O
also	O
offer	O
a	O
blueprint	O
for	O
the	O
types	O
of	O
larger	O
,	O
more	O
comprehensive	O
studies	O
that	O
will	O
be	O
necessary	O
to	O
interpret	O
the	O
large	O
flow	O
of	O
genetic	O
data	O
that	O
will	O
result	O
from	O
next	O
generation	O
DNA	O
sequence	O
analysis	O
utilizing	O
both	O
a	O
much	O
wider	O
variety	O
of	O
fungal	O
pathogen	O
species	O
and	O
also	O
large	O
sets	O
of	O
individual	O
isolates	O
of	O
existing	O
species	O
.	O

Materials	O
and	O
Methods	O

Clustering	O
of	O
sequences	O

Sets	O
of	O
predicted	O
proteins	O
were	O
downloaded	O
for	O
each	O
of	O
the	O
36	O
genomes	O
from	O
respective	O
sequencing	O
project	O
websites	O
(	O
Table	O
1	O
)	O
.	O

Proteins	O
less	O
than	O
40	O
amino	O
acids	O
in	O
length	O
were	O
not	O
included	O
in	O
this	O
analysis	O
.	O

Proteins	O
were	O
clustered	O
using	O
"	O
all	O
against	O
all	O
"	O
BLASTP	O
[	O
104	O
]	O
followed	O
by	O
Markov	O
Chain	O
Clustering	O
(	O
MCL	O
)	O
[	O
27	O
]	O
with	O
2	O
.	O
5	O
as	O
a	O
moderate	O
inflation	O
value	O
and	O
10	O
-	O
10	O
as	O
an	O
E	O
-	O
value	O
cut	O
-	O
off	O
,	O
as	O
described	O
previously	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

Clusters	O
were	O
annotated	O
based	O
on	O
best	O
hit	O
against	O
Swiss	O
-	O
Prot	O
protein	O
database	O
[	O
105	O
]	O
of	O
members	O
of	O
that	O
cluster	O
(	O
e	O
-	O
value	O
<	O
10	O
-	O
20	O
using	O
BLASTP	O
)	O
,	O
or	O
Pfam	O
motifs	O
contained	O
in	O
proteins	O
from	O
the	O
cluster	O
in	O
the	O
absence	O
of	O
Swiss	O
-	O
Prot	O
hits	O
.	O

Identification	O
of	O
Pfam	O
motifs	O

The	O
Pfam	O
-	O
A	O
library	O
from	O
release	O
18	O
.	O
0	O
of	O
the	O
Pfam	O
database	O
was	O
downloaded	O
from	O
the	O
Pfam	O
website	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
sanger	O
.	O
ac	O
.	O
uk	O
/	O
Software	O
/	O
Pfam	O
/	O
)	O
.	O

This	O
library	O
contains	O
7973	O
protein	O
models	O
constructed	O
from	O
manually	O
curated	O
multiple	O
alignments	O
and	O
covers	O
75	O
%	O
of	O
proteins	O
in	O
UniProt	O
[	O
44	O
]	O
,	O
[	O
57	O
]	O
.	O

This	O
library	O
was	O
used	O
to	O
analyse	O
the	O
sequences	O
of	O
predicted	O
proteins	O
for	O
all	O
36	O
fungal	O
genomes	O
to	O
identify	O
the	O
Pfam	O
motifs	O
that	O
each	O
protein	O
contains	O
.	O

The	O
analysis	O
was	O
performed	O
using	O
the	O
"	O
pfam	O
_	O
scan	O
"	O
perl	O
script	O
(	O
version	O
0	O
.	O
5	O
)	O
downloaded	O
from	O
the	O
Pfam	O
website	O
and	O
HMMER	O
software	O
(	O
downloaded	O
from	O
http	O
:	O
/	O
/	O
hmmer	O
.	O
wustl	O
.	O
edu	O
/	O
)	O
.	O

Default	O
thresholds	O
were	O
used	O
,	O
which	O
are	O
hand	O
-	O
curated	O
for	O
every	O
family	O
and	O
designed	O
to	O
minimise	O
false	O
positives	O
[	O
44	O
]	O
.	O

Identification	O
of	O
secreted	O
proteins	O

The	O
N	O
-	O
terminal	O
sequence	O
of	O
each	O
predicted	O
protein	O
from	O
the	O
36	O
fungal	O
genomes	O
used	O
in	O
this	O
study	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
a	O
signal	O
peptide	O
using	O
SignalP	O
3	O
.	O
0	O
[	O
75	O
]	O
and	O
sub	O
-	O
cellular	O
localisation	O
was	O
predicted	O
using	O
WoLF	O
PSORT	O
[	O
76	O
]	O
.	O

Both	O
these	O
programs	O
were	O
installed	O
locally	O
.	O

SignalP	O
3	O
.	O
0	O
uses	O
two	O
different	O
algorithms	O
to	O
identify	O
signal	O
sequences	O
.	O

The	O
secretome	O
for	O
each	O
fungal	O
species	O
was	O
defined	O
as	O
containing	O
those	O
proteins	O
that	O
were	O
predicted	O
have	O
a	O
signal	O
peptide	O
by	O
both	O
prediction	O
algorithms	O
from	O
SignalP	O
3	O
.	O
0	O
and	O
also	O
predicted	O
to	O
be	O
extracellular	O
by	O
WoLF	O
PSORT	O
.	O

Data	O
analysis	O

All	O
the	O
data	O
produced	O
,	O
as	O
described	O
above	O
,	O
was	O
stored	O
in	O
the	O
e	O
-	O
Fungi	O
data	O
warehouse	O
[	O
26	O
]	O
from	O
which	O
it	O
can	O
be	O
accessed	O
via	O
a	O
web	O
-	O
interface	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
e	O
-	O
fungi	O
.	O
org	O
.	O
uk	O
/	O
)	O
.	O

Analyses	O
described	O
in	O
this	O
study	O
were	O
performed	O
using	O
the	O
e	O
-	O
Fungi	O
database	O
.	O

Supporting	O
Information	O

Emergence	O
of	O
Delayed	O
Methylmercury	O
Toxicity	O
after	O
Perinatal	O
Exposure	O
in	O
Metallothionein	O
-	O
Null	O
and	O
Wild	O
-	O
Type	O
C57BL	O
Mice	S-Species

Abstract	O

Background	O

Although	O
a	O
long	O
latency	O
period	O
of	O
toxicity	O
after	O
exposure	O
to	O
methylmercury	O
(	O
MeHg	O
)	O
is	O
known	O
to	O
exist	O
in	O
humans	S-Species
,	O
few	O
animal	O
studies	O
have	O
addressed	O
this	O
issue	O
.	O

Substantiation	O
of	O
delayed	O
MeHg	O
toxicity	O
in	O
animals	O
would	O
affect	O
the	O
risk	O
evaluation	O
of	O
MeHg	O
.	O

Objectives	O

Our	O
goal	O
in	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
existence	O
of	O
a	O
latency	O
period	O
in	O
a	O
rodent	O
model	O
in	O
which	O
the	O
toxicity	O
of	O
perinatal	O
MeHg	O
exposure	O
becomes	O
apparent	O
only	O
later	O
in	O
life	O
.	O

Our	O
study	O
included	O
metallothionein	O
(	O
MT	O
)	O
knockout	O
mice	S-Species
because	O
studies	O
have	O
suggested	O
the	O
potential	O
susceptibility	O
of	O
this	O
strain	O
to	O
the	O
neurodevelopmental	O
toxicity	O
of	O
MeHg	O
.	O

Methods	O

Pregnant	O
MT	O
-	O
null	O
and	O
wild	O
-	O
type	O
C57Bl	O
/	O
6J	O
mice	S-Species
were	O
exposed	O
to	O
MeHg	O
through	O
their	O
diet	O
containing	O
5	O
mu	O
g	O
Hg	O
/	O
g	O
during	O
gestation	O
and	O
early	O
lactation	O
.	O

We	O
examined	O
behavioral	O
functions	O
of	O
the	O
offspring	O
using	O
frequently	O
used	O
paradigms	O
,	O
including	O
open	O
field	O
behavior	O
(	O
OPF	O
)	O
,	O
passive	O
avoidance	O
(	O
PA	O
)	O
,	O
and	O
the	O
Morris	O
water	O
maze	O
(	O
MM	O
)	O
,	O
at	O
ages	O
of	O
12	O
-	O
13	O
and	O
52	O
-	O
53	O
weeks	O
.	O

Results	O

At	O
12	O
weeks	O
of	O
age	O
,	O
behavioral	O
effects	O
of	O
MeHg	O
were	O
not	O
detected	O
,	O
except	O
for	O
OPF	O
performance	O
in	O
MeHg	O
-	O
exposed	O
MT	O
-	O
null	O
females	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
the	O
MeHg	O
-	O
exposed	O
groups	O
showed	O
poorer	O
performance	O
both	O
in	O
PA	O
and	O
MM	O
,	O
and	O
their	O
OPF	O
activity	O
differed	O
from	O
controls	O
.	O

These	O
effects	O
of	O
MeHg	O
appeared	O
exaggerated	O
in	O
the	O
MT	O
-	O
null	O
strain	O
.	O

The	O
brain	O
Hg	O
concentration	O
had	O
leveled	O
off	O
by	O
13	O
weeks	O
of	O
age	O
.	O

Conclusions	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
long	O
latency	O
period	O
after	O
perinatal	O
exposure	O
to	O
low	O
-	O
level	O
MeHg	O
,	O
in	O
which	O
the	O
behavioral	O
effects	O
emerged	O
long	O
after	O
the	O
leveling	O
-	O
off	O
of	O
brain	O
Hg	O
levels	O
.	O

Hence	O
,	O
the	O
initial	O
toxicologic	O
event	O
responsible	O
for	O
the	O
late	O
effects	O
should	O
have	O
occurred	O
before	O
this	O
leveling	O
-	O
off	O
of	O
brain	O
Hg	O
.	O

Methylmercury	O
(	O
MeHg	O
)	O
poses	O
serious	O
and	O
practical	O
concerns	O
for	O
human	S-Species
populations	O
regarding	O
perinatal	O
exposure	O
.	O

Fish	O
,	O
especially	O
large	O
predator	O
(	O
carnivore	O
)	O
fish	O
species	O
,	O
accumulate	O
high	O
concentrations	O
of	O
MeHg	O
through	O
the	O
marine	O
food	O
chain	O
,	O
and	O
exposure	O
of	O
pregnant	O
women	S-Species
to	O
MeHg	O
through	O
the	O
consumption	O
of	O
fish	O
has	O
evoked	O
widespread	O
concern	O
due	O
to	O
potential	O
effects	O
on	O
offspring	O
.	O

Two	O
large	O
-	O
scale	O
cohort	O
studies	O
in	O
fish	O
-	O
eating	O
populations	O
of	O
Seychelles	O
and	O
Faroe	O
islanders	O
are	O
being	O
conducted	O
;	O
although	O
the	O
former	O
has	O
not	O
found	O
consistent	O
adverse	O
developmental	O
effects	O
of	O
MeHg	O
(	O
Myers	O
et	O
al	O
.	O
2007	O
)	O
,	O
the	O
latter	O
has	O
reported	O
adverse	O
effects	O
(	O
Debes	O
et	O
al	O
.	O
2006	O
)	O
.	O

Fundamental	O
reasons	O
for	O
this	O
discrepancy	O
have	O
not	O
been	O
completely	O
elucidated	O
,	O
and	O
many	O
questions	O
remain	O
regarding	O
the	O
neurotoxicity	O
of	O
MeHg	O
,	O
despite	O
extensive	O
study	O
.	O

Among	O
the	O
unanswered	O
questions	O
is	O
whether	O
there	O
is	O
a	O
long	O
latency	O
period	O
for	O
behavioral	O
manifestations	O
after	O
exposure	O
to	O
MeHg	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
;	O
Landrigan	O
et	O
al	O
.	O
2005	O
;	O
Rice	O
1996	O
;	O
Weiss	O
et	O
al	O
.	O
2005a	O
,	O
2005b	O
)	O
.	O

Typical	O
examples	O
of	O
latent	O
toxicity	O
in	O
humans	S-Species
,	O
including	O
both	O
acute	O
and	O
chronic	O
MeHg	O
exposures	O
,	O
have	O
been	O
described	O
in	O
detail	O
elsewhere	O
(	O
Weiss	O
et	O
al	O
.	O
2005a	O
)	O
.	O

Davidson	O
et	O
al	O
.	O

(	O
2006	O
)	O
recently	O
suggested	O
that	O
effects	O
of	O
perinatal	O
exposure	O
to	O
MeHg	O
may	O
emerge	O
9	O
years	O
after	O
birth	O
in	O
the	O
Seychelles	O
cohort	O
.	O

Consequently	O
,	O
risk	O
assessments	O
of	O
MeHg	O
exposure	O
could	O
be	O
inaccurate	O
because	O
studies	O
(	O
human	S-Species
or	O
animal	O
)	O
usually	O
do	O
not	O
focus	O
on	O
later	O
stages	O
of	O
life	O
and	O
therefore	O
could	O
miss	O
delayed	O
effects	O
.	O

The	O
possibility	O
of	O
delayed	O
toxicity	O
is	O
exemplified	O
by	O
the	O
expanded	O
Barker	O
hypothesis	O
,	O
which	O
posits	O
that	O
the	O
origin	O
of	O
some	O
neurodegenerative	O
diseases	O
such	O
as	O
Parkinson	O
and	O
Alzheimer	O
diseases	O
lies	O
in	O
early	O
exposure	O
to	O
environmental	O
chemicals	O
(	O
Landrigan	O
et	O
al	O
.	O
2005	O
)	O
.	O

Although	O
epidemiologic	O
evidence	O
would	O
be	O
ideal	O
for	O
exploring	O
the	O
possibility	O
of	O
delayed	O
toxicity	O
(	O
and	O
,	O
indeed	O
,	O
data	O
from	O
epidemiologic	O
studies	O
form	O
the	O
basis	O
of	O
current	O
risk	O
assessment	O
for	O
developmental	O
toxicity	O
of	O
MeHg	O
)	O
,	O
considering	O
the	O
complex	O
effects	O
of	O
numerous	O
potential	O
confounders	O
and	O
the	O
existence	O
of	O
multiple	O
exposures	O
in	O
human	S-Species
populations	O
,	O
animal	O
models	O
would	O
likely	O
make	O
important	O
contributions	O
to	O
this	O
field	O
.	O

Although	O
numerous	O
animal	O
studies	O
have	O
described	O
the	O
developmental	O
neurotoxicity	O
of	O
MeHg	O
(	O
Watanabe	O
and	O
Satoh	O
,	O
1996	O
)	O
,	O
few	O
have	O
addressed	O
the	O
latency	O
issue	O
.	O

Few	O
studies	O
have	O
evaluated	O
the	O
neurobehavioral	O
effects	O
in	O
rodents	O
longitudinally	O
beyond	O
6	O
months	O
after	O
perinatal	O
exposure	O
.	O

Spyker	O
(	O
1975	O
)	O
addressed	O
this	O
issue	O
in	O
her	O
pioneering	O
work	O
,	O
reporting	O
the	O
late	O
development	O
of	O
behavioral	O
toxicity	O
in	O
mice	S-Species
prenatally	O
exposed	O
to	O
MeHg	O
;	O
it	O
appeared	O
,	O
however	O
,	O
that	O
the	O
substantial	O
mortality	O
and	O
retarded	O
growth	O
among	O
the	O
exposed	O
mice	S-Species
were	O
apparent	O
before	O
weaning	O
,	O
indicating	O
that	O
the	O
doses	O
used	O
(	O
even	O
though	O
some	O
lower	O
dose	O
levels	O
were	O
included	O
)	O
exerted	O
severe	O
toxicity	O
.	O

Using	O
a	O
relatively	O
complex	O
schedule	O
-	O
controlled	O
operant	O
behavior	O
method	O
,	O
rats	S-Species
whose	O
parents	O
were	O
exposed	O
to	O
MeHg	O
(	O
0	O
.	O
5	O
or	O
6	O
.	O
4	O
mg	O
/	O
L	O
)	O
from	O
4	O
weeks	O
before	O
mating	O
and	O
continuing	O
to	O
postnatal	O
day	O
(	O
PND	O
)	O
16	O
were	O
shown	O
to	O
be	O
less	O
sensitive	O
to	O
a	O
change	O
in	O
the	O
reinforcement	O
schedule	O
than	O
were	O
their	O
nonexposed	O
counterparts	O
at	O
28	O
-	O
32	O
months	O
of	O
age	O
(	O
Newland	O
et	O
al	O
.	O
2004	O
)	O
.	O

Mice	S-Species
that	O
were	O
perinatally	O
exposed	O
to	O
1	O
or	O
3	O
mg	O
/	O
L	O
MeHg	O
in	O
drinking	O
water	O
did	O
not	O
show	O
significant	O
deviation	O
from	O
controls	O
in	O
behavioral	O
performance	O
(	O
motor	O
performance	O
,	O
memory	O
,	O
and	O
learning	O
)	O
at	O
5	O
,	O
15	O
,	O
or	O
26	O
months	O
of	O
age	O
,	O
but	O
the	O
lifetime	O
-	O
exposed	O
groups	O
did	O
show	O
a	O
significant	O
deviation	O
(	O
Weiss	O
et	O
al	O
.	O
2005c	O
)	O
.	O

The	O
existence	O
of	O
a	O
latency	O
period	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
absence	O
of	O
effects	O
earlier	O
in	O
life	O
followed	O
by	O
the	O
emergence	O
of	O
effects	O
at	O
a	O
later	O
stage	O
of	O
life	O
)	O
has	O
not	O
been	O
demonstrated	O
in	O
any	O
rodent	O
study	O
.	O

In	O
nonhuman	O
primates	O
,	O
delayed	O
emergence	O
of	O
the	O
signs	O
of	O
neurotoxicity	O
was	O
observed	O
several	O
years	O
after	O
the	O
cessation	O
of	O
a	O
7	O
-	O
year	O
postnatal	O
exposure	O
(	O
Rice	O
1996	O
)	O
.	O

Metallothionein	O
(	O
MT	O
)	O
protects	O
against	O
the	O
toxicities	O
of	O
a	O
variety	O
of	O
metals	O
.	O

We	O
examined	O
the	O
neurotoxicity	O
and	O
developmental	O
toxicity	O
of	O
metallic	O
Hg	O
in	O
MT	O
I	O
/	O
II	O
-	O
knockout	O
mice	S-Species
(	O
Yoshida	O
et	O
al	O
.	O
2004	O
)	O
and	O
demonstrated	O
the	O
susceptibility	O
of	O
this	O
genetically	O
manipulated	O
strain	O
to	O
the	O
toxicity	O
of	O
metallic	O
Hg	O
.	O

In	O
contrast	O
to	O
metallic	O
Hg	O
,	O
MeHg	O
does	O
not	O
induce	O
MT	O
,	O
and	O
MT	O
would	O
not	O
substantially	O
influence	O
the	O
kinetics	O
of	O
MeHg	O
(	O
Yasutake	O
et	O
al	O
.	O
1998	O
)	O
.	O

Several	O
reports	O
,	O
however	O
,	O
have	O
demonstrated	O
protective	O
effects	O
of	O
MT	O
against	O
MeHg	O
toxicity	O
,	O
which	O
was	O
ascribed	O
to	O
the	O
radical	O
scavenging	O
effect	O
of	O
MT	O
(	O
Yao	O
et	O
al	O
.	O
2000	O
)	O
.	O

We	O
also	O
showed	O
that	O
perinatal	O
exposure	O
to	O
MeHg	O
results	O
in	O
altered	O
metabolism	O
of	O
thyroid	O
hormones	O
in	O
neonates	O
that	O
was	O
more	O
distinct	O
in	O
MT	O
-	O
null	O
strains	O
than	O
their	O
wild	O
-	O
type	O
counterparts	O
(	O
Mori	O
et	O
al	O
.	O
2006	O
)	O
.	O

The	O
vulnerability	O
of	O
the	O
MT	O
-	O
null	O
strain	O
suggests	O
that	O
delayed	O
neurobehavioral	O
toxicity	O
due	O
to	O
MeHg	O
,	O
if	O
it	O
does	O
exist	O
,	O
might	O
be	O
more	O
distinctive	O
in	O
this	O
strain	O
.	O

By	O
utilizing	O
the	O
MT	O
-	O
null	O
strain	O
,	O
we	O
aimed	O
to	O
answer	O
the	O
following	O
two	O
questions	O
:	O
First	O
,	O
could	O
we	O
generate	O
a	O
model	O
in	O
which	O
the	O
toxicity	O
of	O
MeHg	O
would	O
emerge	O
or	O
at	O
least	O
become	O
exaggerated	O
later	O
in	O
life	O
as	O
opposed	O
to	O
earlier	O
in	O
life	O
(	O
i	O
.	O
e	O
.	O
,	O
at	O
3	O
-	O
6	O
months	O
,	O
which	O
was	O
the	O
timing	O
for	O
most	O
of	O
the	O
earlier	O
studies	O
that	O
used	O
behavioral	O
evaluations	O
)	O
?	O

Second	O
,	O
would	O
the	O
MT	O
-	O
null	O
strain	O
be	O
affected	O
more	O
than	O
its	O
parent	O
C57BL	O
strain	O
?	O

Answering	O
either	O
of	O
these	O
questions	O
not	O
only	O
could	O
influence	O
the	O
risk	O
evaluation	O
of	O
MeHg	O
,	O
but	O
it	O
could	O
also	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
toxicity	O
for	O
perinatal	O
MeHg	O
exposure	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
used	O
three	O
behavioral	O
paradigms	O
,	O
the	O
open	O
field	O
(	O
OPF	O
)	O
,	O
passive	O
avoidance	O
(	O
PA	O
)	O
,	O
and	O
Morris	O
(	O
water	O
)	O
maze	O
(	O
MM	O
)	O
tests	O
,	O
which	O
are	O
often	O
used	O
in	O
this	O
field	O
and	O
which	O
we	O
used	O
in	O
our	O
previous	O
studies	O
on	O
the	O
effects	O
of	O
Hg	O
vapor	O
(	O
Yoshida	O
et	O
al	O
.	O
2004	O
,	O
2006	O
)	O
.	O

Performances	O
in	O
the	O
MM	O
and	O
PA	O
are	O
said	O
to	O
be	O
the	O
most	O
sensitive	O
to	O
aging	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
.	O

We	O
used	O
a	O
dose	O
of	O
5	O
mu	O
g	O
MeHg	O
/	O
g	O
in	O
the	O
diet	O
,	O
which	O
resulted	O
in	O
a	O
brain	O
Hg	O
level	O
relevant	O
to	O
human	S-Species
risk	O
assessment	O
.	O

We	O
evaluated	O
the	O
behavioral	O
end	O
points	O
twice	O
,	O
once	O
around	O
3	O
months	O
of	O
age	O
and	O
the	O
other	O
time	O
around	O
1	O
year	O
;	O
the	O
latter	O
time	O
roughly	O
corresponds	O
to	O
the	O
period	O
when	O
many	O
behavioral	O
performances	O
,	O
including	O
OPF	O
(	O
Acevedoa	O
et	O
al	O
.	O
2006	O
;	O
Carrie	O
et	O
al	O
.	O
1999	O
;	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
,	O
PA	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
,	O
and	O
MM	O
(	O
Bach	O
et	O
al	O
.	O
1999	O
;	O
Carrie	O
et	O
al	O
.	O
1999	O
)	O
,	O
show	O
alterations	O
in	O
this	O
mouse	S-Species
strain	O
.	O

Materials	O
and	O
Methods	O

Animals	O
and	O
MeHg	O
exposure	O

OLA129	O
/	O
C57BL	O
/	O
6J	O
strain	O
mice	S-Species
(	O
wild	O
type	O
)	O
and	O
MT	O
I	O
/	O
II	O
-	O
knockout	O
mice	S-Species
(	O
MT	O
-	O
null	O
)	O
of	O
this	O
strain	O
were	O
provided	O
by	O
K	O
.	O
H	O
.	O

Choo	O
of	O
the	O
Murdoch	O
Institute	O
,	O
Parkville	O
,	O
Australia	O
(	O
Michalska	O
and	O
Choo	O
1993	O
)	O
and	O
were	O
of	O
a	O
mixed	O
genetic	O
background	O
of	O
129	O
/	O
Ola	O
and	O
C57BL	O
/	O
6	O
strains	O
.	O

F1	O
hybrid	O
mice	S-Species
were	O
mated	O
with	O
C57BL	O
/	O
6	O
mice	S-Species
for	O
six	O
generations	O
at	O
the	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
(	O
Tsukuba	O
,	O
Japan	O
)	O
.	O

At	O
10	O
weeks	O
of	O
age	O
,	O
single	O
male	O
and	O
female	O
mice	S-Species
were	O
allowed	O
to	O
cohabit	O
;	O
every	O
female	O
mouse	S-Species
was	O
checked	O
each	O
morning	O
for	O
the	O
presence	O
of	O
a	O
vaginal	O
plug	O
.	O

When	O
a	O
plug	O
was	O
confirmed	O
,	O
the	O
day	O
was	O
designated	O
as	O
day	O
0	O
of	O
gestation	O
(	O
GD0	O
)	O
.	O

The	O
diet	O
,	O
NIH	O
-	O
07PLD	O
formula	O
(	O
CLEA	O
Japan	O
,	O
Inc	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
contained	O
vitamins	O
and	O
trace	O
elements	O
as	O
follows	O
(	O
per	O
kilogram	O
diet	O
)	O
:	O
3	O
.	O
2	O
mg	O
CuSO4	O
,	O
88	O
mg	O
FeSO4	O
,	O
149	O
mg	O
MnSO4	O
,	O
25	O
mg	O
ZnCO3	O
,	O
1	O
.	O
6	O
mg	O
Ca	O
(	O
IO3	O
)	O
2	O
,	O
11	O
mg	O
vitamin	O
B1	O
,	O
4	O
.	O
7	O
mg	O
vitamin	O
B2	O
,	O
1	O
.	O
9	O
mg	O
vitamin	O
B6	O
,	O
44	O
mg	O
vitamin	O
E	O
,	O
in	O
addition	O
to	O
5	O
mu	O
g	O
MeHg	O
/	O
g	O
.	O

This	O
diet	O
was	O
fed	O
to	O
the	O
pregnant	O
mice	S-Species
starting	O
from	O
GD0	O
through	O
10	O
days	O
after	O
delivery	O
(	O
i	O
.	O
e	O
.	O
,	O
PND10	O
)	O
.	O

Thereafter	O
,	O
we	O
switched	O
mice	S-Species
to	O
a	O
diet	O
that	O
did	O
not	O
contain	O
MeHg	O
.	O

We	O
chose	O
GD0	O
as	O
the	O
beginning	O
of	O
exposure	O
because	O
exposures	O
that	O
started	O
before	O
conception	O
often	O
resulted	O
in	O
fairly	O
high	O
Hg	O
concentrations	O
in	O
fetal	O
/	O
neonatal	O
brains	O
(	O
Kakita	O
et	O
al	O
.	O
2003	O
)	O
,	O
and	O
we	O
chose	O
PND10	O
to	O
cover	O
the	O
early	O
neonatal	O
period	O
,	O
in	O
which	O
considerable	O
brain	O
growth	O
occurs	O
.	O

In	O
our	O
experimental	O
setting	O
,	O
the	O
neonatal	O
mice	S-Species
started	O
to	O
eat	O
from	O
the	O
diet	O
bucket	O
and	O
drink	O
from	O
the	O
water	O
bottle	O
from	O
PND10	O
onward	O
.	O

Control	O
mice	S-Species
were	O
kept	O
on	O
the	O
same	O
diet	O
but	O
without	O
MeHg	O
(	O
<	O
0	O
.	O
01	O
mu	O
g	O
Hg	O
/	O
g	O
)	O
.	O

On	O
PND1	O
,	O
to	O
avoid	O
the	O
confounding	O
effects	O
due	O
to	O
different	O
litter	O
size	O
,	O
we	O
reduced	O
each	O
litter	O
to	O
six	O
pups	O
(	O
three	O
males	O
and	O
three	O
females	O
when	O
possible	O
)	O
,	O
and	O
on	O
PND10	O
,	O
two	O
males	O
and	O
two	O
females	O
from	O
each	O
litter	O
were	O
killed	O
for	O
chemical	O
analyses	O
.	O

The	O
remaining	O
male	O
and	O
female	O
offspring	O
per	O
litter	O
were	O
weaned	O
on	O
PND28	O
and	O
used	O
for	O
subsequent	O
behavioral	O
analyses	O
(	O
either	O
at	O
12	O
-	O
13	O
weeks	O
or	O
52	O
-	O
53	O
weeks	O
,	O
depending	O
on	O
the	O
litter	O
)	O
as	O
described	O
below	O
.	O

We	O
measured	O
body	O
weights	O
of	O
the	O
weaned	O
mice	S-Species
every	O
2	O
weeks	O
.	O

Thus	O
,	O
four	O
experimental	O
groups	O
were	O
used	O
(	O
with	O
or	O
without	O
MeHg	O
exposure	O
for	O
two	O
strains	O
)	O
,	O
and	O
each	O
group	O
consisted	O
of	O
12	O
-	O
13	O
litters	O
.	O

For	O
half	O
of	O
the	O
litters	O
,	O
the	O
behavioral	O
analyses	O
were	O
conducted	O
at	O
12	O
-	O
13	O
weeks	O
of	O
age	O
,	O
and	O
upon	O
completion	O
of	O
the	O
behavioral	O
analyses	O
,	O
the	O
animals	O
were	O
killed	O
under	O
ether	O
anesthesia	O
.	O

We	O
then	O
dissected	O
the	O
organs	O
(	O
brain	O
,	O
liver	O
,	O
and	O
kidneys	O
)	O
for	O
Hg	O
analyses	O
.	O

For	O
the	O
remaining	O
half	O
of	O
the	O
litters	O
,	O
we	O
conducted	O
the	O
behavioral	O
tests	O
at	O
52	O
-	O
53	O
weeks	O
of	O
age	O
.	O

The	O
mice	S-Species
were	O
treated	O
humanely	O
and	O
with	O
regard	O
to	O
alleviation	O
of	O
suffering	O
according	O
to	O
the	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
'	O
Guidelines	O
for	O
Animal	O
Welfare	O
and	O
the	O
guidelines	O
of	O
St	O
.	O

Marianna	O
University	O
.	O

Behavioral	O
evaluations	O

The	O
details	O
of	O
each	O
behavioral	O
procedure	O
have	O
been	O
described	O
elsewhere	O
(	O
Yoshida	O
et	O
al	O
.	O
2006	O
)	O
.	O

Brief	O
descriptions	O
follow	O
.	O

For	O
the	O
OPF	O
test	O
,	O
we	O
used	O
an	O
OPF	O
apparatus	O
(	O
Ohara	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
with	O
a	O
60	O
x	O
60	O
-	O
cm	O
floor	O
surrounded	O
by	O
walls	O
60	O
cm	O
high	O
.	O

The	O
experimental	O
room	O
light	O
was	O
turned	O
off	O
,	O
and	O
a	O
dim	O
light	O
of	O
80	O
lux	O
was	O
lit	O
during	O
the	O
experiment	O
.	O

We	O
placed	O
a	O
mouse	S-Species
in	O
the	O
center	O
of	O
the	O
floor	O
and	O
monitored	O
its	O
behavior	O
for	O
10	O
min	O
using	O
a	O
CCD	O
camera	O
connected	O
to	O
a	O
computer	O
.	O

The	O
position	O
of	O
the	O
center	O
of	O
gravity	O
was	O
calculated	O
by	O
image	O
-	O
analyzing	O
software	O
,	O
which	O
was	O
used	O
to	O
calculate	O
the	O
total	O
distance	O
traveled	O
by	O
the	O
mouse	S-Species
as	O
well	O
as	O
the	O
positional	O
preference	O
(	O
either	O
center	O
or	O
peripheral	O
,	O
where	O
peripheral	O
was	O
defined	O
as	O
the	O
area	O
within	O
10	O
cm	O
from	O
the	O
wall	O
)	O
.	O

We	O
cleaned	O
the	O
OPF	O
apparatus	O
with	O
70	O
%	O
ethanol	O
between	O
trials	O
.	O

The	O
apparatus	O
for	O
the	O
PA	O
test	O
(	O
Ohara	O
Co	O
.	O
Ltd	O
.	O
)	O
consisted	O
of	O
a	O
light	O
compartment	O
that	O
illuminated	O
by	O
a	O
400	O
-	O
lux	O
light	O
and	O
a	O
dark	O
compartment	O
with	O
black	O
opaque	O
walls	O
and	O
lids	O
.	O

The	O
two	O
compartments	O
were	O
separated	O
by	O
a	O
mobile	O
guillotine	O
door	O
.	O

On	O
the	O
first	O
day	O
(	O
training	O
trial	O
)	O
,	O
we	O
placed	O
each	O
mouse	S-Species
in	O
the	O
light	O
compartment	O
facing	O
away	O
from	O
the	O
guillotine	O
door	O
,	O
which	O
was	O
closed	O
.	O

After	O
30	O
sec	O
of	O
introduction	O
,	O
the	O
door	O
was	O
opened	O
;	O
when	O
the	O
mouse	S-Species
entered	O
the	O
dark	O
compartment	O
,	O
a	O
brief	O
electric	O
shock	O
(	O
4	O
mA	O
for	O
2	O
sec	O
)	O
was	O
delivered	O
through	O
the	O
metal	O
grid	O
floor	O
.	O

This	O
would	O
force	O
the	O
mouse	S-Species
back	O
to	O
the	O
light	O
component	O
.	O

The	O
interval	O
between	O
the	O
opening	O
of	O
the	O
door	O
and	O
the	O
entry	O
to	O
the	O
dark	O
room	O
(	O
in	O
seconds	O
)	O
was	O
recorded	O
and	O
defined	O
as	O
the	O
latency	O
.	O

On	O
the	O
next	O
day	O
,	O
the	O
same	O
procedure	O
was	O
repeated	O
,	O
but	O
without	O
the	O
electric	O
shock	O
(	O
retaining	O
trail	O
)	O
.	O

In	O
this	O
PA	O
paradigm	O
,	O
aversive	O
learning	O
was	O
assumed	O
to	O
be	O
established	O
in	O
the	O
training	O
trial	O
,	O
and	O
we	O
used	O
its	O
retention	O
in	O
the	O
retaining	O
trail	O
as	O
the	O
index	O
of	O
learning	O
.	O

Between	O
each	O
individual	O
trial	O
,	O
we	O
cleaned	O
the	O
apparatus	O
with	O
ethanol	O
.	O

The	O
cutoff	O
time	O
of	O
the	O
retention	O
session	O
was	O
300	O
sec	O
.	O

The	O
MM	O
test	O
apparatus	O
(	O
Ohara	O
Co	O
.	O
,	O
Ltd	O
.	O
)	O
was	O
a	O
round	O
-	O
shaped	O
water	O
pool	O
with	O
a	O
diameter	O
of	O
120	O
cm	O
.	O

A	O
small	O
platform	O
was	O
submerged	O
in	O
the	O
water	O
,	O
which	O
provided	O
a	O
place	O
for	O
mice	S-Species
to	O
escape	O
from	O
the	O
water	O
(	O
i	O
.	O
e	O
.	O
,	O
an	O
aversive	O
stimulus	O
,	O
water	O
temperature	O
=	O
23	O
+/-	O
1	O
degrees	O
C	O
)	O
.	O

The	O
water	O
was	O
made	O
opaque	O
by	O
adding	O
white	O
paint	O
so	O
that	O
the	O
mouse	S-Species
could	O
not	O
see	O
the	O
submerged	O
platform	O
.	O

In	O
each	O
trial	O
,	O
we	O
released	O
a	O
mouse	S-Species
into	O
the	O
pool	O
from	O
a	O
determined	O
position	O
along	O
the	O
wall	O
,	O
and	O
the	O
performance	O
of	O
the	O
mouse	S-Species
was	O
monitored	O
by	O
a	O
CCD	O
camera	O
/	O
image	O
analyzer	O
.	O

The	O
time	O
required	O
to	O
reach	O
the	O
platform	O
was	O
recorded	O
.	O

If	O
a	O
mouse	S-Species
could	O
not	O
find	O
the	O
platform	O
within	O
60	O
sec	O
after	O
release	O
,	O
it	O
was	O
led	O
to	O
the	O
platform	O
and	O
placed	O
on	O
it	O
for	O
20	O
sec	O
before	O
being	O
removed	O
.	O

In	O
these	O
cases	O
,	O
a	O
latency	O
of	O
60	O
sec	O
was	O
recorded	O
.	O

We	O
conducted	O
the	O
trial	O
once	O
a	O
day	O
up	O
to	O
the	O
fifth	O
day	O
for	O
each	O
mouse	S-Species
,	O
and	O
the	O
order	O
of	O
each	O
mouse	S-Species
was	O
counterbalanced	O
across	O
the	O
day	O
.	O

On	O
the	O
sixth	O
day	O
,	O
a	O
transfer	O
test	O
(	O
or	O
probe	O
test	O
)	O
,	O
which	O
is	O
a	O
trial	O
without	O
the	O
platform	O
,	O
was	O
conducted	O
;	O
in	O
this	O
procedure	O
,	O
we	O
counted	O
the	O
number	O
of	O
times	O
that	O
the	O
mouse	S-Species
crossed	O
the	O
position	O
where	O
the	O
platform	O
had	O
been	O
.	O

Tissue	O
Hg	O
concentration	O

The	O
tissue	O
samples	O
were	O
homogenized	O
(	O
10	O
%	O
weight	O
/	O
volume	O
)	O
in	O
distilled	O
water	O
using	O
a	O
Polytron	O
homogenizer	O
(	O
Kinematica	O
GmbH	O
,	O
Littau	O
,	O
Switzerland	O
)	O
.	O

We	O
determined	O
Hg	O
levels	O
in	O
the	O
homogenates	O
by	O
the	O
oxygen	O
combustion	O
-	O
gold	O
amalgamation	O
method	O
(	O
Ohkawa	O
et	O
al	O
.	O
1977	O
)	O
using	O
an	O
atomic	O
absorption	O
Hg	O
detector	O
MD	O
-	O
1	O
(	O
Nippon	O
Instruments	O
,	O
Co	O
.	O
Ltd	O
.	O
,	O
Osaka	O
,	O
Japan	O
)	O
.	O

To	O
ensure	O
the	O
accuracy	O
of	O
the	O
measurement	O
,	O
we	O
included	O
reference	O
material	O
from	O
a	O
dogfish	O
(	O
DORM	O
-	O
2	O
;	O
National	O
Research	O
Council	O
of	O
Canada	O
,	O
Ottawa	O
,	O
Ontario	O
,	O
Canada	O
)	O
with	O
a	O
certified	O
value	O
of	O
4	O
.	O
64	O
+/-	O
0	O
.	O
26	O
mu	O
g	O
/	O
g	O
in	O
the	O
analyses	O
;	O
the	O
observed	O
values	O
fell	O
within	O
the	O
certified	O
range	O
.	O

The	O
detection	O
limit	O
of	O
the	O
measurement	O
was	O
0	O
.	O
1	O
ng	O
Hg	O
.	O

Statistics	O

We	O
analyzed	O
behavioral	O
data	O
for	O
OPF	O
and	O
PA	O
by	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
taking	O
sex	O
,	O
strain	O
,	O
and	O
MeHg	O
exposure	O
as	O
the	O
factors	O
.	O

All	O
the	O
interactions	O
among	O
these	O
factors	O
were	O
put	O
into	O
the	O
model	O
.	O

When	O
any	O
of	O
the	O
interactions	O
was	O
highly	O
significant	O
,	O
we	O
analyzed	O
the	O
data	O
separately	O
in	O
an	O
appropriate	O
way	O
;	O
for	O
example	O
,	O
if	O
sex	O
x	O
Hg	O
was	O
significant	O
,	O
the	O
data	O
for	O
males	O
and	O
females	O
were	O
separately	O
analyzed	O
for	O
the	O
effects	O
of	O
strain	O
and	O
Hg	O
.	O

Whenever	O
appropriate	O
,	O
ANOVAs	O
were	O
followed	O
by	O
Mann	O
-	O
Whitney	O
U	O
or	O
Student	O
'	O
s	O
t	O
-	O
tests	O
,	O
depending	O
on	O
the	O
nature	O
and	O
distribution	O
of	O
the	O
variables	O
.	O

We	O
analyzed	O
data	O
for	O
the	O
MM	O
by	O
repeated	O
-	O
measures	O
ANOVA	O
,	O
taking	O
the	O
exposure	O
as	O
between	O
-	O
group	O
and	O
trials	O
as	O
within	O
-	O
group	O
variables	O
.	O

The	O
test	O
was	O
performed	O
for	O
each	O
of	O
the	O
four	O
sex	O
and	O
strain	O
combinations	O
separately	O
.	O

The	O
significance	O
level	O
was	O
set	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Results	O

Body	O
weight	O

Up	O
to	O
20	O
weeks	O
of	O
age	O
,	O
the	O
body	O
weight	O
values	O
of	O
the	O
control	O
and	O
MeHg	O
-	O
exposed	O
groups	O
were	O
not	O
different	O
,	O
regardless	O
of	O
strain	O
or	O
sex	O
.	O

After	O
28	O
weeks	O
,	O
except	O
for	O
the	O
wild	O
-	O
type	O
female	O
groups	O
,	O
the	O
MeHg	O
-	O
exposed	O
groups	O
weighed	O
significantly	O
less	O
than	O
the	O
controls	O
(	O
Figure	O
1	O
)	O
.	O

OPF	O

At	O
12	O
weeks	O
of	O
age	O
,	O
a	O
three	O
-	O
way	O
ANOVA	O
of	O
the	O
locomotion	O
distance	O
revealed	O
that	O
only	O
strain	O
was	O
a	O
significant	O
factor	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
reflecting	O
the	O
longer	O
distance	O
traveled	O
by	O
the	O
MT	O
-	O
null	O
mice	S-Species
(	O
Figure	O
2A	O
)	O
.	O

Strain	O
was	O
also	O
a	O
significant	O
factor	O
for	O
the	O
proportion	O
of	O
the	O
central	O
-	O
area	O
locomotion	O
(	O
Figure	O
3A	O
)	O
,	O
and	O
Hg	O
exposure	O
marginally	O
affected	O
this	O
outcome	O
.	O

In	O
MT	O
-	O
null	O
females	O
,	O
the	O
proportion	O
of	O
central	O
-	O
area	O
locomotion	O
was	O
higher	O
in	O
MeHg	O
-	O
exposed	O
mice	S-Species
than	O
in	O
the	O
controls	O
;	O
this	O
difference	O
was	O
not	O
observed	O
in	O
any	O
other	O
strain	O
-	O
sex	O
combination	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
the	O
strain	O
x	O
Hg	O
interaction	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
an	O
ANOVA	O
of	O
locomotion	O
distance	O
(	O
Figure	O
2B	O
)	O
;	O
MeHg	O
exposure	O
was	O
associated	O
with	O
decreased	O
locomotion	O
distance	O
in	O
wild	O
-	O
type	O
mice	S-Species
and	O
with	O
increased	O
distance	O
in	O
MT	O
-	O
null	O
mice	S-Species
.	O

A	O
strain	O
-	O
wise	O
two	O
-	O
way	O
ANOVA	O
(	O
with	O
sex	O
and	O
Hg	O
as	O
the	O
factors	O
)	O
revealed	O
that	O
only	O
Hg	O
was	O
significant	O
in	O
both	O
strains	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Regarding	O
the	O
proportion	O
of	O
the	O
central	O
-	O
area	O
locomotion	O
,	O
the	O
effects	O
of	O
MeHg	O
appeared	O
to	O
depend	O
on	O
sex	O
[	O
i	O
.	O
e	O
.	O
,	O
sex	O
x	O
Hg	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
three	O
-	O
way	O
ANOVA	O
;	O
Figure	O
3B	O
]	O
.	O

Indeed	O
,	O
a	O
sex	O
-	O
wise	O
two	O
-	O
way	O
ANOVA	O
showed	O
significant	O
effects	O
of	O
Hg	O
only	O
in	O
females	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

PA	O

At	O
12	O
weeks	O
of	O
age	O
,	O
all	O
the	O
groups	O
showed	O
prolonged	O
latency	O
in	O
the	O
second	O
(	O
retention	O
)	O
trial	O
,	O
and	O
no	O
consistent	O
effect	O
of	O
MeHg	O
was	O
recognized	O
regardless	O
of	O
strain	O
or	O
sex	O
(	O
Figure	O
4A	O
)	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
a	O
three	O
-	O
way	O
ANOVA	O
revealed	O
a	O
significant	O
interaction	O
between	O
strain	O
and	O
Hg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
;	O
strain	O
-	O
wise	O
two	O
-	O
way	O
ANOVAs	O
revealed	O
a	O
significant	O
effect	O
of	O
Hg	O
on	O
learning	O
in	O
MT	O
-	O
null	O
mice	S-Species
of	O
both	O
sexes	O
;	O
these	O
groups	O
of	O
mice	S-Species
showed	O
significantly	O
shorter	O
(	O
less	O
than	O
half	O
)	O
latency	O
times	O
compared	O
to	O
control	O
mice	S-Species
(	O
Figure	O
4B	O
)	O
.	O

A	O
notable	O
difference	O
between	O
the	O
results	O
at	O
52	O
weeks	O
of	O
age	O
and	O
those	O
at	O
12	O
weeks	O
was	O
that	O
many	O
of	O
the	O
tested	O
mice	S-Species
exceeded	O
the	O
cutoff	O
time	O
in	O
the	O
retention	O
trials	O
at	O
52	O
weeks	O
,	O
except	O
for	O
the	O
MT	O
-	O
null	O
groups	O
.	O

MM	O

At	O
13	O
weeks	O
of	O
age	O
,	O
repeated	O
-	O
measures	O
ANOVA	O
did	O
not	O
indicate	O
any	O
effects	O
of	O
MeHg	O
(	O
Figure	O
5A	O
)	O
.	O

At	O
52	O
weeks	O
of	O
age	O
(	O
Figure	O
5B	O
)	O
,	O
wild	O
-	O
type	O
males	O
and	O
MT	O
-	O
null	O
females	O
shared	O
the	O
same	O
statistical	O
results	O
;	O
Hg	O
as	O
well	O
as	O
the	O
Hg	O
x	O
trial	O
interaction	O
were	O
statistically	O
significant	O
.	O

Thus	O
,	O
in	O
both	O
cases	O
,	O
the	O
MeHg	O
groups	O
showed	O
a	O
longer	O
latency	O
,	O
hampering	O
learning	O
performance	O
.	O

Tissue	O
Hg	O
concentration	O

At	O
PND10	O
,	O
which	O
was	O
immediately	O
after	O
the	O
exposure	O
,	O
brain	O
Hg	O
concentrations	O
of	O
the	O
neonatal	O
mice	S-Species
were	O
approximately	O
<=	O
0	O
.	O
5	O
mu	O
g	O
/	O
g	O
(	O
Table	O
1	O
)	O
.	O

Although	O
the	O
MT	O
-	O
null	O
mice	S-Species
and	O
females	O
showed	O
slightly	O
higher	O
brain	O
Hg	O
concentrations	O
than	O
the	O
corresponding	O
wild	O
-	O
type	O
group	O
and	O
males	O
,	O
respectively	O
,	O
neither	O
of	O
these	O
differences	O
was	O
significant	O
.	O

At	O
13	O
weeks	O
,	O
when	O
the	O
behavioral	O
tests	O
were	O
completed	O
,	O
the	O
brain	O
Hg	O
concentration	O
was	O
comparable	O
to	O
the	O
control	O
(	O
nonexposed	O
)	O
level	O
(	O
approximately	O
5	O
ng	O
/	O
g	O
in	O
both	O
the	O
exposed	O
and	O
control	O
brains	O
)	O
.	O

Interestingly	O
,	O
MT	O
-	O
null	O
mice	S-Species
had	O
a	O
significantly	O
lower	O
brain	O
Hg	O
concentration	O
than	O
the	O
corresponding	O
wild	O
-	O
type	O
groups	O
.	O

Discussion	O

Results	O
of	O
the	O
present	O
study	O
demonstrate	O
the	O
delayed	O
emergence	O
of	O
neurobehavioral	O
toxicity	O
due	O
to	O
perinatal	O
MeHg	O
exposure	O
,	O
which	O
presumably	O
developed	O
after	O
brain	O
MeHg	O
concentrations	O
had	O
leveled	O
off	O
.	O

This	O
emergent	O
toxicity	O
was	O
exaggerated	O
in	O
MT	O
-	O
null	O
mice	S-Species
and	O
was	O
more	O
distinct	O
in	O
females	O
.	O

To	O
our	O
knowledge	O
,	O
our	O
findings	O
show	O
the	O
first	O
clear	O
-	O
cut	O
demonstrations	O
of	O
a	O
long	O
latency	O
period	O
of	O
MeHg	O
neurobehavioral	O
toxicity	O
in	O
rodents	O
and	O
possible	O
genetic	O
susceptibility	O
for	O
the	O
emergent	O
toxicity	O
.	O

The	O
exposure	O
level	O
should	O
be	O
considered	O
before	O
discussing	O
the	O
end	O
points	O
.	O

On	O
PND10	O
,	O
immediately	O
after	O
the	O
cessation	O
of	O
MeHg	O
exposure	O
,	O
the	O
brain	O
Hg	O
concentration	O
was	O
approximately	O
0	O
.	O
5	O
mu	O
g	O
/	O
g	O
,	O
regardless	O
of	O
the	O
strain	O
or	O
sex	O
.	O

In	O
a	O
previous	O
study	O
,	O
the	O
brain	O
Hg	O
concentration	O
in	O
mice	S-Species
perinatally	O
exposed	O
to	O
6	O
mg	O
MeHg	O
/	O
L	O
(	O
via	O
water	O
)	O
peaked	O
between	O
PND0	O
and	O
PND4	O
and	O
was	O
approximately	O
three	O
times	O
higher	O
than	O
on	O
PND21	O
(	O
Goulet	O
et	O
al	O
.	O
2003	O
)	O
.	O

Therefore	O
,	O
the	O
peak	O
brain	O
Hg	O
concentration	O
,	O
which	O
is	O
presumably	O
observed	O
around	O
birth	O
,	O
can	O
be	O
estimated	O
as	O
about	O
3	O
-	O
fold	O
higher	O
than	O
that	O
on	O
PND10	O
and	O
would	O
be	O
approximately	O
1	O
.	O
5	O
mu	O
g	O
/	O
g	O
(	O
0	O
.	O
5	O
mu	O
g	O
/	O
g	O
x	O
3	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
lowest	O
levels	O
among	O
recent	O
rodent	O
studies	O
.	O

As	O
shown	O
by	O
Sakamoto	O
et	O
al	O
.	O

(	O
2002	O
)	O
in	O
their	O
Figure	O
2	O
,	O
prenatal	O
exposure	O
of	O
rats	S-Species
to	O
MeHg	O
showed	O
a	O
peak	O
brain	O
Hg	O
concentration	O
around	O
PND1	O
that	O
was	O
four	O
to	O
five	O
times	O
greater	O
than	O
the	O
level	O
on	O
PND10	O
.	O

Also	O
,	O
Newland	O
and	O
Rasmussen	O
(	O
2000	O
)	O
reported	O
a	O
slight	O
alteration	O
of	O
a	O
complex	O
operant	O
behavior	O
in	O
rats	S-Species
at	O
ages	O
<	O
2	O
years	O
at	O
brain	O
Hg	O
concentrations	O
as	O
low	O
as	O
0	O
.	O
5	O
mu	O
g	O
/	O
g	O
at	O
birth	O
,	O
although	O
statistical	O
significance	O
of	O
this	O
particular	O
effect	O
was	O
not	O
clear	O
.	O

It	O
should	O
be	O
noted	O
that	O
rats	S-Species
have	O
different	O
Hg	O
kinetics	O
(	O
Hirayama	O
and	O
Yasutake	O
1986	O
;	O
Yasutake	O
and	O
Hirayama	O
1990	O
)	O
due	O
to	O
the	O
high	O
affinity	O
of	O
rat	O
hemoglobin	O
for	O
MeHg	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
)	O
.	O

The	O
most	O
important	O
observation	O
of	O
the	O
present	O
study	O
was	O
that	O
the	O
effects	O
of	O
low	O
-	O
level	O
MeHg	O
exposure	O
were	O
detected	O
only	O
at	O
later	O
stages	O
in	O
the	O
lives	O
of	O
the	O
mice	S-Species
.	O

Except	O
for	O
the	O
central	O
-	O
area	O
occupancy	O
in	O
OPF	O
in	O
MT	O
-	O
null	O
females	O
,	O
no	O
statistically	O
significant	O
effects	O
of	O
MeHg	O
were	O
observed	O
in	O
any	O
of	O
the	O
three	O
behavioral	O
tests	O
at	O
12	O
weeks	O
of	O
age	O
.	O

In	O
contrast	O
,	O
significant	O
effects	O
were	O
observed	O
in	O
all	O
three	O
tests	O
at	O
52	O
weeks	O
of	O
age	O
.	O

The	O
brain	O
Hg	O
concentration	O
of	O
the	O
exposed	O
groups	O
had	O
leveled	O
off	O
and	O
was	O
not	O
distinguishable	O
from	O
the	O
non	O
-	O
exposed	O
group	O
at	O
13	O
weeks	O
of	O
age	O
,	O
immediately	O
after	O
the	O
first	O
phase	O
of	O
the	O
behavioral	O
testing	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
latency	O
period	O
in	O
which	O
the	O
dose	O
and	O
effects	O
could	O
not	O
be	O
detected	O
,	O
although	O
effects	O
were	O
observed	O
9	O
months	O
later	O
.	O

Another	O
notable	O
observation	O
was	O
that	O
the	O
emergent	O
manifestation	O
of	O
toxicity	O
was	O
also	O
recognized	O
in	O
the	O
suppression	O
of	O
body	O
weight	O
(	O
except	O
for	O
wild	O
-	O
type	O
females	O
)	O
,	O
which	O
only	O
became	O
apparent	O
on	O
or	O
after	O
28	O
weeks	O
of	O
age	O
.	O

The	O
existence	O
of	O
a	O
latency	O
period	O
of	O
as	O
long	O
as	O
several	O
years	O
after	O
chronic	O
(	O
7	O
years	O
from	O
birth	O
)	O
,	O
low	O
-	O
level	O
exposure	O
to	O
MeHg	O
has	O
been	O
described	O
in	O
nonhuman	O
primates	O
(	O
Rice	O
1996	O
)	O
.	O

In	O
that	O
case	O
,	O
however	O
,	O
the	O
Hg	O
concentration	O
in	O
the	O
brain	O
remained	O
elevated	O
,	O
presumably	O
as	O
a	O
result	O
of	O
the	O
long	O
exposure	O
.	O

Indeed	O
,	O
Rice	O
(	O
1996	O
)	O
argued	O
that	O
the	O
minute	O
amount	O
of	O
residual	O
brain	O
Hg	O
could	O
have	O
caused	O
the	O
delayed	O
toxicity	O
.	O

This	O
was	O
clearly	O
not	O
the	O
case	O
in	O
the	O
present	O
study	O
because	O
the	O
Hg	O
concentration	O
leveled	O
off	O
around	O
the	O
time	O
of	O
the	O
first	O
phase	O
of	O
the	O
behavioral	O
study	O
.	O

The	O
absence	O
of	O
behavioral	O
effects	O
at	O
12	O
weeks	O
of	O
age	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
residual	O
behavioral	O
effects	O
were	O
due	O
to	O
elevated	O
Hg	O
early	O
in	O
life	O
.	O

Therefore	O
,	O
the	O
behavioral	O
toxicity	O
that	O
surfaced	O
at	O
52	O
weeks	O
of	O
age	O
must	O
have	O
had	O
its	O
origin	O
before	O
the	O
brain	O
Hg	O
concentration	O
leveled	O
off	O
(	O
at	O
or	O
before	O
13	O
weeks	O
of	O
age	O
)	O
,	O
although	O
the	O
redistribution	O
of	O
Hg	O
to	O
the	O
brain	O
from	O
other	O
sites	O
of	O
deposition	O
,	O
such	O
as	O
the	O
liver	O
,	O
cannot	O
be	O
completely	O
excluded	O
.	O

The	O
long	O
silent	O
period	O
before	O
the	O
manifestations	O
of	O
toxicity	O
emerged	O
suggests	O
that	O
a	O
slow	O
process	O
plays	O
a	O
role	O
in	O
this	O
latent	O
toxicity	O
.	O

Although	O
an	O
example	O
of	O
a	O
slow	O
process	O
is	O
aging	O
,	O
52	O
weeks	O
of	O
age	O
might	O
not	O
be	O
sufficiently	O
old	O
for	O
a	O
mouse	S-Species
to	O
be	O
considered	O
aged	O
in	O
the	O
physiologic	O
sense	O
because	O
C57BL	O
/	O
6	O
mice	S-Species
have	O
a	O
relatively	O
long	O
life	O
span	O
among	O
mouse	S-Species
strains	O
[	O
median	O
survival	O
of	O
27	O
-	O
31	O
months	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
]	O
and	O
a	O
survival	O
rate	O
at	O
18	O
-	O
19	O
months	O
as	O
high	O
as	O
90	O
%	O
(	O
Institute	O
on	O
Aging	O
HP	O
)	O
(	O
National	O
Institute	O
on	O
Aging	O
2008	O
)	O
.	O

Nevertheless	O
,	O
various	O
behavioral	O
examinations	O
have	O
shown	O
age	O
-	O
related	O
changes	O
in	O
the	O
performance	O
of	O
mice	S-Species
at	O
approximately	O
1	O
year	O
of	O
age	O
in	O
the	O
OPF	O
(	O
Acevedoa	O
et	O
al	O
.	O
2006	O
;	O
Carrie	O
et	O
al	O
.	O
1999	O
)	O
,	O
MM	O
(	O
Bach	O
et	O
al	O
.	O
1999	O
;	O
Carrie	O
et	O
al	O
.	O
1999	O
)	O
,	O
and	O
PA	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
tests	O
.	O

The	O
observed	O
effects	O
of	O
MeHg	O
,	O
including	O
the	O
deterioration	O
in	O
the	O
PA	O
and	O
MM	O
and	O
suppression	O
in	O
the	O
OPF	O
(	O
in	O
wild	O
-	O
type	O
mice	S-Species
)	O
,	O
were	O
consistent	O
with	O
these	O
reported	O
effects	O
of	O
aging	O
on	O
behavioral	O
function	O
(	O
in	O
the	O
sense	O
described	O
above	O
)	O
,	O
except	O
for	O
the	O
increased	O
OPF	O
activity	O
in	O
the	O
MT	O
-	O
null	O
mice	S-Species
.	O

Regardless	O
of	O
its	O
neural	O
basis	O
,	O
the	O
basis	O
of	O
neurobehavioral	O
toxicity	O
should	O
be	O
sought	O
in	O
early	O
life	O
stages	O
when	O
the	O
brain	O
Hg	O
concentration	O
is	O
highly	O
elevated	O
(	O
approximately	O
1	O
.	O
5	O
mu	O
g	O
/	O
g	O
at	O
its	O
peak	O
)	O
.	O

Some	O
in	O
vivo	O
experiments	O
have	O
demonstrated	O
several	O
candidate	O
mechanisms	O
of	O
perinatal	O
exposure	O
to	O
MeHg	O
,	O
including	O
abnormal	O
migration	O
of	O
neurons	O
and	O
/	O
or	O
glias	O
(	O
Kakita	O
et	O
al	O
.	O
2003	O
;	O
Rodier	O
et	O
al	O
.	O
1984	O
)	O
,	O
but	O
at	O
higher	O
Hg	O
concentrations	O
.	O

Using	O
exactly	O
the	O
same	O
exposure	O
protocol	O
as	O
the	O
present	O
study	O
,	O
we	O
found	O
suppressed	O
activity	O
of	O
type	O
III	O
iodo	O
-	O
thyronine	O
deiodinase	O
,	O
a	O
thyroid	O
hormone	O
-	O
metabolizing	O
enzyme	O
,	O
in	O
the	O
brains	O
of	O
PND10	O
mouse	S-Species
neonates	O
(	O
Mori	O
et	O
al	O
.	O
2006	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
study	O
of	O
higher	O
MeHg	O
doses	O
(	O
Watanabe	O
et	O
al	O
.	O
1999	O
)	O
.	O

This	O
perturbation	O
could	O
be	O
one	O
of	O
the	O
candidate	O
mechanisms	O
responsible	O
for	O
the	O
later	O
anomalous	O
behaviors	O
because	O
even	O
a	O
transient	O
change	O
in	O
thyroid	O
hormones	O
during	O
the	O
critical	O
period	O
of	O
perinatal	O
life	O
exerts	O
long	O
-	O
term	O
consequences	O
(	O
Auso	O
et	O
al	O
.	O
2004	O
)	O
.	O

The	O
effects	O
of	O
MeHg	O
at	O
52	O
weeks	O
of	O
age	O
were	O
influenced	O
by	O
two	O
potential	O
modifying	O
factors	O
,	O
sex	O
and	O
strain	O
.	O

In	O
the	O
OPF	O
,	O
while	O
the	O
locomotion	O
was	O
affected	O
in	O
both	O
strains	O
(	O
although	O
the	O
direction	O
was	O
opposite	O
)	O
,	O
center	O
occupancy	O
was	O
significantly	O
increased	O
only	O
in	O
the	O
MT	O
-	O
null	O
mice	S-Species
.	O

In	O
addition	O
,	O
the	O
effects	O
on	O
PA	O
were	O
significant	O
only	O
in	O
MT	O
-	O
null	O
mice	S-Species
,	O
whereas	O
MeHg	O
at	O
a	O
higher	O
dose	O
was	O
reported	O
to	O
worsen	O
PA	O
performance	O
in	O
rats	S-Species
(	O
6	O
-	O
8	O
weeks	O
of	O
age	O
;	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
.	O

In	O
addition	O
,	O
body	O
weight	O
gain	O
was	O
suppressed	O
in	O
both	O
male	O
and	O
female	O
MT	O
-	O
null	O
mice	S-Species
,	O
whereas	O
in	O
wild	O
-	O
type	O
mice	S-Species
the	O
suppression	O
was	O
observed	O
only	O
in	O
males	O
.	O

Taken	O
together	O
,	O
the	O
MT	O
-	O
null	O
strain	O
appeared	O
to	O
be	O
slightly	O
more	O
susceptible	O
to	O
the	O
late	O
-	O
emergent	O
effects	O
of	O
MeHg	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
shown	O
that	O
MT	O
-	O
I	O
,	O
II	O
is	O
protective	O
against	O
the	O
toxicity	O
of	O
MeHg	O
(	O
Leiva	O
-	O
Presa	O
et	O
al	O
.	O
2004	O
;	O
Yao	O
et	O
al	O
.	O
2000	O
)	O
,	O
and	O
the	O
present	O
results	O
were	O
basically	O
consistent	O
with	O
these	O
reports	O
.	O

We	O
have	O
also	O
reported	O
the	O
susceptibility	O
of	O
the	O
MT	O
-	O
null	O
strain	O
to	O
the	O
neurotoxic	O
effects	O
of	O
metallic	O
Hg	O
(	O
Yoshida	O
et	O
al	O
.	O
2004	O
,	O
2006	O
)	O
.	O

The	O
difference	O
in	O
the	O
susceptibility	O
to	O
MeHg	O
between	O
sexes	O
is	O
still	O
debated	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
;	O
National	O
Research	O
Council	O
2000	O
;	O
Vahter	O
2007	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
some	O
responses	O
to	O
MeHg	O
were	O
different	O
between	O
the	O
sexes	O
,	O
including	O
OPF	O
performance	O
at	O
12	O
and	O
52	O
weeks	O
of	O
age	O
and	O
MM	O
performance	O
at	O
52	O
weeks	O
.	O

The	O
fact	O
that	O
the	O
MT	O
-	O
null	O
female	O
group	O
was	O
the	O
only	O
group	O
affected	O
by	O
MeHg	O
at	O
12	O
weeks	O
may	O
suggest	O
the	O
particular	O
susceptibility	O
of	O
females	O
in	O
this	O
strain	O
.	O

This	O
point	O
needs	O
to	O
be	O
clarified	O
in	O
further	O
experiments	O
.	O

The	O
question	O
remains	O
of	O
why	O
MT	O
-	O
null	O
mice	S-Species
are	O
susceptible	O
to	O
the	O
delayed	O
neurotoxicity	O
of	O
perinatal	O
MeHg	O
.	O

Apparently	O
kinetics	O
play	O
only	O
a	O
minor	O
role	O
because	O
the	O
strain	O
did	O
not	O
show	O
distinct	O
effects	O
on	O
the	O
brain	O
Hg	O
concentration	O
at	O
PND10	O
.	O

The	O
significantly	O
lower	O
brain	O
Hg	O
concentration	O
in	O
MT	O
-	O
null	O
mice	S-Species
compared	O
with	O
corresponding	O
wild	O
-	O
type	O
mice	S-Species
at	O
13	O
weeks	O
of	O
age	O
indicated	O
that	O
MT	O
-	O
I	O
,	O
II	O
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
retention	O
of	O
Hg	O
(	O
or	O
MeHg	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
results	O
of	O
studies	O
of	O
metallic	O
Hg	O
exposure	O
(	O
Yoshida	O
et	O
al	O
.	O
2004	O
,	O
2005	O
)	O
;	O
a	O
lower	O
brain	O
Hg	O
concentration	O
may	O
not	O
guarantee	O
lower	O
toxicity	O
,	O
supporting	O
the	O
protective	O
role	O
of	O
the	O
protein	O
.	O

Earlier	O
studies	O
suggest	O
that	O
brain	O
MT	O
-	O
I	O
,	O
II	O
has	O
an	O
important	O
role	O
both	O
in	O
the	O
response	O
to	O
oxidative	O
injury	O
(	O
Potter	O
et	O
al	O
.	O
2007	O
)	O
and	O
in	O
the	O
process	O
of	O
aging	O
(	O
Kojima	O
et	O
al	O
.	O
1999	O
)	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
MT	O
can	O
exaggerate	O
the	O
toxicity	O
of	O
MeHg	O
by	O
enhancing	O
the	O
initial	O
effects	O
due	O
to	O
oxygen	O
radicals	O
and	O
/	O
or	O
by	O
accelerating	O
functional	O
aging	O
.	O

Apart	O
from	O
this	O
,	O
an	O
intriguing	O
possibility	O
is	O
that	O
the	O
brain	O
-	O
specific	O
isoform	O
,	O
MT	O
-	O
III	O
,	O
might	O
contribute	O
to	O
the	O
results	O
we	O
obtained	O
because	O
the	O
expression	O
of	O
MT	O
-	O
III	O
,	O
together	O
with	O
MT	O
-	O
I	O
,	O
is	O
increased	O
in	O
the	O
brain	O
of	O
old	O
rats	S-Species
,	O
resulting	O
in	O
the	O
low	O
availability	O
of	O
free	O
zinc	O
for	O
synapses	O
(	O
Mocchegiani	O
et	O
al	O
.	O
2004	O
)	O
.	O

The	O
age	O
-	O
dependent	O
expressions	O
of	O
MT	O
isoforms	O
might	O
be	O
modified	O
in	O
MT	O
-	O
null	O
mice	S-Species
.	O

Results	O
of	O
the	O
present	O
study	O
might	O
allow	O
the	O
possibility	O
of	O
alternative	O
interpretations	O
due	O
to	O
some	O
potentially	O
confounding	O
factors	O
.	O

For	O
example	O
,	O
except	O
for	O
the	O
wild	O
-	O
type	O
females	O
,	O
we	O
observed	O
significant	O
differences	O
in	O
body	O
weight	O
between	O
MeHg	O
-	O
exposed	O
and	O
non	O
-	O
exposed	O
groups	O
.	O

Because	O
these	O
differences	O
only	O
became	O
clear	O
later	O
in	O
life	O
,	O
they	O
might	O
be	O
associated	O
with	O
the	O
toxicity	O
that	O
also	O
emerged	O
later	O
in	O
life	O
.	O

Manipulation	O
of	O
body	O
weight	O
in	O
rodents	O
alters	O
activity	O
levels	O
,	O
although	O
the	O
reported	O
results	O
are	O
not	O
always	O
consistent	O
with	O
each	O
other	O
(	O
Harrison	O
and	O
Archer	O
1987	O
;	O
Samuelsson	O
et	O
al	O
.	O
2008	O
)	O
.	O

Also	O
,	O
the	O
differential	O
performance	O
in	O
PA	O
could	O
be	O
related	O
with	O
the	O
potential	O
effects	O
of	O
MeHg	O
on	O
(	O
electric	O
)	O
shock	O
sensitivity	O
,	O
which	O
we	O
did	O
not	O
examine	O
.	O

At	O
least	O
one	O
high	O
-	O
dose	O
study	O
with	O
adult	O
rats	S-Species
showed	O
reduced	O
electric	O
sensitivity	O
due	O
to	O
mercury	O
exposure	O
(	O
Wu	O
et	O
al	O
.	O
1985	O
)	O
.	O

These	O
possibilities	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

To	O
summarize	O
,	O
the	O
present	O
results	O
suggest	O
that	O
an	O
initial	O
(	O
or	O
triggering	O
)	O
toxicologic	O
event	O
occurs	O
before	O
the	O
brain	O
Hg	O
concentration	O
stabilizes	O
and	O
that	O
the	O
nature	O
of	O
this	O
event	O
should	O
be	O
either	O
an	O
acceleration	O
of	O
the	O
aging	O
process	O
or	O
interaction	O
with	O
the	O
aging	O
process	O
.	O

Thus	O
,	O
by	O
identifying	O
the	O
physiologic	O
events	O
associated	O
with	O
the	O
functional	O
aging	O
of	O
the	O
examined	O
behavioral	O
tasks	O
,	O
the	O
fundamental	O
toxicologic	O
scar	O
might	O
be	O
revealed	O
.	O

A	O
Novel	O
Role	O
of	O
the	O
NRF2	O
Transcription	O
Factor	O
in	O
the	O
Regulation	O
of	O
Arsenite	O
-	O
Mediated	O
Keratin	O
16	O
Gene	O
Expression	O
in	O
Human	S-Species
Keratinocytes	O

Abstract	O

Background	O

Inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
skin	O
hyperkeratosis	O
and	O
cancer	O
.	O

Objectives	O

We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
the	O
keratin	O
16	O
(	O
K16	O
)	O
gene	O
by	O
iAs	O
in	O
the	O
human	S-Species
keratinocyte	O
cell	O
line	O
HaCaT	O
.	O

Methods	O

We	O
performed	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
,	O
luciferase	O
assays	O
,	O
Western	O
blots	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
determine	O
the	O
transcriptional	O
regulation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
.	O

We	O
used	O
gene	O
overexpression	O
approaches	O
to	O
elucidate	O
the	O
nuclear	O
factor	O
erythroid	O
-	O
derived	O
2	O
related	O
factor	O
2	O
(	O
NRF2	O
)	O
involved	O
in	O
the	O
K16	O
induction	O
.	O

Results	O

iAs	O
induced	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
K16	O
.	O

We	O
also	O
found	O
that	O
the	O
expression	O
of	O
K16	O
was	O
transcriptionally	O
induced	O
by	O
iAs	O
through	O
activator	O
protein	O
-	O
1	O
-	O
like	O
sites	O
and	O
an	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
in	O
its	O
gene	O
promoter	O
region	O
.	O

Treatment	O
with	O
iAs	O
also	O
enhanced	O
the	O
production	O
and	O
translocation	O
of	O
the	O
NRF2	O
transcription	O
factor	O
,	O
an	O
ARE	O
-	O
binding	O
protein	O
,	O
into	O
the	O
nucleus	O
without	O
modification	O
of	O
its	O
mRNA	O
expression	O
.	O

In	O
addition	O
,	O
iAs	O
elongated	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
.	O

When	O
overexpressed	O
in	O
HaCaT	O
cells	O
,	O
NRF2	O
was	O
also	O
directly	O
involved	O
in	O
not	O
only	O
the	O
up	O
-	O
regulation	O
of	O
the	O
detoxification	O
gene	O
thioredoxin	O
but	O
also	O
K16	O
gene	O
expression	O
.	O

Conclusions	O

Our	O
data	O
clearly	O
indicate	O
that	O
the	O
K16	O
gene	O
is	O
a	O
novel	O
target	O
of	O
NRF2	O
.	O

Furthermore	O
,	O
our	O
findings	O
also	O
suggest	O
that	O
NRF2	O
has	O
opposing	O
roles	O
in	O
the	O
cell	O
--	O
in	O
the	O
activation	O
of	O
detoxification	O
pathways	O
and	O
in	O
promoting	O
the	O
development	O
of	O
skin	O
disorders	O
.	O

Inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
)	O
,	O
a	O
ubiquitous	O
element	O
,	O
is	O
one	O
of	O
the	O
most	O
toxic	O
metals	O
present	O
in	O
the	O
natural	O
environment	O
(	O
Bagla	O
and	O
Kaiser	O
1996	O
)	O
.	O

Arsenicals	O
are	O
found	O
as	O
naturally	O
occurring	O
constituents	O
of	O
soil	O
,	O
food	O
,	O
and	O
drinking	O
water	O
(	O
Wu	O
et	O
al	O
.	O
1989	O
;	O
Yoshida	O
et	O
al	O
.	O
2004	O
)	O
,	O
and	O
exposure	O
to	O
iAs	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
disease	O
outcomes	O
,	O
including	O
disorders	O
of	O
the	O
skin	O
,	O
urinary	O
bladder	O
,	O
liver	O
,	O
and	O
lung	O
(	O
Tchounwou	O
et	O
al	O
.	O
2004	O
)	O
.	O

In	O
particular	O
,	O
skin	O
hyperkeratosis	O
is	O
a	O
characteristic	O
dermatologic	O
lesion	O
associated	O
with	O
ingestion	O
of	O
arsenic	O
from	O
contaminated	O
groundwater	O
(	O
McLellan	O
2002	O
;	O
Yoshida	O
et	O
al	O
.	O
2004	O
)	O
.	O

There	O
is	O
also	O
a	O
significant	O
association	O
between	O
hyperkeratosis	O
,	O
nonmelanoma	O
skin	O
cancer	O
(	O
e	O
.	O
g	O
.	O
,	O
basal	O
cell	O
carcinoma	O
and	O
squamous	O
cell	O
carcinoma	O
)	O
,	O
and	O
Bowen	O
disease	O
(	O
Col	O
et	O
al	O
.	O
1999	O
;	O
Rossman	O
et	O
al	O
.	O
2004	O
)	O
.	O

Furthermore	O
,	O
the	O
pathologic	O
features	O
associated	O
with	O
arsenic	O
-	O
induced	O
hyperkeratosis	O
present	O
as	O
typical	O
acanthotic	O
types	O
of	O
psoriasis	O
-	O
like	O
keratosis	O
,	O
characterized	O
by	O
the	O
aberrant	O
proliferation	O
and	O
terminal	O
differentiation	O
of	O
epidermal	O
keratinocytes	O
(	O
Lee	O
et	O
al	O
.	O
2006	O
)	O
.	O

Many	O
epidemiologic	O
studies	O
have	O
shown	O
that	O
hyperkeratoses	O
are	O
the	O
most	O
frequent	O
precursor	O
lesions	O
of	O
some	O
skin	O
cancers	O
(	O
Bagla	O
and	O
Kaiser	O
1996	O
;	O
Col	O
et	O
al	O
.	O
1999	O
)	O
.	O

The	O
keratins	O
are	O
the	O
most	O
prominent	O
cytoskeletal	O
proteins	O
in	O
keratinocytes	O
and	O
comprise	O
a	O
large	O
family	O
of	O
proteins	O
that	O
form	O
intermediate	O
filament	O
networks	O
in	O
all	O
epithelial	O
cell	O
types	O
(	O
Moll	O
et	O
al	O
.	O
1982	O
)	O
.	O

Keratin	O
16	O
(	O
K16	O
)	O
and	O
keratin	O
6	O
(	O
K6	O
)	O
genes	O
are	O
constitutively	O
expressed	O
in	O
a	O
number	O
of	O
stratified	O
epithelial	O
levels	O
,	O
including	O
the	O
palmar	O
and	O
plantar	O
epidermis	O
(	O
Moll	O
et	O
al	O
.	O
1982	O
)	O
.	O

In	O
skin	O
diseases	O
characterized	O
by	O
aberrant	O
proliferation	O
and	O
differentiation	O
,	O
such	O
as	O
psoriasis	O
and	O
cancer	O
,	O
K16	O
is	O
detectable	O
at	O
higher	O
levels	O
compared	O
with	O
normal	O
tissue	O
(	O
Haider	O
et	O
al	O
.	O
2006	O
)	O
.	O

Furthermore	O
,	O
the	O
tissue	O
-	O
specific	O
overexpression	O
of	O
wild	O
-	O
type	O
K16	O
in	O
the	O
epidermis	O
of	O
transgenic	O
mice	S-Species
results	O
in	O
the	O
hyperproliferation	O
of	O
keratinocytes	O
and	O
aberrant	O
keratinization	O
of	O
cornified	O
layers	O
,	O
leading	O
to	O
hyperkeratosis	O
of	O
the	O
skin	O
(	O
Takahashi	O
et	O
al	O
.	O
1994	O
)	O
.	O

Nuclear	O
factor	O
erythoid	O
-	O
derived	O
2	O
related	O
factor	O
2	O
(	O
NRF2	O
)	O
,	O
a	O
"	O
cap	O
'	O
n	O
'	O
collar	O
"	O
basic	O
leucine	O
zipper	O
transcription	O
factor	O
,	O
regulates	O
a	O
transcriptional	O
program	O
that	O
maintains	O
cellular	O
redox	O
homeostasis	O
and	O
protects	O
cells	O
from	O
oxidative	O
stress	O
and	O
xenobiotic	O
agents	O
(	O
Ishii	O
et	O
al	O
.	O
2000	O
;	O
Moi	O
et	O
al	O
.	O
1994	O
)	O
.	O

Several	O
detoxifying	O
and	O
antioxidant	O
genes	O
,	O
including	O
glutathione	O
-	O
S	O
-	O
transferases	O
(	O
GSTs	O
)	O
,	O
heme	O
oxygenase	O
-	O
1	O
(	O
HMOX1	O
)	O
,	O
and	O
thioredoxin	O
(	O
TXN	O
)	O
,	O
are	O
regulated	O
by	O
NRF2	O
through	O
the	O
antioxidant	O
responsive	O
element	O
(	O
ARE	O
)	O
in	O
the	O
respective	O
promoter	O
regions	O
of	O
these	O
genes	O
(	O
McMahon	O
et	O
al	O
.	O
2001	O
;	O
Wakabayashi	O
et	O
al	O
.	O
2004	O
)	O
.	O

NRF2	O
is	O
held	O
in	O
the	O
cytoplasm	O
by	O
a	O
cytoskeletal	O
-	O
associated	O
specific	O
inhibitory	O
protein	O
(	O
kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
;	O
KEAP1	O
)	O
under	O
normal	O
cellular	O
redox	O
state	O
conditions	O
,	O
where	O
it	O
is	O
continuously	O
targeted	O
by	O
the	O
proteasomal	O
degradation	O
pathway	O
(	O
McMahon	O
et	O
al	O
.	O
2003	O
)	O
.	O

Upon	O
exposure	O
of	O
the	O
cell	O
to	O
oxidative	O
stress	O
or	O
electrophiles	O
,	O
NRF2	O
can	O
escape	O
this	O
KEAP1	O
-	O
mediated	O
repression	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
activate	O
the	O
expression	O
of	O
its	O
target	O
genes	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al	O
.	O
2002	O
;	O
McMahon	O
et	O
al	O
.	O
2003	O
)	O
.	O

Recently	O
,	O
studies	O
of	O
Keap1	O
-	O
/	O
-	O
mice	S-Species
have	O
shown	O
that	O
NRF2	O
accumulates	O
in	O
the	O
nucleus	O
and	O
constitutively	O
activates	O
the	O
transcription	O
of	O
its	O
target	O
genes	O
,	O
even	O
in	O
the	O
absence	O
of	O
stress	O
signals	O
(	O
Wakabayashi	O
et	O
al	O
.	O
2003	O
)	O
.	O

Most	O
interestingly	O
,	O
however	O
,	O
the	O
skin	O
,	O
esophagus	O
,	O
and	O
forestomach	O
of	O
Keap1	O
-	O
deficient	O
mice	S-Species
show	O
cornified	O
layer	O
and	O
hyperkeratosis	O
phenotypes	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
have	O
also	O
shown	O
that	O
the	O
expression	O
of	O
NRF2	O
and	O
ARE	O
-	O
controlled	O
genes	O
is	O
induced	O
by	O
iAs	O
in	O
some	O
cell	O
types	O
(	O
Pi	O
et	O
al	O
.	O
2003	O
;	O
Sakurai	O
et	O
al	O
.	O
2005	O
)	O
.	O

Furthermore	O
,	O
histochemical	O
analyses	O
have	O
indicated	O
that	O
the	O
expression	O
of	O
K16	O
is	O
increased	O
in	O
Bowen	O
disease	O
,	O
basal	O
cell	O
carcinoma	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
induced	O
by	O
arsenicals	O
(	O
Yu	O
et	O
al	O
.	O
1993	O
)	O
.	O

However	O
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
NRF2	O
can	O
regulate	O
the	O
transcriptional	O
activation	O
of	O
K16	O
upon	O
iAs	O
exposure	O
in	O
human	S-Species
keratinocytes	O
.	O

Hence	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
-	O
induced	O
NRF2	O
mediation	O
.	O

Materials	O
and	O
Methods	O

Chemicals	O
and	O
reagents	O

A	O
purified	O
preparation	O
of	O
inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
;	O
NaAsO2	O
;	O
Merck	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
was	O
dissolved	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
and	O
added	O
directly	O
to	O
the	O
culture	O
medium	O
.	O

A	O
fresh	O
iAs	O
solution	O
was	O
prepared	O
for	O
each	O
new	O
experiment	O
.	O

Cycloheximide	O
(	O
CHX	O
)	O
,	O
dimethyl	O
-	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
and	O
a	O
protease	O
inhibitor	O
cocktail	O
were	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

CHX	O
was	O
dissolved	O
in	O
DMSO	O
and	O
stored	O
-	O
20	O
degrees	O
C	O
until	O
use	O
.	O

Cells	O
and	O
culture	O
conditions	O

The	O
human	S-Species
keratinocyte	O
HaCaT	O
cell	O
line	O
was	O
obtained	O
from	O
N	O
.	O
E	O
.	O

Fusenig	O
(	O
German	O
Cancer	O
Research	O
Center	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Cells	O
were	O
maintained	O
in	O
monolayer	O
cultures	O
in	O
95	O
%	O
air	O
and	O
5	O
%	O
CO2	O
at	O
37	O
degrees	O
C	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagles	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
50	O
U	O
/	O
mL	O
penicillin	O
and	O
50	O
mg	O
/	O
mL	O
streptomycin	O
and	O
nonessential	O
amino	O
acids	O
(	O
Gibco	O
BRL	O
,	O
Paisley	O
,	O
UK	O
)	O
.	O

RNA	O
preparation	O
and	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O

We	O
determined	O
RNA	O
expression	O
levels	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
as	O
described	O
previously	O
(	O
Sugioka	O
et	O
al	O
.	O
2004	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
HaCaT	O
cells	O
using	O
the	O
GeneElute	O
Mammalian	O
Total	O
RNA	O
Kit	O
(	O
Sigma	O
)	O
.	O

The	O
specific	O
primers	O
used	O
for	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
and	O
PCR	O
were	O
as	O
follows	O
:	O
K16	O
[	O
forward	O
,	O
5	O
'	O
-	O
GAT	O
GCT	O
TGC	O
TCT	O
GAG	O
AGG	O
TC	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
CCA	O
GCA	O
AGA	O
TCT	O
GGT	O
ACT	O
CC	O
-	O
3	O
'	O
;	O
Gene	O
Bank	O
accession	O
no	O
.	O
NM	O
_	O
005557	O
(	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
2007	O
)	O
]	O
;	O
c	O
-	O
Jun	O
(	O
forward	O
,	O
5	O
'	O
-	O
CCT	O
GTT	O
GCG	O
GCC	O
CCG	O
AAA	O
CT	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
ACC	O
ATG	O
CCT	O
GCC	O
CCG	O
TTG	O
AC	O
-	O
3	O
'	O
;	O
NM	O
_	O
002228	O
)	O
;	O
c	O
-	O
Fos	O
(	O
forward	O
,	O
5	O
'	O
-	O
TTT	O
GCC	O
TAA	O
CCG	O
CCA	O
CGA	O
TGA	O
T	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
TTG	O
CCG	O
CTT	O
TCT	O
GCC	O
ACC	O
TC	O
-	O
3	O
'	O
;	O
NM	O
_	O
005252	O
)	O
;	O
NRF2	O
(	O
forward	O
,	O
5	O
'	O
-	O
AGA	O
TTC	O
ACA	O
GGC	O
CTT	O
TCT	O
CG	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
CAG	O
CTC	O
TCC	O
CTA	O
CCG	O
TTG	O
GA	O
-	O
3	O
'	O
;	O
AF323119	O
)	O
;	O
KEAP1	O
(	O
forward	O
,	O
5	O
'	O
-	O
CAG	O
AGG	O
TGG	O
TGG	O
TGT	O
TGC	O
TTA	O
T	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
AGC	O
TCG	O
TTC	O
ATG	O
ATG	O
CCA	O
AAG	O
-	O
3	O
'	O
;	O
NM	O
_	O
012289	O
)	O
;	O
TXN	O
(	O
forward	O
,	O
5	O
'	O
-	O
CAG	O
GGG	O
AAT	O
GAA	O
AGA	O
AAG	O
G	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
CAA	O
GGT	O
GAA	O
GCA	O
GAT	O
CG	O
-	O
3	O
'	O
;	O
NM	O
_	O
003329	O
)	O
,	O
and	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
as	O
a	O
loading	O
control	O
(	O
forward	O
,	O
5	O
'	O
-	O
ACC	O
ACA	O
GTC	O
CAT	O
GCC	O
ATC	O
AC	O
-	O
3	O
'	O
,	O
and	O
reverse	O
,	O
5	O
'	O
-	O
TCC	O
ACC	O
ACC	O
CTG	O
TTG	O
CTG	O
TA	O
-	O
3	O
'	O
,	O
NM	O
_	O
002046	O
)	O
.	O

PCR	O
products	O
were	O
separated	O
on	O
a	O
1	O
.	O
8	O
%	O
agarose	O
gel	O
and	O
stained	O
with	O
ethidium	O
bromide	O
.	O

Western	O
blot	O
analysis	O

We	O
performed	O
Western	O
blot	O
analysis	O
as	O
described	O
previously	O
(	O
Sugioka	O
et	O
al	O
.	O
2004	O
)	O
.	O

Briefly	O
,	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
were	O
extracted	O
using	O
the	O
NE	O
-	O
PER	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
kit	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

For	O
protein	O
extraction	O
,	O
the	O
cells	O
were	O
lysed	O
in	O
a	O
buffer	O
containing	O
complete	O
protease	O
inhibitor	O
cocktail	O
.	O

We	O
measured	O
protein	O
concentrations	O
using	O
the	O
DC	O
Protein	O
Assay	O
Kit	O
(	O
Bio	O
-	O
Rad	O
,	O
Richmond	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Equal	O
amounts	O
of	O
protein	O
were	O
then	O
resolved	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
transferred	O
to	O
a	O
polyvinylidene	O
fluoride	O
membrane	O
(	O
Amersham	O
Biosciences	O
,	O
Bucks	O
,	O
UK	O
)	O
.	O

Immunoblotting	O
was	O
carried	O
out	O
with	O
specific	O
antibodies	O
in	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
05	O
%	O
Tween	O
20	O
.	O

The	O
primary	O
antibodies	O
were	O
as	O
follows	O
:	O
K16	O
(	O
Neomarkers	O
,	O
Fremont	O
,	O
CA	O
,	O
USA	O
)	O
,	O
NRF2	O
and	O
KEAP1	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
,	O
c	O
-	O
Jun	O
(	O
Cell	O
Signaling	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
,	O
and	O
beta	O
-	O
actin	O
(	O
Sigma	O
)	O
.	O

After	O
washing	O
,	O
the	O
membranes	O
were	O
probed	O
with	O
horseradish	S-Species
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
and	O
developed	O
by	O
chemiluminescence	O
using	O
the	O
ECL	O
Plus	O
Detection	O
Kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Plasmids	O
,	O
transfections	O
,	O
and	O
luciferase	O
assays	O

Human	S-Species
K16	O
promoter	O
regions	O
of	O
varying	O
lengths	O
(	O
pXK	O
-	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
1	O
,	O
and	O
5	O
-	O
2	O
)	O
were	O
provided	O
by	O
Y	O
-	O
N	O
Wang	O
(	O
National	O
Cheng	O
Kung	O
University	O
,	O
Taiwan	O
)	O
.	O

These	O
DNA	O
fragments	O
were	O
prepared	O
from	O
HaCaT	O
cells	O
and	O
were	O
ligated	O
into	O
the	O
pXP	O
-	O
1	O
luciferase	O
vector	O
(	O
Wang	O
and	O
Chang	O
2003	O
)	O
.	O

The	O
p3xARE	O
/	O
Luc	O
vector	O
,	O
harboring	O
three	O
tandem	O
repeats	O
of	O
ARE	O
,	O
was	O
donated	O
by	O
X	O
.	O
L	O
.	O

Chen	O
(	O
Discovery	O
Research	O
,	O
AtheroGenics	O
Inc	O
.	O
,	O
Alpharetta	O
,	O
GA	O
,	O
USA	O
)	O
(	O
Chen	O
et	O
al	O
.	O
2003	O
)	O
.	O

The	O
wild	O
-	O
type	O
NRF2	O
expression	O
vector	O
(	O
WT	O
-	O
NRF2	O
)	O
was	O
a	O
gift	O
from	O
H	O
.	O
S	O
.	O

So	O
(	O
Wonkwang	O
University	O
School	O
of	O
Medicine	O
,	O
Korea	O
)	O
(	O
So	O
et	O
al	O
.	O
2006	O
)	O
.	O

NRF2	O
cDNA	O
was	O
subcloned	O
into	O
a	O
pcDNA3	O
.	O
1	O
(	O
+	O
)	O
vector	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
the	O
transfection	O
of	O
reporter	O
plasmids	O
,	O
we	O
seeded	O
HaCaT	O
cells	O
into	O
six	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
80	O
%	O
the	O
previous	O
day	O
.	O

Cells	O
were	O
then	O
transfected	O
with	O
a	O
total	O
of	O
each	O
luciferase	O
reporter	O
construct	O
(	O
2	O
.	O
5	O
mu	O
g	O
)	O
using	O
LipofectAMINE	O
plus	O
(	O
Invitrogen	O
)	O
.	O

To	O
control	O
for	O
the	O
efficiency	O
of	O
transfection	O
,	O
Renilla	O
luciferase	O
gene	O
expression	O
was	O
monitored	O
using	O
either	O
the	O
pRL	O
-	O
CMV	O
or	O
pRL	O
-	O
TK	O
vectors	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

For	O
overexpression	O
of	O
WT	O
-	O
NRF2	O
,	O
we	O
normalized	O
the	O
total	O
plasmid	O
concentration	O
using	O
the	O
pcDNA3	O
.	O
1	O
(	O
+	O
)	O
empty	O
vector	O
.	O

Thirty	O
-	O
six	O
hours	O
after	O
transfection	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
containing	O
either	O
vehicle	O
(	O
PBS	O
)	O
or	O
iAs	O
for	O
6	O
hr	O
.	O

After	O
iAs	O
exposure	O
,	O
we	O
harvested	O
cells	O
and	O
analyzed	O
them	O
for	O
luciferase	O
activity	O
using	O
a	O
Dual	O
-	O
Luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
.	O

For	O
the	O
investigation	O
of	O
the	O
role	O
of	O
NRF2	O
in	O
regulating	O
K16	O
gene	O
expression	O
,	O
transfection	O
of	O
an	O
NRF2	O
expression	O
plasmid	O
into	O
HaCaT	O
cells	O
was	O
carried	O
out	O
using	O
LipofectAMINE	O
2000	O
(	O
Invitrogen	O
)	O
.	O

Cells	O
were	O
cultured	O
in	O
100	O
-	O
mm	O
plates	O
24	O
hr	O
before	O
transfection	O
.	O

The	O
expression	O
plasmid	O
WT	O
-	O
NRF2	O
(	O
15	O
mu	O
g	O
)	O
was	O
then	O
transfected	O
into	O
the	O
cells	O
for	O
48	O
-	O
60	O
hr	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
used	O
15	O
mu	O
g	O
of	O
the	O
pcDNA3	O
.	O
1	O
(	O
+	O
)	O
empty	O
vector	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
(	O
EMSA	O
)	O

We	O
extracted	O
and	O
measured	O
nuclear	O
proteins	O
as	O
described	O
above	O
.	O

Nuclear	O
protein	O
/	O
DNA	O
complexes	O
were	O
subjected	O
to	O
electrophoresis	O
in	O
nondenaturing	O
5	O
%	O
polyacrylamide	O
gels	O
containing	O
2	O
%	O
glycerol	O
in	O
0	O
.	O
25	O
%	O
Tris	O
-	O
borate	O
/	O
EDTA	O
buffer	O
and	O
transferred	O
to	O
Hybond	O
-	O
N	O
+	O
nylon	O
transfer	O
membranes	O
(	O
Amersham	O
Biosciences	O
)	O
for	O
detection	O
using	O
the	O
Light	O
-	O
Shift	O
EMSA	O
kit	O
(	O
Pierce	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
,	O
with	O
minor	O
modifications	O
.	O

We	O
incubated	O
10	O
-	O
mu	O
g	O
aliquots	O
of	O
nuclear	O
extract	O
with	O
the	O
DNA	O
probe	O
in	O
a	O
binding	O
reaction	O
buffer	O
containing	O
10	O
mM	O
Tris	O
/	O
HCl	O
(	O
pH	O
7	O
.	O
6	O
)	O
,	O
50	O
mM	O
KCl	O
,	O
0	O
.	O
5	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
25	O
mM	O
EDTA	O
,	O
5	O
%	O
glycerol	O
,	O
2	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
05	O
%	O
NP	O
-	O
40	O
detergent	O
,	O
and	O
2	O
mu	O
g	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
.	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

For	O
supershift	O
assays	O
,	O
2	O
mu	O
g	O
of	O
either	O
a	O
polyclonal	O
anti	O
-	O
NRF2	O
or	O
an	O
anti	O
-	O
c	O
-	O
Jun	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
was	O
added	O
with	O
the	O
nuclear	O
protein	O
for	O
2	O
hr	O
at	O
4	O
degrees	O
C	O
before	O
the	O
labeled	O
oligonucleotide	O
probe	O
was	O
added	O
.	O

Biotin	O
-	O
labeled	O
,	O
double	O
-	O
stranded	O
oligonucleotides	O
WT	O
-	O
K16ARE	O
(	O
-	O
157	O
/	O
-	O
132	O
,	O
5	O
'	O
-	O
GGGGAACCTGGAGTCAGCAGT	O
-	O
TAGGA	O
-	O
3	O
'	O
)	O
,	O
containing	O
an	O
ARE	O
site	O
(	O
-	O
148	O
/	O
-	O
140	O
,	O
underlined	O
)	O
in	O
the	O
human	S-Species
K16	O
promoter	O
region	O
,	O
and	O
Mut	O
-	O
K16ARE	O
(	O
5	O
'	O
-	O
GGGGAA	O
-	O
CCTGGAGTCAaaAGTTAGGA	O
-	O
3	O
'	O
,	O
mutated	O
GC	O
box	O
in	O
the	O
ARE	O
)	O
were	O
prepared	O
by	O
Fasmac	O
(	O
Kanagawa	O
,	O
Japan	O
)	O
.	O

A	O
consensus	O
ARE	O
probe	O
was	O
purchased	O
from	O
Panomics	O
,	O
Inc	O
.	O

(	O
Redwood	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
competition	O
binding	O
of	O
the	O
K16	O
ARE	O
-	O
complexes	O
,	O
we	O
used	O
an	O
unlabeled	O
AP	O
-	O
1	O
consensus	O
oligonucleotide	O
(	O
5	O
'	O
-	O
TATC	O
-	O
GATAAGCTATGAGTCATCCGGG	O
-	O
3	O
'	O
)	O
.	O

The	O
binding	O
specificity	O
was	O
confirmed	O
in	O
each	O
case	O
by	O
the	O
addition	O
of	O
a	O
100	O
-	O
fold	O
molar	O
excess	O
of	O
unlabeled	O
oligonucleotide	O
.	O

CHX	O
chase	O
experiment	O

We	O
investigated	O
the	O
posttranscriptional	O
regulation	O
of	O
both	O
the	O
steady	O
-	O
state	O
levels	O
and	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
by	O
CHX	O
chase	O
analysis	O
.	O

Cells	O
were	O
incubated	O
in	O
serum	O
-	O
free	O
medium	O
in	O
the	O
absence	O
or	O
presence	O
of	O
iAs	O
for	O
6	O
hr	O
.	O

The	O
culture	O
medium	O
was	O
then	O
replaced	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
CHX	O
(	O
100	O
mu	O
g	O
/	O
mL	O
)	O
.	O

We	O
prepared	O
cell	O
lysates	O
at	O
0	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
240	O
min	O
after	O
iAs	O
treatment	O
.	O

Whole	O
-	O
cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotted	O
with	O
antibodies	O
against	O
NRF2	O
.	O

Statistics	O

All	O
the	O
data	O
generated	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
and	O
expressed	O
as	O
the	O
mean	O
+/-	O
SD	O
were	O
analyzed	O
by	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

Statistical	O
comparisons	O
were	O
made	O
by	O
logarithmic	O
transformation	O
of	O
the	O
normalized	O
values	O
.	O

We	O
considered	O
p	O
-	O
values	O
<	O
0	O
.	O
01	O
to	O
be	O
statistically	O
significant	O
.	O

Results	O

K16	O
expression	O
is	O
induced	O
by	O
iAs	O
in	O
HaCaT	O
cells	O

We	O
wanted	O
to	O
determine	O
whether	O
the	O
K16	O
mRNA	O
is	O
transcriptionally	O
regulated	O
by	O
iAs	O
,	O
and	O
treated	O
HaCaT	O
cells	O
with	O
this	O
compound	O
for	O
various	O
time	O
periods	O
over	O
a	O
range	O
of	O
doses	O
.	O

After	O
treatment	O
of	O
HaCaT	O
cells	O
with	O
1	O
-	O
20	O
mu	O
M	O
iAs	O
,	O
the	O
expression	O
of	O
K16	O
mRNA	O
was	O
increased	O
compared	O
with	O
the	O
control	O
at	O
6	O
hr	O
(	O
Figure	O
1A	O
)	O
but	O
had	O
declined	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

The	O
increase	O
in	O
the	O
K16	O
protein	O
levels	O
after	O
6	O
hr	O
of	O
iAs	O
exposure	O
was	O
just	O
detectable	O
at	O
10	O
-	O
20	O
mu	O
M	O
,	O
but	O
a	O
dose	O
-	O
dependent	O
increase	O
was	O
more	O
evident	O
at	O
10	O
hr	O
(	O
Figure	O
1B	O
)	O
.	O

This	O
enhancement	O
of	O
K16	O
expression	O
had	O
declined	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Identification	O
of	O
the	O
iAs	O
responsive	O
region	O
in	O
the	O
K16	O
gene	O
promoter	O

To	O
investigate	O
the	O
mechanisms	O
underlying	O
the	O
transactivation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
,	O
we	O
first	O
examined	O
the	O
response	O
of	O
the	O
K16	O
regulatory	O
region	O
to	O
this	O
compound	O
using	O
a	O
luciferase	O
reporter	O
gene	O
assay	O
.	O

The	O
dose	O
-	O
dependent	O
activation	O
of	O
K16	O
transcription	O
after	O
iAs	O
treatment	O
was	O
observed	O
with	O
a	O
construct	O
containing	O
a	O
515	O
-	O
bp	O
fragment	O
of	O
the	O
K16	O
promoter	O
(	O
Figure	O
2A	O
)	O
.	O

To	O
further	O
elucidate	O
the	O
region	O
containing	O
the	O
iAs	O
responsive	O
element	O
,	O
we	O
examined	O
a	O
series	O
of	O
deletions	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
K16	O
gene	O
.	O

The	O
ARE	O
sequence	O
in	O
the	O
pXK	O
-	O
5	O
-	O
1	O
vector	O
contains	O
an	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
-	O
like	O
element	O
followed	O
by	O
a	O
GC	O
box	O
.	O

As	O
shown	O
in	O
Figure	O
2B	O
,	O
an	O
enhancement	O
in	O
the	O
reporter	O
activity	O
levels	O
was	O
observed	O
for	O
the	O
promoter	O
constructs	O
,	O
pXK	O
-	O
1	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
-	O
1	O
,	O
in	O
response	O
to	O
20	O
mu	O
M	O
iAs	O
.	O

A	O
decline	O
in	O
reporter	O
activity	O
,	O
however	O
,	O
depended	O
on	O
the	O
number	O
of	O
AP	O
-	O
1	O
-	O
like	O
sites	O
,	O
and	O
the	O
results	O
for	O
the	O
pXK	O
-	O
5	O
-	O
1	O
construct	O
show	O
also	O
that	O
ARE	O
is	O
activated	O
by	O
iAs	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
activation	O
was	O
observed	O
using	O
a	O
pXK	O
-	O
5	O
-	O
2	O
construct	O
in	O
response	O
to	O
20	O
mu	O
M	O
iAs	O
.	O

Expression	O
of	O
AP	O
-	O
1	O
transcriptions	O
factor	O
and	O
c	O
-	O
Jun	O
production	O
following	O
iAs	O
treatment	O

We	O
examined	O
AP	O
-	O
1	O
transcription	O
factors	O
c	O
-	O
Jun	O
and	O
c	O
-	O
Fos	O
expression	O
in	O
iAs	O
-	O
treated	O
HaCaT	O
cells	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

iAs	O
-	O
induced	O
c	O
-	O
Jun	O
expression	O
was	O
observed	O
during	O
the	O
first	O
3	O
hr	O
after	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

An	O
appreciable	O
induction	O
of	O
c	O
-	O
Jun	O
was	O
also	O
confirmed	O
after	O
6	O
hr	O
,	O
but	O
this	O
was	O
down	O
-	O
regulated	O
by	O
24	O
hr	O
after	O
iAs	O
treatment	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
c	O
-	O
Fos	O
was	O
only	O
transiently	O
detectable	O
at	O
3	O
hr	O
(	O
data	O
not	O
shown	O
)	O
but	O
was	O
not	O
observed	O
during	O
the	O
6	O
-	O
24	O
hr	O
period	O
of	O
this	O
experiment	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
iAs	O
-	O
enhanced	O
c	O
-	O
Jun	O
production	O
can	O
be	O
observed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
at	O
6	O
hr	O
,	O
but	O
it	O
declines	O
from	O
10	O
to	O
24	O
hr	O
.	O

iAs	O
potently	O
induces	O
the	O
translocation	O
of	O
NRF2	O
and	O
activates	O
the	O
ARE	O
of	O
the	O
K16	O
promoter	O

The	O
results	O
of	O
our	O
reporter	O
assays	O
suggested	O
that	O
iAs	O
stimulates	O
not	O
only	O
the	O
AP	O
-	O
1	O
-	O
like	O
sites	O
but	O
also	O
the	O
ARE	O
site	O
within	O
the	O
K16	O
gene	O
promoter	O
in	O
HaCaT	O
cells	O
(	O
Figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
several	O
oxidative	O
stress	O
agents	O
and	O
toxic	O
chemicals	O
,	O
including	O
iAs	O
,	O
have	O
been	O
reported	O
to	O
induce	O
the	O
expression	O
of	O
ARE	O
-	O
dependent	O
genes	O
in	O
several	O
cell	O
types	O
(	O
Pi	O
et	O
al	O
.	O
2003	O
;	O
Sakurai	O
et	O
al	O
.	O
2005	O
)	O
.	O

On	O
the	O
basis	O
of	O
our	O
observations	O
and	O
some	O
recent	O
reports	O
,	O
we	O
thus	O
hypothesized	O
that	O
iAs	O
would	O
have	O
the	O
ability	O
to	O
activate	O
the	O
ARE	O
of	O
the	O
K16	O
gene	O
promoter	O
directly	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
K16	O
expression	O
in	O
HaCaT	O
cells	O
.	O

To	O
confirm	O
that	O
the	O
K16	O
ARE	O
indeed	O
functions	O
as	O
an	O
iAs	O
-	O
responsive	O
transcriptional	O
control	O
element	O
,	O
we	O
performed	O
transient	O
transfections	O
of	O
HaCaT	O
cells	O
with	O
a	O
p3xARE	O
/	O
Luc	O
construct	O
and	O
then	O
subjected	O
these	O
cells	O
to	O
iAs	O
for	O
6	O
hr	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
treatment	O
of	O
HaCaT	O
cells	O
with	O
iAs	O
results	O
in	O
a	O
dramatic	O
increase	O
in	O
ARE	O
-	O
driven	O
promoter	O
activity	O
.	O

Likewise	O
,	O
EMSA	O
using	O
a	O
consensus	O
ARE	O
probe	O
show	O
that	O
iAs	O
-	O
induced	O
ARE	O
-	O
binding	O
complexes	O
increase	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
indicate	O
that	O
iAs	O
has	O
the	O
ability	O
to	O
activate	O
the	O
ARE	O
-	O
driven	O
genes	O
.	O

We	O
performed	O
further	O
EMSA	O
experiments	O
using	O
an	O
ARE	O
probe	O
specific	O
to	O
the	O
K16	O
proximal	O
promoter	O
region	O
(	O
WT	O
-	O
K16ARE	O
)	O
and	O
found	O
that	O
K16ARE	O
-	O
nuclear	O
protein	O
complexes	O
formation	O
is	O
augmented	O
by	O
iAs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
4C	O
)	O
.	O

Moreover	O
,	O
the	O
formation	O
of	O
these	O
complexes	O
is	O
specifically	O
inhibited	O
by	O
the	O
addition	O
of	O
excess	O
unlabeled	O
oligonucleotide	O
competitor	O
(	O
Figure	O
4B	O
,	O
C	O
)	O
,	O
whereas	O
an	O
excess	O
of	O
an	O
unlabeled	O
AP	O
-	O
1	O
probe	O
competes	O
only	O
marginally	O
for	O
K16ARE	O
binding	O
(	O
Figure	O
4C	O
)	O
.	O

The	O
NRF2	O
transcription	O
factor	O
has	O
been	O
shown	O
to	O
bind	O
to	O
AREs	O
upon	O
translocation	O
into	O
the	O
nucleus	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
ARE	O
-	O
mediated	O
genes	O
(	O
Wakabayashi	O
et	O
al	O
.	O
2004	O
)	O
.	O

To	O
examine	O
whether	O
iAs	O
induces	O
and	O
translocates	O
NRF2	O
into	O
the	O
nucleus	O
in	O
HaCaT	O
cells	O
,	O
we	O
treated	O
these	O
cells	O
with	O
iAs	O
for	O
either	O
3	O
or	O
6	O
hr	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
a	O
dose	O
-	O
dependent	O
accumulation	O
of	O
NRF2	O
protein	O
was	O
observed	O
in	O
the	O
nucleus	O
upon	O
treatment	O
with	O
iAs	O
for	O
6	O
hr	O
.	O

This	O
was	O
not	O
observed	O
in	O
the	O
parallel	O
experiment	O
performed	O
over	O
the	O
3	O
-	O
hr	O
time	O
course	O
.	O

Supershift	O
EMSA	O
analysis	O
using	O
an	O
NRF2	O
antibody	O
showed	O
that	O
the	O
iAs	O
-	O
induced	O
and	O
iAs	O
-	O
translocated	O
NRF2	O
protein	O
binds	O
to	O
the	O
WT	O
-	O
K16ARE	O
probe	O
containing	O
the	O
ARE	O
sequence	O
of	O
the	O
K16	O
proximal	O
promoter	O
region	O
(	O
5	O
'	O
-	O
GGAGTCAGC	O
-	O
3	O
'	O
)	O
that	O
comprises	O
an	O
AP	O
-	O
1	O
-	O
like	O
site	O
and	O
a	O
GC	O
box	O
,	O
whereas	O
the	O
supershift	O
of	O
c	O
-	O
Jun	O
was	O
not	O
observed	O
(	O
Figure	O
4E	O
)	O
.	O

To	O
identify	O
whether	O
the	O
GC	O
box	O
is	O
dispensable	O
for	O
the	O
iAs	O
-	O
stimulated	O
binding	O
activity	O
of	O
NRF2	O
,	O
we	O
next	O
performed	O
EMSA	O
analyses	O
with	O
either	O
WT	O
-	O
or	O
a	O
Mut	O
-	O
K16ARE	O
probe	O
containing	O
an	O
intact	O
AP	O
-	O
1	O
-	O
like	O
element	O
but	O
a	O
mutated	O
GC	O
box	O
.	O

As	O
shown	O
in	O
Figure	O
4F	O
,	O
the	O
K16ARE	O
-	O
nuclear	O
protein	O
complexes	O
and	O
supershifted	O
bands	O
that	O
were	O
enhanced	O
by	O
iAs	O
treatment	O
were	O
largely	O
abolished	O
by	O
the	O
addition	O
of	O
the	O
Mut	O
-	O
K16ARE	O
probe	O
.	O

iAs	O
stabilizes	O
the	O
NRF2	O
protein	O

We	O
examined	O
the	O
effects	O
of	O
iAs	O
treatment	O
on	O
the	O
function	O
of	O
KEAP1	O
in	O
HaCaT	O
cells	O
.	O

Treatment	O
with	O
iAs	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
KEAP1	O
mRNA	O
or	O
protein	O
over	O
either	O
a	O
3	O
or	O
6	O
hr	O
time	O
course	O
(	O
Figure	O
5A	O
)	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
iAs	O
on	O
the	O
expression	O
of	O
NRF2	O
mRNA	O
in	O
HaCaT	O
cells	O
.	O

Exposure	O
to	O
iAs	O
did	O
not	O
significantly	O
alter	O
the	O
steady	O
-	O
state	O
levels	O
of	O
NRF2	O
mRNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

Production	O
of	O
NRF2	O
protein	O
,	O
however	O
,	O
was	O
observed	O
to	O
increase	O
in	O
both	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
(	O
Figure	O
4D	O
)	O
.	O

To	O
further	O
examine	O
the	O
stabilization	O
of	O
NRF2	O
protein	O
by	O
iAs	O
,	O
we	O
monitored	O
the	O
decay	O
of	O
basal	O
and	O
iAs	O
-	O
induced	O
NRF2	O
proteins	O
after	O
inhibition	O
of	O
protein	O
synthesis	O
by	O
CHX	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
results	O
of	O
this	O
analysis	O
revealed	O
that	O
the	O
NRF2	O
protein	O
levels	O
decrease	O
by	O
approximately	O
50	O
%	O
within	O
30	O
min	O
of	O
treatment	O
with	O
CHX	O
in	O
cells	O
that	O
had	O
not	O
been	O
exposed	O
to	O
iAs	O
.	O

Only	O
trace	O
amounts	O
of	O
NRF2	O
are	O
then	O
detectable	O
after	O
60	O
min	O
of	O
exposure	O
to	O
CHX	O
in	O
these	O
cells	O
.	O

The	O
HaCaT	O
cells	O
were	O
then	O
pretreated	O
with	O
iAs	O
for	O
6	O
hr	O
before	O
their	O
exposure	O
to	O
CHX	O
in	O
a	O
similar	O
timecourse	O
experiment	O
.	O

The	O
levels	O
of	O
NRF2	O
in	O
these	O
iAs	O
-	O
treated	O
cells	O
were	O
again	O
found	O
to	O
decrease	O
by	O
about	O
50	O
%	O
,	O
but	O
only	O
after	O
120	O
min	O
of	O
CHX	O
exposure	O
.	O

NRF2	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
K16	O
gene	O
expression	O
in	O
HaCaT	O
cells	O

To	O
confirm	O
the	O
functional	O
role	O
of	O
NRF2	O
in	O
the	O
induction	O
of	O
K16	O
gene	O
expression	O
by	O
iAs	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
of	O
K16	O
mRNA	O
is	O
induced	O
by	O
the	O
overexpression	O
of	O
NRF2	O
(	O
WT	O
-	O
NRF2	O
)	O
in	O
HaCaT	O
cells	O
.	O

We	O
also	O
investigated	O
the	O
expression	O
of	O
the	O
detoxification	O
gene	O
TXN	O
,	O
which	O
is	O
highly	O
induced	O
by	O
a	O
variety	O
of	O
oxidative	O
stimuli	O
through	O
NRF2	O
-	O
mediated	O
ARE	O
transactivation	O
(	O
Kim	O
et	O
al	O
.	O
2001	O
)	O
.	O

The	O
expression	O
of	O
TXN	O
gene	O
in	O
untransfected	O
cells	O
after	O
treatment	O
with	O
iAs	O
was	O
stronger	O
than	O
that	O
of	O
the	O
control	O
cells	O
(	O
Figure	O
6A	O
)	O
.	O

When	O
the	O
cells	O
were	O
transfected	O
with	O
WT	O
-	O
NRF2	O
and	O
then	O
treated	O
with	O
or	O
without	O
iAs	O
,	O
the	O
expression	O
of	O
TXN	O
mRNA	O
was	O
augmented	O
markedly	O
compared	O
with	O
the	O
empty	O
-	O
vector	O
control	O
.	O

Similarly	O
,	O
the	O
expression	O
of	O
K16	O
mRNA	O
was	O
also	O
induced	O
in	O
cells	O
transfected	O
with	O
WT	O
-	O
NRF2	O
in	O
the	O
absence	O
or	O
presence	O
of	O
iAs	O
.	O

We	O
next	O
performed	O
a	O
transient	O
transfection	O
of	O
HaCaT	O
cells	O
with	O
the	O
pXK	O
-	O
5	O
-	O
1	O
luciferase	O
vector	O
together	O
with	O
the	O
WT	O
-	O
NRF2	O
vector	O
.	O

The	O
overexpression	O
of	O
NRF2	O
in	O
increasing	O
concentrations	O
resulted	O
in	O
significant	O
enhancement	O
of	O
the	O
ARE	O
-	O
mediated	O
K16	O
promoter	O
activation	O
(	O
Figure	O
6B	O
)	O
.	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
for	O
the	O
first	O
time	O
that	O
iAs	O
induces	O
the	O
transcriptional	O
activation	O
of	O
K16	O
in	O
the	O
human	S-Species
keratinocyte	O
cell	O
line	O
,	O
HaCaT	O
,	O
through	O
the	O
ARE	O
present	O
in	O
its	O
gene	O
promoter	O
.	O

It	O
has	O
been	O
reported	O
previously	O
that	O
treatment	O
with	O
iAs	O
enhances	O
the	O
production	O
and	O
translocation	O
of	O
NRF2	O
into	O
the	O
nucleus	O
in	O
several	O
cell	O
types	O
.	O

However	O
,	O
until	O
now	O
it	O
has	O
remained	O
uncertain	O
whether	O
the	O
induction	O
of	O
NRF2	O
by	O
iAs	O
mediates	O
the	O
transcriptional	O
activation	O
of	O
the	O
K16	O
gene	O
in	O
keratinocytes	O
.	O

In	O
our	O
current	O
experiments	O
,	O
we	O
demonstrated	O
that	O
iAs	O
elongates	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
,	O
which	O
results	O
in	O
its	O
increased	O
expression	O
levels	O
.	O

Furthermore	O
,	O
this	O
iAs	O
-	O
induced	O
NRF2	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
the	O
ARE	O
sequences	O
in	O
the	O
promoter	O
region	O
of	O
the	O
K16	O
gene	O
.	O

Finally	O
,	O
by	O
overexpressing	O
NRF2	O
,	O
we	O
have	O
clarified	O
that	O
its	O
induction	O
is	O
involved	O
in	O
not	O
only	O
the	O
gene	O
expression	O
of	O
the	O
detoxification	O
gene	O
TXN	O
,	O
but	O
also	O
in	O
the	O
upregulation	O
of	O
K16	O
expression	O
in	O
HaCaT	O
cells	O
through	O
the	O
ARE	O
in	O
the	O
K16	O
gene	O
promoter	O
.	O

These	O
experiments	O
indicate	O
an	O
important	O
and	O
novel	O
function	O
for	O
NRF2	O
in	O
the	O
regulation	O
of	O
K16	O
in	O
keratinocytes	O
and	O
also	O
help	O
to	O
further	O
explain	O
the	O
molecular	O
mechanisms	O
underlying	O
arsenic	O
-	O
mediated	O
epidermal	O
hyperkeratosis	O
.	O

In	O
our	O
present	O
experiments	O
,	O
the	O
expression	O
levels	O
of	O
K16	O
mRNA	O
and	O
protein	O
were	O
indeed	O
found	O
to	O
be	O
enhanced	O
by	O
iAs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
addition	O
,	O
luciferase	O
assays	O
of	O
the	O
K16	O
promoter	O
revealed	O
that	O
iAs	O
enhances	O
its	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
which	O
is	O
stimulated	O
by	O
AP	O
-	O
1	O
-	O
like	O
sites	O
and	O
an	O
ARE	O
(	O
Figure	O
2	O
)	O
.	O

The	O
promoter	O
of	O
the	O
human	S-Species
K16	O
gene	O
was	O
recently	O
cloned	O
and	O
sequenced	O
,	O
and	O
several	O
AP	O
-	O
1	O
-	O
like	O
sites	O
were	O
found	O
within	O
the	O
-	O
515	O
-	O
bp	O
region	O
of	O
the	O
gene	O
(	O
Wang	O
and	O
Chang	O
2003	O
)	O
.	O

AP	O
-	O
1	O
transcription	O
factor	O
can	O
be	O
formed	O
by	O
the	O
dimerization	O
of	O
either	O
Jun	O
or	O
Jun	O
/	O
Fos	O
family	O
members	O
(	O
Eferl	O
and	O
Wagner	O
2003	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
increased	O
expression	O
of	O
c	O
-	O
Jun	O
,	O
but	O
not	O
c	O
-	O
Fos	O
was	O
evident	O
in	O
the	O
nuclei	O
of	O
HaCaT	O
cells	O
after	O
iAs	O
treatment	O
(	O
Figure	O
3	O
)	O
.	O

Our	O
findings	O
thus	O
suggest	O
that	O
the	O
activation	O
of	O
c	O
-	O
Jun	O
/	O
AP	O
-	O
1	O
is	O
one	O
of	O
the	O
essential	O
steps	O
in	O
the	O
regulation	O
of	O
K16	O
gene	O
expression	O
by	O
iAs	O
exposure	O
in	O
HaCaT	O
cells	O
.	O

It	O
has	O
been	O
well	O
documented	O
that	O
the	O
ARE	O
core	O
sequence	O
includes	O
an	O
AP	O
-	O
1	O
-	O
like	O
binding	O
site	O
(	O
TGAC	O
/	O
GTCA	O
)	O
,	O
followed	O
by	O
a	O
GC	O
box	O
(	O
Rushmore	O
et	O
al	O
.	O
1991	O
;	O
Xie	O
et	O
al	O
.	O
1995	O
)	O
.	O

We	O
have	O
found	O
in	O
our	O
current	O
analyses	O
that	O
the	O
AP	O
-	O
1	O
-	O
like	O
site	O
within	O
the	O
K16	O
promoter	O
region	O
from	O
-	O
148	O
to	O
-	O
140	O
bp	O
(	O
5	O
'	O
-	O
GGAGTCAGC	O
-	O
3	O
'	O
)	O
resembles	O
a	O
consensus	O
ARE	O
sequence	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
AREs	O
can	O
be	O
specifically	O
bound	O
by	O
complexes	O
of	O
several	O
basic	O
-	O
leucine	O
zipper	O
transcription	O
factors	O
,	O
including	O
NRF2	O
(	O
Ishii	O
et	O
al	O
.	O
2000	O
;	O
Moi	O
et	O
al	O
.	O
1994	O
)	O
.	O

NRF2	O
heterodimerizes	O
with	O
either	O
AP	O
-	O
1	O
or	O
small	O
MAF	O
(	O
MAFG	O
,	O
MAFK	O
,	O
and	O
MAFF	O
)	O
proteins	O
(	O
MAF	O
,	O
v	O
-	O
maf	O
musculoaponeurotic	O
fibrosarcoma	O
oncogene	O
homolog	O
)	O
and	O
binds	O
to	O
the	O
ARE	O
to	O
induce	O
the	O
transcription	O
of	O
ARE	O
-	O
mediated	O
genes	O
(	O
Motohashi	O
et	O
al	O
.	O
2002	O
)	O
.	O

In	O
the	O
present	O
investigation	O
,	O
EMSA	O
and	O
supershift	O
assays	O
showed	O
that	O
the	O
NRF2	O
proteins	O
in	O
the	O
nuclei	O
bind	O
to	O
the	O
ARE	O
sequences	O
of	O
K16	O
promoter	O
region	O
after	O
iAs	O
exposure	O
.	O

iAs	O
-	O
induced	O
c	O
-	O
Jun	O
,	O
however	O
,	O
does	O
not	O
bind	O
to	O
this	O
ARE	O
(	O
Figure	O
4E	O
)	O
.	O

c	O
-	O
Jun	O
may	O
thus	O
act	O
on	O
other	O
AP	O
-	O
1	O
sites	O
within	O
the	O
K16	O
promoter	O
region	O
.	O

These	O
results	O
also	O
suggest	O
that	O
other	O
heterodimer	O
partners	O
of	O
NRF2	O
are	O
involved	O
in	O
the	O
ARE	O
regulation	O
of	O
K16	O
promoter	O
region	O
underlying	O
iAs	O
-	O
mediated	O
the	O
K16	O
gene	O
expression	O
.	O

Gel	O
shifts	O
with	O
an	O
K16Mut	O
-	O
ARE	O
probe	O
(	O
harboring	O
a	O
mutation	O
in	O
the	O
ARE	O
GC	O
box	O
)	O
clearly	O
show	O
that	O
the	O
ARE	O
sequence	O
in	O
the	O
K16	O
promoter	O
,	O
particularly	O
the	O
terminal	O
GC	O
dinucleotide	O
,	O
is	O
essential	O
for	O
mediating	O
iAs	O
-	O
induced	O
K16	O
transactivation	O
and	O
NRF2	O
binding	O
(	O
Figure	O
4F	O
)	O
.	O

Several	O
investigations	O
have	O
suggested	O
that	O
the	O
GC	O
nucleotides	O
within	O
the	O
ARE	O
are	O
essential	O
for	O
both	O
the	O
basal	O
and	O
oxidative	O
stress	O
-	O
induced	O
activities	O
of	O
the	O
ARE	O
-	O
related	O
genes	O
,	O
NAD	O
(	O
P	O
)	O
H	O
dehydrogenase	O
quinone	O
1	O
(	O
NQO1	O
)	O
and	O
glutamate	O
-	O
cysteine	O
ligase	O
catalytic	O
subunit	O
(	O
GCLC	O
)	O
(	O
Wasserman	O
and	O
Fahl	O
1997	O
;	O
Wild	O
et	O
al	O
.	O
1998	O
)	O
.	O

Our	O
current	O
results	O
are	O
consistent	O
with	O
these	O
earlier	O
studies	O
in	O
showing	O
that	O
the	O
formation	O
of	O
the	O
iAs	O
-	O
responsive	O
NRF2	O
/	O
ARE	O
complexes	O
is	O
reduced	O
by	O
a	O
mutation	O
in	O
the	O
GC	O
box	O
.	O

Collectively	O
,	O
our	O
present	O
observations	O
reveal	O
a	O
new	O
molecular	O
mechanism	O
in	O
which	O
iAs	O
-	O
induced	O
K16	O
gene	O
expression	O
is	O
also	O
regulated	O
by	O
activation	O
NRF2	O
/	O
ARE	O
pathways	O
.	O

It	O
has	O
been	O
widely	O
accepted	O
that	O
oxidative	O
stress	O
disrupts	O
sequestration	O
of	O
NRF2	O
by	O
KEAP1	O
,	O
permits	O
NRF2	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
transactivates	O
the	O
expression	O
of	O
various	O
NRF2	O
-	O
mediated	O
genes	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al	O
.	O
2002	O
;	O
McMahon	O
et	O
al	O
.	O
2003	O
)	O
.	O

Our	O
present	O
study	O
showed	O
that	O
iAs	O
elongates	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
but	O
has	O
no	O
effects	O
upon	O
KEAP1	O
expression	O
(	O
Figure	O
5	O
)	O
.	O

Other	O
studies	O
have	O
also	O
demonstrated	O
that	O
the	O
production	O
of	O
NRF2	O
is	O
increased	O
by	O
various	O
inducers	O
via	O
posttranscriptional	O
control	O
(	O
Nguyen	O
et	O
al	O
.	O
2003	O
;	O
Stewart	O
et	O
al	O
.	O
2003	O
)	O
.	O

Several	O
earlier	O
reports	O
also	O
indicated	O
that	O
either	O
oxidative	O
stress	O
or	O
antioxidant	O
substances	O
stabilize	O
the	O
expression	O
of	O
the	O
NRF2	O
protein	O
,	O
either	O
by	O
directly	O
modifying	O
the	O
cysteine	O
residues	O
on	O
KEAP1	O
to	O
disrupt	O
the	O
NRF2	O
/	O
KEAP1	O
complex	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al	O
.	O
2002	O
)	O
or	O
by	O
facilitating	O
the	O
release	O
of	O
NRF2	O
through	O
the	O
phosphorylation	O
of	O
the	O
NRF2	O
/	O
KEAP1	O
complex	O
(	O
Bloom	O
and	O
Jaiswal	O
2003	O
)	O
.	O

These	O
findings	O
are	O
largely	O
consistent	O
with	O
our	O
present	O
finding	O
that	O
iAs	O
stabilizes	O
the	O
expression	O
of	O
NRF2	O
in	O
HaCaT	O
cells	O
by	O
elongating	O
the	O
protein	O
half	O
-	O
life	O
.	O

Recently	O
,	O
Wakabayashi	O
et	O
al	O
.	O

(	O
2003	O
)	O
demonstrated	O
that	O
NRF2	O
accumulates	O
in	O
the	O
nucleus	O
at	O
constitutively	O
high	O
levels	O
and	O
produces	O
various	O
cytoprotective	O
genes	O
in	O
embryonic	O
fibroblast	O
-	O
and	O
liver	O
-	O
derived	O
Keap1	O
-	O
null	O
mice	S-Species
.	O

Surprisingly	O
,	O
these	O
Keap1	O
-	O
deficient	O
mice	S-Species
also	O
show	O
a	O
thicker	O
stratum	O
corneum	O
epidermis	O
,	O
abnormal	O
keratinization	O
,	O
and	O
cornification	O
in	O
the	O
esophagus	O
and	O
forestomach	O
(	O
hyperkeratosis	O
)	O
.	O

K6	O
was	O
found	O
to	O
be	O
strongly	O
expressed	O
in	O
the	O
esophageal	O
epithelium	O
of	O
these	O
mice	S-Species
.	O

These	O
results	O
indicate	O
that	O
K6	O
is	O
also	O
a	O
target	O
gene	O
of	O
NRF2	O
.	O

In	O
addition	O
,	O
the	O
promoter	O
of	O
the	O
K6	O
gene	O
bears	O
a	O
remarkable	O
sequence	O
similarity	O
to	O
the	O
K16	O
promoter	O
(	O
Jiang	O
et	O
al	O
.	O
1993	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
K16	O
gene	O
expression	O
is	O
also	O
regulated	O
by	O
NRF2	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
gene	O
expression	O
and	O
transactivation	O
of	O
K16	O
were	O
dramatically	O
induced	O
by	O
transfection	O
with	O
WT	O
-	O
NRF2	O
via	O
in	O
HaCaT	O
cells	O
,	O
clearly	O
demonstrating	O
that	O
NRF2	O
acts	O
as	O
a	O
direct	O
transcriptional	O
regulator	O
of	O
the	O
K16	O
gene	O
(	O
Figure	O
6	O
)	O
.	O

In	O
addition	O
,	O
we	O
also	O
showed	O
that	O
transfection	O
of	O
HaCaT	O
cells	O
with	O
WT	O
-	O
NRF2	O
induces	O
the	O
expression	O
of	O
detoxification	O
gene	O
TXN	O
(	O
Figure	O
6A	O
)	O
.	O

NRF2	O
may	O
thus	O
have	O
a	O
major	O
role	O
to	O
play	O
in	O
the	O
development	O
of	O
hyperkeratosis	O
,	O
whereas	O
the	O
expression	O
and	O
induction	O
of	O
NRF2	O
is	O
implicated	O
in	O
cell	O
protection	O
against	O
a	O
variety	O
of	O
genotoxic	O
and	O
cytotoxic	O
effects	O
.	O

Hence	O
,	O
based	O
on	O
these	O
results	O
and	O
on	O
the	O
findings	O
from	O
studies	O
of	O
Keap1	O
knockout	O
mice	S-Species
,	O
iAs	O
may	O
both	O
cause	O
hyperkeratosis	O
and	O
induce	O
detoxification	O
enzymes	O
via	O
the	O
modification	O
of	O
NRF2	O
.	O

Given	O
that	O
there	O
are	O
both	O
beneficial	O
and	O
adverse	O
effects	O
of	O
NRF2	O
activity	O
,	O
caution	O
will	O
therefore	O
be	O
needed	O
when	O
using	O
antioxidants	O
for	O
prevention	O
and	O
therapy	O
.	O

Although	O
further	O
investigations	O
are	O
needed	O
,	O
we	O
believe	O
that	O
our	O
findings	O
provide	O
important	O
clues	O
for	O
the	O
design	O
of	O
future	O
therapies	O
for	O
arsenic	O
-	O
mediated	O
hyperkeratosis	O
and	O
for	O
treatments	O
involving	O
the	O
molecular	O
targeting	O
of	O
NRF2	O
.	O

Conclusion	O

Our	O
findings	O
clearly	O
demonstrate	O
that	O
the	O
induction	O
of	O
the	O
K16	O
gene	O
in	O
human	S-Species
keratinocytes	O
by	O
iAs	O
depends	O
on	O
NRF2	O
activation	O
.	O

Our	O
results	O
thus	O
represent	O
a	O
valuable	O
initial	O
effort	O
to	O
elucidate	O
the	O
relationship	O
between	O
the	O
K16	O
gene	O
and	O
the	O
NRF2	O
transcription	O
factor	O
,	O
which	O
may	O
be	O
responsible	O
for	O
hyperkeratosis	O
.	O

Identification	O
and	O
Analysis	O
of	O
Co	O
-	O
Occurrence	O
Networks	O
with	O
NetCutter	O

Abstract	O

Background	O

Co	O
-	O
occurrence	O
analysis	O
is	O
a	O
technique	O
often	O
applied	O
in	O
text	O
mining	O
,	O
comparative	O
genomics	O
,	O
and	O
promoter	O
analysis	O
.	O

The	O
methodologies	O
and	O
statistical	O
models	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
association	O
between	O
co	O
-	O
occurring	O
entities	O
are	O
quite	O
diverse	O
,	O
however	O
.	O

Methodology	O
/	O
Principal	O
Findings	O

We	O
present	O
a	O
general	O
framework	O
for	O
co	O
-	O
occurrence	O
analysis	O
based	O
on	O
a	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
,	O
a	O
novel	O
co	O
-	O
occurrence	O
statistic	O
,	O
and	O
software	O
performing	O
co	O
-	O
occurrence	O
analysis	O
as	O
well	O
as	O
generation	O
and	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
show	O
that	O
the	O
overall	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
depends	O
critically	O
on	O
the	O
choice	O
of	O
the	O
null	O
-	O
model	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
and	O
find	O
that	O
random	O
sampling	O
from	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
optimal	O
stringency	O
.	O

We	O
show	O
that	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
is	O
the	O
most	O
natural	O
co	O
-	O
occurrence	O
probability	O
distribution	O
when	O
vertex	O
degrees	O
of	O
the	O
bipartite	O
graph	O
are	O
variable	O
,	O
which	O
is	O
usually	O
the	O
case	O
.	O

Calculation	O
of	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
is	O
difficult	O
,	O
however	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
fast	O
bi	O
-	O
binomial	O
approximation	O
for	O
calculation	O
of	O
P	O
-	O
values	O
and	O
show	O
that	O
this	O
statistic	O
is	O
superior	O
to	O
other	O
measures	O
of	O
association	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
and	O
the	O
uncertainty	O
coefficient	O
.	O

Furthermore	O
,	O
co	O
-	O
occurrence	O
analysis	O
of	O
more	O
than	O
two	O
entities	O
can	O
be	O
performed	O
using	O
the	O
same	O
statistical	O
model	O
,	O
which	O
leads	O
to	O
increased	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
,	O
robustness	O
towards	O
noise	O
,	O
and	O
the	O
identification	O
of	O
implicit	O
relationships	O
between	O
co	O
-	O
occurring	O
entities	O
.	O

Using	O
NetCutter	O
,	O
we	O
identify	O
a	O
novel	O
protein	O
biosynthesis	O
related	O
set	O
of	O
genes	O
that	O
are	O
frequently	O
coordinately	O
deregulated	O
in	O
human	S-Species
cancer	O
related	O
gene	O
expression	O
studies	O
.	O

NetCutter	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
bio	O
.	O
ifom	O
-	O
ieo	O
-	O
campus	O
.	O
it	O
/	O
NetCutter	O
/	O
)	O
.	O

Conclusion	O

Our	O
approach	O
can	O
be	O
applied	O
to	O
any	O
set	O
of	O
categorical	O
data	O
where	O
co	O
-	O
occurrence	O
analysis	O
might	O
reveal	O
functional	O
relationships	O
such	O
as	O
clinical	O
parameters	O
associated	O
with	O
cancer	O
subtypes	O
or	O
SNPs	O
associated	O
with	O
disease	O
phenotypes	O
.	O

The	O
stringency	O
of	O
our	O
approach	O
is	O
expected	O
to	O
offer	O
an	O
advantage	O
in	O
a	O
variety	O
of	O
applications	O
.	O

Introduction	O

Biological	O
research	O
has	O
experienced	O
a	O
paradigm	O
shift	O
in	O
the	O
last	O
decade	O
catalyzed	O
by	O
the	O
availability	O
of	O
genome	O
sequences	O
and	O
the	O
resulting	O
development	O
of	O
high	O
-	O
throughput	O
technologies	O
.	O

The	O
large	O
data	O
volumes	O
produced	O
by	O
these	O
novel	O
technologies	O
are	O
often	O
published	O
as	O
supplementary	O
material	O
and	O
/	O
or	O
stored	O
in	O
extensive	O
data	O
repositories	O
[	O
1	O
]	O
.	O

Functional	O
interpretation	O
of	O
these	O
data	O
is	O
an	O
ongoing	O
challenge	O
.	O

Co	O
-	O
occurrence	O
analysis	O
,	O
based	O
on	O
the	O
hypothesis	O
that	O
co	O
-	O
occurring	O
entities	O
are	O
functionally	O
linked	O
,	O
is	O
a	O
technique	O
that	O
has	O
been	O
used	O
in	O
three	O
main	O
areas	O
of	O
biological	O
research	O
:	O

Co	O
-	O
occurrence	O
of	O
genes	O
in	O
sequenced	O
genomes	O
relies	O
on	O
the	O
fact	O
that	O
proteins	O
do	O
not	O
function	O
in	O
isolation	O
and	O
are	O
dependent	O
on	O
other	O
proteins	O
,	O
either	O
as	O
direct	O
binding	O
partners	O
,	O
or	O
as	O
catalysts	O
of	O
substrates	O
.	O

Thus	O
,	O
when	O
two	O
proteins	O
significantly	O
co	O
-	O
occur	O
in	O
a	O
large	O
number	O
of	O
genomes	O
or	O
can	O
be	O
observed	O
as	O
fusion	O
proteins	O
in	O
a	O
subset	O
of	O
genomes	O
,	O
they	O
are	O
likely	O
to	O
be	O
binding	O
partners	O
or	O
enzymes	O
needed	O
for	O
a	O
specific	O
metabolic	O
pathway	O
.	O

Examples	O
of	O
those	O
studies	O
have	O
been	O
reported	O
by	O
[	O
2	O
]	O
-	O
[	O
7	O
]	O
.	O

Text	O
mining	O
is	O
a	O
quickly	O
evolving	O
field	O
that	O
aims	O
at	O
developing	O
technologies	O
helping	O
to	O
cope	O
with	O
the	O
functional	O
interpretation	O
of	O
large	O
volumes	O
of	O
publications	O
.	O

Co	O
-	O
occurrence	O
of	O
gene	O
names	O
in	O
publication	O
abstracts	O
,	O
entire	O
publications	O
,	O
or	O
other	O
gene	O
-	O
related	O
databases	O
has	O
been	O
used	O
to	O
derive	O
co	O
-	O
occurrence	O
networks	O
with	O
clear	O
evidence	O
that	O
edges	O
in	O
those	O
networks	O
are	O
reflecting	O
functionally	O
relevant	O
relationships	O
[	O
8	O
]	O
-	O
[	O
11	O
]	O
.	O

Gene	O
names	O
have	O
also	O
been	O
analyzed	O
for	O
co	O
-	O
occurrence	O
with	O
other	O
entities	O
such	O
as	O
mutations	O
[	O
12	O
]	O
,	O
chemical	O
compounds	O
[	O
13	O
]	O
,	O
and	O
disease	O
related	O
keywords	O
[	O
14	O
]	O
.	O

From	O
the	O
resulting	O
networks	O
,	O
hypotheses	O
about	O
candidate	O
genes	O
involved	O
in	O
inherited	O
diseases	O
and	O
drug	O
targets	O
can	O
be	O
derived	O
.	O

Clustering	O
of	O
gene	O
related	O
publications	O
using	O
keywords	O
has	O
been	O
applied	O
to	O
enhance	O
the	O
quality	O
of	O
gene	O
expression	O
clusters	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

More	O
general	O
(	O
non	O
gene	O
-	O
centric	O
)	O
approaches	O
try	O
to	O
organize	O
the	O
literature	O
into	O
functional	O
areas	O
based	O
on	O
co	O
-	O
occurrence	O
of	O
MeSH	O
terms	O
,	O
keywords	O
,	O
diseases	O
,	O
phenotypes	O
,	O
chemicals	O
,	O
and	O
similar	O
objects	O
of	O
biomedical	O
research	O
interest	O
[	O
17	O
]	O
-	O
[	O
21	O
]	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
transcription	O
factor	O
binding	O
motifs	O
has	O
been	O
carried	O
out	O
in	O
a	O
variety	O
of	O
slightly	O
differing	O
ways	O
in	O
a	O
wide	O
range	O
of	O
organisms	O
,	O
including	O
humans	S-Species
.	O

[	O
22	O
]	O
-	O
[	O
33	O
]	O
.	O

The	O
underlying	O
hypothesis	O
is	O
that	O
co	O
-	O
regulated	O
genes	O
,	O
identified	O
usually	O
by	O
gene	O
expression	O
studies	O
,	O
should	O
contain	O
specific	O
combinations	O
of	O
transcription	O
factor	O
binding	O
motifs	O
in	O
their	O
upstream	O
regulatory	O
regions	O
,	O
the	O
identification	O
of	O
which	O
would	O
allow	O
the	O
reverse	O
-	O
engineering	O
of	O
transcription	O
regulatory	O
networks	O
[	O
34	O
]	O
.	O

We	O
have	O
recently	O
applied	O
co	O
-	O
occurrence	O
analysis	O
to	O
studying	O
published	O
gene	O
expression	O
signatures	O
and	O
showed	O
that	O
co	O
-	O
occurrence	O
patterns	O
of	O
genes	O
reflect	O
cancer	O
signaling	O
pathways	O
[	O
35	O
]	O
.	O

Although	O
co	O
-	O
occurrence	O
analysis	O
has	O
a	O
respectable	O
history	O
,	O
the	O
methodologies	O
used	O
in	O
the	O
studies	O
mentioned	O
above	O
could	O
not	O
be	O
easily	O
applied	O
to	O
studying	O
gene	O
expression	O
signatures	O
.	O

There	O
are	O
three	O
main	O
reasons	O
that	O
dictated	O
the	O
use	O
of	O
a	O
different	O
approach	O
.	O

First	O
,	O
gene	O
expression	O
signatures	O
can	O
vary	O
in	O
size	O
by	O
orders	O
of	O
magnitude	O
.	O

Obviously	O
,	O
the	O
larger	O
a	O
signature	O
the	O
more	O
likely	O
it	O
is	O
to	O
find	O
two	O
or	O
more	O
genes	O
co	O
-	O
occurring	O
in	O
that	O
signature	O
.	O

Thus	O
,	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
must	O
be	O
evaluated	O
in	O
the	O
presence	O
of	O
considerable	O
heterogeneity	O
of	O
co	O
-	O
occurrence	O
probabilities	O
among	O
gene	O
lists	O
.	O

As	O
a	O
consequence	O
,	O
the	O
statistics	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
events	O
must	O
reflect	O
this	O
heterogeneity	O
.	O

In	O
particular	O
,	O
it	O
must	O
be	O
based	O
on	O
list	O
-	O
specific	O
co	O
-	O
occurrence	O
probabilities	O
.	O

Second	O
,	O
in	O
the	O
vast	O
majority	O
of	O
previous	O
studies	O
,	O
co	O
-	O
occurrence	O
is	O
analyzed	O
for	O
pair	O
-	O
wise	O
combinations	O
of	O
co	O
-	O
occurring	O
entities	O
.	O

We	O
found	O
that	O
the	O
resulting	O
stringency	O
of	O
this	O
approach	O
is	O
not	O
adequate	O
for	O
the	O
analysis	O
of	O
published	O
gene	O
expression	O
signatures	O
[	O
35	O
]	O
.	O

Third	O
,	O
the	O
null	O
-	O
model	O
against	O
which	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
is	O
tested	O
does	O
not	O
work	O
well	O
for	O
gene	O
expression	O
signatures	O
.	O

A	O
common	O
procedure	O
is	O
to	O
use	O
generic	O
randomization	O
of	O
the	O
entire	O
data	O
set	O
under	O
analysis	O
or	O
to	O
select	O
subsets	O
of	O
data	O
entries	O
randomly	O
for	O
comparison	O
purposes	O
.	O

However	O
,	O
gene	O
expression	O
signatures	O
are	O
composed	O
of	O
distinct	O
gene	O
sets	O
and	O
the	O
null	O
-	O
model	O
must	O
maintain	O
this	O
property	O
,	O
which	O
is	O
not	O
guaranteed	O
using	O
these	O
approaches	O
.	O

Furthermore	O
,	O
the	O
list	O
-	O
specific	O
nature	O
of	O
co	O
-	O
occurrence	O
probabilities	O
cannot	O
be	O
dealt	O
with	O
properly	O
.	O

NetCutter	O
was	O
developed	O
to	O
address	O
these	O
challenges	O
and	O
to	O
provide	O
a	O
generic	O
tool	O
for	O
generating	O
and	O
analyzing	O
co	O
-	O
occurrence	O
networks	O
.	O

Although	O
NetCutter	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
gene	O
expression	O
signatures	O
,	O
it	O
is	O
based	O
on	O
abstract	O
concepts	O
that	O
make	O
it	O
applicable	O
to	O
a	O
wide	O
variety	O
of	O
problems	O
.	O

The	O
input	O
is	O
represented	O
by	O
a	O
bipartite	O
graph	O
that	O
is	O
composed	O
of	O
list	O
-	O
entry	O
pairs	O
,	O
which	O
are	O
stored	O
in	O
tab	O
-	O
separated	O
text	O
format	O
.	O

Co	O
-	O
occurrence	O
of	O
entries	O
in	O
lists	O
is	O
analyzed	O
using	O
pair	O
-	O
wise	O
or	O
higher	O
order	O
combinations	O
of	O
entries	O
.	O

The	O
significance	O
of	O
co	O
-	O
occurrence	O
is	O
tested	O
using	O
a	O
novel	O
bi	O
-	O
binomial	O
approximation	O
of	O
Poisson	O
-	O
binomial	O
statistics	O
(	O
which	O
is	O
a	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
that	O
handles	O
list	O
-	O
length	O
-	O
heterogeneity	O
properly	O
and	O
provides	O
a	O
novel	O
measure	O
of	O
association	O
that	O
is	O
found	O
to	O
be	O
superior	O
to	O
the	O
Jaccard	O
and	O
the	O
uncertainty	O
coefficients	O
.	O

Occurrence	O
probabilities	O
are	O
obtained	O
from	O
an	O
edge	O
-	O
swapping	O
procedure	O
that	O
maintains	O
vertex	O
degrees	O
in	O
the	O
underlying	O
bipartite	O
graph	O
and	O
distinct	O
sets	O
of	O
entries	O
per	O
list	O
.	O

As	O
we	O
shall	O
see	O
below	O
,	O
this	O
procedure	O
has	O
a	O
number	O
of	O
advantages	O
over	O
other	O
possible	O
null	O
-	O
models	O
and	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
near	O
maximum	O
stringency	O
.	O

Last	O
but	O
not	O
least	O
,	O
NetCutter	O
is	O
equipped	O
with	O
a	O
number	O
of	O
algorithms	O
for	O
the	O
identification	O
of	O
network	O
communities	O
,	O
vertex	O
ranking	O
,	O
and	O
convenience	O
tools	O
needed	O
in	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
or	O
any	O
undirected	O
graph	O
.	O

We	O
illustrate	O
the	O
utility	O
of	O
NetCutter	O
in	O
the	O
identification	O
of	O
corresponding	O
clusters	O
of	O
genes	O
and	O
publications	O
from	O
the	O
PubLiME	O
data	O
set	O
.	O

PubLiME	O
(	O
Published	O
Lists	O
of	O
Microarray	O
Experiments	O
)	O
is	O
a	O
repository	O
of	O
published	O
cancer	O
related	O
gene	O
expression	O
signatures	O
(	O
http	O
:	O
/	O
/	O
bio	O
.	O
ifom	O
-	O
ieo	O
-	O
campus	O
.	O
it	O
/	O
Publime	O
)	O
.	O

The	O
concept	O
of	O
cluster	O
correspondence	O
follows	O
from	O
the	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
.	O

Reversing	O
the	O
list	O
-	O
entry	O
order	O
in	O
the	O
bipartite	O
graph	O
permits	O
identifying	O
communities	O
of	O
entries	O
as	O
well	O
as	O
communities	O
of	O
lists	O
.	O

We	O
show	O
that	O
communities	O
of	O
publications	O
corresponding	O
to	O
communities	O
of	O
genes	O
in	O
the	O
PubLiME	O
data	O
set	O
can	O
be	O
used	O
to	O
generate	O
hypotheses	O
about	O
the	O
putative	O
function	O
of	O
gene	O
communities	O
.	O

Results	O

The	O
bipartite	O
graph	O
model	O
of	O
co	O
-	O
occurrence	O
analysis	O

Co	O
-	O
occurrence	O
analysis	O
using	O
NetCutter	O
is	O
based	O
on	O
the	O
abstraction	O
of	O
list	O
-	O
entry	O
pairs	O
.	O

Any	O
entity	O
that	O
co	O
-	O
occurs	O
with	O
some	O
other	O
entity	O
must	O
be	O
confined	O
to	O
some	O
sort	O
of	O
container	O
where	O
co	O
-	O
occurrence	O
is	O
observed	O
.	O

For	O
example	O
,	O
in	O
the	O
case	O
of	O
gene	O
name	O
co	O
-	O
occurrence	O
in	O
PubMed	O
abstracts	O
,	O
the	O
abstract	O
is	O
the	O
container	O
and	O
the	O
gene	O
names	O
are	O
the	O
co	O
-	O
occurring	O
entities	O
.	O

Similarly	O
,	O
co	O
-	O
occurrence	O
of	O
transcription	O
factor	O
binding	O
motifs	O
is	O
observed	O
in	O
gene	O
promoters	O
.	O

The	O
promoters	O
are	O
the	O
containers	O
where	O
motif	O
entities	O
co	O
-	O
occur	O
.	O

The	O
containers	O
generally	O
host	O
more	O
than	O
one	O
entity	O
(	O
otherwise	O
co	O
-	O
occurrence	O
would	O
be	O
impossible	O
)	O
and	O
can	O
be	O
conveniently	O
interpreted	O
as	O
lists	O
.	O

The	O
co	O
-	O
occurring	O
entities	O
are	O
the	O
list	O
entries	O
.	O

Lists	O
and	O
entries	O
form	O
a	O
bipartite	O
graph	O
with	O
one	O
part	O
of	O
the	O
graph	O
representing	O
lists	O
and	O
the	O
other	O
part	O
representing	O
entries	O
.	O

The	O
presence	O
of	O
a	O
given	O
entry	O
in	O
a	O
given	O
list	O
is	O
indicated	O
by	O
an	O
edge	O
between	O
the	O
corresponding	O
list	O
and	O
entry	O
vertices	O
.	O

It	O
is	O
required	O
that	O
each	O
entry	O
can	O
be	O
linked	O
to	O
the	O
same	O
list	O
only	O
once	O
.	O

Without	O
loss	O
of	O
generality	O
,	O
let	O
'	O
s	O
consider	O
genes	O
as	O
entries	O
and	O
PubMedID	O
_	O
listIDs	O
as	O
lists	O
in	O
the	O
following	O
,	O
unless	O
otherwise	O
specified	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

This	O
interpretation	O
of	O
lists	O
and	O
entries	O
has	O
been	O
applied	O
in	O
the	O
co	O
-	O
occurrence	O
analysis	O
of	O
published	O
gene	O
expression	O
signatures	O
[	O
35	O
]	O
.	O

Occurrence	O
probabilities	O
and	O
null	O
-	O
models	O

A	O
prerequisite	O
for	O
co	O
-	O
occurrence	O
analysis	O
is	O
the	O
availability	O
of	O
occurrence	O
probabilities	O
of	O
genes	O
per	O
list	O
.	O

The	O
occurrence	O
probabilities	O
can	O
be	O
derived	O
from	O
randomizing	O
the	O
bipartite	O
graph	O
and	O
are	O
dependent	O
on	O
the	O
choice	O
of	O
the	O
null	O
-	O
model	O
.	O

A	O
null	O
-	O
model	O
creates	O
an	O
occurrence	O
probability	O
matrix	O
where	O
the	O
occurrence	O
probability	O
for	O
each	O
list	O
-	O
gene	O
pair	O
is	O
listed	O
.	O

As	O
a	O
general	O
property	O
of	O
this	O
matrix	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
must	O
equal	O
the	O
number	O
of	O
edges	O
in	O
the	O
bipartite	O
graph	O
.	O

This	O
is	O
because	O
each	O
edge	O
is	O
linked	O
to	O
either	O
side	O
of	O
the	O
bipartite	O
graph	O
with	O
certainty	O
and	O
therefore	O
the	O
sum	O
of	O
occurrence	O
probabilities	O
over	O
all	O
lists	O
(	O
which	O
can	O
be	O
calculated	O
as	O
the	O
row	O
sum	O
if	O
genes	O
are	O
listed	O
vertically	O
or	O
as	O
the	O
column	O
sum	O
if	O
genes	O
are	O
listed	O
horizontally	O
)	O
followed	O
by	O
summing	O
the	O
results	O
over	O
all	O
genes	O
must	O
be	O
1	O
for	O
every	O
edge	O
.	O

The	O
number	O
of	O
matrix	O
elements	O
is	O
given	O
by	O
#	O
genes	O
*	O
#	O
lists	O
and	O
therefore	O
the	O
average	O
occurrence	O
probability	O
for	O
any	O
null	O
-	O
model	O
must	O
be	O
#	O
edges	O
/	O
(	O
#	O
genes	O
*	O
#	O
lists	O
)	O
.	O

As	O
a	O
consequence	O
,	O
different	O
null	O
-	O
models	O
will	O
only	O
be	O
distinguished	O
by	O
the	O
way	O
they	O
attribute	O
occurrence	O
probabilities	O
to	O
vertices	O
with	O
different	O
vertex	O
degrees	O
but	O
not	O
by	O
the	O
average	O
occurrence	O
probability	O
.	O

We	O
consider	O
six	O
different	O
strategies	O
to	O
randomize	O
the	O
bipartite	O
graph	O
.	O

First	O
,	O
we	O
could	O
reconnect	O
all	O
edges	O
of	O
the	O
graph	O
randomly	O
.	O

The	O
probability	O
of	O
being	O
connected	O
by	O
an	O
edge	O
for	O
a	O
given	O
list	O
-	O
gene	O
pair	O
is	O
given	O
by	O
(	O
1	O
/	O
#	O
genes	O
)	O
*	O
(	O
1	O
/	O
#	O
lists	O
)	O
.	O

Since	O
there	O
are	O
#	O
edges	O
edges	O
to	O
be	O
reconnected	O
,	O
the	O
occurrence	O
probability	O
for	O
a	O
single	O
list	O
-	O
gene	O
pair	O
is	O
#	O
edges	O
/	O
(	O
#	O
genes	O
*	O
#	O
lists	O
)	O
,	O
i	O
.	O
e	O
.	O
equal	O
to	O
the	O
average	O
occurrence	O
probability	O
.	O

Thus	O
,	O
this	O
model	O
provides	O
equal	O
occurrence	O
probabilities	O
for	O
all	O
gene	O
-	O
list	O
pairs	O
and	O
does	O
not	O
consider	O
vertex	O
degrees	O
.	O

We	O
call	O
this	O
model	O
the	O
generic	O
randomization	O
(	O
GR	O
)	O
model	O
in	O
the	O
following	O
.	O

Second	O
,	O
we	O
could	O
disconnect	O
the	O
edges	O
on	O
only	O
the	O
list	O
side	O
of	O
the	O
bipartite	O
graph	O
and	O
reconnect	O
them	O
randomly	O
.	O

The	O
occurrence	O
probability	O
of	O
a	O
gene	O
vertex	O
would	O
be	O
given	O
by	O
(	O
gene	O
vertex	O
degree	O
)	O
/	O
#	O
lists	O
.	O

The	O
sum	O
of	O
these	O
probabilities	O
over	O
all	O
lists	O
is	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
and	O
the	O
sum	O
of	O
all	O
gene	O
vertex	O
degrees	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Thus	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
equal	O
to	O
the	O
number	O
of	O
edges	O
,	O
as	O
required	O
.	O

Since	O
this	O
model	O
considers	O
gene	O
vertex	O
degrees	O
,	O
we	O
call	O
it	O
the	O
gene	O
vertex	O
degree	O
(	O
GVD	O
)	O
model	O
.	O

Third	O
,	O
we	O
disconnect	O
the	O
edges	O
on	O
the	O
gene	O
side	O
of	O
the	O
bipartite	O
graph	O
and	O
reconnect	O
them	O
randomly	O
.	O

The	O
probability	O
of	O
a	O
list	O
vertex	O
being	O
connected	O
to	O
a	O
gene	O
would	O
be	O
given	O
by	O
(	O
list	O
vertex	O
degree	O
)	O
/	O
#	O
genes	O
.	O

The	O
sum	O
of	O
these	O
probabilities	O
over	O
all	O
genes	O
is	O
equal	O
to	O
the	O
list	O
vertex	O
degree	O
and	O
the	O
sum	O
of	O
all	O
list	O
vertex	O
degrees	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Again	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Since	O
this	O
model	O
considers	O
list	O
vertex	O
degrees	O
,	O
we	O
call	O
it	O
the	O
list	O
vertex	O
degree	O
(	O
LVD	O
)	O
model	O
.	O

In	O
model	O
four	O
and	O
five	O
,	O
we	O
reconnect	O
edges	O
considering	O
both	O
gene	O
and	O
list	O
vertex	O
degrees	O
and	O
allow	O
multiple	O
edges	O
between	O
list	O
-	O
gene	O
pairs	O
.	O

The	O
occurrence	O
probabilities	O
in	O
model	O
four	O
are	O
calculated	O
according	O
to	O
the	O
binomial	O
distribution	O
.	O

We	O
calculate	O
the	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
for	O
being	O
connected	O
as	O
the	O
cumulative	O
binomial	O
probability	O
of	O
the	O
list	O
-	O
gene	O
pair	O
being	O
chosen	O
at	O
least	O
once	O
in	O
the	O
process	O
of	O
randomly	O
reconnecting	O
the	O
edges	O
.	O

This	O
can	O
be	O
achieved	O
by	O
setting	O
the	O
number	O
of	O
trials	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
,	O
the	O
probability	O
of	O
success	O
equal	O
to	O
the	O
list	O
vertex	O
degree	O
divided	O
by	O
the	O
total	O
number	O
of	O
edges	O
,	O
and	O
the	O
number	O
of	O
successes	O
equal	O
to	O
0	O
.	O

The	O
occurrence	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
is	O
then	O
given	O
by	O
the	O
complement	O
of	O
this	O
probability	O
.	O

This	O
model	O
is	O
called	O
the	O
binomial	O
(	O
BN	O
)	O
model	O
.	O

In	O
model	O
five	O
,	O
we	O
calculate	O
occurrence	O
probabilities	O
according	O
to	O
the	O
hypergeometric	O
distribution	O
.	O

The	O
number	O
of	O
successes	O
in	O
the	O
sample	O
is	O
equal	O
to	O
0	O
,	O
the	O
sample	O
size	O
is	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
,	O
the	O
number	O
of	O
successes	O
in	O
the	O
population	O
is	O
set	O
to	O
the	O
list	O
vertex	O
degree	O
,	O
and	O
the	O
population	O
size	O
is	O
the	O
total	O
number	O
of	O
edges	O
.	O

Again	O
,	O
the	O
occurrence	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
is	O
obtained	O
as	O
the	O
complement	O
of	O
this	O
probability	O
.	O

We	O
call	O
this	O
model	O
the	O
hypergeometric	O
(	O
HG	O
)	O
model	O
.	O

Calculating	O
occurrence	O
probabilities	O
in	O
this	O
manner	O
does	O
not	O
guarantee	O
that	O
the	O
matrix	O
elements	O
add	O
up	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Therefore	O
,	O
the	O
matrices	O
are	O
normalized	O
such	O
that	O
this	O
condition	O
is	O
satisfied	O
by	O
multiplying	O
each	O
matrix	O
element	O
with	O
the	O
factor	O
#	O
edges	O
/	O
(	O
observed	O
matrix	O
sum	O
)	O
,	O
which	O
is	O
generally	O
quite	O
close	O
to	O
1	O
,	O
however	O
.	O

In	O
model	O
six	O
,	O
we	O
again	O
consider	O
vertex	O
degrees	O
,	O
but	O
we	O
require	O
that	O
each	O
list	O
is	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

Thus	O
,	O
multiple	O
edges	O
are	O
forbidden	O
.	O

This	O
condition	O
is	O
satisfied	O
by	O
applying	O
an	O
edge	O
-	O
swapping	O
procedure	O
during	O
graph	O
randomization	O
.	O

Edge	O
-	O
swapping	O
works	O
by	O
randomly	O
choosing	O
two	O
list	O
-	O
gene	O
pairs	O
from	O
the	O
bipartite	O
graph	O
and	O
prior	O
to	O
performing	O
the	O
edge	O
-	O
swap	O
,	O
a	O
test	O
is	O
performed	O
to	O
ensure	O
that	O
the	O
two	O
genes	O
are	O
not	O
already	O
linked	O
to	O
the	O
respective	O
target	O
lists	O
.	O

This	O
procedure	O
is	O
performed	O
a	O
large	O
number	O
of	O
times	O
.	O

To	O
ensure	O
complete	O
randomization	O
of	O
the	O
graph	O
,	O
the	O
number	O
of	O
swaps	O
performed	O
should	O
be	O
significantly	O
larger	O
than	O
the	O
number	O
of	O
edges	O
.	O

After	O
performing	O
R	O
randomizations	O
of	O
the	O
graph	O
and	O
counting	O
the	O
number	O
of	O
times	O
a	O
gene	O
has	O
been	O
linked	O
to	O
a	O
particular	O
list	O
,	O
division	O
of	O
this	O
number	O
by	O
R	O
gives	O
the	O
occurrence	O
probability	O
of	O
a	O
gene	O
in	O
a	O
given	O
list	O
.	O

As	O
will	O
be	O
shown	O
below	O
,	O
edge	O
-	O
swapping	O
produces	O
occurrence	O
probabilities	O
that	O
closely	O
approximate	O
occurrence	O
probabilities	O
obtained	O
by	O
generating	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
,	O
counting	O
the	O
number	O
of	O
times	O
a	O
gene	O
is	O
found	O
part	O
of	O
a	O
list	O
,	O
and	O
dividing	O
this	O
number	O
by	O
the	O
total	O
number	O
of	O
permutations	O
.	O

In	O
the	O
permutation	O
model	O
,	O
the	O
sum	O
of	O
occurrence	O
probabilities	O
of	O
a	O
gene	O
over	O
all	O
lists	O
equals	O
the	O
gene	O
vertex	O
degree	O
(	O
see	O
below	O
)	O
and	O
thus	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
the	O
number	O
of	O
edges	O
.	O

Since	O
permutation	O
sets	O
of	O
bipartite	O
graphs	O
are	O
difficult	O
to	O
calculate	O
,	O
we	O
use	O
the	O
edge	O
-	O
swapping	O
procedure	O
as	O
a	O
close	O
approximation	O
and	O
call	O
this	O
model	O
the	O
edge	O
-	O
swapping	O
(	O
ES	O
)	O
model	O
.	O

Fig	O
.	O

1	O
shows	O
the	O
occurrence	O
probabilities	O
of	O
the	O
different	O
null	O
-	O
models	O
for	O
the	O
bipartite	O
graph	O
shown	O
in	O
Fig	O
.	O

1A	O
.	O

The	O
GR	O
model	O
yields	O
identical	O
occurrence	O
probabilities	O
for	O
all	O
list	O
-	O
gene	O
pairs	O
,	O
which	O
is	O
equal	O
to	O
the	O
average	O
occurrence	O
probability	O
in	O
all	O
models	O
.	O

In	O
the	O
other	O
models	O
,	O
the	O
occurrence	O
probabilities	O
deviate	O
to	O
varying	O
extent	O
from	O
the	O
average	O
occurrence	O
probability	O
as	O
a	O
function	O
of	O
vertex	O
degrees	O
.	O

In	O
the	O
GVD	O
model	O
,	O
the	O
deviations	O
are	O
a	O
function	O
of	O
gene	O
vertex	O
degree	O
and	O
in	O
the	O
LVD	O
model	O
the	O
deviations	O
are	O
dependent	O
on	O
list	O
vertex	O
degrees	O
.	O

In	O
the	O
remaining	O
models	O
,	O
the	O
deviations	O
are	O
functions	O
of	O
both	O
the	O
gene	O
and	O
the	O
list	O
vertex	O
degrees	O
.	O

In	O
all	O
cases	O
,	O
larger	O
than	O
average	O
occurrence	O
probabilities	O
are	O
obtained	O
for	O
larger	O
vertex	O
degrees	O
at	O
the	O
expense	O
of	O
smaller	O
than	O
average	O
occurrence	O
probabilities	O
for	O
smaller	O
vertex	O
degrees	O
.	O

From	O
these	O
data	O
,	O
it	O
is	O
difficult	O
to	O
choose	O
the	O
most	O
effective	O
null	O
-	O
model	O
.	O

A	O
hint	O
can	O
be	O
gleaned	O
from	O
gene1	O
,	O
however	O
.	O

Gene1	O
is	O
present	O
in	O
all	O
lists	O
.	O

Therefore	O
,	O
the	O
co	O
-	O
occurrence	O
probability	O
of	O
gene1	O
with	O
other	O
genes	O
,	O
which	O
is	O
calculated	O
by	O
multiplying	O
the	O
occurrence	O
probabilities	O
of	O
gene1	O
and	O
geneX	O
for	O
every	O
list	O
under	O
study	O
,	O
should	O
depend	O
only	O
on	O
the	O
occurrence	O
probability	O
of	O
this	O
other	O
gene	O
.	O

In	O
other	O
words	O
,	O
the	O
occurrence	O
probability	O
of	O
gene1	O
in	O
all	O
lists	O
should	O
be	O
1	O
.	O
0	O
.	O

Only	O
two	O
models	O
satisfy	O
this	O
constraint	O
:	O
The	O
GVD	O
and	O
the	O
ES	O
models	O
.	O

Since	O
the	O
GVD	O
model	O
does	O
not	O
consider	O
list	O
vertex	O
degrees	O
,	O
it	O
seems	O
that	O
the	O
ES	O
model	O
is	O
the	O
preferred	O
null	O
-	O
model	O
.	O

Expected	O
number	O
of	O
co	O
-	O
occurrences	O

As	O
a	O
general	O
criterion	O
for	O
comparing	O
the	O
effectiveness	O
of	O
different	O
null	O
-	O
models	O
,	O
we	O
have	O
to	O
compare	O
them	O
for	O
the	O
number	O
of	O
expected	O
co	O
-	O
occurrences	O
.	O

The	O
most	O
effective	O
null	O
-	O
model	O
will	O
be	O
the	O
one	O
that	O
maximizes	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

If	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
larger	O
,	O
an	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
in	O
a	O
real	O
bipartite	O
graph	O
will	O
be	O
less	O
significant	O
and	O
thus	O
such	O
a	O
null	O
-	O
model	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
higher	O
stringency	O
.	O

The	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
depends	O
in	O
an	O
obvious	O
fashion	O
on	O
the	O
list	O
vertex	O
degree	O
.	O

If	O
pair	O
-	O
wise	O
co	O
-	O
occurrences	O
are	O
considered	O
,	O
the	O
number	O
of	O
co	O
-	O
occurrences	O
in	O
a	O
list	O
of	O
vertex	O
degree	O
N	O
is	O
given	O
by	O
the	O
binomial	O
coefficient	O
N	O
over	O
2	O
.	O

Larger	O
lists	O
will	O
give	O
rise	O
to	O
more	O
co	O
-	O
occurrences	O
and	O
the	O
number	O
increases	O
quickly	O
with	O
list	O
vertex	O
degree	O
.	O

The	O
dependency	O
of	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
on	O
the	O
gene	O
vertex	O
degree	O
is	O
less	O
obvious	O
and	O
depends	O
strongly	O
on	O
the	O
null	O
-	O
model	O
.	O

A	O
gene	O
that	O
is	O
part	O
of	O
a	O
list	O
with	O
vertex	O
degree	O
N	O
will	O
give	O
rise	O
to	O
N	O
-	O
1	O
co	O
-	O
occurrences	O
in	O
that	O
list	O
.	O

The	O
null	O
-	O
model	O
permits	O
calculating	O
the	O
probability	O
to	O
find	O
this	O
gene	O
in	O
a	O
given	O
list	O
.	O

Thus	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
of	O
a	O
gene	O
is	O
given	O
by	O
the	O
sum	O
of	O
expected	O
co	O
-	O
occurrences	O
in	O
all	O
lists	O
where	O
for	O
a	O
single	O
list	O
the	O
expected	O
co	O
-	O
occurrences	O
are	O
given	O
by	O
(	O
Nl	O
-	O
1	O
)	O
*	O
pl	O
.	O

Nl	O
is	O
the	O
list	O
vertex	O
degree	O
and	O
pl	O
is	O
the	O
occurrence	O
probability	O
of	O
the	O
gene	O
in	O
that	O
list	O
as	O
determined	O
by	O
the	O
null	O
-	O
model	O
.	O

We	O
used	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
to	O
calculate	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
with	O
different	O
null	O
-	O
models	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
2A	O
.	O

The	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
was	O
calculated	O
for	O
all	O
genes	O
in	O
all	O
lists	O
using	O
all	O
null	O
-	O
models	O
and	O
the	O
sum	O
of	O
expected	O
co	O
-	O
occurrences	O
per	O
gene	O
is	O
shown	O
as	O
a	O
scatter	O
plot	O
with	O
the	O
gene	O
vertex	O
degree	O
on	O
the	O
x	O
-	O
axis	O
and	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
on	O
the	O
y	O
-	O
axis	O
.	O

The	O
results	O
in	O
Fig	O
.	O

2A	O
suggest	O
the	O
following	O
ranking	O
of	O
null	O
-	O
models	O
:	O
GR	O
<	O
GVD	O
<	O
LVD	O
<	O
BN	O
=	O
HG	O
<	O
ES	O
.	O

The	O
BN	O
and	O
the	O
HG	O
models	O
perform	O
in	O
an	O
essentially	O
identical	O
way	O
.	O

However	O
,	O
the	O
ES	O
model	O
is	O
the	O
model	O
that	O
yields	O
the	O
largest	O
estimates	O
of	O
expected	O
co	O
-	O
occurrences	O
.	O

The	O
results	O
are	O
also	O
in	O
line	O
with	O
the	O
intuitive	O
expectation	O
that	O
genes	O
with	O
higher	O
vertex	O
degree	O
give	O
rise	O
to	O
more	O
co	O
-	O
occurrences	O
.	O

However	O
,	O
it	O
can	O
be	O
seen	O
that	O
this	O
is	O
not	O
true	O
for	O
all	O
null	O
-	O
models	O
.	O

In	O
particular	O
,	O
it	O
is	O
not	O
true	O
for	O
the	O
GR	O
and	O
the	O
LVD	O
models	O
,	O
which	O
do	O
not	O
consider	O
gene	O
vertex	O
degrees	O
.	O

As	O
outlined	O
above	O
,	O
it	O
is	O
expected	O
that	O
the	O
null	O
-	O
model	O
that	O
yields	O
the	O
highest	O
estimates	O
of	O
expected	O
co	O
-	O
occurrences	O
should	O
permit	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
.	O

In	O
Fig	O
.	O

2B	O
,	O
this	O
hypothesis	O
is	O
tested	O
directly	O
again	O
using	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
.	O

For	O
all	O
null	O
-	O
models	O
,	O
co	O
-	O
occurrence	O
analysis	O
was	O
carried	O
out	O
using	O
module	O
size	O
3	O
and	O
support	O
5	O
(	O
co	O
-	O
occurrence	O
modules	O
must	O
be	O
present	O
in	O
at	O
least	O
five	O
publications	O
)	O
.	O

The	O
choice	O
of	O
these	O
parameters	O
has	O
been	O
discussed	O
in	O
[	O
35	O
]	O
.	O

The	O
number	O
of	O
co	O
-	O
occurrence	O
modules	O
was	O
then	O
determined	O
that	O
have	O
a	O
Z	O
-	O
score	O
higher	O
or	O
equal	O
than	O
the	O
cut	O
-	O
off	O
shown	O
in	O
Fig	O
.	O

2B	O
.	O

The	O
Z	O
-	O
score	O
is	O
calculated	O
from	O
the	O
mean	O
and	O
variance	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
as	O
shown	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
and	O
published	O
in	O
[	O
35	O
]	O
.	O

More	O
details	O
on	O
the	O
probability	O
distribution	O
will	O
be	O
provided	O
below	O
.	O

The	O
GR	O
and	O
GVD	O
models	O
perform	O
very	O
poorly	O
and	O
identify	O
large	O
numbers	O
of	O
modules	O
with	O
high	O
Z	O
-	O
scores	O
.	O

The	O
LVD	O
model	O
performs	O
a	O
little	O
better	O
and	O
approximates	O
the	O
BN	O
and	O
HG	O
models	O
at	O
higher	O
Z	O
-	O
score	O
cut	O
-	O
offs	O
.	O

The	O
BN	O
and	O
HG	O
models	O
give	O
essentially	O
identical	O
results	O
.	O

However	O
,	O
the	O
ES	O
model	O
is	O
the	O
model	O
that	O
yields	O
the	O
fewest	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
and	O
is	O
thus	O
the	O
most	O
stringent	O
.	O

The	O
increased	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
the	O
BN	O
and	O
HG	O
models	O
is	O
also	O
reflected	O
in	O
a	O
higher	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
calculated	O
as	O
the	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
divided	O
by	O
the	O
number	O
of	O
modules	O
found	O
in	O
a	O
randomized	O
bipartite	O
graph	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

The	O
reason	O
for	O
the	O
superior	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
all	O
other	O
models	O
can	O
be	O
explained	O
by	O
examining	O
the	O
average	O
occurrence	O
probability	O
per	O
gene	O
and	O
list	O
vertex	O
degree	O
.	O

Fig	O
.	O

2D	O
and	O
E	O
show	O
the	O
average	O
occurrence	O
probability	O
of	O
genes	O
with	O
the	O
same	O
gene	O
vertex	O
degree	O
as	O
a	O
function	O
of	O
the	O
gene	O
vertex	O
degree	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
ES	O
model	O
yields	O
higher	O
occurrence	O
probability	O
estimates	O
for	O
genes	O
with	O
higher	O
vertex	O
degrees	O
as	O
compared	O
to	O
the	O
BN	O
and	O
HG	O
models	O
.	O

In	O
GR	O
and	O
LVD	O
models	O
,	O
gene	O
vertex	O
degrees	O
are	O
ignored	O
and	O
occurrence	O
probabilities	O
for	O
genes	O
with	O
large	O
vertex	O
degree	O
are	O
very	O
small	O
,	O
which	O
is	O
compensated	O
by	O
larger	O
occurrence	O
probabilities	O
for	O
genes	O
with	O
small	O
vertex	O
degree	O
.	O

The	O
GVD	O
model	O
is	O
identical	O
to	O
the	O
ES	O
model	O
in	O
this	O
setting	O
.	O

Fig	O
.	O

2E	O
shows	O
the	O
average	O
occurrence	O
probability	O
of	O
all	O
lists	O
with	O
the	O
same	O
vertex	O
degree	O
as	O
a	O
function	O
of	O
list	O
vertex	O
degree	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
ES	O
model	O
provides	O
higher	O
occurrence	O
probability	O
estimates	O
for	O
large	O
lists	O
as	O
compared	O
to	O
the	O
BN	O
and	O
HG	O
models	O
.	O

In	O
this	O
setting	O
,	O
the	O
LVD	O
model	O
performs	O
like	O
the	O
ES	O
model	O
while	O
the	O
GR	O
and	O
GVD	O
models	O
yield	O
small	O
occurrence	O
probabilities	O
for	O
large	O
lists	O
.	O

Since	O
it	O
has	O
been	O
shown	O
above	O
that	O
long	O
lists	O
and	O
genes	O
with	O
high	O
vertex	O
degree	O
are	O
responsible	O
for	O
a	O
large	O
part	O
of	O
the	O
total	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
the	O
most	O
stringent	O
null	O
-	O
models	O
,	O
the	O
null	O
-	O
model	O
that	O
provides	O
larger	O
occurrence	O
probability	O
estimates	O
for	O
genes	O
and	O
lists	O
with	O
high	O
vertex	O
degree	O
at	O
the	O
expense	O
of	O
lower	O
estimates	O
for	O
smaller	O
degrees	O
will	O
be	O
the	O
most	O
stringent	O
because	O
large	O
occurrence	O
probabilities	O
make	O
co	O
-	O
occurrence	O
more	O
likely	O
and	O
thus	O
less	O
significant	O
.	O

By	O
these	O
criteria	O
,	O
the	O
ES	O
model	O
is	O
the	O
most	O
stringent	O
of	O
all	O
models	O
tested	O
.	O

The	O
ES	O
model	O
as	O
an	O
approximation	O
of	O
the	O
permutation	O
null	O
-	O
model	O

The	O
data	O
shown	O
above	O
have	O
revealed	O
that	O
the	O
ES	O
model	O
is	O
the	O
best	O
of	O
the	O
models	O
tested	O
.	O

One	O
may	O
wonder	O
,	O
however	O
,	O
whether	O
yet	O
more	O
effective	O
null	O
-	O
models	O
can	O
be	O
found	O
.	O

An	O
obvious	O
choice	O
would	O
be	O
the	O
permutation	O
model	O
.	O

In	O
the	O
permutation	O
model	O
,	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
is	O
created	O
such	O
that	O
each	O
list	O
is	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

The	O
number	O
of	O
graphs	O
where	O
a	O
gene	O
is	O
present	O
in	O
a	O
given	O
list	O
divided	O
by	O
the	O
total	O
number	O
of	O
permutations	O
then	O
provides	O
the	O
occurrence	O
probability	O
estimate	O
.	O

The	O
permutation	O
model	O
is	O
the	O
ideal	O
null	O
-	O
model	O
because	O
it	O
is	O
exhaustive	O
.	O

The	O
problem	O
is	O
that	O
a	O
complete	O
permutation	O
set	O
of	O
bipartite	O
graphs	O
of	O
some	O
complexity	O
is	O
very	O
time	O
consuming	O
to	O
calculate	O
.	O

For	O
example	O
,	O
the	O
simple	O
bipartite	O
graph	O
from	O
Fig	O
.	O

1A	O
is	O
part	O
of	O
a	O
permutation	O
set	O
of	O
455	O
graphs	O
.	O

The	O
number	O
of	O
permutations	O
is	O
increasing	O
quickly	O
as	O
the	O
numbers	O
of	O
genes	O
and	O
lists	O
grow	O
.	O

However	O
,	O
since	O
edge	O
-	O
swapping	O
ensures	O
that	O
gene	O
lists	O
are	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
,	O
each	O
edge	O
-	O
swap	O
produces	O
a	O
graph	O
that	O
is	O
part	O
of	O
the	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
.	O

Edge	O
-	O
swapping	O
can	O
thus	O
be	O
viewed	O
as	O
a	O
random	O
sampling	O
procedure	O
from	O
the	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
.	O

Therefore	O
,	O
occurrence	O
probability	O
estimates	O
derived	O
by	O
edge	O
-	O
swapping	O
should	O
approximate	O
those	O
obtained	O
from	O
the	O
permutation	O
model	O
.	O

We	O
generated	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
graph	O
shown	O
in	O
Fig	O
.	O

1A	O
to	O
verify	O
this	O
hypothesis	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
.	O

3	O
.	O

Fig	O
.	O

3A	O
shows	O
how	O
the	O
number	O
of	O
possible	O
permutations	O
can	O
be	O
calculated	O
.	O

Gene1	O
is	O
present	O
in	O
all	O
lists	O
and	O
does	O
not	O
have	O
an	O
impact	O
on	O
the	O
total	O
number	O
of	O
permutations	O
.	O

Gene2	O
,	O
having	O
vertex	O
degree	O
two	O
,	O
is	O
present	O
in	O
two	O
out	O
of	O
three	O
lists	O
in	O
one	O
out	O
of	O
three	O
possible	O
ways	O
.	O

The	O
remaining	O
genes	O
have	O
vertex	O
degree	O
1	O
and	O
can	O
be	O
freely	O
chosen	O
to	O
fill	O
the	O
empty	O
slots	O
.	O

We	O
can	O
now	O
count	O
exactly	O
how	O
many	O
times	O
a	O
gene	O
is	O
linked	O
to	O
a	O
list	O
and	O
divide	O
these	O
counts	O
by	O
455	O
,	O
the	O
size	O
of	O
the	O
permutation	O
set	O
,	O
to	O
obtain	O
exact	O
occurrence	O
probabilities	O
.	O

These	O
numbers	O
are	O
shown	O
in	O
graphical	O
form	O
in	O
Fig	O
.	O

3B	O
and	O
in	O
numerical	O
form	O
in	O
Fig	O
.	O

3C	O
.	O

Fig	O
.	O

3B	O
also	O
shows	O
the	O
occurrence	O
probability	O
estimates	O
obtained	O
by	O
edge	O
-	O
swapping	O
side	O
-	O
by	O
-	O
side	O
to	O
the	O
exact	O
occurrence	O
probabilities	O
.	O

The	O
graph	O
in	O
Fig	O
.	O

1A	O
was	O
subjected	O
to	O
edge	O
-	O
swapping	O
1000	O
times	O
and	O
the	O
number	O
of	O
times	O
a	O
gene	O
was	O
found	O
present	O
in	O
a	O
list	O
was	O
divided	O
by	O
1000	O
to	O
obtain	O
the	O
occurrence	O
probability	O
.	O

At	O
each	O
run	O
,	O
100	O
random	O
edge	O
swaps	O
were	O
performed	O
to	O
ensure	O
complete	O
randomization	O
of	O
the	O
graph	O
.	O

This	O
procedure	O
was	O
repeated	O
10	O
times	O
and	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
occurrence	O
probability	O
estimates	O
for	O
each	O
gene	O
in	O
each	O
list	O
are	O
shown	O
.	O

In	O
all	O
cases	O
,	O
the	O
mean	O
differs	O
from	O
the	O
real	O
probability	O
by	O
less	O
than	O
two	O
standard	O
deviations	O
,	O
in	O
most	O
cases	O
by	O
less	O
than	O
one	O
standard	O
deviation	O
.	O

Thus	O
,	O
edge	O
-	O
swapping	O
provides	O
reliable	O
estimates	O
of	O
exact	O
occurrence	O
probabilities	O
as	O
determined	O
from	O
a	O
complete	O
permutation	O
set	O
.	O

As	O
an	O
interesting	O
observation	O
,	O
we	O
provide	O
evidence	O
that	O
occurrence	O
probabilities	O
are	O
non	O
-	O
linear	O
functions	O
of	O
vertex	O
degrees	O
in	O
the	O
edge	O
-	O
swapping	O
model	O
.	O

This	O
is	O
illustrated	O
in	O
Fig	O
.	O

3C	O
.	O

Individual	O
and	O
average	O
occurrence	O
probabilities	O
are	O
shown	O
as	O
a	O
function	O
of	O
gene	O
and	O
list	O
vertex	O
degrees	O
.	O

Non	O
-	O
linearity	O
of	O
individual	O
occurrence	O
probabilities	O
can	O
be	O
verified	O
from	O
the	O
counts	O
table	O
underneath	O
the	O
plots	O
.	O

However	O
,	O
the	O
average	O
occurrence	O
probability	O
is	O
found	O
to	O
depend	O
on	O
vertex	O
degrees	O
in	O
a	O
linear	O
fashion	O
instead	O
.	O

This	O
is	O
a	O
consequence	O
of	O
the	O
fact	O
that	O
occurrence	O
probabilities	O
of	O
a	O
gene	O
over	O
all	O
lists	O
add	O
up	O
to	O
the	O
gene	O
vertex	O
degree	O
and	O
that	O
the	O
occurrence	O
probabilities	O
of	O
all	O
genes	O
for	O
a	O
given	O
list	O
add	O
up	O
to	O
the	O
list	O
vertex	O
degree	O
.	O

At	O
the	O
same	O
time	O
,	O
since	O
the	O
most	O
stringent	O
permutation	O
based	O
null	O
-	O
model	O
predicts	O
non	O
-	O
linear	O
dependencies	O
of	O
individual	O
occurrence	O
probabilities	O
on	O
vertex	O
degrees	O
,	O
assuming	O
such	O
linearity	O
in	O
statistical	O
models	O
of	O
co	O
-	O
occurrence	O
will	O
be	O
linked	O
to	O
loss	O
of	O
stringency	O
.	O

We	O
conclude	O
that	O
the	O
ES	O
null	O
-	O
model	O
is	O
the	O
null	O
-	O
model	O
that	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
among	O
the	O
models	O
tested	O
and	O
that	O
it	O
closely	O
approximates	O
occurrence	O
probabilities	O
derived	O
from	O
an	O
ideal	O
permutation	O
model	O
.	O

The	O
increased	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
other	O
models	O
is	O
a	O
consequence	O
of	O
higher	O
occurrence	O
probabilities	O
for	O
genes	O
and	O
list	O
with	O
high	O
vertex	O
degrees	O
,	O
which	O
are	O
giving	O
rise	O
to	O
a	O
large	O
part	O
of	O
all	O
co	O
-	O
occurrences	O
in	O
the	O
bipartite	O
graph	O
.	O

Since	O
large	O
occurrence	O
probabilities	O
make	O
co	O
-	O
occurrence	O
more	O
likely	O
,	O
the	O
analysis	O
becomes	O
more	O
stringent	O
.	O

Co	O
-	O
occurrence	O
probabilities	O

Co	O
-	O
occurrence	O
analysis	O
can	O
be	O
thought	O
of	O
as	O
a	O
Bernoulli	O
experiment	O
with	O
a	O
binomial	O
outcome	O
(	O
a	O
given	O
combination	O
of	O
entries	O
is	O
either	O
present	O
or	O
not	O
present	O
in	O
a	O
given	O
list	O
)	O
.	O

Thus	O
,	O
the	O
Binomial	O
distribution	O
(	O
BD	O
)	O
is	O
a	O
natural	O
choice	O
for	O
judging	O
the	O
significance	O
of	O
the	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

However	O
,	O
the	O
BD	O
is	O
defined	O
for	O
a	O
probability	O
of	O
success	O
which	O
is	O
equal	O
in	O
all	O
trials	O
.	O

The	O
list	O
-	O
specific	O
nature	O
of	O
occurrence	O
probabilities	O
is	O
not	O
compatible	O
with	O
this	O
condition	O
(	O
analysis	O
of	O
each	O
list	O
represents	O
one	O
trial	O
)	O
,	O
which	O
means	O
that	O
co	O
-	O
occurrence	O
analysis	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
better	O
described	O
as	O
a	O
series	O
of	O
Poisson	O
trials	O
,	O
where	O
the	O
probability	O
of	O
success	O
varies	O
from	O
trial	O
to	O
trial	O
.	O

Therefore	O
,	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
must	O
be	O
evaluated	O
using	O
a	O
binomial	O
distribution	O
with	O
trial	O
-	O
specific	O
probabilities	O
,	O
i	O
.	O
e	O
.	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
PBD	O
)	O
.	O

The	O
probability	O
of	O
success	O
in	O
a	O
single	O
Poisson	O
trial	O
can	O
be	O
calculated	O
by	O
multiplying	O
the	O
list	O
-	O
specific	O
occurrence	O
probabilities	O
for	O
the	O
combination	O
of	O
genes	O
under	O
study	O
.	O

The	O
number	O
of	O
occurrence	O
probabilities	O
that	O
need	O
to	O
be	O
multiplied	O
is	O
equal	O
to	O
the	O
module	O
size	O
,	O
i	O
.	O
e	O
.	O
the	O
number	O
of	O
genes	O
whose	O
combination	O
is	O
studied	O
.	O

An	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
a	O
combination	O
of	O
genes	O
can	O
then	O
be	O
evaluated	O
using	O
the	O
PBD	O
,	O
which	O
is	O
given	O
by	O
the	O
formula	O
[	O
36	O
]	O
:	O
(	O
18	O
)	O

The	O
structure	O
of	O
this	O
formula	O
is	O
very	O
similar	O
to	O
the	O
structure	O
of	O
the	O
formula	O
used	O
to	O
calculate	O
the	O
binomial	O
distribution	O
,	O
except	O
that	O
multiplication	O
with	O
a	O
binomial	O
coefficient	O
is	O
replaced	O
by	O
summation	O
over	O
individual	O
terms	O
,	O
which	O
makes	O
calculation	O
of	O
P	O
-	O
values	O
using	O
(	O
18	O
)	O
inefficient	O
(	O
note	O
that	O
equation	O
numbering	O
starts	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
)	O
.	O

Here	O
,	O
Ak	O
denotes	O
the	O
kth	O
set	O
of	O
indices	O
of	O
the	O
i	O
lists	O
where	O
genes	O
are	O
co	O
-	O
occurring	O
(	O
"	O
success	O
"	O
)	O
.	O

There	O
are	O
possible	O
sets	O
and	O
summation	O
is	O
carried	O
out	O
accordingly	O
.	O
denotes	O
the	O
set	O
of	O
indices	O
of	O
N	O
-	O
i	O
lists	O
where	O
genes	O
are	O
not	O
co	O
-	O
occurring	O
(	O
"	O
failure	O
"	O
)	O
.	O

[	O
36	O
]	O
have	O
reported	O
two	O
fast	O
procedures	O
for	O
calculating	O
exact	O
PBD	O
P	O
-	O
values	O
.	O

However	O
,	O
both	O
procedures	O
work	O
with	O
probability	O
ratios	O
and	O
suffer	O
from	O
numerical	O
overflow	O
/	O
underflow	O
problems	O
for	O
large	O
numbers	O
of	O
trials	O
.	O

NetCutter	O
uses	O
two	O
workarounds	O
to	O
circumvent	O
this	O
problem	O
.	O

One	O
is	O
based	O
on	O
using	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
,	O
which	O
can	O
be	O
calculated	O
very	O
easily	O
instead	O
(	O
see	O
below	O
)	O
.	O

The	O
other	O
relies	O
on	O
a	O
fast	O
approximation	O
procedure	O
for	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
,	O
which	O
we	O
call	O
bi	O
-	O
binomial	O
approximation	O
(	O
BBA	O
)	O
or	O
bi	O
-	O
binomial	O
distribution	O
(	O
BBD	O
)	O
.	O

Z	O
-	O
scores	O
and	O
P	O
-	O
values	O
of	O
BBD	O

Given	O
the	O
mean	O
mu	O
(	O
1	O
)	O
and	O
variance	O
sigma	O
2	O
(	O
2	O
)	O
of	O
PBD	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
,	O
the	O
Z	O
-	O
score	O
associated	O
with	O
a	O
given	O
number	O
of	O
co	O
-	O
occurrences	O
x	O
is	O
obtained	O
as	O
:	O
(	O
19	O
)	O

Considering	O
the	O
structure	O
of	O
formulae	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
(	O
Materials	O
and	O
Methods	O
section	O
)	O
,	O
PBD	O
Z	O
-	O
scores	O
can	O
be	O
calculated	O
very	O
easily	O
and	O
provide	O
a	O
simple	O
estimate	O
of	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
modules	O
.	O

However	O
,	O
in	O
contrast	O
to	O
normally	O
distributed	O
Z	O
-	O
scores	O
,	O
binomial	O
and	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
do	O
not	O
correspond	O
to	O
the	O
same	O
P	O
-	O
value	O
for	O
different	O
sets	O
of	O
probabilities	O
of	O
success	O
.	O

To	O
see	O
this	O
,	O
calculate	O
for	O
example	O
the	O
probability	O
of	O
success	O
in	O
a	O
series	O
of	O
100	O
Bernoulli	O
trials	O
with	O
success	O
probability	O
0	O
.	O
1	O
and	O
0	O
.	O
9	O
for	O
the	O
expectation	O
of	O
10	O
and	O
90	O
successes	O
,	O
respectively	O
.	O

The	O
Z	O
-	O
score	O
will	O
be	O
0	O
in	O
both	O
cases	O
but	O
the	O
corresponding	O
cumulative	O
P	O
-	O
values	O
are	O
0	O
.	O
5832	O
and	O
0	O
.	O
5487	O
.	O

Therefore	O
,	O
exact	O
levels	O
of	O
significance	O
cannot	O
be	O
derived	O
from	O
Z	O
-	O
scores	O
alone	O
.	O

Thus	O
,	O
a	O
fast	O
and	O
reliable	O
procedure	O
for	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
is	O
needed	O
.	O

The	O
BBD	O
approximation	O
was	O
developed	O
to	O
solve	O
this	O
problem	O
.	O

The	O
BBD	O
approximation	O
of	O
PBD	O
P	O
-	O
values	O
follows	O
from	O
the	O
relationship	O
between	O
the	O
variance	O
of	O
PBD	O
and	O
the	O
population	O
variance	O
of	O
trial	O
-	O
specific	O
probabilities	O
of	O
success	O
.	O

This	O
relationship	O
is	O
shown	O
in	O
Materials	O
and	O
Methods	O
to	O
be	O
described	O
by	O
(	O
4	O
)	O
:	O
(	O
4	O
)	O

This	O
equation	O
shows	O
that	O
there	O
is	O
an	O
inverse	O
linear	O
relationship	O
between	O
the	O
population	O
variance	O
S2	O
of	O
the	O
N	O
trial	O
probabilities	O
and	O
the	O
variance	O
of	O
PBD	O
sigma	O
2	O
,	O
which	O
means	O
that	O
PBD	O
becomes	O
increasingly	O
narrow	O
as	O
the	O
variance	O
of	O
trial	O
probabilities	O
grows	O
.	O

It	O
also	O
shows	O
that	O
,	O
for	O
constant	O
mean	O
mu	O
and	O
number	O
of	O
trials	O
N	O
,	O
the	O
shape	O
of	O
PBD	O
depends	O
only	O
on	O
the	O
variance	O
of	O
trial	O
probabilities	O
.	O

Therefore	O
,	O
relationship	O
(	O
4	O
)	O
suggests	O
an	O
easy	O
way	O
to	O
approximate	O
PBD	O
P	O
-	O
values	O
.	O

The	O
P	O
-	O
value	O
can	O
be	O
obtained	O
by	O
constructing	O
a	O
set	O
of	O
trial	O
probabilities	O
with	O
equal	O
variance	O
as	O
the	O
original	O
set	O
of	O
trial	O
probabilities	O
,	O
which	O
,	O
however	O
,	O
are	O
not	O
all	O
different	O
.	O

In	O
other	O
words	O
,	O
the	O
series	O
of	O
Poisson	O
trials	O
can	O
be	O
replaced	O
by	O
two	O
sets	O
of	O
Bernoulli	O
trials	O
with	O
trial	O
probabilities	O
p1	O
and	O
p2	O
constructed	O
such	O
that	O
the	O
variance	O
is	O
equal	O
to	O
the	O
original	O
set	O
of	O
trial	O
probabilities	O
.	O

This	O
strategy	O
is	O
illustrated	O
in	O
Fig	O
.	O

4	O
and	O
explains	O
why	O
this	O
approximation	O
is	O
called	O
bi	O
-	O
binomial	O
.	O

The	O
details	O
on	O
how	O
to	O
obtain	O
the	O
values	O
of	O
the	O
two	O
sets	O
of	O
Bernoulli	O
trial	O
probabilities	O
and	O
the	O
number	O
of	O
trials	O
with	O
p1	O
and	O
p2	O
as	O
probabilities	O
of	O
success	O
are	O
provided	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

The	O
precision	O
of	O
the	O
BBD	O
approximation	O
is	O
discussed	O
in	O
supplementary	O
material	O
Simulation	O
S1	O
.	O

In	O
order	O
to	O
evaluate	O
whether	O
BBD	O
P	O
-	O
values	O
as	O
a	O
significance	O
measure	O
of	O
co	O
-	O
occurrence	O
offer	O
an	O
advantage	O
over	O
other	O
measures	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
or	O
the	O
uncertainty	O
coefficient	O
,	O
pair	O
-	O
wise	O
co	O
-	O
occurrence	O
of	O
two	O
genes	O
in	O
200	O
lists	O
with	O
and	O
without	O
list	O
-	O
length	O
-	O
heterogeneity	O
was	O
studied	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Each	O
gene	O
is	O
assumed	O
to	O
occur	O
in	O
100	O
lists	O
.	O

Therefore	O
,	O
the	O
occurrence	O
probabilities	O
of	O
both	O
genes	O
over	O
all	O
200	O
lists	O
must	O
add	O
up	O
to	O
100	O
,	O
regardless	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

For	O
simplicity	O
,	O
occurrence	O
probabilities	O
of	O
both	O
genes	O
are	O
assumed	O
to	O
be	O
equal	O
in	O
any	O
particular	O
list	O
.	O

The	O
co	O
-	O
occurrence	O
probability	O
in	O
a	O
list	O
is	O
then	O
given	O
by	O
the	O
square	O
of	O
the	O
occurrence	O
probability	O
in	O
that	O
list	O
.	O

For	O
all	O
possible	O
co	O
-	O
occurrences	O
from	O
0	O
to	O
100	O
,	O
the	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
were	O
calculated	O
as	O
detailed	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

In	O
addition	O
,	O
cumulative	O
BBD	O
P	O
-	O
values	O
were	O
calculated	O
using	O
the	O
co	O
-	O
occurrence	O
probabilities	O
as	O
trial	O
probabilities	O
.	O

To	O
illustrate	O
the	O
advantage	O
of	O
BBD	O
over	O
BD	O
as	O
co	O
-	O
occurrence	O
probability	O
distribution	O
,	O
cumulative	O
BD	O
P	O
-	O
values	O
of	O
a	O
BD	O
with	O
the	O
same	O
mean	O
as	O
BBD	O
but	O
constant	O
trial	O
probabilities	O
is	O
shown	O
.	O

These	O
trial	O
probabilities	O
can	O
be	O
obtained	O
by	O
dividing	O
the	O
mean	O
of	O
BBD	O
by	O
the	O
number	O
of	O
lists	O
.	O

Three	O
different	O
cases	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
are	O
considered	O
in	O
Fig	O
.	O

5	O
:	O
No	O
heterogeneity	O
(	O
standard	O
deviation	O
0	O
)	O
,	O
heterogeneity	O
with	O
standard	O
deviation	O
0	O
.	O
283	O
and	O
heterogeneity	O
with	O
standard	O
deviation	O
0	O
.	O
401	O
in	O
the	O
occurrence	O
probabilities	O
.	O

The	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
are	O
by	O
definition	O
insensitive	O
to	O
list	O
-	O
length	O
-	O
heterogeneity	O
because	O
differences	O
in	O
co	O
-	O
occurrence	O
probabilities	O
in	O
a	O
given	O
list	O
cannot	O
be	O
considered	O
in	O
their	O
calculation	O
.	O

This	O
is	O
because	O
both	O
coefficients	O
are	O
defined	O
by	O
the	O
counts	O
of	O
the	O
four	O
list	O
classes	O
:	O
both	O
genes	O
absent	O
,	O
both	O
genes	O
present	O
,	O
first	O
gene	O
absent	O
second	O
gene	O
present	O
,	O
and	O
first	O
gene	O
present	O
second	O
gene	O
absent	O
,	O
i	O
.	O
e	O
.	O
by	O
the	O
corresponding	O
contingency	O
table	O
,	O
which	O
does	O
not	O
change	O
with	O
different	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

In	O
the	O
absence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
cumulative	O
P	O
-	O
values	O
of	O
BD	O
and	O
BBD	O
(	O
which	O
are	O
perfectly	O
overlapping	O
as	O
expected	O
)	O
assume	O
0	O
.	O
5	O
at	O
50	O
co	O
-	O
occurrences	O
,	O
which	O
corresponds	O
to	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
calculated	O
as	O
(	O
50	O
=	O
100	O
occurrences	O
per	O
gene	O
/	O
200	O
lists	O
)	O
^	O
2	O
*	O
200	O
lists	O
.	O

The	O
uncertainty	O
coefficient	O
is	O
found	O
to	O
be	O
0	O
and	O
the	O
Jaccard	O
coefficient	O
is	O
0	O
.	O
33333	O
at	O
that	O
point	O
.	O

When	O
there	O
is	O
modest	O
list	O
-	O
length	O
-	O
heterogeneity	O
(	O
standard	O
deviation	O
0	O
.	O
283	O
)	O
,	O
the	O
mean	O
of	O
BBD	O
is	O
shifting	O
to	O
the	O
right	O
.	O

This	O
is	O
because	O
the	O
sum	O
of	O
squares	O
of	O
varying	O
occurrence	O
probabilities	O
(	O
i	O
.	O
e	O
.	O
the	O
sum	O
of	O
co	O
-	O
occurrence	O
probabilities	O
used	O
as	O
trial	O
probabilities	O
,	O
which	O
is	O
equal	O
to	O
the	O
mean	O
of	O
BBD	O
)	O
is	O
always	O
larger	O
than	O
the	O
sum	O
of	O
squares	O
of	O
constant	O
occurrence	O
probabilities	O
with	O
the	O
same	O
average	O
occurrence	O
probability	O
(	O
0	O
.	O
5	O
)	O
.	O

The	O
corresponding	O
BD	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
obtained	O
by	O
dividing	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
by	O
the	O
total	O
number	O
of	O
lists	O
,	O
which	O
means	O
assuming	O
equal	O
co	O
-	O
occurrences	O
in	O
all	O
lists	O
.	O

This	O
visualization	O
is	O
shown	O
to	O
illustrate	O
how	O
BBD	O
(	O
which	O
is	O
narrower	O
than	O
the	O
corresponding	O
BD	O
)	O
gives	O
rise	O
to	O
a	O
steeper	O
cumulative	O
distribution	O
of	O
P	O
-	O
values	O
and	O
as	O
a	O
consequence	O
to	O
more	O
significant	O
P	O
-	O
values	O
for	O
numbers	O
of	O
co	O
-	O
occurrence	O
that	O
are	O
far	O
from	O
the	O
expectation	O
.	O

As	O
the	O
level	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
grows	O
(	O
standard	O
deviation	O
of	O
occurrence	O
probabilities	O
0	O
.	O
401	O
)	O
,	O
the	O
mean	O
of	O
BBD	O
is	O
shifted	O
even	O
further	O
to	O
the	O
right	O
and	O
BBD	O
P	O
-	O
values	O
are	O
distributed	O
in	O
a	O
still	O
steeper	O
fashion	O
as	O
compared	O
to	O
corresponding	O
BD	O
P	O
-	O
values	O
and	O
the	O
interval	O
of	O
non	O
-	O
significant	O
co	O
-	O
occurrences	O
is	O
shrinking	O
further	O
.	O

With	O
modest	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
66	O
,	O
which	O
is	O
associated	O
with	O
a	O
Jaccard	O
coefficient	O
of	O
0	O
.	O
49	O
and	O
an	O
uncertainty	O
coefficient	O
of	O
0	O
.	O
075	O
.	O

In	O
the	O
case	O
of	O
large	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
82	O
with	O
J	O
=	O
0	O
.	O
69	O
and	O
UC	O
=	O
0	O
.	O
32	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
varies	O
strongly	O
with	O
the	O
level	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
and	O
that	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
associated	O
with	O
different	O
values	O
of	O
UC	O
and	O
J	O
.	O

To	O
complicate	O
matters	O
further	O
,	O
66	O
co	O
-	O
occurrences	O
(	O
J	O
=	O
0	O
.	O
49	O
,	O
UC	O
=	O
0	O
.	O
075	O
)	O
represent	O
significant	O
positive	O
association	O
(	O
PBBD	O
=	O
0	O
.	O
996	O
)	O
with	O
equal	O
list	O
lengths	O
,	O
no	O
significant	O
association	O
with	O
modest	O
differences	O
in	O
list	O
length	O
(	O
PBBD	O
=	O
0	O
.	O
536	O
)	O
and	O
strongly	O
negative	O
association	O
(	O
meaning	O
one	O
gene	O
excludes	O
the	O
other	O
)	O
with	O
strong	O
list	O
-	O
length	O
-	O
heterogeneity	O
(	O
PBBD	O
=	O
0	O
.	O
00016	O
)	O
.	O

Thus	O
,	O
the	O
same	O
J	O
and	O
UC	O
association	O
measure	O
is	O
obtained	O
for	O
positive	O
,	O
negative	O
,	O
and	O
absence	O
of	O
association	O
.	O

Therefore	O
,	O
the	O
meaning	O
of	O
these	O
measures	O
cannot	O
be	O
interpreted	O
properly	O
in	O
the	O
absence	O
of	O
knowledge	O
about	O
the	O
occurrence	O
probabilities	O
of	O
the	O
co	O
-	O
occurring	O
entities	O
.	O

Furthermore	O
,	O
the	O
data	O
in	O
Fig	O
.	O

5	O
also	O
show	O
that	O
neither	O
J	O
nor	O
UC	O
can	O
distinguish	O
between	O
positive	O
and	O
negative	O
association	O
while	O
this	O
is	O
easy	O
with	O
cumulative	O
BBD	O
P	O
-	O
values	O
:	O
Large	O
P	O
-	O
values	O
mean	O
positive	O
association	O
and	O
low	O
P	O
-	O
values	O
mean	O
negative	O
association	O
.	O

In	O
summary	O
,	O
we	O
conclude	O
that	O
BBD	O
provides	O
a	O
novel	O
association	O
measure	O
that	O
offers	O
a	O
number	O
of	O
advantages	O
over	O
the	O
existing	O
contingency	O
table	O
based	O
association	O
measures	O
Jaccard	O
coefficient	O
and	O
uncertainty	O
coefficient	O
.	O

The	O
results	O
in	O
Fig	O
.	O

5	O
also	O
show	O
that	O
significance	O
of	O
association	O
depends	O
critically	O
on	O
the	O
specific	O
distribution	O
of	O
co	O
-	O
occurring	O
entities	O
over	O
lists	O
of	O
varying	O
length	O
(	O
because	O
this	O
distribution	O
determines	O
the	O
occurrence	O
probabilities	O
)	O
and	O
that	O
contingency	O
table	O
based	O
methods	O
(	O
which	O
cannot	O
capture	O
this	O
distribution	O
)	O
should	O
be	O
avoided	O
in	O
the	O
presence	O
of	O
significant	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

Generation	O
of	O
co	O
-	O
occurrence	O
networks	O
and	O
the	O
identification	O
of	O
communities	O

The	O
procedures	O
outlined	O
above	O
allow	O
the	O
identification	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
any	O
type	O
of	O
bipartite	O
graph	O
.	O

Three	O
user	O
defined	O
parameters	O
have	O
an	O
impact	O
on	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
:	O
The	O
module	O
size	O
,	O
the	O
support	O
,	O
and	O
the	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
.	O

The	O
module	O
size	O
determines	O
how	O
many	O
entries	O
will	O
be	O
tested	O
for	O
co	O
-	O
occurrence	O
,	O
the	O
support	O
sets	O
a	O
lower	O
boundary	O
on	O
the	O
required	O
number	O
of	O
co	O
-	O
occurrences	O
,	O
and	O
the	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
sets	O
the	O
significance	O
threshold	O
.	O

In	O
general	O
,	O
higher	O
module	O
size	O
leads	O
to	O
more	O
stringent	O
co	O
-	O
occurrence	O
analysis	O
at	O
the	O
cost	O
of	O
computational	O
complexity	O
.	O

The	O
support	O
parameter	O
allows	O
limiting	O
this	O
complexity	O
by	O
filtering	O
out	O
co	O
-	O
occurrence	O
modules	O
which	O
co	O
-	O
occur	O
less	O
frequently	O
than	O
required	O
by	O
the	O
support	O
.	O

The	O
significance	O
cutoff	O
permits	O
adjusting	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
which	O
is	O
calculated	O
as	O
the	O
number	O
of	O
co	O
-	O
occurrence	O
modules	O
observed	O
in	O
the	O
real	O
versus	O
a	O
randomized	O
bipartite	O
graph	O
.	O

The	O
impact	O
of	O
these	O
parameters	O
on	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
has	O
been	O
reported	O
previously	O
for	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
and	O
is	O
illustrated	O
in	O
a	O
simulation	O
study	O
provided	O
as	O
supplementary	O
material	O
Simulation	O
S1	O
.	O

From	O
the	O
set	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
,	O
a	O
co	O
-	O
occurrence	O
network	O
is	O
generated	O
by	O
considering	O
each	O
entry	O
a	O
vertex	O
and	O
drawing	O
an	O
edge	O
between	O
any	O
two	O
vertices	O
,	O
which	O
have	O
been	O
part	O
of	O
the	O
same	O
significant	O
co	O
-	O
occurrence	O
module	O
[	O
35	O
]	O
.	O

An	O
important	O
question	O
in	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
regards	O
the	O
presence	O
of	O
network	O
communities	O
.	O

Communities	O
can	O
be	O
understood	O
as	O
groups	O
of	O
vertices	O
with	O
the	O
property	O
that	O
the	O
number	O
of	O
edges	O
running	O
within	O
groups	O
is	O
larger	O
than	O
expected	O
by	O
chance	O
and	O
that	O
the	O
number	O
of	O
edges	O
running	O
between	O
groups	O
is	O
lower	O
than	O
expected	O
by	O
chance	O
[	O
37	O
]	O
.	O

This	O
problem	O
of	O
partitioning	O
a	O
graph	O
is	O
often	O
referred	O
to	O
as	O
the	O
graph	O
-	O
cut	O
problem	O
(	O
hence	O
the	O
name	O
NetCutter	O
)	O
.	O

NetCutter	O
is	O
built	O
on	O
the	O
Java	O
Universal	O
Network	O
and	O
Graph	O
framework	O
(	O
JUNG	O
)	O
software	O
package	O
(	O
http	O
:	O
/	O
/	O
jung	O
.	O
sourceforge	O
.	O
net	O
)	O
,	O
which	O
provides	O
algorithms	O
for	O
solving	O
this	O
problem	O
.	O

In	O
particular	O
,	O
NetCutter	O
implements	O
the	O
Bicomponent	O
clustering	O
algorithm	O
[	O
38	O
]	O
,	O
the	O
Edge	O
-	O
Betweenness	O
clustering	O
algorithm	O
[	O
39	O
]	O
,	O
and	O
the	O
Exact	O
Flow	O
Community	O
algorithm	O
[	O
40	O
]	O
.	O

Furthermore	O
,	O
there	O
is	O
a	O
clustering	O
tool	O
that	O
is	O
not	O
part	O
of	O
the	O
JUNG	O
package	O
,	O
namely	O
an	O
algorithm	O
identifying	O
communities	O
using	O
eigenvectors	O
of	O
the	O
modularity	O
matrix	O
[	O
37	O
]	O
.	O

The	O
code	O
for	O
this	O
algorithm	O
was	O
kindly	O
provided	O
by	O
Mark	O
Newman	O
in	O
C	O
+	O
+	O
and	O
ported	O
to	O
Java	O
.	O

In	O
addition	O
to	O
these	O
tools	O
,	O
NetCutter	O
provides	O
a	O
number	O
of	O
convenience	O
functions	O
for	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
such	O
as	O
testing	O
the	O
significance	O
of	O
lists	O
reporting	O
a	O
set	O
of	O
entries	O
making	O
up	O
a	O
network	O
community	O
,	O
ranking	O
of	O
vertices	O
,	O
random	O
graph	O
generators	O
for	O
topological	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
and	O
others	O
.	O

Details	O
on	O
all	O
functions	O
are	O
provided	O
in	O
the	O
NetCutter	O
software	O
documentation	O
.	O

One	O
of	O
the	O
possible	O
applications	O
of	O
NetCutter	O
is	O
illustrated	O
below	O
.	O

This	O
application	O
is	O
tightly	O
linked	O
to	O
the	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
.	O

Namely	O
,	O
NetCutter	O
can	O
be	O
used	O
to	O
perform	O
co	O
-	O
occurrence	O
analysis	O
of	O
genes	O
or	O
list	O
derived	O
from	O
the	O
same	O
bipartite	O
graph	O
.	O

The	O
network	O
communities	O
identified	O
in	O
each	O
both	O
reflect	O
the	O
same	O
underlying	O
structure	O
of	O
the	O
bipartite	O
graph	O
.	O

In	O
the	O
case	O
of	O
gene	O
expression	O
signatures	O
stored	O
in	O
PubLiME	O
,	O
clusters	O
of	O
genes	O
correspond	O
to	O
clusters	O
of	O
publications	O
,	O
which	O
can	O
reveal	O
possible	O
functions	O
of	O
gene	O
clusters	O
.	O

Cluster	O
correspondence	O
and	O
association	O
studies	O

The	O
co	O
-	O
occurrence	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
published	O
previously	O
[	O
35	O
]	O
identified	O
5	O
major	O
network	O
communities	O
of	O
genes	O
with	O
consistent	O
functional	O
annotations	O
that	O
are	O
deregulated	O
in	O
cancer	O
related	O
gene	O
expression	O
signatures	O
.	O

This	O
analysis	O
was	O
performed	O
by	O
considering	O
all	O
genes	O
mentioned	O
in	O
a	O
particular	O
publication	O
as	O
a	O
single	O
signature	O
,	O
even	O
though	O
they	O
might	O
have	O
been	O
part	O
of	O
different	O
tables	O
and	O
cluster	O
analyses	O
.	O

Here	O
we	O
present	O
an	O
advanced	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
where	O
each	O
table	O
and	O
/	O
or	O
cluster	O
identified	O
in	O
a	O
given	O
publication	O
is	O
considered	O
as	O
a	O
separate	O
signature	O
.	O

This	O
brings	O
the	O
total	O
number	O
of	O
signatures	O
to	O
be	O
analyzed	O
to	O
1015	O
comprising	O
a	O
total	O
of	O
7358	O
differentially	O
regulated	O
genes	O
derived	O
from	O
233	O
publications	O
reporting	O
cancer	O
related	O
signatures	O
derived	O
from	O
human	S-Species
samples	O
.	O

We	O
use	O
this	O
analysis	O
to	O
illustrate	O
three	O
major	O
points	O
:	O
First	O
,	O
the	O
set	O
of	O
communities	O
reported	O
previously	O
is	O
reproduced	O
by	O
this	O
more	O
fine	O
-	O
grained	O
analysis	O
.	O

Second	O
,	O
the	O
set	O
of	O
gene	O
communities	O
corresponds	O
to	O
a	O
set	O
of	O
publication	O
communities	O
.	O

Third	O
,	O
associations	O
between	O
publications	O
and	O
gene	O
communities	O
can	O
be	O
calculated	O
with	O
higher	O
stringency	O
using	O
the	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
in	O
conjunction	O
with	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
as	O
compared	O
to	O
binomial	O
or	O
hypergeometric	O
statistics	O
.	O

The	O
bipartite	O
graph	O
to	O
be	O
analyzed	O
is	O
composed	O
of	O
PubMedID	O
_	O
listID	O
-	O
gene	O
pairs	O
(	O
see	O
supplementary	O
material	O
Table	O
S1	O
)	O
.	O

Co	O
-	O
occurrence	O
analysis	O
was	O
carried	O
out	O
in	O
two	O
ways	O
:	O
First	O
,	O
gene	O
co	O
-	O
occurrence	O
was	O
analyzed	O
and	O
communities	O
of	O
co	O
-	O
occurring	O
genes	O
were	O
defined	O
by	O
edge	O
-	O
betweenness	O
clustering	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Second	O
,	O
co	O
-	O
occurrence	O
of	O
PubMedID	O
_	O
listIDs	O
was	O
analyzed	O
.	O

To	O
this	O
end	O
,	O
the	O
order	O
of	O
PubMedID	O
_	O
listID	O
-	O
gene	O
pairs	O
was	O
reversed	O
to	O
form	O
GENE	O
-	O
PUBMEDID	O
_	O
LISTID	O
pairs	O
.	O

Thus	O
,	O
the	O
lists	O
in	O
the	O
resulting	O
bipartite	O
graph	O
are	O
formed	O
by	O
genes	O
and	O
the	O
entries	O
are	O
the	O
PubMedID	O
_	O
listIDs	O
where	O
the	O
genes	O
are	O
reported	O
as	O
differentially	O
regulated	O
.	O

Occurrence	O
probabilities	O
for	O
the	O
reversed	O
bipartite	O
graph	O
can	O
be	O
obtained	O
by	O
transposing	O
the	O
occurrence	O
probability	O
matrix	O
of	O
the	O
original	O
bipartite	O
graph	O
.	O

Since	O
the	O
gene	O
communities	O
identified	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
reflect	O
the	O
structure	O
inherent	O
in	O
the	O
bipartite	O
graph	O
(	O
which	O
is	O
not	O
affected	O
by	O
reversing	O
the	O
list	O
-	O
entry	O
order	O
)	O
,	O
co	O
-	O
occurrence	O
analysis	O
of	O
the	O
reversed	O
bipartite	O
graph	O
will	O
result	O
in	O
PubMedID	O
_	O
listID	O
communities	O
that	O
reflect	O
the	O
same	O
underlying	O
structure	O
in	O
the	O
bipartite	O
graph	O
.	O

In	O
other	O
words	O
,	O
PubMedID	O
_	O
listID	O
communities	O
correspond	O
to	O
gene	O
communities	O
.	O

In	O
less	O
abstract	O
terms	O
,	O
the	O
PubMedID	O
_	O
listID	O
communities	O
should	O
correspond	O
to	O
sets	O
of	O
publications	O
that	O
report	O
similar	O
sets	O
of	O
genes	O
as	O
differentially	O
regulated	O
.	O

The	O
identification	O
of	O
communities	O
of	O
publications	O
can	O
help	O
the	O
researcher	O
to	O
easily	O
identify	O
publications	O
studying	O
genes	O
in	O
a	O
gene	O
community	O
that	O
is	O
of	O
interest	O
to	O
the	O
researcher	O
.	O

The	O
results	O
of	O
both	O
types	O
of	O
co	O
-	O
occurrence	O
analysis	O
are	O
displayed	O
in	O
Fig	O
.	O

6	O
.	O

Fig	O
.	O

6A	O
shows	O
the	O
gene	O
clusters	O
identified	O
.	O

The	O
clusters	O
are	O
named	O
after	O
significant	O
enrichments	O
of	O
gene	O
categories	O
as	O
determined	O
by	O
functional	O
category	O
enrichment	O
using	O
DAVID	O
[	O
41	O
]	O
.	O

The	O
P	O
-	O
values	O
shown	O
are	O
Benjamini	O
corrected	O
for	O
multiple	O
testing	O
as	O
reported	O
by	O
DAVID	O
.	O

The	O
clusters	O
are	O
very	O
similar	O
to	O
the	O
clusters	O
published	O
previously	O
[	O
35	O
]	O
.	O

There	O
is	O
one	O
new	O
cluster	O
that	O
is	O
strongly	O
enriched	O
for	O
ribosomal	O
proteins	O
(	O
"	O
protein	O
biosynthesis	O
"	O
cluster	O
)	O
,	O
which	O
has	O
not	O
reached	O
significance	O
in	O
our	O
previous	O
analysis	O
.	O

The	O
"	O
surface	O
antigen	O
"	O
cluster	O
contains	O
many	O
genes	O
that	O
had	O
been	O
reported	O
as	O
part	O
of	O
the	O
"	O
signal	O
transduction	O
"	O
cluster	O
.	O

Altogether	O
,	O
however	O
,	O
these	O
results	O
strongly	O
support	O
the	O
notion	O
that	O
the	O
gene	O
clusters	O
in	O
the	O
PubLiME	O
data	O
set	O
can	O
be	O
reproduced	O
by	O
the	O
more	O
fine	O
-	O
grained	O
analysis	O
that	O
considers	O
sublists	O
in	O
each	O
publication	O
as	O
separate	O
signatures	O
.	O

The	O
corresponding	O
clusters	O
of	O
PubMedID	O
_	O
listIDs	O
are	O
shown	O
in	O
Fig	O
.	O

6B	O
.	O

There	O
are	O
five	O
clusters	O
,	O
which	O
have	O
been	O
named	O
after	O
their	O
corresponding	O
gene	O
cluster	O
.	O

Only	O
one	O
cluster	O
(	O
the	O
"	O
extracellular	O
matrix	O
-	O
immune	O
response	O
cluster	O
"	O
)	O
cannot	O
be	O
separated	O
by	O
edge	O
-	O
betweenness	O
clustering	O
at	O
the	O
point	O
of	O
maximal	O
graph	O
modularity	O
.	O

To	O
see	O
that	O
this	O
naming	O
is	O
indeed	O
justified	O
,	O
we	O
needed	O
to	O
investigate	O
how	O
strongly	O
a	O
given	O
PubMedID	O
_	O
listID	O
is	O
associated	O
with	O
a	O
given	O
gene	O
cluster	O
,	O
i	O
.	O
e	O
.	O
how	O
significant	O
is	O
the	O
overlap	O
of	O
the	O
genes	O
reported	O
in	O
a	O
gene	O
cluster	O
and	O
the	O
genes	O
reported	O
in	O
a	O
PubMedID	O
_	O
listID	O
.	O

Binomial	O
or	O
hypergemetric	O
statistics	O
are	O
generally	O
used	O
to	O
calculate	O
this	O
significance	O
.	O

However	O
,	O
the	O
bipartite	O
graph	O
model	O
in	O
conjunction	O
with	O
the	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
offers	O
a	O
more	O
fine	O
-	O
grained	O
approach	O
based	O
on	O
bi	O
-	O
binomial	O
statistics	O
.	O

The	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
determines	O
occurrence	O
probabilities	O
in	O
such	O
a	O
way	O
that	O
the	O
number	O
of	O
genes	O
in	O
a	O
given	O
PubMedID	O
_	O
listID	O
is	O
associated	O
with	O
insignificant	O
P	O
-	O
values	O
in	O
the	O
context	O
of	O
the	O
complete	O
bipartite	O
graph	O
.	O

However	O
,	O
when	O
a	O
subset	O
of	O
genes	O
is	O
analyzed	O
,	O
e	O
.	O
g	O
.	O
all	O
the	O
genes	O
that	O
are	O
reported	O
in	O
a	O
particular	O
list	O
,	O
the	O
P	O
-	O
value	O
associated	O
with	O
the	O
number	O
of	O
genes	O
contained	O
in	O
this	O
list	O
will	O
likely	O
be	O
highly	O
significant	O
according	O
to	O
how	O
unlikely	O
it	O
is	O
to	O
obtain	O
all	O
the	O
genes	O
contained	O
in	O
a	O
given	O
list	O
in	O
a	O
random	O
draw	O
from	O
all	O
genes	O
present	O
in	O
the	O
bipartite	O
graph	O
.	O

Thus	O
,	O
PubMedID	O
_	O
listID	O
association	O
with	O
a	O
set	O
of	O
genes	O
in	O
the	O
bipartite	O
graph	O
model	O
can	O
be	O
calculated	O
in	O
the	O
following	O
way	O
:	O
The	O
set	O
of	O
genes	O
that	O
is	O
used	O
to	O
analyze	O
association	O
is	O
used	O
to	O
extract	O
a	O
subgraph	O
from	O
the	O
original	O
bipartite	O
graph	O
where	O
occurrence	O
probabilities	O
for	O
each	O
gene	O
-	O
PubMedID	O
_	O
listID	O
pair	O
are	O
identical	O
to	O
those	O
in	O
the	O
original	O
bipartite	O
graph	O
(	O
i	O
.	O
e	O
.	O
they	O
are	O
not	O
recalculated	O
by	O
edge	O
-	O
swapping	O
)	O
.	O

The	O
vertex	O
degree	O
of	O
the	O
PubMedID	O
_	O
listID	O
vertices	O
in	O
the	O
subgraph	O
indicates	O
the	O
number	O
of	O
genes	O
contained	O
in	O
each	O
PubMedID	O
_	O
listID	O
overlapping	O
with	O
the	O
set	O
of	O
genes	O
used	O
to	O
extract	O
the	O
subgraph	O
.	O

From	O
the	O
occurrence	O
probabilities	O
of	O
the	O
genes	O
in	O
a	O
given	O
PubMedID	O
_	O
listID	O
,	O
the	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
can	O
then	O
be	O
calculated	O
for	O
every	O
list	O
vertex	O
degree	O
observed	O
in	O
the	O
subgraph	O
.	O

In	O
Fig	O
.	O

7	O
,	O
the	O
significance	O
of	O
association	O
of	O
the	O
PubMedID	O
_	O
listIDs	O
(	O
see	O
Fig	O
.	O
6B	O
)	O
with	O
the	O
cell	O
cycle	O
cluster	O
of	O
genes	O
(	O
Fig	O
.	O
6A	O
)	O
is	O
calculated	O
.	O

For	O
comparison	O
,	O
binomial	O
and	O
hypergeometric	O
P	O
-	O
values	O
are	O
also	O
shown	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
is	O
larger	O
than	O
the	O
binomial	O
and	O
hypergeometric	O
P	O
-	O
values	O
,	O
which	O
means	O
that	O
the	O
strength	O
of	O
association	O
is	O
evaluated	O
in	O
a	O
more	O
stringent	O
manner	O
using	O
BBD	O
statistics	O
(	O
see	O
Discussion	O
for	O
an	O
explanation	O
of	O
this	O
observation	O
)	O
.	O

The	O
analysis	O
of	O
significant	O
associations	O
between	O
PubMedID	O
_	O
listIDs	O
and	O
gene	O
clusters	O
now	O
permit	O
answering	O
the	O
question	O
whether	O
there	O
is	O
correspondence	O
between	O
gene	O
clusters	O
and	O
PubMedID	O
_	O
listID	O
clusters	O
.	O

The	O
naming	O
of	O
PubMedID	O
_	O
listID	O
clusters	O
shown	O
in	O
Fig	O
.	O

6B	O
is	O
based	O
on	O
the	O
number	O
of	O
PubMedID	O
_	O
listID	O
that	O
are	O
significantly	O
associated	O
with	O
gene	O
clusters	O
shown	O
in	O
Fig	O
.	O

6A	O
.	O

First	O
,	O
for	O
each	O
gene	O
cluster	O
,	O
all	O
the	O
PubMedID	O
_	O
listIDs	O
that	O
are	O
associated	O
with	O
that	O
cluster	O
with	O
more	O
than	O
95	O
%	O
confidence	O
(	O
i	O
.	O
e	O
.	O
cumulative	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
>	O
=	O
0	O
.	O
95	O
)	O
were	O
identified	O
.	O

Second	O
,	O
the	O
number	O
of	O
significant	O
PubMedID	O
_	O
listIDs	O
in	O
each	O
PubMedID	O
_	O
listID	O
cluster	O
was	O
counted	O
for	O
every	O
gene	O
cluster	O
.	O

The	O
significance	O
of	O
this	O
number	O
was	O
then	O
calculated	O
using	O
binomial	O
statistics	O
.	O

The	O
results	O
of	O
this	O
analysis	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Negative	O
decadic	O
logarithms	O
of	O
the	O
binomial	O
P	O
-	O
value	O
are	O
displayed	O
.	O

It	O
is	O
apparent	O
that	O
each	O
PubMedID	O
_	O
listID	O
cluster	O
is	O
strongly	O
associated	O
with	O
at	O
least	O
one	O
gene	O
cluster	O
,	O
except	O
for	O
the	O
"	O
extracellular	O
matrix	O
-	O
immune	O
response	O
"	O
cluster	O
,	O
which	O
is	O
associated	O
with	O
two	O
gene	O
clusters	O
.	O

The	O
strength	O
of	O
these	O
associations	O
suggests	O
that	O
the	O
PubMedID	O
_	O
listID	O
clusters	O
are	O
indeed	O
corresponding	O
to	O
the	O
gene	O
clusters	O
and	O
that	O
both	O
the	O
gene	O
and	O
the	O
PubMedID	O
_	O
listID	O
clusters	O
reflect	O
the	O
structure	O
of	O
the	O
bipartite	O
graph	O
representing	O
the	O
PubLiME	O
data	O
set	O
.	O

Details	O
about	O
all	O
the	O
lists	O
analyzed	O
are	O
attached	O
as	O
supplementary	O
material	O
Table	O
S2	O
.	O

Looking	O
at	O
these	O
lists	O
,	O
some	O
general	O
conclusions	O
about	O
the	O
gene	O
clusters	O
can	O
be	O
drawn	O
.	O

Cell	O
cycle	O
cluster	O
genes	O
have	O
been	O
found	O
deregulated	O
in	O
a	O
wide	O
variety	O
of	O
tumor	O
types	O
such	O
as	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
in	O
biliary	O
tract	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
gastric	O
cancer	O
,	O
prostate	O
cancer	O
,	O
T	O
-	O
cell	O
leukemia	O
,	O
glioma	O
,	O
acute	O
lymphoblastic	O
and	O
myeloblastic	O
leukemias	O
,	O
soft	O
tissue	O
sarcoma	O
,	O
neuroblastoma	O
,	O
as	O
well	O
as	O
in	O
a	O
number	O
of	O
cellular	O
model	O
systems	O
in	O
response	O
to	O
different	O
stimuli	O
.	O

Thus	O
,	O
the	O
cell	O
cycle	O
cluster	O
seems	O
to	O
consist	O
of	O
genes	O
with	O
a	O
general	O
role	O
in	O
oncogenesis	O
.	O

The	O
surface	O
antigen	O
cluster	O
instead	O
seems	O
to	O
be	O
derived	O
preferentially	O
from	O
studies	O
on	O
leukemia	O
.	O

The	O
interferon	O
cluster	O
genes	O
are	O
found	O
deregulated	O
in	O
virus	O
induced	O
pathologies	O
such	O
as	O
papilloma	O
virus	O
induced	O
cervical	O
cancer	O
,	O
and	O
viral	O
hepatitis	O
.	O

Immune	O
response	O
cluster	O
genes	O
were	O
reported	O
as	O
differentially	O
regulated	O
in	O
inflammatory	O
conditions	O
such	O
as	O
ulcerative	O
colitis	O
,	O
Crohn	O
'	O
s	O
disease	O
,	O
and	O
Helicobacter	B-Species
pylori	E-Species
infections	O
.	O

Genes	O
of	O
the	O
extracellular	O
matrix	O
cluster	O
seem	O
to	O
be	O
associated	O
with	O
cancer	O
progression	O
studies	O
and	O
metastatic	O
potential	O
.	O

For	O
the	O
protein	O
biosynthesis	O
cluster	O
,	O
there	O
are	O
15	O
signatures	O
that	O
are	O
significantly	O
enriched	O
for	O
those	O
genes	O
.	O

The	O
cancers	O
studied	O
comprise	O
medulloblastoma	O
,	O
glioblastoma	O
,	O
pancreatic	O
cancer	O
,	O
soft	O
tissue	O
sarcoma	O
,	O
lung	O
carcinoma	O
,	O
breast	O
carcinoma	O
,	O
prostate	O
carcinoma	O
,	O
multiple	O
myeloma	O
,	O
and	O
lymphocytic	O
leukemia	O
.	O

The	O
genes	O
are	O
also	O
found	O
deregulated	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Although	O
the	O
number	O
of	O
signatures	O
is	O
limited	O
,	O
the	O
variation	O
in	O
conditions	O
where	O
the	O
genes	O
are	O
deregulated	O
is	O
compatible	O
with	O
the	O
hypothesis	O
that	O
protein	O
biosynthesis	O
genes	O
,	O
as	O
cell	O
cycle	O
genes	O
,	O
are	O
deregulated	O
in	O
many	O
cancer	O
types	O
,	O
which	O
might	O
reflect	O
the	O
general	O
property	O
of	O
cancer	O
cells	O
to	O
divide	O
and	O
grow	O
in	O
an	O
uncontrolled	O
fashion	O
.	O

Discussion	O

Here	O
we	O
have	O
investigated	O
basic	O
aspects	O
of	O
co	O
-	O
occurrence	O
analysis	O
and	O
present	O
a	O
software	O
tool	O
,	O
NetCutter	O
,	O
which	O
can	O
be	O
used	O
to	O
identify	O
and	O
analyze	O
generic	O
co	O
-	O
occurrence	O
networks	O
.	O

In	O
NetCutter	O
,	O
a	O
co	O
-	O
occurrence	O
data	O
set	O
is	O
represented	O
as	O
a	O
bipartite	O
graph	O
with	O
one	O
part	O
representing	O
lists	O
and	O
the	O
other	O
part	O
list	O
entries	O
whose	O
co	O
-	O
occurrence	O
patterns	O
are	O
studied	O
.	O

The	O
bipartite	O
graph	O
representation	O
of	O
co	O
-	O
occurrence	O
data	O
sets	O
allows	O
the	O
efficacy	O
of	O
different	O
null	O
-	O
models	O
to	O
be	O
tested	O
systematically	O
.	O

We	O
have	O
shown	O
that	O
an	O
edge	O
-	O
swapping	O
procedure	O
used	O
to	O
randomize	O
the	O
bipartite	O
graph	O
generates	O
a	O
null	O
-	O
model	O
that	O
allows	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
.	O

The	O
other	O
null	O
-	O
models	O
tested	O
here	O
tend	O
to	O
underestimate	O
occurrence	O
probabilities	O
of	O
entries	O
per	O
list	O
for	O
lists	O
and	O
genes	O
with	O
high	O
vertex	O
degrees	O
,	O
i	O
.	O
e	O
.	O
for	O
lists	O
and	O
genes	O
where	O
most	O
co	O
-	O
occurrences	O
are	O
observed	O
.	O

As	O
a	O
result	O
,	O
co	O
-	O
occurrences	O
are	O
judged	O
more	O
significant	O
than	O
they	O
really	O
are	O
.	O

Co	O
-	O
occurrence	O
data	O
sets	O
with	O
exactly	O
equal	O
lists	O
lengths	O
are	O
likely	O
to	O
be	O
the	O
exception	O
from	O
the	O
rule	O
.	O

It	O
can	O
be	O
assumed	O
that	O
some	O
list	O
-	O
length	O
-	O
heterogeneity	O
will	O
be	O
present	O
in	O
most	O
circumstances	O
.	O

An	O
important	O
consequence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
regards	O
the	O
co	O
-	O
occurrence	O
probability	O
distribution	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
the	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

Co	O
-	O
occurrence	O
analysis	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
best	O
performed	O
using	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
a	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
.	O

However	O
,	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
for	O
large	O
numbers	O
of	O
lists	O
is	O
difficult	O
using	O
existing	O
procedures	O
[	O
36	O
]	O
.	O

We	O
have	O
presented	O
an	O
approximation	O
to	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
,	O
called	O
bi	O
-	O
binomial	O
distribution	O
,	O
which	O
is	O
based	O
on	O
replacing	O
the	O
set	O
of	O
Poisson	O
trials	O
by	O
two	O
sets	O
of	O
Bernoulli	O
trials	O
.	O

The	O
resulting	O
distribution	O
reproduces	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
nearly	O
exactly	O
and	O
its	O
P	O
-	O
values	O
can	O
be	O
calculated	O
with	O
ease	O
even	O
for	O
thousands	O
of	O
lists	O
(	O
see	O
also	O
supplementary	O
material	O
Simulation	O
S1	O
for	O
details	O
on	O
the	O
precision	O
of	O
BBD	O
)	O
.	O

Importantly	O
,	O
BBD	O
provides	O
a	O
novel	O
measure	O
of	O
association	O
,	O
which	O
is	O
shown	O
to	O
be	O
superior	O
to	O
existing	O
measures	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
and	O
the	O
uncertainty	O
coefficient	O
,	O
whose	O
values	O
cannot	O
be	O
interpreted	O
properly	O
in	O
the	O
absence	O
of	O
knowledge	O
about	O
the	O
occurrence	O
probabilities	O
of	O
co	O
-	O
occurring	O
entities	O
.	O

It	O
is	O
worth	O
noting	O
that	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
are	O
distinguished	O
from	O
Gaussian	O
Z	O
-	O
scores	O
by	O
the	O
fact	O
that	O
they	O
do	O
not	O
correspond	O
to	O
the	O
same	O
P	O
-	O
value	O
for	O
different	O
PBDs	O
,	O
BBDs	O
,	O
and	O
even	O
BDs	O
.	O

This	O
is	O
because	O
the	O
Z	O
-	O
score	O
is	O
an	O
explicit	O
part	O
of	O
the	O
function	O
defining	O
the	O
normal	O
probability	O
density	O
while	O
it	O
is	O
not	O
part	O
of	O
the	O
definitions	O
of	O
BD	O
,	O
PBD	O
,	O
and	O
BBD	O
densities	O
.	O

As	O
a	O
consequence	O
,	O
the	O
simple	O
Poisson	O
-	O
binomial	O
Z	O
-	O
score	O
based	O
approach	O
to	O
evaluating	O
significance	O
of	O
co	O
-	O
occurrence	O
must	O
be	O
complemented	O
with	O
the	O
BBD	O
to	O
approximate	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
in	O
order	O
to	O
enable	O
multiple	O
testing	O
corrections	O
and	O
to	O
allow	O
calculation	O
of	O
confidence	O
levels	O
in	O
association	O
studies	O
precisely	O
.	O

However	O
,	O
NetCutter	O
is	O
equipped	O
with	O
a	O
bipartite	O
graph	O
randomization	O
tool	O
that	O
permits	O
measuring	O
the	O
number	O
of	O
false	O
positives	O
due	O
to	O
multiple	O
testing	O
directly	O
by	O
comparing	O
the	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
to	O
the	O
corresponding	O
number	O
in	O
a	O
randomized	O
version	O
thereof	O
.	O

Randomization	O
is	O
performed	O
by	O
edge	O
-	O
swapping	O
in	O
order	O
to	O
preserve	O
vertex	O
degrees	O
.	O

The	O
resulting	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
that	O
are	O
plotted	O
for	O
each	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
provide	O
a	O
highly	O
reliable	O
and	O
visually	O
intuitive	O
defense	O
mechanism	O
against	O
false	O
positives	O
(	O
see	O
also	O
supplementary	O
material	O
Simulation	O
S1	O
)	O
.	O

In	O
the	O
vast	O
majority	O
of	O
co	O
-	O
occurrence	O
studies	O
,	O
pair	O
-	O
wise	O
co	O
-	O
occurrences	O
have	O
been	O
analyzed	O
using	O
different	O
statistical	O
models	O
.	O

We	O
have	O
observed	O
that	O
the	O
stringency	O
of	O
pair	O
-	O
wise	O
co	O
-	O
occurrence	O
analysis	O
is	O
far	O
below	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
using	O
higher	O
order	O
combinations	O
of	O
co	O
-	O
occurring	O
entities	O
[	O
35	O
]	O
.	O

In	O
NetCutter	O
,	O
co	O
-	O
occurrence	O
analysis	O
is	O
preceded	O
by	O
occurrence	O
analysis	O
,	O
i	O
.	O
e	O
.	O
the	O
occurrence	O
probability	O
of	O
each	O
entry	O
in	O
each	O
list	O
is	O
determined	O
.	O

Starting	O
from	O
occurrence	O
probabilities	O
,	O
co	O
-	O
occurrence	O
probabilities	O
for	O
any	O
size	O
of	O
co	O
-	O
occurrence	O
modules	O
under	O
study	O
can	O
be	O
obtained	O
by	O
multiplying	O
the	O
respective	O
list	O
-	O
specific	O
occurrence	O
probabilities	O
.	O

Given	O
the	O
list	O
-	O
specific	O
co	O
-	O
occurrence	O
probabilities	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
are	O
then	O
calculated	O
in	O
exactly	O
the	O
same	O
way	O
for	O
any	O
module	O
size	O
.	O

As	O
a	O
consequence	O
,	O
NetCutter	O
can	O
perform	O
co	O
-	O
occurrence	O
analysis	O
for	O
higher	O
order	O
combinations	O
of	O
co	O
-	O
occurring	O
entries	O
(	O
i	O
.	O
e	O
.	O
larger	O
module	O
sizes	O
)	O
using	O
the	O
same	O
statistical	O
model	O
.	O

One	O
of	O
the	O
benefits	O
of	O
using	O
higher	O
module	O
sizes	O
is	O
robustness	O
of	O
the	O
analyses	O
in	O
the	O
presence	O
of	O
noise	O
.	O

This	O
is	O
because	O
each	O
edge	O
in	O
the	O
resulting	O
co	O
-	O
occurrence	O
network	O
is	O
evaluated	O
many	O
times	O
since	O
every	O
pair	O
of	O
co	O
-	O
occurring	O
entries	O
can	O
be	O
part	O
of	O
many	O
higher	O
order	O
co	O
-	O
occurrence	O
modules	O
[	O
35	O
]	O
.	O

Another	O
advantage	O
is	O
that	O
implicit	O
relationships	O
between	O
entries	O
,	O
which	O
have	O
never	O
occurred	O
together	O
[	O
18	O
]	O
,	O
can	O
be	O
derived	O
as	O
a	O
natural	O
by	O
-	O
product	O
of	O
using	O
module	O
sizes	O
larger	O
than	O
2	O
.	O

As	O
shown	O
in	O
a	O
simulation	O
study	O
(	O
supplementary	O
material	O
Simulation	O
S1	O
)	O
,	O
the	O
result	O
is	O
a	O
dramatic	O
reduction	O
of	O
misclassifications	O
at	O
higher	O
module	O
sizes	O
.	O

NetCutter	O
can	O
be	O
used	O
to	O
calculate	O
the	O
strength	O
of	O
association	O
between	O
a	O
subset	O
of	O
entries	O
and	O
lists	O
reporting	O
those	O
entries	O
.	O

In	O
this	O
case	O
,	O
the	O
analysis	O
is	O
performed	O
on	O
a	O
subgraph	O
of	O
the	O
original	O
bipartite	O
graph	O
.	O

The	O
subgraph	O
can	O
correspond	O
to	O
communities	O
of	O
entries	O
in	O
the	O
co	O
-	O
occurrence	O
network	O
,	O
or	O
any	O
set	O
of	O
entries	O
of	O
interest	O
.	O

NetCutter	O
will	O
then	O
calculate	O
the	O
significance	O
of	O
observing	O
a	O
given	O
number	O
of	O
occurrences	O
of	O
an	O
entry	O
in	O
the	O
user	O
defined	O
subset	O
of	O
lists	O
using	O
bi	O
-	O
binomal	O
statistics	O
.	O

This	O
analysis	O
mode	O
corresponds	O
to	O
association	O
studies	O
with	O
the	O
advantage	O
that	O
the	O
structure	O
of	O
the	O
underlying	O
bipartite	O
graph	O
(	O
i	O
.	O
e	O
.	O
list	O
length	O
heterogeneity	O
)	O
is	O
considered	O
and	O
handled	O
appropriately	O
using	O
the	O
bi	O
-	O
binomial	O
distribution	O
.	O

As	O
a	O
consequence	O
,	O
association	O
studies	O
can	O
be	O
performed	O
with	O
higher	O
stringency	O
.	O

This	O
result	O
can	O
be	O
understood	O
by	O
examining	O
the	O
occurrence	O
probability	O
matrix	O
that	O
is	O
implicitly	O
assumed	O
in	O
performing	O
binomial	O
or	O
hypergeometric	O
tests	O
for	O
the	O
significance	O
of	O
overlaps	O
.	O

In	O
both	O
tests	O
,	O
a	O
gene	O
is	O
assumed	O
to	O
have	O
an	O
equal	O
opportunity	O
to	O
be	O
present	O
in	O
a	O
list	O
.	O

Therefore	O
,	O
the	O
probability	O
of	O
success	O
for	O
a	O
gene	O
to	O
be	O
part	O
of	O
a	O
list	O
is	O
given	O
by	O
the	O
list	O
vertex	O
degree	O
divided	O
by	O
the	O
total	O
number	O
of	O
genes	O
.	O

In	O
other	O
words	O
,	O
both	O
tests	O
are	O
implicitly	O
based	O
on	O
the	O
list	O
vertex	O
degree	O
model	O
,	O
which	O
has	O
been	O
shown	O
previously	O
to	O
underestimate	O
the	O
occurrence	O
probability	O
and	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
genes	O
with	O
high	O
vertex	O
degree	O
(	O
see	O
Fig	O
.	O
2A	O
)	O
.	O

Since	O
the	O
BBD	O
P	O
-	O
values	O
are	O
calculated	O
from	O
the	O
ES	O
-	O
model	O
,	O
which	O
assigns	O
higher	O
occurrence	O
probabilities	O
to	O
genes	O
with	O
higher	O
vertex	O
degree	O
and	O
more	O
expected	O
co	O
-	O
occurrences	O
,	O
the	O
observed	O
number	O
of	O
overlaps	O
between	O
a	O
set	O
of	O
genes	O
of	O
interest	O
and	O
the	O
content	O
of	O
a	O
given	O
list	O
(	O
which	O
can	O
be	O
viewed	O
as	O
co	O
-	O
occurrence	O
of	O
the	O
overlapping	O
genes	O
in	O
that	O
list	O
)	O
will	O
be	O
judged	O
less	O
significant	O
when	O
the	O
overlapping	O
genes	O
are	O
of	O
high	O
vertex	O
degree	O
(	O
and	O
vice	O
versa	O
when	O
the	O
overlapping	O
genes	O
are	O
of	O
low	O
vertex	O
degree	O
)	O
as	O
compared	O
to	O
binomial	O
or	O
hypergeometric	O
tests	O
.	O

Since	O
the	O
BBD	O
P	O
-	O
values	O
are	O
derived	O
from	O
the	O
most	O
stringent	O
ES	O
null	O
-	O
model	O
,	O
BBD	O
P	O
-	O
values	O
provide	O
a	O
more	O
reliable	O
estimate	O
for	O
the	O
significance	O
of	O
overlap	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
data	O
represented	O
as	O
bipartite	O
graphs	O
permits	O
visualizing	O
the	O
structure	O
of	O
the	O
bipartite	O
graph	O
either	O
as	O
communities	O
of	O
list	O
entries	O
(	O
genes	O
)	O
or	O
as	O
communities	O
of	O
lists	O
(	O
PubMedID	O
_	O
ListID	O
)	O
in	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
have	O
analyzed	O
the	O
PubLiME	O
data	O
set	O
for	O
the	O
presence	O
of	O
corresponding	O
gene	O
and	O
list	O
clusters	O
.	O

In	O
addition	O
to	O
previously	O
published	O
clusters	O
of	O
genes	O
,	O
we	O
describe	O
a	O
novel	O
gene	O
cluster	O
that	O
is	O
composed	O
of	O
protein	O
biosynthesis	O
associated	O
genes	O
[	O
35	O
]	O
.	O

We	O
found	O
that	O
the	O
corresponding	O
clusters	O
of	O
PubMedID	O
_	O
ListID	O
(	O
gene	O
expression	O
signatures	O
)	O
are	O
in	O
general	O
strongly	O
enriched	O
for	O
genes	O
reported	O
in	O
the	O
corresponding	O
gene	O
cluster	O
and	O
that	O
interrogation	O
of	O
corresponding	O
clusters	O
can	O
be	O
used	O
to	O
deduct	O
hypotheses	O
about	O
the	O
putative	O
function	O
of	O
gene	O
clusters	O
.	O

In	O
addition	O
to	O
co	O
-	O
occurrence	O
analysis	O
,	O
NetCutter	O
offers	O
a	O
number	O
of	O
tools	O
for	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
or	O
any	O
undirected	O
graph	O
.	O

In	O
particular	O
,	O
community	O
identification	O
is	O
supported	O
by	O
four	O
different	O
community	O
identification	O
algorithms	O
.	O

NetCutter	O
also	O
offers	O
a	O
range	O
of	O
convenience	O
functions	O
that	O
are	O
of	O
help	O
in	O
network	O
analysis	O
.	O

Worthy	O
of	O
mentioning	O
are	O
the	O
random	O
graph	O
generators	O
that	O
can	O
provide	O
control	O
graphs	O
for	O
topological	O
studies	O
.	O

The	O
complete	O
set	O
of	O
options	O
is	O
described	O
in	O
the	O
software	O
documentation	O
.	O

In	O
summary	O
,	O
we	O
present	O
a	O
general	O
framework	O
for	O
co	O
-	O
occurrence	O
analysis	O
with	O
many	O
potential	O
applications	O
.	O

We	O
illustrate	O
a	O
number	O
of	O
advantages	O
of	O
using	O
the	O
bipartite	O
graph	O
representation	O
of	O
data	O
and	O
the	O
associated	O
statistics	O
.	O

In	O
particular	O
,	O
the	O
identification	O
of	O
corresponding	O
clusters	O
permits	O
the	O
identification	O
of	O
functional	O
subunits	O
such	O
as	O
gene	O
clusters	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
generation	O
of	O
hypotheses	O
about	O
the	O
function	O
of	O
those	O
units	O
by	O
analyzing	O
the	O
corresponding	O
list	O
clusters	O
on	O
the	O
other	O
hand	O
.	O

Future	O
developments	O
will	O
be	O
directed	O
towards	O
the	O
analysis	O
of	O
data	O
sets	O
that	O
are	O
considerably	O
larger	O
than	O
the	O
data	O
sets	O
analyzed	O
so	O
far	O
.	O

For	O
example	O
,	O
co	O
-	O
occurrence	O
analysis	O
might	O
be	O
of	O
interest	O
for	O
the	O
analysis	O
of	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
data	O
sets	O
and	O
association	O
studies	O
of	O
genome	O
variability	O
with	O
disease	O
.	O

Each	O
patient	S-Species
is	O
characterized	O
by	O
a	O
specific	O
range	O
of	O
SNPs	O
.	O

Co	O
-	O
occurrence	O
patterns	O
of	O
patients	S-Species
according	O
to	O
their	O
SNPs	O
could	O
be	O
compared	O
to	O
clinical	O
parameters	O
with	O
the	O
aim	O
of	O
identifying	O
genomic	O
regions	O
associated	O
with	O
disease	O
.	O

The	O
increased	O
stringency	O
of	O
association	O
studies	O
offered	O
by	O
NetCutter	O
may	O
be	O
of	O
use	O
in	O
the	O
analysis	O
of	O
polygenic	O
diseases	O
where	O
conventional	O
methods	O
fail	O
.	O

For	O
being	O
useful	O
in	O
this	O
setting	O
,	O
NetCutter	O
must	O
be	O
capable	O
of	O
analyzing	O
bipartite	O
graphs	O
with	O
millions	O
instead	O
of	O
thousands	O
of	O
vertices	O
.	O

Materials	O
and	O
Methods	O

Implementation	O
of	O
NetCutter	O

NetCutter	O
is	O
written	O
in	O
Java	O
using	O
NetBeans6	O
software	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
netbeans	O
.	O
info	O
/	O
)	O
and	O
tested	O
on	O
the	O
Java	O
Runtime	O
environment	O
1	O
.	O
6	O
.	O
0	O
.	O
0	O
.	O
on	O
a	O
Windows	O
XP	O
Professional	O
computer	O
.	O

The	O
Java	O
Runtime	O
environment	O
,	O
which	O
can	O
be	O
downloaded	O
from	O
http	O
:	O
/	O
/	O
java	O
.	O
sun	O
.	O
com	O
/	O
,	O
must	O
be	O
installed	O
on	O
a	O
computer	O
that	O
is	O
intended	O
to	O
run	O
NetCutter	O
.	O

NetCutter	O
is	O
provided	O
as	O
a	O
single	O
jar	O
file	O
and	O
should	O
run	O
by	O
double	O
clicking	O
the	O
jar	O
file	O
,	O
provided	O
that	O
the	O
Java	O
runtime	O
environment	O
is	O
properly	O
installed	O
.	O

NetCutter	O
makes	O
use	O
of	O
the	O
following	O
software	O
packages	O
and	O
classes	O
:	O
JUNG	O
version	O
1	O
.	O
3	O
(	O
http	O
:	O
/	O
/	O
jung	O
.	O
sourceforge	O
.	O
net	O
/	O
download	O
.	O
html	O
)	O
,	O
Apache	O
Jakarta	O
Commons	O
Collections	O
3	O
.	O
1	O
(	O
http	O
:	O
/	O
/	O
jakarta	O
.	O
apache	O
.	O
org	O
/	O
commons	O
/	O
collections	O
/	O
)	O
,	O
Cern	O
Colt	O
Scientific	O
Library	O
1	O
.	O
2	O
.	O
0	O
(	O
http	O
:	O
/	O
/	O
dsd	O
.	O
lbl	O
.	O
gov	O
/	O
hoschek	O
/	O
colt	O
/	O
)	O
,	O
Xerces	O
(	O
http	O
:	O
/	O
/	O
xerces	O
.	O
apache	O
.	O
org	O
/	O
xerces2	O
-	O
j	O
/	O
index	O
.	O
html	O
)	O
,	O
Jama	O
(	O
http	O
:	O
/	O
/	O
math	O
.	O
nist	O
.	O
gov	O
/	O
javanumerics	O
/	O
jama	O
/	O
)	O
,	O
Netlib	O
Java	O
LAPACK	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
netlib	O
.	O
org	O
/	O
lapack	O
/	O
)	O
,	O
JFreeChart	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
jfree	O
.	O
org	O
/	O
jfreechart	O
/	O
)	O
,	O
partition	O
.	O
java	O
(	O
http	O
:	O
/	O
/	O
astro	O
.	O
u	O
-	O
strasbg	O
.	O
fr	O
/	O
fmurtagh	O
/	O
mda	O
-	O
sw	O
/	O
java	O
/	O
partition	O
.	O
java	O
)	O
.	O

Bi	O
-	O
binomial	O
approximation	O
of	O
Poisson	O
-	O
binomial	O
distribution	O

The	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
has	O
recently	O
been	O
proposed	O
as	O
a	O
statistic	O
that	O
properly	O
handles	O
largely	O
differing	O
sizes	O
of	O
gene	O
expression	O
signatures	O
in	O
meta	O
-	O
analysis	O
of	O
gene	O
expression	O
data	O
[	O
35	O
]	O
.	O

Z	O
-	O
scores	O
have	O
been	O
used	O
to	O
estimate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
because	O
P	O
-	O
value	O
calculation	O
is	O
cumbersome	O
and	O
error	O
prone	O
.	O

Two	O
methods	O
reported	O
by	O
[	O
36	O
]	O
suffer	O
from	O
numerical	O
overflow	O
/	O
underflow	O
problems	O
when	O
large	O
numbers	O
of	O
Poisson	O
trials	O
with	O
probabilities	O
deviating	O
significantly	O
from	O
0	O
.	O
5	O
are	O
being	O
analyzed	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
fast	O
approximation	O
of	O
P	O
-	O
values	O
based	O
on	O
a	O
bi	O
-	O
binomial	O
distribution	O
.	O

The	O
bi	O
-	O
binomial	O
distribution	O
is	O
a	O
special	O
case	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
where	O
the	O
probability	O
of	O
success	O
can	O
assume	O
only	O
two	O
values	O
.	O

In	O
order	O
to	O
achieve	O
a	O
good	O
approximation	O
of	O
the	O
underlying	O
Poisson	O
-	O
binomial	O
distribution	O
,	O
the	O
values	O
of	O
these	O
two	O
probabilities	O
and	O
the	O
number	O
of	O
trials	O
where	O
they	O
are	O
assumed	O
must	O
be	O
determined	O
carefully	O
.	O

As	O
is	O
shown	O
in	O
the	O
following	O
,	O
the	O
values	O
of	O
the	O
two	O
trial	O
probabilities	O
and	O
their	O
number	O
of	O
occurrences	O
follow	O
from	O
the	O
formula	O
used	O
to	O
calculate	O
the	O
variance	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
and	O
from	O
the	O
formula	O
yielding	O
the	O
population	O
variance	O
of	O
trial	O
probabilities	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
to	O
be	O
approximated	O
.	O

The	O
mean	O
mu	O
and	O
the	O
variance	O
sigma	O
2	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
are	O
given	O
by	O
equation	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
respectively	O
.	O
(	O
1	O
)	O
(	O
2	O
)	O
pi	O
is	O
the	O
trial	O
-	O
specific	O
probability	O
of	O
success	O
and	O
N	O
is	O
the	O
total	O
number	O
of	O
trials	O
.	O

For	O
the	O
sake	O
of	O
completeness	O
,	O
a	O
formal	O
proof	O
of	O
equation	O
(	O
1	O
)	O
is	O
reported	O
as	O
supplementary	O
material	O
Proof	O
S1	O
and	O
the	O
proof	O
of	O
equation	O
(	O
2	O
)	O
can	O
be	O
obtained	O
in	O
an	O
analogous	O
fashion	O
.	O

The	O
population	O
variance	O
S2	O
of	O
trial	O
probabilities	O
pi	O
is	O
given	O
by	O
equation	O
(	O
3	O
)	O
.	O
(	O
3	O
)	O

Rearranging	O
equation	O
(	O
3	O
)	O
considering	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
leads	O
to	O
(	O
4	O
)	O
and	O
(	O
5	O
)	O
,	O
where	O
pa	O
denotes	O
the	O
average	O
trial	O
probability	O
of	O
success	O
and	O
qa	O
its	O
complement	O
.	O
(	O
4	O
)	O
(	O
5	O
)	O
Now	O
let	O
'	O
s	O
define	O
two	O
trial	O
probabilities	O
p1	O
and	O
p2	O
,	O
which	O
are	O
used	O
N1	O
and	O
N2	O
times	O
during	O
the	O
Poisson	O
trials	O
,	O
respectively	O
.	O

Thus	O
,	O
N1	O
and	O
N2	O
add	O
up	O
to	O
N	O
.	O
(	O
6	O
)	O

Considering	O
(	O
1	O
)	O
,	O
the	O
average	O
trial	O
probability	O
pa	O
can	O
then	O
be	O
obtained	O
from	O
(	O
7	O
)	O
.	O
(	O
7	O
)	O

Using	O
(	O
7	O
)	O
,	O
p1	O
can	O
thus	O
be	O
calculated	O
as	O
(	O
8	O
)	O
.	O
(	O
8	O
)	O

Similarly	O
,	O
considering	O
(	O
2	O
)	O
,	O
the	O
variance	O
sigma	O
2	O
is	O
given	O
by	O
(	O
9	O
)	O
.	O
(	O
9	O
)	O

Substituting	O
p1	O
in	O
(	O
9	O
)	O
using	O
(	O
8	O
)	O
followed	O
by	O
substituting	O
sigma	O
2	O
in	O
(	O
5	O
)	O
by	O
(	O
9	O
)	O
leads	O
to	O
a	O
quadratic	O
equation	O
for	O
p2	O
as	O
a	O
function	O
of	O
pa	O
,	O
N	O
,	O
and	O
S2	O
,	O
as	O
shown	O
in	O
equation	O
(	O
10	O
)	O
.	O
(	O
10	O
)	O

The	O
solution	O
to	O
(	O
10	O
)	O
is	O
given	O
by	O
(	O
11	O
)	O
.	O
(	O
11	O
)	O

Setting	O
p2	O
to	O
(	O
12	O
)	O
p1	O
can	O
be	O
obtained	O
from	O
(	O
8	O
)	O
and	O
shown	O
to	O
be	O
given	O
by	O
formula	O
(	O
13	O
)	O
:	O
(	O
13	O
)	O
Choosing	O
p2	O
as	O
(	O
12a	O
)	O
leads	O
to	O
p1	O
(	O
13a	O
)	O

Comparing	O
(	O
13a	O
)	O
to	O
(	O
12	O
)	O
and	O
(	O
12a	O
)	O
to	O
(	O
13	O
)	O
,	O
it	O
can	O
be	O
seen	O
that	O
the	O
formulae	O
are	O
identical	O
except	O
for	O
the	O
fact	O
that	O
N1	O
and	O
N2	O
are	O
reversed	O
.	O

Since	O
the	O
assignment	O
of	O
which	O
set	O
of	O
trials	O
is	O
called	O
N1	O
and	O
which	O
set	O
of	O
trials	O
is	O
called	O
N2	O
is	O
completely	O
arbitrary	O
,	O
we	O
can	O
limit	O
the	O
remaining	O
analysis	O
on	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
without	O
loss	O
of	O
generality	O
.	O

Note	O
that	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
do	O
not	O
guarantee	O
that	O
p1	O
and	O
p2	O
are	O
always	O
confined	O
between	O
0	O
and	O
1	O
for	O
any	O
combination	O
of	O
N1	O
and	O
N2	O
.	O

While	O
probabilities	O
smaller	O
than	O
0	O
or	O
bigger	O
than	O
1	O
would	O
still	O
result	O
in	O
a	O
distribution	O
with	O
the	O
same	O
overall	O
variance	O
as	O
the	O
original	O
distribution	O
,	O
P	O
-	O
value	O
calculation	O
will	O
be	O
imprecise	O
because	O
the	O
tails	O
of	O
the	O
distribution	O
will	O
deviate	O
significantly	O
from	O
the	O
original	O
distribution	O
.	O

Thus	O
,	O
we	O
need	O
to	O
define	O
the	O
values	O
N1	O
and	O
N2	O
in	O
such	O
a	O
way	O
that	O
p2	O
<	O
=	O
1	O
and	O
p1	O
>	O
=	O
0	O
.	O

This	O
can	O
be	O
achieved	O
by	O
evaluating	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
.	O

Evaluating	O
(	O
12	O
)	O
for	O
the	O
condition	O
that	O
p2	O
<	O
=	O
1	O
,	O
solving	O
the	O
resulting	O
inequality	O
for	O
N2	O
,	O
and	O
considering	O
(	O
5	O
)	O
,	O
which	O
relates	O
S2	O
and	O
sigma	O
2	O
,	O
we	O
obtain	O
(	O
14	O
)	O
.	O
(	O
14	O
)	O

Similarly	O
,	O
evaluating	O
(	O
13	O
)	O
for	O
the	O
condition	O
p1	O
>	O
=	O
0	O
,	O
solving	O
the	O
resulting	O
inequality	O
for	O
N2	O
,	O
considering	O
(	O
5	O
)	O
,	O
which	O
relates	O
S2	O
and	O
sigma	O
2	O
,	O
and	O
defining	O
mu	O
f	O
the	O
expected	O
number	O
of	O
failures	O
as	O
N	O
*	O
(	O
1	O
-	O
pa	O
)	O
(	O
15	O
)	O
,	O
(	O
15	O
)	O
we	O
obtain	O
(	O
16	O
)	O
(	O
16	O
)	O

The	O
meaning	O
of	O
these	O
boundaries	O
is	O
best	O
illustrated	O
by	O
considering	O
a	O
Poisson	O
-	O
binomial	O
distribution	O
whose	O
variance	O
is	O
0	O
,	O
i	O
.	O
e	O
.	O
that	O
assumes	O
1	O
at	O
X	O
=	O
mu	O
and	O
0	O
otherwise	O
.	O

In	O
this	O
case	O
(	O
14	O
)	O
requires	O
N2	O
<	O
=	O
mu	O
while	O
(	O
16	O
)	O
requires	O
N2	O
>	O
=	O
mu	O
.	O

These	O
conditions	O
can	O
only	O
be	O
fulfilled	O
contemporaneously	O
when	O
N2	O
is	O
set	O
to	O
mu	O
.	O

Intuitively	O
,	O
this	O
means	O
that	O
there	O
are	O
mu	O
trials	O
with	O
probability	O
of	O
success	O
1	O
and	O
N	O
-	O
mu	O
trials	O
with	O
probability	O
of	O
0	O
,	O
resulting	O
in	O
a	O
Poisson	O
-	O
binomial	O
distribution	O
with	O
variance	O
sigma	O
2	O
=	O
0	O
and	O
mean	O
mu	O
.	O

When	O
sigma	O
2	O
is	O
larger	O
than	O
0	O
,	O
the	O
choice	O
of	O
N1	O
and	O
N2	O
is	O
more	O
flexible	O
.	O

However	O
,	O
since	O
the	O
choice	O
of	O
N2	O
=	O
mu	O
is	O
valid	O
for	O
all	O
possible	O
values	O
of	O
sigma	O
2	O
,	O
this	O
is	O
how	O
NetCutter	O
determines	O
N1	O
and	O
N2	O
.	O

When	O
mu	O
is	O
not	O
an	O
integer	O
,	O
N2	O
is	O
set	O
to	O
the	O
integer	O
closest	O
to	O
mu	O
.	O

Having	O
determined	O
p2	O
(	O
12	O
)	O
and	O
p1	O
(	O
13	O
)	O
as	O
well	O
a	O
N1	O
and	O
N2	O
(	O
14	O
,	O
16	O
,	O
6	O
)	O
,	O
we	O
can	O
now	O
calculate	O
the	O
bi	O
-	O
binomial	O
approximation	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
in	O
a	O
fashion	O
that	O
is	O
very	O
similar	O
to	O
calculate	O
the	O
binomial	O
P	O
-	O
value	O
.	O

With	O
q1	O
=	O
1	O
-	O
p1	O
and	O
q2	O
=	O
1	O
-	O
p2	O
we	O
obtain	O
:	O
(	O
17	O
)	O

The	O
summation	O
is	O
necessary	O
because	O
i	O
successes	O
can	O
be	O
obtained	O
from	O
any	O
combination	O
of	O
j	O
p1	O
and	O
i	O
-	O
j	O
p2	O
trials	O
,	O
where	O
j	O
can	O
assume	O
any	O
value	O
from	O
0	O
to	O
i	O
.	O

Calculating	O
Jaccard	O
and	O
uncertainty	O
coefficients	O

For	O
the	O
purpose	O
of	O
comparing	O
the	O
efficacy	O
of	O
the	O
bi	O
-	O
binomial	O
distribution	O
as	O
a	O
significance	O
measure	O
of	O
co	O
-	O
occurrence	O
,	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
(	O
which	O
are	O
also	O
called	O
measures	O
of	O
association	O
)	O
were	O
calculated	O
using	O
the	O
formulae	O
:	O

The	O
Jaccard	O
coefficient	O
J	O
is	O
calculated	O
as	O
the	O
number	O
of	O
times	O
A	O
and	O
B	O
occur	O
together	O
divided	O
by	O
the	O
number	O
of	O
times	O
A	O
occurs	O
without	O
B	O
plus	O
the	O
number	O
of	O
times	O
B	O
occurs	O
without	O
A	O
plus	O
the	O
number	O
of	O
times	O
A	O
and	O
B	O
occur	O
together	O
[	O
42	O
]	O
.	O

The	O
uncertainty	O
coefficient	O
[	O
42	O
]	O
is	O
calculated	O
as	O
:	O
H	O
is	O
the	O
entropy	O
associated	O
with	O
A	O
,	O
B	O
,	O
and	O
AB	O
.	O

For	O
A	O
,	O
the	O
entropy	O
is	O
calculated	O
from	O
the	O
probabilities	O
of	O
A	O
occurring	O
in	O
n1	O
out	O
of	O
N	O
lists	O
(	O
n1	O
/	O
N	O
)	O
and	O
A	O
not	O
occurring	O
in	O
n2	O
out	O
of	O
N	O
lists	O
(	O
n2	O
/	O
N	O
)	O
.	O

Analogous	O
calculations	O
lead	O
to	O
the	O
entropy	O
associated	O
with	O
B	O
.	O

For	O
H	O
(	O
A	O
,	O
B	O
)	O
,	O
the	O
probabilities	O
of	O
A	O
occurring	O
without	O
B	O
,	O
B	O
occurring	O
without	O
A	O
,	O
A	O
and	O
B	O
occurring	O
together	O
,	O
and	O
neither	O
A	O
nor	O
B	O
occurring	O
in	O
the	O
lists	O
are	O
used	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O

The	O
bipartite	O
graph	O
to	O
be	O
analyzed	O
is	O
composed	O
of	O
27619	O
PubMedID	O
_	O
listID	O
-	O
gene	O
pairs	O
(	O
see	O
supplementary	O
material	O
Table	O
S1	O
)	O
.	O

Edge	O
-	O
swapping	O
(	O
1000	O
simulations	O
,	O
see	O
above	O
)	O
was	O
used	O
to	O
determine	O
occurrence	O
probabilities	O
and	O
gene	O
co	O
-	O
occurrence	O
was	O
analyzed	O
using	O
module	O
size	O
3	O
(	O
co	O
-	O
occurrence	O
of	O
three	O
genes	O
)	O
,	O
bi	O
-	O
binomial	O
Z	O
-	O
score	O
cutoff	O
6	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
cutoff	O
1	O
.	O
0E	O
-	O
5	O
,	O
and	O
support	O
5	O
.	O

Supplementary	O
material	O
Simulation	O
S1	O
provides	O
details	O
on	O
why	O
module	O
size	O
3	O
is	O
chosen	O
.	O

The	O
support	O
parameter	O
ensures	O
that	O
each	O
3	O
-	O
gene	O
co	O
-	O
occurrence	O
module	O
is	O
present	O
in	O
at	O
least	O
5	O
signatures	O
.	O

We	O
identified	O
1654	O
significant	O
modules	O
in	O
the	O
test	O
data	O
compared	O
to	O
5	O
modules	O
in	O
a	O
randomized	O
bipartite	O
graph	O
,	O
corresponding	O
to	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
331	O
.	O

The	O
co	O
-	O
occurrence	O
network	O
was	O
generated	O
from	O
the	O
significant	O
co	O
-	O
occurrence	O
modules	O
by	O
drawing	O
an	O
edge	O
between	O
each	O
pair	O
wise	O
combination	O
of	O
genes	O
that	O
are	O
part	O
of	O
the	O
same	O
co	O
-	O
occurrence	O
module	O
.	O

Gene	O
communities	O
were	O
identified	O
in	O
this	O
network	O
by	O
edge	O
-	O
betweenness	O
clustering	O
removing	O
4	O
edges	O
,	O
which	O
resulted	O
in	O
a	O
maximal	O
network	O
modularity	O
of	O
0	O
.	O
63	O
.	O

Modularity	O
is	O
calculated	O
as	O
described	O
by	O
[	O
43	O
]	O
.	O

For	O
the	O
identification	O
of	O
PubMedID	O
_	O
listID	O
clusters	O
,	O
the	O
PubMedID	O
_	O
listID	O
-	O
gene	O
pairs	O
in	O
the	O
original	O
bipartite	O
graph	O
were	O
reversed	O
to	O
form	O
gene	O
-	O
PubMedID	O
_	O
listID	O
pairs	O
.	O

Occurrence	O
probabilities	O
were	O
obtained	O
by	O
transposing	O
the	O
original	O
occurrence	O
probability	O
matrix	O
determined	O
by	O
edge	O
-	O
swapping	O
as	O
described	O
above	O
.	O

PubMedID	O
_	O
listID	O
co	O
-	O
occurrence	O
was	O
analyzed	O
using	O
module	O
size	O
5	O
,	O
Z	O
-	O
score	O
cutoff	O
6	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
cutoff	O
1	O
.	O
0E	O
-	O
5	O
,	O
and	O
support	O
3	O
.	O

Please	O
note	O
that	O
the	O
choice	O
of	O
these	O
parameters	O
is	O
dictated	O
by	O
the	O
parameters	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
.	O

The	O
reversal	O
of	O
the	O
bipartite	O
graph	O
necessitates	O
the	O
support	O
parameter	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
(	O
5	O
)	O
to	O
be	O
used	O
as	O
module	O
size	O
in	O
PubMedID	O
_	O
listID	O
co	O
-	O
occurrence	O
analysis	O
and	O
the	O
module	O
size	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
(	O
3	O
)	O
to	O
be	O
used	O
as	O
the	O
support	O
parameter	O
in	O
PubMedID	O
_	O
listID	O
co	O
-	O
occurrence	O
analysis	O
if	O
the	O
scope	O
of	O
the	O
analysis	O
is	O
the	O
identification	O
of	O
PubMedID	O
_	O
listID	O
clusters	O
that	O
correspond	O
to	O
gene	O
clusters	O
identified	O
before	O
.	O

The	O
significance	O
cutoffs	O
remain	O
unchanged	O
.	O

PubMedID	O
_	O
listID	O
co	O
-	O
occurrence	O
analysis	O
revealed	O
448	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
and	O
6	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
randomized	O
bipartite	O
graph	O
with	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
75	O
.	O

Communities	O
in	O
the	O
resulting	O
co	O
-	O
occurrence	O
network	O
were	O
identified	O
by	O
edge	O
-	O
betweenness	O
clustering	O
removing	O
130	O
edges	O
.	O

The	O
resulting	O
maximal	O
network	O
modularity	O
was	O
found	O
to	O
be	O
0	O
.	O
47	O
.	O

Supporting	O
Information	O

Personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
and	O
physical	O
activity	O
in	O
a	O
deprived	O
urban	O
population	O

Abstract	O

Background	O

Environmental	O
characteristics	O
may	O
be	O
associated	O
with	O
patterns	O
of	O
physical	O
activity	O
in	O
general	O
or	O
with	O
particular	O
types	O
of	O
physical	O
activity	O
such	O
as	O
active	O
travel	O
(	O
walking	O
or	O
cycling	O
for	O
transport	O
)	O
.	O

However	O
,	O
most	O
studies	O
in	O
this	O
field	O
have	O
been	O
conducted	O
in	O
North	O
America	O
and	O
Australia	O
,	O
and	O
hypotheses	O
about	O
putative	O
correlates	O
should	O
be	O
tested	O
in	O
a	O
wider	O
range	O
of	O
sociospatial	O
contexts	O
.	O

We	O
therefore	O
examined	O
the	O
contribution	O
of	O
putative	O
personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
in	O
deprived	O
urban	O
neighbourhoods	O
in	O
Glasgow	O
,	O
Scotland	O
as	O
part	O
of	O
the	O
baseline	O
for	O
a	O
longitudinal	O
study	O
of	O
the	O
effects	O
of	O
opening	O
a	O
new	O
urban	O
motorway	O
(	O
freeway	O
)	O
.	O

Methods	O

We	O
conducted	O
a	O
postal	O
survey	O
of	O
a	O
random	O
sample	O
of	O
residents	O
(	O
n	O
=	O
1322	O
)	O
,	O
collecting	O
data	O
on	O
socioeconomic	O
status	O
,	O
perceptions	O
of	O
the	O
local	O
environment	O
,	O
travel	O
behaviour	O
,	O
physical	O
activity	O
and	O
general	O
health	O
and	O
wellbeing	O
using	O
a	O
new	O
14	O
-	O
item	O
neighbourhood	O
rating	O
scale	O
,	O
a	O
travel	O
diary	O
,	O
the	O
short	O
form	O
of	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
and	O
the	O
SF	O
-	O
8	O
.	O

We	O
analysed	O
the	O
correlates	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
using	O
multivariate	O
logistic	O
regression	O
,	O
first	O
building	O
models	O
using	O
personal	O
(	O
individual	O
and	O
household	O
)	O
explanatory	O
variables	O
and	O
then	O
adding	O
environmental	O
variables	O
.	O

Results	O

Active	O
travel	O
was	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
a	O
long	O
distance	O
to	O
work	O
and	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
whereas	O
overall	O
physical	O
activity	O
was	O
associated	O
with	O
living	O
in	O
social	O
rented	O
accommodation	O
and	O
not	O
being	O
overweight	O
.	O

After	O
adjusting	O
for	O
personal	O
characteristics	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
the	O
objective	O
proximity	O
of	O
respondents	O
'	O
homes	O
to	O
motorway	O
or	O
major	O
road	O
infrastructure	O
explained	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
although	O
we	O
did	O
identify	O
a	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
.	O

Conclusion	O

Apart	O
from	O
access	O
to	O
local	O
amenities	O
,	O
environmental	O
characteristics	O
may	O
have	O
limited	O
influence	O
on	O
active	O
travel	O
in	O
deprived	O
urban	O
populations	O
characterised	O
by	O
a	O
low	O
level	O
of	O
car	O
ownership	O
,	O
in	O
which	O
people	S-Species
may	O
have	O
less	O
capacity	O
for	O
making	O
discretionary	O
travel	O
choices	O
than	O
the	O
populations	O
studied	O
in	O
most	O
published	O
research	O
on	O
the	O
environmental	O
correlates	O
of	O
physical	O
activity	O
.	O

Background	O

Until	O
recently	O
,	O
research	O
on	O
correlates	O
of	O
physical	O
activity	O
was	O
dominated	O
by	O
studies	O
of	O
individual	O
demographic	O
and	O
psychosocial	O
characteristics	O
[	O
1	O
]	O
.	O

This	O
reflected	O
an	O
emphasis	O
on	O
promoting	O
sport	O
,	O
recreation	O
or	O
health	O
-	O
directed	O
exercise	O
using	O
techniques	O
to	O
encourage	O
individual	O
behaviour	O
change	O
[	O
2	O
]	O
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
that	O
such	O
approaches	O
are	O
effective	O
in	O
increasing	O
physical	O
activity	O
in	O
the	O
medium	O
-	O
to	O
-	O
long	O
term	O
[	O
3	O
]	O
.	O

If	O
habitual	O
patterns	O
of	O
behaviour	O
are	O
environmentally	O
cued	O
,	O
sustained	O
change	O
is	O
likely	O
to	O
require	O
a	O
supportive	O
environment	O
in	O
which	O
people	S-Species
can	O
be	O
active	O
[	O
4	O
,	O
5	O
]	O
.	O

There	O
is	O
therefore	O
increasing	O
interest	O
in	O
the	O
influence	O
of	O
the	O
social	O
and	O
physical	O
environment	O
on	O
physical	O
activity	O
.	O

With	O
respect	O
to	O
the	O
physical	O
(	O
natural	O
or	O
built	O
)	O
environment	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
suggests	O
that	O
certain	O
environmental	O
characteristics	O
may	O
be	O
associated	O
with	O
patterns	O
of	O
physical	O
activity	O
in	O
general	O
or	O
with	O
particular	O
types	O
of	O
physical	O
activity	O
such	O
as	O
walking	O
or	O
cycling	O
as	O
modes	O
of	O
transport	O
[	O
4	O
-	O
10	O
]	O
.	O

Among	O
the	O
correlates	O
most	O
frequently	O
identified	O
in	O
such	O
reviews	O
-	O
some	O
ascertained	O
using	O
'	O
objective	O
'	O
measures	O
,	O
and	O
others	O
in	O
terms	O
of	O
people	S-Species
'	O
s	O
perceptions	O
-	O
are	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
,	O
the	O
presence	O
of	O
pavements	O
(	O
sidewalks	O
)	O
,	O
the	O
convenience	O
of	O
facilities	O
for	O
being	O
active	O
,	O
the	O
availability	O
of	O
green	O
space	O
,	O
access	O
to	O
amenities	O
(	O
destinations	O
)	O
within	O
walking	O
or	O
cycling	O
distance	O
,	O
safety	O
from	O
traffic	O
and	O
personal	O
attack	O
,	O
and	O
the	O
lack	O
of	O
heavy	O
traffic	O
.	O

Some	O
of	O
these	O
local	O
characteristics	O
reflect	O
higher	O
-	O
order	O
aspects	O
of	O
urban	O
design	O
and	O
spatial	O
policy	O
such	O
as	O
population	O
density	O
,	O
connectivity	O
and	O
mixed	O
land	O
use	O
[	O
6	O
,	O
8	O
]	O
.	O

Importantly	O
,	O
different	O
characteristics	O
may	O
be	O
associated	O
with	O
different	O
types	O
of	O
physical	O
activity	O
;	O
for	O
example	O
,	O
Owen	O
and	O
colleagues	O
found	O
that	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
was	O
associated	O
with	O
walking	O
for	O
exercise	O
or	O
recreation	O
and	O
with	O
walking	O
in	O
general	O
,	O
but	O
not	O
with	O
walking	O
for	O
transport	O
,	O
whereas	O
perceptions	O
of	O
traffic	O
were	O
associated	O
with	O
walking	O
for	O
transport	O
and	O
walking	O
in	O
general	O
,	O
but	O
not	O
with	O
walking	O
for	O
exercise	O
or	O
recreation	O
[	O
5	O
]	O
.	O

Despite	O
the	O
growing	O
volume	O
of	O
published	O
studies	O
in	O
this	O
field	O
,	O
many	O
authors	O
remain	O
circumspect	O
in	O
their	O
interpretation	O
of	O
the	O
available	O
evidence	O
.	O

Giles	O
-	O
Corti	O
and	O
Donovan	O
have	O
described	O
access	O
to	O
a	O
supportive	O
physical	O
environment	O
as	O
a	O
necessary	O
,	O
but	O
insufficient	O
,	O
condition	O
for	O
an	O
increase	O
in	O
physical	O
activity	O
in	O
the	O
population	O
[	O
11	O
]	O
,	O
while	O
Handy	O
found	O
'	O
convincing	O
'	O
evidence	O
of	O
an	O
association	O
between	O
physical	O
activity	O
and	O
the	O
built	O
environment	O
in	O
general	O
but	O
'	O
less	O
convincing	O
'	O
evidence	O
as	O
to	O
which	O
specific	O
environmental	O
characteristics	O
were	O
most	O
strongly	O
associated	O
[	O
7	O
]	O
.	O

One	O
limitation	O
of	O
the	O
available	O
evidence	O
is	O
that	O
most	O
research	O
has	O
been	O
conducted	O
in	O
North	O
America	O
and	O
Australia	O
[	O
9	O
,	O
12	O
]	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
associations	O
observed	O
in	O
those	O
countries	O
are	O
generalisable	O
to	O
other	O
settings	O
with	O
different	O
aggregate	O
socioeconomic	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
wealth	O
or	O
access	O
to	O
private	O
cars	O
)	O
or	O
environmental	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
climate	O
,	O
patterns	O
of	O
land	O
use	O
,	O
or	O
availability	O
of	O
public	O
transport	O
)	O
.	O

For	O
example	O
,	O
North	O
American	O
researchers	O
are	O
often	O
interested	O
in	O
the	O
presence	O
or	O
absence	O
of	O
pavements	O
(	O
sidewalks	O
)	O
,	O
but	O
it	O
is	O
unusual	O
for	O
streets	O
in	O
the	O
United	O
Kingdom	O
(	O
UK	O
)	O
not	O
to	O
have	O
a	O
pavement	O
or	O
footpath	O
beside	O
them	O
.	O

Hypotheses	O
about	O
putative	O
environmental	O
correlates	O
of	O
physical	O
activity	O
therefore	O
need	O
to	O
be	O
tested	O
in	O
a	O
wider	O
range	O
of	O
settings	O
.	O

A	O
more	O
profound	O
limitation	O
of	O
the	O
available	O
evidence	O
is	O
that	O
identifying	O
a	O
relationship	O
between	O
,	O
for	O
example	O
,	O
urban	O
form	O
and	O
walking	O
for	O
transport	O
is	O
not	O
the	O
same	O
thing	O
as	O
showing	O
that	O
changing	O
the	O
built	O
environment	O
will	O
lead	O
to	O
a	O
change	O
in	O
behaviour	O
[	O
13	O
]	O
.	O

Few	O
researchers	O
have	O
taken	O
up	O
the	O
opportunity	O
(	O
or	O
challenge	O
)	O
presented	O
by	O
'	O
natural	O
experiments	O
'	O
to	O
investigate	O
the	O
effects	O
of	O
environmental	O
interventions	O
on	O
physical	O
activity	O
[	O
14	O
]	O
.	O

We	O
therefore	O
established	O
a	O
longitudinal	O
study	O
to	O
examine	O
changes	O
associated	O
with	O
the	O
opening	O
of	O
a	O
new	O
urban	O
section	O
of	O
the	O
M74	O
motorway	O
(	O
freeway	O
)	O
currently	O
under	O
construction	O
in	O
Glasgow	O
,	O
Scotland	O
.	O

The	O
rationale	O
and	O
design	O
for	O
this	O
study	O
have	O
been	O
described	O
previously	O
[	O
15	O
]	O
.	O

It	O
is	O
claimed	O
that	O
the	O
new	O
motorway	O
,	O
which	O
will	O
mostly	O
pass	O
through	O
or	O
close	O
to	O
densely	O
-	O
populated	O
urban	O
neighbourhoods	O
,	O
will	O
contribute	O
to	O
the	O
regeneration	O
of	O
a	O
region	O
which	O
includes	O
some	O
of	O
the	O
most	O
deprived	O
and	O
least	O
healthy	O
working	O
-	O
class	O
communities	O
in	O
Europe	O
[	O
16	O
]	O
.	O

It	O
is	O
also	O
claimed	O
that	O
the	O
new	O
motorway	O
will	O
divert	O
traffic	O
from	O
local	O
streets	O
,	O
reduce	O
traffic	O
noise	O
and	O
bring	O
new	O
local	O
employment	O
opportunities	O
,	O
thereby	O
improving	O
characteristics	O
of	O
the	O
local	O
environment	O
held	O
to	O
be	O
associated	O
with	O
active	O
travel	O
.	O

Others	O
claim	O
that	O
the	O
new	O
motorway	O
will	O
encourage	O
car	O
use	O
,	O
degrade	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
and	O
reduce	O
the	O
safety	O
and	O
attractiveness	O
of	O
routes	O
for	O
pedestrians	O
and	O
cyclists	O
across	O
the	O
line	O
of	O
the	O
motorway	O
-	O
all	O
changes	O
which	O
may	O
be	O
expected	O
to	O
discourage	O
active	O
travel	O
[	O
15	O
]	O
.	O

The	O
eventual	O
aim	O
of	O
the	O
M74	O
study	O
will	O
be	O
to	O
assess	O
the	O
effects	O
of	O
this	O
major	O
modification	O
to	O
the	O
urban	O
built	O
environment	O
and	O
transport	O
infrastructure	O
on	O
perceptions	O
of	O
the	O
local	O
environment	O
and	O
on	O
population	O
health	O
and	O
health	O
-	O
related	O
behaviour	O
,	O
the	O
primary	O
outcome	O
of	O
interest	O
being	O
a	O
change	O
in	O
the	O
quantity	O
of	O
'	O
active	O
travel	O
'	O
(	O
walking	O
and	O
cycling	O
for	O
transport	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
findings	O
from	O
the	O
cross	O
-	O
sectional	O
(	O
baseline	O
)	O
phase	O
of	O
the	O
study	O
which	O
contribute	O
evidence	O
on	O
the	O
environmental	O
correlates	O
of	O
physical	O
activity	O
in	O
this	O
comparatively	O
deprived	O
urban	O
population	O
.	O

We	O
focus	O
on	O
two	O
specific	O
hypotheses	O
:	O
first	O
,	O
that	O
levels	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
vary	O
with	O
demographic	O
and	O
socioeconomic	O
characteristics	O
,	O
but	O
not	O
necessarily	O
in	O
the	O
same	O
way	O
;	O
second	O
,	O
that	O
these	O
relationships	O
may	O
be	O
partly	O
explained	O
by	O
the	O
perceived	O
characteristics	O
of	O
the	O
local	O
environment	O
in	O
which	O
people	S-Species
live	O
and	O
by	O
their	O
objectively	O
-	O
assessed	O
proximity	O
to	O
motorway	O
and	O
major	O
road	O
infrastructure	O
.	O

Methods	O

Delineation	O
of	O
study	O
areas	O

We	O
used	O
spatially	O
referenced	O
census	O
and	O
transport	O
infrastructure	O
data	O
held	O
and	O
analysed	O
in	O
a	O
geographical	O
information	O
system	O
(	O
GIS	O
)	O
,	O
combined	O
with	O
field	O
visits	O
,	O
to	O
delineate	O
three	O
study	O
areas	O
in	O
Glasgow	O
with	O
similar	O
aggregate	O
socioeconomic	O
characteristics	O
and	O
broadly	O
similar	O
topographical	O
characteristics	O
apart	O
from	O
their	O
proximity	O
to	O
urban	O
motorway	O
infrastructure	O
(	O
Table	O
1	O
,	O
Figure	O
1	O
)	O
.	O

All	O
three	O
study	O
areas	O
extended	O
from	O
inner	O
mixed	O
-	O
use	O
districts	O
close	O
to	O
the	O
city	O
centre	O
to	O
residential	O
suburbs	O
,	O
contained	O
major	O
arterial	O
roads	O
other	O
than	O
motorways	O
,	O
and	O
contained	O
a	O
mixture	O
of	O
housing	O
stock	O
including	O
traditional	O
high	O
-	O
density	O
tenements	O
,	O
high	O
-	O
rise	O
flats	O
and	O
new	O
housing	O
developments	O
(	O
Figure	O
2	O
)	O
.	O

Sampling	O
and	O
survey	O
administration	O

We	O
used	O
the	O
Royal	O
Mail	O
Postcode	O
Address	O
File	O
(	O
PAF	O
)	O
(	O
version	O
2005	O
.	O
3	O
)	O
to	O
identify	O
all	O
residential	O
addresses	O
whose	O
unit	O
postcode	O
(	O
zip	O
code	O
)	O
was	O
within	O
one	O
of	O
the	O
study	O
areas	O
(	O
total	O
n	O
=	O
35601	O
)	O
and	O
drew	O
a	O
random	O
sample	O
of	O
3000	O
households	O
from	O
each	O
area	O
.	O

Unit	O
postcodes	O
(	O
e	O
.	O
g	O
.	O
G12	O
8RZ	O
)	O
are	O
the	O
smallest	O
available	O
unit	O
of	O
postal	O
geography	O
in	O
the	O
UK	O
;	O
residential	O
unit	O
postcodes	O
cover	O
about	O
15	O
addresses	O
on	O
average	O
.	O

We	O
sent	O
the	O
survey	O
to	O
all	O
households	O
(	O
total	O
n	O
=	O
9000	O
)	O
between	O
28	O
September	O
and	O
4	O
October	O
2005	O
and	O
resent	O
the	O
survey	O
to	O
all	O
non	O
-	O
responding	O
households	O
between	O
26	O
and	O
31	O
October	O
2005	O
.	O

We	O
alerted	O
households	O
to	O
the	O
survey	O
by	O
means	O
of	O
a	O
postcard	O
sent	O
a	O
few	O
days	O
in	O
advance	O
,	O
used	O
coloured	O
paper	O
for	O
some	O
of	O
the	O
survey	O
materials	O
,	O
and	O
posted	O
survey	O
packs	O
in	O
white	O
envelopes	O
printed	O
with	O
the	O
university	O
crest	O
;	O
these	O
techniques	O
have	O
been	O
shown	O
in	O
a	O
meta	O
-	O
analysis	O
to	O
be	O
associated	O
with	O
increased	O
response	O
rates	O
to	O
postal	O
surveys	O
[	O
17	O
]	O
.	O

We	O
asked	O
householders	O
to	O
ensure	O
that	O
the	O
questionnaire	O
was	O
completed	O
by	O
a	O
resident	O
aged	O
16	O
or	O
over	O
;	O
if	O
more	O
than	O
one	O
resident	O
was	O
eligible	O
,	O
we	O
asked	O
householders	O
to	O
select	O
the	O
person	S-Species
with	O
the	O
most	O
recent	O
birthday	O
.	O

Respondents	O
who	O
consented	O
to	O
follow	O
-	O
up	O
were	O
entered	O
into	O
a	O
prize	O
draw	O
to	O
win	O
a	O
pound	O
50	O
(	O
euro	O
63	O
;	O
US	O
$	O
92	O
)	O
gift	O
voucher	O
.	O

Responses	O
received	O
more	O
than	O
three	O
months	O
after	O
the	O
first	O
mailing	O
wave	O
were	O
disregarded	O
in	O
analysis	O
.	O

Data	O
collection	O

The	O
questionnaire	O
included	O
items	O
on	O
demographic	O
and	O
socioeconomic	O
characteristics	O
,	O
health	O
and	O
wellbeing	O
(	O
including	O
the	O
the	O
SF	O
-	O
8	O
scale	O
)	O
,	O
perceptions	O
of	O
the	O
local	O
environment	O
,	O
travel	O
behaviour	O
and	O
the	O
short	O
form	O
of	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
(	O
Additional	O
file	O
1	O
)	O
.	O

We	O
developed	O
a	O
new	O
'	O
neighbourhood	O
scale	O
'	O
to	O
assess	O
perceptions	O
of	O
relevant	O
characteristics	O
of	O
the	O
local	O
environment	O
(	O
aesthetics	O
,	O
green	O
space	O
,	O
access	O
to	O
amenities	O
,	O
convenience	O
of	O
routes	O
,	O
traffic	O
,	O
road	O
safety	O
and	O
personal	O
safety	O
)	O
.	O

The	O
development	O
,	O
principal	O
components	O
analysis	O
and	O
reliability	O
of	O
the	O
items	O
in	O
this	O
scale	O
and	O
the	O
derivation	O
and	O
reliability	O
of	O
summary	O
variables	O
are	O
reported	O
in	O
an	O
accompanying	O
paper	O
[	O
18	O
]	O
.	O

Data	O
cleaning	O
and	O
derivation	O
of	O
variables	O

Demographic	O
and	O
socioeconomic	O
characteristics	O

We	O
excluded	O
from	O
analysis	O
all	O
respondents	O
who	O
failed	O
to	O
enter	O
their	O
age	O
or	O
sex	O
.	O

We	O
then	O
examined	O
the	O
distributions	O
of	O
all	O
raw	O
variables	O
and	O
carried	O
out	O
range	O
and	O
consistency	O
checks	O
to	O
identify	O
any	O
anomalous	O
values	O
or	O
variables	O
with	O
a	O
high	O
proportion	O
of	O
missing	O
responses	O
.	O

As	O
a	O
consequence	O
,	O
we	O
collapsed	O
responses	O
on	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
,	O
housing	O
tenure	O
,	O
car	O
access	O
and	O
working	O
situation	O
into	O
fewer	O
categories	O
by	O
merging	O
categories	O
with	O
small	O
numbers	O
of	O
responses	O
;	O
we	O
also	O
disregarded	O
household	O
composition	O
and	O
working	O
situation	O
of	O
spouse	O
or	O
partner	O
in	O
analysis	O
because	O
of	O
the	O
large	O
numbers	O
of	O
missing	O
values	O
for	O
these	O
variables	O
.	O

Health	O
and	O
wellbeing	O

We	O
calculated	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
by	O
converting	O
,	O
where	O
necessary	O
,	O
self	O
-	O
reported	O
heights	O
and	O
weights	O
from	O
imperial	O
to	O
metric	O
units	O
and	O
dividing	O
the	O
height	O
in	O
metres	O
by	O
the	O
square	O
of	O
the	O
weight	O
in	O
kilograms	O
;	O
we	O
also	O
categorised	O
respondents	O
into	O
quintiles	O
of	O
BMI	O
.	O

We	O
calculated	O
physical	O
(	O
PCS	O
-	O
8	O
)	O
and	O
mental	O
(	O
MCS	O
-	O
8	O
)	O
health	O
summary	O
scores	O
from	O
the	O
SF	O
-	O
8	O
data	O
and	O
scaled	O
these	O
to	O
population	O
norms	O
using	O
the	O
method	O
and	O
coefficients	O
given	O
in	O
the	O
SF	O
-	O
8	O
manual	O
[	O
19	O
]	O
.	O

Objective	O
environmental	O
characteristics	O

We	O
linked	O
each	O
record	O
to	O
the	O
unit	O
postcode	O
of	O
residence	O
.	O

We	O
then	O
constructed	O
concentric	O
buffers	O
at	O
100	O
-	O
metre	O
intervals	O
up	O
to	O
500	O
metres	O
around	O
the	O
routes	O
and	O
access	O
points	O
of	O
existing	O
and	O
planned	O
motorways	O
and	O
around	O
the	O
network	O
of	O
other	O
major	O
(	O
A	O
-	O
and	O
B	O
-	O
class	O
)	O
roads	O
,	O
and	O
assigned	O
each	O
respondent	O
to	O
a	O
category	O
of	O
proximity	O
to	O
each	O
type	O
of	O
road	O
infrastructure	O
(	O
within	O
100	O
metres	O
,	O
101	O
-	O
200	O
metres	O
,	O
etc	O
.	O
)	O
based	O
on	O
the	O
location	O
of	O
the	O
centroid	O
of	O
their	O
unit	O
postcode	O
.	O

Travel	O
behaviour	O

For	O
travel	O
time	O
analysis	O
we	O
included	O
travel	O
diaries	O
which	O
recorded	O
no	O
travel	O
at	O
all	O
,	O
but	O
we	O
disregarded	O
travel	O
data	O
from	O
respondents	O
who	O
had	O
not	O
been	O
at	O
home	O
on	O
the	O
day	O
of	O
the	O
travel	O
diary	O
,	O
whose	O
questionnaire	O
had	O
been	O
misprinted	O
such	O
that	O
the	O
travel	O
diary	O
pages	O
were	O
unusable	O
,	O
who	O
had	O
recorded	O
journeys	O
without	O
reporting	O
valid	O
quantitative	O
data	O
on	O
the	O
durations	O
of	O
those	O
journeys	O
,	O
or	O
whose	O
completed	O
travel	O
diary	O
appeared	O
implausible	O
.	O

We	O
also	O
disregarded	O
journeys	O
whose	O
purpose	O
was	O
not	O
stated	O
or	O
was	O
beyond	O
the	O
scope	O
of	O
the	O
travel	O
diary	O
(	O
Additional	O
file	O
1	O
,	O
page	O
8	O
)	O
.	O

We	O
summed	O
the	O
reported	O
travel	O
time	O
for	O
each	O
mode	O
of	O
transport	O
,	O
calculated	O
a	O
total	O
travel	O
time	O
by	O
active	O
modes	O
(	O
walking	O
plus	O
cycling	O
)	O
and	O
by	O
all	O
modes	O
combined	O
,	O
and	O
calculated	O
the	O
proportion	O
of	O
total	O
travel	O
time	O
contributed	O
by	O
each	O
mode	O
of	O
transport	O
.	O

Physical	O
activity	O

We	O
cleaned	O
and	O
analysed	O
IPAQ	O
data	O
in	O
accordance	O
with	O
the	O
IPAQ	O
scoring	O
protocol	O
.	O

We	O
therefore	O
disregarded	O
physical	O
activity	O
data	O
from	O
respondents	O
who	O
had	O
reported	O
more	O
than	O
16	O
hours	O
of	O
physical	O
activity	O
per	O
day	O
or	O
who	O
had	O
missing	O
or	O
internally	O
inconsistent	O
data	O
on	O
the	O
frequency	O
or	O
duration	O
of	O
any	O
of	O
the	O
three	O
categories	O
of	O
physical	O
activity	O
(	O
walking	O
,	O
moderate	O
-	O
intensity	O
activity	O
or	O
vigorous	O
activity	O
)	O
.	O

We	O
also	O
recoded	O
reported	O
durations	O
of	O
activity	O
of	O
less	O
than	O
ten	O
minutes	O
to	O
zero	O
,	O
and	O
of	O
greater	O
than	O
180	O
minutes	O
to	O
180	O
minutes	O
.	O

We	O
calculated	O
the	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
for	O
each	O
respondent	O
(	O
MET	O
-	O
min	O
/	O
week	O
)	O
and	O
used	O
a	O
combination	O
of	O
frequency	O
,	O
duration	O
and	O
total	O
energy	O
expenditure	O
to	O
assign	O
each	O
respondent	O
to	O
a	O
'	O
high	O
'	O
,	O
'	O
moderate	O
'	O
or	O
'	O
low	O
'	O
category	O
of	O
overall	O
physical	O
activity	O
in	O
accordance	O
with	O
the	O
prescribed	O
IPAQ	O
algorithm	O
.	O

The	O
'	O
high	O
'	O
category	O
corresponds	O
to	O
a	O
sufficient	O
level	O
of	O
physical	O
activity	O
to	O
meet	O
current	O
public	O
health	O
recommendations	O
for	O
adults	O
[	O
20	O
]	O
.	O

Analysis	O

We	O
considered	O
it	O
unlikely	O
that	O
the	O
statistical	O
assumptions	O
required	O
for	O
linear	O
regression	O
could	O
be	O
met	O
because	O
the	O
distributions	O
of	O
time	O
spent	O
walking	O
and	O
cycling	O
and	O
of	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
were	O
both	O
strongly	O
positively	O
skewed	O
and	O
dominated	O
by	O
a	O
large	O
number	O
of	O
zero	O
values	O
which	O
meant	O
that	O
the	O
data	O
were	O
not	O
amenable	O
to	O
log	O
-	O
transformation	O
.	O

We	O
therefore	O
modelled	O
the	O
correlates	O
of	O
active	O
travel	O
and	O
physical	O
activity	O
using	O
multivariate	O
logistic	O
regression	O
.	O

We	O
defined	O
'	O
active	O
travel	O
'	O
as	O
a	O
binary	O
condition	O
achieved	O
by	O
any	O
respondent	O
who	O
had	O
reported	O
at	O
least	O
30	O
minutes	O
of	O
travel	O
by	O
walking	O
,	O
cycling	O
or	O
both	O
in	O
their	O
travel	O
diary	O
,	O
reflecting	O
the	O
current	O
recommendation	O
that	O
adults	O
should	O
accumulate	O
at	O
least	O
30	O
minutes	O
of	O
moderate	O
-	O
intensity	O
physical	O
activity	O
on	O
most	O
days	O
of	O
the	O
week	O
[	O
20	O
]	O
,	O
and	O
we	O
defined	O
'	O
physical	O
activity	O
'	O
as	O
a	O
binary	O
condition	O
achieved	O
by	O
any	O
respondent	O
whose	O
overall	O
physical	O
activity	O
was	O
categorised	O
as	O
'	O
high	O
'	O
using	O
IPAQ	O
.	O

We	O
then	O
built	O
separate	O
multivariate	O
models	O
for	O
active	O
travel	O
and	O
physical	O
activity	O
following	O
the	O
method	O
of	O
Hosmer	O
and	O
Lemeshow	O
[	O
21	O
]	O
,	O
first	O
including	O
only	O
'	O
personal	O
'	O
(	O
individual	O
or	O
household	O
)	O
variables	O
and	O
then	O
adding	O
'	O
environmental	O
'	O
variables	O
(	O
Additional	O
file	O
2	O
)	O
.	O

Results	O

Response	O

We	O
received	O
1345	O
completed	O
questionnaires	O
.	O

After	O
subtracting	O
from	O
the	O
numerator	O
23	O
completed	O
questionnaires	O
with	O
missing	O
critical	O
demographic	O
data	O
(	O
age	O
or	O
sex	O
)	O
,	O
and	O
after	O
subtracting	O
from	O
the	O
denominator	O
676	O
addresses	O
from	O
which	O
survey	O
packs	O
were	O
returned	O
as	O
undeliverable	O
,	O
this	O
left	O
1322	O
valid	O
responses	O
to	O
be	O
entered	O
into	O
analysis	O
-	O
a	O
response	O
rate	O
of	O
1322	O
/	O
(	O
9000	O
-	O
676	O
)	O
=	O
15	O
.	O
9	O
%	O
.	O

Characteristics	O
of	O
study	O
participants	S-Species

Demographic	O
and	O
socioeconomic	O
characteristics	O

Respondents	O
were	O
aged	O
between	O
16	O
and	O
89	O
years	O
(	O
median	O
age	O
48	O
years	O
)	O
.	O

804	O
(	O
61	O
%	O
)	O
were	O
women	S-Species
.	O

Only	O
136	O
(	O
26	O
%	O
)	O
of	O
the	O
men	S-Species
and	O
145	O
(	O
18	O
%	O
)	O
of	O
the	O
women	S-Species
reported	O
having	O
access	O
to	O
a	O
bicycle	O
.	O

For	O
those	O
who	O
usually	O
travelled	O
to	O
a	O
place	O
of	O
work	O
or	O
study	O
,	O
the	O
median	O
reported	O
distance	O
was	O
3	O
.	O
5	O
miles	O
(	O
about	O
5	O
.	O
5	O
kilometres	O
)	O
.	O

Other	O
characteristics	O
of	O
study	O
participants	S-Species
are	O
summarised	O
in	O
Table	O
2	O
.	O

Health	O
and	O
wellbeing	O

25	O
%	O
of	O
respondents	O
reported	O
difficulty	O
walking	O
for	O
a	O
quarter	O
of	O
a	O
mile	O
,	O
39	O
%	O
reported	O
a	O
long	O
-	O
term	O
health	O
problem	O
or	O
disability	O
,	O
and	O
50	O
%	O
were	O
overweight	O
(	O
median	O
BMI	O
25	O
.	O
1	O
kg	O
/	O
m2	O
)	O
.	O

The	O
median	O
mental	O
health	O
summary	O
score	O
(	O
MCS	O
-	O
8	O
)	O
was	O
significantly	O
lower	O
(	O
i	O
.	O
e	O
.	O
poorer	O
)	O
than	O
the	O
population	O
norm	O
(	O
median	O
47	O
.	O
3	O
,	O
95	O
%	O
CI	O
46	O
.	O
4	O
to	O
48	O
.	O
1	O
)	O
;	O
the	O
median	O
physical	O
health	O
summary	O
score	O
(	O
PCS	O
-	O
8	O
)	O
was	O
not	O
significantly	O
different	O
from	O
the	O
population	O
norm	O
(	O
median	O
50	O
.	O
9	O
,	O
95	O
%	O
CI	O
49	O
.	O
6	O
to	O
51	O
.	O
7	O
)	O
.	O

Descriptive	O
data	O
on	O
travel	O
behaviour	O
and	O
physical	O
activity	O

Travel	O
behaviour	O

1099	O
travel	O
diaries	O
were	O
suitable	O
for	O
travel	O
time	O
analysis	O
.	O

Men	S-Species
and	O
women	S-Species
were	O
equally	O
likely	O
to	O
have	O
returned	O
usable	O
travel	O
time	O
data	O
,	O
but	O
respondents	O
who	O
were	O
older	O
,	O
retired	O
,	O
or	O
living	O
in	O
social	O
rented	O
accommodation	O
or	O
who	O
did	O
not	O
have	O
access	O
to	O
a	O
car	O
were	O
less	O
likely	O
to	O
have	O
returned	O
usable	O
data	O
.	O

On	O
average	O
,	O
respondents	O
recorded	O
about	O
an	O
hour	O
'	O
s	O
travel	O
per	O
day	O
(	O
mean	O
61	O
.	O
5	O
minutes	O
,	O
median	O
50	O
.	O
0	O
minutes	O
)	O
,	O
of	O
which	O
a	O
minority	O
was	O
spent	O
using	O
active	O
modes	O
of	O
transport	O
(	O
walking	O
or	O
cycling	O
:	O
mean	O
20	O
.	O
0	O
minutes	O
,	O
median	O
10	O
.	O
0	O
minutes	O
)	O
(	O
Table	O
3	O
)	O
.	O

304	O
respondents	O
(	O
28	O
%	O
)	O
recorded	O
at	O
least	O
30	O
minutes	O
of	O
active	O
travel	O
,	O
of	O
whom	O
294	O
(	O
97	O
%	O
)	O
recorded	O
at	O
least	O
30	O
minutes	O
of	O
walking	O
.	O

Physical	O
activity	O

833	O
respondents	O
returned	O
complete	O
physical	O
activity	O
data	O
suitable	O
for	O
analysis	O
.	O

Women	S-Species
and	O
respondents	O
who	O
were	O
older	O
,	O
retired	O
,	O
or	O
living	O
in	O
social	O
rented	O
accommodation	O
or	O
who	O
did	O
not	O
have	O
access	O
to	O
a	O
car	O
were	O
less	O
likely	O
to	O
have	O
returned	O
usable	O
data	O
.	O

Respondents	O
reported	O
a	O
mean	O
of	O
318	O
minutes	O
'	O
walking	O
per	O
week	O
and	O
a	O
mean	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
of	O
3000	O
MET	O
-	O
minutes	O
per	O
week	O
(	O
Table	O
4	O
)	O
.	O

Only	O
316	O
respondents	O
(	O
38	O
%	O
)	O
were	O
categorised	O
as	O
having	O
achieved	O
a	O
'	O
high	O
'	O
(	O
i	O
.	O
e	O
.	O
sufficient	O
)	O
level	O
of	O
physical	O
activity	O
.	O

Correlates	O
of	O
active	O
travel	O

Active	O
travel	O
was	O
significantly	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
more	O
than	O
four	O
miles	O
to	O
work	O
,	O
having	O
access	O
to	O
a	O
bicycle	O
,	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
and	O
the	O
absence	O
of	O
any	O
difficulty	O
walking	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
'	O
personal	O
'	O
correlates	O
of	O
active	O
travel	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
chi	O
2	O
=	O
13	O
.	O
04	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0	O
.	O
11	O
)	O
and	O
explained	O
nearly	O
one	O
-	O
fifth	O
of	O
the	O
total	O
variance	O
in	O
active	O
travel	O
(	O
Nagelkerke	O
'	O
s	O
R2	O
=	O
18	O
.	O
7	O
%	O
)	O
(	O
Table	O
5	O
)	O
.	O

Adding	O
'	O
environmental	O
'	O
variables	O
to	O
the	O
model	O
showed	O
an	O
additional	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
,	O
and	O
an	O
additional	O
significant	O
negative	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
also	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
chi	O
2	O
=	O
10	O
.	O
61	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0	O
.	O
23	O
)	O
and	O
explained	O
slightly	O
more	O
of	O
the	O
total	O
variance	O
in	O
active	O
travel	O
than	O
did	O
the	O
personal	O
model	O
alone	O
(	O
Nagelkerke	O
'	O
s	O
R2	O
=	O
20	O
.	O
1	O
%	O
)	O
(	O
Figure	O
3	O
)	O
.	O

In	O
order	O
to	O
aid	O
interpretation	O
,	O
we	O
also	O
partitioned	O
the	O
dataset	O
into	O
two	O
strata	O
(	O
'	O
No	O
car	O
available	O
'	O
and	O
'	O
Car	O
available	O
'	O
)	O
and	O
refitted	O
the	O
final	O
model	O
separately	O
to	O
each	O
stratum	O
of	O
the	O
dataset	O
(	O
Table	O
6	O
)	O
.	O

This	O
showed	O
that	O
the	O
subset	O
of	O
respondents	O
with	O
no	O
access	O
to	O
a	O
car	O
accounted	O
for	O
the	O
significant	O
overall	O
relationship	O
between	O
active	O
travel	O
and	O
access	O
to	O
a	O
bicycle	O
,	O
whereas	O
those	O
with	O
access	O
to	O
a	O
car	O
accounted	O
for	O
the	O
significant	O
overall	O
relationships	O
with	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
and	O
perceptions	O
of	O
the	O
local	O
environment	O
.	O

The	O
relationship	O
with	O
difficulty	O
walking	O
was	O
also	O
stronger	O
in	O
this	O
group	O
than	O
in	O
those	O
without	O
access	O
to	O
a	O
car	O
.	O

Correlates	O
of	O
physical	O
activity	O

Physical	O
activity	O
was	O
significantly	O
associated	O
with	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
,	O
not	O
being	O
overweight	O
,	O
and	O
the	O
absence	O
of	O
any	O
difficulty	O
walking	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
'	O
personal	O
'	O
correlates	O
of	O
physical	O
activity	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
chi	O
2	O
=	O
3	O
.	O
89	O
,	O
df	O
=	O
7	O
;	O
P	O
=	O
0	O
.	O
89	O
)	O
and	O
explained	O
about	O
one	O
-	O
sixth	O
of	O
the	O
total	O
variance	O
in	O
physical	O
activity	O
(	O
Nagelkerke	O
'	O
s	O
R2	O
=	O
15	O
.	O
9	O
%	O
)	O
(	O
Table	O
7	O
)	O
.	O

Adding	O
'	O
environmental	O
'	O
variables	O
to	O
the	O
model	O
showed	O
an	O
additional	O
significant	O
negative	O
association	O
between	O
physical	O
activity	O
and	O
perception	O
of	O
traffic	O
volume	O
(	O
i	O
.	O
e	O
.	O
respondents	O
who	O
perceived	O
there	O
to	O
be	O
a	O
higher	O
volume	O
of	O
traffic	O
were	O
more	O
likely	O
to	O
report	O
physical	O
activity	O
)	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
personal	O
and	O
environmental	O
correlates	O
of	O
physical	O
activity	O
also	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
chi	O
2	O
=	O
3	O
.	O
86	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0	O
.	O
87	O
)	O
and	O
explained	O
slightly	O
more	O
of	O
the	O
total	O
variance	O
in	O
physical	O
activity	O
than	O
did	O
the	O
personal	O
model	O
alone	O
(	O
Nagelkerke	O
'	O
s	O
16	O
.	O
6	O
%	O
)	O
(	O
Figure	O
3	O
)	O
.	O

Discussion	O

Principal	O
findings	O

In	O
this	O
deprived	O
urban	O
population	O
,	O
the	O
likelihood	O
of	O
reporting	O
active	O
travel	O
was	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
a	O
long	O
distance	O
to	O
work	O
and	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
whereas	O
overall	O
physical	O
activity	O
was	O
associated	O
with	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
and	O
not	O
being	O
overweight	O
.	O

After	O
adjusting	O
for	O
individual	O
and	O
household	O
characteristics	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
the	O
objective	O
proximity	O
of	O
respondents	O
'	O
homes	O
to	O
motorway	O
or	O
major	O
road	O
infrastructure	O
appeared	O
to	O
explain	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
although	O
we	O
did	O
find	O
a	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
.	O

Representativeness	O
and	O
completeness	O
of	O
survey	O
data	O

Our	O
difficulty	O
in	O
obtaining	O
a	O
representative	O
sample	O
of	O
the	O
resident	O
population	O
is	O
not	O
unique	O
to	O
our	O
study	O
.	O

Although	O
our	O
final	O
response	O
rate	O
was	O
low	O
,	O
it	O
was	O
almost	O
identical	O
to	O
that	O
achieved	O
in	O
a	O
recent	O
population	O
-	O
based	O
intervention	O
study	O
elsewhere	O
in	O
Glasgow	O
[	O
22	O
]	O
.	O

Some	O
of	O
the	O
challenges	O
of	O
recruiting	O
research	O
participants	S-Species
in	O
areas	O
of	O
deprivation	O
have	O
been	O
described	O
elsewhere	O
[	O
23	O
]	O
;	O
these	O
are	O
superimposed	O
on	O
a	O
downward	O
trend	O
in	O
participation	O
in	O
even	O
the	O
best	O
-	O
resourced	O
national	O
population	O
surveys	O
[	O
24	O
]	O
and	O
an	O
upward	O
(	O
and	O
socially	O
biased	O
)	O
trend	O
in	O
opt	O
-	O
outs	O
from	O
the	O
main	O
alternative	O
sampling	O
frame	O
,	O
the	O
edited	O
electoral	O
register	O
[	O
25	O
]	O
.	O

Although	O
our	O
achieved	O
sample	O
contained	O
a	O
higher	O
proportion	O
of	O
respondents	O
from	O
owner	O
-	O
occupied	O
and	O
car	O
-	O
owning	O
households	O
than	O
predicted	O
from	O
2001	O
census	O
data	O
for	O
the	O
same	O
census	O
output	O
areas	O
,	O
these	O
differences	O
may	O
be	O
partly	O
accounted	O
for	O
by	O
an	O
upward	O
background	O
trend	O
in	O
owner	O
occupation	O
and	O
car	O
access	O
between	O
2001	O
and	O
2005	O
.	O

Our	O
achieved	O
sample	O
is	O
still	O
clearly	O
disadvantaged	O
overall	O
,	O
in	O
terms	O
of	O
socioeconomic	O
and	O
health	O
status	O
,	O
compared	O
with	O
the	O
country	O
as	O
a	O
whole	O
.	O

It	O
also	O
contains	O
sufficient	O
heterogeneity	O
to	O
enable	O
us	O
to	O
examine	O
,	O
in	O
time	O
,	O
how	O
the	O
effects	O
of	O
the	O
intervention	O
are	O
distributed	O
between	O
socioeconomic	O
groups	O
.	O

We	O
therefore	O
consider	O
our	O
achieved	O
sample	O
fit	O
for	O
purpose	O
.	O

We	O
had	O
to	O
disregard	O
a	O
substantial	O
proportion	O
of	O
cases	O
in	O
analysis	O
because	O
respondents	O
had	O
returned	O
unusable	O
travel	O
time	O
data	O
or	O
had	O
returned	O
physical	O
activity	O
data	O
that	O
were	O
incomplete	O
,	O
internally	O
inconsistent	O
or	O
included	O
a	O
'	O
Don	O
'	O
t	O
know	O
'	O
response	O
and	O
were	O
therefore	O
unacceptable	O
according	O
to	O
the	O
IPAQ	O
scoring	O
protocol	O
.	O

Most	O
published	O
studies	O
using	O
the	O
same	O
,	O
short	O
form	O
of	O
IPAQ	O
have	O
either	O
not	O
reported	O
the	O
distribution	O
of	O
the	O
continuous	O
summary	O
measures	O
or	O
have	O
not	O
reported	O
data	O
for	O
the	O
UK	O
separately	O
from	O
those	O
for	O
other	O
countries	O
where	O
higher	O
levels	O
of	O
physical	O
activity	O
are	O
reported	O
.	O

Despite	O
the	O
high	O
proportion	O
of	O
missing	O
physical	O
activity	O
data	O
in	O
our	O
dataset	O
,	O
however	O
,	O
the	O
aggregate	O
continuous	O
data	O
we	O
obtained	O
were	O
broadly	O
comparable	O
to	O
those	O
reported	O
in	O
R	O
u	O
tten	O
and	O
colleagues	O
'	O
study	O
of	O
a	O
random	O
sample	O
of	O
UK	O
adults	O
[	O
26	O
]	O
.	O

We	O
could	O
have	O
included	O
more	O
cases	O
in	O
physical	O
activity	O
analysis	O
by	O
,	O
for	O
example	O
,	O
imputing	O
missing	O
values	O
,	O
but	O
the	O
results	O
would	O
not	O
have	O
been	O
comparable	O
with	O
others	O
'	O
owing	O
to	O
the	O
substantial	O
deviations	O
from	O
the	O
scoring	O
protocol	O
which	O
would	O
have	O
been	O
required	O
.	O

The	O
frequency	O
of	O
unusable	O
responses	O
was	O
not	O
reported	O
in	O
the	O
international	O
multi	O
-	O
centre	O
study	O
which	O
originally	O
established	O
the	O
validity	O
and	O
reliability	O
of	O
IPAQ	O
[	O
27	O
]	O
.	O

It	O
is	O
possible	O
that	O
offering	O
a	O
'	O
Don	O
'	O
t	O
know	O
'	O
option	O
in	O
the	O
self	O
-	O
completed	O
IPAQ	O
questionnaire	O
encourages	O
respondents	O
to	O
select	O
this	O
rather	O
than	O
to	O
enter	O
what	O
may	O
be	O
a	O
reasonably	O
precise	O
estimate	O
of	O
the	O
actual	O
time	O
spent	O
in	O
physical	O
activity	O
;	O
the	O
respondent	O
has	O
no	O
way	O
of	O
knowing	O
that	O
a	O
single	O
'	O
Don	O
'	O
t	O
know	O
'	O
response	O
will	O
result	O
in	O
all	O
of	O
their	O
physical	O
activity	O
data	O
being	O
disregarded	O
in	O
analysis	O
.	O

This	O
should	O
be	O
considered	O
in	O
any	O
future	O
revision	O
of	O
the	O
IPAQ	O
questionnaire	O
and	O
scoring	O
protocol	O
.	O

Contribution	O
of	O
active	O
travel	O
to	O
overall	O
physical	O
activity	O

The	O
explanatory	O
variables	O
that	O
were	O
significantly	O
associated	O
with	O
active	O
travel	O
but	O
not	O
with	O
physical	O
activity	O
(	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
,	O
access	O
to	O
a	O
bicycle	O
,	O
access	O
to	O
a	O
car	O
,	O
perceived	O
proximity	O
to	O
shops	O
,	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
)	O
all	O
have	O
an	O
obvious	O
intuitive	O
relationship	O
with	O
the	O
use	O
of	O
walking	O
or	O
cycling	O
as	O
modes	O
of	O
transport	O
.	O

That	O
they	O
were	O
not	O
significantly	O
associated	O
with	O
overall	O
physical	O
activity	O
suggests	O
either	O
that	O
active	O
travel	O
contributes	O
only	O
a	O
minority	O
of	O
respondents	O
'	O
overall	O
physical	O
activity	O
or	O
that	O
other	O
factors	O
not	O
measured	O
in	O
this	O
study	O
are	O
more	O
important	O
correlates	O
of	O
overall	O
physical	O
activity	O
than	O
those	O
which	O
determine	O
active	O
travel	O
.	O

A	O
crude	O
comparision	O
of	O
the	O
quantity	O
of	O
active	O
travel	O
reported	O
in	O
the	O
one	O
-	O
day	O
travel	O
diaries	O
with	O
the	O
quantities	O
of	O
physical	O
activity	O
reported	O
using	O
IPAQ	O
suggests	O
that	O
on	O
average	O
,	O
active	O
travel	O
may	O
indeed	O
make	O
only	O
a	O
small	O
(	O
~	O
15	O
%	O
)	O
contribution	O
to	O
overall	O
physical	O
activity	O
in	O
this	O
study	O
population	O
.	O

However	O
,	O
the	O
real	O
contribution	O
may	O
be	O
substantially	O
greater	O
than	O
this	O
if	O
,	O
as	O
has	O
been	O
shown	O
previously	O
,	O
respondents	O
tend	O
to	O
over	O
-	O
report	O
their	O
physical	O
activity	O
using	O
IPAQ	O
[	O
28	O
]	O
.	O

There	O
can	O
be	O
little	O
doubt	O
that	O
active	O
travel	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
total	O
quantity	O
of	O
walking	O
reported	O
in	O
this	O
study	O
population	O
.	O

Irrespective	O
of	O
the	O
true	O
contribution	O
of	O
active	O
travel	O
to	O
overall	O
physical	O
activity	O
,	O
however	O
,	O
it	O
remains	O
likely	O
that	O
other	O
unmeasured	O
personal	O
and	O
social	O
factors	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
may	O
be	O
more	O
important	O
correlates	O
of	O
overall	O
physical	O
activity	O
.	O

Socio	O
-	O
spatial	O
patterning	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O

Respondents	O
living	O
in	O
owner	O
-	O
occupied	O
households	O
were	O
more	O
likely	O
to	O
report	O
active	O
travel	O
than	O
those	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
,	O
but	O
less	O
likely	O
to	O
report	O
sufficient	O
overall	O
physical	O
activity	O
.	O

Since	O
neither	O
working	O
situation	O
nor	O
perceived	O
financial	O
situation	O
emerged	O
as	O
significantly	O
associated	O
with	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
housing	O
tenure	O
and	O
car	O
access	O
are	O
the	O
remaining	O
explanatory	O
variables	O
in	O
this	O
dataset	O
which	O
can	O
be	O
interpreted	O
as	O
markers	O
of	O
socioeconomic	O
status	O
.	O

Although	O
having	O
access	O
to	O
a	O
car	O
clearly	O
reflects	O
the	O
possession	O
of	O
a	O
material	O
asset	O
,	O
it	O
has	O
been	O
argued	O
that	O
this	O
is	O
a	O
less	O
direct	O
marker	O
of	O
socioeconomic	O
status	O
than	O
some	O
other	O
markers	O
because	O
,	O
in	O
Scotland	O
at	O
least	O
,	O
access	O
to	O
a	O
car	O
is	O
a	O
more	O
-	O
or	O
-	O
less	O
essential	O
requirement	O
for	O
living	O
in	O
many	O
rural	O
areas	O
,	O
whereas	O
it	O
is	O
possible	O
to	O
live	O
in	O
a	O
dense	O
urban	O
settlement	O
such	O
as	O
Glasgow	O
without	O
using	O
a	O
car	O
.	O

In	O
the	O
final	O
models	O
in	O
this	O
study	O
,	O
therefore	O
,	O
housing	O
tenure	O
may	O
be	O
regarded	O
as	O
the	O
primary	O
marker	O
of	O
socioeconomic	O
status	O
.	O

The	O
findings	O
consequently	O
suggest	O
conflicting	O
socioeconomic	O
gradients	O
in	O
prevalence	O
:	O
more	O
advantaged	O
respondents	O
were	O
more	O
likely	O
to	O
report	O
active	O
travel	O
,	O
but	O
more	O
disadvantaged	O
respondents	O
were	O
more	O
likely	O
to	O
report	O
sufficient	O
overall	O
physical	O
activity	O
.	O

The	O
higher	O
prevalence	O
of	O
sufficient	O
overall	O
physical	O
activity	O
among	O
the	O
more	O
disadvantaged	O
despite	O
their	O
lower	O
propensity	O
for	O
active	O
travel	O
is	O
likely	O
to	O
reflect	O
higher	O
quantities	O
of	O
physical	O
activity	O
in	O
other	O
domains	O
,	O
particularly	O
occupational	O
and	O
domestic	O
activities	O
,	O
since	O
leisure	O
-	O
time	O
physical	O
activity	O
tends	O
to	O
be	O
higher	O
among	O
more	O
advantaged	O
groups	O
[	O
29	O
]	O
.	O

Environmental	O
characteristics	O
:	O
paradoxical	O
,	O
unmeasured	O
,	O
or	O
irrelevant	O
?	O

The	O
two	O
environmental	O
variables	O
that	O
emerged	O
as	O
significantly	O
associated	O
with	O
active	O
travel	O
,	O
particularly	O
among	O
those	O
without	O
access	O
to	O
a	O
car	O
,	O
were	O
perceived	O
proximity	O
to	O
shops	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
.	O

The	O
positive	O
association	O
with	O
perceived	O
proximity	O
to	O
shops	O
suggests	O
that	O
for	O
active	O
travel	O
to	O
be	O
undertaken	O
in	O
this	O
population	O
,	O
it	O
may	O
be	O
more	O
important	O
that	O
people	S-Species
live	O
close	O
to	O
the	O
amenities	O
they	O
need	O
than	O
that	O
they	O
live	O
in	O
an	O
environment	O
with	O
more	O
favourable	O
subjective	O
or	O
discretionary	O
considerations	O
such	O
as	O
attractiveness	O
or	O
noise	O
.	O

This	O
would	O
be	O
consistent	O
with	O
an	O
understanding	O
that	O
walking	O
as	O
a	O
mode	O
of	O
transport	O
is	O
primarily	O
a	O
way	O
of	O
undertaking	O
journeys	O
which	O
have	O
to	O
be	O
made	O
anyway	O
,	O
as	O
opposed	O
to	O
more	O
discretionary	O
(	O
recreational	O
)	O
forms	O
of	O
walking	O
which	O
may	O
be	O
more	O
susceptible	O
to	O
the	O
influence	O
of	O
less	O
-	O
structural	O
characteristics	O
.	O

Although	O
the	O
negative	O
association	O
with	O
perceived	O
road	O
safety	O
for	O
cyclists	O
appears	O
counter	O
-	O
intuitive	O
,	O
similar	O
'	O
paradoxical	O
inverse	O
relationships	O
'	O
have	O
been	O
reported	O
elsewhere	O
,	O
for	O
example	O
by	O
Titze	O
and	O
colleagues	O
in	O
a	O
study	O
of	O
the	O
correlates	O
of	O
cycling	O
among	O
students	O
[	O
30	O
]	O
and	O
by	O
Humpel	O
and	O
colleagues	O
in	O
a	O
study	O
of	O
correlates	O
of	O
walking	O
for	O
pleasure	O
[	O
31	O
]	O
.	O

Titze	O
and	O
colleagues	O
suggest	O
that	O
respondents	O
who	O
cycle	O
regularly	O
are	O
more	O
likely	O
to	O
be	O
aware	O
of	O
,	O
and	O
report	O
,	O
the	O
danger	O
posed	O
by	O
traffic	O
than	O
non	O
-	O
cyclists	O
or	O
infrequent	O
cyclists	O
.	O

A	O
similar	O
phenomenon	O
could	O
explain	O
the	O
negative	O
association	O
between	O
physical	O
activity	O
and	O
perception	O
of	O
traffic	O
volume	O
.	O

Overall	O
,	O
the	O
influence	O
of	O
the	O
putative	O
environmental	O
characteristics	O
examined	O
in	O
this	O
study	O
on	O
active	O
travel	O
and	O
physical	O
activity	O
appeared	O
small	O
compared	O
with	O
that	O
of	O
the	O
personal	O
characteristics	O
found	O
to	O
be	O
significant	O
,	O
and	O
including	O
environmental	O
characteristics	O
in	O
the	O
models	O
did	O
not	O
substantially	O
modify	O
the	O
influence	O
of	O
personal	O
characteristics	O
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
could	O
reflect	O
an	O
artefact	O
of	O
the	O
research	O
methods	O
(	O
a	O
false	O
negative	O
error	O
)	O
,	O
which	O
could	O
have	O
arisen	O
in	O
various	O
ways	O
.	O

In	O
particular	O
,	O
the	O
'	O
wrong	O
'	O
environmental	O
exposure	O
may	O
have	O
been	O
measured	O
,	O
in	O
that	O
the	O
environmental	O
characteristics	O
examined	O
were	O
those	O
of	O
the	O
immediate	O
surroundings	O
of	O
respondents	O
'	O
homes	O
,	O
whereas	O
the	O
propensity	O
to	O
choose	O
active	O
modes	O
of	O
transport	O
may	O
be	O
more	O
strongly	O
influenced	O
by	O
the	O
characteristics	O
of	O
the	O
environment	O
elsewhere	O
on	O
their	O
routes	O
[	O
30	O
]	O
,	O
for	O
example	O
the	O
perceived	O
danger	O
of	O
cycling	O
in	O
the	O
city	O
centre	O
-	O
an	O
association	O
which	O
may	O
be	O
absent	O
,	O
or	O
at	O
least	O
diluted	O
,	O
when	O
the	O
'	O
exposure	O
'	O
examined	O
is	O
limited	O
to	O
the	O
residential	O
environment	O
.	O

It	O
could	O
also	O
be	O
argued	O
that	O
the	O
apparently	O
weak	O
influence	O
of	O
environmental	O
characteristics	O
in	O
this	O
study	O
reflects	O
a	O
reliance	O
on	O
respondents	O
'	O
perceptions	O
which	O
have	O
not	O
been	O
objectively	O
verified	O
and	O
may	O
therefore	O
be	O
a	O
weak	O
proxy	O
for	O
the	O
'	O
true	O
'	O
objectively	O
-	O
measured	O
characteristics	O
of	O
their	O
surroundings	O
.	O

However	O
,	O
as	O
recent	O
reviews	O
have	O
pointed	O
out	O
,	O
the	O
current	O
weight	O
of	O
evidence	O
for	O
objective	O
environmental	O
correlates	O
of	O
walking	O
is	O
no	O
greater	O
than	O
that	O
for	O
subjective	O
environmental	O
correlates	O
[	O
5	O
]	O
and	O
it	O
is	O
entirely	O
plausible	O
that	O
people	S-Species
'	O
s	O
perceptions	O
of	O
their	O
environment	O
may	O
be	O
at	O
least	O
as	O
important	O
as	O
their	O
objective	O
conditions	O
in	O
influencing	O
their	O
behaviour	O
[	O
6	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
may	O
have	O
demonstrated	O
a	O
real	O
absence	O
of	O
any	O
major	O
association	O
.	O

Although	O
at	O
first	O
sight	O
this	O
appears	O
at	O
odds	O
with	O
the	O
growing	O
body	O
of	O
review	O
-	O
level	O
evidence	O
for	O
environmental	O
correlates	O
of	O
physical	O
activity	O
,	O
Wendel	O
-	O
Vos	O
and	O
colleagues	O
noted	O
that	O
of	O
all	O
the	O
environmental	O
factors	O
examined	O
in	O
all	O
the	O
studies	O
included	O
in	O
their	O
review	O
,	O
analysis	O
showed	O
a	O
'	O
null	O
association	O
'	O
in	O
76	O
%	O
of	O
cases	O
[	O
9	O
]	O
,	O
and	O
our	O
finding	O
that	O
personal	O
factors	O
account	O
for	O
a	O
much	O
larger	O
proportion	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
physical	O
activity	O
than	O
is	O
accounted	O
for	O
by	O
environmental	O
factors	O
is	O
consistent	O
with	O
those	O
of	O
some	O
other	O
European	O
studies	O
[	O
32	O
,	O
33	O
]	O
.	O

In	O
the	O
particular	O
context	O
of	O
this	O
study	O
,	O
residents	O
may	O
simply	O
have	O
adapted	O
to	O
adverse	O
conditions	O
in	O
their	O
local	O
environment	O
in	O
the	O
ways	O
identified	O
by	O
Hedges	O
in	O
a	O
qualitative	O
study	O
of	O
people	S-Species
living	O
close	O
to	O
new	O
roads	O
built	O
in	O
the	O
UK	O
in	O
the	O
1970s	O
[	O
34	O
]	O
-	O
particularly	O
by	O
attitudinal	O
adaptation	O
,	O
which	O
Hedges	O
characterises	O
as	O
developing	O
an	O
attitude	O
that	O
it	O
is	O
futile	O
to	O
resist	O
.	O

One	O
can	O
imagine	O
that	O
in	O
the	O
most	O
deprived	O
areas	O
of	O
Glasgow	O
,	O
people	S-Species
may	O
have	O
become	O
resigned	O
to	O
the	O
nature	O
of	O
their	O
surroundings	O
,	O
seeing	O
them	O
as	O
inevitable	O
and	O
not	O
amenable	O
to	O
change	O
either	O
through	O
environmental	O
improvement	O
or	O
through	O
their	O
moving	O
to	O
another	O
area	O
.	O

Conclusion	O

After	O
demographic	O
and	O
socioeconomic	O
characteristics	O
were	O
taken	O
into	O
account	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
objective	O
proximity	O
to	O
major	O
road	O
infrastructure	O
appeared	O
to	O
explain	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
in	O
this	O
study	O
.	O

Our	O
study	O
population	O
may	O
be	O
both	O
objectively	O
constrained	O
by	O
their	O
socioeconomic	O
circumstances	O
(	O
including	O
comparatively	O
limited	O
access	O
to	O
private	O
cars	O
)	O
and	O
adapted	O
to	O
living	O
in	O
conditions	O
which	O
others	O
would	O
consider	O
to	O
pose	O
a	O
barrier	O
to	O
active	O
travel	O
.	O

Under	O
these	O
circumstances	O
,	O
environmental	O
characteristics	O
which	O
have	O
been	O
found	O
to	O
influence	O
discretionary	O
active	O
travel	O
in	O
studies	O
in	O
other	O
,	O
more	O
affluent	O
populations	O
may	O
simply	O
be	O
irrelevant	O
in	O
a	O
population	O
which	O
is	O
more	O
captive	O
in	O
its	O
travel	O
choices	O
.	O

Environmental	O
correlates	O
of	O
active	O
travel	O
should	O
not	O
be	O
assumed	O
to	O
be	O
generalisable	O
between	O
populations	O
;	O
researchers	O
should	O
continue	O
to	O
test	O
hypotheses	O
about	O
putative	O
environmental	O
correlates	O
in	O
different	O
settings	O
,	O
and	O
policymakers	O
should	O
recognise	O
that	O
the	O
effects	O
of	O
interventions	O
to	O
change	O
the	O
environment	O
are	O
likely	O
to	O
vary	O
between	O
populations	O
and	O
between	O
socioeconomic	O
groups	O
within	O
populations	O
.	O

Competing	O
interests	O

This	O
paper	O
is	O
based	O
on	O
material	O
contained	O
in	O
the	O
first	O
author	O
'	O
s	O
PhD	O
thesis	O
.	O

Authors	O
'	O
contributions	O

DO	O
had	O
the	O
original	O
idea	O
for	O
the	O
study	O
,	O
designed	O
the	O
study	O
and	O
the	O
survey	O
materials	O
,	O
applied	O
for	O
ethical	O
approval	O
,	O
cleaned	O
and	O
coded	O
the	O
survey	O
data	O
,	O
carried	O
out	O
all	O
the	O
geographical	O
and	O
statistical	O
analyses	O
and	O
wrote	O
the	O
paper	O
.	O

MP	O
was	O
DO	O
'	O
s	O
PhD	O
supervisor	O
.	O

RM	O
,	O
NM	O
,	O
MP	O
and	O
SP	O
constituted	O
the	O
steering	O
group	O
for	O
the	O
study	O
,	O
contributed	O
to	O
and	O
advised	O
on	O
the	O
design	O
of	O
the	O
study	O
and	O
the	O
interpretation	O
of	O
the	O
emerging	O
findings	O
,	O
and	O
contributed	O
to	O
the	O
critical	O
revision	O
of	O
the	O
paper	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

Foamy	O
Macrophages	O
from	O
Tuberculous	O
Patients	S-Species
'	O
Granulomas	O
Constitute	O
a	O
Nutrient	O
-	O
Rich	O
Reservoir	O
for	O
M	B-Species
.	I-Species
tuberculosis	E-Species
Persistence	O

Abstract	O

Tuberculosis	O
(	O
TB	O
)	O
is	O
characterized	O
by	O
a	O
tight	O
interplay	O
between	O
Mycobacterium	B-Species
tuberculosis	E-Species
and	O
host	O
cells	O
within	O
granulomas	O
.	O

These	O
cellular	O
aggregates	O
restrict	O
bacterial	O
spreading	O
,	O
but	O
do	O
not	O
kill	O
all	O
the	O
bacilli	O
,	O
which	O
can	O
persist	O
for	O
years	O
.	O

In	O
-	O
depth	O
investigation	O
of	O
M	B-Species
.	I-Species
tuberculosis	E-Species
interactions	O
with	O
granuloma	O
-	O
specific	O
cell	O
populations	O
are	O
needed	O
to	O
gain	O
insight	O
into	O
mycobacterial	O
persistence	O
,	O
and	O
to	O
better	O
understand	O
the	O
physiopathology	O
of	O
the	O
disease	O
.	O

We	O
have	O
analyzed	O
the	O
formation	O
of	O
foamy	O
macrophages	O
(	O
FMs	O
)	O
,	O
a	O
granuloma	O
-	O
specific	O
cell	O
population	O
characterized	O
by	O
its	O
high	O
lipid	O
content	O
,	O
and	O
studied	O
their	O
interaction	O
with	O
the	O
tubercle	O
bacillus	O
.	O

Within	O
our	O
in	O
vitro	O
human	S-Species
granuloma	O
model	O
,	O
M	B-Species
.	I-Species
tuberculosis	E-Species
long	O
chain	O
fatty	O
acids	O
,	O
namely	O
oxygenated	O
mycolic	O
acids	O
(	O
MA	O
)	O
,	O
triggered	O
the	O
differentiation	O
of	O
human	S-Species
monocyte	O
-	O
derived	O
macrophages	O
into	O
FMs	O
.	O

In	O
these	O
cells	O
,	O
mycobacteria	O
no	O
longer	O
replicated	O
and	O
switched	O
to	O
a	O
dormant	O
non	O
-	O
replicative	O
state	O
.	O

Electron	O
microscopy	O
observation	O
of	O
M	B-Species
.	I-Species
tuberculosis	E-Species
-	O
infected	O
FMs	O
showed	O
that	O
the	O
mycobacteria	O
-	O
containing	O
phagosomes	O
migrate	O
towards	O
host	O
cell	O
lipid	O
bodies	O
(	O
LB	O
)	O
,	O
a	O
process	O
which	O
culminates	O
with	O
the	O
engulfment	O
of	O
the	O
bacillus	O
into	O
the	O
lipid	O
droplets	O
and	O
with	O
the	O
accumulation	O
of	O
lipids	O
within	O
the	O
microbe	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
oxygenated	O
mycolic	O
acids	O
from	O
M	B-Species
.	I-Species
tuberculosis	E-Species
play	O
a	O
crucial	O
role	O
in	O
the	O
differentiation	O
of	O
macrophages	O
into	O
FMs	O
.	O

These	O
cells	O
might	O
constitute	O
a	O
reservoir	O
used	O
by	O
the	O
tubercle	O
bacillus	O
for	O
long	O
-	O
term	O
persistence	O
within	O
its	O
human	S-Species
host	O
,	O
and	O
could	O
provide	O
a	O
relevant	O
model	O
for	O
the	O
screening	O
of	O
new	O
antimicrobials	O
against	O
non	O
-	O
replicating	O
persistent	O
mycobacteria	O
.	O

Introduction	O

Tuberculosis	O
caused	O
by	O
Mycobacterium	B-Species
tuberculosis	E-Species
(	O
M	B-Species
.	I-Species
tb	E-Species
)	O
remains	O
one	O
of	O
the	O
leading	O
causes	O
of	O
mortality	O
in	O
the	O
world	O
,	O
with	O
around	O
2	O
million	O
deaths	O
each	O
year	O
[	O
1	O
]	O
.	O

Most	O
individuals	O
remain	O
asymptomatic	O
after	O
the	O
primary	O
infection	O
with	O
only	O
10	O
%	O
at	O
risk	O
of	O
developing	O
an	O
active	O
disease	O
during	O
their	O
life	O
[	O
2	O
]	O
.	O

In	O
asymptomatic	O
individuals	O
,	O
the	O
bacilli	O
are	O
not	O
cleared	O
but	O
rather	O
persist	O
in	O
a	O
dormant	O
state	O
,	O
from	O
which	O
they	O
may	O
reactivate	O
and	O
induce	O
clinical	O
disease	O
at	O
later	O
stages	O
[	O
3	O
]	O
.	O

The	O
prognosis	O
of	O
the	O
disease	O
depends	O
on	O
the	O
host	O
'	O
s	O
efficiency	O
to	O
constrain	O
the	O
bacilli	O
at	O
the	O
site	O
of	O
infection	O
.	O

When	O
inhaled	O
M	B-Species
.	I-Species
tb	E-Species
reach	O
the	O
lungs	O
,	O
they	O
are	O
internalized	O
by	O
lung	O
macrophages	O
.	O

The	O
latter	O
trigger	O
the	O
accumulation	O
at	O
the	O
infectious	O
site	O
of	O
macrophages	O
,	O
lymphocytes	O
and	O
dendritic	O
cells	O
,	O
to	O
form	O
a	O
granuloma	O
,	O
which	O
is	O
a	O
major	O
histo	O
-	O
pathological	O
feature	O
of	O
TB	O
.	O

Within	O
granulomas	O
,	O
macrophages	O
differentiate	O
into	O
epithelio	O
i	O
d	O
cells	O
(	O
differentiated	O
macrophages	O
)	O
,	O
and	O
/	O
or	O
fuse	O
to	O
form	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
.	O

Macrophages	O
with	O
large	O
numbers	O
of	O
lipid	O
-	O
free	O
vacuoles	O
,	O
as	O
well	O
as	O
macrophages	O
filled	O
with	O
lipid	O
-	O
containing	O
bodies	O
,	O
also	O
called	O
foamy	O
macrophages	O
(	O
FM	O
)	O
are	O
also	O
found	O
within	O
granulomatous	O
structures	O
in	O
both	O
experimental	O
animal	O
models	O
and	O
human	S-Species
disease	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

The	O
above	O
cells	O
are	O
surrounded	O
by	O
a	O
rim	O
of	O
lymphocytes	O
,	O
and	O
at	O
later	O
stages	O
,	O
a	O
tight	O
coat	O
of	O
fibroblasts	O
encloses	O
the	O
structure	O
[	O
6	O
]	O
.	O

Although	O
the	O
structure	O
and	O
cell	O
composition	O
of	O
granulomas	O
are	O
well	O
known	O
,	O
the	O
biology	O
of	O
these	O
inflammatory	O
structures	O
and	O
,	O
more	O
specifically	O
,	O
the	O
role	O
of	O
granuloma	O
-	O
specific	O
cell	O
types	O
,	O
remain	O
largely	O
unknown	O
.	O

We	O
have	O
previously	O
developed	O
an	O
in	O
vitro	O
model	O
of	O
human	S-Species
tuberculous	O
granulomas	O
to	O
gain	O
insight	O
into	O
the	O
survival	O
strategies	O
of	O
the	O
tubercle	O
bacillus	O
within	O
its	O
human	S-Species
host	O
.	O

This	O
model	O
now	O
enables	O
the	O
characterization	O
of	O
granuloma	O
-	O
specific	O
cell	O
types	O
,	O
and	O
their	O
modulation	O
by	O
M	B-Species
.	I-Species
tb	E-Species
[	O
7	O
]	O
.	O

The	O
main	O
advantage	O
of	O
this	O
model	O
over	O
in	O
vivo	O
animal	O
models	O
or	O
ex	O
vivo	O
human	S-Species
biopsy	O
samples	O
,	O
is	O
the	O
availability	O
of	O
live	O
granuloma	O
cells	O
which	O
facilitates	O
analysis	O
of	O
their	O
cell	O
biology	O
.	O

Using	O
this	O
model	O
we	O
have	O
recently	O
shown	O
that	O
,	O
within	O
granulomas	O
,	O
large	O
multinucleated	O
giant	O
cells	O
,	O
also	O
known	O
as	O
Langhans	O
giant	O
cells	O
,	O
result	O
from	O
the	O
induction	O
of	O
granuloma	O
macrophage	O
fusion	O
by	O
M	B-Species
.	I-Species
tb	E-Species
glycolipids	O
[	O
8	O
]	O
.	O

We	O
have	O
shown	O
that	O
these	O
cells	O
have	O
lost	O
the	O
ability	O
to	O
mediate	O
bacterial	O
uptake	O
upon	O
maturation	O
,	O
but	O
have	O
conserved	O
their	O
ability	O
to	O
mediate	O
antigen	O
presentation	O
[	O
9	O
]	O
.	O

The	O
differentiation	O
of	O
macrophages	O
into	O
FMs	O
has	O
been	O
particularly	O
well	O
described	O
in	O
individuals	O
developing	O
a	O
postprimary	O
,	O
also	O
known	O
as	O
secondary	O
or	O
adult	O
,	O
TB	O
.	O

These	O
postprimary	O
infections	O
are	O
considered	O
to	O
be	O
the	O
result	O
of	O
re	O
-	O
infection	O
or	O
reactivation	O
of	O
a	O
primary	O
TB	O
[	O
10	O
]	O
.	O

FMs	O
have	O
been	O
described	O
in	O
leprosy	O
patients	S-Species
or	O
M	B-Species
.	I-Species
avium	E-Species
-	O
infected	O
AIDS	O
(	O
Acquired	O
ImmunoDeficiency	O
Syndrome	O
)	O
patients	S-Species
,	O
and	O
in	O
chronic	O
stages	O
of	O
M	B-Species
.	I-Species
tb	E-Species
infection	O
in	O
mice	S-Species
[	O
4	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

The	O
foamy	O
aspect	O
of	O
these	O
macrophages	O
is	O
the	O
result	O
of	O
intracellular	O
lipid	O
accumulation	O
within	O
lipid	O
bodies	O
,	O
also	O
called	O
lipid	O
droplets	O
or	O
lipid	O
vacuoles	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
.	O

In	O
an	O
experimental	O
model	O
of	O
leukocyte	O
infection	O
,	O
it	O
was	O
recently	O
suggested	O
that	O
BCG	O
(	O
Bacille	O
Calmette	O
Guerin	O
)	O
infection	O
can	O
induce	O
,	O
in	O
a	O
TLR2	O
-	O
dependent	O
fashion	O
,	O
the	O
rapid	O
formation	O
of	O
lipid	O
bodies	O
carrying	O
out	O
part	O
of	O
the	O
eicosano	O
i	O
d	O
biosynthesis	O
that	O
usually	O
accompanies	O
the	O
infection	O
,	O
thus	O
pointing	O
to	O
an	O
active	O
role	O
for	O
lipid	O
bodies	O
during	O
the	O
course	O
of	O
infection	O
[	O
16	O
]	O
.	O

However	O
,	O
the	O
mechanisms	O
regulating	O
this	O
lipid	O
accumulation	O
during	O
mycobacterial	O
infection	O
and	O
their	O
significance	O
in	O
the	O
physiopathology	O
of	O
tuberculosis	O
are	O
not	O
understood	O
.	O

Most	O
of	O
the	O
studies	O
on	O
TB	O
granulomas	O
have	O
focused	O
on	O
the	O
contribution	O
of	O
host	O
components	O
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
role	O
played	O
by	O
bacterial	O
constituents	O
in	O
terms	O
of	O
granuloma	O
formation	O
and	O
progression	O
.	O

The	O
present	O
work	O
was	O
aimed	O
at	O
deciphering	O
the	O
role	O
of	O
FMs	O
in	O
M	B-Species
.	I-Species
tb	E-Species
survival	O
within	O
human	S-Species
granulomas	O
.	O

To	O
test	O
our	O
working	O
hypothesis	O
according	O
to	O
which	O
FMs	O
constitute	O
a	O
nutrient	O
-	O
rich	O
reservoir	O
for	O
M	B-Species
.	I-Species
tb	E-Species
persistence	O
,	O
we	O
used	O
our	O
in	O
vitro	O
model	O
of	O
human	S-Species
granulomas	O
to	O
analyze	O
the	O
formation	O
of	O
FMs	O
and	O
their	O
role	O
during	O
M	B-Species
.	I-Species
tb	E-Species
infection	O
.	O

We	O
showed	O
that	O
only	O
highly	O
virulent	O
mycobacteria	O
(	O
M	B-Species
.	I-Species
tb	E-Species
,	O
M	B-Species
.	I-Species
avium	E-Species
)	O
and	O
not	O
saprophytic	O
ones	O
(	O
M	B-Species
.	I-Species
smegmatis	E-Species
)	O
could	O
induce	O
the	O
formation	O
of	O
FMs	O
in	O
mature	O
granulomas	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
oxygenated	O
mycolic	O
acids	O
specifically	O
produced	O
by	O
the	O
above	O
pathogenic	O
species	O
were	O
responsible	O
for	O
FMs	O
formation	O
.	O

Once	O
differentiated	O
,	O
FMs	O
were	O
unable	O
to	O
mediate	O
phagocytosis	O
of	O
new	O
bacilli	O
and	O
their	O
microbicidal	O
activity	O
was	O
reduced	O
.	O

M	B-Species
.	I-Species
tb	E-Species
was	O
not	O
killed	O
in	O
FMs	O
but	O
instead	O
persisted	O
in	O
a	O
non	O
-	O
replicating	O
state	O
,	O
and	O
over	O
-	O
expressed	O
dormancy	O
genes	O
.	O

Noteworthy	O
,	O
in	O
foamy	O
macrophages	O
,	O
M	B-Species
.	I-Species
tb	E-Species
-	O
containing	O
phagosomes	O
were	O
shown	O
to	O
migrate	O
towards	O
lipid	O
bodies	O
which	O
they	O
progressively	O
surrounded	O
and	O
engulfed	O
.	O

As	O
a	O
result	O
,	O
bacteria	O
were	O
freed	O
into	O
lipid	O
bodies	O
,	O
thus	O
favoring	O
the	O
bacilli	O
'	O
s	O
access	O
to	O
nutrients	O
.	O

From	O
these	O
data	O
,	O
we	O
propose	O
that	O
FMs	O
could	O
form	O
a	O
secure	O
reservoir	O
for	O
the	O
tubercle	O
bacilli	O
.	O

Methods	O

Human	S-Species
samples	O

Human	S-Species
blood	O
samples	O
,	O
purchased	O
from	O
the	O
French	O
National	O
Blood	O
provider	O
of	O
Toulouse	O
,	O
were	O
collected	O
from	O
fully	O
anonymized	O
non	O
-	O
tuberculous	O
control	O
donors	O
,	O
an	O
ethical	O
committee	O
approval	O
was	O
,	O
therefore	O
,	O
not	O
necessary	O
.	O

This	O
study	O
was	O
conducted	O
according	O
to	O
the	O
principles	O
expressed	O
in	O
the	O
Helsinki	O
Declaration	O
,	O
with	O
informed	O
consent	O
obtained	O
from	O
each	O
donor	O
.	O

We	O
chose	O
to	O
work	O
on	O
lymph	O
node	O
samples	O
rather	O
than	O
lung	O
biopsies	O
,	O
which	O
are	O
usually	O
only	O
paraffin	O
-	O
embedded	O
,	O
because	O
staining	O
for	O
lipids	O
can	O
only	O
be	O
performed	O
on	O
frozen	O
samples	O
.	O

Lymph	O
node	O
biopsies	O
were	O
taken	O
for	O
diagnosis	O
purposes	O
,	O
in	O
ten	O
non	O
-	O
HIV	S-Species
patients	S-Species
.	O

For	O
each	O
biopsy	O
,	O
a	O
fragment	O
was	O
sent	O
to	O
the	O
microbiology	O
laboratory	O
,	O
another	O
was	O
frozen	O
in	O
liquid	O
nitrogen	O
and	O
the	O
main	O
part	O
was	O
fixed	O
in	O
formalin	O
and	O
paraffin	O
-	O
embedded	O
for	O
histological	O
examination	O
.	O

M	B-Species
.	I-Species
tb	E-Species
was	O
identified	O
in	O
9	O
lymph	O
node	O
biopsies	O
and	O
from	O
the	O
lung	O
aspiration	O
in	O
the	O
last	O
patient	S-Species
.	O

This	O
latter	O
case	O
showed	O
no	O
signs	O
of	O
necrosis	O
,	O
and	O
no	O
FMs	O
were	O
found	O
in	O
the	O
lymph	O
node	O
biopsy	O
.	O

This	O
study	O
complies	O
with	O
the	O
guidelines	O
of	O
the	O
declaration	O
of	O
Helsinki	O
.	O

Bacterial	O
strains	O
and	O
culture	O
conditions	O

Wild	O
-	O
type	O
M	B-Species
.	I-Species
smegmatis	E-Species
and	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
strains	O
were	O
previously	O
described	O
[	O
17	O
]	O
,	O
M	B-Species
.	I-Species
tuberculosis	E-Species
-	O
GFP	O
were	O
a	O
kind	O
gift	O
from	O
Dr	O
.	O
C	O
.	O

Guilhot	O
(	O
CNRS	O
-	O
IPBS	O
,	O
Toulouse	O
France	O
)	O
.	O

Bacilli	O
were	O
grown	O
in	O
Middlebrook	O
7H9	O
medium	O
(	O
Difco	O
)	O
supplemented	O
with	O
10	O
%	O
albumin	O
-	O
dextrose	O
-	O
catalase	O
(	O
Difco	O
)	O
.	O

Fluorescent	O
M	B-Species
.	I-Species
smegmatis	E-Species
and	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
were	O
obtained	O
by	O
FITC	O
labelling	O
as	O
described	O
in	O
[	O
18	O
]	O
.	O

Isolation	O
of	O
RNA	O
from	O
intraphagosomal	O
M	B-Species
.	I-Species
tb	E-Species

Six	O
and	O
12	O
days	O
post	O
-	O
infection	O
(	O
MOI	O
10	O
)	O
,	O
macrophages	O
and	O
FMs	O
(	O
5	O
x	O
106	O
)	O
were	O
washed	O
twice	O
with	O
PBS	O
,	O
scraped	O
off	O
the	O
cell	O
dishes	O
and	O
recovered	O
by	O
centrifugation	O
.	O

The	O
cell	O
pellets	O
were	O
lysed	O
with	O
lysis	O
buffer	O
(	O
RNEasy	O
mini	O
kit	O
,	O
Quiagen	O
)	O
and	O
transferred	O
to	O
2	O
ml	O
Eppendorf	O
-	O
tubes	O
containing	O
a	O
0	O
.	O
5	O
ml	O
suspension	O
of	O
0	O
.	O
1	O
mm	O
-	O
diameter	O
glass	O
beads	O
(	O
Biospec	O
)	O
.	O

Mycobacteria	O
were	O
disrupted	O
using	O
a	O
bead	O
beater	O
(	O
Retsch	O
)	O
followed	O
by	O
a	O
5	O
min	O
centrifugation	O
at	O
14	O
000g	O
.	O

RNA	O
contained	O
in	O
the	O
supernatant	O
was	O
then	O
column	O
-	O
purified	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
conditions	O
using	O
the	O
RNEasy	O
mini	O
kit	O
(	O
Qiagen	O
)	O
and	O
quantified	O
.	O

Quantitative	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O

In	O
RNA	O
samples	O
DNA	O
contamination	O
was	O
excluded	O
by	O
DNAse	O
I	O
treatment	O
(	O
Ambion	O
)	O
.	O

1	O
micro	O
g	O
total	O
RNA	O
was	O
reverse	O
-	O
transcribed	O
using	O
random	O
hexamer	O
primers	O
(	O
Ambion	O
)	O
and	O
Superscript	O
III	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
on	O
cDNA	O
using	O
the	O
SYBR	O
green	O
essay	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Reverse	O
and	O
forward	O
primers	O
used	O
are	O
listed	O
below	O
in	O
Table	O
1	O
.	O

Fluorescence	O
was	O
measured	O
by	O
ABIPrism	O
7300	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
calculated	O
threshold	O
cycle	O
(	O
Ct	O
)	O
value	O
for	O
each	O
gene	O
of	O
interest	O
was	O
normalized	O
to	O
the	O
Ct	O
value	O
for	O
16S	O
and	O
the	O
fold	O
expression	O
was	O
calculated	O
using	O
the	O
formula	O
:	O
fold	O
change	O
=	O
2	O
-	O
Delta	O
.	O
(	O
Delta	O
Ct	O
)	O
[	O
19	O
]	O
.	O

Real	O
-	O
time	O
PCR	O
conditions	O
include	O
initial	O
activation	O
at	O
94	O
degrees	O
C	O
for	O
5	O
min	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
denaturation	O
at	O
94	O
degrees	O
C	O
for	O
30	O
sec	O
,	O
annealing	O
and	O
extension	O
at	O
65	O
degrees	O
C	O
for	O
1	O
min	O
.	O

The	O
gene	O
induction	O
ratios	O
were	O
obtained	O
by	O
comparing	O
gene	O
expression	O
levels	O
in	O
intracellular	O
bacilli	O
with	O
those	O
of	O
log	O
-	O
phase	O
in	O
vitro	O
-	O
grown	O
bacilli	O
.	O

RNAs	O
were	O
isolated	O
from	O
two	O
independent	O
macrophage	O
infections	O
.	O

In	O
vitro	O
human	S-Species
granuloma	O
formation	O

In	O
vitro	O
granulomas	O
were	O
obtained	O
as	O
previously	O
described	O
[	O
7	O
]	O
.	O

Briefly	O
,	O
1	O
x	O
106	O
freshly	O
isolated	O
Peripheral	O
Blood	O
Mononuclear	O
Cells	O
(	O
PBMCs	O
)	O
were	O
incubated	O
with	O
1	O
x	O
104	O
viable	O
M	B-Species
.	I-Species
tb	E-Species
,	O
or	O
1	O
x	O
103	O
viable	O
M	B-Species
.	I-Species
smegmatis	E-Species
or	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
.	O

The	O
culture	O
medium	O
was	O
RPMI	O
-	O
1640	O
+	O
Glutamax	O
(	O
Difco	O
)	O
,	O
containing	O
7	O
.	O
5	O
%	O
human	S-Species
AB	O
serum	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

Macrophage	O
differentiation	O

2	O
.	O
5	O
x	O
106	O
PBMCs	O
prepared	O
in	O
RPMI	O
-	O
1640	O
+	O
Glutamax	O
(	O
Difco	O
)	O
were	O
plated	O
over	O
coverslips	O
in	O
24	O
-	O
well	O
plates	O
.	O

After	O
2	O
h	O
culture	O
at	O
37	O
degrees	O
C	O
,	O
cells	O
were	O
washed	O
3	O
times	O
with	O
PBS	O
and	O
then	O
refed	O
with	O
RPMI	O
-	O
1640	O
+	O
Glutamax	O
(	O
Difco	O
)	O
,	O
containing	O
7	O
.	O
5	O
%	O
human	S-Species
AB	O
serum	O
.	O

After	O
6	O
days	O
of	O
culturing	O
,	O
macrophages	O
were	O
differentiated	O
.	O

Respiratory	O
burst	O
assay	O
with	O
Nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O

Human	S-Species
monocyte	O
derived	O
macrophages	O
were	O
stimulated	O
with	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
for	O
2	O
h	O
at	O
37	O
degrees	O
C	O
,	O
washed	O
and	O
reincubated	O
in	O
mycobacterium	O
-	O
free	O
medium	O
.	O

After	O
2	O
days	O
of	O
differentiation	O
into	O
FMs	O
,	O
macrophages	O
were	O
co	O
-	O
stained	O
with	O
NBT	O
(	O
2	O
mg	O
/	O
ml	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
Nile	O
red	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
.	O

Stained	O
cells	O
were	O
fixed	O
and	O
then	O
analysed	O
with	O
an	O
inverted	O
microscope	O
(	O
Nikon	O
TE	O
300	O
)	O
.	O

Phagocytosis	O
and	O
Survival	O
test	O

For	O
phagocytosis	O
assays	O
,	O
differentiated	O
macrophages	O
were	O
incubated	O
with	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
mycolic	O
acids	O
for	O
2	O
days	O
and	O
then	O
infected	O
with	O
1	O
x	O
108	O
labeled	O
mycobacteria	O
per	O
well	O
for	O
90	O
min	O
,	O
washed	O
3	O
times	O
with	O
PBS	O
and	O
chased	O
for	O
3	O
h	O
in	O
fresh	O
culture	O
medium	O
.	O

For	O
survival	O
experiments	O
,	O
macrophages	O
were	O
infected	O
with	O
M	B-Species
.	I-Species
tuberculosis	E-Species
-	O
GFP	O
(	O
10	O
bacteria	O
/	O
cell	O
)	O
,	O
washed	O
3	O
times	O
with	O
PBS	O
(	O
Gibco	O
)	O
and	O
re	O
-	O
incubated	O
in	O
fresh	O
culture	O
medium	O
.	O

At	O
selected	O
time	O
points	O
thereafter	O
(	O
1	O
,	O
3	O
,	O
6	O
,	O
10	O
and	O
14	O
days	O
)	O
cells	O
were	O
labeled	O
with	O
Nile	O
red	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
,	O
fixed	O
and	O
observed	O
under	O
a	O
confocal	O
microscope	O
.	O

The	O
amount	O
of	O
mycobacteria	O
per	O
cells	O
was	O
evaluated	O
.	O

(	O
100	O
cells	O
were	O
analyzed	O
for	O
each	O
time	O
point	O
)	O
.	O

Lipid	O
body	O
staining	O
and	O
immunostaining	O

Granuloma	O
cells	O
were	O
collected	O
and	O
plated	O
onto	O
glass	O
coverslips	O
with	O
a	O
cytospin	O
(	O
Thermo	O
Shandon	O
)	O
fixed	O
for	O
30	O
min	O
in	O
PBS	O
-	O
PFA	O
4	O
%	O
and	O
stained	O
with	O
Oil	O
red	O
-	O
O	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
as	O
described	O
[	O
20	O
]	O
.	O

The	O
slides	O
were	O
then	O
counterstained	O
with	O
haematoxylin	O
(	O
Dako	O
Cytomation	O
)	O
and	O
observed	O
under	O
an	O
inverted	O
microscope	O
(	O
Nikon	O
TE	O
300	O
)	O
.	O

For	O
fluorescence	O
analysis	O
,	O
granuloma	O
cells	O
or	O
macrophages	O
were	O
collected	O
in	O
PBS	O
,	O
lipid	O
bodies	O
were	O
stained	O
with	O
Nile	O
red	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
0	O
.	O
1	O
micro	O
g	O
/	O
ml	O
,	O
from	O
a	O
stock	O
solution	O
in	O
methanol	O
)	O
for	O
15	O
min	O
washed	O
with	O
PBS	O
,	O
fixed	O
for	O
30	O
min	O
in	O
PBS	O
-	O
PFA	O
4	O
%	O
,	O
mounted	O
with	O
the	O
fluorescent	O
mounting	O
medium	O
(	O
Dako	O
Cytomation	O
)	O
and	O
observed	O
under	O
a	O
confocal	O
microscope	O
.	O

In	O
order	O
to	O
distinguish	O
the	O
lipids	O
contained	O
within	O
lipid	O
bodies	O
,	O
from	O
those	O
of	O
the	O
cell	O
membrane	O
,	O
we	O
used	O
the	O
fluorescent	O
emission	O
spectrum	O
properties	O
of	O
Nile	O
red	O
which	O
depend	O
upon	O
the	O
kind	O
of	O
lipid	O
associated	O
with	O
Nile	O
red	O
,	O
i	O
.	O
e	O
.	O
for	O
triacylglycerol	O
:	O
lambda	O
max	O
em	O
=	O
590	O
nm	O
,	O
for	O
phospholipids	O
:	O
lambda	O
max	O
em	O
=	O
640	O
nm	O
(	O
Molecular	O
Probes	O
handbook	O
)	O
.	O

On	O
confocal	O
microscopy	O
pictures	O
,	O
the	O
phospholipid	O
background	O
of	O
both	O
macrophages	O
and	O
FM	O
appears	O
in	O
red	O
and	O
the	O
triacylglycerol	O
-	O
rich	O
lipid	O
bodies	O
appear	O
in	O
white	O
.	O

Cells	O
were	O
considered	O
to	O
be	O
positive	O
for	O
Nile	O
red	O
staining	O
when	O
more	O
than	O
50	O
%	O
of	O
the	O
cell	O
surface	O
was	O
stained	O
(	O
see	O
Figure	O
S2	O
)	O
.	O

Mycolic	O
acid	O
isolation	O

Bacterial	O
residues	O
obtained	O
after	O
lipid	O
extraction	O
with	O
organic	O
solvents	O
[	O
17	O
]	O
were	O
saponified	O
with	O
a	O
mixture	O
of	O
40	O
%	O
KOH	O
aqueous	O
solution	O
and	O
methoxyethanol	O
(	O
1	O
:	O
7	O
,	O
v	O
/	O
v	O
)	O
at	O
110	O
degrees	O
C	O
for	O
3	O
hours	O
in	O
a	O
screw	O
-	O
capped	O
tube	O
.	O

After	O
acidification	O
,	O
fatty	O
acids	O
were	O
extracted	O
with	O
diethylether	O
,	O
derivatised	O
into	O
methyl	O
esters	O
with	O
diazomethane	O
and	O
analyzed	O
by	O
analytical	O
thin	O
-	O
layer	O
chromatography	O
on	O
silica	O
Gel	O
60	O
(	O
Silica	O
Gel	O
60	O
Macherey	O
-	O
Nagel	O
)	O
using	O
either	O
dicholoromethane	O
or	O
petroleum	O
ether	O
/	O
diethylether	O
(	O
9	O
:	O
1	O
,	O
v	O
/	O
v	O
,	O
five	O
runs	O
)	O
.	O

Visualization	O
of	O
lipid	O
spots	O
was	O
performed	O
by	O
spraying	O
the	O
plates	O
with	O
molybdophosphoric	O
acid	O
(	O
10	O
%	O
in	O
ethanol	O
)	O
,	O
followed	O
by	O
charring	O
.	O

Processing	O
for	O
electron	O
microscopy	O

Granulomas	O
were	O
fixed	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
with	O
2	O
.	O
5	O
%	O
glutaraldehyde	O
in	O
0	O
.	O
1	O
M	O
cacodylate	O
buffer	O
,	O
pH	O
7	O
.	O
2	O
,	O
containing	O
0	O
.	O
1	O
M	O
sucrose	O
,	O
5	O
mM	O
CaCl2	O
and	O
5	O
mM	O
MgCl2	O
.	O

After	O
two	O
successive	O
15	O
-	O
min	O
washes	O
with	O
the	O
same	O
buffer	O
,	O
the	O
granulomas	O
were	O
postfixed	O
for	O
1	O
hour	O
at	O
RT	O
with	O
1	O
%	O
osmium	O
tetroxide	O
(	O
Electron	O
Microscopy	O
Science	O
)	O
in	O
the	O
same	O
buffer	O
devoid	O
of	O
sucrose	O
.	O

The	O
granulomas	O
were	O
scraped	O
off	O
the	O
culture	O
dishes	O
with	O
a	O
rubber	O
policeman	O
and	O
concentrated	O
in	O
1	O
%	O
agarose	O
in	O
the	O
same	O
buffer	O
.	O

After	O
a	O
one	O
hour	O
treatment	O
at	O
room	O
temperature	O
with	O
1	O
%	O
uranyl	O
acetate	O
in	O
Veronal	O
buffer	O
,	O
the	O
samples	O
were	O
dehydrated	O
in	O
a	O
graded	O
series	O
of	O
ethanol	O
and	O
embedded	O
in	O
Spurr	O
resin	O
.	O

Thin	O
sections	O
were	O
stained	O
with	O
uranyl	O
acetate	O
and	O
lead	O
citrate	O
.	O

Image	O
acquisition	O
in	O
confocal	O
microscopy	O

The	O
images	O
were	O
obtained	O
using	O
a	O
Leica	O
confocal	O
fluorescence	O
microscope	O
(	O
SP2	O
)	O
equipped	O
with	O
a	O
Plan	O
Apo	O
40	O
x	O
1	O
.	O
4	O
Ph	O
6	O
objective	O
(	O
Olympus	O
Optical	O
)	O
and	O
CoolSNAP	O
-	O
Pro	O
CF	O
digital	O
camera	O
in	O
conjunction	O
with	O
Image	O
-	O
Pro	O
Plus	O
version	O
4	O
.	O
5	O
.	O
1	O
.	O
3	O
software	O
(	O
Media	O
Cybernetics	O
)	O
.	O

The	O
images	O
were	O
edited	O
using	O
Adobe	O
Photoshop	O
CS2	O
9	O
software	O
(	O
Adobe	O
Systems	O
)	O
.	O

Results	O

Foamy	O
macrophages	O
are	O
strongly	O
associated	O
with	O
necrotic	O
lesions	O
and	O
often	O
contain	O
M	B-Species
.	I-Species
tuberculosis	E-Species

We	O
analyzed	O
lymph	O
node	O
biopsies	O
from	O
10	O
tuberculous	O
patients	S-Species
as	O
a	O
first	O
step	O
for	O
evaluating	O
the	O
role	O
of	O
FMs	O
within	O
tuberculous	O
granulomas	O
.	O

A	O
section	O
through	O
a	O
representative	O
biopsy	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

Well	O
-	O
circumscribed	O
and	O
-	O
differentiated	O
granulomatous	O
structures	O
were	O
observed	O
in	O
all	O
the	O
samples	O
(	O
Figure	O
1A	O
)	O
.	O

Classically	O
,	O
lesions	O
display	O
a	O
necrotic	O
center	O
(	O
N	O
)	O
,	O
an	O
interface	O
area	O
between	O
the	O
necrotic	O
center	O
and	O
the	O
histiocytes	O
(	O
I	O
)	O
,	O
and	O
some	O
peripheral	O
granulomas	O
(	O
G	O
)	O
.	O

Only	O
seven	O
out	O
of	O
ten	O
patients	S-Species
presented	O
lesions	O
displaying	O
central	O
necrosis	O
(	O
Table	O
2	O
)	O
.	O

Staining	O
of	O
the	O
histology	O
samples	O
with	O
Oil	O
red	O
-	O
O	O
,	O
a	O
classic	O
lipid	O
stain	O
,	O
confirmed	O
the	O
presence	O
of	O
FMs	O
within	O
the	O
granulomatous	O
structures	O
in	O
six	O
out	O
of	O
seven	O
samples	O
presenting	O
necrosis	O
(	O
Figure	O
1B	O
)	O
,	O
whereas	O
no	O
FMs	O
were	O
found	O
in	O
the	O
three	O
non	O
-	O
necrotic	O
lesions	O
(	O
Table	O
2	O
)	O
.	O

Noteworthy	O
,	O
in	O
samples	O
with	O
necrotic	O
areas	O
,	O
FMs	O
were	O
always	O
found	O
in	O
the	O
interface	O
region	O
flanking	O
the	O
central	O
necrosis	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
observations	O
firstly	O
confirmed	O
the	O
presence	O
of	O
FMs	O
in	O
most	O
TB	O
patients	S-Species
'	O
lesions	O
thereby	O
suggesting	O
that	O
these	O
cells	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
/	O
maintenance	O
of	O
such	O
lesions	O
.	O

Second	O
,	O
FMs	O
seem	O
to	O
be	O
associated	O
with	O
necrosis	O
,	O
which	O
is	O
a	O
hallmark	O
of	O
TB	O
lesions	O
,	O
since	O
they	O
were	O
observed	O
only	O
in	O
lesions	O
with	O
a	O
necrotic	O
center	O
and	O
preferentially	O
located	O
around	O
the	O
necrotic	O
area	O
.	O

Interestingly	O
,	O
staining	O
,	O
in	O
parallel	O
,	O
of	O
serial	O
thin	O
sections	O
from	O
a	O
patient	S-Species
'	O
s	O
lesion	O
biopsy	O
with	O
Oil	O
red	O
-	O
O	O
(	O
Figure	O
1C	O
)	O
and	O
Ziehl	O
Nielsen	O
(	O
Figure	O
1D	O
)	O
,	O
showed	O
that	O
most	O
of	O
the	O
bacilli	O
(	O
arrow	O
)	O
were	O
located	O
in	O
the	O
same	O
area	O
as	O
FMs	O
,	O
thus	O
suggesting	O
a	O
strong	O
association	O
between	O
the	O
persisting	O
tubercle	O
bacilli	O
and	O
FMs	O
within	O
granulomas	O
.	O

M	B-Species
.	I-Species
tuberculosis	E-Species
induces	O
the	O
formation	O
of	O
FMs	O
within	O
in	O
vitro	O
human	S-Species
tuberculous	O
granulomas	O

To	O
further	O
characterize	O
the	O
role	O
of	O
FMs	O
in	O
the	O
granulomatous	O
response	O
,	O
we	O
assessed	O
whether	O
FM	O
formation	O
in	O
granulomatous	O
structures	O
was	O
triggered	O
only	O
by	O
pathogenic	O
mycobacterial	O
species	O
(	O
M	B-Species
.	I-Species
tb	E-Species
)	O
,	O
or	O
by	O
low	O
virulent	O
ones	O
(	O
M	B-Species
.	I-Species
smegmatis	E-Species
)	O
as	O
well	O
.	O

PBMCs	O
from	O
non	O
-	O
tuberculous	O
control	O
individuals	O
were	O
infected	O
with	O
M	B-Species
.	I-Species
tb	E-Species
or	O
M	B-Species
.	I-Species
smegmatis	E-Species
,	O
following	O
the	O
procedure	O
previously	O
described	O
for	O
the	O
induction	O
of	O
granulomatous	O
structures	O
(	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
and	O
Figure	O
S1	O
)	O
.	O

Granuloma	O
cells	O
collected	O
at	O
days	O
3	O
and	O
11	O
were	O
stained	O
with	O
Oil	O
red	O
-	O
O	O
to	O
visualize	O
the	O
lipid	O
droplets	O
within	O
FMs	O
under	O
the	O
light	O
microscope	O
(	O
Figure	O
2	O
)	O
.	O

At	O
day	O
3	O
,	O
several	O
M	B-Species
.	I-Species
tb	E-Species
-	O
induced	O
granuloma	O
cells	O
already	O
showed	O
lipid	O
bodies	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
cells	O
collected	O
from	O
M	B-Species
.	I-Species
smegmatis	E-Species
-	O
induced	O
granulomas	O
were	O
seldom	O
(	O
5	O
%	O
)	O
positively	O
stained	O
(	O
Figure	O
2B	O
)	O
.	O

Interestingly	O
,	O
M	B-Species
.	I-Species
avium	E-Species
induced	O
FM	O
formation	O
in	O
a	O
similar	O
way	O
to	O
M	B-Species
.	I-Species
tb	E-Species
(	O
not	O
shown	O
)	O
.	O

By	O
day	O
11	O
,	O
the	O
amount	O
of	O
positively	O
stained	O
cells	O
had	O
increased	O
in	O
M	B-Species
.	I-Species
tb	E-Species
-	O
induced	O
granulomas	O
,	O
but	O
not	O
in	O
M	B-Species
.	I-Species
smegmatis	E-Species
-	O
induced	O
ones	O
.	O

In	O
addition	O
,	O
the	O
number	O
of	O
lipid	O
bodies	O
per	O
cell	O
increased	O
dramatically	O
with	O
time	O
,	O
as	O
depited	O
in	O
the	O
enlarged	O
views	O
(	O
Figures	O
2A	O
,	O
C	O
)	O
.	O

The	O
quantitative	O
evaluation	O
of	O
the	O
percentage	O
of	O
FMs	O
within	O
granulomas	O
induced	O
by	O
both	O
strains	O
confirmed	O
the	O
differences	O
observed	O
under	O
the	O
light	O
microscope	O
,	O
and	O
showed	O
a	O
seven	O
-	O
fold	O
difference	O
(	O
44	O
%	O
vs	O
6	O
%	O
respectively	O
)	O
between	O
M	B-Species
.	I-Species
tb	E-Species
and	O
M	B-Species
.	I-Species
smegmatis	E-Species
in	O
terms	O
of	O
their	O
ability	O
to	O
induce	O
FM	O
formation	O
(	O
Figure	O
2D	O
)	O
.	O

Our	O
results	O
therefore	O
show	O
that	O
virulent	O
species	O
such	O
as	O
M	B-Species
.	I-Species
tb	E-Species
and	O
M	B-Species
.	I-Species
avium	E-Species
,	O
contrary	O
to	O
poorly	O
or	O
avirulent	O
ones	O
such	O
as	O
M	B-Species
.	I-Species
smegmatis	E-Species
,	O
are	O
able	O
to	O
induce	O
the	O
formation	O
of	O
FMs	O
within	O
our	O
experimental	O
model	O
.	O

Oxygenated	O
mycolic	O
acids	O
induce	O
the	O
maturation	O
of	O
macrophages	O
into	O
FMs	O

Mycolic	O
acids	O
from	O
M	B-Species
.	I-Species
tb	E-Species
incorporated	O
into	O
liposomes	O
were	O
recently	O
shown	O
to	O
trigger	O
the	O
differentiation	O
of	O
mice	S-Species
peritoneal	O
macrophages	O
into	O
foamy	O
-	O
like	O
cells	O
[	O
21	O
]	O
.	O

Interestingly	O
,	O
both	O
M	B-Species
.	I-Species
tb	E-Species
and	O
M	B-Species
.	I-Species
avium	E-Species
,	O
which	O
induce	O
FM	O
formation	O
,	O
express	O
a	O
family	O
of	O
oxygenated	O
mycolic	O
acids	O
,	O
especially	O
ketomycolic	O
acids	O
,	O
which	O
are	O
not	O
produced	O
by	O
M	B-Species
.	I-Species
smegmatis	E-Species
(	O
Figure	O
3A	O
)	O
.	O

In	O
this	O
context	O
,	O
inactivation	O
of	O
the	O
M	B-Species
.	I-Species
tb	E-Species
hma	O
gene	O
(	O
mmaA4	O
-	O
Rv0642c	O
)	O
was	O
shown	O
to	O
abolish	O
the	O
synthesis	O
of	O
oxygenated	O
keto	O
-	O
and	O
hydroxyl	O
-	O
mycolic	O
acid	O
in	O
the	O
mutant	O
strain	O
[	O
17	O
]	O
.	O

Conversely	O
,	O
transforming	O
M	B-Species
.	I-Species
smegmatis	E-Species
with	O
the	O
hma	O
gene	O
induced	O
the	O
production	O
of	O
both	O
keto	O
-	O
and	O
hydroxyl	O
-	O
mycolic	O
acids	O
[	O
22	O
]	O
,	O
(	O
Figures	O
3B	O
,	O
C	O
)	O
.	O

In	O
the	O
light	O
of	O
both	O
data	O
,	O
we	O
anticipated	O
that	O
oxygenated	O
mycolic	O
acids	O
specifically	O
produced	O
by	O
M	B-Species
.	I-Species
tb	E-Species
and	O
M	B-Species
.	I-Species
avium	E-Species
,	O
under	O
the	O
control	O
of	O
hma	O
,	O
are	O
responsible	O
for	O
FM	O
formation	O
within	O
human	S-Species
granulomas	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
compared	O
FM	O
formation	O
after	O
infection	O
of	O
PBMCs	O
with	O
either	O
the	O
wild	O
-	O
type	O
,	O
or	O
the	O
hma	O
-	O
expressing	O
M	B-Species
.	I-Species
smegmatis	E-Species
strain	O
(	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
)	O
.	O

Granulomas	O
cells	O
were	O
collected	O
3	O
days	O
later	O
and	O
stained	O
with	O
Oil	O
red	O
-	O
O	O
to	O
visualize	O
lipid	O
bodies	O
.	O

Wild	O
-	O
type	O
M	B-Species
.	I-Species
smegmatis	E-Species
-	O
induced	O
granulomas	O
displayed	O
only	O
5	O
.	O
5	O
%	O
of	O
FM	O
,	O
whereas	O
the	O
hma	O
gene	O
-	O
expressing	O
strain	O
induced	O
granulomas	O
bearing	O
a	O
majority	O
(	O
67	O
%	O
)	O
of	O
brightly	O
stained	O
Oil	O
red	O
-	O
O	O
positive	O
cells	O
(	O
Figures	O
4A	O
,	O
B	O
,	O
C	O
)	O
.	O

Induction	O
of	O
FM	O
formation	O
was	O
even	O
greater	O
if	O
isolated	O
macrophages	O
were	O
directly	O
infected	O
with	O
either	O
strain	O
.	O

After	O
only	O
4	O
hours	O
of	O
infection	O
,	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
had	O
already	O
transformed	O
64	O
%	O
of	O
the	O
infected	O
macrophages	O
into	O
lipid	O
body	O
-	O
positive	O
cells	O
(	O
see	O
Figure	O
S2	O
for	O
Nile	O
red	O
positive	O
cells	O
)	O
,	O
whereas	O
only	O
9	O
%	O
of	O
the	O
cells	O
contained	O
lipid	O
bodies	O
after	O
infection	O
with	O
the	O
wild	O
-	O
type	O
strain	O
(	O
Figures	O
4D	O
,	O
E	O
,	O
F	O
)	O
.	O

To	O
confirm	O
the	O
specific	O
role	O
of	O
hma	O
-	O
dependent	O
oxygenated	O
mycolic	O
acids	O
in	O
FM	O
formation	O
,	O
and	O
to	O
rule	O
out	O
a	O
possible	O
combined	O
effect	O
of	O
oxygenated	O
mycolic	O
-	O
acids	O
with	O
other	O
mycobacterial	O
components	O
,	O
mycolic	O
acids	O
isolated	O
from	O
wild	O
-	O
type	O
M	B-Species
.	I-Species
smegmatis	E-Species
or	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
were	O
incubated	O
with	O
isolated	O
macrophages	O
.	O

With	O
mycolic	O
acids	O
isolated	O
from	O
the	O
wild	O
-	O
type	O
strain	O
,	O
only	O
13	O
%	O
of	O
the	O
macrophages	O
were	O
transformed	O
into	O
FM	O
whereas	O
66	O
%	O
of	O
the	O
macrophages	O
incubated	O
with	O
mycolic	O
acids	O
isolated	O
from	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
were	O
strongly	O
stained	O
for	O
lipid	O
bodies	O
(	O
Figures	O
4G	O
,	O
H	O
,	O
I	O
)	O
.	O

These	O
results	O
therefore	O
indicate	O
that	O
oxygenated	O
mycolic	O
acids	O
play	O
a	O
leading	O
role	O
in	O
M	B-Species
.	I-Species
tb	E-Species
-	O
induced	O
FM	O
formation	O
.	O

The	O
phagocytic	O
and	O
bactericidal	O
activities	O
are	O
arrested	O
in	O
FMs	O

To	O
assess	O
the	O
function	O
of	O
granuloma	O
FM	O
,	O
we	O
first	O
evaluated	O
the	O
ability	O
of	O
such	O
cells	O
to	O
mediate	O
phagocytosis	O
.	O

For	O
this	O
purpose	O
,	O
macrophages	O
isolated	O
from	O
PBMCs	O
were	O
exposed	O
to	O
M	B-Species
.	I-Species
smegmatis	E-Species
/	O
hma	O
-	O
derived	O
mycolic	O
acids	O
to	O
induce	O
FM	O
formation	O
.	O

Two	O
days	O
later	O
,	O
the	O
cell	O
population	O
contained	O
a	O
mixture	O
of	O
FM	O
(	O
50	O
-	O
70	O
%	O
)	O
and	O
macrophages	O
(	O
30	O
-	O
50	O
%	O
)	O
,	O
as	O
assessed	O
by	O
Nile	O
red	O
staining	O
(	O
not	O
shown	O
)	O
.	O

The	O
mixed	O
cell	O
population	O
was	O
infected	O
with	O
FITC	O
-	O
labelled	O
M	B-Species
.	I-Species
smegmatis	E-Species
.	O

Intracellular	O
bacilli	O
were	O
found	O
only	O
within	O
Nile	O
red	O
-	O
negative	O
macrophages	O
thereby	O
indicating	O
that	O
FMs	O
are	O
unable	O
to	O
ingest	O
bacteria	O
(	O
Figure	O
5A	O
)	O
.	O

This	O
result	O
was	O
reproduced	O
using	O
other	O
mycobacterial	O
strains	O
,	O
such	O
as	O
M	B-Species
.	I-Species
tb	E-Species
and	O
M	B-Species
.	I-Species
bovis	I-Species
BCG	E-Species
,	O
for	O
infection	O
(	O
not	O
shown	O
)	O
.	O

These	O
results	O
further	O
suggest	O
that	O
the	O
bacilli	O
found	O
in	O
granuloma	O
FMs	O
were	O
internalized	O
by	O
macrophages	O
prior	O
to	O
their	O
transformation	O
into	O
FMs	O
.	O

To	O
assess	O
whether	O
FMs	O
are	O
able	O
to	O
develop	O
a	O
respiratory	O
burst	O
,	O
which	O
is	O
a	O
major	O
intracellular	O
bactericidal	O
activity	O
,	O
the	O
ability	O
of	O
Nile	O
red	O
positive	O
cells	O
(	O
i	O
.	O
e	O
.	O
FMs	O
)	O
to	O
mediate	O
NBT	O
reduction	O
was	O
determined	O
.	O

As	O
shown	O
in	O
Figure	O
5D	O
,	O
only	O
8	O
%	O
of	O
the	O
NBT	O
-	O
positive	O
cells	O
(	O
Figure	O
5B	O
)	O
were	O
Nile	O
red	O
positive	O
FMs	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
once	O
macrophages	O
have	O
differentiated	O
into	O
FMs	O
,	O
they	O
lose	O
the	O
ability	O
to	O
mediate	O
intracellular	O
bactericidal	O
activity	O
.	O

We	O
postulate	O
that	O
FMs	O
could	O
,	O
therefore	O
,	O
form	O
a	O
secure	O
reservoir	O
for	O
the	O
tubercle	O
bacilli	O
.	O

M	B-Species
.	I-Species
tuberculosis	E-Species
persists	O
in	O
a	O
dormant	O
non	O
-	O
replicative	O
state	O
in	O
FMs	O

To	O
evaluate	O
the	O
validity	O
of	O
the	O
above	O
hypothesis	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
M	B-Species
.	I-Species
tb	E-Species
to	O
replicate	O
within	O
FMs	O
.	O

For	O
this	O
purpose	O
,	O
isolated	O
macrophages	O
were	O
infected	O
with	O
M	B-Species
.	I-Species
tb	E-Species
.	O

At	O
selected	O
intervals	O
post	O
-	O
infection	O
,	O
the	O
amount	O
of	O
bacilli	O
per	O
cell	O
was	O
compared	O
in	O
both	O
non	O
-	O
differentiated	O
macrophages	O
and	O
FMs	O
(	O
Figure	O
5E	O
)	O
.	O

Until	O
day	O
6	O
,	O
M	B-Species
.	I-Species
tb	E-Species
replicated	O
in	O
a	O
similar	O
fashion	O
in	O
both	O
cell	O
types	O
.	O

In	O
contrast	O
,	O
after	O
day	O
6	O
post	O
-	O
infection	O
,	O
the	O
amount	O
of	O
bacilli	O
remained	O
stationary	O
in	O
FMs	O
,	O
whereas	O
it	O
continued	O
to	O
increase	O
in	O
macrophages	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
arrest	O
of	O
bacterial	O
replication	O
coincided	O
with	O
completion	O
of	O
macrophage	O
differentiation	O
into	O
FM	O
,	O
i	O
.	O
e	O
.	O
starting	O
from	O
day	O
3	O
post	O
-	O
infection	O
.	O

Our	O
data	O
suggest	O
,	O
that	O
the	O
bacilli	O
found	O
in	O
granuloma	O
FMs	O
were	O
internalized	O
by	O
macrophages	O
prior	O
to	O
their	O
differentiation	O
into	O
FMs	O
and	O
also	O
that	O
bacilli	O
can	O
terminate	O
their	O
replication	O
cycle	O
while	O
macrophages	O
are	O
being	O
transformed	O
into	O
FM	O
,	O
but	O
that	O
replication	O
comes	O
to	O
a	O
halt	O
as	O
soon	O
as	O
the	O
maturation	O
process	O
is	O
complete	O
.	O

We	O
next	O
determined	O
whether	O
the	O
non	O
-	O
replicative	O
bacilli	O
observed	O
in	O
FMs	O
were	O
still	O
alive	O
.	O

For	O
this	O
purpose	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
a	O
series	O
of	O
genes	O
known	O
to	O
be	O
up	O
-	O
regulated	O
when	O
bacilli	O
are	O
in	O
a	O
persistent	O
non	O
-	O
replicating	O
state	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

RNA	O
was	O
,	O
therefore	O
,	O
prepared	O
from	O
both	O
in	O
vitro	O
-	O
grown	O
M	B-Species
.	I-Species
tb	E-Species
and	O
intracellular	O
bacilli	O
at	O
day	O
6	O
and	O
12	O
post	O
-	O
infection	O
.	O

The	O
respective	O
amounts	O
of	O
RNA	O
corresponding	O
to	O
isocitrate	O
lyase	O
,	O
alpha	O
-	O
cristallin	O
,	O
a	O
very	O
hypothetical	O
7	O
.	O
6	O
kDa	O
protein	O
,	O
CHP	O
and	O
DosR	O
proteins	O
were	O
then	O
quantified	O
by	O
RT	O
-	O
PCR	O
.	O

As	O
shown	O
in	O
Table	O
3	O
,	O
the	O
dormancy	O
genes	O
were	O
all	O
strongly	O
up	O
-	O
regulated	O
in	O
intracellular	O
bacilli	O
at	O
day	O
12	O
post	O
-	O
infection	O
.	O

These	O
results	O
further	O
demonstrate	O
that	O
the	O
bacilli	O
are	O
not	O
killed	O
in	O
FMs	O
,	O
but	O
rather	O
persist	O
in	O
a	O
dormant	O
,	O
and	O
therefore	O
non	O
-	O
replicative	O
stage	O
[	O
25	O
]	O
.	O

Interestingly	O
,	O
the	O
dormancy	O
genes	O
were	O
not	O
as	O
strongly	O
expressed	O
at	O
day	O
6	O
,	O
time	O
at	O
which	O
bacteria	O
were	O
still	O
able	O
to	O
replicate	O
in	O
macrophages	O
undergoing	O
differentiation	O
into	O
FMs	O
.	O

Characterization	O
of	O
M	B-Species
.	I-Species
tb	E-Species
survival	O
within	O
FMs	O
and	O
interaction	O
with	O
lipid	O
bodies	O

To	O
gain	O
further	O
insight	O
into	O
the	O
morphological	O
appearance	O
of	O
M	B-Species
.	I-Species
tb	E-Species
within	O
FM	O
and	O
into	O
the	O
interactions	O
between	O
FM	O
lipid	O
bodies	O
(	O
LB	O
)	O
and	O
M	B-Species
.	I-Species
tb	E-Species
-	O
containing	O
phagosomes	O
,	O
granulomas	O
were	O
fixed	O
and	O
processed	O
for	O
conventional	O
electron	O
microscopy	O
at	O
days	O
3	O
and	O
11	O
post	O
-	O
infection	O
.	O

Whatever	O
the	O
time	O
point	O
at	O
which	O
granuloma	O
cells	O
were	O
observed	O
,	O
bacteria	O
were	O
all	O
enclosed	O
in	O
phagosomes	O
,	O
most	O
of	O
which	O
contained	O
a	O
single	O
bacterium	O
.	O

None	O
of	O
them	O
(	O
over	O
a	O
thousand	O
which	O
were	O
examined	O
under	O
the	O
electron	O
microscope	O
)	O
were	O
free	O
in	O
the	O
cytoplasm	O
and	O
only	O
one	O
was	O
enclosed	O
in	O
a	O
classical	O
autophagic	O
vacuole	O
.	O

At	O
day	O
3	O
post	O
-	O
infection	O
,	O
FMs	O
profiles	O
(	O
thin	O
sections	O
)	O
were	O
scarce	O
,	O
representing	O
at	O
most	O
9	O
%	O
of	O
the	O
total	O
population	O
of	O
macrophage	O
profiles	O
observed	O
under	O
the	O
electron	O
microscope	O
(	O
Figure	O
6A	O
)	O
.	O

In	O
addition	O
,	O
86	O
%	O
of	O
the	O
FM	O
profiles	O
displayed	O
at	O
most	O
5	O
small	O
LBs	O
(	O
Figure	O
6B	O
)	O
.	O

At	O
this	O
stage	O
of	O
granuloma	O
formation	O
,	O
bacteria	O
were	O
infrequent	O
in	O
FM	O
,	O
but	O
were	O
found	O
in	O
other	O
types	O
of	O
macrophages	O
.	O

One	O
of	O
these	O
displayed	O
large	O
numbers	O
of	O
vacuoles	O
containing	O
flocculent	O
material	O
and	O
often	O
one	O
or	O
two	O
LBs	O
.	O

Over	O
95	O
%	O
of	O
the	O
bacteria	O
located	O
in	O
the	O
different	O
granuloma	O
macrophages	O
were	O
morphologically	O
intact	O
,	O
and	O
therefore	O
alive	O
[	O
26	O
]	O
.	O

Intact	O
bacteria	O
present	O
no	O
breaks	O
in	O
the	O
cell	O
wall	O
or	O
cytoplasmic	O
membrane	O
and	O
their	O
cytoplasm	O
has	O
preserved	O
its	O
ultrastructural	O
organization	O
and	O
electron	O
opacity	O
.	O

Furthermore	O
,	O
they	O
display	O
no	O
electron	O
translucent	O
intracytoplasmic	O
lipid	O
inclusions	O
(	O
ILI	O
)	O
.	O

Bacteria	O
were	O
also	O
observed	O
in	O
between	O
cells	O
,	O
probably	O
as	O
a	O
result	O
of	O
cell	O
lysis	O
within	O
granulomas	O
.	O

These	O
bacteria	O
were	O
also	O
morphologically	O
intact	O
and	O
devoid	O
of	O
ILI	O
(	O
not	O
shown	O
)	O
.	O

At	O
day	O
11	O
post	O
-	O
infection	O
,	O
M	B-Species
.	I-Species
tb	E-Species
-	O
containing	O
macrophages	O
displaying	O
large	O
numbers	O
of	O
vacuoles	O
with	O
flocculent	O
material	O
were	O
less	O
frequently	O
observed	O
.	O

Interestingly	O
,	O
the	O
amount	O
of	O
such	O
vacuoles	O
had	O
strongly	O
decreased	O
in	O
most	O
of	O
these	O
cells	O
while	O
the	O
number	O
of	O
LBs	O
had	O
increased	O
.	O

The	O
percentage	O
of	O
FM	O
had	O
increased	O
to	O
reach	O
41	O
%	O
of	O
the	O
total	O
population	O
of	O
macrophage	O
profiles	O
within	O
the	O
granulomas	O
(	O
Figure	O
6A	O
)	O
.	O

From	O
these	O
observations	O
,	O
it	O
is	O
tempting	O
to	O
assume	O
that	O
the	O
highly	O
vesiculated	O
macrophages	O
give	O
rise	O
to	O
FMs	O
.	O

Within	O
FMs	O
,	O
the	O
size	O
and	O
amount	O
of	O
LBs	O
had	O
also	O
increased	O
with	O
time	O
since	O
48	O
%	O
of	O
the	O
FM	O
profiles	O
now	O
displayed	O
more	O
than	O
5	O
LB	O
per	O
FM	O
thin	O
section	O
(	O
Figure	O
6B	O
)	O
,	O
randomly	O
distributed	O
within	O
the	O
cells	O
(	O
Figure	O
6C	O
)	O
.	O

About	O
30	O
%	O
of	O
the	O
FM	O
profiles	O
displayed	O
between	O
1	O
and	O
20	O
bacteria	O
,	O
which	O
were	O
morphologically	O
intact	O
and	O
enclosed	O
within	O
phagosomes	O
(	O
Figure	O
6C	O
,	O
enlarged	O
view	O
)	O
.	O

The	O
interaction	O
between	O
these	O
bacteria	O
and	O
the	O
cellular	O
LBs	O
was	O
next	O
examined	O
at	O
day	O
11	O
.	O

Sixty	O
percent	O
of	O
the	O
bacilli	O
were	O
scattered	O
throughout	O
the	O
FMs	O
and	O
displayed	O
no	O
obvious	O
signs	O
of	O
interaction	O
with	O
the	O
cellular	O
LBs	O
.	O

A	O
small	O
fraction	O
of	O
the	O
bacteria	O
(	O
21	O
%	O
)	O
,	O
however	O
,	O
were	O
observed	O
in	O
the	O
close	O
vicinity	O
of	O
cellular	O
LBs	O
.	O

The	O
membrane	O
of	O
the	O
phagosomes	O
in	O
which	O
they	O
were	O
enclosed	O
clearly	O
interacted	O
with	O
cellular	O
LBs	O
(	O
Figures	O
6C	O
,	O
7A	O
,	O
7B	O
,	O
arrows	O
)	O
and	O
became	O
tightly	O
apposed	O
to	O
an	O
increasingly	O
larger	O
surface	O
area	O
of	O
the	O
LB	O
.	O

As	O
a	O
result	O
,	O
the	O
phagosomes	O
started	O
to	O
surround	O
LBs	O
in	O
a	O
zippering	O
fashion	O
(	O
Figures	O
7E	O
,	O
F	O
)	O
.	O

Ultimately	O
,	O
bacilli	O
(	O
19	O
%	O
)	O
were	O
translocated	O
to	O
cellular	O
LBs	O
(	O
Figure	O
7C	O
)	O
.	O

From	O
these	O
observations	O
,	O
it	O
is	O
tempting	O
to	O
assume	O
that	O
M	B-Species
.	I-Species
tb	E-Species
-	O
containing	O
phagosomes	O
engulf	O
cellular	O
LBs	O
rather	O
than	O
fusing	O
with	O
them	O
.	O

This	O
process	O
,	O
which	O
is	O
reminiscent	O
of	O
autophagy	O
,	O
resulted	O
in	O
the	O
transfer	O
of	O
free	O
bacteria	O
into	O
the	O
lumen	O
of	O
cellular	O
LBs	O
(	O
Figure	O
7C	O
)	O
,	O
some	O
of	O
which	O
displayed	O
up	O
to	O
21	O
bacteria	O
(	O
Figure	O
7G	O
)	O
.	O

Interestingly	O
,	O
only	O
altered	O
M	B-Species
.	I-Species
tb	E-Species
found	O
within	O
FM	O
lipid	O
bodies	O
exhibited	O
electron	O
translucent	O
ILIs	O
(	O
Figures	O
7D	O
,	O
G	O
)	O
,	O
thereby	O
suggesting	O
that	O
they	O
are	O
able	O
to	O
accumulate	O
host	O
cell	O
lipids	O
.	O

In	O
previous	O
work	O
,	O
the	O
term	O
altered	O
bacteria	O
had	O
been	O
used	O
to	O
define	O
live	O
bacteria	O
that	O
had	O
acquired	O
ILIs	O
[	O
26	O
]	O
.	O

Since	O
the	O
presence	O
of	O
ILIs	O
within	O
the	O
cytoplasm	O
of	O
M	B-Species
.	I-Species
tb	E-Species
is	O
typical	O
for	O
non	O
-	O
replicating	O
bacteria	O
in	O
a	O
state	O
of	O
dormancy	O
[	O
27	O
]	O
,	O
this	O
further	O
confirms	O
that	O
these	O
bacteria	O
are	O
dormant	O
.	O

Discussion	O

Studies	O
carried	O
out	O
several	O
decades	O
ago	O
suggested	O
that	O
postprimary	O
tuberculosis	O
starts	O
as	O
a	O
lipid	O
pneumonia	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

Indeed	O
,	O
following	O
a	O
first	O
inflammatory	O
process	O
leading	O
to	O
exudates	O
of	O
mononuclear	O
cells	O
within	O
alveolar	O
spaces	O
,	O
early	O
pathologists	O
observed	O
an	O
accumulation	O
of	O
lipid	O
droplets	O
in	O
alveolar	O
macrophages	O
of	O
TB	O
patients	S-Species
.	O

Tubercle	O
bacilli	O
were	O
shown	O
to	O
reside	O
in	O
these	O
lipid	O
-	O
rich	O
macrophages	O
which	O
were	O
named	O
foamy	O
macrophages	O
(	O
FMs	O
)	O
[	O
30	O
]	O
.	O

Recently	O
,	O
histo	O
-	O
pathological	O
analysis	O
of	O
biopsies	O
from	O
patients	S-Species
with	O
untreated	O
tuberculosis	O
confirmed	O
the	O
century	O
-	O
old	O
histological	O
descriptions	O
of	O
postprimary	O
tuberculosis	O
[	O
10	O
]	O
.	O

In	O
this	O
study	O
,	O
Hunter	O
et	O
al	O
showed	O
that	O
postprimary	O
tuberculosis	O
begins	O
as	O
a	O
lipid	O
pneumonia	O
with	O
the	O
accumulation	O
of	O
large	O
amounts	O
of	O
lipid	O
-	O
rich	O
FMs	O
,	O
accompanied	O
by	O
bronchial	O
obstruction	O
.	O

It	O
was	O
also	O
shown	O
that	O
in	O
alveolar	O
foamy	O
macrophages	O
,	O
the	O
bacilli	O
were	O
mainly	O
found	O
within	O
lipid	O
droplets	O
.	O

All	O
these	O
observations	O
underline	O
the	O
important	O
,	O
yet	O
often	O
neglected	O
,	O
role	O
of	O
lipid	O
accumulation	O
,	O
and	O
more	O
precisely	O
FM	O
formation	O
,	O
at	O
the	O
infectious	O
site	O
in	O
the	O
physiopathology	O
of	O
TB	O
.	O

In	O
murine	O
experimental	O
models	O
,	O
FMs	O
accumulate	O
within	O
the	O
outermost	O
layer	O
of	O
granulomatous	O
structures	O
occupying	O
the	O
alveolar	O
spaces	O
during	O
the	O
chronic	O
phase	O
of	O
infection	O
.	O

This	O
strongly	O
suggests	O
that	O
FMs	O
could	O
be	O
involved	O
in	O
lesion	O
cleaning	O
via	O
phagocytic	O
uptake	O
of	O
cellular	O
debris	O
generated	O
by	O
the	O
local	O
inflammatory	O
response	O
.	O

Once	O
filled	O
with	O
debris	O
,	O
FMs	O
would	O
leave	O
the	O
parenchyma	O
through	O
the	O
alveolar	O
spaces	O
up	O
to	O
the	O
superior	O
bronchial	O
tree	O
,	O
to	O
be	O
finally	O
swallowed	O
and	O
digested	O
in	O
the	O
stomach	O
[	O
31	O
]	O
.	O

In	O
fact	O
,	O
this	O
process	O
is	O
very	O
well	O
known	O
,	O
and	O
is	O
a	O
crucial	O
factor	O
for	O
TB	O
diagnosis	O
in	O
children	S-Species
.	O

As	O
infants	S-Species
do	O
not	O
usually	O
generate	O
cavitary	O
lesions	O
,	O
and	O
because	O
it	O
is	O
difficult	O
to	O
detect	O
bacilli	O
in	O
the	O
sputum	O
,	O
the	O
diagnosis	O
is	O
linked	O
to	O
the	O
detection	O
of	O
bacilli	O
in	O
the	O
gastrointestinal	O
lavage	O
[	O
32	O
]	O
.	O

We	O
show	O
that	O
M	B-Species
.	I-Species
tb	E-Species
-	O
induced	O
the	O
transformation	O
of	O
in	O
vitro	O
-	O
grown	O
human	S-Species
granuloma	O
macrophages	O
into	O
FMs	O
within	O
6	O
days	O
,	O
and	O
even	O
more	O
rapidly	O
(	O
3	O
-	O
4	O
hours	O
)	O
in	O
cultured	O
macrophages	O
.	O

Although	O
this	O
event	O
occurs	O
more	O
quickly	O
than	O
in	O
vivo	O
,	O
or	O
in	O
animal	O
models	O
,	O
our	O
data	O
are	O
consistent	O
with	O
the	O
above	O
in	O
vivo	O
observations	O
.	O

Within	O
FMs	O
,	O
bacilli	O
and	O
LBs	O
were	O
often	O
tightly	O
linked	O
,	O
to	O
the	O
point	O
that	O
a	O
non	O
-	O
negligible	O
amount	O
of	O
bacteria	O
were	O
ultimately	O
observed	O
within	O
LBs	O
.	O

Interestingly	O
,	O
some	O
of	O
the	O
bacilli	O
transferred	O
into	O
lipid	O
bodies	O
displayed	O
their	O
own	O
intracytoplasmic	O
lipid	O
inclusions	O
,	O
which	O
are	O
considered	O
to	O
be	O
one	O
of	O
the	O
hallmarks	O
of	O
non	O
-	O
replicating	O
(	O
dormant	O
)	O
M	B-Species
.	I-Species
tb	E-Species
[	O
27	O
]	O
.	O

The	O
recent	O
observation	O
of	O
persistent	O
ILI	O
-	O
containing	O
tubercle	O
bacilli	O
within	O
adipocyte	O
LBs	O
[	O
33	O
]	O
is	O
in	O
good	O
agreement	O
with	O
our	O
observations	O
.	O

Since	O
bacilli	O
residing	O
in	O
phagosomes	O
that	O
do	O
not	O
interact	O
with	O
cellular	O
lipid	O
bodies	O
do	O
not	O
display	O
ILIs	O
,	O
it	O
is	O
tempting	O
to	O
assume	O
that	O
lipids	O
within	O
ILIs	O
are	O
of	O
cellular	O
origin	O
.	O

The	O
accumulation	O
of	O
lipids	O
within	O
bacilli	O
[	O
47	O
]	O
,	O
via	O
interaction	O
with	O
FM	O
lipid	O
bodies	O
could	O
,	O
therefore	O
,	O
be	O
crucial	O
to	O
M	B-Species
.	I-Species
tb	E-Species
persistence	O
.	O

It	O
is	O
indeed	O
known	O
that	O
M	B-Species
.	I-Species
tb	E-Species
accumulates	O
lipids	O
,	O
and	O
more	O
precisely	O
triacylglycerols	O
,	O
during	O
dormancy	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
from	O
which	O
it	O
derives	O
both	O
carbon	O
and	O
energy	O
for	O
its	O
own	O
metabolism	O
.	O

Intracellular	O
persistence	O
of	O
M	B-Species
.	I-Species
tb	E-Species
is	O
also	O
critically	O
linked	O
to	O
the	O
acquisition	O
of	O
host	O
cholesterol	O
through	O
the	O
Mce4	O
transporter	O
system	O
[	O
36	O
]	O
.	O

The	O
question	O
that	O
arises	O
is	O
how	O
do	O
bacteria	O
gain	O
access	O
to	O
lipids	O
from	O
LB	O
?	O

Direct	O
fusion	O
of	O
phagosomes	O
with	O
FM	O
lipid	O
bodies	O
seems	O
unlikely	O
as	O
the	O
membranes	O
of	O
both	O
structures	O
are	O
quite	O
different	O
from	O
one	O
another	O
.	O

Our	O
observations	O
suggest	O
instead	O
that	O
once	O
M	B-Species
.	I-Species
tb	E-Species
-	O
containing	O
phagosomes	O
have	O
established	O
close	O
contact	O
with	O
a	O
lipid	O
body	O
,	O
they	O
surround	O
and	O
engulf	O
the	O
latter	O
by	O
a	O
process	O
that	O
remains	O
to	O
be	O
deciphered	O
.	O

This	O
phenomenon	O
is	O
somewhat	O
reminiscent	O
of	O
autophagy	O
,	O
as	O
observed	O
under	O
conditions	O
of	O
cholesterol	O
depletion	O
in	O
macrophages	O
infected	O
with	O
M	B-Species
.	I-Species
avium	E-Species
[	O
37	O
]	O
.	O

After	O
degradation	O
of	O
the	O
resulting	O
inner	O
membrane	O
,	O
bacteria	O
would	O
be	O
freed	O
within	O
the	O
lipids	O
of	O
the	O
engulfed	O
LB	O
,	O
and	O
therefore	O
be	O
in	O
direct	O
contact	O
with	O
cellular	O
lipids	O
.	O

How	O
bacilli	O
translocate	O
the	O
cellular	O
lipids	O
to	O
their	O
own	O
cytoplasm	O
remains	O
to	O
be	O
established	O
.	O

Another	O
important	O
phenomenon	O
underlined	O
by	O
our	O
study	O
is	O
the	O
strong	O
correlation	O
between	O
the	O
presence	O
of	O
FMs	O
in	O
the	O
granulomatous	O
structures	O
and	O
the	O
development	O
of	O
necrosis	O
within	O
the	O
lesion	O
,	O
as	O
suggested	O
by	O
Pagel	O
over	O
80	O
years	O
ago	O
[	O
29	O
]	O
.	O

Interestingly	O
,	O
FMs	O
were	O
systematically	O
located	O
at	O
the	O
interface	O
region	O
between	O
the	O
histiocytes	O
and	O
the	O
central	O
necrosis	O
area	O
of	O
the	O
biopsied	O
lesions	O
.	O

Although	O
necrosis	O
formation	O
could	O
depend	O
on	O
an	O
indirect	O
effect	O
of	O
the	O
global	O
immune	O
response	O
,	O
our	O
data	O
indicate	O
that	O
the	O
formation	O
of	O
FMs	O
is	O
an	O
important	O
factor	O
favoring	O
the	O
appearance	O
of	O
necrosis	O
.	O

Analysis	O
of	O
larger	O
series	O
of	O
biopsy	O
samples	O
are	O
,	O
however	O
,	O
needed	O
to	O
definitely	O
demonstrate	O
our	O
actual	O
hypothesis	O
according	O
to	O
which	O
FMs	O
play	O
a	O
direct	O
and	O
unique	O
role	O
in	O
necrosis	O
formation	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
we	O
observed	O
that	O
FMs	O
induced	O
from	O
M	B-Species
.	I-Species
tb	E-Species
-	O
infected	O
macrophages	O
displayed	O
permanent	O
TNF	O
-	O
alpha	O
secretion	O
,	O
a	O
potent	O
pro	O
-	O
necrotic	O
factor	O
,	O
whereas	O
M	B-Species
.	I-Species
smegmatis	E-Species
-	O
infected	O
macrophages	O
were	O
poor	O
producers	O
of	O
TNF	O
-	O
alpha	O
.	O

At	O
day	O
4	O
post	O
-	O
infection	O
,	O
TNF	O
-	O
alpha	O
secretion	O
was	O
indeed	O
twofold	O
higher	O
in	O
macrophages	O
(	O
of	O
which	O
70	O
%	O
had	O
differentiated	O
into	O
FMs	O
)	O
infected	O
with	O
M	B-Species
.	I-Species
tb	E-Species
than	O
in	O
those	O
infected	O
with	O
M	B-Species
.	I-Species
smegmatis	E-Species
,	O
as	O
measured	O
both	O
by	O
ELISA	O
and	O
RNA	O
quantification	O
(	O
Peyron	O
,	O
unpublished	O
observations	O
)	O
.	O

However	O
,	O
one	O
must	O
keep	O
in	O
mind	O
that	O
the	O
association	O
of	O
FMs	O
and	O
necrosis	O
may	O
be	O
the	O
consequence	O
of	O
the	O
FM	O
cleaning	O
process	O
of	O
lipoproteins	O
released	O
into	O
the	O
necrotic	O
tissue	O
,	O
as	O
observed	O
in	O
atherosclerosis	O
lesions	O
[	O
38	O
]	O
.	O

It	O
is	O
thus	O
tempting	O
to	O
propose	O
that	O
M	B-Species
.	I-Species
tb	E-Species
mycolic	O
acids	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
necrotic	O
lesions	O
,	O
due	O
to	O
their	O
ability	O
to	O
induce	O
TNF	O
-	O
alpha	O
production	O
by	O
FMs	O
.	O

Whether	O
mycolic	O
acids	O
are	O
directly	O
involved	O
in	O
TNF	O
-	O
alpha	O
production	O
,	O
or	O
only	O
indirectly	O
by	O
inducing	O
FM	O
formation	O
,	O
remains	O
a	O
matter	O
of	O
debate	O
currently	O
under	O
study	O
.	O

Our	O
observations	O
are	O
strikingly	O
similar	O
to	O
the	O
phenomena	O
described	O
for	O
postprimary	O
tuberculosis	O
,	O
that	O
seems	O
to	O
begin	O
as	O
localized	O
foci	O
of	O
pneumonia	O
followed	O
by	O
massive	O
necrosis	O
leading	O
to	O
the	O
formation	O
of	O
pulmonary	O
cavities	O
[	O
10	O
]	O
.	O

If	O
this	O
proves	O
to	O
be	O
the	O
case	O
,	O
then	O
the	O
traditionally	O
admitted	O
phenomenon	O
of	O
cavitation	O
arising	O
from	O
the	O
erosion	O
of	O
caseating	O
granulomatous	O
structures	O
from	O
bronchi	O
can	O
be	O
ruled	O
out	O
[	O
39	O
]	O
.	O

In	O
our	O
study	O
,	O
we	O
successfully	O
induced	O
FM	O
formation	O
from	O
isolated	O
macrophages	O
infected	O
with	O
M	B-Species
.	I-Species
tb	E-Species
,	O
i	O
.	O
e	O
.	O
outside	O
a	O
granulomatous	O
structure	O
,	O
which	O
is	O
consistent	O
with	O
Hunter	O
'	O
s	O
recent	O
proposal	O
.	O

Until	O
now	O
,	O
mycolic	O
acids	O
have	O
been	O
considered	O
to	O
be	O
indirectly	O
involved	O
in	O
virulence	O
mechanisms	O
as	O
being	O
part	O
of	O
complex	O
molecules	O
of	O
the	O
mycobacterial	O
envelope	O
.	O

The	O
most	O
widely	O
studied	O
mycolic	O
acid	O
-	O
containing	O
mycobacterial	O
compound	O
trehalose	O
6	O
,	O
6	O
'	O
dimycolate	O
(	O
TDM	O
)	O
,	O
has	O
been	O
extensively	O
analyzed	O
for	O
its	O
role	O
in	O
virulence	O
since	O
the	O
mid	O
-	O
fifties	O
[	O
40	O
]	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
to	O
interfere	O
with	O
the	O
host	O
granulomatous	O
response	O
[	O
41	O
]	O
.	O

Overall	O
,	O
TDM	O
was	O
mainly	O
shown	O
to	O
mediate	O
macrophage	O
activation	O
and	O
a	O
Th1	O
-	O
type	O
response	O
to	O
M	B-Species
.	I-Species
tb	E-Species
infection	O
(	O
for	O
review	O
,	O
see	O
[	O
25	O
]	O
)	O
.	O

Our	O
results	O
demonstrate	O
a	O
direct	O
role	O
of	O
oxygenated	O
mycolic	O
acids	O
for	O
FM	O
formation	O
,	O
independently	O
from	O
the	O
appearance	O
and	O
stage	O
of	O
the	O
disease	O
.	O

M	B-Species
.	I-Species
tb	E-Species
-	O
specific	O
mycolic	O
acids	O
indeed	O
trigger	O
the	O
transformation	O
of	O
both	O
isolated	O
and	O
granuloma	O
macrophages	O
,	O
into	O
FM	O
.	O

Given	O
the	O
absence	O
of	O
FM	O
formation	O
in	O
M	B-Species
.	I-Species
smegmatis	E-Species
-	O
induced	O
granulomas	O
,	O
despite	O
the	O
induction	O
of	O
a	O
comparative	O
inflammatory	O
response	O
,	O
ascertained	O
by	O
the	O
similar	O
induction	O
of	O
granulomas	O
,	O
this	O
phenomenon	O
clearly	O
depends	O
upon	O
a	O
direct	O
contact	O
with	O
the	O
bacilli	O
,	O
and	O
not	O
to	O
the	O
inflammatory	O
response	O
.	O

Mycolic	O
acids	O
are	O
major	O
and	O
hallmark	O
components	O
of	O
the	O
mycobacterial	O
cell	O
wall	O
.	O

They	O
constitute	O
40	O
-	O
60	O
%	O
of	O
dry	O
weight	O
of	O
the	O
envelope	O
[	O
42	O
]	O
.	O

All	O
members	O
of	O
the	O
complex	O
(	O
e	O
.	O
g	O
.	O
M	B-Species
.	I-Species
tb	E-Species
,	O
Mycobacterium	B-Species
africanum	E-Species
,	O
Mycobacterium	B-Species
bovis	E-Species
and	O
Mycobacterium	B-Species
microti	E-Species
)	O
are	O
able	O
to	O
synthesize	O
the	O
same	O
combination	O
of	O
mycolic	O
acids	O
,	O
i	O
.	O
e	O
.	O
cyclopropanated	O
alpha	O
-	O
mycolic	O
acids	O
,	O
ketomycolic	O
and	O
methoxymycolic	O
acids	O
[	O
17	O
]	O
,	O
which	O
are	O
not	O
synthesized	O
by	O
non	O
-	O
pathogenic	O
mycobacterial	O
species	O
[	O
43	O
]	O
.	O

These	O
structural	O
specificities	O
probably	O
account	O
for	O
part	O
of	O
the	O
pathogenicity	O
of	O
these	O
species	O
,	O
as	O
shown	O
by	O
the	O
impaired	O
virulence	O
of	O
mutant	O
strains	O
deprived	O
of	O
keto	O
and	O
methoxyl	O
groups	O
in	O
experimental	O
infections	O
[	O
17	O
]	O
,	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
.	O

Our	O
study	O
,	O
therefore	O
,	O
gives	O
the	O
first	O
proof	O
of	O
a	O
direct	O
role	O
of	O
isolated	O
mycolic	O
acids	O
in	O
the	O
interplay	O
between	O
M	B-Species
.	I-Species
tb	E-Species
and	O
host	O
cells	O
.	O

Interestingly	O
,	O
this	O
effect	O
is	O
expressed	O
both	O
by	O
whole	O
bacilli	O
and	O
isolated	O
lipids	O
,	O
suggesting	O
that	O
oxygenated	O
mycolic	O
acids	O
are	O
either	O
secreted	O
by	O
the	O
bacilli	O
,	O
or	O
exposed	O
at	O
the	O
cell	O
wall	O
surface	O
in	O
a	O
manner	O
enabling	O
their	O
bioactivity	O
.	O

According	O
to	O
our	O
results	O
,	O
mycolic	O
acids	O
trigger	O
the	O
formation	O
,	O
within	O
granulomas	O
,	O
of	O
FMs	O
in	O
which	O
bacilli	O
can	O
hide	O
and	O
survive	O
.	O

Oxygenated	O
mycolic	O
acids	O
,	O
either	O
free	O
,	O
as	O
constituents	O
of	O
TDM	O
[	O
44	O
]	O
,	O
or	O
linked	O
to	O
the	O
cell	O
wall	O
arabinogalactan	O
[	O
46	O
]	O
,	O
[	O
47	O
]	O
,	O
should	O
,	O
therefore	O
,	O
be	O
considered	O
as	O
major	O
virulence	O
factors	O
enabling	O
M	B-Species
.	I-Species
tb	E-Species
survival	O
for	O
long	O
periods	O
of	O
time	O
in	O
a	O
persistent	O
state	O
.	O

Being	O
an	O
inducer	O
of	O
host	O
lipid	O
accumulation	O
,	O
and	O
FM	O
formation	O
at	O
the	O
site	O
of	O
infection	O
,	O
these	O
oxygenated	O
mycolic	O
acids	O
could	O
,	O
therefore	O
,	O
also	O
be	O
responsible	O
for	O
the	O
induction	O
of	O
necrosis	O
within	O
lesions	O
,	O
thus	O
favoring	O
M	B-Species
.	I-Species
tb	E-Species
dissemination	O
.	O

Interestingly	O
,	O
deletion	O
of	O
the	O
mmaA4	O
(	O
Rv0642c	O
)	O
gene	O
also	O
drastically	O
decreased	O
the	O
ability	O
of	O
M	B-Species
.	I-Species
tb	E-Species
to	O
induce	O
the	O
differentiation	O
of	O
macrophages	O
into	O
FMs	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
the	O
residual	O
ability	O
of	O
this	O
mutant	O
to	O
induce	O
FMs	O
suggests	O
that	O
other	O
mycobacterial	O
factors	O
might	O
partially	O
trigger	O
the	O
formation	O
of	O
FM	O
.	O

With	O
regard	O
to	O
the	O
mycolic	O
acid	O
methyltransferases	O
,	O
given	O
that	O
(	O
i	O
)	O
mmaA2	O
(	O
Rv0644c	O
)	O
and	O
mmaA3	O
(	O
Rv0643c	O
)	O
are	O
pseudogenes	O
in	O
M	B-Species
.	I-Species
leprae	E-Species
and	O
(	O
ii	O
)	O
mmaA4	O
KO	O
present	O
no	O
trans	O
cyclopropanation	O
[	O
45	O
]	O
,	O
thus	O
excluding	O
the	O
involvement	O
of	O
the	O
cmaA2	O
(	O
Rv0503c	O
)	O
gene	O
,	O
we	O
expect	O
that	O
at	O
least	O
pcaA	O
(	O
Rv0470c	O
)	O
,	O
which	O
introduces	O
cis	O
-	O
cyclopropane	O
,	O
may	O
play	O
the	O
same	O
role	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
a	O
pcaA	O
null	O
mutant	O
is	O
unable	O
to	O
persist	O
within	O
infected	O
mice	S-Species
[	O
46	O
]	O
,	O
thus	O
demonstrating	O
the	O
role	O
of	O
a	O
mycolic	O
acid	O
methyltransferase	O
in	O
the	O
chronic	O
stage	O
of	O
infection	O
.	O

Overall	O
,	O
our	O
study	O
has	O
shed	O
light	O
on	O
a	O
previously	O
uncharacterized	O
cell	O
population	O
participating	O
in	O
human	S-Species
tuberculous	O
granulomas	O
,	O
namely	O
foamy	O
macrophages	O
.	O

We	O
propose	O
that	O
the	O
specific	O
induction	O
of	O
FM	O
by	O
M	B-Species
.	I-Species
tb	E-Species
would	O
create	O
a	O
favourable	O
environment	O
for	O
persistent	O
bacteria	O
.	O

In	O
our	O
opinion	O
,	O
FMs	O
could	O
be	O
a	O
safe	O
shelter	O
because	O
they	O
preserve	O
bacilli	O
from	O
a	O
direct	O
contact	O
with	O
granuloma	O
lymphocytes	O
and	O
histiocytes	O
,	O
they	O
lose	O
one	O
of	O
the	O
major	O
macrophage	O
bactericidal	O
activities	O
and	O
they	O
constitute	O
an	O
important	O
source	O
of	O
nutrients	O
for	O
the	O
bacilli	O
thanks	O
to	O
the	O
fatty	O
acids	O
accumulated	O
in	O
their	O
lipid	O
granules	O
.	O

Supporting	O
Information	O

A	O
Case	O
-	O
Control	O
Study	O
to	O
Assess	O
the	O
Relationship	O
between	O
Poverty	O
and	O
Visual	O
Impairment	O
from	O
Cataract	O
in	O
Kenya	O
,	O
the	O
Philippines	O
,	O
and	O
Bangladesh	O

Abstract	O

Background	O

The	O
link	O
between	O
poverty	O
and	O
health	O
is	O
central	O
to	O
the	O
Millennium	O
Development	O
Goals	O
(	O
MDGs	O
)	O
.	O

Poverty	O
can	O
be	O
both	O
a	O
cause	O
and	O
consequence	O
of	O
poor	O
health	O
,	O
but	O
there	O
are	O
few	O
epidemiological	O
studies	O
exploring	O
this	O
complex	O
relationship	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
association	O
between	O
visual	O
impairment	O
from	O
cataract	O
and	O
poverty	O
in	O
adults	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
.	O

Methods	O
and	O
Findings	O

A	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
was	O
conducted	O
in	O
three	O
countries	O
during	O
2005	O
-	O
2006	O
.	O

Cases	O
were	O
persons	S-Species
aged	O
50	O
y	O
or	O
older	O
and	O
visually	O
impaired	O
due	O
to	O
cataract	O
(	O
visual	O
acuity	O
<	O
6	O
/	O
24	O
in	O
the	O
better	O
eye	O
)	O
.	O

Controls	O
were	O
persons	S-Species
age	O
-	O
and	O
sex	O
-	O
matched	O
to	O
the	O
case	O
participants	S-Species
with	O
normal	O
vision	O
selected	O
from	O
the	O
same	O
cluster	O
.	O

Household	O
expenditure	O
was	O
assessed	O
through	O
the	O
collection	O
of	O
detailed	O
consumption	O
data	O
,	O
and	O
asset	O
ownership	O
and	O
self	O
-	O
rated	O
wealth	O
were	O
also	O
measured	O
.	O

In	O
total	O
,	O
596	O
cases	O
and	O
535	O
controls	O
were	O
included	O
in	O
these	O
analyses	O
(	O
Kenya	O
142	O
cases	O
,	O
75	O
controls	O
;	O
Bangladesh	O
216	O
cases	O
,	O
279	O
controls	O
;	O
Philippines	O
238	O
cases	O
,	O
180	O
controls	O
)	O
.	O

Case	O
participants	S-Species
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
per	O
capita	O
expenditure	O
(	O
PCE	O
)	O
compared	O
to	O
controls	O
in	O
Kenya	O
(	O
odds	O
ratio	O
=	O
2	O
.	O
3	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
9	O
-	O
5	O
.	O
5	O
)	O
,	O
Bangladesh	O
(	O
1	O
.	O
9	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
2	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
3	O
.	O
1	O
,	O
1	O
.	O
7	O
-	O
5	O
.	O
7	O
)	O
,	O
and	O
there	O
was	O
significant	O
dose	O
-	O
response	O
relationship	O
across	O
quartiles	O
of	O
PCE	O
.	O

These	O
associations	O
persisted	O
after	O
adjustment	O
for	O
self	O
-	O
rated	O
health	O
and	O
social	O
support	O
indicators	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
the	O
relationship	O
between	O
cataract	O
visual	O
impairment	O
with	O
asset	O
ownership	O
and	O
self	O
-	O
rated	O
wealth	O
.	O

There	O
was	O
no	O
consistent	O
pattern	O
of	O
association	O
between	O
PCE	O
and	O
level	O
of	O
visual	O
impairment	O
due	O
to	O
cataract	O
,	O
sex	O
,	O
or	O
age	O
among	O
the	O
three	O
countries	O
.	O

Conclusions	O

Our	O
data	O
show	O
that	O
people	S-Species
with	O
visual	O
impairment	O
due	O
to	O
cataract	O
were	O
poorer	O
than	O
those	O
with	O
normal	O
sight	O
in	O
all	O
three	O
low	O
-	O
income	O
countries	O
studied	O
.	O

The	O
MDGs	O
are	O
committed	O
to	O
the	O
eradication	O
of	O
extreme	O
poverty	O
and	O
provision	O
of	O
health	O
care	O
to	O
poor	O
people	S-Species
,	O
and	O
this	O
study	O
highlights	O
the	O
need	O
for	O
increased	O
provision	O
of	O
cataract	O
surgery	O
to	O
poor	O
people	S-Species
,	O
as	O
they	O
are	O
particularly	O
vulnerable	O
to	O
visual	O
impairment	O
from	O
cataract	O
.	O

Background	O
.	O

Globally	O
,	O
about	O
45	O
million	O
people	S-Species
are	O
blind	O
.	O

As	O
with	O
many	O
other	O
conditions	O
,	O
avoidable	O
blindness	O
(	O
preventable	O
or	O
curable	O
blindness	O
)	O
is	O
a	O
particular	O
problem	O
for	O
people	S-Species
in	O
developing	O
countries	O
--	O
90	O
%	O
of	O
blind	O
people	S-Species
live	O
in	O
poor	O
regions	O
of	O
the	O
world	O
.	O

Although	O
various	O
infections	O
and	O
disorders	O
can	O
cause	O
blindness	O
,	O
cataract	O
is	O
the	O
most	O
common	O
cause	O
.	O

In	O
cataract	O
,	O
which	O
is	O
responsible	O
for	O
half	O
of	O
all	O
cases	O
of	O
blindness	O
in	O
the	O
world	O
,	O
the	O
lens	O
of	O
the	O
eye	O
gradually	O
becomes	O
cloudy	O
.	O

Because	O
the	O
lens	O
focuses	O
light	O
to	O
produce	O
clear	O
,	O
sharp	O
images	O
,	O
as	O
cataract	O
develops	O
,	O
vision	O
becomes	O
increasingly	O
foggy	O
or	O
fuzzy	O
,	O
colors	O
become	O
less	O
intense	O
,	O
and	O
the	O
ability	O
to	O
see	O
shapes	O
against	O
a	O
background	O
declines	O
.	O

Eventually	O
,	O
vision	O
may	O
be	O
lost	O
completely	O
.	O

Cataract	O
can	O
be	O
treated	O
with	O
an	O
inexpensive	O
,	O
simple	O
operation	O
in	O
which	O
the	O
cloudy	O
lens	O
is	O
surgically	O
removed	O
and	O
an	O
artificial	O
lens	O
is	O
inserted	O
into	O
the	O
eye	O
to	O
restore	O
vision	O
.	O

In	O
developed	O
countries	O
,	O
this	O
operation	O
is	O
common	O
and	O
easily	O
accessible	O
but	O
many	O
poor	O
countries	O
lack	O
the	O
resources	O
to	O
provide	O
the	O
operation	O
to	O
everyone	O
who	O
needs	O
it	O
.	O

In	O
addition	O
,	O
blind	O
people	S-Species
often	O
cannot	O
afford	O
to	O
travel	O
to	O
the	O
hospitals	O
where	O
the	O
operation	O
,	O
which	O
also	O
may	O
come	O
with	O
a	O
fee	O
,	O
is	O
done	O
.	O

Why	O
Was	O
This	O
Study	O
Done	O
?	O

Because	O
blindness	O
may	O
reduce	O
earning	O
potential	O
,	O
many	O
experts	O
believe	O
that	O
poverty	O
and	O
blindness	O
(	O
and	O
,	O
more	O
generally	O
,	O
poor	O
health	O
)	O
are	O
inextricably	O
linked	O
.	O

People	S-Species
become	O
ill	O
more	O
often	O
in	O
poor	O
countries	O
than	O
in	O
wealthy	O
countries	O
because	O
they	O
have	O
insufficient	O
food	O
,	O
live	O
in	O
substandard	O
housing	O
,	O
and	O
have	O
limited	O
access	O
to	O
health	O
care	O
,	O
education	O
,	O
water	O
,	O
and	O
sanitation	O
.	O

Once	O
they	O
are	O
ill	O
,	O
their	O
ability	O
to	O
earn	O
money	O
may	O
be	O
reduced	O
,	O
which	O
increases	O
their	O
personal	O
poverty	O
and	O
slows	O
the	O
economic	O
development	O
of	O
the	O
whole	O
country	O
.	O

Because	O
of	O
this	O
potential	O
link	O
between	O
health	O
and	O
poverty	O
,	O
improvements	O
in	O
health	O
are	O
at	O
the	O
heart	O
of	O
the	O
United	O
Nations	O
Millennium	O
Development	O
Goals	O
,	O
a	O
set	O
of	O
eight	O
goals	O
established	O
in	O
2000	O
with	O
the	O
primary	O
aim	O
of	O
reducing	O
world	O
poverty	O
.	O

However	O
,	O
few	O
studies	O
have	O
actually	O
investigated	O
the	O
complex	O
relationship	O
between	O
poverty	O
and	O
health	O
.	O

Here	O
,	O
the	O
researchers	O
investigate	O
the	O
association	O
between	O
visual	O
impairment	O
from	O
cataract	O
and	O
poverty	O
among	O
adults	O
living	O
in	O
three	O
low	O
-	O
income	O
countries	O
.	O

What	O
Did	O
the	O
Researchers	O
Do	O
and	O
Find	O
?	O

The	O
researchers	O
identified	O
nearly	O
600	O
people	S-Species
aged	O
50	O
y	O
or	O
more	O
with	O
severe	O
cataract	O
-	O
induced	O
visual	O
impairment	O
(	O
"	O
cases	O
"	O
)	O
primarily	O
through	O
a	O
survey	O
of	O
the	O
population	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
.	O

They	O
matched	O
each	O
case	O
to	O
a	O
normally	O
sighted	O
(	O
"	O
control	O
"	O
)	O
person	S-Species
of	O
similar	O
age	O
and	O
sex	O
living	O
nearby	O
.	O

They	O
then	O
assessed	O
a	O
proxy	O
for	O
the	O
income	O
level	O
,	O
measured	O
as	O
"	O
per	O
capita	O
expenditure	O
"	O
(	O
PCE	O
)	O
,	O
of	O
all	O
the	O
study	O
participants	S-Species
(	O
people	S-Species
with	O
cataracts	O
and	O
controls	O
)	O
by	O
collecting	O
information	O
about	O
what	O
their	O
households	O
consumed	O
.	O

The	O
participants	S-Species
'	O
housing	O
conditions	O
and	O
other	O
assets	O
and	O
their	O
self	O
-	O
rated	O
wealth	O
were	O
also	O
measured	O
.	O

In	O
all	O
three	O
countries	O
,	O
cases	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quarter	O
(	O
quartile	O
)	O
of	O
the	O
range	O
of	O
PCEs	O
for	O
that	O
country	O
than	O
controls	O
.	O

In	O
the	O
Philippines	O
,	O
for	O
example	O
,	O
people	S-Species
with	O
cataract	O
-	O
affected	O
vision	O
were	O
three	O
times	O
more	O
likely	O
than	O
normally	O
sighted	O
controls	O
to	O
have	O
a	O
PCE	O
in	O
the	O
lowest	O
quartile	O
than	O
in	O
the	O
highest	O
quartile	O
.	O

The	O
risk	O
of	O
cataract	O
-	O
related	O
visual	O
impairment	O
increased	O
as	O
PCE	O
decreased	O
in	O
all	O
three	O
countries	O
.	O

Similarly	O
,	O
severe	O
cataract	O
-	O
induced	O
visual	O
impairment	O
was	O
more	O
common	O
in	O
those	O
who	O
owned	O
fewer	O
assets	O
and	O
those	O
with	O
lower	O
self	O
-	O
rated	O
wealth	O
.	O

However	O
,	O
there	O
was	O
no	O
consistent	O
association	O
between	O
PCE	O
and	O
the	O
level	O
of	O
cataract	O
-	O
induced	O
visual	O
impairment	O
.	O

What	O
Do	O
These	O
Findings	O
Mean	O
?	O

These	O
findings	O
show	O
that	O
there	O
is	O
an	O
association	O
between	O
visual	O
impairment	O
caused	O
by	O
cataract	O
and	O
poverty	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
.	O

However	O
,	O
because	O
the	O
financial	O
circumstances	O
of	O
the	O
people	S-Species
in	O
this	O
study	O
were	O
assessed	O
after	O
cataracts	O
had	O
impaired	O
their	O
sight	O
,	O
this	O
study	O
does	O
not	O
prove	O
that	O
poverty	O
is	O
a	O
cause	O
of	O
visual	O
impairment	O
.	O

A	O
causal	O
connection	O
between	O
poverty	O
and	O
cataract	O
can	O
only	O
be	O
shown	O
by	O
determining	O
the	O
PCEs	O
of	O
normally	O
sighted	O
people	S-Species
and	O
following	O
them	O
for	O
several	O
years	O
to	O
see	O
who	O
develops	O
cataract	O
.	O

Nevertheless	O
,	O
by	O
confirming	O
an	O
association	O
between	O
poverty	O
and	O
blindness	O
,	O
these	O
findings	O
highlight	O
the	O
need	O
for	O
increased	O
provision	O
of	O
cataract	O
surgery	O
to	O
poor	O
people	S-Species
,	O
particularly	O
since	O
cataract	O
surgery	O
has	O
the	O
potential	O
to	O
improve	O
the	O
quality	O
of	O
life	O
for	O
many	O
people	S-Species
in	O
developing	O
countries	O
at	O
a	O
relatively	O
low	O
cost	O
.	O

Additional	O
Information	O
.	O

Please	O
access	O
these	O
Web	O
sites	O
via	O
the	O
online	O
version	O
of	O
this	O
summary	O
at	O
http	O
:	O
/	O
/	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pmed	O
.	O
0050244	O
.	O

Introduction	O

Improvements	O
in	O
health	O
are	O
at	O
the	O
heart	O
of	O
the	O
Millennium	O
Development	O
Goals	O
,	O
with	O
the	O
recognition	O
that	O
better	O
health	O
is	O
central	O
to	O
the	O
primary	O
aim	O
of	O
reducing	O
poverty	O
as	O
well	O
as	O
important	O
in	O
its	O
own	O
right	O
.	O

Empirical	O
data	O
are	O
needed	O
to	O
back	O
up	O
this	O
claim	O
.	O

Unravelling	O
the	O
relationship	O
between	O
blindness	O
and	O
poverty	O
therefore	O
has	O
important	O
implications	O
,	O
and	O
may	O
also	O
be	O
informative	O
for	O
the	O
association	O
between	O
poverty	O
and	O
other	O
disabilities	O
.	O

Blindness	O
is	O
a	O
common	O
condition	O
globally	O
,	O
affecting	O
approximately	O
45	O
million	O
people	S-Species
,	O
and	O
more	O
than	O
a	O
third	O
of	O
blindness	O
is	O
caused	O
by	O
cataract	O
[	O
1	O
,	O
2	O
]	O
.	O

Globally	O
,	O
the	O
prevalence	O
of	O
blindness	O
is	O
five	O
-	O
fold	O
higher	O
in	O
poor	O
than	O
rich	O
countries	O
[	O
2	O
]	O
.	O

Limited	O
data	O
show	O
that	O
within	O
countries	O
the	O
poor	O
are	O
also	O
more	O
likely	O
to	O
be	O
blind	O
[	O
3	O
,	O
4	O
]	O
.	O

It	O
is	O
frequently	O
asserted	O
that	O
blindness	O
is	O
both	O
a	O
cause	O
and	O
consequence	O
of	O
poverty	O
,	O
but	O
there	O
are	O
few	O
empirical	O
data	O
to	O
support	O
this	O
claim	O
.	O

Poverty	O
may	O
cause	O
cataract	O
blindness	O
,	O
because	O
access	O
to	O
cataract	O
surgery	O
is	O
limited	O
in	O
low	O
-	O
income	O
countries	O
[	O
5	O
]	O
.	O

Furthermore	O
,	O
within	O
poor	O
countries	O
some	O
evidence	O
suggests	O
that	O
lack	O
of	O
money	O
is	O
a	O
major	O
barrier	O
to	O
uptake	O
of	O
cataract	O
surgery	O
by	O
individuals	O
[	O
6	O
-	O
8	O
]	O
.	O

Blindness	O
may	O
also	O
cause	O
poverty	O
,	O
as	O
the	O
blind	O
individual	O
,	O
or	O
the	O
household	O
members	O
who	O
care	O
for	O
them	O
,	O
have	O
a	O
reduced	O
earning	O
potential	O
[	O
4	O
,	O
9	O
]	O
.	O

This	O
complex	O
problem	O
could	O
have	O
serious	O
implications	O
;	O
estimates	O
from	O
The	O
Gambia	O
suggest	O
that	O
there	O
is	O
a	O
substantial	O
economic	O
burden	O
from	O
lost	O
productivity	O
among	O
blind	O
people	S-Species
[	O
10	O
]	O
.	O

Therefore	O
,	O
blindness	O
prevention	O
may	O
ultimately	O
be	O
cost	O
saving	O
[	O
11	O
]	O
.	O

Extrapolations	O
on	O
a	O
global	O
level	O
indicate	O
that	O
a	O
successful	O
eye	O
care	O
programme	O
could	O
prevent	O
more	O
than	O
100	O
million	O
cases	O
of	O
blindness	O
between	O
2000	O
and	O
2020	O
,	O
and	O
consequently	O
save	O
at	O
least	O
US	O
$	O
102	O
billion	O
,	O
which	O
would	O
otherwise	O
be	O
lost	O
to	O
reductions	O
in	O
productivity	O
associated	O
with	O
blindness	O
[	O
12	O
]	O
.	O

However	O
,	O
these	O
estimates	O
are	O
based	O
on	O
extrapolations	O
from	O
limited	O
data	O
and	O
were	O
not	O
based	O
on	O
individual	O
-	O
level	O
data	O
.	O

It	O
is	O
also	O
difficult	O
to	O
identify	O
the	O
component	O
of	O
productivity	O
loss	O
that	O
is	O
due	O
to	O
blindness	O
,	O
as	O
this	O
condition	O
mainly	O
affects	O
older	O
people	S-Species
,	O
who	O
may	O
suffer	O
from	O
other	O
comorbidities	O
that	O
restrict	O
their	O
employment	O
opportunities	O
or	O
make	O
them	O
dependent	O
on	O
the	O
care	O
of	O
others	O
.	O

The	O
Cataract	O
Impact	O
Study	O
was	O
undertaken	O
to	O
assess	O
the	O
relationship	O
between	O
cataract	O
visual	O
impairment	O
and	O
"	O
economic	O
poverty	O
"	O
and	O
quality	O
of	O
life	O
,	O
and	O
to	O
estimate	O
the	O
impact	O
of	O
cataract	O
surgery	O
on	O
these	O
factors	O
in	O
three	O
low	O
-	O
income	O
countries	O
.	O

The	O
aim	O
of	O
the	O
current	O
paper	O
is	O
to	O
assess	O
the	O
association	O
at	O
baseline	O
between	O
visual	O
impairment	O
from	O
cataract	O
and	O
household	O
poverty	O
(	O
measured	O
through	O
consumption	O
,	O
asset	O
ownership	O
,	O
and	O
self	O
-	O
rated	O
wealth	O
)	O
in	O
a	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
in	O
Kenya	O
,	O
the	O
Philippines	O
,	O
and	O
Bangladesh	O
.	O

Methods	O

Setting	O

Case	O
and	O
control	O
participants	S-Species
were	O
recruited	O
from	O
Nakuru	O
district	O
,	O
Kenya	O
(	O
January	O
-	O
February	O
,	O
2005	O
)	O
;	O
Negros	O
island	O
(	O
May	O
-	O
June	O
,	O
2005	O
)	O
and	O
Antique	O
district	O
(	O
April	O
-	O
May	O
,	O
2006	O
)	O
,	O
Philippines	O
;	O
and	O
Satkhira	O
district	O
,	O
Bangladesh	O
(	O
November	O
-	O
December	O
,	O
2005	O
)	O
.	O

Selection	O
of	O
Cases	O
and	O
Controls	O

Persons	S-Species
with	O
cataract	O
visual	O
impairment	O
(	O
cases	O
)	O
and	O
persons	S-Species
without	O
(	O
controls	O
)	O
were	O
primarily	O
recruited	O
through	O
a	O
population	O
-	O
based	O
survey	O
of	O
adults	O
aged	O
>=	O
50	O
y	O
[	O
6	O
-	O
8	O
]	O
.	O

Clusters	O
of	O
50	O
people	S-Species
(	O
regardless	O
of	O
visual	O
impairment	O
)	O
aged	O
>=	O
50	O
y	O
were	O
selected	O
through	O
probability	O
-	O
proportionate	O
to	O
size	O
sampling	O
,	O
using	O
either	O
the	O
census	O
(	O
Philippines	O
and	O
Bangladesh	O
)	O
or	O
electoral	O
role	O
(	O
Kenya	O
)	O
as	O
the	O
sampling	O
frame	O
.	O

Households	O
within	O
clusters	O
were	O
selected	O
through	O
a	O
modification	O
of	O
compact	O
segment	O
sampling	O
,	O
whereby	O
a	O
map	O
was	O
drawn	O
of	O
the	O
enumeration	O
area	O
that	O
was	O
divided	O
into	O
segments	O
,	O
each	O
including	O
approximately	O
50	O
people	S-Species
aged	O
>=	O
50	O
y	O
,	O
and	O
one	O
segment	O
was	O
chosen	O
at	O
random	O
[	O
13	O
]	O
.	O

Households	O
in	O
the	O
segment	O
were	O
included	O
sequentially	O
until	O
50	O
people	S-Species
aged	O
>=	O
50	O
y	O
were	O
identified	O
.	O

The	O
surveys	O
included	O
3	O
,	O
503	O
(	O
93	O
%	O
response	O
rate	O
)	O
people	S-Species
aged	O
>=	O
50	O
y	O
in	O
Kenya	O
,	O
4	O
,	O
868	O
(	O
92	O
%	O
)	O
in	O
Bangladesh	O
,	O
2	O
,	O
774	O
(	O
76	O
%	O
)	O
in	O
Negros	O
,	O
and	O
3	O
,	O
177	O
(	O
83	O
%	O
)	O
in	O
Antique	O
.	O

All	O
people	S-Species
in	O
the	O
survey	O
aged	O
>=	O
50	O
y	O
underwent	O
visual	O
acuity	O
(	O
VA	O
)	O
testing	O
and	O
ophthalmic	O
examination	O
.	O

VA	O
was	O
measured	O
in	O
full	O
daylight	O
with	O
available	O
spectacle	O
correction	O
with	O
a	O
Snellen	O
tumbling	O
"	O
E	O
"	O
chart	O
using	O
optotype	O
size	O
6	O
/	O
18	O
(	O
20	O
/	O
60	O
)	O
on	O
one	O
side	O
and	O
size	O
6	O
/	O
60	O
(	O
20	O
/	O
200	O
)	O
on	O
the	O
other	O
side	O
at	O
6	O
or	O
3	O
metres	O
.	O

If	O
the	O
VA	O
was	O
<	O
6	O
/	O
18	O
in	O
either	O
eye	O
then	O
pinhole	O
vision	O
was	O
also	O
measured	O
.	O

Participants	S-Species
with	O
pinhole	O
vision	O
<	O
6	O
/	O
18	O
but	O
>	O
6	O
/	O
60	O
in	O
the	O
better	O
eye	O
due	O
to	O
age	O
-	O
related	O
cataract	O
were	O
given	O
a	O
second	O
VA	O
test	O
using	O
an	O
"	O
E	O
"	O
of	O
size	O
6	O
/	O
24	O
.	O

The	O
ophthalmologist	O
examined	O
all	O
eyes	O
with	O
a	O
presenting	O
VA	O
<	O
6	O
/	O
18	O
with	O
a	O
torch	O
(	O
i	O
.	O
e	O
.	O
,	O
flashlight	O
)	O
,	O
direct	O
ophthalmoscope	O
,	O
and	O
/	O
or	O
portable	O
slit	O
lamp	O
.	O

The	O
principal	O
cause	O
of	O
blindness	O
or	O
visual	O
impairment	O
was	O
recorded	O
,	O
according	O
to	O
the	O
WHO	O
convention	O
in	O
which	O
the	O
major	O
cause	O
is	O
assigned	O
to	O
the	O
primary	O
disorder	O
or	O
,	O
if	O
there	O
are	O
two	O
existing	O
primary	O
disorders	O
,	O
to	O
the	O
one	O
that	O
is	O
easiest	O
to	O
treat	O
[	O
14	O
]	O
.	O

Survey	O
participants	S-Species
were	O
eligible	O
for	O
inclusion	O
as	O
cases	O
if	O
they	O
were	O
aged	O
>=	O
50	O
y	O
with	O
best	O
corrected	O
visual	O
acuity	O
<	O
6	O
/	O
24	O
in	O
the	O
better	O
eye	O
due	O
to	O
cataract	O
,	O
as	O
diagnosed	O
by	O
an	O
ophthalmologist	O
.	O

All	O
eligible	O
cases	O
identified	O
from	O
these	O
surveys	O
were	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Participants	S-Species
were	O
eligible	O
to	O
be	O
controls	O
if	O
they	O
were	O
aged	O
>=	O
50	O
y	O
,	O
did	O
not	O
have	O
VA	O
<	O
6	O
/	O
24	O
in	O
the	O
better	O
eye	O
due	O
to	O
cataract	O
and	O
did	O
not	O
live	O
in	O
the	O
same	O
household	O
as	O
a	O
case	O
.	O

During	O
the	O
survey	O
a	O
list	O
was	O
maintained	O
of	O
all	O
eligible	O
controls	O
,	O
by	O
age	O
group	O
(	O
50	O
-	O
54	O
,	O
55	O
-	O
59	O
,	O
60	O
-	O
64	O
,	O
65	O
-	O
69	O
,	O
and	O
>	O
70	O
)	O
and	O
sex	O
.	O

Whenever	O
a	O
case	O
was	O
identified	O
,	O
one	O
age	O
-	O
and	O
sex	O
-	O
matched	O
control	O
was	O
randomly	O
selected	O
from	O
the	O
list	O
for	O
inclusion	O
(	O
or	O
up	O
to	O
two	O
controls	O
in	O
Bangladesh	O
)	O
.	O

If	O
no	O
matching	O
eligible	O
controls	O
had	O
been	O
identified	O
in	O
that	O
cluster	O
at	O
that	O
stage	O
of	O
the	O
survey	O
,	O
then	O
the	O
next	O
eligible	O
control	O
in	O
the	O
cluster	O
was	O
recruited	O
.	O

Because	O
of	O
logistical	O
and	O
time	O
constraints	O
,	O
additional	O
cases	O
were	O
also	O
included	O
through	O
community	O
-	O
based	O
case	O
detection	O
.	O

In	O
Kenya	O
and	O
Negros	O
(	O
Philippines	O
)	O
,	O
clusters	O
were	O
randomly	O
selected	O
through	O
probability	O
proportionate	O
to	O
size	O
using	O
the	O
same	O
cluster	O
sampling	O
procedure	O
after	O
completion	O
of	O
the	O
population	O
-	O
based	O
survey	O
.	O

Clusters	O
were	O
visited	O
in	O
advance	O
and	O
asked	O
that	O
all	O
people	S-Species
>=	O
50	O
y	O
with	O
vision	O
problems	O
come	O
to	O
a	O
central	O
point	O
on	O
a	O
specified	O
day	O
,	O
and	O
that	O
a	O
list	O
be	O
made	O
of	O
people	S-Species
unable	O
to	O
attend	O
(	O
e	O
.	O
g	O
.	O
,	O
due	O
to	O
blindness	O
or	O
other	O
physical	O
disability	O
)	O
.	O

After	O
examining	O
patients	S-Species
at	O
the	O
central	O
point	O
,	O
the	O
survey	O
team	O
then	O
visited	O
those	O
unable	O
to	O
leave	O
their	O
houses	O
.	O

Any	O
identified	O
eligible	O
cases	O
that	O
agreed	O
to	O
be	O
part	O
of	O
the	O
study	O
were	O
interviewed	O
in	O
their	O
homes	O
.	O

In	O
Bangladesh	O
and	O
Antique	O
(	O
Philippines	O
)	O
,	O
community	O
case	O
detection	O
was	O
carried	O
out	O
simultaneously	O
with	O
the	O
survey	O
by	O
two	O
of	O
the	O
four	O
teams	O
,	O
so	O
that	O
controls	O
were	O
included	O
for	O
these	O
cases	O
.	O

Within	O
each	O
cluster	O
from	O
the	O
survey	O
,	O
one	O
interviewer	O
was	O
asked	O
to	O
be	O
taken	O
to	O
two	O
community	O
members	O
aged	O
>=	O
50	O
y	O
with	O
eye	O
problems	O
,	O
living	O
within	O
the	O
cluster	O
boundaries	O
but	O
not	O
from	O
the	O
segments	O
selected	O
for	O
the	O
survey	O
.	O

If	O
VA	O
was	O
<	O
6	O
/	O
24	O
with	O
pinhole	O
in	O
the	O
better	O
eye	O
,	O
the	O
ophthalmologist	O
was	O
called	O
to	O
carry	O
out	O
the	O
full	O
eye	O
examination	O
,	O
and	O
eligible	O
cases	O
were	O
included	O
in	O
the	O
study	O
.	O

For	O
the	O
purposes	O
of	O
the	O
present	O
analyses	O
,	O
control	O
individuals	O
with	O
any	O
visual	O
impairment	O
(	O
VA	O
<	O
6	O
/	O
18	O
in	O
the	O
better	O
eye	O
)	O
were	O
excluded	O
(	O
n	O
=	O
14	O
in	O
Kenya	O
,	O
n	O
=	O
53	O
in	O
Bangladesh	O
,	O
n	O
=	O
24	O
in	O
the	O
Philippines	O
)	O
.	O

Case	O
and	O
control	O
participants	S-Species
who	O
were	O
significantly	O
communication	O
impaired	O
(	O
e	O
.	O
g	O
.	O
deafness	O
,	O
dementia	O
,	O
or	O
psychiatric	O
disease	O
)	O
were	O
excluded	O
(	O
fewer	O
than	O
five	O
per	O
country	O
)	O
,	O
and	O
one	O
case	O
was	O
excluded	O
in	O
the	O
Philippines	O
because	O
of	O
missing	O
age	O
data	O
.	O

One	O
household	O
had	O
two	O
eligible	O
cases	O
(	O
Kenya	O
)	O
,	O
and	O
one	O
of	O
these	O
participants	S-Species
was	O
excluded	O
for	O
the	O
poverty	O
analyses	O
as	O
poverty	O
was	O
assessed	O
through	O
household	O
level	O
indicators	O
(	O
see	O
below	O
)	O
.	O

In	O
total	O
,	O
147	O
cases	O
(	O
82	O
from	O
the	O
survey	O
and	O
65	O
from	O
case	O
detection	O
)	O
and	O
79	O
controls	O
were	O
included	O
in	O
Kenya	O
;	O
217	O
cases	O
(	O
162	O
from	O
survey	O
and	O
55	O
from	O
case	O
detection	O
)	O
and	O
280	O
controls	O
in	O
Bangladesh	O
;	O
and	O
238	O
cases	O
(	O
146	O
survey	O
and	O
92	O
case	O
detection	O
)	O
and	O
180	O
controls	O
in	O
the	O
Philippines	O
.	O

Data	O
Collection	O

All	O
case	O
and	O
control	O
participants	S-Species
were	O
interviewed	O
in	O
their	O
homes	O
by	O
trained	O
interviewers	O
in	O
the	O
local	O
language	O
.	O

Each	O
interview	O
lasted	O
approximately	O
1	O
h	O
.	O

Measures	O
of	O
poverty	O
.	O

Poverty	O
was	O
measured	O
through	O
(	O
a	O
)	O
monthly	O
per	O
capita	O
expenditure	O
(	O
PCE	O
)	O
to	O
indicate	O
consumption	O
,	O
(	O
b	O
)	O
asset	O
ownership	O
,	O
and	O
(	O
c	O
)	O
self	O
-	O
rated	O
wealth	O
.	O

The	O
economic	O
part	O
of	O
the	O
questionnaires	O
was	O
adapted	O
through	O
interviews	O
,	O
focus	O
group	O
discussions	O
,	O
and	O
pilot	O
testing	O
in	O
each	O
country	O
to	O
ensure	O
local	O
relevance	O
.	O

The	O
person	S-Species
primarily	O
responsible	O
for	O
household	O
finances	O
(	O
which	O
may	O
have	O
been	O
the	O
case	O
/	O
control	O
or	O
another	O
household	O
member	O
)	O
was	O
interviewed	O
to	O
assess	O
PCE	O
and	O
assets	O
.	O

PCE	O
was	O
measured	O
using	O
methods	O
based	O
on	O
the	O
World	O
Bank	O
'	O
s	O
Living	O
Standards	O
Measurement	O
Study	O
[	O
15	O
]	O
.	O

Items	O
were	O
included	O
on	O
food	O
(	O
42	O
-	O
52	O
items	O
per	O
country	O
)	O
,	O
education	O
(	O
three	O
items	O
)	O
,	O
health	O
(	O
five	O
items	O
)	O
,	O
household	O
expenses	O
(	O
nine	O
items	O
)	O
,	O
and	O
personal	O
expenses	O
(	O
21	O
or	O
22	O
items	O
)	O
.	O

In	O
total	O
,	O
85	O
items	O
were	O
included	O
in	O
the	O
questionnaire	O
in	O
Kenya	O
,	O
90	O
in	O
the	O
Philippines	O
,	O
and	O
79	O
in	O
Bangladesh	O
.	O

The	O
informant	O
was	O
asked	O
to	O
recall	O
the	O
monetary	O
value	O
of	O
food	O
that	O
was	O
purchased	O
,	O
consumed	O
from	O
home	O
production	O
,	O
or	O
received	O
as	O
payment	O
in	O
kind	O
or	O
as	O
gifts	O
.	O

Consumption	O
was	O
assessed	O
over	O
a	O
1	O
-	O
wk	O
period	O
for	O
frequently	O
consumed	O
items	O
,	O
and	O
this	O
was	O
scaled	O
up	O
to	O
estimate	O
monthly	O
consumption	O
.	O

The	O
amount	O
consumed	O
monthly	O
was	O
assessed	O
for	O
items	O
that	O
were	O
consumed	O
more	O
rarely	O
.	O

Monthly	O
rent	O
was	O
recorded	O
among	O
households	O
who	O
rented	O
,	O
and	O
households	O
who	O
owned	O
their	O
property	O
were	O
asked	O
to	O
estimate	O
the	O
amount	O
that	O
they	O
could	O
charge	O
in	O
rent	O
per	O
month	O
.	O

The	O
consumption	O
on	O
all	O
items	O
was	O
summed	O
to	O
calculate	O
total	O
monthly	O
household	O
consumption	O
,	O
and	O
this	O
was	O
converted	O
to	O
United	O
States	O
dollars	O
(	O
US	O
$	O
)	O
at	O
the	O
2005	O
exchange	O
rate	O
(	O
$	O
1	O
=	O
76	O
Kenya	O
shillings	O
,	O
64	O
Bangladesh	O
taka	O
,	O
55	O
Philippine	O
pesos	O
)	O
.	O

Total	O
monthly	O
household	O
consumption	O
was	O
divided	O
by	O
the	O
number	O
of	O
household	O
members	O
to	O
calculate	O
monthly	O
PCE	O
for	O
the	O
household	O
.	O

The	O
household	O
informant	O
was	O
also	O
asked	O
about	O
the	O
number	O
and	O
type	O
of	O
context	O
-	O
specific	O
assets	O
owned	O
by	O
the	O
household	O
,	O
including	O
different	O
types	O
of	O
furniture	O
,	O
electrical	O
equipment	O
,	O
cattle	S-Species
,	O
and	O
vehicles	O
.	O

Information	O
was	O
collected	O
on	O
household	O
characteristics	O
,	O
including	O
the	O
building	O
material	O
of	O
the	O
floor	O
,	O
roof	O
,	O
and	O
walls	O
;	O
type	O
of	O
toilet	O
;	O
and	O
the	O
number	O
of	O
rooms	O
.	O

Self	O
-	O
rated	O
wealth	O
was	O
assessed	O
by	O
asking	O
the	O
household	O
informant	O
to	O
rank	O
the	O
household	O
'	O
s	O
wealth	O
relative	O
to	O
others	O
in	O
the	O
community	O
on	O
a	O
scale	O
from	O
1	O
(	O
poorest	O
)	O
to	O
10	O
(	O
richest	O
)	O
.	O

Covariates	O
.	O

Case	O
and	O
control	O
individuals	O
were	O
interviewed	O
about	O
standard	O
sociodemographic	O
indicators	O
,	O
including	O
household	O
composition	O
,	O
education	O
,	O
and	O
employment	O
.	O

Information	O
was	O
collected	O
on	O
vision	O
-	O
related	O
quality	O
of	O
life	O
using	O
the	O
World	O
Health	O
Organization	O
Prevention	O
of	O
Blindness	O
and	O
Deafness	O
20	O
-	O
item	O
Visual	O
Functioning	O
Questionnaire	O
[	O
16	O
,	O
17	O
]	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
items	O
from	O
the	O
European	O
Quality	O
of	O
Life	O
Questionnaire	O
[	O
18	O
]	O
.	O

Detailed	O
time	O
-	O
use	O
data	O
were	O
collected	O
using	O
methods	O
based	O
on	O
the	O
World	O
Bank	O
'	O
s	O
Living	O
Standards	O
Measurement	O
Study	O
[	O
15	O
]	O
.	O

Training	O
and	O
Fieldwork	O

Interviewers	O
were	O
trained	O
for	O
1	O
wk	O
,	O
including	O
2	O
d	O
of	O
pilot	O
testing	O
.	O

Attempts	O
were	O
made	O
to	O
minimise	O
measurement	O
bias	O
by	O
emphasising	O
the	O
need	O
for	O
consistency	O
in	O
data	O
collection	O
among	O
cases	O
and	O
controls	O
.	O

The	O
questionnaires	O
were	O
translated	O
into	O
the	O
local	O
languages	O
(	O
three	O
in	O
Kenya	O
,	O
three	O
in	O
the	O
Philippines	O
,	O
and	O
one	O
in	O
Bangladesh	O
)	O
and	O
back	O
-	O
translated	O
by	O
independent	O
translators	O
(	O
one	O
for	O
each	O
language	O
)	O
who	O
were	O
also	O
asked	O
to	O
comment	O
on	O
appropriateness	O
of	O
language	O
used	O
for	O
the	O
target	O
population	O
.	O

A	O
review	O
was	O
held	O
to	O
discuss	O
differences	O
in	O
translation	O
and	O
modify	O
accordingly	O
.	O

The	O
questionnaire	O
was	O
piloted	O
in	O
each	O
setting	O
and	O
small	O
modifications	O
to	O
wording	O
of	O
some	O
items	O
were	O
made	O
,	O
where	O
appropriate	O
,	O
to	O
ensure	O
local	O
understanding	O
.	O

Teams	O
were	O
accompanied	O
by	O
a	O
field	O
supervisor	O
at	O
least	O
1	O
d	O
per	O
wk	O
to	O
ensure	O
that	O
high	O
quality	O
was	O
maintained	O
and	O
interviews	O
were	O
observed	O
randomly	O
throughout	O
the	O
study	O
.	O

Statistical	O
Analysis	O

Microsoft	O
Access	O
was	O
used	O
for	O
data	O
entry	O
,	O
and	O
all	O
data	O
were	O
double	O
entered	O
and	O
validated	O
.	O

Analyses	O
were	O
undertaken	O
in	O
SAS	O
version	O
8	O
.	O
2	O
.	O

The	O
mean	O
and	O
range	O
of	O
each	O
expenditure	O
item	O
was	O
calculated	O
to	O
assess	O
whether	O
answers	O
were	O
plausible	O
,	O
and	O
to	O
identify	O
and	O
exclude	O
gross	O
outliers	O
(	O
none	O
identified	O
)	O
.	O

Rental	O
equivalents	O
were	O
imputed	O
based	O
on	O
household	O
characteristics	O
and	O
non	O
-	O
rent	O
expenditure	O
for	O
households	O
where	O
these	O
estimates	O
were	O
missing	O
or	O
unreasonably	O
low	O
(	O
<	O
$	O
1	O
per	O
mo	O
)	O
(	O
four	O
in	O
Kenya	O
,	O
three	O
in	O
Bangladesh	O
,	O
18	O
in	O
the	O
Philippines	O
)	O
.	O

Total	O
monthly	O
household	O
consumption	O
was	O
divided	O
by	O
the	O
number	O
of	O
household	O
members	O
to	O
calculate	O
per	O
capita	O
household	O
expenditure	O
.	O

Per	O
capita	O
household	O
expenditure	O
was	O
divided	O
into	O
quartiles	O
,	O
separately	O
for	O
each	O
country	O
,	O
based	O
on	O
the	O
distribution	O
of	O
the	O
data	O
for	O
the	O
case	O
and	O
control	O
participants	S-Species
combined	O
.	O

Households	O
with	O
incomplete	O
expenditure	O
data	O
were	O
excluded	O
from	O
analyses	O
(	O
five	O
cases	O
and	O
four	O
controls	O
in	O
Kenya	O
;	O
one	O
case	O
and	O
one	O
control	O
in	O
Bangladesh	O
)	O
.	O

A	O
relative	O
index	O
of	O
household	O
assets	O
was	O
derived	O
using	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
to	O
determine	O
weights	O
for	O
a	O
list	O
of	O
assets	O
and	O
wealth	O
indicators	O
[	O
19	O
]	O
.	O

Variables	O
entered	O
into	O
the	O
PCA	O
included	O
building	O
materials	O
of	O
the	O
house	O
,	O
ownership	O
of	O
ten	O
household	O
assets	O
,	O
animal	O
ownership	O
,	O
and	O
education	O
of	O
the	O
head	O
of	O
the	O
household	O
.	O

The	O
derived	O
index	O
was	O
divided	O
into	O
quartiles	O
from	O
poorest	O
(	O
lowest	O
socioeconomic	O
status	O
[	O
SES	O
]	O
index	O
)	O
to	O
least	O
poor	O
(	O
highest	O
SES	O
index	O
)	O
.	O

PCA	O
analyses	O
were	O
undertaken	O
separately	O
for	O
each	O
country	O
.	O

The	O
means	O
of	O
the	O
poverty	O
variables	O
were	O
first	O
compared	O
for	O
cases	O
recruited	O
through	O
the	O
two	O
different	O
methods	O
,	O
and	O
then	O
from	O
cases	O
and	O
controls	O
using	O
t	O
-	O
tests	O
for	O
continuous	O
variables	O
(	O
e	O
.	O
g	O
.	O
,	O
PCE	O
and	O
assets	O
)	O
.	O

For	O
categorical	O
variables	O
(	O
e	O
.	O
g	O
.	O
,	O
household	O
rank	O
)	O
we	O
used	O
the	O
Mann	O
-	O
Whitney	O
test	O
and	O
presented	O
medians	O
and	O
interquartile	O
ranges	O
.	O

PCE	O
was	O
highly	O
skewed	O
and	O
therefore	O
was	O
log	O
transformed	O
for	O
the	O
t	O
-	O
tests	O
.	O

The	O
two	O
-	O
way	O
correlations	O
were	O
calculated	O
between	O
PCE	O
,	O
assets	O
,	O
and	O
household	O
rank	O
,	O
in	O
turn	O
.	O

Logistic	O
regression	O
analyses	O
were	O
undertaken	O
separately	O
for	O
each	O
country	O
,	O
assessing	O
the	O
association	O
between	O
case	O
/	O
control	O
status	O
and	O
sociodemographic	O
and	O
poverty	O
variables	O
.	O

Conditional	O
logistic	O
regression	O
was	O
not	O
undertaken	O
,	O
since	O
the	O
matching	O
was	O
incomplete	O
,	O
so	O
all	O
analyses	O
were	O
adjusted	O
for	O
the	O
matching	O
variables	O
(	O
age	O
,	O
sex	O
,	O
and	O
rural	O
/	O
urban	O
location	O
)	O
.	O

Likelihood	O
ratio	O
tests	O
were	O
undertaken	O
to	O
assess	O
the	O
significance	O
of	O
adding	O
covariates	O
with	O
more	O
than	O
two	O
levels	O
(	O
e	O
.	O
g	O
.	O
,	O
age	O
groups	O
,	O
self	O
-	O
rated	O
health	O
groups	O
)	O
to	O
the	O
model	O
.	O

Tests	O
for	O
trend	O
were	O
undertaken	O
across	O
quartiles	O
of	O
the	O
poverty	O
variables	O
and	O
assessed	O
using	O
the	O
p	O
-	O
value	O
for	O
trend	O
.	O

Analyses	O
were	O
also	O
conducted	O
adjusting	O
for	O
the	O
logistic	O
regression	O
analyses	O
for	O
poverty	O
by	O
social	O
support	O
indicators	O
(	O
marital	O
status	O
and	O
household	O
size	O
)	O
and	O
self	O
-	O
rated	O
health	O
,	O
since	O
these	O
variables	O
may	O
confound	O
the	O
association	O
between	O
cataract	O
visual	O
impairment	O
and	O
poverty	O
.	O

Analyses	O
from	O
the	O
Philippines	O
were	O
also	O
adjusted	O
for	O
study	O
site	O
,	O
since	O
data	O
were	O
obtained	O
from	O
two	O
settings	O
(	O
Negros	O
and	O
Antique	O
)	O
.	O

An	O
attempt	O
was	O
made	O
to	O
disentangle	O
the	O
relationship	O
between	O
poverty	O
and	O
cataract	O
by	O
stratifying	O
the	O
analyses	O
by	O
age	O
,	O
sex	O
,	O
and	O
level	O
of	O
visual	O
impairment	O
among	O
the	O
cases	O
.	O

Ethical	O
Approval	O

Informed	O
signed	O
or	O
thumb	O
-	O
printed	O
consent	O
was	O
obtained	O
from	O
all	O
cases	O
and	O
controls	O
.	O

In	O
Kenya	O
and	O
Bangladesh	O
all	O
cases	O
were	O
offered	O
free	O
cataract	O
surgery	O
at	O
the	O
local	O
hospital	O
,	O
with	O
free	O
transport	O
.	O

In	O
the	O
Philippines	O
,	O
patients	S-Species
were	O
referred	O
for	O
surgery	O
,	O
which	O
was	O
subsidised	O
for	O
patients	S-Species
who	O
could	O
not	O
afford	O
the	O
fee	O
.	O

Ethical	O
approval	O
for	O
this	O
study	O
was	O
obtained	O
from	O
the	O
ethics	O
committees	O
of	O
the	O
London	O
School	O
of	O
Hygiene	O
&	O
Tropical	O
Medicine	O
,	O
the	O
Kenya	O
Medical	O
Research	O
Institute	O
,	O
the	O
Bangladesh	O
Medical	O
Research	O
Council	O
,	O
and	O
the	O
University	O
of	O
St	O
.	O

La	O
Salle	O
,	O
Bacolod	O
,	O
Philippines	O
.	O

This	O
study	O
complied	O
with	O
the	O
guidelines	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Results	O

Sociodemographic	O
Characteristics	O
of	O
Cases	O
and	O
Controls	O

Case	O
and	O
control	O
participants	S-Species
were	O
matched	O
reasonably	O
closely	O
by	O
sex	O
and	O
location	O
.	O

However	O
,	O
within	O
the	O
age	O
category	O
>=	O
70	O
y	O
,	O
cases	O
tended	O
to	O
be	O
older	O
than	O
the	O
controls	O
,	O
so	O
that	O
cases	O
were	O
over	O
-	O
represented	O
in	O
the	O
oldest	O
age	O
groups	O
(	O
75	O
-	O
79	O
and	O
>=	O
80	O
y	O
)	O
compared	O
to	O
controls	O
(	O
Table	O
1	O
)	O
.	O

Cases	O
were	O
less	O
likely	O
to	O
be	O
married	O
than	O
controls	O
,	O
in	O
Kenya	O
(	O
OR	O
0	O
.	O
6	O
,	O
95	O
%	O
CI	O
0	O
.	O
3	O
-	O
1	O
.	O
1	O
)	O
,	O
Bangladesh	O
(	O
0	O
.	O
6	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
0	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
0	O
.	O
7	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
0	O
)	O
,	O
although	O
this	O
only	O
reached	O
statistical	O
significance	O
in	O
Bangladesh	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

There	O
was	O
a	O
strong	O
protective	O
effect	O
of	O
literacy	O
and	O
education	O
on	O
cataract	O
in	O
Bangladesh	O
and	O
Kenya	O
that	O
was	O
not	O
evident	O
in	O
the	O
Philippines	O
.	O

Cases	O
were	O
substantially	O
less	O
likely	O
to	O
have	O
a	O
job	O
other	O
than	O
working	O
in	O
the	O
field	O
compared	O
to	O
controls	O
in	O
all	O
three	O
countries	O
.	O

Cases	O
reported	O
significantly	O
poorer	O
self	O
-	O
rated	O
health	O
than	O
controls	O
--	O
this	O
pattern	O
was	O
particularly	O
evident	O
in	O
the	O
Philippines	O
(	O
OR	O
for	O
lowest	O
versus	O
highest	O
quartile	O
of	O
self	O
-	O
rated	O
health	O
=	O
5	O
.	O
7	O
,	O
95	O
%	O
CI	O
3	O
.	O
0	O
-	O
10	O
.	O
7	O
)	O
but	O
also	O
apparent	O
in	O
Kenya	O
(	O
2	O
.	O
6	O
,	O
1	O
.	O
1	O
-	O
6	O
.	O
2	O
)	O
and	O
Bangladesh	O
(	O
3	O
.	O
3	O
,	O
2	O
.	O
1	O
-	O
5	O
.	O
3	O
)	O
.	O

Summary	O
Wealth	O
Measures	O

All	O
three	O
settings	O
were	O
poor	O
.	O

The	O
mean	O
PCE	O
was	O
less	O
than	O
US	O
$	O
1	O
per	O
person	S-Species
per	O
day	O
in	O
all	O
three	O
settings	O
:	O
US	O
$	O
26	O
.	O
4	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
=	O
US	O
$	O
34	O
.	O
9	O
)	O
in	O
Kenya	O
,	O
US	O
$	O
21	O
.	O
7	O
(	O
US	O
$	O
48	O
.	O
0	O
)	O
in	O
Bangladesh	O
and	O
US	O
$	O
26	O
.	O
1	O
(	O
US	O
$	O
23	O
.	O
5	O
)	O
in	O
the	O
Philippines	O
.	O

The	O
biggest	O
expense	O
was	O
food	O
in	O
all	O
three	O
settings	O
,	O
making	O
up	O
55	O
%	O
of	O
PCE	O
in	O
Kenya	O
,	O
47	O
%	O
in	O
Bangladesh	O
,	O
and	O
64	O
%	O
in	O
the	O
Philippines	O
,	O
followed	O
by	O
household	O
expenses	O
including	O
rent	O
(	O
21	O
%	O
in	O
Kenya	O
,	O
28	O
%	O
Bangladesh	O
,	O
and	O
22	O
%	O
Philippines	O
)	O
(	O
Figure	O
1	O
)	O
.	O

The	O
majority	O
of	O
food	O
consumption	O
was	O
from	O
direct	O
purchase	O
(	O
70	O
%	O
in	O
Kenya	O
,	O
75	O
%	O
in	O
Bangladesh	O
,	O
and	O
77	O
%	O
in	O
the	O
Philippines	O
)	O
or	O
home	O
-	O
grown	O
production	O
(	O
24	O
%	O
in	O
Kenya	O
,	O
22	O
%	O
in	O
Bangladesh	O
,	O
and	O
17	O
%	O
in	O
the	O
Philippines	O
)	O
,	O
and	O
little	O
was	O
from	O
gifts	O
or	O
payments	O
.	O

An	O
asset	O
score	O
was	O
created	O
through	O
PCA	O
in	O
the	O
three	O
settings	O
.	O

The	O
first	O
principal	O
component	O
explained	O
22	O
%	O
of	O
the	O
variability	O
in	O
asset	O
variables	O
in	O
Kenya	O
,	O
25	O
%	O
in	O
Bangladesh	O
,	O
and	O
24	O
%	O
in	O
the	O
Philippines	O
.	O

Self	O
-	O
perceived	O
wealth	O
of	O
the	O
household	O
clustered	O
around	O
the	O
average	O
with	O
a	O
large	O
proportion	O
of	O
households	O
in	O
Kenya	O
(	O
48	O
%	O
)	O
,	O
Bangladesh	O
(	O
43	O
%	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
64	O
%	O
)	O
;	O
households	O
stating	O
that	O
they	O
were	O
ranked	O
between	O
4	O
and	O
6	O
,	O
on	O
a	O
scale	O
from	O
1	O
to	O
10	O
,	O
in	O
terms	O
of	O
wealth	O
in	O
their	O
community	O
.	O

The	O
three	O
measures	O
of	O
poverty	O
were	O
highly	O
correlated	O
,	O
each	O
showing	O
significant	O
correlation	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
with	O
the	O
other	O
measure	O
.	O

Economic	O
and	O
Household	O
Characteristics	O
of	O
Cases	O
and	O
Controls	O

There	O
were	O
no	O
significant	O
differences	O
in	O
PCE	O
,	O
assets	O
,	O
or	O
household	O
rank	O
between	O
cases	O
recruited	O
through	O
the	O
population	O
-	O
based	O
survey	O
and	O
those	O
recruited	O
through	O
case	O
detection	O
,	O
with	O
the	O
exception	O
that	O
the	O
case	O
-	O
detection	O
cases	O
had	O
lower	O
household	O
rank	O
in	O
Kenya	O
(	O
mean	O
=	O
3	O
.	O
7	O
versus	O
3	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Consequently	O
,	O
cases	O
recruited	O
through	O
the	O
two	O
methods	O
were	O
combined	O
in	O
the	O
subsequent	O
analyses	O
.	O

Cases	O
were	O
poorer	O
than	O
controls	O
,	O
in	O
all	O
three	O
settings	O
according	O
to	O
all	O
three	O
poverty	O
measurements	O
(	O
Table	O
2	O
)	O
.	O

The	O
mean	O
PCE	O
was	O
20	O
%	O
-	O
28	O
%	O
lower	O
for	O
members	O
of	O
households	O
with	O
a	O
case	O
than	O
for	O
control	O
households	O
,	O
and	O
this	O
difference	O
was	O
highly	O
significant	O
in	O
Bangladesh	O
and	O
the	O
Philippines	O
;	O
for	O
Kenya	O
it	O
was	O
lower	O
but	O
did	O
not	O
reach	O
significance	O
(	O
p	O
=	O
0	O
.	O
07	O
)	O
.	O

The	O
PCA	O
score	O
for	O
assets	O
was	O
significantly	O
lower	O
among	O
cases	O
than	O
controls	O
in	O
Kenya	O
and	O
Bangladesh	O
,	O
and	O
it	O
was	O
lower	O
in	O
the	O
Philippines	O
although	O
it	O
did	O
not	O
reach	O
significance	O
(	O
p	O
=	O
0	O
.	O
06	O
)	O
.	O

Self	O
-	O
perceived	O
wealth	O
was	O
significantly	O
lower	O
for	O
households	O
with	O
a	O
case	O
compared	O
to	O
control	O
households	O
in	O
Kenya	O
(	O
3	O
.	O
4	O
versus	O
4	O
.	O
5	O
)	O
and	O
Bangladesh	O
(	O
3	O
.	O
9	O
versus	O
4	O
.	O
6	O
)	O
,	O
though	O
not	O
in	O
the	O
Philippines	O
(	O
4	O
.	O
1	O
versus	O
4	O
.	O
3	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
size	O
of	O
the	O
households	O
of	O
cases	O
and	O
controls	O
in	O
any	O
of	O
the	O
three	O
settings	O
.	O

The	O
ratio	O
of	O
dependents	O
(	O
i	O
.	O
e	O
.	O
,	O
household	O
member	O
aged	O
<	O
15	O
or	O
>=	O
50	O
y	O
)	O
to	O
independents	O
(	O
i	O
.	O
e	O
.	O
,	O
household	O
member	O
aged	O
15	O
-	O
50	O
y	O
)	O
was	O
similar	O
between	O
cases	O
and	O
controls	O
in	O
Bangladesh	O
(	O
1	O
.	O
4	O
versus	O
1	O
.	O
4	O
)	O
,	O
but	O
the	O
dependency	O
ratio	O
was	O
higher	O
for	O
controls	O
than	O
cases	O
in	O
Kenya	O
(	O
2	O
.	O
1	O
versus	O
1	O
.	O
6	O
)	O
and	O
the	O
Philippines	O
(	O
1	O
.	O
7	O
versus	O
1	O
.	O
3	O
)	O
,	O
due	O
to	O
the	O
smaller	O
number	O
of	O
people	S-Species
of	O
working	O
age	O
.	O

Patterns	O
of	O
Expenditure	O
in	O
Cases	O
and	O
Controls	O

Figure	O
1	O
shows	O
the	O
total	O
PCE	O
and	O
the	O
allocation	O
of	O
expenditure	O
within	O
quartiles	O
of	O
PCE	O
for	O
cases	O
and	O
controls	O
.	O

Monthly	O
PCE	O
was	O
similar	O
for	O
cases	O
and	O
controls	O
within	O
each	O
of	O
the	O
quartiles	O
of	O
expenditure	O
.	O

There	O
was	O
a	O
gradual	O
increase	O
in	O
PCE	O
between	O
the	O
first	O
three	O
quartiles	O
,	O
and	O
then	O
a	O
rapid	O
increase	O
between	O
the	O
third	O
and	O
the	O
richest	O
quartile	O
.	O

Within	O
the	O
first	O
three	O
quartiles	O
of	O
PCE	O
the	O
majority	O
of	O
expenditure	O
was	O
on	O
food	O
.	O

Substantial	O
expenditure	O
on	O
non	O
-	O
food	O
items	O
was	O
observed	O
only	O
in	O
the	O
highest	O
quartile	O
of	O
expenditure	O
,	O
where	O
about	O
half	O
of	O
expenditure	O
was	O
on	O
non	O
-	O
food	O
items	O
.	O

Similar	O
patterns	O
of	O
PCE	O
were	O
observed	O
for	O
cases	O
and	O
controls	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
within	O
each	O
quartile	O
of	O
expenditure	O
.	O

These	O
results	O
demonstrate	O
that	O
cataract	O
visual	O
impairment	O
was	O
related	O
to	O
reduced	O
PCE	O
,	O
but	O
not	O
allocation	O
of	O
expenditure	O
.	O

Multivariate	O
Analyses	O
of	O
Poverty	O
and	O
Cataract	O
Visual	O
Impairment	O

Multivariate	O
analyses	O
showed	O
that	O
case	O
participants	S-Species
were	O
consistently	O
poorer	O
than	O
controls	O
in	O
Kenya	O
,	O
Bangladesh	O
,	O
and	O
the	O
Philippines	O
,	O
using	O
three	O
different	O
measures	O
of	O
poverty	O
(	O
Table	O
3	O
)	O
.	O

Cases	O
were	O
more	O
likely	O
than	O
controls	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
PCE	O
rather	O
than	O
the	O
highest	O
quartile	O
in	O
Kenya	O
(	O
OR	O
2	O
.	O
3	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
-	O
5	O
.	O
5	O
)	O
,	O
Bangladesh	O
(	O
1	O
.	O
9	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
2	O
)	O
and	O
the	O
Philippines	O
(	O
3	O
.	O
1	O
,	O
1	O
.	O
7	O
-	O
5	O
.	O
7	O
)	O
.	O

In	O
all	O
three	O
settings	O
these	O
associations	O
showed	O
significant	O
dose	O
-	O
response	O
as	O
assessed	O
by	O
the	O
p	O
-	O
value	O
for	O
trend	O
across	O
the	O
quartiles	O
,	O
with	O
decreasing	O
PCE	O
related	O
to	O
case	O
status	O
and	O
these	O
relationships	O
persisted	O
after	O
adjustment	O
for	O
self	O
-	O
rated	O
health	O
and	O
social	O
support	O
indicators	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
the	O
relationship	O
between	O
case	O
-	O
control	O
status	O
and	O
asset	O
ownership	O
.	O

Cases	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
asset	O
ownership	O
rather	O
than	O
the	O
highest	O
quartile	O
compared	O
to	O
controls	O
in	O
Kenya	O
(	O
3	O
.	O
7	O
,	O
1	O
.	O
4	O
-	O
9	O
.	O
6	O
)	O
,	O
Bangladesh	O
(	O
2	O
.	O
6	O
,	O
1	O
.	O
5	O
-	O
4	O
.	O
4	O
)	O
,	O
and	O
the	O
Philippines	O
(	O
2	O
.	O
1	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
8	O
)	O
.	O

Cases	O
were	O
also	O
significantly	O
more	O
likely	O
to	O
be	O
in	O
the	O
lowest	O
quartile	O
of	O
household	O
rank	O
rather	O
than	O
the	O
highest	O
,	O
compared	O
to	O
controls	O
in	O
Kenya	O
(	O
3	O
.	O
5	O
,	O
1	O
.	O
5	O
-	O
8	O
.	O
0	O
)	O
,	O
Bangladesh	O
(	O
2	O
.	O
7	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
7	O
)	O
and	O
the	O
Philippines	O
(	O
2	O
.	O
3	O
,	O
1	O
.	O
1	O
-	O
4	O
.	O
8	O
)	O
.	O

The	O
associations	O
with	O
assets	O
and	O
household	O
rank	O
also	O
showed	O
a	O
significant	O
dose	O
-	O
response	O
relationship	O
,	O
and	O
the	O
associations	O
were	O
largely	O
unchanged	O
after	O
adjustment	O
for	O
self	O
-	O
rated	O
health	O
and	O
social	O
support	O
indicators	O
.	O

In	O
Kenya	O
and	O
Bangladesh	O
the	O
relationship	O
between	O
PCE	O
and	O
case	O
status	O
was	O
somewhat	O
weaker	O
than	O
for	O
the	O
other	O
measures	O
of	O
poverty	O
,	O
while	O
the	O
reverse	O
was	O
true	O
in	O
the	O
Philippines	O
.	O

Stratifying	O
the	O
association	O
between	O
PCE	O
and	O
cataract	O
visual	O
impairment	O
by	O
level	O
of	O
visual	O
impairment	O
showed	O
an	O
inconsistent	O
pattern	O
(	O
Table	O
4	O
)	O
.	O

In	O
Kenya	O
,	O
the	O
association	O
with	O
low	O
PCE	O
was	O
somewhat	O
stronger	O
comparing	O
cataract	O
blind	O
cases	O
to	O
controls	O
(	O
OR	O
3	O
.	O
1	O
,	O
95	O
%	O
CI	O
0	O
.	O
9	O
-	O
10	O
.	O
8	O
)	O
than	O
comparing	O
moderate	O
visually	O
impaired	O
cases	O
to	O
controls	O
(	O
1	O
.	O
8	O
,	O
0	O
.	O
6	O
-	O
5	O
.	O
4	O
)	O
,	O
while	O
this	O
pattern	O
was	O
reversed	O
in	O
Bangladesh	O
(	O
blind	O
cases	O
versus	O
controls	O
:	O
1	O
.	O
8	O
,	O
1	O
.	O
0	O
-	O
3	O
.	O
4	O
;	O
moderately	O
visually	O
impaired	O
cases	O
versus	O
controls	O
:	O
3	O
.	O
1	O
,	O
1	O
.	O
3	O
-	O
7	O
.	O
2	O
)	O
.	O

In	O
the	O
Philippines	O
the	O
association	O
with	O
low	O
PCE	O
was	O
strongest	O
comparing	O
severely	O
visually	O
impaired	O
cases	O
to	O
controls	O
(	O
5	O
.	O
9	O
,	O
2	O
.	O
0	O
-	O
17	O
.	O
6	O
)	O
.	O

The	O
association	O
between	O
cataract	O
visual	O
impairment	O
and	O
PCE	O
was	O
stronger	O
among	O
men	S-Species
than	O
women	S-Species
in	O
Bangladesh	O
and	O
the	O
Philippines	O
,	O
while	O
the	O
reverse	O
was	O
true	O
in	O
Kenya	O
(	O
Table	O
5	O
)	O
.	O

In	O
Kenya	O
and	O
the	O
Philippines	O
the	O
strongest	O
association	O
between	O
cataract	O
and	O
PCE	O
was	O
among	O
people	S-Species
aged	O
70	O
-	O
79	O
y	O
,	O
while	O
in	O
Bangladesh	O
the	O
strongest	O
effect	O
was	O
in	O
people	S-Species
aged	O
over	O
80	O
y	O
.	O

Stratifying	O
the	O
association	O
between	O
assets	O
and	O
household	O
rank	O
with	O
cataract	O
by	O
level	O
of	O
visual	O
impairment	O
,	O
sex	O
,	O
or	O
age	O
broadly	O
repeated	O
these	O
findings	O
,	O
and	O
generally	O
supported	O
the	O
lack	O
of	O
consistent	O
pattern	O
(	O
unpublished	O
data	O
)	O
.	O

Discussion	O

This	O
large	O
,	O
multicentre	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
provides	O
evidence	O
that	O
people	S-Species
with	O
visual	O
impairment	O
from	O
cataract	O
are	O
poorer	O
than	O
control	O
participants	S-Species
with	O
normal	O
vision	O
matched	O
for	O
age	O
and	O
sex	O
.	O

This	O
pattern	O
was	O
evident	O
whether	O
poverty	O
was	O
measured	O
in	O
terms	O
of	O
PCE	O
,	O
assets	O
,	O
or	O
self	O
-	O
rated	O
wealth	O
.	O

Marital	O
status	O
seemed	O
to	O
be	O
protective	O
for	O
cataract	O
visual	O
impairment	O
,	O
possibly	O
indicating	O
the	O
role	O
of	O
social	O
support	O
in	O
health	O
-	O
seeking	O
behaviour	O
.	O

Reduced	O
self	O
-	O
rated	O
health	O
was	O
also	O
strongly	O
related	O
to	O
cataract	O
visual	O
impairment	O
.	O

This	O
demonstrates	O
the	O
impact	O
of	O
poor	O
vision	O
on	O
overall	O
assessments	O
of	O
health	O
and	O
supports	O
our	O
previous	O
finding	O
of	O
a	O
relationship	O
between	O
cataract	O
and	O
quality	O
of	O
life	O
[	O
17	O
]	O
.	O

Adjustment	O
for	O
marital	O
status	O
and	O
self	O
-	O
rated	O
health	O
did	O
not	O
entirely	O
explain	O
the	O
association	O
between	O
poverty	O
and	O
cataract	O
visual	O
impairment	O
,	O
suggesting	O
that	O
it	O
operated	O
through	O
other	O
pathways	O
.	O

Visual	O
impairment	O
could	O
cause	O
poverty	O
through	O
reduced	O
employment	O
opportunities	O
.	O

We	O
might	O
therefore	O
expect	O
to	O
see	O
a	O
stronger	O
relationship	O
between	O
cataract	O
and	O
poverty	O
among	O
the	O
blind	O
case	O
participants	S-Species
who	O
may	O
have	O
fewer	O
employment	O
opportunities	O
than	O
among	O
those	O
less	O
impaired	O
(	O
i	O
.	O
e	O
.	O
,	O
moderate	O
visual	O
impairment	O
)	O
.	O

Poverty	O
may	O
also	O
cause	O
visual	O
impairment	O
through	O
restricted	O
access	O
to	O
cataract	O
surgery	O
.	O

In	O
this	O
case	O
we	O
would	O
expect	O
to	O
see	O
a	O
stronger	O
relationship	O
between	O
poverty	O
and	O
less	O
severely	O
affected	O
cases	O
(	O
i	O
.	O
e	O
.	O
,	O
moderate	O
visual	O
impairment	O
)	O
,	O
as	O
poor	O
families	O
may	O
allocate	O
money	O
for	O
surgery	O
on	O
members	O
who	O
are	O
blind	O
from	O
cataract	O
,	O
so	O
that	O
poverty	O
mainly	O
restricts	O
access	O
to	O
surgery	O
among	O
people	S-Species
who	O
are	O
moderately	O
visually	O
impaired	O
.	O

The	O
relationships	O
that	O
we	O
observed	O
between	O
level	O
of	O
visual	O
impairment	O
and	O
cataract	O
were	O
inconsistent	O
across	O
the	O
three	O
settings	O
.	O

Perhaps	O
this	O
shows	O
that	O
both	O
pathways	O
were	O
operating	O
or	O
that	O
the	O
dynamics	O
of	O
the	O
relationship	O
between	O
poverty	O
and	O
blindness	O
vary	O
in	O
different	O
settings	O
.	O

Levels	O
of	O
literacy	O
and	O
education	O
were	O
lower	O
among	O
cases	O
than	O
controls	O
.	O

These	O
long	O
-	O
term	O
indicators	O
of	O
disadvantage	O
are	O
unlikely	O
to	O
have	O
changed	O
after	O
the	O
onset	O
of	O
cataract	O
.	O

This	O
observation	O
provides	O
some	O
evidence	O
that	O
poverty	O
preceded	O
blindness	O
in	O
our	O
study	O
participants	S-Species
.	O

It	O
is	O
frequently	O
asserted	O
that	O
blindness	O
is	O
both	O
a	O
cause	O
and	O
consequence	O
of	O
poverty	O
,	O
but	O
there	O
are	O
few	O
empirical	O
data	O
to	O
support	O
this	O
claim	O
.	O

Globally	O
,	O
the	O
prevalence	O
of	O
blindness	O
is	O
five	O
-	O
fold	O
higher	O
in	O
poor	O
than	O
rich	O
countries	O
[	O
2	O
]	O
,	O
and	O
data	O
from	O
Pakistan	O
and	O
India	O
suggest	O
that	O
within	O
countries	O
the	O
poor	O
are	O
more	O
likely	O
to	O
be	O
blind	O
[	O
3	O
,	O
4	O
]	O
.	O

Some	O
blinding	O
conditions	O
are	O
a	O
direct	O
consequence	O
of	O
poverty	O
,	O
notably	O
trachoma	O
,	O
which	O
thrives	O
in	O
poor	O
areas	O
lacking	O
water	O
and	O
sanitation	O
[	O
20	O
]	O
.	O

Other	O
blinding	O
diseases	O
clearly	O
contribute	O
to	O
poverty	O
,	O
such	O
as	O
onchocerciasis	O
,	O
which	O
results	O
in	O
the	O
abandonment	O
of	O
the	O
fertile	O
areas	O
near	O
to	O
the	O
rivers	O
where	O
the	O
disease	O
vector	O
thrives	O
[	O
9	O
]	O
.	O

A	O
larger	O
literature	O
shows	O
that	O
poor	O
people	S-Species
are	O
more	O
likely	O
to	O
be	O
ill	O
or	O
disabled	O
than	O
their	O
richer	O
compatriots	O
,	O
ranging	O
from	O
general	O
disability	O
in	O
India	O
,	O
Bulgaria	O
,	O
and	O
Ghana	O
[	O
21	O
]	O
;	O
common	O
mental	O
disorders	O
in	O
Brazil	O
,	O
Chile	O
,	O
India	O
,	O
and	O
Zimbabwe	O
[	O
22	O
]	O
;	O
deafness	O
in	O
Brazil	O
[	O
23	O
]	O
;	O
and	O
tuberculosis	O
in	O
China	O
[	O
24	O
]	O
.	O

There	O
are	O
also	O
some	O
exceptions	O
such	O
as	O
a	O
case	O
-	O
control	O
study	O
in	O
Rwanda	O
which	O
failed	O
to	O
show	O
an	O
association	O
between	O
PCE	O
and	O
musculoskeletal	O
impairment	O
,	O
perhaps	O
because	O
the	O
population	O
was	O
almost	O
universally	O
poor	O
[	O
25	O
]	O
.	O

Poverty	O
may	O
increase	O
the	O
incidence	O
of	O
disease	O
,	O
particularly	O
preventable	O
diseases	O
such	O
as	O
tuberculosis	O
.	O

Poverty	O
may	O
also	O
restrict	O
access	O
to	O
appropriate	O
health	O
care	O
and	O
so	O
prolong	O
the	O
duration	O
of	O
disease	O
.	O

A	O
study	O
in	O
rural	O
Tanzania	O
showed	O
that	O
care	O
-	O
seeking	O
behaviour	O
for	O
childhood	O
illness	O
is	O
worse	O
among	O
poorer	O
families	O
than	O
among	O
the	O
relatively	O
rich	O
families	O
[	O
26	O
]	O
.	O

Another	O
Tanzanian	O
study	O
found	O
that	O
people	S-Species
with	O
higher	O
levels	O
of	O
asset	O
ownership	O
were	O
more	O
likely	O
to	O
obtain	O
antimalarials	O
even	O
though	O
they	O
were	O
less	O
likely	O
to	O
be	O
parasitaemic	O
[	O
27	O
]	O
.	O

With	O
respect	O
to	O
cataract	O
,	O
there	O
is	O
little	O
evidence	O
that	O
prevention	O
is	O
possible	O
,	O
and	O
so	O
the	O
main	O
pathway	O
from	O
poverty	O
to	O
blindness	O
is	O
likely	O
to	O
be	O
through	O
reduced	O
access	O
to	O
cataract	O
surgical	O
services	O
.	O

High	O
health	O
care	O
costs	O
may	O
also	O
exacerbate	O
poverty	O
.	O

A	O
study	O
in	O
rural	O
China	O
showed	O
that	O
ill	O
health	O
increases	O
medical	O
expenditure	O
significantly	O
,	O
which	O
detracts	O
from	O
expenditure	O
on	O
food	O
,	O
education	O
,	O
investment	O
in	O
farming	O
,	O
and	O
participation	O
in	O
social	O
activities	O
[	O
28	O
]	O
.	O

Inability	O
to	O
afford	O
cataract	O
surgery	O
is	O
cited	O
as	O
the	O
major	O
barrier	O
to	O
the	O
uptake	O
of	O
surgery	O
in	O
the	O
surveys	O
conducted	O
in	O
Kenya	O
,	O
the	O
Philippines	O
,	O
and	O
Bangladesh	O
[	O
6	O
-	O
8	O
]	O
.	O

This	O
indicates	O
that	O
the	O
cost	O
of	O
surgery	O
is	O
perceived	O
as	O
substantial	O
by	O
many	O
households	O
,	O
notwithstanding	O
the	O
problems	O
of	O
assessing	O
the	O
complex	O
issue	O
of	O
barriers	O
in	O
the	O
absence	O
of	O
in	O
-	O
depth	O
qualitative	O
interviews	O
.	O

Consequently	O
,	O
there	O
are	O
lower	O
rates	O
of	O
cataract	O
surgery	O
among	O
the	O
poor	O
[	O
3	O
]	O
.	O

Poverty	O
may	O
also	O
limit	O
the	O
employment	O
opportunities	O
of	O
the	O
person	S-Species
with	O
disability	O
or	O
their	O
household	O
members	O
.	O

This	O
pattern	O
has	O
been	O
demonstrated	O
for	O
people	S-Species
with	O
HIV	S-Species
in	O
South	O
Africa	O
[	O
29	O
]	O
,	O
tuberculosis	O
in	O
China	O
[	O
24	O
]	O
,	O
or	O
disability	O
in	O
Sri	O
Lanka	O
[	O
22	O
]	O
.	O

An	O
impact	O
of	O
blindness	O
on	O
reduced	O
employment	O
or	O
income	O
has	O
been	O
observed	O
in	O
Guinea	O
[	O
9	O
]	O
and	O
India	O
[	O
4	O
]	O
.	O

A	O
belief	O
that	O
blindness	O
reduces	O
the	O
employment	O
opportunities	O
of	O
household	O
members	O
is	O
widespread	O
,	O
but	O
so	O
far	O
there	O
is	O
limited	O
supportive	O
evidence	O
.	O

There	O
is	O
a	O
further	O
complication	O
to	O
investigations	O
of	O
the	O
relationship	O
between	O
cataract	O
and	O
poverty	O
,	O
as	O
the	O
individuals	O
with	O
cataract	O
are	O
likely	O
to	O
be	O
elderly	O
and	O
facing	O
multiple	O
disabilities	O
.	O

Our	O
study	O
took	O
account	O
of	O
the	O
potential	O
impact	O
of	O
multiple	O
disabilities	O
,	O
as	O
we	O
adjusted	O
for	O
self	O
-	O
rated	O
health	O
,	O
which	O
is	O
closely	O
related	O
to	O
overall	O
health	O
,	O
and	O
this	O
adjustment	O
had	O
no	O
overall	O
impact	O
on	O
our	O
results	O
[	O
30	O
]	O
.	O

Study	O
Strengths	O

This	O
was	O
a	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
conducted	O
in	O
three	O
countries	O
,	O
allowing	O
international	O
comparisons	O
.	O

This	O
was	O
the	O
first	O
study	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
relate	O
PCE	O
to	O
visual	O
impairment	O
.	O

We	O
also	O
measured	O
assets	O
,	O
which	O
reflects	O
long	O
-	O
term	O
access	O
to	O
resources	O
,	O
and	O
self	O
-	O
rated	O
wealth	O
.	O

We	O
used	O
expenditure	O
as	O
a	O
proxy	O
for	O
income	O
,	O
which	O
has	O
aided	O
both	O
academic	O
and	O
nonacademic	O
investigations	O
.	O

As	O
one	O
example	O
,	O
the	O
notorious	O
Chicago	O
gangster	O
Al	O
Capone	O
managed	O
to	O
escape	O
prosecution	O
for	O
smuggling	O
,	O
gambling	O
,	O
bootlegging	O
,	O
and	O
murder	O
for	O
years	O
,	O
but	O
was	O
eventually	O
convicted	O
of	O
tax	O
evasion	O
,	O
because	O
the	O
jury	O
was	O
convinced	O
that	O
his	O
exorbitant	O
expenses	O
on	O
clothes	O
,	O
furnishing	O
,	O
foods	O
,	O
and	O
gifts	O
were	O
inconsistent	O
with	O
his	O
claim	O
that	O
he	O
had	O
no	O
income	O
.	O

Expenditure	O
often	O
provides	O
a	O
better	O
measure	O
of	O
poverty	O
than	O
income	O
for	O
a	O
number	O
of	O
reasons	O
.	O

Income	O
may	O
be	O
variable	O
by	O
season	O
,	O
whereas	O
households	O
attempt	O
to	O
smooth	O
expenditure	O
over	O
the	O
year	O
.	O

People	S-Species
are	O
more	O
comfortable	O
sharing	O
information	O
about	O
expenditure	O
than	O
income	O
,	O
and	O
it	O
may	O
be	O
a	O
more	O
meaningful	O
measure	O
than	O
income	O
in	O
an	O
agrarian	O
society	O
as	O
it	O
reflects	O
what	O
the	O
household	O
is	O
able	O
to	O
command	O
based	O
on	O
its	O
current	O
income	O
,	O
borrowing	O
ability	O
,	O
or	O
household	O
savings	O
[	O
31	O
]	O
.	O

PCE	O
also	O
has	O
advantages	O
over	O
assets	O
,	O
as	O
it	O
may	O
be	O
more	O
responsive	O
to	O
change	O
,	O
which	O
will	O
be	O
important	O
for	O
the	O
follow	O
-	O
up	O
analyses	O
of	O
the	O
study	O
participants	S-Species
after	O
they	O
have	O
undergone	O
cataract	O
surgery	O
.	O

Study	O
Limitations	O

There	O
are	O
a	O
number	O
of	O
limitations	O
relating	O
to	O
the	O
measurement	O
of	O
poverty	O
in	O
this	O
study	O
.	O

Our	O
analyses	O
focus	O
on	O
monetary	O
indicators	O
of	O
poverty	O
,	O
while	O
we	O
acknowledge	O
that	O
health	O
,	O
education	O
,	O
and	O
housing	O
are	O
also	O
important	O
.	O

We	O
concede	O
that	O
it	O
is	O
difficult	O
to	O
measure	O
expenditure	O
accurately	O
[	O
32	O
,	O
33	O
]	O
,	O
but	O
this	O
also	O
true	O
for	O
the	O
measurement	O
of	O
diet	O
and	O
other	O
variables	O
,	O
which	O
is	O
standard	O
practise	O
in	O
many	O
epidemiological	O
studies	O
.	O

Furthermore	O
,	O
a	O
large	O
number	O
of	O
items	O
were	O
included	O
in	O
our	O
measure	O
of	O
expenditure	O
so	O
that	O
the	O
measure	O
was	O
comprehensive	O
[	O
33	O
]	O
.	O

Expenditure	O
data	O
were	O
not	O
validated	O
through	O
diaries	O
or	O
other	O
means	O
,	O
although	O
assets	O
and	O
self	O
-	O
rated	O
wealth	O
correlated	O
highly	O
with	O
PCE	O
.	O

Other	O
recent	O
estimates	O
of	O
expenditure	O
are	O
not	O
available	O
from	O
surveys	O
conducted	O
in	O
these	O
countries	O
to	O
allow	O
comparison	O
.	O

The	O
per	O
capita	O
estimates	O
of	O
monthly	O
gross	O
national	O
income	O
from	O
the	O
World	O
Development	O
Indicators	O
database	O
show	O
somewhat	O
higher	O
estimates	O
in	O
Kenya	O
(	O
US	O
$	O
48	O
)	O
and	O
Bangladesh	O
(	O
US	O
$	O
40	O
)	O
than	O
our	O
PCE	O
derived	O
estimates	O
,	O
and	O
far	O
higher	O
estimates	O
for	O
the	O
Philippines	O
(	O
US	O
$	O
108	O
)	O
.	O

This	O
discrepancy	O
may	O
be	O
reasonable	O
,	O
as	O
the	O
World	O
Development	O
Indicators	O
reflect	O
national	O
averages	O
,	O
while	O
we	O
sampled	O
the	O
households	O
with	O
elderly	O
people	S-Species
in	O
poor	O
regions	O
of	O
the	O
country	O
,	O
many	O
of	O
whom	O
were	O
visually	O
impaired	O
from	O
cataract	O
.	O

PCE	O
was	O
calculated	O
simply	O
by	O
dividing	O
the	O
total	O
household	O
expenditure	O
by	O
the	O
number	O
of	O
household	O
members	O
,	O
without	O
inclusion	O
of	O
economies	O
of	O
scale	O
or	O
equivalence	O
scales	O
.	O

There	O
is	O
no	O
widely	O
accepted	O
alternative	O
to	O
the	O
simple	O
equal	O
-	O
sharing	O
convention	O
,	O
and	O
the	O
majority	O
of	O
expenditure	O
was	O
on	O
food	O
which	O
does	O
not	O
allow	O
for	O
economies	O
of	O
scale	O
.	O

Furthermore	O
,	O
there	O
were	O
slightly	O
fewer	O
people	S-Species
of	O
working	O
age	O
in	O
the	O
control	O
households	O
in	O
Kenya	O
and	O
the	O
Philippines	O
,	O
so	O
adjustment	O
for	O
equivalence	O
scores	O
would	O
be	O
unlikely	O
to	O
explain	O
the	O
higher	O
poverty	O
among	O
cases	O
.	O

The	O
case	O
and	O
control	O
households	O
were	O
of	O
similar	O
sizes	O
in	O
the	O
three	O
settings	O
,	O
so	O
economies	O
of	O
scales	O
are	O
unlikely	O
to	O
have	O
explained	O
the	O
differences	O
.	O

There	O
were	O
a	O
number	O
of	O
limitations	O
relating	O
to	O
study	O
design	O
.	O

Unfortunately	O
,	O
we	O
did	O
not	O
record	O
the	O
exact	O
numbers	O
of	O
cases	O
and	O
controls	O
who	O
refused	O
to	O
participate	O
or	O
were	O
unable	O
to	O
communicate	O
(	O
believed	O
to	O
be	O
fewer	O
than	O
five	O
in	O
each	O
country	O
)	O
,	O
so	O
the	O
response	O
rate	O
is	O
unknown	O
,	O
but	O
was	O
believed	O
to	O
be	O
high	O
.	O

A	O
variety	O
of	O
methods	O
were	O
used	O
for	O
case	O
recruitment	O
,	O
as	O
we	O
were	O
not	O
able	O
to	O
obtain	O
enough	O
cases	O
through	O
the	O
survey	O
alone	O
.	O

However	O
,	O
cases	O
recruited	O
through	O
the	O
population	O
-	O
based	O
survey	O
and	O
through	O
case	O
detection	O
had	O
similar	O
poverty	O
characteristics	O
.	O

Conclusions	O

Our	O
data	O
show	O
that	O
people	S-Species
with	O
visual	O
impairment	O
due	O
to	O
cataract	O
were	O
poorer	O
than	O
controls	O
in	O
three	O
low	O
income	O
countries	O
,	O
Bangladesh	O
,	O
Kenya	O
,	O
and	O
the	O
Philippines	O
.	O

The	O
Millennium	O
Development	O
Goals	O
are	O
committed	O
to	O
the	O
eradication	O
of	O
extreme	O
poverty	O
and	O
provision	O
of	O
health	O
care	O
to	O
poor	O
people	S-Species
.	O

This	O
study	O
confirms	O
an	O
association	O
between	O
poverty	O
and	O
blindness	O
and	O
highlights	O
the	O
need	O
for	O
increased	O
provision	O
of	O
cataract	O
surgery	O
to	O
poor	O
people	S-Species
,	O
particularly	O
since	O
cataract	O
surgery	O
is	O
a	O
highly	O
cost	O
-	O
effective	O
intervention	O
in	O
these	O
settings	O
[	O
34	O
]	O
.	O

Human	S-Species
genetic	O
selection	O
on	O
the	O
MTHFR	O
677C	O
>	O
T	O
polymorphism	O

Abstract	O

Background	O

The	O
prevalence	O
of	O
genotypes	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
for	O
the	O
MTHFR	O
gene	O
varies	O
among	O
humans	S-Species
.	O

In	O
previous	O
studies	O
,	O
we	O
found	O
changes	O
in	O
the	O
genotypic	O
frequencies	O
of	O
this	O
polymorphism	O
in	O
populations	O
of	O
different	O
ages	O
,	O
suggesting	O
that	O
this	O
could	O
be	O
caused	O
by	O
an	O
increase	O
in	O
the	O
intake	O
of	O
folate	O
and	O
multivitamins	O
by	O
women	S-Species
during	O
the	O
periconceptional	O
period	O
.	O

The	O
aim	O
was	O
to	O
analyze	O
changes	O
in	O
the	O
allelic	O
frequencies	O
of	O
this	O
polymorphism	O
in	O
a	O
Spanish	O
population	O
,	O
including	O
samples	O
from	O
spontaneous	O
abortions	O
(	O
SA	O
)	O
.	O

Methods	O

A	O
total	O
of	O
1305	O
subjects	O
born	O
in	O
the	O
20th	O
century	O
were	O
genotyped	O
for	O
the	O
677C	O
>	O
T	O
polymorphism	O
using	O
allele	O
specific	O
real	O
-	O
time	O
PCR	O
with	O
Taqman	O
(R)	O
probes	O
.	O

A	O
section	O
of	O
our	O
population	O
(	O
n	O
=	O
276	O
)	O
born	O
in	O
1980	O
-	O
1989	O
was	O
compared	O
with	O
fetal	O
samples	O
(	O
n	O
=	O
344	O
)	O
from	O
SA	O
of	O
unknown	O
etiology	O
from	O
the	O
same	O
period	O
.	O

Results	O

An	O
increase	O
in	O
the	O
frequency	O
of	O
the	O
T	O
allele	O
(	O
0	O
.	O
38	O
vs	O
0	O
.	O
47	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
of	O
the	O
TT	O
genotype	O
(	O
0	O
.	O
14	O
vs	O
0	O
.	O
24	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
subjects	O
born	O
in	O
the	O
last	O
quarter	O
of	O
the	O
century	O
was	O
observed	O
.	O

In	O
the	O
1980	O
-	O
1989	O
period	O
,	O
the	O
results	O
show	O
that	O
the	O
frequency	O
of	O
the	O
wild	O
type	O
genotype	O
(	O
CC	O
)	O
is	O
about	O
tenfold	O
lower	O
in	O
the	O
SA	O
samples	O
than	O
in	O
the	O
controls	O
(	O
0	O
.	O
03	O
vs	O
0	O
.	O
33	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
that	O
the	O
frequency	O
of	O
the	O
TT	O
genotype	O
increases	O
in	O
the	O
controls	O
(	O
0	O
.	O
19	O
to	O
0	O
.	O
27	O
)	O
and	O
in	O
the	O
SA	O
samples	O
(	O
0	O
.	O
20	O
to	O
0	O
.	O
33	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
)	O
;	O
r	O
=	O
0	O
.	O
98	O
.	O

Conclusion	O

Selection	O
in	O
favor	O
of	O
the	O
T	O
allele	O
has	O
been	O
detected	O
.	O

This	O
selection	O
could	O
be	O
due	O
to	O
the	O
increased	O
fetal	O
viability	O
in	O
early	O
stages	O
of	O
embryonic	O
development	O
,	O
as	O
is	O
deduced	O
by	O
the	O
increase	O
of	O
mutants	O
in	O
both	O
living	O
and	O
SA	O
populations	O
.	O

Background	O

The	O
methylenetetrahydrofolate	O
reductase	O
enzyme	O
(	O
MTHFR	O
)	O
catalyzes	O
a	O
reaction	O
that	O
produces	O
5	O
-	O
methyltetrahydrofolate	O
(	O
5	O
-	O
methylTHF	O
)	O
,	O
the	O
methyl	O
donor	O
for	O
homocysteine	O
in	O
the	O
synthesis	O
of	O
methionine	O
.	O

The	O
677C	O
>	O
T	O
mutation	O
of	O
the	O
MTHFR	O
gene	O
has	O
been	O
associated	O
with	O
a	O
thermolabile	O
enzyme	O
with	O
decreased	O
activity	O
that	O
may	O
cause	O
an	O
increase	O
in	O
plasma	O
homocysteine	O
concentrations	O
[	O
1	O
]	O
when	O
folate	O
status	O
is	O
poor	O
.	O

This	O
polymorphism	O
is	O
one	O
of	O
the	O
most	O
widely	O
studied	O
clinically	O
relevant	O
polymorphisms	O
in	O
humans	S-Species
,	O
as	O
it	O
is	O
related	O
to	O
cardiovascular	O
disease	O
[	O
2	O
]	O
and	O
neural	O
tube	O
defects	O
(	O
NTD	O
;	O
601634	O
)	O
[	O
3	O
]	O
.	O

A	O
large	O
number	O
of	O
studies	O
have	O
provided	O
a	O
broad	O
overview	O
of	O
the	O
prevalence	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
different	O
human	S-Species
populations	O
,	O
showing	O
that	O
the	O
distribution	O
of	O
frequencies	O
is	O
diverse	O
[	O
4	O
]	O
.	O

These	O
differences	O
have	O
been	O
also	O
observed	O
between	O
groups	O
of	O
different	O
ages	O
in	O
the	O
same	O
Spanish	O
population	O
(	O
older	O
and	O
younger	O
than	O
24	O
years	O
)	O
[	O
5	O
]	O
and	O
in	O
a	O
Swiss	O
population	O
(	O
older	O
and	O
younger	O
than	O
60	O
years	O
)	O
[	O
6	O
]	O
,	O
as	O
well	O
as	O
in	O
a	O
Japanese	O
population	O
[	O
7	O
]	O
.	O

In	O
some	O
populations	O
,	O
such	O
the	O
Toscanians	O
in	O
Italy	O
[	O
8	O
]	O
and	O
Mexicans	O
[	O
9	O
]	O
,	O
the	O
homozygous	O
mutated	O
genotype	O
(	O
TT	O
)	O
has	O
reached	O
frequencies	O
greater	O
than	O
30	O
%	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
Africans	O
the	O
frequency	O
of	O
the	O
TT	O
genotype	O
is	O
very	O
low	O
(	O
less	O
than	O
1	O
%	O
)	O
[	O
10	O
,	O
11	O
]	O
,	O
but	O
,	O
in	O
African	O
-	O
Americans	O
,	O
it	O
has	O
already	O
reached	O
2	O
%	O
[	O
12	O
]	O
.	O

Studies	O
based	O
on	O
the	O
distribution	O
of	O
genotypic	O
and	O
allelic	O
frequencies	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
and	O
the	O
1298A	O
>	O
C	O
polymorphism	O
in	O
the	O
MTHFR	O
gene	O
in	O
Israeli	O
,	O
Japanese	O
and	O
Ghanaian	O
Africans	O
populations	O
[	O
13	O
]	O
concluded	O
that	O
the	O
677T	O
mutation	O
in	O
the	O
MTHFR	O
gene	O
emerged	O
as	O
a	O
founder	O
haplotype	O
with	O
some	O
selective	O
advantage	O
.	O

Recently	O
,	O
preliminary	O
evidence	O
of	O
genetic	O
selection	O
of	O
this	O
polymorphism	O
related	O
to	O
folate	O
intake	O
has	O
been	O
reported	O
[	O
14	O
]	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
analyze	O
the	O
changes	O
in	O
frequencies	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
during	O
the	O
20th	O
century	O
and	O
particularly	O
the	O
evolution	O
of	O
the	O
frequencies	O
during	O
the	O
decade	O
of	O
1980	O
-	O
1989	O
,	O
by	O
comparing	O
the	O
genotype	O
frequencies	O
between	O
living	O
subjects	O
born	O
in	O
this	O
period	O
versus	O
samples	O
of	O
spontaneous	O
abortions	O
(	O
SA	O
)	O
that	O
occurred	O
during	O
in	O
the	O
same	O
time	O
period	O
.	O

Methods	O

Subjects	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
at	O
the	O
University	O
Hospital	O
"	O
Virgen	O
de	O
la	O
Victoria	O
"	O
(	O
M	O
a	O
laga	O
)	O
.	O

One	O
of	O
the	O
study	O
groups	O
consisted	O
of	O
344	O
fetal	O
tissue	O
samples	O
from	O
SA	O
,	O
obtained	O
from	O
the	O
Department	O
of	O
Pathology	O
of	O
the	O
University	O
Hospital	O
Carlos	O
Haya	O
(	O
M	O
a	O
laga	O
)	O
.	O

These	O
samples	O
were	O
selected	O
after	O
checking	O
the	O
clinical	O
history	O
and	O
by	O
the	O
inclusion	O
criteria	O
of	O
containing	O
histologically	O
confirmed	O
fetal	O
tissue	O
collected	O
in	O
the	O
1980s	O
from	O
SA	O
at	O
less	O
than	O
3	O
months	O
(	O
11	O
+/-	O
1	O
.	O
70	O
week	O
)	O
and	O
of	O
unknown	O
etiology	O
.	O

These	O
fetal	O
samples	O
were	O
compared	O
with	O
a	O
control	O
population	O
of	O
276	O
subjects	O
born	O
in	O
the	O
1980s	O
with	O
an	O
average	O
age	O
of	O
22	O
+/-	O
4	O
.	O
58	O
.	O

Another	O
population	O
of	O
subjects	O
born	O
in	O
the	O
south	O
of	O
Spain	O
in	O
the	O
20th	O
century	O
were	O
genotyped	O
(	O
1305	O
subjects	O
,	O
697	O
women	S-Species
and	O
608	O
men	S-Species
)	O
and	O
divided	O
into	O
four	O
groups	O
according	O
to	O
birth	O
date	O
:	O
1900	O
to	O
1925	O
(	O
n	O
=	O
206	O
)	O
;	O
1926	O
to	O
1950	O
(	O
n	O
=	O
320	O
)	O
,	O
1951	O
to	O
1975	O
(	O
n	O
=	O
408	O
)	O
,	O
1976	O
to	O
2000	O
(	O
n	O
=	O
371	O
)	O
.	O

Individuals	O
were	O
selected	O
randomly	O
from	O
different	O
areas	O
of	O
the	O
province	O
of	O
Malaga	O
,	O
in	O
southern	O
Spain	O
,	O
and	O
from	O
different	O
social	O
statuses	O
to	O
avoid	O
a	O
selection	O
bias	O
.	O

All	O
the	O
selected	O
individuals	O
were	O
Caucasian	O
and	O
residents	O
of	O
the	O
study	O
area	O
.	O

The	O
parents	O
of	O
all	O
subjects	O
included	O
in	O
the	O
study	O
were	O
also	O
Caucasian	O
and	O
born	O
in	O
Spain	O
.	O

The	O
possibility	O
of	O
a	O
founder	O
effect	O
or	O
genetic	O
drift	O
was	O
investigated	O
and	O
rejected	O
.	O

All	O
the	O
selected	O
individuals	O
were	O
also	O
genotyped	O
for	O
an	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
and	O
/	O
or	O
the	O
2756A	O
>	O
G	O
polymorphism	O
in	O
the	O
methionine	O
synthase	O
gene	O
(	O
MTR	O
)	O
,	O
in	O
order	O
to	O
determine	O
whether	O
or	O
not	O
our	O
adult	O
and	O
young	O
populations	O
were	O
genetically	O
homogeneous	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
allelic	O
or	O
genotypic	O
frequencies	O
for	O
these	O
genes	O
between	O
the	O
different	O
groups	O
.	O

The	O
population	O
studied	O
was	O
randomly	O
selected	O
according	O
to	O
age	O
.	O

Subjects	O
0	O
-	O
12	O
years	O
old	O
were	O
selected	O
from	O
dried	O
blood	O
spots	O
from	O
neonatal	O
screening	O
papers	O
;	O
subjects	O
10	O
-	O
24	O
years	O
old	O
were	O
recruited	O
from	O
students	O
in	O
primary	O
and	O
secondary	O
schools	O
and	O
in	O
university	O
;	O
subjects	O
25	O
-	O
50	O
years	O
old	O
and	O
>	O
51	O
years	O
old	O
were	O
recruited	O
using	O
their	O
Andalusia	O
Health	O
Service	O
identity	O
cards	O
.	O

After	O
approval	O
by	O
the	O
University	O
Hospital	O
Ethical	O
Committee	O
,	O
all	O
the	O
subjects	O
were	O
contacted	O
,	O
and	O
,	O
from	O
those	O
whose	O
written	O
consent	O
was	O
obtained	O
,	O
10	O
ml	O
of	O
blood	O
was	O
taken	O
.	O

The	O
investigation	O
in	O
this	O
study	O
conforms	O
to	O
the	O
principles	O
outlined	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Genetic	O
analysis	O

The	O
fetal	O
samples	O
were	O
extracted	O
from	O
the	O
archived	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
fetal	O
tissue	O
using	O
the	O
method	O
described	O
by	O
Coombs	O
et	O
al	O
.	O

(	O
1999	O
)	O
[	O
15	O
]	O
.	O

Genomic	O
DNA	O
of	O
the	O
second	O
and	O
third	O
groups	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
using	O
the	O
AquaPure	O
Genomic	O
DNA	O
Blood	O
Kit	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Genotyping	O
was	O
performed	O
using	O
Real	O
Time	O
PCR	O
with	O
allele	O
specific	O
Taqman	O
(R)	O
probes	O
and	O
primers	O
described	O
by	O
Ulvik	O
et	O
al	O
.	O

(	O
2001	O
)	O
[	O
16	O
]	O
and	O
the	O
following	O
optimized	O
protocol	O
for	O
45	O
cycles	O
:	O
10	O
s	O
-	O
94	O
degrees	O
C	O
,	O
40	O
s	O
-	O
54	O
degrees	O
C	O
,	O
15	O
s	O
-	O
72	O
degrees	O
C	O
.	O

The	O
PCR	O
mix	O
(	O
25	O
mu	O
l	O
total	O
volume	O
)	O
consisted	O
of	O
5	O
mu	O
l	O
of	O
genomic	O
DNA	O
,	O
0	O
.	O
5	O
mu	O
l	O
of	O
sense	O
primer	O
,	O
0	O
.	O
62	O
mu	O
l	O
of	O
anti	O
-	O
sense	O
primer	O
,	O
0	O
.	O
85	O
mu	O
l	O
Taqman	O
(R)	O
probe	O
FAM	O
,	O
0	O
.	O
43	O
mu	O
l	O
Taqman	O
(R)	O
probe	O
TET	O
,	O
20	O
mu	O
l	O
PCR	O
-	O
buffer	O
iQ	O
-	O
SupermixTM	O
(	O
Bio	O
-	O
Rad	O
)	O
(	O
containing	O
100	O
mM	O
KCl	O
,	O
40	O
mM	O
Tris	O
-	O
HCl	O
,	O
(	O
pH	O
8	O
.	O
4	O
)	O
1	O
.	O
6	O
mM	O
dNTP	O
(	O
dATP	O
,	O
dCTP	O
,	O
dGTP	O
and	O
dTTP	O
)	O
,	O
iTaq	O
(R)	O
polymerase	O
(	O
50	O
units	O
/	O
mL	O
)	O
and	O
6	O
mM	O
MgCl2	O
)	O
and	O
17	O
.	O
75	O
mu	O
l	O
H2O	O
.	O

Statistical	O
and	O
mathematical	O
analysis	O

All	O
samples	O
were	O
genotyped	O
,	O
and	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
compared	O
.	O

Differences	O
were	O
analyzed	O
statistically	O
using	O
the	O
chi	O
-	O
square	O
test	O
or	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

Correlations	O
are	O
expressed	O
using	O
Pearson	O
'	O
s	O
coefficient	O
(	O
r	O
)	O
.	O

Compliance	O
of	O
genotype	O
distributions	O
with	O
Hardy	O
-	O
Weinberg	O
(	O
HW	O
)	O
equilibrium	O
was	O
evaluated	O
by	O
chi	O
-	O
square	O
analysis	O
.	O

For	O
all	O
tests	O
,	O
a	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

Values	O
are	O
expressed	O
as	O
the	O
mean	O
+/-	O
SD	O
.	O

The	O
genetic	O
selection	O
model	O
was	O
calculated	O
for	O
the	O
evolution	O
of	O
the	O
677C	O
>	O
T	O
genotypes	O
.	O

The	O
genetic	O
selection	O
could	O
be	O
classified	O
as	O
codominant	O
or	O
incompletely	O
dominant	O
and	O
directional	O
with	O
the	O
heterozygous	O
genotype	O
having	O
an	O
intermediate	O
fitness	O
.	O

For	O
this	O
kind	O
of	O
selection	O
,	O
the	O
most	O
appropriate	O
mathematical	O
model	O
is	O
dq	O
=	O
[	O
spq	O
(	O
2hp	O
+	O
q	O
-	O
h	O
)	O
]	O
/	O
[	O
p2	O
+	O
2pq	O
(	O
1	O
-	O
hs	O
)	O
+	O
q2	O
x	O
(	O
1	O
-	O
s	O
)	O
]	O
,	O
where	O
dq	O
is	O
the	O
change	O
of	O
frequency	O
of	O
the	O
allele	O
with	O
lower	O
fitness	O
,	O
s	O
is	O
the	O
fraction	O
of	O
that	O
genotype	O
lost	O
to	O
selection	O
,	O
h	O
is	O
the	O
degree	O
of	O
dominance	O
(	O
between	O
0	O
,	O
for	O
no	O
dominance	O
and	O
1	O
,	O
for	O
complete	O
dominance	O
)	O
,	O
and	O
p	O
is	O
the	O
frequency	O
of	O
the	O
allele	O
with	O
higher	O
fitness	O
.	O

Results	O

We	O
analyzed	O
the	O
genotype	O
frequencies	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
a	O
population	O
born	O
during	O
the	O
20th	O
century	O
.	O

A	O
total	O
of	O
1305	O
subjects	O
were	O
divided	O
into	O
four	O
groups	O
of	O
25	O
years	O
according	O
to	O
birth	O
date	O
.	O

The	O
genotype	O
frequencies	O
were	O
compared	O
between	O
the	O
four	O
quarters	O
of	O
the	O
century	O
and	O
showed	O
very	O
significant	O
changes	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
group	O
born	O
in	O
the	O
last	O
quarter	O
of	O
the	O
20th	O
century	O
(	O
1976	O
-	O
2000	O
)	O
,	O
when	O
compared	O
to	O
any	O
of	O
the	O
other	O
groups	O
.	O

The	O
changes	O
show	O
a	O
decrease	O
of	O
the	O
CC	O
genotype	O
and	O
an	O
increase	O
of	O
the	O
TT	O
genotype	O
in	O
the	O
last	O
25	O
years	O
of	O
the	O
20th	O
century	O
.	O

(	O
Table	O
1	O
)	O

Considering	O
that	O
each	O
25	O
year	O
period	O
corresponds	O
to	O
a	O
generation	O
,	O
allelic	O
frequencies	O
did	O
not	O
change	O
during	O
the	O
first	O
75	O
years	O
of	O
the	O
century	O
(	O
HW	O
equilibrium	O
)	O
.	O

However	O
,	O
we	O
found	O
that	O
allelic	O
and	O
genotypic	O
frequencies	O
for	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
the	O
last	O
quarter	O
of	O
the	O
century	O
are	O
significantly	O
different	O
compared	O
to	O
the	O
previous	O
generation	O
(	O
1951	O
-	O
1975	O
)	O
.	O

The	O
genotype	O
frequencies	O
in	O
the	O
last	O
quarter	O
of	O
the	O
century	O
are	O
not	O
the	O
expected	O
by	O
a	O
HW	O
calculation	O
using	O
the	O
allelic	O
frequencies	O
of	O
the	O
previous	O
generation	O
.	O

This	O
could	O
be	O
described	O
as	O
a	O
consequence	O
of	O
genetic	O
selection	O
found	O
in	O
this	O
population	O
,	O
in	O
the	O
absence	O
of	O
other	O
causes	O
.	O

Applying	O
the	O
mathematical	O
model	O
described	O
above	O
to	O
our	O
population	O
,	O
the	O
calculated	O
fitness	O
(	O
s	O
)	O
is	O
0	O
.	O
5	O
,	O
and	O
it	O
can	O
be	O
predicted	O
that	O
both	O
alleles	O
will	O
be	O
approximately	O
at	O
a	O
frequency	O
of	O
50	O
%	O
in	O
the	O
next	O
generation	O
and	O
allele	O
T	O
will	O
be	O
at	O
90	O
%	O
after	O
seven	O
generations	O
(	O
Figure	O
1A	O
)	O
.	O

Another	O
possibility	O
is	O
that	O
a	O
scenario	O
could	O
be	O
predicted	O
in	O
which	O
both	O
alleles	O
will	O
have	O
frequencies	O
of	O
about	O
50	O
%	O
in	O
the	O
next	O
generation	O
and	O
that	O
they	O
will	O
maintain	O
this	O
stability	O
while	O
conditions	O
remain	O
unchanged	O
.	O

(	O
Figure	O
1B	O
)	O

The	O
comparison	O
of	O
the	O
genotype	O
frequencies	O
between	O
a	O
group	O
of	O
fetal	O
samples	O
from	O
SA	O
that	O
occurred	O
during	O
the	O
1980	O
-	O
1989	O
decade	O
and	O
living	O
subjects	O
born	O
in	O
the	O
same	O
decade	O
showed	O
significant	O
differences	O
in	O
genotype	O
frequencies	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

CC	O
genotypes	O
were	O
almost	O
absent	O
in	O
abortion	O
samples	O
compared	O
to	O
living	O
subjects	O
(	O
0	O
.	O
03	O
vs	O
0	O
.	O
33	O
)	O
,	O
while	O
CT	O
and	O
TT	O
genotypes	O
were	O
overrepresented	O
in	O
the	O
same	O
group	O
.	O

When	O
3	O
-	O
year	O
periods	O
are	O
studied	O
in	O
the	O
decade	O
,	O
we	O
detected	O
a	O
significant	O
increase	O
of	O
the	O
mutated	O
subjects	O
during	O
the	O
decade	O
(	O
CT	O
p	O
<	O
0	O
.	O
05	O
;	O
TT	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Allele	O
frequencies	O
showed	O
the	O
same	O
pattern	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Controls	O
showed	O
the	O
same	O
tendency	O
but	O
without	O
statistical	O
significance	O
.	O

(	O
Table	O
2	O
)	O

The	O
evolution	O
of	O
genotype	O
frequencies	O
during	O
the	O
1980	O
-	O
1989	O
decade	O
of	O
the	O
TT	O
genotypes	O
correlates	O
well	O
in	O
both	O
living	O
populations	O
as	O
well	O
as	O
fetal	O
samples	O
r	O
=	O
0	O
.	O
98	O
(	O
p	O
=	O
0	O
.	O
11	O
)	O
.	O

Discussion	O

Different	O
reports	O
show	O
that	O
the	O
prevalence	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
of	O
the	O
MTHFR	O
gene	O
differs	O
dramatically	O
among	O
human	S-Species
populations	O
.	O

Evidence	O
of	O
this	O
dynamism	O
can	O
be	O
observed	O
in	O
many	O
reports	O
:	O
frequency	O
variations	O
between	O
populations	O
that	O
are	O
geographically	O
very	O
close	O
,	O
even	O
in	O
the	O
same	O
country	O
[	O
8	O
]	O
;	O
changes	O
found	O
in	O
the	O
same	O
race	O
or	O
ethnic	O
group	O
such	O
as	O
Africans	O
[	O
10	O
,	O
11	O
]	O
and	O
African	O
-	O
Americans	O
[	O
12	O
]	O
;	O
the	O
high	O
prevalence	O
of	O
the	O
677C	O
>	O
T	O
poymorphism	O
in	O
populations	O
with	O
special	O
nutritional	O
features	O
such	O
as	O
Mexicans	O
[	O
9	O
]	O
and	O
Japanese	O
[	O
13	O
]	O
;	O
and	O
changes	O
in	O
frequencies	O
between	O
generations	O
of	O
the	O
same	O
population	O
,	O
as	O
has	O
been	O
observed	O
in	O
Spain	O
[	O
5	O
]	O
,	O
Switzerland	O
[	O
6	O
]	O
and	O
Japan	O
[	O
7	O
]	O
.	O

There	O
are	O
numerous	O
interpretations	O
of	O
this	O
great	O
diversity	O
,	O
and	O
most	O
tend	O
to	O
be	O
related	O
to	O
adaptation	O
to	O
external	O
conditions	O
such	O
as	O
climate	O
or	O
nutritional	O
status	O
.	O

Dependence	O
of	O
folate	O
degradation	O
on	O
skin	O
pigmentation	O
[	O
17	O
]	O
,	O
nutritional	O
habits	O
or	O
human	S-Species
intervention	O
periconceptional	O
periods	O
could	O
explain	O
this	O
genetic	O
variation	O
.	O

Definitely	O
,	O
external	O
factors	O
in	O
combination	O
with	O
different	O
levels	O
of	O
MTHFR	O
enzyme	O
activity	O
,	O
conditioned	O
by	O
polymorphisms	O
,	O
could	O
influence	O
the	O
fetal	O
viability	O
of	O
certain	O
genotypes	O
.	O

In	O
1998	O
,	O
we	O
suggested	O
the	O
possibility	O
of	O
genetic	O
selection	O
in	O
Spain	O
in	O
favor	O
of	O
the	O
mutants	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
in	O
the	O
MTHFR	O
gene	O
based	O
on	O
the	O
fact	O
that	O
treatment	O
with	O
vitamins	O
and	O
folates	O
during	O
pregnancy	O
increased	O
the	O
viability	O
of	O
fetuses	O
with	O
the	O
TT	O
homozygous	O
genotype	O
.	O

This	O
hypothesis	O
was	O
based	O
on	O
the	O
increase	O
in	O
the	O
number	O
of	O
mutated	O
individuals	O
found	O
in	O
our	O
population	O
since	O
the	O
mid	O
-	O
1970s	O
[	O
5	O
]	O
and	O
the	O
coincident	O
increased	O
intake	O
of	O
vitamins	O
and	O
folate	O
by	O
pregnant	O
women	S-Species
in	O
Spain	O
[	O
18	O
,	O
19	O
]	O
.	O

In	O
2002	O
,	O
a	O
new	O
study	O
found	O
changes	O
in	O
genotype	O
frequencies	O
for	O
the	O
677C	O
>	O
T	O
and	O
1298A	O
>	O
C	O
polymorphisms	O
in	O
different	O
age	O
groups	O
.	O

Total	O
homocysteine	O
(	O
tHcy	O
)	O
levels	O
in	O
plasma	O
were	O
also	O
analyzed	O
according	O
to	O
the	O
different	O
genotype	O
interactions	O
[	O
20	O
]	O
.	O

That	O
study	O
hypothesized	O
about	O
fetal	O
viability	O
and	O
about	O
a	O
genetic	O
selection	O
model	O
on	O
the	O
basis	O
of	O
non	O
-	O
linkage	O
disequilibrium	O
between	O
both	O
polymorphisms	O
.	O

Recently	O
,	O
a	O
study	O
with	O
fetal	O
and	O
control	O
populations	O
showed	O
the	O
strong	O
influence	O
of	O
these	O
polymorphisms	O
,	O
though	O
mainly	O
of	O
the	O
677C	O
>	O
T	O
polymorphism	O
,	O
on	O
spontaneous	O
early	O
abortion	O
[	O
21	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
significant	O
changes	O
in	O
allelic	O
and	O
genotypic	O
frequencies	O
are	O
detected	O
,	O
as	O
is	O
Hardy	O
-	O
Weinberg	O
disequilibrium	O
,	O
at	O
the	O
677C	O
>	O
T	O
polymorphism	O
.	O

We	O
hypothesize	O
that	O
there	O
is	O
a	O
dynamic	O
process	O
of	O
genetic	O
selection	O
that	O
favors	O
the	O
T	O
allele	O
.	O

This	O
process	O
of	O
selection	O
started	O
during	O
the	O
last	O
quarter	O
of	O
the	O
20th	O
century	O
,	O
during	O
which	O
the	O
frequency	O
for	O
mutant	O
homozygous	O
(	O
TT	O
)	O
rose	O
significantly	O
from	O
14	O
%	O
to	O
24	O
%	O
.	O

We	O
propose	O
that	O
this	O
increase	O
in	O
mutants	O
is	O
due	O
to	O
the	O
inclusion	O
of	O
an	O
external	O
factor	O
that	O
enhances	O
mutant	O
fetal	O
viability	O
.	O

If	O
we	O
apply	O
the	O
mathematical	O
model	O
for	O
dynamic	O
selection	O
developed	O
for	O
diploid	O
organisms	O
with	O
sexual	O
reproduction	O
,	O
the	O
T	O
allele	O
could	O
reach	O
to	O
90	O
%	O
in	O
seven	O
generations	O
in	O
our	O
population	O
(	O
Figure	O
1A	O
)	O
.	O

However	O
,	O
this	O
model	O
assumes	O
selection	O
in	O
a	O
constant	O
environment	O
that	O
applies	O
to	O
all	O
individuals	O
in	O
the	O
population	O
studied	O
.	O

In	O
our	O
case	O
,	O
we	O
suggest	O
that	O
the	O
external	O
factor	O
is	O
related	O
to	O
an	O
increase	O
in	O
folate	O
and	O
vitamin	O
intake	O
in	O
women	S-Species
in	O
periconceptional	O
period	O
and	O
does	O
not	O
affect	O
to	O
all	O
individuals	O
[	O
18	O
,	O
19	O
]	O
.	O

We	O
assume	O
that	O
prediction	O
of	O
a	O
classic	O
selection	O
model	O
in	O
this	O
case	O
is	O
only	O
theoretical	O
.	O

On	O
the	O
basis	O
of	O
a	O
competition	O
between	O
alleles	O
in	O
which	O
an	O
environmental	O
factor	O
favors	O
one	O
allele	O
versus	O
the	O
other	O
,	O
the	O
final	O
result	O
would	O
be	O
that	O
predicted	O
by	O
the	O
previous	O
mathematical	O
model	O
.	O

However	O
in	O
this	O
case	O
,	O
the	O
environment	O
is	O
not	O
selecting	O
against	O
the	O
wild	O
type	O
allele	O
but	O
rather	O
allowing	O
the	O
survival	O
of	O
more	O
mutated	O
alleles	O
.	O

Therefore	O
,	O
the	O
expected	O
result	O
would	O
be	O
not	O
a	O
systematic	O
increase	O
of	O
the	O
mutated	O
allele	O
but	O
the	O
creation	O
of	O
an	O
allelic	O
balance	O
dependent	O
on	O
vitamin	O
and	O
folate	O
abundance	O
conditions	O
.	O

In	O
this	O
case	O
,	O
the	O
mutation	O
would	O
have	O
a	O
lower	O
influence	O
on	O
fetal	O
viability	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
results	O
showed	O
an	O
increase	O
in	O
mutated	O
genotypes	O
(	O
CT	O
and	O
TT	O
)	O
and	O
a	O
strong	O
protection	O
against	O
abortion	O
by	O
the	O
wild	O
type	O
genotype	O
(	O
CC	O
)	O
,	O
which	O
is	O
practically	O
non	O
-	O
existent	O
in	O
the	O
SA	O
group	O
.	O

The	O
frequency	O
of	O
the	O
CC	O
genotype	O
shows	O
no	O
change	O
over	O
the	O
decade	O
studied	O
(	O
1980	O
-	O
1989	O
)	O
,	O
which	O
indicates	O
that	O
folate	O
does	O
not	O
exert	O
a	O
visible	O
effect	O
on	O
this	O
genotype	O
.	O

However	O
,	O
the	O
frequency	O
of	O
the	O
mutated	O
allele	O
increases	O
during	O
this	O
decade	O
,	O
especially	O
in	O
fetuses	O
from	O
abortions	O
,	O
and	O
this	O
increase	O
correlated	O
with	O
the	O
increase	O
of	O
the	O
T	O
allele	O
in	O
the	O
control	O
population	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
effect	O
of	O
folate	O
is	O
crucial	O
to	O
viability	O
during	O
the	O
early	O
stages	O
of	O
embryonic	O
development	O
,	O
but	O
,	O
even	O
with	O
folate	O
,	O
not	O
all	O
embryos	O
will	O
survive	O
until	O
birth	O
.	O

In	O
this	O
population	O
,	O
the	O
mutant	O
allele	O
with	O
lower	O
enzymatic	O
activity	O
has	O
higher	O
fitness	O
than	O
the	O
wild	O
type	O
.	O

In	O
the	O
folate	O
cycle	O
,	O
it	O
can	O
be	O
observed	O
that	O
5	O
,	O
10	O
-	O
methyleneTHF	O
availability	O
may	O
be	O
important	O
.	O

5	O
,	O
10	O
-	O
methyleneTHF	O
is	O
the	O
substrate	O
for	O
several	O
reactions	O
in	O
the	O
cycle	O
,	O
but	O
two	O
of	O
them	O
(	O
5	O
-	O
methylTHF	O
and	O
thymidilate	O
synthesis	O
)	O
might	O
be	O
essential	O
for	O
embryo	O
development	O
in	O
folate	O
deficiency	O
conditions	O
.	O

In	O
both	O
cases	O
,	O
complete	O
or	O
limited	O
MTHFR	O
activity	O
will	O
produce	O
higher	O
or	O
lower	O
5	O
,	O
10	O
-	O
methyleneTHF	O
availability	O
,	O
which	O
might	O
be	O
an	O
essential	O
factor	O
for	O
embryo	O
development	O
,	O
such	O
that	O
a	O
greater	O
folate	O
levels	O
can	O
compensate	O
the	O
lower	O
enzymatic	O
activity	O
of	O
the	O
mutant	O
.	O

The	O
implications	O
of	O
this	O
polymorphism	O
in	O
nucleotide	O
synthesis	O
have	O
not	O
yet	O
been	O
determined	O
,	O
but	O
certain	O
data	O
,	O
such	O
as	O
high	O
levels	O
of	O
uric	O
acid	O
found	O
in	O
mutated	O
subjects	O
[	O
22	O
,	O
23	O
]	O
,	O
suggest	O
that	O
there	O
are	O
different	O
turnover	O
rates	O
associated	O
with	O
different	O
polymorphisms	O
.	O

Conclusion	O

We	O
suggest	O
that	O
there	O
is	O
genetic	O
selection	O
in	O
our	O
population	O
for	O
the	O
T	O
allele	O
of	O
the	O
MTHFR	O
-	O
677C	O
>	O
T	O
polymorphism	O
,	O
whose	O
origin	O
could	O
be	O
an	O
increase	O
in	O
fetal	O
viability	O
during	O
the	O
early	O
stages	O
of	O
embryonic	O
development	O
because	O
of	O
an	O
increase	O
in	O
folate	O
and	O
vitamin	O
intake	O
by	O
women	S-Species
in	O
the	O
periconceptional	O
period	O
that	O
began	O
to	O
be	O
established	O
in	O
Spain	O
in	O
the	O
last	O
quarter	O
of	O
the	O
20th	O
century	O
[	O
18	O
,	O
19	O
]	O
.	O

Higher	O
frequencies	O
for	O
the	O
T	O
allele	O
and	O
TT	O
genotype	O
in	O
our	O
population	O
are	O
observed	O
in	O
the	O
living	O
and	O
SA	O
populations	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

AMO	O
performed	O
the	O
statistical	O
analysis	O
,	O
helped	O
to	O
draft	O
the	O
manuscript	O
and	O
revised	O
it	O
for	O
publication	O
.	O

GC	O
is	O
the	O
corresponding	O
author	O
,	O
participated	O
in	O
the	O
acquisition	O
of	O
samples	O
and	O
carried	O
out	O
the	O
genotyping	O
.	O

ARP	O
carried	O
out	O
the	O
bibliographic	O
search	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

AJJ	O
participated	O
in	O
the	O
selection	O
and	O
the	O
processing	O
of	O
samples	O
.	O

MJG	O
coordinated	O
the	O
laboratory	O
work	O
and	O
selected	O
the	O
genotyping	O
method	O
.	O

AR	O
selected	O
the	O
control	O
subjects	O
and	O
designed	O
the	O
consent	O
form	O
.	O

MR	O
helped	O
in	O
the	O
interpretation	O
of	O
data	O
and	O
tables	O
performance	O
.	O

ARE	O
conceived	O
the	O
study	O
and	O
is	O
the	O
guarantor	O
of	O
this	O
work	O
and	O
the	O
general	O
coordinator	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Protein	O
subfamily	O
assignment	O
using	O
the	O
Conserved	O
Domain	O
Database	O

Abstract	O

Background	O

Domains	O
,	O
evolutionarily	O
conserved	O
units	O
of	O
proteins	O
,	O
are	O
widely	O
used	O
to	O
classify	O
protein	O
sequences	O
and	O
infer	O
protein	O
function	O
.	O

Often	O
,	O
two	O
or	O
more	O
overlapping	O
domain	O
models	O
match	O
a	O
region	O
of	O
a	O
protein	O
sequence	O
.	O

Therefore	O
,	O
procedures	O
are	O
required	O
to	O
choose	O
appropriate	O
domain	O
annotations	O
for	O
the	O
protein	O
.	O

Here	O
,	O
we	O
propose	O
a	O
method	O
for	O
assigning	O
NCBI	O
-	O
curated	O
domains	O
from	O
the	O
Curated	O
Domain	O
Database	O
(	O
CDD	O
)	O
that	O
takes	O
into	O
account	O
the	O
organization	O
of	O
the	O
domains	O
into	O
hierarchies	O
of	O
homologous	O
domain	O
models	O
.	O

Findings	O

Our	O
analysis	O
of	O
alignment	O
scores	O
from	O
NCBI	O
-	O
curated	O
domain	O
assignments	O
suggests	O
that	O
identifying	O
the	O
correct	O
model	O
among	O
closely	O
related	O
models	O
is	O
more	O
difficult	O
than	O
choosing	O
between	O
non	O
-	O
overlapping	O
domain	O
models	O
.	O

We	O
find	O
that	O
simple	O
heuristics	O
based	O
on	O
sorting	O
scores	O
and	O
domain	O
-	O
specific	O
thresholds	O
are	O
effective	O
at	O
reducing	O
classification	O
error	O
.	O

In	O
fact	O
,	O
in	O
our	O
test	O
set	O
,	O
the	O
heuristics	O
result	O
in	O
almost	O
90	O
%	O
of	O
current	O
misclassifications	O
due	O
to	O
missing	O
domain	O
subfamilies	O
being	O
replaced	O
by	O
more	O
generic	O
domain	O
assignments	O
,	O
thereby	O
eliminating	O
a	O
significant	O
amount	O
of	O
error	O
within	O
the	O
database	O
.	O

Conclusion	O

Our	O
proposed	O
domain	O
subfamily	O
assignment	O
rule	O
has	O
been	O
incorporated	O
into	O
the	O
CD	O
-	O
Search	O
software	O
for	O
assigning	O
CDD	O
domains	O
to	O
query	O
protein	O
sequences	O
and	O
has	O
significantly	O
improved	O
pre	O
-	O
calculated	O
domain	O
annotations	O
on	O
protein	O
sequences	O
in	O
NCBI	O
'	O
s	O
Entrez	O
resource	O
.	O

Background	O

A	O
major	O
goal	O
in	O
the	O
post	O
-	O
genomic	O
world	O
is	O
to	O
infer	O
protein	O
function	O
from	O
sequence	O
information	O
.	O

One	O
popular	O
approach	O
is	O
to	O
classify	O
protein	O
families	O
or	O
domains	O
by	O
grouping	O
homologous	O
sequences	O
and	O
annotating	O
the	O
groups	O
with	O
properties	O
such	O
as	O
general	O
function	O
,	O
intracellular	O
location	O
,	O
three	O
-	O
dimensional	O
structure	O
,	O
conserved	O
sequence	O
patterns	O
or	O
motifs	O
,	O
evolutionary	O
origin	O
,	O
and	O
binding	O
and	O
active	O
sites	O
.	O

Novel	O
proteins	O
can	O
be	O
characterized	O
quickly	O
by	O
assigning	O
a	O
group	O
via	O
profile	O
search	O
methods	O
.	O

However	O
,	O
more	O
than	O
one	O
family	O
or	O
subfamily	O
may	O
exhibit	O
similarity	O
to	O
overlapping	O
sequence	O
intervals	O
and	O
to	O
a	O
degree	O
that	O
seems	O
convincing	O
(	O
Figure	O
1	O
)	O
.	O

Assigning	O
the	O
protein	O
to	O
the	O
correct	O
group	O
not	O
only	O
yields	O
the	O
correct	O
annotations	O
,	O
but	O
may	O
also	O
help	O
to	O
avoid	O
propagating	O
annotation	O
errors	O
and	O
alleviate	O
current	O
issues	O
with	O
mislabelling	O
in	O
protein	O
sequence	O
databases	O
[	O
1	O
,	O
2	O
]	O
.	O

Here	O
,	O
we	O
examine	O
the	O
problem	O
of	O
making	O
correct	O
domain	O
assignments	O
from	O
the	O
Conserved	O
Domain	O
Database	O
[	O
3	O
,	O
4	O
]	O
.	O

Domains	O
are	O
evolutionarily	O
conserved	O
units	O
in	O
proteins	O
and	O
frequently	O
correspond	O
to	O
recurrent	O
structural	O
and	O
functional	O
units	O
.	O

The	O
particular	O
function	O
of	O
a	O
protein	O
depends	O
on	O
its	O
combination	O
of	O
domains	O
;	O
two	O
-	O
thirds	O
of	O
prokaryotic	O
proteins	O
and	O
80	O
%	O
of	O
eukaryotic	O
proteins	O
have	O
more	O
than	O
one	O
domain	O
.	O

To	O
create	O
new	O
protein	O
functions	O
,	O
novel	O
domain	O
architectures	O
arise	O
through	O
domain	O
rearrangement	O
and	O
recombination	O
,	O
frequently	O
through	O
gene	O
duplication	O
and	O
fission	O
or	O
fusion	O
events	O
[	O
5	O
,	O
6	O
]	O
.	O

A	O
domain	O
may	O
be	O
represented	O
as	O
a	O
multiple	O
sequence	O
alignment	O
(	O
MSA	O
)	O
of	O
homologous	O
sequence	O
fragments	O
.	O

To	O
identify	O
the	O
domains	O
in	O
a	O
query	O
protein	O
sequence	O
,	O
the	O
MSAs	O
are	O
converted	O
into	O
scoring	O
models	O
such	O
as	O
hidden	O
Markov	O
model	O
or	O
position	O
-	O
specific	O
scoring	O
matrix	O
for	O
use	O
with	O
database	O
search	O
algorithms	O
such	O
HMMER	O
[	O
7	O
]	O
and	O
RPS	O
-	O
BLAST	O
[	O
8	O
]	O
.	O

To	O
refine	O
protein	O
annotation	O
,	O
domains	O
models	O
may	O
be	O
subdivided	O
to	O
represent	O
more	O
specific	O
functions	O
or	O
conserved	O
features	O
.	O

CDD	O
curators	O
apply	O
phylogenetic	O
and	O
structural	O
analysis	O
to	O
construct	O
hierarchies	O
of	O
homologous	O
domain	O
models	O
,	O
related	O
by	O
common	O
descent	O
,	O
to	O
reflect	O
aspects	O
of	O
their	O
evolutionary	O
histories	O
[	O
3	O
,	O
4	O
]	O
.	O

Curation	O
follows	O
an	O
iterative	O
procedure	O
to	O
split	O
domain	O
models	O
into	O
subfamilies	O
that	O
redistributes	O
sequences	O
into	O
more	O
narrowly	O
defined	O
models	O
.	O

In	O
the	O
hierarchy	O
tree	O
structure	O
,	O
the	O
leaf	O
domains	O
represent	O
highly	O
conserved	O
and	O
often	O
orthologous	O
protein	O
subgroups	O
.	O

Their	O
precursor	O
(	O
internal	O
)	O
domains	O
,	O
on	O
the	O
other	O
hand	O
,	O
reflect	O
ancient	O
gene	O
duplication	O
events	O
,	O
as	O
CDD	O
aims	O
to	O
categorize	O
ancient	O
conserved	O
domain	O
families	O
.	O

It	O
may	O
seem	O
natural	O
that	O
once	O
the	O
profiles	O
have	O
been	O
defined	O
,	O
the	O
most	O
significant	O
match	O
to	O
a	O
query	O
sequence	O
is	O
the	O
correct	O
one	O
.	O

Indeed	O
,	O
domains	O
from	O
Pfam	O
[	O
9	O
,	O
10	O
]	O
and	O
SMART	O
[	O
11	O
]	O
are	O
assigned	O
following	O
the	O
lowest	O
alignment	O
E	O
-	O
value	O
that	O
exceeds	O
a	O
family	O
-	O
specific	O
cutoff	O
[	O
12	O
,	O
13	O
]	O
.	O

This	O
straightforward	O
approach	O
works	O
well	O
when	O
the	O
candidate	O
domains	O
are	O
disjoint	O
.	O

Domain	O
subfamilies	O
may	O
be	O
obtained	O
through	O
automated	O
methods	O
such	O
as	O
the	O
SCI	O
-	O
PHY	O
algorithm	O
for	O
identifying	O
functional	O
subtypes	O
of	O
known	O
domain	O
families	O
[	O
14	O
,	O
15	O
]	O
or	O
by	O
mirroring	O
other	O
hierarchical	O
domain	O
classifications	O
such	O
as	O
SCOP	O
[	O
16	O
]	O
and	O
CATH	O
[	O
17	O
]	O
.	O

However	O
,	O
subfamily	O
assignment	O
methods	O
generally	O
attempt	O
to	O
classify	O
a	O
member	O
of	O
a	O
family	O
at	O
the	O
subfamily	O
level	O
given	O
that	O
the	O
family	O
is	O
known	O
,	O
as	O
in	O
a	O
statistical	O
pairwise	O
/	O
profile	O
method	O
proposed	O
for	O
SUPERFAMILY	O
[	O
18	O
-	O
20	O
]	O
.	O

The	O
systematic	O
arrangement	O
of	O
CDD	O
domains	O
requires	O
identifying	O
the	O
most	O
suitable	O
level	O
of	O
resolution	O
among	O
domain	O
models	O
that	O
offer	O
more	O
or	O
less	O
fine	O
-	O
grained	O
descriptions	O
of	O
a	O
protein	O
.	O

We	O
take	O
the	O
viewpoint	O
that	O
if	O
a	O
protein	O
cannot	O
be	O
associated	O
unambiguously	O
with	O
a	O
specific	O
subgroup	O
or	O
may	O
be	O
a	O
member	O
of	O
a	O
subgroup	O
that	O
has	O
not	O
been	O
defined	O
,	O
the	O
protein	O
can	O
be	O
assigned	O
a	O
more	O
generic	O
domain	O
model	O
or	O
the	O
superfamily	O
in	O
general	O
.	O

Consequently	O
the	O
ideal	O
domain	O
assignment	O
to	O
a	O
query	O
sequence	O
will	O
be	O
the	O
most	O
specific	O
domain	O
,	O
within	O
a	O
candidate	O
hierarchy	O
,	O
with	O
a	O
strong	O
match	O
to	O
the	O
sequence	O
.	O

Here	O
,	O
we	O
analyze	O
a	O
set	O
of	O
correct	O
domain	O
assignments	O
from	O
CDD	O
to	O
establish	O
an	O
improved	O
method	O
for	O
assigning	O
domains	O
to	O
query	O
sequences	O
.	O

The	O
effectiveness	O
of	O
a	O
traditional	O
alignment	O
score	O
and	O
domain	O
-	O
specific	O
threshold	O
is	O
of	O
particular	O
interest	O
,	O
as	O
this	O
method	O
is	O
efficient	O
and	O
makes	O
use	O
of	O
alignment	O
information	O
that	O
is	O
already	O
computed	O
for	O
CDD	O
.	O

Constructing	O
a	O
benchmark	O
set	O
of	O
correct	O
domain	O
assignments	O

To	O
benchmark	O
domain	O
assignment	O
heuristics	O
,	O
a	O
reference	O
set	O
of	O
domain	O
assignments	O
is	O
constructed	O
from	O
the	O
NCBI	O
-	O
curated	O
portion	O
of	O
CDD	O
v	O
.	O

2	O
.	O
12	O
.	O

This	O
set	O
contains	O
every	O
sequence	O
fragment	O
present	O
among	O
the	O
MSAs	O
and	O
its	O
domain	O
assignment	O
.	O

The	O
NCBI	O
-	O
curated	O
domains	O
have	O
undergone	O
rigorous	O
testing	O
to	O
optimize	O
the	O
MSAs	O
and	O
distributions	O
of	O
representative	O
sequence	O
fragments	O
.	O

The	O
correct	O
or	O
most	O
specific	O
domain	O
for	O
each	O
sequence	O
in	O
a	O
hierarchy	O
is	O
defined	O
as	O
the	O
domain	O
having	O
no	O
descendant	O
that	O
contains	O
an	O
overlapping	O
sequence	O
interval	O
.	O

Two	O
sequence	O
intervals	O
from	O
one	O
protein	O
are	O
said	O
to	O
overlap	O
if	O
one	O
sequence	O
interval	O
contains	O
at	O
least	O
30	O
%	O
of	O
the	O
positions	O
of	O
the	O
other	O
.	O

While	O
each	O
sequence	O
has	O
been	O
placed	O
in	O
the	O
most	O
specific	O
domain	O
model	O
that	O
characterizes	O
it	O
,	O
this	O
step	O
is	O
required	O
as	O
parent	O
and	O
child	O
domains	O
share	O
overlapping	O
sequences	O
(	O
Figure	O
1	O
)	O
.	O

Sequences	O
with	O
overlapping	O
regions	O
from	O
more	O
than	O
one	O
hierarchy	O
are	O
counted	O
once	O
for	O
each	O
hierarchy	O
.	O

Non	O
-	O
overlapping	O
regions	O
of	O
a	O
protein	O
are	O
treated	O
independently	O
.	O

Alignments	O
between	O
all	O
NCBI	O
-	O
curated	O
domains	O
and	O
proteins	O
present	O
in	O
the	O
public	O
Entrez	O
protein	O
set	O
at	O
time	O
of	O
analysis	O
(	O
September	O
2007	O
)	O
[	O
21	O
]	O
have	O
been	O
pre	O
-	O
computed	O
using	O
RPS	O
-	O
BLAST	O
.	O

In	O
this	O
analysis	O
,	O
the	O
alignment	O
score	O
refers	O
to	O
the	O
bitscore	O
,	O
a	O
normalized	O
version	O
of	O
the	O
raw	O
alignment	O
score	O
between	O
the	O
query	O
sequence	O
and	O
the	O
PSSM	O
,	O
which	O
allows	O
alignments	O
from	O
different	O
searches	O
to	O
be	O
compared	O
.	O

The	O
bitscore	O
corresponds	O
roughly	O
to	O
the	O
alignment	O
E	O
-	O
value	O
and	O
is	O
used	O
instead	O
to	O
avoid	O
real	O
value	O
rounding	O
issues	O
.	O

A	O
significant	O
PSSM	O
-	O
sequence	O
alignment	O
is	O
called	O
a	O
hit	O
,	O
for	O
brevity	O
.	O

We	O
call	O
a	O
match	O
between	O
a	O
sequence	O
region	O
and	O
its	O
correct	O
domain	O
a	O
self	O
hit	O
to	O
distinguish	O
it	O
from	O
other	O
hits	O
to	O
overlapping	O
sequence	O
regions	O
.	O

Other	O
hits	O
to	O
the	O
sequences	O
in	O
the	O
reference	O
dataset	O
serve	O
as	O
examples	O
of	O
incorrect	O
domain	O
assignments	O
.	O

CDD	O
v	O
2	O
.	O
12	O
contains	O
3078	O
NCBI	O
-	O
curated	O
domains	O
in	O
495	O
hierarchies	O
,	O
including	O
298	O
single	O
-	O
domain	O
"	O
hierarchies	O
"	O
and	O
197	O
trees	O
with	O
2357	O
leaf	O
and	O
423	O
internal	O
domains	O
.	O

Many	O
sequence	O
fragments	O
used	O
to	O
construct	O
the	O
NCBI	O
-	O
curated	O
domain	O
profiles	O
come	O
from	O
proteins	O
that	O
have	O
been	O
replaced	O
with	O
newer	O
versions	O
or	O
declared	O
obsolete	O
.	O

Among	O
the	O
109186	O
representative	O
sequences	O
in	O
NCBI	O
-	O
curated	O
domain	O
hierarchies	O
,	O
over	O
21	O
%	O
have	O
no	O
hits	O
and	O
more	O
than	O
90	O
%	O
of	O
those	O
sequences	O
are	O
no	O
longer	O
present	O
in	O
Entrez	O
.	O

This	O
analysis	O
excludes	O
the	O
149	O
curated	O
domains	O
without	O
corresponding	O
live	O
data	O
in	O
Entrez	O
,	O
leaving	O
2929	O
domains	O
.	O

Performance	O
of	O
a	O
simple	O
high	O
-	O
score	O
assignment	O
method	O

We	O
begin	O
by	O
assessing	O
the	O
performance	O
of	O
the	O
previous	O
method	O
for	O
assigning	O
NCBI	O
-	O
curated	O
domains	O
from	O
CDD	O
.	O

The	O
NCBI	O
CD	O
-	O
Search	O
tool	O
[	O
22	O
]	O
has	O
historically	O
relied	O
on	O
alignment	O
E	O
-	O
value	O
and	O
properties	O
such	O
as	O
the	O
source	O
domain	O
database	O
to	O
highlight	O
one	O
or	O
a	O
few	O
most	O
likely	O
domain	O
assignments	O
,	O
without	O
claiming	O
to	O
pinpoint	O
the	O
correct	O
domain	O
assignment	O
.	O

Analysis	O
of	O
all	O
hits	O
to	O
the	O
sequences	O
in	O
the	O
benchmark	O
set	O
reveals	O
that	O
assigning	O
domains	O
by	O
high	O
alignment	O
score	O
alone	O
achieves	O
96	O
%	O
accuracy	O
over	O
all	O
sequences	O
and	O
100	O
%	O
accuracy	O
over	O
the	O
representative	O
sequences	O
for	O
91	O
.	O
5	O
%	O
of	O
domain	O
models	O
.	O

Further	O
,	O
categorizing	O
non	O
-	O
self	O
hits	O
by	O
their	O
hierarchical	O
relationships	O
to	O
the	O
correct	O
domain	O
reveals	O
that	O
assigning	O
to	O
a	O
subclass	O
of	O
the	O
correct	O
domain	O
is	O
the	O
most	O
common	O
type	O
of	O
error	O
when	O
a	O
sequence	O
matches	O
the	O
correct	O
domain	O
and	O
other	O
domains	O
(	O
Table	O
1	O
)	O
.	O

For	O
simplicity	O
,	O
all	O
non	O
-	O
self	O
hits	O
are	O
labelled	O
as	O
incorrect	O
hits	O
in	O
the	O
tables	O
although	O
some	O
child	O
/	O
descendant	O
and	O
parent	O
/	O
ancestor	O
assignments	O
may	O
not	O
be	O
regarded	O
as	O
actual	O
classification	O
errors	O
.	O

Child	O
/	O
descendant	O
domains	O
score	O
higher	O
than	O
the	O
self	O
hit	O
for	O
21	O
.	O
8	O
%	O
of	O
sequences	O
with	O
both	O
types	O
of	O
hits	O
.	O

These	O
higher	O
scores	O
may	O
reflect	O
computational	O
bias	O
from	O
longer	O
profiles	O
,	O
overly	O
cautious	O
assignment	O
of	O
a	O
sequence	O
to	O
a	O
more	O
generic	O
domain	O
,	O
or	O
missing	O
subfamilies	O
.	O

In	O
contrast	O
,	O
higher	O
scores	O
from	O
parent	O
/	O
ancestor	O
domains	O
or	O
domains	O
from	O
other	O
branches	O
of	O
a	O
hierarchy	O
are	O
rarely	O
observed	O
.	O

For	O
additional	O
data	O
and	O
discussion	O
of	O
all	O
analyses	O
described	O
in	O
this	O
document	O
,	O
see	O
[	O
Additional	O
file	O
1	O
]	O
.	O

We	O
define	O
a	O
score	O
threshold	O
for	O
each	O
domain	O
to	O
be	O
the	O
lowest	O
self	O
-	O
hit	O
score	O
to	O
that	O
domain	O
among	O
all	O
of	O
its	O
sequences	O
in	O
the	O
benchmark	O
set	O
.	O

This	O
additional	O
heuristic	O
,	O
in	O
particular	O
,	O
reduces	O
incorrect	O
assignments	O
to	O
subclasses	O
as	O
only	O
9	O
.	O
1	O
%	O
of	O
hits	O
to	O
subclasses	O
score	O
above	O
the	O
thresholds	O
for	O
those	O
subclasses	O
(	O
Table	O
2	O
)	O
.	O

The	O
threshold	O
definition	O
works	O
around	O
the	O
issue	O
of	O
small	O
data	O
size	O
-	O
over	O
60	O
%	O
of	O
domains	O
have	O
20	O
or	O
fewer	O
self	O
hits	O
-	O
and	O
addresses	O
variances	O
in	O
scores	O
between	O
domains	O
due	O
to	O
properties	O
such	O
as	O
length	O
and	O
residue	O
composition	O
,	O
or	O
practical	O
issues	O
such	O
as	O
incomplete	O
local	O
alignments	O
,	O
which	O
are	O
not	O
considered	O
by	O
simple	O
high	O
-	O
score	O
heuristics	O
.	O

The	O
definition	O
is	O
more	O
restrictive	O
than	O
its	O
Pfam	O
counterpart	O
,	O
the	O
minimum	O
alignment	O
score	O
among	O
all	O
sequences	O
in	O
the	O
automated	O
"	O
full	O
alignment	O
"	O
,	O
as	O
NCBI	O
-	O
curated	O
hierarchies	O
in	O
CDD	O
tend	O
to	O
present	O
a	O
finer	O
-	O
grained	O
classification	O
of	O
a	O
protein	O
domain	O
family	O
.	O

Proposed	O
rule	O
for	O
specific	O
domain	O
assignment	O

We	O
propose	O
to	O
label	O
a	O
single	O
domain	O
as	O
correct	O
or	O
specific	O
for	O
a	O
protein	O
sequence	O
region	O
if	O
its	O
alignment	O
score	O
is	O
highest	O
among	O
all	O
domains	O
that	O
align	O
to	O
overlapping	O
regions	O
of	O
the	O
protein	O
sequence	O
and	O
the	O
score	O
exceeds	O
a	O
pre	O
-	O
calculated	O
threshold	O
for	O
the	O
domain	O
,	O
defined	O
as	O
the	O
minimum	O
alignment	O
score	O
among	O
confirmed	O
members	O
of	O
the	O
domain	O
.	O

Sequence	O
intervals	O
that	O
are	O
difficult	O
to	O
group	O
with	O
a	O
specific	O
subclass	O
with	O
high	O
confidence	O
following	O
this	O
rule	O
may	O
receive	O
only	O
generic	O
domain	O
assignments	O
.	O

Assuming	O
that	O
the	O
set	O
of	O
overlapping	O
domains	O
represents	O
an	O
ancient	O
domain	O
superfamily	O
,	O
such	O
a	O
generic	O
assignment	O
would	O
be	O
characterized	O
as	O
membership	O
with	O
the	O
respective	O
superfamily	O
.	O

Reducing	O
misclassifications	O
and	O
errors	O
due	O
to	O
missing	O
subfamilies	O

A	O
more	O
concrete	O
picture	O
of	O
the	O
effect	O
of	O
the	O
proposed	O
rule	O
may	O
be	O
gleaned	O
by	O
quantifying	O
misclassifications	O
,	O
defined	O
to	O
be	O
either	O
descendants	O
of	O
the	O
correct	O
domain	O
or	O
domains	O
that	O
lie	O
in	O
other	O
branches	O
of	O
the	O
correct	O
hierarchy	O
.	O

Averaged	O
over	O
domains	O
in	O
multi	O
-	O
domain	O
hierarchies	O
and	O
counting	O
only	O
sequences	O
with	O
self	O
hits	O
,	O
the	O
misclassification	O
rate	O
using	O
high	O
scores	O
only	O
is	O
2	O
.	O
6	O
%	O
.	O

Incorporating	O
score	O
thresholds	O
to	O
eliminate	O
low	O
-	O
scoring	O
best	O
hits	O
reduces	O
the	O
misclassification	O
rate	O
to	O
0	O
.	O
85	O
%	O
.	O

Misclassifications	O
may	O
also	O
be	O
used	O
to	O
estimate	O
error	O
due	O
to	O
missing	O
subfamilies	O
.	O

Not	O
all	O
subclasses	O
in	O
a	O
domain	O
hierarchy	O
may	O
have	O
been	O
identified	O
as	O
the	O
available	O
sequence	O
databases	O
only	O
provide	O
a	O
terse	O
snapshot	O
of	O
protein	O
domain	O
diversity	O
.	O

We	O
simulate	O
a	O
cross	O
-	O
validation	O
experiment	O
to	O
ask	O
,	O
if	O
an	O
existing	O
domain	O
model	O
were	O
missing	O
from	O
a	O
hierarchy	O
,	O
what	O
fraction	O
of	O
its	O
sequence	O
intervals	O
have	O
best	O
hits	O
to	O
other	O
models	O
in	O
the	O
hierarchy	O
that	O
are	O
not	O
ancestors	O
of	O
the	O
correct	O
model	O
?	O

Averaged	O
over	O
leaf	O
domains	O
,	O
50	O
.	O
9	O
%	O
of	O
domain	O
assignments	O
made	O
from	O
high	O
alignment	O
score	O
alone	O
are	O
misclassifications	O
,	O
compared	O
to	O
6	O
.	O
0	O
%	O
of	O
domain	O
assignments	O
after	O
thresholds	O
are	O
used	O
to	O
screen	O
hits	O
.	O

Function	O
and	O
classification	O
through	O
specific	O
domain	O
assignments	O
:	O
Glycyl	O
radical	O
enzymes	O

To	O
illustrate	O
the	O
effect	O
of	O
our	O
proposed	O
method	O
,	O
we	O
examine	O
domain	O
assignments	O
from	O
the	O
glycyl	O
radical	O
enzymes	O
(	O
RNR	O
_	O
PFL	O
hierarchy	O
)	O
.	O

Its	O
subgroups	O
have	O
distinct	O
and	O
important	O
functions	O
,	O
including	O
ribonucleotide	O
reductases	O
(	O
RNRs	O
)	O
,	O
which	O
synthesize	O
deoxyribonucleotides	O
,	O
and	O
pyruvate	O
-	O
formate	O
lysases	O
(	O
PFLs	O
)	O
,	O
a	O
family	O
of	O
catabolic	O
enzymes	O
.	O

The	O
proposed	O
method	O
places	O
the	O
sequence	O
[	O
Entrez	O
:	O
CAA42118	O
]	O
into	O
RNR	O
class	O
1	O
and	O
places	O
[	O
Entrez	O
:	O
AAZ61477	O
]	O
into	O
RNR	O
class	O
-	O
1	O
-	O
like	O
domain	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
are	O
inferred	O
by	O
their	O
subclass	O
.	O

Other	O
proteins	O
receive	O
generic	O
assignments	O
to	O
this	O
family	O
.	O

For	O
example	O
,	O
PFL2	O
(	O
cd01677	O
)	O
is	O
the	O
best	O
match	O
to	O
[	O
Entrez	O
:	O
ABX41552	O
]	O
and	O
[	O
Entrez	O
:	O
EDQ26237	O
]	O
with	O
alignment	O
scores	O
that	O
fall	O
short	O
of	O
the	O
PFL2	O
threshold	O
.	O

The	O
first	O
alignment	O
includes	O
a	O
long	O
insertion	O
(	O
gap	O
)	O
,	O
and	O
the	O
latter	O
exhibits	O
weak	O
sequence	O
similarity	O
;	O
in	O
both	O
of	O
these	O
scenarios	O
the	O
transfer	O
of	O
functional	O
annotation	O
may	O
not	O
be	O
straightforward	O
.	O

Domain	O
assignments	O
also	O
help	O
to	O
make	O
biological	O
insights	O
.	O

RNRs	O
fall	O
into	O
classes	O
that	O
use	O
different	O
mechanisms	O
and	O
/	O
or	O
cofactors	O
.	O

Class	O
1	O
is	O
oxygen	O
dependent	O
and	O
class	O
3	O
is	O
used	O
by	O
strictly	O
or	O
facultative	O
anaerobic	O
organisms	O
.	O

RNR	O
_	O
1	O
_	O
like	O
has	O
a	O
similar	O
active	O
site	O
to	O
class	O
1	O
and	O
at	O
the	O
time	O
of	O
curation	O
,	O
no	O
specific	O
literature	O
was	O
available	O
about	O
this	O
subclass	O
.	O

We	O
observed	O
that	O
the	O
strictly	O
anaerobic	O
organism	O
Chlorobium	B-Species
limicola	E-Species
DSM	O
24	O
has	O
RNR	O
_	O
3	O
proteins	O
(	O
e	O
.	O
g	O
.	O
[	O
Entrez	O
:	O
ZP	O
_	O
00512827	O
]	O
)	O
as	O
well	O
as	O
an	O
enzyme	O
(	O
[	O
Entrez	O
:	O
ZP	O
_	O
00512727	O
]	O
)	O
that	O
matches	O
RNR	O
_	O
1	O
_	O
like	O
,	O
suggesting	O
that	O
RNR	O
_	O
1	O
_	O
like	O
,	O
a	O
subfamily	O
lacking	O
experimental	O
characterization	O
,	O
may	O
contain	O
non	O
-	O
oxygen	O
dependent	O
versions	O
of	O
RNR	O
_	O
1	O
.	O

Discussion	O

While	O
many	O
sequences	O
can	O
be	O
classified	O
by	O
sequence	O
similarity	O
,	O
profiles	O
of	O
protein	O
domain	O
families	O
make	O
it	O
possible	O
to	O
quickly	O
classify	O
more	O
distant	O
homologs	O
[	O
23	O
]	O
and	O
can	O
better	O
handle	O
multi	O
-	O
domain	O
proteins	O
.	O

An	O
important	O
step	O
in	O
transferring	O
annotations	O
from	O
known	O
protein	O
families	O
is	O
identifying	O
the	O
subclass	O
that	O
provides	O
the	O
best	O
characterization	O
for	O
the	O
protein	O
.	O

Here	O
,	O
we	O
conducted	O
the	O
first	O
focused	O
analysis	O
of	O
domain	O
assignments	O
from	O
CDD	O
in	O
order	O
to	O
assess	O
existing	O
methods	O
for	O
domain	O
and	O
domain	O
subfamily	O
assignment	O
and	O
identify	O
ways	O
to	O
improve	O
the	O
quality	O
of	O
assignments	O
.	O

We	O
find	O
that	O
best	O
-	O
scoring	O
hits	O
are	O
sometimes	O
too	O
specific	O
,	O
causing	O
a	O
sequence	O
to	O
be	O
mislabelled	O
by	O
a	O
subfamily	O
of	O
the	O
correct	O
domain	O
.	O

We	O
propose	O
a	O
subclass	O
assignment	O
procedure	O
that	O
enables	O
concrete	O
assignments	O
,	O
computed	O
quickly	O
using	O
existing	O
data	O
,	O
and	O
demonstrate	O
that	O
this	O
procedure	O
largely	O
avoids	O
over	O
-	O
predictions	O
or	O
false	O
positive	O
assignments	O
and	O
is	O
robust	O
enough	O
to	O
deal	O
with	O
situations	O
such	O
as	O
incomplete	O
hierarchies	O
in	O
which	O
not	O
all	O
subfamilies	O
have	O
been	O
identified	O
.	O

We	O
elected	O
to	O
not	O
employ	O
standard	O
jack	O
-	O
knife	O
or	O
cross	O
-	O
validation	O
testing	O
for	O
a	O
sequence	O
against	O
its	O
correct	O
domain	O
,	O
as	O
the	O
task	O
is	O
to	O
classify	O
sequence	O
fragments	O
that	O
are	O
very	O
similar	O
to	O
a	O
subfamily	O
,	O
where	O
the	O
subfamily	O
model	O
is	O
also	O
constructed	O
from	O
very	O
similar	O
sequences	O
.	O

Although	O
the	O
sequence	O
and	O
domain	O
databases	O
evolve	O
rapidly	O
,	O
we	O
expect	O
our	O
findings	O
to	O
provide	O
an	O
accurate	O
snapshot	O
for	O
some	O
time	O
.	O

A	O
version	O
of	O
our	O
proposed	O
method	O
has	O
been	O
incorporated	O
into	O
the	O
current	O
version	O
of	O
the	O
CD	O
-	O
Search	O
program	O
and	O
the	O
pre	O
-	O
calculated	O
annotation	O
of	O
proteins	O
with	O
domains	O
in	O
NCBI	O
'	O
s	O
Entrez	O
system	O
.	O

Domain	O
assignments	O
to	O
specific	O
orthologous	O
subfamilies	O
or	O
ancient	O
subfamilies	O
are	O
distinguished	O
from	O
non	O
-	O
specific	O
assignments	O
to	O
a	O
domain	O
superfamily	O
.	O

High	O
-	O
confidence	O
annotation	O
of	O
functional	O
sites	O
is	O
also	O
provided	O
following	O
these	O
results	O
.	O

We	O
hope	O
the	O
improved	O
ability	O
to	O
quickly	O
and	O
accurately	O
classify	O
proteins	O
will	O
be	O
a	O
valuable	O
step	O
toward	O
simplifying	O
protein	O
sequence	O
analysis	O
and	O
the	O
computational	O
annotation	O
of	O
genomes	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

JF	O
carried	O
out	O
the	O
experiments	O
and	O
drafted	O
the	O
manuscript	O
.	O

AMB	O
conceived	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
,	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

Supplementary	O
Material	O

Identification	O
of	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
professionals	O
in	O
Ontario	O
,	O
Canada	O
:	O
results	O
from	O
expert	O
panels	O

Abstract	O

Background	O

Demand	O
for	O
rehabilitation	O
services	O
is	O
expected	O
to	O
increase	O
due	O
to	O
factors	O
such	O
as	O
an	O
aging	O
population	O
,	O
workforce	O
pressures	O
,	O
rise	O
in	O
chronic	O
and	O
complex	O
multi	O
-	O
system	O
disorders	O
,	O
advances	O
in	O
technology	O
,	O
and	O
changes	O
in	O
interprofessional	O
health	O
service	O
delivery	O
models	O
.	O

However	O
,	O
health	O
human	S-Species
resource	O
(	O
HHR	O
)	O
strategies	O
for	O
Canadian	O
rehabilitation	O
professionals	O
are	O
lagging	O
behind	O
other	O
professional	O
groups	O
such	O
as	O
physicians	O
and	O
nurses	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
:	O
1	O
)	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
of	O
rehabilitation	O
professionals	O
including	O
occupational	O
therapists	O
,	O
physical	O
therapists	O
and	O
speech	O
language	O
pathologists	O
from	O
the	O
literature	O
;	O
and	O
2	O
)	O
to	O
investigate	O
both	O
the	O
importance	O
and	O
feasibility	O
of	O
the	O
identified	O
strategies	O
using	O
expert	O
panels	O
amongst	O
HHR	O
and	O
education	O
experts	O
.	O

Methods	O

A	O
review	O
of	O
the	O
literature	O
was	O
conducted	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
professionals	O
.	O

Two	O
expert	O
panels	O
,	O
one	O
on	O
Recruitment	O
and	O
Retention	O
and	O
the	O
other	O
on	O
Education	O
were	O
convened	O
to	O
determine	O
the	O
importance	O
and	O
feasibility	O
of	O
the	O
identified	O
strategies	O
.	O

A	O
modified	O
-	O
delphi	O
process	O
was	O
used	O
to	O
gain	O
consensus	O
and	O
to	O
rate	O
the	O
identified	O
strategies	O
along	O
these	O
two	O
dimensions	O
.	O

Results	O

A	O
total	O
of	O
34	O
strategies	O
were	O
identified	O
by	O
the	O
Recruitment	O
and	O
Retention	O
and	O
Education	O
expert	O
panels	O
as	O
being	O
important	O
and	O
feasible	O
for	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
.	O

Seven	O
were	O
categorized	O
under	O
the	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
theme	O
,	O
another	O
seven	O
in	O
Financial	O
Incentives	O
and	O
Marketing	O
,	O
two	O
in	O
Workload	O
and	O
Skill	O
Mix	O
,	O
thirteen	O
in	O
Professional	O
Development	O
and	O
five	O
in	O
Education	O
and	O
Training	O
.	O

Conclusion	O

Based	O
on	O
the	O
results	O
from	O
the	O
expert	O
panels	O
,	O
the	O
three	O
major	O
areas	O
of	O
focus	O
for	O
HHR	O
planning	O
in	O
the	O
rehabilitation	O
sector	O
should	O
include	O
strategies	O
addressing	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
,	O
Financial	O
Incentives	O
and	O
Marketing	O
and	O
Professional	O
Development	O
.	O

Background	O

Demand	O
for	O
rehabilitation	O
services	O
is	O
expected	O
to	O
increase	O
within	O
the	O
next	O
decade	O
primarily	O
due	O
to	O
factors	O
such	O
as	O
an	O
aging	O
population	O
,	O
workforce	O
pressures	O
,	O
rise	O
in	O
chronic	O
and	O
complex	O
multi	O
-	O
system	O
disorders	O
,	O
advances	O
in	O
technology	O
,	O
and	O
changes	O
in	O
health	O
service	O
delivery	O
models	O
[	O
1	O
-	O
4	O
]	O
.	O

In	O
Canada	O
,	O
rehabilitation	O
personnel	O
constitute	O
the	O
third	O
largest	O
health	O
professional	O
group	O
after	O
nurses	O
and	O
physicians	O
.	O

Despite	O
the	O
size	O
of	O
this	O
workforce	O
,	O
studies	O
have	O
consistently	O
reported	O
ongoing	O
shortages	O
of	O
physiotherapists	O
(	O
PTs	O
)	O
,	O
occupational	O
therapists	O
(	O
OTs	O
)	O
and	O
speech	O
-	O
language	O
pathologists	O
(	O
SLPs	O
)	O
across	O
all	O
jurisdictions	O
[	O
5	O
-	O
7	O
]	O
.	O

Similarly	O
,	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
has	O
been	O
considered	O
a	O
challenge	O
internationally	O
,	O
nationally	O
and	O
provincially	O
.	O

At	O
the	O
international	O
level	O
,	O
the	O
literature	O
reports	O
recruitment	O
and	O
retention	O
difficulties	O
of	O
rehabilitation	O
therapists	O
in	O
countries	O
such	O
as	O
Australia	O
,	O
New	O
Zealand	O
,	O
United	O
Kingdom	O
and	O
the	O
United	O
States	O
[	O
8	O
-	O
13	O
]	O
.	O

Provinces	O
across	O
Canada	O
face	O
similar	O
issues	O
;	O
with	O
Ontario	O
projected	O
to	O
face	O
the	O
most	O
difficulty	O
due	O
to	O
its	O
population	O
growth	O
rate	O
[	O
14	O
]	O
.	O

Based	O
on	O
the	O
Canadian	O
Institute	O
for	O
Health	O
Information	O
'	O
s	O
Health	O
Personnel	O
Trends	O
in	O
Canada	O
from	O
1993	O
to	O
2002	O
report	O
,	O
numerous	O
factors	O
have	O
been	O
suggested	O
to	O
influence	O
demand	O
for	O
physiotherapy	O
and	O
occupational	O
therapy	O
services	O
.	O

Factors	O
that	O
may	O
influence	O
increase	O
demand	O
for	O
physiotherapy	O
include	O
:	O
shift	O
in	O
health	O
service	O
delivery	O
models	O
from	O
hospital	O
to	O
community	O
care	O
;	O
earlier	O
patient	S-Species
discharge	O
;	O
increased	O
expectations	O
from	O
aging	O
Canadians	O
concerning	O
more	O
active	O
lifestyles	O
;	O
growing	O
private	O
practice	O
sector	O
and	O
continued	O
shortages	O
for	O
PTs	O
in	O
both	O
private	O
and	O
public	O
sectors	O
in	O
rural	O
,	O
remote	O
and	O
urban	O
settings	O
across	O
Canada	O
[	O
2	O
]	O
.	O

In	O
1993	O
,	O
an	O
Ontario	O
study	O
stated	O
that	O
in	O
order	O
to	O
meet	O
demands	O
of	O
changing	O
health	O
care	O
policy	O
,	O
medical	O
technology	O
and	O
demographic	O
changes	O
in	O
the	O
population	O
,	O
the	O
PT	O
profession	O
required	O
an	O
annual	O
growth	O
rate	O
of	O
4	O
.	O
4	O
%	O
until	O
the	O
year	O
2000	O
[	O
5	O
]	O
.	O

However	O
,	O
the	O
national	O
health	O
personnel	O
databases	O
revealed	O
that	O
the	O
actual	O
average	O
annual	O
growth	O
rate	O
of	O
active	O
PTs	O
in	O
Canada	O
from	O
1995	O
to	O
2004	O
was	O
only	O
2	O
.	O
5	O
%	O
,	O
approximately	O
half	O
of	O
the	O
projected	O
requirement	O
suggested	O
to	O
meet	O
demand	O
[	O
15	O
]	O
.	O

Similarly	O
,	O
in	O
Ontario	O
in	O
the	O
early	O
1990s	O
an	O
increase	O
in	O
demand	O
for	O
OTs	O
was	O
projected	O
because	O
of	O
the	O
reported	O
shortage	O
in	O
OTs	O
and	O
high	O
attrition	O
rate	O
[	O
16	O
]	O
.	O

The	O
shortage	O
of	O
OTs	O
was	O
explained	O
by	O
another	O
Ontario	O
study	O
to	O
be	O
the	O
result	O
of	O
the	O
changing	O
philosophies	O
of	O
care	O
and	O
management	O
for	O
the	O
disabled	O
,	O
and	O
a	O
clearer	O
understanding	O
of	O
the	O
role	O
of	O
OT	O
in	O
the	O
physical	O
and	O
mental	O
well	O
-	O
being	O
of	O
the	O
disabled	O
[	O
17	O
]	O
.	O

In	O
terms	O
of	O
actual	O
shortages	O
,	O
some	O
authors	O
have	O
reported	O
ongoing	O
vacancies	O
and	O
recruitment	O
difficulties	O
for	O
OTs	O
[	O
11	O
,	O
18	O
]	O
while	O
others	O
have	O
reported	O
an	O
increase	O
in	O
demand	O
for	O
both	O
PTs	O
[	O
19	O
]	O
and	O
OTs	O
[	O
20	O
]	O
.	O

Speech	O
language	O
pathology	O
is	O
facing	O
similar	O
service	O
demands	O
.	O

A	O
report	O
released	O
in	O
March	O
2003	O
by	O
the	O
College	O
of	O
Audiologists	O
and	O
Speech	O
-	O
Language	O
Pathologists	O
of	O
Ontario	O
(	O
CASLPO	O
)	O
concluded	O
that	O
based	O
on	O
prevalence	O
rates	O
for	O
Ontario	O
residents	O
with	O
speech	O
,	O
language	O
and	O
related	O
disorders	O
,	O
the	O
demand	O
for	O
service	O
would	O
increase	O
by	O
13	O
%	O
while	O
the	O
number	O
of	O
SLPs	O
would	O
decrease	O
by	O
4	O
%	O
resulting	O
in	O
an	O
overall	O
reduction	O
in	O
service	O
of	O
15	O
%	O
[	O
21	O
]	O
.	O

The	O
American	O
Speech	O
-	O
Language	O
-	O
Hearing	O
Association	O
(	O
ASHA	O
)	O
has	O
been	O
tracking	O
SLP	O
vacancies	O
.	O

In	O
their	O
2005	O
ASHA	O
Speech	O
-	O
Language	O
Pathology	O
Health	O
Care	O
survey	O
,	O
48	O
%	O
of	O
respondents	O
indicated	O
that	O
they	O
had	O
funded	O
unfilled	O
positions	O
for	O
SLPS	O
in	O
their	O
agency	O
[	O
22	O
]	O
.	O

The	O
same	O
survey	O
also	O
reported	O
that	O
65	O
%	O
of	O
respondents	O
in	O
home	O
care	O
indicated	O
that	O
job	O
openings	O
were	O
more	O
numerous	O
than	O
job	O
seekers	O
in	O
their	O
geographic	O
area	O
.	O

While	O
labour	O
market	O
demand	O
and	O
supply	O
are	O
influential	O
factors	O
on	O
recruitment	O
and	O
retention	O
decisions	O
,	O
the	O
development	O
of	O
strategies	O
requires	O
an	O
understanding	O
of	O
conceptual	O
frameworks	O
or	O
theories	O
to	O
categorise	O
and	O
explain	O
how	O
other	O
underlying	O
factors	O
impact	O
health	O
worker	O
'	O
s	O
mobility	O
.	O

For	O
example	O
,	O
Lehmann	O
et	O
al	O
.	O
'	O
s	O
model	O
described	O
that	O
health	O
worker	O
'	O
s	O
decisions	O
to	O
accept	O
and	O
stay	O
in	O
remote	O
areas	O
in	O
the	O
public	O
sector	O
depends	O
on	O
two	O
interrelated	O
aspects	O
:	O
the	O
impact	O
of	O
the	O
different	O
environments	O
(	O
i	O
.	O
e	O
.	O
individual	O
,	O
local	O
,	O
work	O
,	O
national	O
and	O
international	O
)	O
and	O
the	O
location	O
of	O
decision	O
-	O
makers	O
(	O
i	O
.	O
e	O
.	O
local	O
government	O
,	O
Ministry	O
of	O
Health	O
,	O
HR	O
directorate	O
,	O
public	O
service	O
and	O
other	O
ministries	O
)	O
[	O
23	O
]	O
.	O

Behavioural	O
and	O
social	O
science	O
theories	O
,	O
such	O
as	O
those	O
explained	O
by	O
Tett	O
and	O
Meyer	O
,	O
found	O
that	O
job	O
satisfaction	O
and	O
organizational	O
commitment	O
each	O
contribute	O
independently	O
to	O
the	O
prediction	O
of	O
the	O
intention	O
to	O
resign	O
(	O
turnover	O
)	O
,	O
however	O
job	O
satisfaction	O
was	O
a	O
stronger	O
predictor	O
than	O
organizational	O
commitment	O
[	O
24	O
]	O
.	O

Based	O
on	O
this	O
notion	O
,	O
considerable	O
research	O
has	O
been	O
devoted	O
to	O
identifying	O
factors	O
that	O
affect	O
job	O
satisfaction	O
among	O
rehabilitation	O
professionals	O
.	O

While	O
there	O
is	O
no	O
single	O
,	O
agreed	O
upon	O
model	O
of	O
job	O
satisfaction	O
,	O
a	O
variety	O
of	O
theoretical	O
models	O
have	O
been	O
studied	O
to	O
explain	O
concepts	O
and	O
relationships	O
associated	O
with	O
overall	O
job	O
satisfaction	O
.	O

The	O
two	O
most	O
commonly	O
used	O
theories	O
of	O
job	O
satisfaction	O
for	O
rehabilitation	O
professionals	O
are	O
the	O
Herzberg	O
'	O
s	O
Motivation	O
-	O
Hygiene	O
Theory	O
[	O
25	O
]	O
and	O
Mottaz	O
'	O
s	O
concepts	O
of	O
work	O
values	O
and	O
work	O
rewards	O
[	O
26	O
]	O
.	O

A	O
number	O
of	O
rehabilitation	O
studies	O
have	O
used	O
the	O
Herzberg	O
'	O
s	O
Motivation	O
-	O
Hygiene	O
Theory	O
,	O
also	O
known	O
as	O
the	O
two	O
-	O
factor	O
theory	O
of	O
motivation	O
to	O
explain	O
associations	O
between	O
motivation	O
,	O
job	O
satisfaction	O
and	O
retention	O
factors	O
among	O
OTs	O
,	O
PTs	O
and	O
SLPs	O
[	O
27	O
-	O
31	O
]	O
.	O

Frederick	O
Herzberg	O
et	O
al	O
.	O
explained	O
that	O
there	O
were	O
two	O
independent	O
incidents	O
occurring	O
at	O
peoples	S-Species
'	O
jobs	O
:	O
one	O
that	O
made	O
them	O
feel	O
good	O
or	O
satisfied	O
,	O
and	O
another	O
that	O
made	O
them	O
feel	O
bad	O
or	O
dissatisfied	O
at	O
work	O
[	O
25	O
]	O
.	O

Intrinsic	O
factors	O
that	O
motivate	O
people	S-Species
such	O
as	O
achievement	O
,	O
recognition	O
,	O
work	O
itself	O
,	O
responsibility	O
,	O
advancement	O
and	O
personal	O
growth	O
were	O
called	O
the	O
"	O
motivators	O
"	O
which	O
lead	O
to	O
feelings	O
of	O
satisfaction	O
.	O

Extrinsic	O
factors	O
such	O
as	O
work	O
conditions	O
,	O
company	O
policies	O
,	O
supervision	O
,	O
interpersonal	O
work	O
relations	O
,	O
salary	O
and	O
job	O
security	O
,	O
known	O
as	O
"	O
hygiene	O
"	O
factors	O
,	O
were	O
claimed	O
to	O
prevent	O
dissatisfaction	O
.	O

"	O
Motivators	O
"	O
directly	O
affect	O
a	O
person	S-Species
'	O
s	O
motivational	O
drive	O
to	O
do	O
a	O
good	O
job	O
,	O
therefore	O
they	O
are	O
believed	O
to	O
be	O
more	O
important	O
than	O
hygiene	O
factors	O
.	O

Mottaz	O
on	O
the	O
other	O
hand	O
,	O
accounted	O
for	O
individual	O
differences	O
in	O
job	O
satisfaction	O
among	O
workers	O
and	O
based	O
his	O
study	O
on	O
two	O
dimensions	O
:	O
"	O
work	O
rewards	O
"	O
and	O
"	O
work	O
values	O
"	O
[	O
26	O
]	O
.	O

"	O
Work	O
rewards	O
"	O
are	O
perceived	O
characteristics	O
of	O
the	O
job	O
and	O
have	O
three	O
conceptual	O
clusters	O
which	O
include	O
task	O
,	O
social	O
and	O
organizational	O
rewards	O
[	O
26	O
]	O
.	O

Mottaz	O
describes	O
"	O
task	O
rewards	O
"	O
(	O
intrinsic	O
)	O
as	O
having	O
five	O
independent	O
characteristics	O
including	O
:	O
skill	O
variety	O
,	O
task	O
identity	O
,	O
task	O
significance	O
,	O
autonomy	O
and	O
feedback	O
.	O

Examples	O
include	O
interesting	O
and	O
challenging	O
work	O
,	O
self	O
-	O
direction	O
and	O
responsibility	O
,	O
creativity	O
,	O
opportunities	O
to	O
use	O
one	O
'	O
s	O
skills	O
and	O
feedback	O
.	O

In	O
the	O
same	O
study	O
,	O
Mottaz	O
stated	O
that	O
"	O
social	O
rewards	O
"	O
(	O
extrinsic	O
)	O
are	O
derived	O
from	O
the	O
interpersonal	O
relationships	O
established	O
with	O
others	O
at	O
work	O
.	O

Having	O
supportive	O
colleagues	O
and	O
supervisors	O
is	O
an	O
example	O
of	O
this	O
dimension	O
.	O

Lastly	O
,	O
"	O
organizational	O
rewards	O
"	O
(	O
extrinsic	O
)	O
are	O
tangible	O
rewards	O
that	O
are	O
provided	O
by	O
the	O
employer	O
/	O
organization	O
to	O
facilitate	O
performance	O
.	O

Such	O
factors	O
include	O
working	O
conditions	O
,	O
pay	O
and	O
fringe	O
benefits	O
,	O
career	O
advancement	O
and	O
security	O
.	O

The	O
second	O
dimension	O
of	O
job	O
satisfaction	O
is	O
based	O
on	O
"	O
work	O
values	O
"	O
,	O
which	O
is	O
the	O
importance	O
that	O
individuals	O
place	O
on	O
their	O
work	O
rewards	O
[	O
26	O
]	O
.	O

For	O
example	O
,	O
some	O
rehabilitation	O
therapists	O
may	O
value	O
extrinsic	O
rewards	O
such	O
as	O
pay	O
and	O
benefits	O
as	O
more	O
important	O
than	O
intrinsic	O
factors	O
like	O
clinical	O
autonomy	O
and	O
challenging	O
work	O
.	O

Although	O
the	O
Herzberg	O
and	O
Mottaz	O
conceptual	O
frameworks	O
are	O
organized	O
differently	O
,	O
their	O
job	O
satisfaction	O
variables	O
are	O
very	O
similar	O
(	O
i	O
.	O
e	O
.	O
work	O
conditions	O
,	O
pay	O
,	O
interpersonal	O
relationships	O
,	O
etc	O
.	O
)	O
and	O
they	O
both	O
classify	O
these	O
factors	O
as	O
having	O
intrinsic	O
or	O
extrinsic	O
elements	O
.	O

Despite	O
the	O
growing	O
body	O
of	O
literature	O
on	O
recruitment	O
and	O
retention	O
factors	O
in	O
various	O
industries	O
,	O
there	O
is	O
a	O
minimal	O
amount	O
of	O
research	O
studying	O
these	O
factors	O
specifically	O
among	O
rehabilitation	O
professionals	O
.	O

One	O
published	O
study	O
however	O
,	O
did	O
look	O
at	O
extrinsic	O
and	O
intrinsic	O
job	O
satisfaction	O
factors	O
on	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
(	O
OTs	O
,	O
PTs	O
and	O
SLPs	O
)	O
[	O
32	O
]	O
.	O

Results	O
from	O
this	O
study	O
showed	O
that	O
intrinsic	O
factors	O
such	O
as	O
professional	O
growth	O
and	O
having	O
a	O
work	O
environment	O
in	O
line	O
with	O
personal	O
values	O
are	O
more	O
significant	O
in	O
predicting	O
career	O
satisfaction	O
than	O
extrinsic	O
factors	O
such	O
as	O
pay	O
and	O
continuing	O
education	O
.	O

These	O
same	O
intrinsic	O
factors	O
are	O
also	O
significant	O
in	O
predicting	O
retention	O
in	O
rehabilitation	O
professionals	O
.	O

Another	O
study	O
looking	O
at	O
recruitment	O
and	O
retention	O
of	O
allied	O
health	O
professionals	O
in	O
the	O
rural	O
areas	O
in	O
New	O
South	O
Wales	O
identified	O
that	O
the	O
main	O
reasons	O
why	O
people	S-Species
liked	O
working	O
in	O
rural	O
areas	O
were	O
because	O
of	O
the	O
attractive	O
environment	O
and	O
helpful	O
team	O
members	O
[	O
33	O
]	O
.	O

However	O
82	O
%	O
of	O
employees	O
reported	O
that	O
having	O
their	O
partner	O
move	O
away	O
was	O
the	O
number	O
one	O
reason	O
for	O
leaving	O
a	O
rural	O
job	O
.	O

A	O
similar	O
study	O
was	O
conducted	O
among	O
OTs	O
and	O
PTs	O
in	O
Northwestern	O
Ontario	O
[	O
34	O
]	O
.	O

Findings	O
from	O
this	O
study	O
indicated	O
that	O
factors	O
contributing	O
to	O
initial	O
decision	O
on	O
location	O
of	O
practice	O
include	O
availability	O
of	O
leisure	O
/	O
recreation	O
activities	O
,	O
proximity	O
of	O
family	O
origin	O
and	O
influences	O
of	O
spouse	O
/	O
partners	O
.	O

Study	O
results	O
also	O
showed	O
that	O
the	O
main	O
reasons	O
therapists	O
left	O
their	O
job	O
were	O
to	O
be	O
closer	O
to	O
their	O
family	O
,	O
lack	O
of	O
job	O
opportunity	O
and	O
spousal	O
influence	O
.	O

Solely	O
understanding	O
factors	O
that	O
influence	O
recruitment	O
and	O
retention	O
decisions	O
is	O
not	O
sufficient	O
in	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
rehabilitation	O
professionals	O
.	O

In	O
order	O
for	O
the	O
plan	O
to	O
be	O
effective	O
and	O
sustainable	O
in	O
addressing	O
these	O
factors	O
,	O
the	O
most	O
important	O
and	O
feasible	O
workforce	O
strategies	O
needs	O
to	O
be	O
identified	O
.	O

There	O
have	O
been	O
a	O
number	O
of	O
reports	O
on	O
health	O
human	S-Species
resources	O
(	O
HHR	O
)	O
planning	O
,	O
recruitment	O
and	O
retention	O
strategies	O
for	O
physicians	O
[	O
35	O
,	O
36	O
]	O
and	O
nurses	O
[	O
37	O
]	O
,	O
however	O
information	O
regarding	O
rehabilitation	O
professionals	O
is	O
lacking	O
.	O

Canadian	O
reports	O
indicate	O
that	O
the	O
main	O
reason	O
for	O
significant	O
gaps	O
in	O
this	O
field	O
is	O
the	O
absence	O
of	O
current	O
and	O
reliable	O
data	O
available	O
on	O
supply	O
,	O
demand	O
and	O
labour	O
force	O
participation	O
trends	O
for	O
rehabilitation	O
therapists	O
[	O
38	O
-	O
40	O
]	O
.	O

There	O
is	O
some	O
research	O
that	O
has	O
investigated	O
theoretical	O
models	O
of	O
job	O
satisfaction	O
on	O
recruitment	O
and	O
retention	O
[	O
28	O
,	O
32	O
]	O
;	O
however	O
few	O
studies	O
have	O
looked	O
at	O
how	O
these	O
models	O
have	O
been	O
implemented	O
.	O

Other	O
studies	O
have	O
examined	O
the	O
relationship	O
of	O
gender	O
,	O
workplace	O
setting	O
(	O
i	O
.	O
e	O
.	O
hospital	O
,	O
ambulatory	O
,	O
rehabilitation	O
,	O
acute	O
and	O
long	O
-	O
term	O
care	O
)	O
and	O
geographical	O
location	O
(	O
i	O
.	O
e	O
.	O
rural	O
or	O
urban	O
)	O
on	O
job	O
satisfaction	O
and	O
retention	O
among	O
rehabilitation	O
professionals	O
[	O
41	O
-	O
43	O
]	O
.	O

Furthermore	O
,	O
no	O
empirical	O
studies	O
have	O
examined	O
conceptual	O
frameworks	O
for	O
organizing	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
therapists	O
.	O

To	O
address	O
this	O
gap	O
,	O
this	O
research	O
identified	O
recruitment	O
and	O
retention	O
strategies	O
from	O
the	O
literature	O
for	O
rehabilitation	O
professionals	O
and	O
determined	O
their	O
importance	O
and	O
feasibility	O
using	O
expert	O
panels	O
.	O

Methods	O

Phase	O
1	O
:	O
Literature	O
Review	O

Identification	O
of	O
recruitment	O
and	O
retention	O
strategies	O

A	O
review	O
of	O
the	O
literature	O
was	O
conducted	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
therapists	O
.	O

In	O
this	O
study	O
,	O
rehabilitation	O
professionals	O
were	O
defined	O
as	O
physical	O
therapists	O
(	O
PTs	O
)	O
,	O
occupational	O
therapists	O
(	O
OTs	O
)	O
and	O
speech	O
-	O
language	O
pathologists	O
(	O
SLPs	O
)	O
.	O

Both	O
published	O
and	O
non	O
-	O
empirical	O
literature	O
was	O
accessed	O
in	O
this	O
review	O
.	O

Keywords	O
used	O
to	O
search	O
for	O
relevant	O
published	O
studies	O
in	O
the	O
Consolidated	O
International	O
Nursing	O
and	O
Allied	O
Health	O
Sciences	O
Library	O
(	O
CINAHL	O
)	O
(	O
1982	O
to	O
2005	O
)	O
and	O
Medline	O
(	O
1996	O
to	O
2005	O
)	O
included	O
:	O
"	O
health	O
human	S-Species
resources	O
or	O
health	O
manpower	O
"	O
,	O
"	O
rehabilitation	O
or	O
rehabilitation	O
professionals	O
or	O
vocational	O
"	O
,	O
"	O
allied	O
health	O
professionals	O
or	O
personnel	O
"	O
,	O
"	O
recruitment	O
strategies	O
"	O
,	O
"	O
retention	O
strategies	O
"	O
,	O
"	O
physical	O
therapist	O
or	O
physiotherapist	O
"	O
,	O
"	O
occupational	O
therapy	O
or	O
occupational	O
therapist	O
"	O
,	O
"	O
speech	O
-	O
language	O
pathologist	O
or	O
speech	O
-	O
language	O
pathology	O
"	O
.	O

Non	O
-	O
empirical	O
literature	O
searches	O
were	O
made	O
on	O
international	O
and	O
national	O
on	O
-	O
line	O
catalogues	O
and	O
publications	O
from	O
health	O
organizations	O
,	O
professional	O
associations	O
,	O
and	O
hospital	O
and	O
home	O
care	O
organizations	O
.	O

International	O
reports	O
were	O
limited	O
to	O
developed	O
countries	O
since	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
strategies	O
appropriate	O
to	O
the	O
Ontario	O
setting	O
.	O

Organization	O
and	O
consolidation	O
of	O
strategies	O

There	O
was	O
a	O
paucity	O
of	O
peer	O
-	O
reviewed	O
studies	O
obtained	O
exploring	O
rehabilitation	O
HHR	O
strategies	O
,	O
therefore	O
the	O
majority	O
of	O
strategies	O
were	O
selected	O
from	O
grey	O
literature	O
reports	O
from	O
international	O
,	O
national	O
and	O
provincial	O
health	O
organizations	O
.	O

From	O
the	O
literature	O
review	O
,	O
107	O
potential	O
strategies	O
were	O
identified	O
according	O
to	O
their	O
relevance	O
to	O
HHR	O
issues	O
for	O
rehabilitation	O
in	O
Ontario	O
.	O

These	O
strategies	O
were	O
then	O
categorized	O
into	O
two	O
broad	O
groups	O
:	O
A	O
)	O
Recruitment	O
and	O
Retention	O
(	O
n	O
=	O
73	O
)	O
,	O
and	O
B	O
)	O
Education	O
(	O
n	O
=	O
34	O
)	O
.	O

The	O
majority	O
of	O
strategies	O
were	O
not	O
specific	O
to	O
rehabilitation	O
professionals	O
and	O
they	O
were	O
reviewed	O
by	O
a	O
group	O
of	O
three	O
individuals	O
collectively	O
(	O
rehabilitation	O
researcher	O
,	O
manager	O
,	O
and	O
clinician	O
)	O
for	O
duplication	O
,	O
clarity	O
,	O
action	O
focused	O
properties	O
and	O
appropriateness	O
to	O
the	O
Canadian	O
or	O
Ontario	O
setting	O
.	O

When	O
necessary	O
,	O
a	O
small	O
number	O
of	O
strategies	O
were	O
re	O
-	O
worded	O
to	O
be	O
relevant	O
to	O
a	O
rehabilitation	O
context	O
.	O

This	O
analysis	O
resulted	O
in	O
the	O
selection	O
of	O
40	O
Recruitment	O
and	O
Retention	O
and	O
24	O
Education	O
strategies	O
.	O

Only	O
14	O
recruitment	O
and	O
retention	O
and	O
six	O
education	O
strategies	O
were	O
obtained	O
from	O
peer	O
-	O
reviewed	O
articles	O
.	O

Since	O
the	O
majority	O
of	O
strategies	O
were	O
identified	O
from	O
the	O
grey	O
literature	O
,	O
it	O
was	O
not	O
surprising	O
that	O
there	O
was	O
no	O
apriori	O
peer	O
-	O
reviewed	O
conceptual	O
framework	O
that	O
reflected	O
the	O
breadth	O
of	O
the	O
strategies	O
obtained	O
from	O
the	O
literature	O
review	O
.	O

As	O
a	O
result	O
,	O
the	O
themes	O
used	O
by	O
the	O
Health	O
and	O
Community	O
Services	O
Human	S-Species
Resources	O
Sector	O
Study	O
in	O
Newfoundland	O
and	O
Labrador	O
[	O
44	O
]	O
formed	O
the	O
basis	O
for	O
the	O
organizational	O
framework	O
for	O
this	O
study	O
since	O
they	O
aligned	O
with	O
the	O
identified	O
strategies	O
.	O

Each	O
group	O
was	O
further	O
categorized	O
into	O
the	O
five	O
themes	O
(	O
three	O
for	O
Recruitment	O
and	O
Retention	O
and	O
two	O
for	O
Education	O
)	O
.	O

The	O
three	O
Recruitment	O
and	O
Retention	O
strategy	O
themes	O
were	O
:	O
(	O
1	O
)	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
[	O
n	O
=	O
19	O
]	O
;	O
(	O
2	O
)	O
Workload	O
and	O
Skill	O
Mix	O
[	O
n	O
=	O
6	O
]	O
;	O
and	O
(	O
3	O
)	O
Financial	O
Incentives	O
and	O
Marketing	O
[	O
n	O
=	O
15	O
]	O
.	O

The	O
two	O
Education	O
strategy	O
themes	O
were	O
:	O
(	O
1	O
)	O
Education	O
and	O
Training	O
[	O
n	O
=	O
11	O
]	O
and	O
(	O
2	O
)	O
Professional	O
Development	O
(	O
n	O
=	O
13	O
)	O
.	O

Phase	O
2	O
:	O
Expert	O
Panel	O

Participant	S-Species
Selection	O

Once	O
this	O
study	O
was	O
approved	O
by	O
the	O
Research	O
Ethics	O
Board	O
at	O
the	O
University	O
of	O
Toronto	O
,	O
key	O
informants	O
who	O
participated	O
in	O
a	O
previous	O
study	O
regarding	O
rehabilitation	O
supply	O
and	O
demand	O
at	O
the	O
University	O
of	O
Toronto	O
[	O
21	O
]	O
were	O
asked	O
to	O
nominate	O
potential	O
participants	S-Species
for	O
the	O
panels	O
.	O

The	O
selection	O
criteria	O
considered	O
were	O
acknowledged	O
leadership	O
in	O
the	O
panel	O
member	O
'	O
s	O
specialty	O
,	O
expertise	O
in	O
recruitment	O
and	O
retention	O
or	O
education	O
and	O
training	O
of	O
rehabilitation	O
professionals	O
.	O

Absence	O
of	O
conflicts	O
of	O
interest	O
,	O
geographic	O
diversity	O
,	O
and	O
diversity	O
of	O
practice	O
setting	O
were	O
also	O
considered	O
.	O

After	O
purposefully	O
selecting	O
the	O
initial	O
list	O
of	O
candidates	O
from	O
among	O
the	O
nominations	O
,	O
each	O
nominee	O
was	O
contacted	O
to	O
establish	O
their	O
interest	O
and	O
availability	O
.	O

Those	O
who	O
expressed	O
an	O
interest	O
in	O
participating	O
were	O
asked	O
to	O
send	O
their	O
curriculum	O
vitae	O
to	O
help	O
the	O
research	O
team	O
evaluate	O
their	O
contributions	O
to	O
their	O
field	O
of	O
expertise	O
.	O

Once	O
candidate	O
panelists	O
were	O
selected	O
,	O
each	O
received	O
a	O
letter	O
explaining	O
the	O
expert	O
panel	O
process	O
and	O
consent	O
form	O
.	O

Two	O
separate	O
panels	O
were	O
constructed	O
:	O
one	O
for	O
Recruitment	O
and	O
Retention	O
(	O
n	O
=	O
8	O
)	O
and	O
the	O
other	O
for	O
Education	O
(	O
n	O
=	O
9	O
)	O
(	O
Table	O
1	O
)	O
.	O

The	O
size	O
of	O
the	O
panel	O
was	O
large	O
enough	O
to	O
permit	O
diversity	O
of	O
representation	O
while	O
still	O
being	O
small	O
enough	O
to	O
allow	O
all	O
participants	S-Species
to	O
be	O
involved	O
in	O
the	O
group	O
discussion	O
[	O
45	O
]	O
.	O

Expert	O
Panel	O
Process	O
:	O
Round	O
1	O
Survey	O

A	O
modified	O
-	O
delphi	O
technique	O
was	O
then	O
used	O
for	O
the	O
expert	O
panel	O
process	O
,	O
[	O
46	O
,	O
47	O
]	O
based	O
on	O
the	O
RAND	O
/	O
UCLA	O
appropriateness	O
method	O
[	O
45	O
]	O
.	O

In	O
round	O
1	O
,	O
members	O
of	O
the	O
Recruitment	O
and	O
Retention	O
panel	O
were	O
sent	O
an	O
electronic	O
survey	O
containing	O
the	O
40	O
strategies	O
identified	O
from	O
the	O
literature	O
review	O
and	O
the	O
Education	O
panelists	O
were	O
also	O
sent	O
an	O
electronic	O
survey	O
with	O
24	O
strategies	O
.	O

For	O
Round	O
1	O
,	O
each	O
panel	O
was	O
asked	O
to	O
rate	O
the	O
strategies	O
using	O
a	O
nine	O
-	O
point	O
Likert	O
-	O
type	O
rating	O
scale	O
that	O
ranged	O
from	O
"	O
none	O
"	O
(	O
1	O
)	O
to	O
"	O
maximum	O
"	O
(	O
9	O
)	O
,	O
on	O
two	O
key	O
dimensions	O
:	O
Feasibility	O
and	O
Importance	O
.	O

Feasibility	O
was	O
defined	O
as	O
the	O
practicality	O
and	O
cost	O
implications	O
of	O
the	O
strategy	O
and	O
was	O
rated	O
from	O
the	O
respondents	O
'	O
perspective	O
.	O

Importance	O
was	O
defined	O
as	O
how	O
valuable	O
,	O
appropriate	O
and	O
useful	O
the	O
strategy	O
could	O
be	O
for	O
rehabilitation	O
HHR	O
planning	O
in	O
Ontario	O
.	O

At	O
the	O
end	O
of	O
the	O
survey	O
,	O
panelists	O
were	O
given	O
the	O
opportunity	O
to	O
suggest	O
additional	O
strategies	O
that	O
they	O
felt	O
were	O
appropriate	O
to	O
consider	O
.	O

Once	O
completed	O
,	O
panelists	O
were	O
asked	O
to	O
return	O
the	O
survey	O
to	O
the	O
study	O
office	O
by	O
email	O
or	O
fax	O
prior	O
to	O
the	O
expert	O
panel	O
meeting	O
in	O
Round	O
2	O
.	O

Data	O
from	O
each	O
questionnaire	O
were	O
entered	O
into	O
a	O
spreadsheet	O
and	O
tabulated	O
.	O

Descriptive	O
statistics	O
were	O
calculated	O
for	O
each	O
strategy	O
using	O
frequency	O
distributions	O
and	O
proportional	O
percentages	O
of	O
respondents	O
.	O

Importance	O
and	O
feasibility	O
rankings	O
were	O
based	O
on	O
the	O
percentage	O
of	O
expert	O
panelists	O
'	O
low	O
,	O
medium	O
and	O
high	O
ratings	O
.	O

Expert	O
Panel	O
Process	O
Round	O
2	O
:	O
Expert	O
Panel	O
one	O
-	O
day	O
meeting	O

After	O
the	O
independent	O
completion	O
of	O
the	O
survey	O
,	O
each	O
panel	O
was	O
convened	O
separately	O
for	O
a	O
one	O
-	O
day	O
meeting	O
for	O
final	O
discussions	O
,	O
debates	O
and	O
consensus	O
voting	O
to	O
decide	O
on	O
strategies	O
[	O
48	O
]	O
.	O

A	O
strategy	O
that	O
had	O
been	O
scored	O
7	O
,	O
8	O
or	O
9	O
for	O
both	O
feasibility	O
and	O
importance	O
by	O
two	O
-	O
thirds	O
of	O
the	O
panel	O
was	O
considered	O
a	O
high	O
rating	O
.	O

Strategies	O
that	O
had	O
a	O
combination	O
of	O
medium	O
and	O
high	O
scores	O
between	O
4	O
and	O
9	O
in	O
either	O
of	O
the	O
two	O
dimensions	O
were	O
considered	O
medium	O
rated	O
strategies	O
,	O
while	O
low	O
rated	O
strategies	O
had	O
scores	O
between	O
1	O
and	O
3	O
for	O
both	O
dimensions	O
.	O

On	O
the	O
day	O
of	O
the	O
meeting	O
,	O
the	O
panelists	O
were	O
given	O
a	O
copy	O
of	O
the	O
aggregated	O
survey	O
results	O
indicating	O
the	O
ratings	O
of	O
all	O
of	O
the	O
strategies	O
.	O

High	O
and	O
low	O
rated	O
strategies	O
were	O
not	O
discussed	O
as	O
there	O
was	O
already	O
consensus	O
,	O
whereas	O
all	O
medium	O
rated	O
strategies	O
were	O
subject	O
to	O
discussion	O
.	O

Using	O
a	O
nominal	O
group	O
process	O
[	O
47	O
]	O
,	O
each	O
strategy	O
was	O
discussed	O
in	O
turn	O
,	O
and	O
panelists	O
were	O
given	O
an	O
opportunity	O
to	O
raise	O
any	O
issues	O
or	O
concerns	O
regarding	O
the	O
clarity	O
and	O
wording	O
of	O
each	O
strategy	O
.	O

Each	O
of	O
the	O
strategies	O
discussed	O
were	O
then	O
individually	O
rated	O
a	O
second	O
time	O
by	O
each	O
panelist	O
in	O
an	O
attempt	O
to	O
reach	O
further	O
consensus	O
.	O

Results	O

Selection	O
of	O
strategies	O
for	O
Round	O
1	O
:	O
Modified	O
Delphi	O
process	O

Following	O
Round	O
1	O
rating	O
of	O
the	O
40	O
identified	O
strategies	O
,	O
the	O
Recruitment	O
and	O
Retention	O
panel	O
reached	O
consensus	O
on	O
12	O
strategies	O
.	O

However	O
,	O
14	O
had	O
a	O
combination	O
of	O
high	O
/	O
medium	O
importance	O
and	O
feasibility	O
ratings	O
and	O
14	O
had	O
medium	O
ratings	O
on	O
both	O
dimensions	O
,	O
therefore	O
it	O
required	O
further	O
discussion	O
.	O

An	O
additional	O
strategy	O
regarding	O
family	O
relocation	O
programs	O
was	O
added	O
by	O
this	O
panel	O
.	O

The	O
Education	O
Panel	O
ranked	O
16	O
of	O
24	O
strategies	O
with	O
high	O
importance	O
and	O
feasibility	O
after	O
Round	O
1	O
.	O

Since	O
there	O
were	O
only	O
eight	O
strategies	O
with	O
medium	O
ratings	O
,	O
this	O
expert	O
panel	O
decided	O
to	O
review	O
all	O
the	O
strategies	O
at	O
the	O
face	O
-	O
to	O
-	O
face	O
meeting	O
to	O
discuss	O
the	O
rationale	O
that	O
would	O
explain	O
why	O
some	O
of	O
the	O
highly	O
rated	O
strategies	O
were	O
not	O
already	O
implemented	O
and	O
to	O
come	O
to	O
a	O
consensus	O
on	O
the	O
other	O
eight	O
medium	O
rated	O
strategies	O
.	O

They	O
also	O
added	O
an	O
additional	O
strategy	O
for	O
career	O
paths	O
.	O

Selection	O
of	O
strategies	O
for	O
Round	O
2	O
:	O
Face	O
-	O
to	O
-	O
face	O
meeting	O

A	O
total	O
of	O
34	O
strategies	O
were	O
identified	O
by	O
both	O
the	O
Recruitment	O
and	O
Retention	O
and	O
Education	O
expert	O
panels	O
as	O
being	O
important	O
and	O
feasible	O
for	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
professionals	O
.	O

Under	O
the	O
Recruitment	O
and	O
Retention	O
theme	O
,	O
seven	O
were	O
categorized	O
as	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
;	O
two	O
were	O
Workload	O
and	O
Skill	O
Mix	O
,	O
and	O
another	O
seven	O
were	O
Financial	O
Incentives	O
and	O
Marketing	O
.	O

As	O
for	O
the	O
Education	O
panel	O
,	O
five	O
were	O
categorized	O
as	O
Education	O
and	O
Training	O
strategies	O
while	O
the	O
other	O
thirteen	O
were	O
related	O
to	O
Professional	O
Development	O
.	O

As	O
indicated	O
in	O
Table	O
2	O
,	O
at	O
the	O
end	O
of	O
the	O
second	O
round	O
of	O
voting	O
,	O
the	O
Recruitment	O
and	O
Retention	O
panel	O
had	O
a	O
total	O
of	O
16	O
highly	O
important	O
and	O
feasible	O
strategies	O
,	O
8	O
high	O
/	O
medium	O
importance	O
and	O
feasibility	O
,	O
8	O
medium	O
and	O
9	O
low	O
ratings	O
for	O
both	O
dimensions	O
.	O

The	O
Education	O
panel	O
on	O
the	O
other	O
hand	O
had	O
a	O
total	O
of	O
18	O
high	O
,	O
1	O
high	O
/	O
medium	O
,	O
3	O
medium	O
and	O
3	O
low	O
rating	O
strategies	O
.	O

Recruitment	O
and	O
Retention	O
Strategy	O
Rankings	O

Table	O
3	O
provides	O
a	O
detailed	O
description	O
and	O
ranking	O
of	O
each	O
of	O
the	O
recruitment	O
and	O
retention	O
strategies	O
that	O
were	O
rated	O
highly	O
important	O
and	O
feasible	O
.	O

The	O
importance	O
and	O
feasibility	O
rankings	O
were	O
based	O
on	O
the	O
largest	O
proportion	O
of	O
panel	O
members	O
rating	O
a	O
strategy	O
a	O
7	O
,	O
8	O
or	O
9	O
.	O

The	O
overall	O
combined	O
ranking	O
was	O
based	O
on	O
the	O
average	O
of	O
the	O
proportion	O
of	O
these	O
two	O
dimensions	O
.	O

Among	O
these	O
selected	O
strategies	O
,	O
the	O
majority	O
were	O
classified	O
under	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
(	O
44	O
%	O
)	O
and	O
Financial	O
Incentives	O
and	O
Marketing	O
(	O
44	O
%	O
)	O
,	O
followed	O
by	O
Workload	O
and	O
Skill	O
Mix	O
(	O
12	O
%	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
some	O
strategies	O
had	O
equal	O
rankings	O
;	O
therefore	O
the	O
total	O
number	O
of	O
rankings	O
did	O
not	O
equal	O
the	O
total	O
number	O
of	O
strategies	O
.	O

Recruitment	O
and	O
retention	O
strategies	O
that	O
had	O
a	O
combination	O
of	O
high	O
and	O
medium	O
ratings	O
in	O
either	O
of	O
the	O
two	O
dimensions	O
included	O
:	O
sense	O
of	O
empowerment	O
in	O
promoting	O
healthy	O
work	O
environments	O
;	O
team	O
-	O
building	O
exercises	O
;	O
developing	O
participatory	O
decision	O
-	O
making	O
systems	O
;	O
improving	O
rural	O
working	O
conditions	O
;	O
recognizing	O
work	O
-	O
life	O
balance	O
;	O
creating	O
an	O
environment	O
where	O
staff	O
are	O
valued	O
;	O
optimizing	O
scope	O
of	O
practice	O
and	O
work	O
-	O
management	O
autonomy	O
.	O

Strategies	O
that	O
had	O
medium	O
importance	O
and	O
feasibility	O
ratings	O
included	O
:	O
resolving	O
concerns	O
about	O
liability	O
and	O
accountability	O
in	O
collaborative	O
practice	O
;	O
recruiting	O
international	O
trained	O
therapists	O
;	O
opportunity	O
to	O
work	O
in	O
different	O
settings	O
;	O
interprofessional	O
payment	O
schemes	O
;	O
family	O
leave	O
;	O
staff	O
recognition	O
and	O
creating	O
a	O
position	O
for	O
a	O
provincial	O
health	O
professional	O
recruiter	O
.	O

Low	O
importance	O
and	O
feasibility	O
strategies	O
included	O
:	O
word	O
of	O
mouth	O
references	O
;	O
bursaries	O
and	O
retention	O
bonuses	O
;	O
exchange	O
employment	O
opportunities	O
;	O
health	O
promotion	O
;	O
retention	O
workshop	O
;	O
80	O
-	O
20	O
staffing	O
model	O
(	O
80	O
%	O
clinical	O
and	O
20	O
%	O
learning	O
new	O
skills	O
or	O
training	O
others	O
)	O
;	O
using	O
recruitment	O
agencies	O
and	O
providing	O
recruitment	O
bonuses	O
(	O
Table	O
4	O
)	O
.	O

Education	O
Strategy	O
Rankings	O

Education	O
strategies	O
that	O
were	O
rated	O
highly	O
important	O
and	O
feasible	O
are	O
described	O
in	O
Table	O
5	O
.	O

The	O
majority	O
of	O
strategies	O
in	O
this	O
group	O
tend	O
to	O
be	O
in	O
the	O
area	O
of	O
Professional	O
Development	O
(	O
72	O
%	O
)	O
,	O
more	O
so	O
than	O
Education	O
and	O
Training	O
(	O
28	O
%	O
)	O
.	O

The	O
medium	O
rated	O
education	O
strategies	O
included	O
:	O
expand	O
interprofessional	O
education	O
;	O
provide	O
incentives	O
for	O
students	O
interested	O
in	O
rural	O
practice	O
;	O
summer	O
mentorship	O
programs	O
for	O
high	O
school	O
students	O
;	O
and	O
aboriginal	O
student	O
support	O
program	O
.	O

The	O
strategies	O
that	O
were	O
considered	O
neither	O
feasible	O
nor	O
important	O
included	O
:	O
using	O
return	O
of	O
service	O
contracts	O
after	O
professional	O
development	O
;	O
create	O
a	O
tiered	O
pathway	O
approach	O
through	O
modular	O
education	O
and	O
laddered	O
credentialing	O
and	O
in	O
accreditation	O
standards	O
allow	O
greater	O
use	O
of	O
rural	O
practice	O
sites	O
(	O
Table	O
6	O
)	O
.	O

Since	O
the	O
purpose	O
of	O
the	O
panel	O
was	O
to	O
identify	O
recruitment	O
and	O
retention	O
and	O
education	O
strategies	O
that	O
could	O
inform	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
for	O
rehabilitation	O
professionals	O
,	O
there	O
was	O
also	O
discussion	O
about	O
contextual	O
factors	O
that	O
would	O
influence	O
a	O
plan	O
.	O

Panelists	O
commented	O
that	O
key	O
factors	O
to	O
consider	O
prior	O
to	O
implementation	O
of	O
these	O
strategies	O
should	O
include	O
workplace	O
setting	O
,	O
geographical	O
location	O
(	O
i	O
.	O
e	O
.	O
urban	O
and	O
rural	O
)	O
and	O
gender	O
issues	O
.	O

Discussion	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
recruitment	O
and	O
retention	O
strategies	O
to	O
inform	O
the	O
development	O
of	O
HHR	O
planning	O
for	O
rehabilitation	O
professionals	O
in	O
Ontario	O
.	O

This	O
study	O
highlights	O
that	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
,	O
Financial	O
Incentives	O
and	O
Marketing	O
and	O
Professional	O
Development	O
are	O
the	O
three	O
major	O
areas	O
of	O
focus	O
when	O
developing	O
a	O
competitive	O
HR	O
plan	O
in	O
the	O
rehabilitation	O
sector	O
.	O

Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O

Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
strategies	O
ranked	O
among	O
the	O
top	O
category	O
for	O
recruitment	O
and	O
retention	O
of	O
rehabilitation	O
therapists	O
.	O

This	O
has	O
also	O
been	O
found	O
among	O
nurses	O
[	O
44	O
]	O
where	O
it	O
was	O
reported	O
that	O
addressing	O
such	O
factors	O
can	O
affect	O
the	O
overall	O
success	O
of	O
the	O
program	O
[	O
49	O
]	O
.	O

Specifically	O
,	O
our	O
findings	O
showed	O
that	O
the	O
top	O
ranked	O
strategy	O
for	O
both	O
importance	O
and	O
feasibility	O
was	O
improving	O
and	O
maintaining	O
the	O
safety	O
of	O
rehabilitation	O
professionals	O
in	O
the	O
workplace	O
.	O

Specific	O
strategies	O
that	O
could	O
reduce	O
aggression	O
,	O
abuse	O
and	O
violence	O
in	O
the	O
workplace	O
include	O
:	O
zero	O
tolerance	O
policies	O
,	O
access	O
to	O
employee	O
support	O
programs	O
and	O
providing	O
assistance	O
to	O
rehabilitation	O
professionals	O
who	O
work	O
alone	O
(	O
i	O
.	O
e	O
.	O
home	O
care	O
and	O
rural	O
and	O
remote	O
areas	O
)	O
.	O

Since	O
there	O
is	O
less	O
control	O
over	O
the	O
environment	O
in	O
the	O
home	O
care	O
setting	O
,	O
safety	O
may	O
become	O
a	O
greater	O
concern	O
in	O
one	O
practice	O
setting	O
over	O
another	O
.	O

This	O
might	O
suggest	O
that	O
because	O
there	O
is	O
less	O
control	O
in	O
environments	O
such	O
as	O
home	O
care	O
,	O
remote	O
areas	O
,	O
and	O
psychiatric	O
settings	O
,	O
maintaining	O
safety	O
will	O
be	O
more	O
difficult	O
and	O
that	O
solutions	O
will	O
need	O
to	O
be	O
tailored	O
to	O
these	O
settings	O
in	O
order	O
to	O
ensure	O
retention	O
of	O
providers	O
.	O

Although	O
no	O
studies	O
have	O
looked	O
at	O
implementing	O
personal	O
safety	O
strategies	O
for	O
home	O
care	O
therapists	O
,	O
written	O
policies	O
and	O
procedures	O
for	O
home	O
care	O
nurses	O
during	O
inclement	O
weather	O
and	O
for	O
dealing	O
with	O
abusive	O
or	O
dangerous	O
patients	S-Species
,	O
families	O
and	O
neighbourhoods	O
have	O
been	O
reported	O
[	O
50	O
]	O
.	O

In	O
addition	O
to	O
the	O
above	O
,	O
ensuring	O
open	O
and	O
timely	O
communication	O
between	O
employer	O
and	O
worker	O
was	O
also	O
ranked	O
highly	O
among	O
the	O
recruitment	O
and	O
retention	O
strategies	O
.	O

Examples	O
of	O
strategies	O
include	O
:	O
open	O
door	O
policies	O
,	O
employee	O
advisory	O
committees	O
and	O
regular	O
staff	O
meetings	O
and	O
evaluations	O
.	O

Although	O
these	O
strategies	O
were	O
reported	O
to	O
be	O
used	O
among	O
organizations	O
providing	O
services	O
to	O
persons	S-Species
with	O
developmental	O
disabilities	O
in	O
Alberta	O
,	O
there	O
was	O
no	O
description	O
of	O
the	O
organizations	O
,	O
sample	O
size	O
or	O
methodology	O
[	O
51	O
]	O
.	O

Similar	O
findings	O
were	O
found	O
in	O
a	O
qualitative	O
study	O
among	O
16	O
nurses	O
working	O
from	O
diverse	O
practice	O
settings	O
(	O
acute	O
,	O
long	O
-	O
term	O
care	O
,	O
rehabilitation	O
and	O
community	O
;	O
from	O
both	O
urban	O
and	O
rural	O
areas	O
)	O
in	O
a	O
health	O
region	O
in	O
western	O
Canada	O
.	O

From	O
the	O
semi	O
-	O
structured	O
interviews	O
,	O
study	O
participants	S-Species
expressed	O
a	O
desire	O
for	O
improved	O
consultation	O
and	O
communication	O
with	O
nurses	O
regarding	O
changes	O
to	O
the	O
health	O
care	O
system	O
[	O
52	O
]	O
.	O

Financial	O
Incentives	O
and	O
Marketing	O

Another	O
area	O
that	O
was	O
ranked	O
highly	O
was	O
marketing	O
strategies	O
to	O
increase	O
high	O
school	O
student	O
and	O
public	O
awareness	O
of	O
rehabilitation	O
careers	O
.	O

These	O
specific	O
strategies	O
were	O
also	O
recommended	O
by	O
the	O
Ontario	O
Hospital	O
Association	O
(	O
OHA	O
)	O
in	O
order	O
to	O
establish	O
a	O
competitive	O
position	O
for	O
Ontario	O
hospitals	O
in	O
respect	O
of	O
recruitment	O
and	O
retention	O
of	O
health	O
care	O
professionals	O
[	O
53	O
]	O
.	O

Similar	O
strategies	O
have	O
been	O
developed	O
by	O
the	O
American	O
Physical	O
Therapy	O
Association	O
(	O
APTA	O
)	O
in	O
response	O
to	O
the	O
declining	O
number	O
of	O
students	O
applying	O
to	O
Physical	O
Therapy	O
Education	O
Programs	O
[	O
54	O
]	O
.	O

To	O
address	O
this	O
trend	O
,	O
APTA	O
developed	O
a	O
campaign	O
to	O
promote	O
Physical	O
Therapy	O
as	O
the	O
profession	O
of	O
choice	O
to	O
high	O
school	O
and	O
college	O
students	O
across	O
the	O
United	O
States	O
.	O

The	O
potential	O
components	O
of	O
their	O
plan	O
included	O
:	O
developing	O
a	O
"	O
Recruiting	O
Kit	O
"	O
for	O
educators	O
,	O
students	O
and	O
various	O
APTA	O
members	O
to	O
be	O
used	O
in	O
the	O
high	O
school	O
and	O
college	O
settings	O
to	O
introduce	O
Physical	O
Therapy	O
as	O
a	O
career	O
;	O
establishing	O
public	O
relations	O
initiatives	O
that	O
demonstrate	O
the	O
role	O
of	O
Physical	O
Therapy	O
in	O
the	O
public	O
arena	O
targeting	O
minority	O
groups	O
that	O
are	O
underrepresented	O
in	O
the	O
profession	O
;	O
and	O
creating	O
alliances	O
with	O
professional	O
associations	O
of	O
high	O
school	O
guidance	O
counsellors	O
and	O
educators	O
.	O

Based	O
on	O
our	O
finding	O
,	O
the	O
APTA	O
model	O
may	O
have	O
applicability	O
in	O
Ontario	O
.	O

Workload	O
and	O
Skill	O
Mix	O

Of	O
the	O
six	O
Workload	O
and	O
Skill	O
Mix	O
strategies	O
only	O
two	O
were	O
highly	O
rated	O
:	O
implementing	O
a	O
caseload	O
management	O
database	O
and	O
using	O
support	O
personnel	O
.	O

Caseload	O
management	O
has	O
been	O
identified	O
in	O
the	O
literature	O
as	O
an	O
issue	O
affecting	O
all	O
three	O
rehabilitation	O
professions	O
.	O

For	O
example	O
,	O
in	O
physiotherapy	O
,	O
Christie	O
'	O
s	O
study	O
[	O
55	O
]	O
found	O
that	O
caseload	O
expectations	O
tended	O
to	O
be	O
significantly	O
higher	O
than	O
the	O
reality	O
and	O
that	O
caseload	O
varies	O
across	O
different	O
programs	O
.	O

Similarly	O
,	O
the	O
Canadian	O
Association	O
of	O
Speech	O
-	O
Language	O
Pathologists	O
and	O
Audiologists	O
(	O
CASPLA	O
)	O
survey	O
indicated	O
that	O
factors	O
affecting	O
the	O
workload	O
of	O
SLPs	O
include	O
delivery	O
models	O
,	O
client	O
disorder	O
,	O
severity	O
and	O
work	O
setting	O
[	O
56	O
]	O
.	O

A	O
literature	O
review	O
and	O
environmental	O
scan	O
undertaken	O
by	O
the	O
Canadian	O
Association	O
of	O
Occupational	O
Therapists	O
(	O
CAOT	O
)	O
proposed	O
that	O
guiding	O
principles	O
for	O
caseload	O
management	O
should	O
include	O
:	O
evidence	O
-	O
based	O
occupational	O
therapy	O
,	O
cost	O
-	O
effectiveness	O
,	O
accountability	O
,	O
professional	O
leadership	O
and	O
expert	O
judgment	O
,	O
comprehensiveness	O
and	O
flexibility	O
[	O
57	O
]	O
.	O

Therefore	O
,	O
upon	O
implementation	O
of	O
a	O
caseload	O
management	O
database	O
for	O
rehabilitation	O
,	O
key	O
factors	O
to	O
consider	O
include	O
workplace	O
setting	O
and	O
client	O
service	O
delivery	O
models	O
.	O

The	O
other	O
highly	O
rated	O
Workload	O
and	O
Skill	O
Mix	O
strategy	O
was	O
the	O
use	O
of	O
support	O
personnel	O
(	O
i	O
.	O
e	O
.	O
physiotherapy	O
assistants	O
or	O
exercise	O
therapists	O
)	O
to	O
increase	O
efficiency	O
of	O
utilization	O
of	O
scarcer	O
and	O
higher	O
order	O
rehabilitation	O
competencies	O
.	O

Considerations	O
for	O
implementing	O
this	O
strategy	O
include	O
addressing	O
key	O
issues	O
such	O
supply	O
,	O
standards	O
of	O
education	O
,	O
standards	O
of	O
practice	O
and	O
accreditation	O
.	O

These	O
are	O
highlighted	O
in	O
an	O
article	O
by	O
Salvatori	O
[	O
58	O
]	O
who	O
reported	O
that	O
the	O
actual	O
number	O
of	O
OT	O
personnel	O
delivering	O
OT	O
services	O
in	O
Canada	O
remains	O
unknown	O
and	O
that	O
there	O
are	O
no	O
national	O
standards	O
of	O
education	O
nor	O
accreditation	O
process	O
for	O
OT	O
assistants	O
.	O

CAOT	O
believes	O
that	O
in	O
order	O
to	O
utilize	O
support	O
personnel	O
appropriately	O
,	O
studies	O
on	O
human	S-Species
resource	O
needs	O
for	O
occupational	O
therapy	O
and	O
support	O
personnel	O
are	O
first	O
needed	O
with	O
input	O
from	O
OTs	O
,	O
stakeholders	O
,	O
funders	O
,	O
decision	O
makers	O
and	O
health	O
policy	O
planners	O
[	O
59	O
]	O
.	O

Since	O
there	O
is	O
a	O
lack	O
of	O
competency	O
profiles	O
related	O
to	O
the	O
role	O
,	O
responsibilities	O
,	O
and	O
supervision	O
of	O
assistants	O
,	O
particularly	O
with	O
regards	O
to	O
delivering	O
services	O
in	O
unsupervised	O
community	O
-	O
based	O
settings	O
,	O
the	O
type	O
of	O
workplace	O
setting	O
where	O
this	O
strategy	O
may	O
be	O
implemented	O
should	O
be	O
considered	O
[	O
58	O
]	O
.	O

Education	O
and	O
Training	O

Given	O
that	O
60	O
%	O
of	O
highly	O
rated	O
Education	O
and	O
Training	O
strategies	O
targeted	O
rural	O
and	O
remote	O
practices	O
underscores	O
the	O
importance	O
of	O
specific	O
strategies	O
for	O
rural	O
and	O
remote	O
areas	O
in	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
.	O

The	O
need	O
to	O
build	O
on	O
existing	O
mechanisms	O
to	O
expand	O
the	O
availability	O
of	O
rural	O
and	O
remote	O
clinical	O
placements	O
by	O
providing	O
financial	O
and	O
accommodation	O
support	O
was	O
ranked	O
among	O
the	O
top	O
two	O
most	O
important	O
and	O
feasible	O
education	O
strategies	O
for	O
rehabilitation	O
professionals	O
.	O

Not	O
only	O
has	O
this	O
strategy	O
been	O
used	O
as	O
a	O
recruitment	O
tool	O
for	O
rehabilitation	O
students	O
,	O
it	O
has	O
also	O
been	O
reported	O
by	O
Solomon	O
et	O
al	O
.	O

[	O
34	O
]	O
to	O
be	O
effective	O
in	O
retaining	O
OTs	O
and	O
PTs	O
in	O
underserviced	O
Northwestern	O
Ontario	O
communities	O
.	O

Respondents	O
from	O
Solomon	O
et	O
al	O
.	O
'	O
s	O
study	O
reported	O
that	O
the	O
top	O
three	O
benefits	O
of	O
supervising	O
students	O
were	O
that	O
it	O
stimulates	O
thinking	O
,	O
it	O
provides	O
opportunity	O
to	O
contribute	O
to	O
the	O
profession	O
and	O
that	O
it	O
provides	O
access	O
to	O
current	O
information	O
.	O

The	O
reported	O
disadvantages	O
however	O
was	O
that	O
it	O
was	O
time	O
-	O
consuming	O
and	O
students	O
contributed	O
stress	O
to	O
the	O
working	O
environment	O
.	O

Similarly	O
,	O
a	O
two	O
-	O
part	O
study	O
found	O
substantial	O
gaps	O
between	O
financial	O
incentives	O
students	O
deem	O
important	O
in	O
the	O
creation	O
of	O
an	O
appealing	O
clinical	O
placement	O
opportunity	O
and	O
the	O
actual	O
provisions	O
offered	O
to	O
them	O
by	O
Southeastern	O
Ontario	O
communities	O
[	O
60	O
,	O
61	O
]	O
.	O

Although	O
OT	O
and	O
PT	O
students	O
reported	O
that	O
they	O
were	O
more	O
willing	O
to	O
complete	O
a	O
clinical	O
placement	O
in	O
an	O
underserviced	O
community	O
if	O
provided	O
travel	O
stipends	O
,	O
rent	O
-	O
free	O
housing	O
and	O
interprofessional	O
education	O
opportunities	O
,	O
the	O
majority	O
of	O
these	O
incentives	O
were	O
only	O
available	O
to	O
medical	O
students	O
.	O

In	O
addition	O
to	O
training	O
students	O
for	O
rural	O
and	O
remote	O
practice	O
,	O
a	O
longitudinal	O
study	O
reported	O
that	O
perceived	O
opportunity	O
for	O
career	O
development	O
was	O
the	O
most	O
significant	O
factor	O
related	O
to	O
job	O
turnover	O
and	O
regional	O
attrition	O
among	O
physiotherapists	O
working	O
in	O
Northern	O
Ontario	O
[	O
5	O
]	O
.	O

Therefore	O
developing	O
workforce	O
strategies	O
for	O
rehabilitation	O
therapists	O
working	O
in	O
these	O
areas	O
should	O
be	O
among	O
one	O
of	O
the	O
priority	O
areas	O
in	O
HHR	O
planning	O
.	O

Professional	O
Development	O

Our	O
findings	O
indicate	O
that	O
the	O
theme	O
with	O
the	O
largest	O
number	O
of	O
strategies	O
that	O
were	O
considered	O
important	O
and	O
feasible	O
to	O
implement	O
as	O
part	O
of	O
HHR	O
planning	O
was	O
professional	O
development	O
.	O

Many	O
were	O
specific	O
to	O
rural	O
and	O
remote	O
areas	O
.	O

Although	O
the	O
importance	O
of	O
continuous	O
professional	O
development	O
(	O
CPD	O
)	O
in	O
recruitment	O
and	O
retention	O
is	O
well	O
recognized	O
,	O
a	O
Canadian	O
study	O
reported	O
several	O
barriers	O
to	O
its	O
implementation	O
[	O
62	O
]	O
.	O

In	O
the	O
case	O
of	O
OTs	O
employed	O
in	O
public	O
settings	O
in	O
Nova	O
Scotia	O
,	O
Townsend	O
et	O
al	O
.	O

(	O
2006	O
)	O
found	O
that	O
the	O
most	O
powerful	O
deterrent	O
for	O
CPD	O
was	O
the	O
lack	O
of	O
support	O
from	O
workplace	O
policies	O
.	O

Based	O
on	O
their	O
study	O
results	O
,	O
the	O
use	O
of	O
CPD	O
as	O
a	O
recruitment	O
and	O
retention	O
strategy	O
was	O
highly	O
influenced	O
by	O
gender	O
issues	O
,	O
work	O
-	O
life	O
balance	O
,	O
career	O
advancement	O
,	O
working	O
conditions	O
,	O
geographical	O
location	O
,	O
professional	O
versus	O
employer	O
responsibility	O
,	O
and	O
employee	O
benefits	O
.	O

Although	O
occupational	O
therapy	O
is	O
a	O
female	O
-	O
dominated	O
profession	O
,	O
workplace	O
policies	O
did	O
not	O
address	O
issues	O
of	O
gender	O
.	O

For	O
example	O
,	O
therapists	O
in	O
this	O
study	O
indicated	O
that	O
CPD	O
competes	O
with	O
family	O
commitments	O
,	O
therefore	O
these	O
activities	O
are	O
"	O
done	O
largely	O
during	O
personal	O
time	O
,	O
mainly	O
at	O
their	O
own	O
cost	O
,	O
and	O
on	O
top	O
of	O
childcare	O
,	O
eldercare	O
,	O
homemaking	O
and	O
other	O
family	O
responsibilities	O
"	O
[	O
62	O
]	O
.	O

In	O
addition	O
,	O
heavy	O
workloads	O
,	O
lack	O
of	O
salary	O
and	O
career	O
incentives	O
,	O
and	O
lack	O
of	O
policy	O
and	O
funding	O
support	O
are	O
all	O
barriers	O
to	O
CPD	O
.	O

These	O
issues	O
become	O
more	O
pronounced	O
in	O
rural	O
and	O
remote	O
settings	O
because	O
smaller	O
communities	O
often	O
only	O
have	O
one	O
therapist	O
;	O
hence	O
the	O
systemic	O
pressure	O
of	O
workload	O
demands	O
makes	O
it	O
difficult	O
for	O
the	O
therapist	O
to	O
leave	O
patient	S-Species
care	O
.	O

OTs	O
from	O
this	O
study	O
also	O
questioned	O
who	O
was	O
responsible	O
for	O
CPD	O
.	O

Some	O
felt	O
that	O
it	O
was	O
the	O
professional	O
'	O
s	O
responsibility	O
while	O
others	O
felt	O
that	O
it	O
was	O
the	O
responsibility	O
of	O
the	O
employer	O
to	O
provide	O
CPD	O
opportunities	O
.	O

The	O
primary	O
limitation	O
employers	O
faced	O
was	O
the	O
lack	O
of	O
financial	O
resources	O
,	O
however	O
giving	O
employees	O
time	O
off	O
without	O
pay	O
was	O
an	O
alternative	O
strategy	O
utilized	O
instead	O
of	O
funding	O
professional	O
development	O
activities	O
.	O

Although	O
there	O
are	O
professional	O
and	O
provincial	O
variations	O
in	O
funding	O
for	O
CPD	O
across	O
Canada	O
,	O
these	O
results	O
are	O
informative	O
in	O
that	O
it	O
highlights	O
the	O
need	O
for	O
employers	O
to	O
consider	O
how	O
workplace	O
policies	O
can	O
affect	O
recruitment	O
and	O
retention	O
strategies	O
.	O

Limitations	O
of	O
this	O
study	O
should	O
be	O
noted	O
.	O

First	O
,	O
the	O
majority	O
of	O
the	O
strategies	O
were	O
obtained	O
from	O
the	O
grey	O
literature	O
that	O
is	O
not	O
subject	O
to	O
the	O
same	O
scrutiny	O
as	O
the	O
peer	O
-	O
reviewed	O
literature	O
.	O

Second	O
,	O
almost	O
none	O
of	O
the	O
strategies	O
were	O
specifically	O
developed	O
for	O
rehabilitation	O
professionals	O
and	O
in	O
many	O
cases	O
had	O
to	O
be	O
re	O
-	O
worded	O
to	O
fit	O
the	O
rehabilitation	O
context	O
.	O

There	O
is	O
a	O
lack	O
of	O
research	O
on	O
rehabilitation	O
clinicians	O
'	O
perspectives	O
on	O
recruitment	O
and	O
retention	O
strategies	O
;	O
therefore	O
future	O
research	O
should	O
focus	O
on	O
investigating	O
this	O
area	O
.	O

Third	O
,	O
during	O
the	O
face	O
-	O
to	O
-	O
face	O
meeting	O
,	O
bias	O
could	O
have	O
resulted	O
from	O
panelists	O
whose	O
opinion	O
may	O
have	O
influenced	O
others	O
significantly	O
,	O
especially	O
if	O
members	O
came	O
from	O
similar	O
workplace	O
settings	O
.	O

The	O
facilitator	O
of	O
the	O
expert	O
panels	O
however	O
,	O
followed	O
a	O
strict	O
process	O
for	O
managing	O
the	O
discussion	O
and	O
ensured	O
that	O
all	O
panelists	O
were	O
given	O
the	O
opportunity	O
to	O
express	O
their	O
opinions	O
.	O

Finally	O
,	O
although	O
some	O
strategies	O
such	O
as	O
competitive	O
wage	O
packages	O
,	O
training	O
/	O
growth	O
opportunities	O
and	O
professional	O
development	O
are	O
viewed	O
as	O
both	O
a	O
recruitment	O
and	O
retention	O
incentive	O
,	O
other	O
strategies	O
do	O
not	O
overlap	O
and	O
are	O
appropriate	O
for	O
only	O
one	O
of	O
the	O
two	O
tasks	O
.	O

For	O
example	O
,	O
increasing	O
public	O
awareness	O
of	O
rehabilitation	O
careers	O
,	O
providing	O
rural	O
and	O
remote	O
orientation	O
packages	O
and	O
family	O
relocation	O
programs	O
are	O
only	O
appropriate	O
for	O
attracting	O
a	O
worker	O
while	O
ensuring	O
open	O
and	O
timely	O
communication	O
may	O
be	O
seen	O
as	O
a	O
strategy	O
only	O
for	O
retention	O
.	O

Future	O
research	O
should	O
therefore	O
consider	O
studying	O
recruitment	O
and	O
retention	O
strategies	O
separately	O
so	O
that	O
a	O
distinction	O
between	O
the	O
two	O
can	O
be	O
made	O
.	O

Conclusion	O

This	O
study	O
identified	O
34	O
strategies	O
that	O
should	O
be	O
considered	O
as	O
important	O
and	O
feasible	O
for	O
implementation	O
as	O
part	O
of	O
HHR	O
planning	O
for	O
rehabilitation	O
professionals	O
.	O

Although	O
the	O
highest	O
ranked	O
strategies	O
focused	O
on	O
areas	O
of	O
Quality	O
of	O
Worklife	O
and	O
Work	O
Environment	O
,	O
Financial	O
Incentives	O
and	O
Marketing	O
and	O
Professional	O
Development	O
,	O
key	O
factors	O
that	O
need	O
to	O
be	O
considered	O
in	O
the	O
context	O
of	O
implementation	O
include	O
:	O
workplace	O
setting	O
,	O
geographical	O
location	O
and	O
gender	O
issues	O
.	O

While	O
this	O
is	O
the	O
first	O
study	O
to	O
our	O
knowledge	O
that	O
provides	O
a	O
comprehensive	O
list	O
of	O
recruitment	O
and	O
retention	O
strategies	O
relevant	O
to	O
rehabilitation	O
professionals	O
,	O
more	O
information	O
is	O
needed	O
for	O
the	O
development	O
of	O
a	O
HHR	O
plan	O
.	O

Information	O
on	O
trends	O
in	O
labour	O
force	O
participation	O
as	O
well	O
as	O
knowledge	O
regarding	O
the	O
use	O
and	O
effectiveness	O
of	O
recruitment	O
and	O
retention	O
strategies	O
for	O
rehabilitation	O
professionals	O
is	O
needed	O
.	O

More	O
importantly	O
,	O
the	O
success	O
of	O
implementing	O
and	O
sustaining	O
such	O
strategies	O
requires	O
future	O
research	O
to	O
validate	O
these	O
strategies	O
from	O
the	O
perspective	O
of	O
rehabilitation	O
clinicians	O
and	O
human	S-Species
resource	O
decisions	O
makers	O
(	O
i	O
.	O
e	O
.	O
local	O
government	O
,	O
stakeholders	O
,	O
etc	O
.	O
)	O
so	O
that	O
specific	O
barriers	O
and	O
challenges	O
can	O
be	O
identified	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

DT	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
conducted	O
the	O
literature	O
review	O
,	O
analyzed	O
and	O
interpreted	O
the	O
results	O
and	O
drafted	O
the	O
manuscript	O
.	O

LMH	O
,	O
AD	O
,	O
DB	O
and	O
KB	O
were	O
involved	O
in	O
providing	O
feedback	O
and	O
editing	O
the	O
content	O
of	O
the	O
manuscript	O
.	O

MDL	O
recommended	O
participants	S-Species
for	O
the	O
expert	O
panel	O
and	O
was	O
involved	O
in	O
providing	O
feedback	O
and	O
editing	O
the	O
content	O
of	O
the	O
manuscript	O
.	O

SJ	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
recommended	O
participants	S-Species
for	O
the	O
expert	O
panel	O
,	O
organized	O
and	O
consolidated	O
strategies	O
,	O
interpreted	O
the	O
data	O
and	O
edited	O
the	O
content	O
of	O
the	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

A	O
life	O
threatening	O
uterine	O
inversion	O
and	O
massive	O
post	O
partum	O
hemorrhage	O
caused	O
by	O
placenta	O
accrete	O
during	O
Caesarean	O
section	O
in	O
a	O
primigravida	O
:	O
a	O
case	O
report	O

Abstract	O

Background	O

A	O
32	O
-	O
year	O
-	O
old	O
Caucasian	O
primigravida	O
was	O
admitted	O
for	O
elective	O
Caesarean	O
Section	O
at	O
36	O
weeks	O
and	O
6	O
days	O
with	O
the	O
diagnosis	O
of	O
preeclampsia	O
.	O

Case	O
presentation	O

Traction	O
of	O
the	O
umbilical	O
cord	O
after	O
delivery	O
of	O
a	O
healthy	O
baby	O
resulted	O
in	O
uterine	O
inversion	O
.	O

The	O
placenta	O
was	O
found	O
to	O
be	O
densely	O
adherent	O
to	O
the	O
posterior	O
uterine	O
wall	O
.	O

Piecemeal	O
excision	O
of	O
the	O
placenta	O
as	O
close	O
as	O
possible	O
to	O
the	O
uterine	O
lining	O
was	O
then	O
performed	O
.	O

Conclusion	O

In	O
this	O
way	O
we	O
were	O
able	O
to	O
control	O
a	O
massive	O
post	O
partum	O
hemorrhage	O
and	O
preserve	O
the	O
fertility	O
of	O
the	O
patient	S-Species
.	O

Background	O

Placenta	O
accreta	O
is	O
defined	O
as	O
abnormal	O
adherence	O
,	O
either	O
in	O
whole	O
or	O
in	O
part	O
of	O
the	O
afterbirth	O
to	O
the	O
underlying	O
uterine	O
wall	O
.	O

Placenta	O
accreta	O
and	O
other	O
pathological	O
placentations	O
(	O
such	O
as	O
increta	O
,	O
percreta	O
)	O
are	O
rare	O
complications	O
of	O
pregnancy	O
with	O
potential	O
life	O
threatening	O
and	O
fertility	O
threatening	O
consequences	O
.	O

The	O
incidence	O
of	O
placenta	O
accreta	O
has	O
increased	O
ten	O
times	O
over	O
the	O
last	O
fifteen	O
years	O
,	O
which	O
reflects	O
the	O
increase	O
in	O
the	O
rate	O
of	O
Caesarean	O
Sections	O
(	O
CS	O
)	O
[	O
1	O
]	O
.	O

Placenta	O
accreta	O
has	O
become	O
the	O
most	O
important	O
cause	O
of	O
peripartum	O
hysterectomy	O
.	O

A	O
life	O
threatening	O
acute	O
uterine	O
inversion	O
and	O
massive	O
PPH	O
can	O
be	O
caused	O
by	O
placenta	O
accreta	O
during	O
CS	O
but	O
seldom	O
in	O
a	O
primigravida	O
(	O
Figure	O
1	O
)	O
.	O

Case	O
presentation	O

A	O
32	O
year	O
old	O
,	O
primigravida	O
,	O
was	O
admitted	O
in	O
a	O
District	O
General	O
Hospital	O
for	O
elective	O
Caesarean	O
section	O
at	O
36	O
weeks	O
and	O
6	O
days	O
with	O
the	O
diagnosis	O
of	O
preeclampsia	O
.	O

She	O
had	O
two	O
antenatal	O
ultrasound	O
examinations	O
showing	O
a	O
healthy	O
fetus	O
and	O
posterior	O
fundal	O
placenta	O
.	O

The	O
patient	S-Species
had	O
lower	O
segment	O
CS	O
of	O
a	O
healthy	O
male	O
infant	S-Species
under	O
spinal	O
anesthesia	O
.	O

The	O
placenta	O
was	O
found	O
to	O
be	O
densely	O
adherent	O
to	O
the	O
posterior	O
uterine	O
wall	O
.	O

Traction	O
of	O
the	O
umbilical	O
cord	O
was	O
applied	O
and	O
subsequently	O
resulted	O
in	O
uterine	O
inversion	O
.	O

The	O
placenta	O
was	O
removed	O
by	O
'	O
piecemeal	O
'	O
excising	O
as	O
close	O
as	O
possible	O
to	O
the	O
uterine	O
lining	O
.	O

About	O
80	O
%	O
of	O
the	O
placental	O
tissue	O
was	O
removed	O
until	O
the	O
uterine	O
inversion	O
was	O
corrected	O
.	O

The	O
uterus	O
was	O
closed	O
in	O
two	O
layers	O
.	O

Two	O
intra	O
-	O
abdominal	O
drains	O
were	O
sited	O
.	O

The	O
estimated	O
blood	O
loss	O
was	O
2	O
.	O
5	O
litres	O
and	O
five	O
units	O
of	O
blood	O
were	O
transfused	O
together	O
with	O
2	O
units	O
of	O
FFP	O
during	O
intra	O
-	O
operative	O
and	O
post	O
-	O
operative	O
period	O
.	O

In	O
addition	O
,	O
the	O
patient	S-Species
was	O
treated	O
with	O
intravenous	O
oxytocin	O
infusion	O
,	O
pr	O
misoprostol	O
and	O
antibiotics	O
.	O

On	O
the	O
second	O
post	O
partum	O
day	O
,	O
vaginal	O
Doppler	O
ultrasound	O
scan	O
showed	O
significant	O
amount	O
of	O
placental	O
tissues	O
with	O
increased	O
vascularity	O
measuring	O
2	O
.	O
7	O
x	O
6	O
.	O
6	O
x	O
6	O
.	O
8	O
cms	O
within	O
the	O
endometrial	O
cavity	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	S-Species
was	O
discharged	O
on	O
the	O
fifth	O
post	O
-	O
operative	O
day	O
with	O
a	O
conservative	O
management	O
.	O

A	O
follow	O
up	O
Ultrasound	O
scan	O
after	O
two	O
weeks	O
showed	O
reduction	O
of	O
placental	O
mass	O
(	O
Figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
there	O
was	O
significant	O
decrease	O
in	O
serum	O
beta	O
HCG	O
levels	O
from	O
2300	O
u	O
/	O
L	O
on	O
day	O
1	O
to	O
13	O
u	O
/	O
L	O
at	O
four	O
weeks	O
post	O
operatively	O
.	O

The	O
patient	S-Species
remained	O
with	O
minimal	O
vaginal	O
bleeding	O
without	O
abdominal	O
pain	O
.	O

She	O
had	O
two	O
normal	O
periods	O
after	O
stopping	O
breastfeeding	O
and	O
was	O
feeling	O
well	O
.	O

She	O
was	O
discharged	O
from	O
the	O
early	O
pregnancy	O
unit	O
.	O

Discussion	O

A	O
life	O
-	O
threatening	O
uterine	O
inversion	O
can	O
be	O
rarely	O
caused	O
by	O
placenta	O
accreta	O
[	O
2	O
]	O
.	O

Placenta	O
accreta	O
classically	O
presents	O
with	O
retained	O
placenta	O
and	O
hemorrhage	O
.	O

The	O
association	O
between	O
uterine	O
inversion	O
and	O
placenta	O
accreta	O
is	O
unclear	O
,	O
however	O
,	O
strong	O
traction	O
on	O
the	O
umbilical	O
cord	O
with	O
fundal	O
placenta	O
,	O
excessive	O
fundal	O
pressure	O
,	O
relaxed	O
uterus	O
,	O
short	O
umbilical	O
cord	O
,	O
uterine	O
anomalies	O
and	O
antepartum	O
use	O
of	O
magnesium	O
sulphate	O
are	O
known	O
associated	O
factors	O
[	O
2	O
]	O
.	O

Uterine	O
inversion	O
and	O
retain	O
placenta	O
accreta	O
can	O
both	O
be	O
fatal	O
complications	O
[	O
3	O
]	O
.	O

In	O
the	O
case	O
described	O
the	O
placenta	O
accreta	O
was	O
complicated	O
by	O
uterine	O
inversion	O
and	O
subsequent	O
massive	O
post	O
partum	O
hemorrhage	O
,	O
significantly	O
increasing	O
the	O
risk	O
of	O
maternal	O
mortality	O
.	O

Massive	O
post	O
partum	O
hemorrhage	O
is	O
a	O
major	O
cause	O
of	O
maternal	O
mortality	O
in	O
the	O
United	O
Kingdom	O
(	O
why	O
women	S-Species
die	O
latest	O
report	O
)	O
[	O
4	O
]	O
.	O

In	O
this	O
case	O
,	O
the	O
placenta	O
was	O
clamped	O
as	O
close	O
to	O
the	O
uterine	O
cavity	O
as	O
possible	O
and	O
cut	O
.	O

The	O
base	O
of	O
the	O
placenta	O
was	O
overrun	O
with	O
haemostatic	O
sutures	O
and	O
this	O
was	O
repeated	O
until	O
as	O
much	O
of	O
the	O
placenta	O
as	O
possible	O
was	O
removed	O
(	O
Figure	O
4	O
)	O
.	O

Placental	O
removal	O
enabled	O
correction	O
of	O
uterine	O
inversion	O
.	O

Despite	O
the	O
many	O
conditions	O
associated	O
with	O
uterine	O
inversion	O
risk	O
assessment	O
is	O
often	O
lacking	O
making	O
the	O
condition	O
usually	O
unexpected	O
at	O
the	O
time	O
of	O
presentation	O
.	O

The	O
association	O
between	O
abnormal	O
placentation	O
such	O
as	O
placenta	O
accreta	O
and	O
uterine	O
inversion	O
is	O
well	O
supported	O
[	O
2	O
]	O
.	O

Therefore	O
,	O
we	O
advocate	O
antenatal	O
evaluation	O
and	O
risk	O
assessment	O
for	O
placenta	O
accreta	O
[	O
5	O
]	O
.	O

Prenatal	O
Ultrasound	O
reported	O
sensitivity	O
of	O
94	O
%	O
and	O
specificity	O
of	O
79	O
%	O
for	O
placenta	O
accreta	O
,	O
but	O
offer	O
no	O
more	O
than	O
provisional	O
diagnostic	O
probability	O
statement	O
[	O
6	O
]	O
.	O

Moreover	O
,	O
because	O
45	O
%	O
of	O
placenta	O
accreta	O
cases	O
were	O
not	O
detected	O
by	O
ultrasound	O
,	O
it	O
is	O
important	O
to	O
consider	O
avoiding	O
manual	O
removal	O
of	O
placenta	O
if	O
there	O
were	O
intraoperative	O
signs	O
of	O
accreta	O
[	O
6	O
]	O
.	O

If	O
clinically	O
or	O
sonographically	O
the	O
patient	S-Species
is	O
suspected	O
antenatally	O
to	O
be	O
at	O
risk	O
of	O
placenta	O
accreta	O
,	O
appropriate	O
management	O
options	O
should	O
be	O
considered	O
,	O
such	O
as	O
attempted	O
conservative	O
management	O
or	O
hysterectomy	O
and	O
counseling	O
provided	O
about	O
potential	O
sequelae	O
[	O
6	O
]	O
.	O

The	O
traditional	O
management	O
is	O
abdominal	O
hysterectomy	O
,	O
but	O
this	O
operation	O
terminates	O
fertility	O
and	O
may	O
have	O
devastating	O
psychological	O
effects	O
.	O

However	O
,	O
in	O
correct	O
circumstances	O
,	O
a	O
conservative	O
approach	O
may	O
be	O
suitable	O
.	O

Conservative	O
management	O
of	O
abnormally	O
invasive	O
placentation	O
can	O
be	O
effective	O
and	O
fertility	O
can	O
be	O
preserved	O
.	O

It	O
should	O
be	O
only	O
considered	O
in	O
highly	O
selected	O
cases	O
when	O
blood	O
loss	O
is	O
minimal	O
and	O
there	O
is	O
wish	O
for	O
fertility	O
preservation	O
[	O
7	O
]	O
.	O

For	O
women	S-Species
who	O
want	O
to	O
preserve	O
their	O
fertility	O
the	O
placenta	O
should	O
be	O
left	O
intact	O
if	O
possible	O
after	O
caesarean	O
delivery	O
as	O
this	O
approach	O
lowers	O
the	O
risk	O
of	O
subsequent	O
hysterectomy	O
from	O
85	O
%	O
to	O
15	O
%	O
.	O

For	O
women	S-Species
who	O
have	O
completed	O
their	O
family	O
,	O
hysterectomy	O
with	O
placenta	O
left	O
in	O
situ	O
is	O
preferable	O
to	O
lower	O
the	O
maternal	O
morbidity	O
rates	O
[	O
6	O
]	O
.	O

This	O
case	O
report	O
involved	O
conservative	O
management	O
.	O

Peripartum	O
hysterectomy	O
was	O
avoided	O
and	O
the	O
aim	O
was	O
to	O
preserve	O
fertility	O
.	O

Prophylactic	O
antibiotics	O
,	O
post	O
partum	O
oxytocics	O
and	O
the	O
use	O
of	O
misoprostol	O
post	O
operatively	O
helped	O
to	O
prevent	O
further	O
post	O
partum	O
hemorrhage	O
.	O

When	O
a	O
patient	S-Species
isinitially	O
opted	O
for	O
conservative	O
management	O
,	O
the	O
possibility	O
of	O
recurrence	O
should	O
be	O
discussed	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
placentation	O
should	O
be	O
carefully	O
monitored	O
for	O
recurrence	O
in	O
any	O
subsequent	O
pregnancy	O
,	O
particularly	O
if	O
the	O
placenta	O
is	O
located	O
at	O
the	O
same	O
site	O
as	O
the	O
previous	O
placenta	O
accreta	O
.	O

Conservative	O
treatment	O
for	O
placenta	O
accreta	O
may	O
be	O
an	O
alternative	O
procedure	O
in	O
some	O
selected	O
cases	O
.	O

Conclusion	O

We	O
suggest	O
an	O
alternative	O
approach	O
for	O
managing	O
uterine	O
inversion	O
caused	O
by	O
placenta	O
accreta	O
that	O
involved	O
conservative	O
management	O
.	O

This	O
way	O
hysterectomy	O
was	O
avoided	O
and	O
fertility	O
was	O
preserved	O
.	O

Abbreviations	O

CS	O
:	O
Caesarean	O
Section	O
;	O
FFP	O
:	O
Fresh	O
Frozen	O
Plasma	O

Consent	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	S-Species
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
accompanying	O
images	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
-	O
in	O
Chief	O
of	O
this	O
journal	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

All	O
authors	O
have	O
made	O
substantial	O
contribution	O
to	O
concept	O
this	O
case	O
report	O
.	O

Neurogenin2	O
Directs	O
Granule	O
Neuroblast	O
Production	O
and	O
Amplification	O
while	O
NeuroD1	O
Specifies	O
Neuronal	O
Fate	O
during	O
Hippocampal	O
Neurogenesis	O

Abstract	O

The	O
specification	O
and	O
differentiation	O
of	O
dentate	O
gyrus	O
granule	O
neurons	O
in	O
the	O
hippocampus	O
require	O
temporally	O
and	O
spatially	O
coordinated	O
actions	O
of	O
both	O
intrinsic	O
and	O
extrinsic	O
molecules	O
.	O

The	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factor	O
Neurogenin2	O
(	O
Ngn2	O
)	O
and	O
NeuroD1	O
are	O
key	O
regulators	O
in	O
these	O
processes	O
.	O

Based	O
on	O
existing	O
classification	O
,	O
we	O
analyzed	O
the	O
molecular	O
events	O
occurring	O
during	O
hippocampal	O
neurogenesis	O
,	O
primarily	O
focusing	O
on	O
juvenile	O
animals	O
.	O

We	O
found	O
that	O
Ngn2	O
is	O
transiently	O
expressed	O
by	O
late	O
type	O
-	O
2a	O
amplifying	O
progenitors	O
.	O

The	O
Ngn2	O
progenies	O
mature	O
into	O
hippocampal	O
granule	O
neurons	O
.	O

Interestingly	O
,	O
the	O
loss	O
of	O
Ngn2	O
at	O
early	O
stages	O
of	O
development	O
leads	O
to	O
a	O
robust	O
reduction	O
in	O
neurogenesis	O
,	O
but	O
does	O
not	O
disturb	O
granule	O
neuron	O
maturation	O
per	O
se	O
.	O

We	O
found	O
that	O
the	O
role	O
of	O
Ngn2	O
is	O
to	O
maintain	O
progenitors	O
in	O
an	O
undifferentiated	O
state	O
,	O
allowing	O
them	O
to	O
amplify	O
prior	O
to	O
their	O
maturation	O
into	O
granule	O
neurons	O
upon	O
NeuroD1	O
induction	O
.	O

When	O
we	O
overexpressed	O
Ngn2	O
and	O
NeuroD1	O
in	O
vivo	O
,	O
we	O
found	O
NeuroD1	O
to	O
exhibit	O
a	O
more	O
pronounced	O
neuron	O
-	O
inductive	O
effect	O
,	O
leading	O
to	O
granule	O
neuron	O
commitment	O
,	O
than	O
that	O
displayed	O
by	O
Ngn2	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
all	O
markers	O
expressed	O
during	O
the	O
transcriptional	O
control	O
of	O
hippocampal	O
neurogenesis	O
in	O
rodents	O
are	O
also	O
present	O
in	O
the	O
human	S-Species
hippocampus	O
.	O

Taken	O
together	O
,	O
we	O
demonstrate	O
a	O
critical	O
role	O
of	O
for	O
Ngn2	O
and	O
NeuroD1	O
in	O
controlling	O
neuronal	O
commitment	O
and	O
hippocampal	O
granule	O
neuroblast	O
formation	O
,	O
both	O
during	O
embryonic	O
development	O
and	O
in	O
post	O
-	O
natal	O
hippocampal	O
granule	O
neurogenesis	O
.	O

Introduction	O

Neurons	O
are	O
born	O
not	O
only	O
during	O
development	O
of	O
the	O
central	O
nervous	O
system	O
,	O
but	O
neurogenesis	O
also	O
continues	O
into	O
adulthood	O
.	O

In	O
both	O
rodent	S-Species
and	O
human	S-Species
adult	O
brain	O
,	O
neurogenesis	O
is	O
active	O
in	O
two	O
distinct	O
zones	O
of	O
the	O
forebrain	O
:	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
of	O
the	O
lateral	O
ventricle	O
and	O
the	O
subgranular	O
zone	O
(	O
SGZ	O
)	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
(	O
DG	O
)	O
[	O
1	O
]	O
-	O
[	O
5	O
]	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
neurogenesis	O
in	O
the	O
DG	O
is	O
not	O
fully	O
understood	O
.	O

Clearly	O
,	O
a	O
cascade	O
of	O
transcriptional	O
events	O
controls	O
the	O
specification	O
of	O
neuronal	O
identity	O
in	O
the	O
DG	O
[	O
3	O
]	O
,	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
,	O
but	O
details	O
of	O
the	O
expression	O
pattern	O
and	O
function	O
of	O
each	O
transcription	O
factor	O
remain	O
elusive	O
.	O

The	O
paired	O
-	O
box	O
homeodomain	O
transcription	O
factor	O
Pax6	O
and	O
the	O
bHLH	O
transcription	O
factors	O
Ngn2	O
and	O
NeuroD1	O
are	O
important	O
when	O
cells	O
acquire	O
a	O
pan	O
-	O
neuronal	O
character	O
and	O
a	O
specific	O
neuronal	O
subtype	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

In	O
the	O
developing	O
neocortex	O
,	O
Pax6	O
is	O
expressed	O
in	O
dividing	O
radial	O
glial	O
cells	O
at	O
the	O
ventricular	O
surface	O
[	O
9	O
]	O
.	O

In	O
the	O
adult	O
hippocampus	O
,	O
Pax6	O
is	O
expressed	O
in	O
astrocytes	O
in	O
the	O
SGZ	O
and	O
are	O
considered	O
to	O
be	O
the	O
true	O
stem	O
cells	O
[	O
9	O
]	O
,	O
[	O
11	O
]	O
.	O

Loss	O
-	O
and	O
gain	O
-	O
of	O
-	O
function	O
studies	O
indicate	O
that	O
Pax6	O
is	O
involved	O
in	O
regulating	O
the	O
proliferation	O
of	O
neocortical	O
and	O
hippocampal	O
progenitors	O
[	O
9	O
]	O
,	O
[	O
12	O
]	O
-	O
[	O
16	O
]	O
.	O

During	O
neocorticogenesis	O
,	O
high	O
concentrations	O
of	O
Pax6	O
induce	O
the	O
expression	O
of	O
the	O
bHLH	O
transcription	O
factor	O
Neurogenin2	O
(	O
Ngn2	O
)	O
[	O
17	O
]	O
.	O

In	O
turn	O
,	O
Ngn2	O
causes	O
cell	O
cycle	O
exit	O
[	O
18	O
]	O
,	O
an	O
event	O
that	O
takes	O
place	O
when	O
NeuroD1	O
starts	O
to	O
be	O
expressed	O
[	O
19	O
]	O
.	O

In	O
the	O
developing	O
hippocampus	O
,	O
the	O
absence	O
of	O
Ngn2	O
leads	O
to	O
a	O
reduced	O
number	O
of	O
granule	O
neurons	O
[	O
20	O
]	O
.	O

NeuroD1	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
essential	O
for	O
the	O
differentiation	O
and	O
survival	O
of	O
hippocampal	O
granule	O
neurons	O
[	O
10	O
]	O
.	O

Interestingly	O
,	O
in	O
the	O
absence	O
of	O
Ngn2	O
,	O
NeuroD1	O
can	O
still	O
be	O
activated	O
and	O
neuronal	O
differentiation	O
can	O
still	O
take	O
place	O
[	O
20	O
]	O
.	O

This	O
has	O
led	O
to	O
the	O
idea	O
that	O
the	O
primary	O
role	O
of	O
Ngn2	O
is	O
not	O
to	O
direct	O
neuronal	O
differentiation	O
.	O

Only	O
a	O
small	O
number	O
of	O
studies	O
have	O
addressed	O
the	O
role	O
of	O
Ngn2	O
and	O
NeuroD1	O
in	O
hippocampal	O
neurogenesis	O
[	O
10	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

Therefore	O
,	O
we	O
now	O
re	O
-	O
examine	O
their	O
roles	O
in	O
hippocampal	O
neurogenesis	O
in	O
detail	O
,	O
using	O
gain	O
-	O
and	O
loss	O
-	O
of	O
-	O
function	O
experiments	O
.	O

We	O
first	O
establish	O
a	O
hierarchy	O
of	O
transcriptional	O
events	O
that	O
occur	O
during	O
neurogenesis	O
in	O
the	O
DG	O
and	O
then	O
define	O
the	O
place	O
that	O
Ngn2	O
,	O
NeuroD1	O
and	O
other	O
transcription	O
factors	O
have	O
in	O
this	O
cascade	O
.	O

We	O
find	O
that	O
a	O
lack	O
of	O
Ngn2	O
expression	O
result	O
in	O
a	O
markedly	O
smaller	O
hippocampus	O
and	O
an	O
almost	O
complete	O
absence	O
of	O
the	O
DG	O
.	O

We	O
show	O
that	O
Ngn2	O
is	O
required	O
for	O
granule	O
neuroblasts	O
production	O
/	O
amplification	O
.	O

Gain	O
-	O
of	O
-	O
function	O
of	O
NeuroD1	O
during	O
development	O
of	O
the	O
DG	O
results	O
in	O
an	O
efficient	O
generation	O
of	O
granule	O
neuroblasts	O
,	O
an	O
effect	O
that	O
we	O
do	O
not	O
observe	O
when	O
we	O
overexpress	O
Ngn2	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
transcription	O
factors	O
and	O
cellular	O
markers	O
seen	O
in	O
mouse	S-Species
and	O
rat	S-Species
tissue	O
are	O
also	O
present	O
in	O
the	O
human	S-Species
hippocampus	O
.	O

Results	O

Expression	O
of	O
transcription	O
factors	O
and	O
cellular	O
markers	O
define	O
different	O
phases	O
of	O
postnatal	O
hippocampal	O
granule	O
neuron	O
maturation	O

We	O
first	O
analyzed	O
in	O
detail	O
the	O
chronology	O
of	O
expression	O
of	O
different	O
transcription	O
factors	O
and	O
cell	O
-	O
specific	O
markers	O
during	O
DG	O
granule	O
neuron	O
formation	O
and	O
correlated	O
our	O
findings	O
to	O
the	O
previously	O
established	O
classification	O
of	O
adult	O
hippocampal	O
neurogenesis	O
[	O
3	O
]	O
.	O

The	O
current	O
classification	O
describes	O
hippocampal	O
stem	O
cells	O
and	O
progenies	O
into	O
three	O
categories	O
(	O
type	O
-	O
1	O
,	O
-	O
2	O
and	O
-	O
3	O
cells	O
)	O
depending	O
on	O
the	O
markers	O
they	O
express	O
as	O
they	O
mature	O
.	O

In	O
the	O
adult	O
mouse	S-Species
DG	O
,	O
only	O
a	O
very	O
small	O
proportion	O
of	O
cells	O
undergo	O
mitosis	O
at	O
any	O
one	O
given	O
time	O
[	O
22	O
]	O
.	O

Consequently	O
,	O
in	O
adult	O
animals	O
it	O
is	O
difficult	O
to	O
analyze	O
which	O
transcription	O
factors	O
are	O
involved	O
in	O
the	O
transition	O
phase	O
from	O
one	O
cell	O
category	O
to	O
the	O
next	O
.	O

Therefore	O
,	O
we	O
studied	O
2	O
week	O
-	O
old	O
rodents	O
which	O
have	O
higher	O
numbers	O
of	O
maturing	O
granule	O
neurons	O
in	O
the	O
DG	O
.	O

We	O
performed	O
triple	O
immunohistochemistry	O
for	O
all	O
markers	O
of	O
interest	O
and	O
compared	O
results	O
from	O
2	O
week	O
-	O
and	O
2	O
month	O
-	O
old	O
mice	S-Species
(	O
Figure	O
1	O
and	O
figure	O
S1	O
)	O
.	O

We	O
first	O
confirmed	O
that	O
stem	O
cells	O
in	O
the	O
SGZ	O
exhibit	O
characteristics	O
of	O
radial	O
glia	O
[	O
3	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
16	O
]	O
.	O

They	O
extend	O
radial	O
processes	O
from	O
the	O
SGZ	O
to	O
the	O
apex	O
of	O
the	O
subgranular	O
layer	O
(	O
SGL	O
)	O
and	O
the	O
basal	O
molecular	O
layer	O
.	O

Moreover	O
,	O
they	O
express	O
the	O
intermediate	O
filament	O
protein	O
nestin	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
glial	O
glutamate	O
transporter	O
(	O
GLAST	O
)	O
[	O
16	O
]	O
(	O
Figure	O
1A	O
and	O
B	O
and	O
figure	O
S1A	O
and	O
S1B	O
)	O
.	O

The	O
GFAP	O
-	O
and	O
GLAST	O
+	O
cells	O
are	O
defined	O
as	O
type	O
-	O
1	O
cells	O
[	O
3	O
]	O
.	O

They	O
also	O
express	O
the	O
paired	O
-	O
homeodomain	O
transcription	O
factor	O
Pax6	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
divide	O
relatively	O
infrequently	O
,	O
and	O
are	O
believed	O
to	O
undergo	O
symmetric	O
division	O
(	O
giving	O
rise	O
to	O
two	O
identical	O
stem	O
cells	O
)	O
under	O
some	O
conditions	O
.	O

They	O
can	O
also	O
divide	O
asymmetrically	O
and	O
give	O
rise	O
to	O
a	O
new	O
stem	O
cell	O
and	O
one	O
neuronal	O
progenitor	O
,	O
which	O
usually	O
is	O
defined	O
as	O
a	O
type	O
-	O
2	O
cell	O
(	O
Figure	O
2B	O
)	O
[	O
3	O
]	O
.	O

Type	O
-	O
2	O
cells	O
are	O
divided	O
into	O
two	O
different	O
populations	O
:	O
type	O
-	O
2a	O
expressing	O
nestin	O
and	O
type	O
-	O
2b	O
co	O
-	O
expressing	O
nestin	O
and	O
doublecortin	O
(	O
Dcx	O
)	O
[	O
23	O
]	O
.	O

Based	O
on	O
a	O
previous	O
report	O
[	O
24	O
]	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
the	O
T	O
-	O
domain	O
transcription	O
factors	O
Tbr1	O
and	O
Tbr2	O
.	O

We	O
found	O
that	O
Tbr2	O
is	O
expressed	O
in	O
type	O
-	O
2a	O
cells	O
,	O
in	O
agreement	O
with	O
a	O
recent	O
report	O
[	O
25	O
]	O
.	O

In	O
the	O
SGZ	O
of	O
2	O
week	O
-	O
old	O
mice	S-Species
,	O
we	O
found	O
an	O
average	O
of	O
50	O
-	O
70	O
Tbr2	O
+	O
cells	O
per	O
30	O
micro	O
m	O
-	O
thick	O
section	O
throughout	O
the	O
rostro	O
-	O
caudal	O
axis	O
of	O
the	O
dorsal	O
hippocampus	O
.	O

This	O
number	O
was	O
reduced	O
by	O
35	O
%	O
in	O
2	O
month	O
-	O
old	O
mice	S-Species
(	O
Figure	O
1C	O
with	O
figure	O
S1C	O
and	O
data	O
not	O
shown	O
)	O
.	O

As	O
opposed	O
to	O
Tbr1	O
(	O
Figure	O
1D	O
and	O
figure	O
S1D	O
)	O
,	O
Tbr2	O
+	O
cells	O
did	O
not	O
co	O
-	O
express	O
Dcx	O
or	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
1C	O
and	O
figure	O
S1C	O
)	O
.	O

We	O
observed	O
that	O
Tbr1	O
-	O
immuoreactivity	O
gradually	O
decreased	O
as	O
neurons	O
matured	O
and	O
started	O
to	O
express	O
NeuN	O
(	O
Figure	O
1H	O
and	O
figure	O
S1H	O
)	O
.	O

Thus	O
,	O
Tbr2	O
labels	O
type	O
-	O
2	O
cells	O
,	O
while	O
Tbr1	O
is	O
expressed	O
by	O
immature	O
granule	O
neurons	O
.	O

We	O
then	O
examined	O
the	O
molecular	O
phenotype	O
of	O
type	O
-	O
3	O
cells	O
,	O
a	O
cell	O
type	O
that	O
transiently	O
expresses	O
Calretinin	O
[	O
26	O
]	O
.	O

We	O
hypothesized	O
that	O
hippocampal	O
type	O
-	O
3	O
cells	O
might	O
also	O
express	O
the	O
bHLH	O
transcription	O
factor	O
NeuroD1	O
,	O
known	O
to	O
partially	O
overlap	O
with	O
Tbr2	O
and	O
Tbr1	O
in	O
different	O
brain	O
regions	O
[	O
24	O
]	O
.	O

We	O
found	O
that	O
NeuroD1	O
expression	O
in	O
the	O
hippocampus	O
starts	O
in	O
Tbr2	O
+	O
cells	O
and	O
extends	O
to	O
post	O
-	O
mitotic	O
Tbr1	O
+	O
cells	O
,	O
which	O
also	O
express	O
the	O
hippocampal	O
granule	O
identity	O
transcription	O
factor	O
Prox1	O
(	O
Figure	O
1G	O
and	O
1I	O
and	O
figure	O
S1G	O
and	O
S1I	O
)	O
.	O

While	O
Tbr1	O
expression	O
ceases	O
during	O
granule	O
maturation	O
,	O
that	O
of	O
NeuroD1	O
is	O
weakly	O
maintained	O
when	O
NeuN	O
expression	O
starts	O
(	O
Figure	O
1G	O
and	O
1H	O
and	O
figure	O
S1G	O
and	O
S1H	O
)	O
.	O

We	O
found	O
that	O
calretinin	O
expression	O
decreased	O
during	O
granule	O
neuron	O
maturation	O
,	O
before	O
NeuroD1	O
was	O
reduced	O
(	O
Figure	O
1F	O
)	O
.	O

Thus	O
NeuroD1	O
is	O
expressed	O
in	O
type	O
-	O
2b	O
and	O
type	O
-	O
3	O
cells	O
,	O
as	O
well	O
as	O
immature	O
granule	O
neurons	O
.	O

Finally	O
,	O
we	O
found	O
that	O
NeuroD2	O
starts	O
to	O
be	O
expressed	O
just	O
after	O
NeuroD1	O
and	O
,	O
unlike	O
NeuroD1	O
,	O
continues	O
to	O
be	O
highly	O
expressed	O
in	O
mature	O
neurons	O
(	O
Figure	O
1J	O
and	O
data	O
not	O
shown	O
)	O
.	O

Mash1	O
and	O
Ngn2	O
define	O
the	O
early	O
versus	O
late	O
type	O
-	O
2a	O
stage	O
in	O
2	O
weeks	O
old	O
mice	S-Species

Having	O
established	O
the	O
hierarchy	O
of	O
transcription	O
factors	O
and	O
cellular	O
markers	O
appearing	O
during	O
hippocampal	O
neurogenesis	O
,	O
we	O
set	O
out	O
to	O
clarify	O
the	O
position	O
of	O
the	O
two	O
bHLH	O
transcription	O
factors	O
Ngn2	O
and	O
Mash1	O
,	O
in	O
this	O
process	O
.	O

We	O
found	O
that	O
more	O
than	O
90	O
%	O
of	O
Ngn2	O
-	O
immunoreactive	O
cells	O
are	O
Pax6	O
positive	O
(	O
Figure	O
2A	O
)	O
,	O
and	O
almost	O
all	O
co	O
-	O
express	O
Tbr2	O
(	O
Figure	O
2B	O
)	O
.	O

Thus	O
,	O
Ngn2	O
appears	O
to	O
be	O
expressed	O
by	O
type	O
-	O
2a	O
cells	O
.	O

As	O
our	O
antibodies	O
against	O
Ngn2	O
and	O
NeuroD1	O
were	O
made	O
in	O
the	O
same	O
species	O
,	O
we	O
could	O
not	O
determine	O
if	O
there	O
was	O
an	O
overlap	O
between	O
these	O
two	O
proteins	O
.	O

However	O
,	O
by	O
comparing	O
their	O
overlapping	O
expression	O
pattern	O
with	O
that	O
of	O
Tbr2	O
,	O
we	O
propose	O
that	O
some	O
Ngn2	O
+	O
cells	O
co	O
-	O
express	O
NeuroD1	O
,	O
and	O
that	O
they	O
appear	O
at	O
the	O
onset	O
of	O
NeuroD1	O
expression	O
and	O
downregulation	O
of	O
Ngn2	O
.	O

We	O
base	O
this	O
assumption	O
on	O
the	O
facts	O
that	O
more	O
than	O
50	O
%	O
of	O
the	O
Tbr2	O
+	O
cells	O
are	O
Ngn2	O
+	O
and	O
more	O
than	O
50	O
%	O
of	O
Tbr2	O
+	O
cells	O
also	O
express	O
NeuroD1	O
.	O

The	O
expression	O
of	O
Ngn2	O
in	O
adult	O
hippocampus	O
was	O
hard	O
to	O
detect	O
using	O
immunohistochemistry	O
due	O
to	O
the	O
low	O
expression	O
of	O
the	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
it	O
is	O
present	O
,	O
as	O
previously	O
described	O
using	O
reporter	O
mice	S-Species
and	O
as	O
revealed	O
by	O
in	O
situ	O
hybridization	O
[	O
21	O
]	O
.	O

We	O
next	O
examined	O
the	O
expression	O
of	O
Mash1	O
and	O
compared	O
it	O
with	O
that	O
of	O
Ngn2	O
,	O
Pax6	O
and	O
Tbr2	O
.	O

We	O
found	O
some	O
Mash1	O
+	O
cells	O
(	O
10	O
-	O
20	O
cells	O
per	O
section	O
)	O
in	O
the	O
dorsal	O
hippocampus	O
.	O

Almost	O
all	O
of	O
them	O
co	O
-	O
expressed	O
Pax6	O
(	O
Figure	O
2C	O
)	O
.	O

Only	O
few	O
cells	O
co	O
-	O
expressed	O
Tbr2	O
(	O
Figure	O
2D	O
)	O
or	O
Ngn2	O
(	O
Figure	O
2E	O
)	O
,	O
suggesting	O
that	O
Mash1	O
is	O
downregulated	O
when	O
these	O
two	O
proteins	O
are	O
expressed	O
.	O

None	O
of	O
the	O
Mash1	O
-	O
expressing	O
cells	O
were	O
positive	O
for	O
NeuroD1	O
(	O
Figure	O
2F	O
)	O
.	O

Mash1	O
+	O
cells	O
were	O
still	O
undergoing	O
mitosis	O
(	O
Figure	O
2C	O
)	O
and	O
consequently	O
over	O
90	O
%	O
of	O
them	O
co	O
-	O
labeled	O
with	O
the	O
cell	O
-	O
cycle	O
marker	O
Ki67	O
(	O
Figure	O
S1J	O
)	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
Mash1	O
and	O
Ngn2	O
are	O
expressed	O
in	O
early	O
and	O
late	O
stages	O
of	O
maturation	O
of	O
type2a	O
progenitors	O
,	O
respectively	O
,	O
and	O
that	O
both	O
transcription	O
factors	O
are	O
co	O
-	O
expressed	O
briefly	O
when	O
cells	O
transit	O
from	O
early	O
to	O
late	O
phase	O
type2a	O
cells	O
.	O

Ngn2	O
progenies	O
become	O
hippocampal	O
granule	O
neurons	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Mash1	O
null	O
mutant	O
mice	S-Species
hippocampal	O
neurogenesis	O
is	O
not	O
reduced	O
and	O
the	O
hippocampus	O
is	O
not	O
malformed	O
[	O
20	O
]	O
.	O

Therefore	O
we	O
focused	O
our	O
initial	O
analysis	O
on	O
the	O
role	O
of	O
Ngn2	O
in	O
hippocampal	O
neurogenesis	O
.	O

We	O
characterized	O
the	O
fate	O
of	O
Ngn2	O
-	O
expressing	O
cells	O
using	O
Ngn2	O
Knock	O
-	O
in	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
mice	S-Species
(	O
Ngn2	O
+	O
/	O
GFP	O
)	O
[	O
27	O
]	O
.	O

In	O
the	O
SGZ	O
of	O
2	O
week	O
-	O
old	O
hippocampi	O
,	O
we	O
found	O
bright	O
GFP	O
-	O
expressing	O
cells	O
that	O
were	O
positive	O
for	O
Tbr2	O
(	O
Figure	O
2H	O
)	O
,	O
the	O
immature	O
neuronal	O
marker	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
2I	O
)	O
and	O
NeuroD1	O
(	O
Figure	O
2J	O
)	O
.	O

Furthermore	O
,	O
Prox1	O
+	O
,	O
NeuroD2	O
+	O
and	O
calretinin	O
+	O
cells	O
were	O
also	O
weakly	O
positive	O
for	O
GFP	O
.	O

We	O
made	O
similar	O
observations	O
in	O
2	O
month	O
-	O
old	O
mice	S-Species
(	O
data	O
not	O
shown	O
)	O
confirming	O
earlier	O
published	O
results	O
[	O
21	O
]	O
)	O
.	O

We	O
did	O
not	O
observe	O
Mash1	O
+	O
/	O
GFP	O
+	O
and	O
NeuN	O
+	O
/	O
GFP	O
+	O
cells	O
(	O
Figure	O
2G	O
)	O
.	O

These	O
data	O
from	O
Ngn2	O
+	O
/	O
GFP	O
mice	S-Species
are	O
entirely	O
consistent	O
with	O
our	O
earlier	O
observations	O
using	O
immunocytochemistry	O
to	O
label	O
Ngn2	O
-	O
expressing	O
cells	O
and	O
with	O
GFP	O
undergoing	O
slow	O
degradation	O
after	O
the	O
expression	O
of	O
Ngn2	O
has	O
ceased	O
.	O

Importantly	O
,	O
none	O
of	O
the	O
GFP	O
-	O
expressing	O
cells	O
,	O
including	O
those	O
only	O
weakly	O
fluorescent	O
,	O
residing	O
in	O
the	O
SGL	O
expressed	O
the	O
astrocytic	O
marker	O
GFAP	O
or	O
the	O
oligodendrocytic	O
markers	O
CNPase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
the	O
data	O
show	O
that	O
Ngn2	O
progenies	O
become	O
neurons	O
and	O
never	O
generate	O
astrocytes	O
or	O
oligodendrocytes	O
.	O

Marked	O
reduction	O
of	O
hippocampal	O
granule	O
neurons	O
in	O
absence	O
of	O
Ngn2	O

To	O
determine	O
the	O
role	O
of	O
Ngn2	O
during	O
the	O
initiation	O
of	O
hippocampal	O
granule	O
neurogenesis	O
,	O
we	O
analyzed	O
the	O
hippocampus	O
of	O
mice	S-Species
lacking	O
Ngn2	O
(	O
Ngn2GFP	O
/	O
GFP	O
)	O
.	O

In	O
contrast	O
to	O
the	O
mice	S-Species
use	O
by	O
Galichet	O
and	O
coworkers	O
,	O
our	O
mice	S-Species
have	O
a	O
lifespan	O
of	O
only	O
2	O
weeks	O
after	O
birth	O
.	O

Therefore	O
,	O
we	O
analyzed	O
2	O
week	O
-	O
old	O
and	O
younger	O
mice	S-Species
.	O

Consistent	O
with	O
previous	O
observations	O
[	O
20	O
]	O
,	O
the	O
hippocampus	O
in	O
Ngn2GFP	O
/	O
GFP	O
mutants	O
is	O
clearly	O
malformed	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
two	O
week	O
-	O
old	O
Ngn2GFP	O
/	O
GFP	O
mice	S-Species
,	O
the	O
ventral	O
blade	O
of	O
the	O
DG	O
is	O
completely	O
absent	O
.	O

Already	O
on	O
postnatal	O
day	O
1	O
-	O
2	O
,	O
the	O
ventral	O
blade	O
of	O
the	O
DG	O
is	O
malformed	O
along	O
its	O
whole	O
rostro	O
-	O
caudal	O
axis	O
(	O
Figure	O
3B	O
)	O
.	O

As	O
neither	O
migration	O
defects	O
nor	O
cell	O
death	O
cause	O
the	O
reduced	O
number	O
of	O
hippocampal	O
neurons	O
in	O
Ngn2	O
null	O
mice	S-Species
[	O
20	O
]	O
,	O
we	O
asked	O
if	O
Ngn2	O
is	O
necessary	O
for	O
production	O
of	O
hippocampal	O
granule	O
neuroblasts	O
.	O

We	O
first	O
injected	O
2	O
day	O
-	O
old	O
mouse	S-Species
pups	O
with	O
BrdU	O
2	O
hours	O
prior	O
to	O
sacrifice	O
,	O
allowing	O
us	O
to	O
evaluate	O
cell	O
proliferation	O
and	O
ongoing	O
neurogenesis	O
.	O

We	O
also	O
injected	O
BrdU	O
into	O
female	O
mice	S-Species
on	O
their	O
final	O
day	O
of	O
pregnancy	O
and	O
examined	O
the	O
brains	O
of	O
their	O
pups	O
48	O
hours	O
later	O
(	O
corresponding	O
to	O
P1	O
-	O
P2	O
old	O
pups	O
)	O
.	O

This	O
allowed	O
us	O
to	O
assess	O
the	O
number	O
of	O
neurons	O
derived	O
from	O
the	O
last	O
day	O
of	O
intrauterine	O
development	O
.	O

Regardless	O
of	O
whether	O
the	O
mice	S-Species
were	O
WT	O
or	O
hetero	O
/	O
homozygous	O
mutant	O
pups	O
,	O
we	O
found	O
cells	O
that	O
had	O
incorporated	O
BrdU	O
in	O
the	O
hippocampal	O
subventricular	O
zone	O
(	O
hSVZ	O
)	O
,	O
fimbria	O
and	O
the	O
DG	O
(	O
Figure	O
4A	O
and	O
B	O
;	O
[	O
28	O
]	O
)	O
,	O
suggesting	O
that	O
progenitors	O
originating	O
in	O
the	O
hSVZ	O
divide	O
while	O
migrating	O
towards	O
the	O
DG	O
.	O

Most	O
of	O
them	O
were	O
organized	O
in	O
chains	O
typical	O
of	O
migrating	O
cells	O
(	O
Figure	O
4A	O
and	O
B	O
and	O
figure	O
S2	O
)	O
.	O

In	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
mice	S-Species
injected	O
with	O
BrdU	O
2	O
hours	O
prior	O
to	O
sacrifice	O
,	O
we	O
observed	O
a	O
decrease	O
in	O
the	O
number	O
of	O
BrdU	O
+	O
cells	O
compared	O
to	O
heterozygous	O
littermates	O
.	O

Thus	O
,	O
the	O
numbers	O
of	O
newborn	O
cells	O
were	O
reduced	O
in	O
the	O
hSVZ	O
/	O
fimbria	O
(	O
133	O
.	O
3	O
+/-	O
7	O
.	O
5	O
for	O
Ngn2	O
+	O
/	O
GFP	O
vs	O
69	O
.	O
7	O
+/-	O
5	O
.	O
0	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
and	O
DG	O
(	O
132	O
.	O
0	O
+/-	O
9	O
.	O
1	O
for	O
Ngn2	O
+	O
/	O
GFP	O
vs	O
42	O
.	O
6	O
+/-	O
2	O
.	O
2	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
(	O
Figure	O
4C	O
and	O
D	O
)	O
.	O

We	O
also	O
examined	O
the	O
number	O
of	O
newborn	O
cells	O
differentiating	O
into	O
neurons	O
,	O
and	O
identified	O
them	O
by	O
the	O
co	O
-	O
expression	O
of	O
BrdU	O
and	O
NeuroD1	O
.	O

As	O
expected	O
,	O
they	O
were	O
relatively	O
few	O
in	O
numbers	O
because	O
the	O
short	O
delay	O
(	O
2	O
hours	O
)	O
between	O
BrdU	O
administration	O
and	O
sacrifice	O
in	O
this	O
first	O
experimental	O
paradigm	O
.	O

In	O
Ngn2GFP	O
/	O
GFP	O
null	O
mutants	O
,	O
we	O
found	O
the	O
number	O
of	O
cells	O
differentiating	O
into	O
neurons	O
to	O
be	O
reduced	O
by	O
60	O
%	O
and	O
71	O
%	O
in	O
the	O
hSVZ	O
/	O
fimbria	O
(	O
8	O
.	O
6	O
+/-	O
1	O
.	O
4	O
for	O
Ngn2	O
+	O
/	O
GFP	O
vs	O
3	O
.	O
4	O
+/-	O
0	O
.	O
5	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
and	O
DG	O
(	O
9	O
.	O
7	O
+/-	O
1	O
.	O
1	O
for	O
Ngn2	O
+	O
/	O
GFP	O
vs	O
2	O
.	O
8	O
+/-	O
0	O
.	O
6	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
,	O
respectively	O
,	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

As	O
a	O
result	O
,	O
the	O
number	O
of	O
NeuroD1	O
+	O
cells	O
in	O
the	O
DG	O
was	O
reduced	O
by	O
80	O
%	O
(	O
580	O
.	O
3	O
+/-	O
27	O
.	O
7	O
for	O
Ngn2	O
+	O
/	O
GFP	O
vs	O
116	O
.	O
2	O
+/-	O
7	O
.	O
3	O
for	O
Ngn2GFP	O
/	O
GFP	O
;	O
Figure	O
4G	O
)	O
.	O

We	O
obtained	O
similar	O
results	O
in	O
the	O
second	O
paradigm	O
,	O
i	O
.	O
e	O
.	O
in	O
mice	S-Species
that	O
we	O
sacrificed	O
48	O
hours	O
after	O
BrdU	O
administration	O
and	O
in	O
which	O
a	O
larger	O
number	O
of	O
the	O
newborn	O
cells	O
had	O
time	O
to	O
mature	O
into	O
neurons	O
.	O

In	O
this	O
case	O
,	O
the	O
number	O
of	O
BrdU	O
+	O
/	O
NeuroD1	O
+	O
cells	O
in	O
the	O
DG	O
was	O
reduced	O
by	O
73	O
%	O
of	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
animals	O
(	O
91	O
.	O
5	O
+/-	O
24	O
.	O
1	O
for	O
Ngn2	O
+	O
/	O
GFP	O
vs	O
26	O
.	O
4	O
+/-	O
3	O
.	O
3	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
(	O
Figure	O
4J	O
)	O
.	O

We	O
found	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
BrdU	O
+	O
cells	O
that	O
expressed	O
NeuroD1	O
in	O
Ngn2	O
+	O
/	O
GFP	O
and	O
Ngn2GFP	O
/	O
GFP	O
mice	S-Species
(	O
14	O
.	O
2	O
+/-	O
1	O
.	O
0	O
%	O
and	O
17	O
.	O
4	O
+/-	O
1	O
.	O
8	O
%	O
respectively	O
;	O
Figure	O
4K	O
)	O
.	O

This	O
shows	O
that	O
the	O
few	O
cells	O
that	O
manage	O
to	O
proliferate	O
in	O
the	O
Ngn2	O
null	O
mice	S-Species
have	O
the	O
same	O
ability	O
to	O
differentiate	O
into	O
neurons	O
as	O
those	O
in	O
mice	S-Species
with	O
one	O
Ngn2	O
allele	O
.	O

Interestingly	O
,	O
the	O
absence	O
of	O
Ngn2	O
did	O
not	O
alter	O
the	O
identity	O
of	O
neurons	O
in	O
the	O
DG	O
granule	O
layer	O
in	O
2	O
week	O
-	O
old	O
Ngn2	O
null	O
mice	S-Species
.	O

The	O
maturing	O
granule	O
progenitors	O
sequentially	O
expressed	O
Pax6	O
,	O
Tbr2	O
(	O
Figure	O
S3A	O
and	O
S3B	O
)	O
,	O
NeuroD1	O
and	O
Calretinin	O
(	O
Figure	O
4L	O
)	O
,	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
4N	O
)	O
,	O
Tbr1	O
(	O
data	O
not	O
shown	O
)	O
and	O
Prox1	O
(	O
Figure	O
4M	O
)	O
.	O

We	O
confirmed	O
that	O
the	O
same	O
transcriptional	O
cascade	O
is	O
active	O
in	O
the	O
20	O
%	O
(	O
compared	O
to	O
mice	S-Species
with	O
one	O
Ngn2	O
allele	O
)	O
residual	O
granule	O
neurons	O
that	O
are	O
formed	O
two	O
day	O
-	O
old	O
in	O
Ngn2GFP	O
/	O
GFP	O
mice	S-Species
(	O
Figure	O
S3D	O
-	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

We	O
next	O
investigated	O
if	O
the	O
cells	O
that	O
failed	O
to	O
develop	O
into	O
neurons	O
in	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
mice	S-Species
,	O
became	O
glial	O
cells	O
.	O

We	O
found	O
that	O
cells	O
expressing	O
GFP	O
never	O
co	O
-	O
labeled	O
with	O
the	O
astrocyte	O
marker	O
GFAP	O
(	O
Figure	O
4N	O
)	O
or	O
the	O
oligodendrocyte	O
marker	O
CNPase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Altogether	O
,	O
our	O
results	O
show	O
that	O
Ngn2	O
plays	O
an	O
important	O
role	O
during	O
the	O
production	O
/	O
amplification	O
of	O
hippocampal	O
granule	O
neuroblasts	O
,	O
but	O
not	O
the	O
acquisition	O
of	O
the	O
granule	O
neuron	O
identity	O
(	O
Figure	O
S7	O
)	O
.	O

Ngn2	O
controls	O
the	O
amplification	O
of	O
granule	O
neuron	O
progenitors	O

We	O
next	O
monitored	O
the	O
mitogenic	O
activity	O
of	O
Ngn2	O
+	O
cells	O
in	O
the	O
DG	O
of	O
2	O
week	O
-	O
old	O
WT	O
mice	S-Species
.	O

We	O
observed	O
that	O
over	O
50	O
%	O
of	O
Ngn2	O
+	O
cells	O
in	O
the	O
DG	O
of	O
WT	O
mice	S-Species
co	O
-	O
expressed	O
the	O
mitosis	O
marker	O
Ki67	O
(	O
Figure	O
5A	O
)	O
.	O

Inspired	O
by	O
this	O
finding	O
,	O
we	O
injected	O
BrdU	O
into	O
2	O
week	O
-	O
old	O
WT	O
and	O
Ngn2GFP	O
/	O
GFP	O
mice	S-Species
and	O
compared	O
cell	O
proliferation	O
in	O
the	O
DG	O
.	O

We	O
observed	O
92	O
%	O
reduction	O
in	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
SGZ	O
of	O
Ngn2	O
null	O
mutant	O
mice	S-Species
(	O
6	O
.	O
7	O
+/-	O
0	O
.	O
5	O
)	O
compared	O
to	O
WT	O
(	O
83	O
.	O
6	O
+/-	O
1	O
.	O
2	O
)	O
and	O
heterozygotic	O
(	O
data	O
not	O
shown	O
)	O
littermates	O
(	O
Figure	O
5B	O
-	O
C	O
)	O
.	O

This	O
data	O
confirm	O
the	O
importance	O
of	O
Ngn2	O
during	O
the	O
amplification	O
of	O
granule	O
progenitor	O
.	O
s	O
.	O

To	O
further	O
explore	O
whether	O
Ngn2	O
+	O
cells	O
become	O
post	O
-	O
mitotic	O
or	O
still	O
proliferate	O
after	O
Ngn2	O
is	O
downregulated	O
,	O
we	O
performed	O
immunohistochemistry	O
on	O
sections	O
through	O
the	O
DG	O
of	O
Ngn2	O
+	O
/	O
GFP	O
mice	S-Species
.	O

We	O
stained	O
them	O
with	O
the	O
mitosis	O
marker	O
Phospho	O
-	O
histone	O
3	O
(	O
PH3	O
)	O
and	O
NeuroD1	O
,	O
which	O
is	O
downstream	O
of	O
Ngn2	O
in	O
the	O
transcriptional	O
cascade	O
controlling	O
neurogenesis	O
.	O

Thus	O
,	O
in	O
the	O
same	O
sections	O
we	O
could	O
identify	O
whether	O
cells	O
that	O
had	O
initiated	O
Ngn2	O
expression	O
(	O
GFP	O
labeled	O
)	O
,	O
continued	O
to	O
divide	O
(	O
PH3	O
+	O
)	O
or	O
committed	O
to	O
neuronal	O
differentiation	O
(	O
NeuroD1	O
+	O
)	O
.	O

We	O
observed	O
some	O
GFP	O
+	O
cells	O
that	O
co	O
-	O
expressed	O
PH3	O
.	O

They	O
all	O
exhibited	O
morphological	O
characteristics	O
of	O
one	O
of	O
the	O
five	O
mitotic	O
phases	O
:	O
prophase	O
,	O
metaphase	O
,	O
anaphase	O
,	O
telophase	O
and	O
cytokinesis	O
(	O
Figure	O
5D	O
and	O
data	O
not	O
shown	O
)	O
.	O

Unexpectedly	O
,	O
cells	O
that	O
colabeled	O
for	O
GFP	O
,	O
PH3	O
and	O
NeuroD1	O
(	O
Figure	O
5E	O
and	O
figure	O
S4A	O
and	O
S4B	O
)	O
were	O
rare	O
.	O

This	O
indicates	O
that	O
Ngn2	O
+	O
cells	O
undergo	O
division	O
/	O
amplification	O
and	O
that	O
they	O
mature	O
into	O
post	O
-	O
mitotic	O
neurons	O
upon	O
NeuroD1	O
expression	O
.	O

In	O
mice	S-Species
lacking	O
Ngn2	O
,	O
we	O
found	O
the	O
cells	O
expressing	O
GFP	O
localized	O
to	O
the	O
malformed	O
ventral	O
blade	O
of	O
the	O
DG	O
(	O
Figure	O
5F	O
and	O
G	O
)	O
.	O

All	O
of	O
these	O
cells	O
were	O
Ki67	O
+	O
and	O
they	O
only	O
very	O
rarely	O
expressed	O
PH3	O
(	O
Figure	O
5F	O
and	O
G	O
,	O
and	O
figure	O
S4C	O
)	O
in	O
the	O
absence	O
of	O
Ngn2	O
most	O
of	O
the	O
cells	O
are	O
arrested	O
in	O
the	O
cell	O
cycle	O
prior	O
to	O
entering	O
the	O
M	O
phase	O
and	O
their	O
mitosis	O
is	O
impaired	O
.	O

These	O
data	O
suggest	O
that	O
the	O
mechanism	O
of	O
action	O
of	O
Ngn2	O
is	O
conserved	O
from	O
development	O
of	O
the	O
DG	O
to	O
postnatal	O
hippocampal	O
neurogenesis	O
.	O

Our	O
findings	O
suggest	O
that	O
Ngn2	O
regulates	O
amplification	O
and	O
cell	O
cycle	O
exit	O
of	O
DG	O
granule	O
progenitors	O
.	O

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
effects	O
of	O
Ngn2	O
and	O
NeuroD1	O
on	O
mitotic	O
activity	O
in	O
embryonic	O
cortico	O
-	O
hippocampal	O
neurosphere	O
-	O
derived	O
progenitors	O
,	O
5	O
days	O
upon	O
transduction	O
,	O
in	O
vitro	O
.	O

In	O
cultures	O
transduced	O
with	O
Ngn2	O
retrovirus	O
,	O
we	O
found	O
that	O
27	O
.	O
2	O
%	O
(	O
+/-	O
4	O
.	O
1	O
%	O
)	O
of	O
the	O
PH3	O
+	O
cells	O
had	O
been	O
transduced	O
(	O
Figure	O
I1	O
-	O
J	O
)	O
.	O

These	O
cells	O
were	O
immunopositive	O
for	O
MAP2	O
(	O
Figure	O
5I1	O
and	O
I2	O
)	O
and	O
therefore	O
represented	O
dividing	O
neuroblasts	O
.	O

By	O
contrast	O
,	O
in	O
NeuroD1	O
transduced	O
cultures	O
,	O
only	O
7	O
.	O
3	O
%	O
of	O
PH3	O
+	O
cells	O
were	O
GFP	O
+	O
(	O
Figure	O
5H1	O
,	O
H2	O
and	O
J	O
)	O
.	O

All	O
of	O
the	O
NeuroD1	O
-	O
transduced	O
cells	O
became	O
MAP2	O
+	O
(	O
Figure	O
5H	O
)	O
.	O

To	O
confirm	O
this	O
data	O
we	O
pulse	O
-	O
labeled	O
transduced	O
cultures	O
with	O
chlorodeoxyuridine	O
(	O
CldU	O
)	O
for	O
48	O
hours	O
,	O
five	O
days	O
after	O
differentiation	O
.	O

In	O
contrast	O
to	O
NeuroD1	O
-	O
transduced	O
cultures	O
,	O
we	O
observed	O
dividing	O
cells	O
transduced	O
with	O
Ngn2	O
retrovirus	O
that	O
were	O
positive	O
for	O
PH3	O
and	O
that	O
had	O
incorporated	O
CldU	O
(	O
Figure	O
5K	O
-	O
L2	O
)	O
.	O

As	O
the	O
number	O
of	O
cells	O
PH3	O
+	O
/	O
CldU	O
+	O
/	O
GFP	O
+	O
we	O
observed	O
was	O
low	O
,	O
we	O
did	O
not	O
quantify	O
this	O
finding	O
.	O

Collectively	O
,	O
we	O
have	O
shown	O
that	O
Ngn2	O
is	O
required	O
for	O
granule	O
neuroblast	O
production	O
and	O
amplification	O
and	O
that	O
in	O
the	O
absence	O
of	O
Ngn2	O
the	O
progenitors	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

NeuroD1	O
,	O
on	O
the	O
other	O
hand	O
,	O
induces	O
cell	O
cycle	O
exit	O
and	O
promotes	O
rapid	O
neuronal	O
maturation	O
.	O

NeuroD1	O
directs	O
neuronal	O
differentiation	O
and	O
maturation	O

Based	O
on	O
our	O
previous	O
observations	O
we	O
proposed	O
that	O
Ngn2	O
primarily	O
controls	O
amplification	O
of	O
granule	O
neuroblasts	O
and	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
overexpressed	O
Ngn2	O
or	O
NeuroD1	O
in	O
E14	O
.	O
5	O
cortico	O
-	O
hippocampal	O
neurospheres	O
and	O
compared	O
their	O
effects	O
after	O
5	O
days	O
of	O
differentiation	O
of	O
the	O
progenitors	O
.	O

All	O
cortico	O
-	O
hippocampal	O
progenitors	O
expressed	O
Pax6	O
prior	O
to	O
differentiation	O
(	O
Figure	O
S5	O
)	O
.	O

After	O
5	O
days	O
,	O
both	O
factors	O
suppressed	O
Pax6	O
and	O
Sox2	O
(	O
Figure	O
S5	O
,	O
figure	O
6C	O
)	O
and	O
induced	O
expression	O
of	O
Tbr1	O
,	O
Map2	O
,	O
NeuroD1	O
and	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6D	O
and	O
E	O
)	O
.	O

Interestingly	O
,	O
all	O
Ngn2	O
-	O
overexpressing	O
cells	O
co	O
-	O
expressed	O
NeuroD1	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
next	O
explored	O
whether	O
Ngn2	O
overexpression	O
induces	O
NeuroD1	O
expression	O
,	O
and	O
if	O
NeuroD1	O
in	O
turn	O
directs	O
neuronal	O
differentiation	O
.	O

We	O
compared	O
the	O
effects	O
of	O
both	O
transcription	O
factors	O
in	O
progenitors	O
that	O
either	O
do	O
or	O
do	O
not	O
normally	O
express	O
them	O
.	O

Thus	O
,	O
we	O
expressed	O
Ngn2	O
in	O
E14	O
.	O
5	O
neural	O
progenitors	O
isolated	O
from	O
three	O
different	O
brain	O
regions	O
:	O
cortex	O
/	O
hippocampus	O
,	O
lateral	O
ganglionic	O
eminence	O
(	O
LGE	O
)	O
and	O
ventral	O
mesencephalon	O
(	O
VM	O
)	O
.	O

Ngn2	O
expression	O
in	O
the	O
developing	O
forebrain	O
is	O
normally	O
limited	O
to	O
the	O
neocortex	O
,	O
and	O
it	O
does	O
not	O
appear	O
in	O
LGE	O
tissue	O
[	O
29	O
]	O
.	O

In	O
the	O
developing	O
VM	O
,	O
both	O
Ngn2	O
and	O
NeuroD1	O
are	O
expressed	O
,	O
but	O
not	O
when	O
neural	O
progenitors	O
from	O
this	O
region	O
are	O
cultured	O
in	O
vitro	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

In	O
our	O
experiments	O
,	O
cortico	O
-	O
hippocampal	O
progenitors	O
could	O
differentiate	O
into	O
neurons	O
,	O
although	O
they	O
did	O
not	O
normally	O
express	O
NeuroD1	O
(	O
Figure	O
6E	O
)	O
.	O

When	O
we	O
overexpressed	O
Ngn2	O
in	O
VM	O
and	O
LGE	O
progenitors	O
,	O
the	O
cells	O
started	O
to	O
express	O
both	O
NeuroD1	O
and	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6F	O
and	O
G	O
)	O
.	O

We	O
then	O
overexpressed	O
NeuroD1	O
in	O
the	O
same	O
types	O
of	O
cultured	O
progenitors	O
and	O
found	O
that	O
the	O
cells	O
became	O
immunoreactive	O
for	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
NeuroD1	O
is	O
sufficient	O
to	O
direct	O
neuronal	O
differentiation	O
in	O
cortico	O
-	O
hippocampal	O
-	O
,	O
LGE	O
-	O
and	O
VM	O
-	O
derived	O
progenitors	O
.	O

Our	O
results	O
from	O
in	O
vitro	O
cultures	O
and	O
the	O
analysis	O
of	O
the	O
DG	O
of	O
Ngn2	O
mutant	O
animals	O
collectively	O
show	O
the	O
neuron	O
-	O
inducing	O
effect	O
of	O
NeuroD1	O
in	O
hippocampal	O
granule	O
cell	O
progenitors	O
[	O
32	O
]	O
.	O

NeuroD1	O
directs	O
exclusive	O
neuronal	O
differentiation	O
of	O
hippocampal	O
granule	O
neuron	O
progenitors	O

As	O
the	O
next	O
step	O
,	O
we	O
tested	O
the	O
effects	O
of	O
NeuroD1	O
in	O
vivo	O
and	O
compared	O
them	O
with	O
those	O
of	O
Ngn2	O
.	O

We	O
injected	O
retroviruses	O
carrying	O
the	O
gene	O
for	O
either	O
Ngn2	O
[	O
33	O
]	O
or	O
NeuroD1	O
,	O
and	O
the	O
reporter	O
gene	O
eGFP	O
into	O
the	O
ventricles	O
E15	O
.	O
5	O
rat	S-Species
embryos	O
,	O
in	O
utero	O
(	O
Figure	O
7A	O
)	O
.	O

Three	O
weeks	O
later	O
,	O
when	O
the	O
rats	S-Species
were	O
about	O
two	O
weeks	O
old	O
,	O
we	O
examined	O
their	O
hippocampi	O
and	O
analyzed	O
the	O
eGFP	O
+	O
cells	O
.	O

The	O
rats	S-Species
injected	O
with	O
control	O
vector	O
exhibited	O
eGFP	O
+	O
cells	O
within	O
the	O
hippocampus	O
that	O
were	O
either	O
star	O
-	O
shaped	O
,	O
progenitor	O
/	O
glial	O
-	O
like	O
cells	O
(	O
14	O
.	O
8	O
+/-	O
3	O
.	O
4	O
%	O
)	O
or	O
neuron	O
-	O
like	O
cells	O
with	O
long	O
neurites	O
(	O
85	O
.	O
3	O
+/-	O
3	O
.	O
4	O
%	O
)	O
(	O
Figure	O
7B	O
)	O
.	O

In	O
rats	S-Species
that	O
we	O
had	O
injected	O
with	O
the	O
vector	O
encoding	O
Ngn2	O
,	O
the	O
eGFP	O
-	O
labeled	O
,	O
the	O
transduced	O
hippocampal	O
cells	O
were	O
composed	O
of	O
31	O
.	O
9	O
%	O
(	O
+/-	O
5	O
.	O
7	O
%	O
)	O
progenitor	O
/	O
glia	O
-	O
like	O
cells	O
and	O
69	O
.	O
4	O
%	O
(	O
+/-	O
6	O
.	O
1	O
%	O
)	O
neuron	O
-	O
like	O
cells	O
(	O
Figure	O
7B	O
)	O
.	O

The	O
glia	O
-	O
like	O
subpopulation	O
was	O
immunopositive	O
for	O
the	O
astrocytic	O
marker	O
GFAP	O
(	O
Figure	O
7C	O
-	O
D	O
)	O
.	O

In	O
contrast	O
,	O
virtually	O
all	O
of	O
the	O
transduced	O
cells	O
in	O
rats	S-Species
injected	O
with	O
the	O
NeuroD1	O
vector	O
became	O
neuron	O
-	O
like	O
cells	O
(	O
99	O
.	O
9	O
%	O
+/-	O
0	O
.	O
1	O
;	O
Figure	O
7B	O
)	O
.	O

None	O
of	O
these	O
cells	O
stained	O
for	O
GFAP	O
(	O
Figure	O
7E	O
and	O
F	O
)	O
.	O

They	O
were	O
positioned	O
in	O
the	O
external	O
layers	O
of	O
both	O
the	O
ventral	O
and	O
dorsal	O
blades	O
of	O
the	O
DG	O
(	O
Figure	O
7B3	O
,	O
E	O
and	O
I	O
and	O
figure	O
S6A	O
)	O
.	O

When	O
we	O
examined	O
neuronal	O
maturation	O
of	O
Ngn2	O
-	O
and	O
NeuroD1	O
-	O
transduced	O
cells	O
,	O
we	O
observed	O
that	O
only	O
a	O
few	O
of	O
those	O
transduced	O
with	O
the	O
NeuroD1	O
vector	O
expressed	O
the	O
early	O
mature	O
neuronal	O
marker	O
Tbr1	O
(	O
3	O
.	O
1	O
+/-	O
1	O
.	O
4	O
%	O
;	O
Figure	O
7I	O
and	O
J	O
)	O
.	O

They	O
were	O
located	O
within	O
the	O
basal	O
layers	O
,	O
near	O
the	O
SGL	O
,	O
of	O
the	O
ventral	O
and	O
dorsal	O
blades	O
of	O
the	O
DG	O
.	O

In	O
contrast	O
,	O
a	O
greater	O
proportion	O
of	O
the	O
cells	O
transduced	O
with	O
Ngn2	O
still	O
expressed	O
Tbr1	O
(	O
19	O
.	O
6	O
%	O
+/-	O
3	O
.	O
3	O
%	O
;	O
Figure	O
7H	O
and	O
J	O
)	O
,	O
indicating	O
that	O
they	O
were	O
less	O
mature	O
than	O
the	O
vast	O
majority	O
of	O
the	O
NeuroD1	O
-	O
transduced	O
cells	O
.	O

Immunohistochemistry	O
for	O
NeuN	O
confirmed	O
these	O
data	O
(	O
Figure	O
7M	O
and	O
O	O
,	O
and	O
figure	O
S6A	O
)	O
.	O

Indeed	O
,	O
when	O
we	O
overexpressed	O
Ngn2	O
the	O
proportion	O
of	O
hippocampal	O
progenitors	O
that	O
became	O
NeuN	O
+	O
was	O
no	O
greater	O
than	O
in	O
rats	S-Species
transduced	O
with	O
the	O
control	O
virus	O
(	O
Figure	O
7F	O
)	O
.	O

As	O
a	O
whole	O
,	O
our	O
in	O
utero	O
injection	O
experiments	O
confirm	O
that	O
NeuroD1	O
has	O
a	O
stronger	O
neuron	O
-	O
inducing	O
effect	O
than	O
Ngn2	O
when	O
overexpressed	O
in	O
hippocampal	O
progenitors	O
.	O

Involvement	O
of	O
Mash1	O
,	O
Ngn2	O
,	O
Tbr	O
and	O
NeuroD	O
proteins	O
during	O
human	S-Species
hippocampal	O
neurogenesis	O

Finally	O
,	O
we	O
examined	O
whether	O
the	O
transcription	O
factors	O
and	O
cellular	O
markers	O
that	O
are	O
expressed	O
in	O
rodents	O
are	O
also	O
expressed	O
in	O
human	S-Species
hippocampus	O
.	O

We	O
performed	O
immunohistochemistry	O
on	O
aged	O
human	S-Species
hippocampal	O
DG	O
and	O
found	O
GFAP	O
-	O
,	O
Sox2	O
-	O
,	O
Pax6	O
-	O
,	O
Nestin	O
-	O
,	O
Prox1	O
-	O
and	O
NeuN	O
-	O
immunopositive	O
cells	O
.	O

This	O
indicates	O
that	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
,	O
neural	O
progenitors	O
and	O
mature	O
granule	O
neurons	O
are	O
present	O
in	O
the	O
aged	O
human	S-Species
hippocampus	O
(	O
Figure	O
8A	O
-	O
E	O
)	O
.	O

While	O
Prox1	O
is	O
found	O
mainly	O
in	O
granule	O
neurons	O
,	O
Sox2	O
and	O
Pax6	O
are	O
exclusively	O
localized	O
to	O
cells	O
in	O
the	O
SGZ	O
(	O
Figure	O
8D	O
and	O
E	O
)	O
.	O

As	O
for	O
aged	O
rodents	O
,	O
we	O
did	O
not	O
observe	O
the	O
presence	O
of	O
Mash1	O
,	O
Ngn2	O
,	O
Tbr2	O
,	O
Tbr1	O
and	O
NeuroD1	O
proteins	O
in	O
aged	O
human	S-Species
hippocampus	O
,	O
using	O
immunohistochemistry	O
.	O

However	O
,	O
we	O
could	O
identify	O
the	O
presence	O
of	O
the	O
transcripts	O
,	O
using	O
RT	O
-	O
PCR	O
(	O
Figure	O
8F	O
)	O
.	O

In	O
addition	O
,	O
we	O
detected	O
mRNA	O
for	O
Prox1	O
,	O
Calbindin1	O
and	O
Calbindin2	O
/	O
Calretinin	O
(	O
Figure	O
8F	O
)	O
.	O

Interestingly	O
,	O
we	O
also	O
observed	O
Sonic	O
Hedgehog	O
and	O
Wnt	O
-	O
3A	O
transcripts	O
,	O
indicating	O
that	O
they	O
are	O
present	O
in	O
the	O
human	S-Species
DG	O
and	O
supporting	O
previous	O
claims	O
that	O
they	O
are	O
important	O
for	O
the	O
regulation	O
of	O
adult	O
hippocampal	O
neurogenesis	O
(	O
Figure	O
8F	O
;	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
)	O
.	O

Finally	O
,	O
we	O
also	O
found	O
mRNA	O
for	O
GLAST	O
,	O
Pax6	O
and	O
GFAP	O
which	O
suggests	O
that	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
are	O
present	O
in	O
the	O
adult	O
human	S-Species
hippocampus	O
,	O
and	O
may	O
play	O
a	O
role	O
in	O
adult	O
human	S-Species
hippocampal	O
neurogenesis	O
(	O
Figure	O
8F	O
;	O
[	O
8	O
]	O
)	O
.	O

Overall	O
,	O
our	O
data	O
show	O
that	O
different	O
proteins	O
known	O
to	O
play	O
key	O
roles	O
in	O
rodent	S-Species
hippocampal	O
granule	O
neurogenesis	O
are	O
present	O
in	O
the	O
adult	O
human	S-Species
hippocampus	O
.	O

Discussion	O

In	O
this	O
study	O
we	O
determine	O
the	O
functions	O
of	O
Ngn2	O
and	O
NeuroD1	O
during	O
hippocampal	O
neurogenesis	O
.	O

First	O
,	O
we	O
map	O
the	O
hierarchy	O
of	O
molecular	O
markers	O
of	O
neurogenesis	O
in	O
the	O
DG	O
.	O

Second	O
,	O
we	O
describe	O
that	O
Ngn2	O
is	O
necessary	O
for	O
granule	O
progenitor	O
production	O
/	O
amplification	O
.	O

Third	O
,	O
we	O
demonstrate	O
that	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
of	O
granule	O
progenitors	O
.	O

Finally	O
,	O
we	O
show	O
that	O
different	O
cellular	O
markers	O
expressed	O
during	O
hippocampal	O
neurogenesis	O
in	O
rodents	O
are	O
present	O
in	O
human	S-Species
.	O

Sequential	O
expression	O
of	O
different	O
transcription	O
factors	O
and	O
cellular	O
markers	O
during	O
hippocampal	O
neurogenesis	O

We	O
clarified	O
the	O
pattern	O
of	O
expression	O
of	O
various	O
markers	O
expressed	O
during	O
postnatal	O
and	O
adult	O
hippocampal	O
granule	O
neurogenesis	O
in	O
detail	O
.	O

We	O
found	O
that	O
the	O
transcription	O
factor	O
Pax6	O
is	O
initially	O
expressed	O
by	O
both	O
radial	O
glia	O
stem	O
cells	O
(	O
type	O
-	O
1	O
)	O
and	O
early	O
amplifying	O
progenitors	O
(	O
type	O
-	O
2a	O
)	O
.	O

The	O
next	O
transcription	O
factor	O
to	O
appear	O
in	O
chronology	O
is	O
Mash1	O
.	O

Mash1	O
expression	O
characterizes	O
the	O
early	O
stage	O
of	O
hippocampal	O
progenitor	O
amplification	O
(	O
early	O
type	O
-	O
2a	O
)	O
.	O

The	O
role	O
of	O
Mash1	O
during	O
hippocampal	O
granule	O
neurogenesis	O
is	O
still	O
unclear	O
.	O

Mash1	O
null	O
mutant	O
mice	S-Species
do	O
not	O
display	O
any	O
clear	O
malformation	O
of	O
the	O
DG	O
[	O
20	O
]	O
.	O

However	O
,	O
overexpression	O
of	O
Mash1	O
alone	O
in	O
the	O
DG	O
leads	O
to	O
the	O
generation	O
of	O
oligodendrocytes	O
[	O
36	O
]	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
hypothesize	O
that	O
Mash1	O
-	O
expressing	O
cells	O
are	O
not	O
yet	O
committed	O
towards	O
a	O
granule	O
cell	O
fate	O
.	O

They	O
may	O
still	O
have	O
the	O
potential	O
to	O
generate	O
both	O
neurons	O
and	O
oligodendrocytes	O
,	O
as	O
is	O
the	O
case	O
in	O
the	O
SVZ	O
[	O
37	O
]	O
.	O

In	O
agreement	O
with	O
different	O
developing	O
brain	O
regions	O
,	O
we	O
found	O
that	O
Ngn2	O
starts	O
to	O
be	O
expressed	O
in	O
Mash1	O
-	O
positive	O
transiently	O
amplifying	O
progenitors	O
,	O
i	O
.	O
e	O
.	O
"	O
late	O
type	O
-	O
2a	O
cells	O
"	O
according	O
to	O
the	O
classification	O
we	O
propose	O
.	O

We	O
observed	O
that	O
Pax6	O
expression	O
persisted	O
longer	O
than	O
that	O
of	O
Mash1	O
,	O
in	O
Ngn2	O
-	O
expressing	O
cells	O
(	O
late	O
type	O
-	O
2a	O
cells	O
)	O
,	O
in	O
juvenile	O
but	O
not	O
adult	O
DG	O
(	O
Fig	O
.	O
1	O
and	O
figure	O
S1	O
)	O
.	O

Later	O
on	O
,	O
Ngn2	O
is	O
downregulated	O
,	O
whilst	O
Tbr2	O
expression	O
persists	O
(	O
type	O
-	O
2b	O
cells	O
)	O
.	O

The	O
transition	O
from	O
amplifying	O
progenitor	O
to	O
neuroblast	O
is	O
defined	O
by	O
the	O
expression	O
of	O
NeuroD1	O
.	O

Thus	O
,	O
Ngn2	O
is	O
expressed	O
at	O
the	O
beginning	O
of	O
the	O
transiently	O
amplifying	O
progenitor	O
phase	O
while	O
NeuroD1	O
marks	O
the	O
end	O
of	O
that	O
period	O
.	O

This	O
applies	O
both	O
to	O
the	O
juvenile	O
and	O
adult	O
rat	S-Species
brain	O
[	O
21	O
]	O
,	O
[	O
25	O
]	O
.	O

After	O
NeuroD1	O
is	O
turned	O
on	O
the	O
progenitors	O
leave	O
the	O
cell	O
cycle	O
,	O
gradually	O
mature	O
,	O
express	O
PSA	O
-	O
NCAM	O
,	O
NeuroD2	O
,	O
Calretinin	O
,	O
Prox1	O
,	O
Tbr1	O
and	O
,	O
finally	O
,	O
NeuN	O
.	O

NeuroD1	O
expression	O
persists	O
at	O
low	O
levels	O
in	O
mature	O
neurons	O
(	O
Figure	O
9	O
;	O
[	O
10	O
]	O
)	O
.	O

We	O
found	O
the	O
sequential	O
expression	O
of	O
these	O
markers	O
conserved	O
in	O
juvenile	O
(	O
P2	O
and	O
2	O
weeks	O
)	O
and	O
adult	O
rodent	S-Species
brains	O
.	O

Importantly	O
,	O
we	O
observed	O
that	O
the	O
same	O
transcription	O
factors	O
and	O
neuronal	O
markers	O
are	O
also	O
present	O
in	O
the	O
adult	O
human	S-Species
hippocampus	O
and	O
arranged	O
spatially	O
in	O
a	O
manner	O
reminiscent	O
with	O
what	O
we	O
saw	O
in	O
rodents	O
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
some	O
of	O
these	O
markers	O
are	O
expressed	O
for	O
longer	O
or	O
shorter	O
periods	O
at	O
postnatal	O
and	O
adult	O
stages	O
of	O
hippocampal	O
progenitor	O
maturation	O
.	O

Moreover	O
,	O
one	O
can	O
ask	O
to	O
which	O
extent	O
the	O
number	O
of	O
divisions	O
occurring	O
during	O
neuroblasts	O
maturation	O
is	O
conserved	O
at	O
postnatal	O
and	O
adult	O
stages	O
of	O
neurogenesis	O
.	O

A	O
new	O
function	O
for	O
Ngn2	O
in	O
maintenance	O
of	O
a	O
progenitor	O
state	O
for	O
granule	O
neuron	O
production	O
/	O
amplification	O
during	O
embryonic	O
and	O
postnatal	O
hippocampal	O
neurogenesis	O

In	O
agreement	O
with	O
earlier	O
work	O
,	O
we	O
confirm	O
that	O
Ngn2	O
is	O
indispensable	O
for	O
hippocampal	O
development	O
and	O
plays	O
a	O
vital	O
role	O
in	O
postnatal	O
hippocampal	O
granule	O
neurogenesis	O
.	O

Ngn2	O
null	O
mutant	O
animals	O
display	O
a	O
reduced	O
size	O
of	O
the	O
cornu	O
ammonis	O
and	O
a	O
malformed	O
DG	O
(	O
Figure	O
3	O
and	O
4	O
;	O
[	O
20	O
]	O
)	O
.	O

We	O
show	O
that	O
the	O
number	O
of	O
newborn	O
neurons	O
(	O
incorporated	O
BrdU	O
)	O
is	O
decreased	O
in	O
absence	O
of	O
Ngn2	O
,	O
but	O
hippocampal	O
granule	O
neuron	O
subtype	O
specification	O
is	O
not	O
affected	O
,	O
post	O
-	O
nataly	O
.	O

Likewise	O
,	O
neurons	O
from	O
other	O
brain	O
regions	O
,	O
e	O
.	O
g	O
.	O
ventral	O
midbrain	O
dopamine	O
neurons	O
,	O
can	O
be	O
generated	O
in	O
the	O
absence	O
of	O
Ngn2	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

The	O
reduced	O
numbers	O
of	O
mature	O
neurons	O
in	O
the	O
hippocampus	O
and	O
ventral	O
midbrain	O
of	O
Ngn2	O
null	O
mutant	O
animals	O
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
cell	O
death	O
or	O
migration	O
defects	O
[	O
20	O
]	O
,	O
[	O
31	O
]	O
.	O

Instead	O
it	O
may	O
be	O
due	O
to	O
a	O
defect	O
in	O
the	O
generation	O
and	O
/	O
or	O
amplification	O
of	O
neuronal	O
progenitors	O
.	O

Indeed	O
,	O
in	O
the	O
hippocampus	O
of	O
postnatal	O
animals	O
,	O
we	O
observed	O
that	O
cells	O
lacking	O
Ngn2	O
arrest	O
in	O
the	O
cell	O
cycle	O
,	O
maintain	O
Pax6	O
expression	O
and	O
cease	O
to	O
proliferate	O
.	O

When	O
overexpressed	O
in	O
neural	O
progenitors	O
in	O
vitro	O
,	O
Ngn2	O
lead	O
to	O
up	O
-	O
regulation	O
of	O
NeuroD1	O
and	O
caused	O
neuronal	O
differentiation	O
(	O
Figure	O
6	O
)	O
,	O
which	O
was	O
not	O
always	O
the	O
case	O
when	O
we	O
overexpressed	O
the	O
same	O
factor	O
in	O
vivo	O
(	O
Figure	O
7L	O
,	O
N	O
and	O
O	O
)	O
.	O

We	O
also	O
saw	O
that	O
Ngn2	O
does	O
not	O
always	O
efficiently	O
induce	O
cell	O
cycle	O
exit	O
.	O

Typically	O
some	O
mitotically	O
active	O
eGFP	O
+	O
cells	O
were	O
present	O
in	O
the	O
DG	O
of	O
rats	S-Species
injected	O
with	O
the	O
Ngn2	O
retrovirus	O
(	O
Figure	O
7P	O
)	O
,	O
and	O
we	O
observed	O
that	O
cultured	O
Ngn2	O
-	O
transduced	O
cells	O
are	O
still	O
capable	O
of	O
dividing	O
.	O

Thus	O
,	O
Ngn2	O
does	O
not	O
always	O
promote	O
cell	O
cycle	O
exit	O
and	O
neuronal	O
commitment	O
,	O
but	O
depending	O
on	O
the	O
state	O
of	O
the	O
cells	O
,	O
Ngn2	O
may	O
instead	O
promote	O
alternate	O
cellular	O
fates	O
[	O
38	O
]	O
-	O
[	O
40	O
]	O
.	O

Indeed	O
,	O
an	O
earlier	O
study	O
has	O
shown	O
that	O
Ngn2	O
-	O
overexpressing	O
progenitors	O
generate	O
oligodendrocytes	O
when	O
grafted	O
to	O
the	O
adult	O
spinal	O
cord	O
[	O
40	O
]	O
.	O

We	O
have	O
also	O
seen	O
that	O
Ngn2	O
-	O
overexpressing	O
neural	O
progenitors	O
from	O
the	O
embryonic	O
midbrain	O
form	O
astrocytes	O
when	O
grafted	O
to	O
the	O
striatum	O
(	O
unpublished	O
observations	O
)	O
.	O

Probably	O
,	O
Ngn2	O
cannot	O
influence	O
already	O
committed	O
cells	O
,	O
but	O
rather	O
would	O
control	O
neuroblasts	O
production	O
.	O

One	O
could	O
speculate	O
that	O
Ngn2	O
oscillates	O
during	O
granule	O
neuron	O
formation	O
,	O
as	O
recently	O
demonstrated	O
during	O
neocorticogenesis	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

NeuroD1	O
,	O
but	O
not	O
Ngn2	O
,	O
is	O
obligatory	O
for	O
granule	O
neuron	O
progenitor	O
differentiation	O

Hippocampal	O
granule	O
progenitors	O
can	O
mature	O
and	O
express	O
Tbr1	O
and	O
Prox1	O
,	O
both	O
during	O
the	O
development	O
and	O
postnatally	O
,	O
even	O
in	O
the	O
absence	O
of	O
Ngn2	O
.	O

Because	O
neuronal	O
differentiation	O
still	O
occurs	O
in	O
Ngn2	O
null	O
mice	S-Species
,	O
it	O
is	O
clear	O
that	O
compensatory	O
,	O
Ngn2	O
-	O
independent	O
mechanisms	O
induce	O
NeuroD1	O
expression	O
.	O

One	O
candidate	O
is	O
Ngn1	O
,	O
which	O
is	O
expressed	O
during	O
neocorticogenesis	O
,	O
the	O
specification	O
of	O
olfactory	O
sensory	O
neurons	O
and	O
during	O
embryonic	O
rat	S-Species
hippocampal	O
development	O
[	O
43	O
]	O
-	O
[	O
47	O
]	O
.	O

Both	O
Ngn1	O
and	O
Ngn2	O
regulate	O
NeuroD1	O
[	O
19	O
]	O
,	O
[	O
48	O
]	O
.	O

The	O
introduction	O
of	O
two	O
mutant	O
forms	O
of	O
Ngn1	O
,	O
a	O
deletion	O
of	O
the	O
basic	O
region	O
of	O
Ngn1	O
and	O
a	O
substitution	O
of	O
two	O
amino	O
acids	O
in	O
the	O
C	O
-	O
terminal	O
basic	O
region	O
,	O
prevents	O
NeuroD1	O
expression	O
and	O
neuronal	O
differentiation	O
[	O
48	O
]	O
.	O

The	O
double	O
null	O
Ngn1	O
/	O
Ngn2	O
mutant	O
displays	O
a	O
more	O
severe	O
phenotype	O
than	O
single	O
gene	O
(	O
Ngn1	O
or	O
Ngn2	O
)	O
mutant	O
mice	S-Species
.	O

For	O
example	O
,	O
the	O
total	O
brain	O
size	O
of	O
the	O
double	O
mutants	O
is	O
much	O
smaller	O
[	O
10	O
]	O
,	O
[	O
32	O
]	O
.	O

If	O
the	O
role	O
of	O
Ngn1	O
during	O
hippocampal	O
neurogenesis	O
is	O
to	O
activate	O
NeuroD1	O
and	O
that	O
of	O
Ngn2	O
is	O
to	O
control	O
granule	O
neuroblasts	O
production	O
/	O
amplification	O
,	O
the	O
DG	O
of	O
double	O
Ngn1	O
/	O
Ngn2	O
knockout	O
mice	S-Species
should	O
resemble	O
that	O
of	O
NeuroD1	O
null	O
mutant	O
mice	S-Species
.	O

We	O
demonstrated	O
that	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
progenitors	O
isolated	O
from	O
different	O
embryonic	O
brain	O
regions	O
and	O
cultured	O
in	O
vitro	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
NeuroD1	O
induced	O
neuronal	O
differentiation	O
.	O

The	O
neurons	O
generated	O
expressed	O
PSA	O
-	O
NCAM	O
,	O
Dcx	O
and	O
MAP2	O
.	O

After	O
in	O
utero	O
retroviral	O
vector	O
-	O
mediated	O
gene	O
delivery	O
,	O
virtually	O
all	O
cells	O
transduced	O
with	O
NeuroD1	O
became	O
neurons	O
.	O

In	O
contrast	O
,	O
progenitors	O
transduced	O
with	O
Ngn2	O
or	O
control	O
retroviruses	O
adopted	O
a	O
neuron	O
-	O
like	O
morphology	O
in	O
only	O
70	O
-	O
85	O
%	O
of	O
cases	O
.	O

Under	O
in	O
vitro	O
cell	O
culture	O
conditions	O
,	O
when	O
we	O
overexpressed	O
Ngn2	O
in	O
progenitors	O
derived	O
from	O
the	O
LGE	O
we	O
observed	O
robust	O
expression	O
of	O
NeuroD1	O
and	O
neuronal	O
differentiation	O
.	O

These	O
in	O
vitro	O
results	O
differ	O
from	O
those	O
we	O
obtained	O
when	O
we	O
transduced	O
the	O
embryonic	O
brain	O
with	O
a	O
viral	O
vector	O
expressing	O
Ngn2	O
.	O

In	O
this	O
latter	O
case	O
,	O
Ngn2	O
did	O
not	O
induce	O
neurons	O
and	O
the	O
transduced	O
cells	O
did	O
not	O
express	O
NeuroD1	O
.	O

Therefore	O
,	O
Ngn2	O
appears	O
to	O
direct	O
non	O
-	O
neuronal	O
cell	O
type	O
specification	O
in	O
vivo	O
[	O
38	O
]	O
-	O
[	O
40	O
]	O
.	O

Taken	O
together	O
,	O
we	O
have	O
confirmed	O
that	O
NeuroD1	O
plays	O
a	O
key	O
role	O
in	O
neuronal	O
differentiation	O
in	O
the	O
hippocampus	O
,	O
both	O
during	O
development	O
and	O
in	O
the	O
adult	O
brain	O
.	O

Concluding	O
remark	O

We	O
present	O
a	O
detailed	O
classification	O
of	O
different	O
stages	O
in	O
hippocampal	O
neurogenesis	O
.	O

Our	O
detailed	O
molecular	O
mapping	O
of	O
hippocampal	O
neurogenesis	O
allows	O
for	O
a	O
more	O
accurate	O
analysis	O
of	O
how	O
new	O
factors	O
stimulate	O
neurogenesis	O
at	O
different	O
steps	O
in	O
the	O
development	O
of	O
granule	O
neurons	O
.	O

Thereby	O
we	O
hope	O
to	O
facilitate	O
the	O
development	O
of	O
new	O
agents	O
,	O
which	O
stimulate	O
endogenous	O
progenitors	O
in	O
the	O
treatment	O
of	O
diseases	O
.	O

Materials	O
and	O
Methods	O

Animal	O
tissue	O
preparation	O

The	O
creation	O
of	O
the	O
Ngn2	O
transgenic	O
mice	S-Species
was	O
reported	O
elsewhere	O
(	O
ref	O
guillemot	O
)	O
.	O

Heterozygote	O
male	O
and	O
female	O
mice	S-Species
were	O
crossed	O
to	O
obtain	O
WT	O
,	O
heterozygote	O
(	O
Ngn2	O
+	O
/	O
GFP	O
)	O
and	O
null	O
mutant	O
(	O
Ngn2GFP	O
/	O
GFP	O
)	O
animals	O
.	O

Tails	O
of	O
the	O
Ngn2	O
offspring	O
were	O
used	O
to	O
obtain	O
DNA	O
for	O
determination	O
of	O
the	O
genotype	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
as	O
previously	O
reported	O
[	O
31	O
]	O
.	O

As	O
null	O
mutant	O
Ngn2GFP	O
/	O
GFP	O
do	O
not	O
survive	O
longer	O
than	O
2	O
.	O
5	O
-	O
3	O
weeks	O
after	O
birth	O
,	O
Ngn2GFP	O
/	O
GFP	O
and	O
their	O
littermates	O
were	O
sacrificed	O
at	O
the	O
postnatal	O
ages	O
of	O
two	O
days	O
(	O
P2	O
)	O
or	O
two	O
weeks	O
for	O
this	O
study	O
.	O

Neurogenesis	O
was	O
assessed	O
in	O
two	O
weeks	O
or	O
two	O
months	O
old	O
WT	O
mice	S-Species
.	O

Sprague	O
Dawley	O
pregnant	O
rats	S-Species
were	O
ordered	O
from	O
B	O
&	O
K	O
Universal	O
Ltd	O
,	O
Sollentuna	O
,	O
Sweden	O
(	O
hppt	O
:	O
/	O
/	O
www	O
.	O
bku	O
.	O
com	O
)	O
.	O

All	O
animals	O
were	O
housed	O
in	O
groups	O
with	O
ad	O
libitum	O
access	O
to	O
food	O
and	O
water	O
at	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
.	O

All	O
experimental	O
procedures	O
conducted	O
in	O
this	O
study	O
had	O
been	O
approved	O
by	O
the	O
Ethical	O
Committee	O
at	O
Lund	O
University	O
.	O

For	O
immunohistochemical	O
analysis	O
,	O
mice	S-Species
(	O
from	O
two	O
weeks	O
old	O
and	O
adult	O
stage	O
)	O
and	O
juvenile	O
rats	S-Species
were	O
sacrificed	O
by	O
transcardial	O
perfusion	O
with	O
saline	O
for	O
5	O
-	O
10	O
minutes	O
,	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
10	O
minutes	O
.	O

Brains	O
were	O
kept	O
in	O
PFA	O
overnight	O
at	O
4	O
degrees	O
C	O
and	O
subsequently	O
cryopreserved	O
in	O
a	O
20	O
-	O
30	O
%	O
sucrose	O
/	O
0	O
.	O
1	O
M	O
phosphate	O
buffer	O
solution	O
until	O
sectioning	O
on	O
a	O
microtome	O
apparatus	O
(	O
30	O
micro	O
m	O
thickness	O
sections	O
,	O
Microm	O
Zeiss	O
)	O
.	O

Seven	O
series	O
of	O
coronal	O
sections	O
were	O
cut	O
throughout	O
the	O
brain	O
.	O

Free	O
-	O
floating	O
sections	O
were	O
preserved	O
in	O
antifreeze	O
solution	O
until	O
immunohistochemistry	O
was	O
performed	O
.	O

Heads	O
of	O
postanatal	O
two	O
days	O
old	O
mice	S-Species
were	O
decapitated	O
and	O
soaked	O
in	O
PFA	O
4	O
%	O
for	O
24	O
hours	O
,	O
at	O
4	O
degrees	O
C	O
and	O
transferred	O
into	O
sucrose	O
solution	O
until	O
sectioning	O
on	O
cryostat	O
apparatus	O
(	O
16	O
micro	O
m	O
thickness	O
;	O
Leica	O
CM3000	O
)	O
.	O

Sections	O
were	O
mounted	O
on	O
Superfrost	O
glass	O
slides	O
and	O
stored	O
at	O
-	O
80	O
degrees	O
C	O
until	O
immunohistochemistry	O
was	O
performed	O
.	O

Cloning	O
,	O
subcloning	O
,	O
virus	O
production	O
and	O
titer	O
measurement	O

The	O
Moloney	O
leukemia	O
-	O
derived	O
retroviral	O
vectors	O
used	O
in	O
this	O
study	O
,	O
pCMMP	O
-	O
IRES2eGFP	O
-	O
WPRE	O
and	O
pCMMP	O
-	O
Ngn2	O
-	O
IRES2eGFP	O
-	O
WPRE	O
were	O
previously	O
described	O
[	O
40	O
]	O
,	O
[	O
49	O
]	O
.	O

To	O
generate	O
the	O
construct	O
pCMMP	O
-	O
NeuroD1	O
-	O
IRES2eGFP	O
-	O
WPRE	O
,	O
mouse	S-Species
NeuroD1	O
cDNA	O
was	O
amplified	O
from	O
a	O
pCS2	O
+	O
mtNeuroD1	O
plasmid	O
(	O
kindly	O
provided	O
by	O
Professor	O
Jackie	O
Lee	O
,	O
Denver	O
university	O
,	O
Boulder	O
,	O
USA	O
)	O
by	O
PCR	O
to	O
introduce	O
the	O
restriction	O
sites	O
PmeI	O
in	O
5	O
'	O
and	O
XhoI	O
in	O
3	O
'	O
.	O

Amplification	O
of	O
cDNA	O
was	O
performed	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
construction	O
was	O
verified	O
by	O
enzymatic	O
restriction	O
and	O
by	O
DNA	O
sequencing	O
using	O
BigDye	O
3	O
.	O
1	O
(	O
ABI	O
)	O
.	O

All	O
infectious	O
particles	O
were	O
produced	O
using	O
the	O
producer	O
cell	O
line	O
293VSV	O
-	O
G	O
and	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
titer	O
of	O
each	O
retrovirus	O
was	O
measured	O
by	O
flow	O
-	O
cytometry	O
based	O
on	O
eGFP	O
expression	O
,	O
four	O
days	O
following	O
infection	O
of	O
HT1080	O
cells	O
and	O
ranged	O
from	O
0	O
.	O
5	O
x	O
109	O
-	O
2	O
.	O
1	O
x	O
109	O
TU	O
/	O
ml	O
(	O
All	O
details	O
on	O
how	O
to	O
produce	O
infectious	O
particles	O
can	O
be	O
provided	O
upon	O
request	O
)	O
.	O

Neurosphere	O
generation	O
,	O
transduction	O
and	O
differentiation	O

Pregnant	O
female	O
Sprague	B-Species
-	I-Species
Dawley	I-Species
rats	E-Species
(	O
B	O
&	O
K	O
Universal	O
,	O
Sollentuna	O
,	O
Sweden	O
)	O
were	O
terminally	O
anesthetized	O
by	O
an	O
overdose	O
of	O
sodium	O
pentobarbital	O
(	O
i	O
.	O
p	O
.	O
,	O
60	O
ng	O
/	O
ml	O
)	O
.	O

Embryos	O
at	O
stage	O
embryonic	O
day	O
E14	O
.	O
5	O
(	O
Plug	O
day	O
as	O
day	O
0	O
)	O
were	O
collected	O
and	O
cortical	O
-	O
hippocampal	O
neurospheres	O
were	O
generated	O
following	O
dissection	O
of	O
the	O
dorso	O
-	O
posterior	O
part	O
of	O
the	O
cortical	O
tissue	O
,	O
and	O
generated	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

In	O
this	O
study	O
,	O
second	O
passage	O
(	O
P2	O
)	O
neurospheres	O
were	O
used	O
to	O
study	O
the	O
effect	O
of	O
the	O
overexpression	O
of	O
Ngn2	O
and	O
NeuroD1	O
on	O
neuronal	O
differentiation	O
.	O

Each	O
well	O
,	O
containing	O
an	O
equal	O
starting	O
population	O
of	O
200	O
,	O
000	O
cells	O
/	O
ml	O
,	O
corresponding	O
to	O
15	O
-	O
25	O
neurospheres	O
,	O
was	O
transduced	O
independently	O
with	O
each	O
retrovirus	O
at	O
a	O
multiplicity	O
of	O
infection	O
(	O
MOI	O
)	O
of	O
1	O
,	O
in	O
proliferation	O
medium	O
supplemented	O
by	O
protamine	O
-	O
sulfate	O
(	O
4	O
mg	O
/	O
ml	O
,	O
Sigma	O
)	O
.	O

To	O
induce	O
differentiation	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
normal	O
basic	O
differentiation	O
medium	O
two	O
days	O
post	O
-	O
transduction	O
and	O
subsequently	O
changed	O
every	O
other	O
day	O
until	O
fixation	O
.	O

Immunocytochemistry	O
,	O
immunohistochemistry	O
and	O
microscopy	O

The	O
antibodies	O
used	O
in	O
this	O
study	O
are	O
:	O
rabbit	S-Species
anti	O
-	O
GFAP	O
(	O
1	O
:	O
1000	O
;	O
DAKO	O
)	O
,	O
mouse	S-Species
anti	O
-	O
Nestin	O
(	O
1	O
:	O
100	O
;	O
BD	O
PharMingen	O
)	O
,	O
guinea	B-Species
pig	E-Species
anti	O
-	O
Glast	O
(	O
1	O
:	O
500	O
;	O
Chemicon	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
Prox1	O
(	O
1	O
:	O
1000	O
;	O
Covance	O
)	O
,	O
goat	S-Species
anti	O
-	O
Ngn2	O
(	O
1	O
:	O
20	O
;	O
Santa	O
Cruz	O
)	O
,	O
goat	S-Species
anti	O
-	O
NeuroD1	O
(	O
1	O
:	O
200	O
;	O
Santa	O
Cruz	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
Pax6	O
(	O
1	O
:	O
150	O
;	O
Covance	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
Trb2	O
(	O
1	O
:	O
500	O
;	O
Chemicon	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
Trb1	O
:	O
(	O
1	O
:	O
1000	O
;	O
Chemicon	O
)	O
,	O
goat	S-Species
anti	O
-	O
Dcx	O
:	O
(	O
1	O
:	O
500	O
;	O
Santa	O
Cruz	O
)	O
,	O
mouse	S-Species
anti	O
-	O
PSA	O
-	O
NCAM	O
:	O
(	O
1	O
:	O
500	O
;	O
Chemicon	O
)	O
,	O
mouse	S-Species
anti	O
-	O
NeuN	O
(	O
1	O
:	O
300	O
;	O
Chemicon	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
Calretinin	O
(	O
1	O
:	O
500	O
;	O
Swant	O
)	O
;	O
mouse	S-Species
anti	O
-	O
Sox2	O
(	O
1	O
:	O
100	O
;	O
R	O
&	O
D	O
systems	O
)	O
,	O
mouse	S-Species
anti	O
-	O
Mash1	O
(	O
1	O
:	O
100	O
;	O
BD	O
PharMingen	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
NeuroD2	O
(	O
1	O
:	O
300	O
;	O
ABCAM	O
)	O
,	O
mouse	S-Species
anti	O
-	O
MAP2	O
(	O
1	O
:	O
500	O
;	O
Sigma	O
)	O
,	O
rabbit	S-Species
anti	O
-	O
Ki67	O
(	O
1	O
:	O
150	O
;	O
NovaCastra	O
)	O
and	O
rabbit	S-Species
anti	O
-	O
phospho	O
-	O
Histone	O
H3	O
.	O

The	O
secondary	O
antibodies	O
(	O
1	O
:	O
200	O
)	O
Cy2	O
,	O
FITC	O
,	O
Cy3	O
and	O
Cy5	O
were	O
from	O
Jackson	O
IR	O
laboratories	O
,	O
Alexa	O
-	O
fluor	O
488	O
,	O
568	O
,	O
595	O
and	O
647	O
from	O
Invitrogen	O
-	O
Molecular	O
Probes	O
.	O

DAPI	O
(	O
1	O
:	O
1000	O
)	O
was	O
purchased	O
from	O
Sigma	O
.	O

For	O
immunocytochemistry	O
,	O
cultures	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
day	O
five	O
,	O
rinsed	O
with	O
PBS	O
three	O
times	O
prior	O
to	O
pre	O
-	O
incubation	O
with	O
a	O
blocking	O
solution	O
(	O
10	O
%	O
donkey	S-Species
serum	O
,	O
0	O
.	O
25	O
%	O
TritonX100	O
in	O
PBS	O
)	O
for	O
1	O
hour	O
.	O

The	O
remainder	O
of	O
the	O
procedure	O
was	O
performed	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

Specimen	O
analyses	O
were	O
performed	O
using	O
a	O
Leica	O
confocal	O
microscope	O
(	O
Leica	O
software	O
,	O
equipped	O
with	O
a	O
GreNe	O
and	O
a	O
HeNe	O
laser	O
,	O
using	O
the	O
following	O
lines	O
of	O
excitation	O
:	O
488	O
nm	O
,	O
594	O
nm	O
and	O
647	O
nm	O
)	O
.	O

Samples	O
were	O
analyzed	O
using	O
20	O
x	O
,	O
40	O
x	O
and	O
63	O
x	O
objectives	O
,	O
sometimes	O
zoomed	O
.	O

Figures	O
were	O
composed	O
in	O
CANVAS	O
-	O
X	O
software	O
.	O

Bromo	O
-	O
deoxyuridine	O
(	O
BrdU	O
)	O
and	O
Cloro	O
-	O
deoxyuridine	O
(	O
CldU	O
)	O
pulse	O
labeling	O
and	O
immunohisto	O
-	O
and	O
immunocyto	O
-	O
chemistry	O

To	O
assess	O
cell	O
proliferation	O
and	O
ongoing	O
neurogenesis	O
in	O
vivo	O
,	O
animals	O
were	O
injected	O
with	O
BrdU	O
(	O
100	O
mg	O
/	O
kg	O
,	O
Sigma	O
)	O
,	O
two	O
hours	O
prior	O
to	O
sacrifice	O
(	O
for	O
both	O
P2	O
and	O
two	O
weeks	O
old	O
Ngn2	O
mice	S-Species
)	O
.	O

To	O
assess	O
neurogenesis	O
,	O
BrdU	O
(	O
100	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
48	O
hours	O
prior	O
to	O
sacrifice	O
(	O
for	O
P2	O
animals	O
,	O
BrdU	O
was	O
injected	O
in	O
pregnant	O
dams	O
half	O
day	O
prior	O
to	O
give	O
birth	O
)	O
.	O

Immunohistochemistry	O
was	O
carried	O
on	O
as	O
described	O
above	O
using	O
a	O
rat	S-Species
anti	O
-	O
CldU	O
/	O
BrdU	O
primary	O
antibody	O
(	O
1	O
:	O
200	O
,	O
monoclonal	O
,	O
Immunologicalsdirect	O
,	O
Oxfordshire	O
,	O
UK	O
)	O
,	O
with	O
an	O
additional	O
denaturation	O
in	O
1	O
M	O
HCl	O
for	O
30	O
minutes	O
prior	O
to	O
pre	O
-	O
incubation	O
with	O
serum	O
.	O

To	O
assess	O
the	O
neuronal	O
-	O
inducing	O
activity	O
of	O
Ngn2	O
and	O
NeuroD1	O
,	O
transduced	O
cultures	O
were	O
incubated	O
with	O
CldU	O
(	O
20	O
micro	O
M	O
,	O
Sigma	O
)	O
for	O
2	O
days	O
,	O
after	O
a	O
period	O
of	O
differentiation	O
of	O
five	O
days	O
.	O

For	O
immunocytochemistry	O
,	O
cultures	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
at	O
day	O
7	O
,	O
rinsed	O
with	O
PBS	O
three	O
times	O
,	O
treated	O
with	O
1	O
M	O
HCl	O
at	O
65	O
degrees	O
C	O
for	O
5	O
-	O
10	O
min	O
,	O
pre	O
-	O
incubated	O
and	O
then	O
incubated	O
with	O
a	O
rat	S-Species
anti	O
-	O
CldU	O
/	O
BrdU	O
antibody	O
and	O
other	O
primary	O
antibodies	O
.	O

The	O
remainder	O
of	O
the	O
procedure	O
was	O
performed	O
according	O
to	O
the	O
protocol	O
for	O
immunohistochemistry	O
already	O
mentioned	O
.	O

In	O
utero	O
surgery	O

Timed	O
pregnant	O
female	O
Sprague	B-Species
Dawley	I-Species
rats	E-Species
with	O
embryos	O
at	O
gestational	O
age	O
E15	O
.	O
5	O
were	O
anesthetized	O
with	O
halothane	O
.	O

The	O
mother	O
was	O
placed	O
in	O
the	O
lower	O
level	O
of	O
a	O
two	O
-	O
level	O
wooden	O
stage	O
.	O

The	O
abdomen	O
was	O
shaved	O
with	O
an	O
electric	O
razor	O
and	O
then	O
cleaned	O
with	O
70	O
%	O
alcohol	O
.	O

A	O
2	O
-	O
3	O
cm	O
midline	O
laparotomy	O
was	O
performed	O
.	O

Each	O
uterine	O
horn	O
was	O
carefully	O
taken	O
out	O
individually	O
and	O
the	O
number	O
of	O
embryos	O
recorded	O
.	O

One	O
horn	O
was	O
then	O
placed	O
back	O
inside	O
the	O
mother	O
,	O
whilst	O
the	O
other	O
horn	O
was	O
prepared	O
for	O
injection	O
.	O

The	O
embryos	O
were	O
kept	O
moist	O
with	O
constant	O
application	O
of	O
warm	O
saline	O
to	O
prevent	O
dehydration	O
.	O

Approximately	O
2	O
micro	O
l	O
of	O
viral	O
suspension	O
(	O
1	O
x	O
10	O
^	O
9TU	O
/	O
ml	O
)	O
was	O
injected	O
into	O
the	O
lateral	O
ventricle	O
of	O
each	O
embryo	O
,	O
except	O
for	O
the	O
embryo	O
closest	O
to	O
the	O
vagina	O
.	O

After	O
the	O
injections	O
,	O
the	O
uterine	O
horns	O
were	O
placed	O
back	O
into	O
the	O
abdomen	O
.	O

The	O
abdominal	O
wall	O
and	O
the	O
overlying	O
skin	O
were	O
then	O
sutured	O
.	O

Care	O
was	O
taken	O
not	O
to	O
damage	O
abdominal	O
muscles	O
so	O
that	O
normal	O
delivery	O
of	O
the	O
pups	O
was	O
possible	O
at	O
term	O
.	O

The	O
entire	O
surgery	O
generally	O
took	O
about	O
45	O
minutes	O
to	O
one	O
hour	O
.	O

Each	O
mother	O
was	O
allowed	O
to	O
recover	O
in	O
her	O
cage	O
before	O
being	O
returned	O
to	O
the	O
animal	O
stable	O
.	O

Shredded	O
paper	O
was	O
added	O
to	O
each	O
cage	O
to	O
encourage	O
nesting	O
and	O
special	O
care	O
was	O
taken	O
not	O
to	O
stress	O
the	O
mothers	O
.	O

Following	O
normal	O
delivery	O
,	O
the	O
pups	O
were	O
allowed	O
to	O
develop	O
to	O
adulthood	O
up	O
to	O
two	O
weeks	O
.	O

Quantification	O

For	O
the	O
in	O
vivo	O
experiment	O
,	O
manual	O
cell	O
counting	O
was	O
performed	O
on	O
18	O
and	O
30	O
micro	O
m	O
thick	O
brain	O
sections	O
for	O
two	O
days	O
and	O
two	O
weeks	O
old	O
animals	O
,	O
respectively	O
.	O

The	O
brain	O
of	O
P2	O
animals	O
was	O
cut	O
into	O
10	O
series	O
of	O
coronal	O
sections	O
;	O
the	O
brain	O
of	O
two	O
-	O
weeks	O
old	O
animals	O
was	O
cut	O
into	O
7	O
-	O
8	O
series	O
of	O
coronal	O
sections	O
.	O

For	O
each	O
staining	O
,	O
one	O
-	O
two	O
series	O
from	O
three	O
to	O
five	O
different	O
individuals	O
were	O
analyzed	O
per	O
genotype	O
using	O
a	O
confocal	O
microscope	O
with	O
1	O
,	O
2	O
or	O
3	O
lines	O
of	O
excitation	O
,	O
in	O
sequential	O
scanning	O
in	O
order	O
to	O
avoid	O
false	O
positives	O
.	O

When	O
two	O
series	O
were	O
analyzed	O
,	O
only	O
one	O
series	O
was	O
counted	O
.	O

The	O
mean	O
number	O
of	O
cells	O
per	O
hippocampus	O
expressing	O
the	O
markers	O
of	O
interest	O
,	O
was	O
calculated	O
for	O
each	O
brain	O
,	O
based	O
on	O
the	O
analysis	O
of	O
6	O
-	O
8	O
consecutive	O
dorsal	O
hippocampal	O
sections	O
.	O

The	O
final	O
mean	O
number	O
of	O
cells	O
per	O
section	O
was	O
calculated	O
by	O
adding	O
the	O
mean	O
number	O
from	O
each	O
individual	O
.	O

We	O
expressed	O
the	O
data	O
as	O
the	O
mean	O
number	O
of	O
positive	O
cells	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

In	O
this	O
study	O
,	O
more	O
than	O
25	O
Ngn2	O
null	O
,	O
>	O
45	O
Ngn2	O
heterozygotes	O
,	O
and	O
>	O
60	O
WT	O
individuals	O
(	O
including	O
rats	S-Species
injected	O
with	O
retroviruses	O
)	O
were	O
analyzed	O
,	O
in	O
total	O
.	O

Statistical	O
comparison	O
was	O
performed	O
using	O
one	O
-	O
factor	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
transcription	O
factor	O
,	O
cellular	O
marker	O
,	O
genotype	O
or	O
time	O
as	O
variables	O
,	O
followed	O
by	O
post	O
-	O
hoc	O
analysis	O
when	O
significant	O
differences	O
were	O
observed	O
,	O
using	O
Statview	O
5	O
.	O
0	O
software	O
(	O
SAS	O
institute	O
Inc	O
.	O
)	O
.	O

For	O
cell	O
culture	O
experiments	O
,	O
three	O
independent	O
experiments	O
were	O
performed	O
,	O
each	O
in	O
duplicate	O
.	O

The	O
counting	O
was	O
based	O
on	O
seven	O
randomly	O
chosen	O
different	O
fields	O
of	O
view	O
.	O

For	O
each	O
diagram	O
,	O
the	O
level	O
of	O
significance	O
(	O
p	O
-	O
value	O
)	O
is	O
represented	O
as	O
follows	O
:	O
P	O
<	O
0	O
.	O
05	O
=	O
*	O
;	O
P	O
<	O
0	O
.	O
001	O
=	O
*	O
*	O
;	O
P	O
<	O
0	O
.	O
0001	O
=	O
*	O
*	O
*	O
.	O

All	O
data	O
are	O
expressed	O
as	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

Human	S-Species
sample	O
and	O
RT	O
-	O
PCR	O

The	O
brain	O
from	O
a	O
64	O
year	O
-	O
old	O
male	O
was	O
provided	O
by	O
the	O
Harvard	O
Brain	O
Tissue	O
Resource	O
Center	O
.	O

The	O
individual	O
whose	O
brain	O
tissue	O
was	O
being	O
analyzed	O
gave	O
written	O
consent	O
for	O
storage	O
and	O
use	O
of	O
his	O
tissue	O
for	O
research	O
.	O

Five	O
millimeters	O
thick	O
fresh	O
human	S-Species
hippocampal	O
tissue	O
sample	O
was	O
snap	O
frozen	O
.	O

The	O
frozen	O
tissue	O
block	O
was	O
cut	O
into	O
20	O
series	O
of	O
coronal	O
sections	O
,	O
using	O
a	O
cryostat	O
.	O

Every	O
10	O
sections	O
,	O
one	O
section	O
was	O
placed	O
in	O
an	O
Eppendorf	O
tube	O
,	O
on	O
dry	O
ice	O
.	O

Pooled	O
sections	O
were	O
used	O
for	O
RT	O
-	O
PCR	O
.	O

Total	O
RNA	O
was	O
prepared	O
using	O
Trizol	O
and	O
RNAeasy	O
,	O
supplemented	O
with	O
RNAGuard	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
RNA	O
was	O
digested	O
with	O
shrimp	O
DNAse	O
before	O
cDNA	O
synthesis	O
,	O
which	O
was	O
performed	O
using	O
a	O
mix	O
of	O
oligo	O
-	O
dT	O
and	O
random	O
hexamer	O
primers	O
and	O
SuperscriptII	O
reverse	O
transcriptase	O
.	O

Advantage2	O
polymerase	O
mix	O
(	O
Clontech	O
/	O
BRL	O
)	O
was	O
used	O
for	O
PCR	O
,	O
with	O
the	O
following	O
cycling	O
conditions	O
:	O
10	O
cycles	O
of	O
94	O
degrees	O
C	O
for	O
30	O
seconds	O
,	O
68	O
degrees	O
C	O
for	O
2	O
minutes	O
,	O
30	O
cycles	O
of	O
94	O
degrees	O
C	O
for	O
30	O
seconds	O
,	O
60	O
degrees	O
C	O
for	O
1	O
minute	O
,	O
68	O
degrees	O
C	O
for	O
1	O
minute	O
and	O
30	O
seconds	O
,	O
one	O
cycle	O
of	O
68	O
degrees	O
C	O
for	O
2	O
minutes	O
,	O
soak	O
at	O
16	O
degrees	O
C	O
.	O

Primers	O
marked	O
*	O
were	O
designed	O
by	O
PrimerBank	O
.	O

hRPS18	O
(	O
sense	O
)	O
5	O
'	O
-	O
GCCTTTGCCATCACTGCCATT	O
and	O
hRPS18	O
(	O
antisense	O
)	O
5	O
'	O
-	O
GCCAGTGGTCTTGGTGTGCT	O
,	O
hPAX6	O
(	O
sense	O
)	O
5	O
'	O
-	O
GCCCTGGAGAAAGAGTTTGAGAGAACCCATT	O
hPAX6	O
(	O
antisense	O
)	O
5	O
'	O
-	O
GGGGAAATGAGTCCTGTTGAAGTGGTGC	O
,	O
hTBR1	O
(	O
sense	O
)	O
5	O
'	O
-	O
GCGGACACCAATGTGCAAGGAAATCG	O
and	O
hTBR1	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CGAGGGGGTCAGGCGGTCCATGTCACAGC	O
,	O
hTBR2	O
(	O
sense	O
)	O
5	O
'	O
-	O
GACCTGTGGCAAAGCCGACAATAACATGC	O
and	O
hTBR2	O
(	O
antisense	O
)	O
5	O
'	O
-	O
GGGGGTGTCTCTATCCAAGAAGAGCCAAT	O
,	O
hPDHX	O
(	O
=	O
PROX1	O
)	O
(	O
sense	O
)	O
5	O
'	O
-	O
GGGACACTACGGTTCCGTTTAAGTCCAGC	O
and	O
hPDHX	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CTCTCCATCCCAGCTTACATTAACATCTGGCATTTGT	O
,	O
hNGN2	O
(	O
sense	O
)	O
*	O
5	O
'	O
-	O
CATCAAGAAGACCCGTAGACTGA	O
and	O
hNGN2	O
(	O
antisense	O
)	O
*	O
5	O
'	O
-	O
CAACACTGCCTCGGAGAAG	O
,	O
hMASH1	O
(	O
sense	O
)	O
5	O
'	O
-	O
CCTGGATCCGCATGGAAAGCTCTGCCAAGATGGAG	O
and	O
hMASH1	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CCTGGATCCCCCCTCAGAACCAGTTGGTGAAGTCGA	O
,	O
hNEUROD1	O
(	O
sense	O
)	O
5	O
'	O
-	O
GCTCAGGACCTACTAACAACAAAGGAAATCGAAACATG	O
and	O
hNEUROD1	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CAAAGCGTCTGAACGAAGGAGACCAGGT	O
,	O
hGLAST	O
(	O
sense	O
)	O
5	O
'	O
-	O
CATCAGGGAAGATGGGAATGCGAGCTGTAGTCTATTAT	O
and	O
hGLAST	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CCACGGGGGCATACCACATTATTACTGCTACC	O
,	O
hNEST	O
(	O
sense	O
)	O
5	O
'	O
-	O
CAGGAGCGGCTGCGGGCTACTGAAAAGTTCC	O
and	O
hNEST	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CAGGGCTGAGGGGTGGTGCCAAGGAGG	O
,	O
hGFAP	O
(	O
sense	O
)	O
5	O
'	O
-	O
CCACGAGGAGGAGGTTCGGGAACTCCAGGAGC	O
and	O
hGFAP	O
(	O
antisense	O
)	O
5	O
-	O
GGAATGGTGATCCGGTTCTCCTCGCCCTCTAGC	O
,	O
hCALB2	O
(	O
=	O
Calretinin	O
)	O
(	O
sense	O
)	O
5	O
'	O
-	O
GGCTCTGGCATGATGTCAAAGAGTGACAACTTT	O
and	O
hCALB2	O
(	O
antisense	O
)	O
5	O
'	O
-	O
GGGCATCCAGCTCATGCTCGTCAATGTAGCC	O
,	O
hCALB1	O
(	O
sense	O
)	O
5	O
'	O
-	O
GCGAAAGAAGGCTGGATTGGAGTTATCACC	O
and	O
hCALB1	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CCCTCCATCCGACAAAGCCATTATGTTCTTCTTGTATG	O
,	O
hSOX2	O
(	O
sense	O
)	O
5	O
'	O
-	O
GGAGAACCCCAAGATGCACAACTCGGAGAT	O
and	O
hSOX2	O
(	O
antisense	O
)	O
5	O
'	O
-	O
GAGGAAGAGGTAACCACAGGGGGGCTGGAGC	O
,	O
hWNT3A	O
(	O
sense	O
)	O
5	O
'	O
-	O
CCGAGGGCATCAAGATTGGCATCCAGGAGTGC	O
and	O
hWNT3A	O
(	O
antisense	O
)	O
5	O
'	O
-	O
TCGGGTTGCGACCACCAGCATGTCTTCACCTC	O
,	O
hSHH	O
*	O
(	O
sense	O
)	O
5	O
'	O
-	O
ACTCCGAGCGATTTAAGGAACT	O
and	O
hSHH	O
*	O
(	O
antisense	O
)	O
5	O
'	O
-	O
CAGACGTGGTGATGTCCACTG	O
.	O

Supporting	O
Information	O

A	O
novel	O
DNA	O
-	O
binding	O
protein	O
modulating	O
methicillin	O
resistance	O
in	O
Staphylococcus	B-Species
aureus	E-Species

Abstract	O

Background	O

Methicillin	O
resistance	O
in	O
Staphylococcus	B-Species
aureus	E-Species
is	O
conferred	O
by	O
the	O
mecA	O
-	O
encoded	O
penicillin	O
-	O
binding	O
protein	O
PBP2a	O
.	O

Additional	O
genomic	O
factors	O
are	O
also	O
known	O
to	O
influence	O
resistance	O
levels	O
in	O
strain	O
specific	O
ways	O
,	O
although	O
little	O
is	O
known	O
about	O
their	O
contribution	O
to	O
resistance	O
phenotypes	O
in	O
clinical	O
isolates	O
.	O

Here	O
we	O
searched	O
for	O
novel	O
proteins	O
binding	O
to	O
the	O
mec	O
operator	O
,	O
in	O
an	O
attempt	O
to	O
identify	O
new	O
factor	O
(	O
s	O
)	O
controlling	O
methicillin	O
resistance	O
phenotypes	O
.	O

Results	O

Analysis	O
of	O
proteins	O
binding	O
to	O
a	O
DNA	O
fragment	O
containing	O
the	O
mec	O
operator	O
region	O
identified	O
a	O
novel	O
,	O
putative	O
helix	O
-	O
turn	O
-	O
helix	O
DNA	O
-	O
binding	O
protein	O
,	O
SA1665	O
.	O

Nonpolar	O
deletion	O
of	O
SA1665	O
,	O
in	O
heterogeneously	O
methicillin	O
resistant	O
S	B-Species
.	I-Species
aureus	E-Species
(	O
MRSA	S-Species
)	O
of	O
different	O
genetic	O
backgrounds	O
,	O
increased	O
methicillin	O
resistance	O
levels	O
in	O
a	O
strain	O
dependent	O
manner	O
.	O

This	O
phenotype	O
could	O
be	O
fully	O
complemented	O
by	O
reintroducing	O
SA1665	O
in	O
trans	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
,	O
however	O
,	O
revealed	O
that	O
SA1665	O
had	O
no	O
visible	O
influence	O
on	O
mecA	O
transcription	O
or	O
amounts	O
of	O
PBP2a	O
produced	O
.	O

Conclusion	O

SA1665	O
is	O
a	O
new	O
chromosomal	O
factor	O
which	O
influences	O
methicillin	O
resistance	O
in	O
MRSA	S-Species
.	O

Although	O
SA1665	O
bound	O
to	O
the	O
mecA	O
promoter	O
region	O
,	O
it	O
had	O
no	O
apparent	O
influence	O
on	O
mecA	O
transcription	O
or	O
translation	O
,	O
suggesting	O
that	O
this	O
predicted	O
DNA	O
-	O
binding	O
protein	O
modulates	O
resistance	O
indirectly	O
,	O
most	O
likely	O
through	O
the	O
control	O
of	O
other	O
genomic	O
factors	O
which	O
contribute	O
to	O
resistance	O
.	O

Background	O

Methicillin	O
resistant	O
S	B-Species
.	I-Species
aureus	E-Species
(	O
MRSA	S-Species
)	O
are	O
an	O
ever	O
increasing	O
threat	O
,	O
both	O
in	O
clinical	O
settings	O
and	O
more	O
recently	O
as	O
an	O
emerging	O
community	O
acquired	O
pathogen	O
.	O

Their	O
invasiveness	O
and	O
pathogenesis	O
relies	O
on	O
a	O
variable	O
arsenal	O
of	O
virulence	O
factors	O
,	O
paired	O
with	O
resistance	O
to	O
virtually	O
all	O
beta	O
-	O
lactams	O
and	O
their	O
derivatives	O
.	O

Their	O
ability	O
to	O
rapidly	O
generate	O
resistance	O
to	O
other	O
unrelated	O
classes	O
of	O
antibiotics	O
,	O
or	O
to	O
take	O
up	O
additional	O
resistance	O
determinants	O
,	O
severely	O
hampers	O
therapy	O
and	O
eradication	O
.	O

In	O
S	B-Species
.	I-Species
aureus	E-Species
,	O
methicillin	O
resistance	O
is	O
conferred	O
by	O
an	O
acquired	O
,	O
beta	O
-	O
lactam	O
-	O
insensitive	O
penicillin	O
-	O
binding	O
protein	O
(	O
PBP	O
)	O
,	O
PBP2a	O
[	O
1	O
-	O
4	O
]	O
.	O

PBP2a	O
is	O
encoded	O
by	O
mecA	O
,	O
which	O
is	O
divergently	O
transcribed	O
from	O
its	O
cognate	O
regulators	O
,	O
mecR1	O
(	O
sensor	O
/	O
signal	O
transducer	O
)	O
and	O
mecI	O
(	O
repressor	O
)	O
.	O

If	O
mecR1	O
-	O
mecI	O
are	O
absent	O
or	O
truncated	O
,	O
transcriptional	O
control	O
of	O
mecA	O
is	O
taken	O
over	O
by	O
the	O
structurally	O
similar	O
blaZ	O
(	O
penicillinase	O
)	O
regulatory	O
elements	O
blaR1	O
/	O
blaI	O
,	O
if	O
present	O
.	O

In	O
the	O
absence	O
of	O
both	O
regulatory	O
loci	O
,	O
mecA	O
is	O
constitutively	O
transcribed	O
[	O
5	O
,	O
6	O
]	O
.	O

In	O
the	O
presence	O
of	O
beta	O
-	O
lactams	O
,	O
the	O
transmembrane	O
sensor	O
/	O
signal	O
transducers	O
BlaR1	O
/	O
MecR1	O
,	O
undergo	O
a	O
conformational	O
change	O
,	O
followed	O
by	O
autoproteolytic	O
cleavage	O
of	O
the	O
n	O
-	O
terminal	O
cytoplasmic	O
domain	O
,	O
leading	O
to	O
the	O
activation	O
of	O
the	O
cytoplasmic	O
peptidase	O
and	O
subsequent	O
dissociation	O
of	O
the	O
repressor	O
due	O
to	O
proteolytic	O
degradation	O
[	O
7	O
-	O
9	O
]	O
.	O

However	O
,	O
the	O
signal	O
transduction	O
cascade	O
of	O
this	O
regulatory	O
system	O
has	O
still	O
not	O
been	O
completely	O
elucidated	O
.	O

Oxacillin	O
resistance	O
levels	O
conferred	O
by	O
mecA	O
are	O
strain	O
specific	O
and	O
can	O
vary	O
greatly	O
,	O
with	O
oxacillin	O
minimal	O
inhibitory	O
concentrations	O
(	O
MICs	O
)	O
of	O
different	O
strains	O
ranging	O
from	O
phenotypically	O
susceptible	O
levels	O
,	O
as	O
low	O
as	O
1	O
mu	O
g	O
/	O
ml	O
up	O
to	O
extremely	O
high	O
values	O
of	O
>	O
500	O
mu	O
g	O
/	O
ml	O
.	O

Methicillin	O
resistance	O
is	O
also	O
generally	O
expressed	O
heterogeneously	O
.	O

Heterogeneously	O
resistant	O
MRSA	S-Species
,	O
when	O
exposed	O
to	O
beta	O
-	O
lactam	O
antibiotics	O
,	O
segregate	O
highly	O
resistant	O
subpopulations	O
,	O
which	O
are	O
much	O
more	O
resistant	O
than	O
the	O
majority	O
of	O
the	O
cells	O
[	O
10	O
]	O
.	O

The	O
frequency	O
of	O
highly	O
resistant	O
subclones	O
generated	O
is	O
often	O
well	O
above	O
the	O
spontaneous	O
mutation	O
frequency	O
,	O
and	O
once	O
selected	O
high	O
level	O
resistance	O
often	O
remains	O
stable	O
,	O
even	O
in	O
the	O
absence	O
of	O
selective	O
pressure	O
.	O

There	O
is	O
currently	O
no	O
satisfactory	O
genetic	O
model	O
which	O
explains	O
how	O
these	O
higher	O
resistance	O
levels	O
are	O
triggered	O
or	O
selected	O
and	O
exactly	O
what	O
factors	O
are	O
functionally	O
responsible	O
for	O
the	O
increased	O
resistance	O
in	O
clinical	O
isolates	O
.	O

Methicillin	O
resistance	O
levels	O
are	O
known	O
to	O
not	O
directly	O
correlate	O
with	O
mecA	O
transcription	O
or	O
levels	O
of	O
PBP2a	O
produced	O
[	O
11	O
,	O
12	O
]	O
.	O

However	O
,	O
resistance	O
levels	O
can	O
be	O
manipulated	O
by	O
environmental	O
conditions	O
,	O
such	O
as	O
temperature	O
,	O
pH	O
,	O
osmolarity	O
,	O
and	O
medium	O
composition	O
[	O
13	O
,	O
14	O
]	O
.	O

It	O
has	O
been	O
shown	O
experimentally	O
,	O
that	O
in	O
addition	O
to	O
mecA	O
,	O
methicillin	O
resistance	O
depends	O
on	O
the	O
correct	O
interplay	O
of	O
a	O
multitude	O
of	O
genomic	O
factors	O
,	O
termed	O
fem	O
/	O
aux	O
factors	O
,	O
including	O
genes	O
involved	O
in	O
peptidoglycan	O
precursor	O
formation	O
,	O
composition	O
and	O
turnover	O
;	O
teichoic	O
acid	O
synthesis	O
;	O
and	O
genes	O
of	O
unknown	O
or	O
poorly	O
characterised	O
functions	O
[	O
15	O
-	O
18	O
]	O
.	O

In	O
addition	O
to	O
structural	O
genes	O
,	O
many	O
regulatory	O
loci	O
have	O
also	O
been	O
shown	O
to	O
influence	O
resistance	O
levels	O
,	O
including	O
global	O
regulators	O
of	O
virulence	O
factor	O
production	O
such	O
as	O
the	O
quorum	O
sensing	O
agr	O
system	O
,	O
the	O
staphylococcal	O
accessory	O
regulator	O
SarA	O
and	O
the	O
alternate	O
sigma	O
factor	O
sigma	O
B	O
[	O
19	O
,	O
20	O
]	O
;	O
regulators	O
of	O
metabolism	O
,	O
such	O
as	O
the	O
catabolite	O
control	O
protein	O
A	O
(	O
CcpA	O
)	O
[	O
21	O
]	O
;	O
and	O
the	O
VraSR	O
two	O
-	O
component	O
sensor	O
transducer	O
,	O
which	O
induces	O
the	O
cell	O
wall	O
stress	O
stimulon	O
in	O
response	O
to	O
cell	O
wall	O
active	O
antibiotic	O
challenge	O
[	O
22	O
]	O
.	O

The	O
vast	O
MIC	O
differences	O
between	O
MRSA	S-Species
strains	O
,	O
the	O
population	O
heterogeneity	O
within	O
single	O
strains	O
and	O
the	O
dependence	O
of	O
resistance	O
levels	O
on	O
external	O
factors	O
are	O
reflected	O
in	O
these	O
many	O
structural	O
genes	O
and	O
global	O
regulators	O
,	O
which	O
can	O
influence	O
resistance	O
levels	O
.	O

While	O
typically	O
considered	O
nosocomial	O
pathogens	O
,	O
new	O
faster	O
growing	O
and	O
apparently	O
more	O
virulent	O
MRSA	S-Species
have	O
begun	O
spreading	O
in	O
the	O
community	O
.	O

Interestingly	O
,	O
these	O
emerging	O
strains	O
often	O
express	O
very	O
low	O
methicillin	O
resistance	O
,	O
e	O
.	O
g	O
.	O
the	O
MRSA	S-Species
clone	O
spreading	O
amongst	O
intravenous	O
drug	O
users	O
in	O
the	O
Zurich	O
area	O
,	O
which	O
has	O
an	O
in	O
vitro	O
doubling	O
time	O
of	O
25	O
min	O
,	O
but	O
oxacillin	O
MICs	O
of	O
only	O
0	O
.	O
5	O
to	O
4	O
mu	O
g	O
/	O
ml	O
[	O
23	O
]	O
.	O

This	O
particular	O
clone	O
'	O
s	O
low	O
-	O
level	O
resistance	O
is	O
partially	O
due	O
to	O
a	O
promoter	O
mutation	O
,	O
leading	O
to	O
tight	O
repression	O
of	O
mecA	O
,	O
but	O
resistance	O
levels	O
appear	O
to	O
be	O
mainly	O
restricted	O
by	O
unknown	O
factors	O
within	O
its	O
genomic	O
background	O
[	O
12	O
]	O
.	O

To	O
identify	O
potential	O
factors	O
involved	O
in	O
mecA	O
regulation	O
or	O
methicillin	O
resistance	O
levels	O
in	O
such	O
an	O
extremely	O
low	O
level	O
resistant	O
MRSA	S-Species
,	O
we	O
performed	O
DNA	O
-	O
binding	O
protein	O
purification	O
assays	O
,	O
using	O
the	O
mecA	O
operator	O
region	O
as	O
bait	O
.	O

A	O
novel	O
,	O
uncharacterized	O
protein	O
,	O
SA1665	O
,	O
was	O
found	O
to	O
bind	O
to	O
this	O
DNA	O
fragment	O
,	O
and	O
shown	O
to	O
increase	O
methicillin	O
resistance	O
levels	O
when	O
deleted	O
.	O

Results	O

Identification	O
of	O
SA1665	O

MRSA	S-Species
strain	O
CHE482	O
is	O
the	O
type	O
strain	O
for	O
the	O
so	O
-	O
called	O
"	O
drug	O
clone	O
"	O
spreading	O
amongst	O
intravenous	O
drug	O
users	O
in	O
the	O
Zurich	O
area	O
[	O
12	O
,	O
23	O
]	O
.	O

This	O
strain	O
carries	O
mecA	O
and	O
expresses	O
PBP2a	O
,	O
but	O
appears	O
phenotypically	O
methicillin	O
susceptible	O
by	O
conventional	O
phenotypic	O
tests	O
.	O

However	O
,	O
like	O
most	O
other	O
low	O
-	O
level	O
resistant	O
MRSA	S-Species
,	O
it	O
can	O
segregate	O
a	O
small	O
proportion	O
of	O
higher	O
resistant	O
subclones	O
in	O
the	O
presence	O
of	O
beta	O
-	O
lactams	O
.	O

We	O
hypothesized	O
that	O
regulation	O
of	O
methicillin	O
resistance	O
in	O
such	O
low	O
-	O
level	O
resistant	O
clonal	O
lineages	O
may	O
differ	O
qualitatively	O
from	O
classical	O
heterogeneously	O
-	O
or	O
highly	O
-	O
resistant	O
MRSA	S-Species
.	O

A	O
DNA	O
-	O
binding	O
protein	O
purification	O
assay	O
was	O
performed	O
to	O
identify	O
new	O
potential	O
factors	O
involved	O
in	O
the	O
regulation	O
of	O
mecA	O
/	O
PBP2a	O
.	O

The	O
mecA	O
/	O
mecR1	O
intergenic	O
DNA	O
region	O
,	O
including	O
the	O
5	O
'	O
9	O
bp	O
of	O
mecR1	O
and	O
the	O
first	O
52	O
bp	O
of	O
mecA	O
,	O
was	O
used	O
as	O
bait	O
against	O
crude	O
protein	O
extract	O
from	O
strain	O
CHE482	O
.	O

Proteins	O
binding	O
to	O
this	O
DNA	O
fragment	O
were	O
analysed	O
by	O
SDS	O
-	O
PAGE	O
.	O

Even	O
though	O
CHE482	O
contained	O
BlaI	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
mec	O
operator	O
,	O
this	O
band	O
could	O
not	O
be	O
identified	O
on	O
gels	O
due	O
to	O
co	O
-	O
migrating	O
,	O
non	O
-	O
specific	O
bands	O
the	O
same	O
size	O
as	O
BlaI	O
(	O
14	O
.	O
9	O
KDa	O
)	O
that	O
bound	O
to	O
both	O
the	O
DNA	O
-	O
coated	O
and	O
uncoated	O
control	O
beads	O
.	O

The	O
most	O
prominent	O
protein	O
band	O
of	O
~	O
16	O
-	O
20	O
kDa	O
,	O
isolated	O
from	O
DNA	O
-	O
labelled	O
but	O
not	O
from	O
control	O
beads	O
,	O
was	O
identified	O
as	O
the	O
hypothetical	O
protein	O
SA1665	O
(	O
N315	O
genome	O
annotation	O
[	O
BA000018	O
]	O
)	O
(	O
Figure	O
1A	O
)	O
.	O

SA1665	O
encodes	O
a	O
predicted	O
17	O
-	O
kDa	O
protein	O
with	O
an	O
n	O
-	O
terminal	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
HTH	O
)	O
motif	O
characteristic	O
of	O
DNA	O
-	O
binding	O
transcriptional	O
regulators	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
SA1665	O
showed	O
100	O
%	O
identity	O
amongst	O
S	B-Species
.	I-Species
aureus	E-Species
database	O
sequences	O
and	O
97	O
-	O
98	O
%	O
identity	O
amongst	O
other	O
staphylococci	O
,	O
including	O
S	B-Species
.	I-Species
haemolyticus	E-Species
,	O
S	B-Species
.	I-Species
epidermidis	E-Species
and	O
S	B-Species
.	I-Species
saprophyticus	E-Species
,	O
indicating	O
that	O
SA1665	O
is	O
highly	O
conserved	O
.	O

Conversely	O
,	O
there	O
were	O
no	O
orfs	O
highly	O
similar	O
to	O
SA1665	O
found	O
in	O
other	O
bacterial	O
species	O
,	O
with	O
the	O
most	O
similar	O
sequences	O
found	O
in	O
Bacillus	B-Species
licheniformis	E-Species
DSM13	O
and	O
Desulfitobacterium	B-Species
hafniense	I-Species
Y51	E-Species
,	O
which	O
shared	O
only	O
64	O
%	O
and	O
59	O
%	O
similarity	O
,	O
respectively	O
.	O

Electro	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O

EMSA	O
was	O
used	O
to	O
confirm	O
binding	O
of	O
SA1665	O
to	O
the	O
mec	O
operator	O
region	O
.	O

Crude	O
protein	O
extracts	O
of	O
E	B-Species
.	I-Species
coli	I-Species
strain	I-Species
BL21	E-Species
,	O
carrying	O
the	O
empty	O
plasmid	O
(	O
pET28nHis6	O
)	O
or	O
pME20	O
(	O
pET28nHis6	O
-	O
SA1665	O
)	O
which	O
expressed	O
nHis6	O
-	O
SA1665	O
upon	O
induction	O
with	O
IPTG	O
,	O
were	O
incubated	O
with	O
the	O
161	O
-	O
bp	O
biotinylated	O
-	O
DNA	O
fragment	O
previously	O
used	O
as	O
bait	O
in	O
the	O
DNA	O
-	O
binding	O
protein	O
assay	O
.	O

A	O
band	O
shift	O
was	O
observed	O
with	O
extracts	O
from	O
the	O
strain	O
expressing	O
recombinant	O
nHis6	O
-	O
SA1665	O
but	O
not	O
from	O
the	O
control	O
strain	O
carrying	O
the	O
empty	O
plasmid	O
.	O

Several	O
bands	O
resulted	O
from	O
the	O
shift	O
,	O
which	O
is	O
most	O
likely	O
due	O
to	O
protein	O
oligomerisation	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
specificity	O
of	O
the	O
gel	O
shift	O
was	O
also	O
demonstrated	O
by	O
the	O
addition	O
of	O
increasing	O
concentrations	O
of	O
purified	O
nHis6	O
-	O
SA1665	O
protein	O
to	O
the	O
biotinylated	O
-	O
DNA	O
fragment	O
(	O
Figure	O
2B	O
)	O
.	O

Band	O
-	O
shift	O
of	O
the	O
biotinylated	O
DNA	O
was	O
inhibited	O
in	O
the	O
presence	O
of	O
specific	O
competitor	O
DNA	O
but	O
not	O
by	O
the	O
presence	O
of	O
the	O
non	O
-	O
specific	O
competitor	O
DNA	O
,	O
confirming	O
that	O
nHis6	O
-	O
SA1665	O
had	O
a	O
specific	O
binding	O
affinity	O
for	O
the	O
161	O
-	O
bp	O
DNA	O
fragment	O
.	O

Effect	O
of	O
SA1665	O
deletion	O
on	O
beta	O
-	O
lactam	O
resistance	O

To	O
analyse	O
the	O
effect	O
of	O
SA1665	O
inactivation	O
on	O
methicillin	O
resistance	O
,	O
nonpolar	O
markerless	O
deletions	O
of	O
SA1665	O
(	O
Figure	O
1B	O
)	O
were	O
constructed	O
in	O
a	O
selection	O
of	O
clinical	O
MRSA	S-Species
isolates	O
,	O
which	O
varied	O
in	O
their	O
genetic	O
background	O
,	O
SCCmec	O
type	O
,	O
and	O
mecA	O
regulation	O
[	O
24	O
]	O
.	O

Strain	O
CHE482	O
,	O
belongs	O
to	O
clonal	O
complex	O
CC45	O
and	O
sequence	O
type	O
ST45	O
,	O
and	O
contains	O
a	O
novel	O
SCCmec	O
(	O
SCCmecN1	O
[	O
23	O
]	O
)	O
;	O
while	O
strains	O
ZH37	O
(	O
CC45	O
/	O
ST45	O
)	O
and	O
ZH73	O
(	O
CC22	O
/	O
ST22	O
)	O
contain	O
type	O
IV	O
SCCmecs	O
.	O

All	O
three	O
of	O
these	O
strains	O
have	O
truncated	O
mecI	O
/	O
mecR1	O
regulatory	O
loci	O
but	O
intact	O
BlaI	O
/	O
BlaR1	O
loci	O
controlling	O
mecA	O
expression	O
.	O

Strain	O
ZH44	O
(	O
CCT8	O
/	O
ST8	O
)	O
contained	O
a	O
type	O
A	O
mec	O
complex	O
(	O
mecI	O
-	O
mecR1	O
-	O
mecA	O
)	O
within	O
a	O
type	O
II	O
SCCmec	O
,	O
and	O
had	O
no	O
beta	O
-	O
lactamase	O
locus	O
;	O
so	O
mecA	O
was	O
only	O
under	O
the	O
control	O
of	O
its	O
cognate	O
regulators	O
MecI	O
/	O
MecR1	O
.	O

Deletion	O
of	O
SA1665	O
increased	O
oxacillin	O
resistance	O
in	O
all	O
mutants	O
compared	O
to	O
their	O
corresponding	O
parent	O
strains	O
,	O
as	O
demonstrated	O
on	O
oxacillin	O
gradient	O
plates	O
(	O
Figure	O
3A	O
)	O
;	O
with	O
mutants	O
Delta	O
CHE482	O
and	O
Delta	O
ZH37	O
approximately	O
doubling	O
in	O
resistance	O
and	O
Delta	O
ZH44	O
and	O
Delta	O
ZH73	O
expressing	O
considerably	O
higher	O
resistance	O
.	O

Population	O
analysis	O
resistance	O
profiles	O
of	O
the	O
mutants	O
showed	O
a	O
distinct	O
shift	O
at	O
the	O
top	O
of	O
the	O
curve	O
,	O
indicating	O
that	O
the	O
higher	O
resistance	O
was	O
due	O
to	O
increased	O
basal	O
oxacillin	O
resistance	O
levels	O
(	O
Figure	O
3B	O
)	O
.	O

Strains	O
CHE482	O
/	O
Delta	O
CHE482	O
and	O
ZH37	O
/	O
Delta	O
ZH37	O
had	O
very	O
similar	O
resistance	O
profiles	O
,	O
despite	O
having	O
different	O
SCCmec	O
elements	O
,	O
suggesting	O
that	O
it	O
was	O
their	O
common	O
clonal	O
background	O
(	O
CC45	O
)	O
that	O
determined	O
their	O
resistance	O
levels	O
and	O
the	O
extent	O
of	O
resistance	O
increase	O
upon	O
SA1665	O
deletion	O
.	O

Growth	O
curve	O
analyses	O
showed	O
that	O
deletion	O
of	O
SA1665	O
slightly	O
reduced	O
the	O
growth	O
rate	O
of	O
all	O
strains	O
tested	O
(	O
Figure	O
3C	O
)	O
.	O

Wild	O
type	O
growth	O
rates	O
were	O
restored	O
upon	O
complementation	O
(	O
data	O
not	O
shown	O
)	O
.	O

Resistance	O
complementation	O

Plasmids	O
pME26	O
and	O
pME27	O
were	O
constructed	O
for	O
complementation	O
of	O
the	O
deletion	O
mutants	O
.	O

Both	O
plasmids	O
contained	O
the	O
SA1665	O
orf	O
along	O
with	O
its	O
own	O
promoter	O
and	O
transcriptional	O
terminator	O
.	O

Strains	O
Delta	O
CHE482	O
,	O
Delta	O
ZH37	O
,	O
and	O
Delta	O
ZH73	O
were	O
complemented	O
with	O
pME26	O
,	O
and	O
intrinsically	O
kanamycin	O
resistant	O
strain	O
Delta	O
ZH44	O
was	O
complemented	O
with	O
pME27	O
.	O

Wild	O
type	O
-	O
like	O
resistance	O
levels	O
were	O
restored	O
in	O
all	O
mutants	O
by	O
introduction	O
of	O
the	O
complementing	O
plasmids	O
,	O
as	O
shown	O
by	O
gradient	O
plates	O
(	O
Figure	O
3A	O
)	O
.	O

Transcriptional	O
analyses	O

Primer	O
extension	O
,	O
using	O
the	O
5	O
'	O
-	O
biotinylated	O
primer	O
me97	O
,	O
identified	O
two	O
potential	O
SA1665	O
transcriptional	O
start	O
sites	O
(	O
TSS	O
)	O
,	O
76	O
-	O
nt	O
and	O
139	O
-	O
nt	O
upstream	O
of	O
the	O
SA1665	O
ATG	O
start	O
codon	O
(	O
Figure	O
4A	O
)	O
.	O

Predicted	O
sigma	O
A	O
promoter	O
consensus	O
-	O
10	O
/	O
-	O
35	O
box	O
sequences	O
were	O
located	O
upstream	O
of	O
both	O
TSS	O
(	O
Figure	O
4B	O
)	O
.	O

Identical	O
TSS	O
were	O
also	O
identified	O
using	O
the	O
downstream	O
primer	O
me98	O
(	O
data	O
not	O
shown	O
)	O
.	O

Northern	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
SA1665	O
expression	O
and	O
the	O
influence	O
of	O
SA1665	O
deletion	O
on	O
mecA	O
and	O
mecR1	O
transcription	O
.	O

RNA	O
samples	O
taken	O
from	O
different	O
time	O
points	O
over	O
the	O
growth	O
curve	O
of	O
CHE482	O
showed	O
that	O
SA1665	O
was	O
expressed	O
strongly	O
in	O
early	O
exponential	O
phase	O
at	O
OD600	O
nm	O
0	O
.	O
25	O
and	O
0	O
.	O
5	O
,	O
then	O
transcript	O
levels	O
decreased	O
and	O
were	O
almost	O
undetectable	O
in	O
early	O
stationary	O
phase	O
at	O
OD600	O
nm	O
4	O
.	O
0	O
(	O
Figure	O
5A	O
)	O
.	O

In	O
addition	O
to	O
the	O
main	O
transcript	O
of	O
~	O
0	O
.	O
46	O
kb	O
,	O
a	O
weaker	O
,	O
larger	O
transcript	O
of	O
~	O
0	O
.	O
6	O
kb	O
was	O
also	O
visible	O
,	O
especially	O
at	O
later	O
growth	O
stages	O
.	O

Figure	O
5B	O
shows	O
the	O
transcriptional	O
behaviour	O
of	O
SA1665	O
when	O
CHE482	O
cells	O
were	O
challenged	O
with	O
sub	O
-	O
inhibitory	O
(	O
4	O
mu	O
g	O
/	O
ml	O
)	O
and	O
inhibitory	O
(	O
120	O
mu	O
g	O
/	O
ml	O
)	O
concentrations	O
of	O
cefoxitin	O
.	O

These	O
results	O
showed	O
that	O
low	O
levels	O
of	O
cefoxitin	O
,	O
such	O
as	O
those	O
used	O
to	O
induce	O
mecA	O
/	O
mecR1	O
transcription	O
,	O
appeared	O
to	O
slightly	O
decrease	O
SA1665	O
transcription	O
after	O
30	O
min	O
exposure	O
,	O
while	O
larger	O
,	O
inhibitory	O
concentrations	O
caused	O
even	O
more	O
significant	O
alterations	O
in	O
the	O
SA1665	O
transcriptional	O
profile	O
,	O
making	O
it	O
similar	O
to	O
that	O
normally	O
seen	O
in	O
stationary	O
phase	O
growth	O
.	O

These	O
results	O
indicate	O
that	O
transcription	O
of	O
SA1665	O
may	O
respond	O
in	O
some	O
way	O
to	O
cell	O
wall	O
stress	O
,	O
rather	O
than	O
in	O
direct	O
response	O
to	O
the	O
presence	O
of	O
beta	O
-	O
lactams	O
.	O

This	O
observation	O
is	O
based	O
on	O
relatively	O
subtle	O
changes	O
in	O
SA1665	O
transcription	O
,	O
especially	O
at	O
low	O
concentrations	O
of	O
cefoxitin	O
such	O
as	O
those	O
required	O
for	O
mecA	O
/	O
mecR1	O
induction	O
.	O

Since	O
deletion	O
of	O
SA1665	O
has	O
been	O
shown	O
to	O
increase	O
beta	O
-	O
lactam	O
resistance	O
,	O
reduced	O
SA1665	O
transcription	O
in	O
the	O
presence	O
of	O
beta	O
-	O
lactams	O
may	O
also	O
provide	O
some	O
protection	O
against	O
beta	O
-	O
lactam	O
exposure	O
.	O

Northerns	O
also	O
showed	O
that	O
,	O
as	O
expected	O
,	O
the	O
SA1665	O
transcripts	O
were	O
absent	O
from	O
the	O
deletion	O
mutant	O
(	O
Figure	O
5C	O
)	O
,	O
and	O
additional	O
experiments	O
demonstrated	O
that	O
wild	O
type	O
SA1665	O
transcription	O
patterns	O
were	O
restored	O
by	O
complementation	O
of	O
Delta	O
CHE482	O
with	O
pME26	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
effects	O
of	O
SA1665	O
deletion	O
on	O
directly	O
up	O
-	O
and	O
down	O
-	O
stream	O
genes	O
were	O
also	O
investigated	O
.	O

Northern	O
blots	O
of	O
the	O
neighbouring	O
genes	O
SA1664	O
,	O
SA1666	O
and	O
SA1667	O
,	O
showed	O
that	O
expression	O
of	O
all	O
three	O
genes	O
was	O
very	O
weak	O
compared	O
to	O
that	O
of	O
SA1665	O
.	O

A	O
weak	O
transcript	O
of	O
about	O
3	O
kb	O
was	O
present	O
in	O
hybridizations	O
probed	O
with	O
orfs	O
SA1665	O
-	O
SA1667	O
.	O

This	O
band	O
decreased	O
in	O
size	O
in	O
the	O
SA1665	O
mutant	O
when	O
probed	O
with	O
SA1666	O
and	O
SA1667	O
.	O

One	O
of	O
the	O
transcripts	O
hybridising	O
to	O
the	O
SA1664	O
probe	O
also	O
decreased	O
in	O
size	O
by	O
~	O
0	O
.	O
5	O
kb	O
in	O
the	O
SA1665	O
mutant	O
,	O
suggesting	O
that	O
SA1665	O
was	O
present	O
on	O
several	O
transcripts	O
of	O
different	O
lengths	O
,	O
including	O
a	O
high	O
abundance	O
monocistronic	O
transcript	O
and	O
low	O
abundance	O
polycistronic	O
transcripts	O
(	O
Figure	O
5C	O
)	O
.	O

Transcript	O
abundance	O
of	O
both	O
the	O
upstream	O
SA1666	O
-	O
SA1667	O
operon	O
and	O
the	O
downstream	O
SA1664	O
-	O
specific	O
transcript	O
all	O
appeared	O
to	O
increase	O
slightly	O
in	O
Delta	O
CHE482	O
.	O

The	O
significance	O
of	O
these	O
subtle	O
increases	O
in	O
transcription	O
are	O
unknown	O
,	O
however	O
,	O
polar	O
effects	O
from	O
SA1665	O
deletion	O
seem	O
unlikely	O
,	O
based	O
on	O
the	O
facts	O
that	O
all	O
genes	O
were	O
still	O
transcribed	O
,	O
their	O
transcription	O
levels	O
all	O
remained	O
extremely	O
low	O
and	O
the	O
transcriptional	O
terminator	O
of	O
SA1665	O
remained	O
intact	O
in	O
the	O
deletion	O
mutant	O
(	O
Figure	O
1B	O
)	O
.	O

Expression	O
of	O
mecR1	O
and	O
mecA	O
were	O
analysed	O
from	O
RNA	O
of	O
uninduced	O
and	O
induced	O
cultures	O
of	O
CHE482	O
and	O
Delta	O
CHE482	O
.	O

Cells	O
were	O
induced	O
at	O
OD600	O
nm	O
0	O
.	O
25	O
(	O
Figure	O
5D	O
)	O
and	O
1	O
.	O
0	O
(	O
data	O
not	O
shown	O
)	O
with	O
sub	O
-	O
inhibitory	O
concentrations	O
of	O
cefoxitin	O
,	O
to	O
relieve	O
BlaI	O
-	O
repression	O
of	O
mecA	O
.	O

mecR1	O
,	O
although	O
truncated	O
in	O
CHE482	O
,	O
was	O
still	O
transcribed	O
and	O
had	O
the	O
same	O
expression	O
pattern	O
as	O
mecA	O
,	O
as	O
both	O
became	O
derepressed	O
over	O
time	O
and	O
had	O
the	O
highest	O
transcript	O
levels	O
after	O
30	O
min	O
of	O
induction	O
.	O

In	O
the	O
mutant	O
Delta	O
CHE482	O
,	O
transcripts	O
of	O
both	O
mecA	O
and	O
mecR1	O
'	O
were	O
unaffected	O
by	O
SA1665	O
deletion	O
,	O
indicating	O
that	O
SA1665	O
had	O
no	O
influence	O
on	O
their	O
expression	O
at	O
either	O
OD	O
0	O
.	O
25	O
(	O
Figure	O
5D	O
)	O
or	O
OD	O
1	O
.	O
0	O
(	O
data	O
not	O
shown	O
)	O
.	O

SA1665	O
deletion	O
also	O
had	O
no	O
effect	O
on	O
mecA	O
transcription	O
or	O
induction	O
in	O
strains	O
ZH37	O
,	O
ZH44	O
and	O
ZH73	O
(	O
data	O
not	O
shown	O
)	O
.	O

Western	O
blot	O
analysis	O

Mutants	O
of	O
CHE482	O
and	O
of	O
ZH44	O
and	O
ZH73	O
,	O
which	O
had	O
the	O
largest	O
differences	O
in	O
oxacillin	O
resistance	O
levels	O
,	O
were	O
analysed	O
by	O
Western	O
blot	O
analysis	O
to	O
determine	O
if	O
SA1665	O
affected	O
production	O
of	O
PBP2a	O
from	O
mecA	O
.	O

As	O
shown	O
in	O
Figure	O
5E	O
,	O
all	O
pairs	O
of	O
wild	O
type	O
and	O
mutant	O
strains	O
had	O
similar	O
amounts	O
of	O
PBP2a	O
present	O
both	O
before	O
and	O
after	O
induction	O
with	O
cefoxitin	O
,	O
indicating	O
that	O
SA1665	O
deletion	O
did	O
not	O
alter	O
amounts	O
of	O
PBP2a	O
produced	O
.	O

Therefore	O
it	O
seems	O
that	O
SA1665	O
exerts	O
no	O
direct	O
control	O
over	O
mecA	O
or	O
PBP2a	O
expression	O
.	O

Discussion	O

Methicillin	O
resistance	O
in	O
MRSA	S-Species
is	O
primarily	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
mecA	O
gene	O
,	O
however	O
,	O
resistance	O
levels	O
are	O
generally	O
governed	O
by	O
strain	O
-	O
specific	O
factors	O
including	O
mecA	O
regulatory	O
elements	O
and	O
other	O
chromosomal	O
fem	O
/	O
aux	O
factors	O
which	O
either	O
enhance	O
or	O
repress	O
the	O
expression	O
of	O
resistance	O
.	O

For	O
instance	O
,	O
the	O
very	O
low	O
-	O
level	O
methicillin	O
resistance	O
of	O
the	O
Zurich	O
drug	O
clone	O
CHE482	O
,	O
was	O
shown	O
to	O
be	O
controlled	O
by	O
its	O
genetic	O
background	O
[	O
12	O
]	O
suggesting	O
that	O
it	O
either	O
contained	O
or	O
lacked	O
certain	O
fem	O
/	O
aux	O
factors	O
involved	O
in	O
controlling	O
resistance	O
expression	O
.	O

Many	O
of	O
the	O
currently	O
known	O
fem	O
/	O
aux	O
factors	O
are	O
directly	O
or	O
indirectly	O
involved	O
in	O
cell	O
wall	O
synthesis	O
and	O
turnover	O
,	O
or	O
envelope	O
biogenesis	O
,	O
however	O
there	O
still	O
remain	O
factors	O
of	O
unknown	O
function	O
.	O

Most	O
of	O
the	O
currently	O
known	O
fem	O
/	O
aux	O
factors	O
reduce	O
methicillin	O
resistance	O
levels	O
when	O
inactivated	O
.	O

A	O
few	O
genes	O
,	O
such	O
as	O
lytH	O
,	O
dlt	O
,	O
norG	O
,	O
sarV	O
and	O
cidA	O
increase	O
resistance	O
levels	O
upon	O
inactivation	O
or	O
mutation	O
.	O

All	O
of	O
these	O
genes	O
,	O
except	O
norG	O
,	O
which	O
is	O
an	O
efflux	O
pump	O
regulator	O
,	O
play	O
a	O
role	O
in	O
either	O
autolysis	O
or	O
are	O
important	O
for	O
cell	O
physiology	O
and	O
growth	O
[	O
25	O
-	O
30	O
]	O
.	O

Other	O
genes	O
increase	O
beta	O
-	O
lactam	O
resistance	O
upon	O
overexpression	O
,	O
such	O
as	O
hmrA	O
coding	O
for	O
a	O
putative	O
amidohydrolase	O
,	O
hmrB	O
coding	O
for	O
a	O
putative	O
acyl	O
carrier	O
protein	O
[	O
31	O
]	O
,	O
or	O
the	O
NorG	O
-	O
controlled	O
abcA	O
multidrug	O
efflux	O
pump	O
[	O
28	O
]	O
.	O

SA1665	O
,	O
a	O
predicted	O
DNA	O
-	O
binding	O
transcriptional	O
regulator	O
,	O
was	O
found	O
to	O
bind	O
to	O
a	O
DNA	O
fragment	O
containing	O
the	O
mecA	O
promoter	O
region	O
.	O

However	O
,	O
although	O
this	O
protein	O
shifted	O
the	O
mecA	O
operator	O
/	O
5	O
'	O
coding	O
sequence	O
,	O
it	O
did	O
not	O
appear	O
to	O
directly	O
control	O
mecA	O
or	O
mecR1	O
transcription	O
or	O
PBP2a	O
production	O
.	O

Therefore	O
its	O
binding	O
to	O
the	O
mecA	O
region	O
may	O
have	O
no	O
specific	O
regulatory	O
function	O
.	O

Such	O
interactions	O
have	O
been	O
noted	O
before	O
,	O
such	O
as	O
the	O
HTH	O
protein	O
NorG	O
,	O
which	O
was	O
shown	O
to	O
bind	O
specifically	O
to	O
norA	O
,	O
norB	O
and	O
norC	O
promoters	O
,	O
but	O
only	O
transcription	O
of	O
norB	O
was	O
increased	O
when	O
NorG	O
was	O
overexpressed	O
[	O
28	O
]	O
.	O

We	O
have	O
to	O
postulate	O
therefore	O
that	O
SA1665	O
may	O
modulate	O
beta	O
-	O
lactam	O
resistance	O
in	O
a	O
mecA	O
-	O
independent	O
manner	O
,	O
by	O
controlling	O
cellular	O
functions	O
affecting	O
resistance	O
levels	O
.	O

Experiments	O
to	O
determine	O
the	O
SA1665	O
regulon	O
are	O
ongoing	O
.	O

The	O
impact	O
of	O
deleting	O
SA1665	O
in	O
MRSA	S-Species
was	O
extremely	O
strain	O
specific	O
,	O
underlining	O
the	O
importance	O
of	O
the	O
genetic	O
background	O
in	O
governing	O
the	O
final	O
methicillin	O
resistance	O
levels	O
of	O
MRSA	S-Species
,	O
and	O
demonstrating	O
the	O
large	O
genomic	O
variability	O
between	O
different	O
strain	O
lineages	O
.	O

Conclusion	O

SA1665	O
is	O
a	O
previously	O
uncharacterised	O
DNA	O
-	O
binding	O
protein	O
that	O
has	O
a	O
negative	O
effect	O
on	O
beta	O
-	O
lactam	O
resistance	O
in	O
MRSA	S-Species
.	O

The	O
SA1665	O
protein	O
was	O
identified	O
in	O
a	O
DNA	O
-	O
binding	O
protein	O
purification	O
assay	O
,	O
in	O
which	O
it	O
bound	O
to	O
a	O
DNA	O
fragment	O
covering	O
the	O
mec	O
operator	O
region	O
.	O

However	O
,	O
while	O
nonpolar	O
deletion	O
of	O
SA1665	O
was	O
shown	O
to	O
increase	O
oxacillin	O
resistance	O
levels	O
in	O
several	O
heterogeneously	O
resistant	O
MRSA	S-Species
,	O
its	O
deletion	O
had	O
no	O
effect	O
on	O
mecA	O
transcription	O
or	O
PBP2a	O
production	O
.	O

Therefore	O
the	O
negative	O
impact	O
of	O
SA1665	O
on	O
methicillin	O
resistance	O
is	O
most	O
likely	O
to	O
be	O
through	O
the	O
regulation	O
of	O
other	O
chromosomal	O
factors	O
or	O
cellular	O
functions	O
required	O
for	O
methicllin	O
resistance	O
.	O

Methods	O

Strains	O
and	O
growth	O
conditions	O

Strains	O
and	O
plasmids	O
used	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Clinical	O
isolates	O
are	O
from	O
the	O
IMM	O
collection	O
in	O
Zurich	O
,	O
Switzerland	O
.	O

Strains	O
were	O
grown	O
at	O
37	O
degrees	O
C	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
broth	O
,	O
shaking	O
at	O
180	O
rpm	O
,	O
or	O
on	O
LB	O
agar	O
.	O

Media	O
were	O
supplemented	O
with	O
the	O
following	O
antibiotics	O
when	O
appropriate	O
:	O
25	O
or	O
50	O
mu	O
g	O
/	O
ml	O
kanamycin	O
,	O
10	O
mu	O
g	O
/	O
ml	O
chloramphenicol	O
,	O
5	O
or	O
10	O
mu	O
g	O
/	O
ml	O
tetracycline	O
,	O
100	O
mu	O
g	O
/	O
ml	O
ampicillin	O
.	O

Concentrations	O
of	O
cefoxitin	O
used	O
for	O
transcriptional	O
induction	O
were	O
either	O
sub	O
-	O
inhibitory	O
(	O
4	O
mu	O
g	O
/	O
ml	O
)	O
or	O
inhibitory	O
(	O
120	O
mu	O
g	O
/	O
ml	O
)	O
.	O

Susceptibility	O
testing	O

Oxacillin	O
resistance	O
levels	O
were	O
compared	O
by	O
swabbing	O
0	O
.	O
5	O
McFarland	O
cell	O
suspensions	O
across	O
agar	O
plates	O
containing	O
appropriate	O
concentration	O
gradients	O
of	O
oxacillin	O
.	O

For	O
population	O
analysis	O
profiles	O
,	O
appropriate	O
dilutions	O
of	O
an	O
overnight	O
culture	O
,	O
ranging	O
from	O
100	O
to	O
108	O
,	O
were	O
plated	O
on	O
increasing	O
concentrations	O
of	O
oxacillin	O
.	O

Plates	O
were	O
incubated	O
at	O
35	O
degrees	O
C	O
and	O
colony	O
forming	O
units	O
per	O
ml	O
(	O
cfu	O
/	O
ml	O
)	O
were	O
determined	O
after	O
48	O
h	O
.	O

Binding	O
-	O
protein	O
purification	O

Crude	O
protein	O
extracts	O
were	O
isolated	O
from	O
CHE482	O
,	O
grown	O
under	O
normal	O
culture	O
conditions	O
until	O
OD600	O
nm	O
1	O
.	O
5	O
.	O

Cells	O
were	O
harvested	O
,	O
resuspended	O
in	O
PBS	O
(	O
pH	O
7	O
.	O
4	O
)	O
and	O
mechanically	O
lysed	O
using	O
Lysing	O
Matrix	O
B	O
(	O
BIO	O
101	O
Systems	O
)	O
tubes	O
and	O
a	O
FastPrep	O
FP120	O
(	O
BIO	O
101	O
Systems	O
)	O
.	O

Suspensions	O
were	O
clarified	O
by	O
centrifugation	O
and	O
supernatants	O
,	O
containing	O
soluble	O
cytoplasmic	O
proteins	O
,	O
were	O
transferred	O
to	O
Amicon	O
Ultra	O
centrifugal	O
filter	O
devices	O
(	O
Millipore	O
)	O
with	O
a	O
pore	O
cut	O
-	O
off	O
size	O
of	O
10	O
kDa	O
.	O

Proteins	O
were	O
then	O
washed	O
and	O
concentrated	O
in	O
1	O
x	O
binding	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
,	O
1	O
mM	O
EDTA	O
,	O
and	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
M	O
NaCl	O
)	O
.	O

Protein	O
concentrations	O
were	O
measured	O
by	O
Bradford	O
assay	O
(	O
BioRad	O
Laboratories	O
GmbH	O
)	O
[	O
32	O
]	O
.	O

Primer	O
pair	O
me36F	O
/	O
me36Rbiot	O
(	O
Table	O
2	O
)	O
were	O
used	O
to	O
amplify	O
a	O
biotinylated	O
mecA	O
promoter	O
/	O
operator	O
fragment	O
,	O
which	O
was	O
bound	O
to	O
streptavidin	O
coated	O
magnetic	O
beads	O
(	O
Dynabeads	O
M	O
-	O
280	O
Streptavidin	O
,	O
DYNAL	O
BIOTECH	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Binding	O
reactions	O
,	O
containing	O
DNA	O
-	O
coated	O
beads	O
mixed	O
with	O
100	O
mu	O
g	O
of	O
crude	O
protein	O
extract	O
in	O
1	O
x	O
protein	O
binding	O
buffer	O
(	O
20	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
6	O
,	O
1	O
mM	O
EDTA	O
,	O
10	O
mM	O
(	O
NH4	O
)	O
2SO4	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
2	O
%	O
Tween	O
20	O
(	O
w	O
/	O
v	O
)	O
,	O
30	O
mM	O
KCl	O
)	O
,	O
0	O
.	O
02	O
mu	O
g	O
/	O
mu	O
l	O
poly	O
d	O
(	O
I	O
-	O
C	O
)	O
and	O
2	O
ng	O
/	O
mu	O
l	O
poly	O
L	O
-	O
lysine	O
,	O
were	O
incubated	O
at	O
room	O
temperature	O
for	O
30	O
min	O
with	O
constant	O
rotation	O
.	O

Beads	O
were	O
then	O
washed	O
and	O
binding	O
-	O
proteins	O
eluted	O
in	O
elution	O
buffer	O
(	O
1	O
x	O
protein	O
binding	O
buffer	O
containing	O
2	O
M	O
KCl	O
)	O
.	O

Eluted	O
proteins	O
were	O
dialysed	O
against	O
water	O
,	O
concentrated	O
by	O
evaporation	O
,	O
and	O
run	O
on	O
15	O
%	O
SDS	O
polyacrylamide	O
gels	O
.	O

Gels	O
were	O
silver	O
stained	O
using	O
the	O
Protein	O
Silver	O
Staining	O
kit	O
(	O
Amersham	O
Biosciences	O
AB	O
)	O
without	O
the	O
addition	O
of	O
glutaraldehyde	O
.	O

Protein	O
bands	O
were	O
excised	O
from	O
gels	O
and	O
analysed	O
by	O
mass	O
spectrometry	O
(	O
LC	O
/	O
ESI	O
/	O
MS	O
/	O
MS	O
)	O
at	O
the	O
Functional	O
Genomics	O
Centre	O
,	O
Zurich	O
.	O

The	O
SA1665	O
protein	O
sequence	O
[	O
BAB42933	O
]	O
was	O
analysed	O
by	O
Blast	O
search	O
and	O
motif	O
scan	O
.	O

Expression	O
of	O
recombinant	O
SA1665	O
protein	O

SA1665	O
was	O
amplified	O
using	O
primer	O
pair	O
me65BamHI	O
/	O
me65XhoI	O
(	O
Table	O
2	O
)	O
and	O
cloned	O
in	O
-	O
frame	O
into	O
pET28nHis6	O
(	O
unpublished	O
,	O
D	O
.	O
Frey	O
)	O
.	O

The	O
resulting	O
plasmid	O
,	O
pME20	O
,	O
was	O
transformed	O
into	O
E	B-Species
.	I-Species
coli	I-Species
BL21	E-Species
for	O
expression	O
of	O
recombinant	O
nHis6	O
-	O
SA1665	O
protein	O
.	O

To	O
maximise	O
the	O
abundance	O
of	O
soluble	O
protein	O
produced	O
,	O
cultures	O
were	O
grown	O
in	O
osmotic	O
shock	O
medium	O
at	O
37	O
degrees	O
C	O
(	O
1	O
g	O
/	O
l	O
NaCl	O
,	O
16	O
g	O
/	O
l	O
tryptone	O
,	O
10	O
g	O
/	O
l	O
yeast	S-Species
,	O
1	O
M	O
sorbitol	O
,	O
10	O
mM	O
betaine	O
,	O
modified	O
from	O
[	O
33	O
]	O
)	O
to	O
an	O
OD600	O
nm	O
of	O
0	O
.	O
5	O
,	O
cooled	O
briefly	O
on	O
ice	O
,	O
then	O
induced	O
by	O
adding	O
100	O
mu	O
M	O
IPTG	O
and	O
growing	O
overnight	O
at	O
22	O
degrees	O
C	O
.	O

Crude	O
soluble	O
proteins	O
were	O
extracted	O
using	O
CelLyticB	O
2	O
x	O
cell	O
lysis	O
reagent	O
(	O
SIGMA	O
)	O
.	O

HIS	O
-	O
Select	O
Cobalt	O
Affinity	O
Gel	O
(	O
SIGMA	O
)	O
was	O
used	O
to	O
purify	O
recombinant	O
nHis6	O
-	O
SA1665	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Electro	O
mobility	O
shift	O
assay	O

For	O
gel	O
shift	O
assays	O
,	O
6	O
ng	O
aliquots	O
of	O
the	O
biotinylated	O
-	O
DNA	O
fragment	O
used	O
for	O
binding	O
-	O
protein	O
purification	O
were	O
incubated	O
with	O
0	O
-	O
250	O
ng	O
of	O
purified	O
nHis6	O
-	O
SA1665	O
protein	O
in	O
1	O
x	O
binding	O
buffer	O
(	O
20	O
mM	O
Hepes	O
pH	O
7	O
.	O
6	O
,	O
1	O
mM	O
EDTA	O
,	O
10	O
mM	O
(	O
NH4	O
)	O
2SO4	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
2	O
%	O
Tween	O
20	O
(	O
w	O
/	O
v	O
)	O
,	O
30	O
mM	O
KCl	O
)	O
containing	O
0	O
.	O
05	O
mu	O
g	O
/	O
mu	O
l	O
poly	O
d	O
(	O
I	O
-	O
C	O
)	O
(	O
Roche	O
)	O
and	O
5	O
ng	O
/	O
mu	O
l	O
poly	O
L	O
-	O
lysine	O
(	O
Roche	O
)	O
.	O

For	O
control	O
binding	O
reactions	O
,	O
130	O
x	O
unlabelled	O
mec	O
operator	O
DNA	O
(	O
amplified	O
using	O
primers	O
me36F	O
/	O
me36R	O
,	O
Table	O
2	O
)	O
was	O
used	O
as	O
a	O
specific	O
binding	O
competitor	O
and	O
6	O
ng	O
of	O
herring	O
sperm	O
DNA	O
was	O
used	O
as	O
unspecific	O
competitor	O
DNA	O
.	O

Binding	O
was	O
carried	O
out	O
at	O
22	O
degrees	O
C	O
for	O
30	O
min	O
.	O

Samples	O
were	O
run	O
on	O
6	O
%	O
native	O
polyacrylamide	O
gels	O
,	O
contact	O
blotted	O
onto	O
positively	O
charged	O
nylon	O
membrane	O
and	O
detected	O
with	O
the	O
Biotin	O
Chromogenic	O
Detection	O
Kit	O
(	O
Fermentas	O
)	O
.	O

Primer	O
extension	O

RNA	O
was	O
extracted	O
from	O
CHE482	O
cultures	O
that	O
were	O
grown	O
to	O
OD600	O
nm	O
0	O
.	O
5	O
,	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Primer	O
extension	O
reactions	O
were	O
performed	O
using	O
20	O
mu	O
g	O
of	O
total	O
RNA	O
and	O
3	O
pmol	O
of	O
the	O
5	O
'	O
-	O
biotin	O
-	O
labelled	O
primers	O
me97	O
and	O
me98	O
(	O
Table	O
2	O
)	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
,	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Sequencing	O
reactions	O
were	O
performed	O
using	O
the	O
Thermo	O
Sequenase	O
cycle	O
sequencing	O
kit	O
(	O
U	O
.	O
S	O
.	O
Biochemicals	O
)	O
.	O

The	O
Biotin	O
Chromogenic	O
Detection	O
Kit	O
(	O
Fermentas	O
)	O
was	O
used	O
for	O
biotin	O
detection	O
.	O

Markerless	O
deletion	O
of	O
SA1665	O

In	O
frame	O
markerless	O
deletions	O
of	O
SA1665	O
,	O
from	O
the	O
chromosomes	O
of	O
CHE482	O
,	O
ZH37	O
,	O
ZH44	O
,	O
and	O
ZH73	O
,	O
were	O
constructed	O
using	O
the	O
pKOR1	O
allelic	O
replacement	O
system	O
,	O
as	O
described	O
by	O
Bae	O
et	O
al	O
.	O

[	O
34	O
]	O
.	O

Primer	O
pairs	O
used	O
to	O
amplify	O
the	O
DNA	O
fragments	O
flanking	O
SA1665	O
,	O
for	O
recombination	O
into	O
pKOR1	O
were	O
:	O
me62attB1	O
/	O
me51BamHI	O
and	O
me62BamHI	O
/	O
me62attB2	O
(	O
Table	O
2	O
)	O
.	O

All	O
deletion	O
mutants	O
were	O
confirmed	O
by	O
nucleotide	O
sequencing	O
over	O
the	O
deleted	O
region	O
,	O
as	O
well	O
as	O
by	O
Southern	O
blot	O
analysis	O
[	O
35	O
]	O
and	O
pulsed	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
[	O
36	O
]	O
.	O

Cloning	O
of	O
SA1665	O
for	O
complementation	O

A	O
1533	O
-	O
bp	O
DNA	O
fragment	O
,	O
containing	O
SA1665	O
together	O
with	O
690	O
-	O
bp	O
of	O
upstream	O
and	O
379	O
-	O
bp	O
of	O
downstream	O
DNA	O
,	O
was	O
amplified	O
from	O
strain	O
CHE482	O
using	O
primers	O
me94BamHI	O
/	O
me94Asp718	O
(	O
Table	O
2	O
)	O
and	O
cloned	O
into	O
the	O
E	B-Species
.	I-Species
coli	E-Species
/	O
S	B-Species
.	I-Species
aureus	E-Species
shuttle	O
vectors	O
pAW17	O
and	O
pBUS1	O
[	O
37	O
]	O
,	O
creating	O
the	O
complementing	O
plasmids	O
pME26	O
and	O
pME27	O
,	O
respectively	O
.	O

Plasmids	O
were	O
electroporated	O
into	O
RN4220	O
[	O
38	O
]	O
and	O
then	O
transduced	O
into	O
different	O
strains	O
using	O
phage	O
80	O
alpha	O
.	O

Northern	O
blot	O
analysis	O

Strains	O
were	O
grown	O
overnight	O
in	O
LB	O
(	O
Difco	O
)	O
,	O
diluted	O
1	O
:	O
200	O
and	O
grown	O
for	O
another	O
3	O
h	O
.	O

This	O
preculture	O
was	O
used	O
to	O
inoculate	O
150	O
ml	O
(	O
1	O
:	O
1000	O
)	O
of	O
fresh	O
prewarmed	O
LB	O
.	O

Cells	O
were	O
then	O
grown	O
to	O
OD600	O
nm	O
0	O
.	O
25	O
or	O
1	O
.	O
0	O
and	O
either	O
left	O
uninduced	O
or	O
induced	O
with	O
cefoxitin	O
4	O
or	O
120	O
mu	O
g	O
/	O
ml	O
.	O

Cultures	O
were	O
sampled	O
from	O
both	O
uninduced	O
and	O
induced	O
cells	O
at	O
time	O
point	O
0	O
'	O
before	O
induction	O
and	O
at	O
10	O
'	O
and	O
30	O
'	O
(	O
min	O
)	O
after	O
induction	O
.	O

To	O
monitor	O
SA1665	O
expression	O
over	O
growth	O
,	O
separate	O
cultures	O
were	O
also	O
sampled	O
at	O
different	O
growth	O
stages	O
corresponding	O
to	O
OD600	O
nm	O
0	O
.	O
25	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
and	O
4	O
.	O

Total	O
RNA	O
was	O
extracted	O
as	O
described	O
by	O
Cheung	O
et	O
al	O
.	O

[	O
39	O
]	O
.	O

RNA	O
samples	O
(	O
10	O
mu	O
g	O
)	O
were	O
separated	O
in	O
a	O
1	O
.	O
5	O
%	O
agarose	O
-	O
20	O
mM	O
guanidine	O
thiocyanate	O
gel	O
in	O
1	O
x	O
TBE	O
running	O
buffer	O
[	O
40	O
]	O
,	O
then	O
transferred	O
and	O
detected	O
as	O
described	O
previously	O
[	O
41	O
]	O
.	O

Digoxigenin	O
(	O
DIG	O
)	O
labelled	O
-	O
probes	O
were	O
amplified	O
using	O
the	O
PCR	O
DIG	O
Probe	O
synthesis	O
kit	O
(	O
Roche	O
)	O
.	O

Table	O
2	O
contains	O
the	O
list	O
of	O
primer	O
pairs	O
used	O
for	O
the	O
amplification	O
of	O
SA1664	O
,	O
SA1665	O
,	O
SA1666	O
,	O
SA1667	O
,	O
mecR1	O
and	O
mecA	O
[	O
42	O
]	O
probes	O
.	O

All	O
Northern	O
'	O
s	O
were	O
repeated	O
at	O
least	O
two	O
times	O
,	O
using	O
independently	O
isolated	O
RNA	O
samples	O
.	O

Western	O
blot	O
analysis	O

Cells	O
were	O
cultured	O
,	O
as	O
described	O
for	O
Northern	O
blot	O
analysis	O
,	O
to	O
OD600	O
nm	O
1	O
.	O
0	O
,	O
then	O
induced	O
with	O
cefoxitin	O
4	O
mu	O
g	O
/	O
ml	O
.	O

Samples	O
were	O
collected	O
at	O
time	O
0	O
(	O
before	O
induction	O
)	O
,	O
10	O
and	O
30	O
min	O
(	O
after	O
induction	O
)	O
.	O

Cells	O
were	O
harvested	O
by	O
centrifugation	O
,	O
resuspended	O
in	O
PBS	O
pH	O
7	O
.	O
4	O
containing	O
DNase	O
,	O
lysostaphin	O
and	O
lysozyme	O
(	O
150	O
mu	O
g	O
/	O
ml	O
of	O
each	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Suspensions	O
were	O
then	O
sonicated	O
and	O
protein	O
aliquots	O
(	O
15	O
mu	O
g	O
)	O
were	O
separated	O
on	O
7	O
.	O
5	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
,	O
blotted	O
onto	O
nitrocellulose	O
membranes	O
(	O
Hybond	O
)	O
and	O
stained	O
with	O
Ponceau	O
to	O
confirm	O
equal	O
protein	O
loading	O
.	O

PBP2a	O
detection	O
was	O
performed	O
using	O
monoclonal	O
PBP2a	O
antibody	O
(	O
1	O
:	O
20000	O
)	O
from	O
the	O
MRSA	S-Species
-	O
screen	O
kit	O
(	O
Denka	O
Seiken	O
)	O
.	O

Authors	O
'	O
contributions	O

ME	O
carried	O
out	O
molecular	O
genetic	O
and	O
microbiological	O
studies	O
and	O
drafted	O
the	O
manuscript	O
.	O

BB	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

NM	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
study	O
,	O
carried	O
out	O
molecular	O
biological	O
studies	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Organization	O
and	O
structure	O
of	O
the	O
mouse	S-Species
interleukin	O
-	O
2	O
gene	O
.	O

Abstract	O

We	O
have	O
cloned	O
a	O
chromosomal	O
DNA	O
segment	O
which	O
covers	O
the	O
entire	O
sequence	O
for	O
the	O
murine	S-Species
interleukin	O
-	O
2	O
gene	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
gene	O
.	O

The	O
coding	O
regions	O
are	O
separated	O
into	O
four	O
blocks	O
by	O
three	O
introns	O
each	O
of	O
which	O
is	O
located	O
similarly	O
to	O
the	O
corresponding	O
human	S-Species
gene	O
.	O

The	O
exon	O
sequences	O
can	O
be	O
aligned	O
perfectly	O
with	O
the	O
previously	O
cloned	O
cDNA	O
sequence	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
sequences	O
within	O
the	O
5	O
'	O
-	O
flanking	O
region	O
which	O
are	O
highly	O
conserved	O
between	O
mouse	S-Species
and	O
man	S-Species
.	O

The	O
conserved	O
region	O
which	O
spans	O
more	O
than	O
400	O
base	O
pairs	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
IL	O
-	O
2	O
gene	O
expression	O
.	O
Images	O

Volume	O
12	O
Number	O
24	O
1984	O
Nucleic	O
Acids	O
Research	O

Organization	O
and	O
structure	O
of	O
the	O
mouse	S-Species
interleukin	O
-	O
2	O
gene	O

Akira	O
Fuse	O
*	O
,	O
Takashi	O
Fujita	O
,	O
Hidetaro	O
Yasumitsu	O
,	O
Nobukazu	O
Kashima	O
+	O
,	O
Katsushige	O
Hasegawa	O
and	O
Tadatsugu	O
Taniguchi	O
?	O

Department	O
of	O
Biochemistry	O
,	O
Cancer	O
Institute	O
,	O
Japanese	O
Foundation	O
for	O
Cancer	O
Research	O
,	O
Toshimaku	O
,	O
Tokyo	O
170	O
and	O
Institute	O
for	O
Molecular	O
and	O
Cellular	O
Biology	O
,	O
Osaka	O
University	O
,	O
Suita	O
-	O
shi	O
,	O
Osaka	O
565	O
,	O
Japan	O

Received	O
10	O
October	O
1984	O
;	O
Revised	O
and	O
Accepted	O
20	O
November	O
1984	O

ABSTRACT	O

We	O
have	O
cloned	O
a	O
chromosomal	O
DNA	O
segment	O
which	O
covers	O
the	O
entire	O
sequence	O
for	O
the	O
murine	S-Species
interleukin	O
-	O
2	O
gene	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
gene	O
.	O

The	O
coding	O
regions	O
are	O
separated	O
into	O
four	O
blocks	O
by	O
three	O
introns	O
each	O
of	O
which	O
is	O
located	O
similarly	O
to	O
the	O
corresponding	O
human	S-Species
gene	O
.	O

The	O
exon	O
sequences	O
can	O
be	O
aligned	O
perfectly	O
with	O
the	O
previously	O
cloned	O
cDNA	O
sequence	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
sequences	O
within	O
the	O
5	O
'	O
flanking	O
region	O
which	O
are	O
highly	O
conserved	O
between	O
mouse	S-Species
and	O
man	S-Species
.	O

The	O
conserved	O
region	O
which	O
spans	O
more	O
than	O
400	O
base	O
pairs	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
IL	O
-	O
2	O
gene	O
expression	O
.	O

INTRODUCTION	O

Interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
is	O
a	O
lymphokine	O
produced	O
by	O
T	O
cells	O
upon	O
antigenic	O
or	O
mitogenic	O
stimulation	O
and	O
is	O
required	O
for	O
the	O
proliferation	O
of	O
T	O
cells	O
(	O
1	O
,	O
2	O
)	O
.	O

Several	O
other	O
biological	O
activities	O
of	O
IL	O
-	O
2	O
which	O
appear	O
to	O
be	O
crucial	O
in	O
the	O
immune	O
regulation	O
have	O
also	O
been	O
reported	O
(	O
3	O
,	O
4	O
.	O
5	O
.	O
6	O
.	O
7	O
.	O
)	O
.	O

We	O
previously	O
reported	O
isolation	O
and	O
sequence	O
analysis	O
of	O
the	O
cDNA	O
for	O
human	S-Species
IL	O
-	O
2	O
(	O
8	O
)	O
,	O
as	O
well	O
as	O
the	O
chromosomal	O
gene	O
(	O
9	O
)	O
.	O

More	O
recently	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
which	O
encodes	O
murine	S-Species
IL	O
-	O
2	O
(	O
Kashima	O
et	O
al	O
.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

The	O
cDNA	O
contains	O
a	O
unique	O
tandem	O
repeat	O
of	O
CAG	O
sequence	O
which	O
would	O
encode	O
12	O
consecutive	O
glutamine	O
residues	O
in	O
the	O
active	O
IL	O
-	O
2	O
molecule	O
.	O

In	O
order	O
to	O
study	O
the	O
structure	O
of	O
the	O
murine	S-Species
IL	O
-	O
2	O
chromosomal	O
gene	O
and	O
its	O
controlling	O
region	O
,	O
we	O
isolated	O
and	O
analysed	O
a	O
A	O
phage	O
clone	O
containing	O
the	O
gene	O
and	O
its	O
flanking	O
sequences	O
.	O

MATERIALS	O
AND	O
METHODS	O

Southern	O
blotting	O
of	O
total	O
mouse	S-Species
DNA	O

Mouse	S-Species
chromosomal	O
DNA	O
was	O
extracted	O
from	O
liver	O
of	O
BALB	O
/	O
c6	O

?	O
I	O
R	O
L	O
Press	O
Limited	O
,	O
Oxford	O
,	O
England	O
.	O

Nucleic	O
Acids	O
Research	O

Volume	O
12	O
Number	O
24	O
1984	O

9323	O

Nucleic	O
Acids	O
Research	O

mouse	S-Species
as	O
described	O
before	O
(	O
10	O
)	O
.	O

High	O
molecular	O
genomic	O
DNA	O
was	O
digested	O
with	O
various	O
restriction	O
enzymes	O
and	O
electrophoresed	O
on	O
0	O
.	O
8	O
%	O
agarose	O
gel	O
.	O

Blotting	O
analysis	O
of	O
DNA	O
was	O
carried	O
out	O
by	O
the	O
method	O
of	O
Southern	O
(	O
11	O
)	O
.	O

Hybridization	O
was	O
carried	O
out	O
as	O
described	O
previously	O
and	O
filters	O
were	O
washed	O
either	O
in	O
3	O
x	O
SSC	O
at	O
650C	O
(	O
lower	O
stringent	O
condition	O
)	O
or	O
in	O
0	O
.	O
1	O
x	O
SSC	O
at	O
650C	O
(	O
higher	O
stringent	O
condition	O
)	O
.	O

Screening	O
of	O
genomic	O
DNA	O
library	O

A	O
bacteriophage	O
XCharon	O
4A	O
/	O
mouse	S-Species
genomic	O
DNA	O
library	O
prepared	O
with	O
partial	O
EcoRI	O
digests	O
of	O
mouse	S-Species
DNA	O
from	O
MPC	O
11	O
plasmacytoma	O
cells	O
was	O
kindly	O
provided	O
by	O
Dr	O
.	O
T	O
.	O

Honjo	O
.	O

Mouse	S-Species
IL	O
-	O
2	O
-	O
specific	O
clones	O
were	O
screened	O
by	O
the	O
method	O
of	O
Benton	O
and	O
Davis	O
(	O
12	O
)	O
,	O
using	O
700	O
bp	O
PstI	O
-	O
AccI	O
fragment	O
of	O
a	O
cDNA	O
clone	O
,	O
pMIL2	O
-	O
45	O
as	O
the	O
probe	O
(	O
Kashima	O
et	O
al	O
.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

Hybridization	O
was	O
performed	O
as	O
described	O
previously	O
(	O
13	O
)	O
.	O

Positive	O
clones	O
were	O
rescreened	O
at	O
least	O
twice	O
.	O

Subcloninq	O
and	O
sequencing	O
of	O
the	O
mouse	S-Species
IL	O
-	O
2	O
gene	O

Two	O
EcoRI	O
fragments	O
of	O
3	O
.	O
3	O
Kbp	O
and	O
2	O
.	O
8	O
Kbp	O
from	O
the	O
positive	O
recombinant	O
X	O
phage	O
were	O
subcloned	O
into	O
EcoRI	O
site	O
of	O
plasmid	O
pBR322	O
.	O

DNA	O
segments	O
derived	O
from	O
subcloned	O
3	O
.	O
3	O
Kbp	O
and	O
2	O
.	O
8	O
Kbp	O
fragments	O
were	O
labelled	O
at	O
either	O
3	O
'	O
end	O
or	O
5	O
'	O
end	O
,	O
and	O
subjected	O
to	O
sequence	O
analysis	O
by	O
the	O
chemical	O
degradation	O
method	O
(	O
14	O
)	O
.	O

The	O
0	O
.	O
8	O
Kbp	O
EcoRI	O
fragment	O
from	O
the	O
same	O
X	O
phage	O
clone	O
was	O
directly	O
subjected	O
to	O
sequence	O
analysis	O
by	O
the	O
dideoxy	O
chain	O
termination	O
method	O
(	O
15	O
)	O
.	O

RESULTS	O

Total	O
DNA	O
blotting	O
analysis	O

In	O
order	O
to	O
study	O
structural	O
organization	O
of	O
the	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
,	O
we	O
first	O
subjected	O
total	O
mouse	S-Species
DNA	O
to	O
the	O
blotting	O
analysis	O
by	O
using	O
various	O
probes	O
specific	O
for	O
IL	O
-	O
2	O
gene	O
.	O

When	O
mouse	S-Species
DNA	O
was	O
digested	O
with	O
various	O
restriction	O
endonucleases	O
and	O
then	O
probed	O
with	O
a	O
7	O
kb	O
human	S-Species
chromosomal	O
DNA	O
segment	O
which	O
contains	O
the	O
human	S-Species
IL	O
-	O
2	O
gene	O
and	O
its	O
flanking	O
region	O
(	O
Fig	O
.	O
1	O
lane	O
1	O
-	O
8	O
,	O
ref	O
.	O
9	O
.	O
)	O
,	O
single	O
positive	O
band	O
appeared	O
at	O
lower	O
but	O
not	O
at	O
higher	O
stringent	O
condition	O
for	O
washing	O
the	O
filters	O
(	O
see	O
Figure	O
legend	O
)	O
.	O

Additional	O
bands	O
corresponding	O
to	O
those	O
observed	O
by	O
using	O
mouse	S-Species
IL	O
-	O
2	O
cDNA	O
probes	O
(	O
lane	O
13	O
-	O
17	O
)	O
also	O
appeared	O
by	O
longer	O

9324	O

Nucleic	O
Acids	O
Research	O

M	O
1	O
2	O
3	O
4	O
M	O
5	O
6	O
7	O
8	O
M	O
9	O
101112	O
M	O
13	O
141516	O
17	O

a	O
~	O
~	O
3	O
.	O
.	O

I	O
pMIL2	O
-	O
45	O
SacI	O
Acc	O
I	O

CZI	O
~	O
~	O
1	O
1t	O
L2	O
-	O
20	O

Acc	O
I	O

1	O
00	O
tp	O
lX	O
i	O

Fig	O
.	O

1	O
.	O

Blot	O
hybridization	O
analysis	O
of	O
mouse	S-Species
chromosomal	O
DNA	O
.	O

High	O
molecular	O
DNA	O
prepared	O
from	O
Liver	O
BALB	O
/	O
C6	O
mouse	S-Species
was	O
digested	O
with	O
various	O
restriction	O
endonucleases	O
(	O
BamHI	O
for	O
lanes	O
1	O
,	O
5	O
,	O
9	O
,	O
13	O
;	O
EcoRI	O
for	O
lanes	O
2	O
,	O
6	O
,	O
10	O
,	O
14	O
,	O
17	O
;	O
HindIII	O
for	O
lanes	O
3	O
,	O
7	O
,	O
11	O
,	O
15	O
;	O
XbaI	O
for	O
lanes	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
)	O
.	O

The	O
resulting	O
digests	O
were	O
fractionated	O
on	O
0	O
.	O
8	O
%	O
agarose	O
gel	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
filter	O
.	O

Filters	O
were	O
hybridized	O
by	O
the	O
published	O
procedure	O
(	O
13	O
)	O
either	O
with	O
the	O
nick	O
-	O
translated	O
chromosomal	O
DNA	O
containing	O
human	S-Species
IL	O
-	O
2	O
gene	O
and	O
its	O
flanking	O
region	O
(	O
total	O
length	O
,	O
7	O
.	O
0	O
kb	O
,	O
ref	O
.	O
9	O
)	O
(	O
lane	O
1	O
-	O
8	O
)	O
or	O
with	O
the	O
nick	O
-	O
translated	O
cDNA	O
for	O
mouse	S-Species
IL	O
-	O
2	O
(	O
see	O
figure	O
)	O
.	O

Filters	O
were	O
then	O
washed	O
either	O
in	O
3	O
x	O
SSC	O
at	O
65	O
%	O
(	O
lower	O
stringent	O
condition	O
)	O
(	O
lane	O
1	O
-	O
4	O
,	O
9	O
-	O
12	O
)	O
or	O
0	O
.	O
1	O
x	O
SSC	O
at	O
65	O
OC	O
(	O
higher	O
stringent	O
condition	O
)	O
(	O
lane	O
5	O
-	O
8	O
,	O
13	O
-	O
17	O
)	O
.	O

Lane	O
M	O
each	O
contains	O
7	O
size	O
markers	O
with	O
their	O
size	O
being	O
23	O
.	O
7	O
kb	O
,	O
9	O
.	O
5	O
kb	O
,	O
6	O
.	O
7	O
kb	O
,	O
4	O
.	O
3	O
kb	O
,	O
2	O
.	O
3	O
kb	O
,	O
2	O
.	O
0	O
kb	O
and	O
0	O
.	O
6	O
kb	O
,	O
respectively	O
.	O

Brief	O
restriction	O
endonuclease	O
cleavage	O
map	O
for	O
the	O
mouse	S-Species
IL	O
-	O
2	O
cDNAs	O
is	O
presented	O
in	O
the	O
lower	O
part	O
of	O
the	O
figure	O
.	O

exposure	O
of	O
the	O
film	O
(	O
data	O
not	O
shown	O
)	O
.	O

Those	O
results	O
suggest	O
the	O
presence	O
of	O
highly	O
conserved	O
sequences	O
between	O
human	S-Species
and	O
mouse	S-Species
DNA	O
either	O
in	O
the	O
flanking	O
regions	O
or	O
in	O
the	O
introns	O
of	O
the	O
IL	O
-	O
2	O
gene	O
,	O
since	O
the	O
coding	O
regions	O
apparently	O
show	O
lower	O
degree	O
of	O
sequence	O
homology	O
as	O
evidenced	O
in	O
this	O
series	O
of	O
blotting	O
analysis	O
(	O
see	O
below	O
)	O
.	O

When	O
the	O
PstI	O
insert	O
of	O
a	O
mouse	S-Species
IL	O
-	O
2	O
cDNA	O
clone	O
,	O
pMIL2	O
-	O
20	O
,	O
was	O
used	O
as	O
the	O
probe	O
,	O
a	O
simple	O
pattern	O
was	O

9325	O

Nucleic	O
Acids	O
Research	O

obtained	O
at	O
higher	O
stringent	O
condition	O
(	O
lane	O
13	O
-	O
17	O
)	O
.	O

While	O
the	O
EcoRI	O
-	O
digested	O
DNA	O
gave	O
rise	O
to	O
two	O
positive	O
bands	O
(	O
2	O
.	O
8	O
kb	O
and	O
0	O
.	O
8	O
kb	O
)	O
(	O
Fig	O
.	O
1	O
,	O
lane	O
14	O
)	O
by	O
this	O
analysis	O
,	O
one	O
additional	O
band	O
of	O
3	O
.	O
3	O
kb	O
also	O
appeared	O
when	O
the	O
same	O
DNA	O
was	O
probed	O
with	O
a	O
longer	O
cDNA	O
insert	O
from	O
another	O
clone	O
,	O
pMIL2	O
-	O
45	O
(	O
Fig	O
.	O
1	O
,	O
lane	O
17	O
)	O
.	O

The	O
3	O
.	O
3	O
kb	O
band	O
was	O
similar	O
in	O
its	O
size	O
with	O
the	O
positive	O
band	O
which	O
became	O
detectable	O
by	O
probing	O
the	O
same	O
DNA	O
with	O
the	O
7	O
.	O
0	O
kb	O
human	S-Species
DNA	O
probe	O
(	O
Fig	O
.	O
1	O
,	O
lane	O
2	O
)	O
.	O

Since	O
this	O
band	O
appeared	O
with	O
the	O
cDNA	O
probe	O
extending	O
further	O
upstream	O
,	O
it	O
is	O
likely	O
that	O
the	O
5	O
'	O
region	O
of	O
the	O
gene	O
is	O
located	O
within	O
this	O
DNA	O
segment	O
(	O
see	O
below	O
)	O
.	O

Indeed	O
,	O
this	O
3	O
.	O
3	O
kb	O
band	O
did	O
not	O
appear	O
even	O
after	O
longer	O
exposure	O
of	O
lane	O
14	O
(	O
result	O
not	O
shown	O
)	O
.	O

BamHI	O
digest	O
of	O
the	O
mouse	S-Species
DNA	O
(	O
Fig	O
.	O
1	O
,	O
lane	O
1	O
,	O
13	O
)	O
constantly	O
gave	O
a	O
very	O
faint	O
signal	O
which	O
would	O
correspond	O
to	O
a	O
DNA	O
larger	O
than	O
15	O
kb	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggested	O
the	O
presence	O
of	O
a	O
single	O
copy	O
gene	O
for	O
murine	S-Species
IL	O
-	O
2	O
.	O

On	O
the	O
other	O
hand	O
appearance	O
of	O
the	O
multiple	O
positive	O
bands	O
at	O
lower	O
stringent	O
washing	O
condition	O
(	O
lane	O
9	O
-	O
12	O
)	O
indicates	O
the	O
presence	O
of	O
IL	O
-	O
2	O
related	O
sequences	O
within	O
the	O
mouse	S-Species
genome	O
.	O

Screening	O
of	O
recombinant	O
phaqe	O
libraries	O

We	O
next	O
screened	O
a	O
gene	O
library	O
from	O
partial	O
EcoRIdigested	O
DNA	O
from	O
MPC	O
11	O
cells	O
and	O
by	O
using	O
0	O
.	O
8	O
Kbp	O
SacI	O
-	O
AccI	O
cDNA	O
fragment	O
as	O
the	O
probe	O
and	O
isolated	O
14	O
positive	O
clones	O
containing	O
sequences	O
specific	O
to	O
the	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
.	O

Three	O
of	O
the	O
clones	O
analysed	O
all	O
contained	O
three	O
EcoRI	O
fragments	O
whose	O
size	O
is	O
in	O
agreement	O
with	O
the	O
result	O
of	O
blotting	O
analysis	O
of	O
the	O
chromosomal	O
DNA	O
as	O
shown	O
in	O
Fig	O
.	O

1	O
(	O
lane	O
17	O
)	O
.	O

One	O
of	O
these	O
is	O
designated	O
MIL	O
-	O
2G70	O
.	O

Nucleotide	O
sequence	O
analysis	O

Two	O
DNA	O
fragments	O
of	O
3	O
.	O
3	O
Kbp	O
and	O
2	O
.	O
8	O
Kbp	O
were	O
excised	O
from	O
the	O
phage	O
clone	O
MIL	O
-	O
2G70	O
by	O
EcoRI	O
digestion	O
and	O
they	O
were	O
subcloned	O
into	O
pBR322	O
.	O

DNA	O
sequences	O
were	O
determined	O
for	O
selected	O
regions	O
of	O
both	O
inserts	O
and	O
compared	O
to	O
the	O
known	O
cDNA	O
sequences	O
(	O
Kashima	O
et	O
al	O
.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

The	O
strategy	O
used	O
for	O
sequence	O
analysis	O
of	O
the	O
genomic	O
DNA	O
is	O
presented	O
in	O
Fig	O
.	O

2	O
.	O

Comparison	O
of	O
the	O
mouse	S-Species
genomic	O
IL	O
-	O
2	O
sequence	O
with	O
mouse	S-Species
IL	O
-	O
2	O
cDNA	O
sequence	O
revealed	O
that	O
,	O
like	O
the	O
human	S-Species
gene	O
,	O
the	O
gene	O
is	O
divided	O
into	O
four	O
exons	O
.	O

A	O
putative	O

9326	O

Nucleic	O
Acids	O
Research	O

E	O
E	O
E	O
E	O
E	O

500bp	O
s	O
7S	O
P	O
HBH	O
H	O
\	O
A	O

200	O
bp	O
*	O
,	O
-	O
4	O

I	O
4	O
-	O
4	O
-	O
-	O
-	O
-	O
*	O
*	O
-	O
-	O
-	O
4	O

Fig	O
.	O

2	O
.	O

Restriction	O
map	O
and	O
sequencing	O
strategy	O
of	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
.	O

Horizontal	O
lines	O
indicate	O
the	O
length	O
of	O
mouse	S-Species
DNA	O
inserted	O
into	O
the	O
X	O
phage	O
Charon	O
4A	O
or	O
plasmid	O
subclones	O
.	O

Filled	O
blocks	O
,	O
dashed	O
blocks	O
and	O
open	O
blocks	O
indicate	O
protein	O
coding	O
regions	O
,	O
untranslated	O
regions	O
and	O
introns	O
,	O
respectively	O
.	O

Horizontal	O
arrows	O
indicate	O
the	O
direction	O
and	O
extent	O
of	O
sequence	O
determination	O
without	O
ambiguity	O
.	O

Dashed	O
arrows	O
:	O
determination	O
was	O
done	O
by	O
the	O
chain	O
termination	O
method	O
(	O
15	O
)	O
after	O
subcloning	O
the	O
0	O
.	O
8	O
kb	O
fragment	O
into	O
M13	O
.	O

Rest	O
of	O
the	O
sequence	O
determination	O
was	O
carried	O
out	O
by	O
the	O
method	O
of	O
Maxam	O
and	O
Gilbert	O
(	O
14	O
)	O
.	O

A	O
AccI	O
site	O
,	O
B	O
;	O
BamHI	O
site	O
,	O
E	O
;	O
EcoRI	O
site	O
,	O
H	O
;	O
HindIII	O
site	O
,	O
P	O
;	O
PstI	O
site	O
,	O
S	O
;	O
SacI	O
site	O
.	O

capping	O
site	O
or	O
the	O
transcription	O
initiation	O
site	O
was	O
located	O
32	O
bp	O
downstream	O
from	O
a	O
TATAAA	O
consensus	O
promotor	O
sequence	O
(	O
Fig	O
.	O

3	O
)	O
.	O
The	O
first	O
ATG	O
triplet	O
was	O
located	O
79	O
bp	O
downstream	O
from	O
the	O
TATA	O
box	O
.	O

As	O
seen	O
also	O
in	O
the	O
murine	S-Species
IL	O
-	O
2	O
cDNA	O
,	O
there	O
is	O
an	O
unusual	O
repeat	O
of	O
CAG	O
triplet	O
coding	O
for	O
12	O
glutamine	O
residues	O
in	O
a	O
row	O
in	O
the	O
first	O
exon	O
.	O

The	O
second	O
exon	O
(	O
60	O
bp	O
)	O
is	O
separated	O
from	O
the	O
first	O
exon	O
by	O
a	O
short	O
intron	O
consisting	O
of	O
97	O
bp	O
.	O

The	O
second	O
,	O
the	O
third	O
and	O
the	O
fourth	O
exons	O
are	O
interrupted	O
by	O
longer	O
introns	O
whose	O
size	O
is	O
about	O
2	O
.	O
3	O
Kbp	O
and	O
1	O
.	O
6	O
Kbp	O
,	O
respectively	O
.	O

As	O
far	O
as	O
the	O
available	O
sequence	O
data	O
are	O
concerned	O
,	O
it	O
seems	O
that	O
,	O
despite	O
their	O
identical	O
location	O
,	O
intron	O
sequences	O
are	O
distinctly	O
dissimilar	O
except	O
for	O
the	O
junction	O
regions	O
between	O
the	O
human	S-Species
and	O
mouse	S-Species
IL	O
-	O
2	O
genes	O
.	O

There	O
are	O
two	O
potential	O
poly	O
(	O
A	O
)	O
addition	O
signals	O
within	O
the	O
mouse	S-Species
gene	O
(	O
nucleotide	O
positions	O
793	O
-	O
798	O
and	O
924	O
-	O
929	O
in	O
Fig	O
.	O
3	O
)	O
and	O
,	O
based	O
on	O
our	O
sequence	O
data	O
for	O
various	O
cDNA	O
clones	O
,	O
both	O
signals	O
seem	O
to	O
function	O
and	O
give	O
rise	O
to	O
heterogeneous	O
termini	O
of	O
the	O
mRNA	O
in	O
the	O
LBRM	O
-	O
33	O
cells	O
(	O
16	O
)	O
.	O

We	O
have	O
also	O
determined	O
the	O
sequence	O
of	O
about	O
500	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
region	O
of	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
,	O
since	O
(	O
i	O
)	O
promoter	O
/	O
regulatory	O
sequences	O
are	O
located	O
in	O
this	O
region	O
in	O
many	O
other	O
genes	O
of	O
eukaryotes	O
and	O
(	O
ii	O
)	O
this	O
region	O
appeared	O
to	O
contain	O
sequences	O
which	O
show	O
strongest	O
cross	O
-	O
hybridization	O
between	O
human	S-Species
and	O
mouse	S-Species
DNA	O
around	O
the	O
IL	O
-	O
2	O
gene	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
for	O
the	O
5	O
'	O
flanking	O
region	O

9327	O

Nucleic	O
Acids	O
Research	O

-	O
4	O
.	O
0	O

TAGGAGGTAAACCATCTCGAAACGGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAG	O
-	O
400	O
-	O
350	O

GATTTATTCTTTTCATCTATCTCCTCTTGCGCCCGTCCACCACAACAGGCTGCTTACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTT	O

-	O
300	O
-	O
250	O

CATGAGTTACTTTTGTGTCTCCACCCCAAAGAGGAAAATTTTGTTCATACGAAAGGCGTTCATTGTATGAATTAAAACTGCCACCTAAGAG	O

-	O
200	O
-	O
150	O

TGGGCTAACCCGACCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATATGGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAA	O

-	O
100	O
-	O
50	O

AAACAAAGGTAATACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTAATATGTAAAACATCGTGACACCCCCATATTATTTTTC	O
CAGCATTAACAGTATAAATTGCCTCCCATGCTGAAGAGCTGCC	O
TCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGC	O

50	O
100	O

ATG	O
TAC	O
AGC	O
ATG	O
CAG	O
CTC	O
GCA	O
TCC	O
TGT	O
GTC	O
ACA	O
TTG	O
ACA	O
CTT	O
GTG	O
CTC	O
CTT	O
GTC	O
AAC	O
AGC	O
GCA	O
CCC	O
ACT	O
Met	O
Tyr	O
Ser	O
Met	O
Gln	O
Leu	O
Ala	O
Ser	O
Cys	O
Val	O
Thr	O
Leu	O
Thr	O
Leu	O
Val	O
Leu	O
Leu	O
Val	O
Asn	O
Ser	O
Ala	O
Pro	O
Thr	O

150	O

TCA	O
AGC	O
TCC	O
ACT	O
TCA	O
AGC	O
TCT	O
ACA	O
GCG	O
GAA	O
GCA	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
Ser	O
Ser	O
Ser	O
Thr	O
Ser	O
Ser	O
Ser	O
Thr	O
Ala	O
Glu	O
Ala	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O

200	O

CAC	O
CTG	O
GAG	O
CAG	O
CTG	O
TTG	O
ATG	O
GAC	O
CTA	O
CAG	O
GAG	O
CTC	O
CTG	O
AGC	O
AGG	O
ATG	O
GAG	O
GTAAGTGCACAGCCATCCCATC	O
His	O
Leu	O
Glu	O
Gln	O
Leu	O
Leu	O
Met	O
Asp	O
Leu	O
Gln	O
Glu	O
Leu	O
Leu	O
Ser	O
Arg	O
Met	O
Glu	O

TATAGGCAATACCTTTAGCTTTCTTGCCAAAGGCTGTGTTTAATAACCTTTAATAATAATGTTACGCTTTCTCAG	O
AAT	O
TAC	O
AGG	O
AAC	O

lAsn	O
Tyr	O
Arg	O
Asn	O
250	O

CTG	O
AAA	O
CTC	O
CCC	O
AGG	O
ATG	O
CTC	O
ACC	O
TTC	O
AAA	O
TTT	O
TAC	O
TTG	O
CCC	O
AAG	O
CAG	O
GTGAGTGAGTTTCTGTTTAACTGGTGC	O
Leu	O
Lys	O
Leu	O
Pro	O
Arg	O
Met	O
Leu	O
Thr	O
Phe	O
Lys	O
Phe	O
Tyr	O
Leu	O
Pro	O
Lys	O
Gln	O

TCTAATG	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
_	O
_	O

?	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
2000	O
bp	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
?	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
AATGTGAACCTTGTAGTTTCTTTGTAGATTGGAACAATAGTCTGAACTTGTGT	O
TATGCATTGGTAGAGAAACACAGACTTTTTACAAAGTCTAATGAAGCCAGAAGAGCTCACTAGAGTGGCCTAACAGTTAAGGTGACCCTTA	O
TGGTTGTGAGCTCTTGCTCTTCTAGATTTATGGCATCGATTACCTCAGTCCCCCTTTACAGAGGACAGGGAGTGGTAAAAGCTATGTGCTG	O
CCTTCTCTTGATTAGAGAGACTGCAGACTAACTTTCTGGCTCTTCAGTATGTGGTGAGCTGAGCTGATGGTTAAGCTTATTACTCCTCTAG	O

300	O
350	O

GCC	O
ACA	O
GAA	O
TTG	O
AAA	O
GAT	O
CTT	O
CAG	O
TGC	O
CTA	O
GAA	O
GAT	O
GAA	O
CTT	O
GGA	O
CCT	O
CTG	O
CGG	O
CAT	O
GTT	O
CTG	O
GAT	O
TTG	O
Ala	O
Thr	O
Glu	O
Leu	O
Lys	O
Asp	O
Leu	O
Gln	O
Cys	O
Leu	O
Glu	O
Asp	O
Glu	O
Leu	O
Gly	O
Pro	O
Leu	O
Arg	O
His	O
Val	O
Leu	O
Asp	O
Leu	O

490	O

ACT	O
CAA	O
AGC	O
AAA	O
AGC	O
TTT	O
CAA	O
TTG	O
GAA	O
GAT	O
GCT	O
GAG	O
AAT	O
TTC	O
ATC	O
AGC	O
AAT	O
ATC	O
AGA	O
GTA	O
ACT	O
GTT	O
GTA	O
Thr	O
Gln	O
Ser	O
Lys	O
Ser	O
Phe	O
Gln	O
Leu	O
Glu	O
Asp	O
Ala	O
Glu	O
Asn	O
Phe	O
Ile	O
Ser	O
Asn	O
Ile	O
Arg	O
Val	O
Thr	O
Val	O
Val	O
AAA	O
CTA	O
AAG	O
GTAAGGTGTTGCTTTATTTGCTAATCTGGAAATAAAATAGAGAAGAAATGCATTTTTAAGTGGCTTGCCATTTCTGGT	O
Lys	O
Leu	O
Lys	O

CTTTGATGGGTTCTGTGCATTTAGTCAACCAAAGTTTAAAGTCACTGTGCAAGTGAATCC	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
1000	O
bp	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
GAATTCTACAGAAGTGTTCAGTGTTCCCATCAAATGCTCGTTGGTAATCAACTCTGGAGAGCTT	O
TATTTTTTATGCTTTACCATTTGATATCATAATAAAACATAACCCAATAATTGTGATCATTTCAGAAATGTGAATGTTCAATATATTTAAC	O

CAGTGTTAAAATAAATGCCTAAAAGCTCCGTTGAAGAATAATTATATGCAAAGTAAGCTACCTTAGCCTACAATTTTATATTCTTTTTTAG	O

450	O
500	O

GGC	O
TCT	O
GAC	O
AAC	O
ACA	O
TTT	O
GAG	O
TGC	O
CAA	O
TTC	O
GAT	O
GAT	O
GAG	O
TCA	O
GCA	O
ACT	O
GTG	O
GTG	O
GAC	O
TTT	O
CTG	O
AGG	O
AGA	O
Gly	O
Ser	O
Asp	O
Asn	O
Thr	O
Phe	O
Glu	O
Cys	O
Gln	O
Phe	O
Asp	O
Asp	O
GlU	O
Ser	O
Ala	O
Thr	O
Val	O
Val	O
Asp	O
Phe	O
Leu	O
Arg	O
Arg	O

550	O

TGG	O
ATA	O
GCC	O
TTC	O
TGT	O
CAA	O
AGC	O
ATC	O
ATC	O
TCA	O
ACA	O
AGC	O
CCT	O
CAA	O
TAACTATGTACCTCCTGCTTACAACACATAAGGC	O
Trp	O
Ile	O
Ala	O
Phe	O
Cys	O
Gln	O
Ser	O
Ile	O
Ile	O
Ser	O
Thr	O
Ser	O
Pro	O
Gln	O

600	O
650	O

TCTCTATTTAT4TAAATATTTAACTTTAATTTATTTTTGGATGTATTGTTTACTATCTTTTGTAACTACTAGTCTTCAGATGATAAATATG	O

700	O
750	O

GATCTTTAAAGATTCTTTTTGTAAGCCCCAAGGGCTCAAAAATGTTTTAAACTATTTATCTGAAATTATT	O
+	O
ATTATATTGAATTGTTAAAT	O

<	O
4	O
>	O
800	O
850	O

ATCATGTGTAGGTAGACTcATTCA	O
TAAAAGTAmAGATGATTCAAATATAAATAAGCTCAGATGTCTGTCATTTTTAGGACAGCACAAAG	O

900	O
0	O
"	O

TAAGCGCTAAAATAACTTCTCAGTTATTCCTGTGAACTcTATGTTAATCAGTGTTTTCAAGAAATAAAGCTCTCCTCT	O
AAA	O
GATGGCTTGTGGGAAAAGATCTCCTCTCCAGGGAGCTAACATCAGCTCAGAGTTTACTCAAGAATTC	O

Fig	O
.	O

3	O
.	O

Nucleotide	O
sequence	O
of	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
.	O

Four	O
exons	O
are	O
framed	O
.	O

Numbers	O
refer	O
to	O
nucleotide	O
positions	O
of	O
exons	O
from	O
the	O
presumed	O
cap	O
site	O
.	O

Dots	O
and	O
open	O
circles	O
indicate	O
TATA	O
box	O
and	O
poly	O
A	O
additional	O
signals	O
,	O
respectively	O
.	O

9328	O

Nucleic	O
Acids	O
Research	O

-	O
4	O
5	O
0	O
-	O
400	O

TAGGAGGT	O
AAACCA	O
T	O
CTCGAAAC	O
GGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAGGATTTATTCTTTTCATCTATCTCC	O

.	O
0	O
*	O
.	O
0	O
.	O
-	O
*	O
.	O

*	O
.	O
.	O
*	O
-	O
-	O
.	O

-	O
-	O
.	O
*	O
-	O
@	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O
.	O

-	O
-	O
-	O
*	O
-	O
*	O
*	O

TAAAAAGGTAAAACCAGTTCT	O
GAAACAGGAAACCAATACACTTCCTGTTTAATCAACAAATCTAAA	O
CATTTATTCTTTTCATCTGTTTAC	O

-	O
350	O
-	O
300	O

TCTTGCGCCCGTCCACCACAACAGGCTGCT	O
T	O
ACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTTCATGAGTTACTTTTGTGTCTC	O
TCTTGCTCTTGTTCACCACAATA	O
TGCTATTCACATGTTCAGTGTAGTTTTATGACAAAGAAAATTTTC	O
TGAGTTACTTTTGTATCCC	O

-	O
250	O

CA	O
CCCC	O
AAAG	O
AGGAAAATTTGTTTCATACGAAAGGCGTTCATTGTATGAATTAAAACT	O
CCACCTAAGAGTGGGCTAACCCGA	O

*	O
~	O
~	O
~	O
~	O
~	O
.	O
.	O
.	O
.	O
.	O

*	O
.	O
-	O
-	O
*	O
.	O
.	O
-	O
*	O
.	O
-	O
-	O
.	O
*	O
*	O
.	O

*	O
-	O
.	O

-	O
-	O
.	O

*	O
-	O
*	O
-	O
-	O
-	O
*	O
-	O
0	O
@	O
*	O
-	O
-	O
0	O
.	O
.	O

.	O

CACCCCCTTAAAGAAAGGAGGAAAAACTGTTTCATACAGAAGGCGTTAATTGCATGAATTAGAGCTATCACCTAAGTGTGGGCTAATGTAA	O

-	O
200	O
-	O
150	O

CCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATAT	O
GGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAAAAACAAAGGTAA	O
CAAAGAGGGATTTCACCTACATCCATTCAGTCAGTCTTTGGGGGTTTAAA	O
AAATTCCAAAGAGTCATCAGAAGAGGAAAAATGAAGGTAA	O

-	O
100	O
-	O
50	O

TACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTXATATTAAAACATCGTGACACCCCCATATiXrTCCAGCATTAACAG	O
TGTTTTTT	O
CAGACAGGTAAAGTC	O
TTTGAAAATATGTGTAATATGTAAAACATTTTGACACCCCCATAATATTTTTCCAGAATTAACAG	O
ATAAGCCTCCCATGCTGAAGAGCTGCCTATCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGCATG	O
Mouse	S-Species
rTATGCATCTCTTGTTCAAGAGTTCCCTATCACTCTCTTTAATCACTACACACAGTAACCTCAACTCCTGCCACTATG	O
Human	S-Species

Fig	O
.	O

4	O
.	O

Comparison	O
of	O
5	O
'	O
-	O
flanking	O
regions	O
of	O
mouse	S-Species
and	O
human	S-Species
IL	O
-	O
2	O
genes	O
.	O

In	O
aligning	O
the	O
sequences	O
for	O
both	O
genes	O
,	O
gaps	O
were	O
introduced	O
to	O
maximize	O
homology	O
.	O

Dots	O
indicate	O
identical	O
nucleotide	O
sequences	O
.	O

Number	O
1	O
indicates	O
putative	O
transcription	O
initiation	O
site	O
.	O

Inverted	O
repeats	O
are	O
indicated	O
by	O
bars	O
and	O
dashed	O
lines	O
.	O

TATA	O
box	O
is	O
framed	O
.	O

of	O
both	O
genes	O
is	O
illustrated	O
in	O
Fig	O
.	O

4	O
.	O

The	O
nucleotide	O
sequence	O
homology	O
from	O
the	O
TATA	O
box	O
to	O
-	O
470	O
is	O
85	O
%	O
.	O

The	O
highest	O
region	O
of	O
homology	O
was	O
observed	O
between	O
the	O
TATA	O
box	O
and	O
position	O
-	O
97	O
(	O
60	O
bp	O
matches	O
out	O
of	O
64	O
bp	O
)	O
of	O
both	O
genes	O
.	O

DISCUSSION	O

We	O
have	O
isolated	O
recombinant	O
clones	O
for	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
from	O
a	O
phage	O
Charon	O
4A	O
/	O
mouse	S-Species
genomic	O
DNA	O
library	O
and	O
determined	O
the	O
entire	O
sequence	O
of	O
the	O
gene	O
except	O
for	O
the	O
sequence	O
of	O
the	O
internal	O
portion	O
of	O
the	O
second	O
and	O
third	O
introns	O
.	O

The	O
mouse	S-Species
IL	O
-	O
2	O
cDNA	O
sequence	O
was	O
aligned	O
with	O
the	O
genomic	O
sequence	O
and	O
both	O
sequences	O
matched	O
completely	O
each	O
other	O
.	O

The	O
unusual	O
CAG	O
repeats	O
encoding	O
12	O
glutamines	O
which	O
was	O
found	O
previously	O
in	O
the	O
cloned	O
cDNA	O
was	O
shown	O
to	O
be	O
present	O
also	O
in	O
the	O
chromosomal	O
gene	O
.	O

This	O
finding	O
further	O
excludes	O
the	O
possibility	O
that	O
the	O
unique	O
repeat	O
is	O
generated	O
by	O
artifacts	O
during	O
the	O
cDNA	O
cloning	O
process	O
.	O

Although	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
for	O
the	O
deletion	O
of	O
this	O
sequence	O
in	O
the	O
human	S-Species
IL	O
-	O
2	O
gene	O
,	O
it	O
is	O
more	O
likely	O
that	O
the	O
CAG	O
repeat	O
has	O
been	O
generated	O
in	O
the	O
mouse	S-Species
genome	O
rather	O
recently	O
.	O

The	O
repeat	O
could	O
have	O
been	O
generated	O
either	O
by	O
a	O
direct	O
insertion	O
of	O
the	O
sequence	O
or	O
by	O
the	O
duplication	O
after	O
insertion	O
of	O
a	O
unit	O
sequence	O
.	O

9329	O

Nucleic	O
Acids	O
Research	O

Organization	O
of	O
the	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
resembles	O
to	O
that	O
of	O
the	O
human	S-Species
gene	O
(	O
Fig	O
.	O
2	O
.	O
,	O
ref	O
.	O
9	O
)	O
.	O

There	O
seems	O
to	O
be	O
little	O
sequence	O
homology	O
between	O
corresponding	O
introns	O
of	O
mouse	S-Species
and	O
human	S-Species
IL	O
-	O
2	O
genes	O
,	O
except	O
for	O
the	O
intron	O
-	O
exon	O
junctions	O
part	O
of	O
which	O
is	O
thought	O
to	O
be	O
necessary	O
for	O
the	O
RNA	O
splicing	O
(	O
17	O
,	O
18	O
)	O
.	O

Dissimilarity	O
of	O
the	O
intron	O
sequences	O
among	O
the	O
genes	O
which	O
are	O
derived	O
from	O
a	O
common	O
ancestor	O
has	O
been	O
reported	O
in	O
other	O
genes	O
(	O
19	O
,	O
20	O
)	O
.	O

In	O
spite	O
of	O
the	O
divergence	O
in	O
sequence	O
of	O
introns	O
,	O
the	O
size	O
and	O
position	O
of	O
the	O
introns	O
are	O
very	O
similar	O
between	O
the	O
murine	S-Species
and	O
human	S-Species
IL	O
-	O
2	O
genes	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
highly	O
conserved	O
sequences	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	S-Species
and	O
mouse	S-Species
IL	O
-	O
2	O
gene	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Whereas	O
the	O
coding	O
region	O
shows	O
nucleotide	O
sequence	O
homology	O
of	O
72	O
%	O
between	O
the	O
two	O
genes	O
,	O
the	O
5	O
'	O
upstream	O
region	O
spanning	O
about	O
500	O
bp	O
(	O
Fig	O
.	O
4	O
)	O
shows	O
85	O
%	O
homology	O
which	O
was	O
readily	O
detectable	O
by	O
the	O
blotting	O
analysis	O
(	O
Fig	O
.	O
1	O
,	O
lane	O
1	O
-	O
4	O
)	O
.	O

Since	O
we	O
have	O
not	O
yet	O
determined	O
the	O
nucleotide	O
sequence	O
further	O
upstream	O
of	O
the	O
mouse	S-Species
gene	O
,	O
we	O
do	O
not	O
know	O
whether	O
or	O
not	O
this	O
similarity	O
extends	O
further	O
.	O

It	O
is	O
likely	O
that	O
such	O
sequences	O
are	O
involved	O
in	O
the	O
controlled	O
expression	O
of	O
the	O
IL	O
-	O
2	O
genes	O
in	O
activated	O
T	O
-	O
lymphocytes	O
.	O

Work	O
is	O
in	O
progress	O
to	O
identify	O
such	O
DNA	O
sequences	O
by	O
introducing	O
the	O
cloned	O
genes	O
into	O
various	O
lymphocytic	O
cell	O
lines	O
.	O

Our	O
preliminary	O
results	O
indicate	O
that	O
the	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
human	S-Species
IL	O
-	O
2	O
gene	O
mediates	O
mitogen	O
induced	O
expression	O
of	O
the	O
gene	O
in	O
T	O
-	O
lymphocytic	O
cells	O
(	O
Fujita	O
&	O
Taniguchi	O
,	O
unpublished	O
observation	O
)	O
.	O

ACKNOWLEDGEMENTS	O

We	O
thank	O
Dr	O
.	O
T	O
.	O

Honjo	O
for	O
mouse	S-Species
gene	O
library	O
.	O

We	O
are	O
also	O
indepted	O
to	O
Ms	O
.	O
M	O
.	O

Nagatsuka	O
for	O
typing	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Special	O
Project	O
Research	O
,	O
Cancer	O
-	O
Bioscience	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
and	O
Culture	O
,	O
Japan	O
.	O

?	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O

*	O
Present	O
address	O
:	O
Department	O
of	O
Microbiology	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
,	O
Chiba	O
280	O
,	O
Japan	O

+	O
Present	O
address	O
:	O
Central	O
Research	O
Laboratory	O
,	O
Ajinomoto	O
Co	O
.	O
Inc	O
.	O
,	O
Totsuka	O
-	O
ku	O
,	O
Yokohama	O
244	O
,	O
Japan	O

9330	O

Nucleic	O
Acids	O
Research	O

REFERENCES	O

1	O
.	O

Morgan	O
,	O
D	O
.	O

A	O
.	O
,	O
Ruscetti	O
,	O
F	O
.	O

W	O
.	O
and	O
Gallo	O
,	O
R	O
.	O

(	O
1976	O
)	O
Science	O
,	O

193	O
,	O
1007	O
-	O
1008	O
.	O

2	O
.	O

Gil	O
lis	O
,	O
S	O
.	O

Ferm	O
,	O
M	O
.	O

M	O
.	O
,	O
Ou	O
,	O
W	O
.	O
and	O
Smith	O
,	O
K	O
.	O

(	O
1	O
978	O
)	O
J	O
.	O

Immunol	O
.	O
,	O
120	O
,	O
2023	O
-	O
2027	O
.	O

3	O
.	O

Chen	O
,	O
B	O
.	O

M	O
.	O
and	O
Di	O
Sabato	O
,	O
G	O
.	O

(	O
1976	O
)	O
Cell	O
.	O

Immunol	O
.	O
,	O
22	O
,	O
211	O

224	O
.	O

4	O
.	O

Henney	O
,	O
C	O
.	O

S	O
.	O
,	O
Kuribayashi	O
,	O
K	O
.	O
,	O
Kern	O
,	O
D	O
.	O

E	O
.	O
and	O
Gillis	O
,	O
S	O
.	O

(	O
1981	O
)	O
Nature	O
,	O
291	O
,	O
335	O
-	O
338	O
.	O

5	O
.	O

Wagner	O
,	O
H	O
.	O
,	O
Hardt	O
,	O
C	O
.	O
,	O
Heeg	O
,	O
K	O
.	O
,	O
Rollinghoff	O
,	O
M	O
.	O
and	O

Pfizenmaier	O
,	O
K	O
.	O

(	O
1980	O
)	O
Nature	O
,	O
284	O
,	O
278	O
-	O
280	O
.	O

6	O
.	O

Farrar	O
,	O
J	O
.	O

J	O
.	O
,	O
Benjamin	O
,	O
W	O
.	O

R	O
.	O
,	O
Hilfikr	O
M	O
.	O

L	O
.	O
,	O
Howard	O
,	O
M	O
.	O
,	O

Farrar	O
,	O
W	O
.	O

L	O
.	O
and	O
Fuller	O
-	O
Farrar	O
,	O
J	O
.	O

(	O
1982	O
)	O
Immunol	O
.	O

Rev	O
.	O

63	O
,	O
129	O
-	O
166	O
.	O

7	O
.	O

Pearlstein	O
,	O
K	O
.	O
,	O
Palladino	O
,	O
M	O
.	O

A	O
.	O
,	O
Welte	O
,	O
K	O
.	O
and	O
Vilcek	O
,	O
J	O
.	O

(	O
1983	O
)	O
Cell	O
.	O

Immunol	O
.	O
,	O
80	O
,	O
1	O
-	O
9	O
.	O

8	O
.	O

Taniguchi	O
,	O
T	O
.	O
,	O
Matsui	O
,	O
H	O
.	O
,	O
Fujita	O
,	O
T	O
.	O
,	O
Takaoka	O
,	O
C	O
.	O
,	O
Kashima	O
,	O

N	O
.	O
,	O
Yoshimoto	O
,	O
R	O
.	O
and	O
Hamuro	O
,	O
J	O
.	O

(	O
1983	O
)	O
Nature	O
302	O
,	O
305	O
-	O
310	O
.	O

9	O
.	O

Fujita	O
,	O
T	O
.	O
,	O
Takaoka	O
,	O
C	O
.	O
,	O
Matsui	O
,	O
H	O
.	O
and	O
Taniguchi	O
T	O
.	O

(	O
1983	O
)	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
80	O
,	O
7437	O
-	O
7411	O
.	O

10	O
.	O

Ohno	O
,	O
S	O
.	O
and	O
Taniguchi	O
,	O
T	O
.	O

(	O
1982	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

10	O
,	O
967	O

977	O
.	O

11	O
.	O

Southern	O
,	O
E	O
.	O

M	O
.	O

(	O
1975	O
)	O
J	O
.	O

Mol	O
.	O

Biol	O
.	O

98	O
,	O
503	O
-	O
517	O
.	O

12	O
.	O

Benton	O
,	O
W	O
.	O

D	O
.	O
and	O
Davis	O
,	O
R	O
.	O

W	O
.	O

(	O
1977	O
)	O
Science	O
196	O
,	O
180	O
-	O
182	O
.	O

13	O
.	O

Ohno	O
,	O
S	O
.	O
and	O
Taniguchi	O
,	O
T	O
.	O

(	O
1981	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O

78	O
,	O
5305	O
-	O
5309	O
.	O

14	O
.	O

Maxam	O
,	O
A	O
.	O

M	O
.	O
and	O
Gilbert	O
,	O
W	O
.	O

(	O
1980	O
)	O
Meth	O
.	O

Enzymol	O
.	O

65	O
,	O
560	O

580	O
.	O

15	O
.	O

Sanger	O
,	O
F	O
.	O
,	O
Nicklen	O
,	O
S	O
.	O
and	O
Coulson	O
,	O
A	O
.	O

R	O
.	O

(	O
1977	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
74	O
,	O
5463	O
-	O
5467	O
.	O

16	O
.	O

Gillis	O
,	O
S	O
.	O
,	O
Scheid	O
,	O
M	O
.	O
and	O
Watson	O
,	O
J	O
.	O

D	O
.	O
(	O
1980	O
)	O
J	O
.	O

Immunol	O
.	O

,	O
125	O
,	O
2570	O
-	O
2580	O
.	O

17	O
.	O

Breathnach	O
,	O
R	O
.	O
,	O
Benoist	O
,	O
C	O
.	O
,	O
O	O
'	O
Hare	O
,	O
K	O
.	O
,	O
Gannon	O
,	O
F	O
.	O
and	O

Chambon	O
,	O
P	O
.	O
(	O
1978	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
75	O
,	O
4853	O
-	O
4857	O
.	O

18	O
.	O

Lerner	O
,	O
M	O
.	O

R	O
.	O
,	O
Boyle	O
,	O
J	O
.	O

A	O
.	O
,	O
Mount	O
,	O
S	O
.	O

M	O
.	O
,	O
Wolin	O
,	O
S	O
.	O

L	O
.	O
and	O

Steitz	O
,	O
J	O
.	O

A	O
.	O

(	O
1980	O
)	O
Nature	O
,	O
283	O
,	O
220	O
-	O
224	O
.	O

19	O
.	O

Van	O
Ooyen	O
,	O
A	O
.	O
,	O
Van	O
den	O
Berg	O
,	O
J	O
.	O
,	O
Mantei	O
,	O
N	O
.	O
and	O
Weissmann	O
,	O

C	O
.	O
(	O
1979	O
)	O
Science	O
,	O
206	O
,	O
337	O
-	O
344	O
.	O

20	O
.	O

Searle	O
,	O
P	O
.	O

F	O
.	O
,	O
Davison	O
,	O
B	O
.	O

L	O
.	O
,	O
Stuart	O
,	O
G	O
.	O

W	O
.	O
,	O
Wilkie	O
,	O
T	O
.	O

M	O
.	O
,	O

Norstedt	O
,	O
G	O
.	O
and	O
Palmiter	O
,	O
R	O
.	O

D	O
.	O

(	O
1984	O
)	O
Mol	O
.	O

Cell	O
.	O

Biol	O
.	O

4	O
,	O
1221	O
-	O
1230	O
.	O

9331	O

Preparation	O
of	O
oligodeoxyribonucleoside	O
methylphosphonates	O
on	O
a	O
polystyrene	O
support	O
.	O

Abstract	O

An	O
efficient	O
procedure	O
is	O
described	O
for	O
synthesizing	O
deoxyribonucleoside	O
methylphosphonates	O
on	O
polystyrene	O
polymer	O
supports	O
which	O
involves	O
condensing	O
5	O
'	O
-	O
dimethoxytrityldeoxynucleoside	O
3	O
'	O
-	O
methylphosphonates	O
.	O

The	O
oligomers	O
are	O
removed	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
hydrolyzed	O
by	O
treatment	O
with	O
ethylenediamine	O
in	O
ethanol	O
,	O
which	O
avoids	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
.	O

Two	O
types	O
of	O
oligomers	O
were	O
synthesized	O
:	O
those	O
containing	O
only	O
methylphosphonate	O
linkages	O
,	O
d	O
-	O
Np	O
(	O
Np	O
)	O
nN	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5	O
'	O
nucleotide	O
residue	O
,	O
dNp	O
(	O
Np	O
)	O
nN	O
.	O

The	O
latter	O
oligomers	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
,	O
and	O
are	O
separated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
according	O
to	O
their	O
chain	O
length	O
.	O

Piperdine	O
randomly	O
cleaves	O
the	O
oligomer	O
methylphosphonate	O
linkages	O
and	O
generates	O
a	O
series	O
of	O
shorter	O
oligomers	O
whose	O
number	O
corresponds	O
to	O
the	O
length	O
of	O
the	O
original	O
oligomer	O
.	O

Apurinic	O
sites	O
introduced	O
by	O
acid	O
treatment	O
spontaneously	O
hydrolyze	O
to	O
give	O
oligomers	O
which	O
terminate	O
with	O
free	O
3	O
'	O
and	O
5	O
'	O
OH	O
groups	O
.	O

These	O
reactions	O
may	O
be	O
used	O
to	O
characterize	O
the	O
oligomers	O
.	O
Images	O

Vlue1Nubr1193NcecAisRsah	O

Preparation	O
of	O
oligodeoxyribonucleoside	O
methylphosphonates	O
on	O
a	O
polystyrene	O
support	O
P	O
.	O
S	O
.	O
Miller	O
,	O
C	O
.	O
H	O
.	O
Agris	O
,	O
A	O
.	O
Murakami	O
,	O
P	O
.	O
M	O
.	O
Reddy	O
,	O
S	O
.	O
A	O
.	O
Spitz	O
and	O
P	O
.	O
O	O
.	O
P	O
.	O
Ts	O
'	O
o	O

Division	O
of	O
Biophysics	O
,	O
Johns	O
Hopkins	O
University	O
,	O
School	O
of	O
Hygiene	O
and	O
Public	O
Health	O
,	O
Baltimore	O
,	O
MD	O
21205	O
,	O
USA	O

Received	O
26	O
July	O
1983	O
;	O
Accepted	O
5	O
September	O
1983	O

ABSTRACT	O

An	O
efficient	O
procedure	O
is	O
described	O
for	O
synthesizing	O
deoxyribonucleoside	O
methylphosphonates	O
on	O
polystyrene	O
polyner	O
supports	O
which	O
involves	O
condensing	O
5	O
'	O
-	O
dimethoxytrityldeoxynucleoside	O
3	O
'	O
-	O
methylphosphonates	O
.	O

The	O
oligomers	O
are	O
removed	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
hydrolyzed	O
by	O

treatment	O
with	O
ethylenediamine	O
in	O
ethanol	O
,	O
which	O
avoids	O
hydrolysis	O
of	O
the	O

methylphosphonate	O
linkages	O
.	O

Two	O
types	O
of	O
oligomers	O
were	O
synthesized	O
:	O
those	O
containing	O
only	O
methylphosphonate	O
linkages	O
,	O
d	O
-	O
Np	O
(	O
Np	O
)	O
N	O
,	O
and	O
those	O
which	O

terminate	O
with	O
a	O
5	O
'	O
nucleotide	O
residue	O
,	O
dNp	O
(	O
Np	O
)	O
N	O
.	O
-	O
J	O
he	O
latter	O
oligomers	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
,	O
and	O
are	O
separated	O
by	O

polyacrylamide	O
gel	O
electrophoresis	O
according	O
to	O
their	O
chain	O
length	O
.	O

Piperdine	O
randomly	O
cleaves	O
the	O
oligomer	O
methylphosphonate	O
linkages	O
and	O
generates	O
a	O

series	O
of	O
shorter	O
oligomers	O
whose	O
number	O
corresponds	O
to	O
the	O
length	O
of	O
the	O

original	O
oligomer	O
.	O

Apurinic	O
sites	O
introduced	O
by	O
acid	O
treatment	O
spontaneously	O
hydrolyze	O
to	O
give	O
oligomers	O
which	O
terminate	O
with	O
free	O
3	O
'	O
and	O
5	O
'	O
OH	O
groups	O
.	O

These	O
reactions	O
may	O
be	O
used	O
to	O
characterize	O
the	O
oligomers	O
.	O

INTRODUCTION	O

Oligonucleoside	O
methylphosphonates	O
have	O
been	O
used	O
to	O
st	O
-	O
udy	O
the	O
function	O
of	O
specific	O
RNA	O
sequences	O
in	O
biochemical	O
and	O
intact	O
cellular	O
systems	O
(	O
1	O
,	O
2	O
)	O
.	O

Since	O
these	O
nonionic	O
nucleic	O
acid	O
analogs	O
can	O
be	O
taken	O
up	O
intact	O
by	O
mammalian	O
cells	O
and	O
certain	O
bacterial	O
cells	O
in	O
culture	O
,	O
these	O
compounds	O
promise	O
to	O
be	O
useful	O
reagents	O
for	O
exploring	O
and	O
regulating	O
the	O
function	O
of	O
nucleic	O
acids	O
within	O
living	O
cells	O
.	O

In	O
order	O
to	O
carry	O
out	O
more	O
extensive	O
biochemical	O
and	O
biological	O
studies	O
,	O
an	O
efficient	O
method	O
for	O
synthesis	O
of	O
oligonucleoside	O
methylphosphonates	O
of	O
defined	O
sequence	O
is	O
needed	O
.	O

Previously	O
we	O
described	O
the	O
synthesis	O
of	O

methylphosphonate	O
analogs	O
on	O
a	O
silica	O
gel	O
support	O
(	O
3	O
)	O
.	O

Protected	O
nucleoside	O
3	O
'	O
-	O
methylphosphonic	O
chlorides	O
or	O
tetrazolides	O
were	O
used	O
as	O
synthetic	O

intermediates	O
.	O

While	O
oligothymidine	O
methylphosphonates	O
could	O
be	O
efficiently	O
synthesized	O
by	O
this	O
procedure	O
,	O
low	O
yields	O
were	O
encountered	O
when	O
other	O

nucleosides	O
,	O
particularly	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuG	O
were	O
used	O
.	O

Recently	O
Sinha	O
et	O
al	O
.	O

?	O
)	O
I	O
RL	O
Press	O
Limited	O
,	O
Oxford	O
,	O
England	O
.	O

Nucleic	O
Acids	O
Research	O

Volume	O
1	O
1	O
Number	O
18	O
1983	O

6225	O

Nucleic	O
Acids	O
Research	O

described	O
the	O
preparation	O
of	O
oligonucleoside	O
methylphosphophonates	O
on	O
a	O
glass	O
support	O
using	O
nucleoside	O
3	O
'	O
-	O
methylphosphine	O
chlorides	O
as	O
reactive	O
intermediates	O
(	O
4	O
)	O
.	O

In	O
this	O
paper	O
we	O
describe	O
a	O
set	O
of	O
useful	O
methods	O
for	O
the	O
synthesis	O
and	O
analysis	O
of	O
these	O
analogs	O
.	O

The	O
synthesis	O
involves	O
condensation	O
of	O
protected	O
nucleoside	O
3	O
'	O
-	O
methylphosphonate	O
triethylammonium	O
salts	O
with	O
nucleosides	O
or	O

oligomers	O
linked	O
to	O
a	O
polystyrene	O
support	O
.	O

This	O
method	O
has	O
proven	O
to	O
be	O
easy	O
to	O
use	O
and	O
allows	O
relatively	O
rapid	O
synthesis	O
of	O
oligomers	O
of	O
defined	O
sequence	O
up	O
to	O
nine	O
nucleosides	O
in	O
length	O
.	O

We	O
have	O
also	O
developed	O
conditions	O
for	O
the	O

efficient	O
removal	O
of	O
base	O
protecting	O
groups	O
and	O
subsequent	O
purification	O
of	O
the	O
oligomers	O
.	O

A	O
novel	O
hydrolysis	O
reaction	O
which	O
can	O
be	O
used	O
as	O
a	O
basis	O
for	O

characterizing	O
and	O
sequencing	O
these	O
oligonucleotide	O
analogs	O
occurs	O
at	O
apurinic	O
sites	O
created	O
by	O
acid	O
treatment	O
of	O
the	O
oligomers	O
.	O

EXPERIMENTAL	O

Materials	O
and	O
Methods	O

Protected	O
nucleosides	O
,	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
N	O
,	O
were	O
purchased	O
from	O
P	O
.	O
L	O
.	O

Biochemicals	O
and	O
were	O
used	O
without	O
further	O
purification	O
.	O

Protected	O
nucleoside	O
3	O
'	O
-	O
methylphosphonate	O
triethylammoni	O
um	O
salts	O
,	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
*	O
Et3NH	O
,	O
were	O

prepared	O
as	O
previously	O
described	O
(	O
3	O
)	O
.	O

5	O
-	O
Dimethoxytrityl	O
protected	O
nucleosides	O
esterified	O
to	O
1	O
%	O
or	O
2	O
%	O
crosslinked	O
polystyrene	O
were	O
purchased	O
from	O
Chem	O
Genes	O
Inc	O
.	O

The	O
nucleoside	O
loading	O
level	O
was	O
40	O
to	O
120	O
pmol	O
of	O

nucleoside	O
/	O
g	O
of	O
support	O
.	O

Mesitylenesulfonyl	O
-	O
3	O
-	O
nitrotriazole	O
(	O
MSNT	O
)	O
was	O
purchased	O
from	O
Vega	O
Biochemicals	O
.	O

Anhydrous	O
pyridine	O
was	O
prepared	O
by	O

refluxing	O
previously	O
purified	O
pyridine	O
(	O
5	O
)	O
over	O
calcium	O
hydride	O
chips	O
for	O
several	O
hours	O
followed	O
by	O
distillation	O
onto	O
calcium	O
hydride	O
chips	O
in	O
5	O
ml	O
V	O
-	O
vials	O
fitted	O
with	O
Teflon	O
-	O
lined	O
septum	O
caps	O
(	O
Wheaton	O
Scientific	O
)	O
.	O

Lyophilized	O
spleen	O
phosphodiesterase	O
was	O
obtained	O
from	O
P	O
.	O
L	O
.	O

Biochemicals	O
.	O

T	O
-	O
4	O
polynucleotide	O
kinase	O
and	O
[	O
y	O
-	O
32P	O
]	O
-	O
ATP	O
were	O
obtained	O
from	O
New	O
England	O
Nuclear	O
.	O

Reversed	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
carried	O
out	O
on	O
Whatman	O
Inc	O
.	O

C	O
-	O
18	O
(	O
ODS	O
-	O
3	O
)	O
columns	O
(	O
0	O
.	O
4	O
x	O
25	O
cm	O
)	O
.	O

Analytical	O
columns	O
were	O

eluted	O
with	O
50	O
ml	O
linear	O
gradients	O
of	O
acetonitrile	O
in	O
water	O
or	O
acetonitrile	O
in	O
0	O
.	O
1	O
M	O
ammonium	O
acetate	O
(	O
pH	O
5	O
.	O
8	O
)	O
at	O
a	O
flow	O
rate	O
of	O
2	O
.	O
5	O
ml	O
/	O
min	O
.	O

The	O
eluate	O
was	O

monitored	O
at	O
254	O
nm	O
.	O

The	O
following	O
molar	O
extinction	O
coefficients	O
were	O
used	O
at	O
254	O
nm	O
:	O
d	O
-	O
T	O
7	O
,	O
250	O
,	O
dA	O
13	O
,	O
270	O
,	O
dC	O
6	O
,	O
260	O
,	O
dG	O
13	O
,	O
700	O
.	O

Unless	O
otherwise	O
noted	O
,	O
all	O
reactions	O
and	O
operations	O
were	O
carried	O
out	O
at	O
room	O
temperature	O
.	O

General	O
Procedure	O
for	O
Preparing	O
Oligonucleoside	O
Methylphosphonates	O
.	O

The	O

following	O
procedure	O
represents	O
the	O
current	O
method	O
used	O
in	O
our	O
laboratory	O
to	O

6226	O

Nucleic	O
Acids	O
Research	O

synthesize	O
methylphosphonate	O
oligomers	O
.	O

Table	O
I	O
lists	O
some	O
of	O
the	O
oligomers	O
which	O
have	O
been	O
synthesized	O
on	O
polystyrene	O
supports	O
.	O

Oligomers	O
7	O
,	O
8	O
,	O
and	O
10	O
were	O
synthesized	O
as	O
described	O
below	O
.	O

The	O
other	O
oligomers	O
were	O
synthesized	O
in	O
essentially	O
the	O
same	O
manner	O
except	O
the	O
condensation	O
reactions	O
were	O
run	O
in	O
1	O
ml	O
V	O
-	O
vials	O
or	O
in	O
glass	O
reaction	O
columns	O
purchased	O
from	O
Bachem	O
Inc	O
.	O

When	O
the	O

reactions	O
were	O
run	O
in	O
V	O
-	O
vials	O
,	O
the	O
support	O
was	O
dried	O
by	O
several	O
evaporations	O

with	O
anhydrous	O
pyridine	O
in	O
the	O
V	O
-	O
vial	O
(	O
3	O
)	O
.	O

When	O
the	O
reactions	O
were	O
run	O
in	O
the	O
glass	O
reaction	O
column	O
,	O
the	O
support	O
was	O
dried	O
by	O
a	O
single	O
evaporation	O
with	O
anhydrous	O
pyridine	O
overnight	O
at	O
room	O
temperature	O
.	O

Synthesis	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
.	O

The	O
synthetic	O

reactions	O
are	O
most	O
conveniently	O
carried	O
out	O
in	O
a	O
polypropylene	O
col	O
umn	O
(	O
Bio	O
Rad	O
Econo	O
column	O
)	O
fitted	O
with	O
a	O
Teflon	O
3	O
-	O
way	O
valve	O
(	O
Bio	O
Rad	O
)	O
and	O
a	O
rubber	O
septum	O
cap	O
(	O
Wheaton	O
Scientific	O
)	O
.	O

During	O
washing	O
operations	O
,	O
the	O
septum	O
cap	O
is	O
removed	O
and	O
the	O
3	O
-	O
way	O
valve	O
is	O
connected	O
to	O
a	O
filter	O
flask	O
via	O
a	O
Luerer	O

adaptor	O
and	O
tubing	O
set	O
(	O
Bio	O
Rad	O
)	O
.	O

Generally	O
vacuum	O
is	O
not	O
required	O
to	O
wash	O

the	O
support	O
.	O

During	O
the	O
drying	O
step	O
,	O
one	O
port	O
of	O
the	O
3	O
-	O
way	O
valve	O
is	O
connected	O
to	O
a	O
cold	O
trap	O
and	O
vacuum	O
pump	O
via	O
the	O
barrel	O
of	O
a	O
1	O
ml	O
plastic	O
syringe	O
.	O

The	O
other	O
port	O
is	O
connected	O
to	O
a	O
Drierite	O
column	O
filled	O
with	O
dry	O
argon	O
.	O

A	O
reaction	O
cycle	O
consists	O
of	O
the	O
following	O
10	O
steps	O
:	O
1	O
)	O
The	O
support	O
(	O
60	O
mg	O
,	O
1	O
%	O
crosslinked	O
)	O
in	O
the	O
column	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O

methylene	O
chloride	O
/	O
isopropanol	O
(	O
85	O
:	O
15	O
,	O
v	O
/	O
v	O
)	O
.	O

2	O
)	O
The	O
support	O
is	O
treated	O
with	O
2	O
ml	O
of	O
1	O
M	O
zinc	O
bromide	O
in	O
methylene	O
chloride	O
/	O
isopropanol	O
solution	O
.	O

Two	O
fiveminute	O
treatments	O
are	O
used	O
when	O
the	O
support	O
-	O
bound	O
nucleoside	O
is	O

d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
or	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuG	O
,	O
while	O
four	O
treatments	O
are	O
used	O
when	O
the	O
nucleoside	O
is	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
or	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
.	O

After	O
each	O
treatment	O
the	O

orange	O
solution	O
is	O
collected	O
in	O
a	O
clean	O
flask	O
.	O

3	O
)	O
The	O
support	O
is	O
washed	O
with	O
two	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
and	O
the	O
washings	O
are	O

collected	O
in	O
same	O
flask	O
used	O
in	O
step	O
2	O
)	O
.	O

The	O
solution	O
is	O
diluted	O
to	O
50	O
ml	O
and	O
a	O
0	O
.	O
20	O
ml	O
aliquot	O
is	O
dissolved	O
in	O
0	O
.	O
80	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
(	O
3	O
:	O
2	O
,	O

v	O
/	O
v	O
)	O
.	O

The	O
absorbance	O
is	O
determined	O
at	O
500	O
nm	O
and	O
the	O
amount	O
of	O
trityl	O
cation	O
is	O
determined	O
using	O
a	O
molar	O
extinction	O
coefficient	O
of	O
89	O
,	O
000	O
.	O

4	O
)	O
The	O
column	O
is	O
attached	O
to	O
a	O
waste	O
flask	O
and	O
the	O
support	O
is	O
washed	O
with	O
three	O
2	O
ml	O

portions	O
of	O
0	O
.	O
5	O
M	O
triethylammonium	O
acetate	O
in	O
dimethylformamide	O
;	O
three	O
2	O
ml	O

portions	O
of	O
anhydrous	O
pyridine	O
and	O
three	O
2	O
ml	O
portions	O
of	O
diethyl	O
ether	O
.	O

5	O
)	O
The	O
column	O
is	O
fitted	O
with	O
the	O
septum	O
cap	O
and	O
set	O
up	O
in	O
the	O
drying	O
mode	O
under	O

house	O
vacuum	O
for	O
at	O
least	O
5	O
min	O
.	O

6	O
)	O
The	O
support	O
is	O
dried	O
by	O
adding	O
300	O
jl	O
of	O
anhydrous	O
pyridine	O
via	O
a	O
gas	O
tight	O
syringe	O
(	O
Hamilton	O
)	O
.	O

After	O
the	O
support	O
has	O
swollen	O
,	O
the	O
vacuum	O
(	O
oil	O
pump	O
)	O
is	O
applied	O
and	O
the	O
support	O
is	O
warmed	O
with	O
a	O

6227	O

Nucleic	O
Acids	O
Research	O

stream	O
of	O
air	O
from	O
a	O
hair	O
dryer	O
.	O

Evaporation	O
is	O
continued	O
for	O
10	O
min	O
.	O

Dry	O
argon	O
is	O
then	O
admitted	O
and	O
the	O
drying	O
operation	O
is	O
repeated	O
two	O
more	O
times	O
.	O

7	O
)	O
The	O
coupling	O
mixture	O
is	O
prepared	O
by	O
dissolving	O
0	O
.	O
20	O
mmol	O
of	O
MSNT	O
in	O
320	O
pl	O
of	O
anhydrous	O
pyridine	O
.	O

The	O
solution	O
is	O
then	O
transferred	O
to	O
the	O
vial	O

containing	O
0	O
.	O
06	O
mmol	O
of	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
-	O
Et3NH	O
.	O

The	O
nucleotide	O
is	O
dissolved	O
by	O
vortexing	O
and	O
the	O
coupling	O
solution	O
is	O
then	O
added	O
dropwise	O
to	O
the	O
support	O
.	O

It	O
is	O
important	O
to	O
add	O
the	O
solution	O
slowly	O
and	O
to	O
allow	O
the	O
support	O
to	O
swell	O
.	O

Trapped	O
gas	O
bubbles	O
may	O
be	O
removed	O
by	O
gently	O
tapping	O
the	O
column	O
.	O

This	O
entire	O
operation	O
is	O
carried	O
out	O
using	O
one	O
predried	O
syringe	O
.	O

The	O
syringe	O
is	O
left	O
in	O

the	O
V	O
-	O
vial	O
while	O
the	O
reagents	O
are	O
being	O
dissolved	O
.	O

8	O
)	O
The	O
reaction	O
mixture	O
is	O
kept	O
at	O
room	O
temperature	O
for	O
two	O
hrs	O
.	O

9	O
)	O
The	O
column	O
is	O
set	O
up	O
in	O
the	O

washing	O
mode	O
and	O
the	O
support	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
.	O

The	O
solution	O
,	O
which	O
contains	O
unreacted	O
nucleoside	O

3	O
'	O
-	O
methylphosphonate	O
and	O
MSNT	O
,	O
is	O
collected	O
in	O
a	O
separate	O
flask	O
.	O

A	O
50	O
%	O

aqueous	O
pyridine	O
solution	O
(	O
1	O
ml	O
)	O
is	O
added	O
and	O
the	O
solution	O
is	O
kept	O
at	O
40C	O
for	O

later	O
purification	O
and	O
recovery	O
of	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
.	O

10	O
)	O
The	O
support	O
is	O
treated	O
with	O
a	O
solution	O
containing	O
2	O
ml	O
of	O
anhydrous	O
pyridine	O
,	O
1	O
ml	O
of	O
acetic	O

anhydride	O
and	O
20	O
mg	O
of	O
dimethylaminopyridine	O
for	O
30	O
min	O
.	O

(	O
This	O
step	O
was	O
not	O
included	O
for	O
the	O
synthesis	O
of	O
oligomer	O
10	O
)	O
.	O

11	O
)	O
Return	O
to	O
step	O
1	O
,	O
for	O
the	O
next	O
cycle	O
.	O

Removal	O
of	O
Base	O
Protecting	O
Groups	O
.	O

The	O
following	O
general	O
procedure	O
was	O
found	O
to	O
be	O
the	O
most	O
effective	O
method	O
for	O
cleaving	O
the	O
oligonucleotide	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
and	O
for	O
removing	O
the	O
base	O
protecting	O
groups	O
with	O
minimal	O
hydrolysis	O
of	O
the	O
phosphonate	O
backbone	O
.	O

The	O
following	O
steps	O
were	O
used	O
for	O

deprotecting	O
oligomers	O
7	O
,	O
8	O
and	O
10	O
.	O

Oligomer	O
9	O
was	O
deprotected	O
in	O
a	O
similar	O

fashion	O
except	O
step	O
4	O
)	O
was	O
carried	O
out	O
at	O
650C	O
for	O
3	O
hrs	O
.	O

For	O
oligomers	O
1	O
-	O
6	O
,	O
step	O
3	O
)	O
was	O
not	O
included	O
and	O
step	O
4	O
)	O
was	O
carried	O
out	O
at	O
650	O
for	O
3	O
hrs	O
.	O

1	O
)	O
After	O
the	O
final	O
condensation	O
step	O
the	O
support	O
(	O
60	O
mg	O
)	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
;	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O

chloride	O
/	O
isopropanol	O
and	O
three	O
2	O
ml	O
portions	O
of	O
diethyl	O
ether	O
.	O

The	O
support	O
is	O
then	O
dried	O
under	O
house	O
vacuum	O
.	O

2	O
)	O
The	O
support	O
is	O
swollen	O
by	O
addition	O
of	O
2	O
ml	O
of	O
pyridine	O
and	O
the	O
excess	O
is	O
removed	O
under	O
house	O
vacuum	O
.	O

3	O
)	O
The	O
support	O
is	O
treated	O
with	O
3	O
ml	O
of	O
0	O
.	O
017	O
M	O
tetra	O
-	O
n	O
-	O
butylammonium	O
fluoride	O
in	O

tetrahydrofuran	O
/	O
pyridine	O
/	O
water	O
(	O
8	O
:	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
for	O
40	O
hrs	O
at	O
room	O
temperature	O
.	O

No	O
shaking	O
is	O
required	O
.	O

The	O
support	O
is	O
then	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
50	O
%	O
pyridine	O
/	O
water	O
;	O
three	O
2	O
ml	O
portions	O
of	O
pyridine	O
;	O
and	O
three	O
2	O
ml	O

portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
.	O

4	O
)	O
The	O
support	O
is	O
treated	O
with	O
3	O
ml	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
for	O
7	O
hrs	O
at	O
room	O
temperature	O

6228	O

Nucleic	O
Acids	O
Research	O

without	O
shaking	O
.	O

The	O
solution	O
is	O
collected	O
and	O
the	O
support	O
is	O
washed	O
with	O

four	O
2	O
ml	O
portions	O
of	O
pyridine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
and	O
four	O
2	O
ml	O
portions	O
of	O
N	O
,	O
N	O
-	O
dimethylformamide	O
.	O

The	O
combined	O
eluate	O
and	O
washings	O
are	O
evaporated	O
at	O
250C	O
and	O
the	O
oily	O
residue	O
is	O
co	O
-	O
evaporated	O
several	O
time	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

Purification	O
of	O
Oligonucleoside	O
Methylphosphonates	O
.	O

For	O
oligomers	O
which	O

contain	O
only	O
methylphosphonate	O
linkages	O
(	O
1	O
-	O
6	O
)	O
,	O
the	O
residue	O
from	O
step	O
4	O
)	O
of	O
the	O
previous	O
section	O
is	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
solution	O
is	O
chromatographed	O
on	O
a	O
C	O
-	O
18	O
reversed	O
phase	O
column	O
(	O
0	O
.	O
46	O
cm	O
x	O
25	O
cm	O

for	O
100	O
A254	O
units	O
or	O
less	O
;	O
0	O
.	O
9	O
cm	O
x	O
50	O
cm	O
for	O
more	O
than	O
100	O
A254	O
units	O
)	O
using	O
a	O
linear	O
gradient	O
of	O
0	O
%	O
to	O
25	O
%	O
(	O
8	O
-	O
mer	O
or	O
less	O
)	O
or	O
0	O
%	O
to	O
35	O
%	O
(	O
9	O
mer	O
)	O

acetonitrile	O
in	O
water	O
to	O
remove	O
non	O
-	O
tritylated	O
oligomers	O
.	O

The	O
desired	O

tritylated	O
oligomer	O
is	O
eluted	O
with	O
50	O
%	O
acetonitrile	O
in	O
water	O
.	O

The	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
treated	O
with	O
1	O
ml	O
of	O
80	O
%	O
acetic	O
acid	O
in	O
water	O
for	O
1	O
hr	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
are	O
evaporated	O
and	O
the	O

residue	O
is	O
repeatedly	O
evaporated	O
with	O
ethanol	O
to	O
ensure	O
complete	O
removal	O
of	O

acetic	O
acid	O
.	O

The	O
oligomer	O
is	O
then	O
purified	O
by	O
C	O
-	O
18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
25	O
%	O
or	O
30	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

For	O
oligomers	O
which	O
terminate	O
with	O
a	O
5	O
'	O
-	O
nucleoside	O
phosphodiester	O
linkage	O
(	O
7	O
-	O
10	O
)	O
the	O
residue	O
from	O
step	O
4	O
)	O
described	O
in	O
the	O
preceeding	O
section	O
is	O
treated	O
with	O
80	O
%	O
acetic	O
acid	O
in	O
water	O
for	O
15	O
min	O
at	O
room	O
temperature	O
.	O

After	O
removal	O
of	O
the	O
acetic	O
acid	O
by	O
evaporation	O
,	O
the	O
residue	O
is	O
dissolved	O
in	O
20	O
ml	O
of	O
50	O
%	O
aqueous	O
ethanol	O
and	O
the	O
solution	O
is	O
passed	O
through	O
a	O
DEAE	O
cellulose	O
column	O
(	O
2	O
.	O
5	O
x	O
8	O
cm	O
,	O
bicarbonate	O
form	O
)	O
which	O
has	O
been	O
previously	O
washed	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
column	O
is	O
monitored	O
at	O
254	O
nm	O
and	O
washed	O
with	O
50	O
%	O

aqueous	O
ethanol	O
until	O
the	O
pen	O
returns	O
to	O
the	O
baseline	O
.	O

The	O
desired	O
oligomer	O
is	O
then	O
eluted	O
with	O
0	O
.	O
15	O
M	O
triethylammonium	O
bicarbonate	O
in	O
50	O
%	O
aqueous	O

ethanol	O
.	O

The	O
buffer	O
is	O
removed	O
by	O
evaporation	O
and	O
co	O
-	O
evaporated	O
with	O
50	O
%	O

aqueous	O
ethanol	O
.	O

The	O
oligomer	O
is	O
then	O
further	O
purified	O
by	O
C	O
-	O
18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
0	O
.	O
10	O
M	O
ammonium	O
acetate	O
(	O
pH	O
5	O
.	O
8	O
)	O

gradient	O
.	O

The	O
oligomer	O
is	O
freed	O
of	O
ammonium	O
acetate	O
by	O
desalting	O
on	O
a	O
Bio	O
-	O
Gel	O
P	O
-	O
2	O
column	O
(	O
1	O
.	O
5	O
x	O
20	O
cm	O
)	O
.	O

Removal	O
of	O
the	O
5	O
'	O
-	O
Terminal	O
Nucleotide	O
Unit	O
.	O

Oligomers	O
which	O
terminate	O
with	O
a	O
5	O
'	O
-	O
nucleotide	O
phosphodiester	O
may	O
be	O
converted	O
to	O
the	O
oligonucleoside	O

methylphosphonate	O
by	O
the	O
following	O
procedure	O
.	O

The	O
oligomer	O
(	O
3	O
A254	O
units	O
)	O
is	O
dissolved	O
in	O
40	O
pl	O
of	O
water	O
and	O
treated	O
at	O
370C	O
for	O
2	O
hrs	O
with	O
10	O
PI	O
(	O
1	O
-	O
2	O

units	O
)	O
of	O
spleen	O
phosphodiesterase	O
dissolved	O
in	O
water	O
.	O

The	O
completeness	O
of	O
the	O
reaction	O
is	O
determined	O
by	O
reversed	O
phase	O
HPLC	O
.	O

The	O
solution	O
is	O
then	O

6229	O

Nucleic	O
Acids	O
Research	O

diluted	O
with	O
50	O
ul	O
of	O
water	O
and	O
passed	O
through	O
a	O
DEAE	O
cellulose	O
column	O
(	O
0	O
.	O
5	O
x	O
1	O
cm	O
)	O
.	O

The	O
column	O
is	O
washed	O
with	O
500	O
Pl	O
of	O
water	O
and	O
the	O
oligomer	O
is	O
recovered	O
by	O
lyophilization	O
.	O

Recovery	O
of	O
Protected	O
Nucleoside	O
3	O
'	O
-	O
Methylphosphonates	O
.	O

The	O
aqueous	O
pyridine	O
solution	O
from	O
step	O
9	O
)	O
described	O
in	O
General	O
Procedure	O
for	O
Preparing	O

Oligonucleoside	O
Methylphosphonates	O
,	O
is	O
evaporated	O
after	O
addition	O
of	O
0	O
.	O
1	O
ml	O
of	O
triethylamine	O
.	O

The	O
residue	O
is	O
dissolved	O
in	O
50	O
ml	O
of	O
chloroform	O
and	O
the	O

solution	O
is	O
extracted	O
twice	O
with	O
50	O
ml	O
of	O
1	O
M	O
ammonium	O
bicarbonate	O
.	O

The	O

chloroform	O
layer	O
is	O
dried	O
over	O
anhydrous	O
sodium	O
sulfate	O
.	O

Several	O
drops	O
of	O
triethylamine	O
are	O
added	O
to	O
clarify	O
the	O
solution	O
.	O

After	O
filtration	O
the	O

solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
evaporated	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
on	O
an	O
oil	O
pump	O
.	O

The	O
foamy	O
residue	O
is	O
dissolved	O
in	O
2	O
ml	O
of	O
dry	O
methylene	O
chloride	O
and	O
the	O
solution	O
is	O
added	O
dropwise	O
to	O
a	O
stirred	O
solution	O
of	O
1	O
%	O
triethylamine	O
in	O
hexane	O
.	O

The	O
resulting	O
precipitate	O
is	O

collected	O
via	O
filtration	O
on	O
a	O
sintered	O
glass	O
filter	O
,	O
washed	O
with	O
hexane	O
and	O
dried	O
in	O
a	O
vacuum	O
desiccator	O
.	O

Removal	O
of	O
Base	O
Protecting	O
Groups	O
with	O
Ethylenediamine	O
.	O

Several	O
mg	O
of	O

d	O
-	O
I	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
,	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
and	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibu	O
G	O
were	O
each	O
dissolved	O
in	O
250	O
pl	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
solutions	O
were	O
incubated	O
at	O
room	O
temperature	O
.	O

At	O
various	O
times	O
aliquots	O
were	O
chromatographed	O
on	O
silica	O
gel	O
TLC	O
plates	O
which	O
were	O
eluted	O
with	O
10	O
%	O
methanol	O
in	O
chloroform	O
.	O

The	O
spots	O
corresponding	O
to	O
the	O
starting	O
material	O
and	O
the	O
product	O
were	O
cut	O
out	O
and	O

treated	O
with	O
1	O
.	O
5	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
(	O
3	O
:	O
2	O
,	O
v	O
/	O
v	O
)	O
for	O
30	O
min	O
.	O

The	O

absorbance	O
of	O
each	O
solution	O
was	O
measured	O
at	O
500	O
nm	O
and	O
the	O
percent	O
reaction	O
was	O
determined	O
.	O

The	O
half	O
-	O
lives	O
of	O
the	O
reactions	O
are	O
given	O
in	O
Table	O
II	O
.	O

Removal	O
of	O
Protected	O
-	O
Nucleosides	O
from	O
Polystyrene	O
Support	O
.	O

Five	O
mg	O
of	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
(	O
ED	O
(	O
1	O
%	O
crosslinked	O
)	O
,	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
O	O
?	O
(	O
1	O
%	O
crosslinked	O
)	O
,	O

d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
(	O
?	O
)	O
(	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
)	O
and	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuGcD	O
(	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
)	O
were	O
each	O
treated	O
with	O
500	O
ul	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
solution	O
at	O
room	O
temperature	O
.	O

At	O
various	O
times	O
,	O
10	O
pl	O
aliquots	O
were	O

removed	O
,	O
the	O
solvent	O
was	O
evaporated	O
and	O
the	O
residue	O
was	O
dissolved	O
in	O
1	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
solution	O
(	O
3	O
:	O
2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
amount	O
of	O
dimethoxytrityl	O
cation	O
and	O
hence	O
the	O
amount	O
of	O
nucleoside	O
cleaved	O
from	O
the	O
support	O
was	O

determined	O
by	O
measuring	O
the	O
absorbance	O
at	O
500	O
nm	O
.	O

The	O
half	O
lives	O
of	O
the	O
cleavage	O
reactions	O
are	O
given	O
in	O
Table	O
II	O
.	O

Hydrolysis	O
of	O
the	O
Methylphosphonate	O
Linkage	O
by	O
Ethylenediamine	O
.	O

Oligonucleoside	O
methylphosphonates	O
(	O
1	O
.	O
25	O
A254	O
units	O
each	O
)	O
were	O
treated	O
with	O
50	O
il	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
at	O
room	O
temperature	O
.	O

Aliquots	O

6230	O

Nucleic	O
Acids	O
Research	O

(	O
10	O
pl	O
)	O
were	O
withdrawn	O
at	O
various	O
times	O
and	O
the	O
solvents	O
were	O
evaporated	O
.	O

The	O
residue	O
was	O
dissolved	O
in	O
20	O
PI	O
of	O
50	O
%	O
aqueous	O
ethanol	O
and	O
the	O
solution	O

examined	O
by	O
C	O
-	O
18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
25	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

The	O
mole	O
percent	O
of	O
starting	O
oligomer	O
remaining	O
after	O
100	O
hrs	O
of	O
treatment	O
is	O
given	O
in	O
Table	O
III	O
.	O

Hydrolysis	O
of	O
Oligonucleoside	O
Methylphosphonates	O
in	O
Acid	O
.	O

Six	O
A254	O
units	O
of	O
oligomer	O
were	O
dissolved	O
in	O
100	O
pl	O
of	O
0	O
.	O
01	O
M	O
hydrochloric	O
acid	O
solution	O
.	O

The	O

solution	O
was	O
heated	O
at	O
either	O
450	O
or	O
650C	O
.	O

Aliquots	O
(	O
10	O
Pil	O
)	O
were	O
withdrawn	O
at	O
various	O
times	O
and	O
added	O
to	O
10	O
pl	O
of	O
0	O
.	O
015	O
M	O
ammonium	O
hydroxide	O
at	O
0	O
?	O
C	O
.	O

The	O
samples	O
were	O
then	O
injected	O
directly	O
onto	O
a	O
C	O
-	O
18	O
reversed	O
phase	O
column	O
which	O

was	O
eluted	O
with	O
50	O
ml	O
of	O
a	O
linear	O
gradient	O
of	O
0	O
%	O
to	O
25	O
%	O
acetonitrile	O
in	O
water	O

at	O
a	O
flow	O
rate	O
of	O
2	O
.	O
5	O
ml	O
/	O
min	O
.	O

The	O
products	O
of	O
the	O
reaction	O
were	O
determined	O
by	O
comparison	O
with	O
authentic	O
samples	O
.	O

Labeling	O
5	O
'	O
-	O
End	O
of	O
Oligonucleoside	O
Methylphosphonates	O
with	O
T4	O
-	O
Polynucleotide	O
Kinase	O
.	O

Oligonucleoside	O
methylphosphonates	O
(	O
2	O
nmol	O
)	O
were	O
dissolved	O
in	O
a	O
buffer	O
solution	O
containing	O
50	O
mM	O
Tris	O
-	O
HC1	O
(	O
pH	O
9	O
.	O
0	O
)	O
,	O
10	O
mM	O
MgCl2	O
,	O
5	O
mM	O
dithiothreitol	O
,	O
20	O
pM	O
spermidine	O
,	O
and	O
[	O
y	O
-	O
32P	O
]	O
ATP	O
(	O
8	O
ljCi	O
,	O
4Ci	O
/	O
mmol	O
)	O
.	O

T4	O
-	O
polynucleotide	O
kinase	O
(	O
4	O
units	O
)	O
was	O
added	O
to	O
the	O
solution	O
,	O
which	O
was	O
made	O
up	O
to	O
50	O
ul	O
by	O
adding	O
water	O
.	O

The	O
solutions	O
were	O
incubated	O
at	O
370C	O
for	O
2	O
hrs	O
.	O

The	O
reaction	O
was	O
checked	O
by	O
PEI	O
-	O
cellulose	O
TLC	O
.	O

The	O
PEI	O
-	O
cellulose	O
plate	O

(	O
12x2Ocm	O
,	O
Merck	O
)	O
was	O
preactivated	O
by	O
elution	O
with	O
1	O
.	O
2	O
M	O
pyridinium	O
formate	O
(	O
pH	O
3	O
.	O
5	O
)	O
.	O

Small	O
aliquots	O
(	O
0	O
.	O
1	O
pl	O
)	O
of	O
PNK	O
reaction	O
solutions	O
were	O
applied	O
and	O

developed	O
with	O
1	O
.	O
5	O
M	O
pyridinium	O
formate	O
(	O
pH	O
3	O
.	O
5	O
)	O
.	O

The	O
TLC	O
plate	O
was	O
dried	O
and	O
autoradiographed	O
using	O
an	O
intensifying	O
screen	O
at	O
room	O
temperature	O
.	O

Gel	O
Electrophoresis	O
of	O
5	O
'	O
-	O
Labeled	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Polyacrylamide	O
gels	O
were	O
prepared	O
by	O
polymerizing	O
a	O
solution	O
containing	O
18	O
%	O
(	O
w	O
/	O
v	O
)	O
acrylamide	O
,	O
0	O
.	O
8	O
%	O
(	O
w	O
/	O
v	O
)	O
N	O
,	O
N	O
'	O
-	O
methylenebisacrylamide	O
.	O

7M	O
urea	O
,	O
89	O
mM	O
Tris	O
-	O
borate	O
(	O
pH	O
8	O
.	O
2	O
)	O
,	O
2	O
mM	O
EDTA	O
,	O
0	O
.	O
07	O
%	O
(	O
w	O
/	O
v	O
)	O
ammonium	O
persulfate	O
,	O
in	O
the	O

presence	O
of	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N	O
'	O
-	O
tetramethylethylenediamine	O
(	O
20	O
Pil	O
/	O
20	O
ml	O
solution	O
)	O
.	O

The	O

solution	O
was	O
poured	O
into	O
a	O
0	O
.	O
75	O
x	O
140	O
x	O
150	O
mm	O
mold	O
and	O
allowed	O
to	O
polymerize	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

5	O
'	O
-	O
Labeled	O
oligonucleoside	O
methylphosphonates	O
were	O
dissolved	O
in	O
10	O
%	O
aqueous	O
glycerol	O
solution	O
containing	O
0	O
.	O
04	O
%	O
bromophenol	O
blue	O
and	O
applied	O
to	O
the	O
gel	O
.	O

The	O
electrophoresis	O
was	O
run	O
using	O
89	O
mM	O

Tris	O
-	O
Borate	O
buffer	O
containing	O
10	O
mM	O
EDTA	O
.	O

After	O
electrophoresis	O
the	O
gel	O
was	O
dried	O
using	O
a	O
gel	O
-	O
dryer	O
and	O
autoradiographed	O
using	O
intensifying	O
screens	O
at	O
room	O
temperature	O
.	O

Pa	O
rti	O
al	O
Cl	O
eavage	O
of	O
01	O
i	O
gonucl	O
eosi	O
de	O
Methyl	O
phosphonates	O
wi	O
th	O
Hydrochl	O
ori	O
c	O
Aci	O
d	O
or	O
Piperidine	O
.	O

Aliquots	O
(	O
1	O
,	O
jl	O
)	O
from	O
the	O
polynucleotide	O
kinase	O
reaction	O

6231	O

Nucleic	O
Acids	O
Research	O

mixture	O
were	O
incubated	O
with	O
1	O
il	O
of	O
1	O
M	O
hydrochloric	O
acid	O
at	O
37	O
?	O
C	O
for	O
30	O
min	O
.	O

After	O
incubation	O
the	O
solution	O
was	O
neutralized	O
with	O
1	O
Pl	O
of	O
1	O
M	O
ammonium	O

hydroxide	O
and	O
then	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
10	O
min	O
before	O
cooling	O
to	O
00	O
.	O

Alternatively	O
,	O
aliquots	O
(	O
1	O
pl	O
)	O
from	O
the	O
phosphorylation	O

reaction	O
were	O
incubated	O
with	O
1	O
ul	O
of	O
1	O
M	O
aqueous	O
piperidine	O
at	O
370C	O
for	O
10	O
min	O
after	O
which	O
the	O
solution	O
was	O
cooled	O
to	O
0	O
?	O
and	O
evaporated	O
.	O

The	O
treated	O

samples	O
were	O
then	O
subjected	O
to	O
polyacrylamide	O
gel	O
electrophoresis	O
as	O
described	O
above	O
without	O
further	O
purification	O
.	O

RESULTS	O
AND	O
DISCUSSION	O

Synthesis	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Table	O
I	O
shows	O
some	O
of	O
the	O
protected	O
oligonucleoside	O
methylphosphonates	O
which	O
have	O
been	O

synthesized	O
on	O
aminomethyl	O
succinyl	O
-	O
derivatized	O
polystyrene	O
supports	O
.	O

The	O
basic	O
synthetic	O
steps	O
which	O
are	O
shown	O
in	O
Figure	O
1	O
are	O
described	O
in	O
detail	O
in	O
the	O
Experimental	O
section	O
.	O

These	O
steps	O
are	O
:	O
(	O
1	O
)	O
removal	O
of	O
the	O

dimethoxytrityl	O
group	O
with	O
1	O
M	O
zinc	O
bromide	O
solution	O
;	O
(	O
2	O
)	O
drying	O
the	O
support	O

via	O
co	O
-	O
evaporation	O
with	O
anhydrous	O
pyridine	O
;	O
(	O
3	O
)	O
reaction	O
of	O
the	O
support	O
-	O
bound	O

nucleoside	O
or	O
oligonucleotide	O
with	O
a	O
coupling	O
mixture	O
containing	O
0	O
.	O
15	O
to	O
0	O
.	O
2	O
M	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
)	O
-	O
NpjEt3NH	O
and	O
0	O
.	O
3	O
to	O
0	O
.	O
6	O
M	O
mesitylenesulfonyl	O
-	O
3	O
-	O
nitrotriazole	O
in	O
anhydrous	O
pyridine	O
and	O
(	O
4	O
)	O
acetylation	O
of	O
unreacted	O
5	O
'	O
-	O
OH	O
groups	O
with	O
acetic	O

anhydride	O
.	O

The	O
reactions	O
and	O
washing	O
steps	O
were	O
most	O
conveniently	O
carried	O
out	O
in	O
a	O
polypropylene	O
Econo	O
Column	O
fitted	O
with	O
a	O
septum	O
cap	O
and	O
a	O
3	O
-	O
way	O
Teflon	O

DMTrO	O
,	O
O	O
Figure	O
1	O
:	O
Preparation	O
of	O
Protected	O

Oligonucleoside	O
Methylphosphonates	O
on	O
a	O
1	O
T	O
o	O
w	O
Polystyrene	O
Support	O

0	O

H	O
BFvON	O
DlDTrOjO4B	O

U	O
)	O
I	O
CH3	O
-	O
gd	O
-	O
OEt	O
3NH	O

0	O

6232	O

Nucleic	O
Acids	O
Research	O

stopcock	O
.	O

Thus	O
no	O
transfers	O
of	O
the	O
support	O
are	O
required	O
using	O
this	O
apparatus	O
.	O

The	O
synthetic	O
procedure	O
is	O
analogous	O
to	O
the	O
phosphotriester	O
approach	O
used	O
to	O
prepared	O
protected	O
oligonucleotide	O
phosphotriesters	O
on	O
polystyrene	O
supports	O
(	O
6	O
)	O
.	O

However	O
,	O
we	O
found	O
the	O
methylphosrhonate	O
coupling	O
reaction	O
to	O
be	O

extremely	O
sensitive	O
to	O
moisture	O
.	O

Drying	O
procedures	O
such	O
as	O
washing	O
with	O

anhydrous	O
solvent	O
or	O
blowing	O
dry	O
nitrogen	O
gas	O
through	O
the	O
support	O
which	O
are	O
satisfactory	O
for	O
phosphotriester	O
synthesis	O
resulted	O
in	O
low	O
yields	O
of	O
the	O
methylphosphonates	O
.	O

The	O
best	O
yields	O
were	O
obtained	O
when	O
the	O
support	O
was	O

co	O
-	O
evaporated	O
with	O
anhydrous	O
pyridine	O
by	O
directly	O
attaching	O
the	O
reaction	O

column	O
to	O
a	O
vacuum	O
pump	O
and	O
dry	O
-	O
ice	O
trap	O
.	O

Three	O
10	O
min	O
co	O
-	O
evaporations	O
were	O
sufficient	O
to	O
render	O
the	O
support	O
anhydrous	O
.	O

The	O
protected	O
nucleoside	O
3	O
'	O
-	O
methylphosphonate	O
triethylammonium	O
salts	O
used	O
in	O
the	O
coupling	O
reactions	O
were	O
prepared	O
from	O
their	O
cyanoethyl	O
ester	O

derivatives	O
(	O
3	O
)	O
.	O

These	O
monomers	O
were	O
recovered	O
after	O
each	O
coupling	O
step	O
and	O

were	O
freed	O
of	O
unreacted	O
MSNT	O
by	O
a	O
simple	O
extraction	O
step	O
.	O

After	O
precipitation	O
and	O
drying	O
,	O
the	O
monomers	O
could	O
be	O
reused	O
for	O
other	O
syntheses	O
.	O

The	O
ability	O
to	O
recover	O
the	O
unreacted	O
monomers	O
is	O
particularly	O
important	O
for	O
large	O
scale	O

synthesis	O
since	O
large	O
excesses	O
of	O
these	O
materials	O
are	O
employed	O
in	O
the	O
coupling	O
step	O
.	O

This	O
recovery	O
step	O
represents	O
a	O
potential	O
advantage	O
over	O
the	O
phosphine	O
synthetic	O
method	O
(	O
4	O
)	O
,	O
since	O
it	O
is	O
not	O
clear	O
that	O
nucleoside	O
3	O
'	O
-	O
methylphosphine	O
chlorides	O
can	O
be	O
recovered	O
after	O
reaction	O
.	O

Two	O
types	O
of	O
methylphosphonate	O
oligomers	O
were	O
prepared	O
;	O
those	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
,	O
oligomers	O
1	O
-	O
6	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5	O
'	O
-	O
nucleoside	O
3	O
'	O
-	O
p	O
-	O
chlorophenyl	O
phosphotriester	O
moiety	O
,	O

oligomers	O
7	O
-	O
10	O
.	O

Oligomers	O
were	O
synthesized	O
on	O
both	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O

supports	O
.	O

As	O
shown	O
in	O
Table	O
I	O
,	O
the	O
average	O
yield	O
per	O
coupling	O
step	O
which	O
was	O
determined	O
by	O
trityl	O
group	O
analysis	O
was	O
approximately	O
82	O
%	O
,	O
for	O
both	O
types	O
of	O

support	O
.	O

This	O
yield	O
is	O
adequate	O
to	O
allow	O
preparation	O
of	O
protected	O
octamers	O
or	O
nonamers	O
in	O
25	O
%	O
and	O
20	O
%	O
overall	O
yield	O
,	O
respectively	O
.	O

Deprotection	O
.	O

Our	O
previous	O
studies	O
(	O
1	O
)	O
and	O
those	O
of	O
Sinha	O
et	O
al	O
.	O

(	O
4	O
)	O
show	O

that	O
methylphosphonate	O
linkages	O
are	O
cleaved	O
by	O
base	O
.	O

We	O
found	O
this	O
hydrolysis	O
reaction	O
to	O
depend	O
to	O
some	O
extent	O
upon	O
the	O
nucleoside	O
sequence	O
of	O
the	O

oligomer	O
.	O

Hydrolysis	O
of	O
methylphosphonate	O
linkages	O
by	O
concentrated	O
ammonium	O
hydroxide	O
in	O
pyridine	O
(	O
1	O
:	O
1	O
v	O
/	O
v	O
)	O
,	O
the	O
reagent	O
commonly	O
used	O
to	O
remove	O

oligonucleotide	O
base	O
protecting	O
groups	O
,	O
can	O
be	O
largely	O
suppressed	O
if	O
the	O

reactions	O
are	O
run	O
at	O
0	O
?	O
C	O
(	O
1	O
)	O
.	O

However	O
,	O
these	O
conditions	O
are	O
unsatisfactory	O
for	O
removal	O
of	O
oligonucleoside	O
methylphosphonates	O
from	O
the	O
polystyrene	O

6233	O

Nucleic	O
Acids	O
Research	O

Table	O
I	O
.	O
Syntheses	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
on	O

Polystyrene	O
Supports	O

Support	O
Average	O
cross	O
-	O
yield	O
Protected	O
oligomer	O
(	O
a	O
)	O
linking	O
per	O

(	O
%	O
)	O
coupling	O

step	O
(	O
%	O
)	O

1	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCpbzCpbzApT	O
-	O
O	O
1	O
81	O
2	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuGpbzCpbzCpbzApT	O
-	O
1	O
82	O
3	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCpbzApi	O
buGpi	O
buGpTpbzApbzA	O
-	O
G1i	O
2	O
83	O
4	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCLpTpT	O
bzApbzCpbzCpTpibuG	O
-	O
?	O

2	O
85	O
5	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
TpbzCpbzCpTpbzCpbzCpTpibuG	O
-	O
(	O
?	O

2	O
86	O
6	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
TpTpTpbzApbzCpbzCpTpT	O
-	O
?	O

1	O
83	O
7	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApbzApbzA	O
-	O
?	O

1	O
83	O
8	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA4bzCpbzCpbzApT	O
-	O
?	O

1	O
81	O
9	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApibuGpbzCpbzApbzApibuG	O
-	O
(	O
2	O
74	O
10	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApbzApbzApbzApibuGpbzCpbzApbzApibuG	O
-	O
(	O
Q	O
1	O
86	O

(	O
a	O
)	O
p	O
=	O
methylphosphonate	O
linkage	O

T	O
=	O
p	O
-	O
chlorophenyl	O
phosphotriester	O
linkage	O
(	O
Q	O
=	O
polystyrene	O
support	O

(	O
b	O
)	O
Determined	O
by	O
analysis	O
of	O
the	O
dimethoxytrityl	O
group	O
after	O
each	O

coupling	O
step	O
.	O

support	O
.	O

We	O
therefore	O
examined	O
other	O
deprotection	O
procedures	O
.	O

Recently	O
Barnett	O
and	O
Letsinger	O
described	O
removal	O
of	O
base	O
protecting	O
groups	O
from	O
oligonucleotide	O
B	O
,	O
B	O
,	O
0	O
-	O
trichloroethylphosphotriesters	O
using	O
a	O

mixture	O
of	O
ethylenediamine	O
in	O
phenol	O
(	O
7	O
)	O
.	O

We	O
have	O
found	O
ethylenediamine	O
in	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
rapidly	O
and	O
cleanly	O
removes	O
benzoyl	O
and	O
isobutyryl	O
protecting	O
groups	O
from	O
dA	O
,	O
dC	O
and	O
dG	O
nucleosides	O
.	O

This	O
reagent	O
is	O

particularly	O
attractive	O
since	O
it	O
can	O
be	O
easily	O
removed	O
by	O
evaporation	O
.	O

In	O
our	O
initial	O
investigations	O
,	O
ol	O
igonucleoside	O
methylphosphonates	O
were	O

cleaved	O
from	O
the	O
support	O
and	O
base	O
protecting	O
groups	O
were	O
removed	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
at	O
65	O
?	O
C	O
for	O
3	O
hrs	O
.	O

Although	O

preliminary	O
results	O
indicated	O
the	O
methylphosphonate	O
linkages	O
of	O
several	O
dimers	O
were	O
stable	O
to	O
these	O
conditions	O
,	O
we	O
later	O
found	O
that	O
the	O
linkages	O
of	O
onger	O

6234	O

Nucleic	O
Acids	O
Research	O

Table	O
II	O
.	O

Hydrolysis	O
of	O
Protected	O
Nucleosides	O
by	O
Ethylenediamine	O
at	O
220C	O

Protected	O
Time	O
required	O
to	O
Time	O
required	O
to	O
nucleoside	O
remove	O
50	O
%	O
of	O
the	O
cleave	O
50	O
%	O
of	O
the	O

base	O
protecting	O
nucleoside	O
from	O
the	O
groups	O
(	O
min	O
)	O
1	O
%	O
crosslinked	O

support	O
(	O
min	O
)	O

d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
)	O
bzA	O
10	O
105	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
bzC	O
20	O
105	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
i	O
buG	O
40	O
54	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
_	O
105	O

oligomers	O
were	O
hydrolyzed	O
to	O
various	O
extents	O
by	O
this	O
procedure	O
.	O

This	O
of	O

course	O
resulted	O
in	O
loss	O
of	O
product	O
as	O
was	O
evidenced	O
by	O
the	O
presence	O
of	O
shorter	O
oligomers	O
in	O
amounts	O
greater	O
than	O
expected	O
based	O
upon	O
the	O
coupling	O
yields	O
.	O

To	O
circumvent	O
this	O
problem	O
we	O
examined	O
the	O
deprotection	O
reactions	O
at	O
lower	O
temperatures	O
and	O
found	O
they	O
could	O
be	O
run	O
effectively	O
at	O
room	O

temperature	O
.	O

Table	O
II	O
shows	O
the	O
half	O
-	O
lives	O
for	O
removing	O
the	O
base	O
protecting	O
groups	O
from	O
nucleosides	O
at	O
room	O
temperature	O
.	O

While	O
the	O
isobutryl	O
protecting	O
group	O
is	O
removed	O
at	O
the	O
slowest	O
rate	O
,	O
all	O
the	O
groups	O
are	O
completely	O
removed	O
within	O
240	O
min	O
.	O

The	O
sole	O
product	O
of	O
each	O
reaction	O
is	O
the	O
5	O
'	O
-	O
O	O
-	O
dimethoxytritylnucleoside	O
as	O
shown	O
by	O
TLC	O
.	O

Table	O
II	O
also	O
shows	O
the	O
half	O
-	O
lives	O
for	O
cleavage	O
of	O
protected	O
nucleosides	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
.	O

The	O
deoxyguanosine	O
nucleoside	O
is	O
cleaved	O

most	O
rapidly	O
while	O
the	O
other	O
three	O
nucleosides	O
have	O
essentially	O
the	O
same	O
rates	O
of	O
hydrolysis	O
.	O

All	O
the	O
nucleosides	O
are	O
completely	O
removed	O
from	O
the	O
support	O
within	O
7	O
hrs	O
.	O

In	O
contrast	O
,	O
very	O
different	O
rates	O
were	O
observed	O
for	O
the	O
2	O
%	O

crosslinked	O
supports	O
.	O

In	O
these	O
cases	O
,	O
very	O
little	O
cleavage	O
occurred	O
during	O
the	O
first	O
4	O
hrs	O
of	O
incubation	O
after	O
which	O
increasing	O
amounts	O
of	O
nucleoside	O
were	O
released	O
over	O
a	O
24	O
hr	O
period	O
.	O

This	O
effect	O
may	O
be	O
due	O
to	O
the	O
slower	O
swelling	O
rate	O
of	O
the	O
2	O
%	O
crosslinked	O
support	O
versus	O
the	O
1	O
%	O
support	O
.	O

The	O

results	O
of	O
these	O
experiments	O
suggest	O
that	O
,	O
although	O
condensation	O
reactions	O

occur	O
with	O
equal	O
efficiencies	O
on	O
both	O
the	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
supports	O
,	O
the	O
1	O
%	O
support	O
is	O
preferred	O
for	O
syntheses	O
since	O
the	O
oligomers	O
can	O
be	O
removed	O
more	O
readily	O
under	O
mild	O
conditions	O
.	O

The	O
stability	O
of	O
the	O
methylphosphonate	O
linkage	O
in	O
a	O
number	O
of	O
oligomers	O

of	O
varying	O
chain	O
length	O
and	O
base	O
composition	O
was	O
examined	O
following	O
prolonged	O
exposure	O
to	O
ethylenediamine	O
/	O
ethanol	O
at	O
room	O
temperature	O
.	O

As	O
shown	O
in	O
Table	O
III	O
,	O
some	O
of	O
these	O
oligomers	O
,	O
most	O
notably	O
the	O
dimer	O
and	O
d	O
-	O
GpGpT	O
,	O
were	O

6235	O

Nucleic	O
Acids	O
Research	O

Table	O
III	O
.	O

Hydrolysis	O
of	O
Oligonucleoside	O
Methylphosphonates	O
by	O

Ethylenediamine	O
at	O
22	O
?	O
C	O

|	O
Oligomer	O
Mole	O
percent	O
of	O
oligomer	O
remaining	O
after	O
treatment	O
for	O

24	O
hrs	O
48	O
hrs	O
96	O
hrs	O

d	O
-	O
T	O
A	O
100	O
100	O
100	O
d	O
-	O
A5r	O
100	O
100	O
100	O
d	O
-	O
TpT	O
100	O
100	O
100	O
d	O
-	O
l	O
pT	O
95	O
97	O
91	O
d	O
-	O
qgG	O
{	O
T	O
100	O
100	O
100	O
d	O
-	O
ApApA	O
93	O
87	O
75	O
d	O
-	O
C	O
pC	O
ApT	O
92	O
83	O
67	O

completely	O
stable	O
over	O
a	O
96	O
hr	O
period	O
.	O

The	O
maximum	O
rate	O
of	O
hydrolysis	O
for	O
a	O
methylphosphonate	O
linkage	O
in	O
those	O
oligomers	O
which	O
were	O
hydrolyzed	O
is	O

estimated	O
to	O
be	O
0	O
.	O
13	O
mole	O
%	O
/	O
hr	O
.	O

The	O
results	O
of	O
these	O
studies	O
show	O
that	O
the	O
oligonucleoside	O
methylphosphonates	O
could	O
be	O
cleaved	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
and	O
completely	O
freed	O
of	O
base	O
protecting	O
groups	O
with	O
little	O
or	O
no	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkage	O
by	O
treatment	O
with	O

ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
at	O
room	O
temperature	O
for	O
7	O
hrs	O
.	O

These	O
conditions	O
were	O
subsequently	O
adopted	O
for	O
the	O
deprotection	O
step	O
.	O

Purification	O
of	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Two	O
methods	O
were	O
employed	O
to	O
purify	O
oligomers	O
following	O
cleavage	O
from	O
the	O
support	O
.	O

For	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
,	O
the	O
tritylated	O
oligomer	O
was	O
isolated	O

by	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

This	O
separation	O
is	O
based	O
upon	O
the	O
greater	O
affinity	O
of	O
the	O
tritylated	O
oligomer	O
for	O
the	O
hydrophobic	O
C	O
-	O
18	O
matrix	O
of	O
the	O

column	O
.	O

Shorter	O
,	O
non	O
-	O
tritylated	O
oligomers	O
were	O
first	O
eluted	O
with	O
a	O
0	O
%	O
to	O
25	O
%	O
or	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

The	O
tritylated	O
product	O
was	O
then	O
eluted	O
with	O
a	O
step	O
gradient	O
of	O
50	O
%	O
acetonitrile	O
in	O
water	O
.	O

The	O
dimethoxytrityl	O
group	O
was	O
removed	O
from	O
the	O
material	O
in	O
the	O
50	O
%	O

acetonitrile	O
fraction	O
by	O
treatment	O
with	O
80	O
%	O
acetic	O
acid	O
at	O
room	O
temperature	O
.	O

Because	O
these	O
oligomers	O
were	O
originally	O
cleaved	O
from	O
the	O
support	O
by	O

ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
at	O
65	O
?	O
C	O
,	O
we	O
usually	O
found	O
that	O
the	O

tritylated	O
oligomer	O
fraction	O
contained	O
shorter	O
oligomers	O
in	O
addition	O
to	O
the	O
desired	O
product	O
.	O

These	O
were	O
easily	O
separated	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

While	O
this	O
purification	O
procedure	O
is	O
qualitatively	O
satisfactory	O
,	O

recoveries	O
from	O
the	O
reversed	O
phase	O
columns	O
varied	O
from	O
50	O
%	O
to	O
90	O
%	O
.	O

These	O

losses	O
which	O
appeared	O
to	O
be	O
due	O
to	O
irreverisble	O
absorption	O
of	O
the	O
oligomers	O
to	O
the	O
column	O
varied	O
depending	O
on	O
the	O
base	O
composition	O
of	O
the	O
oligomers	O
.	O

6236	O

Nucleic	O
Acids	O
Research	O

Figure	O
2	O
:	O
Purification	O
of	O

d	O
-	O
ApApApApGpCpApApG	O
.	O

(	O
a	O
)	O
Ol	O
igomers	O
obtained	O
after	O
treatment	O
of	O
support	O
wi	O
th	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O

v	O
/	O
v	O
)	O
.	O

(	O
b	O
)	O
Ol	O
igomers	O
obtained	O
after	O
treatment	O
of	O
the	O
mixture	O
in	O
(	O
a	O
)	O
with	O
80	O
%	O
acetic	O
acid	O
.	O

(	O
c	O
)	O
Oligomers	O
eluted	O
from	O
DEAE	O
cellulose	O
column	O
with	O

0	O
.	O
15	O
M	O
triethylammonium	O
bicarbonate	O
.	O

(	O
d	O
)	O
Nonamer	O
obtained	O
after	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

Peaks	O
marked	O

with	O
the	O
symbol	O
(	O
X	O
)	O
are	O
derived	O
from	O
impurities	O
in	O
the	O
solvents	O
used	O
to	O
elute	O
the	O
oligomer	O
from	O
the	O
polystyrene	O
support	O
.	O

d	O
"	O
AAAGCAAGc	O

O	O
I	O
t10	O
15	O
20	O
25	O

Time	O
(	O
min	O
)	O

For	O
the	O
oligomers	O
which	O
terminate	O
with	O
a	O
5	O
'	O
-	O
nucleoside	O
phosphotriester	O
group	O
,	O
the	O
support	O
was	O
first	O
treated	O
for	O
40	O
hrs	O
with	O
tetra	O
-	O
n	O
-	O
butylammonium	O

fluoride	O
(	O
8	O
)	O
to	O
remove	O
the	O
p	O
-	O
chlorophenyl	O
protecting	O
group	O
.	O

These	O
oligomers	O

6237	O

b	O

Nucleic	O
Acids	O
Research	O

were	O
then	O
cleaved	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
were	O
removed	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
for	O
7	O
hrs	O
at	O
room	O
temperature	O
.	O

For	O
example	O
,	O
the	O
reversed	O
phase	O
HPLC	O
profile	O
for	O
products	O

obtained	O
after	O
cleavage	O
of	O
the	O
nonamer	O
,	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ApAjApApGpCpApApG	O
,	O
is	O
shown	O
in	O
Figure	O
2a	O
.	O

The	O
peaks	O
marked	O
with	O
(	O
X	O
)	O
are	O
from	O
impurities	O
in	O
the	O

solvents	O
used	O
to	O
elute	O
the	O
oligomer	O
from	O
the	O
support	O
.	O

The	O
tritylated	O
nonamer	O
appears	O
at	O
22	O
min	O
in	O
the	O
chromatogram	O
and	O
is	O
eluted	O
with	O
50	O
%	O
aqueous	O

acetonitrile	O
.	O

After	O
removal	O
of	O
the	O
dimethoxytrityl	O
group	O
,	O
the	O
nonamer	O
elutes	O
at	O
15	O
.	O
2	O
min	O
(	O
Figure	O
2b	O
)	O
.	O

The	O
peaks	O
which	O
appear	O
between	O
19	O
and	O
25	O
min	O
are	O
shorter	O
oligomers	O
which	O
contain	O
a	O
5	O
'	O
-	O
mesitylenesulfonate	O
group	O
.	O

At	O
this	O
stage	O
,	O
the	O
nonamer	O
was	O
partially	O
purified	O
by	O
ion	O
exchange	O

chromatography	O
on	O
a	O
DEAE	O
cellulose	O
column	O
.	O

This	O
step	O
,	O
which	O
resulted	O
in	O
84	O
%	O
recovery	O
of	O
material	O
loaded	O
onto	O
the	O
column	O
,	O
removed	O
most	O
of	O
the	O
shorter	O

oligomers	O
as	O
shown	O
in	O
Figure	O
2c	O
.	O

After	O
removal	O
of	O
the	O
buffer	O
,	O
the	O
nonamer	O
was	O
purified	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
0	O
.	O
1	O
M	O
ammonium	O
acetate	O
gradient	O
.	O

The	O
recovery	O
of	O
material	O
from	O
the	O
column	O

(	O
84	O
%	O
)	O
appears	O
to	O
be	O
higher	O
when	O
ammonium	O
acetate	O
is	O
used	O
.	O

The	O
pure	O
nonamer	O

(	O
Figure	O
2d	O
)	O
was	O
obtained	O
in	O
10	O
%	O
overall	O
yield	O
based	O
on	O
the	O
amount	O
of	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2	O
Tr	O
]	O
ibuG	O
originally	O
bound	O
to	O
the	O
polystyrene	O
support	O
.	O

The	O
oligomer	O
was	O
desalted	O
on	O
a	O
Bio	O
-	O
Gel	O
P	O
-	O
2	O
gel	O
filtration	O
column	O
.	O

Similar	O
results	O
were	O

obtained	O
for	O
the	O
other	O
oligomers	O
purified	O
by	O
this	O
method	O
.	O

Thus	O
,	O
for	O
example	O
dApApA	O
and	O
d	O
-	O
ApCpCpApT	O
were	O
obtained	O
in	O
44	O
%	O
and	O
22	O
%	O
isolated	O
yields	O
respectively	O
based	O
upon	O
the	O
amount	O
of	O
d	O
-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
N	O
.	O

The	O
5	O
'	O
-	O
terminal	O
nucleotide	O
may	O
be	O
removed	O
enzynatically	O
to	O
give	O
an	O

oligomer	O
which	O
contains	O
only	O
methylphosphonate	O
linkages	O
.	O

Thus	O
treatment	O
of	O

the	O
nonamer	O
,	O
d	O
-	O
ApApApApGpCpApApG	O
,	O
with	O
spleen	O
phosphodiesterase	O
gave	O
d	O
-	O
Ap	O
and	O

the	O
octamer	O
d	O
-	O
ApApApGpCpApApG	O
whose	O
retention	O
time	O
is	O
16	O
.	O
4	O
min	O
on	O
the	O
reversed	O
phase	O
column	O
.	O

The	O
noncharged	O
octamer	O
was	O
freed	O
of	O
d	O
-	O
Ap	O
and	O
enzyne	O
by	O
simply	O
passing	O
it	O
through	O
a	O
small	O
DEAE	O
cellulose	O
column	O
.	O

Characterization	O
.	O

Methylphosphonate	O
linkages	O
are	O
cleaved	O
by	O
base	O
.	O

We	O
have	O
found	O
piperdine	O
is	O
particularly	O
effective	O
.	O

The	O
cleavage	O
occurs	O
in	O
a	O
random	O
manner	O
giving	O
nucleosides	O
,	O
nucleoside	O
3	O
'	O
-	O
or	O
5	O
'	O
-	O
methylphosphonates	O
and	O

nucleoside	O
3	O
'	O
,	O
5	O
'	O
-	O
bis	O
-	O
methylphosphonates	O
.	O

This	O
hydrolysis	O
reaction	O
may	O
be	O
used	O
to	O
characterize	O
dimers	O
,	O
since	O
the	O
identity	O
and	O
ratio	O
of	O
the	O
products	O
formed	O
are	O
easily	O
determined	O
by	O
reversed	O
phase	O
HPLC	O
.	O

However	O
,	O
the	O
method	O
becomes	O
less	O
satisfactory	O
for	O
longer	O
oligomers	O
.	O

Purine	O
-	O
containing	O
oligonucleoside	O
methylphosphonates	O
may	O
be	O
depurinated	O
by	O
treatment	O
with	O
hydrochloric	O
acid	O
at	O
650	O
.	O

The	O
methylphosphonate	O
linkage	O
is	O

6238	O

Nucleic	O
Acids	O
Research	O

9	O
0	O
OH	O
cH3P	O
:	O
O	O
cH	O
CH3P	O

9	O
9	O

CH	O
-	O
P	O
:	O
O	O
C	O
cH	O
:	O
0pO	O

O	O
~	O
~	O
~	O
j4	O
HO	O
OP	O
3	O
0	O
H	O
0	O
0OH0	O

9	O
S	O
S	O

Figure	O
3	O
:	O
Hydrolysis	O
of	O
the	O
internucleoside	O
methylphsophonate	O
linkages	O
at	O
an	O

apurinic	O
site	O
produced	O
by	O
treatment	O
of	O
the	O
oligomer	O
with	O
hydrochloric	O
acid	O
at	O
pH	O
2	O
.	O

resistant	O
to	O
hydrolysis	O
by	O
these	O
conditions	O
as	O
shown	O
by	O
the	O
stability	O
of	O
d	O
-	O
TpT	O
and	O
d	O
-	O
TpTpT	O
.	O

On	O
the	O
other	O
hand	O
,	O
dimers	O
or	O
trimers	O
containing	O
purine	O
bases	O

such	O
as	O
d	O
-	O
ApA	O
,	O
dApT	O
,	O
dTpA	O
or	O
d	O
-	O
ApApA	O
have	O
half	O
-	O
lives	O
between	O
92	O
and	O
144	O
min	O
in	O
0	O
.	O
01	O
M	O
hydrochloric	O
acid	O
.	O

Following	O
neutralization	O
with	O
ammonium	O
hydroxide	O
,	O
the	O
products	O
of	O
these	O
reactions	O
were	O
characterized	O
by	O
reversed	O
phase	O
HPLC	O
.	O

d	O
-	O
ApA	O
gave	O
adenine	O
,	O
while	O
both	O
d	O
-	O
ApT	O
and	O
d	O
-	O
TpA	O
gave	O
adenine	O
and	O
thymidine	O
as	O
the	O
sole	O
products	O
of	O
the	O
reaction	O
.	O

Adenine	O
and	O
d	O
-	O
ApA	O
were	O
the	O
only	O
products	O

observed	O
when	O
d	O
-	O
ApApA	O
was	O
partially	O
hydrolyzed	O
.	O

When	O
d	O
-	O
CpCpApT	O
was	O
completely	O
hydrolyzed	O
in	O
acid	O
three	O
products	O
,	O
d	O
-	O
CpC	O
,	O
adenine	O
and	O
thynidine	O
,	O
were	O
observed	O
in	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
1	O
:	O
1	O
.	O

In	O
contrast	O
to	O
the	O
base	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
group	O
,	O
apurinic	O
sites	O
produced	O
by	O
acid	O
treatment	O
are	O
further	O
hydrolyzed	O
to	O

nucleosides	O
or	O
oligomers	O
with	O
free	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
OH	O
groups	O
.	O

The	O
absence	O
of	O

terminal	O
phosphonate	O
residues	O
suggests	O
hydrolysis	O
occurs	O
as	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
OH	O
group	O
on	O
the	O
4	O
'	O
-	O
carbon	O
generated	O
by	O
opening	O
the	O
ribose	O
at	O
the	O
apurinic	O
site	O
may	O
participate	O
in	O
an	O
intramolecular	O
attack	O
on	O
the	O
adjacent	O
phosphonate	O
linkages	O
which	O
results	O
in	O
removal	O
of	O
the	O
phosphonate	O
residues	O
from	O
the	O
neighboring	O
nucleoside	O
hydroxyls	O
.	O

Previous	O
studies	O
by	O
Agarwal	O
and	O
Riftina	O
indicated	O
dithymidine	O
methyl	O
-	O
or	O
phenylphosphonates	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
(	O
9	O
)	O
.	O

Sinha	O
et	O
al	O
.	O
reported	O
that	O
dimers	O
but	O
not	O
trimers	O
or	O
tetramers	O
served	O
as	O

substrates	O
for	O
this	O
enzyme	O
(	O
4	O
)	O
.	O

We	O
were	O
unable	O
to	O
phosphorylate	O
tetramers	O
or	O
longer	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
.	O

However	O
,	O
those	O
oligomers	O
which	O
terminate	O
with	O
a	O
5	O
'	O
-	O
dAp	O
-	O
residue	O
are	O
readily	O

6239	O

Nucleic	O
Acids	O
Research	O

a	O

ATP	O
1	O

1	O
2	O
3	O
4	O

b	O

6	O
mer	O
Mik	O

6	O
mer	O
go	O

3mer	O
a	O
a	O
a	O
X	O
2mer	O
do	O
ATP	O
411	O

12	O
w	O
34	O

1	O
2	O
3	O
4	O
5	O
6	O

Figure	O
4	O
:	O
(	O
a	O
)	O
PEI	O
-	O
cellulose	O
TLC	O
of	O
T4	O
polynucleotide	O
kinase	O
reactions	O
.	O

1	O
)	O
[	O
y	O
-	O
32p	O
]	O
ATP	O
;	O
2	O
)	O
d	O
-	O
ApApA	O
reaction	O
mixture	O
;	O
3	O
)	O
d	O
-	O
ApGpCpApApG	O

reaction	O
mixture	O
;	O
4	O
)	O
d	O
-	O
ApApApApG	O
_	O
pCpApAeG	O
reaction	O
mixture	O
.	O

The	O
chromatogram	O
was	O
eluted	O
wi	O
th1	O
.	O
5	O
M	O
pyridinium	O
formate	O
,	O
pH	O
3	O
.	O
5	O
.	O

(	O
b	O
)	O
Polyacrylamide	O
gel	O
electrophoresis	O
of	O
phosphoryljted	O

olihonucleoside	O
methylghosphonates	O
.	O

1	O
)	O
markers	O
:	O
d	O
-	O
pTpT	O
(	O
2	O
mer	O
)	O
;	O
d	O
-	O
,	O
3pApApA	O
(	O
3	O
mer	O
)	O
;	O
d	O
-	O
2pApGpCpApApG	O
(	O
6	O
mer	O
)	O
;	O

d	O
-	O
32pApApApApGpCpApApG	O
(	O
9	O
mer	O
.	O

Lanes	O
2	O
-	O
4	O
:	O
products	O
obtained	O

after	O
partTaT	O
fy	O
?	O
rlysis	O
of	O
dl2pApApA	O
(	O
2	O
)	O
;	O
d	O
-	O
2pApGpCpApApG	O
(	O
3	O
)	O
and	O
d	O
-	O
32pApARApApGpCpAZARG	O
;	O
(	O
4	O
)	O
with	O
0	O
.	O
5	O
M	O
piperidine	O
at	O
377C	O
for	O
10	O
min	O
Lanel	O
t	O
:	O
products	O
obtained	O
Wfter	O
partial	O
hydrolysis	O
of	O
d	O
-	O
3Kp	O
-	O
ApGRCpApApG	O
(	O
5	O
)	O
and	O
d	O
-	O
32p	O
-	O
ApApAppGpjCppAjG	O
(	O
6	O
)	O
with	O
0	O
.	O
5	O
M	O
HC1	O
at	O
371C	O
fCor30	O
min	O
.	O

Electrophoresis	O
was	O
carried	O
out	O
at	O

constant	O
voltage	O
(	O
800	O
v	O
)	O
until	O
the	O
bromphenol	O
blue	O
marker	O
dye	O
had	O
migrated	O
halfway	O
down	O
the	O
gel	O
.	O

phosphorylated	O
by	O
polynucleotide	O
kinase	O
.	O

The	O
phosphorylation	O
reaction	O
is	O
easily	O
followed	O
by	O
PEI	O
-	O
cellulose	O
TLC	O
.	O

As	O
shown	O
in	O
Figure	O
4a	O
,	O
the	O
phosphorylated	O
oligomers	O
have	O
a	O
higher	O
Rf	O
values	O
than	O
does	O
d	O
-	O
ATP	O
.	O

The	O
phosphorylated	O
methylphosphonate	O
oligomers	O
can	O
be	O
separated	O
according	O
to	O
their	O
chain	O
lengths	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
on	O
an	O
18	O
%	O
gel	O

containing	O
7	O
M	O
urea	O
as	O
shown	O
in	O
Figure	O
4	O
(	O
b	O
)	O
.	O

Lane	O
1	O
shows	O
the	O
separation	O
of	O
a	O
trimer	O
,	O
hexamer	O
and	O
nonamer	O
.	O

The	O
band	O
which	O
appears	O
directly	O
below	O
the	O

nonamer	O
may	O
arise	O
from	O
traces	O
of	O
contaminating	O
octamer	O
which	O
were	O
not	O
removed	O
during	O
the	O
purification	O
of	O
d	O
-	O
ApApApApGpCpApApG	O
.	O

6240	O

Nucleic	O
Acids	O
Research	O

When	O
the	O
oligomers	O
were	O
partially	O
hydrolyzed	O
with	O
piperidine	O
,	O
a	O
series	O
of	O
new	O
bands	O
appears	O
corresponding	O
to	O
shorter	O
oligomers	O
produced	O
via	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
(	O
Lanes	O
2	O
-	O
4	O
)	O
.	O

Because	O
of	O
the	O
random	O
nature	O
of	O
this	O
cleavage	O
reaction	O
,	O
the	O
oligomers	O
should	O
terminate	O
with	O
either	O
a	O
3	O
'	O
-	O
OH	O
or	O
a	O
3	O
'	O
-	O
methylphosphonate	O
group	O
.	O

In	O
the	O
case	O
of	O
the	O
trimer	O
,	O
32pApApA	O
,	O

hydrolysis	O
gives	O
two	O
bands	O
which	O
correspond	O
to	O
d	O
-	O
32pApA	O
and	O
d	O
-	O
32pApAp	O
(	O
Lane	O
2	O
)	O
.	O

The	O
same	O
products	O
are	O
observed	O
for	O
hydrolysis	O
of	O
the	O
nonamer	O
,	O

d	O
-	O
32pApApApApGpCpApApG	O
(	O
Lane	O
4	O
)	O
.	O

A	O
similar	O
situation	O
is	O
observed	O
for	O

d32pApGpCpApApG	O
although	O
the	O
dimers	O
d	O
-	O
32pApG	O
and	O
d	O
-	O
32pApGp	O
have	O
somewhat	O

different	O
mobilities	O
(	O
Lane	O
3	O
)	O
.	O

These	O
dimers	O
cannot	O
be	O
separated	O
when	O
the	O
gel	O
is	O
run	O
in	O
the	O
absence	O
of	O
urea	O
.	O

It	O
is	O
possible	O
to	O
determine	O
the	O
chain	O
lengths	O
of	O
the	O
original	O
oligomers	O

by	O
counting	O
the	O
number	O
of	O
oligomers	O
produced	O
by	O
partial	O
piperidine	O
hydrolysis	O
.	O

For	O
example	O
,	O
starting	O
with	O
the	O
trimer	O
band	O
,	O
one	O
can	O
observe	O
3	O
bands	O

corresponding	O
to	O
tetramer	O
,	O
pentamer	O
and	O
hexamer	O
for	O
the	O
hydrolysis	O
products	O
of	O
d	O
-	O
32pApGpCpApApG	O
(	O
Lane	O
3	O
)	O
and	O
6	O
bands	O
corresponding	O
to	O
tetramer	O
,	O
pentamer	O
,	O
hexamer	O
,	O
heptamer	O
,	O
octamer	O
and	O
nonamer	O
for	O
the	O
hydrolysis	O
products	O
of	O

32pApApApApGpCpApApG	O
(	O
Lane	O
4	O
)	O
.	O

The	O
positions	O
of	O
the	O
oligomers	O
of	O
the	O
same	O

chain	O
length	O
appear	O
to	O
be	O
very	O
similar	O
which	O
suggests	O
that	O
the	O
mobilities	O
are	O
not	O
greatly	O
affected	O
by	O
base	O
composition	O
on	O
the	O
urea	O
-	O
containing	O
gel	O
.	O

This	O

procedure	O
thus	O
provides	O
a	O
rapid	O
and	O
convenient	O
method	O
for	O
characterizing	O
the	O
methyl	O
phosphonate	O
ol	O
i	O
gomers	O
.	O

Treatment	O
of	O
the	O
phosphorylated	O
oligomers	O
with	O
acid	O
produces	O
shorter	O

oligomers	O
which	O
result	O
from	O
chain	O
cleavage	O
at	O
apurinic	O
sites	O
.	O

In	O
this	O
case	O
the	O
oligomers	O
terminate	O
with	O
a	O
3	O
'	O
-	O
OH	O
group	O
.	O

Treatment	O
of	O
32pApGpCpApALpG	O

produces	O
an	O
intense	O
band	O
corresponding	O
to	O
the	O
pentamer	O
,	O
d	O
-	O
32pApGjCpAjA	O
(	O
Lane	O
5	O
)	O
while	O
treatment	O
of	O
32pApApApApGpCpApApG	O
produces	O
an	O
intense	O
band	O
corresponding	O
to	O
the	O
octamer	O
d	O
-	O
32pApApAPApGpCpApA	O
and	O
fainter	O
bands	O

corresponding	O
to	O
the	O
heptamer	O
,	O
hexamer	O
,	O
tetramer	O
and	O
trimer	O
.	O

These	O
results	O
suggest	O
that	O
under	O
the	O
conditions	O
of	O
the	O
experiment	O
,	O
hydrolysis	O
occurs	O
preferentially	O
at	O
the	O
3	O
'	O
-	O
terminal	O
G	O
residue	O
of	O
both	O
oligomers	O
.	O

It	O
should	O
be	O
possible	O
to	O
extend	O
this	O
methodology	O
to	O
other	O
base	O
specific	O

depurination	O
or	O
depyrimidination	O
reactions	O
similar	O
to	O
those	O
employed	O
in	O
the	O
Maxam	O
-	O
Gilbert	O
sequencing	O
method	O
(	O
10	O
)	O
.	O

Experiments	O
directed	O
toward	O
this	O
goal	O
are	O
currently	O
in	O
progress	O
and	O
will	O
be	O
reported	O
in	O
a	O
future	O
communication	O
.	O

ACKNOWLEDGEMENT	O
:	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
the	O
following	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
:	O
GM	O
16066	O
(	O
P	O
.	O
O	O
.	O
P	O
.	O
T	O
.	O
)	O
and	O
GM	O
31927	O

6241	O

Nucleic	O
Acids	O
Research	O

(	O
P	O
.	O
S	O
.	O
M	O
.	O
)	O
,	O
and	O
from	O
a	O
grant	O
from	O
Association	O
for	O
International	O
Cancer	O
Research	O
.	O

REFERENCES	O
:	O

1	O
.	O

MTTITr	O
,	O
P	O
.	O
S	O
.	O
,	O
McParland	O
,	O
K	O
.	O
B	O
.	O
,	O
Jayaraman	O
,	O
K	O
.	O
and	O
Ts	O
'	O
o	O
,	O
P	O
.	O
O	O
.	O
P	O
.	O

(	O
1981	O
)	O

Biochemistry	O
20	O
,	O
1874	O
-	O
1880	O
.	O

2	O
.	O

Jayaraman	O
,	O
K	O
.	O
,	O
McParland	O
,	O
K	O
.	O
B	O
.	O
,	O
Miller	O
,	O
P	O
.	O
S	O
.	O
and	O
Ts	O
'	O
o	O
,	O
P	O
.	O
O	O
.	O
P	O
.	O

(	O
1981	O
)	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

78	O
,	O
1537	O
-	O
1541	O
.	O

3	O
.	O

Miller	O
,	O
P	O
.	O
S	O
.	O
,	O
Agris	O
,	O
C	O
.	O
H	O
.	O
,	O
Blandin	O
,	O
M	O
.	O
,	O
Murakami	O
,	O
A	O
.	O
,	O
Reddy	O
,	O
P	O
.	O
M	O
.	O
,	O

Spitz	O
,	O
S	O
.	O
A	O
.	O
and	O
Ts	O
'	O
o	O
,	O
P	O
.	O
O	O
.	O
P	O
.	O

(	O
1983	O
)	O
Nucleic	O
Acids	O
Res	O
.	O
,	O
submitted	O
for	O
publ	O
ication	O
.	O

4	O
.	O

Sinha	O
,	O
N	O
.	O
D	O
.	O

Grossbruchaus	O
,	O
V	O
.	O
and	O
Koester	O
,	O
H	O
.	O

(	O
1983	O
)	O
Tetrahedron	O
Letters	O

24	O
,	O
877	O
-	O
880	O
.	O

5	O
.	O

Miller	O
,	O
P	O
.	O
S	O
.	O
,	O
Cheng	O
,	O
D	O
.	O
M	O
.	O
,	O
Dreon	O
,	O
N	O
.	O
,	O
Jayaraman	O
,	O
K	O
.	O
,	O
Kan	O
,	O
L	O
.	O
-	O
S	O
.	O
,	O

Leutzinger	O
,	O
E	O
.	O
E	O
.	O
,	O
Pulford	O
,	O
S	O
.	O
M	O
.	O
and	O
Ts	O
'	O
o	O
,	O
P	O
.	O
O	O
.	O
P	O
.	O

(	O
1980	O
)	O
Biochemistry	O
19	O
,	O
4688	O
-	O
4698	O
.	O

6	O
.	O

Ito	O
,	O
H	O
.	O
,	O
Ike	O
,	O
Y	O
.	O
,	O
Ikuta	O
,	O
S	O
.	O
and	O
Itakura	O
,	O
K	O
.	O
,	O
(	O
1982	O
)	O
Nucleic	O
Acids	O
Res	O

10	O
,	O
1755	O
-	O
1769	O
.	O

7	O
.	O

Barnett	O
,	O
R	O
.	O
W	O
.	O
and	O
Letsinger	O
,	O
R	O
.	O
L	O
.	O

(	O
1981	O
)	O
Tetrahedron	O
Letters	O
22	O
,	O

991	O
-	O
994	O
.	O

6242	O

Further	O
studies	O
on	O
partially	O
purified	O
calf	S-Species
thymus	O
DNA	O
polymerase	O
a	O
.	O

Abstract	O

Attempts	O
to	O
prevent	O
the	O
urea	O
conversion	O
of	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
DNA	O
polymerase	O
alpha	O
to	O
a	O
150	O
-	O
170	O
,	O
000	O
molecular	O
weight	O
form	O
by	O
the	O
inclusion	O
of	O
protease	O
inhibitors	O
have	O
not	O
been	O
successful	O
.	O

No	O
other	O
method	O
has	O
been	O
found	O
capable	O
of	O
dissociating	O
a	O
50	O
-	O
70	O
,	O
000	O
fragment	O
or	O
subunit	O
from	O
the	O
DNA	O
polymerase	O
subunit	O
.	O

Addition	O
of	O
this	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
does	O
not	O
aid	O
the	O
binding	O
of	O
the	O
enzyme	O
to	O
DNA	O
,	O
but	O
does	O
have	O
an	O
effect	O
on	O
the	O
utilisation	O
of	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
by	O
the	O
polymerase	O
subunit	O
.	O

Volume	O
6	O
Number	O
10	O
1979	O

Nucleic	O
Acids	O
Research	O

Further	O
studies	O
on	O
partially	O
purified	O
calf	S-Species
thymus	O
DNA	O
polymerase	O
a	O
Keith	O
McKune	O
and	O
Andrew	O
M	O
.	O
Holmes	O
*	O

Biochemistry	O
Department	O
,	O
Strathclyde	O
University	O
,	O
The	O
Todd	O
Centre	O
,	O
31	O
Taylor	O
Street	O
,	O
Glasgow	O
,	O
G4	O
ONR	O
,	O
UK	O

Received	O
I	O
June	O
1979	O
ABSTRACT	O

Attempts	O
to	O
prevent	O
the	O
urea	O
conversion	O
of	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
DNA	O
polymerase	O
a	O
to	O
a	O
150	O
-	O
170	O
,	O
000	O
molecular	O
weight	O
form	O
by	O
the	O

inclusion	O
of	O
protease	O
inhibitors	O
have	O
not	O
been	O
successful	O
.	O

No	O
other	O
method	O
has	O
been	O
found	O
capable	O
of	O
dissociating	O
a	O
50	O
-	O
70	O
,	O
000	O
fragment	O
or	O
subunit	O
from	O
the	O
DNA	O
polymerase	O
subunit	O
.	O

Addition	O
of	O
this	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
does	O
not	O
aid	O
the	O
binding	O
of	O
the	O
enzyme	O
to	O
DNA	O
,	O
but	O
does	O
have	O
an	O
effect	O
on	O
the	O
utilisation	O
of	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
by	O
the	O
polymerase	O
subunit	O
.	O

INTRODUCTION	O

In	O
mammals	O
DNA	O
polymerase	O
a	O
is	O
thought	O
to	O
be	O
the	O
replicative	O

enzyme	O
,	O
but	O
due	O
to	O
low	O
levels	O
of	O
activity	O
,	O
even	O
in	O
tissues	O
actively	O
making	O
DNA	O
,	O
and	O
to	O
enzyme	O
heterogeneity	O
it	O
has	O
been	O
found	O
difficult	O
to	O
purify	O

However	O
,	O
small	O
samples	O
of	O
DNA	O
polymerase	O
a	O
have	O
been	O
highly	O
purified	O

2	O
,	O
3	O
,	O
4	O
,	O
5	O
from	O
several	O
sources	O
and	O
partially	O
characterised	O

Heterogeneity	O
has	O
been	O
observed	O
in	O
DNA	O
polymerase	O
a	O
from	O
a	O
var	O

6	O
7	O

iety	O
of	O
sources	O
,	O
including	O
rat	S-Species
liver	O
and	O
spleen	O
,	O
Hela	O
cells	O
,	O
baby	O
hamster	O

8	O
9	O
,	O
10	O
11	O

kidney	O
cells	O
,	O
mouse	S-Species
myeloma	O
,	O
Drosophila	S-Species
embryos	O
and	O
calf	S-Species
thymus	O

1	O
,	O
6	O
,	O
12	O
,	O
13	O
.	O

We	O
have	O
previously	O
observed	O
several	O
species	O
of	O
calf	S-Species
thymus	O

DNA	O
polymerase	O
a	O
differing	O
in	O
size	O
and	O
charge	O
.	O

In	O
order	O
of	O
elution	O
from	O
DEAE	O
cellulose	O
they	O
are	O
enzyme	O
A1	O
(	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
)	O
,	O
A2	O
(	O
200	O
-	O
230	O
,	O
000	O
)	O
,	O
B	O
(	O
100	O
-	O
110	O
,	O
000	O
)	O
and	O
C	O
(	O
150	O
-	O
170	O
,	O
000	O
)	O
.	O

A	O
poly	O
(	O
dA	O
)	O
.	O
oligo	O

(	O
dT	O
)	O
10	O
preferring	O
enzyme	O
,	O
enzyrrme	O
D	O
(	O
140	O
-	O
150	O
,	O
000	O
molecular	O
weight	O
)	O
elutes	O
just	O
after	O
enzyme	O
B	O
.	O

The	O
A	O
enzymes	O
seem	O
identical	O
in	O
all	O
properties	O
except	O
their	O
charge	O
.	O

5	O
.	O
0	O
-	O
5	O
.	O

5S	O
enzymes	O
,	O
analagous	O
to	O
B	O
,	O
have	O
been	O
observed	O
to	O

C	O
Information	O
Retrieval	O
Limited	O
1	O
Falconberg	O
Court	O
London	O
Wl	O
V	O
5FG	O
England	O

3341	O

Nucleic	O
Acids	O
Research	O

arise	O
as	O
the	O
result	O
of	O
proteolytic	O
action	O
'	O
,	O
similarly	O
the	O
B	O
enzyme	O
above	O
14	O

,	O
but	O
the	O
relationship	O
of	O
the	O
other	O
observed	O
species	O
is	O
not	O
clear	O
,	O
nor	O
is	O

the	O
problem	O
of	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
species	O
is	O
the	O
replicative	O
enzyme	O
,	O

although	O
circumstantial	O
evidence	O
has	O
implicated	O
a	O
DNA	O
polymerase	O
a	O
to	O
be	O

15	O
the	O
replicative	O
enzyme	O
in	O
adenovirus	S-Species
infected	O
KB	O
cells	O

We	O
have	O
previously	O
shown	O
that	O
several	O
of	O
these	O
enzymes	O
are	O
inter	O

16	O

convertible	O
.	O

In	O
particular	O
,	O
mild	O
urea	O
treatment	O
can	O
convert	O
both	O
A	O

enzymes	O
to	O
C	O
enzyme	O
,	O
with	O
the	O
loss	O
of	O
a	O
subunit	O
or	O
fragment	O
of	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
.	O

The	O
C	O
enzyme	O
retains	O
DNA	O
polymerase	O
activity	O
,	O
but	O

does	O
show	O
differences	O
compared	O
to	O
A	O
enzyme	O
in	O
heat	O
sensitivity	O
and	O
sensitivity	O
to	O
N	O
-	O
ethylmaleimide	O
.	O

Highly	O
purified	O
samples	O
of	O
A	O
and	O
C	O
enzymes	O
when	O
subjected	O
to	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
have	O
shown	O
a	O
corre	O

lation	O
of	O
DNA	O
polymerase	O
activity	O
with	O
a	O
polypeptide	O
band	O
155	O
,	O
000	O
molecular	O
weight	O
.	O

Contaminating	O
material	O
of	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
appeared	O

to	O
obscure	O
the	O
putative	O
50	O
-	O
70	O
,	O
000	O
subunit	O
in	O
gels	O
of	O
A	O
enzyme	O
.	O

The	O
conclusions	O
drawn	O
were	O
that	O
DNA	O
polymerase	O
a	O
is	O
a	O
155	O
,	O
000	O
molecular	O
weight	O

polypeptide	O
(	O
C	O
enzyrrme	O
)	O
which	O
can	O
and	O
does	O
associated	O
with	O
material	O
of	O
50	O

70	O
,	O
000	O
molecular	O
weight	O
to	O
give	O
A	O
enzyme	O
,	O
and	O
that	O
enzyme	O
B	O
is	O
a	O
proteol	O

14	O

ytic	O
degradation	O
product	O
.	O

The	O
relationship	O
of	O
enzyme	O
D	O
to	O
the	O
others	O
is	O

not	O
clear	O
.	O

It	O
is	O
possible	O
that	O
during	O
the	O
enzyme	O
isolation	O
procedure	O
proteolytic	O
action	O
may	O
have	O
taken	O
place	O
on	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
enzyme	O
releasing	O
155	O
,	O
000	O
and	O
50	O
-	O
70	O
,	O
000	O
fragments	O
which	O
remain	O
in	O
association	O

until	O
urea	O
treatment	O
separates	O
them	O
.	O

It	O
is	O
also	O
possible	O
that	O
urea	O
treatment	O
itself	O
renders	O
the	O
enzyme	O
susceptible	O
to	O
contaminating	O
proteases	O
.	O

Further	O
experiments	O
to	O
ascertain	O
whether	O
or	O
not	O
this	O
is	O
the	O
case	O
and	O
,	O
if	O
so	O
,	O
to	O
prevent	O
it	O
,	O
have	O
been	O
carried	O
out	O
.	O

A	O
enzyme	O
can	O
be	O
reconstituted	O
from	O
C	O
enzyme	O
formed	O
by	O
the	O
action	O

of	O
urea	O
on	O
A	O
enzyme	O
by	O
concentrating	O
it	O
with	O
the	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
material	O
.	O

The	O
A	O
enzyrme	O
obtained	O
in	O
this	O
manner	O
is	O
highly	O
purified	O
,	O
as	O
is	O

the	O
C	O
enzyme	O
formed	O
by	O
the	O
urea	O
treatment	O
,	O
and	O
has	O
been	O
used	O
in	O
attempts	O
to	O
show	O
differences	O
in	O
synthetic	O
template	O
-	O
initiator	O
complex	O
utilisation	O

3342	O

Nucleic	O
Acids	O
Research	O

b	O
y	O
the	O
se	O
two	O
enzyme	O
s	O
.	O

MATERIALS	O
AND	O
METHODS	O

Calf	S-Species
thymus	O
was	O
obtained	O
from	O
10	O
-	O
16	O
week	O
old	O
calves	S-Species
and	O
frozen	O
at	O

-	O
20	O
?	O
C	O
until	O
required	O
.	O

Chromatographic	O
media	O
and	O
chemicals	O
were	O
obtained	O

6	O

from	O
sources	O
previously	O
referred	O
to	O
.	O

Radioactive	O
deoxynucleoside	O
tri	O

phosphates	O
were	O
obtained	O
from	O
the	O
Radiochemical	O
Centre	O
,	O
Amersham	O
,	O
Bucks	O
.	O

Synthetic	O
oligo	O
and	O
polynucleotides	O
were	O
obtained	O
from	O
P	O
.	O

L	O
.	O

Biochemicals	O

Inc	O
.	O
,	O
except	O
for	O
poly	O
(	O
dC	O
)	O
which	O
was	O
a	O
gift	O
from	O
Dr	O
.	O
I	O
.	O
R	O
.	O

Johnston	O
and	O
pre	O

17	O

pared	O
from	O
oligo	O
d	O
(	O
C	O
)	O
5	O
as	O
described	O
.	O

N	O
-	O
a	O
-	O
p	O
Tosyl	O
-	O
L	O
-	O
lysine	O
chloromethy	O

lketone	O
HCl	O
and	O
phenylmethylsulphonylfluoride	O
were	O
obtained	O
from	O
Sigma	O
and	O
Trasylol	O
from	O
Bayer	O
.	O

Except	O
where	O
indicated	O
all	O
buffers	O
contained	O
20	O
%	O
w	O
/	O
v	O
glycerol	O
and	O

1	O
mM	O
dithiothreitol	O
.	O

Standard	O
linear	O
phosphate	O
gradients	O
were	O
run	O
between	O
0	O
.	O
03	O
M	O
and	O
0	O
.	O
25	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
8	O
.	O

Gradient	O
salt	O
concentr	O

2	O

ations	O
were	O
measured	O
using	O
a	O
conductivity	O
meter	O
as	O
described	O
.	O

Urea	O
was	O

prepared	O
as	O
a	O
4	O
.	O

8	O
M	O
solution	O
in	O
20	O
%	O
w	O
/	O
v	O
glycerol	O
,	O
stirred	O
with	O
Amberlite	O

MB3	O
and	O
filtered	O
.	O

Dithiothreitol	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
1	O
mM	O
before	O
use	O
.	O

6	O
DNA	O
polymerase	O
was	O
assayed	O
using	O
activated	O
DNA	O
as	O
described	O

except	O
that	O
the	O
buffer	O
was	O
50	O
mM	O
tris	O
HC1	O
,	O
pH	O
7	O
.	O
8	O
.	O

One	O
unit	O
of	O
DNA	O
polymerase	O
activity	O
incorporates	O
ln	O
mol	O
[	O
H	O
]	O
dTMP	O
into	O
an	O
acid	O
insoluble	O
form	O
in	O
one	O
hour	O
at	O
370C	O
.	O

Assays	O
using	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
were	O
carried	O
out	O
at	O
30	O
?	O
C	O
in	O
0	O
.	O

12	O
ml	O
.	O

The	O
template	O
-	O
initiator	O
complexes	O

6	O

were	O
prepared	O
and	O
assays	O
processed	O
as	O
described	O
.	O

All	O
assays	O
contained	O

1	O
mM	O
dithiothreitol	O
,	O
62	O
.	O

5	O
p	O
.	O
g	O
bovine	S-Species
serum	O
albumin	O
,	O
1	O
,	O
ug	O
template	O
-	O
initiator	O
complex	O
,	O
enzyme	O
protein	O
and	O
the	O
relevant	O
[	O
H	O
]	O
deoxynucleoside	O
triphosphate	O
at	O
0	O
.	O
1	O
mM	O
and	O
12	O
-	O
15	O
cpm	O
/	O
pmol	O
.	O

These	O
assays	O
were	O
carried	O
out	O
at	O
either	O
pH	O
6	O
.	O
4	O
in	O
20	O
mM	O
sodium	O
-	O
potassium	O
phosphate	O
,	O
or	O
at	O
pH	O
7	O
.	O
8	O
in	O
50	O
mM	O
tris	O
HCl	O
and	O
contained	O
either	O
10	O
mM	O
MgCl2	O
or	O
1	O
mM	O
MnCl2	O
as	O
indicated	O
.	O

Preliminary	O
purification	O
of	O
DNA	O
polymerase	O
a	O
to	O
Fraction	O
IV	O
was	O
as	O

6	O

described	O
,	O
the	O
purification	O
steps	O
being	O
phosphocellulose	O
chromatography	O
,	O

ammonium	O
sulphate	O
precipitation	O
and	O
gel	O
filtration	O
on	O
Sepharose	O
6B	O
.	O

3343	O

Nucleic	O
Acids	O
Research	O

Enzyme	O
obtained	O
from	O
the	O
DEAE	O
cellulose	O
step	O
is	O
referred	O
to	O
as	O
Fraction	O

V	O
enzyme	O
.	O

Samples	O
were	O
prepared	O
for	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
scanned	O
as	O
previously	O
described2	O

RESULTS	O
AND	O
DISCUSSION	O

(	O
a	O
)	O
Interconversion	O
Studies	O

A	O
enzyme	O
was	O
routinely	O
converted	O
to	O
C	O
enzyme	O
by	O
incubating	O
200500	O
units	O
/	O
ml	O
of	O
Fraction	O
V	O
A	O
enzyme	O
in	O
2	O
.	O
4	O
M	O
urea	O
in	O
0	O
.	O

02	O
M	O
potassium	O

phosphate	O
,	O
pH	O
7	O
.	O
8	O
,	O
for	O
60	O
minutes	O
at	O
0	O
?	O
C	O
.	O

The	O
mixture	O
was	O
then	O
loaded	O
on	O
to	O
a	O
DEAE	O
cellulose	O
,	O
washed	O
with	O
0	O
.	O

03	O
M	O
potassium	O
phosphate	O
pH	O
7	O
.	O

8	O
,	O
and	O
enzyrme	O
eluted	O
either	O
with	O
the	O
standard	O
phosphate	O
gradient	O
or	O
batchwise	O
.	O

Under	O
these	O
conditions	O
usually	O
about	O
50	O
-	O
60	O
%	O
of	O
recovered	O
activity	O
was	O

enzyme	O
C	O
(	O
Fig	O
1	O
a	O
)	O
.	O

Overall	O
recovery	O
was	O
70	O
-	O
80	O
%	O
.	O

A	O
enzyme	O
was	O
recon	O

14	O

stituted	O
essentially	O
as	O
described	O
.	O

The	O
flow	O
through	O
material	O
from	O
the	O

DEAE	O
cellulose	O
column	O
after	O
the	O
urea	O
treatment	O
was	O
loaded	O
on	O
to	O
a	O
1	O
x	O
0	O
.	O

8	O
cm	O
phosphocellulose	O
column	O
,	O
washed	O
with	O
0	O
.	O
03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
8	O
,	O
and	O
the	O
protein	O
eluted	O
with	O
0	O
.	O
25	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O

8	O
.	O

This	O
material	O
,	O
the	O
putative	O
subunit	O
,	O
was	O
vacuum	O
dialysed	O
with	O
the	O
C	O
enzyme	O
produced	O
by	O
the	O
urea	O
treatment	O
,	O
rechromatographed	O
on	O
DEAE	O
cellulose	O
and	O
enzyme	O
eluted	O
batchwise	O
(	O
Fig	O
1	O
b	O
)	O
.	O

Recovery	O
from	O
this	O
procedure	O
was	O

usually	O
50	O
-	O
70	O
%	O
A	O
enzyme	O
.	O

Overall	O
recovery	O
was	O
30	O
-	O
40	O
%	O
of	O
the	O
C	O
enzyme	O
dialysed	O
.	O

If	O
the	O
material	O
eluted	O
from	O
the	O
phosphocellulose	O
by	O
the	O
0	O
.	O

25	O
M	O
potassium	O
phosphate	O
was	O
heated	O
to	O
90	O
?	O
C	O
for	O
5	O
minutes	O
prior	O
to	O
vacuum	O

dialysis	O
with	O
the	O
C	O
enzyme	O
the	O
recovery	O
from	O
the	O
DEAE	O
cellulose	O
column	O

was	O
significantly	O
higher	O
(	O
60	O
-	O
70	O
%	O
of	O
the	O
original	O
C	O
enzyme	O
activity	O
)	O
,	O
but	O
all	O
recoverable	O
DNA	O
polymerase	O
activity	O
was	O
C	O
enzyme	O
.	O

This	O
,	O
together	O
with	O
the	O
fact	O
that	O
the	O
60	O
minute	O
treatment	O
with	O
urea	O
has	O
,	O
on	O
occasions	O
,	O
given	O

rise	O
to	O
a	O
50	O
%	O
increase	O
in	O
DNA	O
polymerase	O
activity	O
prior	O
to	O
loading	O
on	O
to	O
the	O
DEAE	O
cellulose	O
column	O
,	O
would	O
indicate	O
that	O
A	O
enzyme	O
is	O
less	O
active	O
on	O

activated	O
DNA	O
than	O
is	O
C	O
enzyme	O
.	O

If	O
the	O
DEAE	O
cellulose	O
flow	O
through	O
material	O
came	O
from	O
urea	O
treatment	O
of	O
A2	O
enzyme	O
then	O
A2	O
was	O
produced	O
on	O
reconstitution	O
;	O
if	O
from	O
A1	O
then	O
A1	O
was	O
produced	O
.	O

Although	O
the	O
mild	O
urea	O
treatment	O
of	O
A	O
has	O
been	O
used	O
to	O
prepare	O
C	O
of	O

3344	O

Nucleic	O
Acids	O
Research	O

b	O

120	O
180	O
C	O

I	O
I	O
^	O

Figure	O
la	O
DEAE	O
cellulose	O
chromatography	O
after	O
2	O
.	O
4	O
M	O
urea	O
treatment	O
.	O

4	O
,	O
5000	O
units	O
,	O
4	O
.	O
4	O
mg	O
of	O
Fraction	O
II	O
A2	O
enzyme	O
were	O
incubated	O
with	O
urea	O
at	O
a	O
final	O
concentration	O
of	O
2	O
.	O
4	O
M	O
for	O
60	O
minutes	O
at	O
0	O
?	O
C	O
,	O
loaded	O
on	O
to	O
a	O
5	O
x	O
1	O
.	O
4	O
cm	O
DEAE	O
cellulose	O
column	O
,	O
the	O
column	O
was	O
washed	O
with	O
0	O
.	O

03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
8	O
and	O
a	O
200	O
ml	O
standard	O
phosphate	O
gradient	O
applied	O
.	O

2	O
.	O
3	O
ml	O
fractions	O
were	O
collected	O
and	O
10	O
Rl	O
assayed	O
for	O
5	O
minutes	O
.	O

(	O
o	O
-	O
o	O
)	O
no	O

phenylmethylsulphonylfluoride	O
(	O
*	O
-	O
*	O
)	O
3	O
mM	O
phenylmethylsulphonylfluoride	O
(	O
-	O
)	O
phosphate	O
gradient	O
.	O

Figure	O
lb	O
The	O
reconstitution	O
of	O
A2	O
enzyme	O
.	O

3000	O
units	O
for	O
C	O
enzyme	O

derived	O
by	O
urea	O
treatment	O
of	O
A2	O
were	O
vacuum	O
dialysed	O
with	O
the	O
DEAE	O
cellulose	O
flow	O
through	O
material	O
after	O
phosphocellulose	O
chromatography	O
and	O

chromatographed	O
on	O
a	O
2	O
x	O
1	O
.	O

2	O
cm	O
DEAE	O
cellulose	O
column	O
.	O

After	O
washing	O
with	O
0	O
.	O
03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
7	O
,	O
the	O
enzymes	O
were	O
eluted	O
batchwise	O
with	O
the	O
above	O
concentrations	O
of	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O
8	O
.	O

1	O
ml	O
fractions	O
were	O
collected	O
and	O
10	O
.	O
l	O
assayed	O
for	O
10	O
minutes	O
.	O

3345	O

Nucleic	O
Acids	O
Research	O

high	O
specific	O
activity	O
it	O
is	O
possible	O
that	O
conversion	O
of	O
the	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
enzymes	O
to	O
a	O
155	O
-	O
170	O
,	O
000	O
species	O
maybe	O
due	O
to	O
unfolding	O
of	O
the	O
molecule	O
to	O
allow	O
limited	O
attack	O
by	O
contaminating	O
proteases	O
.	O

Accord	O

ingly	O
the	O
urea	O
conversion	O
of	O
A	O
to	O
C	O
was	O
investigated	O
in	O
the	O
presence	O
of	O
certain	O
protease	O
inhibitors	O
.	O

The	O
presence	O
of	O
the	O
serine	O
protease	O
inhibitor	O

phenylmethylsulphonyl	O
-	O
fluoride	O
in	O
the	O
incubation	O
and	O
chromatography	O
buffers	O
did	O
not	O
affect	O
the	O
conversion	O
of	O
A2to	O
C	O
(	O
Fig	O
1	O
a	O
)	O
.	O

Likewise	O
trasylol	O
and	O
Na	O
-	O
p	O
Tosyl	O
-	O
L	O
-	O
lysine	O
chloromethylketone	O
HC1	O
had	O
no	O
effect	O
.	O

However	O
,	O
protease	O
action	O
could	O
have	O
occurred	O
earlier	O
in	O
the	O
purification	O
procedure	O
and	O
the	O
urea	O
could	O
be	O
separating	O
two	O
fragments	O
.	O

Usually	O
the	O
DEAE	O
cellulose	O
profile	O
shows	O
that	O
the	O
majority	O
of	O
the	O
enzyme	O
activity	O
is	O
present	O
as	O
A	O

enzyme	O
(	O
Fig	O
2	O
)	O
.	O

In	O
this	O
instance	O
A1	O
and	O
A2	O
have	O
not	O
been	O
separated	O
.	O

When	O
the	O
temperature	O
of	O
the	O
material	O
in	O
the	O
original	O
blending	O
procedure	O
was	O
kept	O
below	O
0	O
?	O
C	O
or	O
phenylmethylsulphonylfluoride	O
,	O
N	O
-	O
a	O
-	O
p	O
Tosyl	O
-	O
L	O
-	O
lysine	O
chloromethylketone	O
HCl	O
or	O
trasylol	O
was	O
included	O
in	O
the	O
isolation	O
buffers	O
the	O
DEAE	O
cellulose	O
profile	O
was	O
similar	O
.	O

The	O
A	O
enzymes	O
were	O
still	O
capable	O
of	O
conversion	O
by	O
mild	O
urea	O
treatment	O
to	O
C	O
enzyme	O
,	O
indicating	O
that	O
if	O
protease	O
activity	O
is	O
involved	O
then	O
it	O
is	O
not	O
susceptible	O
to	O
these	O
inhibitors	O
.	O

When	O
the	O
calf	S-Species

20FI	O
:	O
Now	O
~	O
~	O
~	O
20	O
20Fr	O
Na	O
06	O

Figure	O
2	O
DEAE	O
cellulose	O
elution	O
profile	O
of	O
calf	S-Species
thymus	O
DNA	O
polymerase	O
a	O
.	O

47	O
,	O
000	O
units	O
,	O
97	O
mg	O
of	O
Fraction	O
IV	O
enzyme	O
prepared	O
from	O
415	O
g	O
of	O
calf	S-Species

thymus	O
were	O
loaded	O
on	O
to	O
a	O
10	O
x	O
1	O
.	O
8	O
cm	O
DEAE	O
cellulose	O
column	O
,	O
after	O
washing	O
with	O
0	O
.	O

03	O
M	O
potassium	O
phosphate	O
,	O
pH	O
7	O
.	O

8	O
a	O
400	O
ml	O
standard	O
phosphate	O
gradient	O
was	O
applied	O
.	O

5	O
ml	O
fractions	O
were	O
collected	O
and	O
10	O
,	O
ul	O
assayed	O
for	O
5	O
minutes	O
.	O

3346	O

Nucleic	O
Acids	O
Research	O

thymus	O
was	O
allowed	O
to	O
warm	O
up	O
during	O
the	O
blending	O
procedure	O
,	O
or	O
the	O
supernatant	O
prior	O
to	O
phosphocellulose	O
chromatography	O
was	O
heated	O
to	O
37	O
?	O
C	O
for	O
30	O
minutes	O
,	O
there	O
was	O
a	O
marked	O
decrease	O
in	O
the	O
amount	O
of	O
A	O
enzyme	O
with	O
a	O
concomitant	O
increase	O
in	O
the	O
amount	O
of	O
B	O
and	O
C	O
(	O
unpublished	O
observation	O
)	O
.	O

The	O
presence	O
of	O
phenylmethylsulphonylfluoride	O
,	O
N	O
-	O
a	O
-	O
p	O
T	O
osyl	O
-	O
L	O
-	O
lysine	O

chloromethylketone	O
HCl	O
or	O
trasylol	O
under	O
these	O
conditions	O
only	O
had	O
a	O
marginal	O
effect	O
on	O
the	O
appearance	O
of	O
C	O
enzyme	O
,	O
but	O
did	O
reduce	O
the	O
amount	O
of	O
B	O

enzyme	O
.	O

Heating	O
the	O
enzyme	O
to	O
37	O
?	O
C	O
after	O
the	O
phosphocellulose	O
step	O
had	O
no	O
effect	O
on	O
the	O
DEAE	O
cellulose	O
elution	O
profile	O
.	O

Attempts	O
to	O
convert	O
A	O
enzyme	O
to	O
C	O
using	O
trypsin	O
have	O
not	O
been	O
successful	O
.	O

A	O
enzyme	O
activity	O
is	O
lost	O
without	O
the	O
appearance	O
of	O
any	O
other	O
species	O
(	O
unpublished	O
observation	O
)	O
,	O
although	O

14	O
the	O
action	O
of	O
trypsin	O
on	O
C	O
enzyme	O
can	O
give	O
rise	O
to	O
small	O
amounts	O
of	O
B	O

Although	O
the	O
conversion	O
of	O
A	O
enzyme	O
to	O
C	O
does	O
not	O
appear	O
to	O
be	O
the	O
result	O
of	O
serine	O
protease	O
action	O
,	O
proteases	O
other	O
than	O
serine	O
proteases	O

18	O

could	O
have	O
been	O
responsible	O
.	O

Also	O
,	O
the	O
fact	O
that	O
A	O
enzyme	O
can	O
be	O
recon	O

stituted	O
from	O
C	O
plus	O
the	O
flow	O
through	O
material	O
from	O
the	O
DEAE	O
cellulose	O
after	O
urea	O
treatment	O
does	O
not	O
necessarily	O
mean	O
we	O
are	O
dealing	O
with	O
two	O
subunits	O
as	O
fragments	O
produced	O
by	O
proteases	O
mray	O
be	O
reassembled	O
to	O
give	O
active	O

enzyme	O
9	O
.	O

However	O
,	O
the	O
fact	O
that	O
a	O
200	O
-	O
230	O
,	O
000	O
molecular	O
weight	O
polypeptide	O
band	O
has	O
never	O
been	O
observed	O
in	O
sodium	O
dodecylsulphate	O
polyacrylamride	O
gels	O
of	O
highly	O
purified	O
A	O
enzyme	O
,	O
or	O
even	O
cruder	O
fractions	O
of	O
A	O

enzyrre	O
(	O
unpublished	O
observation	O
)	O
,	O
may	O
be	O
significant	O
.	O

One	O
might	O
expect	O

some	O
of	O
the	O
enzyme	O
not	O
to	O
have	O
been	O
attacked	O
by	O
whatever	O
is	O
responsible	O
for	O
cleaving	O
the	O
molecule	O
,	O
if	O
,	O
indeed	O
,	O
this	O
does	O
happen	O
.	O

It	O
would	O
appear	O
,	O
therefore	O
,	O
that	O
the	O
A	O
enzyme	O
consists	O
of	O
subunits	O
of	O
155	O
,	O
000	O
and	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
with	O
the	O
small	O
subunit	O
having	O
a	O
slightly	O
different	O
charge	O
in	O
the	O

case	O
of	O
A	O
and	O
A2	O
.	O

It	O
has	O
also	O
been	O
concluded	O
that	O
the	O
heterogeneity	O
in	O
the	O

1	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
~	O
3	O
mouse	S-Species
myeloma	O
DNA	O
polymerase	O
a	O
fraction	O
is	O
not	O
due	O
to	O
proteolysis	O
.	O

However	O
,	O
the	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Sodiurrm	O
dodecylsulphate	O
polyacrylamide	O
gels	O
of	O
reconstituted	O
A	O
enzyme	O
have	O
shown	O
polypeptide	O
bands	O
at	O
150	O
-	O
160	O
,	O
000	O
and	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O

(	O
Fig	O
.	O
3	O
)	O
,	O
but	O
the	O
ratio	O
of	O
staining	O
intensity	O
of	O
the	O
bands	O
does	O
not	O
correspond	O
to	O
a	O
1	O
:	O
1	O
relationship	O
.	O

The	O
ratio	O
of	O
the	O
two	O
bands	O
is	O
variable	O
but	O
is	O
usually	O
between	O
1	O
:	O
2	O
and	O
1	O
:	O
3	O
,	O
indicating	O
,	O
perhaps	O
,	O
that	O
more	O
than	O
one	O
subunit	O
of	O
50	O

3347	O

Nucleic	O
Acids	O
Research	O

TOP	O
123	O
4	O
5	O
6	O

Figure	O
3	O
Scan	O
of	O
a	O
5	O
%	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
of	O

reconstituted	O
A2	O
enzyme	O
.	O

1500	O
units	O
of	O
reconstituted	O
A2	O
enzyme	O
were	O
subjected	O
to	O
polyacrylamide	O
gel	O
electrophoresis	O
under	O
non	O
-	O
denaturing	O
conditions	O
.	O

The	O
gels	O
were	O
sliced	O
,	O
enzyme	O
extracted	O
and	O
assayed	O
and	O
the	O
peak	O

fraction	O
of	O
DNA	O
polymerase	O
activity	O
from	O
three	O
gels	O
were	O
pooled	O
,	O
subjected	O
to	O
sodium	O
dodecyl	O
sulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
on	O
a	O
single	O

gel	O
,	O
stained	O
and	O
scanned	O
at	O
2	O
volt	O
sensitivity	O
as	O
described2	O
.	O

The	O
molecular	O
weight	O
standards	O
were	O
:	O
(	O
1	O
)	O
bovine	S-Species
serum	O
albumin	O
dimer	O
(	O
134	O
,	O
000	O
)	O
,	O
(	O
2	O
)	O
,	O
3	O
galactosidase	O
(	O
130	O
,	O
000	O
)	O
,	O
(	O
3	O
)	O
phosphorylase	O
a	O
(	O
94	O
,	O
000	O
)	O
,	O
(	O
4	O
)	O
bovine	S-Species
serum	O

albumin	O
(	O
68	O
,	O
000	O
)	O
,	O
(	O
5	O
)	O
pyruvate	O
kinase	O
(	O
57	O
,	O
000	O
)	O
and	O
(	O
6	O
)	O
lactate	O
dehydrogenase	O
(	O
35	O
,	O
000	O
)	O
.	O

70	O
,	O
000	O
molecular	O
weight	O
can	O
associate	O
with	O
the	O
155	O
,	O
000	O
subunit	O
.	O

The	O
proportion	O
of	O
the	O
lower	O
molecular	O
weight	O
polypeptide	O
band	O
is	O
higher	O
in	O
the	O
reconstituted	O
A	O
enzyrrme	O
than	O
in	O
the	O
C	O
enzyme	O
preparation	O
from	O
which	O
it	O
was	O
formed	O
,	O
but	O
even	O
the	O
C	O
enzyme	O
contained	O
some	O
material	O
in	O
the	O
region	O
.	O

Breakdown	O
of	O
material	O
from	O
155	O
,	O
000	O
to	O
50	O
-	O
70	O
,	O
000	O
may	O
be	O
partly	O
responsible	O
for	O
the	O
contamination	O
,	O
but	O
the	O
presence	O
of	O
phenylmethylsulphonylfluoride	O
in	O
samples	O
in	O
preparation	O
for	O
sodium	O
dodecylsulphate	O
polyacrylamide	O
gel	O
electrophoresis	O
has	O
not	O
been	O
successful	O
in	O
preventing	O
it	O
.	O

The	O
human	S-Species
KB	O
cell	O

DNA	O
polymerase	O
a	O
,	O
equivalent	O
to	O
the	O
C	O
enzyme	O
,	O
has	O
been	O
reported	O
to	O
consist	O

4	O

of	O
subunits	O
of	O
76	O
,	O
000	O
and	O
66	O
,	O
000	O
molecular	O
weight	O
,	O
but	O
at	O
no	O
time	O
have	O
we	O

observed	O
polypeptide	O
bands	O
at	O
76	O
,	O
000	O
and	O
66	O
,	O
000	O
rising	O
and	O
falling	O
with	O

enzyme	O
activity	O
in	O
any	O
gels	O
of	O
calf	S-Species
thyrrmus	O
enzymes	O
A1	O
,	O
A	O
and	O
C	O
(	O
and	O

2	O
unpublished	O
observations	O
)	O
.	O

(	O
b	O
)	O
Template	O
Studies	O

Use	O
has	O
been	O
made	O
of	O
the	O
urea	O
conversion	O
of	O
A	O
to	O
C	O
and	O
of	O
the	O
reconstitution	O
of	O
A	O
enzyme	O
to	O
obtain	O
samples	O
of	O
highly	O
purified	O
DNA	O
polymerase	O
,	O

specific	O
activity	O
in	O
excess	O
of	O
50	O
,	O
000	O
units	O
/	O
mg	O
,	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
this	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
on	O
the	O
DNA	O
polymerase	O
subunit	O
.	O

Previous	O
results	O
have	O
indicated	O
that	O
A	O
enzyrrme	O
is	O
stabler	O
to	O
heat	O
and	O
less	O

3348	O

Nucleic	O
Acids	O
Research	O

14	O
,	O
21	O

susceptible	O
to	O
N	O
-	O
ethylmaleimide	O
than	O
C	O
enzyme	O
.	O

It	O
has	O
been	O
reported	O

that	O
highly	O
purified	O
DNA	O
polymerase	O
a	O
can	O
be	O
associated	O
with	O
a	O
protein	O
capable	O
of	O
binding	O
to	O
DNA	O
containing	O
no	O
3	O
'	O
OH	O
ends	O
and	O
capable	O
of	O
being	O
released	O
during	O
the	O
DNA	O
polymerase	O
assay	O
.	O

Attempts	O
to	O
dissociate	O
the	O
50	O

70	O
,	O
000	O
molecular	O
weight	O
subunit	O
from	O
the	O
polymerase	O
subunit	O
by	O
incubating	O
A2	O
with	O
DNA	O
polymerase	O
reaction	O
mixes	O
containing	O
activated	O
DNA	O
,	O
poly	O

(	O
dA	O
-	O
T	O
)	O
and	O
poly	O
(	O
dT	O
)	O
.	O
oligo	O
(	O
A	O
)	O
10	O
followed	O
by	O
ultracentrifugation	O
in	O
high	O
salt	O
have	O
been	O
unsuccessful	O
.	O

Similarly	O
A	O
absorbed	O
and	O
eluted	O
from	O
either	O
native	O
or	O
denatured	O
DNA	O
cellulose	O
remained	O
A	O
enzyme	O
.	O

Both	O
A	O
and	O
C	O
enzymes	O

were	O
eluted	O
from	O
the	O
DNA	O
celluloses	O
by	O
less	O
than	O
0	O
.	O

1	O
M	O
NaCl	O
so	O
it	O
does	O
not	O
appear	O
that	O
the	O
subunit	O
enhances	O
the	O
binding	O
of	O
the	O
DNA	O
polymerase	O
subunit	O
to	O
DNA	O
.	O

However	O
,	O
there	O
are	O
differences	O
in	O
the	O
response	O
of	O
A	O
and	O
C	O

enzymes	O
to	O
synthetic	O
template	O
-	O
initiator	O
complexes	O
(	O
Table	O
1	O
)	O
.	O

Even	O
if	O
one	O
takes	O
into	O
account	O
the	O
fact	O
that	O
A	O
enzyme	O
is	O
less	O
active	O
on	O
activated	O
DNA	O

than	O
C	O
enzyme	O
(	O
the	O
addition	O
of	O
the	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
appears	O
to	O
result	O
in	O
a	O
decrease	O
of	O
about	O
30	O
%	O
of	O
polymerase	O
activity	O
on	O
activated	O
DNA	O
)	O
the	O
A	O
enzyme	O
is	O
still	O
more	O
active	O
on	O
these	O
templates	O
.	O

Although	O
there	O
is	O
a	O
variation	O
in	O
activity	O
on	O
these	O
template	O
-	O
initiator	O
comp	O

lexes	O
each	O
time	O
assays	O
are	O
carried	O
out	O
on	O
them	O
depending	O
on	O
the	O
method	O
of	O
preparing	O
the	O
complexes	O
and	O
the	O
base	O
ratio	O
of	O
template	O
to	O
initiator	O
,	O
A	O
enzyme	O
always	O
seems	O
to	O
be	O
significantly	O
more	O
active	O
than	O
C	O
.	O

The	O
A2	O

enzyme	O
at	O
pH	O
7	O
.	O
8	O
,	O
with	O
extra	O
subunit	O
(	O
s	O
)	O
is	O
clearly	O
more	O
effective	O
on	O
the	O

oligoribonucleotide	O
initiator	O
,	O
oligo	O
(	O
A	O
)	O
10	O
than	O
is	O
enzyme	O
C	O
.	O

In	O
view	O
of	O
the	O
proposed	O
RNA	O
initiation	O
of	O
Okazaki	O
pieces	O
this	O
may	O
indicate	O
a	O
role	O
of	O
this	O
subunit	O
in	O
Okazaki	O
piece	O
synthesis	O
,	O
in	O
that	O
it	O
may	O
aid	O
the	O
DNA	O
polymerase	O
to	O
'	O
take	O
over	O
'	O
from	O
the	O
RNA	O
polymerase	O
.	O

Using	O
poly	O
(	O
dA	O
)	O
.	O
oligo	O
(	O
dT	O
)	O
10	O

(	O
A	O
:	O
T	O
=	O
20	O
:	O
1	O
)	O
and	O
following	O
the	O
incorporation	O
of	O
[	O
H	O
]	O
dTMP	O
as	O
a	O
function	O
of	O
time	O
a	O
short	O
lag	O
was	O
observed	O
for	O
C	O
enzyme	O
,	O
but	O
not	O
for	O
A2	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Similar	O
re	O
sult	O
s	O
we	O
re	O
obtained	O
when	O
poly	O
(	O
dC	O
)	O
.	O
oligo	O
(	O
dG	O
)	O
1	O
0	O
(	O
C	O
:	O
G	O
=	O
5	O
:	O
1	O
)	O
wa	O
s	O

used	O
as	O
temrrplate	O
-	O
initiator	O
,	O
but	O
not	O
when	O
poly	O
(	O
dT	O
)	O
.	O
oligo	O
(	O
A	O
)	O
10	O
(	O
T	O
:	O
A	O
=	O
1	O
:	O
1	O
)	O
was	O
used	O
.	O

Neither	O
enzyme	O
showed	O
a	O
lag	O
on	O
this	O
template	O
-	O
initiator	O
complex	O
or	O
on	O
activated	O
DNA	O
.	O

Incorporation	O
versus	O
enzyme	O
concentration	O
also	O
showed	O
this	O
lag	O
for	O
C	O
enzyme	O
on	O
poly	O
(	O
dA	O
)	O
.	O
oligo	O
(	O
dT	O
)	O
10	O
.	O

It	O
is	O
not	O
certain	O
what	O
causes	O

3349	O

Nucleic	O
Acids	O
Research	O

TABLE	O
1	O
Template	O
utilisation	O
by	O
reconstituted	O
A	O
and	O
C	O
derived	O
from	O
A	O
.	O

3H	O
]	O
dNTP	O
Divalent	O
cation	O
A2	O
at	O
pH	O
C	O
at	O
pH	O

Template	O
_	O
6	O
.	O
4	O
7	O
.	O
8	O
6	O
.	O
4	O
7	O
.	O
8	O
Activated	O
DNA	O
dTTP	O
Mg	O
+	O
+	O
100	O
100	O
Activated	O
DNA	O
dATP	O
Mg	O
+	O
+	O
91	O
85	O
Activated	O
DNA	O
dGTP	O
Mg	O
+	O
+	O
85	O
82	O
poly	O
(	O
dA	O
)	O
.	O
oligo	O
(	O
dT	O
)	O
10	O
dTTP	O
Mg	O
66	O
.	O
0	O
4	O
.	O
0	O
20	O
91	O

(	O
A	O
:	O
T	O
=	O
20	O
:	O
1	O
)	O

poly	O
(	O
dA	O
)	O
.	O

oligo	O
(	O
dT	O
)	O
dTTP	O
Mu	O
19	O
.	O
0	O
4	O
.	O

5	O
6	O
.	O

5	O
2	O
.	O
5	O

poly	O
(	O
dA	O
.	O

oig	O
~	O
10	O
(	O
A	O
:	O
T	O
=	O
20	O
:	O
1	O
)	O

poly	O
(	O
dT	O
)	O
.	O

oligo	O
(	O
dA	O
)	O
10	O
dATP	O
Mg	O
2	O
.	O
5	O
<	O
1	O
(	O
1	O
(	O
1	O

(	O
T	O
:	O
A	O
=	O
5	O
:	O
1	O
)	O

poly	O
(	O
dT	O
)	O
.	O
oligo	O
(	O
dA	O
)	O
1	O
dATP	O
Mn	O
+	O
+	O
15	O
.	O
5	O
23	O
.	O
0	O
9	O
.	O

0	O
3	O
.	O

0	O

poly	O
(	O
dT	O
)	O
.	O

oligo	O
(	O
A	O
)	O
10	O
dATP	O
Mg	O
15	O
.	O
0	O
230	O
.	O
0	O
10	O
.	O
0	O
77	O
.	O

5	O

(	O
T	O
:	O
A	O
=	O
1	O
:	O
1	O
)	O

poly	O
(	O
dT	O
)	O
*	O
oligo	O
(	O
A	O
)	O
10	O
dATP	O
Mn	O
41	O
.	O
5	O
75	O
.	O

5	O
19	O
.	O
5	O
21	O
.	O
5	O

(	O
T	O
:	O
A	O
=	O
1	O
:	O
1	O
)	O

poly	O
(	O
dC	O
)	O
.	O

oligo	O
(	O
dG	O
)	O
dGTP	O
Mg	O
+	O
+	O
6	O
.	O

0	O
15	O
.	O
5	O
4	O
.	O

5	O
7	O
.	O

5	O

(	O
C	O
:	O
G	O
=	O
5	O
:	O
1	O
)	O
10	O

poly	O
(	O
dC	O
)	O
.	O

oligo	O
(	O
dG	O
)	O
10	O
dGTP	O
Mn	O
+	O
6	O
.	O

0	O
29	O
.	O
5	O
5	O
.	O

0	O
6	O
.	O

5	O

(	O
C	O
:	O
G	O
=	O
5	O
:	O
1	O
)	O
.	O

.	O

Values	O
given	O
are	O
relative	O
to	O
incorporation	O
of	O
[	O
H	O
]	O
dTMP	O
at	O
pH	O
7	O
.	O

8	O
on	O
activated	O
DNA	O
.	O

For	O
A2	O
this	O
was	O
176	O
.	O
5	O
pmol	O
,	O
for	O
C	O
232	O
pmol	O
.	O

dATP	O
,	O
dCTP	O
,	O
dGTP	O
and	O
dTTP	O
were	O
included	O
for	O
assays	O
using	O
activated	O
DNA	O
,	O
only	O
the	O
deoxynucleoside	O
triphosphate	O
stated	O
was	O
used	O
in	O
the	O
synthetic	O
template	O

initiator	O
complex	O
assays	O
.	O

Assays	O
were	O
for	O
10	O
minutes	O
.	O

The	O
buffers	O
and	O
concentrations	O
of	O
the	O
divalent	O
cations	O
were	O
as	O
in	O
Materials	O
and	O
Methods	O
.	O

this	O
lag	O
,	O
but	O
the	O
annealing	O
of	O
template	O
to	O
initiator	O
is	O
only	O
transient	O
'	O
and	O
the	O
DNA	O
polymerase	O
subunit	O
may	O
have	O
difficulty	O
in	O
stabilising	O
the	O
complex	O
and	O
the	O
50	O
-	O
70	O
,	O
000	O
molecular	O
weight	O
subunit	O
may	O
be	O
able	O
to	O
help	O
the	O
poly	O

merase	O
subunit	O
to	O
overcome	O
this	O
.	O

Addition	O
of	O
the	O
50	O
-	O
70	O
,	O
000	O
subunit	O
to	O
the	O
polymerase	O
subunit	O
prior	O
to	O
assaying	O
with	O
these	O
templates	O
had	O
no	O
effect	O
on	O
activity	O
and	O
it	O
may	O
be	O
that	O
a	O
preincubation	O
period	O
is	O
required	O
before	O
the	O
two	O
3350	O

Nucleic	O
Acids	O
Research	O

Figure	O
4	O
Activity	O
of	O
A2	O
and	O
C	O
enzymes	O
on	O
poly	O
(	O
dA	O
)	O
.	O
oligo	O
(	O
dT	O
)	O
jO	O
(	O
A	O
:	O
T	O
=	O

20	O
:	O
1	O
)	O
as	O
a	O
function	O
of	O
time	O
.	O

50	O
,	O
ul	O
samples	O
were	O
withdrawn	O
at	O
various	O
times	O
from	O
a	O
0	O
.	O

6	O
inl	O
incubation	O
mix	O
at	O
30	O
?	O
C	O
and	O
added	O
to	O
0	O
.	O

5	O
ml	O
0	O
.	O

1	O
M	O
sodium	O

pyrophosphate	O
containing	O
100	O
,	O
ug	O
/	O
ml	O
native	O
calf	S-Species
thymus	O
DNA	O
and	O
processed	O
for	O
counting	O
in	O
the	O
usual	O
manner6	O
.	O

The	O
mix	O
contained	O
1	O
mM	O
dithiothreitol	O
,	O
50	O
mM	O
tris	O
HC1	O
,	O
pH	O
7	O
.	O
8	O
10	O
mM	O
MgC12	O
,	O
0	O
.	O

1	O
mM	O
[	O
3H	O
]	O
dTTP	O
(	O
15	O
cpm	O
/	O
pmol	O
)	O
,	O
312	O
.	O
5	O
,	O
ug	O
bovine	S-Species
serum	O
albumin	O
,	O
5	O
Fg	O
poly	O
(	O
dA	O
)	O
.	O
oligo	O
(	O
dT	O
)	O
(	O
A	O
:	O
T	O
=	O
20	O
:	O
1	O
)	O
and	O
enzyme	O
protein	O
(	O
*	O
-	O
*	O
)	O
3	O
.	O
3	O
units	O
reconstituted	O
A2	O
,	O
(	O
o	O
-	O
o	O
)	O
16	O
.	O

0	O
units	O
urea	O
derived	O
C	O
enzyme	O
.	O

subunits	O
become	O
fully	O
associated	O
.	O

After	O
the	O
lag	O
phase	O
is	O
over	O
the	O
C	O
enzyme	O
is	O
still	O
less	O
active	O
on	O
these	O
template	O
-	O
initiators	O
than	O
A	O
enzyme	O
.	O

That	O
is	O
the	O
A	O
enzyme	O
seems	O
capable	O
of	O
elongating	O
the	O
initiator	O
faster	O
than	O
the	O
C	O
enzyme	O
.	O

Experiments	O
to	O
determine	O
whether	O
the	O
differences	O
in	O
rates	O
of	O
elongation	O
of	O
these	O
template	O
-	O
initiator	O
complexes	O
are	O
differences	O
in	O
processivity	O
of	O
the	O

enzymes	O
under	O
the	O
different	O
pH	O
and	O
divalent	O
cation	O
conditions	O
are	O
under	O
way	O
.	O

ACKNOWLEDGEMENTS	O

We	O
thank	O
the	O
Medical	O
Research	O
Council	O
for	O
a	O
research	O
grant	O
.	O

Communications	O
concerning	O
the	O
paper	O
should	O
be	O
sent	O
to	O
:	O

Dr	O
.	O
A	O
.	O

M	O
.	O

Holmes	O
,	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Strathclyde	O
,	O
The	O
Todd	O
Centre	O
,	O
31	O
Taylor	O
Street	O
,	O
Glasgow	O
G4	O
ONR	O
,	O
U	O
.	O
K	O
.	O

3351	O

Nucleic	O
Acids	O
Research	O

REFERENCES	O

(	O
1	O
)	O
Bollum	O
,	O
F	O
.	O
J	O
.	O

(	O
1975	O
)	O
.	O

Prog	O
.	O

Nucleic	O
Acid	O
Res	O
.	O

Mol	O
.	O

Biol	O
.	O

15	O
,	O

109	O
-	O
144	O
.	O

(	O
2	O
)	O
Holmes	O
,	O
A	O
.	O
M	O
.	O
,	O
Hesslewood	O
,	O
I	O
.	O
P	O
.	O
and	O
Johnston	O
,	O
I	O
.	O
R	O
.	O

(	O
1976	O
)	O
.	O

Eur	O
.	O

J	O
.	O

Biochem	O
.	O

62	O
,	O
229	O
-	O
235	O
.	O

(	O
3	O
)	O
Matsukage	O
,	O
A	O
.	O
,	O
Sivarajan	O
,	O
M	O
.	O
and	O
Wilson	O
,	O
S	O
.	O
H	O
.	O

(	O
1976	O
)	O
.	O

Biochem	O

istry	O
15	O
,	O
5305	O
-	O
5314	O
.	O

(	O
4	O
)	O
Fisher	O
,	O
P	O
.	O
A	O
.	O
and	O
Korn	O
,	O
D	O
.	O

(	O
1977	O
)	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

252	O
,	O
6528	O

6535	O
.	O

(	O
5	O
)	O
Fichot	O
,	O
O	O
.	O
,	O
Pascal	O
,	O
M	O
.	O
,	O
Mechali	O
,	O
M	O
.	O
and	O
De	O
Recondo	O
,	O
A	O
,	O
-	O
M	O
.	O

(	O
1979	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
561	O
,	O
28	O
-	O
41	O
.	O

(	O
6	O
)	O
Holmes	O
,	O
A	O
.	O
M	O
.	O
,	O
Hesslewood	O
,	O
I	O
.	O
R	O
.	O
and	O
Johnston	O
,	O
I	O
.	O
R	O
.	O

(	O
1974	O
)	O
.	O

Eur	O
.	O

J	O
.	O

Biochemn	O
.	O

43	O
,	O
487	O
-	O
499	O
.	O

(	O
7	O
)	O
Noy	O
,	O
G	O
.	O
P	O
.	O
and	O
Weissbach	O
,	O
A	O
.	O

(	O
1977	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O

447	O
,	O
70	O
-	O
83	O
.	O

(	O
8	O
)	O
Craig	O
,	O
R	O
.	O
K	O
.	O
and	O
Keir	O
,	O
H	O
.	O

M	O
.	O

(	O
1975	O
)	O
.	O

Biochem	O
.	O

J	O
.	O

145	O
,	O
225	O
-	O
232	O
.	O

(	O
9	O
)	O
Matsukage	O
,	O
A	O
.	O
,	O
Bohn	O
,	O
E	O
.	O
W	O
.	O
and	O
Wilson	O
,	O
S	O
.	O
H	O
.	O

(	O
1974	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

71	O
,	O
578	O
-	O
582	O
.	O

110	O
)	O
Hachmann	O
,	O
H	O
.	O
J	O
.	O
and	O
Lezius	O
,	O
A	O
.	O
G	O
.	O

(	O
1975	O
)	O
.	O

Eur	O
.	O

J	O
.	O

Biochem	O
.	O

50	O
,	O

357	O
-	O
366	O
.	O

(	O
11	O
)	O
Brakel	O
,	O
C	O
.	O
L	O
.	O
and	O
Blumenthal	O
,	O
A	O
.	O
B	O
.	O

(	O
1977	O
)	O
.	O

Biochemistry	O
,	O
16	O
,	O

3137	O
-	O
3143	O
.	O

(	O
12	O
)	O
Momparler	O
,	O
R	O
.	O
L	O
.	O
,	O
Rossi	O
,	O
M	O
.	O
and	O
Labitan	O
,	O
A	O
.	O

(	O
1973	O
)	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

248	O
,	O
285	O
-	O
293	O
.	O

(	O
13	O
)	O
Yoshida	O
,	O
S	O
.	O
,	O
Konda	O
,	O
T	O
.	O
and	O
Ando	O
,	O
T	O
.	O

(	O
1974	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
353	O
,	O
463	O
-	O
474	O
.	O

(	O
14	O
)	O
Holmes	O
,	O
A	O
.	O
M	O
.	O
,	O
Hesslewood	O
,	O
I	O
.	O
P	O
.	O
,	O
Wickremasinghe	O
,	O
R	O
.	O
G	O
.	O
and	O

Johnston	O
,	O
I	O
.	O
R	O
.	O

(	O
1977	O
)	O
.	O

Biochem	O
.	O

Soc	O
.	O

Symp	O
.	O

42	O
,	O
17	O
-	O
36	O
.	O

(	O
15	O
)	O
De	O
Jong	O
,	O
A	O
.	O
,	O
Van	O
der	O
Vliet	O
,	O
P	O
.	O
and	O
Jansz	O
,	O
H	O
.	O
S	O
.	O

(	O
1977	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
476	O
,	O
156	O
-	O
165	O
.	O

(	O
16	O
)	O
Holmes	O
,	O
A	O
.	O
M	O
.	O
,	O
Hesslewood	O
,	O
I	O
.	O
P	O
.	O
and	O
Johnston	O
,	O
I	O
.	O
R	O
.	O

(	O
1975	O
)	O
.	O

Nature	O
(	O
London	O
)	O
255	O
,	O
420	O
-	O
422	O
.	O

(	O
17	O
)	O
Bollum	O
,	O
F	O
.	O

J	O
.	O

(	O
1966	O
)	O
.	O

Procedures	O
in	O
Nucleic	O
Acid	O
Research	O

(	O
Cantoni	O
,	O
G	O
.	O
L	O
.	O
and	O
Davis	O
,	O
D	O
.	O
R	O
.	O
eds	O
)	O
.	O

pp	O
577	O
-	O
583	O
,	O
Harper	O
and	O
Row	O
,	O
New	O
York	O
.	O

(	O
18	O
)	O
Barrett	O
,	O
A	O
.	O
J	O
.	O

(	O
1975	O
)	O
.	O

Proteases	O
and	O
Biological	O
Control	O
pp	O
467	O
-	O
482	O
,	O

Cold	O
Spring	O
Harbor	O
Laboratory	O
,	O
Cold	O
Spring	O
Harbor	O
.	O

(	O
19	O
)	O
Richards	O
,	O
F	O
.	O

M	O
.	O
and	O
Vithayathil	O
,	O
P	O
.	O
J	O
.	O

(	O
1960	O
)	O
.	O

Brookhaven	O
Symp	O
.	O

Biol	O
.	O

13	O
,	O
115	O
-	O
134	O
.	O

(	O
20	O
)	O
Lowe	O
,	O
P	O
.	O
A	O
.	O
,	O
and	O
Malcolm	O
,	O
A	O
.	O
B	O
.	O
D	O
.	O

(	O
1976	O
)	O
.	O

Eur	O
.	O

J	O
.	O

Biochem	O
.	O

64	O
,	O

177	O
-	O
188	O
.	O

(	O
21	O
)	O
Hesslewood	O
,	O
I	O
.	O
P	O
.	O
,	O
Holmes	O
,	O
A	O
.	O
M	O
.	O
,	O
Wakeling	O
,	O
W	O
.	O
F	O
.	O
and	O
Johnston	O
,	O

I	O
.	O
R	O
.	O

(	O
1978	O
)	O
.	O

Eur	O
.	O

J	O
.	O

Biochenr	O
.	O
.	O

84	O
,	O
123	O
-	O
131	O
.	O

(	O
22	O
)	O
Mechali	O
,	O
M	O
.	O
and	O
De	O
Recondo	O
,	O
A	O
.	O

-	O
M	O
.	O

(	O
1978	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Res	O
.	O

Comm	O
,	O
82	O
,	O
255	O
-	O
264	O
.	O

(	O
23	O
)	O
Chang	O
,	O
L	O
.	O
M	O
.	O
S	O
.	O
,	O
Cassani	O
,	O
G	O
.	O
R	O
.	O
and	O
Bollum	O
,	O
F	O
.	O
J	O
.	O

(	O
1972	O
)	O
.	O

J	O
.	O

Biol	O
.	O

Che	O
.	O

247	O
,	O
7718	O
-	O
7723	O
.	O

(	O
24	O
)	O
Wickremasinghe	O
,	O
R	O
.	O
G	O
.	O
and	O
Johnston	O
,	O
I	O
.	O
R	O
.	O

(	O
1974	O
)	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
,	O
361	O
,	O
37	O
-	O
52	O
.	O

3352	O

Primitive	O
Neuroectodermal	O
Tumor	O
(	O
PNET	O
)	O
of	O
the	O
kidney	O
:	O
a	O
case	O
report	O

Abstract	O

Background	O

A	O
case	O
of	O
Primitive	O
Neuroectodermal	O
Tumor	O
(	O
PNET	O
)	O
of	O
the	O
kidney	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
woman	S-Species
is	O
presented	O
.	O

Few	O
cases	O
are	O
reported	O
in	O
the	O
literature	O
with	O
a	O
variable	O
,	O
nonspecific	O
presentation	O
and	O
an	O
aggressive	O
behaviour	O
.	O

In	O
our	O
case	O
,	O
a	O
radical	O
nephrectomy	O
with	O
lymphadenectomy	O
was	O
performed	O
and	O
there	O
was	O
no	O
residual	O
or	O
recurrent	O
tumour	O
at	O
24	O
-	O
month	O
follow	O
-	O
up	O
.	O

Methods	O

The	O
surgical	O
specimens	O
were	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
embedded	O
.	O

The	O
sections	O
were	O
stained	O
with	O
routinary	O
H	O
&	O
E	O
.	O

Immunohistochemistry	O
was	O
performed	O
.	O

Results	O

The	O
immunohistochemical	O
evaluation	O
revealed	O
a	O
diffuse	O
CD99	O
positivity	O
in	O
the	O
cytoplasm	O
of	O
the	O
neoplastic	O
cells	O
.	O

Pankeratin	O
,	O
cytokeratin	O
AE1	O
/	O
AE3	O
,	O
vimentin	O
,	O
desmin	O
,	O
S100	O
,	O
cromogranin	O
were	O
negative	O
.	O

The	O
clinical	O
presentation	O
and	O
the	O
macroscopic	O
aspect	O
,	O
together	O
with	O
the	O
histological	O
pattern	O
,	O
the	O
cytological	O
characteristic	O
and	O
the	O
cellular	O
immunophenotype	O
addressed	O
the	O
diagnosis	O
towards	O
primary	O
PNET	O
of	O
kidney	O
.	O

Conclusions	O

Since	O
sometimes	O
it	O
is	O
difficult	O
to	O
discriminate	O
between	O
PNET	O
and	O
Ewing	O
'	O
s	O
tumour	O
,	O
we	O
reviewed	O
the	O
difficulties	O
in	O
differential	O
diagnosis	O
.	O

These	O
tumors	O
have	O
a	O
common	O
precursor	O
but	O
the	O
stage	O
of	O
differentiation	O
in	O
which	O
it	O
is	O
blocked	O
is	O
probably	O
different	O
.	O

This	O
could	O
also	O
explain	O
their	O
different	O
biological	O
behaviour	O
and	O
prognosis	O
.	O

Background	O

The	O
peripheral	O
Primitive	O
Neuroectodermal	O
Tumor	O
(	O
PNET	O
)	O
,	O
firstly	O
recognized	O
by	O
Arthur	O
Purdy	O
Stout	O
in	O
1918	O
,	O
is	O
a	O
member	O
of	O
the	O
family	O
of	O
"	O
small	O
round	O
-	O
cell	O
tumors	O
"	O
.	O

Primitive	O
renal	O
localization	O
is	O
very	O
rare	O
.	O

There	O
are	O
almost	O
50	O
cases	O
reported	O
in	O
the	O
literature	O
,	O
although	O
it	O
is	O
difficult	O
to	O
estimate	O
the	O
exact	O
number	O
since	O
often	O
it	O
has	O
not	O
been	O
differentiated	O
from	O
Ewing	O
'	O
s	O
Sarcoma	O
[	O
1	O
-	O
13	O
]	O
.	O

Renal	O
PNET	O
is	O
more	O
aggressive	O
than	O
in	O
the	O
other	O
sites	O
.	O

It	O
frequently	O
arises	O
during	O
childhood	O
or	O
adolescence	O
,	O
having	O
an	O
aggressive	O
clinical	O
course	O
towards	O
metastatic	O
disease	O
and	O
death	O
.	O

It	O
often	O
recurs	O
locally	O
and	O
metastasises	O
early	O
to	O
regional	O
lymph	O
nodes	O
,	O
lungs	O
,	O
liver	O
,	O
bone	O
and	O
bone	O
marrow	O
,	O
resulting	O
in	O
a	O
poor	O
prognosis	O
.	O

The	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
rate	O
,	O
for	O
patients	S-Species
presenting	O
well	O
confined	O
extra	O
-	O
skeletal	O
PNET	O
,	O
is	O
around	O
45	O
-	O
55	O
%	O
and	O
cases	O
with	O
advanced	O
disease	O
at	O
presentation	O
have	O
a	O
median	O
relapse	O
-	O
free	O
survival	O
of	O
only	O
2	O
years	O
[	O
1	O
]	O
.	O

Case	O
presentation	O

A	O
27	O
-	O
year	O
-	O
old	O
woman	S-Species
was	O
referred	O
because	O
of	O
a	O
mild	O
left	O
flank	O
pain	O
and	O
haematuria	O
.	O

Ultrasonography	O
identified	O
a	O
left	O
renal	O
mass	O
homogeneously	O
hyperechogenic	O
in	O
comparison	O
with	O
renal	O
parenchyma	O
.	O

CT	O
scan	O
showed	O
a	O
11	O
mm	O
x	O
8	O
mm	O
x	O
6	O
mm	O
tumor	O
replacing	O
the	O
upper	O
half	O
of	O
the	O
left	O
kidney	O
with	O
extension	O
into	O
the	O
renal	O
vein	O
.	O

Chest	O
x	O
-	O
ray	O
was	O
negative	O
.	O

Pathological	O
stage	O
after	O
radical	O
nephrectomy	O
was	O
T3aN0Mx	O
.	O

The	O
surgical	O
specimens	O
were	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
embedded	O
.	O

The	O
sections	O
were	O
stained	O
with	O
routinary	O
H	O
&	O
E	O
.	O

Immunohistochemistry	O
was	O
performed	O
using	O
avidin	O
biotin	O
complex	O
technique	O
and	O
diaminobenzidine	O
as	O
chromogen	O
.	O

The	O
antibodies	O
used	O
included	O
CD99	O
(	O
Dako	O
,	O
M3601	O
)	O
,	O
pankeratin	O
(	O
Dako	O
,	O
M0821	O
)	O
,	O
cytokeratin	O
AE1	O
/	O
AE3	O
(	O
Dako	O
,	O
M3515	O
)	O
,	O
vimentin	O
(	O
Dako	O
,	O
M7010	O
)	O
,	O
desmin	O
(	O
Dako	O
,	O
M0760	O
)	O
,	O
S100	O
(	O
Dako	O
,	O
Z0311	O
)	O
,	O
and	O
chromogranin	O
A	O
(	O
Dako	O
,	O
M0869	O
)	O
,	O
at	O
suggested	O
dilution	O
.	O

We	O
performed	O
also	O
appropriate	O
routinely	O
positive	O
and	O
negative	O
controls	O
.	O

The	O
tumor	O
was	O
multilobular	O
,	O
grey	O
,	O
glistening	O
,	O
focally	O
hemorrhagic	O
,	O
surrounded	O
by	O
a	O
capsule	O
and	O
with	O
a	O
sharp	O
demarcation	O
from	O
the	O
uninvolved	O
kidney	O
.	O

Histologically	O
,	O
the	O
tumor	O
consisted	O
of	O
small	O
round	O
cells	O
with	O
round	O
nuclei	O
and	O
scant	O
cytoplasm	O
.	O

It	O
presented	O
different	O
patterns	O
,	O
with	O
cohesive	O
lobules	O
or	O
rosettes	O
and	O
perivascular	O
pseudo	O
-	O
rosettes	O
or	O
,	O
in	O
some	O
areas	O
,	O
spindle	O
cellular	O
elements	O
(	O
fig	O
.	O
1	O
)	O
.	O

The	O
immunohistochemical	O
evaluation	O
revealed	O
a	O
diffuse	O
CD99	O
positivity	O
in	O
the	O
cytoplasm	O
of	O
the	O
neoplastic	O
cells	O
(	O
fig	O
.	O
2	O
)	O
;	O
tumoral	O
cells	O
were	O
also	O
visible	O
in	O
the	O
vascular	O
lumens	O
(	O
fig	O
.	O
3	O
)	O
.	O

By	O
contrast	O
,	O
pankeratin	O
,	O
cytokeratin	O
AE1	O
/	O
AE3	O
,	O
vimentin	O
,	O
desmin	O
,	O
S100	O
,	O
cromogranin	O
were	O
negative	O
.	O

The	O
clinical	O
presentation	O
and	O
the	O
macroscopic	O
aspect	O
,	O
together	O
with	O
the	O
histological	O
pattern	O
,	O
the	O
cytological	O
characteristic	O
and	O
the	O
cellular	O
immunophenotype	O
addressed	O
the	O
diagnosis	O
towards	O
primary	O
PNET	O
of	O
kidney	O
.	O

A	O
bone	O
scan	O
did	O
not	O
reveal	O
positive	O
areas	O
.	O

Eight	O
cycles	O
of	O
chemotherapy	O
with	O
Vincristine	O
,	O
Ifosfamide	O
and	O
Adriamycin	O
,	O
four	O
cycles	O
of	O
Ifosfamide	O
and	O
VP16	O
and	O
eight	O
sittings	O
of	O
local	O
radiotherapy	O
were	O
sequentially	O
performed	O
.	O

Follow	O
-	O
up	O
examinations	O
with	O
CT	O
and	O
bone	O
scan	O
failed	O
to	O
show	O
residual	O
or	O
recurrent	O
tumor	O
after	O
24	O
months	O
.	O

Conclusions	O

Primitive	O
Neuroectodermal	O
Tumor	O
of	O
the	O
kidney	O
is	O
a	O
rare	O
entity	O
.	O

The	O
few	O
cases	O
reported	O
revealed	O
a	O
variable	O
presentation	O
and	O
an	O
aggressive	O
behaviour	O
.	O

The	O
distinction	O
from	O
other	O
primary	O
malignancies	O
of	O
the	O
kidneys	O
is	O
crucial	O
for	O
prognosis	O
.	O

The	O
differential	O
diagnosis	O
includes	O
extra	O
-	O
osseous	O
Ewing	O
'	O
s	O
sarcoma	O
,	O
rhabdomyosarcoma	O
,	O
Wilm	O
'	O
s	O
tumor	O
,	O
carcinoid	O
,	O
neuroblastoma	O
,	O
clear	O
cell	O
sarcoma	O
of	O
the	O
kidney	O
,	O
lymphoma	O
,	O
the	O
small	O
cell	O
variant	O
of	O
osteosarcoma	O
,	O
desmoplastic	O
small	O
round	O
cell	O
tumor	O
and	O
nephroblastoma	O
[	O
5	O
]	O
.	O

The	O
Homer	O
-	O
Wright	O
type	O
rosettes	O
,	O
commonly	O
scarce	O
of	O
number	O
or	O
less	O
defined	O
in	O
extra	O
skeletal	O
Ewing	O
'	O
s	O
sarcoma	O
(	O
ES	O
)	O
,	O
are	O
a	O
typical	O
histological	O
feature	O
for	O
PNET	O
and	O
can	O
address	O
the	O
diagnosis	O
although	O
they	O
can	O
be	O
found	O
also	O
in	O
neuroblastoma	O
[	O
5	O
]	O
.	O

To	O
better	O
address	O
the	O
diagnosis	O
,	O
an	O
immunohistochemical	O
analysis	O
is	O
necessary	O
.	O

In	O
our	O
case	O
the	O
presence	O
of	O
MIC	O
-	O
2	O
gene	O
products	O
,	O
known	O
also	O
as	O
CD99	O
,	O
12E7	O
,	O
E2	O
,	O
013	O
and	O
HBA71	O
,	O
suggested	O
a	O
PNET	O
diagnosis	O
.	O

Primitive	O
neuroectodermal	O
tumors	O
only	O
immunorreactive	O
to	O
CD99	O
,	O
even	O
if	O
uncommon	O
,	O
are	O
reported	O
in	O
the	O
literature	O
[	O
13	O
]	O
.	O

The	O
reactivity	O
to	O
vimentin	O
,	O
NSE	O
and	O
S	O
-	O
100	O
may	O
facilitate	O
the	O
diagnosis	O
but	O
is	O
not	O
patognomonic	O
,	O
while	O
CD	O
99	O
positivity	O
is	O
nowadays	O
a	O
clue	O
for	O
the	O
diagnosis	O
.	O

Moreover	O
cytogenetic	O
studies	O
(	O
not	O
performed	O
in	O
our	O
case	O
)	O
demonstrated	O
that	O
PNET	O
and	O
Ewing	O
'	O
s	O
sarcoma	O
can	O
both	O
be	O
associated	O
to	O
a	O
translocation	O
of	O
the	O
long	O
arms	O
of	O
chromosome	O
11	O
and	O
22	O
,	O
t	O
(	O
11	O
;	O
22	O
)	O
(	O
q22	O
;	O
q12	O
)	O
[	O
5	O
]	O
.	O

Despite	O
their	O
genetic	O
and	O
antigenic	O
similarity	O
,	O
many	O
authors	O
currently	O
recognize	O
PNET	O
and	O
extra	O
-	O
skeletal	O
Ewing	O
'	O
s	O
sarcoma	O
of	O
the	O
kidney	O
as	O
separate	O
entities	O
.	O

It	O
is	O
also	O
important	O
to	O
keep	O
separate	O
renal	O
PNET	O
and	O
malignant	O
rhabdomyosarcoma	O
tumor	O
(	O
MRT	O
)	O
.	O

Weeks	O
et	O
al	O
reported	O
8	O
cases	O
suggestive	O
for	O
PNET	O
but	O
mimicking	O
MRT	O
[	O
14	O
]	O
.	O

Although	O
renal	O
PNET	O
and	O
MRT	O
show	O
similar	O
clinico	O
-	O
pathological	O
features	O
,	O
the	O
latter	O
usually	O
occurs	O
in	O
very	O
young	O
children	O
,	O
having	O
a	O
more	O
aggressive	O
prognosis	O
.	O

Rodriguez	O
et	O
al	O
postulated	O
that	O
these	O
two	O
renal	O
neoplasms	O
share	O
a	O
common	O
undifferentiated	O
precursor	O
to	O
explain	O
their	O
similarity	O
and	O
we	O
agree	O
with	O
these	O
Authors	O
[	O
12	O
]	O
.	O

Indeed	O
,	O
the	O
hypothesis	O
that	O
tumors	O
arise	O
from	O
stem	O
cells	O
(	O
SCs	O
)	O
as	O
a	O
consequence	O
of	O
a	O
maturative	O
arrest	O
is	O
now	O
growing	O
[	O
15	O
]	O
.	O

SCs	O
are	O
present	O
in	O
almost	O
all	O
tissues	O
and	O
may	O
originate	O
different	O
cellular	O
lineages	O
by	O
the	O
multi	O
-	O
step	O
process	O
named	O
"	O
differentiation	O
"	O
.	O

The	O
role	O
of	O
SCs	O
in	O
tumorigenesis	O
was	O
clearly	O
demonstrated	O
in	O
a	O
number	O
of	O
carcinogenic	O
models	O
showing	O
that	O
solid	O
and	O
haematopoietic	O
cancers	O
could	O
arise	O
from	O
tissue	O
-	O
specific	O
SCs	O
[	O
16	O
-	O
19	O
]	O
.	O

In	O
agreement	O
with	O
Sell	O
and	O
Pierce	O
,	O
we	O
retain	O
that	O
the	O
degree	O
of	O
malignancy	O
of	O
a	O
carcinoma	O
depends	O
by	O
the	O
stage	O
in	O
which	O
SCs	O
differentiation	O
stopped	O
during	O
carcinogenesis	O
[	O
19	O
]	O
.	O

In	O
particular	O
,	O
since	O
PNET	O
,	O
Ewing	O
'	O
s	O
tumour	O
and	O
MRT	O
have	O
a	O
similar	O
morphology	O
,	O
our	O
hypothesis	O
is	O
that	O
the	O
mesenchimal	O
stem	O
precursor	O
of	O
these	O
tumors	O
is	O
the	O
same	O
,	O
but	O
the	O
stage	O
of	O
differentiation	O
in	O
which	O
it	O
is	O
blocked	O
is	O
different	O
.	O

This	O
could	O
explain	O
why	O
sometimes	O
it	O
is	O
difficult	O
to	O
discriminate	O
between	O
these	O
tumors	O
,	O
notwithstanding	O
they	O
present	O
a	O
different	O
biological	O
behaviour	O
.	O

Competing	O
interests	O

None	O
declared	O
.	O

Authors	O
'	O
contribution	O

All	O
authors	O
contributed	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

The	O
c1	O
genes	O
of	O
P1	O
and	O
P7	O
.	O

Abstract	O

The	O
c1	O
genes	O
of	O
the	O
heteroimmune	O
phages	O
P1	O
and	O
P7	O
were	O
sequenced	O
and	O
their	O
products	O
were	O
compared	O
.	O

P7c1	O
expression	O
was	O
correlated	O
with	O
the	O
translation	O
in	O
vitro	O
of	O
a	O
protein	O
whose	O
predicted	O
molecular	O
weight	O
(	O
33	O
,	O
000	O
daltons	O
)	O
is	O
indistinguishable	O
from	O
that	O
of	O
the	O
P1c1	O
repressor	O
.	O

The	O
c1	O
regions	O
from	O
both	O
P1	O
and	O
P7	O
were	O
found	O
to	O
contain	O
open	O
reading	O
frames	O
capable	O
of	O
coding	O
for	O
a	O
283	O
-	O
amino	O
acid	O
protein	O
whose	O
predicted	O
secondary	O
structure	O
lacks	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
motif	O
commonly	O
associated	O
with	O
repressor	O
proteins	O
.	O

Two	O
P1c1	O
amber	O
mutations	O
were	O
localized	O
to	O
the	O
283	O
-	O
amino	O
acid	O
open	O
reading	O
frame	O
.	O

The	O
P1c1	O
and	O
P7c1	O
sequences	O
were	O
found	O
to	O
differ	O
at	O
only	O
18	O
positions	O
,	O
all	O
but	O
two	O
of	O
which	O
alter	O
the	O
third	O
position	O
of	O
the	O
affected	O
codon	O
and	O
do	O
not	O
alter	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
.	O

Plasmids	O
expressing	O
the	O
c1	O
gene	O
from	O
either	O
phage	O
cause	O
the	O
repression	O
of	O
transcription	O
from	O
a	O
cloned	O
promoter	O
situated	O
upstream	O
of	O
P1c1	O
.	O
Images	O

Volme	O
7	O
Nmbe	O
19198	O
Nulei	O
Acds	O
eserc	O

The	O
cl	O
genes	O
of	O
P1	O
and	O
P7	O

Francis	O
A	O
.	O
Osborne	O
,	O
Sonja	O
R	O
.	O
Stovall	O
and	O
Barbara	O
R	O
.	O
Baumstark	O
*	O

Department	O
of	O
Biology	O
,	O
Georgia	O
State	O
University	O
,	O
Atlanta	O
,	O
GA	O
30303	O
,	O
USA	O

Received	O
July	O
11	O
,	O
1989	O
;	O
Revised	O
and	O
Accepted	O
August	O
29	O
,	O
1989	O
EMBL	O
accession	O
nos	O
X16005	O
,	O
X16006	O

ABSTRACT	O

The	O
cl	O
genes	O
of	O
the	O
heteroimmune	O
phages	O
P1	O
and	O
P7	O
were	O
sequenced	O
and	O
their	O
products	O
were	O
compared	O
.	O

P7cl	O
expression	O
was	O
correlated	O
with	O
the	O
translation	O
in	O
vitro	O
of	O
a	O
protein	O
whose	O
predicted	O
molecular	O
weight	O
(	O
33	O
,	O
000	O
daltons	O
)	O
is	O
indistinguishable	O
from	O
that	O
of	O
the	O
Plcl	O
repressor	O
.	O

The	O
cl	O
regions	O
from	O
both	O
P1	O
and	O
P7	O
were	O
found	O
to	O
contain	O
open	O
reading	O
frames	O
capable	O
of	O
coding	O
for	O
a	O
283	O
-	O
amino	O
acid	O
protein	O
whose	O
predicted	O
secondary	O
structure	O
lacks	O
the	O
helix	O
-	O
tum	O
-	O
helix	O
motif	O
commonly	O
associated	O
with	O
repressor	O
proteins	O
.	O

Two	O
Plcl	O
amber	O
mutations	O
were	O
localized	O
to	O
the	O
283	O
-	O
amino	O
acid	O
open	O
reading	O
frame	O
.	O

The	O
Plcl	O
and	O
P7cl	O
sequences	O
were	O
found	O
to	O
differ	O
at	O
only	O
18	O
positions	O
,	O
all	O
but	O
two	O
of	O
which	O
alter	O
the	O
third	O
position	O
of	O
the	O
affected	O
codon	O
and	O
do	O
not	O
alter	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
.	O

Plasmids	O
expressing	O
the	O
cI	O
gene	O
from	O
either	O
phage	O
cause	O
the	O
repression	O
of	O
transcription	O
from	O
a	O
cloned	O
promoter	O
situated	O
upstream	O
of	O
Plcl	O
.	O

INTRODUCTION	O

The	O
cl	O
genes	O
of	O
the	O
plasmid	O
prophages	O
P1	O
and	O
P7	O
code	O
for	O
repressor	O
proteins	O
that	O
are	O
required	O
for	O
the	O
establishment	O
and	O
maintenance	O
of	O
lysogeny	O
(	O
reviewed	O
in	O
1	O
)	O
.	O

A	O
protein	O
corresponding	O
to	O
the	O
Plcl	O
repressor	O
has	O
been	O
isolated	O
and	O
shown	O
to	O
be	O
a	O
sequence	O
-	O
specific	O
DNA	O
binding	O
protein	O
that	O
recognizes	O
several	O
widely	O
dispersed	O
sites	O
on	O
the	O
phage	O
DNA	O
(	O
2	O
-	O
7	O
)	O
.	O

The	O
consensus	O
DNA	O
sequence	O
recognized	O
by	O
the	O
Plcl	O
repressor	O
(	O
ATTTATTAGAGCA	O
[	O
A	O
/	O
T	O
]	O
T	O
)	O
contains	O
no	O
discernable	O
bilateral	O
symmetry	O
,	O
a	O
feature	O
that	O
is	O
highly	O
unusual	O
among	O
prokaryotic	O
operator	O
sites	O
.	O

P1	O
and	O
P7	O
are	O
heteroimmune	O
;	O
that	O
is	O
,	O
each	O
phage	O
is	O
able	O
to	O
establish	O
a	O
lytic	O
infection	O
on	O
a	O
lysogen	O
of	O
the	O
other	O
phage	O
.	O

In	O
this	O
sense	O
,	O
their	O
relationship	O
is	O
analogous	O
to	O
that	O
of	O
phage	O
X	O
and	O
434	O
,	O
which	O
differ	O
in	O
the	O
DNA	O
specificity	O
of	O
their	O
cI	O
repressor	O
proteins	O
(	O
8	O
)	O
.	O

However	O
,	O
genetic	O
studies	O
indicate	O
that	O
Plcl	O
and	O
P7cl	O
can	O
be	O
crossed	O
into	O
the	O
heterologous	O
phage	O
without	O
affecting	O
the	O
immunity	O
specificity	O
of	O
the	O
recipient	O
(	O
9	O
)	O
.	O

The	O
basis	O
for	O
P1	O
/	O
P7	O
heteroimmunity	O
has	O
been	O
localized	O
to	O
a	O
second	O
regulatory	O
gene	O
,	O
c4	O
,	O
that	O
is	O
unlinked	O
to	O
cl	O
.	O

The	O
c4	O
gene	O
products	O
prevent	O
the	O
expression	O
of	O
antireb	O
,	O
a	O
closely	O
linked	O
gene	O
that	O
interferes	O
with	O
cl	O
-	O
mediated	O
repression	O
(	O
10	O
,	O
11	O
)	O
.	O

According	O
to	O
current	O
models	O
,	O
P1	O
/	O
P7	O
heteroimmunity	O
results	O
from	O
the	O
inability	O
of	O
the	O
c4	O
repressor	O
of	O
one	O
phage	O
to	O
prevent	O
antireb	O
expression	O
from	O
the	O
heteroimmune	O
phage	O
genome	O
(	O
10	O
,	O
11	O
)	O
.	O

Because	O
the	O
cl	O
genes	O
of	O
P1	O
and	O
P7	O
are	O
genetically	O
interchangeable	O
,	O
it	O
is	O
anticipated	O
that	O
the	O
two	O
gene	O
products	O
carry	O
out	O
similar	O
or	O
identical	O
regulatory	O
functions	O
.	O

The	O
studies	O
presented	O
in	O
this	O
paper	O
were	O
undertaken	O
to	O
investigate	O
the	O
biochemical	O
basis	O
for	O
the	O
apparent	O
genetic	O
identity	O
of	O
the	O
two	O
cl	O
genes	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
the	O
DNA	O
sequence	O
of	O
the	O
cl	O
genes	O
of	O
P1	O
and	O
P7	O
and	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
cl	O
repressor	O
proteins	O
.	O

We	O
report	O
that	O
Plcl	O
and	O
P7cl	O
code	O
for	O
proteins	O
of	O
identical	O
size	O
(	O
283	O
amino	O
acids	O
)	O
and	O

Nucleic	O
Acids	O
Research	O

Volume	O
17	O
Number	O
19	O
1989	O

767	O
1	O

(	O
r	O
IRL	O
Press	O

Nucleic	O
Acids	O
Research	O

nearly	O
identical	O
sequence	O
.	O

We	O
report	O
further	O
that	O
both	O
repressors	O
prevent	O
the	O
expression	O
of	O
a	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
Plc	O
1	O
open	O
reading	O
frame	O
,	O
an	O
observation	O
that	O
confirms	O
their	O
functional	O
similarity	O
and	O
suggests	O
an	O
autoregulatory	O
role	O
for	O
the	O
two	O
proteins	O
.	O

Analysis	O
of	O
the	O
secondary	O
structure	O
predicted	O
by	O
the	O
open	O
reading	O
frames	O
does	O
not	O
reveal	O
the	O
characteristic	O
helix	O
-	O
turn	O
-	O
helix	O
(	O
12	O
)	O
or	O
other	O
motifs	O
commonly	O
associated	O
with	O
DNA	O
binding	O
proteins	O
.	O

MATERIALS	O
AND	O
METHODS	O
Bacterial	O
and	O
phage	O
strains	O
.	O

E	B-Species
.	I-Species
coli	E-Species
K336	O
is	O
a	O
SuO	O
derivative	O
of	O
K140	O
(	O
13	O
)	O
.	O

E	B-Species
.	I-Species
coli	E-Species
CB454	O
is	O
a	O
recA	O
-	O
,	O
lacZderivative	O
of	O
K	O
-	O
12	O
(	O
14	O
)	O
.	O

P1	O
+	O
is	O
described	O
by	O
Scott	O
(	O
13	O
)	O
.	O

P7	O
+	O
is	O
the	O
strain	O
of	O
Smith	O
(	O
15	O
)	O
,	O
as	O
described	O
by	O
Scott	O
(	O
16	O
)	O
.	O

P7cl	O
.	O

1	O
contains	O
a	O
missense	O
mutation	O
in	O
the	O
cl	O
gene	O
(	O
17	O
)	O
.	O

The	O
P7	O
phage	O
strains	O
and	O
the	O
cl	O
amber	O
mutant	O
phage	O
strains	O
PIci	O
.	O
245Cm	O
,	O
Plc1	O
.	O

169	O
and	O
P	O
Ic	O
.	O
55	O
(	O
11	O
)	O
were	O
generously	O
provided	O
by	O
June	O
Scott	O
.	O

Enzymes	O
and	O
reagents	O
.	O

Restriction	O
enzymes	O
,	O
T4	O
DNA	O
ligase	O
and	O
polymerase	O
,	O
and	O
the	O
Klenow	O
fragment	O
of	O
E	B-Species
.	I-Species
coli	E-Species
DNA	O
polymerase	O
were	O
purchased	O
from	O
Boehringer	O
Biochemicals	O
or	O
New	O
England	O
Biolabs	O
and	O
reactions	O
were	O
carried	O
out	O
according	O
to	O
the	O
manufacturers	O
'	O
instructions	O
.	O

DNA	O
sequencing	O
kits	O
and	O
in	O
vitro	O
transcription	O
-	O
translation	O
kits	O
were	O
purchased	O
from	O
Bethesda	O
Research	O
Laboratories	O
and	O
Amersham	O
Corporation	O
,	O
respectively	O
.	O

Synthetic	O
oligonucleotides	O
to	O
be	O
used	O
as	O
sequencing	O
primers	O
were	O
prepared	O
on	O
an	O
Applied	O
Biosystems	O
DNA	O
synthesizer	O
.	O

Plasmid	O
construction	O
.	O

pBRB7	O
.	O
2	O
.	O

pBRB7	O
.	O
2	O
(	O
2	O
)	O
contains	O
a	O
3	O
.	O
2	O
kb	O
EcoRI	O
/	O
PvuII	O
fragment	O
from	O
the	O
cl	O
region	O
of	O
P1	O
(	O
Figure	O
1	O
)	O
inserted	O
into	O
the	O
2	O
.	O
3	O
kb	O
EcoRIlPvuII	O
fragment	O
of	O
pBR322	O
that	O
contains	O
the	O
origin	O
of	O
replication	O
and	O
the	O
f3	O
-	O
lactamase	O
gene	O
.	O

pFA02	O
.	O

P7	O
plasmid	O
DNA	O
was	O
digested	O
with	O
PvuII	O
,	O
ligated	O
to	O
similarly	O
digested	O
pBR322	O
,	O
and	O
transformed	O
into	O
E	B-Species
.	I-Species
coli	E-Species
K336	O
.	O

Ampicillin	O
-	O
resistant	O
colonies	O
were	O
screened	O
for	O
cl	O
activity	O
by	O
cross	O
-	O
streak	O
complementation	O
analysis	O
against	O
P7cl	O
.	O
1	O
(	O
18	O
)	O
.	O

pFAO2	O
contains	O
a	O
3	O
.	O
5	O
kb	O
insert	O
of	O
P7	O
DNA	O
.	O

The	O
fragment	O
was	O
localized	O
to	O
the	O
cl	O
region	O
of	O
the	O
P7	O
genome	O
by	O
Southern	O
hybridization	O
against	O
P1	O
and	O
P7	O
DNA	O
that	O
had	O
been	O
digested	O
with	O
BamHI	O
and	O
BglII	O
(	O
data	O
not	O
shown	O
)	O
.	O

pBRBJ69	O
.	O

1	O
and	O
pBRB55	O
.	O

1	O
.	O

The	O
PI	O
cI	O
open	O
reading	O
frame	O
was	O
previously	O
localized	O
to	O
a	O
2	O
.	O
6	O
kb	O
EcoRlIBamHI	O
fragment	O
derived	O
from	O
PlEcoRI	O
-	O
7	O
(	O
2	O
)	O
.	O

This	O
fragment	O
also	O
contains	O
the	O
wildtype	O
allele	O
for	O
the	O
conditional	O
lethal	O
mutation	O
am43	O
(	O
19	O
,	O
20	O
)	O
.	O

To	O
clone	O
the	O
cl	O
reading	O
frame	O
from	O
the	O
amber	O
mutant	O
phage	O
Plc1	O
.	O
169	O
and	O
P	O
Ic	O
.	O
55	O
,	O
we	O
digested	O
phage	O
DNA	O
with	O
EcoRI	O
and	O
BamHI	O
,	O
ligated	O
the	O
digestion	O
products	O
into	O
similarly	O
digested	O
pBR322	O
,	O
and	O
transformed	O
the	O
ligation	O
mixture	O
into	O
E	B-Species
.	I-Species
coli	E-Species
K336	O
.	O

Ampicillin	O
-	O
resistant	O
,	O
tetracyclinesensitive	O
colonies	O
were	O
screened	O
by	O
cross	O
-	O
streak	O
complementation	O
analysis	O
for	O
their	O
ability	O
to	O
support	O
the	O
growth	O
of	O
Plam43	O
.	O

Plasmid	O
DNA	O
isolated	O
from	O
complementation	O
-	O
positive	O
cells	O
was	O
shown	O
by	O
agarose	O
gel	O
electrophoresis	O
to	O
carry	O
plasmids	O
containing	O
the	O
2	O
.	O
6	O
kb	O
EcoRIlBamHI	O
fragment	O
from	O
the	O
cl	O
region	O
.	O

The	O
cl	O
mutant	O
open	O
reading	O
frames	O
were	O
placed	O
under	O
the	O
control	O
of	O
normal	O
regulatory	O
signals	O
present	O
in	O
the	O
cI	O
region	O
by	O
digesting	O
the	O
cl	O
.	O
55	O
and	O
cl	O
.	O

169	O
-	O
containing	O
plasmids	O
with	O
BamHI	O
and	O
PvuII	O
and	O
inserting	O
a	O
601	O
bp	O
BamHI	O
/	O
PvuH	O
fragment	O
containing	O
the	O
cl	O
promoter	O
region	O
(	O
2	O
)	O
.	O

The	O
resulting	O
plasmids	O
,	O
pBRB55	O
.	O
1	O
and	O
pBRB169	O
.	O
1	O
,	O
respectively	O
,	O
contain	O
the	O
3	O
.	O
2	O
kb	O
EcoRllPvuIl	O
fragment	O
analogous	O
to	O
that	O
present	O
in	O
pBRB7	O
.	O
2	O
(	O
Figure	O
1	O
)	O
.	O

pBCB2	O
.	O

13	O
-	O
2	O
.	O
18	O
.	O

To	O
identify	O
cl	O
-	O
repressible	O
promoters	O
,	O
we	O
introduced	O
selected	O
fragments	O

7672	O

Nucleic	O
Acids	O
Research	O

4	O
f	O
-	O
-	O
+	O

I	O
4	O
P1	O
4	O
-	O
4	O
-	O
4	O

ECAR	O
H	O
C	O
B	O
R	O
P	O

4	O
4	O
.	O
4	O
,	O
~	O
4	O
,	O
1	O
1	O
4	O
.	O

I	O
4	O
,	O
I	O
11	O

t	O
t	O
t	O
t	O
t	O
E	O
G	O
R	O
N	O
E	O
B	O
R	O
P	O

4	O
4	O
-	O

4	O

1	O
'	O
'	O
110z	O
I	O
I	O
I	O
I	O
I	O
I	O
1	O

3	O
.	O
2	O
1	O
.	O
5	O
1	O
.	O
0	O
0	O
.	O
5	O
0	O

P7	O

pBRB7	O
.	O
2	O

-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
cl1	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O
-	O

r	O
~	O
/	O
>	O
'	O
pFAO2	O

*	O
-	O
lacZ	O
pBCB2	O
.	O
13	O

<	O
-	O
lacZ	O
Z	O
pBCB2	O
.	O
16	O
<	O
-	O
lacZX	O
pBCB2	O
.	O
18	O

Fig	O
.	O

1	O
.	O

The	O
cl	O
regions	O
of	O
P1	O
and	O
P7	O
.	O

A	O
restriction	O
map	O
is	O
indicated	O
by	O
the	O
solid	O
line	O
in	O
the	O
upper	O
part	O
of	O
the	O
figure	O
.	O

Sites	O
for	O
EcoRI	O
(	O
E	O
)	O
,	O
Pvul	O
(	O
P	O
)	O
,	O
NnrI	O
(	O
N	O
)	O
,	O
Bgll	O
(	O
G	O
)	O
,	O
BamHI	O
(	O
B	O
)	O
,	O
and	O
EcoRV	O
(	O
R	O
)	O
are	O
shown	O
.	O

The	O
sequencing	O
strategy	O
is	O
indicated	O
by	O
the	O
horizontal	O
arrows	O
.	O

Letters	O
and	O
arrows	O
above	O
and	O
below	O
the	O
map	O
refer	O
to	O
sites	O
and	O
sequence	O
analysis	O
for	O
P1	O
and	O
P7	O
,	O
respectively	O
.	O

The	O
size	O
of	O
this	O
region	O
(	O
in	O
kilobase	O
pairs	O
)	O
is	O
indicated	O
below	O
the	O
map	O
.	O

The	O
DNA	O
fragments	O
present	O
in	O
selected	O
plasmids	O
are	O
illustrated	O
by	O
boxes	O
at	O
the	O
bottom	O
of	O
the	O
figure	O
.	O

The	O
dashed	O
line	O
reveals	O
the	O
approximate	O
position	O
of	O
the	O
cl	O
gene	O
(	O
2	O
)	O
.	O

The	O
sites	O
of	O
the	O
-	O
yb	O
mutations	O
introduced	O
into	O
pFA02	O
are	O
indicated	O
by	O
asterisks	O
.	O

pFA02	O
.	O
16	O
and	O
pFA02	O
.	O
26	O
contain	O
insertions	O
located	O
0	O
.	O
9	O
kb	O
and	O
1	O
.	O
4	O
kb	O
,	O
respectively	O
,	O
from	O
the	O
PvuIl	O
site	O
at	O
the	O
left	O
side	O
of	O
the	O
map	O
.	O

The	O
direction	O
of	O
the	O
lacZ	O
open	O
reading	O
frame	O
in	O
pBCB2	O
.	O
13	O
-	O
18	O
is	O
indicated	O
by	O
the	O
adjacent	O
arrow	O
.	O

from	O
the	O
cI	O
region	O
of	O
P1	O
into	O
pCB192	O
,	O
a	O
promoter	O
-	O
probe	O
vector	O
containing	O
promoterless	O
copies	O
of	O
lacZ	O
and	O
galK	O
extending	O
in	O
opposite	O
directions	O
from	O
a	O
multiple	O
cloning	O
site	O
(	O
21	O
)	O
.	O

The	O
source	O
of	O
P1	O
DNA	O
for	O
these	O
constructions	O
was	O
pZHA3	O
,	O
a	O
derivative	O
of	O
pBRB7	O
.	O
2	O
that	O
contains	O
a	O
HindIlI	O
linker	O
at	O
the	O
single	O
EcoRV	O
site	O
located	O
about	O
200	O
bps	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
(	O
Figure	O
1	O
)	O
.	O

pBCB2	O
.	O
13	O
contains	O
a	O
460	O
bp	O
fragment	O
of	O
P1	O
DNA	O
extending	O
from	O
the	O
EcoRV	O
site	O
to	O
a	O
Bgll	O
site	O
within	O
the	O
cI	O
open	O
reading	O
frame	O
.	O

pBCB2	O
.	O

16	O
contains	O
a	O
130	O
bp	O
fragment	O
extending	O
from	O
the	O
EcoRV	O
site	O
to	O
a	O
BamHI	O
site	O
located	O
about	O
100	O
bps	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
,	O
while	O
pBCB2	O
.	O
18	O
contains	O
the	O
region	O
extending	O
from	O
this	O
BamHI	O
site	O
to	O
the	O
Bglll	O
site	O
within	O
the	O
open	O
reading	O
frame	O
(	O
Figure	O
1	O
)	O
.	O

The	O
orientation	O
of	O
the	O
P1	O
DNA	O
fragments	O
within	O
these	O
plasmids	O
was	O
confirmed	O
by	O
restriction	O
mapping	O
and	O
DNA	O
sequencing	O
.	O

To	O
test	O
for	O
the	O
regulation	O
of	O
promoter	O
expression	O
by	O
cl	O
,	O
we	O
transformed	O
pBCB2	O
.	O
13	O
and	O
its	O
derivatives	O
into	O
CB454	O
(	O
pBRB7	O
.	O
152	O
)	O
and	O
CB454	O
(	O
pFAO2	O
.	O
152	O
)	O
,	O
two	O
strains	O
that	O
express	O
P7cl	O
and	O
Pll	O
,	O
respectively	O
,	O
from	O
the	O
pCB192	O
-	O
compatible	O
kanamycin	O
-	O
resistant	O
vector	O
pDPT152	O
(	O
22	O
)	O
.	O

Cells	O
harboring	O
both	O
plasmids	O
were	O
selected	O
by	O
their	O
resistance	O
to	O
both	O
ampicillin	O
and	O
kanamycin	O
.	O

lacZ	O
expression	O
was	O
measured	O
by	O
the	O
procedure	O
of	O
Miller	O
(	O
23	O
)	O
.	O

pBRB7	O
.	O
152	O
was	O
generated	O
by	O
introducing	O
PlEcoRI	O
-	O
7	O
into	O
pDPT152	O
.	O

pBRB7	O
.	O
152	O
has	O
sustained	O
a	O
spontaneous	O
deletion	O
within	O
the	O
EcoRI	O
-	O
7	O
fragment	O
that	O
results	O
in	O
the	O
loss	O
of	O
2	O
.	O
5	O
kb	O
of	O
P1	O
DNA	O
from	O
the	O
far	O
left	O
side	O
of	O
the	O
P1	O
genetic	O
map	O
,	O
but	O
retains	O
the	O
3	O
.	O
2	O
kb	O
PvuHlEcoRI	O
fragment	O
required	O
for	O
cl	O
expression	O
that	O
is	O
present	O
in	O
pBRB7	O
.	O
2	O
(	O
Figure	O
1	O
)	O
.	O

7673	O

z	O

I	O
011Z	O
I	O

e	O
.	O
,	O

Nucleic	O
Acids	O
Research	O

Table	O
1	O
.	O

Complementation	O
of	O
PIci	O
.	O
245	O
by	O
plasmids	O
that	O
contain	O
cI	O
genes	O
.	O

Phenotype	O
Efficiency	O
Relative	O

of	O
of	O
Efficiency	O
of	O
Plasmid	O
cI	O
gene	O
Lysogeny	O
Lysogeny	O
pBR322	O
1	O
.	O
5x	O
10	O
-	O
6	O
6	O
.	O
0x	O
10	O
-	O
6	O
pBRB7	O
.	O
2	O
Plcl	O
+	O
2	O
.	O
5	O
x	O
10	O
-	O
'	O
1	O
.	O
0	O

pBRB55	O
.	O
1	O
Plcl	O
-	O
am	O
1	O
.	O
4	O
x	O
10	O
-	O
6	O
5	O
.	O
6	O
x	O
10	O
-	O
6	O
pBRB169	O
.	O
1	O
PlCl	O
-	O
am	O
2	O
.	O
1	O
x	O
10	O
-	O
6	O
8	O
.	O
4	O
x	O
10	O
-	O
6	O
pFAO2	O
P7cl	O
+	O
8	O
.	O
7	O
x	O
10	O
-	O
2	O
0	O
.	O
35	O

pFAO2	O
.	O
16	O
P7c	O
I	O
-	O
,	O
4	O
.	O
7	O
x	O
10	O
-	O
6	O
1	O
.	O
9	O
X	O
10	O
-	O
5	O
pFAO2	O
.	O
26	O
P7cI	O
-	O
1	O
3	O
.	O
1	O
x	O
10	O
-	O
6	O
1	O
.	O
2	O
x	O
10	O
-	O
5	O

Complementation	O
for	O
lysogeny	O
was	O
carried	O
out	O
as	O
described	O
by	O
Devlin	O
et	O
al	O
.	O

(	O
26	O
)	O
.	O

The	O
plasmids	O
were	O
carried	O
by	O
E	B-Species
.	I-Species
coli	E-Species
K336	O
.	O

Cells	O
were	O
grown	O
to	O
mid	O
-	O
log	O
phase	O
at	O
370	O
in	O
LB	O
containing	O
50	O
tig	O
/	O
m1	O
sodium	O
ampicillin	O
and	O
infected	O
with	O
Plcl	O
.	O
245	O
at	O
a	O
multiplicity	O
of	O
infection	O
of	O
5	O
in	O
the	O
presence	O
of	O
50	O
mM	O
CaC12	O
.	O

After	O
10	O
minutes	O
,	O
non	O
-	O
absorbed	O
phage	O
were	O
removed	O
by	O
centrifugation	O
and	O
the	O
infection	O
was	O
allowed	O
to	O
proceed	O
for	O
2	O
hours	O
at	O
370	O
.	O

The	O
infected	O
cells	O
were	O
plated	O
on	O
LB	O
plates	O
containing	O
50	O
pLg	O
/	O
ml	O
sodium	O
ampicillin	O
,	O
50	O
pLg	O
/	O
ml	O
chloramphenicol	O
,	O
and	O
40	O
mM	O
sodium	O
citrate	O
.	O

The	O
efficiency	O
of	O
lysogeny	O
is	O
defined	O
as	O
the	O
number	O
of	O
ApRCmR	O
cells	O
at	O
the	O
end	O
of	O
infection	O
divided	O
by	O
the	O
number	O
of	O
ApR	O
cells	O
present	O
at	O
the	O
start	O
of	O
the	O
infection	O
.	O

To	O
construct	O
pFA02	O
.	O
152	O
,	O
we	O
introduced	O
a	O
2	O
.	O
8	O
kb	O
EcoRV	O
fragment	O
of	O
P7	O
DNA	O
containing	O
the	O
cl	O
gene	O
(	O
Figure	O
1	O
)	O
into	O
the	O
single	O
EcoRI	O
site	O
of	O
pDPT152	O
after	O
it	O
had	O
been	O
rendered	O
blunt	O
-	O
ended	O
by	O
extension	O
with	O
T4	O
DNA	O
polymerase	O
.	O

cl	O
expression	O
by	O
cells	O
harboring	O
either	O
pBRB7	O
.	O
152	O
or	O
pFA02	O
.	O
152	O
was	O
confirmed	O
by	O
measuring	O
their	O
ability	O
to	O
form	O
chloramphenicol	O
-	O
resistant	O
lysogens	O
when	O
infected	O
with	O
Plcl	O
.	O
245Cm	O
.	O

,	O
yb	O
insertional	O
mutagenesis	O
.	O

Insertional	O
mutagenesis	O
of	O
P7cl	O
was	O
carried	O
out	O
using	O
the	O
'	O
yb	O
transposon	O
of	O
F	O
(	O
24	O
)	O
as	O
described	O
by	O
Devlin	O
et	O
al	O
.	O

(	O
25	O
)	O
.	O

E	B-Species
.	I-Species
coli	E-Species
W1485	O
(	O
pFA02	O
)	O
was	O
mated	O
with	O
the	O
F	O
-	O
strain	O
MX648	O
and	O
subsequently	O
plated	O
on	O
ampicillin	O
(	O
to	O
select	O
for	O
the	O
plasmid	O
)	O
and	O
streptomycin	O
sulfate	O
(	O
to	O
select	O
for	O
the	O
recipient	O
strain	O
)	O
.	O

Transconjugants	O
which	O
could	O
support	O
only	O
lytic	O
growth	O
upon	O
infection	O
by	O
P7cl	O
.	O
1	O
(	O
as	O
scored	O
by	O
cross	O
-	O
streak	O
analysis	O
;	O
18	O
)	O
were	O
assumed	O
to	O
have	O
lost	O
cl	O
-	O
complementing	O
activity	O
and	O
were	O
characterized	O
further	O
.	O

The	O
positions	O
of	O
two	O
cl	O
-	O
insertional	O
mutations	O
,	O
carried	O
by	O
pFA02	O
.	O
16	O
and	O
pFA02	O
.	O
26	O
,	O
were	O
identified	O
by	O
restriction	O
mapping	O
(	O
Figure	O
1	O
)	O
.	O

DNA	O
sequencing	O
.	O

DNA	O
sequence	O
analysis	O
was	O
carried	O
out	O
using	O
the	O
M13	O
-	O
dideoxy	O
technique	O
of	O
Sanger	O
et	O
al	O
.	O

(	O
26	O
)	O
.	O

Selected	O
DNA	O
fragments	O
containing	O
the	O
cl	O
wildtype	O
or	O
mutant	O
genes	O
were	O
introduced	O
into	O
M13	O
mp8	O
or	O
mp9	O
.	O

18	O
-	O
nucleotide	O
oligomers	O
complementary	O
to	O
defined	O
sequences	O
within	O
the	O
cl	O
gene	O
were	O
extended	O
using	O
the	O
Klenow	O
fragment	O
of	O
DNA	O
polymerase	O
in	O
the	O
presence	O
of	O
dideoxynucleotide	O
triphosphates	O
and	O
analyzed	O
by	O
polyacrylamide	O
-	O
urea	O
gel	O
electrophoresis	O
.	O

The	O
sequencing	O
strategy	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

RESULTS	O

Localization	O
of	O
the	O
P7cJ	O
gene	O
.	O

Initial	O
localization	O
of	O
the	O
P7cl	O
gene	O
was	O
undertaken	O
by	O
subjecting	O
pFA02	O
to	O
'	O
yb	O
mutagenesis	O
and	O
determining	O
the	O
map	O
position	O
of	O
inserts	O
which	O
destroy	O
the	O
ability	O
of	O
the	O
plasmids	O
to	O
complement	O
a	O
P7cl	O
-	O
mutation	O
(	O
as	O
determined	O
by	O
cross	O
-	O
streak	O
analysis	O
)	O
.	O

pFA02	O
and	O
the	O
-	O
yb	O
insertion	O
mutants	O
were	O
tested	O
further	O
by	O
comparing	O
their	O
ability	O
to	O
complement	O
a	O
PIcI	O
amber	O
mutation	O
with	O
the	O
complementation	O
activity	O
of	O
plasmids	O
containing	O
cl	O
genes	O
isolated	O

7674	O

Nucleic	O
Acids	O
Research	O

B	O
C	O
D	O
E	O
F	O
G	O

*	O
.	O
4	O

68	O

43	O

29	O
-	O
_	O
-	O
=	O
I	O
=	O
Am	O
~	O
W	O
_	O

18	O

14	O
p	O

Fig	O
.	O

2	O
.	O

In	O
vitro	O
transcription	O
-	O
translation	O
of	O
plasmids	O
carrying	O
the	O
cl	O
region	O
of	O
P1	O
and	O
P7	O
.	O

Proteins	O
encoded	O
by	O
selected	O
plasmids	O
were	O
labeled	O
with	O
35S	O
methionine	O
according	O
to	O
the	O
procedure	O
of	O
DeVries	O
and	O
Zubay	O
(	O
27	O
)	O
,	O
using	O
a	O
commercial	O
in	O
vitro	O
transcription	O
/	O
tramnslation	O
kit	O
from	O
Amersham	O
Corporation	O
.	O

The	O
reaction	O
mixtures	O
were	O
subjected	O
to	O
electrophoresis	O
on	O
a	O
12	O
.	O
5	O
%	O
SDS	O
-	O
polyacrylamide	O
gel	O
and	O
the	O
labeled	O
proteins	O
were	O
visualized	O
by	O
autoradiography	O
.	O

The	O
migration	O
of	O
14C	O
-	O
labeled	O
protein	O
molecular	O
weight	O
standards	O
(	O
Bethesda	O
Research	O
Laboratories	O
)	O
is	O
indicated	O
at	O
the	O
left	O
side	O
of	O
the	O
figure	O
.	O

Plasmids	O
present	O
in	O
each	O
lane	O
are	O
:	O
A	O
.	O

pBRB55	O
.	O
1	O
;	O
B	O
.	O

pBRB169	O
.	O
1	O
;	O
C	O
.	O

pBRB7	O
.	O
2	O
;	O
D	O
.	O

pFAO2	O
;	O
E	O
.	O

pFAO2	O
.	O
16	O
;	O
F	O
.	O

pFAO2	O
.	O
26	O
;	O
G	O
.	O

pBR322	O
.	O

from	O
P1	O
wildtype	O
and	O
amber	O
mutants	O
.	O

Lysogeny	O
by	O
cells	O
infected	O
with	O
Plcl	O
.	O
245Cm	O
was	O
scored	O
as	O
the	O
growth	O
of	O
infected	O
cells	O
on	O
ampicillin	O
(	O
to	O
select	O
for	O
the	O
resident	O
plasmid	O
)	O
and	O
chloramphenicol	O
(	O
to	O
select	O
for	O
the	O
phage	O
genome	O
)	O
.	O

The	O
values	O
observed	O
for	O
the	O
two	O
plasmids	O
containing	O
Plcl	O
and	O
P7cl	O
(	O
pBRB7	O
.	O
2	O
and	O
pFA02	O
,	O
respectively	O
)	O
are	O
very	O
similar	O
and	O
significantly	O
higher	O
than	O
those	O
obtained	O
for	O
pBR322	O
or	O
for	O
any	O
of	O
the	O
plasmids	O
carrying	O

Table	O
2	O
.	O

Assay	O
for	O
lacZ	O
expression	O
from	O
plasmids	O
containing	O
P1	O
DNA	O
fragments	O
.	O

,	O
3	O
-	O
galactosidase	O
activity	O
(	O
units	O
)	O

minus	O
cI	O
plus	O
Pici	O
plus	O
P7cl	O
relative	O
activity	O

(	O
pDPT152	O
)	O
(	O
pBB7	O
.	O
152	O
)	O
(	O
pFA02	O
.	O
152	O
)	O
+	O
PICJ	O
+	O
P7cJ	O

pCB192	O
0	O
.	O
58	O
0	O
.	O
55	O
0	O
.	O
54	O
0	O
.	O
95	O
0	O
.	O
93	O
pBCB2	O
.	O
13	O
154	O
15	O
.	O
2	O
13	O
.	O
6	O
0	O
.	O
10	O
0	O
.	O
09	O
pBCB2	O
.	O
16	O
1	O
.	O
1	O
1	O
.	O
2	O
1	O
.	O
1	O
1	O
.	O
1	O
1	O
.	O
0	O
pBCB2	O
.	O
18	O
4	O
.	O
0	O
3	O
.	O
4	O
3	O
.	O
9	O
0	O
.	O
9	O
1	O
.	O
0	O

Cells	O
containing	O
derivatives	O
of	O
the	O
ApR	O
promoter	O
-	O
probe	O
plasmid	O
pCB192	O
and	O
the	O
compatible	O
KnR	O
plasmid	O
pDPT152	O
were	O
grown	O
in	O
LB	O
at	O
37	O
?	O
.	O

When	O
they	O
reached	O
mid	O
-	O
log	O
phase	O
,	O
the	O
cells	O
were	O
chilled	O
,	O
lysed	O
,	O
and	O
assayed	O
for	O
(	O
3	O
-	O
galactosidase	O
activity	O
according	O
to	O
the	O
procedure	O
of	O
Miller	O
(	O
23	O
)	O
.	O

Plasmids	O
derived	O
from	O
pCB192	O
are	O
indicated	O
at	O
the	O
left	O
side	O
of	O
the	O
Table	O
.	O

Plasmids	O
derived	O
from	O
pDPT152	O
are	O
indicated	O
in	O
parentheses	O
across	O
the	O
top	O
of	O
the	O
Table	O
.	O

The	O
values	O
reported	O
are	O
the	O
average	O
of	O
two	O
independent	O
experiments	O
.	O

Relative	O
activity	O
is	O
defined	O
as	O
the	O
f3	O
-	O
galactosidase	O
activity	O
measured	O
in	O
cells	O
harboring	O
plasmids	O
expressing	O
cl	O
divided	O
by	O
the	O
activity	O
measured	O
in	O
cells	O
carrying	O
only	O
pDPT152	O
.	O

7675	O

Nucleic	O
Acids	O
Research	O

GATATCCAATCAGGAGTACC	O
GCATCACCCAAGACGACCTG	O
GATGATCTCACTGACACAAT	O
CGAATATCTCATGGCCACTA	O
ACCAGCCAGACTCACAATAAATGCA	O
105	O
v	O
-	O
-	O

TtgAca	O
TATAATG	O

CTAATAAATCTATTATTTTC	O
GTTGGATCCTTCTATAATGG	O
TGGCCAACAACTCCCAGTGT	O
AATCCGCTGTGAGTTGTTGG	O
CCATGTCAATTCTGGAGGAGGATCA	O
210	O

b	O
-	O
-	O
-	O
-	O
-	O
I	O
I	O
GGAGGtG	O

ATG	O
ATA	O
AAT	O
TAT	O
GTC	O
TAC	O
GGC	O
GAA	O
CAA	O
CTG	O
TAC	O
CAG	O
GAG	O
TTC	O
GTC	O
AGC	O
TTC	O
AGG	O
GAT	O
CTC	O
TTT	O
CTA	O
AAA	O
AAA	O
GCT	O
GTT	O
GCA	O
CGC	O
GCC	O
CAA	O
300	O
MET	O
lIe	O
Asn	O
Tyr	O
Vat	O
Tyr	O
Gly	O
Glu	O
Gin	O
Leu	O
Tyr	O
Gin	O
Gtu	O
Phe	O
Vat	O
Ser	O
Phe	O
Arg	O
Asp	O
Leu	O
Phe	O
Leu	O
Lys	O
Lys	O
Ala	O
Val	O
Ala	O
Arg	O
Ala	O
Gtn	O

tag	O
(	O
cl	O
.	O
55	O
)	O

CAC	O
GTT	O
GAT	O
GCC	O
GCC	O
AGC	O
GAC	O
GGT	O
CGT	O
CCT	O
GTT	O
CGC	O
CCG	O
GTT	O
GTC	O
GTT	O
CTG	O
CCG	O
TTC	O
AM	O
GM	O
ACG	O
GAC	O
AGC	O
ATT	O
CAG	O
GCT	O
GMA	O
ATT	O
GAT	O
390	O
His	O
Val	O
Asp	O
Ala	O
Ala	O
Ser	O
Asp	O
Gly	O
Arg	O
Pro	O
Vat	O
Arg	O
Pro	O
Vat	O
Vat	O
Vat	O
Leu	O
Pro	O
Phe	O
Lys	O
Glu	O
Thr	O
Asp	O
Ser	O
lIe	O
Gin	O
Ala	O
Glu	O
lie	O
Asp	O

T	O
A	O
C	O
A	O
G	O

AAA	O
TGG	O
ACA	O
TTA	O
ATG	O
GCG	O
CGG	O
GAA	O
CTG	O
GAG	O
CAG	O
TAC	O
CCA	O
GAT	O
CTC	O
MT	O
ATC	O
CCA	O
MG	O
ACT	O
ATT	O
TTA	O
TAT	O
CCT	O
GTA	O
CCT	O
AAC	O
ATC	O
CTT	O
CGC	O
480	O

9	O

Lys	O
Trp	O
Thr	O
Leu	O
MET	O
Ala	O
Arg	O
Glu	O
Leu	O
Gtu	O
Gin	O
Tyr	O
Pro	O
Asp	O
Leu	O
Asn	O
lIe	O
Pro	O
Lys	O
Thr	O
lie	O
Leu	O
Tyr	O
Pro	O
Vat	O
Pro	O
Asn	O
lIe	O
Leu	O
Arg	O

A	O
T	O
C	O

GGT	O
GTG	O
CGT	O
AAG	O
GTT	O
ACG	O
ACT	O
TAT	O
CAG	O
ACA	O
GAA	O
GCA	O
GTG	O
MC	O
AGC	O
GTC	O
AAT	O
ATG	O
ACC	O
GCT	O
GGC	O
CGC	O
ATT	O
ATT	O
CAT	O
CTG	O
ATT	O
GAT	O
AAG	O
GAC	O
570	O
Gly	O
Vat	O
Arg	O
Lys	O
Vat	O
Thr	O
Thr	O
Tyr	O
Gin	O
Thr	O
Glu	O
Ala	O
Vat	O
Asn	O
Ser	O
Vat	O
Asn	O
MET	O
Thr	O
Ala	O
Gly	O
Arg	O
lIe	O
lIe	O
His	O
Leu	O
lIe	O
Asp	O
Lys	O
Asp	O

G	O

ATT	O
CGC	O
ATC	O
CAA	O
AM	O
AGC	O
GCG	O
GGG	O
ATC	O
MT	O
GAG	O
CAC	O
AGT	O
GCG	O
AAA	O
TAC	O
ATA	O
GAG	O
MC	O
CTG	O
GAA	O
GCA	O
ACA	O
AM	O
GAG	O
CTA	O
ATG	O
AAG	O
CAG	O
TAC	O
660	O
lle	O
Arg	O
lIe	O
Gin	O
Lys	O
Ser	O
Ala	O
Gly	O
lIe	O
Asn	O
Gtu	O
His	O
Ser	O
Ala	O
Lys	O
Tyr	O
lIe	O
Gtu	O
Asn	O
Leu	O
Gtu	O
Ala	O
Thr	O
Lys	O
Gtu	O
Leu	O
MET	O
Lys	O
Gin	O
Tyr	O

T	O
T	O

CCG	O
GAG	O
GAT	O
GAA	O
AAA	O
TTC	O
CGT	O
ATG	O
CGC	O
GTA	O
CAC	O
GGC	O
TTT	O
AGC	O
GAA	O
ACA	O
ATG	O
CTG	O
CGC	O
GTC	O
CAT	O
TAC	O
ATT	O
TCC	O
AGT	O
AGC	O
CCT	O
AAC	O
TAC	O
AAT	O
750	O
Pro	O
Glu	O
Asp	O
Glu	O
Lys	O
Phe	O
Arg	O
MET	O
Arg	O
Vat	O
His	O
Gly	O
Phe	O
Ser	O
Gtu	O
Thr	O
MET	O
Leu	O
Arg	O
Vat	O
His	O
Tyr	O
lie	O
Ser	O
Ser	O
Ser	O
Pro	O
Asn	O
Tyr	O
Asn	O

Phe	O

T	O
C	O
G	O
T	O
T	O

I	O
~	O
~	O
~	O
I	O
I	O
II	O

GAT	O
GGC	O
MA	O
TCA	O
GTT	O
AGT	O
TAC	O
CAT	O
GTG	O
CTG	O
CTA	O
TGT	O
GGC	O
GTG	O
TTT	O
ATC	O
TGC	O
GAT	O
GM	O
ACT	O
CTC	O
CGA	O
GAT	O
GGA	O
ATC	O
ATC	O
ATC	O
AAC	O
GGT	O
GAA	O
840	O

e	O
.	O
.	O

Asp	O
Gly	O
Lys	O
Ser	O
Vat	O
Ser	O
Tyr	O
His	O
Vat	O
Leu	O
Leu	O
Cys	O
Gly	O
Vat	O
Phe	O
lie	O
Cys	O
Asp	O
Glu	O
Thr	O
Leu	O
Arg	O
Asp	O
Gly	O
lIe	O
lie	O
lIe	O
Asn	O
Gly	O
Gtu	O

Pro	O

C	O
tag	O
(	O
cl	O
.	O
169	O
)	O

TTT	O
GAG	O
AM	O
GCA	O
AAA	O
TTT	O
AGC	O
CTT	O
TAT	O
GAC	O
TCT	O
ATA	O
GM	O
CCG	O
ATC	O
ATC	O
TGC	O
GAC	O
CGC	O
TGG	O
CCG	O
CAG	O
GCA	O
AM	O
ATA	O
TAT	O
CGC	O
CTG	O
GCA	O
GAT	O
930	O
Phe	O
Gtu	O
Lys	O
Ala	O
Lys	O
Phe	O
Ser	O
Leu	O
Tyr	O
Asp	O
Ser	O
lIe	O
Glu	O
Pro	O
lie	O
lie	O
Cys	O
Asp	O
Arg	O
Trp	O
Pro	O
Gin	O
Ala	O
Lys	O
lIe	O
Tyr	O
Arg	O
Leu	O
Ala	O
Asp	O

T	O

ATT	O
GM	O
MT	O
GTA	O
AM	O
AM	O
CM	O
ATT	O
GCC	O
ATC	O
ACT	O
CGC	O
GM	O
GAG	O
AAA	O
G	O
GTC	O
AM	O
TCA	O
GCC	O
GCA	O
TCA	O
GTT	O
ACG	O
CGC	O
AGC	O
CGC	O
AAA	O
ACT	O
AAG	O
1020	O

n	O
-	O
-	O
-	O
-	O
-	O

lie	O
Glu	O
Asn	O
Vat	O
Lys	O
Lys	O
Gin	O
lIe	O
Ala	O
lie	O
Thr	O
Arg	O
Glu	O
Glu	O
Lys	O
Lys	O
Vat	O
Lys	O
Ser	O
Ala	O
Ala	O
Ser	O
Vat	O
Thr	O
Arg	O
Ser	O
Arg	O
Lys	O
Thr	O
Lys	O

AAG	O
GGG	O
CAG	O
CCA	O
GTA	O
AAC	O
GAC	O
MC	O
CCC	O
GAA	O
AGC	O
GCG	O
CM	O
TAG	O
Lys	O
Gly	O
Gin	O
Pro	O
Val	O
Asn	O
Asp	O
Asn	O
Pro	O
Glu	O
Ser	O
Ala	O
Gin	O
ter	O

Fig	O
.	O

3	O
.	O

DNA	O
sequence	O
of	O
PIcI	O
and	O
P7cl	O
.	O

The	O
DNA	O
sequence	O
of	O
PIcI	O
is	O
indicated	O
.	O

Positions	O
where	O
the	O
sequence	O
of	O
P7cl	O
differs	O
from	O
that	O
of	O
Plcl	O
are	O
indicated	O
above	O
the	O
P1	O
sequence	O
.	O

The	O
amino	O
acid	O
sequence	O
predicted	O
by	O
the	O
open	O
reading	O
frame	O
is	O
given	O
below	O
the	O
sequence	O
.	O

The	O
two	O
amino	O
acid	O
substitutions	O
present	O
in	O
P7cl	O
are	O
shown	O
below	O
the	O
open	O
reading	O
frame	O
.	O

The	O
locations	O
of	O
the	O
amber	O
mutant	O
codons	O
in	O
cl	O
.	O
55	O
and	O
ci	O
.	O

169	O
are	O
indicated	O
by	O
small	O
letters	O
above	O
the	O
sequence	O
.	O

Sites	O
for	O
selected	O
restriction	O
enzymes	O
(	O
EcoRV	O
[	O
v	O
]	O
;	O
BamHI	O
[	O
b	O
]	O
;	O
Bgll	O
[	O
g	O
]	O
;	O
EcoRP	O
[	O
e	O
]	O
;	O
and	O
NruI	O
[	O
n	O
]	O
)	O
are	O
illustrated	O
by	O
dashed	O
lines	O
beneath	O
the	O
sequence	O
.	O

The	O
cl	O
repressor	O
binding	O
site	O
is	O
underlined	O
.	O

Inverted	O
arrows	O
beneath	O
the	O
sequence	O
illustrate	O
the	O
inverted	O
repeat	O
sequence	O
upstream	O
of	O
the	O
open	O
reading	O
frame	O
.	O

Predicted	O
promoter	O
ribosome	O
binding	O
sites	O
are	O
indicated	O
by	O
the	O
presence	O
of	O
the	O
consensus	O
sequences	O
above	O
and	O
below	O
the	O
line	O
,	O
respectively	O
.	O

The	O
DNA	O
sequences	O
of	O
Plcl	O
from	O
bp	O
1	O
-	O
134	O
and	O
bp	O
1	O
-	O
434	O
were	O
reported	O
previously	O
(	O
2	O
,	O
5	O
)	O
.	O

mutant	O
cl	O
genes	O
from	O
either	O
P1	O
or	O
P7	O
(	O
Table	O
1	O
)	O
.	O

The	O
efficiency	O
with	O
which	O
a	O
cloned	O
P7cl	O
gene	O
complements	O
a	O
PlcI	O
mutation	O
confirms	O
previous	O
genetic	O
studies	O
indicating	O
that	O
these	O
two	O
genes	O
are	O
functionally	O
interchangeable	O
(	O
9	O
)	O
.	O

The	O
location	O
of	O
the	O
'	O
y6	O
mutations	O
that	O
destroy	O
cl	O
-	O
complementing	O
activity	O
suggests	O
that	O
the	O
P7cl	O
open	O
reading	O
frame	O
occupies	O
a	O
map	O
position	O
similar	O
to	O
that	O
of	O
the	O
P1	O
open	O
reading	O
frame	O
(	O
Figure	O
1	O
)	O
.	O

7676	O

Nucleic	O
Acids	O
Research	O

Proteins	O
produced	O
by	O
fragments	O
containing	O
Plcl	O
.	O

As	O
an	O
initial	O
step	O
in	O
the	O
comparison	O
of	O
the	O
P1	O
and	O
P7	O
repressors	O
,	O
we	O
analyzed	O
the	O
gene	O
products	O
expressed	O
from	O
the	O
cloned	O
cl	O
regions	O
.	O

In	O
an	O
in	O
vitro	O
transcription	O
-	O
translation	O
reaction	O
,	O
plasmids	O
coding	O
for	O
the	O
wildtpe	O
alleles	O
of	O
either	O
PIcI	O
or	O
P7cl	O
direct	O
the	O
production	O
of	O
a	O
protein	O
with	O
an	O
estimated	O
molecular	O
weight	O
of	O
33	O
,	O
000	O
daltons	O
(	O
Figure	O
2	O
,	O
Lanes	O
C	O
and	O
D	O
)	O
,	O
a	O
size	O
that	O
agrees	O
closely	O
with	O
the	O
predicted	O
molecular	O
weight	O
of	O
the	O
PIcI	O
repressor	O
reported	O
previously	O
(	O
3	O
,	O
28	O
)	O
.	O

The	O
loss	O
of	O
the	O
33	O
,	O
000	O
dalton	O
protein	O
in	O
the	O
cl	O
-	O
'	O
ya	O
-	O
induced	O
P7	O
mutant	O
plasmids	O
(	O
Figure	O
2	O
,	O
Lanes	O
E	O
and	O
F	O
)	O
is	O
consistent	O
with	O
its	O
designation	O
as	O
the	O
P7cl	O
repressor	O
.	O

As	O
expected	O
,	O
the	O
33	O
,	O
000	O
dalton	O
protein	O
is	O
not	O
observed	O
when	O
reaction	O
mixtures	O
contain	O
DNA	O
from	O
Plcl	O
amber	O
mutants	O
(	O
Figure	O
2	O
,	O
Lanes	O
A	O
and	O
B	O
)	O
.	O

DNA	O
sequence	O
analysis	O
of	O
the	O
cl	O
genes	O
.	O

To	O
make	O
a	O
direct	O
comparison	O
between	O
the	O
Plcl	O
and	O
P7cl	O
DNA	O
sequences	O
and	O
to	O
predict	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
repressor	O
proteins	O
,	O
we	O
carried	O
out	O
M	O
13	O
-	O
dideoxy	O
sequence	O
analysis	O
of	O
cloned	O
fragments	O
carrying	O
the	O
cl	O
genes	O
.	O

The	O
sequences	O
of	O
about	O
1	O
kb	O
of	O
P1	O
and	O
P7	O
DNA	O
were	O
determined	O
starting	O
from	O
a	O
common	O
EcoRV	O
site	O
predicted	O
to	O
lie	O
approximately	O
200	O
bps	O
upstream	O
of	O
the	O
cl	O
genes	O
.	O

The	O
P1	O
and	O
P7	O
sequences	O
(	O
Figure	O
3	O
)	O
both	O
contain	O
an	O
ATG	O
initiation	O
codon	O
preceded	O
by	O
a	O
putative	O
ribosome	O
binding	O
sequence	O
(	O
29	O
)	O
situated	O
211	O
bps	O
downstream	O
of	O
the	O
EcoRV	O
site	O
.	O

In	O
each	O
case	O
,	O
the	O
initiation	O
codon	O
is	O
followed	O
by	O
an	O
open	O
reading	O
reading	O
frame	O
extending	O
for	O
283	O
codons	O
.	O

The	O
P1	O
and	O
P7	O
open	O
reading	O
frames	O
code	O
for	O
proteins	O
with	O
predicted	O
molecular	O
weights	O
(	O
32	O
,	O
515	O
and	O
32	O
,	O
499	O
daltons	O
,	O
respectively	O
)	O
that	O
agree	O
closely	O
with	O
the	O
values	O
of	O
the	O
proteins	O
expressed	O
from	O
the	O
cloned	O
DNA	O
fragments	O
(	O
Figure	O
2	O
)	O
and	O
with	O
results	O
predicted	O
independently	O
for	O
the	O
purified	O
PIcI	O
repressor	O
(	O
3	O
-	O
4	O
)	O
.	O

The	O
localization	O
of	O
two	O
PIcI	O
amber	O
mutations	O
to	O
the	O
P1	O
open	O
reading	O
frame	O
confirms	O
its	O
identification	O
as	O
the	O
cI	O
coding	O
sequence	O
.	O

cI	O
.	O

169	O
contains	O
an	O
amber	O
mutation	O
that	O
would	O
result	O
in	O
a	O
protein	O
fragment	O
of	O
26	O
,	O
680	O
daltons	O
,	O
a	O
value	O
that	O
agrees	O
well	O
with	O
the	O
size	O
of	O
a	O
protein	O
fragment	O
observed	O
under	O
the	O
in	O
vitro	O
transcription	O
/	O
translation	O
reaction	O
conditions	O
(	O
Figure	O
2	O
,	O
Lane	O
B	O
)	O
.	O

The	O
cl	O
.	O
55	O
amber	O
mutation	O
lies	O
close	O
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
,	O
resulting	O
in	O
the	O
production	O
of	O
a	O
fragment	O
of	O
55	O
amino	O
acids	O
that	O
is	O
apparently	O
too	O
small	O
to	O
resolve	O
under	O
the	O
electrophoretic	O
conditions	O
used	O
for	O
separation	O
of	O
the	O
proteins	O
.	O

Over	O
60	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
predicted	O
for	O
the	O
PIcI	O
open	O
reading	O
frame	O
has	O
been	O
verified	O
by	O
amino	O
acid	O
sequence	O
analysis	O
of	O
peptide	O
fragments	O
isolated	O
from	O
the	O
purified	O
repressor	O
protein	O
(	O
see	O
accompanying	O
paper	O
,	O
reference	O
3	O
)	O
.	O

The	O
DNA	O
sequences	O
of	O
P1	O
and	O
P7	O
are	O
identical	O
for	O
a	O
399	O
-	O
bp	O
region	O
that	O
extends	O
from	O
the	O
EcoRV	O
site	O
at	O
the	O
5	O
'	O
side	O
of	O
the	O
cl	O
gene	O
to	O
a	O
point	O
188	O
bps	O
within	O
the	O
open	O
reading	O
frame	O
.	O

The	O
sequences	O
within	O
the	O
Plcl	O
and	O
the	O
P7cl	O
open	O
reading	O
frames	O
differ	O
at	O
only	O
18	O
positions	O
,	O
all	O
but	O
two	O
of	O
which	O
occur	O
in	O
the	O
wobble	O
position	O
of	O
the	O
predicted	O
codon	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
functional	O
identity	O
of	O
the	O
P1	O
and	O
P7	O
cl	O
genes	O
is	O
a	O
consequence	O
of	O
their	O
nearly	O
identical	O
amino	O
acid	O
sequence	O
.	O

Analysis	O
of	O
promoters	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
.	O

Expression	O
of	O
Plcl	O
was	O
shown	O
previously	O
to	O
require	O
sequences	O
on	O
the	O
distal	O
side	O
of	O
a	O
BamHI	O
site	O
(	O
2	O
,	O
5	O
)	O
located	O
about	O
100	O
bps	O
upstream	O
of	O
the	O
open	O
reading	O
frame	O
(	O
Figure	O
3	O
)	O
.	O

A	O
binding	O
site	O
for	O
the	O
cl	O
repressor	O
has	O
also	O
been	O
shown	O
to	O
exist	O
close	O
to	O
this	O
BamHI	O
site	O
(	O
2	O
,	O
5	O
,	O
6	O
)	O
.	O

To	O
determine	O
whether	O
this	O
region	O
contains	O
a	O
promoter	O
that	O
is	O
detectable	O
in	O
vivo	O
and	O
,	O
further	O
,	O
to	O
determine	O
whether	O
this	O
promoter	O
can	O
be	O
regulated	O
by	O
cl	O
repressor	O
proteins	O
from	O
either	O
P1	O
or	O
P7	O
,	O
we	O
introduced	O
several	O
DNA	O
fragments	O
from	O
this	O
region	O
into	O
the	O
promoter	O
probe	O
vector	O
pCB192	O
,	O
screened	O
for	O
promoter	O
activity	O
(	O
as	O
monitored	O
by	O
lacZ	O
expression	O
)	O
and	O
checked	O
for	O
repression	O
of	O
this	O
activity	O
in	O
the	O
presence	O
of	O
a	O
compatible	O

7677	O

Nucleic	O
Acids	O
Research	O

plasmid	O
expressing	O
Plcl	O
or	O
P7cl	O
.	O

Cells	O
harboring	O
pBCB2	O
.	O
13	O
(	O
a	O
plasmid	O
which	O
carries	O
a	O
460	O
bp	O
fragment	O
of	O
P1	O
DNA	O
that	O
extends	O
across	O
the	O
BamHI	O
site	O
upstream	O
of	O
cl	O
into	O
the	O
open	O
reading	O
frame	O
)	O
are	O
dark	O
blue	O
in	O
the	O
presence	O
of	O
Xgal	O
and	O
produce	O
significant	O
levels	O
of	O
3	O
-	O
galactosidase	O
(	O
Table	O
2	O
)	O
.	O

In	O
contrast	O
,	O
pBCB2	O
.	O
16	O
and	O
pBCB2	O
.	O
18	O
(	O
which	O
each	O
contain	O
DNA	O
from	O
only	O
one	O
side	O
of	O
the	O
BamHI	O
site	O
located	O
in	O
pBCB2	O
.	O
13	O
)	O
do	O
not	O
confer	O
a	O
blue	O
color	O
on	O
their	O
host	O
cell	O
in	O
the	O
presence	O
of	O
X	O
-	O
Gal	O
and	O
express	O
negligible	O
amounts	O
of	O
3	O
-	O
galactosidase	O
(	O
Table	O
2	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
expression	O
from	O
the	O
promoter	O
identified	O
here	O
requires	O
sequences	O
that	O
span	O
the	O
BamHI	O
site	O
upstream	O
of	O
cl	O
.	O

Expression	O
of	O
cl	O
from	O
a	O
compatible	O
plasmid	O
in	O
the	O
presence	O
of	O
pBCB2	O
.	O

13	O
results	O
in	O
a	O
90	O
%	O
reduction	O
in	O
promoter	O
strength	O
(	O
Table	O
2	O
)	O
.	O

This	O
reduction	O
is	O
seen	O
in	O
the	O
presence	O
of	O
either	O
Plcl	O
or	O
P7cl	O
,	O
indicating	O
that	O
the	O
two	O
repressor	O
proteins	O
are	O
both	O
capable	O
of	O
repressing	O
expression	O
from	O
this	O
promoter	O
.	O

DISCUSSION	O
.	O

The	O
DNA	O
sequences	O
of	O
Plcl	O
and	O
P7cl	O
differ	O
at	O
only	O
18	O
sites	O
,	O
all	O
but	O
two	O
of	O
which	O
occur	O
at	O
the	O
third	O
position	O
of	O
the	O
affected	O
codon	O
.	O

This	O
observation	O
provides	O
biochemical	O
confirmation	O
of	O
the	O
functional	O
identity	O
predicted	O
on	O
the	O
basis	O
of	O
previous	O
genetic	O
analysis	O
(	O
9	O
)	O
.	O

A	O
number	O
of	O
DNA	O
binding	O
proteins	O
exhibit	O
a	O
common	O
structural	O
motif	O
in	O
which	O
two	O
helices	O
are	O
separated	O
by	O
a	O
glycine	O
residue	O
(	O
12	O
)	O
.	O

This	O
motif	O
is	O
not	O
observed	O
in	O
the	O
predicted	O
secondary	O
structures	O
(	O
30	O
)	O
of	O
the	O
Plcl	O
and	O
P7cl	O
amino	O
acid	O
sequences	O
.	O

A	O
sequence	O
with	O
some	O
similarity	O
to	O
the	O
XCro	O
helix	O
-	O
turn	O
-	O
helix	O
region	O
was	O
previously	O
reported	O
near	O
the	O
Nterminus	O
of	O
the	O
PIcI	O
protein	O
(	O
5	O
)	O
;	O
however	O
,	O
it	O
was	O
noted	O
that	O
the	O
potential	O
for	O
helix	O
formation	O
is	O
disrupted	O
by	O
the	O
presence	O
of	O
several	O
prolines	O
within	O
the	O
region	O
.	O

The	O
secondary	O
structure	O
predicted	O
for	O
the	O
Plcl	O
and	O
P7cl	O
repressor	O
proteins	O
(	O
30	O
)	O
does	O
not	O
reveal	O
other	O
structural	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
,	O
Zn	O
fingers	O
(	O
31	O
)	O
,	O
leucine	O
zippers	O
(	O
32	O
)	O
,	O
or	O
helix	O
-	O
loop	O
-	O
helix	O
motifs	O
(	O
33	O
)	O
)	O
that	O
have	O
been	O
associated	O
with	O
DNA	O
binding	O
activity	O
in	O
other	O
systems	O
.	O

A	O
search	O
of	O
the	O
GenBank	O
and	O
EMBL	O
databases	O
does	O
not	O
reveal	O
any	O
other	O
known	O
regulatory	O
proteins	O
with	O
significant	O
amino	O
acid	O
similarity	O
to	O
the	O
Plcl	O
or	O
the	O
P7cl	O
repressor	O
sequences	O
.	O

Since	O
the	O
Plcl	O
repressor	O
differs	O
from	O
most	O
other	O
repressors	O
in	O
DNA	O
binding	O
specificity	O
(	O
i	O
.	O
e	O
.	O
,	O
in	O
its	O
recognition	O
of	O
an	O
asymmetric	O
operator	O
sequence	O
)	O
,	O
it	O
is	O
not	O
unexpected	O
to	O
find	O
that	O
the	O
protein	O
does	O
not	O
exhibit	O
common	O
structural	O
motifs	O
at	O
the	O
amino	O
acid	O
level	O
.	O

The	O
cl	O
-	O
repressible	O
promoter	O
described	O
in	O
this	O
report	O
is	O
located	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
and	O
is	O
oriented	O
in	O
the	O
direction	O
of	O
cl	O
.	O

Because	O
the	O
promoter	O
is	O
present	O
on	O
a	O
multicopy	O
plasmid	O
,	O
it	O
is	O
not	O
possible	O
to	O
make	O
a	O
direct	O
calculation	O
of	O
promoter	O
strength	O
;	O
however	O
,	O
the	O
values	O
observed	O
are	O
about	O
five	O
-	O
fold	O
lower	O
than	O
the	O
levels	O
produced	O
by	O
a	O
derivative	O
of	O
pCB192	O
that	O
contains	O
the	O
plac	O
promoter	O
from	O
pUC19	O
(	O
34	O
)	O
.	O

Because	O
sequences	O
on	O
both	O
sides	O
of	O
the	O
BamHI	O
site	O
located	O
upstream	O
of	O
cl	O
are	O
required	O
for	O
promoter	O
activity	O
(	O
Table	O
2	O
)	O
,	O
we	O
suggest	O
that	O
the	O
promoter	O
spans	O
this	O
site	O
.	O

Less	O
than	O
10	O
bps	O
downstream	O
of	O
this	O
BamHI	O
site	O
is	O
a	O
heptanucleotide	O
sequence	O
(	O
TATAATG	O
)	O
that	O
is	O
identical	O
to	O
the	O
-	O
10	O
consensus	O
sequence	O
for	O
RNA	O
polymerase	O
(	O
35	O
)	O
.	O

If	O
this	O
sequence	O
does	O
indeed	O
correspond	O
to	O
the	O
-	O
10	O
region	O
of	O
the	O
promoter	O
,	O
the	O
-	O
35	O
region	O
would	O
be	O
predicted	O
to	O
lie	O
on	O
the	O
other	O
side	O
of	O
the	O
BamHI	O
site	O
in	O
a	O
region	O
that	O
overlaps	O
a	O
known	O
cI	O
repressor	O
binding	O
site	O
(	O
2	O
-	O
5	O
)	O
.	O

Analysis	O
of	O
this	O
region	O
does	O
not	O
reveal	O
any	O
sequences	O
with	O
significant	O
similarity	O
to	O
the	O
-	O
35	O
consensus	O
sequence	O
.	O

The	O
best	O
fit	O
is	O
the	O
sequence	O
TCTATT	O
(	O
Figure	O
3	O
)	O
,	O
which	O
matches	O
only	O
two	O
positions	O
of	O
the	O
-	O
35	O
consensus	O
(	O
TTGACA	O
)	O
.	O

The	O
lack	O
of	O
a	O
strong	O
-	O
35	O
region	O
is	O
often	O
observed	O
with	O
genes	O
that	O
require	O
an	O
activator	O
.	O

Although	O
a	O
pentanucleotide	O
sequence	O
corresponding	O
to	O
the	O
conserved	O
portion	O
of	O
the	O
CRP	O
protein	O
consensus	O
binding	O
site	O
(	O
36	O
)	O

7678	O

Nucleic	O
Acids	O
Research	O

is	O
located	O
just	O
upstream	O
of	O
the	O
predicted	O
-	O
35	O
region	O
(	O
at	O
position	O
91	O
;	O
Figure	O
3	O
)	O
,	O
a	O
role	O
for	O
CRP	O
-	O
mediated	O
activation	O
in	O
cl	O
expression	O
has	O
not	O
previously	O
been	O
described	O
.	O

The	O
orientation	O
of	O
the	O
promoter	O
and	O
its	O
cl	O
-	O
repressible	O
character	O
raise	O
the	O
possibility	O
that	O
cl	O
expression	O
is	O
autoregulatory	O
.	O

If	O
this	O
is	O
so	O
,	O
one	O
potential	O
activator	O
would	O
be	O
the	O
cl	O
repressor	O
itself	O
.	O

Expression	O
cannot	O
be	O
absolutely	O
dependent	O
on	O
cl	O
-	O
mediated	O
activation	O
,	O
however	O
,	O
because	O
the	O
cloned	O
promoter	O
exhibits	O
significant	O
activity	O
in	O
the	O
absence	O
of	O
the	O
cl	O
gene	O
(	O
Table	O
2	O
)	O
.	O

Under	O
the	O
conditions	O
reported	O
here	O
,	O
the	O
presence	O
of	O
the	O
cl	O
gene	O
results	O
in	O
a	O
decrease	O
rather	O
than	O
an	O
increase	O
in	O
lacZ	O
expression	O
;	O
however	O
,	O
these	O
observations	O
do	O
not	O
rule	O
out	O
a	O
potential	O
activator	O
role	O
for	O
the	O
cl	O
protein	O
,	O
since	O
the	O
ratios	O
of	O
repressor	O
and	O
operator	O
provided	O
by	O
the	O
multicopy	O
plasmids	O
may	O
not	O
be	O
optimal	O
for	O
activation	O
.	O

Physiologically	O
,	O
the	O
role	O
of	O
additional	O
repressor	O
binding	O
sites	O
in	O
regulating	O
cl	O
expression	O
also	O
cannot	O
be	O
discounted	O
.	O

Three	O
potential	O
operator	O
sites	O
have	O
been	O
identified	O
several	O
hundred	O
bps	O
upstream	O
of	O
the	O
cI	O
open	O
reading	O
frame	O
(	O
2	O
-	O
5	O
)	O
;	O
one	O
or	O
more	O
of	O
these	O
could	O
be	O
involved	O
(	O
possibly	O
through	O
a	O
DNA	O
looping	O
mechanism	O
;	O
37	O
)	O
in	O
the	O
activation	O
or	O
repression	O
of	O
cl	O
expression	O
during	O
phage	O
growth	O
.	O

A	O
cl	O
-	O
repressible	O
promoter	O
oriented	O
in	O
the	O
direction	O
of	O
cl	O
was	O
previously	O
reported	O
(	O
38	O
)	O
to	O
be	O
located	O
entirely	O
within	O
PlBamHI	O
-	O
9	O
,	O
a	O
fragment	O
located	O
upstream	O
of	O
cl	O
which	O
is	O
bracketed	O
by	O
the	O
BamHI	O
site	O
within	O
pBCB2	O
.	O

13	O
.	O

Because	O
sequences	O
on	O
both	O
sides	O
of	O
this	O
BamHI	O
site	O
are	O
required	O
for	O
the	O
activity	O
of	O
the	O
promoter	O
in	O
pBCB2	O
.	O
13	O
,	O
we	O
suggest	O
that	O
the	O
previously	O
identified	O
promoter	O
is	O
distinct	O
from	O
the	O
one	O
reported	O
here	O
.	O

The	O
promoter	O
from	O
BamHI	O
-	O
9	O
could	O
correspond	O
to	O
a	O
consensus	O
promoter	O
sequence	O
that	O
is	O
situated	O
about	O
500	O
bps	O
upstream	O
of	O
cl	O
and	O
overlaps	O
a	O
cl	O
repressor	O
binding	O
site	O
(	O
2	O
)	O
.	O

If	O
so	O
,	O
cl	O
expression	O
is	O
likely	O
to	O
be	O
controlled	O
by	O
more	O
than	O
one	O
promoter	O
.	O

Located	O
between	O
this	O
promoter	O
sequence	O
and	O
the	O
promoter	O
encoded	O
on	O
pBCB2	O
.	O

13	O
is	O
an	O
open	O
reading	O
frame	O
whose	O
product	O
(	O
termed	O
coi	O
,	O
or	O
c	O
-	O
one	O
inactivator	O
)	O
has	O
been	O
implicated	O
in	O
the	O
establishment	O
of	O
lytic	O
growth	O
(	O
1	O
,	O
39	O
;	O
B	O
.	O
R	O
.	O
Baumstark	O
,	O
unpublished	O
results	O
)	O
.	O

It	O
has	O
been	O
suggested	O
(	O
2	O
)	O
that	O
the	O
decision	O
to	O
enter	O
lytic	O
or	O
lysogenic	O
growth	O
is	O
influenced	O
by	O
the	O
level	O
of	O
transcription	O
initiated	O
from	O
the	O
distal	O
promoter	O
(	O
which	O
would	O
transcribe	O
coi	O
prior	O
to	O
the	O
transcription	O
of	O
cl	O
)	O
relative	O
to	O
that	O
of	O
the	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
cl	O
gene	O
(	O
which	O
would	O
transcribe	O
only	O
ci	O
)	O
.	O

A	O
32	O
-	O
nucleotide	O
hyphenated	O
inverted	O
repeat	O
sequence	O
is	O
located	O
just	O
upstream	O
of	O
the	O
cl	O
open	O
reading	O
frame	O
(	O
positions	O
146	O
-	O
188	O
;	O
Figure	O
3	O
)	O
.	O

It	O
is	O
not	O
currently	O
known	O
whether	O
this	O
sequence	O
has	O
any	O
regulatory	O
effect	O
on	O
cl	O
expression	O
.	O

Conceivably	O
,	O
the	O
sequence	O
could	O
serve	O
as	O
a	O
recognition	O
site	O
for	O
an	O
as	O
-	O
yet	O
-	O
unidentified	O
regulatory	O
protein	O
.	O

Alternatively	O
,	O
it	O
may	O
affect	O
the	O
secondary	O
structure	O
of	O
the	O
messenger	O
RNA	O
.	O

A	O
transcript	O
extending	O
from	O
a	O
promoter	O
located	O
upstream	O
of	O
the	O
putative	O
coi	O
open	O
reading	O
frame	O
would	O
be	O
capable	O
of	O
forming	O
a	O
stable	O
stem	O
-	O
loop	O
structure	O
containing	O
16	O
bps	O
with	O
a	O
single	O
bp	O
mismatch	O
(	O
AG	O
=	O
-	O
33	O
.	O
6	O
Kcal	O
)	O
of	O
this	O
inverted	O
repeat	O
sequence	O
.	O

Such	O
a	O
structure	O
could	O
potentially	O
serve	O
as	O
a	O
recognition	O
site	O
for	O
a	O
regulatory	O
factor	O
or	O
,	O
alternatively	O
,	O
could	O
mask	O
such	O
a	O
site	O
.	O

On	O
the	O
other	O
hand	O
,	O
transcription	O
originating	O
from	O
the	O
promoter	O
spanning	O
the	O
BamHI	O
site	O
just	O
upstream	O
of	O
cl	O
would	O
start	O
at	O
a	O
site	O
within	O
the	O
inverted	O
repeat	O
sequence	O
,	O
forming	O
a	O
comparatively	O
less	O
stable	O
stem	O
-	O
loop	O
structure	O
of	O
about	O
8	O
bps	O
.	O

The	O
role	O
of	O
the	O
inverted	O
repeat	O
region	O
in	O
the	O
regulation	O
of	O
cl	O
expression	O
is	O
currently	O
under	O
investigation	O
.	O

ACKNOWLEDGEMENTS	O

We	O
thank	O
Heinz	O
Schuster	O
for	O
his	O
review	O
of	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
by	O
National	O
Science	O
Foundation	O
grant	O
DMB	O
-	O
8704146	O
.	O

7679	O

Nucleic	O
Acids	O
Research	O

Abbreviations	O
:	O
bp	O
,	O
basepairs	O
;	O
kb	O
,	O
kilobase	O
pairs	O
;	O
X	O
-	O
Gal	O
,	O
5	O
-	O
Bromo	O
-	O
4	O
-	O
Chloro	O
-	O
3	O
-	O
indolylbeta	O
-	O
D	O
-	O
galactopyranoside	O
.	O

*	O
To	O
whom	O
correspondence	O
should	O
be	O
addressed	O

REFERENCES	O

1	O
.	O

Yarmolinsky	O
,	O
M	O
.	O
B	O
.	O
,	O
and	O
Steinberg	O
,	O
N	O
.	O

(	O
1988	O
)	O
.	O

In	O
Calendar	O
,	O
R	O
.	O
,	O
(	O
ed	O
.	O
)	O
,	O
The	O
Bacteriophages	O
,	O
Plenum	O
Publishing	O

Corp	O
.	O
,	O
NY	O
,	O
Vol	O
.	O

1	O
,	O
pp	O
.	O

291	O
-	O
438	O
.	O

2	O
.	O

Baumstark	O
,	O
B	O
.	O
R	O
.	O
,	O
Stovall	O
,	O
S	O
.	O
R	O
.	O
,	O
and	O
Ashkar	O
,	O
S	O
.	O

(	O
1987	O
)	O
.	O

Virology	O
156	O
,	O
404	O
-	O
413	O
.	O

3	O
.	O

Dreiseikelmann	O
,	O
B	O
.	O
,	O
Velleman	O
,	O
M	O
.	O
,	O
and	O
Schuster	O
,	O
H	O
.	O

(	O
1988	O
)	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

263	O
,	O
1391	O
-	O
1397	O
.	O

4	O
.	O

Heinrich	O
,	O
J	O
.	O
,	O
Riedel	O
,	O
H	O
.	O
-	O
D	O
.	O
,	O
Baumstark	O
,	O
B	O
.	O
R	O
.	O
,	O
Kimura	O
,	O
M	O
.	O
,	O
and	O
Schuster	O
,	O
H	O
.	O

(	O
1989	O
)	O
.	O

Nucleic	O
Acids	O
Res	O
,	O

this	O
volume	O
.	O

5	O
.	O

Eliason	O
,	O
J	O
.	O
L	O
.	O
,	O
and	O
Stemnberg	O
,	O
N	O
.	O

(	O
1987	O
)	O
.	O

J	O
.	O

Mol	O
.	O

Biol	O
.	O

198	O
,	O
281	O
-	O
293	O
.	O

6	O
.	O

Velleman	O
,	O
M	O
.	O
,	O
Dreiseikelmann	O
,	O
B	O
.	O
,	O
and	O
Schuster	O
,	O
H	O
.	O

(	O
1987	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
84	O
,	O
5570	O
-	O
5574	O
.	O

7	O
.	O

Citron	O
,	O
M	O
.	O
,	O
Velleman	O
,	O
M	O
.	O
,	O
and	O
Schuster	O
,	O
H	O
.	O

(	O
1988	O
)	O
.	O

J	O
.	O

Biol	O
.	O

Chem	O
.	O

264	O
,	O
3611	O
-	O
3617	O
.	O

8	O
.	O

Chadwick	O
,	O
P	O
.	O
,	O
Pirotta	O
,	O
V	O
.	O
,	O
Steinberg	O
,	O
R	O
.	O
,	O
Hopkins	O
,	O
N	O
.	O
,	O
and	O
Ptashne	O
,	O
M	O
.	O

(	O
1970	O
)	O
.	O

Cold	O
Spring	O
Harbor	O
Symp	O
.	O

Quant	O
.	O

Biol	O
.	O

35	O
,	O
283	O
-	O
294	O
.	O

9	O
.	O

Chesney	O
,	O
R	O
.	O
H	O
.	O
,	O
and	O
Scott	O
,	O
J	O
.	O
R	O
.	O

(	O
1975	O
)	O
.	O

Virology	O
67	O
,	O
375	O
-	O
384	O
.	O

10	O
.	O

Wandersman	O
,	O
C	O
.	O
,	O
and	O
Yarmolinsky	O
,	O
M	O
.	O

(	O
1977	O
)	O
.	O

Virology	O
78	O
,	O
267	O
-	O
276	O
.	O

11	O
.	O

Scott	O
,	O
J	O
.	O
R	O
.	O
,	O
West	O
,	O
B	O
.	O
W	O
.	O
,	O
and	O
Laping	O
,	O
J	O
.	O
L	O
.	O

(	O
1978	O
)	O
.	O

Virology	O
85	O
,	O
587	O
-	O
600	O
.	O

12	O
.	O

Pabo	O
,	O
C	O
.	O
O	O
.	O
,	O
and	O
Sauer	O
,	O
R	O
.	O

A	O
.	O

(	O
1984	O
)	O
.	O

Ann	O
.	O

Rev	O
.	O

Biochem	O
.	O

53	O
,	O
293	O
-	O
321	O
.	O

13	O
.	O

Scott	O
,	O
J	O
.	O
R	O
.	O

(	O
1974	O
)	O
.	O

Virology	O
62	O
,	O
344	O
-	O
349	O
.	O

14	O
.	O

Schneider	O
,	O
K	O
.	O
,	O
and	O
Beck	O
,	O
C	O
.	O
F	O
.	O

(	O
1987	O
)	O
.	O

Methods	O
in	O
Enzymol	O
.	O

153	O
,	O
452	O
-	O
461	O
.	O

15	O
.	O

Smith	O
,	O
H	O
.	O
W	O
.	O

(	O
1972	O
)	O
.	O

Nature	O
New	O
Biol	O
.	O

238	O
,	O
205	O
-	O
206	O
.	O

16	O
.	O

Scott	O
,	O
J	O
.	O
R	O
.	O

(	O
1975	O
)	O
.	O

Virology	O
65	O
,	O
173	O
-	O
178	O
.	O

17	O
.	O

Scott	O
,	O
J	O
.	O
R	O
.	O
,	O
Kropf	O
,	O
M	O
.	O
M	O
.	O
,	O
and	O
Mendelson	O
,	O
L	O
.	O

(	O
1977	O
)	O
.	O

Virology	O
76	O
,	O
39	O
-	O
46	O
.	O

18	O
.	O

Scott	O
,	O
J	O
.	O
R	O
.	O

(	O
1968	O
)	O
.	O

Virology	O
36	O
,	O
564	O
-	O
574	O
.	O

19	O
.	O

Walker	O
,	O
D	O
.	O
H	O
.	O
,	O
Jr	O
.	O
,	O
and	O
Walker	O
,	O
J	O
.	O
T	O
.	O

(	O
1976	O
)	O
.	O

J	O
.	O

Virol	O
.	O

20	O
,	O
177	O
-	O
187	O
.	O

20	O
.	O

Stemnberg	O
,	O
N	O
.	O

(	O
1979	O
)	O
.	O

Virology	O
96	O
,	O
129	O
-	O
142	O
.	O

21	O
.	O

Schneider	O
,	O
K	O
.	O
,	O
and	O
Beck	O
,	O
C	O
.	O
F	O
.	O

(	O
1986	O
)	O
.	O

Gene	O
42	O
,	O
37	O
-	O
48	O
.	O

22	O
.	O

Taylor	O
,	O
D	O
.	O
P	O
.	O
,	O
and	O
Cohen	O
,	O
S	O
.	O
N	O
.	O

(	O
1979	O
)	O
.	O

J	O
.	O

Bacteriol	O
.	O

137	O
,	O
92	O
-	O
104	O
.	O

23	O
.	O

Miller	O
,	O
J	O
.	O
H	O
.	O

(	O
1972	O
)	O
.	O

In	O
Experiments	O
in	O
Molecular	O
Genetics	O
,	O
Cold	O
Spring	O
Harbor	O
Laboratory	O
,	O
Cold	O
Spring	O

Harbor	O
,	O
N	O
.	O
Y	O
.	O

352	O
-	O
355	O
.	O

24	O
.	O

Guyer	O
,	O
R	O
.	O
S	O
.	O

(	O
1978	O
)	O
.	O

J	O
.	O

Mol	O
.	O

Biol	O
.	O

126	O
,	O
347	O
-	O
365	O
.	O

25	O
.	O

Devlin	O
,	O
B	O
.	O
H	O
.	O
,	O
Baumstark	O
,	O
B	O
.	O
R	O
.	O
,	O
and	O
Scott	O
,	O
J	O
.	O
R	O
.	O

(	O
1982	O
)	O
.	O

Virology	O
120	O
,	O
360	O
-	O
375	O
.	O

26	O
.	O

Sanger	O
,	O
F	O
.	O
,	O
Nicklen	O
,	O
S	O
.	O
,	O
and	O
Coulson	O
,	O
A	O
.	O
R	O
.	O

(	O
1977	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
74	O
,	O
5463	O
-	O
5467	O
.	O

27	O
.	O

DeVries	O
,	O
J	O
.	O
K	O
.	O
,	O
and	O
Zubay	O
,	O
G	O
.	O

(	O
1967	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
57	O
,	O
1010	O
-	O
1012	O
.	O

28	O
.	O

Heilmann	O
,	O
H	O
.	O
,	O
Reeve	O
,	O
J	O
.	O
R	O
.	O
,	O
and	O
Puhler	O
,	O
A	O
.	O

(	O
1980	O
)	O
.	O

Mol	O
.	O

Gen	O
.	O

Genet	O
.	O

178	O
,	O
149	O
-	O
154	O
.	O

29	O
.	O

Shine	O
,	O
J	O
.	O
,	O
and	O
Dalgarno	O
,	O
L	O
.	O

(	O
1974	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
71	O
,	O
1342	O
-	O
1346	O
.	O

30	O
.	O

Chou	O
,	O
P	O
.	O
Y	O
.	O
,	O
and	O
Fasman	O
,	O
G	O
.	O
D	O
.	O

(	O
1978	O
)	O
.	O

Adv	O
.	O

Enzymol	O
.	O

47	O
,	O
45	O
-	O
148	O
.	O

31	O
.	O

Berg	O
,	O
J	O
.	O
M	O
.	O

(	O
1986	O
)	O
.	O

Nature	O
319	O
,	O
264	O
-	O
265	O
.	O

32	O
.	O

Landschultz	O
,	O
W	O
.	O
H	O
.	O
,	O
Johnson	O
,	O
P	O
.	O
F	O
.	O
,	O
and	O
McKnight	O
,	O
S	O
.	O
L	O
.	O

(	O
1988	O
)	O
.	O

Science	O
240	O
,	O
1759	O
-	O
1764	O
.	O

33	O
.	O

Murre	O
,	O
C	O
.	O
,	O
McCaw	O
,	O
P	O
.	O
,	O
and	O
Baltimore	O
,	O
D	O
.	O

Cell	O
56	O
,	O
777	O
-	O
783	O
.	O

34	O
.	O

Anderson	O
,	O
B	O
.	O
E	O
.	O
,	O
Baumstark	O
,	O
B	O
.	O
R	O
.	O
,	O
and	O
Bellini	O
,	O
W	O
.	O
J	O
.	O

(	O
1988	O
)	O
.	O

J	O
.	O

Bacteriol	O
.	O

170	O
,	O
4493	O
-	O
4500	O
.	O

35	O
.	O

Rosenberg	O
,	O
M	O
.	O
,	O
and	O
Court	O
,	O
D	O
.	O

(	O
1979	O
)	O
.	O

Annu	O
.	O

Rev	O
.	O

Genet	O
.	O

13	O
,	O
319	O
-	O
353	O
.	O

36	O
.	O

Ebright	O
,	O
R	O
.	O
H	O
.	O
,	O
Cossart	O
,	O
P	O
.	O
,	O
Gicquel	O
-	O
Sanzey	O
,	O
B	O
.	O
,	O
and	O
Beckwith	O
,	O
J	O
.	O

(	O
1984	O
)	O
.	O

Nature	O
311	O
,	O
232	O
-	O
235	O
.	O

37	O
.	O

Ptashne	O
,	O
M	O
.	O

(	O
1986	O
)	O
.	O

Nature	O
322	O
,	O
697	O
-	O
701	O
.	O

38	O
.	O

Stemnberg	O
,	O
N	O
.	O
,	O
and	O
Hoess	O
,	O
R	O
.	O

(	O
1983	O
)	O
.	O

Annu	O
.	O

Rev	O
.	O

Genet	O
.	O

17	O
,	O
123	O
-	O
154	O
.	O

39	O
.	O

Scott	O
,	O
J	O
.	O
R	O
.	O

(	O
1980	O
)	O
.	O

Curr	O
.	O

Top	O
.	O

Microbiol	O
.	O

Immunol	O
.	O

90	O
,	O
49	O
-	O
65	O
.	O

7680	O

This	O
article	O
,	O
submitted	O
on	O
disc	O
,	O
has	O
been	O
automatically	O

converted	O
into	O
this	O
typeset	O
format	O
by	O
the	O
publisher	O
.	O

Down	O
-	O
regulation	O
of	O
the	O
M6P	O
/	O
IGF	O
-	O
II	O
receptor	O
increases	O
cell	O
proliferation	O
and	O
reduces	O
apoptosis	O
in	O
neonatal	O
rat	S-Species
cardiac	O
myocytes	O

Abstract	O

Background	O

The	O
mannose	O
6	O
-	O
phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
II	O
receptor	O
(	O
M6P	O
/	O
IGF2R	O
)	O
is	O
a	O
multi	O
-	O
functional	O
protein	O
that	O
has	O
been	O
implicated	O
in	O
regulation	O
of	O
cell	O
growth	O
and	O
apoptosis	O
.	O

Cardiac	O
myocytes	O
express	O
relatively	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
,	O
and	O
cardiomyocyte	O
apoptosis	O
has	O
been	O
identified	O
in	O
a	O
variety	O
of	O
cardiovascular	O
disorders	O
,	O
such	O
as	O
myocardial	O
infarction	O
and	O
heart	O
failure	O
.	O

However	O
,	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
the	O
pathogenesis	O
of	O
these	O
conditions	O
has	O
not	O
been	O
determined	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
growth	O
and	O
apoptosis	O
.	O

Results	O

We	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
M6P	O
/	O
IGF2R	O
in	O
neonatal	O
rat	S-Species
cardiac	O
myocytes	O
and	O
examined	O
the	O
effect	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Infection	O
of	O
neonatal	O
cardiomyocytes	O
with	O
an	O
adenovirus	O
expressing	O
a	O
ribozyme	O
targeted	O
against	O
the	O
M6P	O
/	O
IGF2R	O
significantly	O
reduced	O
the	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
,	O
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
Ribonuclease	O
Protection	O
Assay	O
(	O
RPA	O
)	O
.	O

M6P	O
-	O
containing	O
protein	O
binding	O
and	O
endocytosis	O
as	O
well	O
as	O
the	O
M6P	O
/	O
IGF2R	O
-	O
mediated	O
internalization	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
were	O
lower	O
in	O
the	O
ribozyme	O
-	O
treated	O
cells	O
than	O
the	O
control	O
myocytes	O
,	O
indicating	O
that	O
the	O
number	O
of	O
functional	O
M6P	O
/	O
IGF2R	O
in	O
the	O
ribozyme	O
treated	O
cells	O
was	O
reduced	O
.	O

Accordingly	O
,	O
a	O
marked	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
reduced	O
cell	O
susceptibility	O
to	O
hypoxia	O
-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
were	O
observed	O
in	O
the	O
ribozyme	O
-	O
treated	O
cells	O
.	O

Conclusions	O

These	O
findings	O
suggest	O
that	O
M6P	O
/	O
IGF2R	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
growth	O
and	O
apoptosis	O
.	O

Down	O
regulation	O
of	O
this	O
gene	O
in	O
cardiac	O
tissues	O
might	O
be	O
a	O
new	O
approach	O
to	O
prevention	O
of	O
cell	O
death	O
or	O
promotion	O
of	O
mitogenesis	O
for	O
certain	O
heart	O
diseases	O
.	O

Background	O

The	O
mannose	O
6	O
-	O
phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
II	O
receptor	O
(	O
M6P	O
/	O
IGF2R	O
)	O
is	O
a	O
unique	O
protein	O
that	O
interacts	O
with	O
multiple	O
ligands	O
,	O
some	O
of	O
which	O
are	O
important	O
growth	O
regulatory	O
factors	O
[	O
1	O
]	O
.	O

The	O
M6P	O
/	O
IGF2R	O
participates	O
in	O
internalization	O
and	O
lysosomal	O
degradation	O
of	O
IGF	O
-	O
II	O
,	O
a	O
mitogen	O
normally	O
acting	O
through	O
the	O
IGF	O
-	O
I	O
receptor	O
to	O
stimulate	O
cell	O
proliferation	O
[	O
2	O
]	O
.	O

The	O
M6P	O
/	O
IGF2	O
receptor	O
is	O
required	O
for	O
the	O
activation	O
of	O
TGF	O
-	O
beta	O
[	O
3	O
]	O
,	O
a	O
potent	O
growth	O
inhibitor	O
for	O
many	O
cell	O
types	O
.	O

This	O
receptor	O
is	O
also	O
involved	O
in	O
the	O
binding	O
,	O
transport	O
and	O
activation	O
of	O
newly	O
-	O
synthesized	O
lysosomal	O
enzymes	O
,	O
such	O
as	O
cathepsins	O
[	O
4	O
,	O
5	O
]	O
,	O
which	O
have	O
been	O
recently	O
implicated	O
in	O
the	O
induction	O
of	O
apoptosis	O
[	O
6	O
]	O
.	O

On	O
the	O
basis	O
of	O
these	O
functions	O
,	O
the	O
M6P	O
/	O
IGF2R	O
has	O
been	O
proposed	O
to	O
play	O
a	O
significant	O
role	O
in	O
regulation	O
of	O
cell	O
growth	O
and	O
apoptosis	O
[	O
7	O
]	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
is	O
a	O
tightly	O
regulated	O
process	O
used	O
to	O
remove	O
excess	O
,	O
hazardous	O
or	O
damaged	O
somatic	O
cells	O
,	O
and	O
is	O
crucial	O
for	O
the	O
development	O
,	O
maintenance	O
and	O
survival	O
of	O
an	O
organism	O
.	O

However	O
,	O
alterations	O
in	O
the	O
control	O
of	O
apoptosis	O
have	O
also	O
been	O
shown	O
to	O
contribute	O
to	O
human	S-Species
diseases	O
.	O

In	O
fact	O
,	O
morphological	O
and	O
biochemical	O
markers	O
of	O
apoptosis	O
have	O
been	O
identified	O
in	O
a	O
wide	O
variety	O
of	O
cardiovascular	O
disorders	O
,	O
including	O
myocardial	O
infarction	O
and	O
heart	O
failure	O
.	O

This	O
suggests	O
that	O
activation	O
of	O
apoptotic	O
pathways	O
contributes	O
to	O
cardiomyocyte	O
loss	O
and	O
subsequent	O
cardiac	O
dysfunction	O
in	O
these	O
conditions	O
.	O

A	O
number	O
of	O
factors	O
involved	O
in	O
cardiomyocyte	O
apoptosis	O
are	O
currently	O
known	O
and	O
include	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
(	O
IGF	O
-	O
I	O
)	O
,	O
stress	O
-	O
activated	O
protein	O
kinases	O
(	O
SAPKs	O
)	O
and	O
the	O
anti	O
-	O
apoptotic	O
Bcl	O
-	O
2	O
family	O
[	O
8	O
]	O
.	O

There	O
are	O
indications	O
that	O
other	O
factors	O
may	O
be	O
involved	O
in	O
induction	O
and	O
regulation	O
of	O
cardiac	O
apoptosis	O
.	O

However	O
,	O
these	O
potential	O
factors	O
and	O
their	O
corresponding	O
mechanisms	O
have	O
not	O
been	O
identified	O
.	O

Several	O
lines	O
of	O
evidence	O
point	O
to	O
the	O
potential	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
cardiac	O
myocyte	O
proliferation	O
and	O
apoptosis	O
.	O

Cardiac	O
myocytes	O
express	O
relatively	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
and	O
transgenic	O
mice	S-Species
containing	O
a	O
homologous	O
deletion	O
of	O
the	O
M6P	O
/	O
IGF2R	O
gene	O
manifest	O
ventricular	O
hyperplasia	O
due	O
to	O
an	O
increase	O
in	O
cell	O
number	O
[	O
9	O
,	O
10	O
]	O
,	O
suggesting	O
that	O
the	O
M6P	O
/	O
IGF2R	O
normally	O
acts	O
to	O
suppress	O
cardiac	O
myocyte	O
cell	O
growth	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
TGF	O
-	O
beta	O
,	O
a	O
potent	O
growth	O
suppressor	O
whose	O
activation	O
requires	O
the	O
binding	O
of	O
latent	O
TGF	O
-	O
beta	O
to	O
M6P	O
/	O
IGF2R	O
[	O
3	O
]	O
,	O
is	O
commonly	O
upregulated	O
in	O
chronic	O
heart	O
failure	O
[	O
11	O
]	O
.	O

Additional	O
evidence	O
for	O
the	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
apoptosis	O
comes	O
from	O
studies	O
of	O
tumorigenesis	O
.	O

It	O
has	O
been	O
shown	O
that	O
M6P	O
/	O
IGF2R	O
expression	O
is	O
significantly	O
reduced	O
in	O
a	O
variety	O
of	O
tumors	O
and	O
loss	O
of	O
heterozygocity	O
(	O
LOH	O
)	O
at	O
the	O
M6P	O
/	O
IGF2R	O
gene	O
locus	O
6q26	O
have	O
been	O
found	O
in	O
breast	O
,	O
liver	O
cancers	O
and	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
lung	O
[	O
12	O
-	O
15	O
]	O
.	O

Although	O
several	O
studies	O
have	O
examined	O
the	O
effect	O
of	O
M6P	O
/	O
IGF2R	O
over	O
-	O
expression	O
on	O
cell	O
growth	O
[	O
7	O
]	O
,	O
it	O
is	O
not	O
known	O
whether	O
down	O
-	O
regulation	O
of	O
this	O
receptor	O
protein	O
leads	O
to	O
cellular	O
protection	O
against	O
apoptosis	O
.	O

Ribozymes	O
are	O
catalytic	O
RNA	O
molecules	O
that	O
cleave	O
a	O
complementary	O
mRNA	O
sequence	O
[	O
16	O
]	O
,	O
thereby	O
inactivating	O
specific	O
mRNAs	O
and	O
suppressing	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
17	O
,	O
18	O
]	O
.	O

Ribozymes	O
have	O
been	O
shown	O
to	O
be	O
highly	O
specific	O
,	O
efficient	O
and	O
stable	O
.	O

They	O
can	O
be	O
packaged	O
into	O
viral	O
vectors	O
to	O
enhance	O
transfer	O
into	O
cells	O
and	O
to	O
achieve	O
longer	O
expression	O
compared	O
with	O
naked	O
oligonucleotides	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
ribozyme	O
technology	O
to	O
study	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
cell	O
growth	O
.	O

A	O
hammerhead	O
ribozyme	O
against	O
the	O
M6P	O
/	O
IGF2R	O
mRNA	O
was	O
constructed	O
and	O
packaged	O
in	O
an	O
adenoviral	O
vector	O
.	O

We	O
then	O
examined	O
the	O
effect	O
of	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
on	O
cell	O
growth	O
and	O
hypoxia	O
-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

Results	O

Cleavage	O
reaction	O
of	O
the	O
ribozyme	O
in	O
vitro	O

The	O
M6P	O
/	O
IGF2R	O
ribozyme	O
we	O
constructed	O
has	O
13	O
-	O
bp	O
binding	O
arms	O
complementary	O
to	O
the	O
target	O
site	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
,	O
and	O
a	O
catalytic	O
core	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

To	O
evaluate	O
the	O
bioactivity	O
of	O
the	O
ribozyme	O
and	O
the	O
accessibility	O
of	O
the	O
target	O
site	O
,	O
a	O
cleavage	O
reaction	O
was	O
performed	O
in	O
vitro	O
.	O

The	O
substrates	O
,	O
[	O
alpha	O
-	O
32P	O
]	O
labeled	O
RNA	O
transcripts	O
containing	O
45	O
bp	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
or	O
an	O
unmatched	O
sequence	O
,	O
were	O
incubated	O
with	O
the	O
ribozyme	O
as	O
described	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
ribozyme	O
cleaved	O
only	O
the	O
specific	O
M6P	O
/	O
IGF2R	O
mRNA	O
into	O
the	O
expected	O
products	O
.	O

In	O
the	O
assay	O
of	O
time	O
course	O
,	O
the	O
hammerhead	O
ribozyme	O
was	O
able	O
to	O
cleave	O
24	O
.	O
2	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
within	O
10	O
minutes	O
of	O
incubation	O
,	O
50	O
.	O
3	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
within	O
40	O
minutes	O
of	O
incubation	O
,	O
and	O
by	O
640	O
minutes	O
,	O
80	O
.	O
8	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
was	O
converted	O
to	O
the	O
expected	O
products	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

This	O
ribozyme	O
did	O
not	O
digest	O
the	O
unmatched	O
sequence	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

These	O
results	O
indicate	O
a	O
high	O
efficiency	O
and	O
specificity	O
of	O
the	O
ribozyme	O
in	O
vitro	O
.	O

Ribozymes	O
down	O
-	O
regulate	O
M6P	O
/	O
IGF2R	O
expression	O
in	O
cardiac	O
myocytes	O

To	O
examine	O
the	O
ability	O
of	O
the	O
ribozyme	O
to	O
reduce	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
in	O
cultured	O
cardiac	O
myocytes	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
,	O
and	O
subjected	O
to	O
RT	O
-	O
PCR	O
using	O
M6P	O
/	O
IGF2R	O
-	O
specific	O
primers	O
.	O

Primers	O
specific	O
for	O
beta	O
-	O
actin	O
were	O
added	O
to	O
a	O
parallel	O
reaction	O
to	O
serve	O
as	O
an	O
internal	O
standard	O
.	O

Cells	O
were	O
used	O
4	O
days	O
after	O
infection	O
,	O
with	O
average	O
infection	O
efficiency	O
of	O
70	O
-	O
80	O
%	O
(	O
for	O
which	O
a	O
viral	O
dose	O
used	O
had	O
minimal	O
cytotoxicity	O
)	O
.	O

The	O
RT	O
-	O
PCR	O
product	O
of	O
M6P	O
/	O
IGF2R	O
was	O
856	O
bp	O
,	O
and	O
the	O
beta	O
-	O
actin	O
product	O
was	O
285	O
bp	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2A	O
,	O
the	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
-	O
infected	O
cells	O
exhibited	O
a	O
significantly	O
lower	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
than	O
Ad	O
-	O
GFP	O
-	O
infected	O
cells	O
,	O
with	O
a	O
reduction	O
of	O
about	O
50	O
%	O
.	O

This	O
result	O
was	O
confirmed	O
by	O
ribonuclease	O
protection	O
assay	O
(	O
RPA	O
)	O
,	O
in	O
which	O
GAPDH	O
was	O
used	O
as	O
a	O
control	O
(	O
Fig	O
.	O
2C	O
&	O
2D	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
between	O
Ad	O
-	O
GFP	O
-	O
infected	O
cells	O
and	O
uninfected	O
cells	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
infection	O
with	O
the	O
adenovirus	O
itself	O
did	O
not	O
alter	O
the	O
endogenous	O
M6P	O
/	O
IGF2R	O
mRNA	O
level	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
ribozyme	O
was	O
highly	O
effective	O
in	O
suppressing	O
M6P	O
/	O
IGF2R	O
expression	O
in	O
cultured	O
cardiac	O
myocytes	O
.	O

Effect	O
of	O
ribozyme	O
expression	O
on	O
the	O
functional	O
activity	O
of	O
M6P	O
/	O
IGF2R	O

To	O
determine	O
the	O
effect	O
of	O
the	O
ribozyme	O
on	O
the	O
functional	O
activity	O
of	O
M6P	O
/	O
IGF2R	O
,	O
binding	O
and	O
internalization	O
of	O
exogenous	O
125I	O
-	O
IGF	O
-	O
II	O
was	O
measured	O
in	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

3A	O
,	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
showed	O
a	O
54	O
%	O
reduction	O
in	O
125I	O
-	O
IGF	O
-	O
II	O
internalization	O
when	O
compared	O
with	O
the	O
control	O
cells	O
(	O
infected	O
with	O
Ad	O
-	O
GFP	O
)	O
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
the	O
ribozyme	O
on	O
the	O
M6P	O
-	O
binding	O
activity	O
of	O
the	O
M6P	O
/	O
IGF2R	O
using	O
the	O
M6P	O
-	O
bearing	O
lysosomal	O
enzyme	O
,	O
beta	O
-	O
glucuronidase	O
,	O
as	O
a	O
probe	O
.	O

The	O
results	O
showed	O
that	O
the	O
maximal	O
M6P	O
-	O
binding	O
capacity	O
of	O
cells	O
treated	O
with	O
the	O
ribozyme	O
was	O
about	O
50	O
%	O
less	O
than	O
that	O
of	O
controls	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Furthermore	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
cells	O
to	O
internalize	O
exogenous	O
beta	O
-	O
glucuronidase	O
after	O
treatment	O
with	O
ribozyme	O
.	O

Similarly	O
,	O
the	O
M6P	O
-	O
inhibitable	O
endocytosis	O
of	O
beta	O
-	O
glucuronidase	O
by	O
ribozyme	O
-	O
treated	O
cells	O
was	O
about	O
52	O
%	O
less	O
than	O
that	O
of	O
control	O
cells	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

These	O
results	O
confirm	O
that	O
the	O
number	O
of	O
functional	O
M6P	O
/	O
IGF2R	O
in	O
ribozyme	O
-	O
treated	O
cells	O
was	O
reduced	O
.	O

Adenoviral	O
delivery	O
of	O
ribozymes	O
increases	O
the	O
proliferation	O
of	O
cardiac	O
myocytes	O

We	O
examined	O
the	O
effects	O
of	O
the	O
ribozyme	O
on	O
the	O
growth	O
of	O
cultured	O
neonatal	O
rat	S-Species
cardiac	O
myocytes	O
.	O

Morphological	O
evaluation	O
showed	O
a	O
remarkable	O
difference	O
in	O
growth	O
pattern	O
between	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
-	O
infected	O
cells	O
and	O
the	O
control	O
cells	O
:	O
the	O
ribozyme	O
-	O
expressing	O
cells	O
formed	O
larger	O
and	O
more	O
spread	O
colonies	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Assessment	O
of	O
cell	O
proliferative	O
activity	O
by	O
the	O
MTT	O
assay	O
and	O
counts	O
of	O
viable	O
cells	O
showed	O
that	O
the	O
number	O
of	O
cardiac	O
myocytes	O
in	O
ribozyme	O
-	O
expressing	O
cultures	O
was	O
significantly	O
higher	O
than	O
in	O
control	O
cultures	O
(	O
Fig	O
.	O
5	O
)	O
.	O

These	O
results	O
indicate	O
that	O
treatment	O
with	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
can	O
promote	O
cardiac	O
myocyte	O
proliferation	O
.	O

Effect	O
of	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
expression	O
on	O
apoptosis	O
of	O
cardiac	O
myocytes	O

We	O
examined	O
the	O
effects	O
of	O
ribozyme	O
expression	O
on	O
TNF	O
-	O
alpha	O
and	O
hypoxia	O
-	O
induced	O
apoptosis	O
of	O
cultured	O
cardiac	O
myocytes	O
.	O

After	O
a	O
24	O
hr	O
challenge	O
with	O
hypoxia	O
,	O
the	O
number	O
of	O
apoptotic	O
cells	O
in	O
M6P	O
/	O
IGF2R	O
-	O
Rz	O
expressing	O
cultures	O
was	O
38	O
%	O
lower	O
than	O
in	O
control	O
cultures	O
as	O
determined	O
by	O
Hoechst	O
staining	O
(	O
which	O
highlights	O
the	O
nuclei	O
of	O
apoptotic	O
cells	O
)	O
and	O
ELISA	O
(	O
Fig	O
.	O
6A	O
,	O
7A	O
)	O
.	O

MTT	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
viable	O
cells	O
in	O
ribozyme	O
-	O
treated	O
cultures	O
was	O
40	O
%	O
higher	O
than	O
in	O
control	O
cultures	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

After	O
treatment	O
with	O
TNF	O
-	O
alpha	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

6B	O
,	O
a	O
large	O
number	O
of	O
control	O
cells	O
underwent	O
apoptosis	O
,	O
as	O
indicated	O
by	O
morphological	O
changes	O
(	O
small	O
round	O
shape	O
)	O
and	O
bright	O
blue	O
nuclear	O
staining	O
.	O

There	O
were	O
significantly	O
more	O
apoptotic	O
cells	O
in	O
control	O
cultures	O
than	O
in	O
cultures	O
expressing	O
the	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

The	O
number	O
of	O
apoptotic	O
cells	O
,	O
as	O
measured	O
by	O
the	O
cell	O
death	O
ELISA	O
assay	O
,	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
was	O
significantly	O
(	O
about	O
40	O
%	O
)	O
lower	O
than	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

Accordingly	O
,	O
the	O
number	O
of	O
viable	O
cells	O
,	O
as	O
measured	O
by	O
MTT	O
analysis	O
,	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
was	O
significantly	O
(	O
about	O
45	O
%	O
)	O
higher	O
than	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
decreasing	O
M6P	O
/	O
IGF2R	O
expression	O
by	O
ribozyme	O
treatment	O
can	O
reduce	O
cell	O
apoptosis	O
.	O

Discussion	O

Some	O
62	O
,	O
000	O
,	O
000	O
Americans	O
have	O
one	O
or	O
more	O
types	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
CVD	O
is	O
the	O
leading	O
cause	O
(	O
40	O
.	O
1	O
%	O
)	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

Myocardial	O
infarction	O
and	O
heart	O
failure	O
,	O
conditions	O
accompanied	O
by	O
cardiac	O
myocyte	O
apoptosis	O
,	O
represent	O
23	O
%	O
of	O
all	O
CVDs	O
and	O
are	O
a	O
growing	O
clinical	O
challenge	O
in	O
need	O
of	O
novel	O
therapeutic	O
strategies	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
M6P	O
/	O
IGF2R	O
as	O
a	O
potential	O
new	O
therapeutic	O
target	O
for	O
reduction	O
of	O
cardiac	O
apoptosis	O
and	O
cardiac	O
injury	O
in	O
these	O
conditions	O
.	O

Using	O
ribozyme	O
technology	O
we	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
the	O
M6P	O
/	O
IGF2R	O
in	O
neonatal	O
cardiac	O
myocytes	O
.	O

We	O
then	O
examined	O
cell	O
proliferation	O
and	O
apoptosis	O
under	O
normal	O
conditions	O
and	O
post	O
challenge	O
with	O
either	O
hypoxia	O
,	O
a	O
model	O
of	O
ischemia	O
-	O
reperfusion	O
,	O
or	O
TNF	O
-	O
alpha	O
,	O
a	O
cytokine	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
heart	O
failure	O
[	O
19	O
]	O
.	O

Our	O
results	O
demonstrate	O
an	O
association	O
of	O
a	O
decrease	O
in	O
the	O
expression	O
and	O
function	O
of	O
the	O
M6P	O
/	O
IGF2R	O
with	O
increased	O
cell	O
proliferation	O
and	O
decreased	O
cell	O
susceptibility	O
to	O
hypoxia	O
-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

Expression	O
of	O
the	O
ribozyme	O
targeted	O
against	O
the	O
M6P	O
/	O
IGF2R	O
in	O
cardiomyocytes	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
,	O
as	O
measured	O
by	O
RT	O
-	O
PCR	O
and	O
RPA	O
,	O
and	O
of	O
M6P	O
/	O
IGF2R	O
function	O
,	O
as	O
indicated	O
by	O
a	O
decrease	O
in	O
internalization	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
,	O
and	O
beta	O
-	O
glucuronidase	O
binding	O
and	O
endocytosis	O
.	O

MTT	O
analysis	O
and	O
viable	O
cell	O
counts	O
showed	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
cell	O
proliferation	O
of	O
cardiomyocytes	O
,	O
which	O
normally	O
express	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
[	O
20	O
]	O
and	O
have	O
limited	O
proliferative	O
capabilities	O
[	O
21	O
]	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
findings	O
of	O
previous	O
knockout	O
studies	O
[	O
9	O
,	O
10	O
]	O
.	O

Since	O
the	O
M6P	O
/	O
IGF2R	O
has	O
multiple	O
actions	O
on	O
cell	O
growth	O
,	O
its	O
proliferative	O
effect	O
on	O
the	O
heart	O
cells	O
observed	O
in	O
this	O
study	O
might	O
involve	O
multiple	O
mechanisms	O
.	O

However	O
,	O
it	O
is	O
likely	O
that	O
unchecked	O
IGF	O
-	O
II	O
stimulation	O
plays	O
a	O
key	O
role	O
in	O
the	O
effect	O
.	O

Because	O
the	O
M6P	O
/	O
IGF2R	O
is	O
believed	O
to	O
sequester	O
and	O
degrade	O
IGF	O
-	O
II	O
[	O
2	O
]	O
,	O
a	O
decrease	O
in	O
M6P	O
/	O
IGF2R	O
expression	O
and	O
function	O
could	O
result	O
in	O
decreased	O
degradation	O
and	O
hence	O
increased	O
bioavailability	O
of	O
IGF	O
-	O
II	O
to	O
the	O
IGF	O
-	O
I	O
receptor	O
,	O
which	O
mediates	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
IGF	O
-	O
II	O
.	O

Supporting	O
evidence	O
for	O
the	O
involvement	O
of	O
IGF	O
-	O
II	O
in	O
the	O
proliferative	O
effect	O
resulting	O
from	O
loss	O
of	O
M6P	O
/	O
IGF2R	O
function	O
comes	O
from	O
studies	O
of	O
M6P	O
/	O
IGF2R	O
knock	O
-	O
out	O
mice	S-Species
.	O

M6P	O
/	O
IGF2R	O
-	O
null	O
mice	S-Species
display	O
global	O
hyperplasia	O
that	O
coincides	O
with	O
elevated	O
levels	O
of	O
IGF	O
-	O
II	O
.	O

Most	O
importantly	O
,	O
however	O
,	O
the	O
lethal	O
nature	O
of	O
an	O
M6P	O
/	O
IGF2R	O
-	O
null	O
phenotype	O
is	O
reversed	O
in	O
an	O
IGF	O
-	O
II	O
-	O
null	O
background	O
[	O
9	O
]	O
.	O

Our	O
results	O
showing	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
lead	O
to	O
a	O
decrease	O
in	O
IGF	O
-	O
II	O
internalization	O
support	O
the	O
above	O
possibility	O
.	O

However	O
,	O
further	O
investigation	O
to	O
confirm	O
this	O
mechanism	O
is	O
warranted	O
.	O

More	O
importantly	O
,	O
our	O
results	O
also	O
showed	O
that	O
M6P	O
/	O
IGF2R	O
down	O
-	O
regulation	O
resulted	O
in	O
decreased	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
hypoxia	O
-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

There	O
is	O
evidence	O
that	O
lysosomal	O
enzymes	O
,	O
such	O
as	O
cathepsins	O
B	O
and	O
D	O
contribute	O
to	O
hypoxia	O
-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
in	O
vitro	O
[	O
22	O
-	O
25	O
]	O
and	O
in	O
vivo	O
[	O
26	O
,	O
27	O
]	O
.	O

The	O
M6P	O
/	O
IGF2R	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
,	O
transport	O
and	O
activation	O
of	O
lysosomal	O
enzymes	O
,	O
including	O
cathepsins	O
[	O
4	O
,	O
5	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
down	O
-	O
regulation	O
of	O
the	O
M6P	O
/	O
IGF2R	O
results	O
in	O
improper	O
trafficking	O
and	O
activation	O
of	O
cathepsins	O
.	O

This	O
,	O
in	O
turn	O
would	O
eliminate	O
the	O
apoptotic	O
cascades	O
triggered	O
by	O
these	O
enzymes	O
under	O
hypoxia	O
and	O
TNF	O
stimulation	O
and	O
result	O
in	O
decreased	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
apoptosis	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
TNF	O
stimulation	O
involves	O
the	O
activation	O
of	O
TGF	O
-	O
beta	O
[	O
28	O
-	O
30	O
]	O
,	O
a	O
ligand	O
of	O
M6P	O
/	O
IGF2R	O
that	O
has	O
been	O
implicated	O
in	O
the	O
progression	O
of	O
chronic	O
heart	O
failure	O
[	O
11	O
,	O
31	O
]	O
.	O

Therefore	O
,	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
could	O
also	O
lead	O
to	O
a	O
decreased	O
bioavailability	O
of	O
activated	O
TGF	O
-	O
beta	O
,	O
thereby	O
decreasing	O
the	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
the	O
TNF	O
/	O
TGF	O
-	O
beta	O
apoptotic	O
pathway	O
.	O

The	O
detailed	O
mechanism	O
of	O
the	O
observed	O
effects	O
is	O
unknown	O
and	O
requires	O
further	O
investigation	O
.	O

Conclusions	O

The	O
present	O
study	O
demonstrates	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
expression	O
and	O
functional	O
activity	O
of	O
the	O
M6P	O
/	O
IGF2R	O
results	O
in	O
a	O
decrease	O
in	O
the	O
susceptibility	O
of	O
cardiac	O
myocytes	O
to	O
apoptotic	O
stimuli	O
.	O

These	O
findings	O
suggest	O
that	O
this	O
receptor	O
might	O
be	O
involved	O
in	O
cardiac	O
cell	O
growth	O
and	O
apoptosis	O
.	O

The	O
ability	O
of	O
the	O
M6P	O
/	O
IGF2R	O
ribozyme	O
to	O
reduce	O
M6P	O
/	O
IGF2R	O
expression	O
and	O
function	O
in	O
transfected	O
cells	O
verifies	O
the	O
utility	O
of	O
the	O
ribozyme	O
in	O
studying	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
cardiomyocyte	O
growth	O
and	O
apoptosis	O
.	O

In	O
addition	O
to	O
its	O
utility	O
as	O
a	O
research	O
tool	O
,	O
the	O
ribozyme	O
,	O
with	O
further	O
exploration	O
and	O
development	O
,	O
might	O
have	O
potential	O
application	O
as	O
a	O
therapeutic	O
agent	O
to	O
prevent	O
cell	O
death	O
or	O
promote	O
mitogenesis	O
for	O
certain	O
clinical	O
conditions	O
,	O
such	O
as	O
,	O
myocardial	O
infarction	O
and	O
chronic	O
heart	O
failure	O
.	O

Methods	O

Construction	O
of	O
recombinant	O
M6P	O
/	O
IGF2R	O
-	O
RZ	O
adenoviral	O
vector	O

The	O
nucleotide	O
numbers	O
of	O
the	O
rat	S-Species
M6P	O
/	O
IGF2R	O
sequence	O
targeted	O
by	O
the	O
hammerhead	O
ribozyme	O
is	O
1147	O
-	O
1160	O
after	O
coding	O
site	O
(	O
exon	O
9	O
)	O
.	O

The	O
structure	O
of	O
the	O
M6P	O
/	O
IGF2R	O
hammerhead	O
ribozyme	O
is	O
shown	O
in	O
Fig	O
.	O

1	O
.	O

A	O
49	O
bp	O
M6P	O
/	O
IGF2R	O
ribozyme	O
oligonucleotide	O
,	O
5	O
'	O
-	O
GAATTCCCC	O
ACACTG	O
ATGAGCCGCTTCGGCGGCGAAACATTCAAC	O
GCGT	O
-	O
3	O
'	O
and	O
the	O
corresponding	O
reverse	O
complementary	O
strand	O
were	O
synthesized	O
.	O

The	O
fragments	O
were	O
subcloned	O
to	O
produce	O
a	O
plasmid	O
containing	O
a	O
ribozyme	O
against	O
M6P	O
/	O
IGF2R	O
.	O

For	O
construction	O
of	O
the	O
recombinant	O
adenovirus	O
containing	O
the	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
(	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
)	O
,	O
the	O
segments	O
containing	O
the	O
ribozymes	O
were	O
amplified	O
by	O
PCR	O
and	O
cloned	O
into	O
a	O
pAdTrack	O
-	O
CMV	O
vector	O
and	O
then	O
recombined	O
homologously	O
with	O
an	O
adenoviral	O
backbone	O
pAdEasy	O
1	O
vector	O
to	O
generate	O
(	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
)	O
,	O
following	O
the	O
protocol	O
described	O
by	O
He	O
et	O
al	O
.	O

[	O
32	O
]	O
.	O

The	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
carries	O
both	O
the	O
IGF2R	O
-	O
Rz	O
and	O
GFP	O
(	O
as	O
reporter	O
)	O
genes	O
,	O
each	O
under	O
the	O
control	O
of	O
separate	O
cytomegalovirus	O
(	O
CMV	O
)	O
promoters	O
.	O

Another	O
viral	O
vector	O
,	O
pAd	O
-	O
GFP	O
,	O
which	O
carries	O
the	O
GFP	O
gene	O
only	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
,	O
was	O
generated	O
and	O
used	O
as	O
a	O
control	O
vector	O
.	O

The	O
adenoviral	O
vector	O
DNA	O
were	O
linerized	O
with	O
Pac	O
I	O
and	O
transfected	O
into	O
the	O
replication	O
-	O
permissive	O
293	O
cells	O
(	O
E1A	O
transcomplementing	O
cell	O
line	O
)	O
by	O
using	O
Lipofectamine	O
(	O
Life	O
Technologies	O
)	O
to	O
produce	O
E1	O
-	O
deleted	O
,	O
replication	O
-	O
defective	O
recombinant	O
adenovirus	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

Large	O
-	O
scale	O
amplification	O
of	O
recombinant	O
adenovirus	O
in	O
293	O
cells	O
was	O
followed	O
by	O
purification	O
using	O
a	O
discontinuous	O
CsCl	O
gradient	O
.	O

The	O
constructs	O
were	O
confirmed	O
by	O
enzymatic	O
digestion	O
and	O
DNA	O
sequencing	O
.	O

Transcription	O
and	O
cleavage	O
reaction	O
of	O
ribozyme	O
in	O
vitro	O

Plasmids	O
containing	O
the	O
ribozyme	O
or	O
the	O
substrate	O
(	O
either	O
45	O
bp	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
or	O
an	O
unmatched	O
sequence	O
5	O
'	O
-	O
GTGCTGTCTGTATG	O
-	O
3	O
'	O
)	O
were	O
linearized	O
with	O
MluI	O
,	O
respectively	O
.	O

All	O
transcripts	O
were	O
generated	O
with	O
T7	O
RNA	O
polymerase	O
(	O
Promega	O
)	O
.	O

Substrate	O
transcripts	O
were	O
labeled	O
by	O
incorporation	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
UTP	O
(	O
NEN	O
Life	O
Science	O
Products	O
,	O
Inc	O
.	O
)	O
.	O

Specific	O
activity	O
of	O
the	O
[	O
alpha	O
-	O
32P	O
]	O
UTP	O
(	O
10	O
mu	O
Ci	O
/	O
mu	O
l	O
)	O
and	O
the	O
base	O
composition	O
of	O
each	O
substrate	O
molecule	O
were	O
used	O
to	O
calculate	O
the	O
substrate	O
concentration	O
.	O

Ribozyme	O
transcripts	O
were	O
quantified	O
spectrophotometrically	O
.	O

(	O
The	O
half	O
-	O
life	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
is	O
about	O
280	O
minutes	O
)	O
.	O

Cleavage	O
reaction	O
mixture	O
contained	O
substrate	O
RNA	O
(	O
40	O
nM	O
)	O
,	O
increasing	O
amounts	O
of	O
ribozyme	O
(	O
60	O
nM	O
)	O
,	O
20	O
mM	O
MgCl2	O
and	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH8	O
.	O
0	O
,	O
in	O
a	O
final	O
volume	O
of	O
10	O
mu	O
l	O
.	O

The	O
mixture	O
was	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
a	O
time	O
-	O
course	O
of	O
cleavage	O
reaction	O
from	O
0	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
80	O
,	O
160	O
,	O
320	O
,	O
to	O
640	O
minutes	O
and	O
the	O
cleavage	O
reaction	O
was	O
stopped	O
by	O
addition	O
of	O
loading	O
buffer	O
(	O
80	O
%	O
formamide	O
,	O
10	O
mM	O
Na2EDTA	O
,	O
pH	O
8	O
.	O
0	O
,	O
and	O
1	O
mg	O
/	O
ml	O
each	O
bromophenol	O
blue	O
and	O
xylene	O
cyanol	O
)	O
.	O

Cleavage	O
products	O
were	O
analyzed	O
on	O
a	O
15	O
%	O
polyacrylamide	O
and	O
8M	O
urea	O
gel	O
.	O

Product	O
and	O
substrate	O
fragments	O
were	O
quantitated	O
by	O
using	O
NIH	O
Imager	O
.	O

Cell	O
cultures	O
and	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
Rz	O
-	O
IGF2R	O
and	O
Ad	O
-	O
GFP	O

Cardiac	O
myocytes	O
were	O
isolated	O
from	O
1	O
-	O
day	O
-	O
old	O
newborn	O
rats	S-Species
using	O
the	O
Neonatal	O
Cardiomyocyte	O
Isolation	O
System	O
(	O
Worthington	O
)	O
.	O

The	O
isolated	O
cells	O
were	O
plated	O
in	O
6	O
-	O
well	O
plates	O
and	O
cultured	O
in	O
F	O
-	O
10	O
medium	O
containing	O
5	O
%	O
(	O
vol	O
/	O
vol	O
)	O
FBS	O
and	O
10	O
%	O
(	O
vol	O
/	O
vol	O
)	O
horse	S-Species
serum	O
at	O
37	O
degrees	O
C	O
in	O
a	O
tissue	O
culture	O
incubator	O
with	O
5	O
%	O
CO2	O
and	O
98	O
%	O
relative	O
humidity	O
.	O

Cells	O
were	O
used	O
for	O
experiments	O
after	O
2	O
-	O
3	O
days	O
of	O
culture	O
.	O

Viral	O
infections	O
were	O
carried	O
out	O
by	O
adding	O
viral	O
particles	O
at	O
various	O
concentrations	O
(	O
usually	O
,	O
2	O
x	O
108	O
virus	O
particles	O
/	O
ml	O
)	O
to	O
culture	O
medium	O
containing	O
2	O
%	O
(	O
vol	O
/	O
vol	O
)	O
FBS	O
.	O

Initially	O
,	O
optimal	O
viral	O
concentration	O
was	O
determined	O
by	O
using	O
Ad	O
-	O
GFP	O
to	O
achieve	O
an	O
optimal	O
balance	O
of	O
high	O
gene	O
expression	O
and	O
low	O
viral	O
titer	O
to	O
minimize	O
cytotoxicity	O
.	O

After	O
24	O
hours	O
of	O
incubation	O
,	O
the	O
infection	O
medium	O
was	O
replaced	O
with	O
normal	O
(	O
15	O
%	O
vol	O
/	O
vol	O
serum	O
)	O
culture	O
medium	O
.	O

For	O
treatment	O
with	O
IGF	O
-	O
II	O
,	O
cells	O
were	O
incubated	O
with	O
50	O
ng	O
/	O
ml	O
IGF	O
-	O
II	O
after	O
24	O
hours	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
.	O

Four	O
days	O
after	O
infection	O
,	O
cells	O
were	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
of	O
M6P	O
/	O
IGF2R	O
and	O
its	O
effect	O
on	O
cell	O
growth	O
and	O
apoptosis	O
.	O

Analysis	O
of	O
gene	O
expression	O
in	O
cardiac	O
myocytes	O

The	O
M6P	O
/	O
IGF2R	O
transcripts	O
were	O
determined	O
by	O
both	O
RT	O
-	O
PCR	O
and	O
Ribonuclease	O
Protection	O
Assay	O
(	O
RPA	O
)	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
the	O
GeneAmp	O
EZ	O
rTth	O
RNA	O
PCR	O
kit	O
(	O
Roche	O
)	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
Qiagen	O
,	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

M6P	O
/	O
IGF2R	O
transcripts	O
were	O
amplified	O
using	O
the	O
primers	O
(	O
5	O
'	O
-	O
GACAGGCTCGTTCTGACTTA	O
-	O
3	O
'	O
)	O
and	O
(	O
5	O
'	O
-	O
CTTCCACTCTTATCCACAGC	O
-	O
3	O
'	O
)	O
specific	O
to	O
the	O
M6P	O
/	O
IGF2R	O
.	O

Each	O
RT	O
-	O
PCR	O
assay	O
was	O
performed	O
in	O
triplicate	O
and	O
product	O
levels	O
varied	O
by	O
less	O
than	O
3	O
.	O
2	O
%	O
for	O
each	O
RNA	O
sample	O
.	O

Primers	O
specific	O
for	O
beta	O
-	O
actin	O
cDNA	O
were	O
added	O
to	O
a	O
parallel	O
reaction	O
to	O
standardize	O
for	O
variations	O
in	O
PCR	O
between	O
samples	O
.	O

PCR	O
products	O
were	O
resolved	O
on	O
a	O
1	O
.	O
0	O
%	O
agarose	O
gel	O
,	O
visualized	O
under	O
UV	O
light	O
and	O
quantitated	O
using	O
NIH	O
Imager	O
.	O

RPA	O
was	O
performed	O
using	O
the	O
RPA	O
III	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
a	O
total	O
RNA	O
isolation	O
reagent	O
(	O
TRIzol	O
,	O
Gibco	O
BRL	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
plasmid	O
containing	O
the	O
rat	S-Species
M6P	O
/	O
IGF2R	O
gene	O
was	O
linearized	O
and	O
used	O
as	O
a	O
transcription	O
template	O
.	O

Antisense	O
RNA	O
probes	O
were	O
transcribed	O
in	O
vitro	O
using	O
[	O
33P	O
]	O
-	O
UTP	O
,	O
T7	O
polymerase	O
(	O
Riboprobea	O
System	O
T7	O
kit	O
,	O
Promega	O
)	O
,	O
hybridized	O
with	O
the	O
total	O
RNA	O
extracted	O
from	O
the	O
rat	S-Species
cardiomyocytes	O
,	O
and	O
digested	O
with	O
ribonuclease	O
to	O
remove	O
non	O
-	O
hybridized	O
RNA	O
and	O
probe	O
.	O

The	O
protected	O
RNA	O
.	O
RNA	O
was	O
resolved	O
on	O
a	O
denaturing	O
5	O
%	O
sequence	O
gel	O
and	O
subjected	O
to	O
autoradiography	O
.	O

A	O
probe	O
targeting	O
the	O
GAPDH	O
gene	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

Measurement	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
internalization	O

Cells	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
2	O
hrs	O
in	O
serum	O
-	O
free	O
F	O
-	O
10	O
culture	O
medium	O
containing	O
125I	O
-	O
labeled	O
IGF	O
-	O
II	O
(	O
0	O
.	O
5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
excess	O
unlabeled	O
IGF	O
-	O
II	O
(	O
2	O
mu	O
g	O
/	O
ml	O
)	O
.	O

Following	O
the	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
,	O
and	O
cell	O
-	O
associated	O
radioactivity	O
was	O
determined	O
by	O
a	O
gamma	O
counter	O
.	O

Specific	O
internalized	O
125I	O
-	O
IGF	O
-	O
II	O
was	O
calculated	O
by	O
subtracting	O
the	O
count	O
of	O
samples	O
with	O
excessive	O
unlabeled	O
IGF	O
-	O
II	O
from	O
that	O
without	O
unlabeled	O
IGF	O
-	O
II	O
,	O
and	O
normalized	O
to	O
protein	O
contents	O
.	O

Beta	O
-	O
glucuronidase	O
binding	O
assay	O

Binding	O
of	O
beta	O
-	O
glucuronidase	O
was	O
assayed	O
as	O
described	O
previously	O
[	O
34	O
,	O
35	O
]	O
.	O

Briefly	O
,	O
cells	O
were	O
permeabilized	O
with	O
0	O
.	O
25	O
%	O
saponin	O
in	O
50	O
mM	O
Hepes	O
(	O
pH	O
7	O
.	O
0	O
)	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
beta	O
-	O
glycerophosphate	O
,	O
0	O
.	O
5	O
%	O
human	S-Species
serum	O
albumin	O
,	O
and	O
10	O
mM	O
mannose	O
-	O
6	O
-	O
phosphate	O
(	O
M6P	O
)	O
for	O
30	O
minutes	O
on	O
ice	O
.	O

The	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
saponin	O
.	O

They	O
were	O
incubated	O
with	O
20	O
,	O
000	O
units	O
/	O
ml	O
beta	O
-	O
glucuronidase	O
from	O
bovine	S-Species
liver	O
(	O
Sigma	O
)	O
in	O
50	O
mM	O
Hepes	O
(	O
pH	O
7	O
.	O
5	O
)	O
containing	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
beta	O
-	O
glycerophosphate	O
,	O
0	O
.	O
5	O
%	O
human	S-Species
serum	O
albumin	O
,	O
0	O
.	O
5	O
%	O
saponin	O
with	O
or	O
without	O
10	O
mM	O
M6P	O
overnight	O
on	O
ice	O
.	O

Cells	O
were	O
washed	O
five	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
saponin	O
and	O
sonicated	O
in	O
100	O
mM	O
sodium	O
acetate	O
(	O
pH	O
4	O
.	O
6	O
)	O
.	O

The	O
protein	O
concentration	O
of	O
solubilized	O
cell	O
extract	O
was	O
measured	O
and	O
enzyme	O
activity	O
was	O
assayed	O
as	O
follows	O
:	O
for	O
each	O
reaction	O
50	O
ul	O
cell	O
extract	O
were	O
added	O
to	O
500	O
ul	O
of	O
100	O
mM	O
sodium	O
acetate	O
(	O
pH	O
4	O
.	O
0	O
)	O
containing	O
1	O
mM	O
paranitrophenyl	O
(	O
PNP	O
)	O
-	O
beta	O
-	O
glucuronide	O
(	O
Sigma	O
)	O
as	O
substrate	O
.	O

After	O
an	O
incubation	O
period	O
of	O
3	O
hours	O
at	O
37	O
degrees	O
C	O
,	O
500	O
ul	O
1	O
M	O
Na2CO3	O
were	O
added	O
to	O
each	O
reaction	O
and	O
the	O
absorbance	O
was	O
measured	O
at	O
400	O
nm	O
.	O

Experimental	O
values	O
were	O
compared	O
to	O
a	O
standard	O
curve	O
that	O
was	O
constructed	O
using	O
1	O
-	O
100	O
nM	O
solutions	O
of	O
PNP	O
(	O
Sigma	O
)	O
in	O
500	O
ul	O
100	O
mM	O
sodium	O
acetate	O
and	O
500	O
u1	O
1	O
M	O
Na2CO3	O
.	O

Specific	O
activity	O
was	O
calculated	O
as	O
nM	O
of	O
PNP	O
produced	O
/	O
hour	O
/	O
mg	O
of	O
protein	O
.	O

Beta	O
-	O
glucuronidase	O
endocytosis	O
assay	O

Beta	O
-	O
glucuronidase	O
endocytosis	O
assay	O
was	O
carried	O
out	O
as	O
described	O
previously	O
[	O
36	O
]	O
.	O

Briefly	O
,	O
confluent	O
cell	O
cultures	O
were	O
washed	O
twice	O
with	O
pre	O
-	O
warmed	O
serum	O
-	O
free	O
DMEM	O
followed	O
by	O
incubation	O
with	O
DMEM	O
containing	O
5	O
mg	O
/	O
ml	O
human	S-Species
serum	O
albumin	O
and	O
10	O
mM	O
M6P	O
for	O
20	O
minutes	O
.	O

Following	O
incubation	O
cells	O
were	O
washed	O
3	O
times	O
with	O
pre	O
-	O
warmed	O
DMEM	O
.	O

Cells	O
were	O
then	O
incubated	O
in	O
DMEM	O
containing	O
5	O
mg	O
/	O
ml	O
human	S-Species
serum	O
albumin	O
alone	O
or	O
4000	O
units	O
beta	O
-	O
glucuronidase	O
with	O
or	O
without	O
10	O
mM	O
M6P	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
.	O

Following	O
the	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
5	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
subjected	O
to	O
enzyme	O
activity	O
assay	O
as	O
described	O
above	O
.	O

Cell	O
proliferation	O
assay	O
(	O
MTT	O
assay	O
and	O
cell	O
counts	O
)	O

Cardiac	O
myocytes	O
were	O
grown	O
in	O
culture	O
plates	O
(	O
tissue	O
culture	O
grade	O
,	O
12	O
wells	O
,	O
flat	O
bottom	O
)	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
serum	O
-	O
containing	O
culture	O
medium	O
per	O
well	O
,	O
in	O
a	O
humidified	O
atmosphere	O
(	O
37	O
degrees	O
C	O
and	O
5	O
%	O
C02	O
)	O
for	O
3	O
days	O
.	O

After	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
,	O
cells	O
were	O
incubated	O
with	O
or	O
without	O
50	O
ng	O
/	O
ml	O
IGF	O
-	O
II	O
for	O
4	O
days	O
.	O

Following	O
supplementation	O
with	O
IGF	O
-	O
II	O
,	O
100	O
mu	O
l	O
MTT	O
labeling	O
reagent	O
(	O
Roche	O
)	O
were	O
added	O
to	O
each	O
well	O
and	O
cells	O
were	O
incubated	O
for	O
4	O
hours	O
,	O
followed	O
by	O
addition	O
of	O
1	O
ml	O
solubilization	O
solution	O
into	O
each	O
well	O
.	O

The	O
plate	O
was	O
placed	O
in	O
an	O
incubator	O
at	O
37	O
degrees	O
C	O
overnight	O
.	O

Spectrophotometrical	O
absorbency	O
of	O
the	O
samples	O
was	O
measured	O
using	O
an	O
UV	O
-	O
visible	O
Recording	O
Spectrophotometer	O
with	O
wavelength	O
of	O
550	O
-	O
690	O
nm	O
.	O

In	O
addition	O
,	O
the	O
total	O
number	O
of	O
viable	O
cells	O
in	O
each	O
treatment	O
was	O
counted	O
by	O
trypan	O
blue	O
exclusion	O
method	O
using	O
a	O
hemocytometer	O
.	O

Induction	O
and	O
analysis	O
of	O
cell	O
apoptosis	O

Cells	O
were	O
infected	O
with	O
Ad	O
-	O
GFP	O
or	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

Seventy	O
-	O
two	O
hours	O
post	O
infection	O
,	O
cells	O
were	O
treated	O
with	O
TNF	O
(	O
0	O
.	O
1	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
or	O
subjected	O
to	O
hypoxia	O
.	O

For	O
induction	O
of	O
apoptosis	O
by	O
hypoxia	O
,	O
cell	O
culture	O
medium	O
was	O
changed	O
to	O
serum	O
-	O
free	O
F	O
-	O
10	O
saturated	O
with	O
95	O
%	O
N2	O
/	O
5	O
%	O
CO2	O
and	O
cells	O
were	O
placed	O
in	O
a	O
37	O
degrees	O
C	O
airtight	O
box	O
saturated	O
with	O
95	O
%	O
N2	O
/	O
5	O
%	O
CO2	O
for	O
24	O
hrs	O
.	O

For	O
normoxic	O
controls	O
,	O
culture	O
medium	O
was	O
changed	O
to	O
F	O
-	O
10	O
/	O
5	O
%	O
F	O
BS	O
/	O
10	O
%	O
HS	O
and	O
cells	O
were	O
placed	O
in	O
a	O
37	O
degrees	O
C	O
/	O
5	O
%	O
CO2	O
incubator	O
for	O
24	O
hrs	O
before	O
analysis	O
.	O

Apoptotic	O
cells	O
were	O
identified	O
by	O
Hoechst	O
staining	O
using	O
the	O
Vybrant	O
(TM)	O
Apoptosis	O
Kit	O
#	O
5	O
(	O
Molecular	O
Probes	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

In	O
addition	O
,	O
after	O
infection	O
with	O
Ad	O
-	O
GFP	O
or	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
and	O
challenge	O
with	O
either	O
TNF	O
or	O
hypoxia	O
,	O
cell	O
viability	O
was	O
assessed	O
using	O
the	O
MTT	O
assay	O
Kit	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
and	O
cell	O
apoptosis	O
was	O
determined	O
using	O
the	O
Cell	O
Death	O
Detection	O
ELISA	O
Kit	O
assay	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Statistical	O
analysis	O

Students	O
'	O
t	O
-	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
difference	O
between	O
two	O
values	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
.	O

Statistical	O
significance	O
was	O
accepted	O
at	O
the	O
level	O
of	O
p	O
<	O
0	O
.	O
05	O
.	O

List	O
of	O
abbreviations	O
used	O

Ad	O
-	O
GFP	O
,	O
adenovirus	O
carrying	O
GFP	O
gene	O
;	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
,	O
adenovirus	O
carrying	O
both	O
the	O
ribozyme	O
against	O
M6P	O
/	O
IGF2R	O
and	O
the	O
GFP	O
gene	O
;	O
GFP	O
,	O
green	O
fluorescent	O
protein	O
;	O
IGF	O
-	O
II	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
;	O
M6P	O
/	O
IGF2R	O
,	O
mannose	O
6	O
-	O
phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
receptor	O
;	O
Rz	O
,	O
ribozyme	O
.	O

Authors	O
'	O
contributions	O

ZC	O
carried	O
out	O
construction	O
of	O
the	O
ribozyme	O
,	O
production	O
of	O
the	O
viruses	O
,	O
cellular	O
experiments	O
,	O
biochemical	O
assays	O
and	O
data	O
analysis	O
.	O

YG	O
carried	O
out	O
the	O
RPA	O
assay	O
and	O
participated	O
in	O
the	O
molecular	O
biological	O
studies	O
.	O

JXK	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

SledgeHMMER	O
:	O
a	O
web	O
server	O
for	O
batch	O
searching	O
the	O
Pfam	O
database	O

Abstract	O

The	O
SledgeHMMER	O
web	O
server	O
is	O
intended	O
for	O
genome	O
-	O
scale	O
searching	O
of	O
the	O
Pfam	O
database	O
without	O
having	O
to	O
install	O
this	O
database	O
and	O
the	O
HMMER	O
software	O
locally	O
.	O

The	O
server	O
implements	O
a	O
parallelized	O
version	O
of	O
hmmpfam	O
,	O
the	O
program	O
used	O
for	O
searching	O
the	O
Pfam	O
HMM	O
database	O
.	O

Pfam	O
search	O
results	O
have	O
been	O
calculated	O
for	O
the	O
entire	O
Swiss	O
-	O
Prot	O
and	O
TrEmbl	O
database	O
sequences	O
(	O
~	O
1	O
.	O
2	O
million	O
)	O
on	O
256	O
processors	O
of	O
IA64	O
-	O
based	O
teragrid	O
machines	O
.	O

The	O
Pfam	O
database	O
can	O
be	O
searched	O
in	O
local	O
,	O
glocal	O
or	O
merged	O
mode	O
,	O
using	O
either	O
gathering	O
or	O
E	O
-	O
value	O
thresholds	O
.	O

Query	O
sequences	O
are	O
first	O
matched	O
against	O
the	O
pre	O
-	O
calculated	O
entries	O
to	O
retrieve	O
results	O
,	O
and	O
those	O
without	O
matches	O
are	O
processed	O
through	O
a	O
new	O
search	O
process	O
.	O

Results	O
are	O
emailed	O
in	O
a	O
space	O
-	O
delimited	O
tabular	O
format	O
upon	O
completion	O
of	O
the	O
search	O
.	O

While	O
most	O
other	O
Pfam	O
-	O
searching	O
web	O
servers	O
set	O
a	O
limit	O
of	O
one	O
sequence	O
per	O
query	O
,	O
this	O
server	O
processes	O
batch	O
sequences	O
with	O
no	O
limit	O
on	O
the	O
number	O
of	O
input	O
sequences	O
.	O

The	O
web	O
server	O
and	O
downloadable	O
data	O
are	O
accessible	O
from	O
http	O
:	O
/	O
/	O
SledgeHmmer	O
.	O
sdsc	O
.	O
edu	O
.	O

INTRODUCTION	O

Searching	O
for	O
conserved	O
domains	O
has	O
become	O
an	O
integral	O
part	O
of	O
several	O
bioinformatics	O
data	O
analysis	O
pipelines	O
.	O

The	O
Pfam	O
protein	O
families	O
database	O
[	O
(	O
1	O
)	O
;	O
http	O
:	O
/	O
/	O
pfam	O
.	O
wustl	O
.	O
edu	O
]	O
contains	O
the	O
single	O
largest	O
public	O
collection	O
of	O
conserved	O
functional	O
domains	O
and	O
hence	O
is	O
integrated	O
into	O
many	O
bioinformatics	O
resources	O
.	O

The	O
current	O
version	O
(	O
release	O
12	O
)	O
of	O
the	O
Pfam	O
-	O
A	O
database	O
contains	O
7316	O
HMM	O
domains	O
,	O
making	O
it	O
an	O
indispensable	O
resource	O
for	O
protein	O
functional	O
annotation	O
(	O
2	O
)	O
.	O

However	O
,	O
the	O
size	O
of	O
the	O
Pfam	O
database	O
is	O
quite	O
large	O
(	O
~	O
600	O
MB	O
)	O
and	O
genome	O
-	O
scale	O
searching	O
of	O
protein	O
sequences	O
against	O
this	O
database	O
is	O
a	O
highly	O
compute	O
-	O
intensive	O
task	O
.	O

Hence	O
,	O
with	O
the	O
exception	O
of	O
the	O
Sanger	O
Center	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
sanger	O
.	O
ac	O
.	O
uk	O
/	O
Software	O
/	O
Pfam	O
)	O
,	O
all	O
other	O
Pfam	O
-	O
searching	O
servers	O
permit	O
submission	O
of	O
only	O
one	O
protein	O
sequence	O
at	O
a	O
time	O
(	O
http	O
:	O
/	O
/	O
pfam	O
.	O
wustl	O
.	O
edu	O
,	O
http	O
:	O
/	O
/	O
pfam	O
.	O
jouy	O
.	O
inra	O
.	O
fr	O
,	O
http	O
:	O
/	O
/	O
pfam	O
.	O
cgb	O
.	O
ki	O
.	O
se	O
)	O
.	O

Currently	O
,	O
the	O
Sanger	O
Center	O
web	O
server	O
limits	O
batch	O
submission	O
to	O
1000	O
sequences	O
at	O
a	O
time	O
.	O

Other	O
than	O
this	O
,	O
for	O
batch	O
searching	O
,	O
users	O
are	O
required	O
to	O
install	O
the	O
Pfam	O
database	O
and	O
the	O
HMMER	O
software	O
[	O
(	O
3	O
)	O
;	O
http	O
:	O
/	O
/	O
hmmer	O
.	O
wustl	O
.	O
edu	O
)	O
locally	O
.	O

Given	O
the	O
size	O
and	O
dynamic	O
nature	O
of	O
this	O
database	O
(	O
14	O
updates	O
in	O
the	O
last	O
two	O
years	O
)	O
,	O
it	O
is	O
not	O
convenient	O
to	O
maintain	O
the	O
latest	O
versions	O
of	O
these	O
tools	O
locally	O
.	O

Moreover	O
,	O
the	O
hmmpfam	O
program	O
used	O
for	O
searching	O
the	O
Pfam	O
database	O
is	O
very	O
slow	O
and	O
memory	O
intensive	O
(	O
on	O
Solaris	O
machines	O
,	O
the	O
processing	O
speed	O
is	O
about	O
10	O
sequences	O
per	O
1	O
h	O
of	O
CPU	O
time	O
)	O
,	O
making	O
this	O
process	O
a	O
bottleneck	O
in	O
several	O
data	O
analysis	O
pipelines	O
.	O

Web	O
servers	O
that	O
enable	O
batch	O
searching	O
of	O
the	O
Pfam	O
database	O
are	O
extremely	O
beneficial	O
to	O
the	O
user	O
community	O
,	O
especially	O
to	O
those	O
without	O
local	O
access	O
to	O
high	O
-	O
end	O
computational	O
power	O
,	O
memory	O
and	O
disk	O
space	O
.	O

To	O
this	O
end	O
we	O
have	O
developed	O
a	O
parallelized	O
version	O
,	O
as	O
well	O
as	O
an	O
optimized	O
single	O
-	O
processor	O
version	O
,	O
of	O
hmmpfam	O
from	O
release	O
2	O
.	O
3	O
.	O
2	O
of	O
the	O
HMMER	O
software	O
,	O
as	O
described	O
in	O
the	O
next	O
section	O
.	O

Using	O
these	O
programs	O
,	O
we	O
present	O
the	O
SledgeHMMER	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
SledgeHmmer	O
.	O
sdsc	O
.	O
edu	O
)	O
,	O
which	O
is	O
capable	O
of	O
batch	O
searching	O
a	O
large	O
number	O
of	O
protein	O
sequences	O
concurrently	O
.	O

DESIGN	O
AND	O
IMPLEMENTATION	O

The	O
current	O
web	O
service	O
is	O
mainly	O
intended	O
for	O
genome	O
-	O
scale	O
searching	O
of	O
the	O
Pfam	O
-	O
A	O
database	O
.	O

Searches	O
are	O
possible	O
for	O
different	O
Pfam	O
-	O
searching	O
modes	O
such	O
as	O
local	O
,	O
glocal	O
and	O
merged	O
,	O
using	O
either	O
gathering	O
or	O
E	O
-	O
value	O
thresholds	O
.	O

To	O
expedite	O
the	O
response	O
time	O
,	O
we	O
developed	O
a	O
database	O
containing	O
pre	O
-	O
calculated	O
Pfam	O
search	O
results	O
.	O

Query	O
sequences	O
are	O
matched	O
against	O
the	O
pre	O
-	O
calculated	O
entries	O
using	O
hexadecimal	O
hashing	O
methods	O
from	O
the	O
MD5	O
Perl	O
module	O
,	O
and	O
those	O
without	O
matches	O
are	O
separated	O
out	O
.	O

Results	O
for	O
matching	O
sequences	O
are	O
retrieved	O
from	O
the	O
pre	O
-	O
calculated	O
database	O
while	O
,	O
for	O
other	O
sequences	O
,	O
a	O
new	O
search	O
process	O
is	O
initiated	O
using	O
our	O
improved	O
hmmpfam	O
program	O
.	O

Results	O
are	O
emailed	O
in	O
a	O
space	O
-	O
delimited	O
tabular	O
format	O
upon	O
completion	O
of	O
the	O
search	O
.	O

Parallelizing	O
the	O
hmmpfam	O
algorithm	O

Computing	O
batch	O
searches	O
against	O
the	O
Pfam	O
database	O
is	O
a	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
problem	O
,	O
i	O
.	O
e	O
.	O
searching	O
N	O
query	O
sequences	O
against	O
M	O
Pfam	O
HMMs	O
.	O

Thus	O
,	O
this	O
problem	O
can	O
be	O
parallelized	O
across	O
any	O
dimension	O
or	O
across	O
both	O
dimensions	O
.	O

A	O
minor	O
disadvantage	O
of	O
parallelizing	O
across	O
the	O
M	O
dimension	O
is	O
that	O
a	O
global	O
gather	O
needs	O
to	O
be	O
performed	O
at	O
the	O
end	O
of	O
the	O
computation	O
to	O
identify	O
the	O
best	O
matched	O
HMM	O
models	O
.	O

Along	O
the	O
N	O
dimension	O
the	O
computation	O
is	O
completely	O
independent	O
,	O
however	O
;	O
due	O
to	O
the	O
variation	O
in	O
the	O
query	O
sequence	O
lengths	O
,	O
the	O
traditional	O
message	O
passing	O
interface	O
(	O
MPI	O
)	O
technique	O
of	O
splitting	O
the	O
file	O
into	O
equal	O
numbers	O
of	O
sequences	O
may	O
result	O
in	O
load	O
imbalance	O
.	O

Hence	O
,	O
the	O
best	O
way	O
to	O
parallelize	O
code	O
along	O
the	O
N	O
dimension	O
is	O
to	O
stripmine	O
the	O
query	O
sequences	O
as	O
the	O
processors	O
finish	O
working	O
on	O
their	O
previous	O
ones	O
.	O

This	O
can	O
be	O
achieved	O
using	O
an	O
MPI	O
technique	O
in	O
which	O
one	O
processor	O
reads	O
the	O
query	O
sequence	O
file	O
and	O
sends	O
the	O
sequences	O
to	O
all	O
others	O
.	O

Here	O
,	O
we	O
have	O
parallelized	O
the	O
HMMER	O
code	O
along	O
the	O
N	O
dimension	O
(	O
query	O
sequences	O
)	O
using	O
a	O
Unix	O
-	O
based	O
file	O
-	O
locking	O
technique	O
.	O

This	O
implementation	O
requires	O
all	O
the	O
processors	O
,	O
nodes	O
and	O
computers	O
working	O
on	O
a	O
single	O
problem	O
to	O
have	O
access	O
to	O
a	O
file	O
system	O
that	O
honors	O
Unix	O
file	O
locking	O
.	O

So	O
far	O
,	O
we	O
have	O
tested	O
the	O
implementation	O
on	O
AIX	O
,	O
Linux	O
,	O
NFS	O
and	O
GPFS	O
file	O
systems	O
and	O
found	O
our	O
program	O
to	O
work	O
correctly	O
.	O

The	O
advantages	O
of	O
parallelizing	O
with	O
file	O
locking	O
are	O
that	O
(	O
i	O
)	O
new	O
processes	O
can	O
join	O
or	O
leave	O
the	O
process	O
pool	O
in	O
the	O
middle	O
of	O
computing	O
;	O
(	O
ii	O
)	O
almost	O
perfect	O
load	O
balancing	O
can	O
be	O
achieved	O
;	O
(	O
iii	O
)	O
processors	O
with	O
different	O
clock	O
speeds	O
running	O
different	O
operating	O
systems	O
can	O
be	O
part	O
of	O
the	O
same	O
pool	O
;	O
and	O
(	O
iv	O
)	O
systems	O
do	O
not	O
need	O
to	O
have	O
MPI	O
or	O
parallel	O
virtual	O
machine	O
(	O
PVM	O
)	O
installed	O
.	O

Since	O
the	O
parallelized	O
subroutines	O
are	O
written	O
in	O
a	O
separate	O
file	O
as	O
function	O
calls	O
,	O
very	O
little	O
change	O
is	O
needed	O
to	O
the	O
original	O
HMMER	O
code	O
.	O

These	O
parallel	O
routines	O
are	O
generic	O
and	O
,	O
hence	O
,	O
can	O
be	O
used	O
to	O
parallelize	O
other	O
programs	O
with	O
similar	O
computational	O
requirements	O
,	O
such	O
as	O
the	O
BLAST	O
suite	O
of	O
programs	O
.	O

A	O
brief	O
description	O
of	O
the	O
parallel	O
function	O
calls	O
is	O
provided	O
below	O
.	O

All	O
the	O
processes	O
joining	O
the	O
work	O
pool	O
will	O
call	O

The	O
first	O
process	O
that	O
calls	O
this	O
subroutine	O
will	O
create	O
the	O
lockFile	O
and	O
write	O
the	O
starting	O
index	O
.	O

This	O
is	O
the	O
index	O
from	O
which	O
sequence	O
stripmining	O
happens	O
.	O

The	O
rest	O
of	O
the	O
processes	O
open	O
the	O
file	O
stream	O
to	O
the	O
lockFile	O
.	O

Then	O
,	O
inside	O
the	O
main	O
work	O
loop	O
,	O
every	O
process	O
calls	O

resulting	O
in	O
every	O
process	O
getting	O
a	O
unique	O
next	O
available	O
job	O
(	O
index	O
)	O
.	O

Each	O
process	O
computes	O
the	O
homology	O
search	O
for	O
the	O
sequence	O
index	O
matching	O
the	O
unique	O
index	O
obtained	O
.	O

These	O
steps	O
are	O
iterated	O
until	O
no	O
more	O
sequences	O
are	O
left	O
in	O
the	O
query	O
sequence	O
file	O
.	O

Outside	O
the	O
work	O
loop	O
at	O
the	O
end	O
,	O
all	O
the	O
processes	O
call	O

which	O
will	O
close	O
the	O
lockFile	O
.	O

The	O
user	O
has	O
to	O
ensure	O
a	O
unique	O
lockFile	O
for	O
each	O
new	O
query	O
sequence	O
file	O
.	O

If	O
for	O
some	O
reason	O
the	O
work	O
pool	O
is	O
stopped	O
in	O
the	O
middle	O
of	O
a	O
query	O
sequence	O
file	O
,	O
it	O
can	O
continue	O
from	O
the	O
same	O
point	O
by	O
using	O
the	O
same	O
lockFile	O
.	O

In	O
this	O
version	O
of	O
the	O
hmmpfam	O
program	O
,	O
all	O
processes	O
write	O
search	O
results	O
to	O
a	O
single	O
output	O
file	O
.	O

To	O
minimize	O
synchronization	O
overheads	O
,	O
each	O
process	O
writes	O
the	O
output	O
into	O
a	O
temporary	O
buffer	O
and	O
writes	O
once	O
per	O
sequence	O
into	O
the	O
output	O
file	O
.	O

For	O
the	O
sake	O
of	O
convenience	O
,	O
additional	O
synchronization	O
routines	O
are	O
provided	O
for	O
locking	O
and	O
unlocking	O
.	O

This	O
parallel	O
algorithm	O
has	O
been	O
tested	O
on	O
several	O
platforms	O
and	O
file	O
systems	O
including	O
Intel	O
IA32	O
,	O
IA64	O
Linux	O
platforms	O
,	O
power3	O
and	O
power4	O
-	O
based	O
AIX	O
platforms	O
and	O
Sparc4	O
-	O
based	O
Solaris	O
platforms	O
.	O

The	O
code	O
was	O
run	O
on	O
800	O
processors	O
of	O
power4	O
-	O
based	O
datastar	O
machines	O
and	O
256	O
processors	O
of	O
IA64	O
-	O
based	O
teragrid	O
machines	O
located	O
at	O
the	O
San	O
Diego	O
Supercomputer	O
Center	O
(	O
SDSC	O
)	O
to	O
test	O
scalability	O
issues	O
.	O

Single	O
-	O
processor	O
optimization	O
of	O
hmmpfam	O

Initially	O
,	O
we	O
utilized	O
version	O
2	O
.	O
2g	O
of	O
HMMER	O
.	O

Performance	O
analysis	O
revealed	O
that	O
the	O
main	O
computational	O
kernel	O
was	O
accessing	O
the	O
2D	O
arrays	O
with	O
a	O
wrong	O
stride	O
.	O

Correcting	O
this	O
resulted	O
in	O
doubling	O
of	O
the	O
performance	O
;	O
however	O
,	O
the	O
HMMER	O
developer	O
has	O
rectified	O
this	O
issue	O
in	O
release	O
2	O
.	O
3	O
.	O
2	O
.	O

In	O
addition	O
,	O
HMMER	O
reads	O
the	O
database	O
file	O
from	O
disk	O
for	O
every	O
sequence	O
it	O
searches	O
.	O

This	O
is	O
extremely	O
inefficient	O
for	O
batch	O
searches	O
.	O

We	O
have	O
corrected	O
this	O
by	O
reading	O
the	O
whole	O
database	O
into	O
memory	O
once	O
and	O
conducting	O
searches	O
from	O
memory	O
.	O

Performance	O
testing	O

We	O
compared	O
our	O
improved	O
IA64	O
single	O
-	O
processor	O
hmmpfam	O
with	O
the	O
equivalent	O
program	O
from	O
the	O
original	O
HMMER	O
2	O
.	O
3	O
.	O
2	O
release	O
on	O
an	O
Itanium	O
II	O
IA64	O
processor	O
(	O
Figure	O
1	O
)	O
.	O

As	O
expected	O
,	O
the	O
per	O
sequence	O
CPU	O
time	O
for	O
our	O
program	O
is	O
reduced	O
up	O
to	O
10	O
-	O
fold	O
in	O
batch	O
searches	O
,	O
while	O
in	O
the	O
case	O
of	O
the	O
original	O
2	O
.	O
3	O
.	O
2	O
release	O
,	O
it	O
is	O
linear	O
to	O
the	O
number	O
of	O
sequences	O
.	O

Performance	O
difference	O
in	O
single	O
-	O
sequence	O
processing	O
could	O
be	O
attributed	O
to	O
compilation	O
differences	O
.	O

Performance	O
differences	O
resulting	O
in	O
the	O
slope	O
difference	O
of	O
the	O
two	O
plots	O
may	O
be	O
due	O
to	O
the	O
elimination	O
of	O
the	O
need	O
to	O
reload	O
the	O
Pfam	O
database	O
from	O
disk	O
for	O
every	O
sequence	O
in	O
our	O
case	O
.	O

Processing	O
data	O
from	O
disk	O
can	O
be	O
an	O
order	O
of	O
magnitude	O
slower	O
than	O
processing	O
in	O
memory	O
.	O

Scaling	O
tests	O
were	O
conducted	O
on	O
a	O
128	O
-	O
node	O
Itanium	O
II	O
IA64	O
cluster	O
.	O

We	O
used	O
a	O
fixed	O
set	O
of	O
500	O
sequences	O
as	O
the	O
test	O
set	O
and	O
ran	O
on	O
1	O
-	O
32	O
processors	O
.	O

As	O
expected	O
,	O
the	O
time	O
required	O
to	O
process	O
a	O
given	O
set	O
of	O
sequences	O
reduces	O
linearly	O
with	O
the	O
number	O
of	O
processors	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
also	O
indicates	O
that	O
the	O
parallelization	O
overheads	O
using	O
our	O
method	O
are	O
minimal	O
.	O

However	O
,	O
as	O
the	O
ratio	O
of	O
the	O
number	O
of	O
sequences	O
to	O
the	O
number	O
of	O
processors	O
reduces	O
to	O
one	O
,	O
load	O
imbalances	O
due	O
to	O
the	O
processing	O
time	O
differences	O
between	O
different	O
sequences	O
start	O
to	O
dominate	O
,	O
reducing	O
parallel	O
efficiency	O
.	O

Pre	O
-	O
calculated	O
results	O

We	O
have	O
generated	O
pre	O
-	O
calculated	O
Pfam	O
search	O
results	O
for	O
the	O
entire	O
Swiss	O
-	O
Prot	O
and	O
TrEmbl	O
protein	O
sequences	O
(	O
~	O
1	O
.	O
2	O
million	O
)	O
,	O
using	O
our	O
parallelized	O
'	O
hmmpfam	O
'	O
on	O
256	O
processors	O
of	O
IA64	O
-	O
based	O
teragrid	O
machines	O
located	O
at	O
the	O
SDSC	O
.	O

Pfam	O
searches	O
have	O
been	O
performed	O
separately	O
,	O
using	O
either	O
gathering	O
thresholds	O
or	O
E	O
-	O
value	O
cutoffs	O
against	O
glocal	O
(	O
Pfam	O
_	O
ls	O
)	O
or	O
local	O
(	O
Pfam	O
_	O
fs	O
)	O
alignment	O
models	O
.	O

Glocal	O
and	O
local	O
search	O
results	O
were	O
parsed	O
and	O
merged	O
by	O
removing	O
all	O
local	O
search	O
hits	O
that	O
are	O
completely	O
overlapped	O
by	O
glocal	O
search	O
hits	O
.	O

Input	O
and	O
output	O
formats	O

The	O
program	O
takes	O
only	O
FASTA	O
-	O
formatted	O
sequences	O
as	O
input	O
and	O
searches	O
can	O
be	O
done	O
in	O
any	O
search	O
mode	O
,	O
i	O
.	O
e	O
.	O
local	O
,	O
glocal	O
or	O
merged	O
.	O

The	O
maximum	O
E	O
-	O
value	O
allowed	O
for	O
searches	O
is	O
10	O
.	O

SledgeHMMER	O
results	O
are	O
emailed	O
to	O
the	O
user	O
in	O
a	O
space	O
-	O
delimited	O
,	O
one	O
hit	O
per	O
line	O
tabular	O
format	O
(	O
Figure	O
2	O
)	O
.	O

The	O
response	O
time	O
for	O
receiving	O
results	O
depends	O
on	O
the	O
number	O
of	O
query	O
sequences	O
and	O
the	O
fraction	O
of	O
these	O
existing	O
in	O
the	O
pre	O
-	O
calculated	O
entries	O
.	O

DISCUSSION	O

The	O
SledgeHMMER	O
server	O
provides	O
a	O
unique	O
service	O
to	O
the	O
scientific	O
community	O
wishing	O
to	O
batch	O
search	O
the	O
Pfam	O
database	O
on	O
the	O
web	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
only	O
such	O
server	O
that	O
has	O
no	O
limit	O
on	O
the	O
number	O
of	O
input	O
sequences	O
.	O

The	O
current	O
pre	O
-	O
calculated	O
database	O
covers	O
~	O
70	O
%	O
of	O
the	O
available	O
non	O
-	O
redundant	O
protein	O
sequence	O
space	O
,	O
and	O
we	O
plan	O
to	O
add	O
additional	O
new	O
sequences	O
from	O
other	O
resources	O
such	O
as	O
the	O
NR	O
database	O
from	O
GenBank	O
and	O
SEQRES	O
from	O
the	O
PDB	O
(	O
Protein	O
Data	O
Bank	O
)	O
in	O
the	O
future	O
.	O

Our	O
pre	O
-	O
calculated	O
database	O
is	O
updated	O
for	O
every	O
new	O
release	O
of	O
the	O
Pfam	O
database	O
or	O
SPTr	O
databases	O
(	O
Swiss	O
-	O
Prot	O
+	O
TrEMBL	O
)	O
in	O
order	O
to	O
provide	O
access	O
to	O
the	O
most	O
current	O
data	O
.	O

Single	O
-	O
processor	O
optimized	O
hmmpfam	O
binaries	O
and	O
the	O
source	O
code	O
can	O
be	O
downloaded	O
from	O
the	O
current	O
web	O
server	O
.	O

In	O
the	O
future	O
,	O
we	O
intend	O
to	O
make	O
such	O
binaries	O
available	O
for	O
many	O
additional	O
operating	O
systems	O
and	O
propagate	O
these	O
modifications	O
to	O
other	O
HMMER	O
programs	O
as	O
well	O
.	O

Medicinal	O
herb	O
use	O
among	O
asthmatic	O
patients	S-Species
attending	O
a	O
specialty	O
care	O
facility	O
in	O
Trinidad	O

Abstract	O

Background	O

There	O
is	O
an	O
increasing	O
prevalence	O
of	O
asthma	O
in	O
the	O
Caribbean	O
and	O
patients	S-Species
remain	O
non	O
-	O
compliant	O
to	O
therapy	O
despite	O
the	O
development	O
of	O
guidelines	O
for	O
management	O
and	O
prevention	O
.	O

Some	O
patients	S-Species
may	O
self	O
-	O
medicate	O
with	O
medicinal	O
herbs	O
for	O
symptomatic	O
relief	O
,	O
as	O
there	O
is	O
a	O
long	O
tradition	O
of	O
use	O
for	O
a	O
variety	O
of	O
ailments	O
.	O

The	O
study	O
assessed	O
the	O
prevalence	O
of	O
use	O
and	O
the	O
factors	O
affecting	O
the	O
decision	O
to	O
use	O
herbs	O
in	O
asthmatic	O
patients	S-Species
attending	O
a	O
public	O
specialty	O
care	O
clinic	O
in	O
Trinidad	O
.	O

Methods	O

A	O
descriptive	O
,	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
at	O
the	O
Chest	O
Clinic	O
in	O
Trinidad	O
using	O
a	O
de	O
novo	O
,	O
pilot	O
-	O
tested	O
,	O
researcher	O
-	O
administered	O
questionnaire	O
between	O
June	O
and	O
July	O
2003	O
.	O

Results	O

Fifty	O
-	O
eight	O
out	O
of	O
191	O
patients	S-Species
(	O
30	O
.	O
4	O
%	O
)	O
reported	O
using	O
herbal	O
remedies	O
for	O
symptomatic	O
relief	O
.	O

Gender	O
,	O
age	O
,	O
ethnicity	O
,	O
and	O
asthma	O
severity	O
did	O
not	O
influence	O
the	O
decision	O
to	O
use	O
herbs	O
;	O
however	O
,	O
62	O
.	O
5	O
%	O
of	O
patients	S-Species
with	O
tertiary	O
level	O
schooling	O
used	O
herbs	O
,	O
p	O
=	O
0	O
.	O
025	O
.	O

Thirty	O
-	O
four	O
of	O
these	O
58	O
patients	S-Species
(	O
58	O
.	O
6	O
%	O
)	O
obtained	O
herbs	O
from	O
their	O
backyards	O
or	O
the	O
supermarket	O
;	O
only	O
14	O
patients	S-Species
(	O
24	O
.	O
1	O
%	O
)	O
obtained	O
herbs	O
from	O
an	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
.	O

Relatives	O
and	O
friends	O
were	O
the	O
sole	O
source	O
of	O
information	O
for	O
most	O
patients	S-Species
(	O
70	O
.	O
7	O
%	O
)	O
,	O
and	O
only	O
10	O
.	O
3	O
%	O
consulted	O
an	O
herbalist	O
.	O

Ginger	S-Species
,	O
garlic	S-Species
,	O
aloes	O
,	O
shandileer	S-Species
,	O
wild	O
onion	S-Species
,	O
pepper	O
and	O
black	B-Species
sage	E-Species
were	O
the	O
most	O
commonly	O
used	O
herbs	O
.	O

Conclusions	O

Among	O
patients	S-Species
attending	O
the	O
Chest	O
Clinic	O
in	O
Trinidad	O
the	O
use	O
of	O
herbal	O
remedies	O
in	O
asthma	O
is	O
relatively	O
common	O
on	O
the	O
advice	O
of	O
relatives	O
and	O
friends	O
.	O

It	O
is	O
therefore	O
becoming	O
imperative	O
for	O
healthcare	O
providers	O
to	O
become	O
more	O
knowledgeable	O
on	O
this	O
modality	O
and	O
to	O
keep	O
abreast	O
with	O
the	O
latest	O
developments	O
.	O

Background	O

Recent	O
reports	O
from	O
the	O
Caribbean	O
suggest	O
that	O
the	O
incidence	O
of	O
asthma	O
is	O
following	O
the	O
global	O
trend	O
of	O
increasing	O
prevalence	O
.	O

In	O
Jamaica	O
,	O
a	O
prevalence	O
of	O
20	O
.	O
8	O
%	O
for	O
exercise	O
-	O
induced	O
asthma	O
was	O
estimated	O
in	O
a	O
cross	O
-	O
sectional	O
study	O
in	O
schoolchildren	S-Species
[	O
1	O
]	O
.	O

About	O
one	O
in	O
ten	O
patients	S-Species
attending	O
an	O
Accident	O
and	O
Emergency	O
Department	O
in	O
Trinidad	O
were	O
treated	O
for	O
acute	O
severe	O
asthma	O
[	O
2	O
]	O
and	O
over	O
15	O
,	O
000	O
patients	S-Species
attended	O
four	O
A	O
&	O
E	O
departments	O
throughout	O
the	O
island	O
over	O
a	O
12	O
-	O
month	O
period	O
[	O
3	O
]	O
.	O

Inhaled	O
corticosteroids	O
as	O
prophylaxis	O
and	O
'	O
as	O
required	O
'	O
bronchodilator	O
for	O
symptomatic	O
relief	O
are	O
established	O
modalities	O
for	O
asthma	O
management	O
and	O
prevention	O
and	O
the	O
Commonwealth	O
Caribbean	O
Medical	O
Research	O
Council	O
/	O
Global	O
Initiative	O
for	O
Asthma	O
guidelines	O
were	O
adopted	O
in	O
the	O
Caribbean	O
in	O
1997	O
[	O
4	O
]	O
.	O

It	O
has	O
been	O
noted	O
that	O
inefficient	O
management	O
predisposes	O
patients	S-Species
to	O
frequent	O
hospitalization	O
and	O
reduced	O
quality	O
of	O
life	O
.	O

In	O
Trinidad	O
,	O
non	O
-	O
compliance	O
and	O
inadequate	O
inhaler	O
technique	O
negatively	O
impact	O
on	O
effective	O
disease	O
management	O
[	O
5	O
,	O
6	O
]	O
.	O

The	O
frequent	O
unavailability	O
of	O
medication	O
at	O
public	O
health	O
facilities	O
and	O
the	O
prohibitive	O
cost	O
at	O
private	O
pharmacies	O
are	O
significantly	O
associated	O
with	O
non	O
-	O
compliance	O
and	O
consequently	O
poor	O
disease	O
control	O
.	O

In	O
these	O
studies	O
,	O
some	O
patients	S-Species
indicated	O
their	O
use	O
of	O
herbal	O
remedies	O
as	O
an	O
alternative	O
to	O
conventional	O
medicines	O
.	O

Over	O
the	O
last	O
few	O
decades	O
,	O
a	O
global	O
resurgence	O
in	O
the	O
use	O
of	O
herbal	O
remedies	O
has	O
fuelled	O
the	O
growing	O
multi	O
-	O
billion	O
dollar	O
international	O
trade	O
of	O
botanical	O
products	O
.	O

Many	O
patients	S-Species
,	O
dissatisfied	O
with	O
conventional	O
medicines	O
because	O
they	O
expect	O
permanent	O
cures	O
,	O
believe	O
that	O
herbal	O
remedies	O
are	O
'	O
natural	O
'	O
and	O
sometimes	O
self	O
-	O
medicate	O
without	O
informing	O
their	O
attending	O
physician	O
.	O

Although	O
there	O
is	O
a	O
long	O
history	O
of	O
traditional	O
use	O
of	O
medicinal	O
herbs	O
throughout	O
the	O
Caribbean	O
[	O
7	O
,	O
8	O
]	O
few	O
studies	O
were	O
done	O
to	O
assess	O
the	O
prevalence	O
of	O
use	O
.	O

Surveys	O
in	O
Jamaica	O
reported	O
an	O
almost	O
100	O
%	O
use	O
of	O
herbal	O
teas	O
and	O
remedies	O
by	O
respondents	O
throughout	O
the	O
island	O
[	O
9	O
]	O
and	O
71	O
%	O
in	O
paediatrics	O
inpatients	O
at	O
the	O
University	O
Hospital	O
[	O
10	O
]	O
.	O

These	O
studies	O
,	O
however	O
,	O
assessed	O
only	O
the	O
lifetime	O
use	O
of	O
medicinal	O
herbs	O
and	O
did	O
not	O
identify	O
their	O
use	O
for	O
any	O
particular	O
disease	O
.	O

In	O
Trinidad	O
and	O
Tobago	O
,	O
the	O
use	O
of	O
'	O
bush	O
medicine	O
'	O
in	O
diabetic	O
patients	S-Species
attending	O
primary	O
healthcare	O
facilities	O
throughout	O
the	O
island	O
was	O
assessed	O
and	O
although	O
42	O
%	O
reportedly	O
used	O
herbs	O
,	O
only	O
24	O
%	O
used	O
this	O
healthcare	O
modality	O
for	O
self	O
-	O
management	O
of	O
diabetes	O
[	O
11	O
]	O
.	O

Another	O
survey	O
conducted	O
at	O
an	O
outpatient	O
surgical	O
facility	O
in	O
Trinidad	O
indicated	O
a	O
lifetime	O
prevalence	O
of	O
86	O
%	O
among	O
patients	S-Species
[	O
12	O
]	O
for	O
any	O
healthcare	O
issue	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
extent	O
of	O
use	O
of	O
herbal	O
remedies	O
by	O
asthmatic	O
patients	S-Species
attending	O
a	O
specialty	O
chest	O
clinic	O
in	O
Trinidad	O
for	O
symptomatic	O
relief	O
and	O
to	O
determine	O
the	O
factors	O
influencing	O
the	O
patient	S-Species
'	O
s	O
decision	O
to	O
use	O
herbs	O
.	O

Methods	O

The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Faculty	O
of	O
Medical	O
Sciences	O
,	O
University	O
of	O
the	O
West	O
Indies	O
,	O
St	O
.	O

Augustine	O
campus	O
and	O
permission	O
to	O
interview	O
patients	S-Species
was	O
granted	O
by	O
the	O
Director	O
of	O
the	O
Chest	O
Clinic	O
of	O
the	O
Ministry	O
of	O
Health	O
,	O
Trinidad	O
and	O
Tobago	O
.	O

The	O
study	O
was	O
conducted	O
over	O
the	O
two	O
-	O
month	O
period	O
June	O
to	O
July	O
2003	O
.	O

Sample	O
and	O
setting	O

The	O
Chest	O
Clinic	O
was	O
chosen	O
as	O
the	O
source	O
of	O
subjects	O
as	O
this	O
is	O
the	O
only	O
national	O
tertiary	O
level	O
health	O
facility	O
specializing	O
in	O
the	O
management	O
of	O
respiratory	O
diseases	O
.	O

Patients	S-Species
entering	O
the	O
study	O
were	O
physician	O
-	O
diagnosed	O
asthmatics	O
based	O
on	O
self	O
-	O
reporting	O
symptoms	O
of	O
wheezing	O
,	O
chest	O
tightness	O
and	O
nocturnal	O
coughing	O
in	O
the	O
previous	O
year	O
.	O

Patients	S-Species
were	O
recruited	O
by	O
consecutive	O
sampling	O
and	O
the	O
nature	O
and	O
purpose	O
of	O
the	O
study	O
were	O
explained	O
on	O
an	O
individual	O
basis	O
.	O

Those	O
confirming	O
their	O
willingness	O
to	O
participate	O
signed	O
their	O
informed	O
consent	O
and	O
were	O
interviewed	O
using	O
a	O
de	O
novo	O
,	O
pilot	O
-	O
tested	O
,	O
researcher	O
-	O
administered	O
questionnaire	O
.	O

Interview	O
instrument	O

The	O
questionnaire	O
assessed	O
demographic	O
data	O
such	O
as	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
residential	O
district	O
,	O
education	O
,	O
employment	O
and	O
socioeconomic	O
status	O
.	O

Subjects	O
reported	O
their	O
disease	O
severity	O
as	O
intermittent	O
,	O
moderate	O
or	O
severe	O
as	O
determined	O
by	O
the	O
Global	O
Initiative	O
for	O
Asthma	O
(	O
GINA	O
)	O
guidelines	O
with	O
respect	O
to	O
symptom	O
frequency	O
[	O
4	O
]	O
.	O

Patients	S-Species
also	O
reported	O
their	O
use	O
of	O
herbal	O
remedies	O
,	O
identified	O
the	O
herbs	O
used	O
,	O
the	O
frequency	O
of	O
use	O
,	O
source	O
of	O
herbal	O
medicines	O
and	O
the	O
reasons	O
for	O
the	O
use	O
of	O
herbs	O
.	O

Statistical	O
analysis	O

The	O
sample	O
size	O
was	O
calculated	O
as	O
185	O
patients	S-Species
assuming	O
a	O
prevalence	O
of	O
86	O
%	O
[	O
13	O
]	O
with	O
a	O
confidence	O
level	O
of	O
95	O
%	O
.	O

Since	O
all	O
variables	O
were	O
categorical	O
,	O
chi	O
2	O
tests	O
were	O
performed	O
to	O
determine	O
whether	O
there	O
were	O
statistically	O
significant	O
associations	O
between	O
the	O
use	O
of	O
herbs	O
and	O
these	O
variables	O
.	O

The	O
p	O
value	O
was	O
set	O
at	O
<	O
0	O
.	O
05	O
for	O
statistical	O
significance	O
.	O

The	O
data	O
was	O
analyzed	O
using	O
SPSS	O
for	O
Windows	O
(	O
Version	O
9	O
.	O
0	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

Results	O

Demography	O

During	O
the	O
study	O
period	O
one	O
hundred	O
and	O
ninety	O
one	O
patients	S-Species
consented	O
to	O
participate	O
.	O

The	O
demographic	O
details	O
of	O
the	O
sample	O
are	O
given	O
in	O
Table	O
1	O
.	O

Patients	S-Species
between	O
35	O
and	O
64	O
years	O
of	O
age	O
formed	O
the	O
largest	O
portion	O
of	O
the	O
sample	O
(	O
62	O
.	O
3	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	O
gender	O
difference	O
with	O
females	O
outnumbering	O
males	O
by	O
a	O
2	O
:	O
1	O
ratio	O
,	O
p	O
<	O
0	O
.	O
01	O
.	O

Most	O
patients	S-Species
were	O
of	O
Asian	O
Indian	O
origin	O
(	O
58	O
.	O
1	O
%	O
)	O
and	O
resided	O
in	O
suburban	O
areas	O
(	O
60	O
.	O
2	O
%	O
)	O
.	O

There	O
was	O
a	O
high	O
level	O
of	O
unemployment	O
(	O
30	O
.	O
4	O
%	O
)	O
;	O
this	O
could	O
be	O
correlated	O
to	O
primary	O
schooling	O
(	O
seven	O
or	O
less	O
years	O
of	O
formal	O
education	O
)	O
being	O
the	O
highest	O
educational	O
level	O
attained	O
in	O
52	O
.	O
9	O
%	O
and	O
no	O
formal	O
schooling	O
in	O
5	O
.	O
2	O
%	O
of	O
the	O
sample	O
population	O
.	O

Income	O
was	O
low	O
,	O
with	O
42	O
.	O
9	O
%	O
of	O
the	O
sample	O
population	O
earning	O
below	O
US	O
$	O
4	O
,	O
000	O
per	O
year	O
.	O

Antiasthmatic	O
drug	O
use	O

The	O
GINA	O
guidelines	O
were	O
recently	O
adopted	O
in	O
the	O
Caribbean	O
and	O
asthmatic	O
patients	S-Species
are	O
currently	O
treated	O
according	O
to	O
their	O
symptom	O
severity	O
.	O

In	O
our	O
sample	O
population	O
,	O
particularly	O
in	O
patients	S-Species
with	O
moderate	O
and	O
severe	O
symptoms	O
,	O
corticosteroids	O
(	O
controllers	O
)	O
and	O
beta	O
2	O
-	O
agonists	O
(	O
relievers	O
)	O
were	O
prescribed	O
at	O
very	O
high	O
rates	O
,	O
Table	O
2	O
.	O

Almost	O
90	O
%	O
of	O
all	O
patients	S-Species
with	O
moderate	O
symptoms	O
were	O
prescribed	O
drugs	O
in	O
these	O
classes	O
.	O

Almost	O
all	O
patients	S-Species
with	O
severe	O
symptoms	O
were	O
prescribed	O
beta	O
2	O
-	O
agonists	O
.	O

This	O
high	O
level	O
of	O
prescription	O
and	O
use	O
of	O
beta	O
2	O
-	O
agonists	O
suggest	O
a	O
lack	O
of	O
symptomatic	O
control	O
in	O
our	O
sample	O
population	O
.	O

Theophylline	O
and	O
anticholinergics	O
were	O
prescribed	O
in	O
both	O
categories	O
of	O
patients	S-Species
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Factors	O
influencing	O
the	O
use	O
of	O
herbal	O
remedies	O

Gender	O
,	O
age	O
,	O
ethnicity	O
,	O
residential	O
district	O
,	O
employment	O
status	O
,	O
income	O
and	O
asthma	O
severity	O
had	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
use	O
of	O
herbal	O
remedies	O
within	O
the	O
sample	O
population	O
,	O
Table	O
3	O
.	O

However	O
,	O
almost	O
two	O
-	O
thirds	O
(	O
62	O
.	O
5	O
%	O
)	O
of	O
patients	S-Species
with	O
tertiary	O
education	O
used	O
herbal	O
remedies	O
for	O
asthma	O
,	O
p	O
=	O
0	O
.	O
025	O
.	O

Characteristics	O
of	O
patients	S-Species
using	O
herbal	O
remedies	O

Most	O
patients	S-Species
(	O
70	O
.	O
7	O
%	O
)	O
using	O
herbs	O
were	O
advised	O
by	O
a	O
relative	O
or	O
friend	O
and	O
only	O
10	O
.	O
3	O
%	O
sought	O
the	O
advice	O
of	O
an	O
herbalist	O
,	O
Table	O
4	O
.	O

A	O
cultural	O
/	O
traditional	O
basis	O
was	O
the	O
reason	O
for	O
herbal	O
remedy	O
usage	O
in	O
twenty	O
-	O
one	O
(	O
36	O
.	O
2	O
%	O
)	O
patients	S-Species
and	O
another	O
twelve	O
(	O
20	O
.	O
7	O
%	O
)	O
patients	S-Species
used	O
herbs	O
because	O
they	O
felt	O
that	O
were	O
either	O
'	O
natural	O
'	O
or	O
'	O
healthy	O
'	O
.	O

Twelve	O
(	O
20	O
.	O
7	O
%	O
)	O
patients	S-Species
used	O
herbs	O
because	O
they	O
believed	O
that	O
their	O
physician	O
-	O
prescribed	O
allopathic	O
medicines	O
were	O
not	O
working	O
.	O

Most	O
patients	S-Species
(	O
58	O
.	O
6	O
%	O
)	O
obtained	O
their	O
herbs	O
or	O
medicinal	O
plants	O
from	O
either	O
their	O
backyards	O
or	O
the	O
supermarket	O
.	O

Only	O
fourteen	O
(	O
24	O
.	O
1	O
%	O
)	O
obtained	O
their	O
herbal	O
supplies	O
from	O
an	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
.	O

Seventeen	O
(	O
29	O
.	O
3	O
%	O
)	O
of	O
these	O
patients	S-Species
reported	O
using	O
herbs	O
within	O
the	O
last	O
week	O
and	O
most	O
these	O
patients	S-Species
(	O
60	O
.	O
3	O
%	O
)	O
used	O
herbs	O
within	O
the	O
last	O
six	O
months	O
.	O

Many	O
of	O
these	O
patients	S-Species
were	O
using	O
both	O
physician	O
-	O
prescribed	O
antiasthmatic	O
drugs	O
and	O
herbal	O
remedies	O
,	O
Table	O
5	O
.	O

No	O
patient	S-Species
with	O
either	O
moderate	O
or	O
severe	O
symptoms	O
indicated	O
that	O
herbal	O
remedies	O
alone	O
were	O
sufficient	O
to	O
relieve	O
symptomatic	O
episodes	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
most	O
patients	S-Species
with	O
moderate	O
symptoms	O
(	O
57	O
.	O
1	O
%	O
)	O
believed	O
that	O
concurrent	O
use	O
of	O
conventional	O
medications	O
and	O
herbs	O
gave	O
better	O
symptomatic	O
relieve	O
.	O

One	O
the	O
other	O
hand	O
,	O
most	O
patients	S-Species
with	O
severe	O
symptoms	O
(	O
53	O
.	O
8	O
%	O
)	O
believed	O
that	O
physician	O
-	O
prescribed	O
medications	O
worked	O
better	O
than	O
herbal	O
remedies	O
,	O
while	O
23	O
.	O
1	O
%	O
believed	O
that	O
neither	O
relieved	O
their	O
symptoms	O
.	O

Herbs	O
used	O
in	O
asthma	O

Most	O
patients	S-Species
in	O
the	O
sample	O
used	O
more	O
than	O
one	O
medicinal	O
herb	O
simultaneously	O
,	O
which	O
were	O
usually	O
prepared	O
and	O
administered	O
as	O
mixtures	O
in	O
teas	O
.	O

Almost	O
one	O
in	O
four	O
patients	S-Species
using	O
medicinal	O
herbs	O
(	O
22	O
.	O
5	O
%	O
)	O
used	O
either	O
garlic	S-Species
(	O
Allium	B-Species
sativum	E-Species
)	O
or	O
ginger	S-Species
(	O
Zingiber	B-Species
officinale	E-Species
)	O
for	O
symptomatic	O
relief	O
of	O
asthma	O
,	O
Table	O
6	O
.	O

Aloes	O
(	O
Aloe	B-Species
vera	E-Species
)	O
shandileer	S-Species
(	O
Leonotis	B-Species
nepetifolia	E-Species
)	O
,	O
wild	O
onion	S-Species
(	O
Hymenocallis	B-Species
tubiflora	E-Species
)	O
,	O
pepper	O
(	O
Capsicum	O
spp	O
.	O
)	O
tulsi	S-Species
(	O
Ocimum	B-Species
gratissimum	E-Species
)	O
,	O
black	B-Species
sage	E-Species
(	O
Cordia	B-Species
curassavica	E-Species
)	O
,	O
shadon	B-Species
beni	E-Species
(	O
Eryngium	B-Species
foetidium	E-Species
)	O
,	O
lemongrass	S-Species
(	O
Cymbopogon	B-Species
citratus	E-Species
)	O
and	O
nutmeg	S-Species
(	O
Myristica	B-Species
fragrans	E-Species
)	O
were	O
the	O
more	O
popular	O
traditional	O
indigenous	O
West	O
Indian	O
medicinal	O
plants	O
used	O
.	O

Two	O
patients	S-Species
reported	O
using	O
marijuana	O
(	O
leaves	O
and	O
roots	O
)	O
.	O

Herbs	O
of	O
European	O
and	O
North	O
American	O
origin	O
,	O
identified	O
as	O
Echinacea	O
(	O
Echinacea	B-Species
purpurea	E-Species
)	O
,	O
Golden	B-Species
Seal	E-Species
(	O
Hydrastis	B-Species
canadensis	E-Species
)	O
and	O
Chamomile	S-Species
(	O
Matricaria	B-Species
chamomilla	E-Species
)	O
were	O
less	O
frequently	O
used	O
.	O

Five	O
patients	S-Species
reported	O
using	O
trade	O
name	O
imported	O
tablets	O
for	O
asthma	O
.	O

Effect	O
of	O
income	O
and	O
education	O
on	O
the	O
use	O
of	O
herbs	O

Patients	S-Species
using	O
easily	O
accessible	O
herbs	O
such	O
as	O
ginger	S-Species
(	O
Zingiber	B-Species
officinale	E-Species
)	O
and	O
aloes	O
(	O
Aloe	B-Species
vera	E-Species
)	O
,	O
and	O
traditional	O
indigenous	O
medicinal	O
herbs	O
such	O
as	O
shandileer	S-Species
(	O
Leonotis	B-Species
nepetifolia	E-Species
)	O
and	O
tulsi	S-Species
(	O
Ocimum	B-Species
gratissimum	E-Species
)	O
were	O
more	O
likely	O
to	O
be	O
earning	O
less	O
than	O
US	O
$	O
12	O
,	O
000	O
,	O
Table	O
7	O
.	O

Herbs	O
of	O
European	O
or	O
North	O
American	O
origin	O
(	O
Echinacea	B-Species
purpurea	E-Species
and	O
Matricaria	B-Species
chamomilla	E-Species
)	O
were	O
more	O
likely	O
to	O
be	O
used	O
by	O
patients	S-Species
earning	O
in	O
excess	O
of	O
US	O
$	O
12	O
,	O
000	O
per	O
annum	O
.	O

Income	O
did	O
not	O
affect	O
the	O
use	O
of	O
either	O
garlic	S-Species
or	O
cocoa	O
onion	S-Species
.	O

Aloes	O
(	O
Aloe	B-Species
vera	E-Species
)	O
,	O
tulsi	S-Species
(	O
Ocimum	B-Species
gratissimum	E-Species
)	O
and	O
golden	O
seal	O
were	O
preferred	O
in	O
patients	S-Species
with	O
at	O
least	O
twelve	O
years	O
of	O
formal	O
education	O
,	O
Table	O
7	O
.	O

Garlic	S-Species
and	O
Echinacea	S-Species
were	O
the	O
preferred	O
herbal	O
medicines	O
in	O
patients	S-Species
with	O
more	O
than	O
twelve	O
years	O
formal	O
education	O
.	O

Educational	O
level	O
did	O
not	O
affect	O
the	O
patients	S-Species
'	O
decision	O
to	O
use	O
shandileer	S-Species
(	O
Leonotis	B-Species
nepetifolia	E-Species
)	O
,	O
wild	O
onion	S-Species
(	O
Hymenocallis	B-Species
tubiflora	E-Species
)	O
or	O
ginger	S-Species
(	O
Zingibe	B-Species
officinale	E-Species
)	O
.	O

Discussion	O

This	O
is	O
the	O
first	O
study	O
of	O
its	O
kind	O
in	O
the	O
Caribbean	O
to	O
assess	O
the	O
use	O
of	O
medicinal	O
herbs	O
by	O
asthmatic	O
patients	S-Species
attending	O
a	O
specialty	O
care	O
clinic	O
.	O

The	O
findings	O
of	O
this	O
study	O
are	O
instructive	O
as	O
the	O
use	O
of	O
medicinal	O
herbs	O
for	O
self	O
-	O
medication	O
in	O
disease	O
management	O
has	O
far	O
reaching	O
implications	O
on	O
the	O
quality	O
of	O
healthcare	O
delivery	O
[	O
14	O
]	O
.	O

We	O
report	O
a	O
prevalence	O
of	O
30	O
.	O
4	O
%	O
in	O
our	O
patient	S-Species
sample	O
,	O
which	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
UK	O
,	O
Denmark	O
,	O
Singapore	O
and	O
in	O
the	O
US	O
[	O
15	O
-	O
18	O
]	O
.	O

Most	O
patients	S-Species
using	O
medicinal	O
herbs	O
relied	O
on	O
the	O
advice	O
of	O
relatives	O
and	O
friends	O
as	O
their	O
sole	O
source	O
of	O
information	O
,	O
as	O
were	O
caregivers	O
of	O
children	O
in	O
a	O
US	O
study	O
[	O
19	O
]	O
.	O

We	O
suggest	O
that	O
this	O
information	O
on	O
the	O
use	O
of	O
medicinal	O
plants	O
could	O
have	O
come	O
from	O
traditional	O
/	O
cultural	O
knowledge	O
,	O
anecdotal	O
evidence	O
or	O
from	O
the	O
greater	O
public	O
awareness	O
through	O
information	O
networks	O
such	O
as	O
the	O
internet	O
on	O
the	O
potential	O
medicinal	O
benefits	O
of	O
herbs	O
.	O

Asthma	O
is	O
an	O
emerging	O
chronic	O
disease	O
in	O
the	O
Caribbean	O
and	O
we	O
suggest	O
that	O
the	O
traditional	O
knowledge	O
in	O
this	O
area	O
may	O
be	O
relatively	O
'	O
new	O
'	O
and	O
exist	O
in	O
relation	O
to	O
other	O
diseases	O
affecting	O
the	O
respiratory	O
tract	O
,	O
such	O
as	O
cough	O
,	O
the	O
common	O
cold	O
and	O
the	O
flu	O
.	O

This	O
may	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
low	O
prevalence	O
of	O
use	O
of	O
herbs	O
in	O
elderly	O
asthmatic	O
patients	S-Species
,	O
as	O
a	O
strong	O
traditional	O
knowledge	O
may	O
not	O
have	O
existed	O
.	O

We	O
expected	O
a	O
higher	O
prevalence	O
of	O
herbal	O
use	O
in	O
individuals	O
living	O
in	O
rural	O
areas	O
as	O
these	O
districts	O
are	O
depots	O
for	O
traditional	O
knowledge	O
as	O
was	O
reported	O
in	O
Jamaica	O
where	O
rural	O
respondents	O
used	O
a	O
larger	O
variety	O
of	O
herbs	O
than	O
those	O
living	O
in	O
urban	O
areas	O
[	O
10	O
]	O
.	O

As	O
suggested	O
earlier	O
,	O
we	O
suspect	O
that	O
due	O
to	O
the	O
recent	O
emergence	O
of	O
asthma	O
as	O
a	O
chronic	O
disease	O
in	O
the	O
Caribbean	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
traditional	O
knowledge	O
in	O
the	O
management	O
of	O
this	O
disease	O
is	O
not	O
strong	O
and	O
our	O
results	O
are	O
indicative	O
of	O
this	O
.	O

We	O
suspected	O
that	O
employment	O
status	O
could	O
have	O
predicted	O
the	O
use	O
of	O
herbs	O
,	O
however	O
,	O
this	O
was	O
not	O
the	O
case	O
in	O
our	O
study	O
sample	O
.	O

Unemployed	O
patients	S-Species
did	O
not	O
improvise	O
more	O
in	O
their	O
use	O
of	O
herbal	O
remedies	O
than	O
those	O
in	O
other	O
income	O
groups	O
,	O
even	O
though	O
most	O
of	O
the	O
herbs	O
used	O
were	O
relatively	O
common	O
,	O
readily	O
available	O
and	O
cheap	O
.	O

The	O
low	O
socioeconomic	O
status	O
of	O
the	O
majority	O
of	O
the	O
sample	O
may	O
have	O
prohibited	O
both	O
consultation	O
with	O
qualified	O
herbalists	O
and	O
the	O
purchase	O
of	O
imported	O
,	O
processed	O
herbs	O
that	O
would	O
have	O
incurred	O
additional	O
out	O
-	O
of	O
-	O
pocket	O
expense	O
to	O
the	O
patient	S-Species
.	O

What	O
we	O
noted	O
was	O
that	O
there	O
was	O
no	O
difference	O
in	O
the	O
use	O
of	O
herbs	O
across	O
the	O
income	O
ranges	O
and	O
that	O
in	O
fact	O
,	O
patients	S-Species
earning	O
relatively	O
modest	O
annual	O
incomes	O
between	O
$	O
US12	O
,	O
000	O
and	O
$	O
US19	O
,	O
999	O
were	O
most	O
likely	O
to	O
use	O
herbs	O
,	O
although	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Attaining	O
a	O
higher	O
education	O
positively	O
influence	O
the	O
decision	O
to	O
use	O
herbs	O
.	O

We	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
traditional	O
knowledge	O
regarding	O
the	O
medicinal	O
use	O
of	O
herbs	O
for	O
asthma	O
,	O
a	O
higher	O
educational	O
level	O
may	O
predispose	O
an	O
individual	O
to	O
greater	O
access	O
to	O
general	O
knowledge	O
,	O
especially	O
with	O
greater	O
exposure	O
to	O
the	O
internet	O
and	O
other	O
sources	O
of	O
information	O
,	O
and	O
this	O
could	O
be	O
a	O
factor	O
in	O
positively	O
influencing	O
the	O
individual	O
'	O
s	O
decision	O
to	O
use	O
medicinal	O
herbs	O
.	O

The	O
availability	O
of	O
scientific	O
evidence	O
-	O
based	O
information	O
on	O
the	O
efficacy	O
of	O
herbs	O
for	O
diverse	O
healthcare	O
problems	O
may	O
be	O
particularly	O
significant	O
in	O
patients	S-Species
with	O
the	O
resources	O
to	O
avail	O
themselves	O
to	O
such	O
information	O
,	O
particularly	O
those	O
with	O
higher	O
educational	O
and	O
income	O
levels	O
.	O

This	O
is	O
particularly	O
true	O
for	O
garlic	S-Species
and	O
Echinacea	S-Species
,	O
which	O
have	O
been	O
extensively	O
researched	O
and	O
furthermore	O
patients	S-Species
with	O
higher	O
educational	O
and	O
income	O
levels	O
would	O
be	O
more	O
likely	O
be	O
at	O
an	O
advantage	O
to	O
access	O
information	O
via	O
literature	O
or	O
on	O
the	O
world	O
wide	O
web	O
regarding	O
the	O
use	O
of	O
these	O
medicinal	O
plants	O
.	O

Patients	S-Species
using	O
imported	O
,	O
processed	O
,	O
and	O
obviously	O
more	O
expensive	O
herbal	O
medications	O
were	O
on	O
the	O
higher	O
end	O
of	O
the	O
socioeconomic	O
scale	O
and	O
were	O
more	O
likely	O
to	O
afford	O
these	O
medications	O
.	O

It	O
was	O
also	O
observed	O
that	O
garlic	S-Species
and	O
Echinacea	S-Species
were	O
the	O
herbs	O
of	O
choice	O
in	O
patients	S-Species
with	O
higher	O
educational	O
levels	O
.	O

These	O
herbs	O
have	O
a	O
long	O
tradition	O
of	O
use	O
and	O
are	O
widely	O
researched	O
in	O
Europe	O
and	O
North	O
America	O
.	O

The	O
traditional	O
use	O
and	O
strong	O
scientific	O
evidence	O
to	O
support	O
their	O
therapeutic	O
efficacy	O
could	O
be	O
important	O
factors	O
influencing	O
the	O
patient	S-Species
'	O
s	O
decision	O
.	O

It	O
has	O
been	O
suggested	O
elsewhere	O
that	O
patients	S-Species
with	O
higher	O
educational	O
levels	O
also	O
tend	O
be	O
more	O
involved	O
in	O
the	O
management	O
of	O
their	O
health	O
;	O
they	O
tend	O
to	O
self	O
-	O
medicate	O
or	O
even	O
suggest	O
to	O
their	O
physicians	O
the	O
course	O
of	O
therapy	O
.	O

Although	O
one	O
in	O
five	O
patients	S-Species
using	O
medicinal	O
herbs	O
stated	O
that	O
"	O
conventional	O
medicines	O
were	O
not	O
working	O
"	O
as	O
the	O
reason	O
for	O
using	O
this	O
alternative	O
healthcare	O
modality	O
,	O
we	O
noted	O
that	O
asthma	O
severity	O
does	O
not	O
affect	O
the	O
decision	O
to	O
use	O
herbs	O
.	O

In	O
previous	O
studies	O
,	O
poor	O
management	O
was	O
associated	O
with	O
non	O
-	O
compliance	O
with	O
prescribed	O
pharmacotherapy	O
and	O
poor	O
inhaler	O
technique	O
[	O
5	O
,	O
6	O
]	O
.	O

The	O
backyard	O
and	O
home	O
garden	O
were	O
major	O
sources	O
of	O
readily	O
available	O
herbs	O
such	O
as	O
aloes	O
,	O
shadon	B-Species
beni	E-Species
and	O
lemongrass	S-Species
.	O

Wild	O
growing	O
'	O
weeds	O
'	O
such	O
as	O
shandileer	S-Species
,	O
tulsi	S-Species
,	O
cocoa	O
onion	S-Species
and	O
black	B-Species
sage	E-Species
were	O
also	O
identified	O
.	O

The	O
supermarket	O
was	O
a	O
major	O
source	O
of	O
inexpensive	O
common	O
medicinal	O
herbs	O
such	O
as	O
garlic	S-Species
,	O
ginger	S-Species
and	O
nutmeg	S-Species
.	O

The	O
identification	O
of	O
these	O
medicinal	O
herbs	O
provides	O
an	O
opportunity	O
to	O
investigate	O
West	O
Indian	O
plants	O
used	O
to	O
treat	O
asthma	O
to	O
determine	O
whether	O
they	O
possess	O
pharmacological	O
properties	O
.	O

Scientific	O
investigations	O
have	O
shown	O
that	O
some	O
of	O
these	O
herbs	O
possess	O
pharmacological	O
and	O
anti	O
-	O
inflammatory	O
properties	O
,	O
and	O
these	O
may	O
be	O
useful	O
in	O
suppressing	O
the	O
characteristic	O
exaggerated	O
immune	O
response	O
in	O
asthma	O
[	O
20	O
-	O
24	O
]	O
.	O

Pepper	O
and	O
bayleaf	S-Species
have	O
also	O
been	O
shown	O
to	O
exhibit	O
anti	O
-	O
inflammatory	O
properties	O
[	O
[	O
25	O
,	O
26	O
]	O
27	O
]	O
.	O

There	O
is	O
an	O
imperative	O
to	O
commence	O
scientific	O
investigations	O
on	O
traditional	O
West	O
Indian	O
medicinal	O
plants	O
to	O
determine	O
their	O
therapeutic	O
efficacy	O
and	O
safety	O
.	O

The	O
survey	O
instrument	O
specifically	O
asked	O
questions	O
on	O
the	O
use	O
of	O
medicinal	O
herbs	O
in	O
asthma	O
and	O
did	O
not	O
inquire	O
about	O
the	O
use	O
of	O
herbs	O
as	O
customary	O
teas	O
or	O
tonics	O
.	O

We	O
therefore	O
did	O
not	O
determine	O
lifetime	O
prevalence	O
for	O
the	O
use	O
of	O
herbs	O
in	O
our	O
patient	S-Species
sample	O
,	O
but	O
we	O
suppose	O
that	O
had	O
this	O
been	O
included	O
that	O
there	O
might	O
have	O
been	O
a	O
prevalence	O
similar	O
to	O
those	O
reported	O
in	O
the	O
Jamaica	O
[	O
10	O
,	O
11	O
]	O
and	O
Trinidad	O
[	O
13	O
]	O
surveys	O
.	O

The	O
survey	O
was	O
also	O
limited	O
in	O
that	O
by	O
electing	O
to	O
conduct	O
the	O
study	O
at	O
a	O
public	O
health	O
facility	O
we	O
obviously	O
had	O
a	O
bias	O
towards	O
patients	S-Species
at	O
the	O
lower	O
rung	O
of	O
the	O
socioeconomic	O
ladder	O
,	O
with	O
lower	O
income	O
and	O
educational	O
status	O
.	O

As	O
a	O
consequence	O
,	O
the	O
results	O
reflected	O
patients	S-Species
from	O
this	O
demographic	O
background	O
.	O

We	O
may	O
have	O
expected	O
a	O
different	O
outcome	O
in	O
asthmatic	O
patients	S-Species
attending	O
private	O
institutions	O
,	O
where	O
their	O
characteristics	O
would	O
have	O
been	O
slightly	O
different	O
,	O
as	O
we	O
noted	O
that	O
even	O
in	O
our	O
sample	O
the	O
small	O
number	O
of	O
persons	O
with	O
higher	O
income	O
and	O
educational	O
status	O
tended	O
to	O
use	O
more	O
medicinal	O
herbs	O
for	O
symptomatic	O
relief	O
.	O

We	O
did	O
not	O
assess	O
whether	O
patients	S-Species
informed	O
their	O
attending	O
physician	O
at	O
the	O
clinic	O
about	O
their	O
use	O
of	O
herbs	O
or	O
determined	O
whether	O
the	O
knowledge	O
or	O
attitudes	O
of	O
these	O
physicians	O
regarding	O
the	O
use	O
of	O
herbs	O
influenced	O
the	O
patients	S-Species
'	O
decision	O
to	O
use	O
herbs	O
.	O

The	O
study	O
was	O
also	O
limited	O
in	O
that	O
we	O
did	O
not	O
ascertain	O
the	O
out	O
-	O
of	O
-	O
pocket	O
expense	O
for	O
herbal	O
remedies	O
by	O
patients	S-Species
,	O
although	O
most	O
stated	O
that	O
herbal	O
medicines	O
(	O
which	O
we	O
supposed	O
were	O
processed	O
,	O
imported	O
products	O
)	O
were	O
more	O
expensive	O
than	O
conventional	O
medicines	O
.	O

We	O
assumed	O
that	O
an	O
additional	O
expense	O
would	O
have	O
only	O
been	O
incurred	O
by	O
those	O
patients	S-Species
purchasing	O
processed	O
,	O
imported	O
herbs	O
obtained	O
from	O
a	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
(	O
24	O
.	O
1	O
%	O
)	O
and	O
who	O
actually	O
consulted	O
a	O
herbalist	O
(	O
10	O
.	O
3	O
%	O
)	O
.	O

We	O
also	O
reasoned	O
that	O
since	O
all	O
the	O
other	O
herbs	O
used	O
were	O
inexpensive	O
and	O
available	O
from	O
either	O
the	O
backyard	O
garden	O
or	O
supermarket	O
(	O
58	O
.	O
6	O
%	O
)	O
that	O
the	O
cost	O
to	O
patients	S-Species
selecting	O
these	O
remedies	O
was	O
minimal	O
.	O

Conclusions	O

The	O
findings	O
of	O
this	O
study	O
are	O
important	O
in	O
that	O
local	O
medicinal	O
plants	O
in	O
Trinidad	O
have	O
been	O
identified	O
in	O
the	O
self	O
-	O
management	O
of	O
asthma	O
in	O
a	O
significant	O
number	O
of	O
patients	S-Species
attending	O
the	O
specialty	O
clinic	O
.	O

These	O
identified	O
herbs	O
can	O
now	O
be	O
targeted	O
for	O
scientific	O
investigation	O
to	O
determine	O
whether	O
their	O
pharmacological	O
efficacy	O
will	O
assist	O
in	O
the	O
development	O
of	O
viable	O
healthcare	O
alternatives	O
in	O
a	O
developing	O
country	O
.	O

These	O
findings	O
are	O
also	O
important	O
for	O
policymakers	O
in	O
the	O
health	O
sector	O
who	O
are	O
given	O
the	O
mandate	O
to	O
regulate	O
issues	O
pertaining	O
to	O
the	O
public	O
'	O
s	O
health	O
.	O

We	O
are	O
also	O
becoming	O
more	O
aware	O
of	O
the	O
potential	O
for	O
critical	O
interplay	O
between	O
herbs	O
and	O
drugs	O
when	O
taken	O
concomitantly	O
to	O
produce	O
life	O
-	O
threatening	O
interactions	O
.	O

Since	O
herbs	O
are	O
here	O
to	O
stay	O
and	O
patients	S-Species
will	O
continue	O
to	O
self	O
-	O
medicate	O
with	O
increasing	O
frequency	O
,	O
it	O
is	O
imperative	O
that	O
healthcare	O
providers	O
become	O
more	O
knowledgeable	O
on	O
this	O
modality	O
and	O
keep	O
abreast	O
with	O
the	O
latest	O
developments	O
in	O
herbal	O
therapy	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

YNC	O
was	O
the	O
P	O
.	O
I	O
.	O
in	O
this	O
study	O
.	O

He	O
was	O
responsible	O
for	O
the	O
study	O
concept	O
,	O
development	O
of	O
methodology	O
,	O
coordinating	O
the	O
research	O
activities	O
,	O
analyzing	O
the	O
data	O
,	O
and	O
writing	O
the	O
manuscript	O
.	O

AFW	O
was	O
responsible	O
for	O
data	O
input	O
and	O
analysis	O
.	O

DA	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
,	O
data	O
input	O
and	O
analysis	O
and	O
presentation	O
at	O
regional	O
conference	O
.	O

RC	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
,	O
data	O
input	O
and	O
analysis	O
.	O

NW	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

RM	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

OS	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

DW	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
